{"id":"360G-Wellcome-221604_Z_20_Z","title":"Immunometabolic cross-talk in the inflamed diabetic heart","Region":"Greater London","currency":"GBP","awardDate":"2020-11-11T00:00:00+00:00","Sponsor(s)":"Prof Mark Caulfield","Internal ID":"221604/Z/20/Z","description":"Diabetic cardiomyopathy (dbCM) is a complication of type II diabetes (T2D), characterised by systemic inflammation, impaired cardiac function and disrupted metabolism. However, the impact of systemic inflammation on the development of the myocardial inflammation and cardiac metabolic derangement that lead to dbCM remain unknown. This study will address how chronic adaptive inflammation driven by systemic metabolic stress in T2D causes cardiac dysfunction. Specifically, I hypothesise that it is caused by inflammation due to T-cell infiltration and not by direct metabolic perturbations that can lead to impaired energetics (reduced PCr/ATP ratio). Specifically, the aim is to use integrated experimental approach combining metabolic analysis with T-cell phenotypic profiling in murine and human T2D to address three research challenges:\n\nA. Does infiltration of cardiotropic T-cells impair cardiac substrate plasticity and energetics in dbCM?\n\nB. Do myocardial succinate efflux and signalling via SUCNR1 promote cardiac Teff and/or Treg activation by modifying T-cell metabolism and do they enhance pro-inflammatory T-cell differentiation?\n\nC. Does stimulation of GCK-mediated glycolysis increase regulatory T-cell migration to the heart causing a switch in the nature of immune response from pro-inflammatory to immunosuppressive? Does the resultant reduction in myocardial exposure to pro-inflammatory cytokines improve cardiac function and mitochondrial performance? \n","plannedDates":[{"endDate":"2025-01-10T00:00:00+00:00","startDate":"2021-01-11T00:00:00+00:00","startDateDateOnly":"2021-01-11","endDateDateOnly":"2025-01-10"}],"amountAwarded":630613,"Financial Year":"2020/21","Lead Applicant":"Dr Dunja Aksentijevic","grantProgramme":[{"title":"Career Re-Entry Fellowship","title_keyword":"Career Re-Entry Fellowship"}],"Applicant Surname":"Aksentijevic","Partnership Value":630613,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Queen-Mary-University-of-London","name":"Queen Mary University of London","addressCountry":"United Kingdom","id_and_name":"[\"Queen Mary University of London\", \"360G-Wellcome-ORG:Queen-Mary-University-of-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Queen-Mary-University-of-London","name":"Queen Mary University of London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Immunometabolic cross-talk in the inflamed diabetic heart Diabetic cardiomyopathy (dbCM) is a complication of type II diabetes (T2D), characterised by systemic inflammation, impaired cardiac function and disrupted metabolism. However, the impact of systemic inflammation on the development of the myocardial inflammation and cardiac metabolic derangement that lead to dbCM remain unknown. This study will address how chronic adaptive inflammation driven by systemic metabolic stress in T2D causes cardiac dysfunction. Specifically, I hypothesise that it is caused by inflammation due to T-cell infiltration and not by direct metabolic perturbations that can lead to impaired energetics (reduced PCr/ATP ratio). Specifically, the aim is to use integrated experimental approach combining metabolic analysis with T-cell phenotypic profiling in murine and human T2D to address three research challenges:\n\nA. Does infiltration of cardiotropic T-cells impair cardiac substrate plasticity and energetics in dbCM?\n\nB. Do myocardial succinate efflux and signalling via SUCNR1 promote cardiac Teff and/or Treg activation by modifying T-cell metabolism and do they enhance pro-inflammatory T-cell differentiation?\n\nC. Does stimulation of GCK-mediated glycolysis increase regulatory T-cell migration to the heart causing a switch in the nature of immune response from pro-inflammatory to immunosuppressive? Does the resultant reduction in myocardial exposure to pro-inflammatory cytokines improve cardiac function and mitochondrial performance? \n","awardDateDateOnly":"2020-11-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adaptive Immunity","Animals","Diabetes Mellitus, Type 2","Energy Metabolism","Glycolysis","Humans","Inflammation","Mice","T-Lymphocytes","T-Lymphocytes, Regulatory"]}
{"id":"360G-Wellcome-221598_Z_20_Z","title":"Oral Ketamine Capsules - A new potential treatment for Depression. A pharmacokinetic and pharmacodynamic assessment of Ketamine and Metabolites in a dose-escalating, placebo-controlled clinical trial in healthy subjects.","Region":"Scotland","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221598/Z/20/Z","description":"Neurocentrx has developed oral capsule formulations of Ketamine, aiming to be new treatments for Depression. Ketamine is a synthetic drug created in the 1960\u2019s. It is on the \"essential medicine\" list of the World Health Organisation (WHO), approved and licensed by health regulators worldwide as an injectable anaesthetic. More recently, and at sub-anaesthetic doses, clinical trials have shown that some patients with depression have a rapid response to injectable ketamine (hours or days). Most other anti-depressant medicines take many weeks to work. No oral ketamine products are currently available as a licensed medicine worldwide. Our project will assess oral capsules in healthy people in a clinical trial. We will assess absorption and excretion with increasing doses of drug and measure any side-effects. These data will be essential to accurately plan trials in depression patients where we will then look for benefits. Oral capsules could be used at home, and are hoped to be a cheaper treatment option, with fewer side-effects for patients. The summary above may be amended from time to time by mutual agreement of the Parties. For this clause agreement by email will be sufficient to render a valid amendment to the summary).","plannedDates":[{"endDate":"2022-04-10T00:00:00+00:00","startDate":"2020-11-09T00:00:00+00:00","startDateDateOnly":"2020-11-09","endDateDateOnly":"2022-04-10"}],"amountAwarded":498326,"Financial Year":"2019/20","Lead Applicant":"Dr Carmel Reilly","grantProgramme":[{"title":"Innovator Award","title_keyword":"Innovator Award"}],"Applicant Surname":"Reilly","Partnership Value":498326,"Approval Committee":"Innovator Awards Advisory Group","Other Applicant(s)":"Dr Mario Juruena","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Neurocentrx-Pharma-Ltd","name":"Neurocentrx Pharma Ltd","addressCountry":"United Kingdom","id_and_name":"[\"Neurocentrx Pharma Ltd\", \"360G-Wellcome-ORG:Neurocentrx-Pharma-Ltd\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Neurocentrx-Pharma-Ltd","name":"Neurocentrx Pharma Ltd"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Oral Ketamine Capsules - A new potential treatment for Depression. A pharmacokinetic and pharmacodynamic assessment of Ketamine and Metabolites in a dose-escalating, placebo-controlled clinical trial in healthy subjects. Neurocentrx has developed oral capsule formulations of Ketamine, aiming to be new treatments for Depression. Ketamine is a synthetic drug created in the 1960\u2019s. It is on the \"essential medicine\" list of the World Health Organisation (WHO), approved and licensed by health regulators worldwide as an injectable anaesthetic. More recently, and at sub-anaesthetic doses, clinical trials have shown that some patients with depression have a rapid response to injectable ketamine (hours or days). Most other anti-depressant medicines take many weeks to work. No oral ketamine products are currently available as a licensed medicine worldwide. Our project will assess oral capsules in healthy people in a clinical trial. We will assess absorption and excretion with increasing doses of drug and measure any side-effects. These data will be essential to accurately plan trials in depression patients where we will then look for benefits. Oral capsules could be used at home, and are hoped to be a cheaper treatment option, with fewer side-effects for patients. The summary above may be amended from time to time by mutual agreement of the Parties. For this clause agreement by email will be sufficient to render a valid amendment to the summary).","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Administration, Oral","Adult","Capsules","Dose-Response Relationship, Drug","Double-Blind Method","Humans","Ketamine","Research Design"]}
{"id":"360G-Wellcome-221597_Z_20_Z","title":"The evaluation of novel GBS conjugates prepared from GBS capsular polysaccharides and GBS conserved surface proteins\u2019","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221597/Z/20/Z","description":"Group B Streptococcus (GBS) bacterial infection is a major health concern and a leading cause of sepsis and meningitis in infants, particularly in Africa. A promising prevention for GBS infection in newborns is maternal immunization with a GBS vaccine. Currently no vaccine for GBS is available. Several conjugate GBS vaccines using GBS surface-expressed polysaccharides linked to carrier proteins are under development. We are proposing a novel vaccine design using GBS polysaccharides conjugated to GBS conserved surface proteins which induce immune responses in infected individuals, making them potential candidates as carrier proteins for novel GBS vaccines. It combines two virulence factors of GBS with the potential to provide not only enhanced overall protection compared to traditional conjugate vaccines but also to potentially provide protection against those serotypes not included in the vaccine. It could lead to the development of an affordable and cost-effective vaccine that protects against all GBS serotypes.","plannedDates":[{"endDate":"2022-10-30T00:00:00+00:00","startDate":"2021-05-03T00:00:00+00:00","startDateDateOnly":"2021-05-03","endDateDateOnly":"2022-10-30"}],"amountAwarded":398043,"Financial Year":"2019/20","Lead Applicant":"Dr Seanette Wilson","grantProgramme":[{"title":"Innovator Award","title_keyword":"Innovator Award"}],"Applicant Surname":"Wilson","Partnership Value":398043,"Approval Committee":"Innovator Awards Advisory Group","Other Applicant(s)":"Dr Gaurav Kwatra","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:The-Biovac-Institute","name":"The Biovac Institute","addressCountry":"South Africa","id_and_name":"[\"The Biovac Institute\", \"360G-Wellcome-ORG:The-Biovac-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:The-Biovac-Institute","name":"The Biovac Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The evaluation of novel GBS conjugates prepared from GBS capsular polysaccharides and GBS conserved surface proteins\u2019 Group B Streptococcus (GBS) bacterial infection is a major health concern and a leading cause of sepsis and meningitis in infants, particularly in Africa. A promising prevention for GBS infection in newborns is maternal immunization with a GBS vaccine. Currently no vaccine for GBS is available. Several conjugate GBS vaccines using GBS surface-expressed polysaccharides linked to carrier proteins are under development. We are proposing a novel vaccine design using GBS polysaccharides conjugated to GBS conserved surface proteins which induce immune responses in infected individuals, making them potential candidates as carrier proteins for novel GBS vaccines. It combines two virulence factors of GBS with the potential to provide not only enhanced overall protection compared to traditional conjugate vaccines but also to potentially provide protection against those serotypes not included in the vaccine. It could lead to the development of an affordable and cost-effective vaccine that protects against all GBS serotypes.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Antibodies, Bacterial","Bacterial Capsules","Humans","Serogroup","Streptococcal Infections","Streptococcal Vaccines","Streptococcus agalactiae","Vaccines, Conjugate"]}
{"id":"360G-Wellcome-221595_Z_20_Z","title":"Preclinical Toxicology Testing and IND application for a Novel Cholera Conjugate Vaccine","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221595/Z/20/Z","description":"Cholera is a disease of inequity that continues to disproportionately affect the world\u2019s poorest and\nmost vulnerable people. An oral cholera vaccine (OCV) is available and in use around the world,\nbut it has lower efficacy in young children than in adults and a relatively short duration of protection\nnecessitating re-vaccination every few years. We are developing a new conjugate vaccine that\noffers the promise of improved efficacy in all age groups, including those less than 5 years, and an\nextended duration of protection, thus reducing the requirements for repetitive vaccination to sustain\npopulation immunity. It can be implemented in place of OCV or as a complementary tool to prevent\nor limit outbreaks in high risk settings, and build enduring population immunity that will costeffectively\ncontrol cholera over the decades required to build definitive public health capacities in at\nrisk countries.","plannedDates":[{"endDate":"2021-10-31T00:00:00+00:00","startDate":"2020-11-01T00:00:00+00:00","startDateDateOnly":"2020-11-01","endDateDateOnly":"2021-10-31"}],"amountAwarded":456865,"Financial Year":"2019/20","Lead Applicant":"Dr Julia Lynch","grantProgramme":[{"title":"Innovator Award","title_keyword":"Innovator Award"}],"Applicant Surname":"Lynch","Partnership Value":456865,"Approval Committee":"Innovator Awards Advisory Group","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:International-Vaccine-Institute","name":"International Vaccine Institute","addressCountry":"Korea, South","id_and_name":"[\"International Vaccine Institute\", \"360G-Wellcome-ORG:International-Vaccine-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:International-Vaccine-Institute","name":"International Vaccine Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Preclinical Toxicology Testing and IND application for a Novel Cholera Conjugate Vaccine Cholera is a disease of inequity that continues to disproportionately affect the world\u2019s poorest and\nmost vulnerable people. An oral cholera vaccine (OCV) is available and in use around the world,\nbut it has lower efficacy in young children than in adults and a relatively short duration of protection\nnecessitating re-vaccination every few years. We are developing a new conjugate vaccine that\noffers the promise of improved efficacy in all age groups, including those less than 5 years, and an\nextended duration of protection, thus reducing the requirements for repetitive vaccination to sustain\npopulation immunity. It can be implemented in place of OCV or as a complementary tool to prevent\nor limit outbreaks in high risk settings, and build enduring population immunity that will costeffectively\ncontrol cholera over the decades required to build definitive public health capacities in at\nrisk countries.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Administration, Oral","Adolescent","Adult","Child","Child, Preschool","Cholera","Cholera Vaccines","Humans"]}
{"id":"360G-Wellcome-221590_Z_20_Z","title":"AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment ","Region":"North West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221590/Z/20/Z","description":"Conventional evaluation of new medicines is not fast enough for a pandemic. Our aim is to accelerate this process, rapidly identifying which drugs are safe and potentially effective treatments for COVID-19. AGILE is an innovative, multi-arm, multi-dose, multi-stage Phase I/IIa Bayesian adaptive platform protocol to evaluate experimental COVID-19 therapies, and to funnel plausible candidates into large Phase IIb/III trials such as RECOVERY and SOLIDARITY. We will efficiently eliminate candidates with little or no prospect of clinical success.\n\nAGILE will recruit COVID-19 patients into very early phase clinical studies, including first-in-human. The innovative design allows us to move seamlessly from first-in-human use to finding the optimal dose for COVID-19 patients. The trial is pragmatic (requiring only small numbers of patients), adaptive (so that the right drug is tested in the right group of COVID-19 patients, either in the community or in hospital) and statistically efficient (so that several drugs can be tested in parallel, making best use of a small number of patients). Our primary focus is population-scalable antiviral drugs for early treatment of COVID-19, for which we will recruit primarily in the community. AGILE has full regulatory and ethics approvals in the UK.\n \n","plannedDates":[{"endDate":"2023-01-31T00:00:00+00:00","startDate":"2021-02-01T00:00:00+00:00","startDateDateOnly":"2021-02-01","endDateDateOnly":"2023-01-31"}],"amountAwarded":3069077,"Financial Year":"2019/20","Lead Applicant":"Prof Saye Khoo","grantProgramme":[{"title":"Therapeutics Accelerator ","title_keyword":"Therapeutics Accelerator "}],"Applicant Surname":"Khoo","Partnership Value":3069077,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Richard Fitzgerald, Prof Gareth Griffiths, Prof Sir Munir Pirmohamed, Dr Mohammed Lamorde, Prof Catherine Orrell, Prof David Lalloo, Dr Shevin Jacob, Dr Thomas Fletcher, Prof Andrew Owen, Prof Francois Venter, Prof Thomas Jaki, Dr Bella Starling, Prof William Greenhalf, Sir Michael Jacobs","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool","addressCountry":"United Kingdom","id_and_name":"[\"University of Liverpool\", \"360G-Wellcome-ORG:University-of-Liverpool\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment  Conventional evaluation of new medicines is not fast enough for a pandemic. Our aim is to accelerate this process, rapidly identifying which drugs are safe and potentially effective treatments for COVID-19. AGILE is an innovative, multi-arm, multi-dose, multi-stage Phase I/IIa Bayesian adaptive platform protocol to evaluate experimental COVID-19 therapies, and to funnel plausible candidates into large Phase IIb/III trials such as RECOVERY and SOLIDARITY. We will efficiently eliminate candidates with little or no prospect of clinical success.\n\nAGILE will recruit COVID-19 patients into very early phase clinical studies, including first-in-human. The innovative design allows us to move seamlessly from first-in-human use to finding the optimal dose for COVID-19 patients. The trial is pragmatic (requiring only small numbers of patients), adaptive (so that the right drug is tested in the right group of COVID-19 patients, either in the community or in hospital) and statistically efficient (so that several drugs can be tested in parallel, making best use of a small number of patients). Our primary focus is population-scalable antiviral drugs for early treatment of COVID-19, for which we will recruit primarily in the community. AGILE has full regulatory and ethics approvals in the UK.\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Antiviral Agents","Bayes Theorem","Clinical Trials, Phase I as Topic","Humans","Research Design"]}
{"id":"360G-Wellcome-221589_Z_20_Z","title":"Development of a Universal Group A Streptococcus Glycoconjugate Vaccine","Region":"Scotland","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221589/Z/20/Z","description":"The pathogenic bacterium Group A Streptococcus (GAS) causes a range of infections, ranging from mild tonsillitis to invasive necrotising fasciitis, sepsis and toxic shock syndrome. GAS also induces severe long-lasting autoimmune disease, including rheumatic heart disease. Annually, GAS infections kill  > 500,000 people worldwide. While antibiotics are considered a reliable first line of defence against GAS infections, globally emerging antimicrobial resistance is an enormous threat. The WHO has included GAS in its vaccine priority list to finally reduce the high mortality and morbidity. We will use our developed novel modular system to produce the first dual-acting and lowcost GAS vaccine candidates targeting all  > 150 GAS strains. Our approach provides the first robust and affordable solution to target and prevent GAS infections, urgently required for the global population and in particular the people in low-income countries.","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2021-10-01T00:00:00+00:00","startDateDateOnly":"2021-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":402298,"Financial Year":"2019/20","Lead Applicant":"Dr Helge Dorfmueller","grantProgramme":[{"title":"Innovator Award","title_keyword":"Innovator Award"}],"Applicant Surname":"Dorfmueller","Partnership Value":402298,"Approval Committee":"Innovator Awards Advisory Group","Other Applicant(s)":"Prof Brendan Wren","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee","addressCountry":"United Kingdom","id_and_name":"[\"University of Dundee\", \"360G-Wellcome-ORG:University-of-Dundee\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Development of a Universal Group A Streptococcus Glycoconjugate Vaccine The pathogenic bacterium Group A Streptococcus (GAS) causes a range of infections, ranging from mild tonsillitis to invasive necrotising fasciitis, sepsis and toxic shock syndrome. GAS also induces severe long-lasting autoimmune disease, including rheumatic heart disease. Annually, GAS infections kill  > 500,000 people worldwide. While antibiotics are considered a reliable first line of defence against GAS infections, globally emerging antimicrobial resistance is an enormous threat. The WHO has included GAS in its vaccine priority list to finally reduce the high mortality and morbidity. We will use our developed novel modular system to produce the first dual-acting and lowcost GAS vaccine candidates targeting all  > 150 GAS strains. Our approach provides the first robust and affordable solution to target and prevent GAS infections, urgently required for the global population and in particular the people in low-income countries.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Streptococcal Infections","Streptococcal Vaccines","Streptococcus pyogenes"]}
{"id":"360G-Wellcome-221586_Z_20_Z","title":"\u2018DuoChol: A low-cost, thermostable dry formulation whole-cell / B-subunit enterocoated capsule oral cholera vaccine.\u2019","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221586/Z/20/Z","description":"\"The Project aims at completion of the preclinical development of a new, improved oral cholera vaccine (OCV), DuoChol. This is a proposed thermostable OCV consisting of a lyophilized mixture of formalin-killed V. cholerae O1 Ogawa and Inaba strain whole-cells and cholera toxin B-subunit (rCTB) formulated in an enterocoated capsule. The two strains are isogenic except for the single serotype determining wbeT gene, and this allows them to be co-cultured to high density, which together with inexpensive high-yield rCTB production ensures low-cost manufacturing. The Project will build a solid platform for the subsequent clinical development of DuoChol, whose affordable cost, practical formulation and higher efficacy compared with current OCVs will make this a very attractive OCV for use in national cholera control programs and ideal for use in cholera outbreaks where rapid deployment and maximal early efficacy is of the essence.","plannedDates":[{"endDate":"2022-07-29T00:00:00+00:00","startDate":"2021-03-01T00:00:00+00:00","startDateDateOnly":"2021-03-01","endDateDateOnly":"2022-07-29"}],"amountAwarded":1130853,"Financial Year":"2019/20","Lead Applicant":"Prof Jan Holmgren","grantProgramme":[{"title":"Innovations AIGH Enterics Flagship ","title_keyword":"Innovations AIGH Enterics Flagship "}],"Applicant Surname":"Holmgren","Partnership Value":1130853,"Approval Committee":"Science, Innovation and Translation Programme Advisory Group","Other Applicant(s)":"Dr Michael Lebens, Dr Manuela Terrinoni, Dr Stefan Nordqvist","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Gothenburg","name":"University of Gothenburg","addressCountry":"Sweden","id_and_name":"[\"University of Gothenburg\", \"360G-Wellcome-ORG:University-of-Gothenburg\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Gothenburg","name":"University of Gothenburg"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"\u2018DuoChol: A low-cost, thermostable dry formulation whole-cell / B-subunit enterocoated capsule oral cholera vaccine.\u2019 \"The Project aims at completion of the preclinical development of a new, improved oral cholera vaccine (OCV), DuoChol. This is a proposed thermostable OCV consisting of a lyophilized mixture of formalin-killed V. cholerae O1 Ogawa and Inaba strain whole-cells and cholera toxin B-subunit (rCTB) formulated in an enterocoated capsule. The two strains are isogenic except for the single serotype determining wbeT gene, and this allows them to be co-cultured to high density, which together with inexpensive high-yield rCTB production ensures low-cost manufacturing. The Project will build a solid platform for the subsequent clinical development of DuoChol, whose affordable cost, practical formulation and higher efficacy compared with current OCVs will make this a very attractive OCV for use in national cholera control programs and ideal for use in cholera outbreaks where rapid deployment and maximal early efficacy is of the essence.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Administration, Oral","Cholera","Cholera Vaccines","Humans","Vibrio cholerae"]}
{"id":"360G-Wellcome-221582_Z_20_Z","title":"Predicting CBT response from fear conditioning","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221582/Z/20/Z","description":"Responses to psychological interventions for anxiety vary greatly. Clients and clinicians want better ways to predict outcomes. One contender is fear extinction, the process through which exposure, the \"behavioural\" part of Cognitive Behavioural Therapy (CBT) is thought to work. Whilst there are robust differences in fear extinction between individuals with anxiety disorders versus controls, evidence that extinction predicts CBT response is modest. \n\n We first became interested in fear extinction as a mechanistic tool to help understand how CBT works. In order to build algorithms from numerous potential predictors, including fear extinction, we needed to undertake fear conditioning at a scale. We developed a smartphone App FLARe, that remotely delivers a fear conditioning paradigm. Our validation studies showed that fear extinction data from our App mirror that from gold-standard in-lab delivery. \n\nWe now want to test the extent to which App-delivered fear extinction data predicts CBT response. We will assess young adults with high anxiety using our App before enrolling them in CBT. We will test the strength of correlation between fear extinction and treatment outcome. We will also explore the extent to which this association is stronger in specific sub-groups (e.g. those who completed more exposure homework during treatment).\n","plannedDates":[{"endDate":"2022-04-01T00:00:00+00:00","startDate":"2020-12-01T00:00:00+00:00","startDateDateOnly":"2020-12-01","endDateDateOnly":"2022-04-01"}],"amountAwarded":347602,"Financial Year":"2019/20","Lead Applicant":"Prof Thalia Eley","grantProgramme":[{"title":"Strategic Support: Science","title_keyword":"Strategic Support: Science"}],"Applicant Surname":"Eley","Partnership Value":347602,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Colette Hirsch, Prof Gerome Breen","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Predicting CBT response from fear conditioning Responses to psychological interventions for anxiety vary greatly. Clients and clinicians want better ways to predict outcomes. One contender is fear extinction, the process through which exposure, the \"behavioural\" part of Cognitive Behavioural Therapy (CBT) is thought to work. Whilst there are robust differences in fear extinction between individuals with anxiety disorders versus controls, evidence that extinction predicts CBT response is modest. \n\n We first became interested in fear extinction as a mechanistic tool to help understand how CBT works. In order to build algorithms from numerous potential predictors, including fear extinction, we needed to undertake fear conditioning at a scale. We developed a smartphone App FLARe, that remotely delivers a fear conditioning paradigm. Our validation studies showed that fear extinction data from our App mirror that from gold-standard in-lab delivery. \n\nWe now want to test the extent to which App-delivered fear extinction data predicts CBT response. We will assess young adults with high anxiety using our App before enrolling them in CBT. We will test the strength of correlation between fear extinction and treatment outcome. We will also explore the extent to which this association is stronger in specific sub-groups (e.g. those who completed more exposure homework during treatment).\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adult","Anxiety Disorders","Cognitive Behavioral Therapy","Extinction, Psychological","Fear","Female","Humans","Male","Mobile Applications","Smartphone","Young Adult"]}
{"id":"360G-Wellcome-221579_Z_20_Z","title":"Understanding the impact of COVID-19 on bacterial sepsis, antibiotic consumption and stewardship, and antimicrobial resistance","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221579/Z/20/Z","description":"This study aims to address the following questions through a global network of hospitals: \n\n\n Is there evidence for a reduction in the total number or rates (per 1,000 inpatients) of blood cultures taken over twelve months?\n Has there been changes in antimicrobial usage (quantitative and qualitative)? \n Are there major changes in antibiotic resistance profiles from major pathogens?\n Have there been changes in antimicrobial stewardship and why? \n What is the overall change in the management of these patients?\n What is the impact of COVID-19 on infection control practices during the pandemic? \n Is there any evidence of reduction in nosocomial infections and bacterial outbreaks during the COVID-19 pandemic? \n\n\nWe will collect clinical (patient-based [severe pneumonia, ARDS, sepsis patients], hospital and microbiological data from 11 countries (UK, Switzerland, Italy, Brazil, Nigeria, Malawi, Turkey, Iran, India, Bangladesh and South Korea).  \n\nOur primary outcome will be to determine if there has been a reduction in blood cultures taken. Secondary outcomes include whether 1. changes in antimicrobial usage 2. major changes in antibiotic resistance profiles from major pathogens in hospitals during COVID-19 and correlate resistance profiles with antibiotic usage. 3. changes in infection control practices and other aspects of sepsis management behaviour during the COVID-19 pandemic.\n","plannedDates":[{"endDate":"2022-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2022-08-31"}],"amountAwarded":765283,"Financial Year":"2019/20","Lead Applicant":"Prof Timothy Walsh","grantProgramme":[{"title":"Discretionary award \u2013 DRI","title_keyword":"Discretionary award \u2013 DRI"}],"Applicant Surname":"Walsh","Partnership Value":765283,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Prof Stephan Harbarth, Dr Catrin Moore, Dr Ly-Mee Yu, Prof Nicholas Feasey, Prof Ben Cooper, Prof Christiane Dolecek","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding the impact of COVID-19 on bacterial sepsis, antibiotic consumption and stewardship, and antimicrobial resistance This study aims to address the following questions through a global network of hospitals: \n\n\n Is there evidence for a reduction in the total number or rates (per 1,000 inpatients) of blood cultures taken over twelve months?\n Has there been changes in antimicrobial usage (quantitative and qualitative)? \n Are there major changes in antibiotic resistance profiles from major pathogens?\n Have there been changes in antimicrobial stewardship and why? \n What is the overall change in the management of these patients?\n What is the impact of COVID-19 on infection control practices during the pandemic? \n Is there any evidence of reduction in nosocomial infections and bacterial outbreaks during the COVID-19 pandemic? \n\n\nWe will collect clinical (patient-based [severe pneumonia, ARDS, sepsis patients], hospital and microbiological data from 11 countries (UK, Switzerland, Italy, Brazil, Nigeria, Malawi, Turkey, Iran, India, Bangladesh and South Korea).  \n\nOur primary outcome will be to determine if there has been a reduction in blood cultures taken. Secondary outcomes include whether 1. changes in antimicrobial usage 2. major changes in antibiotic resistance profiles from major pathogens in hospitals during COVID-19 and correlate resistance profiles with antibiotic usage. 3. changes in infection control practices and other aspects of sepsis management behaviour during the COVID-19 pandemic.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anti-Bacterial Agents","Bacterial Infections","Cross Infection","Drug Resistance, Bacterial","Drug Utilization","Hospitals","Humans","Sepsis"]}
{"id":"360G-Wellcome-221576_Z_20_Z","title":"Unit for Health Evidence and Policy ","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221576/Z/20/Z","description":"This proposal outlines the establishment of a pilot Unit for Health Evidence and Policy within CDT-Africa, a World Bank African Centre for Excellence based at Addis Ababa University, Ethiopia. Building on strong operational research into Neglected Tropical Diseases, and existing relationships within Ethiopia\u2019s Ministry of Health, the Unit for Health Policy and Evidence will identify challenges to research uptake, pilot and evaluate an approach to improving research uptake, and produce a framework to guide future research uptake in this setting and possibly more broadly.\n\nThe pilot Unit for Health Policy and Evidence will be a 12-month project, divided into two Periods. Period 1 will comprise stakeholder consultation through two Theory of Change workshops and other interviews as necessary. During Period 2, research uptake in an NTD area defined in Period 1 will be evaluated using the Diversity Approach (see below). A Research Uptake Framework will be developed and a dissemination workshop held with key national and international stakeholders.\n \n","plannedDates":[{"endDate":"2021-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2021-12-31"}],"amountAwarded":48135,"Financial Year":"2019/20","Lead Applicant":"Dr Abebaw Fekadu","grantProgramme":[{"title":"Discretionary Award - Policy ","title_keyword":"Discretionary Award - Policy "}],"Partnership Name":"NIHR/Wellcome Global health Partnership","Applicant Surname":"Fekadu","Partnership Value":96271,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Addis-Ababa-University","name":"Addis Ababa University","addressCountry":"Ethiopia","id_and_name":"[\"Addis Ababa University\", \"360G-Wellcome-ORG:Addis-Ababa-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Addis-Ababa-University","name":"Addis Ababa University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Unit for Health Evidence and Policy  This proposal outlines the establishment of a pilot Unit for Health Evidence and Policy within CDT-Africa, a World Bank African Centre for Excellence based at Addis Ababa University, Ethiopia. Building on strong operational research into Neglected Tropical Diseases, and existing relationships within Ethiopia\u2019s Ministry of Health, the Unit for Health Policy and Evidence will identify challenges to research uptake, pilot and evaluate an approach to improving research uptake, and produce a framework to guide future research uptake in this setting and possibly more broadly.\n\nThe pilot Unit for Health Policy and Evidence will be a 12-month project, divided into two Periods. Period 1 will comprise stakeholder consultation through two Theory of Change workshops and other interviews as necessary. During Period 2, research uptake in an NTD area defined in Period 1 will be evaluated using the Diversity Approach (see below). A Research Uptake Framework will be developed and a dissemination workshop held with key national and international stakeholders.\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Ethiopia","Health Policy","Humans","Pilot Projects","Policy Making","Universities"]}
{"id":"360G-Wellcome-221575_Z_20_Z","title":"AVID-CC Adalimumab for COVID19 in community care","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221575/Z/20/Z","description":"While the first wave of COVID-19 is passing, we have yet to identify effective treatments. Most treatments have been used late in the illness. There is a pressing need to identify treatments delivered in community settings that avoid hospital admission. Novel immunomodulatory treatments have a well understood safety profile but are not suitable for studies such as Principle which rely on remote assessment. Hospital at home is a developing networ;  teams of consultant physicians and nurses deliver high intensity care in community settings, commonly using point of care diagnostics. This provides a suitable framework for evaluation of novel therapies. This approach has parallels with healthcare systems employed in low and middle income countries and so the results will directly inform the delivery of interventions in these settings. \n\nMultiple strands of evidence identify TNFa as an important mediator of the hyperinflammatory state that is associated with poor outcome. Early intervention with anti-TNF therapy has the potential to substantially mitigate its effects and improve outcomes. Adalimumab is an established subcutaneous anti-TNF therapy. We propose a randomised dose ranging study in community settings to establish whether it can mitigate progression to respiratory failure (requirement for oxygen, non invasive and invasive ventilation) or death. \n\n \n","plannedDates":[{"endDate":"2021-12-31T00:00:00+00:00","startDate":"2020-08-01T00:00:00+00:00","startDateDateOnly":"2020-08-01","endDateDateOnly":"2021-12-31"}],"amountAwarded":1495762,"Financial Year":"2019/20","Lead Applicant":"Prof Duncan Richards","grantProgramme":[{"title":"Therapeutics Accelerator ","title_keyword":"Therapeutics Accelerator "}],"Applicant Surname":"Richards","Partnership Value":1495762,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Prof Sir Marc Feldmann, Dr Matthew Rowland, Prof Jonathan Cook, Prof Daniel Lasserson","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"AVID-CC Adalimumab for COVID19 in community care While the first wave of COVID-19 is passing, we have yet to identify effective treatments. Most treatments have been used late in the illness. There is a pressing need to identify treatments delivered in community settings that avoid hospital admission. Novel immunomodulatory treatments have a well understood safety profile but are not suitable for studies such as Principle which rely on remote assessment. Hospital at home is a developing networ;  teams of consultant physicians and nurses deliver high intensity care in community settings, commonly using point of care diagnostics. This provides a suitable framework for evaluation of novel therapies. This approach has parallels with healthcare systems employed in low and middle income countries and so the results will directly inform the delivery of interventions in these settings. \n\nMultiple strands of evidence identify TNFa as an important mediator of the hyperinflammatory state that is associated with poor outcome. Early intervention with anti-TNF therapy has the potential to substantially mitigate its effects and improve outcomes. Adalimumab is an established subcutaneous anti-TNF therapy. We propose a randomised dose ranging study in community settings to establish whether it can mitigate progression to respiratory failure (requirement for oxygen, non invasive and invasive ventilation) or death. \n\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adalimumab","Anti-Inflammatory Agents","Humans","Tumor Necrosis Factor-alpha"]}
{"id":"360G-Wellcome-221574_Z_20_Z","title":"Wellcome Longitudinal Population Study COVID-19 Steering Group and Secretariat","Region":"South West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221574/Z/20/Z","description":"Our objective is to provide an efficient coordinating body (\"secretariat\") for the continued development, deployment, collection and analysis of a shared COVID-19 questionnaire across UK cohorts.\n\nThe value of undertaking this in multiple longitudinal UK cohorts is that data can be collected in extremely well characterised members of the population across a wide demographic range who are already engaged in research, who have had data and biological samples collected on them, who have an established collection of record linked data already record linked and who sit behind supported infrastructure able to undertake novel data collection and research. Each of these cohorts is research active and collectively offers a depth or domain expertise not available within any one cohort, including that of UK Biobank. In this first coordination of COVID-19 research in deeply characterised UK cohorts, we identified the added value of a core questionnaire prospectively aligned to capture data pertinent to understanding COVID-19, as well as the direct and indirect consequences of the pandemic on health, wellbeing, social and economic outcomes.\n","plannedDates":[{"endDate":"2021-06-30T00:00:00+00:00","startDate":"2020-07-01T00:00:00+00:00","startDateDateOnly":"2020-07-01","endDateDateOnly":"2021-06-30"}],"amountAwarded":120585,"Financial Year":"2019/20","Lead Applicant":"Prof Nicholas Timpson","grantProgramme":[{"title":"Strategic Support: Science","title_keyword":"Strategic Support: Science"}],"Applicant Surname":"Timpson","Partnership Value":120585,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Wellcome Longitudinal Population Study COVID-19 Steering Group and Secretariat Our objective is to provide an efficient coordinating body (\"secretariat\") for the continued development, deployment, collection and analysis of a shared COVID-19 questionnaire across UK cohorts.\n\nThe value of undertaking this in multiple longitudinal UK cohorts is that data can be collected in extremely well characterised members of the population across a wide demographic range who are already engaged in research, who have had data and biological samples collected on them, who have an established collection of record linked data already record linked and who sit behind supported infrastructure able to undertake novel data collection and research. Each of these cohorts is research active and collectively offers a depth or domain expertise not available within any one cohort, including that of UK Biobank. In this first coordination of COVID-19 research in deeply characterised UK cohorts, we identified the added value of a core questionnaire prospectively aligned to capture data pertinent to understanding COVID-19, as well as the direct and indirect consequences of the pandemic on health, wellbeing, social and economic outcomes.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aged","Biological Specimen Banks","Biomedical Research","Female","Humans","Longitudinal Studies","Male","Middle Aged","Surveys and Questionnaires","United Kingdom"]}
{"id":"360G-Wellcome-221572_Z_20_Z","title":"\u2018Harnessing endogenous mechanisms to promote cardiac regeneration\u2019","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221572/Z/20/Z","description":"Ischaemic heart disease remains a major cause of disability and death world-wide. When a\nmajor blood vessel in the heart suddenly becomes blocked, the muscle that it supplies dies\nand is replaced with scar tissue. This is what happens in a heart attack. The scarred heart\nno longer pumps blood properly and 40% of patients who develop heart failure die within 5\nyears. There is currently no treatment to help make new heart muscle after a heart attack.\nWe have identified a protein already present in the body, a single injection of which within a\nfew hours after injury can dramatically improve heart function by limiting damage and\npromoting repair. We will now engineer this protein molecule to retain only the regenerative\nproperties, whilst eliminating potential unwanted effects. We anticipate the engineered\nproduct to be safe, limit the damage after a heart attack and also promote regeneration of\nheart muscle.","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":504745,"Financial Year":"2019/20","Lead Applicant":"Prof Jagdeep Nanchahal","grantProgramme":[{"title":"Innovator Award","title_keyword":"Innovator Award"}],"Applicant Surname":"Nanchahal","Partnership Value":504745,"Approval Committee":"Innovator Awards Advisory Group","Other Applicant(s)":"Dr Wyatt Yue, Prof Chas Bountra, Dr Nicola Burgess-Brown, Prof Robin Choudhury, Prof Sir Marc Feldmann, Prof Paul Riley, Prof Carolyn Carr","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"\u2018Harnessing endogenous mechanisms to promote cardiac regeneration\u2019 Ischaemic heart disease remains a major cause of disability and death world-wide. When a\nmajor blood vessel in the heart suddenly becomes blocked, the muscle that it supplies dies\nand is replaced with scar tissue. This is what happens in a heart attack. The scarred heart\nno longer pumps blood properly and 40% of patients who develop heart failure die within 5\nyears. There is currently no treatment to help make new heart muscle after a heart attack.\nWe have identified a protein already present in the body, a single injection of which within a\nfew hours after injury can dramatically improve heart function by limiting damage and\npromoting repair. We will now engineer this protein molecule to retain only the regenerative\nproperties, whilst eliminating potential unwanted effects. We anticipate the engineered\nproduct to be safe, limit the damage after a heart attack and also promote regeneration of\nheart muscle.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Humans","Mice","Myocardium","Myocytes, Cardiac","Regeneration","Tissue Engineering"]}
{"id":"360G-Wellcome-221571_Z_20_Z","title":"POETIC-COVID \u2013 Providing Essential Treatment in Critical Illness for COVID-19","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221571/Z/20/Z","description":"As COVID-19 lacks a definitive treatment, critical care is the primary therapeutic means for\nreducing mortality. How the world effectively scales up critical care will be a fundamental\ndeterminant of the overall impact of the pandemic. Advanced critical care may be difficult or\nimpossible to scale-up in many settings and instead, essential, life-saving treatments should\nbe provided to all who need. Essential Emergency and Critical Care (EECC) is the basic,\nlow-cost care required by critically ill patients, such as oxygen and intravenous fluids, and\nthe system-wide requirements for their provision. The project will assess the costeffectiveness\nof EECC and advanced critical care in Tanzania and Kenya, and analyse the\nimpact of the global and national response strategies to COVID-19 on critical care services.\nThe project aims to guide COVID-19 responses in LMICs towards scalable strategies with\nthe greatest potential for increased survival of critically ill patients, both in the pandemic and\nbeyond.","plannedDates":[{"endDate":"2021-12-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2021-12-31"}],"amountAwarded":498656,"Financial Year":"2019/20","Lead Applicant":"Dr Tim Baker","grantProgramme":[{"title":"Discretionary Award \u2013 Innovations","title_keyword":"Discretionary Award \u2013 Innovations"}],"Applicant Surname":"Baker","Partnership Value":498656,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"London School of Hygiene & Tropical Medicine\", \"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"POETIC-COVID \u2013 Providing Essential Treatment in Critical Illness for COVID-19 As COVID-19 lacks a definitive treatment, critical care is the primary therapeutic means for\nreducing mortality. How the world effectively scales up critical care will be a fundamental\ndeterminant of the overall impact of the pandemic. Advanced critical care may be difficult or\nimpossible to scale-up in many settings and instead, essential, life-saving treatments should\nbe provided to all who need. Essential Emergency and Critical Care (EECC) is the basic,\nlow-cost care required by critically ill patients, such as oxygen and intravenous fluids, and\nthe system-wide requirements for their provision. The project will assess the costeffectiveness\nof EECC and advanced critical care in Tanzania and Kenya, and analyse the\nimpact of the global and national response strategies to COVID-19 on critical care services.\nThe project aims to guide COVID-19 responses in LMICs towards scalable strategies with\nthe greatest potential for increased survival of critically ill patients, both in the pandemic and\nbeyond.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Critical Care","Critical Illness","Humans","Kenya","Tanzania"]}
{"id":"360G-Wellcome-221570_Z_20_Z","title":"Responsive Dialogues to Improve Public Engagement on AMR","Region":"North West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221570/Z/20/Z","description":"The diminishing effectiveness of antimicrobials is a public health challenge of major global importance. In the Global South, where health systems are weaker and the burden of severe bacterial infection greater, the impact is already being acutely felt. In Malawi, a Ministerial AMR Unit has been established to coordinate Malawi\u2019s response, culminating in a National Action Plan.  However, the implementation of the Action Plan needs key stakeholders \u2013 including affected community members \u2013 to develop and implement interventions. This project will undertake facilitated dialogues with stakeholders in two different contexts: rural Chikwawa and urban Blantyre. Through four Responsive Dialogues events per area, participants from national, district and community levels will share their understandings, experiences and perspectives on AMR, leading to the co-creation of concrete policy asks and actions.  Conversations will be carefully designed and facilitated to enable evidence about AMR to be shared, understood and used to generate ideas, as well as to inform policies governing how AMR is addressed. Through this approach the project will work closely with the AMR unit to cocreate local actions, that communities themselves can carry out to reduce the burden of AMR as well as policies and interventions that reflect people\u2019s lived realities. \n","plannedDates":[{"endDate":"2022-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2022-09-30"}],"amountAwarded":248385,"Financial Year":"2019/20","Lead Applicant":"Dr Eleanor MacPherson","grantProgramme":[{"title":"Discretionary Award - Public Engagement","title_keyword":"Discretionary Award - Public Engagement"}],"Applicant Surname":"MacPherson","Partnership Value":248385,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"Liverpool School of Tropical Medicine\", \"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Responsive Dialogues to Improve Public Engagement on AMR The diminishing effectiveness of antimicrobials is a public health challenge of major global importance. In the Global South, where health systems are weaker and the burden of severe bacterial infection greater, the impact is already being acutely felt. In Malawi, a Ministerial AMR Unit has been established to coordinate Malawi\u2019s response, culminating in a National Action Plan.  However, the implementation of the Action Plan needs key stakeholders \u2013 including affected community members \u2013 to develop and implement interventions. This project will undertake facilitated dialogues with stakeholders in two different contexts: rural Chikwawa and urban Blantyre. Through four Responsive Dialogues events per area, participants from national, district and community levels will share their understandings, experiences and perspectives on AMR, leading to the co-creation of concrete policy asks and actions.  Conversations will be carefully designed and facilitated to enable evidence about AMR to be shared, understood and used to generate ideas, as well as to inform policies governing how AMR is addressed. Through this approach the project will work closely with the AMR unit to cocreate local actions, that communities themselves can carry out to reduce the burden of AMR as well as policies and interventions that reflect people\u2019s lived realities. \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Community Participation","Humans","Malawi","Public Health"]}
{"id":"360G-Wellcome-224028_Z_21_Z","title":"Economic analysis of health impacts of carbon pricing on land-use ","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"224028/Z/21/Z","description":"The proposed work is \u2013 to our knowledge - the first integrated economic analysis of a single policy intervention and its potential to influence three interlinked threats: the global health crises of both non-communicable diseases and new infectious diseases such as Covid-19, as well as environmental degradation, including biodiversity loss and climate change.\n\nThe work will comprise modelling the consequences of carbon pricing, set at a level compatible with keeping climate change within planetary boundaries, with outcomes including land-system change, agricultural production, food prices, diets and health outcomes, and effects on infectious disease and biodiversity. The analysis will consider potential differential effects of carbon pricing across socio-economic groups, and between high, medium and low-income countries, as a basis for considering policy interventions to mitigate inequitable outcomes.\n\nThis analysis will contribute to the goal of The Lancet-Chatham House Commission which is to identify actions that can impact positively across the shared drivers of the three threats to human and planetary health described above. Importantly it will provide novel evidence for the ways in which co-benefits and\nco-costs of interventions might form a significant part of the political and economic cases for intervening at national and international levels and optimising policy design.\n","plannedDates":[{"endDate":"2021-12-27T00:00:00+00:00","startDate":"2021-06-28T00:00:00+00:00","startDateDateOnly":"2021-06-28","endDateDateOnly":"2021-12-27"}],"amountAwarded":50000,"Financial Year":"2020/21","Lead Applicant":"Prof Dame Theresa Marteau","grantProgramme":[{"title":"Discretionary Award - OPOH","title_keyword":"Discretionary Award - OPOH"}],"Applicant Surname":"Marteau","Partnership Value":50000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Economic analysis of health impacts of carbon pricing on land-use  The proposed work is \u2013 to our knowledge - the first integrated economic analysis of a single policy intervention and its potential to influence three interlinked threats: the global health crises of both non-communicable diseases and new infectious diseases such as Covid-19, as well as environmental degradation, including biodiversity loss and climate change.\n\nThe work will comprise modelling the consequences of carbon pricing, set at a level compatible with keeping climate change within planetary boundaries, with outcomes including land-system change, agricultural production, food prices, diets and health outcomes, and effects on infectious disease and biodiversity. The analysis will consider potential differential effects of carbon pricing across socio-economic groups, and between high, medium and low-income countries, as a basis for considering policy interventions to mitigate inequitable outcomes.\n\nThis analysis will contribute to the goal of The Lancet-Chatham House Commission which is to identify actions that can impact positively across the shared drivers of the three threats to human and planetary health described above. Importantly it will provide novel evidence for the ways in which co-benefits and\nco-costs of interventions might form a significant part of the political and economic cases for intervening at national and international levels and optimising policy design.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Agriculture","Carbon","Climate Change","Conservation of Natural Resources","Developing Countries","Global Health","Humans"]}
{"id":"360G-Wellcome-224017_Z_21_Z","title":"Topic Level bite-sized CPD in Science","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"224017/Z/21/Z","description":"The purpose of the project is to test the impact and value of delivering subject-specific CPD in upper primary, lower secondary science through \u2018bite-sized\u2019 online courses linked to micro-accreditation. It will:\n\n\n develop three online CPD units focusing on teaching more challenging ideas in science to pupils at upper primary and lower secondary level (ages 9-13)\n test \u2018proof of principle\u2019 that a structured online CPD course comprising \u2018bite-sized\u2019 CPD units supports teachers of primary and lower secondary science in strengthening their subject knowledge (SK) and their pedagogic content knowledge (PCK); and indirectly improves pupils\u2019 understanding of difficult ideas in science;\n enable teachers using the CPD resources to gain micro-accreditation in those topics, recognising and certifying their skills and knowledge, and explore ways to promote the value of this accreditation to senior leadership and more widely, including as evidence towards other accreditations such as Chartered Science Teacher (CSciTeach);\n test the \u2018buy-in\u2019 to the value of micro-accreditation by senior leadership in building up a pool of teachers who are skilled, confident (and ultimately deployed) to teach age and stage appropriate topics of the science curriculum; and as a tool to inform individual professional learning needs, promotion; and support targeted recruitment and retention strategies.\n\n\n \n","plannedDates":[{"endDate":"2023-02-15T00:00:00+00:00","startDate":"2021-08-16T00:00:00+00:00","startDateDateOnly":"2021-08-16","endDateDateOnly":"2023-02-15"}],"amountAwarded":128102,"Financial Year":"2020/21","Lead Applicant":"Ms Marianne E Cutler","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"E Cutler","Partnership Value":128102,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Prof Judith Bennett","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:The-Association-for-Science-Education","name":"The Association for Science Education","addressCountry":"United Kingdom","id_and_name":"[\"The Association for Science Education\", \"360G-Wellcome-ORG:The-Association-for-Science-Education\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:The-Association-for-Science-Education","name":"The Association for Science Education"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Topic Level bite-sized CPD in Science The purpose of the project is to test the impact and value of delivering subject-specific CPD in upper primary, lower secondary science through \u2018bite-sized\u2019 online courses linked to micro-accreditation. It will:\n\n\n develop three online CPD units focusing on teaching more challenging ideas in science to pupils at upper primary and lower secondary level (ages 9-13)\n test \u2018proof of principle\u2019 that a structured online CPD course comprising \u2018bite-sized\u2019 CPD units supports teachers of primary and lower secondary science in strengthening their subject knowledge (SK) and their pedagogic content knowledge (PCK); and indirectly improves pupils\u2019 understanding of difficult ideas in science;\n enable teachers using the CPD resources to gain micro-accreditation in those topics, recognising and certifying their skills and knowledge, and explore ways to promote the value of this accreditation to senior leadership and more widely, including as evidence towards other accreditations such as Chartered Science Teacher (CSciTeach);\n test the \u2018buy-in\u2019 to the value of micro-accreditation by senior leadership in building up a pool of teachers who are skilled, confident (and ultimately deployed) to teach age and stage appropriate topics of the science curriculum; and as a tool to inform individual professional learning needs, promotion; and support targeted recruitment and retention strategies.\n\n\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adolescent","Curriculum","Humans","Internet","Leadership","Science"]}
{"id":"360G-Wellcome-224016_Z_21_Z","title":"Making change happen in teacher professional development","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"224016/Z/21/Z","description":"There is a strong evidence base on effective continuing professional development (CPD) for teachers, but in spite of this evidence, there has been limited sustained change towards the goal of all teachers being able to participate in high quality professional development throughout their careers. To address this, greater understanding is needed of how to make change happen: the implementation of innovations and programmes in relation to policy and entitlements and the school environment; and the mechanisms and processes which underpin change.\nApplying insights from implementation science and theory-based evaluation, our proposed research will identify a series of \u2018mechanisms for change\u2019 applicable to teacher CPD policy and practice in school environments in England, to guide CPD practice by schools and policy-makers. Four complementary project strands (a systematic evidence review; STEM CPD policy analysis; investigating effective change implementation in CPD, through mixed methods of survey and case studies; stakeholder engagement and dissemination) will lead to evidence-based guidance for effective implementation of CPD in England at multiple system levels, whether a local system (e.g. a single department or school CPD), larger system (e.g. programmes for a specific teacher subject group or phase) or the whole education system (e.g. increasing access to CPD). \n","plannedDates":[{"endDate":"2023-02-28T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2023-02-28"}],"amountAwarded":153054,"Financial Year":"2020/21","Lead Applicant":"Prof Emily Perry","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Perry","Partnership Value":153054,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Sheffield-Hallam-University","name":"Sheffield Hallam University","addressCountry":"United Kingdom","id_and_name":"[\"Sheffield Hallam University\", \"360G-Wellcome-ORG:Sheffield-Hallam-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Sheffield-Hallam-University","name":"Sheffield Hallam University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Making change happen in teacher professional development There is a strong evidence base on effective continuing professional development (CPD) for teachers, but in spite of this evidence, there has been limited sustained change towards the goal of all teachers being able to participate in high quality professional development throughout their careers. To address this, greater understanding is needed of how to make change happen: the implementation of innovations and programmes in relation to policy and entitlements and the school environment; and the mechanisms and processes which underpin change.\nApplying insights from implementation science and theory-based evaluation, our proposed research will identify a series of \u2018mechanisms for change\u2019 applicable to teacher CPD policy and practice in school environments in England, to guide CPD practice by schools and policy-makers. Four complementary project strands (a systematic evidence review; STEM CPD policy analysis; investigating effective change implementation in CPD, through mixed methods of survey and case studies; stakeholder engagement and dissemination) will lead to evidence-based guidance for effective implementation of CPD in England at multiple system levels, whether a local system (e.g. a single department or school CPD), larger system (e.g. programmes for a specific teacher subject group or phase) or the whole education system (e.g. increasing access to CPD). \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["England","Humans","School Teachers","Schools","Staff Development"]}
{"id":"360G-Wellcome-224009_Z_21_Z","title":"Mindscapes Curatorial Research Fellow","Region":"International","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"224009/Z/21/Z","description":"Mindscapes Curatorial Research Fellow\nFull-time position with CARMAH, reporting to the Director\n\nThis post-doctoral fellowship appointment will assist with the research and development phase of a new project looking at aspects of mental health with a specific focus on Berlin. Alongside pursuing self-directed research, the fellow will work closely with members of Wellcome\u2019s International Cultural Programmes team and Wellcome\u2019s Germany Office under the direction of the International Cultural Producer Danielle Olsen to: \n\n- Develop external partnerships across the city with partner organisations on the theme of mental health in Berlin investigating potential archives, collections, institutions and community led organisations that could provide a focus for transdisciplinary research\n\n- Serve as connector across participant spaces and places, developing creative new links with international city partners (in Bengaluru, New York and Tokyo) as the project develops\n\n- Assist in developing interdisciplinary and inclusive methods and processes between and across the Arts and Sciences on a mental health theme\n\n- Participate in a launch meeting in July 2021 on a mental health theme with a Berlin City focus\n\n- Explore crossover and hybrid experimental curatorial possibilities utilizing original creative work, events, and public programming.\n \n","plannedDates":[{"endDate":"2023-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2023-06-30"}],"amountAwarded":137623,"Financial Year":"2020/21","Lead Applicant":"Prof Sharon Macdonald","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Macdonald","Partnership Value":137623,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Humboldt-University-of-Berlin","name":"Humboldt University of Berlin","addressCountry":"Germany","id_and_name":"[\"Humboldt University of Berlin\", \"360G-Wellcome-ORG:Humboldt-University-of-Berlin\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Humboldt-University-of-Berlin","name":"Humboldt University of Berlin"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mindscapes Curatorial Research Fellow Mindscapes Curatorial Research Fellow\nFull-time position with CARMAH, reporting to the Director\n\nThis post-doctoral fellowship appointment will assist with the research and development phase of a new project looking at aspects of mental health with a specific focus on Berlin. Alongside pursuing self-directed research, the fellow will work closely with members of Wellcome\u2019s International Cultural Programmes team and Wellcome\u2019s Germany Office under the direction of the International Cultural Producer Danielle Olsen to: \n\n- Develop external partnerships across the city with partner organisations on the theme of mental health in Berlin investigating potential archives, collections, institutions and community led organisations that could provide a focus for transdisciplinary research\n\n- Serve as connector across participant spaces and places, developing creative new links with international city partners (in Bengaluru, New York and Tokyo) as the project develops\n\n- Assist in developing interdisciplinary and inclusive methods and processes between and across the Arts and Sciences on a mental health theme\n\n- Participate in a launch meeting in July 2021 on a mental health theme with a Berlin City focus\n\n- Explore crossover and hybrid experimental curatorial possibilities utilizing original creative work, events, and public programming.\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Berlin","Fellowships and Scholarships","Germany","Humans","Mental Health","Mental Health Services"]}
{"id":"360G-Wellcome-224008_Z_21_Z","title":"Equity and quality in local learning systems (EQuaLLS)","Region":"East Midlands","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"224008/Z/21/Z","description":"Schooling in England is complex and evolving. Large-scale academisation has fragmented local landscapes and created multiple models for knowledge exchange, increasing the risk that continuing professional development (CPD) for teachers becomes variable in terms of quality, equity of access, and impact. More recently, national CPD frameworks have been made more coherent, while local areas are being encouraged to coordinate CPD offers through new Teaching School Hubs.\n\nUnderstanding how this systemic process of fragmentation and re-formation is impacting on CPD for schools and teachers is a pressing concern. The EQuaLLS project will focus on \u2018local learning systems\u2019 (LLS): place-based localities encompassing a mix of school structures and hub arrangements for teacher CPD.\n\nUsing primary mathematics as a case study, we will research 'to what extent, and how, do LLS operate to provide high quality, inclusive professional learning for schools?' In four phases, we will: i) harness existing knowledge; ii) identify three representative localities and 18 schools for study; iii) investigate equity and quality of primary mathematics CPD; and iv) analyse findings, identify implications and disseminate these widely.\n\nThe findings will inform policy and practice, helping school and system leaders to shape and navigate high quality, inclusive and effective local CPD systems.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":132988,"Financial Year":"2020/21","Lead Applicant":"Prof Toby Greany","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Greany","Partnership Value":132988,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Nottingham","name":"University of Nottingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Nottingham\", \"360G-Wellcome-ORG:University-of-Nottingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Nottingham","name":"University of Nottingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Equity and quality in local learning systems (EQuaLLS) Schooling in England is complex and evolving. Large-scale academisation has fragmented local landscapes and created multiple models for knowledge exchange, increasing the risk that continuing professional development (CPD) for teachers becomes variable in terms of quality, equity of access, and impact. More recently, national CPD frameworks have been made more coherent, while local areas are being encouraged to coordinate CPD offers through new Teaching School Hubs.\n\nUnderstanding how this systemic process of fragmentation and re-formation is impacting on CPD for schools and teachers is a pressing concern. The EQuaLLS project will focus on \u2018local learning systems\u2019 (LLS): place-based localities encompassing a mix of school structures and hub arrangements for teacher CPD.\n\nUsing primary mathematics as a case study, we will research 'to what extent, and how, do LLS operate to provide high quality, inclusive professional learning for schools?' In four phases, we will: i) harness existing knowledge; ii) identify three representative localities and 18 schools for study; iii) investigate equity and quality of primary mathematics CPD; and iv) analyse findings, identify implications and disseminate these widely.\n\nThe findings will inform policy and practice, helping school and system leaders to shape and navigate high quality, inclusive and effective local CPD systems.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["England","Humans","Learning","School Teachers","Schools","Teacher Training"]}
{"id":"360G-Wellcome-223888_Z_21_Z","title":"Generating collective solutions to reduce unnecessary antibiotic use in Vietnam","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"223888/Z/21/Z","description":"Antibiotic resistance in Vietnam is amongst the highest in the world, driven by high levels of antibiotic use for human and animal health. Community understanding and perceptions about antibiotics and antibiotic resistance is poor, and antibiotics are often prescribed inappropriately in healthcare settings. There is limited evidence for the effectiveness of public engagement approaches to promote appropriate antibiotic use, compared to more traditional education-based methods, or for understanding the pathways and facilitating conditions for successful behaviour change.\n\nWe will facilitate community-wide change in the way people prescribe and use antibiotics for human and animal health. We will compare three different One Health approaches to change behaviour: training for human and animal health-workers; a public information campaign for communities and farmers; and participatory action research groups. Activators in communities and healthcare settings will guide groups through a four-phase action cycle similar to Wellcome\u2019s Responsive Dialogues approach, covering: 1. Understanding the problem of antibiotic resistance; 2. Planning and implementing strategies; 3. Monitoring strategies and generating evidence; 4. Evaluating strategies and planning future actions. We will evaluate the impact on knowledge and behaviour through qualitative and quantitative methods. We will engage local researchers and policymakers through formative discussions and dissemination meetings.\n","plannedDates":[{"endDate":"2023-06-30T00:00:00+00:00","startDate":"2021-10-01T00:00:00+00:00","startDateDateOnly":"2021-10-01","endDateDateOnly":"2023-06-30"}],"amountAwarded":140158,"Financial Year":"2020/21","Lead Applicant":"Dr Sonia Lewycka","grantProgramme":[{"title":"Discretionary Award - Public Engagement","title_keyword":"Discretionary Award - Public Engagement"}],"Applicant Surname":"Lewycka","Partnership Value":140158,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Generating collective solutions to reduce unnecessary antibiotic use in Vietnam Antibiotic resistance in Vietnam is amongst the highest in the world, driven by high levels of antibiotic use for human and animal health. Community understanding and perceptions about antibiotics and antibiotic resistance is poor, and antibiotics are often prescribed inappropriately in healthcare settings. There is limited evidence for the effectiveness of public engagement approaches to promote appropriate antibiotic use, compared to more traditional education-based methods, or for understanding the pathways and facilitating conditions for successful behaviour change.\n\nWe will facilitate community-wide change in the way people prescribe and use antibiotics for human and animal health. We will compare three different One Health approaches to change behaviour: training for human and animal health-workers; a public information campaign for communities and farmers; and participatory action research groups. Activators in communities and healthcare settings will guide groups through a four-phase action cycle similar to Wellcome\u2019s Responsive Dialogues approach, covering: 1. Understanding the problem of antibiotic resistance; 2. Planning and implementing strategies; 3. Monitoring strategies and generating evidence; 4. Evaluating strategies and planning future actions. We will evaluate the impact on knowledge and behaviour through qualitative and quantitative methods. We will engage local researchers and policymakers through formative discussions and dissemination meetings.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Anti-Bacterial Agents","Drug Resistance, Microbial","Health Knowledge, Attitudes, Practice","Humans","Vietnam"]}
{"id":"360G-Wellcome-223801_Z_21_A","title":"Neuromatch Summer Academy","Region":"International","currency":"GBP","awardDate":"2021-04-30T00:00:00+00:00","Internal ID":"223801/Z/21/A","description":"Not available","plannedDates":[{"endDate":"2021-08-05T00:00:00+00:00","startDate":"2021-07-05T00:00:00+00:00","startDateDateOnly":"2021-07-05","endDateDateOnly":"2021-08-05"}],"amountAwarded":20000,"Financial Year":"2020/21","Lead Applicant":"Dr G. Sean Escola","grantProgramme":[{"title":"Strategic Support: Science","title_keyword":"Strategic Support: Science"}],"Applicant Surname":"Escola","Partnership Value":20000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Neuromatch-Academy-Inc","name":"Neuromatch Academy, Inc","addressCountry":"United States","id_and_name":"[\"Neuromatch Academy, Inc\", \"360G-Wellcome-ORG:Neuromatch-Academy-Inc\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Neuromatch-Academy-Inc","name":"Neuromatch Academy, Inc"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Neuromatch Summer Academy Not available","awardDateDateOnly":"2021-04-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","History, 20th Century","Humans"]}
{"id":"360G-Wellcome-223777_Z_21_Z","title":"My Planet Now","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"223777/Z/21/Z","description":"My Planet Now is a cinematic short film and feature documentary for worldwide release that seek to break new ground and provide a genuine moment of global coming together on the climate crisis. \n\nThe films will tell the global story of the climate crisis in a uniquely human way by inviting ordinary citizens from around the world to film and share their personal stories of their relationship to the planet and experience of climate change. By making these people our co-directors and enabling viewers to experience the world through them, they will offer a sense of connection to the crisis that is unfiltered, intimate and immediate \u2013 strikingly different from typical climate crisis documentaries. \n\nThe films will marry stories from the frontlines with stories that offer hope and offer a constructive way forward. Critically, they will also bring attention, insight and understanding to the relationship between health and climate, in alignment with Wellcome\u2019s strategic objectives. \n\nThe feature documentary\u2019s large-scale, multi-pronged impact campaign will target global and national decision-makers, key stakeholders and the public (including specific target communities). A central theme will be the relationship between climate and health, and we have enjoyed positive initial discussions with WHO about this prospect.\n \n","plannedDates":[{"endDate":"2021-09-15T00:00:00+00:00","startDate":"2021-05-16T00:00:00+00:00","startDateDateOnly":"2021-05-16","endDateDateOnly":"2021-09-15"}],"amountAwarded":35000,"Financial Year":"2020/21","Lead Applicant":"Mr Henry Singer","grantProgramme":[{"title":"Discretionary Award - Public Engagement","title_keyword":"Discretionary Award - Public Engagement"}],"Applicant Surname":"Singer","Partnership Value":35000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Sandpaper-Films","name":"Sandpaper Films","addressCountry":"United Kingdom","id_and_name":"[\"Sandpaper Films\", \"360G-Wellcome-ORG:Sandpaper-Films\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Sandpaper-Films","name":"Sandpaper Films"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"My Planet Now My Planet Now is a cinematic short film and feature documentary for worldwide release that seek to break new ground and provide a genuine moment of global coming together on the climate crisis. \n\nThe films will tell the global story of the climate crisis in a uniquely human way by inviting ordinary citizens from around the world to film and share their personal stories of their relationship to the planet and experience of climate change. By making these people our co-directors and enabling viewers to experience the world through them, they will offer a sense of connection to the crisis that is unfiltered, intimate and immediate \u2013 strikingly different from typical climate crisis documentaries. \n\nThe films will marry stories from the frontlines with stories that offer hope and offer a constructive way forward. Critically, they will also bring attention, insight and understanding to the relationship between health and climate, in alignment with Wellcome\u2019s strategic objectives. \n\nThe feature documentary\u2019s large-scale, multi-pronged impact campaign will target global and national decision-makers, key stakeholders and the public (including specific target communities). A central theme will be the relationship between climate and health, and we have enjoyed positive initial discussions with WHO about this prospect.\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Climate Change","Decision Making","Disasters","Humans"]}
{"id":"360G-Wellcome-223771_Z_21_Z","title":"Mental Health Science Summit Bursaries","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"223771/Z/21/Z","description":"The MQ Mental Health Science Summit, in collaboration with Wellcome, is an interdisciplinary mental health science conference. It brings together people from all disciplines and sectors, focused on transforming mental health. Key to this is the involvement of people with lived experience of mental illness, early career researchers, and delegates from LMICs. \n\nAttendance at the Summit is ticketed. Many delegates are attending in a work capacity, and so are both salaried and have their costs covered by their organisation. For certain groups of key delegates, the ticket price is prohibitive. This is particularly true for people with lived experience who often attend such events in a voluntary capacity and some of whom are insecurely employed, early career researchers who often do not have research grants available to cover conference attendance, and delegates from LMICs who are economically less able to have such funds available. \n\nFollowing Wellcome' Cat Sebastian\u2019s contributions to the organising committee, we are applying for \u00a34,000 to enable subsidised places for delegates from these three groups to attend the Summit. This will enable 30 delegates to attend. Aa agreed, any funds not spent on bursaries for this year\u2019s Summit will be used to widen access at subsequent events.\n","plannedDates":[{"endDate":"2021-06-11T00:00:00+00:00","startDate":"2021-05-12T00:00:00+00:00","startDateDateOnly":"2021-05-12","endDateDateOnly":"2021-06-11"}],"amountAwarded":6880,"Financial Year":"2020/21","Lead Applicant":"Ms Emily Wheeler","grantProgramme":[{"title":"Discretionary Award - Mental Health","title_keyword":"Discretionary Award - Mental Health"}],"Applicant Surname":"Wheeler","Partnership Value":6880,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:MQ-Transforming-Mental-Health","name":"MQ Transforming Mental Health","addressCountry":"United Kingdom","id_and_name":"[\"MQ Transforming Mental Health\", \"360G-Wellcome-ORG:MQ-Transforming-Mental-Health\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:MQ-Transforming-Mental-Health","name":"MQ Transforming Mental Health"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mental Health Science Summit Bursaries The MQ Mental Health Science Summit, in collaboration with Wellcome, is an interdisciplinary mental health science conference. It brings together people from all disciplines and sectors, focused on transforming mental health. Key to this is the involvement of people with lived experience of mental illness, early career researchers, and delegates from LMICs. \n\nAttendance at the Summit is ticketed. Many delegates are attending in a work capacity, and so are both salaried and have their costs covered by their organisation. For certain groups of key delegates, the ticket price is prohibitive. This is particularly true for people with lived experience who often attend such events in a voluntary capacity and some of whom are insecurely employed, early career researchers who often do not have research grants available to cover conference attendance, and delegates from LMICs who are economically less able to have such funds available. \n\nFollowing Wellcome' Cat Sebastian\u2019s contributions to the organising committee, we are applying for \u00a34,000 to enable subsidised places for delegates from these three groups to attend the Summit. This will enable 30 delegates to attend. Aa agreed, any funds not spent on bursaries for this year\u2019s Summit will be used to widen access at subsequent events.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Congresses as Topic","Humans","Mental Disorders","Mental Health","Mental Health Services"]}
{"id":"360G-Wellcome-223770_Z_21_Z","title":"Accelerating Drug Discovery with Symbolic-Numerics in SciML","Region":"International","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"223770/Z/21/Z","description":"Pharmaceutical companies understand the need for modeling stochasticity, by which we can improve the reliability and effectiveness of drugs across the whole population. Our 2020 review in Trends in Pharmacological Sciences, one of the highest impact journals in pharmacology, argued that deterministic models that ignore stochasticity bias clinical and pre-clinical trial analyses. The quantitative systems pharmacology (QSP) groups within drug companies are the core units that model and predict patient outcomes, dramatically reducing the research and development timeline by predicting which drugs will fail before clinical trials begin. These groups have recently adopted stochastic dynamical models in order to better achieve their goals. Discussing with CJ Musante, Global Head of Pharmacology at Pfizer, the main reason that stochastic models are not more widely used is due to a lack of software that addresses the needs of QSP modelers. Stochastic models are more predictive of patient outcomes, but computationally expensive. Moreover, turnaround times needed by QSP teams are too short to make use of stochastic models with current software. This proposal addresses this problem, proposing to build software tooling which automates the construction and solution of stochastic models in a way that is orders of magnitude faster than what exists today.\n","plannedDates":[{"endDate":"2022-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2022-08-31"}],"amountAwarded":98806,"Financial Year":"2020/21","Lead Applicant":"Prof Samuel Isaacson","grantProgramme":[{"title":"Discretionary Award \u2013 DSH","title_keyword":"Discretionary Award \u2013 DSH"}],"Applicant Surname":"Isaacson","Partnership Value":98806,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Boston-University","name":"Boston University","addressCountry":"United States","id_and_name":"[\"Boston University\", \"360G-Wellcome-ORG:Boston-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Boston-University","name":"Boston University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Accelerating Drug Discovery with Symbolic-Numerics in SciML Pharmaceutical companies understand the need for modeling stochasticity, by which we can improve the reliability and effectiveness of drugs across the whole population. Our 2020 review in Trends in Pharmacological Sciences, one of the highest impact journals in pharmacology, argued that deterministic models that ignore stochasticity bias clinical and pre-clinical trial analyses. The quantitative systems pharmacology (QSP) groups within drug companies are the core units that model and predict patient outcomes, dramatically reducing the research and development timeline by predicting which drugs will fail before clinical trials begin. These groups have recently adopted stochastic dynamical models in order to better achieve their goals. Discussing with CJ Musante, Global Head of Pharmacology at Pfizer, the main reason that stochastic models are not more widely used is due to a lack of software that addresses the needs of QSP modelers. Stochastic models are more predictive of patient outcomes, but computationally expensive. Moreover, turnaround times needed by QSP teams are too short to make use of stochastic models with current software. This proposal addresses this problem, proposing to build software tooling which automates the construction and solution of stochastic models in a way that is orders of magnitude faster than what exists today.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Clinical Trials as Topic","Drug Discovery","Humans","Software","Stochastic Processes"]}
{"id":"360G-Wellcome-223762_Z_21_Z","title":"Exploring options for government support for charity-funded medical research","Region":"Greater London","currency":"GBP","awardDate":"2021-05-31T00:00:00+00:00","Internal ID":"223762/Z/21/Z","description":"Not available","plannedDates":[{"endDate":"2021-07-19T00:00:00+00:00","startDate":"2021-05-07T00:00:00+00:00","startDateDateOnly":"2021-05-07","endDateDateOnly":"2021-07-19"}],"amountAwarded":30000,"Financial Year":"2020/21","Lead Applicant":"Dr Catriona Manville","grantProgramme":[{"title":"Discretionary Award - Policy ","title_keyword":"Discretionary Award - Policy "}],"Applicant Surname":"Manville","Partnership Value":30000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Association-of-Medical-Research-Charities","name":"Association of Medical Research Charities","addressCountry":"United Kingdom","id_and_name":"[\"Association of Medical Research Charities\", \"360G-Wellcome-ORG:Association-of-Medical-Research-Charities\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Association-of-Medical-Research-Charities","name":"Association of Medical Research Charities"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Exploring options for government support for charity-funded medical research Not available","awardDateDateOnly":"2021-05-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","United States"]}
{"id":"360G-Wellcome-223755_Z_21_Z","title":"Human Cell Atlas 2021 Meetings","Region":"International","currency":"GBP","awardDate":"2021-05-31T00:00:00+00:00","Internal ID":"223755/Z/21/Z","description":"This year\u2019s Human Cell Atlas General Meeting will convene our community virtually to share updates and insights on new HCA research and initiatives, as well as to highlight the work of the HCA Biological Networks and continue to build on progress from the HCA Biological Network Seminar Series. \n\nKey outcomes of this meeting will include a shared appreciation for recent advances and future needs that will facilitate the construction of an integrated atlas; progress toward strategic roadmaps for different organs, tissues, and systems; and an enhanced understanding of how the Human Cell Atlas will provide a healthy reference for the understanding of disease.\n\nEvent Overview\n\nDay 1: Plenary talks and networking opportunities.\nThemes: HCA Overview, Computational Advancements and Cross-Cutting Approaches\n\nDay 2: Poster viewings, biological network interactive sessions, and breakout sessions.\nTheme: HCA Biological Network updates, and plan to organize to build out roadmaps.\n\nDay 3: Plenary talks, panel discussions and networking opportunities.\nTheme: HCA and Disease Impact, and Defining 10-year plan.\n\nA portion of the requested funds will also provide partial support for the 2021 HCA Asia General Meeting, to be held in November or December 2021.\n","plannedDates":[{"endDate":"2022-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2022-06-30"}],"amountAwarded":39724,"Financial Year":"2020/21","Lead Applicant":"Dr John Randell","grantProgramme":[{"title":"Strategic Support: Science","title_keyword":"Strategic Support: Science"}],"Applicant Surname":"Randell","Partnership Value":39724,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Human-Cell-Atlas-Incorporated","name":"Human Cell Atlas, Incorporated","addressCountry":"United States","id_and_name":"[\"Human Cell Atlas, Incorporated\", \"360G-Wellcome-ORG:Human-Cell-Atlas-Incorporated\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Human-Cell-Atlas-Incorporated","name":"Human Cell Atlas, Incorporated"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Human Cell Atlas 2021 Meetings This year\u2019s Human Cell Atlas General Meeting will convene our community virtually to share updates and insights on new HCA research and initiatives, as well as to highlight the work of the HCA Biological Networks and continue to build on progress from the HCA Biological Network Seminar Series. \n\nKey outcomes of this meeting will include a shared appreciation for recent advances and future needs that will facilitate the construction of an integrated atlas; progress toward strategic roadmaps for different organs, tissues, and systems; and an enhanced understanding of how the Human Cell Atlas will provide a healthy reference for the understanding of disease.\n\nEvent Overview\n\nDay 1: Plenary talks and networking opportunities.\nThemes: HCA Overview, Computational Advancements and Cross-Cutting Approaches\n\nDay 2: Poster viewings, biological network interactive sessions, and breakout sessions.\nTheme: HCA Biological Network updates, and plan to organize to build out roadmaps.\n\nDay 3: Plenary talks, panel discussions and networking opportunities.\nTheme: HCA and Disease Impact, and Defining 10-year plan.\n\nA portion of the requested funds will also provide partial support for the 2021 HCA Asia General Meeting, to be held in November or December 2021.\n","awardDateDateOnly":"2021-05-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Atlases as Topic","Humans"]}
{"id":"360G-Wellcome-223695_Z_21_Z","title":"Reading Health in the Collections of the Museum of the Home","Region":"Greater London","currency":"GBP","awardDate":"2021-06-18T00:00:00+00:00","Internal ID":"223695/Z/21/Z","description":"This project will examine some of the many links that exist between reading and domestic healing in the collection of the Museum of the Home. The focus of the project will be the under-utilised collection of books relating to health and the domestic environment, dating from the seventeenth to twentieth centuries. For many, the primary location of their experiences of health and ill health was the home; in this context, the reader was the \u2018patient\u2019 and the book took the place of a medical practitioner. How were these texts intended to impact their readers\u2019 domestic practices and their wellbeing \u2013 and how did readers interact with these texts? Influenced by Roy Porter\u2019s \u2018Doing Medical History from Below\u2019, I will examine the intimate relationships between medical books and their readers, focusing on the \u2018patient\u2019s\u2019 experience. Research produced during the Fellowship will inform a gallery redisplay, in addition to providing material for future development of the Rooms through Time galleries. The project will connect a wider audience of museum visitors to these stories through accessible written content as well as the Museum\u2019s public engagement programmes, encouraging understanding of and reflection on a shared history of domestic health.\n","plannedDates":[{"endDate":"2022-03-19T00:00:00+00:00","startDate":"2021-09-20T00:00:00+00:00","startDateDateOnly":"2021-09-20","endDateDateOnly":"2022-03-19"}],"amountAwarded":13029,"Financial Year":"2020/21","Lead Applicant":"Ms Laura Blair","grantProgramme":[{"title":"WT/POST Fellowship","title_keyword":"WT/POST Fellowship"}],"Applicant Surname":"Blair","Partnership Value":13029,"Approval Committee":"Secondment Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Queen-Mary-University-of-London","name":"Queen Mary University of London","addressCountry":"United Kingdom","id_and_name":"[\"Queen Mary University of London\", \"360G-Wellcome-ORG:Queen-Mary-University-of-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Queen-Mary-University-of-London","name":"Queen Mary University of London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Reading Health in the Collections of the Museum of the Home This project will examine some of the many links that exist between reading and domestic healing in the collection of the Museum of the Home. The focus of the project will be the under-utilised collection of books relating to health and the domestic environment, dating from the seventeenth to twentieth centuries. For many, the primary location of their experiences of health and ill health was the home; in this context, the reader was the \u2018patient\u2019 and the book took the place of a medical practitioner. How were these texts intended to impact their readers\u2019 domestic practices and their wellbeing \u2013 and how did readers interact with these texts? Influenced by Roy Porter\u2019s \u2018Doing Medical History from Below\u2019, I will examine the intimate relationships between medical books and their readers, focusing on the \u2018patient\u2019s\u2019 experience. Research produced during the Fellowship will inform a gallery redisplay, in addition to providing material for future development of the Rooms through Time galleries. The project will connect a wider audience of museum visitors to these stories through accessible written content as well as the Museum\u2019s public engagement programmes, encouraging understanding of and reflection on a shared history of domestic health.\n","awardDateDateOnly":"2021-06-18","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Museums"]}
{"id":"360G-Wellcome-223690_Z_21_Z","title":"The New Jerusalems: post-war New Town archives in Britain and Ireland","Region":"South East","currency":"GBP","awardDate":"2021-05-20T00:00:00+00:00","Internal ID":"223690/Z/21/Z","description":"The project will make accessible for research eleven archives from post-war new towns in England, Wales and Ireland.  Eight of these archives will be catalogued and all will be safeguarded through conservation and preservation work.  The new towns included are: Basildon, Bracknell, Crawley, Cwmbran, Newton Aycliffe, Peterlee, Redditch, Runcorn, Shannon, Stevenage and Warrington.\n\nThe archives are held by nine partner organisations brought together through the Association of New Towns Archives and Museums.  The Association builds on existing academic partnerships, and this project will develop those further.  Key outcomes include not only itemised catalogues and protected collections, but also a collaborative dissemination programme.\n\nThis project will provide a substantial increase in the evidence base available for researchers seeking to interrogate the new towns\u2019 legacy. The project is particularly timely in the context of the current public health emergency.  New towns have much to contribute to current policy making in urban planning and public health including: new homes to reduce overcrowding; generous public green space; amenities within 15 minutes of the home; and supporting walking and cycling. There is renewed interest in many aspects of new town design as plans are made for social recovery in the aftermath of Covid-19. \n \n","plannedDates":[{"endDate":"2025-10-31T00:00:00+00:00","startDate":"2021-11-01T00:00:00+00:00","startDateDateOnly":"2021-11-01","endDateDateOnly":"2025-10-31"}],"amountAwarded":427809,"Financial Year":"2020/21","Lead Applicant":"Mrs Wendy Walker","grantProgramme":[{"title":"Research Resources Award","title_keyword":"Research Resources Award"}],"Applicant Surname":"Walker","Partnership Value":427809,"Approval Committee":"Research Resources Committee","Other Applicant(s)":"Dr Kirsten Mulrennan, Mr Mark Stevens, Ms Liz Bregazzi, Mr Christopher Bennett, Mr Richard Anderson, Dr Lisa Snook, Ms Claire Haslam, Ms Lisa Greenhalgh","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:West-Sussex-County-Council","name":"West Sussex County Council","addressCountry":"United Kingdom","id_and_name":"[\"West Sussex County Council\", \"360G-Wellcome-ORG:West-Sussex-County-Council\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:West-Sussex-County-Council","name":"West Sussex County Council"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The New Jerusalems: post-war New Town archives in Britain and Ireland The project will make accessible for research eleven archives from post-war new towns in England, Wales and Ireland.  Eight of these archives will be catalogued and all will be safeguarded through conservation and preservation work.  The new towns included are: Basildon, Bracknell, Crawley, Cwmbran, Newton Aycliffe, Peterlee, Redditch, Runcorn, Shannon, Stevenage and Warrington.\n\nThe archives are held by nine partner organisations brought together through the Association of New Towns Archives and Museums.  The Association builds on existing academic partnerships, and this project will develop those further.  Key outcomes include not only itemised catalogues and protected collections, but also a collaborative dissemination programme.\n\nThis project will provide a substantial increase in the evidence base available for researchers seeking to interrogate the new towns\u2019 legacy. The project is particularly timely in the context of the current public health emergency.  New towns have much to contribute to current policy making in urban planning and public health including: new homes to reduce overcrowding; generous public green space; amenities within 15 minutes of the home; and supporting walking and cycling. There is renewed interest in many aspects of new town design as plans are made for social recovery in the aftermath of Covid-19. \n \n","awardDateDateOnly":"2021-05-20","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["England","History, 20th Century","Humans","Ireland","United Kingdom","Wales"]}
{"id":"360G-Wellcome-223679_Z_21_Z","title":"Mass-Observing Covid-19","Region":"South East","currency":"GBP","awardDate":"2021-05-20T00:00:00+00:00","Internal ID":"223679/Z/21/Z","description":"Mass-Observation (M-O) has been recording everyday life in Britain since 1937. Since the start of the Covid-19 crisis, we have collected over 8500 pieces of narrative life writing, ranging in format from open-questionnaire responses and day diaries to diaries kept for several months by self-selecting volunteers of all ages from around the UK. This unique set of large-scale qualitative data offers extensive research value and potential to contextualise quantitative data generated throughout the pandemic. \n\nThis project will open up the extensive collections of qualitative data relating to the impact of Covid-19 on the mental and physical health and social welfare of volunteer writers around the UK. We will build a tool for discovery and exploration that allows researchers to interrogate these collections. \n\nA database will comprise metadata on the writers and writing that enables researchers across disciplines to interrogate the content of the data, thereby contributing to our understanding of the social and personal impact on UK health and wellbeing during the Covid-19 pandemic. The tool is designed to open up access to the texts that have been submitted, allowing researchers to select relevant materials and export the data into their own choice of research tools for analysis. \n","plannedDates":[{"endDate":"2023-04-30T00:00:00+00:00","startDate":"2021-11-01T00:00:00+00:00","startDateDateOnly":"2021-11-01","endDateDateOnly":"2023-04-30"}],"amountAwarded":180137,"Financial Year":"2020/21","Lead Applicant":"Dr Fiona Courage","grantProgramme":[{"title":"Research Resources Award","title_keyword":"Research Resources Award"}],"Applicant Surname":"Courage","Partnership Value":180137,"Approval Committee":"Research Resources Committee","Other Applicant(s)":"Ms Kirsty Pattrick","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Sussex","name":"University of Sussex","addressCountry":"United Kingdom","id_and_name":"[\"University of Sussex\", \"360G-Wellcome-ORG:University-of-Sussex\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Sussex","name":"University of Sussex"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mass-Observing Covid-19 Mass-Observation (M-O) has been recording everyday life in Britain since 1937. Since the start of the Covid-19 crisis, we have collected over 8500 pieces of narrative life writing, ranging in format from open-questionnaire responses and day diaries to diaries kept for several months by self-selecting volunteers of all ages from around the UK. This unique set of large-scale qualitative data offers extensive research value and potential to contextualise quantitative data generated throughout the pandemic. \n\nThis project will open up the extensive collections of qualitative data relating to the impact of Covid-19 on the mental and physical health and social welfare of volunteer writers around the UK. We will build a tool for discovery and exploration that allows researchers to interrogate these collections. \n\nA database will comprise metadata on the writers and writing that enables researchers across disciplines to interrogate the content of the data, thereby contributing to our understanding of the social and personal impact on UK health and wellbeing during the Covid-19 pandemic. The tool is designed to open up access to the texts that have been submitted, allowing researchers to select relevant materials and export the data into their own choice of research tools for analysis. \n","awardDateDateOnly":"2021-05-20","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Databases, Factual","Humans","Mental Health","Narration","Surveys and Questionnaires","United Kingdom","Writing"]}
{"id":"360G-Wellcome-223678_Z_21_Z","title":"Incorporating the Social Dimension of Pollution and Health into UNEP's Programmes and Mid-Term Strategy","Region":"South East","currency":"GBP","awardDate":"2021-06-18T00:00:00+00:00","Internal ID":"223678/Z/21/Z","description":"Through a collaboration with the United Nations Environment Programme (UNEP), this 6-month secondment will bring insights from the fields of environmental justice, medical anthropology, and health geography into UNEP\u2019s implementation plan \"Toward a Pollution Free Planet\". The point of departure for this collaboration is premised on an understanding of pollution as embedded in wider processes of industrialisation that causes social fragmentation and a diffused disempowerment of the communities it affects. As this represents an underexplored area of work in international policymaking, this secondment will focus on understanding and proposing implementation pathways that can lead to increased participation of communities in initiatives to curb pollution.\n\nThe outputs produced through this secondment will be integrated within UNEP\u2019s Pollution and Health unit's work on integrated methodologies and tools. The first half of the secondment will be spent conducting a literature review on pollution and community action in the form of a report. The report will focus on identifying the factors that promote and hinder community participation, resilience, and agency. The second half of the secondment will be spent to produce an indicators framework to be utilized to assess the effectiveness of UNEP\u2019s implementation plan in engaging the public and fostering participation and resilience.  \n","plannedDates":[{"endDate":"2022-06-30T00:00:00+00:00","startDate":"2022-01-01T00:00:00+00:00","startDateDateOnly":"2022-01-01","endDateDateOnly":"2022-06-30"}],"amountAwarded":14328,"Financial Year":"2020/21","Lead Applicant":"Mr Angelo Raffaele Ippolito","grantProgramme":[{"title":"WT/POST Fellowship","title_keyword":"WT/POST Fellowship"}],"Applicant Surname":"Ippolito","Partnership Value":14328,"Approval Committee":"Secondment Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Incorporating the Social Dimension of Pollution and Health into UNEP's Programmes and Mid-Term Strategy Through a collaboration with the United Nations Environment Programme (UNEP), this 6-month secondment will bring insights from the fields of environmental justice, medical anthropology, and health geography into UNEP\u2019s implementation plan \"Toward a Pollution Free Planet\". The point of departure for this collaboration is premised on an understanding of pollution as embedded in wider processes of industrialisation that causes social fragmentation and a diffused disempowerment of the communities it affects. As this represents an underexplored area of work in international policymaking, this secondment will focus on understanding and proposing implementation pathways that can lead to increased participation of communities in initiatives to curb pollution.\n\nThe outputs produced through this secondment will be integrated within UNEP\u2019s Pollution and Health unit's work on integrated methodologies and tools. The first half of the secondment will be spent conducting a literature review on pollution and community action in the form of a report. The report will focus on identifying the factors that promote and hinder community participation, resilience, and agency. The second half of the secondment will be spent to produce an indicators framework to be utilized to assess the effectiveness of UNEP\u2019s implementation plan in engaging the public and fostering participation and resilience.  \n","awardDateDateOnly":"2021-06-18","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Environment","Environmental Pollution","Humans","Public Health","Social Justice"]}
{"id":"360G-Wellcome-223675_Z_21_Z","title":"The Archive of Tomorrow: Health Information and Misinformation in the UK Web Archive","Region":"Scotland","currency":"GBP","awardDate":"2021-05-20T00:00:00+00:00","Internal ID":"223675/Z/21/Z","description":"This pilot project will preserve and provide research access to 10,000 websites relating to health information (and misinformation), and will use this collection to enable more health research on the UK Web Archive.\n\nOur project brings together four co-applicant institutions, and a network of other organisations and researchers, to tackle one of the most pressing research issues of our time: how can the story of changing online health information be captured and understood?\n\nDuring the Covid-19 pandemic, online health advice, data and scientific evidence have been contested, revised, used and mis-used with global consequences \u2013 but the digital record of this activity is fragile and hard to access.\n\nWe will:\n\n\n Curate a new research-ready collection of websites within the UKWA, with the theme of Health Information and Misinformation, ensuring a wide representation of diverse and otherwise under-collected sources.\n Use this collection as a test-bed to explore options for metadata, computational analysis, ethics and rights issues.\n Build a research network across disciplines including use cases, involving researchers in the process of building, evaluating and using collections.\n Produce a project report with recommendations for future work and advocacy for change to make web archives more representative, inclusive and open for health research.\n\n","plannedDates":[{"endDate":"2023-01-31T00:00:00+00:00","startDate":"2021-12-01T00:00:00+00:00","startDateDateOnly":"2021-12-01","endDateDateOnly":"2023-01-31"}],"amountAwarded":230958,"Financial Year":"2020/21","Lead Applicant":"Dr Joseph Marshall","grantProgramme":[{"title":"Research Resources Award","title_keyword":"Research Resources Award"}],"Applicant Surname":"Marshall","Partnership Value":230958,"Approval Committee":"Research Resources Committee","Other Applicant(s)":"Ms Caylin Smith, Ms Sara Thomson, Ms Susan Thomas","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:National-Library-of-Scotland","name":"National Library of Scotland","addressCountry":"United Kingdom","id_and_name":"[\"National Library of Scotland\", \"360G-Wellcome-ORG:National-Library-of-Scotland\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:National-Library-of-Scotland","name":"National Library of Scotland"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The Archive of Tomorrow: Health Information and Misinformation in the UK Web Archive This pilot project will preserve and provide research access to 10,000 websites relating to health information (and misinformation), and will use this collection to enable more health research on the UK Web Archive.\n\nOur project brings together four co-applicant institutions, and a network of other organisations and researchers, to tackle one of the most pressing research issues of our time: how can the story of changing online health information be captured and understood?\n\nDuring the Covid-19 pandemic, online health advice, data and scientific evidence have been contested, revised, used and mis-used with global consequences \u2013 but the digital record of this activity is fragile and hard to access.\n\nWe will:\n\n\n Curate a new research-ready collection of websites within the UKWA, with the theme of Health Information and Misinformation, ensuring a wide representation of diverse and otherwise under-collected sources.\n Use this collection as a test-bed to explore options for metadata, computational analysis, ethics and rights issues.\n Build a research network across disciplines including use cases, involving researchers in the process of building, evaluating and using collections.\n Produce a project report with recommendations for future work and advocacy for change to make web archives more representative, inclusive and open for health research.\n\n","awardDateDateOnly":"2021-05-20","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Information Dissemination","Internet","Pilot Projects","United Kingdom"]}
{"id":"360G-Wellcome-223672_Z_21_Z","title":"Public Health Animation in Leeds","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2021-05-20T00:00:00+00:00","Internal ID":"223672/Z/21/Z","description":"Leeds Animation Workshop (LAW) is a not-for-profit cooperative company established in 1978 and run by women. It produces and distributes animated films on social, health and educational issues, with international distribution. Subjects include childcare, violence against women, bereavement, child protection, parenting and relationships, gender and equal opportunities, bullying and homelessness. LAW has created films for audiences with learning difficulties and provides training in basic animation for adults and young people.\n\nThe LAW archive is a unique survival. It is the only complete archive of a collective independent filmmaking organisation. The archive is key to understanding the production of public information films and provides a counterpoint to \u2018establishment\u2019 films of the period. This is an essential national and international resource for exploring intersections between feminist activism, creative practice, and public health information.\n\nThe project will:\n\n\n Secure the archive in a publicly accessible repository, appraised, organised and repackaged to archival standards.\n Create an online catalogue with detailed index points to enable network mapping and exploration.\n Showcase interdisciplinary research opportunities, and create new research networks through the University of Leeds and beyond.\n Embed the archive in research led teaching and lifelong learning, including online delivery.\n\n","plannedDates":[{"endDate":"2024-05-09T00:00:00+00:00","startDate":"2022-01-10T00:00:00+00:00","startDateDateOnly":"2022-01-10","endDateDateOnly":"2024-05-09"}],"amountAwarded":113611,"Financial Year":"2020/21","Lead Applicant":"Ms Joanne Fitton","grantProgramme":[{"title":"Research Resources Award","title_keyword":"Research Resources Award"}],"Applicant Surname":"Fitton","Partnership Value":113611,"Approval Committee":"Research Resources Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds","addressCountry":"United Kingdom","id_and_name":"[\"University of Leeds\", \"360G-Wellcome-ORG:University-of-Leeds\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Public Health Animation in Leeds Leeds Animation Workshop (LAW) is a not-for-profit cooperative company established in 1978 and run by women. It produces and distributes animated films on social, health and educational issues, with international distribution. Subjects include childcare, violence against women, bereavement, child protection, parenting and relationships, gender and equal opportunities, bullying and homelessness. LAW has created films for audiences with learning difficulties and provides training in basic animation for adults and young people.\n\nThe LAW archive is a unique survival. It is the only complete archive of a collective independent filmmaking organisation. The archive is key to understanding the production of public information films and provides a counterpoint to \u2018establishment\u2019 films of the period. This is an essential national and international resource for exploring intersections between feminist activism, creative practice, and public health information.\n\nThe project will:\n\n\n Secure the archive in a publicly accessible repository, appraised, organised and repackaged to archival standards.\n Create an online catalogue with detailed index points to enable network mapping and exploration.\n Showcase interdisciplinary research opportunities, and create new research networks through the University of Leeds and beyond.\n Embed the archive in research led teaching and lifelong learning, including online delivery.\n\n","awardDateDateOnly":"2021-05-20","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Public Health"]}
{"id":"360G-Wellcome-223661_Z_21_Z","title":"Curious cures: enhancing the discoverability of medieval medical recipes","Region":"East of England","currency":"GBP","awardDate":"2021-05-20T00:00:00+00:00","Internal ID":"223661/Z/21/Z","description":"This two-year, collaborative project will open up to health researchers worldwide 187 medieval manuscripts containing medical recipes across Cambridge collections, and the currently inaccessible corpus of approximately 8000 Latin and Middle English medical recipes that they contain.\n\n \n\nA combined programme of manuscript digitisation, cataloguing and conservation will provide multiple points of entry.  Researchers will see recipes in their original form: through high-resolution images viewable via the Cambridge Digital Library (CUDL), and medium-resolution images available for free download and reuse via CUDL and International Image Interoperability Framework (IIIF) manifests.\n\n \n\nFully searchable XML descriptions of the manuscripts\u2019 contents, physical characteristics, and histories will be published alongside, revealing the intellectual and material contexts in which these texts were circulated and received.  Adhering to interoperable TEI guidelines, these descriptions will facilitate cross-collection discovery, building strong links with comparable manuscripts in Oxford and Manchester.\n\n \n\nHyperdiplomatic transcriptions, created using Transkribus, will provide a level of detail unmatched by existing finding aids, enabling keyword searching and granular, computational analysis of the recipes.  The project will empower other organisations to undertake similar work with their collections by creating a robust and extensible methodology, and disseminating it through a website, workshops and symposium for researchers, curators and libraries.\n","plannedDates":[{"endDate":"2024-02-29T00:00:00+00:00","startDate":"2022-03-01T00:00:00+00:00","startDateDateOnly":"2022-03-01","endDateDateOnly":"2024-02-29"}],"amountAwarded":493456,"Financial Year":"2020/21","Lead Applicant":"Dr James Freeman","grantProgramme":[{"title":"Research Resources Award","title_keyword":"Research Resources Award"}],"Applicant Surname":"Freeman","Partnership Value":493456,"Approval Committee":"Research Resources Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Curious cures: enhancing the discoverability of medieval medical recipes This two-year, collaborative project will open up to health researchers worldwide 187 medieval manuscripts containing medical recipes across Cambridge collections, and the currently inaccessible corpus of approximately 8000 Latin and Middle English medical recipes that they contain.\n\n \n\nA combined programme of manuscript digitisation, cataloguing and conservation will provide multiple points of entry.  Researchers will see recipes in their original form: through high-resolution images viewable via the Cambridge Digital Library (CUDL), and medium-resolution images available for free download and reuse via CUDL and International Image Interoperability Framework (IIIF) manifests.\n\n \n\nFully searchable XML descriptions of the manuscripts\u2019 contents, physical characteristics, and histories will be published alongside, revealing the intellectual and material contexts in which these texts were circulated and received.  Adhering to interoperable TEI guidelines, these descriptions will facilitate cross-collection discovery, building strong links with comparable manuscripts in Oxford and Manchester.\n\n \n\nHyperdiplomatic transcriptions, created using Transkribus, will provide a level of detail unmatched by existing finding aids, enabling keyword searching and granular, computational analysis of the recipes.  The project will empower other organisations to undertake similar work with their collections by creating a robust and extensible methodology, and disseminating it through a website, workshops and symposium for researchers, curators and libraries.\n","awardDateDateOnly":"2021-05-20","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["History, Medieval","Humans"]}
{"id":"360G-Wellcome-223653_Z_21_Z","title":"Exploring Disability: an archive and history of disabled people\u2019s experience of disability and the journey from a medical to a social model perspective.","Region":"North East","currency":"GBP","awardDate":"2021-05-20T00:00:00+00:00","Internal ID":"223653/Z/21/Z","description":"The GMCDP archive collection reveals the changing perspectives, language and attitudes towards disabled people that have occurred over recent decades. It highlights changes in medical practices, discussions and debates around bio-ethics and end of life issues, campaigns for independent living, the self-organisation of disabled people, development of disability culture, and the significant impact of wider health determinants (education, income/poverty levels, employment, housing etc). The GMCDP Archive is the largest, most comprehensive archive of the lives and experience of disabled people and the activism in England (JT Assessment)\n\nThe project will:\n\n\n Work with Archives+ to catalogue and classify the collection.\n Make the catalogue available online.\n Establish a viable and sustainable system for viewing the collection (providing physical access to research material).\n Make parts of the collection available digitally online (e.g. seminal papers).\n Ensure that all openly available material is presented for viewing in a range of accessible formats and that there is an on-going system in place to transcribe new and/or restricted material. A significant challenge, but essential element of the project.\n Share our learning on making collections fully accessible by developing guidance and toolkits, delivering workshops and training to other collection holders.\n Connect with relevant institutions to promote the resource.\n\n","plannedDates":[{"endDate":"2024-10-14T00:00:00+00:00","startDate":"2021-10-15T00:00:00+00:00","startDateDateOnly":"2021-10-15","endDateDateOnly":"2024-10-14"}],"amountAwarded":308990,"Financial Year":"2020/21","Lead Applicant":"Miss Nicola McDonagh","grantProgramme":[{"title":"Research Resources Award","title_keyword":"Research Resources Award"}],"Applicant Surname":"McDonagh","Partnership Value":308990,"Approval Committee":"Research Resources Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Greater-Manchester-Coalition-of-Disabled-People","name":"Greater Manchester Coalition of Disabled People","addressCountry":"United Kingdom","id_and_name":"[\"Greater Manchester Coalition of Disabled People\", \"360G-Wellcome-ORG:Greater-Manchester-Coalition-of-Disabled-People\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Greater-Manchester-Coalition-of-Disabled-People","name":"Greater Manchester Coalition of Disabled People"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Exploring Disability: an archive and history of disabled people\u2019s experience of disability and the journey from a medical to a social model perspective. The GMCDP archive collection reveals the changing perspectives, language and attitudes towards disabled people that have occurred over recent decades. It highlights changes in medical practices, discussions and debates around bio-ethics and end of life issues, campaigns for independent living, the self-organisation of disabled people, development of disability culture, and the significant impact of wider health determinants (education, income/poverty levels, employment, housing etc). The GMCDP Archive is the largest, most comprehensive archive of the lives and experience of disabled people and the activism in England (JT Assessment)\n\nThe project will:\n\n\n Work with Archives+ to catalogue and classify the collection.\n Make the catalogue available online.\n Establish a viable and sustainable system for viewing the collection (providing physical access to research material).\n Make parts of the collection available digitally online (e.g. seminal papers).\n Ensure that all openly available material is presented for viewing in a range of accessible formats and that there is an on-going system in place to transcribe new and/or restricted material. A significant challenge, but essential element of the project.\n Share our learning on making collections fully accessible by developing guidance and toolkits, delivering workshops and training to other collection holders.\n Connect with relevant institutions to promote the resource.\n\n","awardDateDateOnly":"2021-05-20","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Disabled Persons","England","Humans"]}
{"id":"360G-Wellcome-223651_Z_21_Z","title":"Emergency oxygen response for COVID-19","Region":"International","currency":"GBP","awardDate":"2021-04-30T00:00:00+00:00","Internal ID":"223651/Z/21/Z","description":"The O2 Taskforce is coordinating access to emergency oxygen for COVID-19 patients in LMICs. Since the start of the pandemic, affordable, sustainable access to oxygen has been a growing challenge LMICs. COVID-19 has put huge pressure on health systems, with hospitals running out of oxygen, has resulted in preventable deaths and huge burden on families of hospitalized patients. Oxygen is an essential medicine, and despite being vital for the effective treatment of hospitalized COVID-19 patients, access in LMICs is limited due to cost, infrastructure and logistical barriers. The O2 Taskforce has identified an immediate need of approx. US$ 90 million over the next 1 \u2013 2 months, with a US$1.6 billion need estimated for LMICs over the next 12 months to support.\n\n \n\nThe proposal will secure funding ($10 million) for acute oxygen COVID-19 needs in LMICs as identified by the O2 Taskforce. The funds will support countries to access oxygen and to unlock available resources to build more sustainable, resilient oxygen systems. Activities may include technical assistance for implementation of oxygen services, investments for market interventions and for additional country assessments/development of country funding proposals. This investment is intended to accelerate and amplify the impact of follow on scale-up funding.","plannedDates":[{"endDate":"2022-02-16T00:00:00+00:00","startDate":"2021-05-18T00:00:00+00:00","startDateDateOnly":"2021-05-18","endDateDateOnly":"2022-02-16"}],"amountAwarded":7247952,"Financial Year":"2020/21","Lead Applicant":"Dr Philippe Duneton","grantProgramme":[{"title":"Coronavirus","title_keyword":"Coronavirus"}],"Applicant Surname":"Duneton","Partnership Value":7247952,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:World-Health-Organization-Switzerland","name":"World Health Organization, Switzerland","addressCountry":"Switzerland","id_and_name":"[\"World Health Organization, Switzerland\", \"360G-Wellcome-ORG:World-Health-Organization-Switzerland\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:World-Health-Organization-Switzerland","name":"World Health Organization, Switzerland"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Emergency oxygen response for COVID-19 The O2 Taskforce is coordinating access to emergency oxygen for COVID-19 patients in LMICs. Since the start of the pandemic, affordable, sustainable access to oxygen has been a growing challenge LMICs. COVID-19 has put huge pressure on health systems, with hospitals running out of oxygen, has resulted in preventable deaths and huge burden on families of hospitalized patients. Oxygen is an essential medicine, and despite being vital for the effective treatment of hospitalized COVID-19 patients, access in LMICs is limited due to cost, infrastructure and logistical barriers. The O2 Taskforce has identified an immediate need of approx. US$ 90 million over the next 1 \u2013 2 months, with a US$1.6 billion need estimated for LMICs over the next 12 months to support.\n\n \n\nThe proposal will secure funding ($10 million) for acute oxygen COVID-19 needs in LMICs as identified by the O2 Taskforce. The funds will support countries to access oxygen and to unlock available resources to build more sustainable, resilient oxygen systems. Activities may include technical assistance for implementation of oxygen services, investments for market interventions and for additional country assessments/development of country funding proposals. This investment is intended to accelerate and amplify the impact of follow on scale-up funding.","awardDateDateOnly":"2021-04-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Health Services Accessibility","Humans","Oxygen","Oxygen Inhalation Therapy"]}
{"id":"360G-Wellcome-223642_Z_21_Z","title":"Research on Research Institute \u2013 CWTS-Leiden Costs - 2021","Region":"International","currency":"GBP","awardDate":"2021-04-30T00:00:00+00:00","Internal ID":"223642/Z/21/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":39956,"Financial Year":"2020/21","Lead Applicant":"Prof Sarah De Rijcke","grantProgramme":[{"title":"Research on Research Institute Grant ","title_keyword":"Research on Research Institute Grant "}],"Applicant Surname":"De Rijcke","Partnership Value":39956,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leiden","name":"University of Leiden","addressCountry":"Netherlands","id_and_name":"[\"University of Leiden\", \"360G-Wellcome-ORG:University-of-Leiden\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leiden","name":"University of Leiden"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Research on Research Institute \u2013 CWTS-Leiden Costs - 2021 Not available","awardDateDateOnly":"2021-04-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biomedical Research","Humans"]}
{"id":"360G-Wellcome-223633_Z_21_Z","title":"Inequalities in Longevity by Education in OECD Countries ","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2021-06-18T00:00:00+00:00","Internal ID":"223633/Z/21/Z","description":"Socioeconomic inequalities in health are an increasingly central policy concern and accurate measurement is crucial in identifying effective policies to reduce health inequalities. I propose updating and refining previous OECD work examining inequalities in longevity by education in member countries around 2011. Updating the analysis involves using more recent data from national mortality registers linked to administrative data on education. Refining the analysis involves applying appropriate methods to allow for biases due to missing data. This is important since education data are often collected via the workforce, so there may be systematic patterns of missingness relating to non-participation in the workforce, which are associated with education.\n\n \n\nThe key goal is to devise a robust methodology for routinely calculating educational inequalities in longevity in a time- and labour-effective manner. The project contributes to the OECD mission of promoting wellbeing, and specifically the OECD work package \u2018Health inequalities and inclusive growth\u2019 and report \u2018Health at a Glance\u2019. It will also help the OECD become the main authority on educational longevity inequalities in member countries.\n","plannedDates":[{"endDate":"2022-01-04T00:00:00+00:00","startDate":"2021-07-05T00:00:00+00:00","startDateDateOnly":"2021-07-05","endDateDateOnly":"2022-01-04"}],"amountAwarded":15306,"Financial Year":"2020/21","Lead Applicant":"Mr Christopher L\u00fcbker","grantProgramme":[{"title":"WT/POST Fellowship","title_keyword":"WT/POST Fellowship"}],"Applicant Surname":"L\u00fcbker","Partnership Value":15306,"Approval Committee":"Secondment Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-York","name":"University of York","addressCountry":"United Kingdom","id_and_name":"[\"University of York\", \"360G-Wellcome-ORG:University-of-York\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-York","name":"University of York"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Inequalities in Longevity by Education in OECD Countries  Socioeconomic inequalities in health are an increasingly central policy concern and accurate measurement is crucial in identifying effective policies to reduce health inequalities. I propose updating and refining previous OECD work examining inequalities in longevity by education in member countries around 2011. Updating the analysis involves using more recent data from national mortality registers linked to administrative data on education. Refining the analysis involves applying appropriate methods to allow for biases due to missing data. This is important since education data are often collected via the workforce, so there may be systematic patterns of missingness relating to non-participation in the workforce, which are associated with education.\n\n \n\nThe key goal is to devise a robust methodology for routinely calculating educational inequalities in longevity in a time- and labour-effective manner. The project contributes to the OECD mission of promoting wellbeing, and specifically the OECD work package \u2018Health inequalities and inclusive growth\u2019 and report \u2018Health at a Glance\u2019. It will also help the OECD become the main authority on educational longevity inequalities in member countries.\n","awardDateDateOnly":"2021-06-18","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Educational Status","Health Policy","Health Status Disparities","Humans","Socioeconomic Factors"]}
{"id":"360G-Wellcome-223625_Z_21_Z","title":"UK participation in EU Joint Action - Sharing Health Data ","Region":"Greater London","currency":"GBP","awardDate":"2021-04-30T00:00:00+00:00","Internal ID":"223625/Z/21/Z","description":"\n Execute UK assigned tasks and responsibilities within the Joint Action to a high standard, establishing the UK as a valued and trusted partner.\n Gather a body of evidence of NHS and UK expertise on data processing in the health sector to contribute to the development of the European Health Data Space.\n Regularly convene and consult a wide range of UK stakeholders to ensure that UK health data interests across the sector are fully understood and represented.\n Maintain regular updates and briefings on the scope and objectives of the development of the European Health Data Space, to maximise UK preparedness.\n Identify and pursue opportunities to progress UK interests in the health sector, and on digital policy development more broadly.\n\n","plannedDates":[{"endDate":"2023-04-18T00:00:00+00:00","startDate":"2021-05-19T00:00:00+00:00","startDateDateOnly":"2021-05-19","endDateDateOnly":"2023-04-18"}],"amountAwarded":116653,"Financial Year":"2020/21","Lead Applicant":"Dr Layla McCay","grantProgramme":[{"title":"Discretionary Award \u2013 DSH","title_keyword":"Discretionary Award \u2013 DSH"}],"Applicant Surname":"McCay","Partnership Value":116653,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:NHS-Confederation","name":"NHS Confederation","addressCountry":"United Kingdom","id_and_name":"[\"NHS Confederation\", \"360G-Wellcome-ORG:NHS-Confederation\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:NHS-Confederation","name":"NHS Confederation"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"UK participation in EU Joint Action - Sharing Health Data  \n Execute UK assigned tasks and responsibilities within the Joint Action to a high standard, establishing the UK as a valued and trusted partner.\n Gather a body of evidence of NHS and UK expertise on data processing in the health sector to contribute to the development of the European Health Data Space.\n Regularly convene and consult a wide range of UK stakeholders to ensure that UK health data interests across the sector are fully understood and represented.\n Maintain regular updates and briefings on the scope and objectives of the development of the European Health Data Space, to maximise UK preparedness.\n Identify and pursue opportunities to progress UK interests in the health sector, and on digital policy development more broadly.\n\n","awardDateDateOnly":"2021-04-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Europe","European Union","Humans","Information Dissemination","State Medicine","United Kingdom"]}
{"id":"360G-Wellcome-223611_Z_21_Z","title":"AMR Action Fund","Region":"International","currency":"GBP","awardDate":"2020-12-31T00:00:00+00:00","Internal ID":"223611/Z/21/Z","description":"The AMR Action Fund aims to bridge the funding gaps and technical barriers that antibiotic developers face as they head into later-stage development and ensure new treatments for drug-resistant infections are available to the patients who need them the most. We aim to bring 2-4 new antibiotics to patients by 2030. We will work with partners to create market conditions that enable sustainable investment in the antibiotic pipeline.","plannedDates":[{"endDate":"2033-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2033-03-31"}],"amountAwarded":50000000,"Financial Year":"2020/21","Lead Applicant":"Dr Henry Skinner","grantProgramme":[{"title":"Discretionary award \u2013 DRI","title_keyword":"Discretionary award \u2013 DRI"}],"Applicant Surname":"Skinner","Partnership Value":50000000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:AMR-Action-Fund-GP-LLC","name":"AMR Action Fund GP, LLC","addressCountry":"United States","id_and_name":"[\"AMR Action Fund GP, LLC\", \"360G-Wellcome-ORG:AMR-Action-Fund-GP-LLC\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:AMR-Action-Fund-GP-LLC","name":"AMR Action Fund GP, LLC"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"AMR Action Fund The AMR Action Fund aims to bridge the funding gaps and technical barriers that antibiotic developers face as they head into later-stage development and ensure new treatments for drug-resistant infections are available to the patients who need them the most. We aim to bring 2-4 new antibiotics to patients by 2030. We will work with partners to create market conditions that enable sustainable investment in the antibiotic pipeline.","awardDateDateOnly":"2020-12-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anti-Bacterial Agents","Humans"]}
{"id":"360G-Wellcome-223606_Z_21_Z","title":"Rethinking How to Understand the Burden of Antibiotic Resistant Bacteria: establishing best-practice through comparative analyses","Region":"South East","currency":"GBP","awardDate":"2021-05-31T00:00:00+00:00","Internal ID":"223606/Z/21/Z","description":"This work will complement the Global Research on AntiMicrobial (GRAM) project estimating the global burden of drug resistant infections (antimicrobial resistance, AMR). The work will  establish the best practice in quantifying the burden of AMR through the comparative analysis of selected data sets from the GRAM project and synthetic data generated using mechanistic models. Key goals include comparative estimates of the burden of AMR  for selected data sets and evaluations of the appropriateness of different analytical approaches for different types of data and different epidemiological processes. In particular, the work will determine: i) under what circumstances the assumption that resistant infections fully replace sensitive infections with the same species is appropriate for quantifying the burden of AMR; ii) under what circumstances the contrasting assumption that resistant infections add to the burden rather than replacing sensitive infections is appropriate; and iii) under what circumstances the intermediate assumption of partial replacement is appropriate. \n","plannedDates":[{"endDate":"2023-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2023-08-31"}],"amountAwarded":104589,"Financial Year":"2020/21","Lead Applicant":"Prof Ben Cooper","grantProgramme":[{"title":"Discretionary award \u2013 DRI","title_keyword":"Discretionary award \u2013 DRI"}],"Applicant Surname":"Cooper","Partnership Value":104589,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Catrin Moore","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Rethinking How to Understand the Burden of Antibiotic Resistant Bacteria: establishing best-practice through comparative analyses This work will complement the Global Research on AntiMicrobial (GRAM) project estimating the global burden of drug resistant infections (antimicrobial resistance, AMR). The work will  establish the best practice in quantifying the burden of AMR through the comparative analysis of selected data sets from the GRAM project and synthetic data generated using mechanistic models. Key goals include comparative estimates of the burden of AMR  for selected data sets and evaluations of the appropriateness of different analytical approaches for different types of data and different epidemiological processes. In particular, the work will determine: i) under what circumstances the assumption that resistant infections fully replace sensitive infections with the same species is appropriate for quantifying the burden of AMR; ii) under what circumstances the contrasting assumption that resistant infections add to the burden rather than replacing sensitive infections is appropriate; and iii) under what circumstances the intermediate assumption of partial replacement is appropriate. \n","awardDateDateOnly":"2021-05-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anti-Bacterial Agents","Drug Resistance, Bacterial","Drug Resistance, Microbial","Drug Resistance, Multiple, Bacterial","Global Health","Humans"]}
{"id":"360G-Wellcome-223604_Z_21_Z","title":"Developing Snakebite Research Hubs- Improving Evidence based decision making in Snakebite in Africa","Region":"North West","currency":"GBP","awardDate":"2021-04-30T00:00:00+00:00","Internal ID":"223604/Z/21/Z","description":"Snakebite has recently been recognised as a Neglected Tropical Disease, In addition to the limited availability of high quality antivenoms, one of the major challenges to improving outcomes is that there is currently no established mechanism for a) determining the key evidence gaps, b) coordinating the necessary research and evidence generation and c) providing appropriate scientific and technical advice to governments and Ministries of Health to inform appropriate policy development.\n\nThis application seeks to undertake the initial work necessary for planning how these public health and policy issues could be addressed in sub-Saharan Africa. It will comprise two main phases:\n\na) a wide-ranging scoping review and mapping of critical issues and priorities\n\nb) exploration of the best approaches and structures to address the issues identified in phase 1 and development of a clear strategy and plan to implement a solution\n\n \n\nThe overarching aim is: To undertake the preliminary work necessary to identify the barriers to evidence-based decision making at national and regional level for snakebite in Africa and to inform the optimal design of a major research and policy initiative that will overcome these barriers.\n","plannedDates":[{"endDate":"2022-03-03T00:00:00+00:00","startDate":"2021-06-01T00:00:00+00:00","startDateDateOnly":"2021-06-01","endDateDateOnly":"2022-03-03"}],"amountAwarded":115255,"Financial Year":"2020/21","Lead Applicant":"Prof David Lalloo","grantProgramme":[{"title":"Discretionary Award - Snakebite","title_keyword":"Discretionary Award - Snakebite"}],"Applicant Surname":"Lalloo","Partnership Value":115255,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"Liverpool School of Tropical Medicine\", \"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Developing Snakebite Research Hubs- Improving Evidence based decision making in Snakebite in Africa Snakebite has recently been recognised as a Neglected Tropical Disease, In addition to the limited availability of high quality antivenoms, one of the major challenges to improving outcomes is that there is currently no established mechanism for a) determining the key evidence gaps, b) coordinating the necessary research and evidence generation and c) providing appropriate scientific and technical advice to governments and Ministries of Health to inform appropriate policy development.\n\nThis application seeks to undertake the initial work necessary for planning how these public health and policy issues could be addressed in sub-Saharan Africa. It will comprise two main phases:\n\na) a wide-ranging scoping review and mapping of critical issues and priorities\n\nb) exploration of the best approaches and structures to address the issues identified in phase 1 and development of a clear strategy and plan to implement a solution\n\n \n\nThe overarching aim is: To undertake the preliminary work necessary to identify the barriers to evidence-based decision making at national and regional level for snakebite in Africa and to inform the optimal design of a major research and policy initiative that will overcome these barriers.\n","awardDateDateOnly":"2021-04-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa South of the Sahara","Antivenins","Health Policy","Humans","Policy Making","Public Health","Snake Bites"]}
{"id":"360G-Wellcome-223602_Z_21_Z","title":"Global Heating and Health Public Engagement Programme (G2H-PEP)","Region":"International","currency":"GBP","awardDate":"2021-03-31T00:00:00+00:00","Internal ID":"223602/Z/21/Z","description":"Critical to realizing APHRC\u2019s vision of transforming lives in Africa through research is public engagement with research and health concepts. We are submitting this Development Grant to facilitate the preparation of the Transformation pilot grant for which the team has been invited to apply. During the development, a mix of senior and junior staff from APHRC will work with expert consultants and engage stakeholders in the area of Global Heating and its impact on Health to develop the plan for fellowship support and training program for The Global Heating and Health Public Engagement Programme (G2H-PEP). The pilot of this Leadership Transformation Programme will produce a cohort of fellows who will have an extended network of contacts working on public engagement, and will have gained leadership skills and tools to ensure their wellbeing and resilience while developing as leaders in a living system. The overall objective of the program will be to produce a network of public engagement fellows interested in global heating and its health impacts. The co-design process will ensure that the pilot cohort goes through a relevant training program and receives the support necessary for meaningful engagement with the public.\n","plannedDates":[{"endDate":"2021-07-08T00:00:00+00:00","startDate":"2021-04-08T00:00:00+00:00","startDateDateOnly":"2021-04-08","endDateDateOnly":"2021-07-08"}],"amountAwarded":9960,"Financial Year":"2020/21","Lead Applicant":"Dr Evelyn Gitau","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Gitau","Partnership Value":9960,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:African-Population-and-Health-Research-Centre-Kenya","name":"African Population & Health Research Centre, Kenya","addressCountry":"Kenya","id_and_name":"[\"African Population & Health Research Centre, Kenya\", \"360G-Wellcome-ORG:African-Population-and-Health-Research-Centre-Kenya\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:African-Population-and-Health-Research-Centre-Kenya","name":"African Population & Health Research Centre, Kenya"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Global Heating and Health Public Engagement Programme (G2H-PEP) Critical to realizing APHRC\u2019s vision of transforming lives in Africa through research is public engagement with research and health concepts. We are submitting this Development Grant to facilitate the preparation of the Transformation pilot grant for which the team has been invited to apply. During the development, a mix of senior and junior staff from APHRC will work with expert consultants and engage stakeholders in the area of Global Heating and its impact on Health to develop the plan for fellowship support and training program for The Global Heating and Health Public Engagement Programme (G2H-PEP). The pilot of this Leadership Transformation Programme will produce a cohort of fellows who will have an extended network of contacts working on public engagement, and will have gained leadership skills and tools to ensure their wellbeing and resilience while developing as leaders in a living system. The overall objective of the program will be to produce a network of public engagement fellows interested in global heating and its health impacts. The co-design process will ensure that the pilot cohort goes through a relevant training program and receives the support necessary for meaningful engagement with the public.\n","awardDateDateOnly":"2021-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Global Health","Humans","Leadership","Pilot Projects","Program Development","Program Evaluation"]}
{"id":"360G-Wellcome-223599_Z_21_Z","title":"Proof of Concept - Dalberg","Region":"Greater London","currency":"GBP","awardDate":"2021-03-31T00:00:00+00:00","Internal ID":"223599/Z/21/Z","description":"This proposal is to help develop an initial proof of concept of the Transformation Programme pilot for public engagement leaders. We propose working for ~4 weeks to help refine and build out what this proof of concept would look like - specifically as it relates to the flow, curriculum and approach of the pilot programme. \n","plannedDates":[{"endDate":"2021-06-01T00:00:00+00:00","startDate":"2021-05-03T00:00:00+00:00","startDateDateOnly":"2021-05-03","endDateDateOnly":"2021-06-01"}],"amountAwarded":10000,"Financial Year":"2020/21","Lead Applicant":"Mr Shyam Sundaram","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Sundaram","Partnership Value":10000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Dalberg-Global-Development-Advisors-Limited","name":"Dalberg Global Development Advisors Limited","addressCountry":"United Kingdom","id_and_name":"[\"Dalberg Global Development Advisors Limited\", \"360G-Wellcome-ORG:Dalberg-Global-Development-Advisors-Limited\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Dalberg-Global-Development-Advisors-Limited","name":"Dalberg Global Development Advisors Limited"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Proof of Concept - Dalberg This proposal is to help develop an initial proof of concept of the Transformation Programme pilot for public engagement leaders. We propose working for ~4 weeks to help refine and build out what this proof of concept would look like - specifically as it relates to the flow, curriculum and approach of the pilot programme. \n","awardDateDateOnly":"2021-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Curriculum","Humans","Leadership","Pilot Projects"]}
{"id":"360G-Wellcome-223553_Z_21_Z","title":"Assessing the prospective impacts of Universal Basic Income on anxiety and depression among 14-24-year-olds","Region":"North West","currency":"GBP","awardDate":"2021-05-31T00:00:00+00:00","Internal ID":"223553/Z/21/Z","description":"In a context of austerity, pandemic and unemployment, 14- to 24-year-olds have above-average levels of anxiety, significant rates of depression and lower life satisfaction than previous cohorts. Building on our model of upstream socioeconomic pathways for health impact, this project examines prospective impact of Universal Basic Income, a system of unconditional cash transfers, on anxiety and depression among 14-24s. It brings together an established, multi-disciplinary team to:\n\nObjective 1)     create a \u2018risk\u2019 factor for anxiety and depression among 14-24s from existing data\n\nO2)       deploy the RSA\u2019s Citizen Engagement Workshops and focus groups with disabled people to advance designs for a \u2018transitional UBI\u2019 for 14-17s, an overall scheme aimed specifically at mental health impact, and account for additional needs\n\nO3)       use the \u2018risk\u2019 factor to model the impact of the cash transfer schemes from 2) on anxiety and depression among 14-24s\n\nO4)       design research protocols to measure impacts in different schemes using the examples of ActEarly\u2019s Bradford pilot and the RSA/Scottish Government\u2019s prospective Dunfermline trial\n\nThis will lead to a series of publications, an end of project report published by the RSA and a set of impact measurement research materials. We will seek to \u2018leverage\u2019 these to secure further funded research.\n","plannedDates":[{"endDate":"2022-01-30T00:00:00+00:00","startDate":"2021-08-01T00:00:00+00:00","startDateDateOnly":"2021-08-01","endDateDateOnly":"2022-01-30"}],"amountAwarded":163036,"Financial Year":"2020/21","Lead Applicant":"Dr Matthew Johnson","grantProgramme":[{"title":"Discretionary Award - Mental Health","title_keyword":"Discretionary Award - Mental Health"}],"Applicant Surname":"Johnson","Partnership Value":163036,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Lancaster-University","name":"Lancaster University","addressCountry":"United Kingdom","id_and_name":"[\"Lancaster University\", \"360G-Wellcome-ORG:Lancaster-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Lancaster-University","name":"Lancaster University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Assessing the prospective impacts of Universal Basic Income on anxiety and depression among 14-24-year-olds In a context of austerity, pandemic and unemployment, 14- to 24-year-olds have above-average levels of anxiety, significant rates of depression and lower life satisfaction than previous cohorts. Building on our model of upstream socioeconomic pathways for health impact, this project examines prospective impact of Universal Basic Income, a system of unconditional cash transfers, on anxiety and depression among 14-24s. It brings together an established, multi-disciplinary team to:\n\nObjective 1)     create a \u2018risk\u2019 factor for anxiety and depression among 14-24s from existing data\n\nO2)       deploy the RSA\u2019s Citizen Engagement Workshops and focus groups with disabled people to advance designs for a \u2018transitional UBI\u2019 for 14-17s, an overall scheme aimed specifically at mental health impact, and account for additional needs\n\nO3)       use the \u2018risk\u2019 factor to model the impact of the cash transfer schemes from 2) on anxiety and depression among 14-24s\n\nO4)       design research protocols to measure impacts in different schemes using the examples of ActEarly\u2019s Bradford pilot and the RSA/Scottish Government\u2019s prospective Dunfermline trial\n\nThis will lead to a series of publications, an end of project report published by the RSA and a set of impact measurement research materials. We will seek to \u2018leverage\u2019 these to secure further funded research.\n","awardDateDateOnly":"2021-05-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adolescent","Anxiety","Depression","Focus Groups","Humans","Personal Satisfaction","Prospective Studies","Unemployment"]}
{"id":"360G-Wellcome-223550_Z_21_Z","title":"The International Digital Health & AI Research Collaborative (I-DAIR)","Region":"International","currency":"GBP","awardDate":"2021-05-31T00:00:00+00:00","Internal ID":"223550/Z/21/Z","description":"I-DAIR is a Geneva-based global platform to enable inclusive, impactful, and responsible research into digital health and Artificial Intelligence (AI) for health. I-DAIR\u2019s mission is the transformation of personal and public health through collaborative research and development of digital technologies. This proposal for a grant of GBP 2 million over two years (2021- 2022) to fund the key capabilities necessary for I-DAIR to fulfill its primary functions as an enabler of digital health and as a convener of key stakeholders for digital health. The grant will complement a CHF 7 million (GBP 5.4 million) investment by Fondation Botnar, which has allowed I-DAIR to start building a Project Team and begin a two year incubation phase, with launch scheduled for 2022. By enabling key strategic outcomes, Wellcome\u2019s contribution will allow the Project Team to make the case for I-DAIR at launch as a global catalyst for digital health and artificial intelligence (AI) research and development (R & D), and for democratising the R & D landscape by bringing more attention to networks, needs and opportunities in low-and middle-income countries. \n","plannedDates":[{"endDate":"2023-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2023-06-30"}],"amountAwarded":1982664,"Financial Year":"2020/21","Lead Applicant":"Dr Amandeep Gill","grantProgramme":[{"title":"Discretionary Award \u2013 DSH","title_keyword":"Discretionary Award \u2013 DSH"}],"Applicant Surname":"Gill","Partnership Value":1982664,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:The-Graduate-Institute-of-International-and-Development-Studies","name":"The Graduate Institute of International and Development Studies","addressCountry":"Switzerland","id_and_name":"[\"The Graduate Institute of International and Development Studies\", \"360G-Wellcome-ORG:The-Graduate-Institute-of-International-and-Development-Studies\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:The-Graduate-Institute-of-International-and-Development-Studies","name":"The Graduate Institute of International and Development Studies"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The International Digital Health & AI Research Collaborative (I-DAIR) I-DAIR is a Geneva-based global platform to enable inclusive, impactful, and responsible research into digital health and Artificial Intelligence (AI) for health. I-DAIR\u2019s mission is the transformation of personal and public health through collaborative research and development of digital technologies. This proposal for a grant of GBP 2 million over two years (2021- 2022) to fund the key capabilities necessary for I-DAIR to fulfill its primary functions as an enabler of digital health and as a convener of key stakeholders for digital health. The grant will complement a CHF 7 million (GBP 5.4 million) investment by Fondation Botnar, which has allowed I-DAIR to start building a Project Team and begin a two year incubation phase, with launch scheduled for 2022. By enabling key strategic outcomes, Wellcome\u2019s contribution will allow the Project Team to make the case for I-DAIR at launch as a global catalyst for digital health and artificial intelligence (AI) research and development (R & D), and for democratising the R & D landscape by bringing more attention to networks, needs and opportunities in low-and middle-income countries. \n","awardDateDateOnly":"2021-05-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Artificial Intelligence","Cooperative Behavior","Global Health","Humans"]}
{"id":"360G-Wellcome-223542_Z_21_Z","title":"Independent High-Level Panel: Financing for Pandemic Prevention, Preparedness and Response","Region":"International","currency":"GBP","awardDate":"2021-03-31T00:00:00+00:00","Internal ID":"223542/Z/21/Z","description":" \n\nA high-level panel, led by co-chairs Tharman Shanmugaratnam, Lawrence H. Summers and Ngozi Okonjo-Iweala, has been mandated by the Italian presidency of the G20 to propose reforms and other measures that will lead to more reliable and sustainable financing of pandemic prevention, preparedness, and response. To support the deliberations and decision-making of the panel, Bruegel and CGD will establish a team to lead the analysis and content development of the proposals. The work of the project team and the panel is aimed at eliciting concrete and cooperative action by the G20 finance ministers. The team will develop an outline for the final report of the panel for discussion and feedback with the co-Chairs. Furthermore, the team will carry out three background analyses that will enable the informed discussion and brainstorming among panel members and the development of financing proposals: i/ landscaping current financing and issues, existing asks and proposals, ii/ landscaping current financing and issues, existing asks and proposals and iii/ governance, organization, and incentives. Reflecting the panel\u2019s views as well as the teams\u2019 own analyses, a draft and then final report will be developed building on the initial outline and the background analyses and consultations. \n","plannedDates":[{"endDate":"2021-10-31T00:00:00+00:00","startDate":"2021-02-01T00:00:00+00:00","startDateDateOnly":"2021-02-01","endDateDateOnly":"2021-10-31"}],"amountAwarded":139270,"Financial Year":"2020/21","Lead Applicant":"Ms Scarlett Varga","grantProgramme":[{"title":"Discretionary Award - Policy ","title_keyword":"Discretionary Award - Policy "}],"Applicant Surname":"Varga","Partnership Value":139270,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Bruegel","name":"Bruegel","addressCountry":"Belgium","id_and_name":"[\"Bruegel\", \"360G-Wellcome-ORG:Bruegel\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Bruegel","name":"Bruegel"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Independent High-Level Panel: Financing for Pandemic Prevention, Preparedness and Response  \n\nA high-level panel, led by co-chairs Tharman Shanmugaratnam, Lawrence H. Summers and Ngozi Okonjo-Iweala, has been mandated by the Italian presidency of the G20 to propose reforms and other measures that will lead to more reliable and sustainable financing of pandemic prevention, preparedness, and response. To support the deliberations and decision-making of the panel, Bruegel and CGD will establish a team to lead the analysis and content development of the proposals. The work of the project team and the panel is aimed at eliciting concrete and cooperative action by the G20 finance ministers. The team will develop an outline for the final report of the panel for discussion and feedback with the co-Chairs. Furthermore, the team will carry out three background analyses that will enable the informed discussion and brainstorming among panel members and the development of financing proposals: i/ landscaping current financing and issues, existing asks and proposals, ii/ landscaping current financing and issues, existing asks and proposals and iii/ governance, organization, and incentives. Reflecting the panel\u2019s views as well as the teams\u2019 own analyses, a draft and then final report will be developed building on the initial outline and the background analyses and consultations. \n","awardDateDateOnly":"2021-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Healthcare Financing","Humans","Italy"]}
{"id":"360G-Wellcome-223541_Z_21_Z","title":"What influences cancer services uptake in Ghana and how can this information support policy-making?","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"223541/Z/21/Z","description":"My research is about what influences people in Ghana to use cancer services. Cancer is an increasing problem in Ghana due to changes to lifestyle and population age. Many things influence cancer services use including, disease beliefs, stigma, healthcare trust, and costs. The Ghanaian health system seeks to expand cancer services in a way that benefits as many as possible, but challenges remain in understanding why some patients do not attend.\n\n\nI plan to use mixed methods to explore what influences cancer service use and how this information can be useful for Ghanaian policymakers. A key stage will involve surveying public members\u2019 beliefs and behaviours. I will analyse data collected to see how information about age, gender and job relate to peoples\u2019 views and might influence whether they would use cancer services; I also hope to build profiles of types of people to help policymakers target help to those most in need. To further understand and check the analysis, I will use narrative interviews with a range of the public to listen to what they think and why they act as they do.\n\n\nI will bring together the findings and discuss with policymakers how this could help inform their decision-making.\n","plannedDates":[{"endDate":"2023-09-01T00:00:00+00:00","startDate":"2020-09-02T00:00:00+00:00","startDateDateOnly":"2020-09-02","endDateDateOnly":"2023-09-01"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Chloe Tuck","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Tuck","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield","addressCountry":"United Kingdom","id_and_name":"[\"University of Sheffield\", \"360G-Wellcome-ORG:University-of-Sheffield\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"What influences cancer services uptake in Ghana and how can this information support policy-making? My research is about what influences people in Ghana to use cancer services. Cancer is an increasing problem in Ghana due to changes to lifestyle and population age. Many things influence cancer services use including, disease beliefs, stigma, healthcare trust, and costs. The Ghanaian health system seeks to expand cancer services in a way that benefits as many as possible, but challenges remain in understanding why some patients do not attend.\n\n\nI plan to use mixed methods to explore what influences cancer service use and how this information can be useful for Ghanaian policymakers. A key stage will involve surveying public members\u2019 beliefs and behaviours. I will analyse data collected to see how information about age, gender and job relate to peoples\u2019 views and might influence whether they would use cancer services; I also hope to build profiles of types of people to help policymakers target help to those most in need. To further understand and check the analysis, I will use narrative interviews with a range of the public to listen to what they think and why they act as they do.\n\n\nI will bring together the findings and discuss with policymakers how this could help inform their decision-making.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adult","Aged","Decision Making","Female","Ghana","Health Policy","Humans","Male","Middle Aged","Neoplasms","Social Stigma"]}
{"id":"360G-Wellcome-223535_Z_21_Z","title":"RSTMH small grants for snakebite 2021-23","Region":"Greater London","currency":"GBP","awardDate":"2021-03-31T00:00:00+00:00","Internal ID":"223535/Z/21/Z","description":"Snakebite is a strategic priority for RSTMH given its high levels of death and disability. Although there has been an increase in research funding recently, there is still an unmet need to encourage junior researchers to undertake a career in snakebite research. The RSTMH Small Grants Programme is a unique grant funding programme open to early career researchers from anywhere in the world that aims to fill a gap in the research career pathway. RSTMH grants are for up to \u00a35,000 to those early in their careers (e.g. researchers, healthcare professionals, NGO workers, health economists, social scientists) who are working in a field relevant to tropical medicine or global health.  These grants typically represent the first time someone has received funding in their own name and helps develop their research and management skills.\n\nIn 2020, Wellcome piloted a partnership with RSMTH to fund 10 grants in snakebite research. With Wellcome funding, RSTMH awarded grants to African, Asian, South American and European nationals across various snakebite research areas. Following on from the success of the pilot, RSTMH is seeking funding for a 3-year partnership with Wellcome to fund 10 projects per year and up to 30 in total in snakebite research.\n\n \n","plannedDates":[{"endDate":"2024-06-17T00:00:00+00:00","startDate":"2021-06-18T00:00:00+00:00","startDateDateOnly":"2021-06-18","endDateDateOnly":"2024-06-17"}],"amountAwarded":166200,"Financial Year":"2020/21","Lead Applicant":"Ms Tamar Ghosh","grantProgramme":[{"title":"Discretionary Award - Snakebite","title_keyword":"Discretionary Award - Snakebite"}],"Applicant Surname":"Ghosh","Partnership Value":166200,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Royal-Society-of-Tropical-Medicine-and-Hygiene","name":"Royal Society of Tropical Medicine and Hygiene","addressCountry":"United Kingdom","id_and_name":"[\"Royal Society of Tropical Medicine and Hygiene\", \"360G-Wellcome-ORG:Royal-Society-of-Tropical-Medicine-and-Hygiene\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Royal-Society-of-Tropical-Medicine-and-Hygiene","name":"Royal Society of Tropical Medicine and Hygiene"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"RSTMH small grants for snakebite 2021-23 Snakebite is a strategic priority for RSTMH given its high levels of death and disability. Although there has been an increase in research funding recently, there is still an unmet need to encourage junior researchers to undertake a career in snakebite research. The RSTMH Small Grants Programme is a unique grant funding programme open to early career researchers from anywhere in the world that aims to fill a gap in the research career pathway. RSTMH grants are for up to \u00a35,000 to those early in their careers (e.g. researchers, healthcare professionals, NGO workers, health economists, social scientists) who are working in a field relevant to tropical medicine or global health.  These grants typically represent the first time someone has received funding in their own name and helps develop their research and management skills.\n\nIn 2020, Wellcome piloted a partnership with RSMTH to fund 10 grants in snakebite research. With Wellcome funding, RSTMH awarded grants to African, Asian, South American and European nationals across various snakebite research areas. Following on from the success of the pilot, RSTMH is seeking funding for a 3-year partnership with Wellcome to fund 10 projects per year and up to 30 in total in snakebite research.\n\n \n","awardDateDateOnly":"2021-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biomedical Research","Financing, Organized","Humans","Research Personnel","Research Support as Topic","Snake Bites"]}
{"id":"360G-Wellcome-223534_Z_21_Z","title":"International Health Advocacy for Climate Action -- GCHA capacity grant","Region":"International","currency":"GBP","awardDate":"2021-03-31T00:00:00+00:00","Internal ID":"223534/Z/21/Z","description":"Climate change presents a unique and urgent threat to planetary health.  Compounded by the COVID19 pandemic, we face a very real risk of losing 50 years of global development, exacerbating health, economic, and social inequities.\n\nCOP26 will provide a special opportunity for global leaders to set a course for a healthy and green recovery. \n\nInformed voices from across the globe are crucial in driving decision makers to deliver ambitious climate action. Health workers are among society's most trusted and respected professionals, and the health case for climate action is powerful, offering millions of lives saved through reduced non-communicable diseases, health resilience, and adaptation, and fully offsetting the costs of mitigation through health cost savings.\n\nWellcome Trust funding will enable the Global Climate Health Alliance (GCHA) to amplify the voices of medical and other health professionals globally, including those in low and middle income countries (LMIC) which have been underrepresented in the international climate conversation, on the massive health opportunities of climate action. \n\nWe will build capacity, link new voices to media advocacy opportunities, and disseminate Wellcome coalition asks through our global networks, thereby influencing climate action at the national and international level in the run up to COP.\n\n \n","plannedDates":[{"endDate":"2021-12-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2021-12-31"}],"amountAwarded":46492,"Financial Year":"2020/21","Lead Applicant":"Dr Jennifer Miller","grantProgramme":[{"title":"Discretionary Award - OPOH","title_keyword":"Discretionary Award - OPOH"}],"Applicant Surname":"Miller","Partnership Value":46492,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Social-Good-Fund","name":"Social Good Fund","addressCountry":"United States","id_and_name":"[\"Social Good Fund\", \"360G-Wellcome-ORG:Social-Good-Fund\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Social-Good-Fund","name":"Social Good Fund"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"International Health Advocacy for Climate Action -- GCHA capacity grant Climate change presents a unique and urgent threat to planetary health.  Compounded by the COVID19 pandemic, we face a very real risk of losing 50 years of global development, exacerbating health, economic, and social inequities.\n\nCOP26 will provide a special opportunity for global leaders to set a course for a healthy and green recovery. \n\nInformed voices from across the globe are crucial in driving decision makers to deliver ambitious climate action. Health workers are among society's most trusted and respected professionals, and the health case for climate action is powerful, offering millions of lives saved through reduced non-communicable diseases, health resilience, and adaptation, and fully offsetting the costs of mitigation through health cost savings.\n\nWellcome Trust funding will enable the Global Climate Health Alliance (GCHA) to amplify the voices of medical and other health professionals globally, including those in low and middle income countries (LMIC) which have been underrepresented in the international climate conversation, on the massive health opportunities of climate action. \n\nWe will build capacity, link new voices to media advocacy opportunities, and disseminate Wellcome coalition asks through our global networks, thereby influencing climate action at the national and international level in the run up to COP.\n\n \n","awardDateDateOnly":"2021-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Climate Change","Developing Countries","Global Health","Humans","International Cooperation"]}
{"id":"360G-Wellcome-223533_Z_21_Z","title":"Strengthening the climate and health capacity of AfGH and SfGH     ","Region":"Greater London","currency":"GBP","awardDate":"2021-03-31T00:00:00+00:00","Internal ID":"223533/Z/21/Z","description":"Action for Global Health (AfGH) and Students for Global Health (SfGH) in partnership aim to increase our respective health networks' (reaching more than 50 organisations), and members' (in 34 student branches) contribution to a shared climate and health agenda through capacity building, mobilising, and increasing collaboration between key stakeholders (our members, partners and other actors) and supporting synthesised advocacy and campaign events in the lead up to COP26. In particular we will focus on increasing access to engagement with youth, global south and NMIC stakeholders on the intersection of health and climate.\n\nWe will partner to work with the 'Climate Change Coalition' to activate and engage cross sectoral partners including global south, LMIC and youth organisations around a shared policy agenda and build support for sustainable health and climate change strategies leading up to G7 and COP26. We will actively participate in the climate coalition and build our and other actors' resources to activate and mobilise support for health and climate. We will draw on the breadth and strength of our members collective experience and expertise to actively engage with and broaden understanding of the intersection between health and climate.\n","plannedDates":[{"endDate":"2022-03-02T00:00:00+00:00","startDate":"2021-05-01T00:00:00+00:00","startDateDateOnly":"2021-05-01","endDateDateOnly":"2022-03-02"}],"amountAwarded":49936,"Financial Year":"2020/21","Lead Applicant":"Ms Gjori Langeland","grantProgramme":[{"title":"Discretionary Award - OPOH","title_keyword":"Discretionary Award - OPOH"}],"Applicant Surname":"Langeland","Partnership Value":49936,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:STOPAIDS","name":"STOPAIDS","addressCountry":"United Kingdom","id_and_name":"[\"STOPAIDS\", \"360G-Wellcome-ORG:STOPAIDS\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:STOPAIDS","name":"STOPAIDS"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Strengthening the climate and health capacity of AfGH and SfGH      Action for Global Health (AfGH) and Students for Global Health (SfGH) in partnership aim to increase our respective health networks' (reaching more than 50 organisations), and members' (in 34 student branches) contribution to a shared climate and health agenda through capacity building, mobilising, and increasing collaboration between key stakeholders (our members, partners and other actors) and supporting synthesised advocacy and campaign events in the lead up to COP26. In particular we will focus on increasing access to engagement with youth, global south and NMIC stakeholders on the intersection of health and climate.\n\nWe will partner to work with the 'Climate Change Coalition' to activate and engage cross sectoral partners including global south, LMIC and youth organisations around a shared policy agenda and build support for sustainable health and climate change strategies leading up to G7 and COP26. We will actively participate in the climate coalition and build our and other actors' resources to activate and mobilise support for health and climate. We will draw on the breadth and strength of our members collective experience and expertise to actively engage with and broaden understanding of the intersection between health and climate.\n","awardDateDateOnly":"2021-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Capacity Building","Climate Change","Cooperative Behavior","Global Health","Humans"]}
{"id":"360G-Wellcome-223532_Z_21_Z","title":"Secretariat Support for G20 High Level Independent Panel (HLIP) ","Region":"International","currency":"GBP","awardDate":"2021-05-31T00:00:00+00:00","Internal ID":"223532/Z/21/Z","description":"The G20, as proposed by the Italian G20 Presidency, has mandated a High-Level Independent Panel (HLIP) to recommend actionable solutions for reliable and sustainable financing of the global commons for pandemic prevention, surveillance, preparedness and response. The Panel\u2019s recommendations will be presented to the G20 Finance Ministers and Central Bank Governors Meeting in July. To provide the HLIP with support for logistics, coordination, outreach, and communication/engagement, The National Academy of Medicine (NAM) proposes to establish a joint Secretariat comprised of 4-5 individuals from the NAM and the Wellcome Trust. From February through October 2021, it is expected that the joint Secretariat will support the execution of the independent review by the HLIP. The work of the Secretariat during these eight months will include: 1) meeting logistics and organization; 2) meeting facilitation (agenda setting, conduct, and procedures); 3) outreach and communication with key political and other stakeholders; and, as needed 4) limited research/analytical/writing support for health-related content.\n","plannedDates":[{"endDate":"2021-10-31T00:00:00+00:00","startDate":"2021-02-01T00:00:00+00:00","startDateDateOnly":"2021-02-01","endDateDateOnly":"2021-10-31"}],"amountAwarded":198620,"Financial Year":"2020/21","Lead Applicant":"Mrs Morgan Kanarek","grantProgramme":[{"title":"Discretionary Award - Policy ","title_keyword":"Discretionary Award - Policy "}],"Applicant Surname":"Kanarek","Partnership Value":198620,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:National-Academy-of-Sciences-America-NAS","name":"National Academy of Sciences, America (NAS)","addressCountry":"United States","id_and_name":"[\"National Academy of Sciences, America (NAS)\", \"360G-Wellcome-ORG:National-Academy-of-Sciences-America-NAS\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:National-Academy-of-Sciences-America-NAS","name":"National Academy of Sciences, America (NAS)"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Secretariat Support for G20 High Level Independent Panel (HLIP)  The G20, as proposed by the Italian G20 Presidency, has mandated a High-Level Independent Panel (HLIP) to recommend actionable solutions for reliable and sustainable financing of the global commons for pandemic prevention, surveillance, preparedness and response. The Panel\u2019s recommendations will be presented to the G20 Finance Ministers and Central Bank Governors Meeting in July. To provide the HLIP with support for logistics, coordination, outreach, and communication/engagement, The National Academy of Medicine (NAM) proposes to establish a joint Secretariat comprised of 4-5 individuals from the NAM and the Wellcome Trust. From February through October 2021, it is expected that the joint Secretariat will support the execution of the independent review by the HLIP. The work of the Secretariat during these eight months will include: 1) meeting logistics and organization; 2) meeting facilitation (agenda setting, conduct, and procedures); 3) outreach and communication with key political and other stakeholders; and, as needed 4) limited research/analytical/writing support for health-related content.\n","awardDateDateOnly":"2021-05-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Italy"]}
{"id":"360G-Wellcome-223488_Z_21_Z","title":"Decolonization and global health research: initiating an African centred exchange","Region":"South East","currency":"GBP","awardDate":"2021-04-30T00:00:00+00:00","Internal ID":"223488/Z/21/Z","description":"This award will support a series of interactions between academics from diverse backgrounds with a shared interest in mapping, analyzing and critically unpacking decolonization debates in global health research.  Decolonization discussions and activism have become far more prominent over the last year, bringing both opportunities for positive transformation (through disruption, change and renewed interest in global power inequities) as well as challenges (including the \u2018trending\u2019 of the decolonization agenda leading to \u2013 at worst \u2013 the \u2018colonization\u2019 of the arena itself).  Now, as much as ever, decolonization discussions and debates need to be critically examined.  We will organize a set of exchanges and activities to: 1 Unpack and reflect upon the term \u2018global health research\u2019 using a decolonization lens; 2 Examine how tacit, or embedded, forms of knowledge from Africa are drawn upon and feature in global health research; 3 Imagine what a decolonized or African-centred, and ethical, research initiative in global health might look like; and 4 Share our learning, advocate for change, and identify an African home for future work.  We will incorporate a covid-19 research lens, but only in recognition that covid-19 will shine a light upon or amplify far longer and deeper policies and processes.  \n","plannedDates":[{"endDate":"2023-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2023-08-31"}],"amountAwarded":199522,"Financial Year":"2020/21","Lead Applicant":"Prof Catherine Molyneux","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Molyneux","Partnership Value":199522,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Decolonization and global health research: initiating an African centred exchange This award will support a series of interactions between academics from diverse backgrounds with a shared interest in mapping, analyzing and critically unpacking decolonization debates in global health research.  Decolonization discussions and activism have become far more prominent over the last year, bringing both opportunities for positive transformation (through disruption, change and renewed interest in global power inequities) as well as challenges (including the \u2018trending\u2019 of the decolonization agenda leading to \u2013 at worst \u2013 the \u2018colonization\u2019 of the arena itself).  Now, as much as ever, decolonization discussions and debates need to be critically examined.  We will organize a set of exchanges and activities to: 1 Unpack and reflect upon the term \u2018global health research\u2019 using a decolonization lens; 2 Examine how tacit, or embedded, forms of knowledge from Africa are drawn upon and feature in global health research; 3 Imagine what a decolonized or African-centred, and ethical, research initiative in global health might look like; and 4 Share our learning, advocate for change, and identify an African home for future work.  We will incorporate a covid-19 research lens, but only in recognition that covid-19 will shine a light upon or amplify far longer and deeper policies and processes.  \n","awardDateDateOnly":"2021-04-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa","Africa South of the Sahara","Global Health","Humans"]}
{"id":"360G-Wellcome-223483_Z_21_Z","title":"SA-UK/MH: Medical Humanities co-working between South Africa and the UK.","Region":"Scotland","currency":"GBP","awardDate":"2021-04-30T00:00:00+00:00","Internal ID":"223483/Z/21/Z","description":"This programme of exchange and networking will:\n\ni. Energise the Medical Humanities research ecosystem in South Africa as it evolves.\n\nii. Embed the research environment at the CSHHH Glasgow, and its current partners, in this process.\n\niii. Seed a cohort of early-career scholars in the Medical Humanities with experience of research, training and teaching collectively in both South Africa and the UK.\n\n \n\nContext\n\nSince 2018 members of the CSHHH Glasgow and the University of Johannesburg have worked together in the Medical Humanities. The Wellcome Trust and both universities invested in these activities. Following the success of this co-working, partners from the University of the Witwatersrand and the University of Cape Town joined the collaboration. The core objective is to connect the four institutions in order to jointly conduct research, training and teaching so that Medical Humanities research ecosystems continue to grow together in both countries.\n\n \n\nActivities\n\nThe focus is on seeding those ecosystems through investment in the researchers of the future and fresh collaboration across the countries and institutions.  The programme will enable;\n\n1. Four Masters students and one Ph.D. candidate to be co-supervised by the PIs.\n\n2. Enhanced networking and communications capacity, including new online resources and platforms.\n\n \n","plannedDates":[{"endDate":"2024-07-31T00:00:00+00:00","startDate":"2021-08-01T00:00:00+00:00","startDateDateOnly":"2021-08-01","endDateDateOnly":"2024-07-31"}],"amountAwarded":190026,"Financial Year":"2020/21","Lead Applicant":"Prof James Mills","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Mills","Partnership Value":190026,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Strathclyde","name":"University of Strathclyde","addressCountry":"United Kingdom","id_and_name":"[\"University of Strathclyde\", \"360G-Wellcome-ORG:University-of-Strathclyde\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Strathclyde","name":"University of Strathclyde"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"SA-UK/MH: Medical Humanities co-working between South Africa and the UK. This programme of exchange and networking will:\n\ni. Energise the Medical Humanities research ecosystem in South Africa as it evolves.\n\nii. Embed the research environment at the CSHHH Glasgow, and its current partners, in this process.\n\niii. Seed a cohort of early-career scholars in the Medical Humanities with experience of research, training and teaching collectively in both South Africa and the UK.\n\n \n\nContext\n\nSince 2018 members of the CSHHH Glasgow and the University of Johannesburg have worked together in the Medical Humanities. The Wellcome Trust and both universities invested in these activities. Following the success of this co-working, partners from the University of the Witwatersrand and the University of Cape Town joined the collaboration. The core objective is to connect the four institutions in order to jointly conduct research, training and teaching so that Medical Humanities research ecosystems continue to grow together in both countries.\n\n \n\nActivities\n\nThe focus is on seeding those ecosystems through investment in the researchers of the future and fresh collaboration across the countries and institutions.  The programme will enable;\n\n1. Four Masters students and one Ph.D. candidate to be co-supervised by the PIs.\n\n2. Enhanced networking and communications capacity, including new online resources and platforms.\n\n \n","awardDateDateOnly":"2021-04-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biomedical Research","Education, Medical","Humanities","Humans","Research","South Africa","Students, Medical","United Kingdom","Universities"]}
{"id":"360G-Wellcome-223463_Z_21_Z","title":"An ethical investigation into environmental sustainability in healthcare. ","Region":"North West","currency":"GBP","awardDate":"2021-05-11T00:00:00+00:00","Sponsor(s)":"Dr Joanne Knight","Internal ID":"223463/Z/21/Z","description":"Healthcare as an industry is one of the most environmentally destructive on earth in almost every respect (e.g. energy use, harmful gas emissions, and physical waste). The enormous environmental toll of delivering healthcare is fundamentally at odds with healthcare's goal of improving health and wellbeing. Indeed, it is the drive to achieve healthcare excellence with world class medical safety and effective treatments that is ultimately so resource intensive and polluting. This project aims to address the dilemma of how to ethically make medical decisions that adequately account for patients and the environment. In particular, I am interested in how we can ethically make trade offs between what is owed to individuals, collective groups, and future generations. For example, what might be best for the treatment of an individual may harm the environment and be detrimental to collective society or future generations. What is the best course of action? I use these three groups as lenses to examine three case studies of areas of environmental concern in medicine: the environmental cost of medical treatments; medical waste production; and the environmental benefits of remote treatment. My findings aim to inform this cutting edge area of applied ethics, healthcare policy and practice.\n","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2021-10-01T00:00:00+00:00","startDateDateOnly":"2021-10-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":98426,"Financial Year":"2020/21","Lead Applicant":"Dr Joshua Parker","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Parker","Partnership Value":98426,"Approval Committee":"ERG11 Social Science and Bioethics, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Lancaster-University","name":"Lancaster University","addressCountry":"United Kingdom","id_and_name":"[\"Lancaster University\", \"360G-Wellcome-ORG:Lancaster-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Lancaster-University","name":"Lancaster University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"An ethical investigation into environmental sustainability in healthcare.  Healthcare as an industry is one of the most environmentally destructive on earth in almost every respect (e.g. energy use, harmful gas emissions, and physical waste). The enormous environmental toll of delivering healthcare is fundamentally at odds with healthcare's goal of improving health and wellbeing. Indeed, it is the drive to achieve healthcare excellence with world class medical safety and effective treatments that is ultimately so resource intensive and polluting. This project aims to address the dilemma of how to ethically make medical decisions that adequately account for patients and the environment. In particular, I am interested in how we can ethically make trade offs between what is owed to individuals, collective groups, and future generations. For example, what might be best for the treatment of an individual may harm the environment and be detrimental to collective society or future generations. What is the best course of action? I use these three groups as lenses to examine three case studies of areas of environmental concern in medicine: the environmental cost of medical treatments; medical waste production; and the environmental benefits of remote treatment. My findings aim to inform this cutting edge area of applied ethics, healthcare policy and practice.\n","awardDateDateOnly":"2021-05-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Delivery of Health Care","Environment","Environmental Health","Humans"]}
{"id":"360G-Wellcome-223461_Z_21_Z","title":"Conflict, Mental Health and Peace in Colombia: Improving Global Health Practice Through the Integration of Mental Health and Psychosocial Support (MHPSS) and Peacebuilding","Region":"Greater London","currency":"GBP","awardDate":"2021-05-11T00:00:00+00:00","Sponsor(s)":"Dr Rochelle Burgess","Internal ID":"223461/Z/21/Z","description":"With 22.1% of global conflict-affected populations afflicted by mental disorders, Mental Health and Psychosocial Support (MHPSS) has become an increasingly important set of interventions (Charlson et al., 2019). However, care has remained removed from broader socio-political and historical context. This is despite that the psychosocial\" is conceptualised as one\u2019s psychological development within, and in interaction with, the social environment (Glass, 2000). In conflict-affected contexts where social environments become strained, structural issues of reconstruction are typically managed by \"peacebuilding\" actors. In other words, MHPSS and peacebuilding remain siloed, ignoring that peace and mental health are intrinsically linked. Furthermore, interventions remain top-down and externally driven.\n\nAccordingly, this research builds atop interdisciplinary critiques of both fields and asks, \"can community-based critical psychology approaches effectively integrate and improve MHPSS and peacebuilding practice in conflict-affected areas?\". Focusing on fieldwork with conflict-affected youth in Bogot\u00e1, Colombia, this research will take a Participatory Action Research approach in collaboration with local partners and communities, whereby Critical Community Psychology theories will be applied for the development of integrated \"psychosocial peacebuilding\" approaches. Through the introduction of these theoretical and methodological innovations, a \"skeleton\" of a model can be developed to be \"fleshed out\" and implemented in other conflict-affected contexts.\n","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2021-10-01T00:00:00+00:00","startDateDateOnly":"2021-10-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":127173,"Financial Year":"2020/21","Lead Applicant":"Mr Eric Frasco","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Frasco","Partnership Value":127173,"Approval Committee":"ERG11 Social Science and Bioethics, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Conflict, Mental Health and Peace in Colombia: Improving Global Health Practice Through the Integration of Mental Health and Psychosocial Support (MHPSS) and Peacebuilding With 22.1% of global conflict-affected populations afflicted by mental disorders, Mental Health and Psychosocial Support (MHPSS) has become an increasingly important set of interventions (Charlson et al., 2019). However, care has remained removed from broader socio-political and historical context. This is despite that the psychosocial\" is conceptualised as one\u2019s psychological development within, and in interaction with, the social environment (Glass, 2000). In conflict-affected contexts where social environments become strained, structural issues of reconstruction are typically managed by \"peacebuilding\" actors. In other words, MHPSS and peacebuilding remain siloed, ignoring that peace and mental health are intrinsically linked. Furthermore, interventions remain top-down and externally driven.\n\nAccordingly, this research builds atop interdisciplinary critiques of both fields and asks, \"can community-based critical psychology approaches effectively integrate and improve MHPSS and peacebuilding practice in conflict-affected areas?\". Focusing on fieldwork with conflict-affected youth in Bogot\u00e1, Colombia, this research will take a Participatory Action Research approach in collaboration with local partners and communities, whereby Critical Community Psychology theories will be applied for the development of integrated \"psychosocial peacebuilding\" approaches. Through the introduction of these theoretical and methodological innovations, a \"skeleton\" of a model can be developed to be \"fleshed out\" and implemented in other conflict-affected contexts.\n","awardDateDateOnly":"2021-05-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Colombia","Global Health","Humans","Mental Disorders","Mental Health","Social Support"]}
{"id":"360G-Wellcome-223452_Z_21_Z","title":"Renewing Phenomenological Psychopathology","Region":"West Midlands","currency":"GBP","awardDate":"2021-04-30T00:00:00+00:00","Internal ID":"223452/Z/21/Z","description":"Neuroscience and genetics have failed to deliver new treatments for mental disorders. It has been suggested by the NIMH that progress in biomedical approaches has been hampered by our conceptualization and taxonomy of psychiatric disorders and psychopathology. A renewed emphasis on experiential components and first-person perspectives is required to address this problem. Historically, phenomenology, as a branch of philosophy, has provided this methodology and knowledge to the mental health sciences. However, phenomenological psychopathology remains somewhat fossilized in the humanities and social sciences of the mid-20th century. This co-led international award will (1) renew phenomenological psychopathology with the recent contributions of analytic philosophy of mind, hermeneutics, structuralist/post-structuralist philosophy, history, literature, values-based practice, developmental psychology and service user research; and (2) reinvigorate phenomenology for mental health as the philosophical science of subjectivity and first-person experience. \n\nWe will develop international scholars from across disciplines and career stages to develop their research leadership and management activities and to engage in Award activities including international exchange fellowships small grants and, knowledge exchange events. The award will commence the reconstruction of phenomenological psychopathology for the 21st century as a democratic discipline with a historicized and inclusive account of the experience of the mental disorder developed.\n \n","plannedDates":[{"endDate":"2023-10-03T00:00:00+00:00","startDate":"2021-10-04T00:00:00+00:00","startDateDateOnly":"2021-10-04","endDateDateOnly":"2023-10-03"}],"amountAwarded":201902,"Financial Year":"2020/21","Lead Applicant":"Prof Matthew Broome","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Broome","Partnership Value":201902,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Birmingham\", \"360G-Wellcome-ORG:University-of-Birmingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Renewing Phenomenological Psychopathology Neuroscience and genetics have failed to deliver new treatments for mental disorders. It has been suggested by the NIMH that progress in biomedical approaches has been hampered by our conceptualization and taxonomy of psychiatric disorders and psychopathology. A renewed emphasis on experiential components and first-person perspectives is required to address this problem. Historically, phenomenology, as a branch of philosophy, has provided this methodology and knowledge to the mental health sciences. However, phenomenological psychopathology remains somewhat fossilized in the humanities and social sciences of the mid-20th century. This co-led international award will (1) renew phenomenological psychopathology with the recent contributions of analytic philosophy of mind, hermeneutics, structuralist/post-structuralist philosophy, history, literature, values-based practice, developmental psychology and service user research; and (2) reinvigorate phenomenology for mental health as the philosophical science of subjectivity and first-person experience. \n\nWe will develop international scholars from across disciplines and career stages to develop their research leadership and management activities and to engage in Award activities including international exchange fellowships small grants and, knowledge exchange events. The award will commence the reconstruction of phenomenological psychopathology for the 21st century as a democratic discipline with a historicized and inclusive account of the experience of the mental disorder developed.\n \n","awardDateDateOnly":"2021-04-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["History, 20th Century","History, 21st Century","Humans","Mental Disorders","Philosophy"]}
{"id":"360G-Wellcome-223447_Z_21_Z","title":"The gendered harms of \u2018voluntary return\u2019: women\u2019s experiences of disrupted relatedness, bodily precariousness, and gender-based violence in the UK and Punjab","Region":"South East","currency":"GBP","awardDate":"2021-05-11T00:00:00+00:00","Sponsor(s)":"Prof Dr Linda Mulcahy","Internal ID":"223447/Z/21/Z","description":"Since 2012, the UK\u2019s \u2018hostile environment\u2019 immigration regime has sought to precaritise non-citizens\u2019 lives, and thereby encourage their voluntary departure. In recognition of this explicitly violent objective, empirical legal scholars have increasingly sought to elucidate migrants\u2019 experiences of adversity in the UK with attention to the legal structures and practices that comprise this regime. This research will seek to expand this focus to return practices. Previous research on return has overwhelmingly focused on deportation \u2013 which comprises a minority of returns from the UK \u2013 and neglected voluntary return, despite its statistical and conceptual significance to the hostile environment regime. As voluntary return also affects far more women than deportation, the practice carries additional importance for scholars of gender and migration. Through ethnographic and narrative accounts of South Asian women\u2019s lived experiences of \u2018voluntary return\u2019 from the UK to Punjab, this research will foreground voluntary return\u2019s impacts for women\u2019s health, safety, wellbeing and relationships, and consider whether these experiences might be conceptualised as \u2018gendered harms\u2019. These findings will develop understandings of migrant women's autonomy, dignity and bodily integrity, and states' obligations to non-citizens under a political and legal system that sharply differentiates their rights from those of citizens.\n","plannedDates":[{"endDate":"2024-10-09T00:00:00+00:00","startDate":"2021-10-10T00:00:00+00:00","startDateDateOnly":"2021-10-10","endDateDateOnly":"2024-10-09"}],"amountAwarded":107696,"Financial Year":"2020/21","Lead Applicant":"Miss Vidya Ramachandran","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Ramachandran","Partnership Value":107696,"Approval Committee":"ERG11 Social Science and Bioethics, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The gendered harms of \u2018voluntary return\u2019: women\u2019s experiences of disrupted relatedness, bodily precariousness, and gender-based violence in the UK and Punjab Since 2012, the UK\u2019s \u2018hostile environment\u2019 immigration regime has sought to precaritise non-citizens\u2019 lives, and thereby encourage their voluntary departure. In recognition of this explicitly violent objective, empirical legal scholars have increasingly sought to elucidate migrants\u2019 experiences of adversity in the UK with attention to the legal structures and practices that comprise this regime. This research will seek to expand this focus to return practices. Previous research on return has overwhelmingly focused on deportation \u2013 which comprises a minority of returns from the UK \u2013 and neglected voluntary return, despite its statistical and conceptual significance to the hostile environment regime. As voluntary return also affects far more women than deportation, the practice carries additional importance for scholars of gender and migration. Through ethnographic and narrative accounts of South Asian women\u2019s lived experiences of \u2018voluntary return\u2019 from the UK to Punjab, this research will foreground voluntary return\u2019s impacts for women\u2019s health, safety, wellbeing and relationships, and consider whether these experiences might be conceptualised as \u2018gendered harms\u2019. These findings will develop understandings of migrant women's autonomy, dignity and bodily integrity, and states' obligations to non-citizens under a political and legal system that sharply differentiates their rights from those of citizens.\n","awardDateDateOnly":"2021-05-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anthropology, Cultural","Emigration and Immigration","Female","Humans","Transients and Migrants","United Kingdom","Violence"]}
{"id":"360G-Wellcome-223442_Z_21_Z","title":"Metropolitan Modernism, Venereal Disease and Social Hygiene, 1899-1945","Region":"Greater London","currency":"GBP","awardDate":"2021-05-11T00:00:00+00:00","Sponsor(s)":"Prof Peter Swaab","Internal ID":"223442/Z/21/Z","description":"Following the lapse of the Contagious Diseases Acts in the late nineteenth century - legislation that allowed for the routine inspection of prostitutes in order to reduce the rates of STDs - rising rates of venereal disease created, by the outbreak of war in 1914, an atmosphere of widespread sex panic that associated the disease with moral infection, particularly in metropolitan locales. My research proposes that the venereal disease epidemic of the early twentieth century was a significant medical and cultural event of particular concern to literary modernists in and around the city, including Joyce, Woolf, Eliot and Pound, and Lawrence, and activated a nexus of interrelated concerns such as anxieties surrounding birth control, prostitution, and non-procreative intercourse. This project will demonstrate how the eugenic language of social hygiene influenced modernist aesthetic strategies and suggest that literary modernism itself contributed to emerging ideas of sexual health by reflecting contemporary fears of illness and contamination. In doing so, it will deepen our understandings of the place of the literary in the production of medical knowledge at this time, and examine the crucial role of cultural forms in the dissemination and transmission of public health discourse in the early twentieth century.\n","plannedDates":[{"endDate":"2024-09-19T00:00:00+00:00","startDate":"2021-09-20T00:00:00+00:00","startDateDateOnly":"2021-09-20","endDateDateOnly":"2024-09-19"}],"amountAwarded":95026,"Financial Year":"2020/21","Lead Applicant":"Mr Christopher Jones","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Jones","Partnership Value":95026,"Approval Committee":"ERG10 Medical Humanities, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Metropolitan Modernism, Venereal Disease and Social Hygiene, 1899-1945 Following the lapse of the Contagious Diseases Acts in the late nineteenth century - legislation that allowed for the routine inspection of prostitutes in order to reduce the rates of STDs - rising rates of venereal disease created, by the outbreak of war in 1914, an atmosphere of widespread sex panic that associated the disease with moral infection, particularly in metropolitan locales. My research proposes that the venereal disease epidemic of the early twentieth century was a significant medical and cultural event of particular concern to literary modernists in and around the city, including Joyce, Woolf, Eliot and Pound, and Lawrence, and activated a nexus of interrelated concerns such as anxieties surrounding birth control, prostitution, and non-procreative intercourse. This project will demonstrate how the eugenic language of social hygiene influenced modernist aesthetic strategies and suggest that literary modernism itself contributed to emerging ideas of sexual health by reflecting contemporary fears of illness and contamination. In doing so, it will deepen our understandings of the place of the literary in the production of medical knowledge at this time, and examine the crucial role of cultural forms in the dissemination and transmission of public health discourse in the early twentieth century.\n","awardDateDateOnly":"2021-05-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Disease Outbreaks","Eugenics","History, 19th Century","History, 20th Century","Humans","Hygiene"]}
{"id":"360G-Wellcome-223422_Z_21_Z","title":"Blurring the Boundaries: A Study of Advanced Nursing Practice in the United Kingdom (1990-2010)","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2021-05-11T00:00:00+00:00","Sponsor(s)":"Prof Barry Doyle","Internal ID":"223422/Z/21/Z","description":"Advanced nursing practice has been of tremendous value to British healthcare. The government, NHS managers and patients alike have placed high expectations on Advanced Nurse Practitioners (ANPs), and researchers have concluded that ANPs have risen to the challenge. However, it is ironic that while ANPs have been deployed across varying sectors of British healthcare, neither the government nor the NMC - nursing's regulatory body - has placed legal parameters around the role's boundary of practice. There is no doubt that professional boundaries in healthcare have shifted. Before the 1990s, nurses had been innovatively expanding their practice boundaries in response to service needs. Consequently, the ANP role evolved under changing healthcare needs. It could be interpreted that British medical history does not understand advanced practice. Therefore this study will draw on the example of the USA and interpret such evidence to be applicable to the British context. Nursing historiography currently lacks any historical analysis of the implementation of Advanced Nurse Practitioners, their role and advance practice's evolution. This thesis will correct this oversight and be the first to write a holistic historical analysis of advanced practice's scope of practice. \n","plannedDates":[{"endDate":"2025-01-16T00:00:00+00:00","startDate":"2022-01-17T00:00:00+00:00","startDateDateOnly":"2022-01-17","endDateDateOnly":"2025-01-16"}],"amountAwarded":99326,"Financial Year":"2020/21","Lead Applicant":"Miss Kelly Swaby","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Swaby","Partnership Value":99326,"Approval Committee":"ERG10 Medical Humanities, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Huddersfield","name":"University of Huddersfield","addressCountry":"United Kingdom","id_and_name":"[\"University of Huddersfield\", \"360G-Wellcome-ORG:University-of-Huddersfield\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Huddersfield","name":"University of Huddersfield"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Blurring the Boundaries: A Study of Advanced Nursing Practice in the United Kingdom (1990-2010) Advanced nursing practice has been of tremendous value to British healthcare. The government, NHS managers and patients alike have placed high expectations on Advanced Nurse Practitioners (ANPs), and researchers have concluded that ANPs have risen to the challenge. However, it is ironic that while ANPs have been deployed across varying sectors of British healthcare, neither the government nor the NMC - nursing's regulatory body - has placed legal parameters around the role's boundary of practice. There is no doubt that professional boundaries in healthcare have shifted. Before the 1990s, nurses had been innovatively expanding their practice boundaries in response to service needs. Consequently, the ANP role evolved under changing healthcare needs. It could be interpreted that British medical history does not understand advanced practice. Therefore this study will draw on the example of the USA and interpret such evidence to be applicable to the British context. Nursing historiography currently lacks any historical analysis of the implementation of Advanced Nurse Practitioners, their role and advance practice's evolution. This thesis will correct this oversight and be the first to write a holistic historical analysis of advanced practice's scope of practice. \n","awardDateDateOnly":"2021-05-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Advanced Practice Nursing","Humans","Nurse Practitioners","Nurse's Role","United Kingdom"]}
{"id":"360G-Wellcome-223410_Z_21_Z","title":"Temporalities in Tension: Rethinking Healthcare Provisions for Sexual Migrants","Region":"Greater London","currency":"GBP","awardDate":"2021-05-11T00:00:00+00:00","Sponsor(s)":"Dr Claire Thomson","Internal ID":"223410/Z/21/Z","description":"This work responds to a growing volume of research on the wellbeing of sexual migrants. Little attention has been paid to defining migration in this literature, which is often understood in a purely spatial sense. In this project, I claim that sexual migrants \u2013 whether from the UK or abroad \u2013 traverse temporal, as well as spatial, boundaries. This, I claim, has important implications for sexual wellbeing and risk. Through ethnographic research in a London sexual health clinic, including two sets of 15 semi-structured interviews with service users and ten interviews with clinic staff, I seek to uncover the extent to which abrupt shifts between timelines, such as coming out of the closet, transitioning, or moving to radically new environments such as halls of residence or retirement homes, contribute to sexual risk. This research will problematise racist and imperialist geographies of risk that locate risk in faraway lands, while also bringing to light corrective measures that will improve patient experiences and health outcomes of temporal migrants, from wherever they originate. These measures include a recalibration of eligibility criteria for targeted risk reduction interventions and an identification of further training needs for sexual health staff working with temporal migrants.\n","plannedDates":[{"endDate":"2024-09-26T00:00:00+00:00","startDate":"2021-09-27T00:00:00+00:00","startDateDateOnly":"2021-09-27","endDateDateOnly":"2024-09-26"}],"amountAwarded":95373,"Financial Year":"2020/21","Lead Applicant":"Mx Arthur Davis","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Davis","Partnership Value":95373,"Approval Committee":"ERG11 Social Science and Bioethics, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Temporalities in Tension: Rethinking Healthcare Provisions for Sexual Migrants This work responds to a growing volume of research on the wellbeing of sexual migrants. Little attention has been paid to defining migration in this literature, which is often understood in a purely spatial sense. In this project, I claim that sexual migrants \u2013 whether from the UK or abroad \u2013 traverse temporal, as well as spatial, boundaries. This, I claim, has important implications for sexual wellbeing and risk. Through ethnographic research in a London sexual health clinic, including two sets of 15 semi-structured interviews with service users and ten interviews with clinic staff, I seek to uncover the extent to which abrupt shifts between timelines, such as coming out of the closet, transitioning, or moving to radically new environments such as halls of residence or retirement homes, contribute to sexual risk. This research will problematise racist and imperialist geographies of risk that locate risk in faraway lands, while also bringing to light corrective measures that will improve patient experiences and health outcomes of temporal migrants, from wherever they originate. These measures include a recalibration of eligibility criteria for targeted risk reduction interventions and an identification of further training needs for sexual health staff working with temporal migrants.\n","awardDateDateOnly":"2021-05-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anthropology, Cultural","Female","Humans","Interviews as Topic","London","Male","Qualitative Research","Sexual Behavior","Sexual Health","Transients and Migrants"]}
{"id":"360G-Wellcome-223403_Z_21_Z","title":"Exploring \u2018the domestic\u2019 in contemporary hospice architecture: a critical examination of the architecture and design of in-patient palliative care facilities in England","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2021-05-11T00:00:00+00:00","Sponsor(s)":"Prof Graham Ferrier","Internal ID":"223403/Z/21/Z","description":"This project proposes a new critical study of English hospice architecture, aimed at making evidence-based recommendations for inclusive hospice design. Although 40 million people need palliative care worldwide annually, relatively little research has examined the settings in which palliative care is administered or attempted to understand how patients, visitors and staff experience them. The widespread tendency in contemporary hospice architecture to make palliative care settings resemble domestic residences is rarely interrogated, despite potential problems surrounding the home\u2019s complexity and the question of whose home is being imitated. A better understanding of hospice architecture is needed to establish how to design hospices inclusively for individuals from all socio-economic and cultural backgrounds, especially given documented disadvantage in access for some groups.\n\nThis project will employ an interdisciplinary methodology, examining English palliative care facilities through site visits and analysis of primary documents, and exploring how individuals experience these environments through ethnographic field work, including observation, interviews and focus groups.\n\nThis study will provide a novel examination of English hospice architecture, highlighting the voices of the users of palliative care settings. Findings will be synthesised into recommendations for policy makers on how to address the issue of domestic design inclusively in palliative care settings.\n","plannedDates":[{"endDate":"2024-09-19T00:00:00+00:00","startDate":"2021-09-20T00:00:00+00:00","startDateDateOnly":"2021-09-20","endDateDateOnly":"2024-09-19"}],"amountAwarded":106241,"Financial Year":"2020/21","Lead Applicant":"Ms Lucia Crowther","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Crowther","Partnership Value":106241,"Approval Committee":"ERG10 Medical Humanities, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Hull","name":"University of Hull","addressCountry":"United Kingdom","id_and_name":"[\"University of Hull\", \"360G-Wellcome-ORG:University-of-Hull\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Hull","name":"University of Hull"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Exploring \u2018the domestic\u2019 in contemporary hospice architecture: a critical examination of the architecture and design of in-patient palliative care facilities in England This project proposes a new critical study of English hospice architecture, aimed at making evidence-based recommendations for inclusive hospice design. Although 40 million people need palliative care worldwide annually, relatively little research has examined the settings in which palliative care is administered or attempted to understand how patients, visitors and staff experience them. The widespread tendency in contemporary hospice architecture to make palliative care settings resemble domestic residences is rarely interrogated, despite potential problems surrounding the home\u2019s complexity and the question of whose home is being imitated. A better understanding of hospice architecture is needed to establish how to design hospices inclusively for individuals from all socio-economic and cultural backgrounds, especially given documented disadvantage in access for some groups.\n\nThis project will employ an interdisciplinary methodology, examining English palliative care facilities through site visits and analysis of primary documents, and exploring how individuals experience these environments through ethnographic field work, including observation, interviews and focus groups.\n\nThis study will provide a novel examination of English hospice architecture, highlighting the voices of the users of palliative care settings. Findings will be synthesised into recommendations for policy makers on how to address the issue of domestic design inclusively in palliative care settings.\n","awardDateDateOnly":"2021-05-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anthropology, Cultural","England","Focus Groups","Hospice Care","Hospice and Palliative Care Nursing","Humans","Palliative Care"]}
{"id":"360G-Wellcome-223402_Z_21_Z","title":"The Progress Paradox: Exploring the nexus between development, social inequalities, and mental distress in northern Pakistan","Region":"Scotland","currency":"GBP","awardDate":"2021-05-11T00:00:00+00:00","Sponsor(s)":"Prof Linda McKie","Internal ID":"223402/Z/21/Z","description":"Mental health activists and service-users have long argued for research and interventions to take into consideration structural determinants of mental distress such as violence and inequality. Yet, current scholarship on high rates of mental distress amongst women in Pakistan focus on proximal social determinants (factors pertaining to individuals and families).\n\n \n\nThis project challenges public health investigations that places responsibility of poor mental health of women in the region on family conflict, thereby misplacing causal accountability and missing the opportunity for large-scale transformation and social change. Taking poor mental health amongst women in northern Pakistan as a case study, this project examines how structural determinants such as gender inequality, poverty, and impact of development interventions, shape women\u2019s mental health in northern Pakistan. The proposed research will comprise of in-depth interviews, participant observation and archival research in Gilgit Baltistan, where high rates of suicides/attempted suicides have been recorded.\n\n \n\nThe project draws on critical perspectives from the fields of global mental health, international development, and gender studies. It aims to provide evidence and insights to researchers, mental health service providers, advocates, and policymakers in delivering health and gender justice through informed interventions and policies in Pakistan, and more broadly, South Asia.\n","plannedDates":[{"endDate":"2024-08-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2024-08-30"}],"amountAwarded":110278,"Financial Year":"2020/21","Lead Applicant":"Ms Laila Rajani","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Rajani","Partnership Value":110278,"Approval Committee":"ERG11 Social Science and Bioethics, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The Progress Paradox: Exploring the nexus between development, social inequalities, and mental distress in northern Pakistan Mental health activists and service-users have long argued for research and interventions to take into consideration structural determinants of mental distress such as violence and inequality. Yet, current scholarship on high rates of mental distress amongst women in Pakistan focus on proximal social determinants (factors pertaining to individuals and families).\n\n \n\nThis project challenges public health investigations that places responsibility of poor mental health of women in the region on family conflict, thereby misplacing causal accountability and missing the opportunity for large-scale transformation and social change. Taking poor mental health amongst women in northern Pakistan as a case study, this project examines how structural determinants such as gender inequality, poverty, and impact of development interventions, shape women\u2019s mental health in northern Pakistan. The proposed research will comprise of in-depth interviews, participant observation and archival research in Gilgit Baltistan, where high rates of suicides/attempted suicides have been recorded.\n\n \n\nThe project draws on critical perspectives from the fields of global mental health, international development, and gender studies. It aims to provide evidence and insights to researchers, mental health service providers, advocates, and policymakers in delivering health and gender justice through informed interventions and policies in Pakistan, and more broadly, South Asia.\n","awardDateDateOnly":"2021-05-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Asia","Female","Humans","Interviews as Topic","Mental Health","Pakistan","Social Determinants of Health","Suicide","Women's Health"]}
{"id":"360G-Wellcome-223377_Z_21_Z","title":"Embodied Inequalities of the Anthropocene. Building Capacity in Medical Anthropology","Region":"Greater London","currency":"GBP","awardDate":"2021-04-30T00:00:00+00:00","Internal ID":"223377/Z/21/Z","description":"This collaboration between Brazil, Mexico and the UK brings together environmental, indigenous, biosocial, multispecies, gender and theoretical expertise in Medical Anthropology, to extend interdisciplinary engagement concerning how the Anthropocene epoch impacts on human health. Supported by a post-doctoral researcher in each of the collaborating centres, we will develop Medical Anthropology in four areas: i) indigenous experience and coloniality of the Anthropocene, ii) gender, reproduction and environmental justice, iii) multispecies ethnography and human-animal health,  iv) COVID-19 and public understanding of the Anthropocene. From this research and in conjunction with open access publisher UCL Press, we will develop a tri-lingual digital resource for teaching and public reference.\n\nOur collaboration will begin online with bi-monthly meetings followed in February 2022 by a three day virtual cross-disciplinary seminar with invited expertise in science, geography, politics and history. We will work collaboratively to examine how these disciplines can inform Medical Anthropology of the Anthropocene and to identify articulations with policy and practice as these impact on human and environmental wellbeing. In November 2022 we will hold a face-to-face workshop in Mexico to develop dissemination and publications including the digital teaching resource and a multilingual special edition of a Latin American Medical Anthropology journal.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2021-10-01T00:00:00+00:00","startDateDateOnly":"2021-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":201912,"Financial Year":"2020/21","Lead Applicant":"Dr Sahra Gibbon","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Gibbon","Partnership Value":201912,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Embodied Inequalities of the Anthropocene. Building Capacity in Medical Anthropology This collaboration between Brazil, Mexico and the UK brings together environmental, indigenous, biosocial, multispecies, gender and theoretical expertise in Medical Anthropology, to extend interdisciplinary engagement concerning how the Anthropocene epoch impacts on human health. Supported by a post-doctoral researcher in each of the collaborating centres, we will develop Medical Anthropology in four areas: i) indigenous experience and coloniality of the Anthropocene, ii) gender, reproduction and environmental justice, iii) multispecies ethnography and human-animal health,  iv) COVID-19 and public understanding of the Anthropocene. From this research and in conjunction with open access publisher UCL Press, we will develop a tri-lingual digital resource for teaching and public reference.\n\nOur collaboration will begin online with bi-monthly meetings followed in February 2022 by a three day virtual cross-disciplinary seminar with invited expertise in science, geography, politics and history. We will work collaboratively to examine how these disciplines can inform Medical Anthropology of the Anthropocene and to identify articulations with policy and practice as these impact on human and environmental wellbeing. In November 2022 we will hold a face-to-face workshop in Mexico to develop dissemination and publications including the digital teaching resource and a multilingual special edition of a Latin American Medical Anthropology journal.\n","awardDateDateOnly":"2021-04-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anthropology, Cultural","Brazil","Humans","Mexico"]}
{"id":"360G-Wellcome-223350_Z_21_Z","title":"Humour and polemic in UK disability arts and its institutions, 1976-2010","Region":"Greater London","currency":"GBP","awardDate":"2021-05-11T00:00:00+00:00","Sponsor(s)":"Prof L Nead","Internal ID":"223350/Z/21/Z","description":"This practice-led project, from a disabled artist-researcher, investigates humour as a form of activism within the UK Disability Arts Movement. Focusing on the under-researched National Disability Arts Collection and Archives, it will document the emergence and uses of critical or polemical humour between 1976 and 2010. This archival research, supported by conversations with the movement\u2019s artists, will combine object-orientated creative practice and sensory enthnography with historiographical research.\n\nArt history has neglected these artists, who created institutions essential to UK arts today. Overlooked by disability studies too, their transgressive humour critically engaged with changing ideas of disability. For the medical humanities, the research will create new knowledge of how disabled people have driven and understood changing ideas of disability. For critical medical humanities, this project will offer a new paradigm of disability arts research, specifically addressing the significance of the disabled artist-subject as researcher. \n\nAt a time when the experience of disability in the UK is increasingly individualised, understanding this humour\u2019s agency, collectivity and its effectiveness in disability activism is urgent. This study will inform arts policy, re-position disability activism within art history, and inform critical understanding of how ideas of disability are influenced and understood by disabled people.\n","plannedDates":[{"endDate":"2024-09-04T00:00:00+00:00","startDate":"2021-09-05T00:00:00+00:00","startDateDateOnly":"2021-09-05","endDateDateOnly":"2024-09-04"}],"amountAwarded":89482,"Financial Year":"2020/21","Lead Applicant":"Ms Laura Cowley","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Cowley","Partnership Value":89482,"Approval Committee":"ERG10 Medical Humanities, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Birkbeck-University-of-London","name":"Birkbeck University of London","addressCountry":"United Kingdom","id_and_name":"[\"Birkbeck University of London\", \"360G-Wellcome-ORG:Birkbeck-University-of-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Birkbeck-University-of-London","name":"Birkbeck University of London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Humour and polemic in UK disability arts and its institutions, 1976-2010 This practice-led project, from a disabled artist-researcher, investigates humour as a form of activism within the UK Disability Arts Movement. Focusing on the under-researched National Disability Arts Collection and Archives, it will document the emergence and uses of critical or polemical humour between 1976 and 2010. This archival research, supported by conversations with the movement\u2019s artists, will combine object-orientated creative practice and sensory enthnography with historiographical research.\n\nArt history has neglected these artists, who created institutions essential to UK arts today. Overlooked by disability studies too, their transgressive humour critically engaged with changing ideas of disability. For the medical humanities, the research will create new knowledge of how disabled people have driven and understood changing ideas of disability. For critical medical humanities, this project will offer a new paradigm of disability arts research, specifically addressing the significance of the disabled artist-subject as researcher. \n\nAt a time when the experience of disability in the UK is increasingly individualised, understanding this humour\u2019s agency, collectivity and its effectiveness in disability activism is urgent. This study will inform arts policy, re-position disability activism within art history, and inform critical understanding of how ideas of disability are influenced and understood by disabled people.\n","awardDateDateOnly":"2021-05-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Art","Disabled Persons","History, 20th Century","Humanities","Humans","United Kingdom"]}
{"id":"360G-Wellcome-223328_Z_21_Z","title":"The Beaumont Society: Trans Cultures, Identities and Everyday Subjectivities, 1966-2004 ","Region":"Greater London","currency":"GBP","awardDate":"2021-05-11T00:00:00+00:00","Sponsor(s)":"Prof Matt Cook","Internal ID":"223328/Z/21/Z","description":"This project will be the first comprehensive history of the Beaumont Society, a UK based trans support network. It will focus on the ways that members of the Society conceptualised their sense of self,  both within the organisation and in relation to other trans and cis gender people and cultures. This research will be much more than a history of the society itself but will make significant strides in historicising trans identities and experiences in the UK, exploring the ways trans people negotiated the medical and health discourse that have historically legitimised trans identity, alongside other ways of understanding gender crossing in their everyday lives. These perspectives will in addition allow for reconsideration of wider themes of belonging and selfhood and the changing nature of social movements from the 1960s to the early years of the internet. Using a combination of archival research and oral history the project will be organised thematically, examining trans subjectivities through the everyday including domestic life, work, clubs and leisure, and other countercultural and political movements. The relationship of trans identities and experience to shifting gender norms will be a cross cutting theme. \n","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2021-10-01T00:00:00+00:00","startDateDateOnly":"2021-10-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":87362,"Financial Year":"2020/21","Lead Applicant":"Ms Leila Sellers","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Sellers","Partnership Value":87362,"Approval Committee":"ERG10 Medical Humanities, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Birkbeck-University-of-London","name":"Birkbeck University of London","addressCountry":"United Kingdom","id_and_name":"[\"Birkbeck University of London\", \"360G-Wellcome-ORG:Birkbeck-University-of-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Birkbeck-University-of-London","name":"Birkbeck University of London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The Beaumont Society: Trans Cultures, Identities and Everyday Subjectivities, 1966-2004  This project will be the first comprehensive history of the Beaumont Society, a UK based trans support network. It will focus on the ways that members of the Society conceptualised their sense of self,  both within the organisation and in relation to other trans and cis gender people and cultures. This research will be much more than a history of the society itself but will make significant strides in historicising trans identities and experiences in the UK, exploring the ways trans people negotiated the medical and health discourse that have historically legitimised trans identity, alongside other ways of understanding gender crossing in their everyday lives. These perspectives will in addition allow for reconsideration of wider themes of belonging and selfhood and the changing nature of social movements from the 1960s to the early years of the internet. Using a combination of archival research and oral history the project will be organised thematically, examining trans subjectivities through the everyday including domestic life, work, clubs and leisure, and other countercultural and political movements. The relationship of trans identities and experience to shifting gender norms will be a cross cutting theme. \n","awardDateDateOnly":"2021-05-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Gender Identity","History, 20th Century","Humans","United Kingdom"]}
{"id":"360G-Wellcome-223327_Z_21_Z","title":"Zoonotic divergences: humans, rats and micro-organisms in Guarani-Mbya villages of Jaragu\u00e1 Indigenous Land (S\u00e3o Paulo/SP, Brazil)","Region":"Scotland","currency":"GBP","awardDate":"2021-05-11T00:00:00+00:00","Sponsor(s)":"Dr Paloma Gay y Blasco","Internal ID":"223327/Z/21/Z","description":"My PhD research aims to deepen anthropological understandings of health, illness and disease in contexts where the Guarani-Mbya people, rodents and microorganisms become entangled through leptospirosis within the Jaragua´ Indigenous Land \u2013 a small territory surrounded by the city of Sa~o Paulo, Brazil\u2019s largest metropolis. My project will be based on the ethnographic study of multispecies relations entangling indigenous people, Leptospira spp bacteria, governmental agencies of disease and rodent control, and health professionals. The project will focus on the examination of Guarani-Mbya perceptions of and practices around rodent-borne infection so as to unsettle the colonial vestiges of epidemiological reasoning that continues to inform understandings of zoonosis. This investigation of human-rodent relations will be path-breaking for Amerindian Studies, as, for the most part, these have focused on animal-human relations primarily in contexts of hunting and pet-keeping. The ethnographic data produced by the project will also be useful for reconceptualizing and developing rodent-management strategies and community-led programmes in other Amerindian contexts, contributing to critically expanding the One Health initiative towards an ethnographic-based, decolonized, community-led, and multispecies approach. [zoonosis, Amerindian Studies, rats, Guarani-Mbya, Brazil]\n","plannedDates":[{"endDate":"2024-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2024-08-31"}],"amountAwarded":131210,"Financial Year":"2020/21","Lead Applicant":"Mr Bruno Santos","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Santos","Partnership Value":131210,"Approval Committee":"ERG11 Social Science and Bioethics, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-St-Andrews","name":"University of St Andrews","addressCountry":"United Kingdom","id_and_name":"[\"University of St Andrews\", \"360G-Wellcome-ORG:University-of-St-Andrews\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-St-Andrews","name":"University of St Andrews"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Zoonotic divergences: humans, rats and micro-organisms in Guarani-Mbya villages of Jaragu\u00e1 Indigenous Land (S\u00e3o Paulo/SP, Brazil) My PhD research aims to deepen anthropological understandings of health, illness and disease in contexts where the Guarani-Mbya people, rodents and microorganisms become entangled through leptospirosis within the Jaragua´ Indigenous Land \u2013 a small territory surrounded by the city of Sa~o Paulo, Brazil\u2019s largest metropolis. My project will be based on the ethnographic study of multispecies relations entangling indigenous people, Leptospira spp bacteria, governmental agencies of disease and rodent control, and health professionals. The project will focus on the examination of Guarani-Mbya perceptions of and practices around rodent-borne infection so as to unsettle the colonial vestiges of epidemiological reasoning that continues to inform understandings of zoonosis. This investigation of human-rodent relations will be path-breaking for Amerindian Studies, as, for the most part, these have focused on animal-human relations primarily in contexts of hunting and pet-keeping. The ethnographic data produced by the project will also be useful for reconceptualizing and developing rodent-management strategies and community-led programmes in other Amerindian contexts, contributing to critically expanding the One Health initiative towards an ethnographic-based, decolonized, community-led, and multispecies approach. [zoonosis, Amerindian Studies, rats, Guarani-Mbya, Brazil]\n","awardDateDateOnly":"2021-05-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Brazil","Humans","Indians, South American","Leptospira","Leptospirosis","Rats","Rodent Diseases","Rodentia","Zoonoses"]}
{"id":"360G-Wellcome-223322_Z_21_Z","title":"Transnationalism and Changing Medical Practice Paradigms in Exile Tibetan Medicine  and the West ","Region":"Scotland","currency":"GBP","awardDate":"2021-05-11T00:00:00+00:00","Sponsor(s)":"Prof Linda McKie","Internal ID":"223322/Z/21/Z","description":"Transnational medical practice is a common phenomenon in contemporary Tibetan medicine, especially among exile practitioners in India and Nepal. Both in the form of medical tours abroad or local treatments of foreign patients and via telemedicine, doctors provide transnational medical care. However, as a result of the deterritorialization of practice and practitioners or new phenomena like telemedicine and innovations in medical treatment options, varying degrees of changes in contrast to national treatment paradigms occur that raise questions about the efficacy or benefit for patients. This research seeks to explore and analyse transnational Tibetan medical practice and asks to what extent this trend transforms essential principles, perceptions, and representations of Tibetan medicine. The aim is to determine and question tendencies towards a modern or global Tibetan medicine, following Wujastyk and Smith's categories of modern and global Ayurveda. Using the methods of participant observation and semi-structured interviews with Tibetan medical doctors and patients, I will conduct a 13 months long multi-sited ethnographic fieldwork in India, Nepal, and Europe. Ultimately, the research will help to understand the challenges to and possibilities for globalised medical practice, contributing to the growing anthropological interest in global health.\n\nKeywords: Tibetan medicine, transnational medical practice, therapeutic travel, telemedicine\n","plannedDates":[{"endDate":"2024-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2024-08-31"}],"amountAwarded":133183,"Financial Year":"2020/21","Lead Applicant":"Miss Patricia Mundelius","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Mundelius","Partnership Value":133183,"Approval Committee":"ERG11 Social Science and Bioethics, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Transnationalism and Changing Medical Practice Paradigms in Exile Tibetan Medicine  and the West  Transnational medical practice is a common phenomenon in contemporary Tibetan medicine, especially among exile practitioners in India and Nepal. Both in the form of medical tours abroad or local treatments of foreign patients and via telemedicine, doctors provide transnational medical care. However, as a result of the deterritorialization of practice and practitioners or new phenomena like telemedicine and innovations in medical treatment options, varying degrees of changes in contrast to national treatment paradigms occur that raise questions about the efficacy or benefit for patients. This research seeks to explore and analyse transnational Tibetan medical practice and asks to what extent this trend transforms essential principles, perceptions, and representations of Tibetan medicine. The aim is to determine and question tendencies towards a modern or global Tibetan medicine, following Wujastyk and Smith's categories of modern and global Ayurveda. Using the methods of participant observation and semi-structured interviews with Tibetan medical doctors and patients, I will conduct a 13 months long multi-sited ethnographic fieldwork in India, Nepal, and Europe. Ultimately, the research will help to understand the challenges to and possibilities for globalised medical practice, contributing to the growing anthropological interest in global health.\n\nKeywords: Tibetan medicine, transnational medical practice, therapeutic travel, telemedicine\n","awardDateDateOnly":"2021-05-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","India","Nepal","Physicians"]}
{"id":"360G-Wellcome-223312_Z_21_Z","title":"Medicine, charm or treasure? Mediterranean red coral in England c.1600-1750.","Region":"South East","currency":"GBP","awardDate":"2021-05-11T00:00:00+00:00","Sponsor(s)":"Prof Catherine Richardson","Internal ID":"223312/Z/21/Z","description":"Mediterranean red coral has long been treasured around the world and is currently under threat from intensive fishing, oil drilling and rising sea temperatures caused by climate change. This project will explore the value placed on Mediterranean red coral, Corallium rubrum, a natural material sourced and prized in medieval and Renaissance Italy but also a culturally significant foreign import to Protestant England c.1600-1750. While coral is highly visible in early modern English sources, the historical importance of coral to English beliefs about physical and mental health is yet to be analysed. Drawing on a wealth of documentary evidence, material and visual culture, held in The National Archives, V & A, British Museum, Wellcome Collection, Science Museum and National Portrait Gallery, I will examine how coral was used as a medicinal ingredient, contributed to a domestic armoury against natural and supernatural threats, and was also a luxury commodity, perceived to be a material imbued with particular values, properties and powers in English society. Once considered to be a limitless natural treasure of the seas, the ecological threat to red coral in the Mediterranean makes understanding our long history of engagement with this precious species all the more critical at this time.\n","plannedDates":[{"endDate":"2024-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2024-08-31"}],"amountAwarded":86903,"Financial Year":"2020/21","Lead Applicant":"Ms Francesca Richards","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Richards","Partnership Value":86903,"Approval Committee":"ERG10 Medical Humanities, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Kent","name":"University of Kent","addressCountry":"United Kingdom","id_and_name":"[\"University of Kent\", \"360G-Wellcome-ORG:University-of-Kent\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Kent","name":"University of Kent"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Medicine, charm or treasure? Mediterranean red coral in England c.1600-1750. Mediterranean red coral has long been treasured around the world and is currently under threat from intensive fishing, oil drilling and rising sea temperatures caused by climate change. This project will explore the value placed on Mediterranean red coral, Corallium rubrum, a natural material sourced and prized in medieval and Renaissance Italy but also a culturally significant foreign import to Protestant England c.1600-1750. While coral is highly visible in early modern English sources, the historical importance of coral to English beliefs about physical and mental health is yet to be analysed. Drawing on a wealth of documentary evidence, material and visual culture, held in The National Archives, V & A, British Museum, Wellcome Collection, Science Museum and National Portrait Gallery, I will examine how coral was used as a medicinal ingredient, contributed to a domestic armoury against natural and supernatural threats, and was also a luxury commodity, perceived to be a material imbued with particular values, properties and powers in English society. Once considered to be a limitless natural treasure of the seas, the ecological threat to red coral in the Mediterranean makes understanding our long history of engagement with this precious species all the more critical at this time.\n","awardDateDateOnly":"2021-05-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Anthozoa","Climate Change","England","Italy","Museums"]}
{"id":"360G-Wellcome-223294_Z_21_Z","title":"Skeleton Merchants as Agents of Socio-Scientific Advancements: Exploring the History of Bone Trade in Colonial and Postcolonial India, 1858\u20131985 ","Region":"South East","currency":"GBP","awardDate":"2021-05-11T00:00:00+00:00","Sponsor(s)":"Dr Erica Charters","Internal ID":"223294/Z/21/Z","description":"My dissertation seeks to argue that the modern Western Scientific advancement was largely predicated on the supply of South Asian bones from India to Britain during the legal creation of the British Raj in 1858. In doing so, it attempts to link the trade of bones and bodies to what I call the \u2018Red Industry\u2019\u2014a full-fledged socio-economic establishment employing numerous labourers, specialized in different units, which thereby assumed a pivotal place in the network of imperial capitalism, propelled by profit. Besides leading to the emergence of ancillary industries, wherein bones are seen as potentially esoteric, aesthetic and even agricultural resources, I argue that the \u2018Red market\u2019 also projected itself as indispensable with regards to the contributions in various socio-medical fields: forensic anthropology, phrenological works, osteo-archaeological discoveries and leading studies on Osteoporosis. Focusing primarily on the local perceptions of the dead, and the surrounding inter and intra-caste polemics on dissection, the work essentially seeks to bridge the long-standing gap between the trade economy and the overarching historical debates predominantly concerning bio-ethics and public health, while interacting with law, labour, society and medicine throughout the mid-nineteenth to the late twentieth centuries\u2014the era of decolonization. \n\nKeywords:\n\nBritish Raj, South Asia, Public Health, Medicine\n","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":171260,"Financial Year":"2020/21","Lead Applicant":"Miss Nilanjana Dutta","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Dutta","Partnership Value":171260,"Approval Committee":"ERG10 Medical Humanities, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Skeleton Merchants as Agents of Socio-Scientific Advancements: Exploring the History of Bone Trade in Colonial and Postcolonial India, 1858\u20131985  My dissertation seeks to argue that the modern Western Scientific advancement was largely predicated on the supply of South Asian bones from India to Britain during the legal creation of the British Raj in 1858. In doing so, it attempts to link the trade of bones and bodies to what I call the \u2018Red Industry\u2019\u2014a full-fledged socio-economic establishment employing numerous labourers, specialized in different units, which thereby assumed a pivotal place in the network of imperial capitalism, propelled by profit. Besides leading to the emergence of ancillary industries, wherein bones are seen as potentially esoteric, aesthetic and even agricultural resources, I argue that the \u2018Red market\u2019 also projected itself as indispensable with regards to the contributions in various socio-medical fields: forensic anthropology, phrenological works, osteo-archaeological discoveries and leading studies on Osteoporosis. Focusing primarily on the local perceptions of the dead, and the surrounding inter and intra-caste polemics on dissection, the work essentially seeks to bridge the long-standing gap between the trade economy and the overarching historical debates predominantly concerning bio-ethics and public health, while interacting with law, labour, society and medicine throughout the mid-nineteenth to the late twentieth centuries\u2014the era of decolonization. \n\nKeywords:\n\nBritish Raj, South Asia, Public Health, Medicine\n","awardDateDateOnly":"2021-05-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Asia","Bone and Bones","History, 18th Century","History, 19th Century","History, 20th Century","History, Medieval","Humans","India","United Kingdom"]}
{"id":"360G-Wellcome-223290_Z_21_Z","title":"Bioethics Research: Interdisciplinary Group of Early Career Researchers: Bristol-Kyoto-Yonsei (BRIDGES:BKY)","Region":"South West","currency":"GBP","awardDate":"2021-04-30T00:00:00+00:00","Internal ID":"223290/Z/21/Z","description":"Building on a developing track record of collaboration between Bristol, Kyoto and Yonsei, BRIDGES:BKY aims to address shared bioethical challenges, through sharing learning and expertise, to benefit postgraduate and early career researchers (PGR/ECRs). Our four challenge areas are: (1) ageing and end-of-life care; (2) clinical ethics support; (3) reproduction and genomics; and (4) theories and approaches in bioethics. These are shared (indeed, global) challenges, which invite new research, and in which the partners have complementary research interests. Guided by these challenges, BRIDGES:BKY will share learning and expertise, including on different methodological approaches to research in these areas. BRIDGES:BKY will leverage our existing links and partnerships to deliver new opportunities to PGR/ECR participants, drawn from across the partner institutions (and beyond), to participate in, and benefit from training workshops, conferences and a (virtual) visiting researcher scheme. Supported by teleconferencing and a dedicated website, activities will be virtual, with some in-person elements (where appropriate). All partners will host and contribute to these activities, through which PGR/ECR participants will develop their knowledge and skills, and their - and the partners\u2019 - future collaborative research endeavours will be shaped. \n","plannedDates":[{"endDate":"2023-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2023-08-31"}],"amountAwarded":201781,"Financial Year":"2020/21","Lead Applicant":"Prof Richard Huxtable","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Huxtable","Partnership Value":201781,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Bioethics Research: Interdisciplinary Group of Early Career Researchers: Bristol-Kyoto-Yonsei (BRIDGES:BKY) Building on a developing track record of collaboration between Bristol, Kyoto and Yonsei, BRIDGES:BKY aims to address shared bioethical challenges, through sharing learning and expertise, to benefit postgraduate and early career researchers (PGR/ECRs). Our four challenge areas are: (1) ageing and end-of-life care; (2) clinical ethics support; (3) reproduction and genomics; and (4) theories and approaches in bioethics. These are shared (indeed, global) challenges, which invite new research, and in which the partners have complementary research interests. Guided by these challenges, BRIDGES:BKY will share learning and expertise, including on different methodological approaches to research in these areas. BRIDGES:BKY will leverage our existing links and partnerships to deliver new opportunities to PGR/ECR participants, drawn from across the partner institutions (and beyond), to participate in, and benefit from training workshops, conferences and a (virtual) visiting researcher scheme. Supported by teleconferencing and a dedicated website, activities will be virtual, with some in-person elements (where appropriate). All partners will host and contribute to these activities, through which PGR/ECR participants will develop their knowledge and skills, and their - and the partners\u2019 - future collaborative research endeavours will be shaped. \n","awardDateDateOnly":"2021-04-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Bioethics","Biomedical Research","Cooperative Behavior","Humans","Research Personnel"]}
{"id":"360G-Wellcome-223287_Z_21_Z","title":"Health Professional Responses to Deathbed Phenomena: Implications for medical knowledge and care","Region":"Greater London","currency":"GBP","awardDate":"2021-05-11T00:00:00+00:00","Sponsor(s)":"Prof Monica Greco","Internal ID":"223287/Z/21/Z","description":"Meaningful dreams, visions and coincidences are a remarkably common feature of the dying process. While patients and families report their profound spiritual significance, mainstream clinical literature explains them in materialist terms. This project asks how health professionals respond to such events on the ground, whether they reflect this materialist approach or if there are examples of healthworkers engaging in more ontologically and epistemologically open ways. The research will explore how philosophical responses influence the day-to-day practices of care. It will also ask whether variation in interpretations of such events runs along existing lines of social or cultural difference among both healthworkers and patients. I will take a methodologically interdisciplinary approach combining an ethnography of a hospice in-patient unit (utilising my experience as a palliative care nurse) with narrative interviews of staff who have responded to deathbed experiences. Drawing on feminist care theory, science and technology studies and the medical humanities this study will explore the significance of responses to deathbed phenomena for both clinical knowledge practices and patient care. \n","plannedDates":[{"endDate":"2027-10-03T00:00:00+00:00","startDate":"2021-10-04T00:00:00+00:00","startDateDateOnly":"2021-10-04","endDateDateOnly":"2027-10-03"}],"amountAwarded":94754,"Financial Year":"2020/21","Lead Applicant":"Ms Rachel Cummings","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Cummings","Partnership Value":94754,"Approval Committee":"ERG10 Medical Humanities, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Goldsmiths-University-of-London","name":"Goldsmiths, University of London","addressCountry":"United Kingdom","id_and_name":"[\"Goldsmiths, University of London\", \"360G-Wellcome-ORG:Goldsmiths-University-of-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Goldsmiths-University-of-London","name":"Goldsmiths, University of London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Health Professional Responses to Deathbed Phenomena: Implications for medical knowledge and care Meaningful dreams, visions and coincidences are a remarkably common feature of the dying process. While patients and families report their profound spiritual significance, mainstream clinical literature explains them in materialist terms. This project asks how health professionals respond to such events on the ground, whether they reflect this materialist approach or if there are examples of healthworkers engaging in more ontologically and epistemologically open ways. The research will explore how philosophical responses influence the day-to-day practices of care. It will also ask whether variation in interpretations of such events runs along existing lines of social or cultural difference among both healthworkers and patients. I will take a methodologically interdisciplinary approach combining an ethnography of a hospice in-patient unit (utilising my experience as a palliative care nurse) with narrative interviews of staff who have responded to deathbed experiences. Drawing on feminist care theory, science and technology studies and the medical humanities this study will explore the significance of responses to deathbed phenomena for both clinical knowledge practices and patient care. \n","awardDateDateOnly":"2021-05-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anthropology, Cultural","Attitude to Death","Hospice Care","Humans","Palliative Care","Terminal Care"]}
{"id":"360G-Wellcome-223271_Z_21_Z","title":" Leveraging COG-UK expertise to support the global dissemination of SARS-CoV-2 genome sequencing","Region":"East of England","currency":"GBP","awardDate":"2021-04-30T00:00:00+00:00","Internal ID":"223271/Z/21/Z","description":"Control of the COVID-19 pandemic depends on the development and equitable roll-out of vaccines that remain effective over time.  But the evolution of SARS-CoV-2 variants that exhibit variable degrees of immune evasion, and other characteristics including greater transmissibility and/or lethality, threaten to undermine our ability to control COVID-19. It is widely accepted that vaccines will need to be altered over time as the virus mutates. Effective vaccine re-development is dependent upon the availability of global viral sequence data, but there is a lack of sequence data for much of the world, including low, middle and high-income countries. The COVID-19 Genomics UK Consortium (COG-UK) (including the Wellcome Sanger Institute) will leverage its expertise to develop a comprehensive global learning programme on SARS-CoV-2 genome sequencing (COG-GLOBAL). This will be achieved by working with experienced on-line educators. Specific aims include the development of an open access, online modular global learning programme on SARS-CoV-2 sequencing and analysis, allowing users to follow pathways of learning according to professional expertise (laboratory scientist, clinical practitioner, data scientist  &  epidemiologist, bioinformatician or policy maker); and the development of train-the-trainer courses in collaboration with the Wellcome Connecting Science Advanced Courses, Wellcome Africa and Asia Programmes, and other contributors.\n","plannedDates":[{"endDate":"2023-06-02T00:00:00+00:00","startDate":"2021-06-03T00:00:00+00:00","startDateDateOnly":"2021-06-03","endDateDateOnly":"2023-06-02"}],"amountAwarded":492566,"Financial Year":"2020/21","Lead Applicant":"Prof Sharon Peacock","grantProgramme":[{"title":"Coronavirus","title_keyword":"Coronavirus"}],"Partnership Name":"Wellcome-DFID Epidemic Response","Applicant Surname":"Peacock","Partnership Value":492566,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":" Leveraging COG-UK expertise to support the global dissemination of SARS-CoV-2 genome sequencing Control of the COVID-19 pandemic depends on the development and equitable roll-out of vaccines that remain effective over time.  But the evolution of SARS-CoV-2 variants that exhibit variable degrees of immune evasion, and other characteristics including greater transmissibility and/or lethality, threaten to undermine our ability to control COVID-19. It is widely accepted that vaccines will need to be altered over time as the virus mutates. Effective vaccine re-development is dependent upon the availability of global viral sequence data, but there is a lack of sequence data for much of the world, including low, middle and high-income countries. The COVID-19 Genomics UK Consortium (COG-UK) (including the Wellcome Sanger Institute) will leverage its expertise to develop a comprehensive global learning programme on SARS-CoV-2 genome sequencing (COG-GLOBAL). This will be achieved by working with experienced on-line educators. Specific aims include the development of an open access, online modular global learning programme on SARS-CoV-2 sequencing and analysis, allowing users to follow pathways of learning according to professional expertise (laboratory scientist, clinical practitioner, data scientist  &  epidemiologist, bioinformatician or policy maker); and the development of train-the-trainer courses in collaboration with the Wellcome Connecting Science Advanced Courses, Wellcome Africa and Asia Programmes, and other contributors.\n","awardDateDateOnly":"2021-04-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa","Global Health","Humans","United Kingdom","Viral Vaccines"]}
{"id":"360G-Wellcome-223271_A_21_Z","title":" Leveraging COG-UK expertise to support the global dissemination of SARS-CoV-2 genome sequencing","Region":"East of England","currency":"GBP","awardDate":"2021-04-30T00:00:00+00:00","Internal ID":"223271/A/21/Z","description":"Control of the COVID-19 pandemic depends on the development and equitable roll-out of vaccines that remain effective over time.  But the evolution of SARS-CoV-2 variants that exhibit variable degrees of immune evasion, and other characteristics including greater transmissibility and/or lethality, threaten to undermine our ability to control COVID-19. It is widely accepted that vaccines will need to be altered over time as the virus mutates. Effective vaccine re-development is dependent upon the availability of global viral sequence data, but there is a lack of sequence data for much of the world, including low, middle and high-income countries. The COVID-19 Genomics UK Consortium (COG-UK) (including the Wellcome Sanger Institute) will leverage its expertise to develop a comprehensive global learning programme on SARS-CoV-2 genome sequencing (COG-GLOBAL). This will be achieved by working with experienced on-line educators. Specific aims include the development of an open access, online modular global learning programme on SARS-CoV-2 sequencing and analysis, allowing users to follow pathways of learning according to professional expertise (laboratory scientist, clinical practitioner, data scientist  &  epidemiologist, bioinformatician or policy maker); and the development of train-the-trainer courses in collaboration with the Wellcome Connecting Science Advanced Courses, Wellcome Africa and Asia Programmes, and other contributors.\n","plannedDates":[{"endDate":"2023-06-02T00:00:00+00:00","startDate":"2021-06-03T00:00:00+00:00","startDateDateOnly":"2021-06-03","endDateDateOnly":"2023-06-02"}],"amountAwarded":463888,"Financial Year":"2020/21","Lead Applicant":"Prof Julian Rayner","grantProgramme":[{"title":"Sanger Resource Collaboration","title_keyword":"Sanger Resource Collaboration"}],"Partnership Name":"Wellcome-DFID Epidemic Preparedness","Applicant Surname":"Rayner","Partnership Value":463888,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Wellcome-Trust-Sanger-Institute","name":"Wellcome Trust Sanger Institute","addressCountry":"United Kingdom","id_and_name":"[\"Wellcome Trust Sanger Institute\", \"360G-Wellcome-ORG:Wellcome-Trust-Sanger-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Wellcome-Trust-Sanger-Institute","name":"Wellcome Trust Sanger Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":" Leveraging COG-UK expertise to support the global dissemination of SARS-CoV-2 genome sequencing Control of the COVID-19 pandemic depends on the development and equitable roll-out of vaccines that remain effective over time.  But the evolution of SARS-CoV-2 variants that exhibit variable degrees of immune evasion, and other characteristics including greater transmissibility and/or lethality, threaten to undermine our ability to control COVID-19. It is widely accepted that vaccines will need to be altered over time as the virus mutates. Effective vaccine re-development is dependent upon the availability of global viral sequence data, but there is a lack of sequence data for much of the world, including low, middle and high-income countries. The COVID-19 Genomics UK Consortium (COG-UK) (including the Wellcome Sanger Institute) will leverage its expertise to develop a comprehensive global learning programme on SARS-CoV-2 genome sequencing (COG-GLOBAL). This will be achieved by working with experienced on-line educators. Specific aims include the development of an open access, online modular global learning programme on SARS-CoV-2 sequencing and analysis, allowing users to follow pathways of learning according to professional expertise (laboratory scientist, clinical practitioner, data scientist  &  epidemiologist, bioinformatician or policy maker); and the development of train-the-trainer courses in collaboration with the Wellcome Connecting Science Advanced Courses, Wellcome Africa and Asia Programmes, and other contributors.\n","awardDateDateOnly":"2021-04-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa","Global Health","Humans","United Kingdom","Viral Vaccines"]}
{"id":"360G-Wellcome-223223_Z_21_Z","title":"Open Research Central","Region":"Greater London","currency":"GBP","awardDate":"2021-03-31T00:00:00+00:00","Internal ID":"223223/Z/21/Z","description":"The open access movement has demonstrated that \"openness\" is a benefit to the creation, dissemination, and reuse of knowledge. Through a variety of policies and initiatives, there is renewed momentum for sharing research outputs as part of a more connected and collaborative open research ecosystem.  However, there remains a need for consensus around how best to deliver a research dissemination system that maximises the benefits for both science and society, and the researchers upon which such a system depends.\n\nOpen Research Central (ORC) is a not-for-profit organization that aims to change the paradigm for primary research dissemination by bringing together key representatives across the scholarly ecosystem to define standards, build a movement to expand adoption of these standards, encourage the community to provide researchers with services that meet these standards and promote these standards.\n\nTo build further momentum and adoption globally of open research publishing approaches, the ORC Board wish to secure resource for 18 months to underpin more significant fund raising efforts to enable ORC to deliver on its mission, to develop and start to put into place a sustainability plan, and to support the Board in the day-to-day running and management of ORC.\n","plannedDates":[{"endDate":"2022-11-30T00:00:00+00:00","startDate":"2021-06-01T00:00:00+00:00","startDateDateOnly":"2021-06-01","endDateDateOnly":"2022-11-30"}],"amountAwarded":16000,"Financial Year":"2020/21","Lead Applicant":"Dr Rebecca Lawrence","grantProgramme":[{"title":"Discretionary Award - Open research","title_keyword":"Discretionary Award - Open research"}],"Applicant Surname":"Lawrence","Partnership Value":16000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Open-Research-Central","name":"Open Research Central","addressCountry":"United Kingdom","id_and_name":"[\"Open Research Central\", \"360G-Wellcome-ORG:Open-Research-Central\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Open-Research-Central","name":"Open Research Central"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Research Central The open access movement has demonstrated that \"openness\" is a benefit to the creation, dissemination, and reuse of knowledge. Through a variety of policies and initiatives, there is renewed momentum for sharing research outputs as part of a more connected and collaborative open research ecosystem.  However, there remains a need for consensus around how best to deliver a research dissemination system that maximises the benefits for both science and society, and the researchers upon which such a system depends.\n\nOpen Research Central (ORC) is a not-for-profit organization that aims to change the paradigm for primary research dissemination by bringing together key representatives across the scholarly ecosystem to define standards, build a movement to expand adoption of these standards, encourage the community to provide researchers with services that meet these standards and promote these standards.\n\nTo build further momentum and adoption globally of open research publishing approaches, the ORC Board wish to secure resource for 18 months to underpin more significant fund raising efforts to enable ORC to deliver on its mission, to develop and start to put into place a sustainability plan, and to support the Board in the day-to-day running and management of ORC.\n","awardDateDateOnly":"2021-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cooperative Behavior","Humans","Information Dissemination"]}
{"id":"360G-Wellcome-223080_Z_21_Z","title":"Advancing the global health agenda with the Paris Peace Forum","Region":"International","currency":"GBP","awardDate":"2021-04-30T00:00:00+00:00","Internal ID":"223080/Z/21/Z","description":"The Paris Peace Forum will host a series of discussions to maintain the partnership developed by ACT-A  (Access to COVID-19 Tools Accelerator) and the governance of global health at the top of the political agenda and further deliver concrete solutions while contributing to the construction of an overall governance framework in the sector. The proposal includes hosting discussions taking place in the framework of a pilot, year-long partnership between the Forum and Wellcome Trust. These discussions would mobilize stakeholders of the Forum\u2019s community and beyond. The Forum would naturally seek Wellcome\u2019s guidance and advice on the scope, topics, invitees, and outputs of these discussions. Stakeholders would be invited to participate in each discussion based on their institutional focus and expertise and on the basis of their capacity to contribute to and implement the desired outcomes. With the support provided by the Wellcome Trust, the Forum could convene two roundtables in 2021, to provide for sufficient time for preparation, eventually for follow-up actions in between and potentially to leverage to key moments in the annual Forum cycle: the Spring meetings of the Paris Peace Forum (May 2021) and the fourth edition of the annual event (11-13 November, 2021).\n","plannedDates":[{"endDate":"2022-04-20T00:00:00+00:00","startDate":"2021-04-21T00:00:00+00:00","startDateDateOnly":"2021-04-21","endDateDateOnly":"2022-04-20"}],"amountAwarded":85186,"Financial Year":"2020/21","Lead Applicant":"Mr Adrien Abecassis","grantProgramme":[{"title":"Discretionary Award - Policy ","title_keyword":"Discretionary Award - Policy "}],"Applicant Surname":"Abecassis","Partnership Value":85186,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Paris-Peace-Forum","name":"Paris Peace Forum","addressCountry":"France","id_and_name":"[\"Paris Peace Forum\", \"360G-Wellcome-ORG:Paris-Peace-Forum\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Paris-Peace-Forum","name":"Paris Peace Forum"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Advancing the global health agenda with the Paris Peace Forum The Paris Peace Forum will host a series of discussions to maintain the partnership developed by ACT-A  (Access to COVID-19 Tools Accelerator) and the governance of global health at the top of the political agenda and further deliver concrete solutions while contributing to the construction of an overall governance framework in the sector. The proposal includes hosting discussions taking place in the framework of a pilot, year-long partnership between the Forum and Wellcome Trust. These discussions would mobilize stakeholders of the Forum\u2019s community and beyond. The Forum would naturally seek Wellcome\u2019s guidance and advice on the scope, topics, invitees, and outputs of these discussions. Stakeholders would be invited to participate in each discussion based on their institutional focus and expertise and on the basis of their capacity to contribute to and implement the desired outcomes. With the support provided by the Wellcome Trust, the Forum could convene two roundtables in 2021, to provide for sufficient time for preparation, eventually for follow-up actions in between and potentially to leverage to key moments in the annual Forum cycle: the Spring meetings of the Paris Peace Forum (May 2021) and the fourth edition of the annual event (11-13 November, 2021).\n","awardDateDateOnly":"2021-04-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Global Health","Humans","International Cooperation"]}
{"id":"360G-Wellcome-223068_Z_21_Z","title":"Panel on Financing for Pandemic Prevention, Preparedness and Response","Region":"International","currency":"GBP","awardDate":"2021-03-31T00:00:00+00:00","Internal ID":"223068/Z/21/Z","description":"A new high-level panel, led by co-chairs Tharman Shanmugaratnam and Lawrence H. Summers, has been mandated by the Italian presidency of the G20 to propose reforms and other measures that will lead to more reliable and sustainable financing of pandemic prevention, preparedness, and response. To support the panel's deliberations and decision-making, CGD and Bruegel propose establishing a team to lead the analysis and content development of the proposals, with logistical, outreach, engagement, and coordination support from a secretariat at Wellcome and the US National Academies of Medicine. The team will develop a short scoping note on the economic rationale behind prioritizing public investment in prevention, preparedness, and response, an outline of the final report for discussion and feedback from the co-chairs, background analyses (on landscaping current financing and issues, existing asks and proposals; setting a financing goal and assessing its value for money; and governance, organization, and incentives), a long list of 10-15 proposals for governance reform and/or new or existing financing sources and mechanisms (with pros and cons for the panel's consideration), and a final report reflecting the panel\u2019s views and the teams\u2019 own analyses.\n","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2021-02-01T00:00:00+00:00","startDateDateOnly":"2021-02-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":146002,"Financial Year":"2020/21","Lead Applicant":"Ms Kendra White","grantProgramme":[{"title":"Discretionary Award - Policy ","title_keyword":"Discretionary Award - Policy "}],"Applicant Surname":"White","Partnership Value":146002,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Center-for-Global-Development","name":"Center for Global Development","addressCountry":"United States","id_and_name":"[\"Center for Global Development\", \"360G-Wellcome-ORG:Center-for-Global-Development\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Center-for-Global-Development","name":"Center for Global Development"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Panel on Financing for Pandemic Prevention, Preparedness and Response A new high-level panel, led by co-chairs Tharman Shanmugaratnam and Lawrence H. Summers, has been mandated by the Italian presidency of the G20 to propose reforms and other measures that will lead to more reliable and sustainable financing of pandemic prevention, preparedness, and response. To support the panel's deliberations and decision-making, CGD and Bruegel propose establishing a team to lead the analysis and content development of the proposals, with logistical, outreach, engagement, and coordination support from a secretariat at Wellcome and the US National Academies of Medicine. The team will develop a short scoping note on the economic rationale behind prioritizing public investment in prevention, preparedness, and response, an outline of the final report for discussion and feedback from the co-chairs, background analyses (on landscaping current financing and issues, existing asks and proposals; setting a financing goal and assessing its value for money; and governance, organization, and incentives), a long list of 10-15 proposals for governance reform and/or new or existing financing sources and mechanisms (with pros and cons for the panel's consideration), and a final report reflecting the panel\u2019s views and the teams\u2019 own analyses.\n","awardDateDateOnly":"2021-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Healthcare Financing","Humans","Italy"]}
{"id":"360G-Wellcome-223032_Z_21_Z","title":"THE ARM RACE: HOW WE CONQUERED COVID (WORKING TITLE)","Region":"International","currency":"GBP","awardDate":"2021-03-31T00:00:00+00:00","Internal ID":"223032/Z/21/Z","description":"\"THE ARM RACE: HOW WE CONQUERED COVID\" (working title) is a documentary film that will be the dispositive chronicle of the global race to research, develop, manufacture and distribute COVID-19 vaccines in the most enormous coordinated effort ever undertaken. In this unprecedented moment in history, the film will celebrate the herculean efforts of the scientific, research and immunization community during a complex time of mistrust, vaccine hesitancy, and misinformation - when trust in science itself has come under fire.\n\nThe stories track development of vaccines, (including research built on previous work fighting outbreaks including Ebola and HIV/AIDS,) and how public health agencies from hospitals to the WHO are responding to the crisis. Our narrative goes beyond the lab, delving into the complexities of underserved populations, equitable access and inclusion. We see opportunities in additional content, leveraging existing assets, foregrounding the making of the film and our collaboration with the global public health community. This project will spark interest in science\u2019s potential to solve global health challenges by documenting the largest public health effort in human history, while also offering insights into our successes and failures to help prepare the next generation to better respond to future pandemics. \n\n\n \n","plannedDates":[{"endDate":"2021-08-07T00:00:00+00:00","startDate":"2021-02-08T00:00:00+00:00","startDateDateOnly":"2021-02-08","endDateDateOnly":"2021-08-07"}],"amountAwarded":236035,"Financial Year":"2020/21","Lead Applicant":"Ms Mira Chang","grantProgramme":[{"title":"Discretionary Award - Vaccines","title_keyword":"Discretionary Award - Vaccines"}],"Applicant Surname":"Chang","Partnership Value":236035,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Utah-Film-Center","name":"Utah Film Center","addressCountry":"United States","id_and_name":"[\"Utah Film Center\", \"360G-Wellcome-ORG:Utah-Film-Center\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Utah-Film-Center","name":"Utah Film Center"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"THE ARM RACE: HOW WE CONQUERED COVID (WORKING TITLE) \"THE ARM RACE: HOW WE CONQUERED COVID\" (working title) is a documentary film that will be the dispositive chronicle of the global race to research, develop, manufacture and distribute COVID-19 vaccines in the most enormous coordinated effort ever undertaken. In this unprecedented moment in history, the film will celebrate the herculean efforts of the scientific, research and immunization community during a complex time of mistrust, vaccine hesitancy, and misinformation - when trust in science itself has come under fire.\n\nThe stories track development of vaccines, (including research built on previous work fighting outbreaks including Ebola and HIV/AIDS,) and how public health agencies from hospitals to the WHO are responding to the crisis. Our narrative goes beyond the lab, delving into the complexities of underserved populations, equitable access and inclusion. We see opportunities in additional content, leveraging existing assets, foregrounding the making of the film and our collaboration with the global public health community. This project will spark interest in science\u2019s potential to solve global health challenges by documenting the largest public health effort in human history, while also offering insights into our successes and failures to help prepare the next generation to better respond to future pandemics. \n\n\n \n","awardDateDateOnly":"2021-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Global Health","Humans","Public Health","Trust","Vaccination","Vaccines"]}
{"id":"360G-Wellcome-223016_Z_21_Z","title":"Can we develop a \"cognitive vaccine\" for intrusive memories of traumatic events from working in the COVID-19 pandemic? A novel and brief intervention to support ICU staff","Region":"South East","currency":"GBP","awardDate":"2021-03-31T00:00:00+00:00","Internal ID":"223016/Z/21/Z","description":"Intensive care unit (ICU) staff face repeated exposure to traumatic work-related events and have reported high levels of posttraumatic symptoms during the pandemic. Novel, scalable and preventative interventions are required.\n\n\nWe are developing a \"cognitive vaccine\" approach for ICU staff against one key symptom \u2013 intrusive memories of traumatic events. These are unwanted, distressing and disrupt functioning.\n\nOur novel, brief gameplay intervention is repeatable, flexible, non-stigmatising, scalable, and driven by mental health science.\n\n\nThis digital intervention is guided by an initial session of psychologist support, then self-administered; delivered same day or months post-trauma, suitable for repeated trauma exposure, fits with busy lives of ICU staff, without discussing trauma detail.\n\n\nPart 1 uses a Bayesian design to optimise and co-develop procedures with ICU professionals and move at speed under pandemic conditions, allowing limited rollout (guided-version) in these unprecedented times.\n\nPart 2 uses a pragmatic RCT (three arms: guided/non-guided/attention-control) testing clinical effectiveness and acceptability to inform clinical practice. If the non-guided intervention is effective (i.e. no psychologist support) it will accelerate the speed of rollout.\n\nMeanwhile through global mental health workshops with stakeholder communities we seek to understand the views of various communities worldwide regarding implementation of this novel intervention form.\n","plannedDates":[{"endDate":"2023-12-03T00:00:00+00:00","startDate":"2021-05-04T00:00:00+00:00","startDateDateOnly":"2021-05-04","endDateDateOnly":"2023-12-03"}],"amountAwarded":910964,"Financial Year":"2020/21","Lead Applicant":"Prof Emily Holmes","grantProgramme":[{"title":"Discretionary Award - Mental Health","title_keyword":"Discretionary Award - Mental Health"}],"Applicant Surname":"Holmes","Partnership Value":910964,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Mr Jonathan Kingslake","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:P1vital-Products-Ltd","name":"P1vital Products Ltd","addressCountry":"United Kingdom","id_and_name":"[\"P1vital Products Ltd\", \"360G-Wellcome-ORG:P1vital-Products-Ltd\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:P1vital-Products-Ltd","name":"P1vital Products Ltd"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Can we develop a \"cognitive vaccine\" for intrusive memories of traumatic events from working in the COVID-19 pandemic? A novel and brief intervention to support ICU staff Intensive care unit (ICU) staff face repeated exposure to traumatic work-related events and have reported high levels of posttraumatic symptoms during the pandemic. Novel, scalable and preventative interventions are required.\n\n\nWe are developing a \"cognitive vaccine\" approach for ICU staff against one key symptom \u2013 intrusive memories of traumatic events. These are unwanted, distressing and disrupt functioning.\n\nOur novel, brief gameplay intervention is repeatable, flexible, non-stigmatising, scalable, and driven by mental health science.\n\n\nThis digital intervention is guided by an initial session of psychologist support, then self-administered; delivered same day or months post-trauma, suitable for repeated trauma exposure, fits with busy lives of ICU staff, without discussing trauma detail.\n\n\nPart 1 uses a Bayesian design to optimise and co-develop procedures with ICU professionals and move at speed under pandemic conditions, allowing limited rollout (guided-version) in these unprecedented times.\n\nPart 2 uses a pragmatic RCT (three arms: guided/non-guided/attention-control) testing clinical effectiveness and acceptability to inform clinical practice. If the non-guided intervention is effective (i.e. no psychologist support) it will accelerate the speed of rollout.\n\nMeanwhile through global mental health workshops with stakeholder communities we seek to understand the views of various communities worldwide regarding implementation of this novel intervention form.\n","awardDateDateOnly":"2021-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Critical Care","Humans","Intensive Care Units","Psychological Trauma","Stress Disorders, Post-Traumatic"]}
{"id":"360G-Wellcome-223009_Z_21_Z","title":"Combining computational structural biology methods to visualise the dynamics of cell-virus interactions at molecular resolution","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"223009/Z/21/Z","description":"Archaea are single-celled organisms distinct from bacteria, but that share a number of traits. Like some bacteria, many archaea have a surface layer (S-layer) surrounding the cell, which is a proteinaceous lattice that helps protect the cell from attack from viruses. Understanding how the viruses bind to the S-layer will help us to understand how they infect the cells.\n\nUsing cryo-electron microscopy (cryo-EM), an increasingly popular technique for obtaining structural information about proteins, we will study a variety of archaeal S-layers and some of the viruses that infect them. This data will then be combined with molecular dynamics (MD) for a multiscale investigation of how these S-layer proteins move and interact over time.  By solving the structures of the S-layers using cryo-EM, then simulating the interaction of the proteins in the lattice using MD, we push method development to lead the way in cellular structural biology.\n\nWith this work we will develop the understanding of viral entry in archaea, and the structure-function relationship of S-layers which has implications on the evolution of life. Tomography will provide cellular context to structures, and direct the large-scale MD simulations, built up from smaller simulations of atomic structures solved by cryo-EM.\n","plannedDates":[{"endDate":"2024-03-31T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2024-03-31"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mx Zo Ford","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Ford","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Combining computational structural biology methods to visualise the dynamics of cell-virus interactions at molecular resolution Archaea are single-celled organisms distinct from bacteria, but that share a number of traits. Like some bacteria, many archaea have a surface layer (S-layer) surrounding the cell, which is a proteinaceous lattice that helps protect the cell from attack from viruses. Understanding how the viruses bind to the S-layer will help us to understand how they infect the cells.\n\nUsing cryo-electron microscopy (cryo-EM), an increasingly popular technique for obtaining structural information about proteins, we will study a variety of archaeal S-layers and some of the viruses that infect them. This data will then be combined with molecular dynamics (MD) for a multiscale investigation of how these S-layer proteins move and interact over time.  By solving the structures of the S-layers using cryo-EM, then simulating the interaction of the proteins in the lattice using MD, we push method development to lead the way in cellular structural biology.\n\nWith this work we will develop the understanding of viral entry in archaea, and the structure-function relationship of S-layers which has implications on the evolution of life. Tomography will provide cellular context to structures, and direct the large-scale MD simulations, built up from smaller simulations of atomic structures solved by cryo-EM.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Archaea","Cryoelectron Microscopy","Electron Microscope Tomography","Molecular Dynamics Simulation","Viruses"]}
{"id":"360G-Wellcome-222995_Z_21_Z","title":"Novel allosteric modulators of nicotinic acetylcholine receptors implicated in cognitive dysfunction ","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222995/Z/21/Z","description":"Nicotinic acetylcholine receptor (nAChR) subtypes such as alpha7 and alpha4beta2 have been implicated in a range of psychiatric illnesses, including schizophrenia and Alzheimer\u2019s disease. During the past two decades, the identification of multiple nAChR allosteric modulators (drugs that alter the response of a receptor to its natural agonists) have attracted significant interest. A recent study conducted in this laboratory reported an in silico screening of the DrugBank database against a predicted alpha7 nAChR allosteric site. Amongst the compounds identified in this study, the Na-K-Cl cotransporter inhibitor furosemide was found to be a potent positive allosteric modulator (PAM) of the alpha7 nAChR in electrophysiological assays. The objective of the present project is to expand on our understanding of how the chemical composition of allosteric modulators such as furosemide and its structural analogues influences their allosteric modulatory properties at nAChRs subtypes such as alpha7 and alpha4beta2. I will attempt this via the synthesis of a library of novel compounds (including furosemide analogues). Subsequent electrophysiological and computational (e.g. computer docking) studies of these compounds with respect to their allosteric modulatory activity at the alpha7 and alpha4beta2 nAChRs will be undertaken with the aim of developing a clearer understanding of their structure-activity relationship. \n","plannedDates":[{"endDate":"2023-09-14T00:00:00+00:00","startDate":"2020-09-15T00:00:00+00:00","startDateDateOnly":"2020-09-15","endDateDateOnly":"2023-09-14"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr William Goldring","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Goldring","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Novel allosteric modulators of nicotinic acetylcholine receptors implicated in cognitive dysfunction  Nicotinic acetylcholine receptor (nAChR) subtypes such as alpha7 and alpha4beta2 have been implicated in a range of psychiatric illnesses, including schizophrenia and Alzheimer\u2019s disease. During the past two decades, the identification of multiple nAChR allosteric modulators (drugs that alter the response of a receptor to its natural agonists) have attracted significant interest. A recent study conducted in this laboratory reported an in silico screening of the DrugBank database against a predicted alpha7 nAChR allosteric site. Amongst the compounds identified in this study, the Na-K-Cl cotransporter inhibitor furosemide was found to be a potent positive allosteric modulator (PAM) of the alpha7 nAChR in electrophysiological assays. The objective of the present project is to expand on our understanding of how the chemical composition of allosteric modulators such as furosemide and its structural analogues influences their allosteric modulatory properties at nAChRs subtypes such as alpha7 and alpha4beta2. I will attempt this via the synthesis of a library of novel compounds (including furosemide analogues). Subsequent electrophysiological and computational (e.g. computer docking) studies of these compounds with respect to their allosteric modulatory activity at the alpha7 and alpha4beta2 nAChRs will be undertaken with the aim of developing a clearer understanding of their structure-activity relationship. \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Allosteric Regulation","Allosteric Site","Animals","Furosemide","Humans","Molecular Docking Simulation","Structure-Activity Relationship","alpha7 Nicotinic Acetylcholine Receptor"]}
{"id":"360G-Wellcome-222984_Z_21_Z","title":"iGEM competition 2021","Region":"Scotland","currency":"GBP","awardDate":"2021-01-29T00:00:00+00:00","Internal ID":"222984/Z/21/Z","description":"This grant will support the 2021 International Genetically Engineered Machine Competition (iGEM), by supporting UK undergraduate students from the synthetic biology community to take part in it.\nThe provided funding will be used to support the students\u2019 stipends, some consumable and travel support for the teams that have successfully applied to the competition.\nWellcome has funded the iGEM programme for several years as this is an interesting model to develop interdisciplinary thinking and skills for students. Funding is provided in partnership with BBSRC who also make available a \u00a350k contribution.\nWellcome (Luigi Martino) will be involved at the selection stage and receive a brief report about the respective activities at the end of the year.\n\nCOVID-19 effect on the competition. The hope is that this year\u2019s teams will have the ability to undertake wet-lab-work. If this is made impossible by the potential restricted access to lab spaces, the selected teams will be asked to submit a written proposal reporting the design and strategy to build their chosen genetically engineered machine.","plannedDates":[{"endDate":"2021-12-31T00:00:00+00:00","startDate":"2021-02-01T00:00:00+00:00","startDateDateOnly":"2021-02-01","endDateDateOnly":"2021-12-31"}],"amountAwarded":50000,"Financial Year":"2020/21","Lead Applicant":"Dr Mathis Riehle","grantProgramme":[{"title":"Strategic Support: Science","title_keyword":"Strategic Support: Science"}],"Applicant Surname":"Riehle","Partnership Value":50000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow","addressCountry":"United Kingdom","id_and_name":"[\"University of Glasgow\", \"360G-Wellcome-ORG:University-of-Glasgow\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"iGEM competition 2021 This grant will support the 2021 International Genetically Engineered Machine Competition (iGEM), by supporting UK undergraduate students from the synthetic biology community to take part in it.\nThe provided funding will be used to support the students\u2019 stipends, some consumable and travel support for the teams that have successfully applied to the competition.\nWellcome has funded the iGEM programme for several years as this is an interesting model to develop interdisciplinary thinking and skills for students. Funding is provided in partnership with BBSRC who also make available a \u00a350k contribution.\nWellcome (Luigi Martino) will be involved at the selection stage and receive a brief report about the respective activities at the end of the year.\n\nCOVID-19 effect on the competition. The hope is that this year\u2019s teams will have the ability to undertake wet-lab-work. If this is made impossible by the potential restricted access to lab spaces, the selected teams will be asked to submit a written proposal reporting the design and strategy to build their chosen genetically engineered machine.","awardDateDateOnly":"2021-01-29","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Students","Synthetic Biology","United Kingdom"]}
{"id":"360G-Wellcome-222963_Z_21_Z","title":"Emergency Efforts to Sustain UK Government Support for ODA","Region":"Greater London","currency":"GBP","awardDate":"2021-03-31T00:00:00+00:00","Internal ID":"222963/Z/21/Z","description":"In the 2020 Spending Review HMG signaled its intent to renege on a manifesto commitment and cut ODA form 0.7 to 0.5% of GNI (on top of the budget cut that happened automatically due to economic contraction). To do this, HMG wishes to repeal the relevant in coming months.\n\nWork to sustain the Government\u2019s support for ODA is already delivering results with an increasingly credible threat of a government rebellion and sustained media interest. However, increasingly our political intel says we may be at risk of winning the vote and losing the argument. Put simply, \u2018hard whipping\u2019 of a rebellion, combined with some horse-trading between different groups, might be enough to carry a vote but it won\u2019t stop the debate flaring back up. This grant would allow us to scale the emergency effort around the legislation while also creating a more enabling environment for the longer team:\n\n\n by bolstering our public affairs capability in Qs 1/ 2,\n by expanding our local organising effort to an additional ten constituencies from Q1-4 and\n by expanding our comms plans from Q1-4.\n  \n\n\nA key part of this partnership would be Wellcome\u2019s inclusion in regular political updates, intel and learning sessions.\n","plannedDates":[{"endDate":"2022-02-28T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2022-02-28"}],"amountAwarded":150000,"Financial Year":"2020/21","Lead Applicant":"Ms Kirsty McNeill","grantProgramme":[{"title":"Discretionary Award - Policy ","title_keyword":"Discretionary Award - Policy "}],"Applicant Surname":"McNeill","Partnership Value":150000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Save-the-Children","name":"Save the Children","addressCountry":"United Kingdom","id_and_name":"[\"Save the Children\", \"360G-Wellcome-ORG:Save-the-Children\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Save-the-Children","name":"Save the Children"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Emergency Efforts to Sustain UK Government Support for ODA In the 2020 Spending Review HMG signaled its intent to renege on a manifesto commitment and cut ODA form 0.7 to 0.5% of GNI (on top of the budget cut that happened automatically due to economic contraction). To do this, HMG wishes to repeal the relevant in coming months.\n\nWork to sustain the Government\u2019s support for ODA is already delivering results with an increasingly credible threat of a government rebellion and sustained media interest. However, increasingly our political intel says we may be at risk of winning the vote and losing the argument. Put simply, \u2018hard whipping\u2019 of a rebellion, combined with some horse-trading between different groups, might be enough to carry a vote but it won\u2019t stop the debate flaring back up. This grant would allow us to scale the emergency effort around the legislation while also creating a more enabling environment for the longer team:\n\n\n by bolstering our public affairs capability in Qs 1/ 2,\n by expanding our local organising effort to an additional ten constituencies from Q1-4 and\n by expanding our comms plans from Q1-4.\n  \n\n\nA key part of this partnership would be Wellcome\u2019s inclusion in regular political updates, intel and learning sessions.\n","awardDateDateOnly":"2021-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Budgets","Humans","Politics","United Kingdom"]}
{"id":"360G-Wellcome-222962_Z_21_Z","title":"Targeting individual bromodomain and extra terminal domain (BET) proteins (BRD2-4) to modulate breast cancer angiogenesis","Region":"East Midlands","currency":"GBP","awardDate":"2021-11-01T00:00:00+00:00","Internal ID":"222962/Z/21/Z","description":"Tumour cells requires oxygen and nutrient to grow. As tumours outgrow their existing blood supply they develop regions that have low oxygen (hypoxia) and nutrient levels. These regions are often found in breast cancer and they are associated with resistance to chemotherapy and radiotherapy. Cancer cells exposed to low oxygen release chemical signals that stimulate the growth of new blood vessels which can then deliver the required oxygen and nutrients. There are four Bromodomain and extra terminal (BET) proteins that bind to sections of the DNA that has been chemically modified to indicate if a gene should be active or inactive. The BET proteins then recruit other proteins which are important for transcribing genes. It has been shown that drugs that inhibit the BET proteins change how the cells respond to hypoxia and reduce the growth of new blood vessels.\nI will investigate how the BET proteins regulate the growth of new blood vessels and identify which of the four BET proteins is the best target for new therapies. Regulating blood vessel growth can lead to the reperfusion of tumours and allow radiotherapy and chemotherapy to effectively treat patients with solid tumours.\n\n \n","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mrs Ashia Wheeler-Crawford","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Wheeler-Crawford","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Nottingham","name":"University of Nottingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Nottingham\", \"360G-Wellcome-ORG:University-of-Nottingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Nottingham","name":"University of Nottingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Targeting individual bromodomain and extra terminal domain (BET) proteins (BRD2-4) to modulate breast cancer angiogenesis Tumour cells requires oxygen and nutrient to grow. As tumours outgrow their existing blood supply they develop regions that have low oxygen (hypoxia) and nutrient levels. These regions are often found in breast cancer and they are associated with resistance to chemotherapy and radiotherapy. Cancer cells exposed to low oxygen release chemical signals that stimulate the growth of new blood vessels which can then deliver the required oxygen and nutrients. There are four Bromodomain and extra terminal (BET) proteins that bind to sections of the DNA that has been chemically modified to indicate if a gene should be active or inactive. The BET proteins then recruit other proteins which are important for transcribing genes. It has been shown that drugs that inhibit the BET proteins change how the cells respond to hypoxia and reduce the growth of new blood vessels.\nI will investigate how the BET proteins regulate the growth of new blood vessels and identify which of the four BET proteins is the best target for new therapies. Regulating blood vessel growth can lead to the reperfusion of tumours and allow radiotherapy and chemotherapy to effectively treat patients with solid tumours.\n\n \n","awardDateDateOnly":"2021-11-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Breast Neoplasms","Cell Proliferation","Female","Humans","Oxygen","Transcription Factors"]}
{"id":"360G-Wellcome-222959_Z_21_Z","title":"A GWAS of the progression of abdominal aortic aneurysms and simultaneous use of genetic and non-genetic information in the evaluation of screening and diagnostic testing pathways","Region":"East Midlands","currency":"GBP","awardDate":"2021-11-01T00:00:00+00:00","Internal ID":"222959/Z/21/Z","description":"In the UK, men aged 65 are invited to screening to check for an Abdominal Aortic Aneurysm (AAA).  Untreated aneurysms may rupture, which is usually fatal, although many aneurysms do not progress to this stage.  There are known risk factors for AAA such as smoking and family history.  Evidence of genetic association with AAA has been found which means that some people are more at risk from birth of having an aneurysm.\n\nI plan to investigate the role of genetics in both the presence and progression of disease, utilising data from UKBiobank, the UK Aneurysm Growth Study and AAA-Express.  These findings will be adopted into a hypothetical computer model.  I will investigate the possibility of targeted screening for AAA. This involves identification of risk factors that will also consider the benefit of genetic data to identify individuals at high risk of AAA for screening invitation. I will then investigate an adapted clinical pathway after detection of aneurysm based on the risk of rupture. Incorporating genetic information may improve patient outcomes and the cost-effectiveness of the screening program by limiting screening to those most at risk and by ensuring that those diagnosed with an aneurysm have the most appropriate clinical intervention.\n","plannedDates":[{"endDate":"2024-09-27T00:00:00+00:00","startDate":"2020-09-28T00:00:00+00:00","startDateDateOnly":"2020-09-28","endDateDateOnly":"2024-09-27"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Katie Saxby","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Saxby","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leicester","name":"University of Leicester","addressCountry":"United Kingdom","id_and_name":"[\"University of Leicester\", \"360G-Wellcome-ORG:University-of-Leicester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leicester","name":"University of Leicester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A GWAS of the progression of abdominal aortic aneurysms and simultaneous use of genetic and non-genetic information in the evaluation of screening and diagnostic testing pathways In the UK, men aged 65 are invited to screening to check for an Abdominal Aortic Aneurysm (AAA).  Untreated aneurysms may rupture, which is usually fatal, although many aneurysms do not progress to this stage.  There are known risk factors for AAA such as smoking and family history.  Evidence of genetic association with AAA has been found which means that some people are more at risk from birth of having an aneurysm.\n\nI plan to investigate the role of genetics in both the presence and progression of disease, utilising data from UKBiobank, the UK Aneurysm Growth Study and AAA-Express.  These findings will be adopted into a hypothetical computer model.  I will investigate the possibility of targeted screening for AAA. This involves identification of risk factors that will also consider the benefit of genetic data to identify individuals at high risk of AAA for screening invitation. I will then investigate an adapted clinical pathway after detection of aneurysm based on the risk of rupture. Incorporating genetic information may improve patient outcomes and the cost-effectiveness of the screening program by limiting screening to those most at risk and by ensuring that those diagnosed with an aneurysm have the most appropriate clinical intervention.\n","awardDateDateOnly":"2021-11-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aged","Aortic Aneurysm, Abdominal","Aortic Rupture","Disease Progression","Humans","Male","Mass Screening","Risk Factors","United Kingdom"]}
{"id":"360G-Wellcome-222958_Z_21_Z","title":"Assessing the contribution of common and rare short tandem repeats (STRs) to the risk of developing idiopathic pulmonary fibrosis (IPF).","Region":"East Midlands","currency":"GBP","awardDate":"2021-11-01T00:00:00+00:00","Internal ID":"222958/Z/21/Z","description":"Idiopathic Pulmonary Fibrosis (IPF) affects around five people in every 100,000 in the UK and is amongst the most devastating of lung diseases, with a median survival time of 3 years and variable progression. Comparable disease prevalence (6.8 per 100,000 persons) has also been reported in other countries such as the USA, Italy, and Canada. About 5000 cases are detected annually in the UK, and there is rising disease prevalence globally. Despite the substantial disease burden, there is little understanding of the disease etiology, and it has a poor prognosis. Other than a lung transplant, the available drugs are not curative. The majority of cases are diagnosed in patients  > 50 years and males are disproportionately affected than females. Both genetic and environmental factors have been associated with IPF. The genetic mutations described so far only account for about 19% of genetic risk associated with IPF. Therefore, the analysis of other types of genetic variations is pertinent. In particular, our study will use whole-genome sequences in case-control cohorts to identify other genetic mutations associated with IPF susceptibility. Identifying risky mutations can help understand disease etiology and develop more targeted therapies.\n","plannedDates":[{"endDate":"2024-09-28T00:00:00+00:00","startDate":"2020-09-29T00:00:00+00:00","startDateDateOnly":"2020-09-29","endDateDateOnly":"2024-09-28"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr John Oketch","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Oketch","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leicester","name":"University of Leicester","addressCountry":"United Kingdom","id_and_name":"[\"University of Leicester\", \"360G-Wellcome-ORG:University-of-Leicester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leicester","name":"University of Leicester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Assessing the contribution of common and rare short tandem repeats (STRs) to the risk of developing idiopathic pulmonary fibrosis (IPF). Idiopathic Pulmonary Fibrosis (IPF) affects around five people in every 100,000 in the UK and is amongst the most devastating of lung diseases, with a median survival time of 3 years and variable progression. Comparable disease prevalence (6.8 per 100,000 persons) has also been reported in other countries such as the USA, Italy, and Canada. About 5000 cases are detected annually in the UK, and there is rising disease prevalence globally. Despite the substantial disease burden, there is little understanding of the disease etiology, and it has a poor prognosis. Other than a lung transplant, the available drugs are not curative. The majority of cases are diagnosed in patients  > 50 years and males are disproportionately affected than females. Both genetic and environmental factors have been associated with IPF. The genetic mutations described so far only account for about 19% of genetic risk associated with IPF. Therefore, the analysis of other types of genetic variations is pertinent. In particular, our study will use whole-genome sequences in case-control cohorts to identify other genetic mutations associated with IPF susceptibility. Identifying risky mutations can help understand disease etiology and develop more targeted therapies.\n","awardDateDateOnly":"2021-11-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aged","Case-Control Studies","Female","Genetic Predisposition to Disease","Humans","Idiopathic Pulmonary Fibrosis","Male","Middle Aged","Mutation"]}
{"id":"360G-Wellcome-222956_Z_21_Z","title":"Understanding the genetic basis of radiotherapy toxicity","Region":"East Midlands","currency":"GBP","awardDate":"2021-11-01T00:00:00+00:00","Internal ID":"222956/Z/21/Z","description":"Patients differ in the way they respond to radiation treatment.  Approximately 5% of patients are sensitive to radiotherapy and at risk of suffering long-term side-effects (1). However, there is no effective way to identify these patients. The REQUITE trial was established with the aim of reducing long-term side-effects from radiation (2). A total of 4438 cancer patients were enrolled in the study. Before receiving radiotherapy, patients completed a questionnaire and provided a blood sample which was analysed for genetic variants. \nThe researchers tested for other biomarkers that might predict sensitivity to radiation. One example includes the radiation-induced cell death assay called RILA. This is a measure of the percentage of white blood cells that are killed by radiation (3). The researchers found that a low RILA score is associated with long-term side-effects. \nMy research aims include finding possible genetic associations with the RILA assay. In addition to finding possible genetic associations to predict late side-effects in breast cancer patients and a genetic study on patient reported outcome measures such as quality of life scores. The overall long-term goal of this project is to integrate biomarkers, genetic and clinical data to help predict which patients will suffer from worse side-effects. \n \n","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Harkeran Jandu","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Jandu","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leicester","name":"University of Leicester","addressCountry":"United Kingdom","id_and_name":"[\"University of Leicester\", \"360G-Wellcome-ORG:University-of-Leicester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leicester","name":"University of Leicester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding the genetic basis of radiotherapy toxicity Patients differ in the way they respond to radiation treatment.  Approximately 5% of patients are sensitive to radiotherapy and at risk of suffering long-term side-effects (1). However, there is no effective way to identify these patients. The REQUITE trial was established with the aim of reducing long-term side-effects from radiation (2). A total of 4438 cancer patients were enrolled in the study. Before receiving radiotherapy, patients completed a questionnaire and provided a blood sample which was analysed for genetic variants. \nThe researchers tested for other biomarkers that might predict sensitivity to radiation. One example includes the radiation-induced cell death assay called RILA. This is a measure of the percentage of white blood cells that are killed by radiation (3). The researchers found that a low RILA score is associated with long-term side-effects. \nMy research aims include finding possible genetic associations with the RILA assay. In addition to finding possible genetic associations to predict late side-effects in breast cancer patients and a genetic study on patient reported outcome measures such as quality of life scores. The overall long-term goal of this project is to integrate biomarkers, genetic and clinical data to help predict which patients will suffer from worse side-effects. \n \n","awardDateDateOnly":"2021-11-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adult","Aged","Biomarkers, Tumor","Breast Neoplasms","Female","Humans","Male","Middle Aged","Quality of Life","Radiotherapy","Surveys and Questionnaires"]}
{"id":"360G-Wellcome-222955_Z_21_Z","title":"The genetic epidemiology of lung scarring","Region":"East Midlands","currency":"GBP","awardDate":"2021-11-01T00:00:00+00:00","Internal ID":"222955/Z/21/Z","description":"Idiopathic Lung Fibrosis (IPF) is a disease which leads to death three years after diagnosis in half of cases. IPF is a complex genetic disease - variants of DNA that contribute to disease risk have been identified, though we have yet to fully understand how these risk factors lead to lung scarring. \n\nA Genome-Wide Association Study (GWAS) can be used to determine which regions of DNA are associated with disease.  GWAS can be used to look at individual variant sites in the DNA called Single Nucleotide Polymorphisms (SNPs).  By comparing the entire DNAs (Genomes) of people with and without IPF, we can narrow down the suspected sequences that may contribute to the development of the disease to very fine resolution.\n\nOnce SNPs associated with IPF are identified, we then need to understand why they are associated. Determining which SNP leads to IPF requires 1) Linking SNPs to genes, 2) finding biochemical pathways associated with these genes, and 3) finding drugs that can be used to target the biochemical pathways. These steps enable us to understand the pathology of IPF and could lead to the identification of potential drug treatments for this currently incurable disease. \n","plannedDates":[{"endDate":"2024-09-27T00:00:00+00:00","startDate":"2020-09-28T00:00:00+00:00","startDateDateOnly":"2020-09-28","endDateDateOnly":"2024-09-27"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Daniel Chin","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Chin","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leicester","name":"University of Leicester","addressCountry":"United Kingdom","id_and_name":"[\"University of Leicester\", \"360G-Wellcome-ORG:University-of-Leicester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leicester","name":"University of Leicester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The genetic epidemiology of lung scarring Idiopathic Lung Fibrosis (IPF) is a disease which leads to death three years after diagnosis in half of cases. IPF is a complex genetic disease - variants of DNA that contribute to disease risk have been identified, though we have yet to fully understand how these risk factors lead to lung scarring. \n\nA Genome-Wide Association Study (GWAS) can be used to determine which regions of DNA are associated with disease.  GWAS can be used to look at individual variant sites in the DNA called Single Nucleotide Polymorphisms (SNPs).  By comparing the entire DNAs (Genomes) of people with and without IPF, we can narrow down the suspected sequences that may contribute to the development of the disease to very fine resolution.\n\nOnce SNPs associated with IPF are identified, we then need to understand why they are associated. Determining which SNP leads to IPF requires 1) Linking SNPs to genes, 2) finding biochemical pathways associated with these genes, and 3) finding drugs that can be used to target the biochemical pathways. These steps enable us to understand the pathology of IPF and could lead to the identification of potential drug treatments for this currently incurable disease. \n","awardDateDateOnly":"2021-11-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cicatrix","Genome-Wide Association Study","Humans","Idiopathic Pulmonary Fibrosis","Polymorphism, Single Nucleotide","Risk Factors"]}
{"id":"360G-Wellcome-222954_Z_21_Z","title":"Must the relatives be told? Legal and ethical issues in relation to the non-disclosure of genetic information by healthcare professionals to relatives","Region":"East Midlands","currency":"GBP","awardDate":"2021-11-01T00:00:00+00:00","Internal ID":"222954/Z/21/Z","description":"Genetic information is becoming increasingly utilised by healthcare professionals in order to provide patients with more precise diagnosis and treatments. An individual's genetic information may show their risk of inheriting a genetic disorder, and although most individuals would consent to healthcare professionals sharing their genetic information with relatives who may also be at risk, some individuals refuse. It can be argued that a failure to disclose the risks of inheriting genetic disorders to relatives is ethically wrong, because it restricts the autonomy of individuals to make life choices. Alternatively, it can be contended that it is legally wrong for a healthcare professional to not adhere to the duty of confidentiality that they owe to patients.\n\nThis debate demonstrates the conflict of duties that healthcare professionals face as the use of genetic information in medicine develops, and highlights the need to develop a new legal  framework which takes into account the needs of patients, relatives, and healthcare professionals. In order to create an appropriate legal framework, I aim to assess academic commentary, examine case law, and conduct qualitative interviews with healthcare professionals in order to assess scientific opinion, and potentially inform new policy guidance.\n","plannedDates":[{"endDate":"2024-09-27T00:00:00+00:00","startDate":"2020-09-28T00:00:00+00:00","startDateDateOnly":"2020-09-28","endDateDateOnly":"2024-09-27"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Jasmine Blow","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Blow","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leicester","name":"University of Leicester","addressCountry":"United Kingdom","id_and_name":"[\"University of Leicester\", \"360G-Wellcome-ORG:University-of-Leicester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leicester","name":"University of Leicester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Must the relatives be told? Legal and ethical issues in relation to the non-disclosure of genetic information by healthcare professionals to relatives Genetic information is becoming increasingly utilised by healthcare professionals in order to provide patients with more precise diagnosis and treatments. An individual's genetic information may show their risk of inheriting a genetic disorder, and although most individuals would consent to healthcare professionals sharing their genetic information with relatives who may also be at risk, some individuals refuse. It can be argued that a failure to disclose the risks of inheriting genetic disorders to relatives is ethically wrong, because it restricts the autonomy of individuals to make life choices. Alternatively, it can be contended that it is legally wrong for a healthcare professional to not adhere to the duty of confidentiality that they owe to patients.\n\nThis debate demonstrates the conflict of duties that healthcare professionals face as the use of genetic information in medicine develops, and highlights the need to develop a new legal  framework which takes into account the needs of patients, relatives, and healthcare professionals. In order to create an appropriate legal framework, I aim to assess academic commentary, examine case law, and conduct qualitative interviews with healthcare professionals in order to assess scientific opinion, and potentially inform new policy guidance.\n","awardDateDateOnly":"2021-11-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Confidentiality","Disclosure","Genetic Testing","Health Personnel","Humans","Informed Consent"]}
{"id":"360G-Wellcome-222949_Z_21_Z","title":"Synthesis and evaluation of novel antagonists and fluorescent ligands for the human P2Y2 receptor","Region":"East Midlands","currency":"GBP","awardDate":"2021-11-01T00:00:00+00:00","Internal ID":"222949/Z/21/Z","description":"The human P2Y2 receptor is one of a large and diverse family of disease-relevant drug targets called G protein-coupled receptors. The P2Y2 receptor is a promising therapeutic target for important conditions, including metastatic cancer. However, no drugs which block the P2Y2 receptor have ever entered clinical trials.\n\nThe research group recently published an initial study where novel P2Y2 receptor inhibitors, that prevent the action of the receptor, with good biological activity were produced. The project will build on this previous work to design, synthesise and evaluate further inhibitors with improved biological activity and drug-like properties to make them more clinically viable. The design of these inhibitors will be driven by visualisation of key interactions with the P2Y2 receptor in computational models. Another subsequent part of the project will involve equipping these novel inhibitors with a light emitting fluorescent dye that can be used to investigate their interaction with the P2Y2 receptor in cell and tissue-based experiments with state of the art imaging equipment. \n\nNovel, high affinity and drug-like P2Y2 receptor inhibitors and their fluorescently-labelled counterparts would provide a vital tool to further validate the role of P2Y2 in disease and aid in the development of clinically viable drugs.\n\n \n\n \n","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Rebecca Knight","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Knight","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Nottingham","name":"University of Nottingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Nottingham\", \"360G-Wellcome-ORG:University-of-Nottingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Nottingham","name":"University of Nottingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Synthesis and evaluation of novel antagonists and fluorescent ligands for the human P2Y2 receptor The human P2Y2 receptor is one of a large and diverse family of disease-relevant drug targets called G protein-coupled receptors. The P2Y2 receptor is a promising therapeutic target for important conditions, including metastatic cancer. However, no drugs which block the P2Y2 receptor have ever entered clinical trials.\n\nThe research group recently published an initial study where novel P2Y2 receptor inhibitors, that prevent the action of the receptor, with good biological activity were produced. The project will build on this previous work to design, synthesise and evaluate further inhibitors with improved biological activity and drug-like properties to make them more clinically viable. The design of these inhibitors will be driven by visualisation of key interactions with the P2Y2 receptor in computational models. Another subsequent part of the project will involve equipping these novel inhibitors with a light emitting fluorescent dye that can be used to investigate their interaction with the P2Y2 receptor in cell and tissue-based experiments with state of the art imaging equipment. \n\nNovel, high affinity and drug-like P2Y2 receptor inhibitors and their fluorescently-labelled counterparts would provide a vital tool to further validate the role of P2Y2 in disease and aid in the development of clinically viable drugs.\n\n \n\n \n","awardDateDateOnly":"2021-11-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Fluorescent Dyes","Humans"]}
{"id":"360G-Wellcome-222914_Z_21_Z","title":"Learning Data Driven Medical Checklists For Multi-Disciplinary Consult Scheduling","Region":"International","currency":"GBP","awardDate":"2021-03-31T00:00:00+00:00","Internal ID":"222914/Z/21/Z","description":"Checklists are simple tools that are often used to promote safety in clinical applications, because they can easily be integrated into a clinical workflow deployment without the need for extensive training or additional technology. Currently, machine learning in health focuses on large, complex deep neural networks. In comparison with deep neural networks, checklists are far easier to use, understand, and scrutinize. In practice, checklists are difficult to develop, and the vast majority of real-world checklists are hand-crafted by panels of experts.\n\nGiven the widespread integration of electronic health data over the past decade, our goal is to learn checklists from data for clinical tasks. The main application of our method, in partnership with Dr. Leo Celi at Beth Israel Deaconess Medical Center (BIDMC) in Boston, is to predict mortality in patients eligible for Continuous Renal Replacement Therapy (CRRT).\n\nA generated checklist for CRRT is clinically desirable in the intensive care unit as a mechanism to trigger a multidisciplinary discussion with the patient\u2019s family, to consider the value of the treatment weighed against the physical burden and cost. Thus we include operational considerations such as number of items in the checklist, the false negative/positive rate tradeoff, and fairness across protected groups. \n \n","plannedDates":[{"endDate":"2022-07-14T00:00:00+00:00","startDate":"2021-04-15T00:00:00+00:00","startDateDateOnly":"2021-04-15","endDateDateOnly":"2022-07-14"}],"amountAwarded":79188,"Financial Year":"2020/21","Lead Applicant":"Dr Marzyeh Ghassemi","grantProgramme":[{"title":"Discretionary Award \u2013 DSH","title_keyword":"Discretionary Award \u2013 DSH"}],"Applicant Surname":"Ghassemi","Partnership Value":79188,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Toronto","name":"University of Toronto","addressCountry":"Canada","id_and_name":"[\"University of Toronto\", \"360G-Wellcome-ORG:University-of-Toronto\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Toronto","name":"University of Toronto"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Learning Data Driven Medical Checklists For Multi-Disciplinary Consult Scheduling Checklists are simple tools that are often used to promote safety in clinical applications, because they can easily be integrated into a clinical workflow deployment without the need for extensive training or additional technology. Currently, machine learning in health focuses on large, complex deep neural networks. In comparison with deep neural networks, checklists are far easier to use, understand, and scrutinize. In practice, checklists are difficult to develop, and the vast majority of real-world checklists are hand-crafted by panels of experts.\n\nGiven the widespread integration of electronic health data over the past decade, our goal is to learn checklists from data for clinical tasks. The main application of our method, in partnership with Dr. Leo Celi at Beth Israel Deaconess Medical Center (BIDMC) in Boston, is to predict mortality in patients eligible for Continuous Renal Replacement Therapy (CRRT).\n\nA generated checklist for CRRT is clinically desirable in the intensive care unit as a mechanism to trigger a multidisciplinary discussion with the patient\u2019s family, to consider the value of the treatment weighed against the physical burden and cost. Thus we include operational considerations such as number of items in the checklist, the false negative/positive rate tradeoff, and fairness across protected groups. \n \n","awardDateDateOnly":"2021-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Checklist","Electronic Health Records","Humans","Neural Networks, Computer","Renal Replacement Therapy","Workflow"]}
{"id":"360G-Wellcome-222908_Z_21_Z","title":"Liquid-phase Transmission Electron microscopy of RNA polymerase dynamics","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222908/Z/21/Z","description":"Proteins control most cellular functions, made possible by their unique and diverse range of 3D structures and the dynamics within them. Methods to determine protein structure have revolutionised the understanding of cell function and dysfunction on the molecular level as well as drug design, however, these methods generally require static molecules. One rapidly developing method to probe protein structure uses transmission electron microscopy to take highly magnified images of cryogenically frozen proteins which can be computationally combined into a 3D model, however, freezing the sample prevents any real-time dynamics. We aim to optimise this method with new liquid-phase transmission electron microscopy technology, to film and understand structural dynamics of proteins in real-time in solution. This will require the development of electron microscopy techniques to image the protein clearly, image processing techniques to analyse the movies taken and molecular dynamics to understand and verify the results seen. We, therefore, aim to develop liquid-phase transmission electron microscopy as a technique to probe protein dynamics in solution, allowing the study of protein function, dysfunction and dynamic responses to stimuli, for example, drug binding. This will focus on RNA polymerase as a model system with physiologically relevant dynamics. \n","plannedDates":[{"endDate":"2023-12-22T00:00:00+00:00","startDate":"2020-12-23T00:00:00+00:00","startDateDateOnly":"2020-12-23","endDateDateOnly":"2023-12-22"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Gabriel Ing","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Ing","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Liquid-phase Transmission Electron microscopy of RNA polymerase dynamics Proteins control most cellular functions, made possible by their unique and diverse range of 3D structures and the dynamics within them. Methods to determine protein structure have revolutionised the understanding of cell function and dysfunction on the molecular level as well as drug design, however, these methods generally require static molecules. One rapidly developing method to probe protein structure uses transmission electron microscopy to take highly magnified images of cryogenically frozen proteins which can be computationally combined into a 3D model, however, freezing the sample prevents any real-time dynamics. We aim to optimise this method with new liquid-phase transmission electron microscopy technology, to film and understand structural dynamics of proteins in real-time in solution. This will require the development of electron microscopy techniques to image the protein clearly, image processing techniques to analyse the movies taken and molecular dynamics to understand and verify the results seen. We, therefore, aim to develop liquid-phase transmission electron microscopy as a technique to probe protein dynamics in solution, allowing the study of protein function, dysfunction and dynamic responses to stimuli, for example, drug binding. This will focus on RNA polymerase as a model system with physiologically relevant dynamics. \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cryoelectron Microscopy","DNA-Directed RNA Polymerases","Microscopy","Molecular Dynamics Simulation"]}
{"id":"360G-Wellcome-222906_Z_21_Z","title":"Structural and mechanistic investigations of the SWI/SNF chromatin remodeller","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222906/Z/21/Z","description":"Packaging the two metres of chromosomal DNA found in every human cell is achieved by wrapping DNA around histone proteins in complexes called nucleosomes. Generally, DNA wrapped within nucleosomes is rendered inaccessible to enzymes and DNA-binding factors involved in normal DNA processes such as gene expression, DNA damage repair and chromosome replication. Chromatin remodellers are large molecular machines that disrupt the interaction between DNA and histones, exposing the DNA and therefore making it accessible for fundamental biological processes. I will be focussing on a particular chromatin remodeller called SWI/SNF that uses chemical energy to move, modify and eject nucleosomes. Around 20% of human tumours have been shown to have mutated SWI/SNF, highlighting the complex as one of the most commonly affected targets in cancer. The aim of my project is to use structural (cryo-EM) and single molecule (FRET) analysis to probe the molecular details of the interaction of SWI/SNF with the nucleosome. Moreover, we will visualise SWI/SNF in action, in an attempt to understand how the machine remodels nucleosomes and leading to further understanding of its role in cancer. Our results will provide a platform for the future development of drugs that specifically target mutated SWI/SNF complexes in numerous cancers.\n","plannedDates":[{"endDate":"2023-12-22T00:00:00+00:00","startDate":"2020-12-23T00:00:00+00:00","startDateDateOnly":"2020-12-23","endDateDateOnly":"2023-12-22"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Debbie Woods","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Woods","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Birkbeck-University-of-London","name":"Birkbeck University of London","addressCountry":"United Kingdom","id_and_name":"[\"Birkbeck University of London\", \"360G-Wellcome-ORG:Birkbeck-University-of-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Birkbeck-University-of-London","name":"Birkbeck University of London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Structural and mechanistic investigations of the SWI/SNF chromatin remodeller Packaging the two metres of chromosomal DNA found in every human cell is achieved by wrapping DNA around histone proteins in complexes called nucleosomes. Generally, DNA wrapped within nucleosomes is rendered inaccessible to enzymes and DNA-binding factors involved in normal DNA processes such as gene expression, DNA damage repair and chromosome replication. Chromatin remodellers are large molecular machines that disrupt the interaction between DNA and histones, exposing the DNA and therefore making it accessible for fundamental biological processes. I will be focussing on a particular chromatin remodeller called SWI/SNF that uses chemical energy to move, modify and eject nucleosomes. Around 20% of human tumours have been shown to have mutated SWI/SNF, highlighting the complex as one of the most commonly affected targets in cancer. The aim of my project is to use structural (cryo-EM) and single molecule (FRET) analysis to probe the molecular details of the interaction of SWI/SNF with the nucleosome. Moreover, we will visualise SWI/SNF in action, in an attempt to understand how the machine remodels nucleosomes and leading to further understanding of its role in cancer. Our results will provide a platform for the future development of drugs that specifically target mutated SWI/SNF complexes in numerous cancers.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Chromatin","Chromatin Assembly and Disassembly","Cryoelectron Microscopy","DNA","Fluorescence Resonance Energy Transfer","Humans","Models, Molecular","Nucleosomes"]}
{"id":"360G-Wellcome-222905_Z_21_Z","title":"Structural Investigations of Sodium Channel Mutations Associated with Neurological Diseases","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222905/Z/21/Z","description":"Sodium channels (Navs) are proteins which are found in cells around the body, including the central and peripheral nervous system and heart muscles. These proteins span the cell membrane and form channels which specifically allows sodium ions to cross the membrane under certain conditions. This influx of sodium ions in neurons is responsible for information processing and is critical for nervous system function. Genetic mutations in Navs can cause multiple diseases including epilepsy, chronic pain and cardiac arrhythmias. Generally, these mutations reduce the function of Navs, disrupting the balance of information, for example in the brain sometimes resulting in epilepsy. Specific drugs therefore need to be developed in order to re-establish this balance either by adding to Navs\u2019 functionality or reducing it. We aim to use structural biology techniques, including x-ray crystallography and potentially cryo-EM to visualise potential drug binding sites. We will also look at common disease-causing mutations allowing us to identify drugs which will not only target a specific subtype of Nav but also a specific mutation. In particular we will be looking at repurposing already commercially available drugs. This work has the potential to identify drugs for Nav related diseases and provide new treatment options for patients.\n \n","plannedDates":[{"endDate":"2023-12-22T00:00:00+00:00","startDate":"2020-12-23T00:00:00+00:00","startDateDateOnly":"2020-12-23","endDateDateOnly":"2023-12-22"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Frances Thomas","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Thomas","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Birkbeck-University-of-London","name":"Birkbeck University of London","addressCountry":"United Kingdom","id_and_name":"[\"Birkbeck University of London\", \"360G-Wellcome-ORG:Birkbeck-University-of-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Birkbeck-University-of-London","name":"Birkbeck University of London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Structural Investigations of Sodium Channel Mutations Associated with Neurological Diseases Sodium channels (Navs) are proteins which are found in cells around the body, including the central and peripheral nervous system and heart muscles. These proteins span the cell membrane and form channels which specifically allows sodium ions to cross the membrane under certain conditions. This influx of sodium ions in neurons is responsible for information processing and is critical for nervous system function. Genetic mutations in Navs can cause multiple diseases including epilepsy, chronic pain and cardiac arrhythmias. Generally, these mutations reduce the function of Navs, disrupting the balance of information, for example in the brain sometimes resulting in epilepsy. Specific drugs therefore need to be developed in order to re-establish this balance either by adding to Navs\u2019 functionality or reducing it. We aim to use structural biology techniques, including x-ray crystallography and potentially cryo-EM to visualise potential drug binding sites. We will also look at common disease-causing mutations allowing us to identify drugs which will not only target a specific subtype of Nav but also a specific mutation. In particular we will be looking at repurposing already commercially available drugs. This work has the potential to identify drugs for Nav related diseases and provide new treatment options for patients.\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Crystallography, X-Ray","Epilepsy","Humans","Models, Molecular","Mutation"]}
{"id":"360G-Wellcome-222888_Z_21_Z","title":"Generative models for biological methods of control","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222888/Z/21/Z","description":"Behavioural phenotypes are highly relevant to many diseases, particularly those involving neurodegeneration, such as Friedreich\u2019s Ataxia or Parkinson\u2019s disease. While these behavioural phenotypes arise from low-level molecular and cellular processes, they are highly complex. As a result, identifying structure within behavioural data can be challenging. Generative models are a type of model which are able to generate new instances of data, unlike discriminative models which can only discriminate between existing instances. As a result, these models must solve the more complex problem of whether a given data instance is likely, as opposed to what classification it most likely belongs to. This means they must learn the underlying distributions of the data itself, often capturing more meaningful correlations as a result. Building generative models of behaviour can therefore offer deeper insight into the structure of behaviour, as well as a means of analysis through synthesis, where the ability of a model to successfully reproduce naturally observed behaviour provides further validation of the model. These models can also be used to investigate the impact of disease on behaviour through attempts to \u2018corrupt\u2019 the model\u2019s underlying processes and compare the output to experimental data obtained from individuals with a particular disease.\n\n\n \n","plannedDates":[{"endDate":"2023-11-30T00:00:00+00:00","startDate":"2020-12-01T00:00:00+00:00","startDateDateOnly":"2020-12-01","endDateDateOnly":"2023-11-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Max Grogan","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Grogan","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Generative models for biological methods of control Behavioural phenotypes are highly relevant to many diseases, particularly those involving neurodegeneration, such as Friedreich\u2019s Ataxia or Parkinson\u2019s disease. While these behavioural phenotypes arise from low-level molecular and cellular processes, they are highly complex. As a result, identifying structure within behavioural data can be challenging. Generative models are a type of model which are able to generate new instances of data, unlike discriminative models which can only discriminate between existing instances. As a result, these models must solve the more complex problem of whether a given data instance is likely, as opposed to what classification it most likely belongs to. This means they must learn the underlying distributions of the data itself, often capturing more meaningful correlations as a result. Building generative models of behaviour can therefore offer deeper insight into the structure of behaviour, as well as a means of analysis through synthesis, where the ability of a model to successfully reproduce naturally observed behaviour provides further validation of the model. These models can also be used to investigate the impact of disease on behaviour through attempts to \u2018corrupt\u2019 the model\u2019s underlying processes and compare the output to experimental data obtained from individuals with a particular disease.\n\n\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Models, Biological","Phenotype"]}
{"id":"360G-Wellcome-222887_Z_21_Z","title":"UCH photography exhibition","Region":"Greater London","currency":"GBP","awardDate":"2021-01-29T00:00:00+00:00","Internal ID":"222887/Z/21/Z","description":"Produce, print and install an exhibition of photographs by Tom Pilston documenting University College Hospital (UCH) staff working on the Covid pandemic.  Exhibtion to be in UCH lobby in Euston Road \n","plannedDates":[{"endDate":"2021-03-18T00:00:00+00:00","startDate":"2021-02-19T00:00:00+00:00","startDateDateOnly":"2021-02-19","endDateDateOnly":"2021-03-18"}],"amountAwarded":2000,"Financial Year":"2020/21","Lead Applicant":"Mr Adrian Evans","grantProgramme":[{"title":"Discretionary Award \u2013 Directorate","title_keyword":"Discretionary Award \u2013 Directorate"}],"Applicant Surname":"Evans","Partnership Value":2000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Panos-Pictures","name":"Panos Pictures","addressCountry":"United Kingdom","id_and_name":"[\"Panos Pictures\", \"360G-Wellcome-ORG:Panos-Pictures\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Panos-Pictures","name":"Panos Pictures"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"UCH photography exhibition Produce, print and install an exhibition of photographs by Tom Pilston documenting University College Hospital (UCH) staff working on the Covid pandemic.  Exhibtion to be in UCH lobby in Euston Road \n","awardDateDateOnly":"2021-01-29","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Hospitals, University","Humans","Photography","Universities"]}
{"id":"360G-Wellcome-222884_Z_21_Z","title":"Advancing product development and use of monoclonal antibodies for infectious disease in low and middle income countries (LMICs)\u2019","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"222884/Z/21/Z","description":"The project supports activities in the Immunization, Vaccines and biologicals\ndepartment of the WHO that aim to advance the product development and use of\nmonoclonal antibodies (mAbs) for infectious diseases, with a focus on meeting the\nneeds of Low and Middle Income Countries (LMICs). Three specific activities will be\ncarried out. First, a stakeholder consultation on monoclonal antibody technologies will\nbe held to discuss which would best support affordability and accessibility in LMICs.\nSecond, an application to establish rabies mAbs on the WHO model list of essential\nmedicines (EML) would set the precedent for inclusion of additional infectious diseases\nmAbs in the future. Thirdly, an assessment of diphtheria immunoglobulin supply and\npotential demand for mAb-based products will be carried out which could serve as a\nmethodology to be used to assess other mAb based products.\"","plannedDates":[{"endDate":"2022-11-28T00:00:00+00:00","startDate":"2021-06-01T00:00:00+00:00","startDateDateOnly":"2021-06-01","endDateDateOnly":"2022-11-28"}],"amountAwarded":143272,"Financial Year":"2019/20","Lead Applicant":"Dr Birgitte Giersing","grantProgramme":[{"title":"Innovations AIGH Enterics Flagship ","title_keyword":"Innovations AIGH Enterics Flagship "}],"Applicant Surname":"Giersing","Partnership Value":143272,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:World-Health-Organization-Switzerland","name":"World Health Organization, Switzerland","addressCountry":"Switzerland","id_and_name":"[\"World Health Organization, Switzerland\", \"360G-Wellcome-ORG:World-Health-Organization-Switzerland\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:World-Health-Organization-Switzerland","name":"World Health Organization, Switzerland"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Advancing product development and use of monoclonal antibodies for infectious disease in low and middle income countries (LMICs)\u2019 The project supports activities in the Immunization, Vaccines and biologicals\ndepartment of the WHO that aim to advance the product development and use of\nmonoclonal antibodies (mAbs) for infectious diseases, with a focus on meeting the\nneeds of Low and Middle Income Countries (LMICs). Three specific activities will be\ncarried out. First, a stakeholder consultation on monoclonal antibody technologies will\nbe held to discuss which would best support affordability and accessibility in LMICs.\nSecond, an application to establish rabies mAbs on the WHO model list of essential\nmedicines (EML) would set the precedent for inclusion of additional infectious diseases\nmAbs in the future. Thirdly, an assessment of diphtheria immunoglobulin supply and\npotential demand for mAb-based products will be carried out which could serve as a\nmethodology to be used to assess other mAb based products.\"","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Antibodies, Monoclonal","Developing Countries","Humans","Rabies"]}
{"id":"360G-Wellcome-222874_Z_21_Z","title":"Doing natality: making babies, making kin in Africa","Region":"International","currency":"GBP","awardDate":"2021-03-15T00:00:00+00:00","Internal ID":"222874/Z/21/Z","description":"Africa has the fastest growing population in the world. At the same time the continent has some of the highest rates of infertility. Most people long to have children for diverse reasons. Those unable to have children seek ways to improve their chances of conceiving. These may include biomedical interventions, vernacular healing practices, changing or adding partners or making kin through adoption and child circulation. Yet despite the diversity of lived experiences and practices of reproduction across the continent, most research and interventions into reproductive health in Africa frame it primarily in terms of risk, pathology, mortality, and irresponsibility. Doing Natality engages a team from four African countries, working across demography, social sciences, medical humanities and science and technology studies, to develop a research agenda that centers the notion of \"doing natality\". We aim to explore practices of doing natality as articulation of love, care, beginning something new and securing better futures in raising children. We thereby open up a new space to interrogate and explore the usefulness of the notion of \"doing natality\" as heuristic, theoretical and methodological tool by asking what it means for African women, men and couples to have (or not have) children.\n \n","plannedDates":[{"endDate":"2026-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2026-08-31"}],"amountAwarded":1064246,"Financial Year":"2020/21","Lead Applicant":"Dr Nozipho Nolwazi Mkhwanazi","grantProgramme":[{"title":"Research Development Award in H&SS","title_keyword":"Research Development Award in H&SS"}],"Applicant Surname":"Mkhwanazi","Partnership Value":1064246,"Approval Committee":"Research Development Awards Committee","Other Applicant(s)":"Prof Richard Rottenburg","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-the-Witwatersrand","name":"University of the Witwatersrand","addressCountry":"South Africa","id_and_name":"[\"University of the Witwatersrand\", \"360G-Wellcome-ORG:University-of-the-Witwatersrand\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-the-Witwatersrand","name":"University of the Witwatersrand"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Doing natality: making babies, making kin in Africa Africa has the fastest growing population in the world. At the same time the continent has some of the highest rates of infertility. Most people long to have children for diverse reasons. Those unable to have children seek ways to improve their chances of conceiving. These may include biomedical interventions, vernacular healing practices, changing or adding partners or making kin through adoption and child circulation. Yet despite the diversity of lived experiences and practices of reproduction across the continent, most research and interventions into reproductive health in Africa frame it primarily in terms of risk, pathology, mortality, and irresponsibility. Doing Natality engages a team from four African countries, working across demography, social sciences, medical humanities and science and technology studies, to develop a research agenda that centers the notion of \"doing natality\". We aim to explore practices of doing natality as articulation of love, care, beginning something new and securing better futures in raising children. We thereby open up a new space to interrogate and explore the usefulness of the notion of \"doing natality\" as heuristic, theoretical and methodological tool by asking what it means for African women, men and couples to have (or not have) children.\n \n","awardDateDateOnly":"2021-03-15","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa","Child","Female","Humans","Male"]}
{"id":"360G-Wellcome-222872_Z_21_Z","title":"Setting an Emancipatory Agenda: Disabled People's Research Network","Region":"South West","currency":"GBP","awardDate":"2021-03-15T00:00:00+00:00","Internal ID":"222872/Z/21/Z","description":"Social science research has long been criticised for failing to improve the life chances of disabled people. Current research agendas are determined \u2018top down\u2019 by policy makers, and researchers risk objectifying disabled participants by conducting research \u2018on\u2019 them (as opposed to \u2018with\u2019 them). Our radical and exciting proposal challenges the status quo by developing an inclusive agenda and establishing a Disabled People\u2019s Research Network. Our vision is to place academic and non-academic disabled people at the heart of research development, and our entire project will be co-produced by working with disabled people\u2019s organisations. Our activities will identify new salient questions and reinvent social science methodology by exploring how the arts and humanities can enable disabled people to evidence and share their lived experiences. We will develop more inclusive forms of knowledge exchange between universities and disabled people, and we will work with policy makers to maximise disabled people\u2019s research impact. We will empower disabled people as agents of change and our activities will include a range of fellowships for disabled people and a highly innovative research training course led by disabled people. Our network will reinvent how universities work with disabled people, in addition to methodological and epistemological development.\n","plannedDates":[{"endDate":"2026-07-31T00:00:00+00:00","startDate":"2021-08-01T00:00:00+00:00","startDateDateOnly":"2021-08-01","endDateDateOnly":"2026-07-31"}],"amountAwarded":1040680,"Financial Year":"2020/21","Lead Applicant":"Dr Ben Simmons","grantProgramme":[{"title":"Research Development Award in H&SS","title_keyword":"Research Development Award in H&SS"}],"Applicant Surname":"Simmons","Partnership Value":1040680,"Approval Committee":"Research Development Awards Committee","Other Applicant(s)":"Dr Stuart Read, Prof Martin Levinson","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Bath-Spa-University","name":"Bath Spa University","addressCountry":"United Kingdom","id_and_name":"[\"Bath Spa University\", \"360G-Wellcome-ORG:Bath-Spa-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Bath-Spa-University","name":"Bath Spa University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Setting an Emancipatory Agenda: Disabled People's Research Network Social science research has long been criticised for failing to improve the life chances of disabled people. Current research agendas are determined \u2018top down\u2019 by policy makers, and researchers risk objectifying disabled participants by conducting research \u2018on\u2019 them (as opposed to \u2018with\u2019 them). Our radical and exciting proposal challenges the status quo by developing an inclusive agenda and establishing a Disabled People\u2019s Research Network. Our vision is to place academic and non-academic disabled people at the heart of research development, and our entire project will be co-produced by working with disabled people\u2019s organisations. Our activities will identify new salient questions and reinvent social science methodology by exploring how the arts and humanities can enable disabled people to evidence and share their lived experiences. We will develop more inclusive forms of knowledge exchange between universities and disabled people, and we will work with policy makers to maximise disabled people\u2019s research impact. We will empower disabled people as agents of change and our activities will include a range of fellowships for disabled people and a highly innovative research training course led by disabled people. Our network will reinvent how universities work with disabled people, in addition to methodological and epistemological development.\n","awardDateDateOnly":"2021-03-15","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Disabled Persons","Humans","Research","Social Sciences","Universities"]}
{"id":"360G-Wellcome-222871_Z_21_Z","title":"LivingBodiesObjects: Technology and the Spaces of Health","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2021-03-15T00:00:00+00:00","Internal ID":"222871/Z/21/Z","description":"LivingBodiesObjects is an experiment in the making and understanding of interactions between bodies, technologies, objects and health, designed to test and extend the boundaries of Medical Humanities research. Working with a range of partners, it will take place in the context of multi-purpose/use laboratory spaces (both physical and virtual) that invite differing conceptions and practices of health experiences, and responses to them. The ambition of the project lies in the imaginative creation of these spaces and not in any pre-emption of the materials they might produce. The laboratories will be specifically designed to figure ideas and creativity, making spaces that provoke, facilitate and respond to the ideas and questions raised by bodies as they encounter different forms of technology.  Centring on the ways in which individuals and communities collaborate to produce work within dynamic and generative locations, the laboratories will also link to more traditional laboratory activities such as equipment, testing and use. As a specific research development initiative, the project will further extend interdisciplinary health research practice at the University of Leeds, where its work will inform and further develop a research culture through the foregrounding of innovation in professional research management, career development and equality, diversity and inclusion. \n","plannedDates":[{"endDate":"2024-12-31T00:00:00+00:00","startDate":"2022-01-01T00:00:00+00:00","startDateDateOnly":"2022-01-01","endDateDateOnly":"2024-12-31"}],"amountAwarded":1016937,"Financial Year":"2020/21","Lead Applicant":"Prof Stuart Murray","grantProgramme":[{"title":"Research Development Award in H&SS","title_keyword":"Research Development Award in H&SS"}],"Applicant Surname":"Murray","Partnership Value":1016937,"Approval Committee":"Research Development Awards Committee","Other Applicant(s)":"Dr Clare Barker, Mrs Faye Robinson, Dr Amelia DeFalco, Dr Tom Jackson, Prof James Stark","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds","addressCountry":"United Kingdom","id_and_name":"[\"University of Leeds\", \"360G-Wellcome-ORG:University-of-Leeds\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"LivingBodiesObjects: Technology and the Spaces of Health LivingBodiesObjects is an experiment in the making and understanding of interactions between bodies, technologies, objects and health, designed to test and extend the boundaries of Medical Humanities research. Working with a range of partners, it will take place in the context of multi-purpose/use laboratory spaces (both physical and virtual) that invite differing conceptions and practices of health experiences, and responses to them. The ambition of the project lies in the imaginative creation of these spaces and not in any pre-emption of the materials they might produce. The laboratories will be specifically designed to figure ideas and creativity, making spaces that provoke, facilitate and respond to the ideas and questions raised by bodies as they encounter different forms of technology.  Centring on the ways in which individuals and communities collaborate to produce work within dynamic and generative locations, the laboratories will also link to more traditional laboratory activities such as equipment, testing and use. As a specific research development initiative, the project will further extend interdisciplinary health research practice at the University of Leeds, where its work will inform and further develop a research culture through the foregrounding of innovation in professional research management, career development and equality, diversity and inclusion. \n","awardDateDateOnly":"2021-03-15","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biomedical Research","Humanities","Humans","Inventions","Laboratories","Research"]}
{"id":"360G-Wellcome-222863_Z_21_Z","title":"Centre for the Social Study of Microbes","Region":"International","currency":"GBP","awardDate":"2021-03-15T00:00:00+00:00","Internal ID":"222863/Z/21/Z","description":"The aim of this Research Development Award is to establish a leading centre for the social study of microbes. Since their discovery, microbes have been predominantly defined as pathogenic and threatening to human and animal health. Recently, however, societal, and scientific views about microbes, immunity, and antibiotics have started to acknowledge the beneficial and symbiotic qualities of bacteria, viruses and fungi. Existing social scientific language is insufficient and outdated in describing the complex and entwined relationships between humans, nonhumans, microbes, and environments. These relations with microbes raise profound challenges for the foundations of social theory.\n \n\nStrategically situated within an emerging network of research, this application will establish an egalitarian and experimental research infrastructure to develop new social scientific concepts and methodology to address the challenge. The Centre will host international research fellows and an art residency, and organise social theory and methodology workshops, two academic seminars annually, and a yearly PhD Summer School to support younger generations of scholars. Not only is this work theoretically essential, it is also key to understanding and acting upon the way humans relate to microbes and other nonhumans, a vital objective for developing sustainable ways of planetary co-existence.\n","plannedDates":[{"endDate":"2026-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2026-08-31"}],"amountAwarded":996460,"Financial Year":"2020/21","Lead Applicant":"Dr Salla Sariola","grantProgramme":[{"title":"Research Development Award in H&SS","title_keyword":"Research Development Award in H&SS"}],"Applicant Surname":"Sariola","Partnership Value":996460,"Approval Committee":"Research Development Awards Committee","Other Applicant(s)":"Dr Jose Ca\u00f1ada, Dr Mikko Jauho","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Helsinki","name":"University of Helsinki","addressCountry":"Finland","id_and_name":"[\"University of Helsinki\", \"360G-Wellcome-ORG:University-of-Helsinki\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Helsinki","name":"University of Helsinki"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Centre for the Social Study of Microbes The aim of this Research Development Award is to establish a leading centre for the social study of microbes. Since their discovery, microbes have been predominantly defined as pathogenic and threatening to human and animal health. Recently, however, societal, and scientific views about microbes, immunity, and antibiotics have started to acknowledge the beneficial and symbiotic qualities of bacteria, viruses and fungi. Existing social scientific language is insufficient and outdated in describing the complex and entwined relationships between humans, nonhumans, microbes, and environments. These relations with microbes raise profound challenges for the foundations of social theory.\n \n\nStrategically situated within an emerging network of research, this application will establish an egalitarian and experimental research infrastructure to develop new social scientific concepts and methodology to address the challenge. The Centre will host international research fellows and an art residency, and organise social theory and methodology workshops, two academic seminars annually, and a yearly PhD Summer School to support younger generations of scholars. Not only is this work theoretically essential, it is also key to understanding and acting upon the way humans relate to microbes and other nonhumans, a vital objective for developing sustainable ways of planetary co-existence.\n","awardDateDateOnly":"2021-03-15","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Fungi","Humans"]}
{"id":"360G-Wellcome-222859_Z_21_Z","title":"Leaving no-one behind in Research","Region":"North West","currency":"GBP","awardDate":"2021-03-15T00:00:00+00:00","Internal ID":"222859/Z/21/Z","description":"Three paradoxes in global research ethics seriously harm vulnerable populations. \n\n \n\nFirst, health research works. Yet, to protect vulnerable populations from exploitation, they are often excluded from it.\n\n \n\nSecond, international collaborative research works. Yet, major trust issues block collaborations with vulnerable populations who have previously been exploited.\n\n \n\nThird, the further apart researcher and end-user experiences are, the more urgent the co-creation of research becomes. Yet, successful co-creation methods for non-clinical health research with vulnerable populations in low and middle income countries (LMICs) barely exist.\n\n \n\nAll three paradoxes restrict non-clinical health research in LMICs.\n\n \n\nLeaving no one behind in research will build an extensive research agenda to tackle all three paradoxes by:\n\n\n radically rethinking the concept of vulnerability and what appropriate protection mechanisms for the vulnerable would look like.\n enabling indigenous peoples and sex worker teams to define what vulnerability means to them and how they want to be protected in research.\n developing a humanities method for non-clinical health research that would make research less risky for vulnerable populations.\n\n\n \n\nThe above will be achieved by a highly-experienced research leader and her UK team in a network with two African teams representing vulnerable populations.\n","plannedDates":[{"endDate":"2025-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2025-06-30"}],"amountAwarded":733684,"Financial Year":"2020/21","Lead Applicant":"Prof Doris Schroeder","grantProgramme":[{"title":"Research Development Award in H&SS","title_keyword":"Research Development Award in H&SS"}],"Applicant Surname":"Schroeder","Partnership Value":733684,"Approval Committee":"Research Development Awards Committee","Other Applicant(s)":"Dr Joshua Kimani, Dr Roger Chennells","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Central-Lancashire","name":"University of Central Lancashire","addressCountry":"United Kingdom","id_and_name":"[\"University of Central Lancashire\", \"360G-Wellcome-ORG:University-of-Central-Lancashire\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Central-Lancashire","name":"University of Central Lancashire"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Leaving no-one behind in Research Three paradoxes in global research ethics seriously harm vulnerable populations. \n\n \n\nFirst, health research works. Yet, to protect vulnerable populations from exploitation, they are often excluded from it.\n\n \n\nSecond, international collaborative research works. Yet, major trust issues block collaborations with vulnerable populations who have previously been exploited.\n\n \n\nThird, the further apart researcher and end-user experiences are, the more urgent the co-creation of research becomes. Yet, successful co-creation methods for non-clinical health research with vulnerable populations in low and middle income countries (LMICs) barely exist.\n\n \n\nAll three paradoxes restrict non-clinical health research in LMICs.\n\n \n\nLeaving no one behind in research will build an extensive research agenda to tackle all three paradoxes by:\n\n\n radically rethinking the concept of vulnerability and what appropriate protection mechanisms for the vulnerable would look like.\n enabling indigenous peoples and sex worker teams to define what vulnerability means to them and how they want to be protected in research.\n developing a humanities method for non-clinical health research that would make research less risky for vulnerable populations.\n\n\n \n\nThe above will be achieved by a highly-experienced research leader and her UK team in a network with two African teams representing vulnerable populations.\n","awardDateDateOnly":"2021-03-15","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biomedical Research","Developing Countries","Humans","Poverty","Vulnerable Populations"]}
{"id":"360G-Wellcome-222858_Z_21_Z","title":"The Future of Human Reproduction: transformative agendas and methods for the Humanities and Social Sciences","Region":"North West","currency":"GBP","awardDate":"2021-03-15T00:00:00+00:00","Internal ID":"222858/Z/21/Z","description":"New and emerging reproductive technologies have the potential, within a generation or two, to profoundly disrupt established social practices linked to human reproduction and parenting, as well as the concepts of relatedness and family.  Better understanding the cultural, ethical, legal, and social issues that this prospect raises is the principal substantive research aim of this programme.  We will examine three such technologies.\n\nEctogenesis could allow us to develop fetuses wholly outside the body, to create children who have not been \u2018born\u2019 (in the usual sense of that term).\n\nGenome editing will mean that future children can be \u2018chosen\u2019 or \u2018designed\u2019 with far greater levels of precision than at present.\n\nNew methods of creating eggs and sperm will enable the creation of children with two genetic parents of the same sex, or who have multiple genetic parents, or perhaps no determinate genetic parents at all.\n\nUsing these cases as focal points, we will develop transformative new research methods and modes of interdisciplinary working - for example, by integrating speculative design methodologies with those of bioethics, law, literature, linguistics, and psychology.  Our ultimate aim is for this to lead to a novel research paradigm for the study of disruptive emerging technologies.\n\n \n","plannedDates":[{"endDate":"2025-08-02T00:00:00+00:00","startDate":"2022-05-03T00:00:00+00:00","startDateDateOnly":"2022-05-03","endDateDateOnly":"2025-08-02"}],"amountAwarded":1019767,"Financial Year":"2020/21","Lead Applicant":"Prof Stephen Wilkinson","grantProgramme":[{"title":"Research Development Award in H&SS","title_keyword":"Research Development Award in H&SS"}],"Applicant Surname":"Wilkinson","Partnership Value":1019767,"Approval Committee":"Research Development Awards Committee","Other Applicant(s)":"Dr Emmanuel Tsekleves, Prof Elena Semino, Dr Kirsty Dunn, Prof Sharon Ruston, Prof Sara Fovargue","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Lancaster-University","name":"Lancaster University","addressCountry":"United Kingdom","id_and_name":"[\"Lancaster University\", \"360G-Wellcome-ORG:Lancaster-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Lancaster-University","name":"Lancaster University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The Future of Human Reproduction: transformative agendas and methods for the Humanities and Social Sciences New and emerging reproductive technologies have the potential, within a generation or two, to profoundly disrupt established social practices linked to human reproduction and parenting, as well as the concepts of relatedness and family.  Better understanding the cultural, ethical, legal, and social issues that this prospect raises is the principal substantive research aim of this programme.  We will examine three such technologies.\n\nEctogenesis could allow us to develop fetuses wholly outside the body, to create children who have not been \u2018born\u2019 (in the usual sense of that term).\n\nGenome editing will mean that future children can be \u2018chosen\u2019 or \u2018designed\u2019 with far greater levels of precision than at present.\n\nNew methods of creating eggs and sperm will enable the creation of children with two genetic parents of the same sex, or who have multiple genetic parents, or perhaps no determinate genetic parents at all.\n\nUsing these cases as focal points, we will develop transformative new research methods and modes of interdisciplinary working - for example, by integrating speculative design methodologies with those of bioethics, law, literature, linguistics, and psychology.  Our ultimate aim is for this to lead to a novel research paradigm for the study of disruptive emerging technologies.\n\n \n","awardDateDateOnly":"2021-03-15","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Child","Female","Gene Editing","Humans","Male","Parents"]}
{"id":"360G-Wellcome-222853_Z_21_Z","title":"A new voice for R&D investment","Region":"Greater London","currency":"GBP","awardDate":"2021-04-30T00:00:00+00:00","Internal ID":"222853/Z/21/Z","description":"See attached document.\n","plannedDates":[{"endDate":"2024-05-24T00:00:00+00:00","startDate":"2021-05-24T00:00:00+00:00","startDateDateOnly":"2021-05-24","endDateDateOnly":"2024-05-24"}],"amountAwarded":1122000,"Financial Year":"2020/21","Lead Applicant":"Dr Sarah Main","grantProgramme":[{"title":"Discretionary Award - Policy ","title_keyword":"Discretionary Award - Policy "}],"Applicant Surname":"Main","Partnership Value":1122000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Campaign-for-Science-and-Engineering","name":"Campaign for Science and Engineering","addressCountry":"United Kingdom","id_and_name":"[\"Campaign for Science and Engineering\", \"360G-Wellcome-ORG:Campaign-for-Science-and-Engineering\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Campaign-for-Science-and-Engineering","name":"Campaign for Science and Engineering"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A new voice for R&D investment See attached document.\n","awardDateDateOnly":"2021-04-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":[]}
{"id":"360G-Wellcome-222852_Z_21_Z","title":"Enhanced analysis of microscopy images using deep learning: applications to histopathology of ovarian cancer","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222852/Z/21/Z","description":"Single Molecule Localisation Microscopy (SMLM) has enabled scientists to observe biological processes at a molecular level. These techniques typically generate 3D point cloud data which localise individual molecules within the specimen. The spatial statistics of these point clouds have then been used to classify, segment or co-localise molecules to support hypotheses regarding the underlying biological processes occurring in the sample. As this is currently achieved through non-deep learning approaches (eg: Ripley's functions, DBSCAN, graph based or shallow neural networks), I will investigate the applicability of existing deep learning solutions on SMLM point cloud data. From this set of existing work, I will design and evaluate possible improvements to these systems. Improvements in the performance of these models could provide better acuity in the post-processing of SMLM images, and thereby improve our understanding of the fundamental biological processes involved. \n","plannedDates":[{"endDate":"2023-10-04T00:00:00+00:00","startDate":"2020-10-05T00:00:00+00:00","startDateDateOnly":"2020-10-05","endDateDateOnly":"2023-10-04"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Miguel Boland","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Boland","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Enhanced analysis of microscopy images using deep learning: applications to histopathology of ovarian cancer Single Molecule Localisation Microscopy (SMLM) has enabled scientists to observe biological processes at a molecular level. These techniques typically generate 3D point cloud data which localise individual molecules within the specimen. The spatial statistics of these point clouds have then been used to classify, segment or co-localise molecules to support hypotheses regarding the underlying biological processes occurring in the sample. As this is currently achieved through non-deep learning approaches (eg: Ripley's functions, DBSCAN, graph based or shallow neural networks), I will investigate the applicability of existing deep learning solutions on SMLM point cloud data. From this set of existing work, I will design and evaluate possible improvements to these systems. Improvements in the performance of these models could provide better acuity in the post-processing of SMLM images, and thereby improve our understanding of the fundamental biological processes involved. \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Deep Learning","Female","Humans","Image Processing, Computer-Assisted","Microscopy","Neural Networks, Computer","Ovarian Neoplasms"]}
{"id":"360G-Wellcome-222851_Z_21_Z","title":"Adaptive motor learning through systems-level modelling of neural populations","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222851/Z/21/Z","description":"The brain can learn a variety of motor skills, from using chopsticks to playing the piano. Some skills are easier to learn than others, and this may be affected by the skills that you already have.\n\nWe are interested in how motor learning occurs in populations of neurons. Networks of neurons work together to produce different neural activity patterns that drive learning and movement. The possible patterns that can be produced thus depend on the structure of the network, and this can be affected by existing skill sets.\n\nWe will use artificial neural networks to computationally model motor learning. We will train the model on different motor tasks and see how they adapt to learning new ones. This will be coupled with experimental data that measure neural activity in monkeys and mice during motor tasks. By understanding how the brain learns new movements, we can gain insight into applications of assistive devices and therapies for motor function.\n","plannedDates":[{"endDate":"2023-10-04T00:00:00+00:00","startDate":"2020-10-05T00:00:00+00:00","startDateDateOnly":"2020-10-05","endDateDateOnly":"2023-10-04"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Joanna Chang","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Chang","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Adaptive motor learning through systems-level modelling of neural populations The brain can learn a variety of motor skills, from using chopsticks to playing the piano. Some skills are easier to learn than others, and this may be affected by the skills that you already have.\n\nWe are interested in how motor learning occurs in populations of neurons. Networks of neurons work together to produce different neural activity patterns that drive learning and movement. The possible patterns that can be produced thus depend on the structure of the network, and this can be affected by existing skill sets.\n\nWe will use artificial neural networks to computationally model motor learning. We will train the model on different motor tasks and see how they adapt to learning new ones. This will be coupled with experimental data that measure neural activity in monkeys and mice during motor tasks. By understanding how the brain learns new movements, we can gain insight into applications of assistive devices and therapies for motor function.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Learning","Models, Neurological","Motor Cortex","Motor Skills","Movement","Neural Networks, Computer","Neurons"]}
{"id":"360G-Wellcome-222846_Z_21_Z","title":"A novel anti-tumour tri-specific engager to promote T cell and NK cell activation within the tumour microenvironment ","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222846/Z/21/Z","description":"Antibodies are proteins, naturally produced by the immune system, that bind other molecules. This interaction can block the function of the bound molecule and is exploited in anti-tumour treatments. For instance, antibodies can block immune inhibitory receptors. These receptors are responsible for stopping the immune system from killing infected cells and cancer cells. For various reasons, some cancer patients do not respond to treatments with antibodies. Some can be attributed to the relatively large size of antibodies and the presence of immune inhibitory molecules within the tumour.\n\nThe aim of our project is to develop a new anti-tumour treatment to unleash the capacity of the immune system to attack and kill cancer cells. Our goal is to use genetic engineering to design small antibody proteins that can bind more than one distinct immune inhibitory receptor simultaneously. By doing this, we aim to restore the natural ability of the patient to recognise and eliminate tumour cells.\n \n","plannedDates":[{"endDate":"2023-11-08T00:00:00+00:00","startDate":"2020-11-09T00:00:00+00:00","startDateDateOnly":"2020-11-09","endDateDateOnly":"2023-11-08"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Fernando Jimenez-Gallardo","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Jimenez-Gallardo","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A novel anti-tumour tri-specific engager to promote T cell and NK cell activation within the tumour microenvironment  Antibodies are proteins, naturally produced by the immune system, that bind other molecules. This interaction can block the function of the bound molecule and is exploited in anti-tumour treatments. For instance, antibodies can block immune inhibitory receptors. These receptors are responsible for stopping the immune system from killing infected cells and cancer cells. For various reasons, some cancer patients do not respond to treatments with antibodies. Some can be attributed to the relatively large size of antibodies and the presence of immune inhibitory molecules within the tumour.\n\nThe aim of our project is to develop a new anti-tumour treatment to unleash the capacity of the immune system to attack and kill cancer cells. Our goal is to use genetic engineering to design small antibody proteins that can bind more than one distinct immune inhibitory receptor simultaneously. By doing this, we aim to restore the natural ability of the patient to recognise and eliminate tumour cells.\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Immunotherapy","Killer Cells, Natural","Neoplasms","Tumor Microenvironment"]}
{"id":"360G-Wellcome-222845_Z_21_Z","title":"Inferring structural properties of the myocardial substrate from multipolar electrogram recordings using deep learning","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222845/Z/21/Z","description":"The contraction of the heart muscle is caused by the propagation of electrical signal throughout the heart. This signal is propagated from cell to cell through proteins called ion channels and gap junctions. Physiological and pathological heterogeneities and changes in the expression of these proteins, result in the conductivity field of the heart tissue being non-homogeneous and anisotropic. This can result in electrical waves that propagate abnormally and can cause atrial fibrillation, which is an irregular beat in the upper chambers of the heart, the atria, and one of the most common cardiovascular diseases.\n\nThe aim of this project is to test the hypothesis that data from electrograms, recorded by electrodes in direct contact with the heart, can be used to estimate the conductivity field of the cardiac tissue. Deep learning methods will be used to solve this inverse problem, first applied in synthetic data, and then validated in a biological setting.\n\nBy reconstructing the conductivity field of the heart muscle from electrograms, the currently-low success rate of the treatment of atrial fibrillation through ablation will be increased, since the clinicians will have a better indication of the position of the low-conductivity tissue that has to be ablated.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Konstantinos Ntagiantas","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Ntagiantas","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Inferring structural properties of the myocardial substrate from multipolar electrogram recordings using deep learning The contraction of the heart muscle is caused by the propagation of electrical signal throughout the heart. This signal is propagated from cell to cell through proteins called ion channels and gap junctions. Physiological and pathological heterogeneities and changes in the expression of these proteins, result in the conductivity field of the heart tissue being non-homogeneous and anisotropic. This can result in electrical waves that propagate abnormally and can cause atrial fibrillation, which is an irregular beat in the upper chambers of the heart, the atria, and one of the most common cardiovascular diseases.\n\nThe aim of this project is to test the hypothesis that data from electrograms, recorded by electrodes in direct contact with the heart, can be used to estimate the conductivity field of the cardiac tissue. Deep learning methods will be used to solve this inverse problem, first applied in synthetic data, and then validated in a biological setting.\n\nBy reconstructing the conductivity field of the heart muscle from electrograms, the currently-low success rate of the treatment of atrial fibrillation through ablation will be increased, since the clinicians will have a better indication of the position of the low-conductivity tissue that has to be ablated.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Atrial Fibrillation","Electric Conductivity","Electrodes","Heart","Heart Conduction System","Humans"]}
{"id":"360G-Wellcome-222844_Z_21_Z","title":"Determining the roles of the Artemis nuclease in genome stability at the replication fork","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222844/Z/21/Z","description":"Damage to DNA occurs constantly within our cells. If this damage is not repaired, it can lead to mutations in our genome when cells divide, which can cause cancer. So, to protect the integrity of our DNA, cells have evolved a variety of mechanisms to fix these lesions.\n\n\nOne protein that plays a key role in these processes is Artemis, which acts in the repair of several different forms of damage by incising sections of damaged DNA. I will study this protein using a range of biochemical, genetic and cell biology techniques. These will characterise the reactions that Artemis catalyses at sites of DNA damage, whether it requires interacting partners or modifications to do so and will enhance our understanding of the functions of each of its domains. I will also be collaborating with chemists to develop inhibitors against Artemis.\n\n\nBy better understanding the mechanisms that protect our DNA at the molecular level, we can improve cancer treatments. Chemotherapeutic drugs often kill tumour cells by damaging their DNA and cancers can evolve resistance to these treatments by increasing their capacity for repair. Inhibitors targeting Artemis could therefore be used to help overcome resistance to chemotherapeutic drugs and radiotherapy.\n","plannedDates":[{"endDate":"2024-01-10T00:00:00+00:00","startDate":"2021-01-11T00:00:00+00:00","startDateDateOnly":"2021-01-11","endDateDateOnly":"2024-01-10"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Lucy Henderson","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Henderson","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Determining the roles of the Artemis nuclease in genome stability at the replication fork Damage to DNA occurs constantly within our cells. If this damage is not repaired, it can lead to mutations in our genome when cells divide, which can cause cancer. So, to protect the integrity of our DNA, cells have evolved a variety of mechanisms to fix these lesions.\n\n\nOne protein that plays a key role in these processes is Artemis, which acts in the repair of several different forms of damage by incising sections of damaged DNA. I will study this protein using a range of biochemical, genetic and cell biology techniques. These will characterise the reactions that Artemis catalyses at sites of DNA damage, whether it requires interacting partners or modifications to do so and will enhance our understanding of the functions of each of its domains. I will also be collaborating with chemists to develop inhibitors against Artemis.\n\n\nBy better understanding the mechanisms that protect our DNA at the molecular level, we can improve cancer treatments. Chemotherapeutic drugs often kill tumour cells by damaging their DNA and cancers can evolve resistance to these treatments by increasing their capacity for repair. Inhibitors targeting Artemis could therefore be used to help overcome resistance to chemotherapeutic drugs and radiotherapy.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Artemisinins","DNA Damage","DNA Repair","Humans","Neoplasms"]}
{"id":"360G-Wellcome-222843_Z_21_Z","title":"Dissecting structural and functional contributions of promoter interactions in gene regulation","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222843/Z/21/Z","description":"Understanding how complex multicellular organisms, made up from trillions of cells within multiple tissues, develop from a single fertilised egg requires turning specific genes on and off at the right place and time, in a pre-determined order. The entire process is encoded within the DNA sequence of the genome in each individual cell. In humans, there are about 20,000 genes, which encode functional units such as enzymes or haemoglobin, but these only constitute 1-2% of the DNA sequence in each cell. The DNA also contains surrounding regulatory elements that control the output of genes. There are 3 classes of such elements: promoters, enhancers and boundary elements. It is becoming increasingly clear that the roles of these elements overlap one another.  \n\nIn this work, I will study the characteristics of promoter interactions and the resulting impact on gene regulation. I will be particularly interested in how promoters control gene expression by changing the three-dimensional architecture of the genome as well as the conditions by which promoters interact with enhancers. Ultimately understanding the process of gene expression will enable us to understand how these genes are normally switched on and off during development and how this goes awry in human disease. \n","plannedDates":[{"endDate":"2024-01-06T00:00:00+00:00","startDate":"2021-01-07T00:00:00+00:00","startDateDateOnly":"2021-01-07","endDateDateOnly":"2024-01-06"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Lucy Cornell","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Cornell","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Dissecting structural and functional contributions of promoter interactions in gene regulation Understanding how complex multicellular organisms, made up from trillions of cells within multiple tissues, develop from a single fertilised egg requires turning specific genes on and off at the right place and time, in a pre-determined order. The entire process is encoded within the DNA sequence of the genome in each individual cell. In humans, there are about 20,000 genes, which encode functional units such as enzymes or haemoglobin, but these only constitute 1-2% of the DNA sequence in each cell. The DNA also contains surrounding regulatory elements that control the output of genes. There are 3 classes of such elements: promoters, enhancers and boundary elements. It is becoming increasingly clear that the roles of these elements overlap one another.  \n\nIn this work, I will study the characteristics of promoter interactions and the resulting impact on gene regulation. I will be particularly interested in how promoters control gene expression by changing the three-dimensional architecture of the genome as well as the conditions by which promoters interact with enhancers. Ultimately understanding the process of gene expression will enable us to understand how these genes are normally switched on and off during development and how this goes awry in human disease. \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Enhancer Elements, Genetic","Gene Expression Regulation","Humans","Promoter Regions, Genetic"]}
{"id":"360G-Wellcome-222842_Z_21_Z","title":"Mechanisms of RUNX1 regulation in human developmental haematopoiesis and childhood leukaemia","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222842/Z/21/Z","description":"All adult blood cells are derived from prenatal blood stem cells produced in the embryo, where the process is dependent on a gene named RUNX1. Blood cell formation and the development of various blood cancers (leukaemia) are sensitive to RUNX1 levels. In my DPhil, I will characterise the mechanisms regulating RUNX1 levels in normal and malignant human blood cell formation. I will use a \"test tube\" experimental approach to model human fetal blood cell formation, by differentiating stem cells into immature blood cells (progenitors). I will characterize the dynamic regulatory changes in the RUNX1 genomic region at distinct blood progenitor stages. These data will form the benchmark for the examination of RUNX1 regulation in primary human blood progenitor cells and childhood acute lymphoblastic leukaemia (ALL) samples. Lastly, RUNX1 regulation will be perturbed through genetic and epigenetic engineering, to identify the contribution of aberrant RUNX1 expression to the development of childhood leukaemia. This comparative approach will help us understand not only regulatory mechanisms of normal human blood cell formation, and how well this process can be modelled in a test tube, but also how altered regulation of RUNX1 affects leukaemia development.\n","plannedDates":[{"endDate":"2024-01-16T00:00:00+00:00","startDate":"2021-01-17T00:00:00+00:00","startDateDateOnly":"2021-01-17","endDateDateOnly":"2024-01-16"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Alessandro Cavallo","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Cavallo","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mechanisms of RUNX1 regulation in human developmental haematopoiesis and childhood leukaemia All adult blood cells are derived from prenatal blood stem cells produced in the embryo, where the process is dependent on a gene named RUNX1. Blood cell formation and the development of various blood cancers (leukaemia) are sensitive to RUNX1 levels. In my DPhil, I will characterise the mechanisms regulating RUNX1 levels in normal and malignant human blood cell formation. I will use a \"test tube\" experimental approach to model human fetal blood cell formation, by differentiating stem cells into immature blood cells (progenitors). I will characterize the dynamic regulatory changes in the RUNX1 genomic region at distinct blood progenitor stages. These data will form the benchmark for the examination of RUNX1 regulation in primary human blood progenitor cells and childhood acute lymphoblastic leukaemia (ALL) samples. Lastly, RUNX1 regulation will be perturbed through genetic and epigenetic engineering, to identify the contribution of aberrant RUNX1 expression to the development of childhood leukaemia. This comparative approach will help us understand not only regulatory mechanisms of normal human blood cell formation, and how well this process can be modelled in a test tube, but also how altered regulation of RUNX1 affects leukaemia development.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Core Binding Factor Alpha 2 Subunit","Epigenesis, Genetic","Hematopoietic Stem Cells","Humans","Precursor Cell Lymphoblastic Leukemia-Lymphoma"]}
{"id":"360G-Wellcome-222841_Z_21_Z","title":"Mechanisms of Transcriptional Regulation by H3K4 Methyltransferases at CpG Islands","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222841/Z/21/Z","description":"The genetic information of each cell is stored in the nucleus as DNA wrapped around histone proteins, a structure termed chromatin. Apart from packaging DNA into the confined space of the nucleus, histone proteins serve as a template on which chemical modifications can be placed. These modifications can determine whether the associated gene is actively being used to produce messenger RNA (mRNA) and subsequently its product. I am studying the four \u2018writers\u2019 of one such modification, tri-methylation of lysine 4 on histone H3 (H3K4me3). These four enzymes, SET1A, SET1B, MLL1, and MLL2, have major roles in activating genes, but they seem to do so in a way that is separate and distinct from their roles as the writers of this modification. To understand how these enzymes activate genes, I am using genetically engineered cells in which these enzymes can be rapidly degraded by treating the cells with a small molecule. By removing these enzymes separately and in combination, I can analyse how these enzymes contribute to the overall levels of mRNA and H3K4me3 of the cell using sequencing techniques. The results of this project will be expected to increase our understanding of how genes are activated.  \n\n \n","plannedDates":[{"endDate":"2024-01-03T00:00:00+00:00","startDate":"2021-01-04T00:00:00+00:00","startDateDateOnly":"2021-01-04","endDateDateOnly":"2024-01-03"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr HO YU ALAN AU","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"AU","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mechanisms of Transcriptional Regulation by H3K4 Methyltransferases at CpG Islands The genetic information of each cell is stored in the nucleus as DNA wrapped around histone proteins, a structure termed chromatin. Apart from packaging DNA into the confined space of the nucleus, histone proteins serve as a template on which chemical modifications can be placed. These modifications can determine whether the associated gene is actively being used to produce messenger RNA (mRNA) and subsequently its product. I am studying the four \u2018writers\u2019 of one such modification, tri-methylation of lysine 4 on histone H3 (H3K4me3). These four enzymes, SET1A, SET1B, MLL1, and MLL2, have major roles in activating genes, but they seem to do so in a way that is separate and distinct from their roles as the writers of this modification. To understand how these enzymes activate genes, I am using genetically engineered cells in which these enzymes can be rapidly degraded by treating the cells with a small molecule. By removing these enzymes separately and in combination, I can analyse how these enzymes contribute to the overall levels of mRNA and H3K4me3 of the cell using sequencing techniques. The results of this project will be expected to increase our understanding of how genes are activated.  \n\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["CpG Islands","Histone-Lysine N-Methyltransferase","Histones","Humans","RNA, Messenger"]}
{"id":"360G-Wellcome-222837_Z_21_Z","title":"Development of pathway-based predictive models and their use in multi-omics clinical studies","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222837/Z/21/Z","description":"As the field of systems biology continues to develop, huge volumes of molecular data are being generated, including 'omics' data which aims to characterise activity at various levels of the biological system, such as genomics, transcriptomics, and metabolomics. A key challenge is the integration of multiple omics datasets to obtain a more holistic understanding of how the layers of the biological system work together. Pathway analysis is a method for assigning molecular entities to their respective biological pathways, to better facilitate biological interpretation of omics data. Current tools for the integration of multi-omics data focus on integrating the data at the level of individual molecules. However, the integration of omics data at the level of biological pathways has not yet been investigated. As biological entities are known to interact within pathways, I propose the development of a novel method for combining multi-omics data by integrating the layers at the pathway level using statistical/machine learning approaches. This work will result in novel methods researchers can use for integrating omics data at the pathway level, with a focus on improving interpretability, sensitivity (the ability to detect biological signals), and predictive ability (using the model to predict e.g. disease status) of current methods. \n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Cecilia Wieder","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Wieder","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Development of pathway-based predictive models and their use in multi-omics clinical studies As the field of systems biology continues to develop, huge volumes of molecular data are being generated, including 'omics' data which aims to characterise activity at various levels of the biological system, such as genomics, transcriptomics, and metabolomics. A key challenge is the integration of multiple omics datasets to obtain a more holistic understanding of how the layers of the biological system work together. Pathway analysis is a method for assigning molecular entities to their respective biological pathways, to better facilitate biological interpretation of omics data. Current tools for the integration of multi-omics data focus on integrating the data at the level of individual molecules. However, the integration of omics data at the level of biological pathways has not yet been investigated. As biological entities are known to interact within pathways, I propose the development of a novel method for combining multi-omics data by integrating the layers at the pathway level using statistical/machine learning approaches. This work will result in novel methods researchers can use for integrating omics data at the pathway level, with a focus on improving interpretability, sensitivity (the ability to detect biological signals), and predictive ability (using the model to predict e.g. disease status) of current methods. \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Machine Learning","Metabolomics","Systems Biology"]}
{"id":"360G-Wellcome-222830_Z_21_Z","title":"Electrical stimulation for chronic diabetic ulcers healing ","Region":"North West","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222830/Z/21/Z","description":"Wound healing is a complex process wherein the tissue undergoes inflammation, repair and maturation to re-establish initial equilibrium. When transition between the stages fails, the tissue remains stuck in an inflammatory state, deferring healing and greatly increasing the probability of systemic infection, which may lead to member amputation or even death. Chronic wounds are prevalent in diabetic patients and represent an individual as well as a societal financial burden. Despite of this, it is still unclear how to robustly regulate the process to exit the chronic state and few advanced therapies show evidence of improving the outcome compared to standard treatment. Electric stimulation (ES) is a promising non-invasive procedure that was shown to influence the behaviour of the cells leading the immune and repair response to skin damage. ES was shown to modulate  exchange of calcium whose changes in level are correlated with wound stages. The project aim is to define effective time dependent ES regimes that promote the healing of diabetic ulcers by characterizing normal and diabetic-derived cells and their response to ES. Furthermore, calcium signalling will be investigated to reveal ES mechanisms driving cellular response.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Miruna Verdes","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Verdes","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Electrical stimulation for chronic diabetic ulcers healing  Wound healing is a complex process wherein the tissue undergoes inflammation, repair and maturation to re-establish initial equilibrium. When transition between the stages fails, the tissue remains stuck in an inflammatory state, deferring healing and greatly increasing the probability of systemic infection, which may lead to member amputation or even death. Chronic wounds are prevalent in diabetic patients and represent an individual as well as a societal financial burden. Despite of this, it is still unclear how to robustly regulate the process to exit the chronic state and few advanced therapies show evidence of improving the outcome compared to standard treatment. Electric stimulation (ES) is a promising non-invasive procedure that was shown to influence the behaviour of the cells leading the immune and repair response to skin damage. ES was shown to modulate  exchange of calcium whose changes in level are correlated with wound stages. The project aim is to define effective time dependent ES regimes that promote the healing of diabetic ulcers by characterizing normal and diabetic-derived cells and their response to ES. Furthermore, calcium signalling will be investigated to reveal ES mechanisms driving cellular response.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Calcium","Calcium Signaling","Electric Stimulation","Electric Stimulation Therapy","Humans","Wound Healing"]}
{"id":"360G-Wellcome-222829_Z_21_Z","title":"Next-generation diffusion MRI: Illuminating the black holes of the brain ","Region":"South East","currency":"GBP","awardDate":"2021-05-05T00:00:00+00:00","Sponsor(s)":"Prof Clare Mackay, Dr Shaihan Malik, Prof Lawrence Wald","Internal ID":"222829/Z/21/Z","description":"A major challenge in establishing novel therapeutics for neurological diseases is the assessment of tissue health. The inaccessibility of the brain for biopsy has motivated the development of novel technologies, with diffusion Magnetic Resonance Imaging (MRI) emerging as one of the most promising techniques to non-invasively assess brain tissue. Diffusion MRI generates images sensitive to the microscopic motions of water within and around cells. It has demonstrated considerable potential to identify novel biomarkers in a number of neurological diseases.\n\nDespite this promise, conventional diffusion MRI methods have failed to access certain key brain regions. In these regions, rapid signal-decay (short-T2) leads to low-quality images with the appearance of \u2018black holes\u2019. I propose to establish an imaging platform that enables us to assess tissue health in these previously inaccessible regions. I will achieve this using a little-known but powerful technique, \u2018steady-state diffusion\u2019.\n\nBuilding on a framework I have recently developed, I will:\n \n\n\n Transform steady-state diffusion images into those with clear biological interpretation.\n Enable in vivo use by overcoming its extreme motion-sensitivity.\n Reduce examination times by integrating the estimation of signal dependencies.\n\n\n\nUtilising this platform, I will investigate the substantia nigra, a black hole brain region of critical importance in Parkinson\u2019s disease.\n","plannedDates":[{"endDate":"2025-07-31T00:00:00+00:00","startDate":"2021-08-01T00:00:00+00:00","startDateDateOnly":"2021-08-01","endDateDateOnly":"2025-07-31"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Benjamin Tendler","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Tendler","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Next-generation diffusion MRI: Illuminating the black holes of the brain  A major challenge in establishing novel therapeutics for neurological diseases is the assessment of tissue health. The inaccessibility of the brain for biopsy has motivated the development of novel technologies, with diffusion Magnetic Resonance Imaging (MRI) emerging as one of the most promising techniques to non-invasively assess brain tissue. Diffusion MRI generates images sensitive to the microscopic motions of water within and around cells. It has demonstrated considerable potential to identify novel biomarkers in a number of neurological diseases.\n\nDespite this promise, conventional diffusion MRI methods have failed to access certain key brain regions. In these regions, rapid signal-decay (short-T2) leads to low-quality images with the appearance of \u2018black holes\u2019. I propose to establish an imaging platform that enables us to assess tissue health in these previously inaccessible regions. I will achieve this using a little-known but powerful technique, \u2018steady-state diffusion\u2019.\n\nBuilding on a framework I have recently developed, I will:\n \n\n\n Transform steady-state diffusion images into those with clear biological interpretation.\n Enable in vivo use by overcoming its extreme motion-sensitivity.\n Reduce examination times by integrating the estimation of signal dependencies.\n\n\n\nUtilising this platform, I will investigate the substantia nigra, a black hole brain region of critical importance in Parkinson\u2019s disease.\n","awardDateDateOnly":"2021-05-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Brain","Diffusion Magnetic Resonance Imaging","Humans","Parkinson Disease","Substantia Nigra"]}
{"id":"360G-Wellcome-222825_Z_21_Z","title":"Study of the dark proteome in innate immunity","Region":"Greater London","currency":"GBP","awardDate":"2021-05-05T00:00:00+00:00","Sponsor(s)":"Dr Venizelos Papayannopoulos, Dr Simon Els\u00e4sser","Internal ID":"222825/Z/21/Z","description":"Intrinsically disordered proteins/domains (IDPs/IDRs) are highly flexible and lack a defined secondary or tertiary structure. Their highly reactive and versatile interaction surface contains diverse small linear motifs that enable IDP/IDRs to act as key regulatory protein interaction and signalling hubs. In addition, a new set of small proteins have recently emerged by the identification of thousands of microproteins or smORF-encoded peptides (sPEPs) from which a few validated sPEPs play crucial regulatory roles via protein-protein interactions and add a new regulatory dimension to multiple cellular processes. Due to the size of sPEPs and high flexibility of IDPs, conventional tagging, biochemical and cell biological approaches are not suitable for the study of these type of proteins. I will overcome this by implementing a pipeline to achieve the orthogonal site-specific incorporation of minimally invasive non-canonical amino acids in IDPs and sPEPs. With this approach I aim to study the protein-protein interaction networks, localization and function of IDPs and sPEPs involved in innate immune processes such as the antiviral response or neutrophil defense mechanisms against pathogen invasion.\n","plannedDates":[{"endDate":"2025-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2025-08-31"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Iker Valle Aramburu","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Valle Aramburu","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:The-Francis-Crick-Institute","name":"The Francis Crick Institute","addressCountry":"United Kingdom","id_and_name":"[\"The Francis Crick Institute\", \"360G-Wellcome-ORG:The-Francis-Crick-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:The-Francis-Crick-Institute","name":"The Francis Crick Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Study of the dark proteome in innate immunity Intrinsically disordered proteins/domains (IDPs/IDRs) are highly flexible and lack a defined secondary or tertiary structure. Their highly reactive and versatile interaction surface contains diverse small linear motifs that enable IDP/IDRs to act as key regulatory protein interaction and signalling hubs. In addition, a new set of small proteins have recently emerged by the identification of thousands of microproteins or smORF-encoded peptides (sPEPs) from which a few validated sPEPs play crucial regulatory roles via protein-protein interactions and add a new regulatory dimension to multiple cellular processes. Due to the size of sPEPs and high flexibility of IDPs, conventional tagging, biochemical and cell biological approaches are not suitable for the study of these type of proteins. I will overcome this by implementing a pipeline to achieve the orthogonal site-specific incorporation of minimally invasive non-canonical amino acids in IDPs and sPEPs. With this approach I aim to study the protein-protein interaction networks, localization and function of IDPs and sPEPs involved in innate immune processes such as the antiviral response or neutrophil defense mechanisms against pathogen invasion.\n","awardDateDateOnly":"2021-05-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Immunity, Innate","Intrinsically Disordered Proteins","Peptides"]}
{"id":"360G-Wellcome-222824_Z_21_Z","title":"Exploiting SUMOylation to target MYC-driven cancers","Region":"North West","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222824/Z/21/Z","description":"MYC is a protein which is known to contribute to the development of cancer. It is found in many different types of cancer cells at much higher levels than it would be in healthy cells. As a result, MYC has been identified as a protein that could be targeted to treat cancer patients. However, developing a drug that inhibits MYC directly has proved challenging. Therefore, scientists have instead focused on targeting MYC indirectly. For example, several genes have been identified that when inhibited, result in the death of only cells that have too much MYC, such as cancer cells. This means that healthy cells with normal levels of MYC will not be affected. An example of one such gene is SAE2. SAE2 is an enzyme which catalyses the first step in a series of reactions called the SUMOylation pathway. Although this is an encouraging observation, it remains unclear why inhibiting SAE2 kills cancer cells with too much MYC. Therefore, the aim of my project is to find out why and how SAE2 inhibitors kill these MYC-overexpressing cancer cells. This will help determine whether we can use SAE2 inhibitors to treat cancer patients whose tumours possess too much MYC.\n \n","plannedDates":[{"endDate":"2023-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2023-12-31"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Rhys Owen","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Owen","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Exploiting SUMOylation to target MYC-driven cancers MYC is a protein which is known to contribute to the development of cancer. It is found in many different types of cancer cells at much higher levels than it would be in healthy cells. As a result, MYC has been identified as a protein that could be targeted to treat cancer patients. However, developing a drug that inhibits MYC directly has proved challenging. Therefore, scientists have instead focused on targeting MYC indirectly. For example, several genes have been identified that when inhibited, result in the death of only cells that have too much MYC, such as cancer cells. This means that healthy cells with normal levels of MYC will not be affected. An example of one such gene is SAE2. SAE2 is an enzyme which catalyses the first step in a series of reactions called the SUMOylation pathway. Although this is an encouraging observation, it remains unclear why inhibiting SAE2 kills cancer cells with too much MYC. Therefore, the aim of my project is to find out why and how SAE2 inhibitors kill these MYC-overexpressing cancer cells. This will help determine whether we can use SAE2 inhibitors to treat cancer patients whose tumours possess too much MYC.\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Antineoplastic Agents","Cell Line, Tumor","Humans","Neoplasms","Proto-Oncogene Proteins c-myc","Sumoylation"]}
{"id":"360G-Wellcome-222822_Z_21_Z","title":"Neuronal identity and numbers in the development of neocortical activity","Region":"Greater London","currency":"GBP","awardDate":"2021-05-05T00:00:00+00:00","Sponsor(s)":"Prof Oscar Mar\u00edn, Prof Kenneth Harris","Internal ID":"222822/Z/21/Z","description":"The function of the cerebral cortex relies on the cellular balance between excitatory (pyramidal cells) and inhibitory neurons (interneurons), which is disrupted in disorders such as autism or schizophrenia. The emergence of cortical function relies on spontaneous synchronous activity among large groups of pyramidal cells and interneurons, which later desynchronize for efficient information processing. Prior to this shift in network activity, interneuron numbers are adjusted through activity-dependent programmed cell death mechanisms. The contribution of interneuron programmed cell death to the change in network dynamics and the identity of the cell types participating in these events remain unclear. I will address these questions by combining in vivo longitudinal functional imaging of the postnatal somatosensory cortex with cell type identification via multiplex in situ RNA localization. This strategy will allow correlating the identity of one neuron with its activity pattern and participation in network dynamics during early postnatal development. I will perform complementary experiments in mouse models engineered to contain abnormal numbers of cortical interneurons, thereby assessing the importance of neuronal numbers for­ cortical function. This project addresses the fundamental question of how neuronal diversity and numbers contribute to the emergence of functional circuits during physiological and pathological brain wiring.\n \n","plannedDates":[{"endDate":"2025-05-31T00:00:00+00:00","startDate":"2021-06-01T00:00:00+00:00","startDateDateOnly":"2021-06-01","endDateDateOnly":"2025-05-31"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Ioana Genescu","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Genescu","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Neuronal identity and numbers in the development of neocortical activity The function of the cerebral cortex relies on the cellular balance between excitatory (pyramidal cells) and inhibitory neurons (interneurons), which is disrupted in disorders such as autism or schizophrenia. The emergence of cortical function relies on spontaneous synchronous activity among large groups of pyramidal cells and interneurons, which later desynchronize for efficient information processing. Prior to this shift in network activity, interneuron numbers are adjusted through activity-dependent programmed cell death mechanisms. The contribution of interneuron programmed cell death to the change in network dynamics and the identity of the cell types participating in these events remain unclear. I will address these questions by combining in vivo longitudinal functional imaging of the postnatal somatosensory cortex with cell type identification via multiplex in situ RNA localization. This strategy will allow correlating the identity of one neuron with its activity pattern and participation in network dynamics during early postnatal development. I will perform complementary experiments in mouse models engineered to contain abnormal numbers of cortical interneurons, thereby assessing the importance of neuronal numbers for­ cortical function. This project addresses the fundamental question of how neuronal diversity and numbers contribute to the emergence of functional circuits during physiological and pathological brain wiring.\n \n","awardDateDateOnly":"2021-05-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cerebral Cortex","Interneurons","Mice","Neocortex","Pyramidal Cells","Somatosensory Cortex"]}
{"id":"360G-Wellcome-222817_Z_21_Z","title":"Principles behind neural representations in complex tasks","Region":"South East","currency":"GBP","awardDate":"2021-05-05T00:00:00+00:00","Sponsor(s)":"Prof Surya Ganguli, Prof Timothy Behrens","Internal ID":"222817/Z/21/Z","description":"Generalisation is central to intelligent behaviour. Recent work has shown the classic dichotomy of hippocampal function, relational memory and spatial cognition, can be unified through the language of generalisation. Here the structure of the task (spatial navigation, transitive inference etc) is learned and abstracted in order to be reused when entering new environments. Animals (and hippocampus) do more than just space and memory. They display complex behaviours that are reused and arbitrarily combined in novel situations. This raises the exciting possibility that animals learn the structure of behaviours and generalise them to new situations (e.g. the steps to baking a cake are reusable for making cookies). The common role of generalisation and abstraction would unify representations of behavioural (reinforcement) learning with spatial map-like learning.\n\nMy research will build detailed theories and precise computational models to find a formalism with a common language for representations of reinforcement learning and space. Though much of the reinforcement learning literature has focused on more intuitive notions of reward and value to find in neural data, my models will predict that neurons additionally represent the structure of the behavioural tasks. I will look for this neural signature in data from both old and ongoing experiments.\n","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2021-10-01T00:00:00+00:00","startDateDateOnly":"2021-10-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr James Whittington","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Whittington","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Principles behind neural representations in complex tasks Generalisation is central to intelligent behaviour. Recent work has shown the classic dichotomy of hippocampal function, relational memory and spatial cognition, can be unified through the language of generalisation. Here the structure of the task (spatial navigation, transitive inference etc) is learned and abstracted in order to be reused when entering new environments. Animals (and hippocampus) do more than just space and memory. They display complex behaviours that are reused and arbitrarily combined in novel situations. This raises the exciting possibility that animals learn the structure of behaviours and generalise them to new situations (e.g. the steps to baking a cake are reusable for making cookies). The common role of generalisation and abstraction would unify representations of behavioural (reinforcement) learning with spatial map-like learning.\n\nMy research will build detailed theories and precise computational models to find a formalism with a common language for representations of reinforcement learning and space. Though much of the reinforcement learning literature has focused on more intuitive notions of reward and value to find in neural data, my models will predict that neurons additionally represent the structure of the behavioural tasks. I will look for this neural signature in data from both old and ongoing experiments.\n","awardDateDateOnly":"2021-05-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Hippocampus","Learning","Memory","Models, Neurological","Neurons","Reinforcement, Psychology","Reward"]}
{"id":"360G-Wellcome-222815_Z_21_Z","title":"Modelling the impact of increased extracellular matrix stiffness on mammary epithelial cells","Region":"North West","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222815/Z/21/Z","description":"Mammographic density (MD) refers to the proportion of the breast occupied by radiographically dense tissue, as assessed by mammography. It has been shown that women with significantly higher MD are four times more likely to develop breast cancer than those with predominantly radio-lucent tissue. High MD is associated with increased stiffness of the stromal extracellular matrix (ECM) surrounding the breast epithelial ducts. Despite a clear mechanistic link between ECM stiffness and breast cancer risk, little is known about how mammary epithelial cells (MECs) sense and respond to the altered mechanical properties of the surrounding microenvironment.\n\nWe want to understand how MECs within the duct mechanically sense altered stiffness of their surrounding ECM by using 3D culture models combined with mathematical modelling. We will utilise 3D traction force microscopy (TFM) to measure the forces on MECs within a 3D ECM model of tuneable mechanical stiffness. We will use these observations, alongside other biological readouts, to parameterise an individual-cell based mathematical model of a 3D acinar structure. We will develop this model to provide quantitative predictions enabling mechanistic insight into the behaviour of MECs and the link between high mammographic density and increased breast cancer risk.\n \n","plannedDates":[{"endDate":"2024-01-03T00:00:00+00:00","startDate":"2021-01-04T00:00:00+00:00","startDateDateOnly":"2021-01-04","endDateDateOnly":"2024-01-03"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mx Isobel Taylor-Hearn","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Taylor-Hearn","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Modelling the impact of increased extracellular matrix stiffness on mammary epithelial cells Mammographic density (MD) refers to the proportion of the breast occupied by radiographically dense tissue, as assessed by mammography. It has been shown that women with significantly higher MD are four times more likely to develop breast cancer than those with predominantly radio-lucent tissue. High MD is associated with increased stiffness of the stromal extracellular matrix (ECM) surrounding the breast epithelial ducts. Despite a clear mechanistic link between ECM stiffness and breast cancer risk, little is known about how mammary epithelial cells (MECs) sense and respond to the altered mechanical properties of the surrounding microenvironment.\n\nWe want to understand how MECs within the duct mechanically sense altered stiffness of their surrounding ECM by using 3D culture models combined with mathematical modelling. We will utilise 3D traction force microscopy (TFM) to measure the forces on MECs within a 3D ECM model of tuneable mechanical stiffness. We will use these observations, alongside other biological readouts, to parameterise an individual-cell based mathematical model of a 3D acinar structure. We will develop this model to provide quantitative predictions enabling mechanistic insight into the behaviour of MECs and the link between high mammographic density and increased breast cancer risk.\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Breast","Breast Density","Breast Neoplasms","Epithelial Cells","Extracellular Matrix","Female","Humans","Mammary Glands, Animal","Mammary Glands, Human","Models, Biological"]}
{"id":"360G-Wellcome-222814_Z_21_Z","title":"Quantitative investigation of the control of mRNA degradation in Drosophila early embryogenesis and the impact of stability on developmental processes","Region":"North West","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222814/Z/21/Z","description":"Gene expression allows organisms to convert the genetic code in their DNA into proteins which carry out specialised functions in cells. In early embryonic development, cells tailor their gene expression programme to make specific sets of proteins which allow them to transform into a particular type of cell, for example, a skin cell or a neuron. Gene expression has multiple stages including how the process begins, the tuning and travel of RNA molecules along their journey, their conversion into protein as well as the mechanisms by which the cell disposes of them. My work focuses on these degradation mechanisms. We will use large datasets and computational methods including machine learning to estimate degradation rates across different genes throughout embryonic development in the fruitfly model organism and understand the mechanisms controlling these. Our findings will be validated using cutting-edge methods for imaging mRNAs. We will then use other experimental biology techniques including CRISPR-Cas9 genome engineering to change degradation rates of individual mRNAs and examine the effects on cell fates and developmental processes. This will provide us with a greater understanding of how gene expression is controlled, which has implications for many human diseases including cancer, and applications to regenerative medicine.\n","plannedDates":[{"endDate":"2023-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2023-12-31"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Jennifer Love","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Love","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Quantitative investigation of the control of mRNA degradation in Drosophila early embryogenesis and the impact of stability on developmental processes Gene expression allows organisms to convert the genetic code in their DNA into proteins which carry out specialised functions in cells. In early embryonic development, cells tailor their gene expression programme to make specific sets of proteins which allow them to transform into a particular type of cell, for example, a skin cell or a neuron. Gene expression has multiple stages including how the process begins, the tuning and travel of RNA molecules along their journey, their conversion into protein as well as the mechanisms by which the cell disposes of them. My work focuses on these degradation mechanisms. We will use large datasets and computational methods including machine learning to estimate degradation rates across different genes throughout embryonic development in the fruitfly model organism and understand the mechanisms controlling these. Our findings will be validated using cutting-edge methods for imaging mRNAs. We will then use other experimental biology techniques including CRISPR-Cas9 genome engineering to change degradation rates of individual mRNAs and examine the effects on cell fates and developmental processes. This will provide us with a greater understanding of how gene expression is controlled, which has implications for many human diseases including cancer, and applications to regenerative medicine.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Drosophila","Drosophila Proteins","Drosophila melanogaster","Embryo, Nonmammalian","Embryonic Development","Gene Expression Regulation, Developmental","Machine Learning","RNA, Messenger"]}
{"id":"360G-Wellcome-222811_Z_21_Z","title":"Using genetics to stratify patients and improve prediction of clinically relevant outcomes in psychiatry and neurology","Region":"Greater London","currency":"GBP","awardDate":"2021-05-05T00:00:00+00:00","Sponsor(s)":"Dr Alexander Gusev, Dr Laura Huckins, Prof Naomi Wray, Prof Ammar Al-Chalabi","Internal ID":"222811/Z/21/Z","description":"This project investigates the genetic basis of psychiatric disorders and neurological diseases with three key goals.\n\nFirst, to gain insight into the molecular mechanisms underlying genetic associations with these outcomes through the integration of genome-wide association study (GWAS) summary statistics with a range of newly released functional genomic annotations. These include variant-level annotations such as the effect of genetic variation on gene expression, methylation and chromosome structure within relevant tissues and cell types, as well as gene-level annotations such as expression profiles across tissues, cell types and developmental stages.\n\nSecond, functionally informed polygenic scores, such as imputed and observed gene expression risk scores, will be stratified by enriched functional genomic annotations and used for clustering patients into aetiological subtypes, which will then be characterised using sociodemographic and clinical variables.\n\nLastly, this study will evaluate the utility of machine learning models containing functionally informed polygenic scores and cluster membership information for prediction of diagnosis, prognosis and treatment response. I will use data from a range of ancestral populations to improve the accuracy of genetic predictors in all populations. Together this project can inform novel drug development, identify clinical subgroups, and promote personalised medicine through improved prediction of clinically relevant outcomes.\n \n","plannedDates":[{"endDate":"2025-10-27T00:00:00+00:00","startDate":"2021-10-28T00:00:00+00:00","startDateDateOnly":"2021-10-28","endDateDateOnly":"2025-10-27"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Oliver Pain","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Pain","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Using genetics to stratify patients and improve prediction of clinically relevant outcomes in psychiatry and neurology This project investigates the genetic basis of psychiatric disorders and neurological diseases with three key goals.\n\nFirst, to gain insight into the molecular mechanisms underlying genetic associations with these outcomes through the integration of genome-wide association study (GWAS) summary statistics with a range of newly released functional genomic annotations. These include variant-level annotations such as the effect of genetic variation on gene expression, methylation and chromosome structure within relevant tissues and cell types, as well as gene-level annotations such as expression profiles across tissues, cell types and developmental stages.\n\nSecond, functionally informed polygenic scores, such as imputed and observed gene expression risk scores, will be stratified by enriched functional genomic annotations and used for clustering patients into aetiological subtypes, which will then be characterised using sociodemographic and clinical variables.\n\nLastly, this study will evaluate the utility of machine learning models containing functionally informed polygenic scores and cluster membership information for prediction of diagnosis, prognosis and treatment response. I will use data from a range of ancestral populations to improve the accuracy of genetic predictors in all populations. Together this project can inform novel drug development, identify clinical subgroups, and promote personalised medicine through improved prediction of clinically relevant outcomes.\n \n","awardDateDateOnly":"2021-05-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cluster Analysis","Genetic Predisposition to Disease","Genome-Wide Association Study","Humans","Machine Learning","Multifactorial Inheritance","Prognosis","Psychiatry"]}
{"id":"360G-Wellcome-222810_Z_21_Z","title":"The role of the kinetochore in meiotic aneuploidy","Region":"Scotland","currency":"GBP","awardDate":"2021-05-05T00:00:00+00:00","Sponsor(s)":"Dr Tony Ly, Prof Aaron Straight, Prof Adele Marston","Internal ID":"222810/Z/21/Z","description":"The kinetochore is a molecular structure that segregates chromosomes by connecting them to spindle microtubules. In the first meiotic division the kinetochores of duplicated sister-chromatids mono-orient to the same spindle pole, allowing the segregation of the paternal and maternal chromosomes. In human oocytes, meiotic chromosome segregation is highly error-prone, often resulting in chromosomal abnormalities. This worsens with advanced age, leading to miscarriages or trisomies such as Down syndrome, especially in older women. My project aims to define the molecular adaptations to kinetochores that allow mono-orientation in meiosis and understand how these might be defective in human oocytes. I will develop Xenopus laevis oocyte cytoplasmic extracts as a system in which to assemble meiotic kinetochores in vitro and use biochemical analysis to determine their molecular components. Using cell biological assays in oocytes, I will determine how these components work together to mono-orient meiosis-I kinetochores. Furthermore, I will use patient donated surplus human oocytes obtained from IVF clinics to investigate how deficiency in mono-orientation contributes to age-related chromosomal abnormalities.\n","plannedDates":[{"endDate":"2025-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2025-06-30"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Gerard Pieper","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Pieper","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The role of the kinetochore in meiotic aneuploidy The kinetochore is a molecular structure that segregates chromosomes by connecting them to spindle microtubules. In the first meiotic division the kinetochores of duplicated sister-chromatids mono-orient to the same spindle pole, allowing the segregation of the paternal and maternal chromosomes. In human oocytes, meiotic chromosome segregation is highly error-prone, often resulting in chromosomal abnormalities. This worsens with advanced age, leading to miscarriages or trisomies such as Down syndrome, especially in older women. My project aims to define the molecular adaptations to kinetochores that allow mono-orientation in meiosis and understand how these might be defective in human oocytes. I will develop Xenopus laevis oocyte cytoplasmic extracts as a system in which to assemble meiotic kinetochores in vitro and use biochemical analysis to determine their molecular components. Using cell biological assays in oocytes, I will determine how these components work together to mono-orient meiosis-I kinetochores. Furthermore, I will use patient donated surplus human oocytes obtained from IVF clinics to investigate how deficiency in mono-orientation contributes to age-related chromosomal abnormalities.\n","awardDateDateOnly":"2021-05-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aneuploidy","Animals","Chromosome Segregation","Female","Humans","Kinetochores","Meiosis","Microtubules","Oocytes","Spindle Apparatus","Xenopus laevis"]}
{"id":"360G-Wellcome-222807_Z_21_Z","title":"The role of claustrum in value-based decision-making","Region":"South East","currency":"GBP","awardDate":"2021-05-05T00:00:00+00:00","Sponsor(s)":"Dr Adam Packer, Dr Armin Lak, Prof Kenji Doya","Internal ID":"222807/Z/21/Z","description":"Human and animals make decisions to harvest the most valuable rewards. This process requires a precise valuation of choice options and appropriate action selection. Despite the fact that many brain regions have been implicated in different aspects of value computation and decision making, the roles of the claustrum, a region with extensive brain-wide connectivity, in value-based decisions have remained unknown. This fellowship combines circuit, behavioural and computational tools to determine the role of the claustrum in value-based decisions. \nI will train mice on a value-based decision-making paradigm. First, I will assess the importance of claustral neural activity in choice behaviour by combining viral injection strategies and three-photon microscopy. Then, I will create a biologically realistic spiking neural network and simulate the effect of claustrum on multiple upstream regions. By using Neuropixels systems and optogenetics, I will delineate how long-range inputs from the claustrum contribute to the value signal in frontal regions by recording spiking activity while silencing claustral cells. These results will provide fundamental insights into the neural circuitry of decision-making.\n","plannedDates":[{"endDate":"2025-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2025-06-30"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Huriye Atilgan","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Atilgan","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The role of claustrum in value-based decision-making Human and animals make decisions to harvest the most valuable rewards. This process requires a precise valuation of choice options and appropriate action selection. Despite the fact that many brain regions have been implicated in different aspects of value computation and decision making, the roles of the claustrum, a region with extensive brain-wide connectivity, in value-based decisions have remained unknown. This fellowship combines circuit, behavioural and computational tools to determine the role of the claustrum in value-based decisions. \nI will train mice on a value-based decision-making paradigm. First, I will assess the importance of claustral neural activity in choice behaviour by combining viral injection strategies and three-photon microscopy. Then, I will create a biologically realistic spiking neural network and simulate the effect of claustrum on multiple upstream regions. By using Neuropixels systems and optogenetics, I will delineate how long-range inputs from the claustrum contribute to the value signal in frontal regions by recording spiking activity while silencing claustral cells. These results will provide fundamental insights into the neural circuitry of decision-making.\n","awardDateDateOnly":"2021-05-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Choice Behavior","Decision Making","Mice","Neurons","Optogenetics","Reward"]}
{"id":"360G-Wellcome-222806_Z_21_Z","title":"\u201cInvestigating regulatory landscapes in oesophageal adenocarcinoma\u201d","Region":"North West","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222806/Z/21/Z","description":"Oesophageal cancer is the 14th most prevalent cancer and the 7th most common cause of cancer death in the UK.  Oesophageal Adenocarcinoma (OAC) is the most common subtype within Western populations. A poor understanding of the disease drives poor patient outcomes.\n\nThe disease is thought to arise from a pre-cancerous state known as Barrett\u2019s Oesophagus (BO). Changes in the regulation of transcription and chromatin environment have been identified in the transition from regular oesophageal tissue to BO to OAC. This includes evidence of reversion to an embryonic developmental cell state. Additionally, Little is known about the changes in gene regulatory networks and chromatin environment which initiates and maintains metastatic cancer state.   \n\nI will use functional genomics approaches to identify elements which play a role in transcriptional regulation such as enhancers, super-enhancers and silencers. This will include developing bioinformatics methods to scale up existing unsupervised clustering methods and experimentally validating bioinformatics results e.g. endogenous reporter assays for enhancers. I will compare the regulatory landscape in regular and metastatic OAC, and embryonic tissue from the oesophagus, stomach and duodenum. This will help elucidate the origins of OAC and molecular drivers of OAC metastasis and provide bioinformatics tools potentially applicable to other diseases.\n","plannedDates":[{"endDate":"2023-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2023-12-31"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr William Morgans","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Morgans","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"\u201cInvestigating regulatory landscapes in oesophageal adenocarcinoma\u201d Oesophageal cancer is the 14th most prevalent cancer and the 7th most common cause of cancer death in the UK.  Oesophageal Adenocarcinoma (OAC) is the most common subtype within Western populations. A poor understanding of the disease drives poor patient outcomes.\n\nThe disease is thought to arise from a pre-cancerous state known as Barrett\u2019s Oesophagus (BO). Changes in the regulation of transcription and chromatin environment have been identified in the transition from regular oesophageal tissue to BO to OAC. This includes evidence of reversion to an embryonic developmental cell state. Additionally, Little is known about the changes in gene regulatory networks and chromatin environment which initiates and maintains metastatic cancer state.   \n\nI will use functional genomics approaches to identify elements which play a role in transcriptional regulation such as enhancers, super-enhancers and silencers. This will include developing bioinformatics methods to scale up existing unsupervised clustering methods and experimentally validating bioinformatics results e.g. endogenous reporter assays for enhancers. I will compare the regulatory landscape in regular and metastatic OAC, and embryonic tissue from the oesophagus, stomach and duodenum. This will help elucidate the origins of OAC and molecular drivers of OAC metastasis and provide bioinformatics tools potentially applicable to other diseases.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adenocarcinoma","Barrett Esophagus","Enhancer Elements, Genetic","Esophageal Neoplasms","Gene Expression Regulation, Neoplastic","Gene Regulatory Networks","Humans","Regulatory Sequences, Nucleic Acid"]}
{"id":"360G-Wellcome-222800_Z_21_Z","title":"Deciphering the mechanisms of epigenetic evolution driving leukaemia","Region":"East of England","currency":"GBP","awardDate":"2021-05-05T00:00:00+00:00","Sponsor(s)":"Prof Wolf Reik, Prof Bradley Bernstein, Prof Brian Huntly","Internal ID":"222800/Z/21/Z","description":"Epigenetic lesions occur at the early stages of cancer development, and have important roles in tumour initiation and progression. However, our understanding of how cancer cells acquire, propagate and select such aberrant epigenetic states remains very limited.\n\n \n\nTherefore, I propose to define the mechanisms by which initiating epigenetic defects drive tumour evolution in Acute Myeloid Leukemia (AML), a deadly bone marrow cancer with no effective treatment.\n\n \n\nI hypothesize that initiating genetic defects in the DNA methylation machinery (TET2 mutations) catalyse epigenetic diversity. The resulting epiclones might acquire properties that increase cellular fitness, predisposing cells to undergo transformation and generating a substrate for selection. Using state-of-the-art single cell DNA methylation and transcriptomic technologies coupled with lineage tracing, I will quantify stably propagated epigenetic diversity in TET2 deficient cells (Aim1), and identify selective advantage of high-fitness epiclones upon cell-extrinsic pressures (Aim2). I will then characterize putative driver epimutations in longitudinal AML patient samples and demonstrate their functional role promoting leukaemic transformation using locus-specific epigenomic editing tools (dCas9-DNMT3A; Aim3).\n\n \n\nThis research will shed light into the fundamental molecular mechanisms driving epigenetic diversification and selection of cancer cells, with the potential to bring an entirely new dimension to cancer treatment by intercepting tumour evolution.\n","plannedDates":[{"endDate":"2025-08-14T00:00:00+00:00","startDate":"2021-08-15T00:00:00+00:00","startDateDateOnly":"2021-08-15","endDateDateOnly":"2025-08-14"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Alba Rodriguez Meira","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Rodriguez Meira","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Deciphering the mechanisms of epigenetic evolution driving leukaemia Epigenetic lesions occur at the early stages of cancer development, and have important roles in tumour initiation and progression. However, our understanding of how cancer cells acquire, propagate and select such aberrant epigenetic states remains very limited.\n\n \n\nTherefore, I propose to define the mechanisms by which initiating epigenetic defects drive tumour evolution in Acute Myeloid Leukemia (AML), a deadly bone marrow cancer with no effective treatment.\n\n \n\nI hypothesize that initiating genetic defects in the DNA methylation machinery (TET2 mutations) catalyse epigenetic diversity. The resulting epiclones might acquire properties that increase cellular fitness, predisposing cells to undergo transformation and generating a substrate for selection. Using state-of-the-art single cell DNA methylation and transcriptomic technologies coupled with lineage tracing, I will quantify stably propagated epigenetic diversity in TET2 deficient cells (Aim1), and identify selective advantage of high-fitness epiclones upon cell-extrinsic pressures (Aim2). I will then characterize putative driver epimutations in longitudinal AML patient samples and demonstrate their functional role promoting leukaemic transformation using locus-specific epigenomic editing tools (dCas9-DNMT3A; Aim3).\n\n \n\nThis research will shed light into the fundamental molecular mechanisms driving epigenetic diversification and selection of cancer cells, with the potential to bring an entirely new dimension to cancer treatment by intercepting tumour evolution.\n","awardDateDateOnly":"2021-05-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cell Lineage","Cell Transformation, Neoplastic","DNA (Cytosine-5-)-Methyltransferases","DNA Methylation","Epigenesis, Genetic","Humans","Leukemia, Myeloid, Acute","Mutation"]}
{"id":"360G-Wellcome-222799_Z_21_Z","title":"How does structural anatomy enable uniquely human brain function?","Region":"South East","currency":"GBP","awardDate":"2021-05-05T00:00:00+00:00","Sponsor(s)":"Prof Boris Bernhardt, Prof Heidi Johansen-Berg, Prof Saad Jbabdi","Internal ID":"222799/Z/21/Z","description":"This project aims to advance our understanding of how the human brain evolved to support our unique cognitive skills. Using multimodal neuroimaging, I will investigate the structure-function coupling in the human brain and relate it to species differences in brain organization across the primate lineage. I will focus on the temporal lobe as a model system given its vital role in higher cognitive functions and because it underwent strong reorganization during evolution. To characterize individual patterns of brain organization optimally, I will use a gradient-based approach, where manifold identification techniques are employed to model spatial trends of variance in the data. MRI-based gradient analyses will be complemented and validated by using microstructural information from the BigBrain-Project and from gene expression data. Lastly, I will compare human temporal lobe organization to that of non-human primates to assess how divergent principles of brain organization relate to uniquely human brain function.\n\nIn sum, the present project will explore temporal lobe architecture by (1) studying human macro- and microstructural brain architecture in a gradient-based approach (2) relating structural and functional features in a unified framework to account for patterns of organization at the individual subject-level (3) comparing these relationships to those in non-human primates. \n \n","plannedDates":[{"endDate":"2025-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2025-06-30"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Ms Nicole Eichert","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Eichert","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"How does structural anatomy enable uniquely human brain function? This project aims to advance our understanding of how the human brain evolved to support our unique cognitive skills. Using multimodal neuroimaging, I will investigate the structure-function coupling in the human brain and relate it to species differences in brain organization across the primate lineage. I will focus on the temporal lobe as a model system given its vital role in higher cognitive functions and because it underwent strong reorganization during evolution. To characterize individual patterns of brain organization optimally, I will use a gradient-based approach, where manifold identification techniques are employed to model spatial trends of variance in the data. MRI-based gradient analyses will be complemented and validated by using microstructural information from the BigBrain-Project and from gene expression data. Lastly, I will compare human temporal lobe organization to that of non-human primates to assess how divergent principles of brain organization relate to uniquely human brain function.\n\nIn sum, the present project will explore temporal lobe architecture by (1) studying human macro- and microstructural brain architecture in a gradient-based approach (2) relating structural and functional features in a unified framework to account for patterns of organization at the individual subject-level (3) comparing these relationships to those in non-human primates. \n \n","awardDateDateOnly":"2021-05-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Brain","Brain Mapping","Humans","Magnetic Resonance Imaging","Temporal Lobe"]}
{"id":"360G-Wellcome-222795_Z_21_Z","title":"The evolution of bacterial resistance to the Type 6 Secretion System","Region":"North West","currency":"GBP","awardDate":"2021-05-05T00:00:00+00:00","Sponsor(s)":"Prof Marek Basler, Prof Michael Brockhurst","Internal ID":"222795/Z/21/Z","description":"Commensal microorganisms protect their hosts from pathogens, denying space and resources to would-be invaders. To bypass this host protection, many human pathogens deploy a needle-like apparatus\u2014the Type 6 Secretion System (T6SS)\u2014to inject lethal toxins into commensal cells, thereby establishing infection. Bacterial resistance to T6SS attacks is therefore expected to be a crucial predictor of pathogen proliferation and consequent disease severity. However, it remains unknown when, and how, bacteria evolve the capacity to resist T6SS attacks, hampering efforts to predict or leverage this host protection. \n\nMy project will address this knowledge gap by characterising the emergence of T6SS resistance in Escherichia coli. Combining in vitro and in silico approaches, I will first determine the specificity, fitness costs, and genetic bases of evolved resistance, against diverse toxins deployed by Acinetobacter baylyi, a well-studied T6SS attacker species. Next, I will examine how the evolution of T6SS resistance is affected by attacker toxin arsenal and attacker counter-adaptation, to explain why attackers typically deploy multiple toxins in nature. My ultimate goal is to provide a systematic understanding of how commensal bacteria resist toxin-mediated attacks. In the longer term, this may offer applications for the design of invasion-resistant bacterial communities, and improved biotherapeutics.\n","plannedDates":[{"endDate":"2025-12-31T00:00:00+00:00","startDate":"2022-01-01T00:00:00+00:00","startDateDateOnly":"2022-01-01","endDateDateOnly":"2025-12-31"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr William Smith","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Smith","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The evolution of bacterial resistance to the Type 6 Secretion System Commensal microorganisms protect their hosts from pathogens, denying space and resources to would-be invaders. To bypass this host protection, many human pathogens deploy a needle-like apparatus\u2014the Type 6 Secretion System (T6SS)\u2014to inject lethal toxins into commensal cells, thereby establishing infection. Bacterial resistance to T6SS attacks is therefore expected to be a crucial predictor of pathogen proliferation and consequent disease severity. However, it remains unknown when, and how, bacteria evolve the capacity to resist T6SS attacks, hampering efforts to predict or leverage this host protection. \n\nMy project will address this knowledge gap by characterising the emergence of T6SS resistance in Escherichia coli. Combining in vitro and in silico approaches, I will first determine the specificity, fitness costs, and genetic bases of evolved resistance, against diverse toxins deployed by Acinetobacter baylyi, a well-studied T6SS attacker species. Next, I will examine how the evolution of T6SS resistance is affected by attacker toxin arsenal and attacker counter-adaptation, to explain why attackers typically deploy multiple toxins in nature. My ultimate goal is to provide a systematic understanding of how commensal bacteria resist toxin-mediated attacks. In the longer term, this may offer applications for the design of invasion-resistant bacterial communities, and improved biotherapeutics.\n","awardDateDateOnly":"2021-05-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Acinetobacter","Biological Evolution","Escherichia coli","Type III Secretion Systems","Type VI Secretion Systems"]}
{"id":"360G-Wellcome-222793_Z_21_Z","title":"Determining fate: Dissecting the dynamics of atypical memory B cell recruitment to protective immune responses in respiratory infection","Region":"East of England","currency":"GBP","awardDate":"2021-05-05T00:00:00+00:00","Sponsor(s)":"Dr Michelle Linterman, Prof Matteo Iannacone","Internal ID":"222793/Z/21/Z","description":"Memory B cells (MBCs) are central to co-ordinated immune responses required to resolve viral infections and mediate protection following pathogen clearance or vaccination. I propose that a newly described subset of atypical MBCs (defined by expression of CD11c and T-bet) preferentially reside within peripheral tissues, where they can differentiate in-situ to provide rapid and localised protection against pathogenic threats. This project will investigate the mechanistic basis for CD11c+T-bet+MBC differentiation following immunisation, testing the hypothesis that Th1 skewed T follicular helper cells (Tfh) regulate the divergence of CD11c+T-bet+MBCs from classical memory responses and their migration to non-lymphoid tissues. CD11c+T-bet+MBC induction will be characterised alongside subsets of Tfh subsets in vaccinated humans and mice, with fate-mapping systems and interventional mouse models used to dissect: (1) the tissue homing capacity of CD11c+T-bet+MBCs; (2) their contribution to establishing protective immunity; and (3) the involvement of CD4-derived signals to CD11c+T-bet+MBC differentiation. These will be complemented by state-of-the-art imaging technologies to visualise the spatial dynamics of CD11c+T-bet+MBCs and Tfh within germinal centre responses following immunisation. Together, these data will reveal whether Th1 polarised Tfh seed populations of CD11c+T-bet+MBCs in tissues to establish local protection against infection. Findings may facilitate tailored development of strategies to enhance immunity.\n \n","plannedDates":[{"endDate":"2025-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2025-06-30"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Alice Burton","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Burton","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Babraham-Institute","name":"Babraham Institute","addressCountry":"United Kingdom","id_and_name":"[\"Babraham Institute\", \"360G-Wellcome-ORG:Babraham-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Babraham-Institute","name":"Babraham Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Determining fate: Dissecting the dynamics of atypical memory B cell recruitment to protective immune responses in respiratory infection Memory B cells (MBCs) are central to co-ordinated immune responses required to resolve viral infections and mediate protection following pathogen clearance or vaccination. I propose that a newly described subset of atypical MBCs (defined by expression of CD11c and T-bet) preferentially reside within peripheral tissues, where they can differentiate in-situ to provide rapid and localised protection against pathogenic threats. This project will investigate the mechanistic basis for CD11c+T-bet+MBC differentiation following immunisation, testing the hypothesis that Th1 skewed T follicular helper cells (Tfh) regulate the divergence of CD11c+T-bet+MBCs from classical memory responses and their migration to non-lymphoid tissues. CD11c+T-bet+MBC induction will be characterised alongside subsets of Tfh subsets in vaccinated humans and mice, with fate-mapping systems and interventional mouse models used to dissect: (1) the tissue homing capacity of CD11c+T-bet+MBCs; (2) their contribution to establishing protective immunity; and (3) the involvement of CD4-derived signals to CD11c+T-bet+MBC differentiation. These will be complemented by state-of-the-art imaging technologies to visualise the spatial dynamics of CD11c+T-bet+MBCs and Tfh within germinal centre responses following immunisation. Together, these data will reveal whether Th1 polarised Tfh seed populations of CD11c+T-bet+MBCs in tissues to establish local protection against infection. Findings may facilitate tailored development of strategies to enhance immunity.\n \n","awardDateDateOnly":"2021-05-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","B-Lymphocytes","Cell Differentiation","Germinal Center","Immunologic Memory","Mice","Mice, Inbred C57BL","T-Lymphocytes, Helper-Inducer","Th1 Cells"]}
{"id":"360G-Wellcome-222784_Z_21_Z","title":"Incompleteness and the ethics of new and emerging health technologies: fostering African conversations on relational ontology, epistemic justice and academic activism","Region":"International","currency":"GBP","awardDate":"2021-03-15T00:00:00+00:00","Internal ID":"222784/Z/21/Z","description":"In this project, we propose to create opportunities for African theory-building by fostering critical reflection, exchange of knowledge and perspectives, and collaboration and writing between African scholars from different disciplines, with a focus on exploring how African thought could influence critical engagement with the ethics of new and emerging health technologies globally. Starting with a recognition of incompleteness and the conviviality that requires, the focus of this project will be on a) developing conceptual accounts of how African thought could inform on key ethical questions raised by new and emerging health technologies, b) better understanding how we can ensure epistemic justice in our scholarship and which diversity matters; and c) understanding how particular African research contexts drive us towards academic activism. The programme seeks to create opportunities for exchange and joint reflection, in an aim to push the audacity with which African scholars can take ownership of, and lead, reflection on the ethics of new and emerging health technologies. The programme will dive into questions relating to African personhood, relational autonomy, epistemic justice and academic activism to explore how African ways of seeing and being in the world could enrich global conversations about science and technology. \n","plannedDates":[{"endDate":"2026-02-28T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2026-02-28"}],"amountAwarded":1058630,"Financial Year":"2020/21","Lead Applicant":"Dr Jantina De Vries","grantProgramme":[{"title":"Research Development Award in H&SS","title_keyword":"Research Development Award in H&SS"}],"Applicant Surname":"De Vries","Partnership Value":1058630,"Approval Committee":"Research Development Awards Committee","Other Applicant(s)":"Prof Francis Nyamnjoh","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cape-Town","name":"University of Cape Town","addressCountry":"South Africa","id_and_name":"[\"University of Cape Town\", \"360G-Wellcome-ORG:University-of-Cape-Town\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cape-Town","name":"University of Cape Town"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Incompleteness and the ethics of new and emerging health technologies: fostering African conversations on relational ontology, epistemic justice and academic activism In this project, we propose to create opportunities for African theory-building by fostering critical reflection, exchange of knowledge and perspectives, and collaboration and writing between African scholars from different disciplines, with a focus on exploring how African thought could influence critical engagement with the ethics of new and emerging health technologies globally. Starting with a recognition of incompleteness and the conviviality that requires, the focus of this project will be on a) developing conceptual accounts of how African thought could inform on key ethical questions raised by new and emerging health technologies, b) better understanding how we can ensure epistemic justice in our scholarship and which diversity matters; and c) understanding how particular African research contexts drive us towards academic activism. The programme seeks to create opportunities for exchange and joint reflection, in an aim to push the audacity with which African scholars can take ownership of, and lead, reflection on the ethics of new and emerging health technologies. The programme will dive into questions relating to African personhood, relational autonomy, epistemic justice and academic activism to explore how African ways of seeing and being in the world could enrich global conversations about science and technology. \n","awardDateDateOnly":"2021-03-15","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa","Humans","Social Justice","Technology"]}
{"id":"360G-Wellcome-222783_Z_21_Z","title":"Lancet Commission on Gender and Global Health","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"222783/Z/21/Z","description":"We are launching a Lancet Commission on Gender and Global Health that intends to ensure that global health take gender into consideration. A continued failure to consider and act on gender in public health policies, programmes and practices results in lost opportunities to improve health outcomes across society, equitably and sustainably. \nWe have drawn together a cross- and inter-disciplinary Commission that benefits from the expertise and experience of around 20 Commissioners from different backgrounds, geographical settings and genders. The Commission will be guided by Dr Richard Horton and Dr Jocalyn Clark from The Lancet, and will be co-Chaired by Professor Pascale Allotey from UNU-IIGH, Professor Sarah Hawkes from UCL and Mr Elhadj As Sy, Chair of the Board of the Kofi Annan Foundation. \n\nWe plan to launch the Commission in October 2020 after the Berlin World Health Summit (WHS). We will organise a 2-day meeting bringing Commissioners together for the first time, to discuss the direction and content of the Commission and establish a workplan covering the next 2-3 years. Funding is required to host the launch in Berlin, and to follow up with post-launch co-ordination and communication activities. \n \n","plannedDates":[{"endDate":"2022-01-10T00:00:00+00:00","startDate":"2021-01-11T00:00:00+00:00","startDateDateOnly":"2021-01-11","endDateDateOnly":"2022-01-10"}],"amountAwarded":50000,"Financial Year":"2019/20","Lead Applicant":"Prof Sarah Hawkes","grantProgramme":[{"title":"Discretionary Award - Diversity and Inclusion","title_keyword":"Discretionary Award - Diversity and Inclusion"}],"Applicant Surname":"Hawkes","Partnership Value":50000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Lancet Commission on Gender and Global Health We are launching a Lancet Commission on Gender and Global Health that intends to ensure that global health take gender into consideration. A continued failure to consider and act on gender in public health policies, programmes and practices results in lost opportunities to improve health outcomes across society, equitably and sustainably. \nWe have drawn together a cross- and inter-disciplinary Commission that benefits from the expertise and experience of around 20 Commissioners from different backgrounds, geographical settings and genders. The Commission will be guided by Dr Richard Horton and Dr Jocalyn Clark from The Lancet, and will be co-Chaired by Professor Pascale Allotey from UNU-IIGH, Professor Sarah Hawkes from UCL and Mr Elhadj As Sy, Chair of the Board of the Kofi Annan Foundation. \n\nWe plan to launch the Commission in October 2020 after the Berlin World Health Summit (WHS). We will organise a 2-day meeting bringing Commissioners together for the first time, to discuss the direction and content of the Commission and establish a workplan covering the next 2-3 years. Funding is required to host the launch in Berlin, and to follow up with post-launch co-ordination and communication activities. \n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Global Health","Health Policy","Humans","International Cooperation","World Health Organization"]}
{"id":"360G-Wellcome-222782_Z_21_Z","title":"A neural Cartesian coordinate system for generating flexible internal goals","Region":"South East","currency":"GBP","awardDate":"2021-05-05T00:00:00+00:00","Sponsor(s)":"Prof Shaul Druckmann, Prof Rachel Wilson, Prof Scott Waddell","Internal ID":"222782/Z/21/Z","description":"The Drosophila brain provides a unique opportunity to study the neural mechanisms underlying navigation. Recent work has revealed much about the fly brain\u2019s ring-shaped \u2018compass\u2019 region. Within it, a single \u2018compass needle\u2019 of activity represents the fly\u2019s heading. When the fly is pursuing a specific heading goal, it locomotes in a straight line, often holding the sun at a specific arbitrary angle (e.g., 90°), which holds the 'needle' stationary. If the fly is pushed off course, the circuitry downstream of the compass kicks in to reorient the fly toward its goal, moving the sun back to 90° and the \u2018needle\u2019 back to its original state. How does the brain initialise a specific angular goal (e.g., holding the sun at 90°)? We hypothesise that an asymmetry in a specific brain region (called the asymmetrical body) provides a coordinate system for writing new spatial goals into working memory. This asymmetry may be used to initialise a new spatial goal with respect to a landmark at an arbitrary angle. I will i) use computational modelling to explore the predictions of this hypothesis, ii) use calcium imaging to test these predictions, and iii) use specific genetic manipulations to perturb this process.\n","plannedDates":[{"endDate":"2025-07-31T00:00:00+00:00","startDate":"2021-08-01T00:00:00+00:00","startDateDateOnly":"2021-08-01","endDateDateOnly":"2025-07-31"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Alexander Bates","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Bates","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A neural Cartesian coordinate system for generating flexible internal goals The Drosophila brain provides a unique opportunity to study the neural mechanisms underlying navigation. Recent work has revealed much about the fly brain\u2019s ring-shaped \u2018compass\u2019 region. Within it, a single \u2018compass needle\u2019 of activity represents the fly\u2019s heading. When the fly is pursuing a specific heading goal, it locomotes in a straight line, often holding the sun at a specific arbitrary angle (e.g., 90°), which holds the 'needle' stationary. If the fly is pushed off course, the circuitry downstream of the compass kicks in to reorient the fly toward its goal, moving the sun back to 90° and the \u2018needle\u2019 back to its original state. How does the brain initialise a specific angular goal (e.g., holding the sun at 90°)? We hypothesise that an asymmetry in a specific brain region (called the asymmetrical body) provides a coordinate system for writing new spatial goals into working memory. This asymmetry may be used to initialise a new spatial goal with respect to a landmark at an arbitrary angle. I will i) use computational modelling to explore the predictions of this hypothesis, ii) use calcium imaging to test these predictions, and iii) use specific genetic manipulations to perturb this process.\n","awardDateDateOnly":"2021-05-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Brain","Drosophila","Drosophila melanogaster","Memory, Short-Term","Spatial Navigation"]}
{"id":"360G-Wellcome-222781_Z_21_Z","title":"Multiscale computational and experimental investigation of ventricular arrhythmogenesis in diabetes","Region":"South East","currency":"GBP","awardDate":"2021-05-05T00:00:00+00:00","Sponsor(s)":"Prof Donald Bers, Prof Manuela Zaccolo","Internal ID":"222781/Z/21/Z","description":"Ventricular arrhythmia is the leading cause of death in diabetes, but its mechanisms remain poorly understood, leading to suboptimal therapy. I propose an interdisciplinary project to address this unmet need, combining multiscale human cardiac simulations and experimental studies. I will use my recent computational model of a human myocyte ToR-ORd, which was extensively validated for arrhythmia research, disease representation, and drug assessment.\n\nGoal 1) To build a computational model of a single diabetic myocyte and use it to elucidate how distinct aspects of diabetic remodelling contribute to arrhythmia, also investigating the role of glucose level disturbance.\n\nGoal 2) To demonstrate how remodelling of cardiac sympathetic signalling at the myocyte level affects diabetic arrhythmia vulnerability using simulations informed by newly collected FRET imaging data.\n\nGoal 3) To integrate the single-cell results into 3D models of ventricles based on patient-specific clinical imaging data, investigating the diabetic remodelling of cardiac conduction properties.\n\nGoal 4) To produce a computational tool to search for new drugs with promising antiarrhythmic effects in diabetes and to assess existing therapies, suggesting their optimisation.\n\nIn summary, the project is likely to impact future diabetic therapy and to bring new insights into the so-far poorly understood area of diabetic arrhythmogenesis.\n","plannedDates":[{"endDate":"2025-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2025-08-31"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Jakub Tomek","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Tomek","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Multiscale computational and experimental investigation of ventricular arrhythmogenesis in diabetes Ventricular arrhythmia is the leading cause of death in diabetes, but its mechanisms remain poorly understood, leading to suboptimal therapy. I propose an interdisciplinary project to address this unmet need, combining multiscale human cardiac simulations and experimental studies. I will use my recent computational model of a human myocyte ToR-ORd, which was extensively validated for arrhythmia research, disease representation, and drug assessment.\n\nGoal 1) To build a computational model of a single diabetic myocyte and use it to elucidate how distinct aspects of diabetic remodelling contribute to arrhythmia, also investigating the role of glucose level disturbance.\n\nGoal 2) To demonstrate how remodelling of cardiac sympathetic signalling at the myocyte level affects diabetic arrhythmia vulnerability using simulations informed by newly collected FRET imaging data.\n\nGoal 3) To integrate the single-cell results into 3D models of ventricles based on patient-specific clinical imaging data, investigating the diabetic remodelling of cardiac conduction properties.\n\nGoal 4) To produce a computational tool to search for new drugs with promising antiarrhythmic effects in diabetes and to assess existing therapies, suggesting their optimisation.\n\nIn summary, the project is likely to impact future diabetic therapy and to bring new insights into the so-far poorly understood area of diabetic arrhythmogenesis.\n","awardDateDateOnly":"2021-05-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Arrhythmias, Cardiac","Computer Simulation","Diabetes Mellitus, Type 2","Heart Ventricles","Humans","Models, Cardiovascular","Myocytes, Cardiac"]}
{"id":"360G-Wellcome-222780_Z_21_Z","title":"Investigation of the structural and biochemical properties of mammalian tolloid proteinases","Region":"North West","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222780/Z/21/Z","description":"The family of BMP1/Tolloid-like proteases (B/TPs) is involved in a variety of important functions in mammalian tissue development. Firstly, B/TPs cut collagen precursors to allow their assembly in the extra-cellular matrix (ECM). Mutations or a loss of function of B/TPs result in several developmental defects or can result in death during the embryonic stage. The second role of B/TPs is activating different growth factors. These messenger molecules are involved in communicating with cells during the formation of different tissues, including bones and the brain.\n\nOur work aims to understand how B/TPs carry out their function and how mutations result in diseases. To do so, we aim to determine the 3-dimensional structure of two members of the B/TP family using cryogenic electron microscopy. Furthermore, we want to understand how B/TPs interact with their substrates, as well as known effector proteins. We hope our results will allow for a better understanding of B/TP function and regulation and provide potential basis for therapeutic approaches for B/TP-associated diseases.\n","plannedDates":[{"endDate":"2024-01-03T00:00:00+00:00","startDate":"2021-01-04T00:00:00+00:00","startDateDateOnly":"2021-01-04","endDateDateOnly":"2024-01-03"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Mark Becker","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Becker","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigation of the structural and biochemical properties of mammalian tolloid proteinases The family of BMP1/Tolloid-like proteases (B/TPs) is involved in a variety of important functions in mammalian tissue development. Firstly, B/TPs cut collagen precursors to allow their assembly in the extra-cellular matrix (ECM). Mutations or a loss of function of B/TPs result in several developmental defects or can result in death during the embryonic stage. The second role of B/TPs is activating different growth factors. These messenger molecules are involved in communicating with cells during the formation of different tissues, including bones and the brain.\n\nOur work aims to understand how B/TPs carry out their function and how mutations result in diseases. To do so, we aim to determine the 3-dimensional structure of two members of the B/TP family using cryogenic electron microscopy. Furthermore, we want to understand how B/TPs interact with their substrates, as well as known effector proteins. We hope our results will allow for a better understanding of B/TP function and regulation and provide potential basis for therapeutic approaches for B/TP-associated diseases.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cryoelectron Microscopy","Humans","Models, Molecular"]}
{"id":"360G-Wellcome-222777_Z_21_Z","title":"NK cells in memory responses to influenza: Which, Where and How?","Region":"Scotland","currency":"GBP","awardDate":"2021-05-05T00:00:00+00:00","Sponsor(s)":"Dr Leo Carlin, Dr Roser Vento-Tormo, Dr Megan MacLeod, Prof Gerard Graham","Internal ID":"222777/Z/21/Z","description":"NK cells are innate lymphocytes with crucial roles against viruses and tumours. There is growing evidence that NK cells display immune memory, however many key open questions remain. While memory NK cells where shown in several models and proved to be protective in adoptive transfer experiments, the mechanisms behind these phenomena remain unclear. Answering such questions could reshape our understanding of immune memory and provide new strategies against infectious disease and cancer. Using state-of-the-art scRNA-seq, 3D imaging and precision mouse models, I plan to study NK cell memory following influenza infection. I aim to decipher 1) which subpopulations of NK cells acquire memory, 2) where memory NK cells are located within the lung architecture and which cells (adaptive, innate or stromal) they interacting with, and 3) how memory NK cells act in concert with other memory cells in secondary immunity in immunosufficient hosts. With my background in NK cells and innate memory and the excellent array of sponsors with complementary expertise in influenza, chemokines, computational analysis and 3D imaging, this project provides the ideal platform for novel findings in the field of NK cell memory, expansion of my skillset in cutting-edge techniques, and optimally enables my transition to independence.\n \n","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2021-10-01T00:00:00+00:00","startDateDateOnly":"2021-10-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Orhan Rasid","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Rasid","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow","addressCountry":"United Kingdom","id_and_name":"[\"University of Glasgow\", \"360G-Wellcome-ORG:University-of-Glasgow\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"NK cells in memory responses to influenza: Which, Where and How? NK cells are innate lymphocytes with crucial roles against viruses and tumours. There is growing evidence that NK cells display immune memory, however many key open questions remain. While memory NK cells where shown in several models and proved to be protective in adoptive transfer experiments, the mechanisms behind these phenomena remain unclear. Answering such questions could reshape our understanding of immune memory and provide new strategies against infectious disease and cancer. Using state-of-the-art scRNA-seq, 3D imaging and precision mouse models, I plan to study NK cell memory following influenza infection. I aim to decipher 1) which subpopulations of NK cells acquire memory, 2) where memory NK cells are located within the lung architecture and which cells (adaptive, innate or stromal) they interacting with, and 3) how memory NK cells act in concert with other memory cells in secondary immunity in immunosufficient hosts. With my background in NK cells and innate memory and the excellent array of sponsors with complementary expertise in influenza, chemokines, computational analysis and 3D imaging, this project provides the ideal platform for novel findings in the field of NK cell memory, expansion of my skillset in cutting-edge techniques, and optimally enables my transition to independence.\n \n","awardDateDateOnly":"2021-05-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adoptive Transfer","Animals","Humans","Immunologic Memory","Influenza A virus","Influenza, Human","Killer Cells, Natural","Mice","Orthomyxoviridae Infections"]}
{"id":"360G-Wellcome-222776_Z_21_Z","title":"Structural and Biophysical Characterisation of ESCRT-0","Region":"North West","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222776/Z/21/Z","description":"In order to sense and respond to outside events, eukaryotic cells utilise many different proteins on their surface to finely control activities such as growth and movement. Key to regulating these processes is the uptake of these proteins from the cell surface, and their destruction at the lysosome in a process coordinated by the Endosomal Sorting Complexes Required for Transport (ESCRT) machinery. The first of these complexes, ESCRT-0, recognises a universal signal (ubiquitin), which is attached to these proteins and marks them for destruction by directing them to the lysosome where they are broken apart and recycled. In order to understand how ESCRT-0 works, we need to know what it looks like. We intend to investigate this by using the technique cryo-electron microscopy, which will allow us to understand the shape of ESCRT-0 at the atomic level. We will also use an array of biophysical techniques to investigate how the structure of ESCRT-0 changes when it binds to ubiquitinated proteins, and whether this binding helps to promote the subsequent stages of the ESCRT process. Together, this should tell us what the role of ESCRT-0 is at the head of the ESCRT pathway.\n","plannedDates":[{"endDate":"2023-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2023-12-31"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr David Marshall","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Marshall","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Structural and Biophysical Characterisation of ESCRT-0 In order to sense and respond to outside events, eukaryotic cells utilise many different proteins on their surface to finely control activities such as growth and movement. Key to regulating these processes is the uptake of these proteins from the cell surface, and their destruction at the lysosome in a process coordinated by the Endosomal Sorting Complexes Required for Transport (ESCRT) machinery. The first of these complexes, ESCRT-0, recognises a universal signal (ubiquitin), which is attached to these proteins and marks them for destruction by directing them to the lysosome where they are broken apart and recycled. In order to understand how ESCRT-0 works, we need to know what it looks like. We intend to investigate this by using the technique cryo-electron microscopy, which will allow us to understand the shape of ESCRT-0 at the atomic level. We will also use an array of biophysical techniques to investigate how the structure of ESCRT-0 changes when it binds to ubiquitinated proteins, and whether this binding helps to promote the subsequent stages of the ESCRT process. Together, this should tell us what the role of ESCRT-0 is at the head of the ESCRT pathway.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cryoelectron Microscopy","Endosomal Sorting Complexes Required for Transport","Endosomes","Humans","Lysosomes","Protein Binding","Ubiquitin"]}
{"id":"360G-Wellcome-222770_Z_21_Z","title":"Investigating the effect of climate extremes and global warming on HIV outcomes in sub-Saharan Africa","Region":"South West","currency":"GBP","awardDate":"2021-05-05T00:00:00+00:00","Sponsor(s)":"Dr Leigh Johnson, Dr Andrea Low, Prof Peter Vickerman, Prof Thorsten Wagener","Internal ID":"222770/Z/21/Z","description":"Sub-Saharan Africa (SSA) has the highest HIV burden in the world and will be the region most affected by climate change, with the largest projected decrease in rainfall and limited resources to deal with the consequences. Global warming will lead to more droughts and decreased food yields, resulting in increased food insecurity. Emerging evidence suggests food insecurity could lead to increased HIV transmission risk and sub-optimal HIV treatment outcomes, due to such factors as women resorting to selling sex for survival, access to HIV treatment being interrupted, and decreased HIV treatment absorption in the absence of food.\n\n \n\nThis project will:\n\n- involve epidemiological analyses (regression, systematic reviews, meta-analyses) on large HIV datasets from SSA to improve the evidence base for the effect of drought and food insecurity on HIV treatment outcomes, HIV incidence and sexual risk behaviours in SSA.\n\n- use mathematical modelling to simulate the existing impact of drought and food insecurity on HIV transmission and morbidity in several countries in Eastern and Southern Africa.\n\n- model the potential effect of global warming in these countries on increasing the impact of drought and food insecurity on HIV transmission and morbidity, as well as the impact of potential interventions.\n","plannedDates":[{"endDate":"2025-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2025-06-30"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Adam Trickey","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Trickey","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the effect of climate extremes and global warming on HIV outcomes in sub-Saharan Africa Sub-Saharan Africa (SSA) has the highest HIV burden in the world and will be the region most affected by climate change, with the largest projected decrease in rainfall and limited resources to deal with the consequences. Global warming will lead to more droughts and decreased food yields, resulting in increased food insecurity. Emerging evidence suggests food insecurity could lead to increased HIV transmission risk and sub-optimal HIV treatment outcomes, due to such factors as women resorting to selling sex for survival, access to HIV treatment being interrupted, and decreased HIV treatment absorption in the absence of food.\n\n \n\nThis project will:\n\n- involve epidemiological analyses (regression, systematic reviews, meta-analyses) on large HIV datasets from SSA to improve the evidence base for the effect of drought and food insecurity on HIV treatment outcomes, HIV incidence and sexual risk behaviours in SSA.\n\n- use mathematical modelling to simulate the existing impact of drought and food insecurity on HIV transmission and morbidity in several countries in Eastern and Southern Africa.\n\n- model the potential effect of global warming in these countries on increasing the impact of drought and food insecurity on HIV transmission and morbidity, as well as the impact of potential interventions.\n","awardDateDateOnly":"2021-05-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa South of the Sahara","Climate Change","Female","Food Supply","HIV Infections","Humans","Incidence","Models, Theoretical"]}
{"id":"360G-Wellcome-222768_Z_21_Z","title":"Anomalous Transport of Organelles","Region":"North West","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222768/Z/21/Z","description":"From active transport by motor proteins to passive transport in the crowded cytoplasmic environment, the movement of organelles within cells is critical for cell function. This transport exhibits non-Brownian anomalous transport: sub-diffusion and super-diffusion. Abnormal transport can lead to disease, and understanding how this occurs requires systematic quantification of organelle movement combined with predictions based on biologically motivated random walk models with multiple states of motion. To simplify tracking and analysis we will study organelle motility in neurons that are one dimensional, due to the thinness of the axon, rather than the fibroblasts we studied previously. We will obtain and analyse organelle trajectories by live-cell imaging of cultured human neuronal-like cells, and individual neurons in the nematode C. elegans. Then we will determine how selected disease-causing mutations in dynein regulators affect motility. We will develop new mathematical models for non-Markovian stochastic transport and fractional Brownian motion with random Hurst exponents, validating and improving models using experimental data. Lastly, we will generate new neural network/machine learning algorithms to better segment and estimate different states of motion and use these to predict the effect of dynein disruption on motility in human motor neurons that can be 1m long.\n","plannedDates":[{"endDate":"2023-09-15T00:00:00+00:00","startDate":"2020-09-16T00:00:00+00:00","startDateDateOnly":"2020-09-16","endDateDateOnly":"2023-09-15"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Anna Gavrilova","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Gavrilova","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Anomalous Transport of Organelles From active transport by motor proteins to passive transport in the crowded cytoplasmic environment, the movement of organelles within cells is critical for cell function. This transport exhibits non-Brownian anomalous transport: sub-diffusion and super-diffusion. Abnormal transport can lead to disease, and understanding how this occurs requires systematic quantification of organelle movement combined with predictions based on biologically motivated random walk models with multiple states of motion. To simplify tracking and analysis we will study organelle motility in neurons that are one dimensional, due to the thinness of the axon, rather than the fibroblasts we studied previously. We will obtain and analyse organelle trajectories by live-cell imaging of cultured human neuronal-like cells, and individual neurons in the nematode C. elegans. Then we will determine how selected disease-causing mutations in dynein regulators affect motility. We will develop new mathematical models for non-Markovian stochastic transport and fractional Brownian motion with random Hurst exponents, validating and improving models using experimental data. Lastly, we will generate new neural network/machine learning algorithms to better segment and estimate different states of motion and use these to predict the effect of dynein disruption on motility in human motor neurons that can be 1m long.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Biological Transport","Caenorhabditis elegans","Dyneins","Humans","Machine Learning","Neural Networks, Computer"]}
{"id":"360G-Wellcome-222767_Z_21_Z","title":"Unravelling the mechanisms of mammalian Polycomb-dependent gene repression through functional evolutionary analysis","Region":"South East","currency":"GBP","awardDate":"2021-05-05T00:00:00+00:00","Sponsor(s)":"Dr Arnau Seb\u00e9-Pedr\u00f3s, Prof Robert Klose, Prof David Booth","Internal ID":"222767/Z/21/Z","description":"Polycomb group proteins are chromatin regulators which are essential for mammalian development and are often dysregulated in diseases including cancer. Polycomb proteins make up two distinct complexes, Polycomb Repressive Complex 1 and 2 (PRC1/2). In mammals these complexes have expanded and evolved into a complex interconnected system making it challenging to disentangle the core principles through which they function. I will utilize Salpingoeca rosetta, a choanoflagellate, to dissect a more \"ancestral-like\" Polycomb system and through a comparative approach unravel the basic core principles through which animal PRCs operate. Firstly, I will interrogate the composition (Aim1) and dissect the biochemical properties and enzymatic activities of S. rosetta (Sr)PRCs (Aim2) to reveal the conserved properties of animals PRCs. I will then utilize genome-wide mapping approaches to address the function of SrPRCs and, using mutants for PRC components, test whether their activities are coupled in the genome (Aim3). Together, these discoveries will provide essential new insight into the principles through which animal PRCs act and will shed light on how they become perturbed in disease. This in turn will inform new avenues for targeted therapeutic intervention in diseases where alternations to PRC function are pathogenic.\n","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2021-10-01T00:00:00+00:00","startDateDateOnly":"2021-10-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr James Gahan","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Gahan","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Unravelling the mechanisms of mammalian Polycomb-dependent gene repression through functional evolutionary analysis Polycomb group proteins are chromatin regulators which are essential for mammalian development and are often dysregulated in diseases including cancer. Polycomb proteins make up two distinct complexes, Polycomb Repressive Complex 1 and 2 (PRC1/2). In mammals these complexes have expanded and evolved into a complex interconnected system making it challenging to disentangle the core principles through which they function. I will utilize Salpingoeca rosetta, a choanoflagellate, to dissect a more \"ancestral-like\" Polycomb system and through a comparative approach unravel the basic core principles through which animal PRCs operate. Firstly, I will interrogate the composition (Aim1) and dissect the biochemical properties and enzymatic activities of S. rosetta (Sr)PRCs (Aim2) to reveal the conserved properties of animals PRCs. I will then utilize genome-wide mapping approaches to address the function of SrPRCs and, using mutants for PRC components, test whether their activities are coupled in the genome (Aim3). Together, these discoveries will provide essential new insight into the principles through which animal PRCs act and will shed light on how they become perturbed in disease. This in turn will inform new avenues for targeted therapeutic intervention in diseases where alternations to PRC function are pathogenic.\n","awardDateDateOnly":"2021-05-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Chromatin","Evolution, Molecular","Genome","Polycomb Repressive Complex 1","Polycomb Repressive Complex 2","Polycomb-Group Proteins"]}
{"id":"360G-Wellcome-222757_Z_21_Z","title":"Characterising the Novel Role of Inositol-5 Phosphatase B in B Cell Receptor Activation, Endocytosis and Signalling","Region":"North West","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222757/Z/21/Z","description":"White blood cells (WBCs) play a fundamental role in coordinating our immune system in response to infection. WBCs known as B cells produce antibodies and contribute to lasting immunity upon re-exposure to the same infection. Unfortunately, B cells are also responsible for various immune disorders and lymphatic cancers. This makes understanding the mechanisms controlling B cell behaviour vital for treating these diseases. B cell physiology is heavily regulated by a cell surface receptor known as the B cell receptor (BCR). We have uncovered a novel mechanism by  BCR function is mediated through a specific enzyme that targets fat-like molecules called lipids. I aim to understand this previously unappreciated mechanism of regulation using a multidisciplinary approach. I will use biochemical and mass spectrometric approaches to determine how these enzymes are recruited to BCRs. I will genetically engineer cell lines which lack these enzymes to explore the functional impacts of their absence on BCR activation and signalling, measuring changes using flow cytometry and cutting-edge live-cell microscopy. Validating these enzymes as critical for BCR function will not only enhance our overall understanding of this complex process but also reveal new targets for therapeutic intervention.\n","plannedDates":[{"endDate":"2023-09-22T00:00:00+00:00","startDate":"2020-09-23T00:00:00+00:00","startDateDateOnly":"2020-09-23","endDateDateOnly":"2023-09-22"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Connor Wallis","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Wallis","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Characterising the Novel Role of Inositol-5 Phosphatase B in B Cell Receptor Activation, Endocytosis and Signalling White blood cells (WBCs) play a fundamental role in coordinating our immune system in response to infection. WBCs known as B cells produce antibodies and contribute to lasting immunity upon re-exposure to the same infection. Unfortunately, B cells are also responsible for various immune disorders and lymphatic cancers. This makes understanding the mechanisms controlling B cell behaviour vital for treating these diseases. B cell physiology is heavily regulated by a cell surface receptor known as the B cell receptor (BCR). We have uncovered a novel mechanism by  BCR function is mediated through a specific enzyme that targets fat-like molecules called lipids. I aim to understand this previously unappreciated mechanism of regulation using a multidisciplinary approach. I will use biochemical and mass spectrometric approaches to determine how these enzymes are recruited to BCRs. I will genetically engineer cell lines which lack these enzymes to explore the functional impacts of their absence on BCR activation and signalling, measuring changes using flow cytometry and cutting-edge live-cell microscopy. Validating these enzymes as critical for BCR function will not only enhance our overall understanding of this complex process but also reveal new targets for therapeutic intervention.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["B-Lymphocytes","Humans","Mass Spectrometry","Receptors, Antigen, B-Cell","Signal Transduction"]}
{"id":"360G-Wellcome-222750_Z_21_Z","title":"Testing the role of physical activity in promoting resilience against stress-related psychopathology among young people","Region":"Greater London","currency":"GBP","awardDate":"2021-05-05T00:00:00+00:00","Sponsor(s)":"Prof Andrea Danese, Dr Charlotte Cecil, Prof Jaakko Kaprio, Prof Mark Gilthorpe, Dr Jean-Baptiste Pingault, Prof Marcus Munafo","Internal ID":"222750/Z/21/Z","description":"\nStress-related psychopathology (e.g. depression and anxiety) affects one in eight children in the UK. It is therefore crucial to identify modifiable protective factors that can promote mental health in young people. Physical activity is a promising target for the prevention of depression and anxiety. However, the extent to which it can reduce the burden of mental disorders in young people is not known. This is due to the breadth of environmental, social, and genetic factors that could confound the relationship between physical activity and psychopathology. Furthermore, it is unclear whether physical activity can promote resilience to psychopathology in children who are at higher risk by virtue of genetic liability or adversity.  \n\nI will apply cutting-edge causal inference methods, such as G-methods, Mendelian randomisation, and twin designs, to test whether physical activity can promote resilience against the development of stress-related psychopathology, using data from large population-based cohorts of children from the UK, Netherlands, Norway, and Finland. Triangulating evidence from multiple analytical approaches will allow me to strengthen causal inferences from observational data and minimise potential biases associated with each method. In turn, the findings will indicate whether interventions targeting physical activity are likely to hold promise to prevent stress-related psychopathology.\n \n","plannedDates":[{"endDate":"2025-10-03T00:00:00+00:00","startDate":"2021-10-04T00:00:00+00:00","startDateDateOnly":"2021-10-04","endDateDateOnly":"2025-10-03"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Ms Eleonora Iob","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Iob","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Testing the role of physical activity in promoting resilience against stress-related psychopathology among young people \nStress-related psychopathology (e.g. depression and anxiety) affects one in eight children in the UK. It is therefore crucial to identify modifiable protective factors that can promote mental health in young people. Physical activity is a promising target for the prevention of depression and anxiety. However, the extent to which it can reduce the burden of mental disorders in young people is not known. This is due to the breadth of environmental, social, and genetic factors that could confound the relationship between physical activity and psychopathology. Furthermore, it is unclear whether physical activity can promote resilience to psychopathology in children who are at higher risk by virtue of genetic liability or adversity.  \n\nI will apply cutting-edge causal inference methods, such as G-methods, Mendelian randomisation, and twin designs, to test whether physical activity can promote resilience against the development of stress-related psychopathology, using data from large population-based cohorts of children from the UK, Netherlands, Norway, and Finland. Triangulating evidence from multiple analytical approaches will allow me to strengthen causal inferences from observational data and minimise potential biases associated with each method. In turn, the findings will indicate whether interventions targeting physical activity are likely to hold promise to prevent stress-related psychopathology.\n \n","awardDateDateOnly":"2021-05-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adolescent","Child","Depression","Exercise","Female","Finland","Humans","Male","Norway","Psychopathology","Resilience, Psychological","Stress, Psychological","United Kingdom"]}
{"id":"360G-Wellcome-222749_Z_21_Z","title":"Molecular and cellular mechanisms directing neuronal microtubule rearrangements during vertebrate CNS development","Region":"North West","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222749/Z/21/Z","description":"Polarity, the asymmetric organisation of cellular components, is crucial for the function of many cell types. Newborn neurons in the developing spinal cord shed their tips to move to their final location, causing them to lose polarity and the ability to distinguish their front from their back. These neurons must then regain polarity to extend a long process, called an axon, which makes connections with other neurons. In the developing embryo, neurons polarise in response to external cues from the surrounding tissue, which determine the orientation in which the axon will form, and therefore the direction it will grow in, or if it forms at all. Thus, neuron polarisation is essential for the formation of neuronal circuitry; however, the mechanisms of vertebrate neuron polarisation within tissue are unclear. I will study the molecular and cellular mechanisms that direct this key cell-biological process using cutting-edge live imaging and super-resolution microscopy of developing neurons in the embryonic chick spinal cord. Not only will this work help us understand how the nervous system is built, but it will also enrich our understanding of the general cellular mechanisms of polarity transition in development and disease. \n","plannedDates":[{"endDate":"2023-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2023-12-31"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Victoria Higgs","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Higgs","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Molecular and cellular mechanisms directing neuronal microtubule rearrangements during vertebrate CNS development Polarity, the asymmetric organisation of cellular components, is crucial for the function of many cell types. Newborn neurons in the developing spinal cord shed their tips to move to their final location, causing them to lose polarity and the ability to distinguish their front from their back. These neurons must then regain polarity to extend a long process, called an axon, which makes connections with other neurons. In the developing embryo, neurons polarise in response to external cues from the surrounding tissue, which determine the orientation in which the axon will form, and therefore the direction it will grow in, or if it forms at all. Thus, neuron polarisation is essential for the formation of neuronal circuitry; however, the mechanisms of vertebrate neuron polarisation within tissue are unclear. I will study the molecular and cellular mechanisms that direct this key cell-biological process using cutting-edge live imaging and super-resolution microscopy of developing neurons in the embryonic chick spinal cord. Not only will this work help us understand how the nervous system is built, but it will also enrich our understanding of the general cellular mechanisms of polarity transition in development and disease. \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Axons","Cell Polarity","Chick Embryo","Chickens","Microtubules","Neurons","Spinal Cord"]}
{"id":"360G-Wellcome-222748_Z_21_Z","title":"Unravelling the molecular signalling underlying human brown adipogenesis","Region":"East of England","currency":"GBP","awardDate":"2021-05-05T00:00:00+00:00","Sponsor(s)":"Prof Antonio Vidal-Puig, Prof Kathryn Lilley","Internal ID":"222748/Z/21/Z","description":"Obesity and associated comorbidities are significant unresolved global health problems. Despite intense research and various social policies, most of the available non-invasive treatments are ineffective in the long term, and the best therapeutic option remains highly mutilating bariatric surgery. Thus, the unmet need is to identify novel, long-term safe treatments. The activation of the brown adipose tissue (BAT), an energy-dissipating organ, is a promising strategy to treat obesity if the challenges of accumulating enough BAT mass and optimised activity are resolved. Since obese people do not have enough BAT, it is crucial to identify at which step of the differentiation and/or activation the BAT of obese patients fails, and whether we can pharmacologically bypass these functional bottlenecks. Recently, Vidal-Puig's lab has optimised a unique differentiation protocol that recapitulates step-by-step the developmental path of human BAT from stem cells. I aim to use this tool to decipher the signals regulating the process and provide an accurate stage-by-stage molecular map of human brown adipogenesis. These data will help to infer novel pharmacologically targetable molecules to improve differentiation and activation of BAT in obese patients and provide essential information for its analysis and classification in patients based on its maturation and functional stage.\n \n","plannedDates":[{"endDate":"2025-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2025-06-30"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Sonia Rodriguez Fernandez","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Rodriguez Fernandez","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Unravelling the molecular signalling underlying human brown adipogenesis Obesity and associated comorbidities are significant unresolved global health problems. Despite intense research and various social policies, most of the available non-invasive treatments are ineffective in the long term, and the best therapeutic option remains highly mutilating bariatric surgery. Thus, the unmet need is to identify novel, long-term safe treatments. The activation of the brown adipose tissue (BAT), an energy-dissipating organ, is a promising strategy to treat obesity if the challenges of accumulating enough BAT mass and optimised activity are resolved. Since obese people do not have enough BAT, it is crucial to identify at which step of the differentiation and/or activation the BAT of obese patients fails, and whether we can pharmacologically bypass these functional bottlenecks. Recently, Vidal-Puig's lab has optimised a unique differentiation protocol that recapitulates step-by-step the developmental path of human BAT from stem cells. I aim to use this tool to decipher the signals regulating the process and provide an accurate stage-by-stage molecular map of human brown adipogenesis. These data will help to infer novel pharmacologically targetable molecules to improve differentiation and activation of BAT in obese patients and provide essential information for its analysis and classification in patients based on its maturation and functional stage.\n \n","awardDateDateOnly":"2021-05-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adipocytes, Brown","Adipogenesis","Adipose Tissue, Brown","Cell Differentiation","Humans","Obesity","Stem Cells"]}
{"id":"360G-Wellcome-222747_Z_21_Z","title":"Identifying the Neural and Cognitive Contributors to Dizziness in Older Adults","Region":"Greater London","currency":"GBP","awardDate":"2021-05-05T00:00:00+00:00","Sponsor(s)":"Prof Adolfo Bronstein, Prof Stephen Lord","Internal ID":"222747/Z/21/Z","description":"Dizziness is common in older adults and is strongly associated with more frequent falls. Nonetheless, treating this condition represents a significant challenge as clinicians are often unable to identify a physical cause (and, thus, dizziness is \u2018unexplained\u2019). Pilot work implies that unexplained dizziness may stem from attempts to consciously process balance. However, a causal relationship has not been established. Further, the specific mechanisms through which conscious processing influences dizziness remain unknown. My goals are to (i) investigate whether conscious balance processing is causally associated with symptoms of unexplained dizziness, and (ii) identify the neuro-cognitive mechanism/s that likely underpin such a relationship.\n\n\nI will conduct a programme of research to test the hypothesis that conscious balance processing influences dizziness through a hypersensitivity to sensory input, in that even minor fluctuations within \u2018normal\u2019 bounds are perceived as unsteadiness. I will measure symptoms of dizziness and assess sensory processing during baseline balance conditions, as well as during experimental manipulations that either promote or prevent conscious balance processing. Data will be compared between older adults with unexplained dizziness and age-matched controls. This work will advance our understanding of how neuro-cognitive factors contribute to dizziness, informing the development of novel therapies that target these mechanisms.\n","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2021-10-01T00:00:00+00:00","startDateDateOnly":"2021-10-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Toby Ellmers","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Ellmers","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Identifying the Neural and Cognitive Contributors to Dizziness in Older Adults Dizziness is common in older adults and is strongly associated with more frequent falls. Nonetheless, treating this condition represents a significant challenge as clinicians are often unable to identify a physical cause (and, thus, dizziness is \u2018unexplained\u2019). Pilot work implies that unexplained dizziness may stem from attempts to consciously process balance. However, a causal relationship has not been established. Further, the specific mechanisms through which conscious processing influences dizziness remain unknown. My goals are to (i) investigate whether conscious balance processing is causally associated with symptoms of unexplained dizziness, and (ii) identify the neuro-cognitive mechanism/s that likely underpin such a relationship.\n\n\nI will conduct a programme of research to test the hypothesis that conscious balance processing influences dizziness through a hypersensitivity to sensory input, in that even minor fluctuations within \u2018normal\u2019 bounds are perceived as unsteadiness. I will measure symptoms of dizziness and assess sensory processing during baseline balance conditions, as well as during experimental manipulations that either promote or prevent conscious balance processing. Data will be compared between older adults with unexplained dizziness and age-matched controls. This work will advance our understanding of how neuro-cognitive factors contribute to dizziness, informing the development of novel therapies that target these mechanisms.\n","awardDateDateOnly":"2021-05-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aged","Cognition","Consciousness","Dizziness","Female","Goals","Humans","Postural Balance"]}
{"id":"360G-Wellcome-222745_Z_21_Z","title":"The State of the World's Children 2021 Focus Groups","Region":"Greater London","currency":"GBP","awardDate":"2021-02-26T00:00:00+00:00","Internal ID":"222745/Z/21/Z","description":"UNICEF proposes multi-country focus groups to gather insights on young people\u2019s mental health and well-being. This reflects our and Wellcome Trust\u2019s mutual commitment to engaging youth as partners in the design and implementation of action research that affects them. The proposed research will be featured in UNICEF\u2019s flagship State of the World\u2019s Children report, ensuring that the knowledge, expertise, and lived experiences of young people are part of the global dialogue on research, policy, and programming priorities.\n\nKey research questions include: \n\n\n How do adolescents perceive and understand mental health, both positive and negative?\n What are the key emotional and behavioral challenges facing adolescents in communities around the world, and what do they identify as risk and protective factors?\n What are the positive and harmful ways adolescent are coping with mental health problems?\n What are the barriers and reinforcing factors to their help-seeking behavior?\n What are adolescent ideas and solutions around structural, community, peer, and self-care approaches to mental health promotion, prevention, and support?\n\n\nThis research will create opportunities both for promoting positive youth development as well as increase youth voice in the scientific study and body of evidence around mental health of young people.\n\n \n\n \n\n \n","plannedDates":[{"endDate":"2022-08-28T00:00:00+00:00","startDate":"2021-03-01T00:00:00+00:00","startDateDateOnly":"2021-03-01","endDateDateOnly":"2022-08-28"}],"amountAwarded":79672,"Financial Year":"2020/21","Lead Applicant":"Mr Brian Keeley","grantProgramme":[{"title":"Discretionary Award - Mental Health","title_keyword":"Discretionary Award - Mental Health"}],"Applicant Surname":"Keeley","Partnership Value":79672,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:UNICEF-UK","name":"UNICEF UK","addressCountry":"United Kingdom","id_and_name":"[\"UNICEF UK\", \"360G-Wellcome-ORG:UNICEF-UK\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:UNICEF-UK","name":"UNICEF UK"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The State of the World's Children 2021 Focus Groups UNICEF proposes multi-country focus groups to gather insights on young people\u2019s mental health and well-being. This reflects our and Wellcome Trust\u2019s mutual commitment to engaging youth as partners in the design and implementation of action research that affects them. The proposed research will be featured in UNICEF\u2019s flagship State of the World\u2019s Children report, ensuring that the knowledge, expertise, and lived experiences of young people are part of the global dialogue on research, policy, and programming priorities.\n\nKey research questions include: \n\n\n How do adolescents perceive and understand mental health, both positive and negative?\n What are the key emotional and behavioral challenges facing adolescents in communities around the world, and what do they identify as risk and protective factors?\n What are the positive and harmful ways adolescent are coping with mental health problems?\n What are the barriers and reinforcing factors to their help-seeking behavior?\n What are adolescent ideas and solutions around structural, community, peer, and self-care approaches to mental health promotion, prevention, and support?\n\n\nThis research will create opportunities both for promoting positive youth development as well as increase youth voice in the scientific study and body of evidence around mental health of young people.\n\n \n\n \n\n \n","awardDateDateOnly":"2021-02-26","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adolescent","Adolescent Behavior","Child","Female","Focus Groups","Humans","Male","Mental Health"]}
{"id":"360G-Wellcome-222736_Z_21_Z","title":"Investigation into the effects of elevated oxidative stress on wound healing in vivo","Region":"South West","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222736/Z/21/Z","description":"Body tissues, such as the skin, must be able to rapidly repair themselves in response to injury. However, some individuals (particularly those with underlying health conditions) suffer from debilitating \u2018chronic\u2019 wounds that fail to heal, which are often persistently infected. These non-healing wounds are poorly understood and represent a significant burden to healthcare systems and economies.\n\nDamaged tissues recruit immune cells to \u2018clean\u2019 the wound, removing dead cells and producing toxic oxygen molecules to kill invading germs. This inflammatory response is essential for normal wound healing. However, overproduction of toxic molecules could cause \u2018collateral damage\u2019 to our own cells (termed \u2018oxidative stress\u2019) and hinder repair. To combat this, we have evolved a powerful network of \u2018biological shields\u2019 to protect injured tissues, including antioxidant production. \n\nMy work will explore whether defects in this protective machinery are responsible for the failure of infected/diabetic wounds to heal and whether we can rescue healing by boosting protection. For this, I will use the fruit fly (Drosophila), exploiting their translucency (and genetic tractability) to study wound repair live \u2018in vivo\u2019. In parallel, I will use \u2018genetic epidemiology\u2019 to investigate their clinical relevance, by seeing if variations in equivalent human genes have links to disease. \n","plannedDates":[{"endDate":"2023-10-11T00:00:00+00:00","startDate":"2020-10-12T00:00:00+00:00","startDateDateOnly":"2020-10-12","endDateDateOnly":"2023-10-11"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Henry Young","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Young","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigation into the effects of elevated oxidative stress on wound healing in vivo Body tissues, such as the skin, must be able to rapidly repair themselves in response to injury. However, some individuals (particularly those with underlying health conditions) suffer from debilitating \u2018chronic\u2019 wounds that fail to heal, which are often persistently infected. These non-healing wounds are poorly understood and represent a significant burden to healthcare systems and economies.\n\nDamaged tissues recruit immune cells to \u2018clean\u2019 the wound, removing dead cells and producing toxic oxygen molecules to kill invading germs. This inflammatory response is essential for normal wound healing. However, overproduction of toxic molecules could cause \u2018collateral damage\u2019 to our own cells (termed \u2018oxidative stress\u2019) and hinder repair. To combat this, we have evolved a powerful network of \u2018biological shields\u2019 to protect injured tissues, including antioxidant production. \n\nMy work will explore whether defects in this protective machinery are responsible for the failure of infected/diabetic wounds to heal and whether we can rescue healing by boosting protection. For this, I will use the fruit fly (Drosophila), exploiting their translucency (and genetic tractability) to study wound repair live \u2018in vivo\u2019. In parallel, I will use \u2018genetic epidemiology\u2019 to investigate their clinical relevance, by seeing if variations in equivalent human genes have links to disease. \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Drosophila","Drosophila melanogaster","Humans","Oxidative Stress","Wound Healing"]}
{"id":"360G-Wellcome-222735_Z_21_Z","title":"Molecular, genetic and life course approaches to investigate the role of reproductive factors on risk of breast cancer in women ","Region":"South West","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222735/Z/21/Z","description":"Breast cancer (BrCa) is one of the most common forms of cancer, affecting 1 in 7 women and accounting for 7% of all deaths in the UK between 2015-2017. Numerous risk factors have been associated with BrCa including age, family history and body mass index, as well as factors involved in women\u2019s reproductive health. Reproductive events such as early puberty and later menopause have been associated with increased BrCa risk. Much of the current literature has assessed reproductive events independently without consideration of other reproductive events, and these event\u2019s causal role in BrCa development has not been fully investigated.\n\nMy aim is to use multiple approaches to explore the role of reproductive events for improving understanding of BrCa. Firstly, I will assess how these reproductive events have an effect, either independently or in combination, on BrCa risk, across the life course. Secondly, I will use newly developed methods to further assess if reproductive events play a role in causing BrCa. Finally, I will assess to what extent epigenetic modifications, changes to the DNA which influence gene regulation, play a role in the relationship between reproductive events and BrCa. This work will improve our understanding of the causes of BrCa.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Claire Prince","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Prince","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Molecular, genetic and life course approaches to investigate the role of reproductive factors on risk of breast cancer in women  Breast cancer (BrCa) is one of the most common forms of cancer, affecting 1 in 7 women and accounting for 7% of all deaths in the UK between 2015-2017. Numerous risk factors have been associated with BrCa including age, family history and body mass index, as well as factors involved in women\u2019s reproductive health. Reproductive events such as early puberty and later menopause have been associated with increased BrCa risk. Much of the current literature has assessed reproductive events independently without consideration of other reproductive events, and these event\u2019s causal role in BrCa development has not been fully investigated.\n\nMy aim is to use multiple approaches to explore the role of reproductive events for improving understanding of BrCa. Firstly, I will assess how these reproductive events have an effect, either independently or in combination, on BrCa risk, across the life course. Secondly, I will use newly developed methods to further assess if reproductive events play a role in causing BrCa. Finally, I will assess to what extent epigenetic modifications, changes to the DNA which influence gene regulation, play a role in the relationship between reproductive events and BrCa. This work will improve our understanding of the causes of BrCa.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["BRCA1 Protein","Breast Neoplasms","Epigenesis, Genetic","Female","Genetic Predisposition to Disease","Humans","Risk Factors"]}
{"id":"360G-Wellcome-222734_Z_21_Z","title":"Functional Studies of Mutations in Osteoporosis Drug Targets in the Zebrafish","Region":"South West","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222734/Z/21/Z","description":"Osteoporosis is a disease which weakens bones, making individuals more prone to fractures even after a minor fall. It is a prevalent disease, affecting around 1 in 3 women and 1 in 5 men which accounts for 28 million people over the age of 50 across Europe. Individuals suffering with osteoporosis put a significant burden on health care services as they can require long term hospitalisation after surgery, as well as social care packages and physiotherapy. Current treatments aim to stop bone degradation, whereas there are few treatments available to re-build bone and thus help prevent further fractures. New bone-building drug targets can be discovered by investigating the genetic changes which cause people to have naturally high bone mass. In my project, I will use human genetic datasets for genetic changes relevant to bone metabolism to select two novel candidate genes. I will use zebrafish as a model, since their rapid life cycle and transparent bodies allow for imaging of fluorescent proteins that help us understand how the candidate genes affect bone homeostasis. Cultured zebrafish scales will be used to screen for compounds targeted to these candidate genes to test their bone-building capacity informing potential novel osteoporosis treatments.\n","plannedDates":[{"endDate":"2023-09-22T00:00:00+00:00","startDate":"2020-09-23T00:00:00+00:00","startDateDateOnly":"2020-09-23","endDateDateOnly":"2023-09-22"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Georgina McDonald","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"McDonald","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Functional Studies of Mutations in Osteoporosis Drug Targets in the Zebrafish Osteoporosis is a disease which weakens bones, making individuals more prone to fractures even after a minor fall. It is a prevalent disease, affecting around 1 in 3 women and 1 in 5 men which accounts for 28 million people over the age of 50 across Europe. Individuals suffering with osteoporosis put a significant burden on health care services as they can require long term hospitalisation after surgery, as well as social care packages and physiotherapy. Current treatments aim to stop bone degradation, whereas there are few treatments available to re-build bone and thus help prevent further fractures. New bone-building drug targets can be discovered by investigating the genetic changes which cause people to have naturally high bone mass. In my project, I will use human genetic datasets for genetic changes relevant to bone metabolism to select two novel candidate genes. I will use zebrafish as a model, since their rapid life cycle and transparent bodies allow for imaging of fluorescent proteins that help us understand how the candidate genes affect bone homeostasis. Cultured zebrafish scales will be used to screen for compounds targeted to these candidate genes to test their bone-building capacity informing potential novel osteoporosis treatments.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Disease Models, Animal","Humans","Osteoporosis","Zebrafish"]}
{"id":"360G-Wellcome-222733_Z_21_Z","title":"An Investigation into the Fundamentals of Mitochondrial \u2018Stop-Transfer\u2019 Import and Processing ","Region":"South West","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222733/Z/21/Z","description":"Background \n\nMitochondria are membrane-bound organelles implicated in cellular energy generation and an increasing number of cellular processes. Critically, these processes rely on proteins being imported into the mitochondria via the mitochondrial protein import apparatus. \u2018Stop-transfer\u2019 import (Figure 1) is a means to achieve delivery of proteins to a mitochondrial sub-compartment termed the inter-membrane space (IMS). PTEN-induced kinase 1 (PINK1), a mammalian mitochondrial protein kinase and Mgm1, a mitochondrial protein in yeast, are both implicated in mitochondrial \u2018health\u2019 and are critical substrates of this pathway.\n\n \n\nApproach \n\nThorough mechanistic characterization of stop-transfer protein import and the role of processing of these proteins is required to better understand delivery to the IMS in native and damage contexts. I will apply biochemical and biophysical (spectroscopic) approaches to report on import into the IMS using purified PINK1 and Mgm1 in mammalian and yeast cell-based import assays respectively, while also focusing on the role of interacting proteins during the import process, markedly TOM/TIM proteins and PGAM5. \n\n \n\nImpact\n\nDesign of a probe to report on mitochondrial import into the IMS will reveal new details of the molecular control of stop-transfer import and its regulation, markedly for critical substrates such as PINK1 implicated in human disease.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr James Lorriman","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Lorriman","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"An Investigation into the Fundamentals of Mitochondrial \u2018Stop-Transfer\u2019 Import and Processing  Background \n\nMitochondria are membrane-bound organelles implicated in cellular energy generation and an increasing number of cellular processes. Critically, these processes rely on proteins being imported into the mitochondria via the mitochondrial protein import apparatus. \u2018Stop-transfer\u2019 import (Figure 1) is a means to achieve delivery of proteins to a mitochondrial sub-compartment termed the inter-membrane space (IMS). PTEN-induced kinase 1 (PINK1), a mammalian mitochondrial protein kinase and Mgm1, a mitochondrial protein in yeast, are both implicated in mitochondrial \u2018health\u2019 and are critical substrates of this pathway.\n\n \n\nApproach \n\nThorough mechanistic characterization of stop-transfer protein import and the role of processing of these proteins is required to better understand delivery to the IMS in native and damage contexts. I will apply biochemical and biophysical (spectroscopic) approaches to report on import into the IMS using purified PINK1 and Mgm1 in mammalian and yeast cell-based import assays respectively, while also focusing on the role of interacting proteins during the import process, markedly TOM/TIM proteins and PGAM5. \n\n \n\nImpact\n\nDesign of a probe to report on mitochondrial import into the IMS will reveal new details of the molecular control of stop-transfer import and its regulation, markedly for critical substrates such as PINK1 implicated in human disease.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Mitochondria","Mitochondrial Proteins","PTEN Phosphohydrolase","Protein Binding","Protein Kinases","Saccharomyces cerevisiae","Saccharomyces cerevisiae Proteins"]}
{"id":"360G-Wellcome-222732_Z_21_Z","title":"Investigating the regulation of NETs by cell cycle proteins.","Region":"South West","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222732/Z/21/Z","description":"Neutrophils are the most abundant immune cell in circulation. They are the first to respond to infection and tissue damage. Once activated, they migrate into affected tissues to kill microbes using effector mechanisms. These are: pathogen engulfment, secretion of toxic granules, or, releasing neutrophil extracellular traps (NETs). NETs are large, web-like structures comprised of DNA and neutrophil proteins. NETs trap microbes to prevent them spreading and therefore limit tissue damage. However, NET production is tightly controlled because they can also damage our own tissues. Moreover, uncontrolled neutrophil activity and NET release can exacerbate some diseases such as cancer and malaria. \n\n \n\nDespite their disease relevance, how neutrophils \u2018decide\u2019 to react to microbes and inflammation is not well known. Therefore, the aim of this project is to understand which genes control neutrophil behaviour. We will test the hypothesis that the same set of genes that regulate cell division, also regulate NET release. Furthermore, we will also examine if neutrophil changes during cancer make them more prone to making NETs and contribute to disease progression.\n\nThis project will lead to deeper understanding of the role of cell cycle genes in NET formation and elucidate their role in neutrophil populations associated with inflammatory disease.\n","plannedDates":[{"endDate":"2023-09-19T00:00:00+00:00","startDate":"2020-09-20T00:00:00+00:00","startDateDateOnly":"2020-09-20","endDateDateOnly":"2023-09-19"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Willem Gibbs","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Gibbs","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the regulation of NETs by cell cycle proteins. Neutrophils are the most abundant immune cell in circulation. They are the first to respond to infection and tissue damage. Once activated, they migrate into affected tissues to kill microbes using effector mechanisms. These are: pathogen engulfment, secretion of toxic granules, or, releasing neutrophil extracellular traps (NETs). NETs are large, web-like structures comprised of DNA and neutrophil proteins. NETs trap microbes to prevent them spreading and therefore limit tissue damage. However, NET production is tightly controlled because they can also damage our own tissues. Moreover, uncontrolled neutrophil activity and NET release can exacerbate some diseases such as cancer and malaria. \n\n \n\nDespite their disease relevance, how neutrophils \u2018decide\u2019 to react to microbes and inflammation is not well known. Therefore, the aim of this project is to understand which genes control neutrophil behaviour. We will test the hypothesis that the same set of genes that regulate cell division, also regulate NET release. Furthermore, we will also examine if neutrophil changes during cancer make them more prone to making NETs and contribute to disease progression.\n\nThis project will lead to deeper understanding of the role of cell cycle genes in NET formation and elucidate their role in neutrophil populations associated with inflammatory disease.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cell Cycle","Cell Division","Extracellular Traps","Humans","Neutrophils"]}
{"id":"360G-Wellcome-222731_Z_21_Z","title":"How does wound inflammation impact on other cell lineages at the repair site \u2013 in vitro and live imaging studies in zebrafish","Region":"South West","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222731/Z/21/Z","description":"Wound healing is the process by which skin integrity is restored following injury. At any site of tissue damage, the body activates a complex series of events to heal the wound. Each stage is necessary for effective tissue repair. Inflammation has evolved to prevent infection by pathogens. Besides killing bacteria, signals from inflammatory cells also coordinate other aspects of wound healing. However, these signals may also have negative consequences such a scarring, and if inflammation is not resolved, this can lead to chronic wounds such as diabetic foot ulcers can result. During my PhD I will investigate how inflammation impacts on three lesser studied cell types in wound healing, melanocytes (pigment cells), adipocytes (fat cells) and the cutaneous nerves in skin. It is thought these three cells could play interesting, but as yet unknown roles in wound repair, which may aid repair or be pathological. I will use live imaging in the translucent zebrafish to look at how these cells interact with inflammation, and what signals may cause this. This work could reveal the impacts of inflammation at the wound repair site, which could have impact on wound treatment in the clinic.\n \n","plannedDates":[{"endDate":"2023-09-22T00:00:00+00:00","startDate":"2020-09-23T00:00:00+00:00","startDateDateOnly":"2020-09-23","endDateDateOnly":"2023-09-22"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Anne George","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"George","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"How does wound inflammation impact on other cell lineages at the repair site \u2013 in vitro and live imaging studies in zebrafish Wound healing is the process by which skin integrity is restored following injury. At any site of tissue damage, the body activates a complex series of events to heal the wound. Each stage is necessary for effective tissue repair. Inflammation has evolved to prevent infection by pathogens. Besides killing bacteria, signals from inflammatory cells also coordinate other aspects of wound healing. However, these signals may also have negative consequences such a scarring, and if inflammation is not resolved, this can lead to chronic wounds such as diabetic foot ulcers can result. During my PhD I will investigate how inflammation impacts on three lesser studied cell types in wound healing, melanocytes (pigment cells), adipocytes (fat cells) and the cutaneous nerves in skin. It is thought these three cells could play interesting, but as yet unknown roles in wound repair, which may aid repair or be pathological. I will use live imaging in the translucent zebrafish to look at how these cells interact with inflammation, and what signals may cause this. This work could reveal the impacts of inflammation at the wound repair site, which could have impact on wound treatment in the clinic.\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Humans","Inflammation","Melanocytes","Skin","Wound Healing","Zebrafish"]}
{"id":"360G-Wellcome-222730_Z_21_Z","title":"The Human Gut Microbiome as a Modifier of Human Health","Region":"South West","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222730/Z/21/Z","description":"My project will aim to investigate the role of the human gut microbiome in health and disease outcomes, in particular to assess its role in the link between dietary composition and obesity. The human gut microbiome is a huge community of microorganisms that exist within our digestive systems that interact to aid digestion, protect against pathogens and create metabolites. Although previous evidence suggests the gut microbiome plays a role in health and diseases, much of the literature (arising from animal or observational human studies) attempting to assess this relationship has so far been inconsistent and unable to prove cause-and-effect relationships. I aim to combine epidemiological, genetic and causal inference methods to establish relationships between dietary composition and the microbiome and between the microbiome and health outcomes (focusing on obesity). Dietary composition is one of the key exposures dominating the literature as a likely regulator of the gut microbiome, with a diet high in dietary fibre for example being correlated with high microbial diversity. Lower microbial diversity has been observed in the gut of people with obesity, amongst other diseases. By filling the gaps in the evidence, this research has the potential to be translated into clinical practice and industry.\n\n \n","plannedDates":[{"endDate":"2023-12-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-12-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Rosalyn Fraser","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Fraser","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The Human Gut Microbiome as a Modifier of Human Health My project will aim to investigate the role of the human gut microbiome in health and disease outcomes, in particular to assess its role in the link between dietary composition and obesity. The human gut microbiome is a huge community of microorganisms that exist within our digestive systems that interact to aid digestion, protect against pathogens and create metabolites. Although previous evidence suggests the gut microbiome plays a role in health and diseases, much of the literature (arising from animal or observational human studies) attempting to assess this relationship has so far been inconsistent and unable to prove cause-and-effect relationships. I aim to combine epidemiological, genetic and causal inference methods to establish relationships between dietary composition and the microbiome and between the microbiome and health outcomes (focusing on obesity). Dietary composition is one of the key exposures dominating the literature as a likely regulator of the gut microbiome, with a diet high in dietary fibre for example being correlated with high microbial diversity. Lower microbial diversity has been observed in the gut of people with obesity, amongst other diseases. By filling the gaps in the evidence, this research has the potential to be translated into clinical practice and industry.\n\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Diet","Dietary Fiber","Gastrointestinal Microbiome","Humans","Obesity"]}
{"id":"360G-Wellcome-222729_Z_21_Z","title":"Dissecting causal relationships and molecular mechanisms in disease using genetic risk profiles","Region":"South West","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222729/Z/21/Z","description":"Many common diseases such as obesity, diabetes and hypertension are caused by a combination of genetic, environmental and lifestyle factors. Better understandings of the causal factors of complex diseases may aid disease prevention and health research. Conventionally, studies on disease causal factors rely on health intervention experiments which cost enormous time and labour. The recent availability of large-scale databases, which contains genetic, lifestyle and disease information on tens of thousands of individuals, allows researchers to construct polygenic risk scores (PRS) to represent individuals\u2019 genetic liability to develop a trait or disease. This score could be used to investigate disease causal factors in Mendelian randomisation (MR) analyses, a genetics-based approach analogous to a randomized controlled trial. My PhD will involve constructing and analysing the PRS for complex diseases and generating a large resource of PRS and MR results which we plan to share with the scientific community. I will improve the method of PRS constructions and develop analytical pipelines to identify causal modifiable risk factors for diseases, key genes and pathways underlying disease mechanisms. Furthermore, I will also assess the capability of PRS to predict causal risk factors during childhood which may therefore have important implications for preventing later life disease.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Si Fang","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Fang","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Dissecting causal relationships and molecular mechanisms in disease using genetic risk profiles Many common diseases such as obesity, diabetes and hypertension are caused by a combination of genetic, environmental and lifestyle factors. Better understandings of the causal factors of complex diseases may aid disease prevention and health research. Conventionally, studies on disease causal factors rely on health intervention experiments which cost enormous time and labour. The recent availability of large-scale databases, which contains genetic, lifestyle and disease information on tens of thousands of individuals, allows researchers to construct polygenic risk scores (PRS) to represent individuals\u2019 genetic liability to develop a trait or disease. This score could be used to investigate disease causal factors in Mendelian randomisation (MR) analyses, a genetics-based approach analogous to a randomized controlled trial. My PhD will involve constructing and analysing the PRS for complex diseases and generating a large resource of PRS and MR results which we plan to share with the scientific community. I will improve the method of PRS constructions and develop analytical pipelines to identify causal modifiable risk factors for diseases, key genes and pathways underlying disease mechanisms. Furthermore, I will also assess the capability of PRS to predict causal risk factors during childhood which may therefore have important implications for preventing later life disease.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Causality","Genetic Predisposition to Disease","Humans","Mendelian Randomization Analysis","Multifactorial Inheritance","Obesity","Risk Factors"]}
{"id":"360G-Wellcome-222698_Z_21_Z","title":"Development of small molecule inhibitors of the SARS-CoV-2 protease PLpro for the treatment and prevention of Covid-19","Region":"International","currency":"GBP","awardDate":"2021-02-04T00:00:00+00:00","Internal ID":"222698/Z/21/Z","description":"The SARS-CoV-2 pandemic is a global health emergency that highlighted the need for new antiviral medicines and better pandemic preparedness. Our drug-discovery program focusses on a critical protein present in all coronaviruses, the papain-like protease PLpro. PLpro is essential for viral replication, but also stops our alarm systems to respond to viral infection, To achieve the latter, it removes \u2018ubiquitin\u2019 and ubiquitin-like signals required for inflammation and anti-viral signalling. Our world-leading experts in ubiquitin research, drug-discovery and infectious disease biology have leveraged our state-of-the-art facilities to identify new drug candidates to block PLpro. We have screened  > 400,000 small molecule compounds and identified new chemical scaffolds that inhibit PLpro from SARS-CoV-2 without affecting human enzymes. Our program will deliver new antivirals to prevent or treat COVID-19 and also develop a library of efficacious drug candidates to combat future coronavirus outbreaks","plannedDates":[{"endDate":"2022-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2022-06-30"}],"amountAwarded":500000,"Financial Year":"2020/21","Lead Applicant":"Prof David Komander","grantProgramme":[{"title":"Innovator Award","title_keyword":"Innovator Award"}],"Applicant Surname":"Komander","Partnership Value":500000,"Approval Committee":"Innovator Awards Advisory Group","Other Applicant(s)":"Prof Guillaume Lessene, Dr Melissa Call, Prof Marc Pellegrini","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Walter-and-Eliza-Hall-Institute-of-Medical-Research","name":"Walter and Eliza Hall Institute of Medical Research","addressCountry":"Australia","id_and_name":"[\"Walter and Eliza Hall Institute of Medical Research\", \"360G-Wellcome-ORG:Walter-and-Eliza-Hall-Institute-of-Medical-Research\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Walter-and-Eliza-Hall-Institute-of-Medical-Research","name":"Walter and Eliza Hall Institute of Medical Research"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Development of small molecule inhibitors of the SARS-CoV-2 protease PLpro for the treatment and prevention of Covid-19 The SARS-CoV-2 pandemic is a global health emergency that highlighted the need for new antiviral medicines and better pandemic preparedness. Our drug-discovery program focusses on a critical protein present in all coronaviruses, the papain-like protease PLpro. PLpro is essential for viral replication, but also stops our alarm systems to respond to viral infection, To achieve the latter, it removes \u2018ubiquitin\u2019 and ubiquitin-like signals required for inflammation and anti-viral signalling. Our world-leading experts in ubiquitin research, drug-discovery and infectious disease biology have leveraged our state-of-the-art facilities to identify new drug candidates to block PLpro. We have screened  > 400,000 small molecule compounds and identified new chemical scaffolds that inhibit PLpro from SARS-CoV-2 without affecting human enzymes. Our program will deliver new antivirals to prevent or treat COVID-19 and also develop a library of efficacious drug candidates to combat future coronavirus outbreaks","awardDateDateOnly":"2021-02-04","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Antiviral Agents","Coronavirus","Drug Discovery","Humans","SARS Virus","Small Molecule Libraries","Virus Replication"]}
{"id":"360G-Wellcome-222695_Z_21_Z","title":"Development of in-vivo 19F Clinical MR imaging Using a Novel 19F/1H Coil in Combination with an Intravenous Perfluorocarbon (ABL-101)","Region":"Scotland","currency":"GBP","awardDate":"2021-02-04T00:00:00+00:00","Internal ID":"222695/Z/21/Z","description":"Inflammation is part of the body's defence system against a wide range of harmful stimuli.\nInflammation also plays an important role in human diseases, including stroke, Alzheimer's,\nhardening of arteries, arthritis, and cancer. The ability to image inflammation inside the\nhuman body would provide an improved understanding of this process and provide new\nopportunities for diagnosing disease and guiding treatment. ABL-101 is a fluorinated oxygen\ncarrier which is being investigated for treatment of stroke. It is made up of a large number of\nfluorine atoms that can be visualised in MRI using a detector that is tuned to fluorine (19F\nMRI). Once injected, cells that are also part of the inflammatory response (macrophages)\ntake up ABL-101. ABL-101 could therefore be an imaging agent for inflammation. 19F MRI\nuses a specially developed radiofrequency coil and some specialised programming that Dr\nSantosh and the team at the University of Glasgow wish to assess as a vital step to\ndeveloping clinical uses.","plannedDates":[{"endDate":"2023-10-31T00:00:00+00:00","startDate":"2021-08-01T00:00:00+00:00","startDateDateOnly":"2021-08-01","endDateDateOnly":"2023-10-31"}],"amountAwarded":317317,"Financial Year":"2020/21","Lead Applicant":"Dr Celestine Santosh","grantProgramme":[{"title":"Innovator Award","title_keyword":"Innovator Award"}],"Applicant Surname":"Santosh","Partnership Value":317317,"Approval Committee":"Innovator Awards Advisory Group","Other Applicant(s)":"Prof David Porter, Dr Alex McConnachie, Dr Natasha Fullerton, Dr Shajan Gunamony, Prof Keith Muir","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow","addressCountry":"United Kingdom","id_and_name":"[\"University of Glasgow\", \"360G-Wellcome-ORG:University-of-Glasgow\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Development of in-vivo 19F Clinical MR imaging Using a Novel 19F/1H Coil in Combination with an Intravenous Perfluorocarbon (ABL-101) Inflammation is part of the body's defence system against a wide range of harmful stimuli.\nInflammation also plays an important role in human diseases, including stroke, Alzheimer's,\nhardening of arteries, arthritis, and cancer. The ability to image inflammation inside the\nhuman body would provide an improved understanding of this process and provide new\nopportunities for diagnosing disease and guiding treatment. ABL-101 is a fluorinated oxygen\ncarrier which is being investigated for treatment of stroke. It is made up of a large number of\nfluorine atoms that can be visualised in MRI using a detector that is tuned to fluorine (19F\nMRI). Once injected, cells that are also part of the inflammatory response (macrophages)\ntake up ABL-101. ABL-101 could therefore be an imaging agent for inflammation. 19F MRI\nuses a specially developed radiofrequency coil and some specialised programming that Dr\nSantosh and the team at the University of Glasgow wish to assess as a vital step to\ndeveloping clinical uses.","awardDateDateOnly":"2021-02-04","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Fluorine","Fluorine-19 Magnetic Resonance Imaging","Fluorocarbons","Humans","Inflammation","Magnetic Resonance Imaging"]}
{"id":"360G-Wellcome-222667_Z_21_Z","title":"Investigating Intracellular Processes in Macrophages During Candida albicans Infection","Region":"Scotland","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222667/Z/21/Z","description":"While most fungal infections are cleared by the immune system in healthy individuals, in immunocompromised people or in patients after invasive medical procedures these pathogens can cause life threatening systemic infections. With mortality rates around 50%  our current treatments are insufficient. Thus, research to better understand these infections is required.\n\nCandida albicans is the most common human fungal pathogen and a frequent cause of hospital acquired infections. Macrophages are one of the first cells in our immune system to identify Candida and initiate an antifungal response; but how infection affects intracellular processes in macrophages is not completely understood.\n\nI intend to further investigate which intracellular processes are altered during Candida infection. In previous work, we studied the total proteins in macrophages during infection, and we found Candida infection appeared to dysregulate an oxidative stress mechanism, Nrf2/Keap1, in a novel way. We plan to further study this mechanism, as well as more broadly look for novel mechanisms of regulation. This project will contribute to understanding our immune system\u2019s functional response to fungal infection and will bring us closer to creating new therapeutics to prevent systemic fungal infections.\n","plannedDates":[{"endDate":"2023-11-30T00:00:00+00:00","startDate":"2020-12-01T00:00:00+00:00","startDateDateOnly":"2020-12-01","endDateDateOnly":"2023-11-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Christa Baker","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Baker","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee","addressCountry":"United Kingdom","id_and_name":"[\"University of Dundee\", \"360G-Wellcome-ORG:University-of-Dundee\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating Intracellular Processes in Macrophages During Candida albicans Infection While most fungal infections are cleared by the immune system in healthy individuals, in immunocompromised people or in patients after invasive medical procedures these pathogens can cause life threatening systemic infections. With mortality rates around 50%  our current treatments are insufficient. Thus, research to better understand these infections is required.\n\nCandida albicans is the most common human fungal pathogen and a frequent cause of hospital acquired infections. Macrophages are one of the first cells in our immune system to identify Candida and initiate an antifungal response; but how infection affects intracellular processes in macrophages is not completely understood.\n\nI intend to further investigate which intracellular processes are altered during Candida infection. In previous work, we studied the total proteins in macrophages during infection, and we found Candida infection appeared to dysregulate an oxidative stress mechanism, Nrf2/Keap1, in a novel way. We plan to further study this mechanism, as well as more broadly look for novel mechanisms of regulation. This project will contribute to understanding our immune system\u2019s functional response to fungal infection and will bring us closer to creating new therapeutics to prevent systemic fungal infections.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Candida albicans","Candidiasis","Humans","Kelch-Like ECH-Associated Protein 1","Macrophages","Mice","NF-E2-Related Factor 2","Oxidative Stress","Reactive Oxygen Species"]}
{"id":"360G-Wellcome-222638_Z_21_Z","title":"Structural and molecular investigation of neuronal adenylyl cyclases underlying synaptic plasticity","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222638/Z/21/Z","description":"Long-lasting changes in strength between synapses are a key element of learning and memory. The intracellular second messenger cyclic AMP (cAMP) plays a key role alongside Ca2+ in coordinating such synaptic plasticity. cAMP signalling operates in localised \u2018nanodomains\u2019 that are centred on the enzymes that synthesize cAMP \u2013 adenylyl cyclases. In neurons, two Ca2+-sensitive cyclases (AC1 and AC8) are particularly important in signalling underlying synaptic plasticity. These enzymes are relatively understudied, partly due to technical hurdles.\n\nI will take advantage of novel crosslinking approaches, and state-of-the-art mammalian cell expression systems to overcome these hurdles and study the enzymes in three ways. First, I will use crosslinking of extracts from rat cerebellum (where the cyclases are abundant) to identify and characterise their molecular interactions. Second, I will employ inducible expression in suspension cultures of mammalian cells to express large amounts of the cyclases. This will enable me to study their three-dimensional structure \u2013 a key step in fully understanding their function. Third, I will use a high-throughput assay to screen for novel ligands of neuronal cyclases. This multidisciplinary approach will address a basic element of neuronal signalling that is critical in brain regions including the cerebellum, hippocampus, and the striatum.\n","plannedDates":[{"endDate":"2023-11-22T00:00:00+00:00","startDate":"2020-11-23T00:00:00+00:00","startDateDateOnly":"2020-11-23","endDateDateOnly":"2023-11-22"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Ryan Dowsell","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Dowsell","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Structural and molecular investigation of neuronal adenylyl cyclases underlying synaptic plasticity Long-lasting changes in strength between synapses are a key element of learning and memory. The intracellular second messenger cyclic AMP (cAMP) plays a key role alongside Ca2+ in coordinating such synaptic plasticity. cAMP signalling operates in localised \u2018nanodomains\u2019 that are centred on the enzymes that synthesize cAMP \u2013 adenylyl cyclases. In neurons, two Ca2+-sensitive cyclases (AC1 and AC8) are particularly important in signalling underlying synaptic plasticity. These enzymes are relatively understudied, partly due to technical hurdles.\n\nI will take advantage of novel crosslinking approaches, and state-of-the-art mammalian cell expression systems to overcome these hurdles and study the enzymes in three ways. First, I will use crosslinking of extracts from rat cerebellum (where the cyclases are abundant) to identify and characterise their molecular interactions. Second, I will employ inducible expression in suspension cultures of mammalian cells to express large amounts of the cyclases. This will enable me to study their three-dimensional structure \u2013 a key step in fully understanding their function. Third, I will use a high-throughput assay to screen for novel ligands of neuronal cyclases. This multidisciplinary approach will address a basic element of neuronal signalling that is critical in brain regions including the cerebellum, hippocampus, and the striatum.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adenylyl Cyclases","Animals","Cells, Cultured","Cerebellum","Cyclic AMP","Neurons","Rats","Rats, Wistar","Signal Transduction"]}
{"id":"360G-Wellcome-222636_Z_21_Z","title":"Clinical Trial Community Engagement Lab","Region":"International","currency":"GBP","awardDate":"2021-02-26T00:00:00+00:00","Internal ID":"222636/Z/21/Z","description":"Community engagement is an essential component in clinical trials, and it is regarded as an ethical requirement of most ethics review committees before the trial protocols can be approved.  However, there is a scarcity of studies that have objectively assessed the impact of best engagement practices on recruitment and retention rates. \n\nUsing an in-depth review of the literature, in-depth interviews, and focus group discussions with relevant stakeholders, we will develop clinical trial community engagement best practices. We will then establish and pilot an implementation assessment tool that would be used to assess the extent of implementation of these practices.  Finally, we will conduct a randomized controlled study to assess the efficacy of best practices on the recruitment and retention rates of clinical trials in a randomized controlled trial, where trials in the intervention arm will be assigned to implement the new best practices, and control trials will implement their originally planned engagement approaches. The implementation assessment tool will be used to measure the extent of adherence to the newly established best practices in both arms. We will then assess the enhancers and barriers to the successful implementation of clinical trial best community engagement practices.   \n","plannedDates":[{"endDate":"2025-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2025-03-31"}],"amountAwarded":447509,"Financial Year":"2020/21","Lead Applicant":"Dr Ally Olotu","grantProgramme":[{"title":"Discretionary Award - Public Engagement","title_keyword":"Discretionary Award - Public Engagement"}],"Applicant Surname":"Olotu","Partnership Value":447509,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Ifakara-Health-Institute","name":"Ifakara Health Institute","addressCountry":"Tanzania","id_and_name":"[\"Ifakara Health Institute\", \"360G-Wellcome-ORG:Ifakara-Health-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Ifakara-Health-Institute","name":"Ifakara Health Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Clinical Trial Community Engagement Lab Community engagement is an essential component in clinical trials, and it is regarded as an ethical requirement of most ethics review committees before the trial protocols can be approved.  However, there is a scarcity of studies that have objectively assessed the impact of best engagement practices on recruitment and retention rates. \n\nUsing an in-depth review of the literature, in-depth interviews, and focus group discussions with relevant stakeholders, we will develop clinical trial community engagement best practices. We will then establish and pilot an implementation assessment tool that would be used to assess the extent of implementation of these practices.  Finally, we will conduct a randomized controlled study to assess the efficacy of best practices on the recruitment and retention rates of clinical trials in a randomized controlled trial, where trials in the intervention arm will be assigned to implement the new best practices, and control trials will implement their originally planned engagement approaches. The implementation assessment tool will be used to measure the extent of adherence to the newly established best practices in both arms. We will then assess the enhancers and barriers to the successful implementation of clinical trial best community engagement practices.   \n","awardDateDateOnly":"2021-02-26","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Focus Groups","Humans","Patient Selection","Qualitative Research","Randomized Controlled Trials as Topic","Research Design","Stakeholder Participation"]}
{"id":"360G-Wellcome-222624_Z_21_Z","title":"Ready2Respond, a public-private collaborating platform to address pandemic preparedness gaps in lower income countries","Region":"International","currency":"GBP","awardDate":"2020-12-31T00:00:00+00:00","Internal ID":"222624/Z/21/Z","description":"Early 2019, a group of global health leaders with expertise in influenza, vaccinology and pandemic preparedness convened  in London, for a Wellcome Trust-supported \"Shaping Meeting to explore the value of a coordinated work plan for epidemic and pandemic influenza vaccine preparedness.\" Ready2Respond was formed as a global collaboration of partners committed to enhancing lower income countries\u2019 readiness to respond against influenza and respiratory viral pandemics. With a Secretariat established at The Task Force for Global Health, Ready2Respond identified challenges and actionable solutions to promote pandemic preparedness. Though initially based on influenza preparedness, these priorities now include COVID-19.\n\nThree Expert Working Groups will design and execute cross-collaborative projects within three strategic priorities.\n\n\n Burden of Disease\n Risk Communication and Community Engagement\n Vaccine Access\n\n\nReady2Respond seeks an initial grant from the Wellcome Trust of US$ $196,650. This initial grant will allow to:\n\n\n retain a Director, tasked with developing a comprehensive action plan with potential projects to start in 2021.\n execute a mapping study of organizations and agencies working on global seasonal and/or pandemic vaccine preparedness to ensure the relevance of Ready2Respond\u2019s mission and activities in the preparedness ecosystem.\n support communication activities to secure funds for identified projects from potential partner organizations.\n\n","plannedDates":[{"endDate":"2021-06-09T00:00:00+00:00","startDate":"2021-02-09T00:00:00+00:00","startDateDateOnly":"2021-02-09","endDateDateOnly":"2021-06-09"}],"amountAwarded":147298,"Financial Year":"2020/21","Lead Applicant":"Dr Marie Mazur","grantProgramme":[{"title":"Discretionary Award - Vaccines","title_keyword":"Discretionary Award - Vaccines"}],"Applicant Surname":"Mazur","Partnership Value":147298,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Task-Force-for-Global-Health","name":"Task Force for Global Health","addressCountry":"United States","id_and_name":"[\"Task Force for Global Health\", \"360G-Wellcome-ORG:Task-Force-for-Global-Health\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Task-Force-for-Global-Health","name":"Task Force for Global Health"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Ready2Respond, a public-private collaborating platform to address pandemic preparedness gaps in lower income countries Early 2019, a group of global health leaders with expertise in influenza, vaccinology and pandemic preparedness convened  in London, for a Wellcome Trust-supported \"Shaping Meeting to explore the value of a coordinated work plan for epidemic and pandemic influenza vaccine preparedness.\" Ready2Respond was formed as a global collaboration of partners committed to enhancing lower income countries\u2019 readiness to respond against influenza and respiratory viral pandemics. With a Secretariat established at The Task Force for Global Health, Ready2Respond identified challenges and actionable solutions to promote pandemic preparedness. Though initially based on influenza preparedness, these priorities now include COVID-19.\n\nThree Expert Working Groups will design and execute cross-collaborative projects within three strategic priorities.\n\n\n Burden of Disease\n Risk Communication and Community Engagement\n Vaccine Access\n\n\nReady2Respond seeks an initial grant from the Wellcome Trust of US$ $196,650. This initial grant will allow to:\n\n\n retain a Director, tasked with developing a comprehensive action plan with potential projects to start in 2021.\n execute a mapping study of organizations and agencies working on global seasonal and/or pandemic vaccine preparedness to ensure the relevance of Ready2Respond\u2019s mission and activities in the preparedness ecosystem.\n support communication activities to secure funds for identified projects from potential partner organizations.\n\n","awardDateDateOnly":"2020-12-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Communication","Global Health","Humans","Influenza Vaccines","Influenza, Human","London","Pandemics"]}
{"id":"360G-Wellcome-222623_Z_21_Z","title":"Controlling thymus function to improve T-cell immunity in the aged.","Region":"Greater London","currency":"GBP","awardDate":"2021-04-20T00:00:00+00:00","Sponsor(s)":"Prof Hans Stauss","Internal ID":"222623/Z/21/Z","description":"Effective adaptive immunity is dependent on T-cell development in the thymus. The thymus undergoes age-related involution, leading to reduced T-cell output. This is suggested to compromise T-cell immunity and increase risk of disease severity in the elderly. However, it was unknown whether enhancing thymic function would ameliorate the immune defects observed in the elderly. \n\nTranscriptional assessment of thymic epithelial cells (TECs) through development facilitated the generation of genetically altered mouse models in which thymic involution was prevented or reversed. Both models restored normal peripheral T cell populations, and, critically, enhanced the survival of aging hosts when challenged with Toxoplasma gondii. Therefore, TEC-mediated restoration of thymic function improves immunity with age.  \n\nBased on these findings, I propose to identify progenitor-successor relationships within adult TECs that maintain the adult thymus and identify age-associated alterations in these populations that could contribute to thymic atrophy. Moreover, I will investigate the mechanisms by which restored thymus function improves immunity in aged mice. Collectively, my proposal will provide an important understanding of how TECs shape immune responses in the elderly, and inform TEC-mediated approaches of thymic regeneration to aid prevention of the degeneration of T-cell immunity that accompanies aging.\n","plannedDates":[{"endDate":"2026-09-30T00:00:00+00:00","startDate":"2021-10-01T00:00:00+00:00","startDateDateOnly":"2021-10-01","endDateDateOnly":"2026-09-30"}],"amountAwarded":1341438,"Financial Year":"2020/21","Lead Applicant":"Dr Jennifer Cowan","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Cowan","Partnership Value":1341438,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Controlling thymus function to improve T-cell immunity in the aged. Effective adaptive immunity is dependent on T-cell development in the thymus. The thymus undergoes age-related involution, leading to reduced T-cell output. This is suggested to compromise T-cell immunity and increase risk of disease severity in the elderly. However, it was unknown whether enhancing thymic function would ameliorate the immune defects observed in the elderly. \n\nTranscriptional assessment of thymic epithelial cells (TECs) through development facilitated the generation of genetically altered mouse models in which thymic involution was prevented or reversed. Both models restored normal peripheral T cell populations, and, critically, enhanced the survival of aging hosts when challenged with Toxoplasma gondii. Therefore, TEC-mediated restoration of thymic function improves immunity with age.  \n\nBased on these findings, I propose to identify progenitor-successor relationships within adult TECs that maintain the adult thymus and identify age-associated alterations in these populations that could contribute to thymic atrophy. Moreover, I will investigate the mechanisms by which restored thymus function improves immunity in aged mice. Collectively, my proposal will provide an important understanding of how TECs shape immune responses in the elderly, and inform TEC-mediated approaches of thymic regeneration to aid prevention of the degeneration of T-cell immunity that accompanies aging.\n","awardDateDateOnly":"2021-04-20","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aging","Animals","Epithelial Cells","Mice","T-Lymphocytes","Thymus Gland","Toxoplasma"]}
{"id":"360G-Wellcome-222609_Z_21_Z","title":"The origins of individuality in the Drosophila visual system","Region":"Greater London","currency":"GBP","awardDate":"2021-04-20T00:00:00+00:00","Sponsor(s)":"Prof Oscar Mar\u00edn","Internal ID":"222609/Z/21/Z","description":"Why are all brains different from each other and where does this variability come from? A plethora of animal experiments demonstrate the importance of environmental and genetic influence in creating behavioural variation. A third factor named stochastic developmental processes is less established. Despite recent advancements, a systematic review of variation in brain wiring, its origins, and behavioural consequences is still lacking.\n\nMy main research goal is to understand the contributions of genetic, stochastic, and environmental factors to variation in brain wiring and behavioural individuality. Recently, I have shown that stochastic, non-heritable developmental processes can result in individually variable wiring diagrams that are associated with individual behavioural characteristics. This system provides a tractable genetic and neuronal model for individuality.\n\nBased on this work, I hypothesize that (1) stochastic developmental processes are a general neuronal property affecting synaptic distributions, wiring and behaviour, and (2) that stochastic wiring differences affect several behaviours ranging from visual guided responses to circadian activity patterns. Within this framework, I aim to answer two key questions on the origins of individuality:1. Is circuit variability a general nervous system property and what are its origins? 2. Does circuit variability contribute to other visual and non-visual behavioural paradigms?\n","plannedDates":[{"endDate":"2026-12-31T00:00:00+00:00","startDate":"2022-01-01T00:00:00+00:00","startDateDateOnly":"2022-01-01","endDateDateOnly":"2026-12-31"}],"amountAwarded":1376391,"Financial Year":"2020/21","Lead Applicant":"Dr Gerit Linneweber","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Linneweber","Partnership Value":1376391,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The origins of individuality in the Drosophila visual system Why are all brains different from each other and where does this variability come from? A plethora of animal experiments demonstrate the importance of environmental and genetic influence in creating behavioural variation. A third factor named stochastic developmental processes is less established. Despite recent advancements, a systematic review of variation in brain wiring, its origins, and behavioural consequences is still lacking.\n\nMy main research goal is to understand the contributions of genetic, stochastic, and environmental factors to variation in brain wiring and behavioural individuality. Recently, I have shown that stochastic, non-heritable developmental processes can result in individually variable wiring diagrams that are associated with individual behavioural characteristics. This system provides a tractable genetic and neuronal model for individuality.\n\nBased on this work, I hypothesize that (1) stochastic developmental processes are a general neuronal property affecting synaptic distributions, wiring and behaviour, and (2) that stochastic wiring differences affect several behaviours ranging from visual guided responses to circadian activity patterns. Within this framework, I aim to answer two key questions on the origins of individuality:1. Is circuit variability a general nervous system property and what are its origins? 2. Does circuit variability contribute to other visual and non-visual behavioural paradigms?\n","awardDateDateOnly":"2021-04-20","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Brain","Drosophila","Drosophila melanogaster"]}
{"id":"360G-Wellcome-222588_Z_21_Z","title":"Dissecting robustness mechanisms via signalling adaptation and trafficking plasticity during developmental and pathological cell migration","Region":"Greater London","currency":"GBP","awardDate":"2021-04-20T00:00:00+00:00","Sponsor(s)":"Prof Barbara Conradt","Internal ID":"222588/Z/21/Z","description":"Robustness mechanisms are ubiquitous in biological systems where they act to ensure a stable outcome despite intrinsic (genetic) and extrinsic (environmental) variabilities. However, the underlying mechanisms are often unclear. In my proposed research, I will investigate the mechanistic basis of how systems deal with change in the context of cell migration during development, immune responses, and cancer invasion. Cell migration models I will use for my study include: the posterior lateral line primordium (pLLP) migration in development and macrophage recruitment during wound immune response in zebrafish, and invasion of cultured cancer cells.\n\nThe main goals of the proposed original project are: (1) Characterizing the molecular mechanisms and network architectural designs that enable robust adaptation during cell migration in a multicellular organism, (2) Analysing the requirement of regulated membrane trafficking switching during chemotactic adaptation, and (3) Quantitatively defining the role of dynamic buffering in breast cancer spreading.\n\nTo achieve these goals, an interdisciplinary approach will be taken, combining live imaging, genetics, biochemistry and phosphoproteomics. I will generate datasets bridging molecular, cellular, and tissue scales to obtain a systems level understanding of adaptive responses. This work will have broad implications for understanding chemotactic adaptation in development, physiology and disease.\n \n","plannedDates":[{"endDate":"2026-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2026-06-30"}],"amountAwarded":1343501,"Financial Year":"2020/21","Lead Applicant":"Dr Mie Wong","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Wong","Partnership Value":1343501,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Dissecting robustness mechanisms via signalling adaptation and trafficking plasticity during developmental and pathological cell migration Robustness mechanisms are ubiquitous in biological systems where they act to ensure a stable outcome despite intrinsic (genetic) and extrinsic (environmental) variabilities. However, the underlying mechanisms are often unclear. In my proposed research, I will investigate the mechanistic basis of how systems deal with change in the context of cell migration during development, immune responses, and cancer invasion. Cell migration models I will use for my study include: the posterior lateral line primordium (pLLP) migration in development and macrophage recruitment during wound immune response in zebrafish, and invasion of cultured cancer cells.\n\nThe main goals of the proposed original project are: (1) Characterizing the molecular mechanisms and network architectural designs that enable robust adaptation during cell migration in a multicellular organism, (2) Analysing the requirement of regulated membrane trafficking switching during chemotactic adaptation, and (3) Quantitatively defining the role of dynamic buffering in breast cancer spreading.\n\nTo achieve these goals, an interdisciplinary approach will be taken, combining live imaging, genetics, biochemistry and phosphoproteomics. I will generate datasets bridging molecular, cellular, and tissue scales to obtain a systems level understanding of adaptive responses. This work will have broad implications for understanding chemotactic adaptation in development, physiology and disease.\n \n","awardDateDateOnly":"2021-04-20","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Breast Neoplasms","Cell Movement","Chemotaxis","Humans","Macrophages","Proteomics","Zebrafish"]}
{"id":"360G-Wellcome-222583_Z_21_Z","title":"The roles of modern and ancestral visual pathways in the mammalian brain, for defensive behaviours and spatial navigation","Region":"East of England","currency":"GBP","awardDate":"2021-04-20T00:00:00+00:00","Sponsor(s)":"Prof Sarah Bray","Internal ID":"222583/Z/21/Z","description":"In order to survive, animals need to avoid predators and skillfully navigate the environment. These behaviors critically depend on the sense of vision. In mammals, two distinct systems process visual information: the evolutionarily ancient superior colliculus and the modern visual cortex. We will define their relative functions in two natural behaviors essential for survival: (1)innate defensive responses and (2)spatial navigation.\n\n \n\n1)We will study the visual cortex's role in controlling innate defensive behaviors triggered by the superior colliculus. We will focus on the mouse postrhinal-cortex (POR), capitalizing on my discovery that the superior colliculus has, through POR, a dedicated cortical space from which it receives direct excitatory feedback.(Beltramo,Science,2020). We will test the hypothesis that POR, relaying contextual information about the estimated threatening nature of visual stimuli, controls collicular function's plasticity. By silencing distinct cortico-collicular projections, we will determine how the visual cortex shapes the flexibility of colliculus-mediated innate behaviors.\n\n \n\n2)We will investigate the contributions of the two visual pathways in spatial navigation, studying how visual input is transformed into the spatial maps found in the entorhinal/hippocampal formation. Perturbing the activity of distinct visual streams, we will establish how the superior colliculus and visual cortex influence the internal maps that guide navigation.\n\n \n","plannedDates":[{"endDate":"2026-07-14T00:00:00+00:00","startDate":"2021-07-15T00:00:00+00:00","startDateDateOnly":"2021-07-15","endDateDateOnly":"2026-07-14"}],"amountAwarded":1578744,"Financial Year":"2020/21","Lead Applicant":"Dr Riccardo Beltramo","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Beltramo","Partnership Value":1578744,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The roles of modern and ancestral visual pathways in the mammalian brain, for defensive behaviours and spatial navigation In order to survive, animals need to avoid predators and skillfully navigate the environment. These behaviors critically depend on the sense of vision. In mammals, two distinct systems process visual information: the evolutionarily ancient superior colliculus and the modern visual cortex. We will define their relative functions in two natural behaviors essential for survival: (1)innate defensive responses and (2)spatial navigation.\n\n \n\n1)We will study the visual cortex's role in controlling innate defensive behaviors triggered by the superior colliculus. We will focus on the mouse postrhinal-cortex (POR), capitalizing on my discovery that the superior colliculus has, through POR, a dedicated cortical space from which it receives direct excitatory feedback.(Beltramo,Science,2020). We will test the hypothesis that POR, relaying contextual information about the estimated threatening nature of visual stimuli, controls collicular function's plasticity. By silencing distinct cortico-collicular projections, we will determine how the visual cortex shapes the flexibility of colliculus-mediated innate behaviors.\n\n \n\n2)We will investigate the contributions of the two visual pathways in spatial navigation, studying how visual input is transformed into the spatial maps found in the entorhinal/hippocampal formation. Perturbing the activity of distinct visual streams, we will establish how the superior colliculus and visual cortex influence the internal maps that guide navigation.\n\n \n","awardDateDateOnly":"2021-04-20","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Entorhinal Cortex","Male","Mice","Mice, Inbred C57BL","Spatial Navigation","Superior Colliculi","Visual Cortex","Visual Pathways"]}
{"id":"360G-Wellcome-222582_Z_21_Z","title":"Placental epigenetic programming: elucidating a role in cellular identity and transcriptional plasticity","Region":"East of England","currency":"GBP","awardDate":"2021-04-20T00:00:00+00:00","Sponsor(s)":"Prof Kathy Niakan","Internal ID":"222582/Z/21/Z","description":"Pregnancy complications affect as many as one in four pregnancies, yet there remains a critical gap in our knowledge of their underlying aetiologies. As the maternal-foetal interface, the placenta is essential for healthy pregnancy, with poor function being strongly associated with pregnancy complications. However, there is little mechanistic understanding of the molecular events regulating placental development. My research programme will investigate mechanisms of epigenetic programming and gene regulation in early placental trophoblast and reveal how these underpin the development of a functional placenta. Specifically, I will test the hypothesis that epigenetic programming in placental trophoblast is critical for (1) setting up the gene regulatory landscapes in placental cell types and (2) directing appropriate differentiation during placentation. I will apply cutting-edge ultra-low input sequencing methodologies to characterise gene expression, epigenetic marks, transcription factor binding and 3D chromatin folding in multipotent trophoblast cells in mouse embryos. Using single-cell sequencing and histopathology, placental genomic regulation and function will be evaluated in knockout mouse models for epigenetic modifiers, including several histone and DNA methyltransferases. This research will be fundamental to our understanding of placental development and provide novel insights into how errors in epigenetic programming can lead to compromised placental function in pregnancy.\n","plannedDates":[{"endDate":"2026-09-30T00:00:00+00:00","startDate":"2021-10-01T00:00:00+00:00","startDateDateOnly":"2021-10-01","endDateDateOnly":"2026-09-30"}],"amountAwarded":1350129,"Financial Year":"2020/21","Lead Applicant":"Dr Courtney Hanna","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Hanna","Partnership Value":1350129,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Placental epigenetic programming: elucidating a role in cellular identity and transcriptional plasticity Pregnancy complications affect as many as one in four pregnancies, yet there remains a critical gap in our knowledge of their underlying aetiologies. As the maternal-foetal interface, the placenta is essential for healthy pregnancy, with poor function being strongly associated with pregnancy complications. However, there is little mechanistic understanding of the molecular events regulating placental development. My research programme will investigate mechanisms of epigenetic programming and gene regulation in early placental trophoblast and reveal how these underpin the development of a functional placenta. Specifically, I will test the hypothesis that epigenetic programming in placental trophoblast is critical for (1) setting up the gene regulatory landscapes in placental cell types and (2) directing appropriate differentiation during placentation. I will apply cutting-edge ultra-low input sequencing methodologies to characterise gene expression, epigenetic marks, transcription factor binding and 3D chromatin folding in multipotent trophoblast cells in mouse embryos. Using single-cell sequencing and histopathology, placental genomic regulation and function will be evaluated in knockout mouse models for epigenetic modifiers, including several histone and DNA methyltransferases. This research will be fundamental to our understanding of placental development and provide novel insights into how errors in epigenetic programming can lead to compromised placental function in pregnancy.\n","awardDateDateOnly":"2021-04-20","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","DNA Methylation","Epigenesis, Genetic","Female","Gene Expression Regulation, Developmental","Mice","Mice, Knockout","Placenta","Placentation","Pregnancy","Single-Cell Analysis","Trophoblasts"]}
{"id":"360G-Wellcome-222575_Z_21_Z","title":"The mechano-biology of cell division","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2021-04-20T00:00:00+00:00","Sponsor(s)":"Prof Kathryn Ayscough","Internal ID":"222575/Z/21/Z","description":"Cell division in epithelial sheets is crucial for tissue renewal, yet unchecked division leads to tissue dysplasia and ultimately cancer. The aim of this project is to discover how cell division is regulated in normal epithelial tissue and how it is perturbed by oncogenic mutations to disrupt tissue integrity. In previous work, I showed how activation of an oncogene, Ras, directly impacts cell division by controlling the shape, contractility and mechanics of single mitotic cells. I now ask how this finding plays out in a complex tissue environment. To do this, I will employ a multi-disciplinary approach, combining imaging and quantitative cell biology with biophysical techniques to study cell division mechanics in normal epithelial monolayers and Ras-mutant pancreatic cancer tumoroids. I will ask how the actin cytoskeleton is regulated during epithelial cell division to permit dynamic cell shape changes while maintaining cell-cell adhesion and preserving barrier function. I will determine how k-Ras activation perturbs this, identifying key mechanistic links between Ras/ERK-dependent transcription and morphological phenotypes. Finally, I will address how these Ras-induced changes to cell division alter the growth and organization of 3D tissue structures in pancreatic cancer.\n","plannedDates":[{"endDate":"2026-10-31T00:00:00+00:00","startDate":"2021-11-01T00:00:00+00:00","startDateDateOnly":"2021-11-01","endDateDateOnly":"2026-10-31"}],"amountAwarded":1029715,"Financial Year":"2020/21","Lead Applicant":"Dr Helen Matthews","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Matthews","Partnership Value":1029715,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield","addressCountry":"United Kingdom","id_and_name":"[\"University of Sheffield\", \"360G-Wellcome-ORG:University-of-Sheffield\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The mechano-biology of cell division Cell division in epithelial sheets is crucial for tissue renewal, yet unchecked division leads to tissue dysplasia and ultimately cancer. The aim of this project is to discover how cell division is regulated in normal epithelial tissue and how it is perturbed by oncogenic mutations to disrupt tissue integrity. In previous work, I showed how activation of an oncogene, Ras, directly impacts cell division by controlling the shape, contractility and mechanics of single mitotic cells. I now ask how this finding plays out in a complex tissue environment. To do this, I will employ a multi-disciplinary approach, combining imaging and quantitative cell biology with biophysical techniques to study cell division mechanics in normal epithelial monolayers and Ras-mutant pancreatic cancer tumoroids. I will ask how the actin cytoskeleton is regulated during epithelial cell division to permit dynamic cell shape changes while maintaining cell-cell adhesion and preserving barrier function. I will determine how k-Ras activation perturbs this, identifying key mechanistic links between Ras/ERK-dependent transcription and morphological phenotypes. Finally, I will address how these Ras-induced changes to cell division alter the growth and organization of 3D tissue structures in pancreatic cancer.\n","awardDateDateOnly":"2021-04-20","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cell Division","Epithelial Cells","Humans","Mutation","Pancreatic Neoplasms","Proto-Oncogene Proteins p21(ras)","ras Proteins"]}
{"id":"360G-Wellcome-222574_Z_21_Z","title":"National COVID Testing Africa AAPs/Centre","Region":"South East","currency":"GBP","awardDate":"2021-01-29T00:00:00+00:00","Internal ID":"222574/Z/21/Z","description":"Aims and key deliverables;\n\n\n To provide consistent technical support to national testing programmes for SARS-CoV-2 in Kenya, Malawi and South Africa.\n To support epidemiological research, clinical trials, immunological studies and genomics work\n To consolidate and maintain positive relationships with national policy makers.\n\n\nOur respective Wellcome AAPs/Centre (i.e. MLW, KEMRI-Wellcome, AHRI and CIDRI-Africa) have responded to the COVID-19 pandemic by making resources and staff available for SARS-CoV-2 testing, accounting currently for significant proportions of the local and/or national testing capacities, especially during surges.  It is ethically imperative to provide national support alongside research-driven testing, and we have found this testing provided an opportunity to develop stronger relationships with national Government, with the potential for research that is better aligned to informing policy and with a better position to communicate.  The immediate need has been covered by re-allocating resources for paused activities.  The proposal here will bridge the gap between our immediate response and more sustainable long-term funding. This will allow us to sustain the enhanced relationships developed through our response to the pandemic, and will avoid the reputational risks that might be associated with failing to support the obvious ongoing need while establishing more sustainable long-term projects and core provisions.\n","plannedDates":[{"endDate":"2022-04-21T00:00:00+00:00","startDate":"2021-02-17T00:00:00+00:00","startDateDateOnly":"2021-02-17","endDateDateOnly":"2022-04-21"}],"amountAwarded":773978,"Financial Year":"2020/21","Lead Applicant":"Prof Philip Bejon","grantProgramme":[{"title":"Coronavirus","title_keyword":"Coronavirus"}],"Applicant Surname":"Bejon","Partnership Value":773978,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Prof Willem Hanekom, Dr Lynette Oyier, Honorary Professor Robert Wilkinson, Prof Stephen Gordon","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"National COVID Testing Africa AAPs/Centre Aims and key deliverables;\n\n\n To provide consistent technical support to national testing programmes for SARS-CoV-2 in Kenya, Malawi and South Africa.\n To support epidemiological research, clinical trials, immunological studies and genomics work\n To consolidate and maintain positive relationships with national policy makers.\n\n\nOur respective Wellcome AAPs/Centre (i.e. MLW, KEMRI-Wellcome, AHRI and CIDRI-Africa) have responded to the COVID-19 pandemic by making resources and staff available for SARS-CoV-2 testing, accounting currently for significant proportions of the local and/or national testing capacities, especially during surges.  It is ethically imperative to provide national support alongside research-driven testing, and we have found this testing provided an opportunity to develop stronger relationships with national Government, with the potential for research that is better aligned to informing policy and with a better position to communicate.  The immediate need has been covered by re-allocating resources for paused activities.  The proposal here will bridge the gap between our immediate response and more sustainable long-term funding. This will allow us to sustain the enhanced relationships developed through our response to the pandemic, and will avoid the reputational risks that might be associated with failing to support the obvious ongoing need while establishing more sustainable long-term projects and core provisions.\n","awardDateDateOnly":"2021-01-29","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Kenya","Malawi","South Africa"]}
{"id":"360G-Wellcome-222573_Z_21_Z","title":"Dissecting the molecular basis of single gene choice in African trypanosomes","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2021-04-20T00:00:00+00:00","Sponsor(s)":"Prof James Moir","Internal ID":"222573/Z/21/Z","description":"     Several pathogens, such as African trypanosomes or malaria parasites, undergo antigenic variation in order to evade the host immune response. A key feature for successful antigenic variation is the ability to express a single antigen at a time, in other words monogenic-expression. Trypanosomes express a single variant-surface-glycoprotein (VSG) from thousands of possible genes, a fine example of extreme biology.\n\n     Single gene choice remains one of the biggest mysteries of eukaryotic gene expression and the machinery responsible remained elusive in every organism. I recently identified a protein complex that sustains VSG-monogenic expression and is responsible for the spatial integration of the single active-VSG with an RNA-processing centre. I will study the function of this novel protein complex, identify other relevant factors and use VSGs as a model-system to study how nuclear compartments can be organised to enhance gene expression. To pursue these questions, I will apply a wide range of genetic and biochemical approaches that include proximity labelling coupled with mass-spectrometry, next-generation-sequencing, CryoEM, super-resolution and live microscopy.\n\n     The mechanistic understanding of how monogenic-expression is initiated and maintained is of great value as it is critical for sustaining infections by trypanosomes, as well as several other pathogens that undergo antigenic variation.\n","plannedDates":[{"endDate":"2026-12-31T00:00:00+00:00","startDate":"2022-01-01T00:00:00+00:00","startDateDateOnly":"2022-01-01","endDateDateOnly":"2026-12-31"}],"amountAwarded":1036024,"Financial Year":"2020/21","Lead Applicant":"Dr Joana Faria","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Faria","Partnership Value":1036024,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-York","name":"University of York","addressCountry":"United Kingdom","id_and_name":"[\"University of York\", \"360G-Wellcome-ORG:University-of-York\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-York","name":"University of York"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Dissecting the molecular basis of single gene choice in African trypanosomes      Several pathogens, such as African trypanosomes or malaria parasites, undergo antigenic variation in order to evade the host immune response. A key feature for successful antigenic variation is the ability to express a single antigen at a time, in other words monogenic-expression. Trypanosomes express a single variant-surface-glycoprotein (VSG) from thousands of possible genes, a fine example of extreme biology.\n\n     Single gene choice remains one of the biggest mysteries of eukaryotic gene expression and the machinery responsible remained elusive in every organism. I recently identified a protein complex that sustains VSG-monogenic expression and is responsible for the spatial integration of the single active-VSG with an RNA-processing centre. I will study the function of this novel protein complex, identify other relevant factors and use VSGs as a model-system to study how nuclear compartments can be organised to enhance gene expression. To pursue these questions, I will apply a wide range of genetic and biochemical approaches that include proximity labelling coupled with mass-spectrometry, next-generation-sequencing, CryoEM, super-resolution and live microscopy.\n\n     The mechanistic understanding of how monogenic-expression is initiated and maintained is of great value as it is critical for sustaining infections by trypanosomes, as well as several other pathogens that undergo antigenic variation.\n","awardDateDateOnly":"2021-04-20","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Glycoproteins","Mass Spectrometry","Protozoan Proteins","Trypanosoma brucei brucei"]}
{"id":"360G-Wellcome-222567_Z_21_Z","title":"Understanding the role of myosin super relaxation in cardiac health and disease","Region":"South East","currency":"GBP","awardDate":"2021-04-20T00:00:00+00:00","Sponsor(s)":"Prof Hugh Watkins","Internal ID":"222567/Z/21/Z","description":"A novel energy conserving mechanism, myosin super relaxation (SRX) has recently been discovered in cardiac muscle. SRX is a structural state of myosin, where myosin heads are folded away from actin, preventing force producing actomyosin interactions and contraction.\n\nLittle is known about the key regulatory systems that govern the formation of myosin SRX in cardiac biology. It is evident that phosphorylation of key sarcomeric proteins play an important role, but the cellular signalling that underlies these changes is poorly defined.\n\nI aim to define these cellular signalling pathways and how they control sarcomeric protein phosphorylation. I will define how far reaching myosin SRX destabilisation is as a disease causing mechanism. To do this I will employ CRISPR/Cas-9 technologies to develop stem cell models of hypertrophic cardiomyopathy, HCM, a debilitating genetic condition that affects 1 in 500 people. I will augment these human stem cell models with human and murine tissue samples to define SRX abundance and regulation in acquired cardiovascular conditions including atrial fibrillation, heart failure, hypertension, myocardial infarction, and ageing.\n\nIn doing so I will define sub-sets of disease pathomechanisms in inherited and acquired cardiomyopathies to allow precision targeting of therapeutics, which will bring significant benefit to patients.\n","plannedDates":[{"endDate":"2026-12-01T00:00:00+00:00","startDate":"2021-12-02T00:00:00+00:00","startDateDateOnly":"2021-12-02","endDateDateOnly":"2026-12-01"}],"amountAwarded":1056320,"Financial Year":"2020/21","Lead Applicant":"Dr Christopher Toepfer","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Toepfer","Partnership Value":1056320,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding the role of myosin super relaxation in cardiac health and disease A novel energy conserving mechanism, myosin super relaxation (SRX) has recently been discovered in cardiac muscle. SRX is a structural state of myosin, where myosin heads are folded away from actin, preventing force producing actomyosin interactions and contraction.\n\nLittle is known about the key regulatory systems that govern the formation of myosin SRX in cardiac biology. It is evident that phosphorylation of key sarcomeric proteins play an important role, but the cellular signalling that underlies these changes is poorly defined.\n\nI aim to define these cellular signalling pathways and how they control sarcomeric protein phosphorylation. I will define how far reaching myosin SRX destabilisation is as a disease causing mechanism. To do this I will employ CRISPR/Cas-9 technologies to develop stem cell models of hypertrophic cardiomyopathy, HCM, a debilitating genetic condition that affects 1 in 500 people. I will augment these human stem cell models with human and murine tissue samples to define SRX abundance and regulation in acquired cardiovascular conditions including atrial fibrillation, heart failure, hypertension, myocardial infarction, and ageing.\n\nIn doing so I will define sub-sets of disease pathomechanisms in inherited and acquired cardiomyopathies to allow precision targeting of therapeutics, which will bring significant benefit to patients.\n","awardDateDateOnly":"2021-04-20","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cardiomyopathy, Hypertrophic","Humans","Mice","Sarcomeres"]}
{"id":"360G-Wellcome-222566_Z_21_Z","title":"Healthy, sustainable and equitable: Integrating knowledge on food choice to optimise interventions","Region":"South East","currency":"GBP","awardDate":"2021-04-20T00:00:00+00:00","Sponsor(s)":"Prof Richard Hobbs","Internal ID":"222566/Z/21/Z","description":"Changing diets could lead to substantial benefits both in terms of health and environmental impact, with the urgent need to change food consumption being increasingly recognised. Drawing on evidence from interventions targeting unhealthy diets could accelerate progress towards more sustainable diets by quickly narrowing down the choice of interventions to improve food selections. However, we need to ascertain whether key differences between healthier vs. more sustainable foods (including social norms, preferences and knowledge) impact on intervention effectiveness, and/or contribute to inequalities in responsiveness to these interventions.\n\nThis programme of work will examine differences in the impact of interventions targeting (a) healthier vs. less healthy foods and (b) more vs. less sustainable foods, and whether impact differs by socioeconomic position (SEP). It will identify key moderators and mediators of the impact of interventions, and the extent to which these contribute to any differential impact by intervention target or SEP.\n\nThe programme comprises (1) a conceptual review; (2) experimental studies; (3) field studies in worksite cafeterias and in stores; (4) secondary analyses of purchasing data (e.g. from supermarkets). Identifying the moderators and mediators of dietary interventions will help prioritise the most promising interventions for sustainable and equitable diets.\n","plannedDates":[{"endDate":"2027-11-30T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2027-11-30"}],"amountAwarded":917024,"Financial Year":"2020/21","Lead Applicant":"Dr Rachel Pechey","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Pechey","Partnership Value":917024,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Healthy, sustainable and equitable: Integrating knowledge on food choice to optimise interventions Changing diets could lead to substantial benefits both in terms of health and environmental impact, with the urgent need to change food consumption being increasingly recognised. Drawing on evidence from interventions targeting unhealthy diets could accelerate progress towards more sustainable diets by quickly narrowing down the choice of interventions to improve food selections. However, we need to ascertain whether key differences between healthier vs. more sustainable foods (including social norms, preferences and knowledge) impact on intervention effectiveness, and/or contribute to inequalities in responsiveness to these interventions.\n\nThis programme of work will examine differences in the impact of interventions targeting (a) healthier vs. less healthy foods and (b) more vs. less sustainable foods, and whether impact differs by socioeconomic position (SEP). It will identify key moderators and mediators of the impact of interventions, and the extent to which these contribute to any differential impact by intervention target or SEP.\n\nThe programme comprises (1) a conceptual review; (2) experimental studies; (3) field studies in worksite cafeterias and in stores; (4) secondary analyses of purchasing data (e.g. from supermarkets). Identifying the moderators and mediators of dietary interventions will help prioritise the most promising interventions for sustainable and equitable diets.\n","awardDateDateOnly":"2021-04-20","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Diet","Diet, Healthy","Health Behavior","Health Promotion","Humans","Social Norms","Socioeconomic Factors"]}
{"id":"360G-Wellcome-222551_Z_21_Z","title":"Transmissible cancer evolution and host interaction","Region":"East of England","currency":"GBP","awardDate":"2021-04-13T00:00:00+00:00","Internal ID":"222551/Z/21/Z","description":"Transmissible cancers are malignant somatic cell lineages that spread between individuals by the allogeneic transfer of living cancer cells. These cancers, whose three known instances in mammals affect dogs and Tasmanian devils, provide a unique perspective on cancer evolution and host interaction. I will investigate this by deeply sequencing whole genomes from 1100 tumours selected from across each cancer\u2019s range, together with matched bulk RNA sequencing and targeted single-cell RNA sequencing. Time-resolved phylogenetic trees for each clone will be annotated with mutation and gene expression data, and the source and consequence of mutation explored. Host cell contribution to the tumour microenvironment, and its variation across hundreds of tumours, will be assessed using allelic and cell-type deconvolution. Combining genetic, microenvironment composition and clinical data, I will explain how the immunological interface between allogeneic cancer and host varies between individuals, and how this interaction controls the outcome of disease. The inherent heterogeneity and short lifespans of most cancers may obscure their underlying biological patterns. By capturing variation in hundreds of clonally derived tumours inhabiting different hosts, I seek to deeply probe the mutational, evolutionary and immunological principles of cancer.\n","plannedDates":[{"endDate":"2028-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2028-08-31"}],"amountAwarded":1660717,"Financial Year":"2020/21","Lead Applicant":"Prof Elizabeth Murchison","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Murchison","Partnership Value":1660717,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Transmissible cancer evolution and host interaction Transmissible cancers are malignant somatic cell lineages that spread between individuals by the allogeneic transfer of living cancer cells. These cancers, whose three known instances in mammals affect dogs and Tasmanian devils, provide a unique perspective on cancer evolution and host interaction. I will investigate this by deeply sequencing whole genomes from 1100 tumours selected from across each cancer\u2019s range, together with matched bulk RNA sequencing and targeted single-cell RNA sequencing. Time-resolved phylogenetic trees for each clone will be annotated with mutation and gene expression data, and the source and consequence of mutation explored. Host cell contribution to the tumour microenvironment, and its variation across hundreds of tumours, will be assessed using allelic and cell-type deconvolution. Combining genetic, microenvironment composition and clinical data, I will explain how the immunological interface between allogeneic cancer and host varies between individuals, and how this interaction controls the outcome of disease. The inherent heterogeneity and short lifespans of most cancers may obscure their underlying biological patterns. By capturing variation in hundreds of clonally derived tumours inhabiting different hosts, I seek to deeply probe the mutational, evolutionary and immunological principles of cancer.\n","awardDateDateOnly":"2021-04-13","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Dogs","Evolution, Molecular","Humans","Mutation","Neoplasms","Phylogeny","Sequence Analysis, RNA","Single-Cell Analysis","Tumor Microenvironment"]}
{"id":"360G-Wellcome-222551_A_21_Z","title":"Transmissible cancer evolution and host interaction","Region":"East of England","currency":"GBP","awardDate":"2021-04-13T00:00:00+00:00","Internal ID":"222551/A/21/Z","description":"Transmissible cancers are malignant somatic cell lineages that spread between individuals by the allogeneic transfer of living cancer cells. These cancers, whose three known instances in mammals affect dogs and Tasmanian devils, provide a unique perspective on cancer evolution and host interaction. I will investigate this by deeply sequencing whole genomes from 1100 tumours selected from across each cancer\u2019s range, together with matched bulk RNA sequencing and targeted single-cell RNA sequencing. Time-resolved phylogenetic trees for each clone will be annotated with mutation and gene expression data, and the source and consequence of mutation explored. Host cell contribution to the tumour microenvironment, and its variation across hundreds of tumours, will be assessed using allelic and cell-type deconvolution. Combining genetic, microenvironment composition and clinical data, I will explain how the immunological interface between allogeneic cancer and host varies between individuals, and how this interaction controls the outcome of disease. The inherent heterogeneity and short lifespans of most cancers may obscure their underlying biological patterns. By capturing variation in hundreds of clonally derived tumours inhabiting different hosts, I seek to deeply probe the mutational, evolutionary and immunological principles of cancer.\n","plannedDates":[{"endDate":"2028-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2028-08-31"}],"amountAwarded":1422364,"Financial Year":"2020/21","Lead Applicant":"Prof Sir Michael Stratton","grantProgramme":[{"title":"Sanger Resource Collaboration","title_keyword":"Sanger Resource Collaboration"}],"Applicant Surname":"Stratton","Partnership Value":1422364,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Wellcome-Trust-Sanger-Institute","name":"Wellcome Trust Sanger Institute","addressCountry":"United Kingdom","id_and_name":"[\"Wellcome Trust Sanger Institute\", \"360G-Wellcome-ORG:Wellcome-Trust-Sanger-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Wellcome-Trust-Sanger-Institute","name":"Wellcome Trust Sanger Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Transmissible cancer evolution and host interaction Transmissible cancers are malignant somatic cell lineages that spread between individuals by the allogeneic transfer of living cancer cells. These cancers, whose three known instances in mammals affect dogs and Tasmanian devils, provide a unique perspective on cancer evolution and host interaction. I will investigate this by deeply sequencing whole genomes from 1100 tumours selected from across each cancer\u2019s range, together with matched bulk RNA sequencing and targeted single-cell RNA sequencing. Time-resolved phylogenetic trees for each clone will be annotated with mutation and gene expression data, and the source and consequence of mutation explored. Host cell contribution to the tumour microenvironment, and its variation across hundreds of tumours, will be assessed using allelic and cell-type deconvolution. Combining genetic, microenvironment composition and clinical data, I will explain how the immunological interface between allogeneic cancer and host varies between individuals, and how this interaction controls the outcome of disease. The inherent heterogeneity and short lifespans of most cancers may obscure their underlying biological patterns. By capturing variation in hundreds of clonally derived tumours inhabiting different hosts, I seek to deeply probe the mutational, evolutionary and immunological principles of cancer.\n","awardDateDateOnly":"2021-04-13","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Dogs","Evolution, Molecular","Humans","Mutation","Neoplasms","Phylogeny","Sequence Analysis, RNA","Single-Cell Analysis","Tumor Microenvironment"]}
{"id":"360G-Wellcome-222548_Z_21_Z","title":"Differential immune transcription in health and disease","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222548/Z/21/Z","description":"In immune conditions such as sepsis, treatment options can be limited by a lack of understanding of the causes of the condition, as well as the vast differences in how the immune system of the patient can respond. While expression differences between genes explain some of the variance between patient outcomes, there is still a lot of variability unaccounted for, and how this relates to the genome remains to be studied. RNA sequencing performed on samples from large existing cohorts of patients will give transcript level information, revealing not only the expression levels but also information such as how the genes are differentially spliced between individuals. With paired medical records I will relate these observed transcript differences with patient outcomes, as well as infer how innate genotypes can modulate these effects. Provided microbiological information on the cause of the condition or infection will allow me to also understand the differences in human responses to infection type. This knowledge will lead to a more personalised treatment regime for patients based on the course of their illness and innate characteristics, as well as giving the option to better predict and address the cause of their illness.\n \n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Alexander Tokolyi","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Tokolyi","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Differential immune transcription in health and disease In immune conditions such as sepsis, treatment options can be limited by a lack of understanding of the causes of the condition, as well as the vast differences in how the immune system of the patient can respond. While expression differences between genes explain some of the variance between patient outcomes, there is still a lot of variability unaccounted for, and how this relates to the genome remains to be studied. RNA sequencing performed on samples from large existing cohorts of patients will give transcript level information, revealing not only the expression levels but also information such as how the genes are differentially spliced between individuals. With paired medical records I will relate these observed transcript differences with patient outcomes, as well as infer how innate genotypes can modulate these effects. Provided microbiological information on the cause of the condition or infection will allow me to also understand the differences in human responses to infection type. This knowledge will lead to a more personalised treatment regime for patients based on the course of their illness and innate characteristics, as well as giving the option to better predict and address the cause of their illness.\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Gene Expression Profiling","Genotype","Humans","Immunity, Innate"]}
{"id":"360G-Wellcome-222547_Z_21_Z","title":"Beyond GWAS: Exploring complex disease with WGS and scRNA-seq","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222547/Z/21/Z","description":"Inflammatory bowel disease (IBD) is a disease of the gut affecting over 2.5 million people in Europe alone. Through genome-wide association studies, over 240 genomic regions have been identified as significantly associated with the disease or its two subtypes: Crohn\u2019s disease and ulcerative colitis (1,2). However the mutations, genes and cell-types that drive disease progression, are still unknown and for many patients, IBD remains incredibly difficult to treat. The Anderson group has undertaken two distinct, large-scale projects in an effort to fill in many of the gaps in existing knowledge. Firstly, whole genome and exome sequencing of large cohorts of healthy and diseased individuals is being undertaken to better understand the disease-associated regions. During my PhD I will use this data to examine the effect that deletions, insertions and inversions of large chunks of DNA can have on IBD. The second major ongoing project is single-cell sequencing of terminal ileum, rectal and blood samples taken from healthy individuals and patients with Crohn's disease. In the second half of my PhD project, I will use the single-cell data to determine the genes, pathways and cells involved in Crohn\u2019s disease.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Oluwatobi Alegbe","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Alegbe","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Beyond GWAS: Exploring complex disease with WGS and scRNA-seq Inflammatory bowel disease (IBD) is a disease of the gut affecting over 2.5 million people in Europe alone. Through genome-wide association studies, over 240 genomic regions have been identified as significantly associated with the disease or its two subtypes: Crohn\u2019s disease and ulcerative colitis (1,2). However the mutations, genes and cell-types that drive disease progression, are still unknown and for many patients, IBD remains incredibly difficult to treat. The Anderson group has undertaken two distinct, large-scale projects in an effort to fill in many of the gaps in existing knowledge. Firstly, whole genome and exome sequencing of large cohorts of healthy and diseased individuals is being undertaken to better understand the disease-associated regions. During my PhD I will use this data to examine the effect that deletions, insertions and inversions of large chunks of DNA can have on IBD. The second major ongoing project is single-cell sequencing of terminal ileum, rectal and blood samples taken from healthy individuals and patients with Crohn's disease. In the second half of my PhD project, I will use the single-cell data to determine the genes, pathways and cells involved in Crohn\u2019s disease.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Crohn Disease","Genome-Wide Association Study","Humans","Inflammatory Bowel Diseases","Single-Cell Analysis","Whole Exome Sequencing"]}
{"id":"360G-Wellcome-222545_Z_21_Z","title":"Four-Year PhD Studentship in Basic Science  UNS118254","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222545/Z/21/Z","description":"Metabolic health depends on a myriad of genes and the environment. Variation in these genes across individuals can predispose them to obesity, Type II Diabetes (T2D) and other metabolic syndromes. Early works focused on how a few mutated genes could cause rare and severe metabolic diseases. A lot has been learnt about appetite and weight regulation by studying those genes whose mutations have large impact on metabolic health. However, common forms of obesity and T2D are attributed to multiple genetic variations, whose individual effects are hard to observe. We aim to understand how these mutations with little observable impacts affect our metabolic health. We hope to gain more insights into the fundamental genetics of metabolism from these rare mutations by combining data-driven epidemiological methods and molecular biology techniques. Epidemiological methods will statistically identify how the presence of some mutated genes correlate with alterations in metabolic health. Then, using molecular biology techniques, we will investigate the causations and mechanisms of these statistical correlations. To this end, we will clone the mutated genes in cellular models and measure the changes in their activities.\n","plannedDates":[{"endDate":"2024-04-06T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2024-04-06"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Dr Xiaoming Liu","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Liu","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Four-Year PhD Studentship in Basic Science  UNS118254 Metabolic health depends on a myriad of genes and the environment. Variation in these genes across individuals can predispose them to obesity, Type II Diabetes (T2D) and other metabolic syndromes. Early works focused on how a few mutated genes could cause rare and severe metabolic diseases. A lot has been learnt about appetite and weight regulation by studying those genes whose mutations have large impact on metabolic health. However, common forms of obesity and T2D are attributed to multiple genetic variations, whose individual effects are hard to observe. We aim to understand how these mutations with little observable impacts affect our metabolic health. We hope to gain more insights into the fundamental genetics of metabolism from these rare mutations by combining data-driven epidemiological methods and molecular biology techniques. Epidemiological methods will statistically identify how the presence of some mutated genes correlate with alterations in metabolic health. Then, using molecular biology techniques, we will investigate the causations and mechanisms of these statistical correlations. To this end, we will clone the mutated genes in cellular models and measure the changes in their activities.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Diabetes Mellitus, Type 2","Humans","Mutation","Obesity","Students"]}
{"id":"360G-Wellcome-222544_Z_21_Z","title":"Mechanisms and regulation of PEPITEM secretion","Region":"West Midlands","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222544/Z/21/Z","description":"The migration of immune cells such as T-lymphocytes to areas of inflammation plays an important role in the inflammatory response. T-lymphocyte migration follows a circadian (daily) rhythm, with more T-lymphocytes migrating into tissues in the morning than the evening. If this process is not carefully regulated, this can lead to an exaggerated inflammatory response which contributes to diseases. PEPITEM is a small peptide hormone which inhibits T-lymphocyte migration and is made by another type of immune cells, B-lymphocytes. Patients with inflammatory diseases cannot make PEPITEM in sufficient quantities to control T-lymphocyte migration. Our preliminary studies indicate that a protein able to cleave other proteins (protease) is responsible for PEPITEM release from B-lymphocytes and that this might be under circadian control. In my project, I aim to identify the protease that leads to PEPITEM release, and investigate how the PEPITEM pathway follows circadian oscillations. I will look at the expression of genes and proteins involved in the PEPITEM pathway at different time of the day to see how this pathway is regulated by circadian rhythms. This project will help to understand the dysregulation of inflammation that occurs in many chronic inflammatory diseases.\n","plannedDates":[{"endDate":"2023-10-04T00:00:00+00:00","startDate":"2020-10-05T00:00:00+00:00","startDateDateOnly":"2020-10-05","endDateDateOnly":"2023-10-04"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Poppy Nathan","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Nathan","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Birmingham\", \"360G-Wellcome-ORG:University-of-Birmingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mechanisms and regulation of PEPITEM secretion The migration of immune cells such as T-lymphocytes to areas of inflammation plays an important role in the inflammatory response. T-lymphocyte migration follows a circadian (daily) rhythm, with more T-lymphocytes migrating into tissues in the morning than the evening. If this process is not carefully regulated, this can lead to an exaggerated inflammatory response which contributes to diseases. PEPITEM is a small peptide hormone which inhibits T-lymphocyte migration and is made by another type of immune cells, B-lymphocytes. Patients with inflammatory diseases cannot make PEPITEM in sufficient quantities to control T-lymphocyte migration. Our preliminary studies indicate that a protein able to cleave other proteins (protease) is responsible for PEPITEM release from B-lymphocytes and that this might be under circadian control. In my project, I aim to identify the protease that leads to PEPITEM release, and investigate how the PEPITEM pathway follows circadian oscillations. I will look at the expression of genes and proteins involved in the PEPITEM pathway at different time of the day to see how this pathway is regulated by circadian rhythms. This project will help to understand the dysregulation of inflammation that occurs in many chronic inflammatory diseases.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["B-Lymphocytes","Cell Movement","Circadian Clocks","Circadian Rhythm","Humans","Inflammation","T-Lymphocytes"]}
{"id":"360G-Wellcome-222543_Z_21_Z","title":"Climate, Health and Behaviour \u2013 A One Year Research and Development Grant.","Region":"Greater London","currency":"GBP","awardDate":"2020-11-30T00:00:00+00:00","Internal ID":"222543/Z/21/Z","description":"Not available","plannedDates":[{"endDate":"2022-04-30T00:00:00+00:00","startDate":"2021-05-01T00:00:00+00:00","startDateDateOnly":"2021-05-01","endDateDateOnly":"2022-04-30"}],"amountAwarded":249100,"Financial Year":"2020/21","Lead Applicant":"Mr Brad Irwin","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Irwin","Partnership Value":249100,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Mx Harry Cutmore, Ms Camilla Tham","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Natural-History-Museum","name":"Natural History Museum","addressCountry":"United Kingdom","id_and_name":"[\"Natural History Museum\", \"360G-Wellcome-ORG:Natural-History-Museum\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Natural-History-Museum","name":"Natural History Museum"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Climate, Health and Behaviour \u2013 A One Year Research and Development Grant. Not available","awardDateDateOnly":"2020-11-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Climate Change","Humans","Research"]}
{"id":"360G-Wellcome-222541_Z_21_Z","title":"A Multifunctional Genetic Probe for Networking Lysosomal Calcium Biology","Region":"North West","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222541/Z/21/Z","description":"The lysosome, once thought to be a cellular \u2018trash-can\u2019, is now found to be the key to understanding the signalling controlling human ageing, neurodegeneration, and a range of diseases from diabetes to cancer. Developing tools to understand how the lysosome works will be key to future biological studies.\n\nIn this project, we will develop and analyse a new imaging probe which will allow us to examine calcium signalling in functional lysosomes in live-imaging, proteomic and lipidomic modalities to develop a fine-grained understanding of how lysosomes function in health and disease.\n\nThe genetic probe we are developing makes it easy to isolate, image, and manipulate lysosomes in living cells and in cellular extracts using one transfectable tool, offering many avenues of application to basic and industry-focused research. One key regulator of lysosomal calcium storage is the messenger NAADP, which we will examine in detail. We will produce coordinated maps of the behaviour of calcium levels inside the lysosome under conditions known to alter NAADP signalling, coupled with the metabolic and proteomic profiles of lysosomes in the same conditions and in mutants of the muscular dystrophy gene INPP5K: giving a comprehensive map of the regulation of this key signalling axis.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Izaak Cheetham-Wilkinson","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Cheetham-Wilkinson","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool","addressCountry":"United Kingdom","id_and_name":"[\"University of Liverpool\", \"360G-Wellcome-ORG:University-of-Liverpool\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A Multifunctional Genetic Probe for Networking Lysosomal Calcium Biology The lysosome, once thought to be a cellular \u2018trash-can\u2019, is now found to be the key to understanding the signalling controlling human ageing, neurodegeneration, and a range of diseases from diabetes to cancer. Developing tools to understand how the lysosome works will be key to future biological studies.\n\nIn this project, we will develop and analyse a new imaging probe which will allow us to examine calcium signalling in functional lysosomes in live-imaging, proteomic and lipidomic modalities to develop a fine-grained understanding of how lysosomes function in health and disease.\n\nThe genetic probe we are developing makes it easy to isolate, image, and manipulate lysosomes in living cells and in cellular extracts using one transfectable tool, offering many avenues of application to basic and industry-focused research. One key regulator of lysosomal calcium storage is the messenger NAADP, which we will examine in detail. We will produce coordinated maps of the behaviour of calcium levels inside the lysosome under conditions known to alter NAADP signalling, coupled with the metabolic and proteomic profiles of lysosomes in the same conditions and in mutants of the muscular dystrophy gene INPP5K: giving a comprehensive map of the regulation of this key signalling axis.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Calcium","Humans","Lysosomes","Proteomics","Signal Transduction"]}
{"id":"360G-Wellcome-222540_Z_21_Z","title":"Characterisation and modulation of CTLA-4 trafficking: Focus on reversible ubiquitylation ","Region":"North West","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222540/Z/21/Z","description":"Cancer immunotherapy harnesses the potency of the immune system to reinvigorate anti-tumour effects. CTLA-4 is a protein that acts as a brake on the immune system; blocking CTLA-4 can disengage the brake on immune cells, thereby freeing our immune system to attack tumours.  Although therapies entailing a CTLA-4 blockade has led to promising results, they have yet to achieve their full clinical potential. To improve CTLA-4-targeting treatment, a thorough understanding of CTLA-4 function at the cell biology level is essential. Modulating the number of CTLA-4 present on the surface of immune cells is an emerging therapeutic strategy in cancer immunotherapy. Generally, protein levels at the cell surface are controlled by two major events: protein internalisation and transport to the cell surface. Very often, internalised proteins that will be degraded by the cell\u2019s \"garbage disposal system\" are temporarily tagged by ubiquitin, which will later be removed by an enzyme. Here, we aim to explore how CTLA-4 traffics in the immune cells by 1) identifying the key proteins that regulate CTLA-4 levels on the cell surface and 2) characterising the enzymes that control CTLA-4 degradation using state-of-the-art screening approaches.\n \n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Pei Yee Tey","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Tey","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool","addressCountry":"United Kingdom","id_and_name":"[\"University of Liverpool\", \"360G-Wellcome-ORG:University-of-Liverpool\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Characterisation and modulation of CTLA-4 trafficking: Focus on reversible ubiquitylation  Cancer immunotherapy harnesses the potency of the immune system to reinvigorate anti-tumour effects. CTLA-4 is a protein that acts as a brake on the immune system; blocking CTLA-4 can disengage the brake on immune cells, thereby freeing our immune system to attack tumours.  Although therapies entailing a CTLA-4 blockade has led to promising results, they have yet to achieve their full clinical potential. To improve CTLA-4-targeting treatment, a thorough understanding of CTLA-4 function at the cell biology level is essential. Modulating the number of CTLA-4 present on the surface of immune cells is an emerging therapeutic strategy in cancer immunotherapy. Generally, protein levels at the cell surface are controlled by two major events: protein internalisation and transport to the cell surface. Very often, internalised proteins that will be degraded by the cell\u2019s \"garbage disposal system\" are temporarily tagged by ubiquitin, which will later be removed by an enzyme. Here, we aim to explore how CTLA-4 traffics in the immune cells by 1) identifying the key proteins that regulate CTLA-4 levels on the cell surface and 2) characterising the enzymes that control CTLA-4 degradation using state-of-the-art screening approaches.\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["CTLA-4 Antigen","Humans","Immunotherapy","Neoplasms"]}
{"id":"360G-Wellcome-222539_Z_21_Z","title":"Decoding the enigma of PhosphoUbiquitin and PINK1","Region":"North West","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222539/Z/21/Z","description":"Mitochondria are organelles within cells which are responsible for energy production. High energy demands or cellular stress can result to dysfunctional mitochondria. When mitochondria become damaged, they should be removed, in order to keep cells healthy. Cells have complicated mechanisms for recognizing and successfully destroying damaged mitochondria, as well as other dysfunctional organelles and proteins. The aggregation of dysfunctional organelles or proteins is the hallmark of many neurodegenerative diseases. A main degradation system in cells is autophagy, which essentially means self-eating, during which the damaged cellular components are isolated in a vesicle to be broken down. The autophagy of mitochondria is called mitophagy. The first step for mitophagy is the \u2018decoration\u2019 of mitochondria with a protein called ubiquitin. Ubiquitin in several cases acts a signal for degradation not only for damaged mitochondria, but for other dysfunctional organelles and proteins. In mitochondria, specifically, the addition of phosphate in ubiquitin is critical for initiating their degradation. Here, we want to define if these phosphoubiquitin tags are also found in proteins outside of mitochondria, and which proteins are capable of recognize these unique tags. These experiments will help us to understand deeper the fundamental process of mitophagy, which is disordered in Parkinson\u2019s disease.\n \n \n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Ioanna Georgiou","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Georgiou","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool","addressCountry":"United Kingdom","id_and_name":"[\"University of Liverpool\", \"360G-Wellcome-ORG:University-of-Liverpool\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Decoding the enigma of PhosphoUbiquitin and PINK1 Mitochondria are organelles within cells which are responsible for energy production. High energy demands or cellular stress can result to dysfunctional mitochondria. When mitochondria become damaged, they should be removed, in order to keep cells healthy. Cells have complicated mechanisms for recognizing and successfully destroying damaged mitochondria, as well as other dysfunctional organelles and proteins. The aggregation of dysfunctional organelles or proteins is the hallmark of many neurodegenerative diseases. A main degradation system in cells is autophagy, which essentially means self-eating, during which the damaged cellular components are isolated in a vesicle to be broken down. The autophagy of mitochondria is called mitophagy. The first step for mitophagy is the \u2018decoration\u2019 of mitochondria with a protein called ubiquitin. Ubiquitin in several cases acts a signal for degradation not only for damaged mitochondria, but for other dysfunctional organelles and proteins. In mitochondria, specifically, the addition of phosphate in ubiquitin is critical for initiating their degradation. Here, we want to define if these phosphoubiquitin tags are also found in proteins outside of mitochondria, and which proteins are capable of recognize these unique tags. These experiments will help us to understand deeper the fundamental process of mitophagy, which is disordered in Parkinson\u2019s disease.\n \n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Mitochondria","Mitophagy","Ubiquitin","Ubiquitin-Protein Ligases"]}
{"id":"360G-Wellcome-222538_Z_21_Z","title":"Functional characterisation of CYP2C9 variants of uncertain significance","Region":"North West","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222538/Z/21/Z","description":"The liver is the main site for the elimination of medicines taken by people (a process termed drug metabolism).  There are many enzymes involved in drug metabolism \u2013 one of these is cytochrome P450 2C9 (CYP2C9). CYP2C9 metabolises approximately 13% of all clinically used medications.  One example is warfarin [1].\n\nThe activity of CYP2C9 varies between individuals which can affect drug efficacy and increase the likelihood for adverse drug reactions [2\u20134].  This is due to several factors including concurrent disease and the intake of other medications.  Genetic factors also affect the activity of CYP2C9 \u2013 these are termed genetic polymorphisms.  The function (i.e. whether they increase or decrease activity of CYP2C9) of almost half of these polymorphisms is not well-defined [5]. Preliminary work performed in the Pirmohamed lab has identified 16 high impact (e.g. frameshifts), 159 moderate impact (e.g. missense variants) and more than 8000 non-coding variants.\n\nThe key goals of the project are:\n\n\n Correlate genetic variation in CYP2C9 to clinical outcomes using the UK BioBank, 100K Genomes Project and a well-characterised warfarin cohort\n Assess the effect of genetic variants on metabolomic parameters\n Prioritise variants for in vitro functional studies using CRISPR-Cas9, with effects on metabolism evaluated using LC-MS\n\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Maria Imran","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Imran","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool","addressCountry":"United Kingdom","id_and_name":"[\"University of Liverpool\", \"360G-Wellcome-ORG:University-of-Liverpool\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Functional characterisation of CYP2C9 variants of uncertain significance The liver is the main site for the elimination of medicines taken by people (a process termed drug metabolism).  There are many enzymes involved in drug metabolism \u2013 one of these is cytochrome P450 2C9 (CYP2C9). CYP2C9 metabolises approximately 13% of all clinically used medications.  One example is warfarin [1].\n\nThe activity of CYP2C9 varies between individuals which can affect drug efficacy and increase the likelihood for adverse drug reactions [2\u20134].  This is due to several factors including concurrent disease and the intake of other medications.  Genetic factors also affect the activity of CYP2C9 \u2013 these are termed genetic polymorphisms.  The function (i.e. whether they increase or decrease activity of CYP2C9) of almost half of these polymorphisms is not well-defined [5]. Preliminary work performed in the Pirmohamed lab has identified 16 high impact (e.g. frameshifts), 159 moderate impact (e.g. missense variants) and more than 8000 non-coding variants.\n\nThe key goals of the project are:\n\n\n Correlate genetic variation in CYP2C9 to clinical outcomes using the UK BioBank, 100K Genomes Project and a well-characterised warfarin cohort\n Assess the effect of genetic variants on metabolomic parameters\n Prioritise variants for in vitro functional studies using CRISPR-Cas9, with effects on metabolism evaluated using LC-MS\n\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anticoagulants","Chromatography, Liquid","Cytochrome P-450 CYP2C9","Humans","United Kingdom","Warfarin"]}
{"id":"360G-Wellcome-222537_Z_21_Z","title":"Investigating the cytoprotective role of NRF proteins against drug-induced cardiovascular toxicity","Region":"North West","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222537/Z/21/Z","description":"Many drugs used to treat cancers and HIV cause life-threatening heart problems which limits their use. Research into how to reduce this risk has previously been difficult due to a lack of experimental methods which accurately mimic the human cardiac system. However, new 3D human-cell models have been developed which reproduce the adverse drug reactions seen in patients. These new models have been used to show that increased expression of an important protective protein NFE2L (NRF2), provides protection from the toxic effects caused by a commonly used breast cancer drug. We believe that by increasing the activity of human NFE2L proteins (NFE2L1-3), we may protect cardiac cells from other adverse drug effects. Here, we will combine 3D human cardiac models with gene editing methods and advanced cell imaging techniques to manipulate expression of all NRF family proteins and monitor the protective effects under normal and high-glucose conditions, which are known to reduce the protective effects of NRF2. The results from this study will aid the development of new therapeutic strategies to prevent or reverse heart toxicity from commonly used cancer and HIV drugs.\n \n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr James Roberts","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Roberts","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool","addressCountry":"United Kingdom","id_and_name":"[\"University of Liverpool\", \"360G-Wellcome-ORG:University-of-Liverpool\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the cytoprotective role of NRF proteins against drug-induced cardiovascular toxicity Many drugs used to treat cancers and HIV cause life-threatening heart problems which limits their use. Research into how to reduce this risk has previously been difficult due to a lack of experimental methods which accurately mimic the human cardiac system. However, new 3D human-cell models have been developed which reproduce the adverse drug reactions seen in patients. These new models have been used to show that increased expression of an important protective protein NFE2L (NRF2), provides protection from the toxic effects caused by a commonly used breast cancer drug. We believe that by increasing the activity of human NFE2L proteins (NFE2L1-3), we may protect cardiac cells from other adverse drug effects. Here, we will combine 3D human cardiac models with gene editing methods and advanced cell imaging techniques to manipulate expression of all NRF family proteins and monitor the protective effects under normal and high-glucose conditions, which are known to reduce the protective effects of NRF2. The results from this study will aid the development of new therapeutic strategies to prevent or reverse heart toxicity from commonly used cancer and HIV drugs.\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cell Line","Glucose","Humans","Myocytes, Cardiac","NF-E2-Related Factor 2"]}
{"id":"360G-Wellcome-222535_Z_21_Z","title":"Evolutionary epigenetics of X-chromosome inactivation","Region":"Greater London","currency":"GBP","awardDate":"2021-04-13T00:00:00+00:00","Internal ID":"222535/Z/21/Z","description":"How epigenetic pathways regulate development and disease remains a major question in human biology. A remarkable paradigm for understanding epigenetic mechanisms is X-chromosome inactivation, the silencing of one X chromosome in females (XX) that equalises X-dosage with males (XY). X-inactivation in eutherian (placental) mammals is mediated by the non-coding RNA (ncRNA) Xist. How Xist silences the X chromosome, and how expression of Xist is regulated, remain poorly understood. Marsupials diverged from eutherian (placental) mammals 160 million years ago, and exhibit distinctive developmental features that make them ideal for studying development and disease. Using our colony of opossums, we identified RSX and XSR, the marsupial equivalents of Xist and Tsix, providing a comparative system for understanding RNA-mediated chromatin remodelling. In this proposal, we will deploy the opossum model system to identify deeply conserved epigenetic mechanisms regulating mammalian X-inactivation and X-chromosome reactivation, and to elucidate how they interface with global epigenomic changes in the early embryo and germline. Our datasets will shed light on the evolution of mammalian lineage specification, pluripotency, imprinting and germline development. We will apply genome editing to marsupials for the first time, accelerating discovery in other research fields, including cancer biology, neurobiology and infectious disease.\n","plannedDates":[{"endDate":"2026-12-31T00:00:00+00:00","startDate":"2022-01-01T00:00:00+00:00","startDateDateOnly":"2022-01-01","endDateDateOnly":"2026-12-31"}],"amountAwarded":2023433,"Financial Year":"2020/21","Lead Applicant":"Dr James Turner","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Turner","Partnership Value":2023433,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:The-Francis-Crick-Institute","name":"The Francis Crick Institute","addressCountry":"United Kingdom","id_and_name":"[\"The Francis Crick Institute\", \"360G-Wellcome-ORG:The-Francis-Crick-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:The-Francis-Crick-Institute","name":"The Francis Crick Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Evolutionary epigenetics of X-chromosome inactivation How epigenetic pathways regulate development and disease remains a major question in human biology. A remarkable paradigm for understanding epigenetic mechanisms is X-chromosome inactivation, the silencing of one X chromosome in females (XX) that equalises X-dosage with males (XY). X-inactivation in eutherian (placental) mammals is mediated by the non-coding RNA (ncRNA) Xist. How Xist silences the X chromosome, and how expression of Xist is regulated, remain poorly understood. Marsupials diverged from eutherian (placental) mammals 160 million years ago, and exhibit distinctive developmental features that make them ideal for studying development and disease. Using our colony of opossums, we identified RSX and XSR, the marsupial equivalents of Xist and Tsix, providing a comparative system for understanding RNA-mediated chromatin remodelling. In this proposal, we will deploy the opossum model system to identify deeply conserved epigenetic mechanisms regulating mammalian X-inactivation and X-chromosome reactivation, and to elucidate how they interface with global epigenomic changes in the early embryo and germline. Our datasets will shed light on the evolution of mammalian lineage specification, pluripotency, imprinting and germline development. We will apply genome editing to marsupials for the first time, accelerating discovery in other research fields, including cancer biology, neurobiology and infectious disease.\n","awardDateDateOnly":"2021-04-13","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Biological Evolution","Epigenesis, Genetic","Evolution, Molecular","Female","Genomic Imprinting","Humans","Male","Marsupialia","Mice","RNA, Long Noncoding","X Chromosome","X Chromosome Inactivation"]}
{"id":"360G-Wellcome-222531_Z_21_Z","title":"Regulation of immune signalling via ubiquitin-mediated receptor degradation","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2021-04-13T00:00:00+00:00","Internal ID":"222531/Z/21/Z","description":"Immune receptor turnover and subcellular localisation are regulated by attachment of ubiquitin, which controls receptor internalisation and endosomal-lysosomal degradation. Receptor ubiquitylation is fine-tuned by ubiquitin-processing enzymes, ligands and adaptor proteins, which regulate immune signalling output in a spatio-temporal manner. We identified a new signalling complex called BRISC, which is a deubiquitylase (DUB) and required for recycling of interferon and Toll-like receptors (TLRs). BRISC partners with adaptor proteins SHMT2 and EPS15 to regulate interferon and TLR signalling, although the role for each adaptor is unclear.\n\nMy laboratory uncovered a fascinating molecular mechanism by which vitamin B6 regulates BRISC activity, thus revealing a new example of metabolic control of immune signalling. Here, we aim to uncover how BRISC activity is controlled and directed to immune receptors. Using an integrated structural biology approach we aim to understand how BRISC partners with new adaptor proteins to perform its functions. Using BRISC-selective chemical probes in cell-based assays we aim to ascertain BRISC\u2019s role in elevated inflammation in normal and disease conditions. These new tool compounds represent an exciting opportunity to better understand BRISC activity, receptor degradation and immune signalling functions, and how DUBs can be exploited as therapeutic targets for autoimmune diseases.\n","plannedDates":[{"endDate":"2026-04-09T00:00:00+00:00","startDate":"2021-04-10T00:00:00+00:00","startDateDateOnly":"2021-04-10","endDateDateOnly":"2026-04-09"}],"amountAwarded":2141297,"Financial Year":"2020/21","Lead Applicant":"Dr Elton Zeqiraj","grantProgramme":[{"title":"Senior Research Fellowship","title_keyword":"Senior Research Fellowship"}],"Applicant Surname":"Zeqiraj","Partnership Value":2141297,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds","addressCountry":"United Kingdom","id_and_name":"[\"University of Leeds\", \"360G-Wellcome-ORG:University-of-Leeds\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Regulation of immune signalling via ubiquitin-mediated receptor degradation Immune receptor turnover and subcellular localisation are regulated by attachment of ubiquitin, which controls receptor internalisation and endosomal-lysosomal degradation. Receptor ubiquitylation is fine-tuned by ubiquitin-processing enzymes, ligands and adaptor proteins, which regulate immune signalling output in a spatio-temporal manner. We identified a new signalling complex called BRISC, which is a deubiquitylase (DUB) and required for recycling of interferon and Toll-like receptors (TLRs). BRISC partners with adaptor proteins SHMT2 and EPS15 to regulate interferon and TLR signalling, although the role for each adaptor is unclear.\n\nMy laboratory uncovered a fascinating molecular mechanism by which vitamin B6 regulates BRISC activity, thus revealing a new example of metabolic control of immune signalling. Here, we aim to uncover how BRISC activity is controlled and directed to immune receptors. Using an integrated structural biology approach we aim to understand how BRISC partners with new adaptor proteins to perform its functions. Using BRISC-selective chemical probes in cell-based assays we aim to ascertain BRISC\u2019s role in elevated inflammation in normal and disease conditions. These new tool compounds represent an exciting opportunity to better understand BRISC activity, receptor degradation and immune signalling functions, and how DUBs can be exploited as therapeutic targets for autoimmune diseases.\n","awardDateDateOnly":"2021-04-13","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Signal Transduction","Ubiquitination"]}
{"id":"360G-Wellcome-222530_Z_21_Z","title":"Predicting Acute and Post-Recovery Outcomes in Cerebral Malaria by Optical Coherence Tomography ","Region":"North West","currency":"GBP","awardDate":"2021-04-13T00:00:00+00:00","Internal ID":"222530/Z/21/Z","description":"Severe brain swelling leads to death in cerebral malaria (CM) but detection requires MRI. Almost no children with CM have access to MRI, therefore an alternative is required to identify patients for intervention. Optical coherence tomography (OCT) can detect raised intracranial pressure and ischaemic injury by imaging the optic nerve head, and retina respectively. We aim to study OCT as a method to identify patients at risk of death from brain swelling and disability from ischaemia; and to develop a low-cost OCT device with integrated AI image analysis.\n\n \n\nWe will conduct a controlled cohort study of 120 children with CM in Malawi to compare OCT to MRI in detecting severe brain swelling. We will follow them for a year with neuro-developmental assessments to investigate retinal OCT in predicting neurological deficits; and correlate retinal and cerebral atrophy. We will also assess OCT in quantifying raised intracranial pressure in non-malarial coma, and retinal haemorrhages for predicting worsening of brain swelling in CM.\n\n \n\nWe will use fibreoptic and micro-electromechanical advances to develop handheld OCT design and make a low-cost, robust device suitable for malaria-endemic settings. We will develop AI techniques to automatically segment and quantify optic nerve head swelling and intraretinal hyper-reflectivity (ischaemia).\n","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2021-10-01T00:00:00+00:00","startDateDateOnly":"2021-10-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":1378334,"Financial Year":"2020/21","Lead Applicant":"Dr Nicholas Beare","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Beare","Partnership Value":1378334,"Approval Committee":"Science Interview Panel","Other Applicant(s)":"Dr Yalin Zheng","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool","addressCountry":"United Kingdom","id_and_name":"[\"University of Liverpool\", \"360G-Wellcome-ORG:University-of-Liverpool\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Predicting Acute and Post-Recovery Outcomes in Cerebral Malaria by Optical Coherence Tomography  Severe brain swelling leads to death in cerebral malaria (CM) but detection requires MRI. Almost no children with CM have access to MRI, therefore an alternative is required to identify patients for intervention. Optical coherence tomography (OCT) can detect raised intracranial pressure and ischaemic injury by imaging the optic nerve head, and retina respectively. We aim to study OCT as a method to identify patients at risk of death from brain swelling and disability from ischaemia; and to develop a low-cost OCT device with integrated AI image analysis.\n\n \n\nWe will conduct a controlled cohort study of 120 children with CM in Malawi to compare OCT to MRI in detecting severe brain swelling. We will follow them for a year with neuro-developmental assessments to investigate retinal OCT in predicting neurological deficits; and correlate retinal and cerebral atrophy. We will also assess OCT in quantifying raised intracranial pressure in non-malarial coma, and retinal haemorrhages for predicting worsening of brain swelling in CM.\n\n \n\nWe will use fibreoptic and micro-electromechanical advances to develop handheld OCT design and make a low-cost, robust device suitable for malaria-endemic settings. We will develop AI techniques to automatically segment and quantify optic nerve head swelling and intraretinal hyper-reflectivity (ischaemia).\n","awardDateDateOnly":"2021-04-13","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Child","Child, Preschool","Cohort Studies","Female","Humans","Intracranial Pressure","Magnetic Resonance Imaging","Malawi","Male","Retina","Tomography, Optical Coherence"]}
{"id":"360G-Wellcome-222528_Z_21_Z","title":"Defining the functional basis of the enhanced survival and replication of African Salmonella in human phagocytic cells","Region":"North West","currency":"GBP","awardDate":"2021-04-13T00:00:00+00:00","Internal ID":"222528/Z/21/Z","description":"Invasive non-typhoidal Salmonella disease (iNTS) has emerged as a major killer in sub-Saharan Africa, responsible for ~500,000 deaths since 20091. The disease primarily affects people who are immunocompromised by HIV, malaria, anaemia or malnourishment2, and has a high case-fatality-rate (14.5%1).\n\n \n\nIn Africa, iNTS is caused by one clade of S.Typhimurium and two clades of S.Enteritidis3\u20135. Despite many decades of research on gene function and infection biology of Salmonella, the pathoadaptive mutations that have driven the emergence of African clades are unknown. Such knowledge is vital to decipher iNTS pathogenesis and develop control strategies in the future.\n\n \n\nTo address this knowledge gap, I will decipher the mechanisms that African and gastroenteritis-associated Salmonella employ to survive and replicate within a core niche, human phagocytic cells. I will achieve this using our powerful combination of comparative genomics and transcriptomics, plus new innovations in experimental evolution and genome-wide, high-throughput fitness assays.\n\n \n\nBy understanding the molecular basis of the intra-macrophage lifestyle, I will determine whether these neglected African-Salmonella pathovariants have used common or divergent approaches to combat the antibacterial properties of human cells.\n\n \n\nMy Research Question is:\n\nHow do African Salmonella pathovariants survive and replicate so effectively in human macrophages?\n\n \n","plannedDates":[{"endDate":"2027-04-30T00:00:00+00:00","startDate":"2022-05-01T00:00:00+00:00","startDateDateOnly":"2022-05-01","endDateDateOnly":"2027-04-30"}],"amountAwarded":1671997,"Financial Year":"2020/21","Lead Applicant":"Prof Jay Hinton","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Hinton","Partnership Value":1671997,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool","addressCountry":"United Kingdom","id_and_name":"[\"University of Liverpool\", \"360G-Wellcome-ORG:University-of-Liverpool\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Defining the functional basis of the enhanced survival and replication of African Salmonella in human phagocytic cells Invasive non-typhoidal Salmonella disease (iNTS) has emerged as a major killer in sub-Saharan Africa, responsible for ~500,000 deaths since 20091. The disease primarily affects people who are immunocompromised by HIV, malaria, anaemia or malnourishment2, and has a high case-fatality-rate (14.5%1).\n\n \n\nIn Africa, iNTS is caused by one clade of S.Typhimurium and two clades of S.Enteritidis3\u20135. Despite many decades of research on gene function and infection biology of Salmonella, the pathoadaptive mutations that have driven the emergence of African clades are unknown. Such knowledge is vital to decipher iNTS pathogenesis and develop control strategies in the future.\n\n \n\nTo address this knowledge gap, I will decipher the mechanisms that African and gastroenteritis-associated Salmonella employ to survive and replicate within a core niche, human phagocytic cells. I will achieve this using our powerful combination of comparative genomics and transcriptomics, plus new innovations in experimental evolution and genome-wide, high-throughput fitness assays.\n\n \n\nBy understanding the molecular basis of the intra-macrophage lifestyle, I will determine whether these neglected African-Salmonella pathovariants have used common or divergent approaches to combat the antibacterial properties of human cells.\n\n \n\nMy Research Question is:\n\nHow do African Salmonella pathovariants survive and replicate so effectively in human macrophages?\n\n \n","awardDateDateOnly":"2021-04-13","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Genome, Bacterial","Humans","Macrophages","Salmonella Infections","Salmonella typhimurium"]}
{"id":"360G-Wellcome-222525_Z_21_Z","title":"Putting bioethics at the heart of WHO and beyond","Region":"International","currency":"GBP","awardDate":"2020-11-30T00:00:00+00:00","Internal ID":"222525/Z/21/Z","description":"The WHO Global Ethics Unit is part of the newly formed Science Division and would like to capitalize on the potential of the division and the global leadership shown by the team during the current COVID-19 pandemic, to truly embed ethics at the heart of decision-making at WHO.\n\n \n\nThis proposal focuses on adding value to our current work programme. Additional technical and coordinating capacity will allow us to better leverage our vast bioethics networks and collaborative partnership with bioethics groups around the world to: support regional and in-country bioethics capacity needs; further develop a community of ethics experts; develop the global ethics agenda and focus on key areas of unmet or continuing need, including health emergency preparedness and response. Additional resource will also allow us to be more responsive to demand set by the WHO and global research and health communities.\n","plannedDates":[{"endDate":"2024-02-29T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2024-02-29"}],"amountAwarded":1786326,"Financial Year":"2020/21","Lead Applicant":"Ms Katherine Littler","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Littler","Partnership Value":1786326,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:World-Health-Organization-Switzerland","name":"World Health Organization, Switzerland","addressCountry":"Switzerland","id_and_name":"[\"World Health Organization, Switzerland\", \"360G-Wellcome-ORG:World-Health-Organization-Switzerland\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:World-Health-Organization-Switzerland","name":"World Health Organization, Switzerland"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Putting bioethics at the heart of WHO and beyond The WHO Global Ethics Unit is part of the newly formed Science Division and would like to capitalize on the potential of the division and the global leadership shown by the team during the current COVID-19 pandemic, to truly embed ethics at the heart of decision-making at WHO.\n\n \n\nThis proposal focuses on adding value to our current work programme. Additional technical and coordinating capacity will allow us to better leverage our vast bioethics networks and collaborative partnership with bioethics groups around the world to: support regional and in-country bioethics capacity needs; further develop a community of ethics experts; develop the global ethics agenda and focus on key areas of unmet or continuing need, including health emergency preparedness and response. Additional resource will also allow us to be more responsive to demand set by the WHO and global research and health communities.\n","awardDateDateOnly":"2020-11-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Bioethics","Capacity Building","Decision Making","Global Health","Humans","International Cooperation","Leadership"]}
{"id":"360G-Wellcome-222519_Z_21_Z","title":"Mitochondrial dynamics in CNS health and disease","Region":"Greater London","currency":"GBP","awardDate":"2021-04-13T00:00:00+00:00","Internal ID":"222519/Z/21/Z","description":"The tight regulation of mitochondrial transport and anchoring in brain cells is essential for providing ATP at the correct spatial location to power neural function and computation, and for providing calcium buffering at sites of calcium entry or release. Using a multidisciplinary approach, combining imaging, biochemistry, electrophysiology and mouse transgenics we will determine the molecular and cellular mechanisms by which the cytoskeleton coordinates mitochondrial transport, localisation and remodelling in neurons and glial cells. The influence of this regulation on the development and maintenance of neuronal connectivity, function, plasticity and pathology will then be determined in vitro and in vivo. The main objectives are to define (i) the role of Miro proteins as central coordinators of the activity-dependent transport, positioning and remodelling of mitochondria through the microtubule, actin and septin cytoskeletons; (ii) how mitochondrial position and calcium buffering in neurons and glia impacts the formation, maintenance and plasticity of synapses; and (iii) the mechanisms by which disrupted mitochondrial dynamics lead to neuronal pathology and neurodegeneration. Our proposal will provide unique insight into how mitochondrial networks in neurons and astrocytes contribute to regulating the operation and plasticity of synapses and how their disruption leads to neuronal pathology in brain diseases.\n","plannedDates":[{"endDate":"2026-05-31T00:00:00+00:00","startDate":"2021-06-01T00:00:00+00:00","startDateDateOnly":"2021-06-01","endDateDateOnly":"2026-05-31"}],"amountAwarded":1871095,"Financial Year":"2020/21","Lead Applicant":"Prof Josef Kittler","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Kittler","Partnership Value":1871095,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mitochondrial dynamics in CNS health and disease The tight regulation of mitochondrial transport and anchoring in brain cells is essential for providing ATP at the correct spatial location to power neural function and computation, and for providing calcium buffering at sites of calcium entry or release. Using a multidisciplinary approach, combining imaging, biochemistry, electrophysiology and mouse transgenics we will determine the molecular and cellular mechanisms by which the cytoskeleton coordinates mitochondrial transport, localisation and remodelling in neurons and glial cells. The influence of this regulation on the development and maintenance of neuronal connectivity, function, plasticity and pathology will then be determined in vitro and in vivo. The main objectives are to define (i) the role of Miro proteins as central coordinators of the activity-dependent transport, positioning and remodelling of mitochondria through the microtubule, actin and septin cytoskeletons; (ii) how mitochondrial position and calcium buffering in neurons and glia impacts the formation, maintenance and plasticity of synapses; and (iii) the mechanisms by which disrupted mitochondrial dynamics lead to neuronal pathology and neurodegeneration. Our proposal will provide unique insight into how mitochondrial networks in neurons and astrocytes contribute to regulating the operation and plasticity of synapses and how their disruption leads to neuronal pathology in brain diseases.\n","awardDateDateOnly":"2021-04-13","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Astrocytes","Calcium","Mice","Mice, Transgenic","Microtubules","Mitochondria","Neuroglia","Neurons","Synapses"]}
{"id":"360G-Wellcome-222516_Z_21_Z","title":"RNA processing and degradation","Region":"Scotland","currency":"GBP","awardDate":"2021-04-13T00:00:00+00:00","Internal ID":"222516/Z/21/Z","description":"All living systems \u2013 cells or organisms \u2013 operate in and must adapt to constantly changing environments. RNA transcription, processing and assembly with protein complexes form the core of the gene expression system, but many key features remain unclear. At times, very substantial changes take place; for example, in response to sudden environmental changes, following infection or during developmental progression. To address unresolved questions in RNA biology, we developed biochemical techniques to identify key, relevant RNA-protein, RNA-RNA and protein-protein interactions. These will be improved and applied in the proposed work, supported by bioinformatics. RNA systems are highly conserved in evolution, so techniques developed in yeast can be adapted for human cells and applied to understand disease. RNA biology in a cellular context is subject to dynamic changes. Kinetic analyses will therefore be applied, particularly during changes in cell state.\nSpecific topics: \n1: How is the nascent RNA linked to transcription termination and RNA processing\n2: How does RNA metabolism respond to environmental stress?\n3: How is host RNA metabolism remodelled during Coronavirus infection? \n4: What are the roles of ncRNAs in neuronal development?\nThe insights generated, and the experimental and bioinformatics techniques developed, will underpin future work by many groups.\n","plannedDates":[{"endDate":"2026-09-30T00:00:00+00:00","startDate":"2021-10-01T00:00:00+00:00","startDateDateOnly":"2021-10-01","endDateDateOnly":"2026-09-30"}],"amountAwarded":2760782,"Financial Year":"2020/21","Lead Applicant":"Prof David Tollervey","grantProgramme":[{"title":"Principal Research Fellowship Renewal","title_keyword":"Principal Research Fellowship Renewal"}],"Applicant Surname":"Tollervey","Partnership Value":2760782,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"RNA processing and degradation All living systems \u2013 cells or organisms \u2013 operate in and must adapt to constantly changing environments. RNA transcription, processing and assembly with protein complexes form the core of the gene expression system, but many key features remain unclear. At times, very substantial changes take place; for example, in response to sudden environmental changes, following infection or during developmental progression. To address unresolved questions in RNA biology, we developed biochemical techniques to identify key, relevant RNA-protein, RNA-RNA and protein-protein interactions. These will be improved and applied in the proposed work, supported by bioinformatics. RNA systems are highly conserved in evolution, so techniques developed in yeast can be adapted for human cells and applied to understand disease. RNA biology in a cellular context is subject to dynamic changes. Kinetic analyses will therefore be applied, particularly during changes in cell state.\nSpecific topics: \n1: How is the nascent RNA linked to transcription termination and RNA processing\n2: How does RNA metabolism respond to environmental stress?\n3: How is host RNA metabolism remodelled during Coronavirus infection? \n4: What are the roles of ncRNAs in neuronal development?\nThe insights generated, and the experimental and bioinformatics techniques developed, will underpin future work by many groups.\n","awardDateDateOnly":"2021-04-13","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Host-Pathogen Interactions","Humans","RNA","RNA, Viral"]}
{"id":"360G-Wellcome-222507_Z_21_Z","title":"Understanding proteins that interpret genome context to stabilise cell states","Region":"Scotland","currency":"GBP","awardDate":"2021-04-13T00:00:00+00:00","Internal ID":"222507/Z/21/Z","description":"The character of a cell is determined during differentiation by selective gene activation and silencing. In addition to high level decisions about which genes are on or off, it is now clear that levels of transcription in each differentiated cell must be precisely calibrated. This proposal seeks a comprehensive understanding of two proteins, SALL4 and MeCP2, that optimise transcription programmes in order to stabilise cellular states. Despite very different biological outputs, SALL4 and MeCP2 share striking similarities. Both are DNA binding proteins that recognise short, frequent DNA sequence motifs; both interact with histone deacetylase-containing corepressor complexes to modulate expression of many genes; and both are of proven biological and biomedical importance. Our intention is to study these proteins in parallel using a molecular genetic approach in order to elucidate fundamental mechanisms that consolidate cell identity before and after differentiation. To explore the generality of this form of transcriptional control, we will screen for novel transcription modulators that also interpret regionally variable genomic features by sensing short DNA sequence motifs. Our findings will have implications for regenerative medicine and reveal the molecular basis of diseases caused by deficiency of these and similar proteins, including Rett syndrome, Okihiro syndrome and cancer.\n \n","plannedDates":[{"endDate":"2026-12-31T00:00:00+00:00","startDate":"2022-01-01T00:00:00+00:00","startDateDateOnly":"2022-01-01","endDateDateOnly":"2026-12-31"}],"amountAwarded":2500000,"Financial Year":"2020/21","Lead Applicant":"Prof Adrian Bird","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Bird","Partnership Value":2500000,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding proteins that interpret genome context to stabilise cell states The character of a cell is determined during differentiation by selective gene activation and silencing. In addition to high level decisions about which genes are on or off, it is now clear that levels of transcription in each differentiated cell must be precisely calibrated. This proposal seeks a comprehensive understanding of two proteins, SALL4 and MeCP2, that optimise transcription programmes in order to stabilise cellular states. Despite very different biological outputs, SALL4 and MeCP2 share striking similarities. Both are DNA binding proteins that recognise short, frequent DNA sequence motifs; both interact with histone deacetylase-containing corepressor complexes to modulate expression of many genes; and both are of proven biological and biomedical importance. Our intention is to study these proteins in parallel using a molecular genetic approach in order to elucidate fundamental mechanisms that consolidate cell identity before and after differentiation. To explore the generality of this form of transcriptional control, we will screen for novel transcription modulators that also interpret regionally variable genomic features by sensing short DNA sequence motifs. Our findings will have implications for regenerative medicine and reveal the molecular basis of diseases caused by deficiency of these and similar proteins, including Rett syndrome, Okihiro syndrome and cancer.\n \n","awardDateDateOnly":"2021-04-13","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cell Differentiation","DNA","Gene Expression Regulation","Humans","Methyl-CpG-Binding Protein 2","Transcription, Genetic"]}
{"id":"360G-Wellcome-222506_Z_21_Z","title":"Forensic epidemiology and impact of substandard and falsified antimicrobials on public health","Region":"South East","currency":"GBP","awardDate":"2021-04-13T00:00:00+00:00","Internal ID":"222506/Z/21/Z","description":"Substandard and falsified (SF) antimicrobials are a massive but underappreciated global health challenge in great need of innovative research to inform interventions. We will build on our collective pioneering research, to construct an innovative, multidisciplinary research hub that will improve understanding and inform global policy and action. Leading specialists investigating illegal wildlife trade, forensic genomics and chemistry, social network analysis and modelling, will work together to answer two main aims:\n\n1.  How can innovative forensic tools be used to identify sources and trade routes?\n \nHow can novel genomic (\u2018pharmabiome\u2019), chemical and isotopic analysis with social network techniques be used to characterise the epidemiology of SF antimicrobials to inform policy and action to improve our global pharmaceutical supply quality? We will conduct high-throughput sequencing and novel chemical analysis of falsified and genuine antimicrobials to determine their comparative pharmabiome/chemical spectra, followed by social network analysis of  origins and trade routes.\n \n2.  What are the public health impacts of SF antimicrobials?\n \nWhat are the modelled impacts of SF antimicrobials on patient outcome, global public health, especially engendering antimicrobial resistance and how can these be minimised? Using a One Health approach, which pathogen-antimicrobial pairs are at greatest risk of SF antimicrobials?\n\n \n","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2021-10-01T00:00:00+00:00","startDateDateOnly":"2021-10-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":2904144,"Financial Year":"2020/21","Lead Applicant":"Prof Paul Newton","grantProgramme":[{"title":"Collaborative Award in Science","title_keyword":"Collaborative Award in Science"}],"Applicant Surname":"Newton","Partnership Value":2904144,"Approval Committee":"Science Interview Panel","Other Applicant(s)":"Dr Clark Freifeld, Dr Luana Bontempo, Prof Federico Varese, Prof Ben Cooper, Prof Rob Ogden, Prof Heather Hamill","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Forensic epidemiology and impact of substandard and falsified antimicrobials on public health Substandard and falsified (SF) antimicrobials are a massive but underappreciated global health challenge in great need of innovative research to inform interventions. We will build on our collective pioneering research, to construct an innovative, multidisciplinary research hub that will improve understanding and inform global policy and action. Leading specialists investigating illegal wildlife trade, forensic genomics and chemistry, social network analysis and modelling, will work together to answer two main aims:\n\n1.  How can innovative forensic tools be used to identify sources and trade routes?\n \nHow can novel genomic (\u2018pharmabiome\u2019), chemical and isotopic analysis with social network techniques be used to characterise the epidemiology of SF antimicrobials to inform policy and action to improve our global pharmaceutical supply quality? We will conduct high-throughput sequencing and novel chemical analysis of falsified and genuine antimicrobials to determine their comparative pharmabiome/chemical spectra, followed by social network analysis of  origins and trade routes.\n \n2.  What are the public health impacts of SF antimicrobials?\n \nWhat are the modelled impacts of SF antimicrobials on patient outcome, global public health, especially engendering antimicrobial resistance and how can these be minimised? Using a One Health approach, which pathogen-antimicrobial pairs are at greatest risk of SF antimicrobials?\n\n \n","awardDateDateOnly":"2021-04-13","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anti-Infective Agents","Humans","Public Health"]}
{"id":"360G-Wellcome-222503_Z_21_Z","title":"How cells convert cytosol-invading bacteria into anti-bacterial signalling platforms","Region":"East of England","currency":"GBP","awardDate":"2021-04-13T00:00:00+00:00","Internal ID":"222503/Z/21/Z","description":"Our cytosol could provide ample resources for invasive bacteria, yet is maintained in a remarkably sterile state. We recently discovered that cells deposit polyvalent protein arrays at bacterial surfaces to convert cytosol-invading bacteria into anti-bacterial signalling platforms. The deposition of M1-linked ubiquitin chains by the E3 ubiquitin ligase LUBAC recruits and activates IKK complexes, resulting in NF-kB signalling, while the deposition of guanylate-binding proteins (GBPs) recruits and is required for the LPS-dependent activation of Caspase-4, resulting in pyroptotic cell death and the release of IL-18. Here, we will explore this novel principle of cell-autonomous immunity to better understand cytosolic anti-bacterial defence.\n\nWe will therefore investigate\n\n\n The origin and function of ubiquitin-dependent signalling platforms, with special emphasis on the ubiquitylation of bacterial lipopolysaccharide (LPS) by the E3 ubiquitin ligase RNF213, which represents the unprecedented ubiquitylation of a non-proteinaceous substrate\n The origin and function of the GBP-dependent signalling platform, specifically its assembly mechanism and how it promotes activation of caspase-4 and other downstream effectors.\n\n","plannedDates":[{"endDate":"2026-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2026-06-30"}],"amountAwarded":1151174,"Financial Year":"2020/21","Lead Applicant":"Dr Felix Randow","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Randow","Partnership Value":1151174,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:MRC-Laboratory-of-Molecular-Biology","name":"MRC Laboratory of Molecular Biology","addressCountry":"United Kingdom","id_and_name":"[\"MRC Laboratory of Molecular Biology\", \"360G-Wellcome-ORG:MRC-Laboratory-of-Molecular-Biology\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:MRC-Laboratory-of-Molecular-Biology","name":"MRC Laboratory of Molecular Biology"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"How cells convert cytosol-invading bacteria into anti-bacterial signalling platforms Our cytosol could provide ample resources for invasive bacteria, yet is maintained in a remarkably sterile state. We recently discovered that cells deposit polyvalent protein arrays at bacterial surfaces to convert cytosol-invading bacteria into anti-bacterial signalling platforms. The deposition of M1-linked ubiquitin chains by the E3 ubiquitin ligase LUBAC recruits and activates IKK complexes, resulting in NF-kB signalling, while the deposition of guanylate-binding proteins (GBPs) recruits and is required for the LPS-dependent activation of Caspase-4, resulting in pyroptotic cell death and the release of IL-18. Here, we will explore this novel principle of cell-autonomous immunity to better understand cytosolic anti-bacterial defence.\n\nWe will therefore investigate\n\n\n The origin and function of ubiquitin-dependent signalling platforms, with special emphasis on the ubiquitylation of bacterial lipopolysaccharide (LPS) by the E3 ubiquitin ligase RNF213, which represents the unprecedented ubiquitylation of a non-proteinaceous substrate\n The origin and function of the GBP-dependent signalling platform, specifically its assembly mechanism and how it promotes activation of caspase-4 and other downstream effectors.\n\n","awardDateDateOnly":"2021-04-13","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cytosol","Humans","I-kappa B Kinase","Lipopolysaccharides","NF-kappa B","Signal Transduction","Ubiquitin","Ubiquitin-Protein Ligases","Ubiquitination"]}
{"id":"360G-Wellcome-222497_Z_21_Z","title":"How does the purine metabolic checkpoint FAMIN prevent immunopathology?","Region":"East of England","currency":"GBP","awardDate":"2021-04-13T00:00:00+00:00","Internal ID":"222497/Z/21/Z","description":"Children with Still's disease, the paradigm of autoinflammation-cum-autoimmunity, are predisposed to developing a cytokine storm with excessive activation of T lymphocytes upon viral infection. Loss-of-function of FAMIN is the sole known cause for monogenic Still's disease. We de-orphaned FAMIN as an unprecedented purine nucleoside enzyme that combines ADA-, PNP- and MTAP-like activities with adenosine phosphorolysis \u2013 challenging fundamental principles of purine metabolism. Dendritic cells with absent FAMIN activity prime for excess antigen-specific cytotoxicity, IFNgamma secretion, and T cell expansion, resulting in exaggerated virus-specific T cell responses and immunopathology. Enhanced priming is already manifest with hypomorphic FAMIN-I254V, for which ~6.3% of mankind is homozygous, and which predisposes for Crohn's disease and leprosy. Here we will address FAMIN biology from virtually atomic to organismal resolution: We will explore how FAMIN operates in a cell, and how it controls energy metabolism, ascertaining redox and pH homeostasis. We will investigate how FAMIN in dendritic cells potently restrains T cell priming, and whether the FAMIN-coordinated biochemical mechanisms are involved in often fatal virus-induced cytokine release syndromes. This work will reveal an ancient biochemical mechanism that potently controls adaptive immune activation at a very fundamental level, providing insight into immunity to pathogens, autoinflammation and autoimmunity. \n","plannedDates":[{"endDate":"2026-05-31T00:00:00+00:00","startDate":"2021-06-01T00:00:00+00:00","startDateDateOnly":"2021-06-01","endDateDateOnly":"2026-05-31"}],"amountAwarded":2444805,"Financial Year":"2020/21","Lead Applicant":"Prof Arthur Kaser","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Kaser","Partnership Value":2444805,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"How does the purine metabolic checkpoint FAMIN prevent immunopathology? Children with Still's disease, the paradigm of autoinflammation-cum-autoimmunity, are predisposed to developing a cytokine storm with excessive activation of T lymphocytes upon viral infection. Loss-of-function of FAMIN is the sole known cause for monogenic Still's disease. We de-orphaned FAMIN as an unprecedented purine nucleoside enzyme that combines ADA-, PNP- and MTAP-like activities with adenosine phosphorolysis \u2013 challenging fundamental principles of purine metabolism. Dendritic cells with absent FAMIN activity prime for excess antigen-specific cytotoxicity, IFNgamma secretion, and T cell expansion, resulting in exaggerated virus-specific T cell responses and immunopathology. Enhanced priming is already manifest with hypomorphic FAMIN-I254V, for which ~6.3% of mankind is homozygous, and which predisposes for Crohn's disease and leprosy. Here we will address FAMIN biology from virtually atomic to organismal resolution: We will explore how FAMIN operates in a cell, and how it controls energy metabolism, ascertaining redox and pH homeostasis. We will investigate how FAMIN in dendritic cells potently restrains T cell priming, and whether the FAMIN-coordinated biochemical mechanisms are involved in often fatal virus-induced cytokine release syndromes. This work will reveal an ancient biochemical mechanism that potently controls adaptive immune activation at a very fundamental level, providing insight into immunity to pathogens, autoinflammation and autoimmunity. \n","awardDateDateOnly":"2021-04-13","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adaptive Immunity","Animals","Cytokines","Dendritic Cells","Humans","T-Lymphocytes"]}
{"id":"360G-Wellcome-222494_Z_21_Z","title":"Protein phosphorylation dynamics: investigating a new dimension of regulatory control during mitosis ","Region":"Scotland","currency":"GBP","awardDate":"2021-04-13T00:00:00+00:00","Internal ID":"222494/Z/21/Z","description":"Protein phosphorylation regulates protein function in a switch-like manner. Although each phosphorylation site only exists in two states (on/off), the frequency of switching between these states can vary dramatically. Individual molecules that flash on and off rapidly can possess unique signalling properties, but these are difficult to study because dynamic information remains hidden from current analytical methods. We will use heavy-[18O2]-ATP and mass spectrometry to quantify, for the first time, the rate that individual substrates are phosphorylated and dephosphorylated over time. We will measure this globally and characterise different complexes during mitosis that rely on phosphorylation-dephosphorylation cycles to function correctly (BUBc/RepoMan/Centralspindlin/COMA). We will study how these cycles control signal-switching and protein binding-release events, which we predict are needed to order mitotic progression, generate gradients of activity and/or assemble protein complexes. These concepts will be tested with purified components, mathematical modelling and quantitative microscopy. Although we use mitosis as a model system, this work has far-reaching implications. If binary phosphorylation events generate more complex outputs by varying their on/off rates, then any pathway could use this property to transmit information differently. It is therefore crucial to investigate this phenomenon because these rates could be modulated to drive both signalling and disease.\n","plannedDates":[{"endDate":"2024-05-31T00:00:00+00:00","startDate":"2021-06-01T00:00:00+00:00","startDateDateOnly":"2021-06-01","endDateDateOnly":"2024-05-31"}],"amountAwarded":1088447,"Financial Year":"2020/21","Lead Applicant":"Dr Adrian Saurin","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Saurin","Partnership Value":1088447,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee","addressCountry":"United Kingdom","id_and_name":"[\"University of Dundee\", \"360G-Wellcome-ORG:University-of-Dundee\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Protein phosphorylation dynamics: investigating a new dimension of regulatory control during mitosis  Protein phosphorylation regulates protein function in a switch-like manner. Although each phosphorylation site only exists in two states (on/off), the frequency of switching between these states can vary dramatically. Individual molecules that flash on and off rapidly can possess unique signalling properties, but these are difficult to study because dynamic information remains hidden from current analytical methods. We will use heavy-[18O2]-ATP and mass spectrometry to quantify, for the first time, the rate that individual substrates are phosphorylated and dephosphorylated over time. We will measure this globally and characterise different complexes during mitosis that rely on phosphorylation-dephosphorylation cycles to function correctly (BUBc/RepoMan/Centralspindlin/COMA). We will study how these cycles control signal-switching and protein binding-release events, which we predict are needed to order mitotic progression, generate gradients of activity and/or assemble protein complexes. These concepts will be tested with purified components, mathematical modelling and quantitative microscopy. Although we use mitosis as a model system, this work has far-reaching implications. If binary phosphorylation events generate more complex outputs by varying their on/off rates, then any pathway could use this property to transmit information differently. It is therefore crucial to investigate this phenomenon because these rates could be modulated to drive both signalling and disease.\n","awardDateDateOnly":"2021-04-13","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adenosine Triphosphate","Humans","Mass Spectrometry","Mitosis","Phosphorylation"]}
{"id":"360G-Wellcome-222493_Z_21_Z","title":"Understanding the diverse molecular mechanisms of chromatin-targeted histone deacetylase complexes","Region":"East Midlands","currency":"GBP","awardDate":"2021-04-13T00:00:00+00:00","Internal ID":"222493/Z/21/Z","description":"Eukaryotic gene regulation depends upon a plethora of multi-protein complexes that both control the organisation of chromatin and establish specific patterns of post-translational modifications of histone tails. These histone marks are key to the processes of gene regulation. Deciphering the roles and mechanisms of the complexes that regulate chromatin is one of greatest challenges in understanding how genome activity is controlled.\n\nWe aim to understand the roles and mechanism of action of a family of essential, non-redundant histone deacetylase complexes that control chromatin accessibility across the genome. These HDAC complexes share a common catalytic engine, but contain very different accessory proteins and have diverse oligomeric states. Although these are essential complexes, conserved from nematodes to man, we have only a very limited understanding of their mechanism of action.\n\nWe will take two approaches to determine the mechanisms through which these complexes engage with their chromatin substrates and to understand how this determines their biological function.\n\nWe will use structural techniques to determine the architectures of three exemplar complexes in complex with chromatin. We will use genomic and proteomic techniques to explore how these structures mediate their distinct biological activities.\n","plannedDates":[{"endDate":"2026-10-31T00:00:00+00:00","startDate":"2021-11-01T00:00:00+00:00","startDateDateOnly":"2021-11-01","endDateDateOnly":"2026-10-31"}],"amountAwarded":2337836,"Financial Year":"2020/21","Lead Applicant":"Prof John Schwabe","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Schwabe","Partnership Value":2337836,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leicester","name":"University of Leicester","addressCountry":"United Kingdom","id_and_name":"[\"University of Leicester\", \"360G-Wellcome-ORG:University-of-Leicester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leicester","name":"University of Leicester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding the diverse molecular mechanisms of chromatin-targeted histone deacetylase complexes Eukaryotic gene regulation depends upon a plethora of multi-protein complexes that both control the organisation of chromatin and establish specific patterns of post-translational modifications of histone tails. These histone marks are key to the processes of gene regulation. Deciphering the roles and mechanisms of the complexes that regulate chromatin is one of greatest challenges in understanding how genome activity is controlled.\n\nWe aim to understand the roles and mechanism of action of a family of essential, non-redundant histone deacetylase complexes that control chromatin accessibility across the genome. These HDAC complexes share a common catalytic engine, but contain very different accessory proteins and have diverse oligomeric states. Although these are essential complexes, conserved from nematodes to man, we have only a very limited understanding of their mechanism of action.\n\nWe will take two approaches to determine the mechanisms through which these complexes engage with their chromatin substrates and to understand how this determines their biological function.\n\nWe will use structural techniques to determine the architectures of three exemplar complexes in complex with chromatin. We will use genomic and proteomic techniques to explore how these structures mediate their distinct biological activities.\n","awardDateDateOnly":"2021-04-13","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Chromatin","Histone Deacetylases","Histones","Humans","Proteomics"]}
{"id":"360G-Wellcome-222489_Z_21_Z","title":"Design and implementation of a translational drug development platform for COVID-19 to generate preclinical evidence in support of treatment arms of the ANTICOV clinical trial ","Region":"International","currency":"GBP","awardDate":"2021-03-31T00:00:00+00:00","Internal ID":"222489/Z/21/Z","description":"Through the rapid establishment of a translational pathway, DNDi and its partners aim at providing the next generation of candidate medicines for SARS-CoV-2 clinical trials as well as integrating back-translations to validate the most appropriate preclinical models. The project is planned to run from September 2020-December 2021, with a total budget of 1.97M GBP, split into three pillars of activities composed of short and medium- term deliverables:  \n\n\n \n Pillar 1 : Selection of the best combination of repurposed antiviral drugs to include into the 3rd arm of the ANTICOV clinical trial and the next back-ups \n \n \n Pillar 2 : Support candidate progression through an integrated pharmacometrics package involving both Physiologically-Based Pharmacokinetic (PBPK) and population pharmacokinetic (PopPK) modelling approaches \n \n \n Pillar 3 : Development of a translational platform and performance of a comparative analysis of selected drugs/combinations (including those from Pillar 1) to better understand and refine the screening cascade with best translational value; definition of a Target Candidate Profile (TCP) for SARS-CoV-2 mild infection\n \n\n\nThis project will cement a collaborative partnership in the SARS-CoV-2 translational space that will pave the way to future longer-term discovery projects and preparedness for additional future threats. \n\nKey words: COVID-19 / Drug re-purposing / Translational drug development pathway \n","plannedDates":[{"endDate":"2021-12-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2021-12-31"}],"amountAwarded":1464291,"Financial Year":"2020/21","Lead Applicant":"Dr Laurent Fraisse","grantProgramme":[{"title":"Therapeutics Accelerator ","title_keyword":"Therapeutics Accelerator "}],"Applicant Surname":"Fraisse","Partnership Value":1464291,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Drugs-for-Neglected-Diseases-Initiative","name":"Drugs for Neglected Diseases Initiative","addressCountry":"Switzerland","id_and_name":"[\"Drugs for Neglected Diseases Initiative\", \"360G-Wellcome-ORG:Drugs-for-Neglected-Diseases-Initiative\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Drugs-for-Neglected-Diseases-Initiative","name":"Drugs for Neglected Diseases Initiative"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Design and implementation of a translational drug development platform for COVID-19 to generate preclinical evidence in support of treatment arms of the ANTICOV clinical trial  Through the rapid establishment of a translational pathway, DNDi and its partners aim at providing the next generation of candidate medicines for SARS-CoV-2 clinical trials as well as integrating back-translations to validate the most appropriate preclinical models. The project is planned to run from September 2020-December 2021, with a total budget of 1.97M GBP, split into three pillars of activities composed of short and medium- term deliverables:  \n\n\n \n Pillar 1 : Selection of the best combination of repurposed antiviral drugs to include into the 3rd arm of the ANTICOV clinical trial and the next back-ups \n \n \n Pillar 2 : Support candidate progression through an integrated pharmacometrics package involving both Physiologically-Based Pharmacokinetic (PBPK) and population pharmacokinetic (PopPK) modelling approaches \n \n \n Pillar 3 : Development of a translational platform and performance of a comparative analysis of selected drugs/combinations (including those from Pillar 1) to better understand and refine the screening cascade with best translational value; definition of a Target Candidate Profile (TCP) for SARS-CoV-2 mild infection\n \n\n\nThis project will cement a collaborative partnership in the SARS-CoV-2 translational space that will pave the way to future longer-term discovery projects and preparedness for additional future threats. \n\nKey words: COVID-19 / Drug re-purposing / Translational drug development pathway \n","awardDateDateOnly":"2021-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Antiviral Agents","Drug Discovery","Humans","Translational Medical Research"]}
{"id":"360G-Wellcome-222487_Z_21_Z","title":"Regulation of innate immune responses by the TPL-2/ABIN-2/NF-\u03baB1 p105 complex","Region":"Greater London","currency":"GBP","awardDate":"2021-04-13T00:00:00+00:00","Internal ID":"222487/Z/21/Z","description":"The TPL-2/ABIN-2/NF-kappaB1 p105 complex is essential for transmitting Toll-like receptor (TLR) signals, turning on inflammatory responses via TPL-2 kinase activation of ERK1/2 and p38alpha MAP kinases. This proposal will investigate the roles in innate immunity of the newly discovered functions of the TPL-2 complex in stimulating phagosome maturation in macrophages independently of MAP kinase activation.\n\n1) TPL-2 and ABIN-2 regulation of phagosome function in professional phagocytes.\n\nMechanisms of TPL-2 and ABIN-2 regulation of phagosome maturation in mouse and human macrophages will be established.\n\nRoles of TPL-2 and ABIN-2 regulation of phagosome function in mouse neutrophils and dendritic cells will be investigated.\n\n2) TPL-2 and ABIN-2 regulation of innate immune responses to pathogenic bacteria.\n\nRoles of TPL-2 and ABIN-2 regulation of phagosome function in mouse immune responses to Staphylococcus aureus will be determined.\n\n3) TPL-2 induction of phagosome maturation in inflammatory bowel disease (IBD).\n\nThe human MAP3K8 gene encoding TPL-2 is linked genetically to the development of IBD, an auto-inflammatory disease that involves an abnormal mucosal immune response to intestinal bacteria. The role of TPL-2 regulation of phagosome function in gut inflammation will be investigated, using human monocyte-derived macrophages from IBD patients/control individuals, and the Citrobacter rodentium mouse model of colitis.\n\n\n \n","plannedDates":[{"endDate":"2027-01-03T00:00:00+00:00","startDate":"2022-01-04T00:00:00+00:00","startDateDateOnly":"2022-01-04","endDateDateOnly":"2027-01-03"}],"amountAwarded":1564396,"Financial Year":"2020/21","Lead Applicant":"Prof Steven Ley","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Ley","Partnership Value":1564396,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Regulation of innate immune responses by the TPL-2/ABIN-2/NF-\u03baB1 p105 complex The TPL-2/ABIN-2/NF-kappaB1 p105 complex is essential for transmitting Toll-like receptor (TLR) signals, turning on inflammatory responses via TPL-2 kinase activation of ERK1/2 and p38alpha MAP kinases. This proposal will investigate the roles in innate immunity of the newly discovered functions of the TPL-2 complex in stimulating phagosome maturation in macrophages independently of MAP kinase activation.\n\n1) TPL-2 and ABIN-2 regulation of phagosome function in professional phagocytes.\n\nMechanisms of TPL-2 and ABIN-2 regulation of phagosome maturation in mouse and human macrophages will be established.\n\nRoles of TPL-2 and ABIN-2 regulation of phagosome function in mouse neutrophils and dendritic cells will be investigated.\n\n2) TPL-2 and ABIN-2 regulation of innate immune responses to pathogenic bacteria.\n\nRoles of TPL-2 and ABIN-2 regulation of phagosome function in mouse immune responses to Staphylococcus aureus will be determined.\n\n3) TPL-2 induction of phagosome maturation in inflammatory bowel disease (IBD).\n\nThe human MAP3K8 gene encoding TPL-2 is linked genetically to the development of IBD, an auto-inflammatory disease that involves an abnormal mucosal immune response to intestinal bacteria. The role of TPL-2 regulation of phagosome function in gut inflammation will be investigated, using human monocyte-derived macrophages from IBD patients/control individuals, and the Citrobacter rodentium mouse model of colitis.\n\n\n \n","awardDateDateOnly":"2021-04-13","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Citrobacter rodentium","Colitis","Humans","Immunity, Innate","MAP Kinase Signaling System","Macrophages","Mice","Mice, Inbred C57BL","Mice, Knockout","NF-kappa B","Neutrophils"]}
{"id":"360G-Wellcome-222460_Z_21_Z","title":"Cell cycle control in archaea","Region":"East of England","currency":"GBP","awardDate":"2021-04-13T00:00:00+00:00","Internal ID":"222460/Z/21/Z","description":"To sustain life, cells must first duplicate their genome and then segregate both copies into two daughter cells at division. This requires regulation. In eukaryotes, the timing of DNA replication, segregation and cytokinesis are coordinated by a cell cycle clock, which marks time through the rise and sudden fall in the activity of a conserved set of CDK-Cyclins. Interestingly, the archaeon Sulfolobus acidocaldarius possesses a cell division cycle like ours, with distinct phases of DNA replication and cell division separated by gap phases, while lacking obvious homologues of CDK-Cyclins. Since Sulfolobus and eukaryotes are thought to share a common ancestor ( > 1,000,000,000 years ago), and use similar machinery to fire origins and to complete cell abscission, this suggests that cell cycle regulation predates eukaryotes and the evolution of CDK-Cyclins. Building on our recent discoveries, in this proposal we aim to test this hypothesis by studying the role and regulation of proteasome-mediated protein degradation in resetting the Sulfolobus cell cycle. Through this work we expect to identify core common regulatory principles of cell cycle control and to identify cell cycle control machinery that has been conserved from archaea to eukaryotes - shedding new light on the origins of the eukaryotic cell cycle.\n","plannedDates":[{"endDate":"2026-12-31T00:00:00+00:00","startDate":"2022-01-01T00:00:00+00:00","startDateDateOnly":"2022-01-01","endDateDateOnly":"2026-12-31"}],"amountAwarded":1182524,"Financial Year":"2020/21","Lead Applicant":"Dr Buzz Baum","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Baum","Partnership Value":1182524,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:MRC-Laboratory-of-Molecular-Biology","name":"MRC Laboratory of Molecular Biology","addressCountry":"United Kingdom","id_and_name":"[\"MRC Laboratory of Molecular Biology\", \"360G-Wellcome-ORG:MRC-Laboratory-of-Molecular-Biology\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:MRC-Laboratory-of-Molecular-Biology","name":"MRC Laboratory of Molecular Biology"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Cell cycle control in archaea To sustain life, cells must first duplicate their genome and then segregate both copies into two daughter cells at division. This requires regulation. In eukaryotes, the timing of DNA replication, segregation and cytokinesis are coordinated by a cell cycle clock, which marks time through the rise and sudden fall in the activity of a conserved set of CDK-Cyclins. Interestingly, the archaeon Sulfolobus acidocaldarius possesses a cell division cycle like ours, with distinct phases of DNA replication and cell division separated by gap phases, while lacking obvious homologues of CDK-Cyclins. Since Sulfolobus and eukaryotes are thought to share a common ancestor ( > 1,000,000,000 years ago), and use similar machinery to fire origins and to complete cell abscission, this suggests that cell cycle regulation predates eukaryotes and the evolution of CDK-Cyclins. Building on our recent discoveries, in this proposal we aim to test this hypothesis by studying the role and regulation of proteasome-mediated protein degradation in resetting the Sulfolobus cell cycle. Through this work we expect to identify core common regulatory principles of cell cycle control and to identify cell cycle control machinery that has been conserved from archaea to eukaryotes - shedding new light on the origins of the eukaryotic cell cycle.\n","awardDateDateOnly":"2021-04-13","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anaphase-Promoting Complex-Cyclosome","Archaeal Proteins","Cell Cycle","Cell Cycle Proteins","DNA Replication","Proteasome Endopeptidase Complex"]}
{"id":"360G-Wellcome-222457_Z_21_Z","title":"Neural mechanisms of memory & prediction, finding structure in experience","Region":"Greater London","currency":"GBP","awardDate":"2021-04-13T00:00:00+00:00","Internal ID":"222457/Z/21/Z","description":"Higher cognitive functions by which we learn to understand our environment and behave flexibly within it rely on the construction, from sequential experience, of a coherent representation of our situation (aka an internal \u2018model\u2019 or \u2018cognitive map\u2019). I aim to understand the neural basis of his process via precise mathematical models that directly link low-level neuronal mechanisms to behaviour in prediction, planning, generalisation and memory. This project involves convergent computational and experimental work in mice and humans at the neuronal, systems and behavioural levels, using methods ranging from multi-photon imaging in mice, through virtual reality and neural-level electrophysiology in mice and epilepsy patients, to functional brain imaging in healthy volunteers. Three streams of work address the integration of sensory information and actions into a common representation, how representations of states structured by transitions allow path integration and prediction for planning, and how such representations interface with encoding and retrieval during memory. Success will provide a quantitative understanding of how neural activity in medial temporal, retrosplenial and medial prefrontal brain areas support these complex cognitive functions, and a starting point for relating cognitive symptoms to dysfunction of this neural system in conditions such as posttraumatic stress disorder, schizophrenia and Alzheimers disease.\n","plannedDates":[{"endDate":"2026-09-30T00:00:00+00:00","startDate":"2021-10-01T00:00:00+00:00","startDateDateOnly":"2021-10-01","endDateDateOnly":"2026-09-30"}],"amountAwarded":2864125,"Financial Year":"2020/21","Lead Applicant":"Prof Neil Burgess","grantProgramme":[{"title":"Principal Research Fellowship Renewal","title_keyword":"Principal Research Fellowship Renewal"}],"Applicant Surname":"Burgess","Partnership Value":2864125,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Neural mechanisms of memory & prediction, finding structure in experience Higher cognitive functions by which we learn to understand our environment and behave flexibly within it rely on the construction, from sequential experience, of a coherent representation of our situation (aka an internal \u2018model\u2019 or \u2018cognitive map\u2019). I aim to understand the neural basis of his process via precise mathematical models that directly link low-level neuronal mechanisms to behaviour in prediction, planning, generalisation and memory. This project involves convergent computational and experimental work in mice and humans at the neuronal, systems and behavioural levels, using methods ranging from multi-photon imaging in mice, through virtual reality and neural-level electrophysiology in mice and epilepsy patients, to functional brain imaging in healthy volunteers. Three streams of work address the integration of sensory information and actions into a common representation, how representations of states structured by transitions allow path integration and prediction for planning, and how such representations interface with encoding and retrieval during memory. Success will provide a quantitative understanding of how neural activity in medial temporal, retrosplenial and medial prefrontal brain areas support these complex cognitive functions, and a starting point for relating cognitive symptoms to dysfunction of this neural system in conditions such as posttraumatic stress disorder, schizophrenia and Alzheimers disease.\n","awardDateDateOnly":"2021-04-13","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Brain","Cognition","Epilepsy","Humans","Memory","Mice","Models, Neurological"]}
{"id":"360G-Wellcome-222446_Z_21_Z","title":"Boosting memory consolidation for rehabilitation ","Region":"South East","currency":"GBP","awardDate":"2021-04-13T00:00:00+00:00","Internal ID":"222446/Z/21/Z","description":"Rehabilitation after brain damage such as stroke depends in part on the brain\u2019s ability to reorganise. It is therefore critical that we understand how brain plasticity after injury happens, and how it can be influenced. \nClinical gains with rehabilitative training should depend not only on gains made during practice but also on offline consolidation, particularly during sleep. Therefore, if we can identify modifiable processes of consolidation, and amplify those to boost consolidation, that would be predicted to improve outcomes.\nUsing rodent models to understand the mechanisms of offline consolidation, we will identify (1) modifiable electrophysiological signals (reactivation, slow waves, or sleep spindles) that occur with consolidation and (2) imaging read-outs of plasticity, including myelin plasticity, associated with successful consolidation. These will be taken forward into human studies to develop non-invasive closed-loop devices to manipulate functional processes of consolidation during sleep after stroke. This will pave the way for future trials to test whether low-cost interventions that boost consolidation and plasticity can deliver lasting clinical improvements. \n","plannedDates":[{"endDate":"2026-12-31T00:00:00+00:00","startDate":"2022-01-01T00:00:00+00:00","startDateDateOnly":"2022-01-01","endDateDateOnly":"2026-12-31"}],"amountAwarded":3118574,"Financial Year":"2020/21","Lead Applicant":"Prof Heidi Johansen-Berg","grantProgramme":[{"title":"Principal Research Fellowship Renewal","title_keyword":"Principal Research Fellowship Renewal"}],"Applicant Surname":"Johansen-Berg","Partnership Value":3118574,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Boosting memory consolidation for rehabilitation  Rehabilitation after brain damage such as stroke depends in part on the brain\u2019s ability to reorganise. It is therefore critical that we understand how brain plasticity after injury happens, and how it can be influenced. \nClinical gains with rehabilitative training should depend not only on gains made during practice but also on offline consolidation, particularly during sleep. Therefore, if we can identify modifiable processes of consolidation, and amplify those to boost consolidation, that would be predicted to improve outcomes.\nUsing rodent models to understand the mechanisms of offline consolidation, we will identify (1) modifiable electrophysiological signals (reactivation, slow waves, or sleep spindles) that occur with consolidation and (2) imaging read-outs of plasticity, including myelin plasticity, associated with successful consolidation. These will be taken forward into human studies to develop non-invasive closed-loop devices to manipulate functional processes of consolidation during sleep after stroke. This will pave the way for future trials to test whether low-cost interventions that boost consolidation and plasticity can deliver lasting clinical improvements. \n","awardDateDateOnly":"2021-04-13","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Brain","Disease Models, Animal","Memory Consolidation","Neuronal Plasticity","Rats","Sleep","Stroke"]}
{"id":"360G-Wellcome-222442_Z_21_Z","title":"Brain CD4 T cells and their influence over microglial homeostasis","Region":"East of England","currency":"GBP","awardDate":"2021-04-13T00:00:00+00:00","Internal ID":"222442/Z/21/Z","description":"Microglia are the main immunological cell of the brain. These residential cells possess both immunological and neurodevelopmental functions, and have pathological roles during age- and injury-associated dementia. We recently characterised a new addition to the neuroimmunological landscape: transiently-resident brain CD4 T cells. Brain T cells are required to trigger the post-natal differentiation of foetal microglia, licensing their neurodevelopmental functions. Much remains unknown about potential further interactions between brain CD4 T cells and microglia. We have adapted cutting-edge technology to enable the parallel study of brain CD4 T cells and microglia. First, will use an adapted flow-based ProCode approach to unravel the molecular control over CD4 T cell entry to the brain and acquisition of the residential phenotype. Second, we have developed a novel genetic tool for competitive chimeric analysis, allowing us to study microglia niche-sensing and the role of interaction with CD4 T cells on microgliosis. Third, we will single cell lineage tracing to dissect the clonal evolution of microglia, and the influence of CD4 T cell interaction on microglial clonal dominance during ageing and following traumatic brain injury. The results will generate new insight into neuroimmune inter-cellular dynamics, and will validate new tools with broad applicability to biomedical sciences.\n","plannedDates":[{"endDate":"2026-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2026-06-30"}],"amountAwarded":1854976,"Financial Year":"2020/21","Lead Applicant":"Prof Adrian Liston","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Liston","Partnership Value":1854976,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Babraham-Institute","name":"Babraham Institute","addressCountry":"United Kingdom","id_and_name":"[\"Babraham Institute\", \"360G-Wellcome-ORG:Babraham-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Babraham-Institute","name":"Babraham Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Brain CD4 T cells and their influence over microglial homeostasis Microglia are the main immunological cell of the brain. These residential cells possess both immunological and neurodevelopmental functions, and have pathological roles during age- and injury-associated dementia. We recently characterised a new addition to the neuroimmunological landscape: transiently-resident brain CD4 T cells. Brain T cells are required to trigger the post-natal differentiation of foetal microglia, licensing their neurodevelopmental functions. Much remains unknown about potential further interactions between brain CD4 T cells and microglia. We have adapted cutting-edge technology to enable the parallel study of brain CD4 T cells and microglia. First, will use an adapted flow-based ProCode approach to unravel the molecular control over CD4 T cell entry to the brain and acquisition of the residential phenotype. Second, we have developed a novel genetic tool for competitive chimeric analysis, allowing us to study microglia niche-sensing and the role of interaction with CD4 T cells on microgliosis. Third, we will single cell lineage tracing to dissect the clonal evolution of microglia, and the influence of CD4 T cell interaction on microglial clonal dominance during ageing and following traumatic brain injury. The results will generate new insight into neuroimmune inter-cellular dynamics, and will validate new tools with broad applicability to biomedical sciences.\n","awardDateDateOnly":"2021-04-13","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Brain","CD4-Positive T-Lymphocytes","Mice","Microglia"]}
{"id":"360G-Wellcome-222436_Z_21_Z","title":"The Research Software Alliance (ReSA)","Region":"International","currency":"GBP","awardDate":"2021-01-29T00:00:00+00:00","Internal ID":"222436/Z/21/Z","description":"Research software is a critical component of open research, and an increased focus on research software challenges will further the objectives of Wellcome Trust\u2019s Open Research programme to maximise research impact. The Research Software Alliance (ReSA) advances the vision that software is valued as a fundamental  component of research. This proposal will support ReSA to bring research software communities together to collaborate on the advancement of research software, utilising application of the FAIR principles as a catalyst for this global endeavour.\n\nThis project seeks USD$157,250 to engage the research software community to apply the FAIR principles to research software. to achieve three aims:\n \n\n\n FAIR4RS WG project direction to develop agreed FAIR for research software principles\n FAIR4RS Roadmap leadership to map FAIR for research software projects into a longer-term strategic framework\n \n People Roadmap to support the development of career paths and reward structures to complement the FAIR4RS Roadmap \n \n\n\n\nThis proposal will accelerate the development of an open research system that recognises and supports research software. This will provide researchers with the skills and resources to fully utilise research software, in a system where policy makers and funders value research software, and where organisations adequately reward staff with software expertise.\n","plannedDates":[{"endDate":"2022-03-09T00:00:00+00:00","startDate":"2021-02-08T00:00:00+00:00","startDateDateOnly":"2021-02-08","endDateDateOnly":"2022-03-09"}],"amountAwarded":115046,"Financial Year":"2020/21","Lead Applicant":"Dr Michelle Barker","grantProgramme":[{"title":"Discretionary Award - Open research","title_keyword":"Discretionary Award - Open research"}],"Applicant Surname":"Barker","Partnership Value":115046,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Code-for-Science-and-Society","name":"Code for Science and Society","addressCountry":"United States","id_and_name":"[\"Code for Science and Society\", \"360G-Wellcome-ORG:Code-for-Science-and-Society\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Code-for-Science-and-Society","name":"Code for Science and Society"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The Research Software Alliance (ReSA) Research software is a critical component of open research, and an increased focus on research software challenges will further the objectives of Wellcome Trust\u2019s Open Research programme to maximise research impact. The Research Software Alliance (ReSA) advances the vision that software is valued as a fundamental  component of research. This proposal will support ReSA to bring research software communities together to collaborate on the advancement of research software, utilising application of the FAIR principles as a catalyst for this global endeavour.\n\nThis project seeks USD$157,250 to engage the research software community to apply the FAIR principles to research software. to achieve three aims:\n \n\n\n FAIR4RS WG project direction to develop agreed FAIR for research software principles\n FAIR4RS Roadmap leadership to map FAIR for research software projects into a longer-term strategic framework\n \n People Roadmap to support the development of career paths and reward structures to complement the FAIR4RS Roadmap \n \n\n\n\nThis proposal will accelerate the development of an open research system that recognises and supports research software. This will provide researchers with the skills and resources to fully utilise research software, in a system where policy makers and funders value research software, and where organisations adequately reward staff with software expertise.\n","awardDateDateOnly":"2021-01-29","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Leadership","Research","Software"]}
{"id":"360G-Wellcome-222433_Z_21_Z","title":"Interferon and Human Pandemic Viruses ","Region":"Greater London","currency":"GBP","awardDate":"2021-04-13T00:00:00+00:00","Internal ID":"222433/Z/21/Z","description":"We wish to define the key interferon (IFN)-stimulated gene (ISG) effectors for three pathogenic human viruses \u2013 HIV-1, SARS-CoV-2 and influenza virus \u2013 and understand the molecular basis for antiviral function.  Specific ISGs will be identified in unbiased gene silencing (siRNA/ CRISPRi) screens, some of which we have developed.  For HIV-1, we will initially focus on the antiviral mechanisms and post-transcriptional regulation of post-entry inhibitors we have identified, human-TRIM5alpha and MX2, including the central roles played by ubiquitination and phosphorylation.  Our discovery that NCOA7 suppresses endocytic virus infection (e.g., SARS-CoV-2) provides the opportunity to study how the endolysosomal system can be dysregulated, potentially through altering vacuolar-ATPase activity.  New screens for ISGs targeting SARS-CoV-2 or influenza virus will be undertaken using wild-type viruses as well as engineered strains carrying disruptions in candidate IFN- or ISG-antagonists.  We will explore the molecular mechanisms and regulatory pathways used by the most potent ISGs using multiple complementary experimental approaches, including proteomic and approved drug screens, and determine how these viruses escape or survive ISG action.  By understanding the ISG effectors that can control these viruses, we will gain fresh insights into viral replication strategies, disease processes and host immunity, and inform future antiviral therapeutic development.\n \n","plannedDates":[{"endDate":"2026-08-01T00:00:00+00:00","startDate":"2021-08-02T00:00:00+00:00","startDateDateOnly":"2021-08-02","endDateDateOnly":"2026-08-01"}],"amountAwarded":2030820,"Financial Year":"2020/21","Lead Applicant":"Prof Michael Malim","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Malim","Partnership Value":2030820,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Interferon and Human Pandemic Viruses  We wish to define the key interferon (IFN)-stimulated gene (ISG) effectors for three pathogenic human viruses \u2013 HIV-1, SARS-CoV-2 and influenza virus \u2013 and understand the molecular basis for antiviral function.  Specific ISGs will be identified in unbiased gene silencing (siRNA/ CRISPRi) screens, some of which we have developed.  For HIV-1, we will initially focus on the antiviral mechanisms and post-transcriptional regulation of post-entry inhibitors we have identified, human-TRIM5alpha and MX2, including the central roles played by ubiquitination and phosphorylation.  Our discovery that NCOA7 suppresses endocytic virus infection (e.g., SARS-CoV-2) provides the opportunity to study how the endolysosomal system can be dysregulated, potentially through altering vacuolar-ATPase activity.  New screens for ISGs targeting SARS-CoV-2 or influenza virus will be undertaken using wild-type viruses as well as engineered strains carrying disruptions in candidate IFN- or ISG-antagonists.  We will explore the molecular mechanisms and regulatory pathways used by the most potent ISGs using multiple complementary experimental approaches, including proteomic and approved drug screens, and determine how these viruses escape or survive ISG action.  By understanding the ISG effectors that can control these viruses, we will gain fresh insights into viral replication strategies, disease processes and host immunity, and inform future antiviral therapeutic development.\n \n","awardDateDateOnly":"2021-04-13","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Antiviral Agents","HIV-1","Host-Pathogen Interactions","Humans","Influenza A virus","Lysosomes","Ubiquitination","Virus Replication"]}
{"id":"360G-Wellcome-222432_Z_21_Z","title":"Development of community-led approaches to support sexual and reproductive health among survivors of trafficking in Uganda and Sierra Leone.","Region":"North West","currency":"GBP","awardDate":"2020-11-30T00:00:00+00:00","Internal ID":"222432/Z/21/Z","description":"Not available","plannedDates":[{"endDate":"2021-07-31T00:00:00+00:00","startDate":"2020-08-01T00:00:00+00:00","startDateDateOnly":"2020-08-01","endDateDateOnly":"2021-07-31"}],"amountAwarded":44838,"Financial Year":"2020/21","Lead Applicant":"Dr Tara Tancred","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Tancred","Partnership Value":44838,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"Liverpool School of Tropical Medicine\", \"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Development of community-led approaches to support sexual and reproductive health among survivors of trafficking in Uganda and Sierra Leone. Not available","awardDateDateOnly":"2020-11-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Female","Human Trafficking","Humans","Male","Reproductive Health","Sierra Leone","Survivors","Uganda"]}
{"id":"360G-Wellcome-222431_Z_21_Z","title":"Mobile health for mobile people.","Region":"South East","currency":"GBP","awardDate":"2020-11-30T00:00:00+00:00","Internal ID":"222431/Z/21/Z","description":"Not available","plannedDates":[{"endDate":"2021-07-31T00:00:00+00:00","startDate":"2020-08-01T00:00:00+00:00","startDateDateOnly":"2020-08-01","endDateDateOnly":"2021-07-31"}],"amountAwarded":45045,"Financial Year":"2020/21","Lead Applicant":"Dr Olivier Sterck","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Sterck","Partnership Value":45045,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mobile health for mobile people. Not available","awardDateDateOnly":"2020-11-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Telemedicine"]}
{"id":"360G-Wellcome-222430_Z_21_Z","title":"Consortium on improving access to integrated Sexual and Reproductive Health and Mental Health services among mobile populations.","Region":"South East","currency":"GBP","awardDate":"2020-11-30T00:00:00+00:00","Internal ID":"222430/Z/21/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-12-01T00:00:00+00:00","startDateDateOnly":"2020-12-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":43573,"Financial Year":"2020/21","Lead Applicant":"Prof Priyamwada Deshingkar","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Deshingkar","Partnership Value":43573,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Sussex","name":"University of Sussex","addressCountry":"United Kingdom","id_and_name":"[\"University of Sussex\", \"360G-Wellcome-ORG:University-of-Sussex\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Sussex","name":"University of Sussex"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Consortium on improving access to integrated Sexual and Reproductive Health and Mental Health services among mobile populations. Not available","awardDateDateOnly":"2020-11-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Female","Health Services Accessibility","Humans","Mental Health Services","Reproductive Health","Reproductive Health Services","Sexual Behavior","Sexual Health"]}
{"id":"360G-Wellcome-222429_Z_21_Z","title":"There isn't an app for this! Regulating the Migration of Health Data in Africa.","Region":"West Midlands","currency":"GBP","awardDate":"2020-11-30T00:00:00+00:00","Internal ID":"222429/Z/21/Z","description":"Not available","plannedDates":[{"endDate":"2021-08-16T00:00:00+00:00","startDate":"2020-08-17T00:00:00+00:00","startDateDateOnly":"2020-08-17","endDateDateOnly":"2021-08-16"}],"amountAwarded":45043,"Financial Year":"2020/21","Lead Applicant":"Dr Sharifah Sekalala","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Sekalala","Partnership Value":45043,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Warwick","name":"University of Warwick","addressCountry":"United Kingdom","id_and_name":"[\"University of Warwick\", \"360G-Wellcome-ORG:University-of-Warwick\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Warwick","name":"University of Warwick"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"There isn't an app for this! Regulating the Migration of Health Data in Africa. Not available","awardDateDateOnly":"2020-11-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa","Humans"]}
{"id":"360G-Wellcome-222418_Z_21_Z","title":"TYPIST ARTIST PIRATE KING","Region":"Greater London","currency":"GBP","awardDate":"2020-11-30T00:00:00+00:00","Internal ID":"222418/Z/21/Z","description":"Typist Artist Pirate King is an innovative and accessible dramatic feature film drawn from the extensive archives of art, diaries and letters held at Wellcome of artist and mental health survivor, Audrey Amiss. The film is a first person account and offers a rich insight into how Amiss saw and experienced the world.\n            Amiss described herself as someone who people crossed the road to avoid. The film does not \u2018other\u2019 her, and, for those who did cross the road to avoid her, creates the opportunity to identify with her. The film is a powerful contribution to conversations about mental health stigma and plays an important role in creating representation that can help erase stigma.\n            For the many people who define themselves as mental health patients/ clients/ users/ former users/ survivors, the film is actively speaking to them. It does not merely address a so called \"neuro-normal\" audience but represents how ways of thinking, experiencing and seeing the world are diverse and urgently deserve to be represented in their complexity for all to see and engage with.\n            We anticipate a significant international release of the film, followed later by it being used as valuable study material within academia.\n \n","plannedDates":[{"endDate":"2021-10-01T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2021-10-01"}],"amountAwarded":100000,"Financial Year":"2020/21","Lead Applicant":"Ms Cairo Cannon","grantProgramme":[{"title":"Discretionary Award - Public Engagement","title_keyword":"Discretionary Award - Public Engagement"}],"Applicant Surname":"Cannon","Partnership Value":100000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Cannon-and-Morley-Productions-Ltd","name":"Cannon and Morley Productions Ltd","addressCountry":"United Kingdom","id_and_name":"[\"Cannon and Morley Productions Ltd\", \"360G-Wellcome-ORG:Cannon-and-Morley-Productions-Ltd\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Cannon-and-Morley-Productions-Ltd","name":"Cannon and Morley Productions Ltd"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"TYPIST ARTIST PIRATE KING Typist Artist Pirate King is an innovative and accessible dramatic feature film drawn from the extensive archives of art, diaries and letters held at Wellcome of artist and mental health survivor, Audrey Amiss. The film is a first person account and offers a rich insight into how Amiss saw and experienced the world.\n            Amiss described herself as someone who people crossed the road to avoid. The film does not \u2018other\u2019 her, and, for those who did cross the road to avoid her, creates the opportunity to identify with her. The film is a powerful contribution to conversations about mental health stigma and plays an important role in creating representation that can help erase stigma.\n            For the many people who define themselves as mental health patients/ clients/ users/ former users/ survivors, the film is actively speaking to them. It does not merely address a so called \"neuro-normal\" audience but represents how ways of thinking, experiencing and seeing the world are diverse and urgently deserve to be represented in their complexity for all to see and engage with.\n            We anticipate a significant international release of the film, followed later by it being used as valuable study material within academia.\n \n","awardDateDateOnly":"2020-11-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Mental Disorders","Mental Health","Social Stigma"]}
{"id":"360G-Wellcome-222413_Z_21_Z","title":"Risk-benefit assessment of snakebite antivenoms","Region":"International","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222413/Z/21/Z","description":"Not available","plannedDates":[{"endDate":"2022-09-08T00:00:00+00:00","startDate":"2021-07-12T00:00:00+00:00","startDateDateOnly":"2021-07-12","endDateDateOnly":"2022-09-08"}],"amountAwarded":2135985,"Financial Year":"2020/21","Lead Applicant":"Ms Carmen Rodriguez Hernandez","grantProgramme":[{"title":"Discretionary Award - Snakebite","title_keyword":"Discretionary Award - Snakebite"}],"Applicant Surname":"Rodriguez Hernandez","Partnership Value":2135985,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Prof Juan Calvete","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:World-Health-Organization-Switzerland","name":"World Health Organization, Switzerland","addressCountry":"Switzerland","id_and_name":"[\"World Health Organization, Switzerland\", \"360G-Wellcome-ORG:World-Health-Organization-Switzerland\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:World-Health-Organization-Switzerland","name":"World Health Organization, Switzerland"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Risk-benefit assessment of snakebite antivenoms Not available","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Antivenins","Humans","Snake Bites","Snakes"]}
{"id":"360G-Wellcome-222412_Z_21_Z","title":"Designing Sustainable Market Systems for New Antibiotics","Region":"International","currency":"GBP","awardDate":"2021-03-31T00:00:00+00:00","Internal ID":"222412/Z/21/Z","description":"In partnership with the Wellcome Trust, the Milken Institute's FasterCures and the Financial Innovations Lab program will examine ways to engage, accelerate or modify existing models or design new models that can support the development and commercialization of new antibiotics. The project will look to thoroughly vet the barriers and incentives for implementing a more sustainable system, focusing on identifying fund models and financing mechanisms that are applicable across disease areas and markets. The Lab will utilize the Milken Institute\u2019s network and expertise to thoroughly vet funding models to ensure they are operational and provide a platform towards implementation.\n\nUsing the Lab\u2019s signature model, the project will: 1) complete independent research and stakeholder interviews on the nuances of the issue area to complete a landscape analyses; 2) host a moderated, in-person roundtable with interdisciplinary leaders, including non-governmental organizations, researchers, policymakers, investors, financial institutions, academics, and industry experts to generate market-based solutions, and 3) produce a summary report on the findings of the roundtable, including policy recommendations and models for financial incentives. By leveraging a diverse pool of knowledge, the Lab will develop solutions to help fund and expedite new, innovative ways of funding new antibiotic development and commercialization.\n","plannedDates":[{"endDate":"2021-12-21T00:00:00+00:00","startDate":"2021-03-24T00:00:00+00:00","startDateDateOnly":"2021-03-24","endDateDateOnly":"2021-12-21"}],"amountAwarded":303984,"Financial Year":"2020/21","Lead Applicant":"Ms Esther Krofah","grantProgramme":[{"title":"Discretionary award \u2013 DRI","title_keyword":"Discretionary award \u2013 DRI"}],"Applicant Surname":"Krofah","Partnership Value":303984,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Ms Caitlin MacLean, Dr Brenda Huneycutt","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Milken-Institute","name":"Milken Institute","addressCountry":"United States","id_and_name":"[\"Milken Institute\", \"360G-Wellcome-ORG:Milken-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Milken-Institute","name":"Milken Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Designing Sustainable Market Systems for New Antibiotics In partnership with the Wellcome Trust, the Milken Institute's FasterCures and the Financial Innovations Lab program will examine ways to engage, accelerate or modify existing models or design new models that can support the development and commercialization of new antibiotics. The project will look to thoroughly vet the barriers and incentives for implementing a more sustainable system, focusing on identifying fund models and financing mechanisms that are applicable across disease areas and markets. The Lab will utilize the Milken Institute\u2019s network and expertise to thoroughly vet funding models to ensure they are operational and provide a platform towards implementation.\n\nUsing the Lab\u2019s signature model, the project will: 1) complete independent research and stakeholder interviews on the nuances of the issue area to complete a landscape analyses; 2) host a moderated, in-person roundtable with interdisciplinary leaders, including non-governmental organizations, researchers, policymakers, investors, financial institutions, academics, and industry experts to generate market-based solutions, and 3) produce a summary report on the findings of the roundtable, including policy recommendations and models for financial incentives. By leveraging a diverse pool of knowledge, the Lab will develop solutions to help fund and expedite new, innovative ways of funding new antibiotic development and commercialization.\n","awardDateDateOnly":"2021-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Anti-Bacterial Agents","Humans","Milk","Research Support as Topic"]}
{"id":"360G-Wellcome-222410_Z_21_Z","title":"IDDO: FAIR, equitable and sustainable data platform for infectious diseases","Region":"South East","currency":"GBP","awardDate":"2021-02-26T00:00:00+00:00","Internal ID":"222410/Z/21/Z","description":"The COVID-19 pandemic has once again exposed the lack of coordination and cooperation across the research and development efforts of the infectious disease community. A key indicator of this failing is the lack of international, interoperable data platforms to provide rapid insight into disease pathogenesis and treatment. Access to data is an important tool for accelerating evidence, product development, and scientific innovation.\n\nEnhanced technology, infrastructure and systems for data platforms will increase Findability, Accessibility, Interoperability, and Reuse (FAIR), so that science can advance in a rapid, robust and innovative way, saving lives in the affected communities.\n\nRecognising the importance and complexity of the task at hand, this project brings together the vast experience of IDDO, Vivli, and other key stakeholders to deliver a broad, effective, and sustainable data platform(s) for infectious diseases.\n\nIn this project, IDDO will:\n\n\n Enhance its platform for improved findability, discovery, and persistence which ensures that data are available in the long-term;\n Optimise and accelerate its data curation capacity;\n Streamline and accelerate its data access workflow;\n Develop a business plan to secure the sustainability and success of the platform\n\n","plannedDates":[{"endDate":"2024-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2024-03-31"}],"amountAwarded":4794788,"Financial Year":"2020/21","Lead Applicant":"Prof Philippe J Guerin","grantProgramme":[{"title":"Discretionary Award \u2013 DSH","title_keyword":"Discretionary Award \u2013 DSH"}],"Applicant Surname":"Guerin","Partnership Value":4794788,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Laura Merson","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"IDDO: FAIR, equitable and sustainable data platform for infectious diseases The COVID-19 pandemic has once again exposed the lack of coordination and cooperation across the research and development efforts of the infectious disease community. A key indicator of this failing is the lack of international, interoperable data platforms to provide rapid insight into disease pathogenesis and treatment. Access to data is an important tool for accelerating evidence, product development, and scientific innovation.\n\nEnhanced technology, infrastructure and systems for data platforms will increase Findability, Accessibility, Interoperability, and Reuse (FAIR), so that science can advance in a rapid, robust and innovative way, saving lives in the affected communities.\n\nRecognising the importance and complexity of the task at hand, this project brings together the vast experience of IDDO, Vivli, and other key stakeholders to deliver a broad, effective, and sustainable data platform(s) for infectious diseases.\n\nIn this project, IDDO will:\n\n\n Enhance its platform for improved findability, discovery, and persistence which ensures that data are available in the long-term;\n Optimise and accelerate its data curation capacity;\n Streamline and accelerate its data access workflow;\n Develop a business plan to secure the sustainability and success of the platform\n\n","awardDateDateOnly":"2021-02-26","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Communicable Diseases","Humans"]}
{"id":"360G-Wellcome-222407_Z_21_Z","title":"Manufacture of a GMP SARS-CoV-2 challenge agent","Region":"Greater London","currency":"GBP","awardDate":"2020-11-30T00:00:00+00:00","Internal ID":"222407/Z/21/Z","description":"In the current COVID-19 emergency, a controlled SARS-COV-2 human infection model (CHIM) has the potential to accelerate the understanding of pathogenesis, induction of immunity and immune mechanisms of resistance to disease, as well as a means to test novel diagnostics and treatments, especially between waves of the pandemic, when occurrence of natural disease is relatively uncommon. A large number of SARS-COV-2 vaccine candidates are at various stages of development internationally including those which have recently entered mid-late stage clinical testing in field studies. In order to make the greatest public health impact, there is an urgent need to select the most promising vaccines in the shortest possible timeframe. In addition, human infection challenge can contribute to the identification of correlates and mechanisms of protection against infection and shedding of virus in vaccinated volunteers. Finally, the model may be useful in the determination of the durability of protection in seropositive individuals with documented prior wild type infection. This proposal is a dose titration study to generate two GMP challenge agents and establish the safety of a wild-type SARS-COV-2 controlled infection in the upper respiratory tract of young healthy volunteers that will allow swift and robust assessment of vaccine efficacy.\n \n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":4178641,"Financial Year":"2020/21","Lead Applicant":"Dr Christopher Chiu","grantProgramme":[{"title":"Human Infection Studies (Full)","title_keyword":"Human Infection Studies (Full)"}],"Applicant Surname":"Chiu","Partnership Value":4178641,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Prof Peter Openshaw, Prof Wendy Barclay, Prof Helen McShane","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Manufacture of a GMP SARS-CoV-2 challenge agent In the current COVID-19 emergency, a controlled SARS-COV-2 human infection model (CHIM) has the potential to accelerate the understanding of pathogenesis, induction of immunity and immune mechanisms of resistance to disease, as well as a means to test novel diagnostics and treatments, especially between waves of the pandemic, when occurrence of natural disease is relatively uncommon. A large number of SARS-COV-2 vaccine candidates are at various stages of development internationally including those which have recently entered mid-late stage clinical testing in field studies. In order to make the greatest public health impact, there is an urgent need to select the most promising vaccines in the shortest possible timeframe. In addition, human infection challenge can contribute to the identification of correlates and mechanisms of protection against infection and shedding of virus in vaccinated volunteers. Finally, the model may be useful in the determination of the durability of protection in seropositive individuals with documented prior wild type infection. This proposal is a dose titration study to generate two GMP challenge agents and establish the safety of a wild-type SARS-COV-2 controlled infection in the upper respiratory tract of young healthy volunteers that will allow swift and robust assessment of vaccine efficacy.\n \n","awardDateDateOnly":"2020-11-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Healthy Volunteers","Humans"]}
{"id":"360G-Wellcome-222406_Z_21_Z","title":"RECOVERY International","Region":"South East","currency":"GBP","awardDate":"2020-11-30T00:00:00+00:00","Internal ID":"222406/Z/21/Z","description":"The Phase 3 RECOVERY platform has been a success, recruiting over 13,500 patients and producing 3 clear, world practice-changing results in the first 100 days of recruitment. The RECOVERY team has been approached by clinical investigators from various LMICs who wish to participate in RECOVERY. As it becomes clear that this pandemic will continue at various locations and paces over the next 24 months, there is an opportunity to increase the impact of the RECOVERY trial by expanding internationally. Expansion has the potential to speed up the assessment of novel treatments, increase the global relevance of the trial results, build capacity, and reduce wasted efforts on small uninformative studies. The key goal is to establish RECOVERY internationally, initially in Indonesia, Nepal and Vietnam, with a view to opening sites also in Africa. \n\n \n","plannedDates":[{"endDate":"2022-11-30T00:00:00+00:00","startDate":"2020-12-01T00:00:00+00:00","startDateDateOnly":"2020-12-01","endDateDateOnly":"2022-11-30"}],"amountAwarded":2134694,"Financial Year":"2020/21","Lead Applicant":"Prof Peter Horby","grantProgramme":[{"title":"Therapeutics Accelerator ","title_keyword":"Therapeutics Accelerator "}],"Applicant Surname":"Horby","Partnership Value":2134694,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Prof Guy Thwaites, Dr Raph Hamers, Dr Buddha Basnyat","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"RECOVERY International The Phase 3 RECOVERY platform has been a success, recruiting over 13,500 patients and producing 3 clear, world practice-changing results in the first 100 days of recruitment. The RECOVERY team has been approached by clinical investigators from various LMICs who wish to participate in RECOVERY. As it becomes clear that this pandemic will continue at various locations and paces over the next 24 months, there is an opportunity to increase the impact of the RECOVERY trial by expanding internationally. Expansion has the potential to speed up the assessment of novel treatments, increase the global relevance of the trial results, build capacity, and reduce wasted efforts on small uninformative studies. The key goal is to establish RECOVERY internationally, initially in Indonesia, Nepal and Vietnam, with a view to opening sites also in Africa. \n\n \n","awardDateDateOnly":"2020-11-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Clinical Trials as Topic","Humans","Indonesia","Patient Selection"]}
{"id":"360G-Wellcome-222405_Z_21_Z","title":"What are the determinants of vulnerability to County Lines exploitation? What are the health and economic costs of County Lines?","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222405/Z/21/Z","description":"County lines (CL) trafficking is a model of illegal drug (heroin and crack cocaine) distribution that has emerged recently in the UK, whereby city-based dealing groups exploit the labour of children and adults, often in vulnerable circumstances in order to deal directly to smaller coastal and market towns. Involvement in CL is associated with experiencing a wide range of health harms including violence and sexual exploitation.\n\nCL is causally complex. The many individual-level risk factors currently thought to lead to vulnerability CL exploitation (mental health issues, prior histories of abuse and neglect, being excluded from mainstream education, being in care, prior offending, drug addition, disability) are themselves determined by complex, interacting upstream socio-economic factors. In order to capture this complexity, I aim to take a systems modelling approach to CL trafficking \u2013 viewing the CL phenomenon as an emergent property of a dynamic and open, adaptive system. This model could then be used for \u2018what-if\u2019 policy scenario testing, estimating the possibility for cooperation or conflict between the goals and activities of a wide range of statutory bodies, and could guide the design of coordinated cross-sectoral interventions.\n","plannedDates":[{"endDate":"2023-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2023-08-31"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Kate Hayes","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Hayes","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield","addressCountry":"United Kingdom","id_and_name":"[\"University of Sheffield\", \"360G-Wellcome-ORG:University-of-Sheffield\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"What are the determinants of vulnerability to County Lines exploitation? What are the health and economic costs of County Lines? County lines (CL) trafficking is a model of illegal drug (heroin and crack cocaine) distribution that has emerged recently in the UK, whereby city-based dealing groups exploit the labour of children and adults, often in vulnerable circumstances in order to deal directly to smaller coastal and market towns. Involvement in CL is associated with experiencing a wide range of health harms including violence and sexual exploitation.\n\nCL is causally complex. The many individual-level risk factors currently thought to lead to vulnerability CL exploitation (mental health issues, prior histories of abuse and neglect, being excluded from mainstream education, being in care, prior offending, drug addition, disability) are themselves determined by complex, interacting upstream socio-economic factors. In order to capture this complexity, I aim to take a systems modelling approach to CL trafficking \u2013 viewing the CL phenomenon as an emergent property of a dynamic and open, adaptive system. This model could then be used for \u2018what-if\u2019 policy scenario testing, estimating the possibility for cooperation or conflict between the goals and activities of a wide range of statutory bodies, and could guide the design of coordinated cross-sectoral interventions.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Risk Factors","United Kingdom"]}
{"id":"360G-Wellcome-222401_Z_21_Z","title":"Neural circuits regulating appetite in an uncertain environment","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222401/Z/21/Z","description":"Dietary sodium \u2013 typically, common salt \u2013 is essential to all animals for health and survival, but when consumed in excess it is profoundly damaging, being a leading risk factor for cardiovascular morbidity and mortality worldwide. Eating salty foods is often a pleasurable experience, leaving many individuals struggling to keep their diet healthy.\n\nWhether the taste of salt is rewarding or not depends on the brain\u2019s reward pathways, which make salt less rewarding when the body needs it less. However, periods of sodium deprivation can subvert this, often leading to consumption beyond physiological requirements. This response to a period of deprivation may explain why some individuals are unable to regulate their sodium intake in daily life.\n\nTo better understand the brain circuitry regulating sodium appetite, I will use a combination of animal behavioural and neuroscientific techniques. My focus will be on dopamine, a key neurotransmitter involved in the brain's reward pathways, in addition to electrical activity in the wider brain. I will observe these aspects of brain function during periods of sodium deprivation to shed light on their role in overextending the sodium appetite beyond healthy consumption, delivering new insights about the brain\u2019s role in nutritional disorders and appetite regulation.\n","plannedDates":[{"endDate":"2023-10-11T00:00:00+00:00","startDate":"2020-10-12T00:00:00+00:00","startDateDateOnly":"2020-10-12","endDateDateOnly":"2023-10-11"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Aeron Laffere","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Laffere","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Neural circuits regulating appetite in an uncertain environment Dietary sodium \u2013 typically, common salt \u2013 is essential to all animals for health and survival, but when consumed in excess it is profoundly damaging, being a leading risk factor for cardiovascular morbidity and mortality worldwide. Eating salty foods is often a pleasurable experience, leaving many individuals struggling to keep their diet healthy.\n\nWhether the taste of salt is rewarding or not depends on the brain\u2019s reward pathways, which make salt less rewarding when the body needs it less. However, periods of sodium deprivation can subvert this, often leading to consumption beyond physiological requirements. This response to a period of deprivation may explain why some individuals are unable to regulate their sodium intake in daily life.\n\nTo better understand the brain circuitry regulating sodium appetite, I will use a combination of animal behavioural and neuroscientific techniques. My focus will be on dopamine, a key neurotransmitter involved in the brain's reward pathways, in addition to electrical activity in the wider brain. I will observe these aspects of brain function during periods of sodium deprivation to shed light on their role in overextending the sodium appetite beyond healthy consumption, delivering new insights about the brain\u2019s role in nutritional disorders and appetite regulation.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Appetite","Brain","Humans","Reward","Sodium Chloride, Dietary"]}
{"id":"360G-Wellcome-222400_Z_21_Z","title":"Determining the role of ubiquitin in transmission stage Plasmodium","Region":"Scotland","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222400/Z/21/Z","description":"Approximately half of the global population is currently at risk of malaria infection, with an estimated 0.5 million deaths annually. Malaria is caused by Plasmodium parasites, which have a complex life cycle involving a vertebrate host and mosquito vector. Blood stage parasites cause the symptoms of malaria in humans, and are therefore the target of most current therapies. In order to reduce the incidence of malaria, and therefore global disease burden, a drug to block transmission between the host and vector is needed. The complex regulation required in transmission stage parasites remains poorly understood. Ubiquitylation is a well-researched post-translational modification which is commonly associated with protein degradation, but also has a range of effects from protein re-localisation to induction or arrest of cell signalling events. The role of ubiquitin in transmission stage parasite development is unknown. We aim firstly to identify the \u2018ubiquitome\u2019 of Plasmodium bergheiparasites during transmission stage development using ubiquitin capture systems and mass spectrometry. We subsequently aim to investigate the role of these ubiquitylated proteins during transmission using genetic engineering. These results will improve our understanding of the role ubiquitin may play in the regulation of transmission stage parasite development, and inform future drug discovery efforts.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Nila Johnson","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Johnson","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Determining the role of ubiquitin in transmission stage Plasmodium Approximately half of the global population is currently at risk of malaria infection, with an estimated 0.5 million deaths annually. Malaria is caused by Plasmodium parasites, which have a complex life cycle involving a vertebrate host and mosquito vector. Blood stage parasites cause the symptoms of malaria in humans, and are therefore the target of most current therapies. In order to reduce the incidence of malaria, and therefore global disease burden, a drug to block transmission between the host and vector is needed. The complex regulation required in transmission stage parasites remains poorly understood. Ubiquitylation is a well-researched post-translational modification which is commonly associated with protein degradation, but also has a range of effects from protein re-localisation to induction or arrest of cell signalling events. The role of ubiquitin in transmission stage parasite development is unknown. We aim firstly to identify the \u2018ubiquitome\u2019 of Plasmodium bergheiparasites during transmission stage development using ubiquitin capture systems and mass spectrometry. We subsequently aim to investigate the role of these ubiquitylated proteins during transmission using genetic engineering. These results will improve our understanding of the role ubiquitin may play in the regulation of transmission stage parasite development, and inform future drug discovery efforts.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Humans","Malaria","Plasmodium berghei","Protein Processing, Post-Translational","Ubiquitin","Ubiquitin-Protein Ligases","Ubiquitination"]}
{"id":"360G-Wellcome-222398_Z_21_Z","title":"Role of mixed lineage leukaemia (MLL) proteins 1 and 2 during mesoderm differentiation","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222398/Z/21/Z","description":"In the early mammalian embryo, there is a clump of identical \"na\u00efve pluripotent\" cells. After implantation in the mother\u2019s uterus, these cells diverge into a multitude of different cell types during a process called gastrulation. During this process, the three main lineages of the mammalian body, ectoderm, mesoderm and endoderm, are formed and shortly after, the basic body plan and body axes are established. Here, we focus on formation of mesoderm that gives rise to cell types such as blood cells.\n\nWhile every cell in our body is in principle equipped with an exact copy of the same genetic information, in the form of DNA wrapped around proteins called histones, it is poorly understood how protein complexes that modify these histones, such as the MLL/COMPASS complex, control the process of mesoderm differentiation.\n\nTo address this, I will use advanced imaging techniques that can watch individual MLL/COMPASS or the DNA sites to which they bind. I will use embryonic stem cells that mimic in a dish the changes that occur as pluripotent cells differentiate towards mesoderm.\n\nWe hope to understand the driving forces behind the transition from pluripotent cells towards mesoderm lineages, providing overarching mechanistic principles of lineage diversification.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Maike Steindel","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Steindel","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Role of mixed lineage leukaemia (MLL) proteins 1 and 2 during mesoderm differentiation In the early mammalian embryo, there is a clump of identical \"na\u00efve pluripotent\" cells. After implantation in the mother\u2019s uterus, these cells diverge into a multitude of different cell types during a process called gastrulation. During this process, the three main lineages of the mammalian body, ectoderm, mesoderm and endoderm, are formed and shortly after, the basic body plan and body axes are established. Here, we focus on formation of mesoderm that gives rise to cell types such as blood cells.\n\nWhile every cell in our body is in principle equipped with an exact copy of the same genetic information, in the form of DNA wrapped around proteins called histones, it is poorly understood how protein complexes that modify these histones, such as the MLL/COMPASS complex, control the process of mesoderm differentiation.\n\nTo address this, I will use advanced imaging techniques that can watch individual MLL/COMPASS or the DNA sites to which they bind. I will use embryonic stem cells that mimic in a dish the changes that occur as pluripotent cells differentiate towards mesoderm.\n\nWe hope to understand the driving forces behind the transition from pluripotent cells towards mesoderm lineages, providing overarching mechanistic principles of lineage diversification.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cell Differentiation","Cell Lineage","Embryonic Stem Cells","Endoderm","Histones","Humans","Mesoderm","Mice","Pluripotent Stem Cells"]}
{"id":"360G-Wellcome-222396_Z_21_Z","title":"Building Trustworthy Clinical AI: from algorithms to clinical deployment","Region":"International","currency":"GBP","awardDate":"2021-03-31T00:00:00+00:00","Internal ID":"222396/Z/21/Z","description":"The goal of this proposal is to develop, implement, and evaluate machine learning algorithms for trustworthy clinical AI. The proposed technology aims to support a wide range of healthcare\napplications, including diagnostics, treatment personalization, and prediction of treatment outcomes. These applications utilize diverse sources of data, including clinical notes, images, and test results. Rather than designing a disease/application-specific AI algorithm, we are interested in developing a capacity that can be readily embedded into existing AI models to improve their transparency and ability to incorporate human feedback as well as strengthen their data privacy guarantees. The Jameel Clinic team has deployed AI tools in many clinical areas. These tools would be our testing ground for measuring the effectiveness and flexibility of the proposed platform.\n","plannedDates":[{"endDate":"2024-03-14T00:00:00+00:00","startDate":"2021-03-15T00:00:00+00:00","startDateDateOnly":"2021-03-15","endDateDateOnly":"2024-03-14"}],"amountAwarded":3446620,"Financial Year":"2020/21","Lead Applicant":"Prof Regina Barzilay","grantProgramme":[{"title":"Discretionary Award \u2013 DSH","title_keyword":"Discretionary Award \u2013 DSH"}],"Applicant Surname":"Barzilay","Partnership Value":3446620,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Massachusetts-Institute-of-Technology","name":"Massachusetts Institute of Technology","addressCountry":"United States","id_and_name":"[\"Massachusetts Institute of Technology\", \"360G-Wellcome-ORG:Massachusetts-Institute-of-Technology\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Massachusetts-Institute-of-Technology","name":"Massachusetts Institute of Technology"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Building Trustworthy Clinical AI: from algorithms to clinical deployment The goal of this proposal is to develop, implement, and evaluate machine learning algorithms for trustworthy clinical AI. The proposed technology aims to support a wide range of healthcare\napplications, including diagnostics, treatment personalization, and prediction of treatment outcomes. These applications utilize diverse sources of data, including clinical notes, images, and test results. Rather than designing a disease/application-specific AI algorithm, we are interested in developing a capacity that can be readily embedded into existing AI models to improve their transparency and ability to incorporate human feedback as well as strengthen their data privacy guarantees. The Jameel Clinic team has deployed AI tools in many clinical areas. These tools would be our testing ground for measuring the effectiveness and flexibility of the proposed platform.\n","awardDateDateOnly":"2021-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Algorithms","Computer Security","Humans","Machine Learning","Precision Medicine"]}
{"id":"360G-Wellcome-222394_Z_21_Z","title":"Economic modelling of cervical cancer control interventions in sub Saharan African countries: A scenario analysis of the 2030 elimination targets for Nigeria","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222394/Z/21/Z","description":" \n\nSub-Saharan African countries continue to bear the burden of cervical cancer. High cancer incidence and high mortality rates can be decreased by  available evidence-based interventions, such as vaccination, screening, and early referral for treatment, if they are implemented on a large scale. The large-scale programs though are expensive and not always affordable in low-income countries.    \n\nIn this study, I aim to examine the economic costs and effect of the World Health Organization cervical cancer elimination strategy in Nigerian health system by 2030. The strategy involves attaining immunisation coverage of 90% for Human papilloma virus (HPV) vaccination, cervical cancer screening coverage of 70% and 90% treatment targets for identified cases . \n\nI will review existing literature, conduct key informant interviews and simulation exercises to provide evidence on the appropriate resources and infrastructural investments required to attain the targets for HPV vaccination, cervical cancer screening and treatments of pre-invasive and invasive cervical cancer in Nigeria by 2030. \n\nThe study will provide evidence to guide decision makers in Nigeria and other sub-Saharan countries in allocating resources to address cervical cancer control in a  robust, evidence-based and equitable manner.\n \n","plannedDates":[{"endDate":"2023-09-15T00:00:00+00:00","startDate":"2020-09-16T00:00:00+00:00","startDateDateOnly":"2020-09-16","endDateDateOnly":"2023-09-15"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Dr Oluwatosin Kuti","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Kuti","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield","addressCountry":"United Kingdom","id_and_name":"[\"University of Sheffield\", \"360G-Wellcome-ORG:University-of-Sheffield\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Economic modelling of cervical cancer control interventions in sub Saharan African countries: A scenario analysis of the 2030 elimination targets for Nigeria  \n\nSub-Saharan African countries continue to bear the burden of cervical cancer. High cancer incidence and high mortality rates can be decreased by  available evidence-based interventions, such as vaccination, screening, and early referral for treatment, if they are implemented on a large scale. The large-scale programs though are expensive and not always affordable in low-income countries.    \n\nIn this study, I aim to examine the economic costs and effect of the World Health Organization cervical cancer elimination strategy in Nigerian health system by 2030. The strategy involves attaining immunisation coverage of 90% for Human papilloma virus (HPV) vaccination, cervical cancer screening coverage of 70% and 90% treatment targets for identified cases . \n\nI will review existing literature, conduct key informant interviews and simulation exercises to provide evidence on the appropriate resources and infrastructural investments required to attain the targets for HPV vaccination, cervical cancer screening and treatments of pre-invasive and invasive cervical cancer in Nigeria by 2030. \n\nThe study will provide evidence to guide decision makers in Nigeria and other sub-Saharan countries in allocating resources to address cervical cancer control in a  robust, evidence-based and equitable manner.\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa South of the Sahara","Developing Countries","Early Detection of Cancer","Female","Humans","Nigeria","Papillomavirus Infections","Papillomavirus Vaccines","Uterine Cervical Neoplasms","Vaccination"]}
{"id":"360G-Wellcome-222393_Z_21_Z","title":"Sources of relaxation differences in quantitative MRI","Region":"Wales","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222393/Z/21/Z","description":"Magnetic resonance imaging (MRI) it is a powerful technique which allows  brain tissue to be explored indirectly. Despite more than 40 years of innovation, the standard clinical MRI protocol remains largely unchanged: a set of 3 images influenced by \u2018relaxation\u2019 phenomena, namely how quickly tissue returns to equilibrium when perturbed by a radiofrequency pulse. Radiologists detect pathology through differences in relative intensity. While recent advances can estimate relaxation times directly, facilitating quantitative MRI, the biophysical origins of differences in relaxation times are poorly understood. In brain tissue, differences in cell size, orientation and make-up have all been posited, but their contributions have not yet been fully characterised. I will use computer simulations and real MRI experiments to tease-apart these mechanisms. This will include validating the specificity of different imaging parameters in animal-models using histology and further evaluating their sensitivity in the human brain at different stage of development. My aim is to make quantitative MRI more interpretable, boosting its clinical utility both in neuroscience and medicine.\n \n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Veronica Dell'Acqua","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Dell'Acqua","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University","addressCountry":"United Kingdom","id_and_name":"[\"Cardiff University\", \"360G-Wellcome-ORG:Cardiff-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Sources of relaxation differences in quantitative MRI Magnetic resonance imaging (MRI) it is a powerful technique which allows  brain tissue to be explored indirectly. Despite more than 40 years of innovation, the standard clinical MRI protocol remains largely unchanged: a set of 3 images influenced by \u2018relaxation\u2019 phenomena, namely how quickly tissue returns to equilibrium when perturbed by a radiofrequency pulse. Radiologists detect pathology through differences in relative intensity. While recent advances can estimate relaxation times directly, facilitating quantitative MRI, the biophysical origins of differences in relaxation times are poorly understood. In brain tissue, differences in cell size, orientation and make-up have all been posited, but their contributions have not yet been fully characterised. I will use computer simulations and real MRI experiments to tease-apart these mechanisms. This will include validating the specificity of different imaging parameters in animal-models using histology and further evaluating their sensitivity in the human brain at different stage of development. My aim is to make quantitative MRI more interpretable, boosting its clinical utility both in neuroscience and medicine.\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Brain","Humans","Magnetic Resonance Imaging"]}
{"id":"360G-Wellcome-222392_Z_21_Z","title":"Examining the role of endothelial derived galectins in vascular inflammation","Region":"West Midlands","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222392/Z/21/Z","description":"The inflammatory response is a sophisticated mechanism used by the body to protect against injury and invading microorganisms and requires the trafficking of disease-fighting immune cells from the bloodstream to the site of injury. Resolution of the inflammatory response involves removal of immune-related infiltrate which if left unresolved can lead to chronic inflammatory pathologies. Carbohydrate-binding proteins called galectins, are expressed by cells that line the blood vessels and play fundamental roles in both the initiation and resolution of the inflammatory response. Changes in the frictional force generated by blood flow through the blood vessels can be detected by these cells which leads to subsequent changes in gene expression and release of these immune-modulating proteins. We aim to investigate and characterise the factors that regulate the endogenous expression of galectins from endothelial cells lining the blood vessels and the functional role they play in vascular inflammation. We aim to use a combination of inventive in vitro, ex vivo and in vivo experiments that combine physiological flow conditions and inflammatory mediators, to study the role of endothelial galectins in vascular inflammation and the mechanisms that underlie this.\n","plannedDates":[{"endDate":"2023-10-10T00:00:00+00:00","startDate":"2020-10-11T00:00:00+00:00","startDateDateOnly":"2020-10-11","endDateDateOnly":"2023-10-10"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Abbey Lightfoot","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Lightfoot","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Birmingham\", \"360G-Wellcome-ORG:University-of-Birmingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Examining the role of endothelial derived galectins in vascular inflammation The inflammatory response is a sophisticated mechanism used by the body to protect against injury and invading microorganisms and requires the trafficking of disease-fighting immune cells from the bloodstream to the site of injury. Resolution of the inflammatory response involves removal of immune-related infiltrate which if left unresolved can lead to chronic inflammatory pathologies. Carbohydrate-binding proteins called galectins, are expressed by cells that line the blood vessels and play fundamental roles in both the initiation and resolution of the inflammatory response. Changes in the frictional force generated by blood flow through the blood vessels can be detected by these cells which leads to subsequent changes in gene expression and release of these immune-modulating proteins. We aim to investigate and characterise the factors that regulate the endogenous expression of galectins from endothelial cells lining the blood vessels and the functional role they play in vascular inflammation. We aim to use a combination of inventive in vitro, ex vivo and in vivo experiments that combine physiological flow conditions and inflammatory mediators, to study the role of endothelial galectins in vascular inflammation and the mechanisms that underlie this.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Endothelial Cells","Endothelium, Vascular","Galectins","Humans","Inflammation","Mice"]}
{"id":"360G-Wellcome-222391_Z_21_Z","title":"Interplay between Nod-like receptor apoptosis inhibitory proteins and prostaglandins in colonic infection, inflammation and cancer","Region":"West Midlands","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222391/Z/21/Z","description":"Maintenance of gut health is dependent on the complex interactions between different cell types in the intestines and the immune system. Communication between these cells ensures that the barrier between the body and the gut contents is not disrupted and enables threats, such as harmful bacteria, to be detected by one cell subset and eliminated by another. The interactions between these cell types are disrupted during inflammation and disease, such as colitis, cancer, and infection. Understanding these signals and how they are perturbed during disease is vital. Certain bacteria are detected using receptors called NAIPs; we aim to understand how activation of NAIPs subsequently affects the rest of the immune system and how this impacts disease development. We will delete NAIPs from epithelial cells in the gut and identify resultant changes in immune cells. We will test this in models of colitis, colorectal cancer and Salmonella infection. I will look at changes in gene expression following NAIP deletion and identify the soluble mediators which influence the immune response. This project will aid our understanding of NAIPs during inflammatory disease development and thus generate potential targets for treating these diseases in the future.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Lisa Scarfe","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Scarfe","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Birmingham\", \"360G-Wellcome-ORG:University-of-Birmingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Interplay between Nod-like receptor apoptosis inhibitory proteins and prostaglandins in colonic infection, inflammation and cancer Maintenance of gut health is dependent on the complex interactions between different cell types in the intestines and the immune system. Communication between these cells ensures that the barrier between the body and the gut contents is not disrupted and enables threats, such as harmful bacteria, to be detected by one cell subset and eliminated by another. The interactions between these cell types are disrupted during inflammation and disease, such as colitis, cancer, and infection. Understanding these signals and how they are perturbed during disease is vital. Certain bacteria are detected using receptors called NAIPs; we aim to understand how activation of NAIPs subsequently affects the rest of the immune system and how this impacts disease development. We will delete NAIPs from epithelial cells in the gut and identify resultant changes in immune cells. We will test this in models of colitis, colorectal cancer and Salmonella infection. I will look at changes in gene expression following NAIP deletion and identify the soluble mediators which influence the immune response. This project will aid our understanding of NAIPs during inflammatory disease development and thus generate potential targets for treating these diseases in the future.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Colitis","Epithelial Cells","Humans","Intestinal Mucosa","Mice","Salmonella Infections"]}
{"id":"360G-Wellcome-222390_Z_21_Z","title":"Investigating the role of IFNg in controlling checkpoint receptor expression in response to immunotherapy","Region":"West Midlands","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222390/Z/21/Z","description":"Cancers are composed of mutant self-cells that exploit their environment to grow. The immune system can identify these altered cells as harmful and kill them. However, in some patients this immune response can become dampened over time. This is due to expression of \"immune checkpoints\" on a population of white blood cells called T cells. These checkpoints act as brakes on the immune response. In recent years, scientists have developed drugs to block these checkpoints, with the aim of releasing the brake on the immune system to attack the tumour (called immune checkpoint blockade ICB). However, ICB is effective in less than half of patients. One of the effects of ICB is to encourage T cells to make the inflammatory cytokine IFNgamma, which aids in eliminating the cancerous cells. Our initial studies suggest that some important immune checkpoints, such as Lag3, are increased by the cytokine IFNgamma, which may limit the success of ICB therapy. We aim to understand how IFNgamma controls these immune checkpoints on T cells in animal models of cancer. By using mice where their T cells cannot sense IFNgamma we will test whether making T cells insensitive to IFNgamma can improve ICB therapy.\n","plannedDates":[{"endDate":"2023-09-27T00:00:00+00:00","startDate":"2020-09-28T00:00:00+00:00","startDateDateOnly":"2020-09-28","endDateDateOnly":"2023-09-27"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr David Lecky","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Lecky","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Birmingham\", \"360G-Wellcome-ORG:University-of-Birmingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the role of IFNg in controlling checkpoint receptor expression in response to immunotherapy Cancers are composed of mutant self-cells that exploit their environment to grow. The immune system can identify these altered cells as harmful and kill them. However, in some patients this immune response can become dampened over time. This is due to expression of \"immune checkpoints\" on a population of white blood cells called T cells. These checkpoints act as brakes on the immune response. In recent years, scientists have developed drugs to block these checkpoints, with the aim of releasing the brake on the immune system to attack the tumour (called immune checkpoint blockade ICB). However, ICB is effective in less than half of patients. One of the effects of ICB is to encourage T cells to make the inflammatory cytokine IFNgamma, which aids in eliminating the cancerous cells. Our initial studies suggest that some important immune checkpoints, such as Lag3, are increased by the cytokine IFNgamma, which may limit the success of ICB therapy. We aim to understand how IFNgamma controls these immune checkpoints on T cells in animal models of cancer. By using mice where their T cells cannot sense IFNgamma we will test whether making T cells insensitive to IFNgamma can improve ICB therapy.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Humans","Immunotherapy","Mice","Neoplasms","T-Lymphocytes"]}
{"id":"360G-Wellcome-222389_Z_21_Z","title":"Investigating the mechanisms of thromboinflammation induced by infection","Region":"West Midlands","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222389/Z/21/Z","description":"Thrombosis is estimated to contribute to 25% of deaths worldwide, yet our understanding of the mechanisms behind thrombus formation and related inflammation remain poor. This so-called thromboinflammation can occur as a result of severe infection, for example in sepsis and severe COVID-19. We aim to probe the lifecycle of the thrombus, and understand why it differs between different organs. To do this, we will use the well-established mouse models of Salmonella infection to study the composition of thrombi in different organs. We also aim to investigate the response of human platelets (the main component of many thrombi) to different strains of Salmonella, allowing identification of host and bacterial-specific factors that are affecting the thrombotic response after infection. \nThis research will help further our understanding of the mechanisms behind the dysregulated inflammatory processes that occur upon infection, including during COVID-19, that can lead to fatal consequences.\n","plannedDates":[{"endDate":"2023-09-27T00:00:00+00:00","startDate":"2020-09-28T00:00:00+00:00","startDateDateOnly":"2020-09-28","endDateDateOnly":"2023-09-27"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Rachel Lamerton","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Lamerton","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Birmingham\", \"360G-Wellcome-ORG:University-of-Birmingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the mechanisms of thromboinflammation induced by infection Thrombosis is estimated to contribute to 25% of deaths worldwide, yet our understanding of the mechanisms behind thrombus formation and related inflammation remain poor. This so-called thromboinflammation can occur as a result of severe infection, for example in sepsis and severe COVID-19. We aim to probe the lifecycle of the thrombus, and understand why it differs between different organs. To do this, we will use the well-established mouse models of Salmonella infection to study the composition of thrombi in different organs. We also aim to investigate the response of human platelets (the main component of many thrombi) to different strains of Salmonella, allowing identification of host and bacterial-specific factors that are affecting the thrombotic response after infection. \nThis research will help further our understanding of the mechanisms behind the dysregulated inflammatory processes that occur upon infection, including during COVID-19, that can lead to fatal consequences.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Blood Platelets","Disease Models, Animal","Humans","Inflammation","Mice","Salmonella","Salmonella Infections","Thrombosis"]}
{"id":"360G-Wellcome-222388_Z_21_Z","title":"Defining pathways of infection induced inflammation in the CNS","Region":"West Midlands","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222388/Z/21/Z","description":"While the importance of smallest cells in blood, namely platelets, in blood clotting is well understood, there is increasing interest in their role in regulating the inflammatory response. Our preliminary observations have revealed platelet aggregation and recruitment within the meninges following infection with the fungus Cryptococcus neoformans, the main causative agent of cryptococcal meningitis. Meningeal inflammation is one of the main contributors towards death in patients with cryptococcal meningitis, and thus targeting this is a potential therapeutic strategy for a disease which kills over 180,000 people every year. This project aims to understand how platelets and leukocytes (e.g. meningeal macrophages) drive inflammation and disease progression within the central nervous system during fungal meningitis. Using techniques such as flow cytometry and microscopy, we will determine platelet-leukocyte interactions during fungal infection in the CNS and define the molecular mechanisms governing these responses. Previous studies have shown disrupting platelet-macrophage interactions worsens disease outcome in sepsis, thus there is scope for targeting these interactions therapeutically. The results from this project will significantly advance our understanding of the pathology of cryptococcal meningitis, a disease associated with high morbidity and mortality, whilst providing novel insights into the immune functions of platelets which are poorly understood.\n","plannedDates":[{"endDate":"2023-10-04T00:00:00+00:00","startDate":"2020-10-05T00:00:00+00:00","startDateDateOnly":"2020-10-05","endDateDateOnly":"2023-10-04"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Sofia Hain Porter","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Hain Porter","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Birmingham\", \"360G-Wellcome-ORG:University-of-Birmingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Defining pathways of infection induced inflammation in the CNS While the importance of smallest cells in blood, namely platelets, in blood clotting is well understood, there is increasing interest in their role in regulating the inflammatory response. Our preliminary observations have revealed platelet aggregation and recruitment within the meninges following infection with the fungus Cryptococcus neoformans, the main causative agent of cryptococcal meningitis. Meningeal inflammation is one of the main contributors towards death in patients with cryptococcal meningitis, and thus targeting this is a potential therapeutic strategy for a disease which kills over 180,000 people every year. This project aims to understand how platelets and leukocytes (e.g. meningeal macrophages) drive inflammation and disease progression within the central nervous system during fungal meningitis. Using techniques such as flow cytometry and microscopy, we will determine platelet-leukocyte interactions during fungal infection in the CNS and define the molecular mechanisms governing these responses. Previous studies have shown disrupting platelet-macrophage interactions worsens disease outcome in sepsis, thus there is scope for targeting these interactions therapeutically. The results from this project will significantly advance our understanding of the pathology of cryptococcal meningitis, a disease associated with high morbidity and mortality, whilst providing novel insights into the immune functions of platelets which are poorly understood.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Blood Platelets","Central Nervous System","Cryptococcus neoformans","Humans","Inflammation","Leukocytes","Macrophages"]}
{"id":"360G-Wellcome-222387_Z_21_Z","title":"Understanding biotin mediated metformin resistance within Pseudomonas aeruginosa","Region":"West Midlands","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222387/Z/21/Z","description":"Biotin synthesis deficient mutants of Pseudomonas aeruginosa can be killed by the diabetes drug metformin. I previously hypothesised that metformin disrupts metabolism and energy production, but not enough to kill Pseudomonas. This loss in energy may be compensated for by biotin mediated energy production, and therefore when this is also lost metformin has antimicrobial activity. I aim to understand the mechanism of action of metformin, the resistance mechanism of biotin and to try produce a novel combination therapy using metformin and a biotin production inhibitor. I will test P. aeruginosa growth in different carbon source medias +/- metformin to validate if metformin mechanism of action is metabolism linked. I will also try to elucidate the target of metformin via a suppressor screen and the use of TRADIS. Alternatively, I propose 2D-TPP. To validate if biotin resistance is related to bio-energetic compensation I propose an extracellular ATP accumulation assay. Next, the biotin synthesis enzyme BioA would be purified and an existing drug library will be used to screen for inhibitors. Should time permit, I will elucidate the structure of BioA using x-ray crystallography. These studies will help produce or inform the production of a novel combination therapy for P. aeruginosa infection.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Hannah Doherty","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Doherty","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Birmingham\", \"360G-Wellcome-ORG:University-of-Birmingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding biotin mediated metformin resistance within Pseudomonas aeruginosa Biotin synthesis deficient mutants of Pseudomonas aeruginosa can be killed by the diabetes drug metformin. I previously hypothesised that metformin disrupts metabolism and energy production, but not enough to kill Pseudomonas. This loss in energy may be compensated for by biotin mediated energy production, and therefore when this is also lost metformin has antimicrobial activity. I aim to understand the mechanism of action of metformin, the resistance mechanism of biotin and to try produce a novel combination therapy using metformin and a biotin production inhibitor. I will test P. aeruginosa growth in different carbon source medias +/- metformin to validate if metformin mechanism of action is metabolism linked. I will also try to elucidate the target of metformin via a suppressor screen and the use of TRADIS. Alternatively, I propose 2D-TPP. To validate if biotin resistance is related to bio-energetic compensation I propose an extracellular ATP accumulation assay. Next, the biotin synthesis enzyme BioA would be purified and an existing drug library will be used to screen for inhibitors. Should time permit, I will elucidate the structure of BioA using x-ray crystallography. These studies will help produce or inform the production of a novel combination therapy for P. aeruginosa infection.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adenosine Triphosphate","Biotin","Carbon-Nitrogen Ligases","Crystallography, X-Ray","Metformin","Pseudomonas aeruginosa"]}
{"id":"360G-Wellcome-222386_Z_21_Z","title":"Defining the role of RND efflux pumps in antibiotic resistance","Region":"West Midlands","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222386/Z/21/Z","description":"I will investigate the role of efflux pumps in antibiotic resistance by researching two themes. Firstly, by looking at the function, prevalence and impact of plasmid encoded efflux pumps. There have been increasing reports of plasmid encoded RND efflux genes. To our knowledge no one has collated the incidence of RND pumps found on plasmids, their spread or potential roles in antibiotic resistance via the efflux of antibiotics. Using a clinical Acinetobacter pittii isolate, I will define the functional role of RND efflux pump genes in the laboratory for example by using efflux assays to measure export and minimum inhibitory concentration experiments to define the substrate profile.\n\nThe second theme will explore two Acinetobacter species: A. baumannii and A. lwoffii. Both species inhabit the same niche (hospitals) and cause high numbers of infections in immunocompromised patients. We wish to understand why A. baumannii is drug resistant and A. lwoffii is drug susceptible. To do this we will look at the variations in the resistance and efflux pump genes in clinical isolates of both species and hypothesise why A. lwoffii has not yet developed drug resistance and if there are any indications that it might in the future. \n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Elizabeth Darby","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Darby","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Birmingham\", \"360G-Wellcome-ORG:University-of-Birmingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Defining the role of RND efflux pumps in antibiotic resistance I will investigate the role of efflux pumps in antibiotic resistance by researching two themes. Firstly, by looking at the function, prevalence and impact of plasmid encoded efflux pumps. There have been increasing reports of plasmid encoded RND efflux genes. To our knowledge no one has collated the incidence of RND pumps found on plasmids, their spread or potential roles in antibiotic resistance via the efflux of antibiotics. Using a clinical Acinetobacter pittii isolate, I will define the functional role of RND efflux pump genes in the laboratory for example by using efflux assays to measure export and minimum inhibitory concentration experiments to define the substrate profile.\n\nThe second theme will explore two Acinetobacter species: A. baumannii and A. lwoffii. Both species inhabit the same niche (hospitals) and cause high numbers of infections in immunocompromised patients. We wish to understand why A. baumannii is drug resistant and A. lwoffii is drug susceptible. To do this we will look at the variations in the resistance and efflux pump genes in clinical isolates of both species and hypothesise why A. lwoffii has not yet developed drug resistance and if there are any indications that it might in the future. \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Acinetobacter","Acinetobacter Infections","Acinetobacter baumannii","Anti-Bacterial Agents","Drug Resistance, Bacterial","Drug Resistance, Multiple, Bacterial","Humans","Membrane Transport Proteins","Microbial Sensitivity Tests","Plasmids"]}
{"id":"360G-Wellcome-222385_Z_21_Z","title":"Metagenomics for antimicrobial resistance in respiratory diseases","Region":"West Midlands","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222385/Z/21/Z","description":"Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity and mortality globally (Quaderi and Hurst, 2018). Worsening of typical daily symptoms (acute exacerbations) are frequently instigated by infection or pollution and are associated with a greater mortality (Toraldo and Conte, 2019). Antibiotic treatment is often used to alleviate exacerbations (NICE guideline, 2018).\n\nThe aim of this study is to collect longitudinal respiratory samples from COPD patients at baseline and post-exacerbation, including following antimicrobial treatment, and using the technique of shotgun metagenomics with long read nanopore sequencing, to probe the microbial community structure and investigate the presence and burden of antimicrobial resistance (AMR) genes. Method development will be required as respiratory samples have a significant proportion of human DNA which can make detection and analysis of microbial reads difficult (Hasan et al, 2016).\n\nI will explore different extraction and human DNA depletion methods to enable a greater sequencing depth of microbial reads to be obtained, while minimising bias on community taxon distribution. AMR genes detected will be related to specific organisms and clinical data. This will help inform treatments used in the management of COPD and identify potential biomarkers to predict clinical outcomes (Leitao Filho et al, 2019).\n","plannedDates":[{"endDate":"2023-09-27T00:00:00+00:00","startDate":"2020-09-28T00:00:00+00:00","startDateDateOnly":"2020-09-28","endDateDateOnly":"2023-09-27"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Charles Cooper","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Cooper","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Birmingham\", \"360G-Wellcome-ORG:University-of-Birmingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Metagenomics for antimicrobial resistance in respiratory diseases Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity and mortality globally (Quaderi and Hurst, 2018). Worsening of typical daily symptoms (acute exacerbations) are frequently instigated by infection or pollution and are associated with a greater mortality (Toraldo and Conte, 2019). Antibiotic treatment is often used to alleviate exacerbations (NICE guideline, 2018).\n\nThe aim of this study is to collect longitudinal respiratory samples from COPD patients at baseline and post-exacerbation, including following antimicrobial treatment, and using the technique of shotgun metagenomics with long read nanopore sequencing, to probe the microbial community structure and investigate the presence and burden of antimicrobial resistance (AMR) genes. Method development will be required as respiratory samples have a significant proportion of human DNA which can make detection and analysis of microbial reads difficult (Hasan et al, 2016).\n\nI will explore different extraction and human DNA depletion methods to enable a greater sequencing depth of microbial reads to be obtained, while minimising bias on community taxon distribution. AMR genes detected will be related to specific organisms and clinical data. This will help inform treatments used in the management of COPD and identify potential biomarkers to predict clinical outcomes (Leitao Filho et al, 2019).\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anti-Bacterial Agents","Disease Progression","Drug Resistance, Bacterial","Humans","Metagenome","Metagenomics","Microbiota","Pulmonary Disease, Chronic Obstructive"]}
{"id":"360G-Wellcome-222384_Z_21_Z","title":"Does host age affect the emergence and spread of antimicrobial resistance?","Region":"Scotland","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222384/Z/21/Z","description":"Antimicrobial resistance (AMR) and population aging are currently two of the greatest threats to the human race. While extensive research has been carried out on each individually, little is known about the impact of aging on AMR. This is somewhat surprising since a decrease in efficacy of antibiotics married with a population-wide increased susceptibility to infection due to aging could be catastrophic. During this project, I aim to characterise the relationship between host age and likelihood of contracting an infection which is resistant to one or more antibiotics, or the rate at which resistance develops during treatment. This will be carried out using electronic health records and meta-analysis. Mechanisms which may give rise to these relationships will then be proposed, tested using mathematical modelling, and further investigated using the model organism Drosophila melanogaster. Understanding the relationship between age and AMR may highlight certain patient groups where AMR interventions should be focussed, or where use of certain antimicrobials should be increased or reduced. Targeting antibiotic interventions in this way is hoped to slow the rapid spread of resistance which may be exacerbated by an aging population and preserve antibiotic efficacy to prevent a dramatic increase in morbidity and mortality. \n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Lucy Binsted","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Binsted","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Does host age affect the emergence and spread of antimicrobial resistance? Antimicrobial resistance (AMR) and population aging are currently two of the greatest threats to the human race. While extensive research has been carried out on each individually, little is known about the impact of aging on AMR. This is somewhat surprising since a decrease in efficacy of antibiotics married with a population-wide increased susceptibility to infection due to aging could be catastrophic. During this project, I aim to characterise the relationship between host age and likelihood of contracting an infection which is resistant to one or more antibiotics, or the rate at which resistance develops during treatment. This will be carried out using electronic health records and meta-analysis. Mechanisms which may give rise to these relationships will then be proposed, tested using mathematical modelling, and further investigated using the model organism Drosophila melanogaster. Understanding the relationship between age and AMR may highlight certain patient groups where AMR interventions should be focussed, or where use of certain antimicrobials should be increased or reduced. Targeting antibiotic interventions in this way is hoped to slow the rapid spread of resistance which may be exacerbated by an aging population and preserve antibiotic efficacy to prevent a dramatic increase in morbidity and mortality. \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aging","Animals","Anti-Bacterial Agents","Drosophila melanogaster","Drug Resistance, Bacterial","Humans","Models, Theoretical"]}
{"id":"360G-Wellcome-222383_Z_21_Z","title":"Prevention is better than a cure: Novel biomaterials to stop biofilms formation on blood contacting catheters","Region":"East Midlands","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222383/Z/21/Z","description":"Antimicrobial-resistant pathogens are of increasing concern, and the O\u2019Neill report [https://amr-review.org] predicts that, by 2050, more deaths globally will be caused by antimicrobial-resistant infections than cancer. One solution is reducing antimicrobial dependence. Our approach is preventing formation of biofilms (communities of microbes attached to surfaces) on blood-contacting catheters. The immune system is then able to deal with the infection, preventing antimicrobial treatment (Jeffery and Mundy 2020).\n\nHook et al (Hook et al. 2012) identified polymers that resist biofilm formation in the absence of blood, now used to coat urinary catheters (Jeffery et al. 2019) with Wellcome Trust funding.\n\nIn vitro testing of candidate co-polymer coatings in bacterial culture in blood and the analysis of the adsorption of blood components on their surface will allow optimisation of biofilm resistance and haemocompatibility of the coating. Co-polymerising with protein biofouling resistant monomers will be conducted, leading to materials that perform both anti-protein biofouling and anti-biofilm functions. Determination of mechanical properties will ensure integrity of the coating during mechanical deformation. Once optimised, the coating will be tested in an in vivo foreign body infection model.\n\nThis technology has the potential for patients with blood-contacting catheters to experience fewer infections and associated risks.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Claire Saxby","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Saxby","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Nottingham","name":"University of Nottingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Nottingham\", \"360G-Wellcome-ORG:University-of-Nottingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Nottingham","name":"University of Nottingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Prevention is better than a cure: Novel biomaterials to stop biofilms formation on blood contacting catheters Antimicrobial-resistant pathogens are of increasing concern, and the O\u2019Neill report [https://amr-review.org] predicts that, by 2050, more deaths globally will be caused by antimicrobial-resistant infections than cancer. One solution is reducing antimicrobial dependence. Our approach is preventing formation of biofilms (communities of microbes attached to surfaces) on blood-contacting catheters. The immune system is then able to deal with the infection, preventing antimicrobial treatment (Jeffery and Mundy 2020).\n\nHook et al (Hook et al. 2012) identified polymers that resist biofilm formation in the absence of blood, now used to coat urinary catheters (Jeffery et al. 2019) with Wellcome Trust funding.\n\nIn vitro testing of candidate co-polymer coatings in bacterial culture in blood and the analysis of the adsorption of blood components on their surface will allow optimisation of biofilm resistance and haemocompatibility of the coating. Co-polymerising with protein biofouling resistant monomers will be conducted, leading to materials that perform both anti-protein biofouling and anti-biofilm functions. Determination of mechanical properties will ensure integrity of the coating during mechanical deformation. Once optimised, the coating will be tested in an in vivo foreign body infection model.\n\nThis technology has the potential for patients with blood-contacting catheters to experience fewer infections and associated risks.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Bacterial Adhesion","Biofilms","Biofouling","Catheter-Related Infections","Catheters","Coated Materials, Biocompatible","Humans","Polymers"]}
{"id":"360G-Wellcome-222382_Z_21_Z","title":"Understanding adult human hematopoiesis in ageing and chemotherapy","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222382/Z/21/Z","description":"The resilience of the human hematopoietic system declines with age as it becomes more susceptible to age-related disorders or malignancies, produces lower blood counts and is less capable of fighting off infections. When subjected to chemotherapy, it can be severely challenged, but cell counts will usually recover in 2 to 3 weeks. However, in older patients, the recovery can be slower, and individuals over the age of 75 are unable to tolerate more intense regimens.\n\nIn my project, I will compare and contrast the clonal composition and functional characteristics of hematopoietic cells from patients before and after receiving chemotherapy. To achieve this, blood samples of consenting patients between the ages of 40 and 90 will be obtained before and after their treatment, and I will grow single-cell derived colonies and then profile their DNA and single-cell RNA. This will allow me to measure how perturbation of the systemic environment affects the clonal composition of blood, how the proliferative capacities of cells are affected and what functional changes occur in their transcriptomes.\n\nThis study will help us understand to what extent the fitness of hematopoietic stem cells is environment-dependent and how ageing affects the recovery time after chemotherapy.\n","plannedDates":[{"endDate":"2023-10-05T00:00:00+00:00","startDate":"2020-10-06T00:00:00+00:00","startDateDateOnly":"2020-10-06","endDateDateOnly":"2023-10-05"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Lori Dolores Kregar","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Kregar","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding adult human hematopoiesis in ageing and chemotherapy The resilience of the human hematopoietic system declines with age as it becomes more susceptible to age-related disorders or malignancies, produces lower blood counts and is less capable of fighting off infections. When subjected to chemotherapy, it can be severely challenged, but cell counts will usually recover in 2 to 3 weeks. However, in older patients, the recovery can be slower, and individuals over the age of 75 are unable to tolerate more intense regimens.\n\nIn my project, I will compare and contrast the clonal composition and functional characteristics of hematopoietic cells from patients before and after receiving chemotherapy. To achieve this, blood samples of consenting patients between the ages of 40 and 90 will be obtained before and after their treatment, and I will grow single-cell derived colonies and then profile their DNA and single-cell RNA. This will allow me to measure how perturbation of the systemic environment affects the clonal composition of blood, how the proliferative capacities of cells are affected and what functional changes occur in their transcriptomes.\n\nThis study will help us understand to what extent the fitness of hematopoietic stem cells is environment-dependent and how ageing affects the recovery time after chemotherapy.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adult","Aged","Aging","Hematopoiesis","Hematopoietic Stem Cell Transplantation","Hematopoietic Stem Cells","Humans","Middle Aged","Single-Cell Analysis"]}
{"id":"360G-Wellcome-222381_Z_21_Z","title":"Hydrodynamic interactions in molecular simulations at the biological mesoscale","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222381/Z/21/Z","description":"Macromolecules under flow at the biological mesoscale (10 nm  L  t  L  >  1 mum, t  >  1 mus) whereas atomistic scales (L  t  \n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Ryan Cocking","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Cocking","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds","addressCountry":"United Kingdom","id_and_name":"[\"University of Leeds\", \"360G-Wellcome-ORG:University-of-Leeds\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Hydrodynamic interactions in molecular simulations at the biological mesoscale Macromolecules under flow at the biological mesoscale (10 nm  L  t  L  >  1 mum, t  >  1 mus) whereas atomistic scales (L  t  \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Hydrodynamics","Macromolecular Substances","Molecular Dynamics Simulation"]}
{"id":"360G-Wellcome-222380_Z_21_Z","title":"Characterisation of a novel GBA-L444P BAC transgenic mouse model of Parkinson\u2019s disease.","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222380/Z/21/Z","description":"Parkinson\u2019s disease (PD) is the second most common neurodegenerative disorder, currently affecting 145,000 people in the UK. It is known that specific mutations in certain genes can increase the risk of developing Parkinson\u2019s disease. One such gene is GBA, which represents the greatest genetic risk factor for developing PD. Despite this, we still don't fully understand how mutations in GBA increase the risk of developing PD and progress is limited by the lack of relevant animal models of GBA-associated PD. The Wade-Martins lab has therefore developed a new mouse model to study GBA-associated PD. These mice harbour a human GBA gene, which contains a mutation called L444P. My project will use biochemical, electrophysiological and behavioural techniques to investigate how disease in these mice progresses with age. I will also assess the effectiveness of potential therapeutic strategies at restoring the function of GBA. The second phase of my project will characterise pathology in stem cell derived dopaminergic neurons from Parkinson\u2019s patients. These neurons also carry the L444P mutation in GBA, which will allow the translation of pathological findings in the mice into human neurons. This project will contribute to the field\u2019s understanding of the pathology of GBA-associated PD.\n","plannedDates":[{"endDate":"2023-10-11T00:00:00+00:00","startDate":"2020-10-12T00:00:00+00:00","startDateDateOnly":"2020-10-12","endDateDateOnly":"2023-10-11"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Tara Diviney","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Diviney","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Characterisation of a novel GBA-L444P BAC transgenic mouse model of Parkinson\u2019s disease. Parkinson\u2019s disease (PD) is the second most common neurodegenerative disorder, currently affecting 145,000 people in the UK. It is known that specific mutations in certain genes can increase the risk of developing Parkinson\u2019s disease. One such gene is GBA, which represents the greatest genetic risk factor for developing PD. Despite this, we still don't fully understand how mutations in GBA increase the risk of developing PD and progress is limited by the lack of relevant animal models of GBA-associated PD. The Wade-Martins lab has therefore developed a new mouse model to study GBA-associated PD. These mice harbour a human GBA gene, which contains a mutation called L444P. My project will use biochemical, electrophysiological and behavioural techniques to investigate how disease in these mice progresses with age. I will also assess the effectiveness of potential therapeutic strategies at restoring the function of GBA. The second phase of my project will characterise pathology in stem cell derived dopaminergic neurons from Parkinson\u2019s patients. These neurons also carry the L444P mutation in GBA, which will allow the translation of pathological findings in the mice into human neurons. This project will contribute to the field\u2019s understanding of the pathology of GBA-associated PD.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Disease Models, Animal","Dopaminergic Neurons","Humans","Mice","Mice, Transgenic","Mutation","Parkinson Disease"]}
{"id":"360G-Wellcome-222379_Z_21_Z","title":"The evaluation of azoreductases as infection specific targets for antimicrobial delivery","Region":"East Midlands","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222379/Z/21/Z","description":"Bacterial biofilms pose a major threat to global health, due to their ability to evade antibiotics and host defence systems; therefore, leading to the development of chronic infections. The process of biofilm development is regulated by a series of molecular pathways, including cell-to-cell quorum sensing (QS) signalling. The disruption of this QS signalling pathway, through the use of QS inhibitors, shows great potential for the treatment of biofilm infections, while minimizing the selection pressure exerted on the bacteria. The incorporation of nanoparticle drug delivery systems enables the enhancement of antimicrobials delivery, including an increase in drug solubility and prolonged systemic circulation. Furthermore, these materials can be equipped with stimuli-responsive switches enabling a targeted drug delivery. Of particular interest is the use of poly(b-amino esters) (PBAEs) reported to selectively target and accumulate within bacterial biofilms. We hypothesize azoreductase enzymes, released by bacteria, can induce the opening of PBAE nanoparticles equipped with azobenzene moieties. This targeted cleavage of the azo bond would result in the release of encapsulated QS inhibitors, leading to the prevention of biofilm maturation. This delivery pathway has the potential of significantly enhancing the efficiency of antimicrobial delivery to biofilms, enabling the prevention of highly challenging chronic infections.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Karolina Kasza","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Kasza","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Nottingham","name":"University of Nottingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Nottingham\", \"360G-Wellcome-ORG:University-of-Nottingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Nottingham","name":"University of Nottingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The evaluation of azoreductases as infection specific targets for antimicrobial delivery Bacterial biofilms pose a major threat to global health, due to their ability to evade antibiotics and host defence systems; therefore, leading to the development of chronic infections. The process of biofilm development is regulated by a series of molecular pathways, including cell-to-cell quorum sensing (QS) signalling. The disruption of this QS signalling pathway, through the use of QS inhibitors, shows great potential for the treatment of biofilm infections, while minimizing the selection pressure exerted on the bacteria. The incorporation of nanoparticle drug delivery systems enables the enhancement of antimicrobials delivery, including an increase in drug solubility and prolonged systemic circulation. Furthermore, these materials can be equipped with stimuli-responsive switches enabling a targeted drug delivery. Of particular interest is the use of poly(b-amino esters) (PBAEs) reported to selectively target and accumulate within bacterial biofilms. We hypothesize azoreductase enzymes, released by bacteria, can induce the opening of PBAE nanoparticles equipped with azobenzene moieties. This targeted cleavage of the azo bond would result in the release of encapsulated QS inhibitors, leading to the prevention of biofilm maturation. This delivery pathway has the potential of significantly enhancing the efficiency of antimicrobial delivery to biofilms, enabling the prevention of highly challenging chronic infections.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anti-Bacterial Agents","Azo Compounds","Biofilms","Drug Delivery Systems","Nanoparticles","Pseudomonas aeruginosa","Quorum Sensing"]}
{"id":"360G-Wellcome-222378_Z_21_Z","title":"Testing the roles of polyamines in predator-prey interactions of B. bacteriovorus","Region":"East Midlands","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222378/Z/21/Z","description":"Antibiotic resistance is one of the greatest threats to human health faced today. Infections previously treatable with antibiotics no longer respond, and bacteria have emerged that are resistant to all currently available antibiotics (O\u2019Neill, 2016). As such, it is imperative to find novel treatment options including new antibiotics but also to develop alternative methods. One such method is to use other bacteria for our own benefit. Bdellovibrio bacteriovorus is a small, highly motile bacterium with an interesting food - it preys upon other bacteria, eating them from the inside out, including many bacteria that cause harmful infections in humans.  However more must be known about the predatory behaviour of Bdellovibrio before it can used in the clinic. This project focuses on chemical signals (polyamines) produced by Bdellovibrio, its prey, and its potential patient hosts. It asks how these signals alter the predatory ability of Bdellovibrio. This will increase our understanding of how Bdellovibrio senses its prey in host and natural environments and the signals it needs to continue the hunt. More detailed knowledge of this predatory behaviour in vitro will allow us to better predict how Bdellovibrio may behave in vivo inside a patient during future potential therapeutic uses.\n","plannedDates":[{"endDate":"2023-09-22T00:00:00+00:00","startDate":"2020-09-23T00:00:00+00:00","startDateDateOnly":"2020-09-23","endDateDateOnly":"2023-09-22"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Rhian Ford","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Ford","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Nottingham","name":"University of Nottingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Nottingham\", \"360G-Wellcome-ORG:University-of-Nottingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Nottingham","name":"University of Nottingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Testing the roles of polyamines in predator-prey interactions of B. bacteriovorus Antibiotic resistance is one of the greatest threats to human health faced today. Infections previously treatable with antibiotics no longer respond, and bacteria have emerged that are resistant to all currently available antibiotics (O\u2019Neill, 2016). As such, it is imperative to find novel treatment options including new antibiotics but also to develop alternative methods. One such method is to use other bacteria for our own benefit. Bdellovibrio bacteriovorus is a small, highly motile bacterium with an interesting food - it preys upon other bacteria, eating them from the inside out, including many bacteria that cause harmful infections in humans.  However more must be known about the predatory behaviour of Bdellovibrio before it can used in the clinic. This project focuses on chemical signals (polyamines) produced by Bdellovibrio, its prey, and its potential patient hosts. It asks how these signals alter the predatory ability of Bdellovibrio. This will increase our understanding of how Bdellovibrio senses its prey in host and natural environments and the signals it needs to continue the hunt. More detailed knowledge of this predatory behaviour in vitro will allow us to better predict how Bdellovibrio may behave in vivo inside a patient during future potential therapeutic uses.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anti-Bacterial Agents","Humans","Predatory Behavior"]}
{"id":"360G-Wellcome-222377_Z_21_Z","title":"The use of global connectivity estimates in real-time models of international infectious disease spread","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222377/Z/21/Z","description":"Human mobility plays an important part in the spread of infectious diseases. Mathematical models can assess the risk that an emerging outbreak will spread internationally, providing decision-makers with information to support early surveillance and control measures. In this project I will aim to improve how well these models capture international mobility patterns by exploring the suitability of different measures of connectivity. I will compare flight passenger data (which is commonly used in international infectious disease spread models) with alternative transport passenger statistics and novel data, such as location data from mobile phones. I will use these data sources (both individually and in combination) in models to make predictions of the risks of imported and exported disease cases, and assess how well these different models can retrospectively predict the global spread of COVID-19. I will use these findings to develop a statistical model and tools that are ready in advance of future outbreaks to make rapid assessments of the risks that they will spread geographically. The project will lead to more realistic models of international infectious disease spread and thus improve the information that is available to support decision-makers in controlling future outbreaks before they become widespread.\n \n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Jack Wardle","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Wardle","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The use of global connectivity estimates in real-time models of international infectious disease spread Human mobility plays an important part in the spread of infectious diseases. Mathematical models can assess the risk that an emerging outbreak will spread internationally, providing decision-makers with information to support early surveillance and control measures. In this project I will aim to improve how well these models capture international mobility patterns by exploring the suitability of different measures of connectivity. I will compare flight passenger data (which is commonly used in international infectious disease spread models) with alternative transport passenger statistics and novel data, such as location data from mobile phones. I will use these data sources (both individually and in combination) in models to make predictions of the risks of imported and exported disease cases, and assess how well these different models can retrospectively predict the global spread of COVID-19. I will use these findings to develop a statistical model and tools that are ready in advance of future outbreaks to make rapid assessments of the risks that they will spread geographically. The project will lead to more realistic models of international infectious disease spread and thus improve the information that is available to support decision-makers in controlling future outbreaks before they become widespread.\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cell Phone","Communicable Diseases","Disease Outbreaks","Global Health","Humans","Models, Theoretical"]}
{"id":"360G-Wellcome-222376_Z_21_Z","title":"Determinants and consequences of HIV treatment amongst adolescents and young adults in sub-Saharan Africa","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222376/Z/21/Z","description":"Adolescents and young adults (10 to 24-year olds) account for a significant proportion of people living with HIV globally. Due to psychosocial and biological changes associated with individuals in this age category, they are more likely to have poorer treatment outcomes compared to younger children and older adults. Two interventions that have shown potential to improve outcomes in this age group include timely disclosure of adolescents\u2019 HIV status to them and inclusion of the highly potent integrase inhibitor 'dolutegravir' into antiretroviral therapy regimens. However, there is limited knowledge on the psychosocial impacts of disclosure, and level of uptake and impact of dolutegravir use among adolescents and young adults in sub-Saharan Africa.\n\nI aim to analyse data from a longitudinal, community-traced cohort study of HIV-positive adolescents in South Africa (Mzantsi Wakho) to assess the effects of timely HIV status disclosure on anxiety, depression, behaviour and suicide. I also aim to analyse routine HIV program data and develop a mathematical model of HIV progression, to estimate the level of uptake and effects of dolutegravir on treatment outcomes among adolescents and young adults.\n\nMy findings will help improve current HIV status disclosure guidelines and assess the progress in dolutegravir transition among young individuals.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Dr Olanrewaju Edun","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Edun","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Determinants and consequences of HIV treatment amongst adolescents and young adults in sub-Saharan Africa Adolescents and young adults (10 to 24-year olds) account for a significant proportion of people living with HIV globally. Due to psychosocial and biological changes associated with individuals in this age category, they are more likely to have poorer treatment outcomes compared to younger children and older adults. Two interventions that have shown potential to improve outcomes in this age group include timely disclosure of adolescents\u2019 HIV status to them and inclusion of the highly potent integrase inhibitor 'dolutegravir' into antiretroviral therapy regimens. However, there is limited knowledge on the psychosocial impacts of disclosure, and level of uptake and impact of dolutegravir use among adolescents and young adults in sub-Saharan Africa.\n\nI aim to analyse data from a longitudinal, community-traced cohort study of HIV-positive adolescents in South Africa (Mzantsi Wakho) to assess the effects of timely HIV status disclosure on anxiety, depression, behaviour and suicide. I also aim to analyse routine HIV program data and develop a mathematical model of HIV progression, to estimate the level of uptake and effects of dolutegravir on treatment outcomes among adolescents and young adults.\n\nMy findings will help improve current HIV status disclosure guidelines and assess the progress in dolutegravir transition among young individuals.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adolescent","Africa South of the Sahara","Anxiety","Cohort Studies","Depression","Disclosure","Female","HIV Infections","HIV Integrase Inhibitors","Heterocyclic Compounds, 3-Ring","Humans","Longitudinal Studies","Male","Models, Theoretical","Piperazines","Pyridones","South Africa","Young Adult"]}
{"id":"360G-Wellcome-222375_Z_21_Z","title":"Characterising the effect of seasonality on the spatiotemporal transmission dynamics of dengue virus.","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222375/Z/21/Z","description":"Dengue virus (DENV) transmission is dependent on the vector capacity of mosquito populations (their ability to carry and transmit DENV), which is influenced by seasonally varying traits such as mosquito lifespan. Novel and effective DENV control measures include the release of mosquitoes infected with Wolbachia bacteria,  which confers reduced vector capacity, and vaccination. The high global economic and health burden of DENV is increasing with growing urbanisation and climate change. To target control measures to areas with the greatest burden of DENV, accurate estimates of where DENV is spreading the most are necessary.\n\nWe will develop DENV transmission models which integrate mosquito traits fitted to data describing the number of reported DENV cases over time in South East Asia and South America. The models will be further developed (addition of spatial structure) to explore the impact of population movement on the spread of DENV. In addition, the potential impact of novel control measures will be evaluated, including the release of Wolbachia infected mosquitoes, to explore their impact on DENV transmission. This research is therefore of high relevance to public health and to the DENV research field.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Victoria Cox","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Cox","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Characterising the effect of seasonality on the spatiotemporal transmission dynamics of dengue virus. Dengue virus (DENV) transmission is dependent on the vector capacity of mosquito populations (their ability to carry and transmit DENV), which is influenced by seasonally varying traits such as mosquito lifespan. Novel and effective DENV control measures include the release of mosquitoes infected with Wolbachia bacteria,  which confers reduced vector capacity, and vaccination. The high global economic and health burden of DENV is increasing with growing urbanisation and climate change. To target control measures to areas with the greatest burden of DENV, accurate estimates of where DENV is spreading the most are necessary.\n\nWe will develop DENV transmission models which integrate mosquito traits fitted to data describing the number of reported DENV cases over time in South East Asia and South America. The models will be further developed (addition of spatial structure) to explore the impact of population movement on the spread of DENV. In addition, the potential impact of novel control measures will be evaluated, including the release of Wolbachia infected mosquitoes, to explore their impact on DENV transmission. This research is therefore of high relevance to public health and to the DENV research field.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aedes","Animals","Dengue","Dengue Virus","Humans","Models, Biological","Mosquito Vectors","Seasons","Wolbachia"]}
{"id":"360G-Wellcome-222374_Z_21_Z","title":"Developing novel phylodynamic modelling methods for  forecasting infectious disease outbreak detection and transmission dynamics ","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222374/Z/21/Z","description":"Phylodynamic methods utilising genetic and epidemiological data, such as contact-tracing, hot-spot identification and modelling of strain-specific transmission dynamics, can provide a useful way for forecasting infectious disease outbreaks and transmission dynamics of interest. However, information from epidemiological investigations and genome sequences are rarely utilised together in current gold-standard methods used for outbreak assessment (2). We propose to develop novel phylodynamic methods for real-time outbreak detection of RNA-viruses (Sars-CovV-2, Influenza) using contact-tracing and predicted hotspot identification, as well as further developing understanding of transmission dynamics at the strain-specific level in a sustained outbreak over time. Sars-CoV-2 sequence data is sourced from COG-UK and linked to epidemiological patient data from PHE (3). Influenza sequence data is sourced from PHE, including strain-specific samples for Influenza A and B, and linked to epidemiological patient data from 2015 to present (4). Methods will be developed into publicly available R packages for application in future RNA-virus outbreaks. We aim to advance methods for incorporating genome sequence data into real-time forecasting of outbreak detection (5\u20138). Additionally, by increasing understanding of strain-specific transmission dynamics, we will advance understanding of seasonal infectious disease transmission at local, community and national level, and inform annual vaccine development in the UK (9).\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Olivia Boyd","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Boyd","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Developing novel phylodynamic modelling methods for  forecasting infectious disease outbreak detection and transmission dynamics  Phylodynamic methods utilising genetic and epidemiological data, such as contact-tracing, hot-spot identification and modelling of strain-specific transmission dynamics, can provide a useful way for forecasting infectious disease outbreaks and transmission dynamics of interest. However, information from epidemiological investigations and genome sequences are rarely utilised together in current gold-standard methods used for outbreak assessment (2). We propose to develop novel phylodynamic methods for real-time outbreak detection of RNA-viruses (Sars-CovV-2, Influenza) using contact-tracing and predicted hotspot identification, as well as further developing understanding of transmission dynamics at the strain-specific level in a sustained outbreak over time. Sars-CoV-2 sequence data is sourced from COG-UK and linked to epidemiological patient data from PHE (3). Influenza sequence data is sourced from PHE, including strain-specific samples for Influenza A and B, and linked to epidemiological patient data from 2015 to present (4). Methods will be developed into publicly available R packages for application in future RNA-virus outbreaks. We aim to advance methods for incorporating genome sequence data into real-time forecasting of outbreak detection (5\u20138). Additionally, by increasing understanding of strain-specific transmission dynamics, we will advance understanding of seasonal infectious disease transmission at local, community and national level, and inform annual vaccine development in the UK (9).\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Disease Outbreaks","Forecasting","Humans","Influenza, Human","United Kingdom"]}
{"id":"360G-Wellcome-222373_Z_21_Z","title":"Structure, dynamics and function of OMPs in physiological-like membranes","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222373/Z/21/Z","description":"The outer membrane (OM) of gram-negative bacteria is the first line of defence against exogenous threats, and helps confer antibiotic resistance and enable biofilm formation. It is an asymmetric bilayer, consisting of an outer leaflet of lipopolysaccharide (LPS) and an inner leaflet of phospholipids and cardiolipin, and is crowded with outer membrane proteins (OMPs). While much is known about OMPs in symmetric phospholipid membranes, the effects of LPS, membrane asymmetry and protein crowding remain largely unclear \u2013 although they have been shown to be important. I will explore the structure, dynamics and function of OMPs in native-like membranes through an interdisciplinary approach combining molecular dynamics simulations, cryo-electron microscopy and biochemical/biophysical approaches. Specifically, I will develop protocols to generate OM-like asymmetric vesicles. Exploiting cryo-electron microscopy and molecular dynamics simulation methodology, I will elucidate the effects of the physiological OM components on FusA (a model OMP) in a broad range of asymmetric membrane contexts. In addition, substrate binding and in vivo function of FusA will be determined. Together, this work will elucidate details of how the OM modulates OMPs, providing clearer pathways to understand gram-negative bacterial biology, the role of the OM in antibiotic resistance and to develop better therapeutics.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Jonathan Machin","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Machin","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds","addressCountry":"United Kingdom","id_and_name":"[\"University of Leeds\", \"360G-Wellcome-ORG:University-of-Leeds\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Structure, dynamics and function of OMPs in physiological-like membranes The outer membrane (OM) of gram-negative bacteria is the first line of defence against exogenous threats, and helps confer antibiotic resistance and enable biofilm formation. It is an asymmetric bilayer, consisting of an outer leaflet of lipopolysaccharide (LPS) and an inner leaflet of phospholipids and cardiolipin, and is crowded with outer membrane proteins (OMPs). While much is known about OMPs in symmetric phospholipid membranes, the effects of LPS, membrane asymmetry and protein crowding remain largely unclear \u2013 although they have been shown to be important. I will explore the structure, dynamics and function of OMPs in native-like membranes through an interdisciplinary approach combining molecular dynamics simulations, cryo-electron microscopy and biochemical/biophysical approaches. Specifically, I will develop protocols to generate OM-like asymmetric vesicles. Exploiting cryo-electron microscopy and molecular dynamics simulation methodology, I will elucidate the effects of the physiological OM components on FusA (a model OMP) in a broad range of asymmetric membrane contexts. In addition, substrate binding and in vivo function of FusA will be determined. Together, this work will elucidate details of how the OM modulates OMPs, providing clearer pathways to understand gram-negative bacterial biology, the role of the OM in antibiotic resistance and to develop better therapeutics.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Bacterial Outer Membrane Proteins","Cryoelectron Microscopy","Gram-Negative Bacteria","Lipopolysaccharides","Molecular Dynamics Simulation"]}
{"id":"360G-Wellcome-222372_Z_21_Z","title":"Structural and functional characterisation of E3 ligase complexes involved in inflammation","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222372/Z/21/Z","description":"Tissue damage and infection can elicit a specific response in the bone marrow called emergency haematopoiesis, which results in the production of myeloid-type blood cells. This response is mediated by a protein complex signalling hub called the Myddosome. After damage or infection resolution, the termination of emergency haematopoiesis is crucial, as prolonged emergency haematopoiesis may result in chronic inflammation, autoimmune disease and cancer. As such, termination of emergency haematopoiesis is carefully regulated by orchestrating a series of signalling events.\nUsing a multidisciplinary approach involving structural and cellular biology, this project aims to understand the molecular and functional basis of Myddosome-regulating complexes that participate in termination of emergency haematopoiesis. To achieve this, I will use cryo-electron microscopy to gain high resolution structures and use mutational analysis to probe protein-protein interactions and their functions. Results from this project will provide structural and functional information which will enable us to design potential therapeutics against immune-mediated diseases and hematopoietic cell proliferation.\n \n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Linda Makhlouf","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Makhlouf","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds","addressCountry":"United Kingdom","id_and_name":"[\"University of Leeds\", \"360G-Wellcome-ORG:University-of-Leeds\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Structural and functional characterisation of E3 ligase complexes involved in inflammation Tissue damage and infection can elicit a specific response in the bone marrow called emergency haematopoiesis, which results in the production of myeloid-type blood cells. This response is mediated by a protein complex signalling hub called the Myddosome. After damage or infection resolution, the termination of emergency haematopoiesis is crucial, as prolonged emergency haematopoiesis may result in chronic inflammation, autoimmune disease and cancer. As such, termination of emergency haematopoiesis is carefully regulated by orchestrating a series of signalling events.\nUsing a multidisciplinary approach involving structural and cellular biology, this project aims to understand the molecular and functional basis of Myddosome-regulating complexes that participate in termination of emergency haematopoiesis. To achieve this, I will use cryo-electron microscopy to gain high resolution structures and use mutational analysis to probe protein-protein interactions and their functions. Results from this project will provide structural and functional information which will enable us to design potential therapeutics against immune-mediated diseases and hematopoietic cell proliferation.\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cryoelectron Microscopy","Hematopoiesis","Hematopoietic Stem Cells","Humans","Signal Transduction","Ubiquitin-Protein Ligases"]}
{"id":"360G-Wellcome-222371_Z_21_Z","title":"Defining the structural mechanism of the cellular response to DNA inter-strand crosslinks: structural characterization and inhibition of SLF1-SLF2 with its interacting partners.","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222371/Z/21/Z","description":"Interstrand crosslinks (ICLs) are the most toxic form of DNA damage, forming a blockage to essential cellular processes by preventing separation of the two strands of our DNA.  DNA crosslinking agents that induce this form of damage have been at the frontline of chemotherapy for over 50 years.  However, to protect our genomes from their constant exposure to DNA damage sources, our cells have specialised repair pathways to detect and remove ICLs. Understanding the molecular details of DNA damage repair pathways is therefore essential for advancing cancer research. Using a range of structural techniques and functional assays, including X-Ray crystallography and Cryo-EM, I will focus on a structurally uncharacterised complex involved in recruiting SMC (structural maintenance of chromosome) 5/6 to sites of double strand breaks (DSBs) introduced during the Fanconi Anaemia pathway, a major ICL repair pathway in proliferating cells. This complex, SLF1-SLF2, directly interacts with the E3 ubiquitin ligase, Rad18, which binds sites of DSBs marked by post-translational modifications, appearing to define a linear recruitment pathway for SMC5/6. This study will provide further insight into how toxic ICLs are resolved and could identify novel interactions that can be specifically inhibited for development of new cancer treatments to enhance chemotherapy.\n \n","plannedDates":[{"endDate":"2023-09-15T00:00:00+00:00","startDate":"2020-09-16T00:00:00+00:00","startDateDateOnly":"2020-09-16","endDateDateOnly":"2023-09-15"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Emma Ryder","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Ryder","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds","addressCountry":"United Kingdom","id_and_name":"[\"University of Leeds\", \"360G-Wellcome-ORG:University-of-Leeds\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Defining the structural mechanism of the cellular response to DNA inter-strand crosslinks: structural characterization and inhibition of SLF1-SLF2 with its interacting partners. Interstrand crosslinks (ICLs) are the most toxic form of DNA damage, forming a blockage to essential cellular processes by preventing separation of the two strands of our DNA.  DNA crosslinking agents that induce this form of damage have been at the frontline of chemotherapy for over 50 years.  However, to protect our genomes from their constant exposure to DNA damage sources, our cells have specialised repair pathways to detect and remove ICLs. Understanding the molecular details of DNA damage repair pathways is therefore essential for advancing cancer research. Using a range of structural techniques and functional assays, including X-Ray crystallography and Cryo-EM, I will focus on a structurally uncharacterised complex involved in recruiting SMC (structural maintenance of chromosome) 5/6 to sites of double strand breaks (DSBs) introduced during the Fanconi Anaemia pathway, a major ICL repair pathway in proliferating cells. This complex, SLF1-SLF2, directly interacts with the E3 ubiquitin ligase, Rad18, which binds sites of DSBs marked by post-translational modifications, appearing to define a linear recruitment pathway for SMC5/6. This study will provide further insight into how toxic ICLs are resolved and could identify novel interactions that can be specifically inhibited for development of new cancer treatments to enhance chemotherapy.\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cross-Linking Reagents","Cryoelectron Microscopy","Crystallography, X-Ray","DNA Breaks, Double-Stranded","DNA Damage","DNA Repair","Fanconi Anemia","Fanconi Anemia Complementation Group D2 Protein","Humans","Models, Molecular","Protein Binding","Ubiquitin-Protein Ligases","Ubiquitination"]}
{"id":"360G-Wellcome-222370_Z_21_Z","title":"Determining the architecture of the HCV replication complex","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222370/Z/21/Z","description":"The hepatitis C virus (HCV) infection induces an intracellular rearrangement in the host cell forming many vesicles referred to as replication organelles. In particular, double membrane vesicles (DMVs) are proposed sites for the HCV replication. The HCV polyprotein is composed of structural and non-structural proteins. Five of the non-structural proteins form the replication complex. I aim to determine the ultrastructure of the HCV replication complex by taking a multidisciplinary approach. I will use biochemical, biophysical and structural analyses, including confocal microscopy, super-resolution approaches and cryo-CLEM, to visualise how and where these non-structural proteins form the replication complex. I aim to investigate in detail whether the replication complex is formed inside the DMV or on the surface. I will also determine the topology of nascent HCV RNA which will provide extensive knowledge about HCV replication. These studies will help to explain the concerted action of non-structural proteins and their role in HCV replication. \n \n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mrs Upasana Sykora","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Sykora","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds","addressCountry":"United Kingdom","id_and_name":"[\"University of Leeds\", \"360G-Wellcome-ORG:University-of-Leeds\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Determining the architecture of the HCV replication complex The hepatitis C virus (HCV) infection induces an intracellular rearrangement in the host cell forming many vesicles referred to as replication organelles. In particular, double membrane vesicles (DMVs) are proposed sites for the HCV replication. The HCV polyprotein is composed of structural and non-structural proteins. Five of the non-structural proteins form the replication complex. I aim to determine the ultrastructure of the HCV replication complex by taking a multidisciplinary approach. I will use biochemical, biophysical and structural analyses, including confocal microscopy, super-resolution approaches and cryo-CLEM, to visualise how and where these non-structural proteins form the replication complex. I aim to investigate in detail whether the replication complex is formed inside the DMV or on the surface. I will also determine the topology of nascent HCV RNA which will provide extensive knowledge about HCV replication. These studies will help to explain the concerted action of non-structural proteins and their role in HCV replication. \n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cryoelectron Microscopy","Hepacivirus","Hepatitis C","Humans","RNA, Viral","Virus Replication"]}
{"id":"360G-Wellcome-222369_Z_21_Z","title":"Mechanisms of neurodegeneration and repair following demyelination in zebrafish","Region":"Scotland","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222369/Z/21/Z","description":"In the neurodegenerative disease multiple sclerosis (MS), the lipid-rich layer surrounding nerve fibres known as myelin is lost, in a process known as demyelination. While this is thought to contribute to neuronal loss seen in MS, it is not clear exactly how neurons respond to demyelination, which prevents targeting key mechanisms that could be responsible for neurodegeneration in disease.\nIn animal models of demyelination, it has been observed that synapses, the structures that allow neurons to communicate with one another, are lost. Synapses are also affected in MS, which could contribute to clinical disability and cognitive impairment. We expect that synapse loss is an early feature of the neuronal response to demyelination, and if prevented, may protect neurons from degeneration. In this study, we aim to understand mechanisms of synapse loss and neurodegeneration after demyelination, and to determine if they are direct effects of demyelination or mediated by immune cells that respond to demyelination. We will employ zebrafish as a model, because we can follow individual neurons and synapses before, during and after demyelination using live imaging. This research will allow us to investigate the relationship between demyelination and synapse loss and identify strategies to prevent neuronal loss from ocurring.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Donia Arafa","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Arafa","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mechanisms of neurodegeneration and repair following demyelination in zebrafish In the neurodegenerative disease multiple sclerosis (MS), the lipid-rich layer surrounding nerve fibres known as myelin is lost, in a process known as demyelination. While this is thought to contribute to neuronal loss seen in MS, it is not clear exactly how neurons respond to demyelination, which prevents targeting key mechanisms that could be responsible for neurodegeneration in disease.\nIn animal models of demyelination, it has been observed that synapses, the structures that allow neurons to communicate with one another, are lost. Synapses are also affected in MS, which could contribute to clinical disability and cognitive impairment. We expect that synapse loss is an early feature of the neuronal response to demyelination, and if prevented, may protect neurons from degeneration. In this study, we aim to understand mechanisms of synapse loss and neurodegeneration after demyelination, and to determine if they are direct effects of demyelination or mediated by immune cells that respond to demyelination. We will employ zebrafish as a model, because we can follow individual neurons and synapses before, during and after demyelination using live imaging. This research will allow us to investigate the relationship between demyelination and synapse loss and identify strategies to prevent neuronal loss from ocurring.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Demyelinating Diseases","Disease Models, Animal","Multiple Sclerosis","Myelin Sheath","Synapses","Zebrafish"]}
{"id":"360G-Wellcome-222368_Z_21_Z","title":"Effects of lifestyle and phylogeny on occipital lobe organisation across primate species","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222368/Z/21/Z","description":"The way a brain is organised stems from a combination of evolutionary and environmental influences. I aim to understand how these factors have shaped how different primate brains are organised. Specifically, I am interested in how visual experience and evolutionary adaptations have shaped the organisation of the occipital (visual) lobe.\n\nTo study occipital lobe organisation, I will reconstruct white matter tracts from MRI scans of primate brains. I will then use computational approaches to compare these tracts, finding which tracts differ between species. Using our knowledge of phylogenetic relationships and different animals\u2019 lifestyles, I can test hypotheses about which tracts diverged at different points in evolutionary history, and about which adaptations are unique to different ecological niches. Afterwards, I will explore how ecological specialisations affect connectivity on a cellular level, in finer-grained detail than MRI can offer, by staining brain slices for axons and their myelin and analysing the innervation patterns of specific white matter tracts.\n\nThis work will yield insights into the evolution of the primate visual system and illuminate how it evolved to subserve uniquely human functions like reading. This work will additionally help us understand principles of brain diversity, with implications for evolutionary biology and translational neuroscience.\n","plannedDates":[{"endDate":"2023-10-10T00:00:00+00:00","startDate":"2020-10-11T00:00:00+00:00","startDateDateOnly":"2020-10-11","endDateDateOnly":"2023-10-10"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Jasper Hunt","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Hunt","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Effects of lifestyle and phylogeny on occipital lobe organisation across primate species The way a brain is organised stems from a combination of evolutionary and environmental influences. I aim to understand how these factors have shaped how different primate brains are organised. Specifically, I am interested in how visual experience and evolutionary adaptations have shaped the organisation of the occipital (visual) lobe.\n\nTo study occipital lobe organisation, I will reconstruct white matter tracts from MRI scans of primate brains. I will then use computational approaches to compare these tracts, finding which tracts differ between species. Using our knowledge of phylogenetic relationships and different animals\u2019 lifestyles, I can test hypotheses about which tracts diverged at different points in evolutionary history, and about which adaptations are unique to different ecological niches. Afterwards, I will explore how ecological specialisations affect connectivity on a cellular level, in finer-grained detail than MRI can offer, by staining brain slices for axons and their myelin and analysing the innervation patterns of specific white matter tracts.\n\nThis work will yield insights into the evolution of the primate visual system and illuminate how it evolved to subserve uniquely human functions like reading. This work will additionally help us understand principles of brain diversity, with implications for evolutionary biology and translational neuroscience.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Biological Evolution","Brain","Humans","Magnetic Resonance Imaging","Occipital Lobe","Phylogeny","Primates","Visual Pathways","White Matter"]}
{"id":"360G-Wellcome-222367_Z_21_Z","title":"The present is saturated with the past and pregnant with the future: continuous temporal integration of past and future events in the brain","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222367/Z/21/Z","description":"The environment is continuously changing. Our nervous system is capable of integrating these changes over time, facilitating an adaptive interaction with the world. At any moment, our brains are retaining past experiences and estimating future events. In the words of the philosopher Gottfried Leibniz: the present is saturated with the past and pregnant with the future. For example, when two people are having a conversation, retentions of what has just been said are needed in order to construct what will be said in the immediate future.\n\nDuring my doctoral research, I will try to answer the question of whether retention of immediately past events and anticipation of future ones influences present perception both in the visual and in the auditory domains. By manipulating task demands, I also hope to explore whether such effects are flexible and context dependent. To explore how different brain regions across the visual and auditory systems allow for retention and anticipation, I will record electrical brain activity of participants while they observe learned and unlearned sequences of stimuli, such that we can manipulate their anticipation of what is coming . This work will advance the understanding of how events in the environment are integrated in time.\n","plannedDates":[{"endDate":"2023-10-10T00:00:00+00:00","startDate":"2020-10-11T00:00:00+00:00","startDateDateOnly":"2020-10-11","endDateDateOnly":"2023-10-10"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Irene Echeverria Altuna","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Echeverria Altuna","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The present is saturated with the past and pregnant with the future: continuous temporal integration of past and future events in the brain The environment is continuously changing. Our nervous system is capable of integrating these changes over time, facilitating an adaptive interaction with the world. At any moment, our brains are retaining past experiences and estimating future events. In the words of the philosopher Gottfried Leibniz: the present is saturated with the past and pregnant with the future. For example, when two people are having a conversation, retentions of what has just been said are needed in order to construct what will be said in the immediate future.\n\nDuring my doctoral research, I will try to answer the question of whether retention of immediately past events and anticipation of future ones influences present perception both in the visual and in the auditory domains. By manipulating task demands, I also hope to explore whether such effects are flexible and context dependent. To explore how different brain regions across the visual and auditory systems allow for retention and anticipation, I will record electrical brain activity of participants while they observe learned and unlearned sequences of stimuli, such that we can manipulate their anticipation of what is coming . This work will advance the understanding of how events in the environment are integrated in time.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Auditory Perception","Brain","Humans","Visual Perception"]}
{"id":"360G-Wellcome-222366_Z_21_Z","title":"The role of Xist binding partners in Xist localization","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222366/Z/21/Z","description":"X chromosome inactivation (XCI) is the mechanism that equalises X-linked gene expression in mammalian XX females relative to XY males. It is triggered by the expression of the 17Kb long non- coding RNA Xist. Upon transcription, Xist spreads in cis \u2018coating\u2019 the elected inactive X (Xi) and recruits factors acting in concert to modify the underlying chromatin and repress gene activity. A crucial step for XCI is the limited in cis localization of Xist, ensuring its action is restricted to the Xi elect only. Previous studies revealed Xist to be tightly anchored to the Xi territory through interaction with nuclear matrix proteins, however the mechanisms governing this process remain poorly understood. I will investigate the nature and the single-cell dynamics of Xist interactions with its anchoring factors through the genetic dissection of their functional domains in mouse model systems, using a combination of molecular biology and advanced microscopy approaches, such as live imaging and super resolution microscopy. Our research will elucidate the single-cell interplay between Xist and its localisation factors and their potential role in influencing Xist behaviour, providing insights into the mechanisms governing Xist spreading and retention within the Xi territory.\n","plannedDates":[{"endDate":"2023-10-05T00:00:00+00:00","startDate":"2020-10-06T00:00:00+00:00","startDateDateOnly":"2020-10-06","endDateDateOnly":"2023-10-05"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Clelia Accalai","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Accalai","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The role of Xist binding partners in Xist localization X chromosome inactivation (XCI) is the mechanism that equalises X-linked gene expression in mammalian XX females relative to XY males. It is triggered by the expression of the 17Kb long non- coding RNA Xist. Upon transcription, Xist spreads in cis \u2018coating\u2019 the elected inactive X (Xi) and recruits factors acting in concert to modify the underlying chromatin and repress gene activity. A crucial step for XCI is the limited in cis localization of Xist, ensuring its action is restricted to the Xi elect only. Previous studies revealed Xist to be tightly anchored to the Xi territory through interaction with nuclear matrix proteins, however the mechanisms governing this process remain poorly understood. I will investigate the nature and the single-cell dynamics of Xist interactions with its anchoring factors through the genetic dissection of their functional domains in mouse model systems, using a combination of molecular biology and advanced microscopy approaches, such as live imaging and super resolution microscopy. Our research will elucidate the single-cell interplay between Xist and its localisation factors and their potential role in influencing Xist behaviour, providing insights into the mechanisms governing Xist spreading and retention within the Xi territory.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Female","Male","Mice","RNA, Long Noncoding","Single-Cell Analysis","X Chromosome","X Chromosome Inactivation"]}
{"id":"360G-Wellcome-222365_Z_21_Z","title":"Identification, characterisation and therapeutic targeting of gene regulatory complexes and networks in leukaemic stem cells.","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222365/Z/21/Z","description":"Transcription factor (TF) networks are cardinally dysregulated in Acute Myeloid Leukaemia (AML), with many of these dysregulated TFs known to have developmental and homeostatic roles in normal haematopoiesis. I will focus on the E-twenty six (ETS) TF Pu.1 that is known to play an important role in myeloid and lymphoid development. Conventionally, Pu.1 is better known as a tumour suppressor during AML development but, more recent studies within the Huntly Lab have suggested an alternative role for Pu.1 in the maintenance of AML.\n\nI will be using an Npm1c/Flt3-ITD double-mutant mouse model, which recapitulates AML, to study Pu.1 in relevant leukaemic cell populations. I propose to study Pu.1 using chromatin-related genomic and proteomic techniques and will integrate these with gene expression analyses across normal-, early AML- and late AML-derived cell types. I will then aim to corroborating my findings from murine systems in AML patient samples. An understanding of changes in gene expression and the 3D chromatin structure caused by the binding of PU.1 and/or its interactors will unveil novel mechanisms of transcriptional regulation in the AML setting. Looking into the future, the combination of these experimental approaches may enable the development of therapeutics to specifically target PU.1-associated pathways AML.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Jaana Bagri","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Bagri","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Identification, characterisation and therapeutic targeting of gene regulatory complexes and networks in leukaemic stem cells. Transcription factor (TF) networks are cardinally dysregulated in Acute Myeloid Leukaemia (AML), with many of these dysregulated TFs known to have developmental and homeostatic roles in normal haematopoiesis. I will focus on the E-twenty six (ETS) TF Pu.1 that is known to play an important role in myeloid and lymphoid development. Conventionally, Pu.1 is better known as a tumour suppressor during AML development but, more recent studies within the Huntly Lab have suggested an alternative role for Pu.1 in the maintenance of AML.\n\nI will be using an Npm1c/Flt3-ITD double-mutant mouse model, which recapitulates AML, to study Pu.1 in relevant leukaemic cell populations. I propose to study Pu.1 using chromatin-related genomic and proteomic techniques and will integrate these with gene expression analyses across normal-, early AML- and late AML-derived cell types. I will then aim to corroborating my findings from murine systems in AML patient samples. An understanding of changes in gene expression and the 3D chromatin structure caused by the binding of PU.1 and/or its interactors will unveil novel mechanisms of transcriptional regulation in the AML setting. Looking into the future, the combination of these experimental approaches may enable the development of therapeutics to specifically target PU.1-associated pathways AML.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Gene Expression Regulation, Leukemic","Humans","Leukemia, Myeloid, Acute","Mice","Proteomics","fms-Like Tyrosine Kinase 3"]}
{"id":"360G-Wellcome-222364_Z_21_Z","title":"Examining the use of infectious disease modelling in international outbreak response","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222364/Z/21/Z","description":"Infectious disease modelling (IDM) is a branch of epidemiology that uses mathematical models to predict the spread of disease, often through a population. It is especially useful for estimating the impact of prevention and control measures.\n\nAfter attending recent international conferences, the clear take-home message is that IDM research does not always reach healthcare decision-makers in a usable format, in useful time. \u2018Healthcare decision-makers\u2019 include such organisations as the WHO; Centres for Disease Control; International health NGOs; and country-specific Governments and Departments of Health. The bridge between researchers and decision-makers is especially challenging in emergency epidemic-response situations, where crucial action must be taken immediately.\n\nIn applied epidemiological research, the goal should be to inform evidence-based healthcare decision-making - answering the policy questions that need an answer. How do we ensure this can be achieved effectively?\n\nThis PhD seeks to analyse the use of infectious disease modelling in pandemics and large epidemics, by scrutinizing existing models and working closely with both influential modellers and global healthcare decision-makers on a broad range of outbreak case-studies. We will identify existing challenges on the interface of these two fields and work to develop a document of best practice, implementing change at the international level.\n \n","plannedDates":[{"endDate":"2023-10-07T00:00:00+00:00","startDate":"2020-10-08T00:00:00+00:00","startDateDateOnly":"2020-10-08","endDateDateOnly":"2023-10-07"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Liza Hadley","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Hadley","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Examining the use of infectious disease modelling in international outbreak response Infectious disease modelling (IDM) is a branch of epidemiology that uses mathematical models to predict the spread of disease, often through a population. It is especially useful for estimating the impact of prevention and control measures.\n\nAfter attending recent international conferences, the clear take-home message is that IDM research does not always reach healthcare decision-makers in a usable format, in useful time. \u2018Healthcare decision-makers\u2019 include such organisations as the WHO; Centres for Disease Control; International health NGOs; and country-specific Governments and Departments of Health. The bridge between researchers and decision-makers is especially challenging in emergency epidemic-response situations, where crucial action must be taken immediately.\n\nIn applied epidemiological research, the goal should be to inform evidence-based healthcare decision-making - answering the policy questions that need an answer. How do we ensure this can be achieved effectively?\n\nThis PhD seeks to analyse the use of infectious disease modelling in pandemics and large epidemics, by scrutinizing existing models and working closely with both influential modellers and global healthcare decision-makers on a broad range of outbreak case-studies. We will identify existing challenges on the interface of these two fields and work to develop a document of best practice, implementing change at the international level.\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Communicable Diseases","Disease Outbreaks","Epidemics","Humans","Models, Theoretical"]}
{"id":"360G-Wellcome-222363_Z_21_Z","title":"Promoting an Adult Phenotype in Erythroblasts and Megakaryocytes derived from Human Pluripotent Stem Cells through a Forward Programming Approach","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222363/Z/21/Z","description":"Red blood cells (RBCs) and platelets are important cells in the blood required for oxygen delivery and blood clotting, respectively. Having too few of these cells, which can be caused by things such as cancer treatment, can lead to severe health problems. Although this is treatable using voluntary blood donations, in coming years more donations will be needed. Alternative options must therefore be developed. In answer to this, the Ghevaert group has developed a method (known as 'forward programming', or 'FOP') to artificially produce RBCs and platelets from stem cells in the lab. Unfortunately the cells produced by FOP are less functional than the adult cells found in our bodies, meaning that improvements must still be made. Using a computer program, I will redesign FOP so that it produces more functional RBCs and platelets from stem cells. This redesigning will involve changing the core ingredients used to drive FOP, so that FOP is more likely to produce adult cells. I will also investigate why it is so difficult to produce adult RBCs and platelets from stem cells. Consequently this work will guide future research in a more informed direction, and may provide a viable alternative to donated blood products.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Rebecca McDonald","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"McDonald","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Promoting an Adult Phenotype in Erythroblasts and Megakaryocytes derived from Human Pluripotent Stem Cells through a Forward Programming Approach Red blood cells (RBCs) and platelets are important cells in the blood required for oxygen delivery and blood clotting, respectively. Having too few of these cells, which can be caused by things such as cancer treatment, can lead to severe health problems. Although this is treatable using voluntary blood donations, in coming years more donations will be needed. Alternative options must therefore be developed. In answer to this, the Ghevaert group has developed a method (known as 'forward programming', or 'FOP') to artificially produce RBCs and platelets from stem cells in the lab. Unfortunately the cells produced by FOP are less functional than the adult cells found in our bodies, meaning that improvements must still be made. Using a computer program, I will redesign FOP so that it produces more functional RBCs and platelets from stem cells. This redesigning will involve changing the core ingredients used to drive FOP, so that FOP is more likely to produce adult cells. I will also investigate why it is so difficult to produce adult RBCs and platelets from stem cells. Consequently this work will guide future research in a more informed direction, and may provide a viable alternative to donated blood products.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Blood Platelets","Cell Differentiation","Erythrocytes","Humans"]}
{"id":"360G-Wellcome-222362_Z_21_Z","title":"Genetic and non-genetic factors driving the expansion and progression of clonal haematopoiesis","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222362/Z/21/Z","description":"Myeloid malignancies are a range of blood cancers caused by specific mutations in blood cells. These mutations cause affected cells to grow more rapidly and make up a greater proportion of our blood over time in a process known as clonal haematopoiesis (CH). Recent studies have shown CH is commonly found in otherwise healthy individuals with some fraction going on to develop myeloid malignancies. We have previously shown that some of these mutations are particularly common in elderly individuals, although how they lead to CH is currently unknown. My research will study human bone marrow samples and mice carrying these mutations to understand how they cause CH and why they are more common in the elderly. In particular, I hope to identify factors present in the bone marrow of elderly people that alters the behaviour of blood cells carrying these mutations and leads to CH. This could be used to determine which individuals carrying these mutations are at high risk of progression to myeloid malignancy and develop treatments to stop or reverse this process.\n\n \n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Matthew McLoughlin","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"McLoughlin","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Genetic and non-genetic factors driving the expansion and progression of clonal haematopoiesis Myeloid malignancies are a range of blood cancers caused by specific mutations in blood cells. These mutations cause affected cells to grow more rapidly and make up a greater proportion of our blood over time in a process known as clonal haematopoiesis (CH). Recent studies have shown CH is commonly found in otherwise healthy individuals with some fraction going on to develop myeloid malignancies. We have previously shown that some of these mutations are particularly common in elderly individuals, although how they lead to CH is currently unknown. My research will study human bone marrow samples and mice carrying these mutations to understand how they cause CH and why they are more common in the elderly. In particular, I hope to identify factors present in the bone marrow of elderly people that alters the behaviour of blood cells carrying these mutations and leads to CH. This could be used to determine which individuals carrying these mutations are at high risk of progression to myeloid malignancy and develop treatments to stop or reverse this process.\n\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aged","Aging","Animals","Bone Marrow","Disease Progression","Hematologic Neoplasms","Hematopoiesis","Hematopoietic Stem Cells","Humans","Mice","Mutation","Myeloid Cells"]}
{"id":"360G-Wellcome-222361_Z_21_Z","title":"Circuit and Molecular Mechanisms of Olfactory Associative Learning","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222361/Z/21/Z","description":"To direct behaviour effectively, animals need to constantly update the value and predictions of the sensory stimuli they encounter. To solve this task, all brains have the ability to change sensory processing and behaviour according to previous experiences, a process termed learning. The aim of this project is to identify what changes in sensory processing underlie the integration of conflicting (rewarding and aversive) experiences which produce opposite behaviour. I will use C. elegans because it has small and anatomically well described circuits for associative learning that share functional features with those of more complex brains and can be manipulated with single cell resolution. I will combine behavioural analysis, genetic manipulation of neuronal communication and imaging of neuronal activity to dissect the mechanisms of neural plasticity that underlie a switch in odour preferences after sexual conditioning. This will consist in identifying the neurons within the circuit for odour processing that release a neuromodulator and establishing the changes in information flow arising from neuromodulation.  These studies will provide a mechanistic understanding for integration and resolution of conflict during learning that will illuminate how this process occurs in more complex brains.  \n \n","plannedDates":[{"endDate":"2023-09-27T00:00:00+00:00","startDate":"2020-09-28T00:00:00+00:00","startDateDateOnly":"2020-09-28","endDateDateOnly":"2023-09-27"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Susana Colinas Fischer","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Colinas Fischer","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Circuit and Molecular Mechanisms of Olfactory Associative Learning To direct behaviour effectively, animals need to constantly update the value and predictions of the sensory stimuli they encounter. To solve this task, all brains have the ability to change sensory processing and behaviour according to previous experiences, a process termed learning. The aim of this project is to identify what changes in sensory processing underlie the integration of conflicting (rewarding and aversive) experiences which produce opposite behaviour. I will use C. elegans because it has small and anatomically well described circuits for associative learning that share functional features with those of more complex brains and can be manipulated with single cell resolution. I will combine behavioural analysis, genetic manipulation of neuronal communication and imaging of neuronal activity to dissect the mechanisms of neural plasticity that underlie a switch in odour preferences after sexual conditioning. This will consist in identifying the neurons within the circuit for odour processing that release a neuromodulator and establishing the changes in information flow arising from neuromodulation.  These studies will provide a mechanistic understanding for integration and resolution of conflict during learning that will illuminate how this process occurs in more complex brains.  \n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Caenorhabditis elegans","Conditioning, Classical","Learning","Neuronal Plasticity","Odorants","Olfactory Perception","Reward","Smell"]}
{"id":"360G-Wellcome-222360_Z_21_Z","title":"Investigating the role of CTHRC1 in biliary fibrosis","Region":"Scotland","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222360/Z/21/Z","description":"Fibrosis (scarring) is a necessary part of regeneration, a stable scaffold around which cells can reorganise themselves to regain function is essential. In the liver, there are different modes in which fibrosis occurs, we need to learn more about what makes them different.\n\n844 million people worldwide have chronic liver disease, with about two million deaths per year. Chronic liver disease can progress to cirrhosis, liver cancer and death. Treatment is limited to removal of the underlying cause or liver transplantation. Importantly, the greater the fibrosis a patient has the poorer the outcomes. Therefore, developing antifibrotic therapies for patients with chronic liver disease will impact significantly on morbidity and mortality. Primary biliary cholangitis (PBC) is a chronic liver disease resulting in destruction of the bile ducts. We have identified a protein called CTHRC1, expressed on scar-forming cells surrounding the duct, in patients with PBC. These cells play a role in fibrosis and disease progression.\n\nTo investigate how CTHRC1 contributes to liver fibrosis in PBC I will use liver tissue and cells from PBC patients and mouse models of liver fibrosis to explore whether targeting the function of CTHRC1 could be a new treatment for patients with liver fibrosis.\n \n","plannedDates":[{"endDate":"2023-09-08T00:00:00+00:00","startDate":"2020-09-09T00:00:00+00:00","startDateDateOnly":"2020-09-09","endDateDateOnly":"2023-09-08"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr David Wilson","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Wilson","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the role of CTHRC1 in biliary fibrosis Fibrosis (scarring) is a necessary part of regeneration, a stable scaffold around which cells can reorganise themselves to regain function is essential. In the liver, there are different modes in which fibrosis occurs, we need to learn more about what makes them different.\n\n844 million people worldwide have chronic liver disease, with about two million deaths per year. Chronic liver disease can progress to cirrhosis, liver cancer and death. Treatment is limited to removal of the underlying cause or liver transplantation. Importantly, the greater the fibrosis a patient has the poorer the outcomes. Therefore, developing antifibrotic therapies for patients with chronic liver disease will impact significantly on morbidity and mortality. Primary biliary cholangitis (PBC) is a chronic liver disease resulting in destruction of the bile ducts. We have identified a protein called CTHRC1, expressed on scar-forming cells surrounding the duct, in patients with PBC. These cells play a role in fibrosis and disease progression.\n\nTo investigate how CTHRC1 contributes to liver fibrosis in PBC I will use liver tissue and cells from PBC patients and mouse models of liver fibrosis to explore whether targeting the function of CTHRC1 could be a new treatment for patients with liver fibrosis.\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Bile Ducts","Disease Models, Animal","Humans","Liver Cirrhosis","Liver Cirrhosis, Biliary","Mice"]}
{"id":"360G-Wellcome-222359_Z_21_Z","title":"The Epicardium as the Conductor of Cardiovascular Cells in Cardiac Regeneration","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222359/Z/21/Z","description":"Regenerative cardiovascular medicine is emerging as a novel therapeutic alternative to heart transplantation in patients suffering from chronic heart failure. This approach aims to restore cardiac functionality by exogenous transplantation of stem cell-derived cardiomyocytes. Although promising, challenges to cardiac repair remain, for example with respect to cell maturation and revascularisation. It has recently been shown in rats, that these challenges can be improved by co-transplantation of stem cell-derived epicardial cells. One plausible explanation for these improvements is paracrine-mediated effects. Paracrine signalling involves secretion of signalling factors in cells to alter the behaviour of surrounding cells, often in a gradient-dependent manner. Paracrine signalling factors include secreted proteins and miRNAs. They can be secreted into the extracellular space directly or packed into small extracellular vesicles, called exosomes. I aim to identify and characterise paracrine signalling factors of stem cell-derived epicardial cells, which promote myocardial maturation and vascularisation. Candidate paracrine signalling factors will be selected based on gene, protein, and miRNA expression and functionally characterised in vitro and in vivo. Identification of effective paracrine signalling factors will make it possible to address selected cardiac repair processes, resulting in new approaches to therapy.\n","plannedDates":[{"endDate":"2023-09-26T00:00:00+00:00","startDate":"2020-09-27T00:00:00+00:00","startDateDateOnly":"2020-09-27","endDateDateOnly":"2023-09-26"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Patrick Rericha","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Rericha","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The Epicardium as the Conductor of Cardiovascular Cells in Cardiac Regeneration Regenerative cardiovascular medicine is emerging as a novel therapeutic alternative to heart transplantation in patients suffering from chronic heart failure. This approach aims to restore cardiac functionality by exogenous transplantation of stem cell-derived cardiomyocytes. Although promising, challenges to cardiac repair remain, for example with respect to cell maturation and revascularisation. It has recently been shown in rats, that these challenges can be improved by co-transplantation of stem cell-derived epicardial cells. One plausible explanation for these improvements is paracrine-mediated effects. Paracrine signalling involves secretion of signalling factors in cells to alter the behaviour of surrounding cells, often in a gradient-dependent manner. Paracrine signalling factors include secreted proteins and miRNAs. They can be secreted into the extracellular space directly or packed into small extracellular vesicles, called exosomes. I aim to identify and characterise paracrine signalling factors of stem cell-derived epicardial cells, which promote myocardial maturation and vascularisation. Candidate paracrine signalling factors will be selected based on gene, protein, and miRNA expression and functionally characterised in vitro and in vivo. Identification of effective paracrine signalling factors will make it possible to address selected cardiac repair processes, resulting in new approaches to therapy.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Exosomes","Humans","MicroRNAs","Myocytes, Cardiac","Paracrine Communication","Pericardium","Regeneration","Signal Transduction","Stem Cells"]}
{"id":"360G-Wellcome-222358_Z_21_Z","title":"Investigating ancestral structure in the founding populations of modern humans in Africa","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222358/Z/21/Z","description":"Current research suggests that homo sapiens originated in numerous subdivided populations, opposing the traditional view that we evolved from a single region/population. Existing methods for detecting the size of ancestral populations are limited by their assumption that populations develop in isolation (without mixing with other populations), therefore necessitating new methods that can detect ancient population mixing.\n\nMy approach is to simulate different population ancestries \u2013 generally speaking, mixing vs non mixing \u2013 and see if any of the current methods for population size estimation hold any information in their model parameters that change in the presence of population mixture. Using these results, I will aim to analyse the extent of mixing in ancestral African populations by examining real genome data of extant peoples, such as the San and Yoruba. The impact of my research will be to shed more light upon the origin of homo-sapiens as we developed in Africa, 150,000 to 400,000 years ago.\n \n","plannedDates":[{"endDate":"2023-10-10T00:00:00+00:00","startDate":"2020-10-11T00:00:00+00:00","startDateDateOnly":"2020-10-11","endDateDateOnly":"2023-10-10"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Trevor Cousins","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Cousins","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating ancestral structure in the founding populations of modern humans in Africa Current research suggests that homo sapiens originated in numerous subdivided populations, opposing the traditional view that we evolved from a single region/population. Existing methods for detecting the size of ancestral populations are limited by their assumption that populations develop in isolation (without mixing with other populations), therefore necessitating new methods that can detect ancient population mixing.\n\nMy approach is to simulate different population ancestries \u2013 generally speaking, mixing vs non mixing \u2013 and see if any of the current methods for population size estimation hold any information in their model parameters that change in the presence of population mixture. Using these results, I will aim to analyse the extent of mixing in ancestral African populations by examining real genome data of extant peoples, such as the San and Yoruba. The impact of my research will be to shed more light upon the origin of homo-sapiens as we developed in Africa, 150,000 to 400,000 years ago.\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa","African Continental Ancestry Group","Genetics, Population","Genome, Human","Humans"]}
{"id":"360G-Wellcome-222357_Z_21_Z","title":"Yellow fever vaccination- will a booster be needed?","Region":"Greater London","currency":"GBP","awardDate":"2021-04-30T00:00:00+00:00","Internal ID":"222357/Z/21/Z","description":"A highly effective vaccine against yellow fever (YF) is available and part of the Expanded Program on Immunisation in YF endemic countries. Following a change in WHO guidance in 2014, YF vaccination is now restricted to a single dose given in infancy and expected to provide life-long protection. Recent data have highlighted that this schedule might be insufficient as low antibody titres have been documented in infants who received a primary dose at the age of 9 months. A booster dose of the vaccine might be required in order to ensure long-term protection. Data to support future decisions regarding the ideal timing of  a potential booster dose and its subsequent immunogenicity are now urgently required.\n\nOur Aim is to assess if a YF booster dose is required for children who received a single dose of YF vaccination in infancy and if so, at what age this booster dose might be most effective to administer.\n\nWe will enrol three well characterised cohorts of children aged between 15 months and 8 years of age with available data on primary immune response to YF vaccination to determine ideal timing for a booster and examine underlying innate and cellular immune responses related to sero-protection.\n","plannedDates":[{"endDate":"2022-05-01T00:00:00+00:00","startDate":"2020-11-02T00:00:00+00:00","startDateDateOnly":"2020-11-02","endDateDateOnly":"2022-05-01"}],"amountAwarded":331006,"Financial Year":"2020/21","Lead Applicant":"Prof Beate Kampmann","grantProgramme":[{"title":"DFID-Wellcome Epidemic Preparedness Grant","title_keyword":"DFID-Wellcome Epidemic Preparedness Grant"}],"Partnership Name":"Wellcome-DFID Epidemic Response","Applicant Surname":"Kampmann","Partnership Value":662012,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Ed Clarke","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"London School of Hygiene & Tropical Medicine\", \"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Yellow fever vaccination- will a booster be needed? A highly effective vaccine against yellow fever (YF) is available and part of the Expanded Program on Immunisation in YF endemic countries. Following a change in WHO guidance in 2014, YF vaccination is now restricted to a single dose given in infancy and expected to provide life-long protection. Recent data have highlighted that this schedule might be insufficient as low antibody titres have been documented in infants who received a primary dose at the age of 9 months. A booster dose of the vaccine might be required in order to ensure long-term protection. Data to support future decisions regarding the ideal timing of  a potential booster dose and its subsequent immunogenicity are now urgently required.\n\nOur Aim is to assess if a YF booster dose is required for children who received a single dose of YF vaccination in infancy and if so, at what age this booster dose might be most effective to administer.\n\nWe will enrol three well characterised cohorts of children aged between 15 months and 8 years of age with available data on primary immune response to YF vaccination to determine ideal timing for a booster and examine underlying innate and cellular immune responses related to sero-protection.\n","awardDateDateOnly":"2021-04-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Child, Preschool","Female","Humans","Immunization, Secondary","Infant","Male","Vaccination","Yellow Fever","Yellow Fever Vaccine"]}
{"id":"360G-Wellcome-222356_Z_21_Z","title":"Determining the function of intestinal macrophage subsets in health, inflammation and repair","Region":"Scotland","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222356/Z/21/Z","description":"Intestinal macrophages are crucial in maintaining gut homeostasis and, during health powerful regulatory mechanisms exist to maintain intestinal macrophages in an anti-inflammatory state, allowing them to exist in their antigen- and microbe-rich environment. However, macrophages are now also considered key drivers of intestinal pathologies, such as inflammatory bowel disease (IBD). Moreover, proinflammatory macrophages accumulate in the intestine and promote reduced epithelial-barrier integrity in response to distant inflammation, including cerebral ischemia (stroke). How macrophages can play such seemingly paradoxical roles remains unclear. One line of thought is that functionally-distinct macrophages subsets may dominate in certain contexts, i.e. health, inflammation and repair. Recent work from our lab uncovered at least two transcriptionally-distinct intestinal macrophage subsets, however their locations and functions within the gut wall in different contexts remain unclear. I aim to determine the roles of these macrophage subsets in intestinal inflammation caused by local insult or distant injury, as well as tissue repair. I will use immunofluorescence and flow cytometry together with novel genetic depletion models to assess the spatial and functional characteristics macrophage subsets in experimental IBD and intestinal inflammation caused by cerebral ischemia. These studies will determine whether the paradoxical roles of intestinal macrophages are explained by functional heterogeneity.\n","plannedDates":[{"endDate":"2023-10-03T00:00:00+00:00","startDate":"2020-10-04T00:00:00+00:00","startDateDateOnly":"2020-10-04","endDateDateOnly":"2023-10-03"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Lizi Hegarty","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Hegarty","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Determining the function of intestinal macrophage subsets in health, inflammation and repair Intestinal macrophages are crucial in maintaining gut homeostasis and, during health powerful regulatory mechanisms exist to maintain intestinal macrophages in an anti-inflammatory state, allowing them to exist in their antigen- and microbe-rich environment. However, macrophages are now also considered key drivers of intestinal pathologies, such as inflammatory bowel disease (IBD). Moreover, proinflammatory macrophages accumulate in the intestine and promote reduced epithelial-barrier integrity in response to distant inflammation, including cerebral ischemia (stroke). How macrophages can play such seemingly paradoxical roles remains unclear. One line of thought is that functionally-distinct macrophages subsets may dominate in certain contexts, i.e. health, inflammation and repair. Recent work from our lab uncovered at least two transcriptionally-distinct intestinal macrophage subsets, however their locations and functions within the gut wall in different contexts remain unclear. I aim to determine the roles of these macrophage subsets in intestinal inflammation caused by local insult or distant injury, as well as tissue repair. I will use immunofluorescence and flow cytometry together with novel genetic depletion models to assess the spatial and functional characteristics macrophage subsets in experimental IBD and intestinal inflammation caused by cerebral ischemia. These studies will determine whether the paradoxical roles of intestinal macrophages are explained by functional heterogeneity.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Brain Ischemia","Humans","Inflammation","Inflammatory Bowel Diseases","Intestinal Mucosa","Macrophages","Mice"]}
{"id":"360G-Wellcome-222355_Z_21_Z","title":"Non-distancing: The role of direct cell-cell contact in cancer initiation and early progression","Region":"Scotland","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222355/Z/21/Z","description":"Cells must communicate with their neighbours, send, and receive various information as they build and regenerate tissues. This communication is often not well understood, for example during the very first steps of cancer growth. Pre-neoplastic cells (PNCs) (the first cells carrying oncogenic mutations that will lead to cancer) are surrounded by healthy neighbours and contacted by patrolling innate immune cells. I want to know how these interactions between healthy cells of the body and the very first cancer cells may lead to the arrest or support of tumour development.\nEvidence from the Feng group shows that neutrophils and macrophages contact emerging PNCs in the skin, and that this interaction results in increased proliferation of cancer-cell colonies (van den Berg et al., 2019). A new synthetic-biology tool called SynNotch allows us to precisely report on direct cell-cell contact at the single cell level (Morsut et al., 2016). I will engineer this tool into the zebrafish, where it will allow us to report on cell-to-cell contact in real-time, and in the living animals. Using this tool, I will study the effects of PNC-immune cell contact.\nAdditionally, I will study the effects of contact between PNCs and healthy neighbour cells in cell culture.\n","plannedDates":[{"endDate":"2023-10-03T00:00:00+00:00","startDate":"2020-10-04T00:00:00+00:00","startDateDateOnly":"2020-10-04","endDateDateOnly":"2023-10-03"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Jennifer Annoh","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Annoh","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Non-distancing: The role of direct cell-cell contact in cancer initiation and early progression Cells must communicate with their neighbours, send, and receive various information as they build and regenerate tissues. This communication is often not well understood, for example during the very first steps of cancer growth. Pre-neoplastic cells (PNCs) (the first cells carrying oncogenic mutations that will lead to cancer) are surrounded by healthy neighbours and contacted by patrolling innate immune cells. I want to know how these interactions between healthy cells of the body and the very first cancer cells may lead to the arrest or support of tumour development.\nEvidence from the Feng group shows that neutrophils and macrophages contact emerging PNCs in the skin, and that this interaction results in increased proliferation of cancer-cell colonies (van den Berg et al., 2019). A new synthetic-biology tool called SynNotch allows us to precisely report on direct cell-cell contact at the single cell level (Morsut et al., 2016). I will engineer this tool into the zebrafish, where it will allow us to report on cell-to-cell contact in real-time, and in the living animals. Using this tool, I will study the effects of PNC-immune cell contact.\nAdditionally, I will study the effects of contact between PNCs and healthy neighbour cells in cell culture.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Humans","Immunity, Innate","Macrophages","Neoplasms","Zebrafish"]}
{"id":"360G-Wellcome-222354_Z_21_Z","title":"Elucidating the functions of Pbx1 during pancreatic cell differentiation ","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222354/Z/21/Z","description":"Pbx1 is a TALE homeodomain transcription factor whose diverse regulatory function makes it indispensable for organogenesis (Selleri et al., 2019). Its activity is essential for early pancreatic development as embryos with homozygous deficiency of Pbx1 exhibit pancreatic hypoplasia and cell differentiation defects prior to death in utero at E15.5 (Kim et al., 2002). However, the basic mechanisms underlying the requirements for Pbx in mammalian pancreatic development remain largely unexplored. Using a conditional Cre-Lox system, I will focus on Pbx1 deletion in pancreatic epithelium at various stages of mouse development and in the adult pancreas to determine its role in maintaining pancreatic cell type identity. I will also establish a human induced pluripotent stem cell model to assess whether developmental mechanisms involving Pbx1 observed in mice are also conserved in humans. Here, I will use CRISPRi-Cas9 gene editing to reversibly inhibit Pbx1 at different stages of pancreatic cell differentiation. Lastly, I will construct a gene regulatory network of the pancreatic epithelium using chromatin immunoprecipitation and RNA sequencing data at various developmental stages to test Pbx1 targets both in vivo and in vitro. This project has great potential for advancing the field of diabetes research, disease modelling and cell therapies.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Abigail Isaacson","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Isaacson","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Elucidating the functions of Pbx1 during pancreatic cell differentiation  Pbx1 is a TALE homeodomain transcription factor whose diverse regulatory function makes it indispensable for organogenesis (Selleri et al., 2019). Its activity is essential for early pancreatic development as embryos with homozygous deficiency of Pbx1 exhibit pancreatic hypoplasia and cell differentiation defects prior to death in utero at E15.5 (Kim et al., 2002). However, the basic mechanisms underlying the requirements for Pbx in mammalian pancreatic development remain largely unexplored. Using a conditional Cre-Lox system, I will focus on Pbx1 deletion in pancreatic epithelium at various stages of mouse development and in the adult pancreas to determine its role in maintaining pancreatic cell type identity. I will also establish a human induced pluripotent stem cell model to assess whether developmental mechanisms involving Pbx1 observed in mice are also conserved in humans. Here, I will use CRISPRi-Cas9 gene editing to reversibly inhibit Pbx1 at different stages of pancreatic cell differentiation. Lastly, I will construct a gene regulatory network of the pancreatic epithelium using chromatin immunoprecipitation and RNA sequencing data at various developmental stages to test Pbx1 targets both in vivo and in vitro. This project has great potential for advancing the field of diabetes research, disease modelling and cell therapies.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","CRISPR-Cas Systems","Cell Differentiation","Gene Expression Regulation, Developmental","Gene Regulatory Networks","Homeodomain Proteins","Humans","Insulin-Secreting Cells","Mice","Pancreas","Transcription Factors"]}
{"id":"360G-Wellcome-222353_Z_21_Z","title":"Reconstructing a Gene Regulatory Network for cell fate decisions in the sensory nervous system","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222353/Z/21/Z","description":"The nervous system is the most complex organ in our body with thousands of different cell types. How is such diversity generated? This remains one of the key questions in developmental biology, which ultimately will inform regenerative medicine and cell reprogramming. Single cell technologies have shed light on how progenitor cells may commit to a particular fate, challenging the long-standing assumptions that cell differentiation is a smooth, continuous process.\n\nThis project will dissect the molecular mechanisms controlling how progenitors give rise to different cell types in the sensory nervous system of the vertebrate head. Despite a wealth of information on signalling, cell movements and timing of this process, a mechanistic understanding of how progenitors diversify is still missing. This is therefore an ideal context to apply a systematic, single-cell approach to identify and characterise cell fate decisions.\n\nI will obtain single cell gene expression and chromatin state data from the developing chick embryo and use this to predict developmental trajectories, branchpoints, and candidate transcription factors regulating these branch points. I will then use perturbation analysis to validate these predictions. Together, this will reconstruct the molecular circuitry, the gene regulatory network, that drives cell fate decisions in the sensory nervous system.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Eva Hamrud","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Hamrud","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Reconstructing a Gene Regulatory Network for cell fate decisions in the sensory nervous system The nervous system is the most complex organ in our body with thousands of different cell types. How is such diversity generated? This remains one of the key questions in developmental biology, which ultimately will inform regenerative medicine and cell reprogramming. Single cell technologies have shed light on how progenitor cells may commit to a particular fate, challenging the long-standing assumptions that cell differentiation is a smooth, continuous process.\n\nThis project will dissect the molecular mechanisms controlling how progenitors give rise to different cell types in the sensory nervous system of the vertebrate head. Despite a wealth of information on signalling, cell movements and timing of this process, a mechanistic understanding of how progenitors diversify is still missing. This is therefore an ideal context to apply a systematic, single-cell approach to identify and characterise cell fate decisions.\n\nI will obtain single cell gene expression and chromatin state data from the developing chick embryo and use this to predict developmental trajectories, branchpoints, and candidate transcription factors regulating these branch points. I will then use perturbation analysis to validate these predictions. Together, this will reconstruct the molecular circuitry, the gene regulatory network, that drives cell fate decisions in the sensory nervous system.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cell Differentiation","Cell Lineage","Chick Embryo","Chickens","Gene Expression Regulation, Developmental","Gene Regulatory Networks","Mice","Single-Cell Analysis","Transcription Factors"]}
{"id":"360G-Wellcome-222352_Z_21_Z","title":"Muscle stem cell function in facioscapulohumeral muscular dystrophy","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222352/Z/21/Z","description":"Facioscapulohumeral muscular dystrophy (FSHD) is the third most common inherited muscular dystrophy, and involves progressive muscle weakness and wasting, beginning in muscles of the face, shoulder, upper back and lower legs. FSHD is caused by inappropriate expression of a protein called DUX4 in adult tissue. DUX4 is a transcription factor, meaning that it controls expression of other genes. DUX4 upsets the carefully orchestrated pattern of gene expression that allows muscle to function effectively, causing cells to die. However, exactly how DUX4 expression induces muscle cell death/loss are not well understood.\n\nMuscle normally repairs efficiently due to resident stem cells, but loss of muscle in FSHD indicates a compromised repair mechanism. I aim to characterize muscle stem cells in FSHD by examining protein and gene expression in muscle biopsies from FSHD patients. I also aim to explore the dynamics and effects of DUX4 expression on development and function of muscle stem cells, as well as subsequent myofiber formation and regeneration, using induced pluripotent stem cells from FSHD patients and in vivo models. This work will inform whether deficits in muscle stem cell function contribute to the muscle wasting observed in FSHD pathology, and explore potential regenerative therapies.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Elise Engquist","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Engquist","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Muscle stem cell function in facioscapulohumeral muscular dystrophy Facioscapulohumeral muscular dystrophy (FSHD) is the third most common inherited muscular dystrophy, and involves progressive muscle weakness and wasting, beginning in muscles of the face, shoulder, upper back and lower legs. FSHD is caused by inappropriate expression of a protein called DUX4 in adult tissue. DUX4 is a transcription factor, meaning that it controls expression of other genes. DUX4 upsets the carefully orchestrated pattern of gene expression that allows muscle to function effectively, causing cells to die. However, exactly how DUX4 expression induces muscle cell death/loss are not well understood.\n\nMuscle normally repairs efficiently due to resident stem cells, but loss of muscle in FSHD indicates a compromised repair mechanism. I aim to characterize muscle stem cells in FSHD by examining protein and gene expression in muscle biopsies from FSHD patients. I also aim to explore the dynamics and effects of DUX4 expression on development and function of muscle stem cells, as well as subsequent myofiber formation and regeneration, using induced pluripotent stem cells from FSHD patients and in vivo models. This work will inform whether deficits in muscle stem cell function contribute to the muscle wasting observed in FSHD pathology, and explore potential regenerative therapies.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Homeodomain Proteins","Humans","Induced Pluripotent Stem Cells","Muscle, Skeletal","Muscular Dystrophy, Facioscapulohumeral","Regeneration"]}
{"id":"360G-Wellcome-222351_Z_21_Z","title":"Tissue-resident macrophage activation and regulation in injury and recovery","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222351/Z/21/Z","description":"In this project, we hypothesise that there exist a tight regulation of macrophage activation following tissue injury to create environments permissive to different stages of tissue repair. Making use of human iPSC-derived macrophages (iMacs), we aim to gain insight into how they become activated after tissue damage, particularly through scavenger receptors in collaboration with other pattern recognition receptors. By studying knockout iMac models, we will then seek to understand how the IL-10/PGE2 axis and regulatory T cells limit excessive activation. Lastly, we aim to deliver in vivo evidence that some of these pathways are involved in promoting either organ inflammation or homeostasis restoration by using carbon tetrachloride (CCl4)-induced acute liver injury mouse model. A full understanding of these mechanisms will guide the development of potential therapeutic targets that harness specific macrophage properties for clinical benefit.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Wai Heng Chung","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Chung","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Tissue-resident macrophage activation and regulation in injury and recovery In this project, we hypothesise that there exist a tight regulation of macrophage activation following tissue injury to create environments permissive to different stages of tissue repair. Making use of human iPSC-derived macrophages (iMacs), we aim to gain insight into how they become activated after tissue damage, particularly through scavenger receptors in collaboration with other pattern recognition receptors. By studying knockout iMac models, we will then seek to understand how the IL-10/PGE2 axis and regulatory T cells limit excessive activation. Lastly, we aim to deliver in vivo evidence that some of these pathways are involved in promoting either organ inflammation or homeostasis restoration by using carbon tetrachloride (CCl4)-induced acute liver injury mouse model. A full understanding of these mechanisms will guide the development of potential therapeutic targets that harness specific macrophage properties for clinical benefit.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Carbon Tetrachloride","Chemical and Drug Induced Liver Injury","Dinoprostone","Humans","Interleukin-10","Macrophages","Mice","Mice, Inbred C57BL","Mice, Knockout","T-Lymphocytes, Regulatory"]}
{"id":"360G-Wellcome-222350_Z_21_Z","title":"Obtaining macrophages from induced pluripotent stem cells to investigate the influence of the host genetic background on the outcome of HIV-1 infection","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222350/Z/21/Z","description":"The influence of host genetic factors upon HIV-1 infection is still not fully elucidated. As the virus relies on the host cell machinery and proteins to replicate, host genetics are a key determinant not only of the proteins expressed but also of their functional capabilities \u2013 therefore dictating the outcome of virus infection. This research aims to link the natural occurring genetic variation found in the human population with the inherent variability in the capacity of cells from different individuals to support HIV-1 growth. The work will employ well characterised cells from a bank of human induced pluripotent stem cells to obtain macrophages, which are natural targets of HIV-1 infection. Experimental procedures will include characterising how the virus infects and replicates in macrophages, and employing a bespoke bioinformatics pipeline to compare the genome sequences and transcriptomes of cells showing extreme infection phenotypes. With this approach, we aim to identify novel host factors that can regulate viral replication. These results will add new insights into the understanding of HIV-1 infection and disease (AIDS) and suggest avenues to explore as potential novel therapeutic strategies to treat and control HIV-1.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Nathalia Almeida dos Santos","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Almeida dos Santos","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Obtaining macrophages from induced pluripotent stem cells to investigate the influence of the host genetic background on the outcome of HIV-1 infection The influence of host genetic factors upon HIV-1 infection is still not fully elucidated. As the virus relies on the host cell machinery and proteins to replicate, host genetics are a key determinant not only of the proteins expressed but also of their functional capabilities \u2013 therefore dictating the outcome of virus infection. This research aims to link the natural occurring genetic variation found in the human population with the inherent variability in the capacity of cells from different individuals to support HIV-1 growth. The work will employ well characterised cells from a bank of human induced pluripotent stem cells to obtain macrophages, which are natural targets of HIV-1 infection. Experimental procedures will include characterising how the virus infects and replicates in macrophages, and employing a bespoke bioinformatics pipeline to compare the genome sequences and transcriptomes of cells showing extreme infection phenotypes. With this approach, we aim to identify novel host factors that can regulate viral replication. These results will add new insights into the understanding of HIV-1 infection and disease (AIDS) and suggest avenues to explore as potential novel therapeutic strategies to treat and control HIV-1.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["HIV Infections","HIV-1","Host-Pathogen Interactions","Humans","Induced Pluripotent Stem Cells","Macrophages","Virus Replication"]}
{"id":"360G-Wellcome-222349_Z_21_Z","title":"Immune-system dysfunction across major psychiatric disorders","Region":"Scotland","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222349/Z/21/Z","description":"Currently, diagnosis of psychiatric disorders is based on symptoms rather than underlying biological cause. However, symptoms can vary within a disorder and are common across many different disorders. Therefore, it is possible there are shared biological causes for overlapping symptoms across disorders. Immune system dysfunction has been suggested as a potential cause of symptoms and altered brain structure common to many disorders.\n\nI aim to identify groups of individuals with psychiatric symptoms and a genetic predisposition to immune dysfunction. To do this, I will analyse multiple large datasets of people with detailed information about their genetics, brain structure (from MRI neuroimaging), mental health and lifestyle. I will then uncover which specific components of the immune system are different in these groups of individuals. Using epidemiological statistical methods, I will test whether immune dysfunction causes psychiatric symptoms and altered brain structure. I also aim to extend this research to include a large dataset of young individuals (9 -11 years), to determine earlier origins of such relationships between immune dysfunction, alterations in brain structure and development of psychiatric symptoms.\n\nThese studies will identify shared biological causes common to many psychiatric disorders to help improve diagnosis, prognosis and move towards personalised treatment.\n","plannedDates":[{"endDate":"2023-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2023-08-31"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Amelia Edmondson-Stait","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Edmondson-Stait","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Immune-system dysfunction across major psychiatric disorders Currently, diagnosis of psychiatric disorders is based on symptoms rather than underlying biological cause. However, symptoms can vary within a disorder and are common across many different disorders. Therefore, it is possible there are shared biological causes for overlapping symptoms across disorders. Immune system dysfunction has been suggested as a potential cause of symptoms and altered brain structure common to many disorders.\n\nI aim to identify groups of individuals with psychiatric symptoms and a genetic predisposition to immune dysfunction. To do this, I will analyse multiple large datasets of people with detailed information about their genetics, brain structure (from MRI neuroimaging), mental health and lifestyle. I will then uncover which specific components of the immune system are different in these groups of individuals. Using epidemiological statistical methods, I will test whether immune dysfunction causes psychiatric symptoms and altered brain structure. I also aim to extend this research to include a large dataset of young individuals (9 -11 years), to determine earlier origins of such relationships between immune dysfunction, alterations in brain structure and development of psychiatric symptoms.\n\nThese studies will identify shared biological causes common to many psychiatric disorders to help improve diagnosis, prognosis and move towards personalised treatment.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Brain","Child","Humans","Mental Disorders"]}
{"id":"360G-Wellcome-222348_Z_21_Z","title":"Discovery and impact of schizophrenia rare genetic variation using next-generation sequencing","Region":"Wales","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222348/Z/21/Z","description":"Schizophrenia is a psychiatric disorder which affects around 1% of the population. There is no one single cause of schizophrenia, but genetics is known to play a substantial role. The genes involved in risk for the disorder span many different genes. Mutations thought to be linked to schizophrenia are often seen in individuals without a schizophrenia diagnosis, and I plan to investigate the impact these mutations have on an individual\u2019s characteristics. I will use large-scale datasets in which every protein-coding base pair has been sequenced, highlighting any mutations. I will use information on an individual\u2019s characteristics along with this genetic data to investigate the impacts of mutations in schizophrenia associated genes in both people with a schizophrenia diagnosis, and in those without. I also aim to discover new genes linked to schizophrenia, which will provide insights into the underlying biology of the disorder.\n\n \n","plannedDates":[{"endDate":"2023-10-23T00:00:00+00:00","startDate":"2020-10-24T00:00:00+00:00","startDateDateOnly":"2020-10-24","endDateDateOnly":"2023-10-23"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Eilidh Fenner","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Fenner","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University","addressCountry":"United Kingdom","id_and_name":"[\"Cardiff University\", \"360G-Wellcome-ORG:Cardiff-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Discovery and impact of schizophrenia rare genetic variation using next-generation sequencing Schizophrenia is a psychiatric disorder which affects around 1% of the population. There is no one single cause of schizophrenia, but genetics is known to play a substantial role. The genes involved in risk for the disorder span many different genes. Mutations thought to be linked to schizophrenia are often seen in individuals without a schizophrenia diagnosis, and I plan to investigate the impact these mutations have on an individual\u2019s characteristics. I will use large-scale datasets in which every protein-coding base pair has been sequenced, highlighting any mutations. I will use information on an individual\u2019s characteristics along with this genetic data to investigate the impacts of mutations in schizophrenia associated genes in both people with a schizophrenia diagnosis, and in those without. I also aim to discover new genes linked to schizophrenia, which will provide insights into the underlying biology of the disorder.\n\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Databases, Genetic","Genetic Predisposition to Disease","Genetic Variation","High-Throughput Nucleotide Sequencing","Humans","Mutation","Schizophrenia"]}
{"id":"360G-Wellcome-222347_Z_21_Z","title":"Neural and cognitive mechanisms of temporally-extended decision-making, goal pursuit and learning","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222347/Z/21/Z","description":"Whether it be catching prey or making dinner, rewards in natural environments take time to pursue. This requires planning into the future, setting goals, and flexibly switching between different strategies when needed. In my PhD I will use computational models alongside fMRI and MEG imaging techniques to explore how humans plan and make decisions in temporally extended environments. In particular, I\u2019m interested in the role of the human frontal lobes in prospective value-based decision-making and goal maintenance. \n\nI will investigate the neural mechanisms by which humans pursue goals and suppress alternative courses of action, versus deciding to abandon goals. In addition, I will examine how individuals differ in this tendency to commit to goals, which may have relevance for our understanding of various psychiatric disorders such as OCD, apathy, and depression. In future projects I will use MEG to investigate the moment-by-moment brain activity responsible for tracking changing rewards, and using this information to make predictions about the future. Finally, I am also interested in how humans weigh up different types of value across time, such as the value of information or increased agency.\n","plannedDates":[{"endDate":"2023-09-27T00:00:00+00:00","startDate":"2020-09-28T00:00:00+00:00","startDateDateOnly":"2020-09-28","endDateDateOnly":"2023-09-27"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Eleanor Holton","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Holton","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Neural and cognitive mechanisms of temporally-extended decision-making, goal pursuit and learning Whether it be catching prey or making dinner, rewards in natural environments take time to pursue. This requires planning into the future, setting goals, and flexibly switching between different strategies when needed. In my PhD I will use computational models alongside fMRI and MEG imaging techniques to explore how humans plan and make decisions in temporally extended environments. In particular, I\u2019m interested in the role of the human frontal lobes in prospective value-based decision-making and goal maintenance. \n\nI will investigate the neural mechanisms by which humans pursue goals and suppress alternative courses of action, versus deciding to abandon goals. In addition, I will examine how individuals differ in this tendency to commit to goals, which may have relevance for our understanding of various psychiatric disorders such as OCD, apathy, and depression. In future projects I will use MEG to investigate the moment-by-moment brain activity responsible for tracking changing rewards, and using this information to make predictions about the future. Finally, I am also interested in how humans weigh up different types of value across time, such as the value of information or increased agency.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Decision Making","Frontal Lobe","Goals","Humans","Magnetic Resonance Imaging","Models, Neurological","Reward"]}
{"id":"360G-Wellcome-222346_Z_21_Z","title":"Accelerating Access to Individual Participant-Level Data via the Vivli Platform","Region":"International","currency":"GBP","awardDate":"2021-02-26T00:00:00+00:00","Internal ID":"222346/Z/21/Z","description":"Data repositories (such as IDDO and Vivli) have played a significant role in making research data available for secondary use. However, access to data needs to be further enhanced for accelerated innovations on infectious diseases by addressing the friction in data contribution, discoverability, access, and reuse. There is a strong alignment between Vivli the Wellcome\u2019s visions of improving the discovery and accessibility of Individual Participant Data related to COVID-19 in the short term, and for other infectious diseases in the long term.  With this grant we seek direct support for discoverability and accessibility of data related to COVID-19, and to directly support Vivli to become an effective node in the \"FAIR Data Network\".\n\nThe grant will focus on the following primary objectives:\n\n\n Recognition and credit for data contributions, \n Accelerated access to Individual Participant Data (IPD) hosted by Vivli,\n Discoverability of IDDO studies via the Vivli platform, and\n Discoverability of IPD hosted by Vivli and its platform partners (including IDDO) based on rich metadata).        \n\n","plannedDates":[{"endDate":"2024-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2024-03-31"}],"amountAwarded":1028765,"Financial Year":"2020/21","Lead Applicant":"Dr Rebecca Li","grantProgramme":[{"title":"Discretionary Award \u2013 DSH","title_keyword":"Discretionary Award \u2013 DSH"}],"Applicant Surname":"Li","Partnership Value":1028765,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Vivli-Centre-for-Global-Clinical-Research-Data","name":"Vivli (Centre for Global Clinical Research Data)","addressCountry":"United States","id_and_name":"[\"Vivli (Centre for Global Clinical Research Data)\", \"360G-Wellcome-ORG:Vivli-Centre-for-Global-Clinical-Research-Data\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Vivli-Centre-for-Global-Clinical-Research-Data","name":"Vivli (Centre for Global Clinical Research Data)"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Accelerating Access to Individual Participant-Level Data via the Vivli Platform Data repositories (such as IDDO and Vivli) have played a significant role in making research data available for secondary use. However, access to data needs to be further enhanced for accelerated innovations on infectious diseases by addressing the friction in data contribution, discoverability, access, and reuse. There is a strong alignment between Vivli the Wellcome\u2019s visions of improving the discovery and accessibility of Individual Participant Data related to COVID-19 in the short term, and for other infectious diseases in the long term.  With this grant we seek direct support for discoverability and accessibility of data related to COVID-19, and to directly support Vivli to become an effective node in the \"FAIR Data Network\".\n\nThe grant will focus on the following primary objectives:\n\n\n Recognition and credit for data contributions, \n Accelerated access to Individual Participant Data (IPD) hosted by Vivli,\n Discoverability of IDDO studies via the Vivli platform, and\n Discoverability of IPD hosted by Vivli and its platform partners (including IDDO) based on rich metadata).        \n\n","awardDateDateOnly":"2021-02-26","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Information Dissemination","Information Storage and Retrieval","Metadata"]}
{"id":"360G-Wellcome-222345_Z_21_Z","title":"Computational investigation into the interplay between pro-arrhythmic and mechanical abnormalities","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222345/Z/21/Z","description":"\nCardiac electrical activity and contractile output have a complex relationship \u2013 electrical activity signals contraction and contractile output can then affect electrical signalling via feedback mechanisms. Computational modelling allows us to understand this relationship further, particularly regarding two important applications.\n\nCardiac toxicity is a leading reason behind pharmaceuticals being withdrawn during development, but current screening methods centred on animal testing raise concerns with ethics and accuracy. Recent developments have suggested computational testing is a viable alternative, outperforming animal models in predicting risk from dangerous arrhythmias. I will incorporate contractile mechanics into our drug testing pipeline such that we can also assess their effect on contractile output.\n\nSudden cardiac death (SCD) is a leading cause of mortality worldwide, usually caused by arrhythmias. Various treatments exist to prevent SCD, but accurate risk stratification tools are needed to identify those at high risk for developing arrhythmias causing SCD. Measures of contractile output, such as ejection fraction (EF), are used, but the relationship between them and arrhythmic risk is currently unclear, as most people experiencing SCD have preserved EF. I will use an electromechanical model to investigate the mechanisms underlying this relationship so that we can more effectively identify and treat this high-risk population.\n","plannedDates":[{"endDate":"2023-12-31T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-12-31"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Hannah Smith","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Smith","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Computational investigation into the interplay between pro-arrhythmic and mechanical abnormalities \nCardiac electrical activity and contractile output have a complex relationship \u2013 electrical activity signals contraction and contractile output can then affect electrical signalling via feedback mechanisms. Computational modelling allows us to understand this relationship further, particularly regarding two important applications.\n\nCardiac toxicity is a leading reason behind pharmaceuticals being withdrawn during development, but current screening methods centred on animal testing raise concerns with ethics and accuracy. Recent developments have suggested computational testing is a viable alternative, outperforming animal models in predicting risk from dangerous arrhythmias. I will incorporate contractile mechanics into our drug testing pipeline such that we can also assess their effect on contractile output.\n\nSudden cardiac death (SCD) is a leading cause of mortality worldwide, usually caused by arrhythmias. Various treatments exist to prevent SCD, but accurate risk stratification tools are needed to identify those at high risk for developing arrhythmias causing SCD. Measures of contractile output, such as ejection fraction (EF), are used, but the relationship between them and arrhythmic risk is currently unclear, as most people experiencing SCD have preserved EF. I will use an electromechanical model to investigate the mechanisms underlying this relationship so that we can more effectively identify and treat this high-risk population.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Arrhythmias, Cardiac","Death, Sudden, Cardiac","Humans","Myocardial Contraction","Risk Assessment"]}
{"id":"360G-Wellcome-222344_Z_21_Z","title":"Decoding heterogeneity and specialisation of interstitial synovial macrophages: what, where and how","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222344/Z/21/Z","description":"\nRheumatoid arthritis is an autoinflammatory condition that mainly affects the joints. Increased permeability of the blood vessels and recruitment of immune cells into the joint likely play a role at the onset of this disease. For immune cells to enter the joint, a signal sent by joint tissue-resident cells is required. A specific subtype of tissue-resident immune cells, called synovial macrophages are suspected to be the source of this initial signal. It has been shown that synovial macrophages consist of different macrophage populations with unclear functions within the joint and during arthritis development. Exploration of synovial macrophages via computational methods, namely single-cell RNA sequencing, revealed a subpopulation of macrophages defined by high gene expression of aquaporin 1(AQP1). This population was not previously defined in the literature and the overall role of AQP1 in macrophages is unknown. Furthermore, AQP1-positive macrophages expressed high levels of genes associated with bioactive lipid signalling previously shown to influence the inflammation in animal arthritis models. In my project, I aim to characterize the AQP1-positive macrophages, define their function and position within the joint, and finally identify the contribution of these cells in bioactive lipid signalling and induction of inflammatory arthritis.\n \n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Barbora Schonfeldova","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Schonfeldova","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Decoding heterogeneity and specialisation of interstitial synovial macrophages: what, where and how \nRheumatoid arthritis is an autoinflammatory condition that mainly affects the joints. Increased permeability of the blood vessels and recruitment of immune cells into the joint likely play a role at the onset of this disease. For immune cells to enter the joint, a signal sent by joint tissue-resident cells is required. A specific subtype of tissue-resident immune cells, called synovial macrophages are suspected to be the source of this initial signal. It has been shown that synovial macrophages consist of different macrophage populations with unclear functions within the joint and during arthritis development. Exploration of synovial macrophages via computational methods, namely single-cell RNA sequencing, revealed a subpopulation of macrophages defined by high gene expression of aquaporin 1(AQP1). This population was not previously defined in the literature and the overall role of AQP1 in macrophages is unknown. Furthermore, AQP1-positive macrophages expressed high levels of genes associated with bioactive lipid signalling previously shown to influence the inflammation in animal arthritis models. In my project, I aim to characterize the AQP1-positive macrophages, define their function and position within the joint, and finally identify the contribution of these cells in bioactive lipid signalling and induction of inflammatory arthritis.\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Aquaporin 4","Aquaporins","Gene Expression Profiling","Humans","Macrophages","Sequence Analysis, RNA","Signal Transduction","Single-Cell Analysis","Synovial Membrane"]}
{"id":"360G-Wellcome-222343_Z_21_Z","title":"Precision genome editing with tandem autologous transplantation as a therapy for multiple severe immune-mediated diseases.   ","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222343/Z/21/Z","description":"Immune-mediated diseases (IMDs) affect around 10% of the global population. Treatment of IMDs generally consists of immunomodulatory drugs to suppress active disease, but can have variable efficacy and can be associated with sometimes severe side effects. An alternative treatment for IMDs such as severe multiple sclerosis (MS) and scleroderma, is autologous stem cell transplantation (ASCT), which is emerging as a safe and effective therapeutic approach, although disease recurrence and secondary IMD development can occur.\n\nThe objective of our research is to test precision genome editing approaches for the treatment of several different IMDs by editing haemopoietic stem cells (HSCs). Edited HSCs would be for use in an autologous transplant to reconstitute the patient\u2019s immune system with genome-modified cells to both treat and prevent the recurrence and development of IMDs.\n \n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Minette Salmon","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Salmon","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Precision genome editing with tandem autologous transplantation as a therapy for multiple severe immune-mediated diseases.    Immune-mediated diseases (IMDs) affect around 10% of the global population. Treatment of IMDs generally consists of immunomodulatory drugs to suppress active disease, but can have variable efficacy and can be associated with sometimes severe side effects. An alternative treatment for IMDs such as severe multiple sclerosis (MS) and scleroderma, is autologous stem cell transplantation (ASCT), which is emerging as a safe and effective therapeutic approach, although disease recurrence and secondary IMD development can occur.\n\nThe objective of our research is to test precision genome editing approaches for the treatment of several different IMDs by editing haemopoietic stem cells (HSCs). Edited HSCs would be for use in an autologous transplant to reconstitute the patient\u2019s immune system with genome-modified cells to both treat and prevent the recurrence and development of IMDs.\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Gene Editing","Genetic Therapy","Hematopoietic Stem Cell Transplantation","Humans","Transplantation, Autologous"]}
{"id":"360G-Wellcome-222342_Z_21_Z","title":"Patient-derived monoclonal antibodies as a precise tool to understand the pathophysiology of Caspr2-antibody encephalitis","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222342/Z/21/Z","description":"The production of autoantibodies by our immune system can be protective. In some cases, it can result in brain inflammation with memory disturbances and seizures.\n\nMy work aims to understand the basis of these disorders by studying a prototypical condition associated with antibodies against Caspr2. To study Caspr2-antibodies, I clone out patient antibodies from their blood and cerebrospinal fluid and study their characteristics using a suite of biochemical techniques. I will relate this to the properties of the cells which make these antibodies, also isolated from blood and cerebrospinal fluid, to address questions about the underlying immunology such as which cells first make the antibodies and which cells carry the most harmful antibodies. \n\nAfter cloning, the antibodies will be subjected to in vitro tests to study their effects on nerve cells. Those with most potent effects will be injected into mice to observe their influence on memory, mood and seizures. In addition, real-time recordings of epileptogenic activity in awake animals will be used to investigate how the antibodies can lead to seizures. \n\nThese studies will utilise patient-derived antibodies as a powerful tool to decipher their relative contributions to human neurological illness and offer directed future methods to target their production. \n \n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Sofija Paneva","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Paneva","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Patient-derived monoclonal antibodies as a precise tool to understand the pathophysiology of Caspr2-antibody encephalitis The production of autoantibodies by our immune system can be protective. In some cases, it can result in brain inflammation with memory disturbances and seizures.\n\nMy work aims to understand the basis of these disorders by studying a prototypical condition associated with antibodies against Caspr2. To study Caspr2-antibodies, I clone out patient antibodies from their blood and cerebrospinal fluid and study their characteristics using a suite of biochemical techniques. I will relate this to the properties of the cells which make these antibodies, also isolated from blood and cerebrospinal fluid, to address questions about the underlying immunology such as which cells first make the antibodies and which cells carry the most harmful antibodies. \n\nAfter cloning, the antibodies will be subjected to in vitro tests to study their effects on nerve cells. Those with most potent effects will be injected into mice to observe their influence on memory, mood and seizures. In addition, real-time recordings of epileptogenic activity in awake animals will be used to investigate how the antibodies can lead to seizures. \n\nThese studies will utilise patient-derived antibodies as a powerful tool to decipher their relative contributions to human neurological illness and offer directed future methods to target their production. \n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Autoantibodies","Humans","Mice","Seizures"]}
{"id":"360G-Wellcome-222341_Z_21_Z","title":"Structure and function of membrane proteins important in synaptic signalling","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222341/Z/21/Z","description":"Membrane proteins are integral to synaptic signalling, a process that enables the communication between a neuron and its target cell. Understanding the structure and function of such proteins is key to deciphering the biochemistry of our nervous system, which in turn will aid the development of new therapeutics. In this project, I aim to solve the 3D structure of membrane proteins using either cryo-electron microscopy or x-ray crystallography. The candidate proteins include: a) muscle-type acetylcholine receptor, an ion channel that is implicated in congenital myasthenic syndrome and myasthenia gravis, and b) the SLC1A family of membrane transporters which includes glutamate transporters and neutral amino acid exchangers \u2013 members of this family are associated with neurological disorders (Alzheimer\u2019s disease, epilepsy and Huntington\u2019s disease), cancer and other metabolic disorders. I will also test the effects of various compounds on purified proteins. These compounds could become useful tools for future studies or even evolve into therapeutics. \n \n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Anna Li","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Li","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Structure and function of membrane proteins important in synaptic signalling Membrane proteins are integral to synaptic signalling, a process that enables the communication between a neuron and its target cell. Understanding the structure and function of such proteins is key to deciphering the biochemistry of our nervous system, which in turn will aid the development of new therapeutics. In this project, I aim to solve the 3D structure of membrane proteins using either cryo-electron microscopy or x-ray crystallography. The candidate proteins include: a) muscle-type acetylcholine receptor, an ion channel that is implicated in congenital myasthenic syndrome and myasthenia gravis, and b) the SLC1A family of membrane transporters which includes glutamate transporters and neutral amino acid exchangers \u2013 members of this family are associated with neurological disorders (Alzheimer\u2019s disease, epilepsy and Huntington\u2019s disease), cancer and other metabolic disorders. I will also test the effects of various compounds on purified proteins. These compounds could become useful tools for future studies or even evolve into therapeutics. \n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cryoelectron Microscopy","Crystallography, X-Ray","Humans","Models, Molecular","Myasthenia Gravis","Receptors, Cholinergic"]}
{"id":"360G-Wellcome-222340_Z_21_Z","title":"Determining the structure of Pseudomonas aeruginosa Lipopolysaccharide across spatial scales","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222340/Z/21/Z","description":"Pseudomonas aeruginosa (P. aeruginosa) is a major human pathogen, needing urgent development of novel antimicrobials. It lives in bacterial communities called biofilms and severe infections are typical within hospital settings. Due to increased antibiotic tolerance of P. aeruginosa in biofilms, treatment is lacking and infections can be fatal, especially for those who are immunocompromised.  \n\nLipopolysaccharide (LPS) is the main component on the outer membrane of the bacteria, which protects the cell and provides rigidity. LPS is important for bacterial survival as it interacts with our immune signals, protecting bacteria from being killed. LPS also contributes to antibiotic resistance, due to variations of LPS in different bacterial strains. Additionally, it forms part of the physical barrier within the membrane, preventing antibiotics from entering. Using biochemical and structural techniques, including CryoEM and CryoET, I will determine what P. aeruginosa LPS looks like in vitro purified, on the outer membrane of single P. aeruginosa cells and within the biofilm environment. \n\nAccomplishing this will further our understanding of how LPS functions and reveal the structure of this essential drug target. Ultimately, this information will help us understand how to treat P. aeruginosa antibiotic resistant infections more effectively and provide insight for novel antibiotic development. \n \n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Suzanne Letham","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Letham","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Determining the structure of Pseudomonas aeruginosa Lipopolysaccharide across spatial scales Pseudomonas aeruginosa (P. aeruginosa) is a major human pathogen, needing urgent development of novel antimicrobials. It lives in bacterial communities called biofilms and severe infections are typical within hospital settings. Due to increased antibiotic tolerance of P. aeruginosa in biofilms, treatment is lacking and infections can be fatal, especially for those who are immunocompromised.  \n\nLipopolysaccharide (LPS) is the main component on the outer membrane of the bacteria, which protects the cell and provides rigidity. LPS is important for bacterial survival as it interacts with our immune signals, protecting bacteria from being killed. LPS also contributes to antibiotic resistance, due to variations of LPS in different bacterial strains. Additionally, it forms part of the physical barrier within the membrane, preventing antibiotics from entering. Using biochemical and structural techniques, including CryoEM and CryoET, I will determine what P. aeruginosa LPS looks like in vitro purified, on the outer membrane of single P. aeruginosa cells and within the biofilm environment. \n\nAccomplishing this will further our understanding of how LPS functions and reveal the structure of this essential drug target. Ultimately, this information will help us understand how to treat P. aeruginosa antibiotic resistant infections more effectively and provide insight for novel antibiotic development. \n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anti-Bacterial Agents","Biofilms","Humans","Lipopolysaccharides","Pseudomonas Infections","Pseudomonas aeruginosa"]}
{"id":"360G-Wellcome-222339_Z_21_Z","title":"Exploring the interdependence between cell cycle dynamics and cellular differentiation at the single-cell level","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222339/Z/21/Z","description":"The cell cycle and cellular differentiation, two of the most fundamental biological processes, have been shown to be interdependent in embryonic stem cells, and during the development of blood cells and neurons. I aim to understand whether cell cycle alterations are associated with cellular differentiation in other developmental contexts as well, and how both processes jointly shape the cell\u2019s epigenome and higher-order chromatin structures. To this end, I will establish a murine embryonic stem cell line stably expressing fluorescent cell cycle reporters, which will allow me to jointly quantify cell cycle progression and perform single-cell RNA sequencing and single-cell ATAC-sequencing during cell cycling and cellular differentiation. I will also use a low input chromosome conformation capture technique to study the regulatory genome interactions around cell cycle genes and master transcription factors in the same cells, which will allow me to characterise the regulatory elements governing the expression of these genes. These studies will help us better understand the interdependence between the cell cycle and cellular differentiation, which might have important implications for stem cell research, regenerative medicine, and for our understanding of the fundamental processes governing organismal development.\n","plannedDates":[{"endDate":"2023-01-12T00:00:00+00:00","startDate":"2020-10-13T00:00:00+00:00","startDateDateOnly":"2020-10-13","endDateDateOnly":"2023-01-12"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Jennifer Herrmann","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Herrmann","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Exploring the interdependence between cell cycle dynamics and cellular differentiation at the single-cell level The cell cycle and cellular differentiation, two of the most fundamental biological processes, have been shown to be interdependent in embryonic stem cells, and during the development of blood cells and neurons. I aim to understand whether cell cycle alterations are associated with cellular differentiation in other developmental contexts as well, and how both processes jointly shape the cell\u2019s epigenome and higher-order chromatin structures. To this end, I will establish a murine embryonic stem cell line stably expressing fluorescent cell cycle reporters, which will allow me to jointly quantify cell cycle progression and perform single-cell RNA sequencing and single-cell ATAC-sequencing during cell cycling and cellular differentiation. I will also use a low input chromosome conformation capture technique to study the regulatory genome interactions around cell cycle genes and master transcription factors in the same cells, which will allow me to characterise the regulatory elements governing the expression of these genes. These studies will help us better understand the interdependence between the cell cycle and cellular differentiation, which might have important implications for stem cell research, regenerative medicine, and for our understanding of the fundamental processes governing organismal development.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cell Cycle","Cell Differentiation","Embryonic Stem Cells","Mice","Mouse Embryonic Stem Cells","Single-Cell Analysis"]}
{"id":"360G-Wellcome-222338_Z_21_Z","title":"Structure-Function Studies of Lipid Transporters","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222338/Z/21/Z","description":"Lipid transporters are a class of membrane proteins that perform critical functions in many organisms. These proteins transport lipid molecules from one leaflet of a lipid bilayer to the other leaflet. In bacteria, lipid transporters can confer resistance to antibiotics, whereas in humans, dysregulation of lipid transporters has been implicated in a number of neurological disorders, highlighting the important role these proteins can play in health and disease. However, the mechanism of action of many of these transporters is poorly understood, in part due to the difficulties involved in the structural studies of membrane proteins. Therefore, this project aims to look at two lipid transporters that are implicated in health and disease: the bacterial Multiple Peptide Resistance Factor (MprF) and the human transporter TMEM16K. The focus in both cases will be on structural elucidation using a combination of cryo-EM and crystallography. The information obtained from these structural studies will be used in combination with biophysical assays to advance our fundamental understanding about the function of these proteins, whilst providing the groundwork that could be used to develop future novel therapeutics to target these proteins.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Matthew Hankins","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Hankins","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Structure-Function Studies of Lipid Transporters Lipid transporters are a class of membrane proteins that perform critical functions in many organisms. These proteins transport lipid molecules from one leaflet of a lipid bilayer to the other leaflet. In bacteria, lipid transporters can confer resistance to antibiotics, whereas in humans, dysregulation of lipid transporters has been implicated in a number of neurological disorders, highlighting the important role these proteins can play in health and disease. However, the mechanism of action of many of these transporters is poorly understood, in part due to the difficulties involved in the structural studies of membrane proteins. Therefore, this project aims to look at two lipid transporters that are implicated in health and disease: the bacterial Multiple Peptide Resistance Factor (MprF) and the human transporter TMEM16K. The focus in both cases will be on structural elucidation using a combination of cryo-EM and crystallography. The information obtained from these structural studies will be used in combination with biophysical assays to advance our fundamental understanding about the function of these proteins, whilst providing the groundwork that could be used to develop future novel therapeutics to target these proteins.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Lipid Bilayers","Membrane Transport Proteins"]}
{"id":"360G-Wellcome-222337_Z_21_Z","title":"(Neuro)Immune Regulation of Endocrine Organ Function","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222337/Z/21/Z","description":"Building on the identification of macrophages which modulate sympathetic nerve signalling in adipose tissue (AT), our lab has recently also discovered tissue-resident macrophages within other endocrine organs thought to be sympathetically-innervated \u2013 including the adrenal glands (AGs). A role has not yet been described for these AG-resident macrophages, which localise to regions of both the adrenal cortex and medulla. Interestingly, a ring of macrophages unique to the female mouse inner-cortex suggests possible sexually-dimorphic immuno-endocrine interactions. Using bulk RNA-sequencing, whole-mount imaging and in vitro assays, I aim to phenotypically and functionally characterise male and female adrenal macrophages. I will compare the transcriptomes of male and female macrophages sorted from either the cortex or medulla, and use differentially-expressed genes between the sexes to find novel markers of female inner-cortical macrophages \u2013 which may also allude to their function. In addition I will also confirm the presence or absence of AG sympathetic innervation, as a role for these macrophages in the modulation of adrenal sympathetic nerve signalling similar to AT cannot yet be excluded. This will provide new insights into sexual dimorphism of immuno-adrenal homeostasis, which may underlie the incompletely understood pathologies of sex-biased adrenopathies such as polycystic ovary syndrome or Addison\u2019s disease.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Emma Haberman","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Haberman","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"(Neuro)Immune Regulation of Endocrine Organ Function Building on the identification of macrophages which modulate sympathetic nerve signalling in adipose tissue (AT), our lab has recently also discovered tissue-resident macrophages within other endocrine organs thought to be sympathetically-innervated \u2013 including the adrenal glands (AGs). A role has not yet been described for these AG-resident macrophages, which localise to regions of both the adrenal cortex and medulla. Interestingly, a ring of macrophages unique to the female mouse inner-cortex suggests possible sexually-dimorphic immuno-endocrine interactions. Using bulk RNA-sequencing, whole-mount imaging and in vitro assays, I aim to phenotypically and functionally characterise male and female adrenal macrophages. I will compare the transcriptomes of male and female macrophages sorted from either the cortex or medulla, and use differentially-expressed genes between the sexes to find novel markers of female inner-cortical macrophages \u2013 which may also allude to their function. In addition I will also confirm the presence or absence of AG sympathetic innervation, as a role for these macrophages in the modulation of adrenal sympathetic nerve signalling similar to AT cannot yet be excluded. This will provide new insights into sexual dimorphism of immuno-adrenal homeostasis, which may underlie the incompletely understood pathologies of sex-biased adrenopathies such as polycystic ovary syndrome or Addison\u2019s disease.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adrenal Glands","Animals","Female","Gene Expression Profiling","Macrophages","Male","Mice","Sex Characteristics","Sympathetic Nervous System","Transcriptome"]}
{"id":"360G-Wellcome-222336_Z_21_Z","title":"Efficient embeddings of genealogical processes","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222336/Z/21/Z","description":"A central objective of population genetics is finding objects that describe the relatedness structure of a group. For closely related individuals these can be family genealogies. On a larger timescale they can be evolutionary phylogenies. In general, such tree-like structures can be obtained by calculating the smallest number of generations needed to go back in time to find a common ancestor between a pair of individuals, through a mathematical framework known as coalescent theory. However, due to random recombination events that occur in the genome between generations, the most recent common ancestor for a pair of individuals varies along the genome, resulting in different tree structures for the same group on adjacent sites in the genome. Due to the highly structured nature of coalescent trees it has proven very difficult to obtain a precise probabilistic description of these random tree sequences. Our project aims to develop statistical methods that can encode coalescent trees and recombination events into a more amenable mathematical form, thus giving a close approximation to the underlying stochastic process. Efficient representations of the coalescent will facilitate all analyses of population structure and have the potential to increase the accuracy of genetic imputations and disease association models.\n \n","plannedDates":[{"endDate":"2023-10-10T00:00:00+00:00","startDate":"2020-10-11T00:00:00+00:00","startDateDateOnly":"2020-10-11","endDateDateOnly":"2023-10-10"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Arni Freyr Gunnarsson","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Gunnarsson","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Efficient embeddings of genealogical processes A central objective of population genetics is finding objects that describe the relatedness structure of a group. For closely related individuals these can be family genealogies. On a larger timescale they can be evolutionary phylogenies. In general, such tree-like structures can be obtained by calculating the smallest number of generations needed to go back in time to find a common ancestor between a pair of individuals, through a mathematical framework known as coalescent theory. However, due to random recombination events that occur in the genome between generations, the most recent common ancestor for a pair of individuals varies along the genome, resulting in different tree structures for the same group on adjacent sites in the genome. Due to the highly structured nature of coalescent trees it has proven very difficult to obtain a precise probabilistic description of these random tree sequences. Our project aims to develop statistical methods that can encode coalescent trees and recombination events into a more amenable mathematical form, thus giving a close approximation to the underlying stochastic process. Efficient representations of the coalescent will facilitate all analyses of population structure and have the potential to increase the accuracy of genetic imputations and disease association models.\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Evolution, Molecular","Genetics, Population","Humans","Models, Genetic","Phylogeny","Recombination, Genetic"]}
{"id":"360G-Wellcome-222335_Z_21_Z","title":"Rational engineering of antibody binding kinetics","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222335/Z/21/Z","description":"Therapeutic antibodies \u2013 drugs made from defence molecules produced by the body \u2013 are becoming increasingly important in treatment of diseases ranging from cancer to hepatitis. These drugs work by binding to the molecules they target called antigens. In order to be effective, an antibody must bind its antigen tightly and this depends in part on how fast it binds the antigen. For example, it has been shown in a set of antibodies against malaria that the ability of antibodies to neutralise the pathogen is highly dependent on the binding rate. Our research will use a multidisciplinary approach to engineer antibodies with the aim of achieving faster binding. Using both computational tools and experiments that characterise the physical properties of antibodies, we aim to identify factors that contribute to the rate of binding. Next, we would like to use this knowledge to generate software to predict changes that can be introduced to an antibody to increase its binding rate. As a way to validate our conclusions, we plan to improve antibodies against malaria. These studies will provide us with insight into the factors that make good therapeutic antibodies and also provide a tool for use by the wider scientific community.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Bora Guloglu","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Guloglu","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Rational engineering of antibody binding kinetics Therapeutic antibodies \u2013 drugs made from defence molecules produced by the body \u2013 are becoming increasingly important in treatment of diseases ranging from cancer to hepatitis. These drugs work by binding to the molecules they target called antigens. In order to be effective, an antibody must bind its antigen tightly and this depends in part on how fast it binds the antigen. For example, it has been shown in a set of antibodies against malaria that the ability of antibodies to neutralise the pathogen is highly dependent on the binding rate. Our research will use a multidisciplinary approach to engineer antibodies with the aim of achieving faster binding. Using both computational tools and experiments that characterise the physical properties of antibodies, we aim to identify factors that contribute to the rate of binding. Next, we would like to use this knowledge to generate software to predict changes that can be introduced to an antibody to increase its binding rate. As a way to validate our conclusions, we plan to improve antibodies against malaria. These studies will provide us with insight into the factors that make good therapeutic antibodies and also provide a tool for use by the wider scientific community.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Malaria","Software"]}
{"id":"360G-Wellcome-222334_Z_21_Z","title":"Exploring the genetic determinants of the portability of GWAS associations and polygenic risk score performance across populations","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222334/Z/21/Z","description":"Over the last 10-15 years, large datasets containing genetic, physical and medical information for thousands of people (such as the UK Biobank) have allowed researchers to detect many genetic mutations that increase disease risk or explain variation in other physical traits.\n\nAn important limitation of most of the studies conducted so far is that they mainly use data from people of European ancestry. This is significant, because there is increasing evidence that genetic differences between populations limit the validity and applicability of findings from European samples in other populations.\n\nWe propose to address one aspect of this problem by exploring genetic variation that affects the accuracy of a set of relevant mutations in predicting a physical trait or disease within a single population. This is an important first step in understanding the causes of the poor portability of findings across populations.\n\nWe expect that our work will identify relevant new genetic mutations, or interactions between them, which impact particular traits and diseases (as well as corroborate previous findings) and that this information will then improve our ability to understand the causes of, and predict, disease risk in understudied populations.\n","plannedDates":[{"endDate":"2023-10-12T00:00:00+00:00","startDate":"2020-10-13T00:00:00+00:00","startDateDateOnly":"2020-10-13","endDateDateOnly":"2023-10-12"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Lino Andr\u00e9 Fonseca Ferreira","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Fonseca Ferreira","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Exploring the genetic determinants of the portability of GWAS associations and polygenic risk score performance across populations Over the last 10-15 years, large datasets containing genetic, physical and medical information for thousands of people (such as the UK Biobank) have allowed researchers to detect many genetic mutations that increase disease risk or explain variation in other physical traits.\n\nAn important limitation of most of the studies conducted so far is that they mainly use data from people of European ancestry. This is significant, because there is increasing evidence that genetic differences between populations limit the validity and applicability of findings from European samples in other populations.\n\nWe propose to address one aspect of this problem by exploring genetic variation that affects the accuracy of a set of relevant mutations in predicting a physical trait or disease within a single population. This is an important first step in understanding the causes of the poor portability of findings across populations.\n\nWe expect that our work will identify relevant new genetic mutations, or interactions between them, which impact particular traits and diseases (as well as corroborate previous findings) and that this information will then improve our ability to understand the causes of, and predict, disease risk in understudied populations.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["European Continental Ancestry Group","Genetic Predisposition to Disease","Genetic Variation","Genome-Wide Association Study","Humans","Models, Genetic","Multifactorial Inheritance","Polymorphism, Single Nucleotide"]}
{"id":"360G-Wellcome-222333_Z_21_Z","title":"The role of ADAM10 in modulating cell-cell interactions","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222333/Z/21/Z","description":"Efficient clearance of dying and dead cells, a process called efferocytosis, is crucial for tissue homeostasis and a healthy, well-regulated organism. Dying/dead cells are cleared by cells called phagocytes, principally macrophages. We recently identified the leukocyte-expressed glycoprotein CD43 as a molecule that acts as a \u2018don\u2019t-eat-me\u2019 signal for macrophages, and showed it was rapidly and completely cleaved from the surface of dying T cells. We also demonstrated that ADAM10 (A Desintegrin And Metalloproteinase Domain-containing protein 10) is the enzyme responsible for CD43 cleavage from dying cells, therefore removing the don\u2019t-eat-me signal, triggering phagocytic uptake. CD43 cleavage by ADAM10 is a novel observation that may be more generally applicable to other \u2018mucin-like\u2019 glycoproteins with similar don\u2019t-eat-me properties. To explore this, we will take two approaches: i) probe leukocyte surface molecules with similar biophysical properties to CD43 for ADAM10 cleavage; ii) take an unbiased broader approach using mass spectrometry (MS) to reveal other proteins cleaved by ADAM10 during cell death. Once identified, we will analyse their function in regulating efferocytosis of dying leukocytes. This will shed light on how these molecules modulate clearance of dying and dead cells to ensure healthy tissue homeostasis, and will yield insights into immune cell-cell interactions.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Linnea Drexhage","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Drexhage","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The role of ADAM10 in modulating cell-cell interactions Efficient clearance of dying and dead cells, a process called efferocytosis, is crucial for tissue homeostasis and a healthy, well-regulated organism. Dying/dead cells are cleared by cells called phagocytes, principally macrophages. We recently identified the leukocyte-expressed glycoprotein CD43 as a molecule that acts as a \u2018don\u2019t-eat-me\u2019 signal for macrophages, and showed it was rapidly and completely cleaved from the surface of dying T cells. We also demonstrated that ADAM10 (A Desintegrin And Metalloproteinase Domain-containing protein 10) is the enzyme responsible for CD43 cleavage from dying cells, therefore removing the don\u2019t-eat-me signal, triggering phagocytic uptake. CD43 cleavage by ADAM10 is a novel observation that may be more generally applicable to other \u2018mucin-like\u2019 glycoproteins with similar don\u2019t-eat-me properties. To explore this, we will take two approaches: i) probe leukocyte surface molecules with similar biophysical properties to CD43 for ADAM10 cleavage; ii) take an unbiased broader approach using mass spectrometry (MS) to reveal other proteins cleaved by ADAM10 during cell death. Once identified, we will analyse their function in regulating efferocytosis of dying leukocytes. This will shed light on how these molecules modulate clearance of dying and dead cells to ensure healthy tissue homeostasis, and will yield insights into immune cell-cell interactions.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["ADAM10 Protein","Animals","Cell Membrane","Humans","Leukocytes","Macrophages","Membrane Proteins","Phagocytosis"]}
{"id":"360G-Wellcome-222332_Z_21_Z","title":"Understanding the molecular basis for the ubiquitin-dependent activation of the TAK1/TAB complex","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222332/Z/21/Z","description":"Cells respond and adapt to various stimuli through a variety of detectors, which receive the signal. To ensure that a signal is transmitted, key decision-making hubs that interpret the incoming signal and define the output are required.\n\nI am interested in one signalling hub the TAK1-TAB complex, which is vital for cells to respond to an infection or other external signals and decides cell death or survival. Correct interpretation of the signal by the TAK1-TAB complex is vital: human diseases ranging from inflammatory diseases, certain cancers and neurological disorders arise from defects within these hubs. \n\nI will use a toolkit of biochemical and biophysical techniques to understand how the TAK1-TAB complex is regulated and obtain molecular snapshots that will provide the three-dimensional structure of the complex before and after signal activation. \n\nUnderstanding the structure of this key signalling hub will, for the first time, provide a glimpse into its regulation. Furthermore, the structure will provide an explanation of how certain genetic mutations in the assembly and architecture of the TAK1-TAB complex leads to certain diseases, notably Crohn's disease and amyotrophic lateral sclerosis. \n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Larissa Dietz","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Dietz","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding the molecular basis for the ubiquitin-dependent activation of the TAK1/TAB complex Cells respond and adapt to various stimuli through a variety of detectors, which receive the signal. To ensure that a signal is transmitted, key decision-making hubs that interpret the incoming signal and define the output are required.\n\nI am interested in one signalling hub the TAK1-TAB complex, which is vital for cells to respond to an infection or other external signals and decides cell death or survival. Correct interpretation of the signal by the TAK1-TAB complex is vital: human diseases ranging from inflammatory diseases, certain cancers and neurological disorders arise from defects within these hubs. \n\nI will use a toolkit of biochemical and biophysical techniques to understand how the TAK1-TAB complex is regulated and obtain molecular snapshots that will provide the three-dimensional structure of the complex before and after signal activation. \n\nUnderstanding the structure of this key signalling hub will, for the first time, provide a glimpse into its regulation. Furthermore, the structure will provide an explanation of how certain genetic mutations in the assembly and architecture of the TAK1-TAB complex leads to certain diseases, notably Crohn's disease and amyotrophic lateral sclerosis. \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","MAP Kinase Kinase Kinases","Signal Transduction","Ubiquitin"]}
{"id":"360G-Wellcome-222331_Z_21_Z","title":"Understanding the role of circadian and hypoxic signalling pathways in HIV infection","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222331/Z/21/Z","description":"Rhythmicity is fundamental for the existence of life and 24 h circadian rhythms regulate every cell of the body. Synchronizing biological processes to certain times of the day optimizes the host response to invading pathogens and asynchrony can increase the severity of infection. Another basis of human life is oxygen and following infection, viruses can experience environments with variable oxygen tension that can influence their replication and persistence. Previous studies from our laboratory have shown that the circadian system and oxygen signalling pathways can independently influence viral infection. My project will study the interplay between these pathways to understand their role in human immunodeficiency virus (HIV) infection. I will use laboratory models of active or latent HIV replication along with genetic and pharmacological agents that modulate hypoxia and circadian pathways to study their role in the viral life cycle. Our goal is to uncover new therapeutic approaches.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Helene Borrmann","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Borrmann","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding the role of circadian and hypoxic signalling pathways in HIV infection Rhythmicity is fundamental for the existence of life and 24 h circadian rhythms regulate every cell of the body. Synchronizing biological processes to certain times of the day optimizes the host response to invading pathogens and asynchrony can increase the severity of infection. Another basis of human life is oxygen and following infection, viruses can experience environments with variable oxygen tension that can influence their replication and persistence. Previous studies from our laboratory have shown that the circadian system and oxygen signalling pathways can independently influence viral infection. My project will study the interplay between these pathways to understand their role in human immunodeficiency virus (HIV) infection. I will use laboratory models of active or latent HIV replication along with genetic and pharmacological agents that modulate hypoxia and circadian pathways to study their role in the viral life cycle. Our goal is to uncover new therapeutic approaches.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Circadian Rhythm","HIV Infections","Humans","Hypoxia","Oxygen","Signal Transduction","Virus Replication"]}
{"id":"360G-Wellcome-222330_Z_21_Z","title":"Structural and biochemical studies on mRNA 3\u2019-end processing and transcription termination in fission yeast ","Region":"South East","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222330/Z/21/Z","description":"In the cell, genetic information from the DNA is copied into RNA molecules in the nucleus of the cell before being exported to the cytoplasm, where the information they carry is used to make proteins. In eukaryotes, these messenger RNA molecules (mRNA) are modified before they are exported out of the nucleus. An enzyme called the Cleavage and Polyadenylation Factor (CPF) cleaves the mRNA at the end and adds a string of adenosines to create a polyA tail. This polyA tail is important for the stability of the mRNA, and the cleavage process ensures that the enzyme that makes the mRNA, RNA Polymerase II, stops at the end of the gene and goes back to the beginning to repeat the process of making mRNA. The aim of my project is to study how the CPF modifies mRNA and interacts with RNA Polymerase II to ensure functional mRNA are properly produced. I will use techniques such as electron microscopy and x-ray crystallography, as well as biochemical techniques, to look at the structure of CPF to understand how it works. Through this work, we expect to gain a more detailed understanding of this fundamental biological process.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Ho-Ching Alex Au","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Au","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Structural and biochemical studies on mRNA 3\u2019-end processing and transcription termination in fission yeast  In the cell, genetic information from the DNA is copied into RNA molecules in the nucleus of the cell before being exported to the cytoplasm, where the information they carry is used to make proteins. In eukaryotes, these messenger RNA molecules (mRNA) are modified before they are exported out of the nucleus. An enzyme called the Cleavage and Polyadenylation Factor (CPF) cleaves the mRNA at the end and adds a string of adenosines to create a polyA tail. This polyA tail is important for the stability of the mRNA, and the cleavage process ensures that the enzyme that makes the mRNA, RNA Polymerase II, stops at the end of the gene and goes back to the beginning to repeat the process of making mRNA. The aim of my project is to study how the CPF modifies mRNA and interacts with RNA Polymerase II to ensure functional mRNA are properly produced. I will use techniques such as electron microscopy and x-ray crystallography, as well as biochemical techniques, to look at the structure of CPF to understand how it works. Through this work, we expect to gain a more detailed understanding of this fundamental biological process.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Crystallography, X-Ray","Models, Molecular","Poly A","Polyadenylation","RNA Polymerase II","RNA, Messenger","Schizosaccharomyces","Schizosaccharomyces pombe Proteins","mRNA Cleavage and Polyadenylation Factors"]}
{"id":"360G-Wellcome-222329_Z_21_Z","title":"Characterising HIV-1 infections in East African epidemics: an interdisciplinary approach to analysing network dynamics and transmission clusters using viral phylodynamics and agent-based modelling.","Region":"Scotland","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222329/Z/21/Z","description":"With a yearly 1.7 million new people infected with HIV, the HIV/AIDS epidemic remains a major global health threat. Characterising HIV transmissions using phylogenetic tools like phylogeography and phylodynamics aids our understanding of HIV infections, both evolutionarily and epidemiologically, shaping epidemic control measures through increased knowledge on transmission events and thus, their prevention. \nSub-Saharan Africa (SSA) constitutes 59% of all new HIV infections, and phylogenetic studies highlighting HIV transmission dynamics have historically been less common in this region due to limited sequence availability. However, the recent sequencing upscale in SSA will inform the poorly understood structure of transmission networks and HIV epidemic dynamics in the region. \nI aim to use viral phylogenetics, epidemiology and mathematical modelling to investigate the evolutionary dynamics of HIV-1 transmission networks in East African epidemics: firstly, using HIV-1 sequences from a trial in rural Uganda and Kenya, I will characterise HIV-1 infections and analyse HIV-1 transmission networks and cluster dynamics; secondly, I will undertake a comparative analysis of HIV-1 phylodynamics amongst different East African study populations; finally, I will model local transmission dynamics and intervention effects in these populations. \nAltogether this will ultimately inform the design and evaluation of HIV prevention interventions.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Emma Pujol Hodge","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Pujol Hodge","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Characterising HIV-1 infections in East African epidemics: an interdisciplinary approach to analysing network dynamics and transmission clusters using viral phylodynamics and agent-based modelling. With a yearly 1.7 million new people infected with HIV, the HIV/AIDS epidemic remains a major global health threat. Characterising HIV transmissions using phylogenetic tools like phylogeography and phylodynamics aids our understanding of HIV infections, both evolutionarily and epidemiologically, shaping epidemic control measures through increased knowledge on transmission events and thus, their prevention. \nSub-Saharan Africa (SSA) constitutes 59% of all new HIV infections, and phylogenetic studies highlighting HIV transmission dynamics have historically been less common in this region due to limited sequence availability. However, the recent sequencing upscale in SSA will inform the poorly understood structure of transmission networks and HIV epidemic dynamics in the region. \nI aim to use viral phylogenetics, epidemiology and mathematical modelling to investigate the evolutionary dynamics of HIV-1 transmission networks in East African epidemics: firstly, using HIV-1 sequences from a trial in rural Uganda and Kenya, I will characterise HIV-1 infections and analyse HIV-1 transmission networks and cluster dynamics; secondly, I will undertake a comparative analysis of HIV-1 phylodynamics amongst different East African study populations; finally, I will model local transmission dynamics and intervention effects in these populations. \nAltogether this will ultimately inform the design and evaluation of HIV prevention interventions.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa South of the Sahara","Epidemics","HIV Infections","HIV-1","Humans","Phylogeny","Phylogeography","Uganda"]}
{"id":"360G-Wellcome-222328_Z_21_Z","title":"Defining the transcriptome of the first functional haematopoietic stem cells in the mouse embryo.","Region":"Scotland","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222328/Z/21/Z","description":"Despite clinical demand for hematopoietic stem cell (HSC) transplantations for patients with blood cancers or hematologic diseases, little progress has been achieved in in vitro generation or expansion of HSCs. Cellular reprogramming by overexpression of critical transcription factors has been impeded by our incomplete understanding of how HSCs develop in the embryo. The very first HSCs are generated from endothelial cells in the aorta-gonad-mesonephros region in the embryo, with only a few functional stem cells hidden among other blood progenitors. Separating true HSCs from other blood progenitor cells in the embryo has proven challenging because they have similar surface protein expression. Moreover, testing function and then sequencing cells is impossible and HSCs differentiate and alter their transcriptome in expansion. Therefore, new methods of identifying functional HSCs are needed to advance our understanding of these clinically relevant cells. I aim to develop a model that predicts HSC function based on the precise levels of gene expression. I will then test the predictions of the model and determine if narrowing the ranges of gene expression can distinguish HSCs from progenitor cells. Accurate predictions will inform future studies into in vitro generation and expansion as precise required gene expression levels will be uncovered.\n","plannedDates":[{"endDate":"2023-10-03T00:00:00+00:00","startDate":"2020-10-04T00:00:00+00:00","startDateDateOnly":"2020-10-04","endDateDateOnly":"2023-10-03"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Anna Popravko","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Popravko","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Defining the transcriptome of the first functional haematopoietic stem cells in the mouse embryo. Despite clinical demand for hematopoietic stem cell (HSC) transplantations for patients with blood cancers or hematologic diseases, little progress has been achieved in in vitro generation or expansion of HSCs. Cellular reprogramming by overexpression of critical transcription factors has been impeded by our incomplete understanding of how HSCs develop in the embryo. The very first HSCs are generated from endothelial cells in the aorta-gonad-mesonephros region in the embryo, with only a few functional stem cells hidden among other blood progenitors. Separating true HSCs from other blood progenitor cells in the embryo has proven challenging because they have similar surface protein expression. Moreover, testing function and then sequencing cells is impossible and HSCs differentiate and alter their transcriptome in expansion. Therefore, new methods of identifying functional HSCs are needed to advance our understanding of these clinically relevant cells. I aim to develop a model that predicts HSC function based on the precise levels of gene expression. I will then test the predictions of the model and determine if narrowing the ranges of gene expression can distinguish HSCs from progenitor cells. Accurate predictions will inform future studies into in vitro generation and expansion as precise required gene expression levels will be uncovered.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Endothelial Cells","Hematopoiesis","Hematopoietic Stem Cell Transplantation","Hematopoietic Stem Cells","Mice","Transcriptome"]}
{"id":"360G-Wellcome-222327_Z_21_Z","title":" Predicting the epidemic potential of RNA viruses using viral sequence information and machine learning","Region":"Scotland","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222327/Z/21/Z","description":"Among all known emerging pathogens, RNA viruses are overrepresented and pose a particular high risk of emergence. New RNA virus species have been detected steadily since the 1950s and their discovery is projected to continue in the future. Studying the epidemic potential of new RNA viruses is therefore important, however obtaining relevant epidemiological data requires extensive field and/or laboratory studies. These studies could be better directed if a priori predictions about the epidemiology of RNA viruses can be made.\n\nHere, I propose to investigate whether predictions about the epidemiology of RNA viruses can be made using machine learning and genome sequences. Using an existing database containing epidemiological relevant data on all human infective-RNA viruses, I will use multivariate statistical analyses to establish which epidemiological characteristics correlate with genomic biases calculated from genome sequences. Using this information, I will devise machine learning models to make predictions about the epidemic potential of RNA viruses. Lastly, I intend to investigate how genomic biases change over time during an epidemic and link these to changes seen in the epidemiology of RNA viruses. If successful, my research could inform targeted surveillance to combat emerging RNA viruses.\n \n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Thomas Dalhuisen","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Dalhuisen","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":" Predicting the epidemic potential of RNA viruses using viral sequence information and machine learning Among all known emerging pathogens, RNA viruses are overrepresented and pose a particular high risk of emergence. New RNA virus species have been detected steadily since the 1950s and their discovery is projected to continue in the future. Studying the epidemic potential of new RNA viruses is therefore important, however obtaining relevant epidemiological data requires extensive field and/or laboratory studies. These studies could be better directed if a priori predictions about the epidemiology of RNA viruses can be made.\n\nHere, I propose to investigate whether predictions about the epidemiology of RNA viruses can be made using machine learning and genome sequences. Using an existing database containing epidemiological relevant data on all human infective-RNA viruses, I will use multivariate statistical analyses to establish which epidemiological characteristics correlate with genomic biases calculated from genome sequences. Using this information, I will devise machine learning models to make predictions about the epidemic potential of RNA viruses. Lastly, I intend to investigate how genomic biases change over time during an epidemic and link these to changes seen in the epidemiology of RNA viruses. If successful, my research could inform targeted surveillance to combat emerging RNA viruses.\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Epidemics","Genome, Viral","Humans","Machine Learning"]}
{"id":"360G-Wellcome-222326_Z_21_Z","title":"Telomeric chromatin and VSG allelic exclusion in African trypanosomes","Region":"Scotland","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222326/Z/21/Z","description":"Trypanosomes are single-celled parasites that causes lethal diseases in humans and livestock. The parasite is covered in variable surface glycoprotein (VSG) that enables host immune system evasion. VSG is often swapped by \u2018antigen switching\u2019, which is central for the parasite\u2019s virulence.\nMy group found that the active VSG suppresses expression of other VSGs. As VSG genes are located near the ends of chromosomes, we hypothesise that the characteristic and highly repetitive sequences at chromosome ends are important for suppression. To facilitate studying this, I will manipulate the dosage of these sequences using new genome editing tools (CRISPR/Cas9).\nAlso, I will explore the function of the proteins that package these regions. Again, I will use CRISPR/Cas9 to create parasites with a single copy of each gene encoding these packaging proteins, allowing me to manipulate those genes as well. These proteins impact DNA repair, DNA replication and gene regulation.\nThis project will provide new insight into how chromosome \u2018caps\u2019 function, how VSG genes behave at these locations and may also reveal potential drug targets.\n","plannedDates":[{"endDate":"2023-09-21T00:00:00+00:00","startDate":"2020-09-22T00:00:00+00:00","startDateDateOnly":"2020-09-22","endDateDateOnly":"2023-09-21"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Marketa Novotna","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Novotna","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee","addressCountry":"United Kingdom","id_and_name":"[\"University of Dundee\", \"360G-Wellcome-ORG:University-of-Dundee\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Telomeric chromatin and VSG allelic exclusion in African trypanosomes Trypanosomes are single-celled parasites that causes lethal diseases in humans and livestock. The parasite is covered in variable surface glycoprotein (VSG) that enables host immune system evasion. VSG is often swapped by \u2018antigen switching\u2019, which is central for the parasite\u2019s virulence.\nMy group found that the active VSG suppresses expression of other VSGs. As VSG genes are located near the ends of chromosomes, we hypothesise that the characteristic and highly repetitive sequences at chromosome ends are important for suppression. To facilitate studying this, I will manipulate the dosage of these sequences using new genome editing tools (CRISPR/Cas9).\nAlso, I will explore the function of the proteins that package these regions. Again, I will use CRISPR/Cas9 to create parasites with a single copy of each gene encoding these packaging proteins, allowing me to manipulate those genes as well. These proteins impact DNA repair, DNA replication and gene regulation.\nThis project will provide new insight into how chromosome \u2018caps\u2019 function, how VSG genes behave at these locations and may also reveal potential drug targets.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["CRISPR-Cas Systems","Gene Editing","Genome, Protozoan","Protozoan Proteins","Telomere","Trypanosoma brucei brucei"]}
{"id":"360G-Wellcome-222324_Z_21_Z","title":"\u201cUsing the force\u201d: An investigation into the perception of stiffness in CTLs and its importance in activation and killing in cancer.","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222324/Z/21/Z","description":"Cytotoxic T lymphocytes (CTLs) are important agents of immunity responsible for clearance of infected or malignant cells. The understanding of their activation is incomplete. Recent advances have unveiled their ability to sense the stiffness of the opposing surface, with stiffer surfaces resulting in larger forces being transmitted to the CTL, promoting activation, leading to CTL-mediated killing of the target cell. Furthermore, decreased stiffness of malignant cells has been observed and posited as an avenue for their evasion of the immune system.\n\nI will create cell lines in which intracellular stresses can be visualized with state-of-the-art microscopy via force probes. I will activate CTLs to varying degrees and measure the effect on the force probes. I will knock out cytoskeleton-associated genes in order to screen for genes that are involved in CTL force perception. Interactions between T cells and target cells of manipulated stiffness will also be investigated as a means of understanding the role of target cell stiffness in malignant immune evasion. A final screen will be performed to identify gene mutations associated with this immune evasion in target cells.\n\nThis work will broaden our understanding of T cell function and provide us with useful avenues for cancer immunotherapy.\n","plannedDates":[{"endDate":"2023-10-04T00:00:00+00:00","startDate":"2020-10-05T00:00:00+00:00","startDateDateOnly":"2020-10-05","endDateDateOnly":"2023-10-04"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Adam Rochussen","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Rochussen","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"\u201cUsing the force\u201d: An investigation into the perception of stiffness in CTLs and its importance in activation and killing in cancer. Cytotoxic T lymphocytes (CTLs) are important agents of immunity responsible for clearance of infected or malignant cells. The understanding of their activation is incomplete. Recent advances have unveiled their ability to sense the stiffness of the opposing surface, with stiffer surfaces resulting in larger forces being transmitted to the CTL, promoting activation, leading to CTL-mediated killing of the target cell. Furthermore, decreased stiffness of malignant cells has been observed and posited as an avenue for their evasion of the immune system.\n\nI will create cell lines in which intracellular stresses can be visualized with state-of-the-art microscopy via force probes. I will activate CTLs to varying degrees and measure the effect on the force probes. I will knock out cytoskeleton-associated genes in order to screen for genes that are involved in CTL force perception. Interactions between T cells and target cells of manipulated stiffness will also be investigated as a means of understanding the role of target cell stiffness in malignant immune evasion. A final screen will be performed to identify gene mutations associated with this immune evasion in target cells.\n\nThis work will broaden our understanding of T cell function and provide us with useful avenues for cancer immunotherapy.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cytoskeleton","Cytotoxicity, Immunologic","Humans","Neoplasms","T-Lymphocytes, Cytotoxic"]}
{"id":"360G-Wellcome-222323_Z_21_Z","title":"Dissection of the function of the Plasmodium falciparum protein families EBL and RH during erythrocyte invasion.","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222323/Z/21/Z","description":"Plasmodium falciparum causes  > 90% of malaria mortality, killing over 400,000 people annually. To multiply, P. falciparum parasites must invade human erythrocytes. Invasion begins with attachment of the parasite to the erythrocyte, followed by reorientation to position the parasite to invade. These early steps depend on two families of membrane proteins: Erythrocyte Binding Like proteins (EBLs) and Reticulocyte Binding Protein Homologues (RBLs). There are four members of each family in the P. falciparum genome that can individually be deleted without blocking invasion. EBLs and RBLs are therefore believed to be functionally interchangeable, but this has never been systematically investigated and all Plasmodium parasites maintain both families suggesting considerable selection pressure against loss of one family. To determine if the families have distinct roles, this project will characterise invasion of single and double protein knock-outs using advanced video microscopy tools, and visualise the localisation of proteins simultaneously using fluorescence microscopy. New antimalarial therapies are needed as P. falciparum has developed resistance to every antimalarial drug available and the only licensed malaria vaccine is  \n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Emma Jones","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Jones","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Dissection of the function of the Plasmodium falciparum protein families EBL and RH during erythrocyte invasion. Plasmodium falciparum causes  > 90% of malaria mortality, killing over 400,000 people annually. To multiply, P. falciparum parasites must invade human erythrocytes. Invasion begins with attachment of the parasite to the erythrocyte, followed by reorientation to position the parasite to invade. These early steps depend on two families of membrane proteins: Erythrocyte Binding Like proteins (EBLs) and Reticulocyte Binding Protein Homologues (RBLs). There are four members of each family in the P. falciparum genome that can individually be deleted without blocking invasion. EBLs and RBLs are therefore believed to be functionally interchangeable, but this has never been systematically investigated and all Plasmodium parasites maintain both families suggesting considerable selection pressure against loss of one family. To determine if the families have distinct roles, this project will characterise invasion of single and double protein knock-outs using advanced video microscopy tools, and visualise the localisation of proteins simultaneously using fluorescence microscopy. New antimalarial therapies are needed as P. falciparum has developed resistance to every antimalarial drug available and the only licensed malaria vaccine is  \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Erythrocytes","Humans","Malaria, Falciparum","Membrane Proteins","Plasmodium falciparum","Protozoan Proteins"]}
{"id":"360G-Wellcome-222322_Z_21_Z","title":"Development of artificial oligonucleotide catalysts (XNAzymes) for specific targeting of disease-associated RNA.","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222322/Z/21/Z","description":"Nucleic acids (DNA  &  RNA) are commonly known for their ability to store genetic information. However, when single-stranded, nucleic acids can also fold into sophisticated 3D structures including catalysts capable of speeding up chemical transformations. RNA-cutting catalysts can be programmed to target specific RNA sequences in order to turn off harmful mutant genes or destroy viruses. However, catalysts composed of natural DNA and RNA, among other limitations, are rapidly degraded in the blood, hampering their clinical applications. Recently, it has become possible to evolve such catalysts in the test tube using robust, artificial alternatives to DNA known as \"xeno nucleic acids\" (XNAs). Our aim, therefore, is to explore the use of biologically stable XNA chemistries to evolve novel enzymes (\"XNAzymes\") capable of degrading disease-associated RNA (aberrant mRNA, microRNA and viral RNA). We will establish systems for engineering XNAzymes using chemistries resistant to degradation and which (unlike protein enzymes) do not trigger unwanted immune responses. Currently, there are few clinically-suitable molecular tools for manipulation of cellular RNAs and they often lack precision, XNAzymes are thus promising alternatives.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Maria Donde","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Donde","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Development of artificial oligonucleotide catalysts (XNAzymes) for specific targeting of disease-associated RNA. Nucleic acids (DNA  &  RNA) are commonly known for their ability to store genetic information. However, when single-stranded, nucleic acids can also fold into sophisticated 3D structures including catalysts capable of speeding up chemical transformations. RNA-cutting catalysts can be programmed to target specific RNA sequences in order to turn off harmful mutant genes or destroy viruses. However, catalysts composed of natural DNA and RNA, among other limitations, are rapidly degraded in the blood, hampering their clinical applications. Recently, it has become possible to evolve such catalysts in the test tube using robust, artificial alternatives to DNA known as \"xeno nucleic acids\" (XNAs). Our aim, therefore, is to explore the use of biologically stable XNA chemistries to evolve novel enzymes (\"XNAzymes\") capable of degrading disease-associated RNA (aberrant mRNA, microRNA and viral RNA). We will establish systems for engineering XNAzymes using chemistries resistant to degradation and which (unlike protein enzymes) do not trigger unwanted immune responses. Currently, there are few clinically-suitable molecular tools for manipulation of cellular RNAs and they often lack precision, XNAzymes are thus promising alternatives.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Catalysis","Humans","MicroRNAs","RNA"]}
{"id":"360G-Wellcome-222321_Z_21_Z","title":"The contribution of T cells to PI3K\u03b4 and Bcl6-dependent B cell lymphomagenesis","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222321/Z/21/Z","description":"Non-Hodgkin Lymphoma (NHL) accounts for 4% (14,100) of new cancer cases every year (UK) with a survival rate of 55% (2013-2017). Diffuse Large B Cell Lymphoma (DLBCL) is a common subtype of NHL which arises from high affinity B cells. The lipid signalling enzyme phosphoinositide-3 kinase delta (PI3Kdelta) is critical for the development of these B cells and is often mutated (hyperactive) in DLBCL. \nWe identified that hyperactive PI3Kdelta cooperates with the oncogene B-cell lymphoma 6 (Bcl6) to drive lymphomagenesis and that this was accelerated in the absence of a functioning immune system. Furthermore, restricting PI3Kdelta hyperactivity to CD4+ T cells was sufficient to drive lymphoma progression. I aim to investigate the cooperativity between PI3Kdelta and Bcl6 in B cell lymphomagenesis by combining flow cytometry and transcriptomic approaches to identify and characterise B and CD4+ T cell populations in our lymphoma models. Transfer of selected populations into immunocompromised mice, followed by tumour analysis by histology, will allow me to identify the cellular origin of the malignant B cells and the CD4+ T cell populations responsible for driving lymphomagenesis upon PI3Kdelta dysregulation. This study will illuminate the cooperation between PI3Kdelta and Bcl6 in B cell lymphoma with important future therapeutic implications.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Julius Baeck","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Baeck","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The contribution of T cells to PI3K\u03b4 and Bcl6-dependent B cell lymphomagenesis Non-Hodgkin Lymphoma (NHL) accounts for 4% (14,100) of new cancer cases every year (UK) with a survival rate of 55% (2013-2017). Diffuse Large B Cell Lymphoma (DLBCL) is a common subtype of NHL which arises from high affinity B cells. The lipid signalling enzyme phosphoinositide-3 kinase delta (PI3Kdelta) is critical for the development of these B cells and is often mutated (hyperactive) in DLBCL. \nWe identified that hyperactive PI3Kdelta cooperates with the oncogene B-cell lymphoma 6 (Bcl6) to drive lymphomagenesis and that this was accelerated in the absence of a functioning immune system. Furthermore, restricting PI3Kdelta hyperactivity to CD4+ T cells was sufficient to drive lymphoma progression. I aim to investigate the cooperativity between PI3Kdelta and Bcl6 in B cell lymphomagenesis by combining flow cytometry and transcriptomic approaches to identify and characterise B and CD4+ T cell populations in our lymphoma models. Transfer of selected populations into immunocompromised mice, followed by tumour analysis by histology, will allow me to identify the cellular origin of the malignant B cells and the CD4+ T cell populations responsible for driving lymphomagenesis upon PI3Kdelta dysregulation. This study will illuminate the cooperation between PI3Kdelta and Bcl6 in B cell lymphoma with important future therapeutic implications.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","B-Lymphocytes","CD4-Positive T-Lymphocytes","Class I Phosphatidylinositol 3-Kinases","Humans","Lymphoma, Large B-Cell, Diffuse","Mice","Phosphatidylinositol 3-Kinases"]}
{"id":"360G-Wellcome-222320_Z_21_Z","title":"Investigating signalling pathways in intraepithelial lymphocytes (IEL) in the small intestine","Region":"Scotland","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222320/Z/21/Z","description":"Intraepithelial lymphocytes (IEL) are T cells that reside interspersed between intestinal epithelial cells in the gut. They provide protection to the gut by coordinating immune responses towards pathogens and producing factors which maintain the gut epithelial barrier. However, dysregulated IEL function has been associated with increased gut inflammation promoting inflammatory diseases of the gut including coeliac disease and inflammatory bowel disease. The signals which activate IEL and the intracellular machinery used to communicate these signals to have an effect within the cell are relatively unknown. I propose to investigate the signalling pathways in IEL using techniques such as flow cytometry, mass spectrometry and RNA sequencing. I will stimulate IEL through cell surface receptors to initiate the downstream signalling events. I will compare the IEL response to stimulation with conventional T cell responses to determine similarities and differences in IEL signalling. I will look at proteins which have become phosphorylated upon stimulation and, using a RiboTag mouse, detect which proteins are translated as a result of the activation. I will also investigate IEL signalling in vivo. These studies will increase understanding of how IEL become activated and offer opportunities to manipulate these pathways in the treatment of disease.\n","plannedDates":[{"endDate":"2023-10-30T00:00:00+00:00","startDate":"2020-10-31T00:00:00+00:00","startDateDateOnly":"2020-10-31","endDateDateOnly":"2023-10-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Harriet Watt","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Watt","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee","addressCountry":"United Kingdom","id_and_name":"[\"University of Dundee\", \"360G-Wellcome-ORG:University-of-Dundee\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating signalling pathways in intraepithelial lymphocytes (IEL) in the small intestine Intraepithelial lymphocytes (IEL) are T cells that reside interspersed between intestinal epithelial cells in the gut. They provide protection to the gut by coordinating immune responses towards pathogens and producing factors which maintain the gut epithelial barrier. However, dysregulated IEL function has been associated with increased gut inflammation promoting inflammatory diseases of the gut including coeliac disease and inflammatory bowel disease. The signals which activate IEL and the intracellular machinery used to communicate these signals to have an effect within the cell are relatively unknown. I propose to investigate the signalling pathways in IEL using techniques such as flow cytometry, mass spectrometry and RNA sequencing. I will stimulate IEL through cell surface receptors to initiate the downstream signalling events. I will compare the IEL response to stimulation with conventional T cell responses to determine similarities and differences in IEL signalling. I will look at proteins which have become phosphorylated upon stimulation and, using a RiboTag mouse, detect which proteins are translated as a result of the activation. I will also investigate IEL signalling in vivo. These studies will increase understanding of how IEL become activated and offer opportunities to manipulate these pathways in the treatment of disease.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Epithelial Cells","Inflammatory Bowel Diseases","Intestinal Mucosa","Intestine, Small","Lymphocyte Activation","Mice","Signal Transduction","T-Lymphocytes"]}
{"id":"360G-Wellcome-222319_Z_21_Z","title":"Defining the role of Bacillus subtilis exoproteases during biofilm formation","Region":"Scotland","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222319/Z/21/Z","description":"Biofilms are communities of microorganisms that attach to surfaces or interfaces which contain one or multiple species and can be beneficial or detrimental for human health. Biofilm formation is tightly regulated by controlling production of exopolysaccharides and extracellular proteins that combine with components including extracellular DNA and extracellular proteases to form a sticky matrix. I am interested in the role of extracellular proteases during biofilm formation. It has been hypothesized that extracellular proteases might be involved in matrix remodelling, cellular dispersal and/or in food acquisition in poor-nutrient conditions. Using the bacterium Bacillus subtilis, I will use biochemical and proteomics approaches to quantify how abundant and how active the extracellular proteases are during biofilm formation. I will also assess if extracellular proteases can be shared among the population and if they confer a selective advantage in certain nutrient environments. By combining live-cell imaging and mathematical modelling, I will also explore how extracellular proteases influence spatial distribution of mixed populations during biofilm formation. The insights garnered with this study will help to understand how exoproteases support biofilm formation in diverse environments and more globally help us to understand why biofilm can be so persistent.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Thibault Rosazza","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Rosazza","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee","addressCountry":"United Kingdom","id_and_name":"[\"University of Dundee\", \"360G-Wellcome-ORG:University-of-Dundee\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Defining the role of Bacillus subtilis exoproteases during biofilm formation Biofilms are communities of microorganisms that attach to surfaces or interfaces which contain one or multiple species and can be beneficial or detrimental for human health. Biofilm formation is tightly regulated by controlling production of exopolysaccharides and extracellular proteins that combine with components including extracellular DNA and extracellular proteases to form a sticky matrix. I am interested in the role of extracellular proteases during biofilm formation. It has been hypothesized that extracellular proteases might be involved in matrix remodelling, cellular dispersal and/or in food acquisition in poor-nutrient conditions. Using the bacterium Bacillus subtilis, I will use biochemical and proteomics approaches to quantify how abundant and how active the extracellular proteases are during biofilm formation. I will also assess if extracellular proteases can be shared among the population and if they confer a selective advantage in certain nutrient environments. By combining live-cell imaging and mathematical modelling, I will also explore how extracellular proteases influence spatial distribution of mixed populations during biofilm formation. The insights garnered with this study will help to understand how exoproteases support biofilm formation in diverse environments and more globally help us to understand why biofilm can be so persistent.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Bacillus subtilis","Bacterial Proteins","Biofilms","Proteomics"]}
{"id":"360G-Wellcome-222318_Z_21_Z","title":"Dissecting molecular mechanisms mediating ERK1/2 regulation of neural differentiation","Region":"Scotland","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222318/Z/21/Z","description":"During embryogenesis, that is the process of embryonic development after fertilisation, cells divide many times, and at some point, these cells become different from one another. This process requires turning on specific genes that make distinct cell types, such as nerve or muscle cells. My project aims to find out how this happens focusing on a specific cell type called neuromesodermal progenitors (NMP) that can contribute to two different embryonic tissues, depending on exposure to specific signals. One such signal is the Fibroblast growth factor (FGF) which regulates neural induction. It is known that inhibition of ERK1/2 activity, a protein controlled by FGF, is involved in the activation of neural genes in NMP cells. This process requires the removal of a protein complex called Polycomb, that blocks the activation of these genes. However, how the Polycomb protein complex is removed is unknown.  During my PhD project, an analysis of the proteins with changed activity upon ERK1/2 protein inactivation, will begin to dissect the molecular mechanisms regulating neural differentiation. My findings may facilitate improved protocols for directed differentiation of human cells in vitro and have wider implications for how cell state can be manipulated for therapeutic effect.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Elisenda Raga Gil","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Raga Gil","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee","addressCountry":"United Kingdom","id_and_name":"[\"University of Dundee\", \"360G-Wellcome-ORG:University-of-Dundee\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Dissecting molecular mechanisms mediating ERK1/2 regulation of neural differentiation During embryogenesis, that is the process of embryonic development after fertilisation, cells divide many times, and at some point, these cells become different from one another. This process requires turning on specific genes that make distinct cell types, such as nerve or muscle cells. My project aims to find out how this happens focusing on a specific cell type called neuromesodermal progenitors (NMP) that can contribute to two different embryonic tissues, depending on exposure to specific signals. One such signal is the Fibroblast growth factor (FGF) which regulates neural induction. It is known that inhibition of ERK1/2 activity, a protein controlled by FGF, is involved in the activation of neural genes in NMP cells. This process requires the removal of a protein complex called Polycomb, that blocks the activation of these genes. However, how the Polycomb protein complex is removed is unknown.  During my PhD project, an analysis of the proteins with changed activity upon ERK1/2 protein inactivation, will begin to dissect the molecular mechanisms regulating neural differentiation. My findings may facilitate improved protocols for directed differentiation of human cells in vitro and have wider implications for how cell state can be manipulated for therapeutic effect.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cell Differentiation","Fibroblast Growth Factors","Humans","MAP Kinase Signaling System"]}
{"id":"360G-Wellcome-222317_Z_21_Z","title":"Investigating the biological function of the E3 ligase, HOIL-1","Region":"Scotland","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222317/Z/21/Z","description":"Ubiquitin is a small protein that is attached to different targets affecting their subsequent behaviour. This addition can \u2018tag\u2019 the target for destruction by the cell, affect its localisation or promote various interactions with other proteins. E3 ligases are a group of enzymes responsible for the addition of ubiquitin onto a target, and I am interested in an E3 ligase termed HOIL-1. People who lack HOIL-1 accumulate abnormal glucose deposits called polyglucosan in their cardiac tissue, leading to heart failure. These observations suggest that HOIL-1 has a critical role in preventing the accumulation of such deposits and the overall goal of my project is to discover how this is achieved. In my initial experiments, I found that HOIL-1 is able to attach ubiquitin to glucose and thus, I hypothesise that by tagging with ubiquitin, HOIL-1 marks this molecule for destruction. People lacking HOIL-1 cannot initiate destruction and therefore accumulate the abnormal polyglucosan deposits. My aim for this project is to gain insight into how ubiquitin is added by HOIL-1. Furthermore, I aim to identify additional targets associated with HOIL-1. By discovering its targets, we can further understand its role within the human body and consequently, its potential role in disease.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Elisha McCrory","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"McCrory","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee","addressCountry":"United Kingdom","id_and_name":"[\"University of Dundee\", \"360G-Wellcome-ORG:University-of-Dundee\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the biological function of the E3 ligase, HOIL-1 Ubiquitin is a small protein that is attached to different targets affecting their subsequent behaviour. This addition can \u2018tag\u2019 the target for destruction by the cell, affect its localisation or promote various interactions with other proteins. E3 ligases are a group of enzymes responsible for the addition of ubiquitin onto a target, and I am interested in an E3 ligase termed HOIL-1. People who lack HOIL-1 accumulate abnormal glucose deposits called polyglucosan in their cardiac tissue, leading to heart failure. These observations suggest that HOIL-1 has a critical role in preventing the accumulation of such deposits and the overall goal of my project is to discover how this is achieved. In my initial experiments, I found that HOIL-1 is able to attach ubiquitin to glucose and thus, I hypothesise that by tagging with ubiquitin, HOIL-1 marks this molecule for destruction. People lacking HOIL-1 cannot initiate destruction and therefore accumulate the abnormal polyglucosan deposits. My aim for this project is to gain insight into how ubiquitin is added by HOIL-1. Furthermore, I aim to identify additional targets associated with HOIL-1. By discovering its targets, we can further understand its role within the human body and consequently, its potential role in disease.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Glucose","Heart Failure","Humans","Ubiquitin-Protein Ligases"]}
{"id":"360G-Wellcome-222316_Z_21_Z","title":"The Role of SEMA3G in the Maintenance of Pulmonary Vascular Integrity","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222316/Z/21/Z","description":"Pulmonary arterial hypertension (PAH) is a fatal disease in which the blood vessels of the lung thicken and narrow, causing an increase in blood pressure and eventually right heart failure. In order to develop new therapies for PAH the mechanisms underlying the progression of lung vessel damage must be determined. Many PAH cases are caused by a mutation of one of many components of the bone morphogenetic protein signalling pathway, however the effect of these mutations on blood vessel stability is still unknown. This project aims to examine the role of semaphorin 3G (SEMA3G), a protein that we have shown to be regulated by the bone morphogenetic protein (BMP) signalling pathway, in maintaining blood vessel integrity. Endothelial dysfunction is central to a number of pulmonary pathologies including PAH. I will investigate the role of BMP9 and BMP10 in regulating SEMA3G expression in the endothelium and specifically the functional role the protein plays in endothelial and mural cell interactions. In order to determine this, I will develop 3D co-culture assays using pulmonary microvascular endothelial cells and pericytes. These studies will further our understanding of the mechanisms controlling vascular homeostasis and potential pathways that can be targeted in the treatment of PAH.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Sarah Mirza","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Mirza","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The Role of SEMA3G in the Maintenance of Pulmonary Vascular Integrity Pulmonary arterial hypertension (PAH) is a fatal disease in which the blood vessels of the lung thicken and narrow, causing an increase in blood pressure and eventually right heart failure. In order to develop new therapies for PAH the mechanisms underlying the progression of lung vessel damage must be determined. Many PAH cases are caused by a mutation of one of many components of the bone morphogenetic protein signalling pathway, however the effect of these mutations on blood vessel stability is still unknown. This project aims to examine the role of semaphorin 3G (SEMA3G), a protein that we have shown to be regulated by the bone morphogenetic protein (BMP) signalling pathway, in maintaining blood vessel integrity. Endothelial dysfunction is central to a number of pulmonary pathologies including PAH. I will investigate the role of BMP9 and BMP10 in regulating SEMA3G expression in the endothelium and specifically the functional role the protein plays in endothelial and mural cell interactions. In order to determine this, I will develop 3D co-culture assays using pulmonary microvascular endothelial cells and pericytes. These studies will further our understanding of the mechanisms controlling vascular homeostasis and potential pathways that can be targeted in the treatment of PAH.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Bone Morphogenetic Protein 2","Bone Morphogenetic Protein Receptors, Type II","Bone Morphogenetic Proteins","Endothelial Cells","Endothelium, Vascular","Humans","Hypertension, Pulmonary","Pericytes","Pulmonary Artery","Semaphorins","Signal Transduction"]}
{"id":"360G-Wellcome-222315_Z_21_Z","title":"Role of median eminence oligodendrocytes in the development of obesity","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222315/Z/21/Z","description":"One\u2019s appetite and body weight are primarily controlled by neurons in a brain region called the hypothalamus, which respond to signals from the organs involved in digestion and metabolism. These signals reach the hypothalamus after being transported through another brain reigon, the median eminence (ME). New evidence suggests that non-neuronal cells, called oligodendrocytes (OL), may contribute to the ME\u2019s control of signal entry to the hypothalamus; OLs intentionally die and are replaced throughout adult life and express receptors for peripheral signals, both behaviours which change based on nutritional status (i.e. when one last ate) and coincide with changes in permeability of the ME.\n\nWe aim to determine how obesity disrupts the function of OLs in the ME, and how this may alter ME permeability. We will block certain functions of OLs in obese mice and identify the physiological consequences, identifying genes involved in these processes. We will use this data to identify candidate mechanisms which may alter OL function and influence healthy physiology. We will also explore the possibility that a new class of obesity drug, which mimic the signalling of hormones naturally released in the body, have their therapeutic effect by targeting OLs and changing ME permeability.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Robert Hansford","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Hansford","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Role of median eminence oligodendrocytes in the development of obesity One\u2019s appetite and body weight are primarily controlled by neurons in a brain region called the hypothalamus, which respond to signals from the organs involved in digestion and metabolism. These signals reach the hypothalamus after being transported through another brain reigon, the median eminence (ME). New evidence suggests that non-neuronal cells, called oligodendrocytes (OL), may contribute to the ME\u2019s control of signal entry to the hypothalamus; OLs intentionally die and are replaced throughout adult life and express receptors for peripheral signals, both behaviours which change based on nutritional status (i.e. when one last ate) and coincide with changes in permeability of the ME.\n\nWe aim to determine how obesity disrupts the function of OLs in the ME, and how this may alter ME permeability. We will block certain functions of OLs in obese mice and identify the physiological consequences, identifying genes involved in these processes. We will use this data to identify candidate mechanisms which may alter OL function and influence healthy physiology. We will also explore the possibility that a new class of obesity drug, which mimic the signalling of hormones naturally released in the body, have their therapeutic effect by targeting OLs and changing ME permeability.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Hypothalamus","Mice","Mice, Obese","Obesity","Oligodendroglia"]}
{"id":"360G-Wellcome-222314_Z_21_Z","title":"Characterising adipocyte protein trafficking/secretion in response to fed and fasted signals in metabolic health and disease ","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222314/Z/21/Z","description":"\n \n  \n   Fat tissue plays a key role in storing energy as fat after feeding, and releasing this energy when needed (fasting). In order to change between storing and releasing energy, fat cells have to change the proteins at its surface to allow transport of nutrients in and out of the cell. In addition, fat cells release proteins that signal to other tissues in the body depending on whether food has just been consumed (\u2018fed\u2019), or if the body has not received any food for several hours (\u2018fasted\u2019). In this project we will study how the hormones, insulin (present in a fed state) and noradrenaline (present in a fasted state) change how proteins are localised within fat to promote energy storage/release, and how these hormones change the proteins fat cells secrete. In obesity the ability of fat cells to store and release energy and secrete different hormones depending if the body is in a fed or fasted state appears to be disrupted. By also studying this in cells treated to mimic the obese-state we will shed light on how changes to these processes may contribute to the metabolic disturbances associated with obesity (e.g. type 2 diabetes).\n    \n  \n \n\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Olivia Conway","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Conway","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Characterising adipocyte protein trafficking/secretion in response to fed and fasted signals in metabolic health and disease  \n \n  \n   Fat tissue plays a key role in storing energy as fat after feeding, and releasing this energy when needed (fasting). In order to change between storing and releasing energy, fat cells have to change the proteins at its surface to allow transport of nutrients in and out of the cell. In addition, fat cells release proteins that signal to other tissues in the body depending on whether food has just been consumed (\u2018fed\u2019), or if the body has not received any food for several hours (\u2018fasted\u2019). In this project we will study how the hormones, insulin (present in a fed state) and noradrenaline (present in a fasted state) change how proteins are localised within fat to promote energy storage/release, and how these hormones change the proteins fat cells secrete. In obesity the ability of fat cells to store and release energy and secrete different hormones depending if the body is in a fed or fasted state appears to be disrupted. By also studying this in cells treated to mimic the obese-state we will shed light on how changes to these processes may contribute to the metabolic disturbances associated with obesity (e.g. type 2 diabetes).\n    \n  \n \n\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Energy Metabolism","Fasting","Insulin","Mice","Norepinephrine","Obesity"]}
{"id":"360G-Wellcome-222312_Z_21_Z","title":"Investigating mechanisms and rescue of a novel microgliopathy caused by dysfunctional LRRC33/NRROS","Region":"Scotland","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222312/Z/21/Z","description":"Recent discoveries have suggested a dysfunctional immune system of the brain plays a significant role in a set of diseases known as microgliopathies. New disorders of this type are still being identified, but ones which have so far been uncovered lead to significant brain damage and decreased lifespan. Our group has discovered a developmental microgliopathy-like disease in a patient caused by a defect in a protein named LRRC33. However, we do not fully understand the impact this defect has on the brain\u2019s immune system, how it affects different types of brain cells, and how it leads to disease onset. We aim to investigate these questions using a combination of animal models and patient post-mortem tissue. We will also seek to determine whether we can repair brain damage in our animal disease model by suppressing the brain\u2019s immune system. Strategies such as these, along with improved knowledge of the biology of the disease, could potentially lay the foundations for development of treatments for these microgliopathies, of which there are currently none.\n \n","plannedDates":[{"endDate":"2023-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2023-08-31"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Michael Sewell","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Sewell","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating mechanisms and rescue of a novel microgliopathy caused by dysfunctional LRRC33/NRROS Recent discoveries have suggested a dysfunctional immune system of the brain plays a significant role in a set of diseases known as microgliopathies. New disorders of this type are still being identified, but ones which have so far been uncovered lead to significant brain damage and decreased lifespan. Our group has discovered a developmental microgliopathy-like disease in a patient caused by a defect in a protein named LRRC33. However, we do not fully understand the impact this defect has on the brain\u2019s immune system, how it affects different types of brain cells, and how it leads to disease onset. We aim to investigate these questions using a combination of animal models and patient post-mortem tissue. We will also seek to determine whether we can repair brain damage in our animal disease model by suppressing the brain\u2019s immune system. Strategies such as these, along with improved knowledge of the biology of the disease, could potentially lay the foundations for development of treatments for these microgliopathies, of which there are currently none.\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Autopsy","Brain","Disease Models, Animal","Humans"]}
{"id":"360G-Wellcome-222311_Z_21_Z","title":"Neural mechanisms of attachment in early life.","Region":"Scotland","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222311/Z/21/Z","description":"Kin recognition is an organism's ability to distinguish between genetically close or distant individuals1, which facilitates social attachment among kin2. This is crucial after birth when parental care is needed. Kin responsive neurons have been identified in the rat lateral septum3, a brain structure associated with human kin-affiliation4,5. Human and animal data suggest that endogenous opioids in the brain mediate social attachment and an endogenous opioid-releasing circuit extends from the hypothalamus to the lateral septum. 6\u20138 In my project, I will test to see if this circuit mediates maternal attachment in early life. I will first confirm preliminary findings from our team that opioid action in the septum is necessary for maternal attachment by activating/inhibiting the lateral septal opioid system and characterising the resulting effects on maternal attachment behaviour in rat pups. To understand the cellular mechanisms involved, I will characterise the activity of lateral septum neurons when endogenous opioids are released. Finally, to explore if the findings are translatable to humans, I will investigate associations between attachment types and septal structure and connectivity in infants. These studies may help elucidate the physiology of early attachment and ultimately provide a rationale for improving the environment of care in early life.\n","plannedDates":[{"endDate":"2023-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2023-08-31"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Lorena Jim\u00e9nez S\u00e1nchez","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Jim\u00e9nez S\u00e1nchez","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Neural mechanisms of attachment in early life. Kin recognition is an organism's ability to distinguish between genetically close or distant individuals1, which facilitates social attachment among kin2. This is crucial after birth when parental care is needed. Kin responsive neurons have been identified in the rat lateral septum3, a brain structure associated with human kin-affiliation4,5. Human and animal data suggest that endogenous opioids in the brain mediate social attachment and an endogenous opioid-releasing circuit extends from the hypothalamus to the lateral septum. 6\u20138 In my project, I will test to see if this circuit mediates maternal attachment in early life. I will first confirm preliminary findings from our team that opioid action in the septum is necessary for maternal attachment by activating/inhibiting the lateral septal opioid system and characterising the resulting effects on maternal attachment behaviour in rat pups. To understand the cellular mechanisms involved, I will characterise the activity of lateral septum neurons when endogenous opioids are released. Finally, to explore if the findings are translatable to humans, I will investigate associations between attachment types and septal structure and connectivity in infants. These studies may help elucidate the physiology of early attachment and ultimately provide a rationale for improving the environment of care in early life.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Female","Maternal Behavior","Maternal Deprivation","Object Attachment","Rats"]}
{"id":"360G-Wellcome-222310_Z_21_Z","title":"Investigating microglial senescence in central nervous system health and disease","Region":"Scotland","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222310/Z/21/Z","description":"Neurodegenerative diseases cause progressive loss of nerve cells in the brain, resulting in impaired cognition and/or movement. There are currently no treatments for these diseases and therefore, another approach to developing treatments is required. With ageing, dysfunctional or \"senescent\" cells accumulate in the body and are involved in various neurodegenerative diseases. Microglia are specialised immune cells in the brain responsible for keeping surrounding nerve cells healthy. Microglia can become senescent, meaning they struggle to maintain nerve cell health. We hypothesise that senescent microglia regulate neurodegeneration. However, how senescent microglia differ in ageing and neurodegenerative disease is unknown and it is unclear how senescent microglia contribute to neurodegeneration. I will explore this using immunofluorescence, whereby senescent microglia and associated neurodegeneration can be identified by staining cells with specific markers. I will also induce and prevent microglial senescence specifically, using two specially designed mouse models, and assess neurodegeneration. It is also unknown what causes microglial senescence but ageing and long-term inflammation throughout the body likely contribute. I will investigate how microglia become senescent in mouse models undergoing ageing or long-term inflammation. This work aims to improve understanding of the role of senescent microglia in neurodegeneration and provide alternative targets for treatments.\n","plannedDates":[{"endDate":"2023-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2023-08-31"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Sarah Kent","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Kent","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating microglial senescence in central nervous system health and disease Neurodegenerative diseases cause progressive loss of nerve cells in the brain, resulting in impaired cognition and/or movement. There are currently no treatments for these diseases and therefore, another approach to developing treatments is required. With ageing, dysfunctional or \"senescent\" cells accumulate in the body and are involved in various neurodegenerative diseases. Microglia are specialised immune cells in the brain responsible for keeping surrounding nerve cells healthy. Microglia can become senescent, meaning they struggle to maintain nerve cell health. We hypothesise that senescent microglia regulate neurodegeneration. However, how senescent microglia differ in ageing and neurodegenerative disease is unknown and it is unclear how senescent microglia contribute to neurodegeneration. I will explore this using immunofluorescence, whereby senescent microglia and associated neurodegeneration can be identified by staining cells with specific markers. I will also induce and prevent microglial senescence specifically, using two specially designed mouse models, and assess neurodegeneration. It is also unknown what causes microglial senescence but ageing and long-term inflammation throughout the body likely contribute. I will investigate how microglia become senescent in mouse models undergoing ageing or long-term inflammation. This work aims to improve understanding of the role of senescent microglia in neurodegeneration and provide alternative targets for treatments.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aging","Animals","Cellular Senescence","Disease Models, Animal","Inflammation","Mice","Microglia","Nerve Degeneration","Neurodegenerative Diseases"]}
{"id":"360G-Wellcome-222309_Z_21_Z","title":"Profiling neuroinflammatory signatures of disease heterogeneity in C9orf72-associated ALS-FTD","Region":"Scotland","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222309/Z/21/Z","description":"Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) lie on a disease spectrum. Individuals affected by these conditions may have problems with movement (symptoms of ALS), thinking and behaviour (symptoms of FTD), or a combination of both. Even families with the same genetic cause, such as a C9orf72 mutation, can develop very diverse disease symptoms and there is currently no way of predicting how someone will be affected. This uncertainty is not only difficult for patients; it also affects our ability to conduct clinical trials, as some treatments may only work on a subset of patients, and disease heterogeneity may confound outcome measures. It has recently been suggested that neuroinflammation influences disease presentation along the ALS-FTD spectrum. I aim to explore this by creating a cohort of deeply clinically phenotyped post-mortem brain tissue. I will investigate neuroinflammatory gene expression in key tissues, aiming to create a holistic image of neuroinflammatory dynamics along the spectrum. Finally, I will validate my findings in a human stem cell-derived model and explore specific therapeutic approaches to target neuroinflammatory dysregulation. These studies will help shed light on methods to treat individual patients and symptoms, improving the outlook for clinical trials in this field.\n \n","plannedDates":[{"endDate":"2023-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2023-08-31"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Olivia Rifai","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Rifai","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Profiling neuroinflammatory signatures of disease heterogeneity in C9orf72-associated ALS-FTD Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) lie on a disease spectrum. Individuals affected by these conditions may have problems with movement (symptoms of ALS), thinking and behaviour (symptoms of FTD), or a combination of both. Even families with the same genetic cause, such as a C9orf72 mutation, can develop very diverse disease symptoms and there is currently no way of predicting how someone will be affected. This uncertainty is not only difficult for patients; it also affects our ability to conduct clinical trials, as some treatments may only work on a subset of patients, and disease heterogeneity may confound outcome measures. It has recently been suggested that neuroinflammation influences disease presentation along the ALS-FTD spectrum. I aim to explore this by creating a cohort of deeply clinically phenotyped post-mortem brain tissue. I will investigate neuroinflammatory gene expression in key tissues, aiming to create a holistic image of neuroinflammatory dynamics along the spectrum. Finally, I will validate my findings in a human stem cell-derived model and explore specific therapeutic approaches to target neuroinflammatory dysregulation. These studies will help shed light on methods to treat individual patients and symptoms, improving the outlook for clinical trials in this field.\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Amyotrophic Lateral Sclerosis","Brain","C9orf72 Protein","DNA Repeat Expansion","Frontotemporal Dementia","Humans","Inflammation"]}
{"id":"360G-Wellcome-222308_Z_21_Z","title":"Contribution of macrophages to the different clinical manifestations of cutaneous leishmaniasis caused by Leishmania aethiopica","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222308/Z/21/Z","description":"Cutaneous leishmaniasis (CL) is a neglected tropical disease with about 1 million new cases per year. It is caused by parasites that are transmitted by sandflies. There are a number of different forms of the disease, ranging from small, self-healing lesions on the skin, to permanently disfiguring facial lesions. It is not well understood how the parasite can result in such a wide range of outcomes. \n\nOur aim is to gain a better understanding of the interaction between the human immune system and the parasite. We are doing this by investigating how key immune cells called macrophages interact with parasites isolated from different patients. This may reveal key differences between the different forms of CL. We are achieving this through a highly collaborative approach with experts in different fields. \n\nWe hope that this research will shed light on our understanding of the diversity of CL as a disease and why some patients develop severe, life-changing lesions. \n","plannedDates":[{"endDate":"2023-10-07T00:00:00+00:00","startDate":"2020-10-08T00:00:00+00:00","startDateDateOnly":"2020-10-08","endDateDateOnly":"2023-10-07"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Edward Cruz Cervera","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Cruz Cervera","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Contribution of macrophages to the different clinical manifestations of cutaneous leishmaniasis caused by Leishmania aethiopica Cutaneous leishmaniasis (CL) is a neglected tropical disease with about 1 million new cases per year. It is caused by parasites that are transmitted by sandflies. There are a number of different forms of the disease, ranging from small, self-healing lesions on the skin, to permanently disfiguring facial lesions. It is not well understood how the parasite can result in such a wide range of outcomes. \n\nOur aim is to gain a better understanding of the interaction between the human immune system and the parasite. We are doing this by investigating how key immune cells called macrophages interact with parasites isolated from different patients. This may reveal key differences between the different forms of CL. We are achieving this through a highly collaborative approach with experts in different fields. \n\nWe hope that this research will shed light on our understanding of the diversity of CL as a disease and why some patients develop severe, life-changing lesions. \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Humans","Leishmania","Leishmania major","Leishmaniasis, Cutaneous","Macrophages"]}
{"id":"360G-Wellcome-222307_Z_21_Z","title":"Investigating the microglial role of ALS/FTD risk gene TBK1","Region":"Wales","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222307/Z/21/Z","description":"Neuronal dysfunction and degeneration are central to amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and co-existent ALS/FTD. However, it is increasingly being recognised that non-neuronal cells actively contribute to disease pathogenesis. Recent genetic studies have identified several ALS/FTD risk genes with immune roles, highlighting immune dysfunction as a key early pathogenic mechanism. We aim to investigate the role of one of these genes, TANK-binding kinase 1 (TBK1), in microglia, the resident immune cells of the brain. We will use stable microglial cell lines and human induced pluripotent stem cell-derived microglia, along with pharmacological inhibition and genetic manipulation of TBK1, to investigate the role of TBK1 in key microglial functions. In particular we aim to determine the role of TBK1 in microglial immune signalling, phagocytic activity, autophagy and mitochondrial homeostasis using cutting-edge high content imaging techniques and cellular assays. By doing so, we hope to define the role of TBK1 in microglia and further understand how deficits in TBK1 function may drive neuronal loss in ALS/FTD, with the ultimate aim of identifying novel therapeutic targets. \n","plannedDates":[{"endDate":"2023-10-25T00:00:00+00:00","startDate":"2020-10-26T00:00:00+00:00","startDateDateOnly":"2020-10-26","endDateDateOnly":"2023-10-25"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Uroosa Chughtai","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Chughtai","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University","addressCountry":"United Kingdom","id_and_name":"[\"Cardiff University\", \"360G-Wellcome-ORG:Cardiff-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the microglial role of ALS/FTD risk gene TBK1 Neuronal dysfunction and degeneration are central to amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and co-existent ALS/FTD. However, it is increasingly being recognised that non-neuronal cells actively contribute to disease pathogenesis. Recent genetic studies have identified several ALS/FTD risk genes with immune roles, highlighting immune dysfunction as a key early pathogenic mechanism. We aim to investigate the role of one of these genes, TANK-binding kinase 1 (TBK1), in microglia, the resident immune cells of the brain. We will use stable microglial cell lines and human induced pluripotent stem cell-derived microglia, along with pharmacological inhibition and genetic manipulation of TBK1, to investigate the role of TBK1 in key microglial functions. In particular we aim to determine the role of TBK1 in microglial immune signalling, phagocytic activity, autophagy and mitochondrial homeostasis using cutting-edge high content imaging techniques and cellular assays. By doing so, we hope to define the role of TBK1 in microglia and further understand how deficits in TBK1 function may drive neuronal loss in ALS/FTD, with the ultimate aim of identifying novel therapeutic targets. \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Amyotrophic Lateral Sclerosis","Autophagy","Cell Line","Frontotemporal Dementia","Humans","Induced Pluripotent Stem Cells","Microglia","Mitochondria"]}
{"id":"360G-Wellcome-222305_Z_21_Z","title":"Defining the Protective Immune Response to SARS CoV2 Using a Human Challenge Model","Region":"South East","currency":"GBP","awardDate":"2020-11-30T00:00:00+00:00","Internal ID":"222305/Z/21/Z","description":"Understanding the nature, effectiveness and durability of the human immune response to SARS CoV2 is crucial for vaccine development and effective public health management. We are beginning to understand the pattern and kinetics of the humoral response to natural infection but are less certain about other aspects of the response. We are unable to establish with certainty whether an individual with a particular titre of antibody, or a particular T cell response, is likely to be protected from reinfection and, if so, for how long. These are central questions for the development of an effective vaccine. A controlled human infection model will provide a more detailed understanding of the protective immune response. It will provide the opportunity to interrogate the full extent of the immune response at the time of exposure and will also allow the evaluation of the durability of immune responses of all kinds and how they correlate with protection.\n\nKey goals:\n\n\n To establish an MHRA-approved SARS CoV2 viral stock for use in a controlled human infection model\n To determine a challenge dose which is safe and allows virus to be recoverable from infected subjects\n\n","plannedDates":[{"endDate":"2022-07-01T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2022-07-01"}],"amountAwarded":1120861,"Financial Year":"2020/21","Lead Applicant":"Prof Helen McShane","grantProgramme":[{"title":"Human Infection Studies (Full)","title_keyword":"Human Infection Studies (Full)"}],"Applicant Surname":"McShane","Partnership Value":1120861,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Christopher Chiu, Prof Andrew Pollard","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Defining the Protective Immune Response to SARS CoV2 Using a Human Challenge Model Understanding the nature, effectiveness and durability of the human immune response to SARS CoV2 is crucial for vaccine development and effective public health management. We are beginning to understand the pattern and kinetics of the humoral response to natural infection but are less certain about other aspects of the response. We are unable to establish with certainty whether an individual with a particular titre of antibody, or a particular T cell response, is likely to be protected from reinfection and, if so, for how long. These are central questions for the development of an effective vaccine. A controlled human infection model will provide a more detailed understanding of the protective immune response. It will provide the opportunity to interrogate the full extent of the immune response at the time of exposure and will also allow the evaluation of the durability of immune responses of all kinds and how they correlate with protection.\n\nKey goals:\n\n\n To establish an MHRA-approved SARS CoV2 viral stock for use in a controlled human infection model\n To determine a challenge dose which is safe and allows virus to be recoverable from infected subjects\n\n","awardDateDateOnly":"2020-11-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Antibodies, Viral","Humans","Immunity, Humoral","T-Lymphocytes"]}
{"id":"360G-Wellcome-222304_Z_21_Z","title":"Role of the bone marrow niche in regulating the haematopoietic stem cell response to infection","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222304/Z/21/Z","description":"During infections, such as malaria, which is caused by plasmodium parasites, platelets and red blood cells are destroyed. Hematopoietic stem cells, which are responsible for the production of all the cell types of the blood system, are then put under stress to produce high numbers of platelets and red blood cells. Hematopoietic stem cells are found in the bone marrow, surrounded by many types of other cells. This project aims to investigate how only a specific subset of stem cells becomes activated to replenish the platelet cell counts. I will study the expression and function of specific genes in cells of the environment of stem cells and in stem cells themselves using microscopy-based assays on tissue slices and genetically edited cells implanted into mice. I will use intravital microscopy to study behaviours of stem cells such as cell division and movement, in the bone marrow in the skull. The results of this project could lead to the development of improved treatments for malaria patients and patients with bone marrow transplants.\n","plannedDates":[{"endDate":"2023-09-27T00:00:00+00:00","startDate":"2020-09-28T00:00:00+00:00","startDateDateOnly":"2020-09-28","endDateDateOnly":"2023-09-27"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Marine Secchi","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Secchi","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Role of the bone marrow niche in regulating the haematopoietic stem cell response to infection During infections, such as malaria, which is caused by plasmodium parasites, platelets and red blood cells are destroyed. Hematopoietic stem cells, which are responsible for the production of all the cell types of the blood system, are then put under stress to produce high numbers of platelets and red blood cells. Hematopoietic stem cells are found in the bone marrow, surrounded by many types of other cells. This project aims to investigate how only a specific subset of stem cells becomes activated to replenish the platelet cell counts. I will study the expression and function of specific genes in cells of the environment of stem cells and in stem cells themselves using microscopy-based assays on tissue slices and genetically edited cells implanted into mice. I will use intravital microscopy to study behaviours of stem cells such as cell division and movement, in the bone marrow in the skull. The results of this project could lead to the development of improved treatments for malaria patients and patients with bone marrow transplants.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Bone Marrow Cells","Hematopoietic Stem Cell Transplantation","Hematopoietic Stem Cells","Humans","Mice","Mice, Inbred C57BL","Stem Cell Niche"]}
{"id":"360G-Wellcome-222303_Z_21_Z","title":"Investigating how the presence of neutrophils in the lungs prior to infection with respiratory viruses can exacerbate disease severity in mice","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222303/Z/21/Z","description":"Respiratory viruses such as RSV, influenza viruses and the recently emerged SARS-CoV-2, represent a major global burden to public health. While infection with such viruses will often only result in mild \"cold-like\" symptoms, many will result in severe disease and require hospitalisation. Why some people get seriously ill while others only develop mild symptoms is not yet understood.\n\nRecent studies in both humans and mice have suggested that the presence of white blood cells, known as neutrophils, in the lungs prior to infection with respiratory virus results in more severe disease. The aim of this project is to investigate how the presence of these neutrophils alter the immune response to respiratory virus and ultimately how this drives more severe disease.\n\nTo achieve our aims, we will use mouse models to characterise how and which parts of the immune environment in the lung that is changed by the presence of neutrophils prior to infection with respiratory virus and how this influence the severity of disease.\n\nThis work will help us to better understand why some individuals are more at risk of severe disease following respiratory viral infection and help the development of effective treatments and vaccines.\n","plannedDates":[{"endDate":"2023-10-04T00:00:00+00:00","startDate":"2020-10-05T00:00:00+00:00","startDateDateOnly":"2020-10-05","endDateDateOnly":"2023-10-04"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Amber Owen","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Owen","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating how the presence of neutrophils in the lungs prior to infection with respiratory viruses can exacerbate disease severity in mice Respiratory viruses such as RSV, influenza viruses and the recently emerged SARS-CoV-2, represent a major global burden to public health. While infection with such viruses will often only result in mild \"cold-like\" symptoms, many will result in severe disease and require hospitalisation. Why some people get seriously ill while others only develop mild symptoms is not yet understood.\n\nRecent studies in both humans and mice have suggested that the presence of white blood cells, known as neutrophils, in the lungs prior to infection with respiratory virus results in more severe disease. The aim of this project is to investigate how the presence of these neutrophils alter the immune response to respiratory virus and ultimately how this drives more severe disease.\n\nTo achieve our aims, we will use mouse models to characterise how and which parts of the immune environment in the lung that is changed by the presence of neutrophils prior to infection with respiratory virus and how this influence the severity of disease.\n\nThis work will help us to better understand why some individuals are more at risk of severe disease following respiratory viral infection and help the development of effective treatments and vaccines.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Disease Models, Animal","Humans","Lung","Mice","Neutrophils","Orthomyxoviridae Infections","Respiratory Tract Infections"]}
{"id":"360G-Wellcome-222302_Z_21_Z","title":"Spatiotemporal host and viral transcriptomics, host restriction and DNA sensing at single cell and single molecule resolution","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222302/Z/21/Z","description":"During the earliest stages of infection, the initiation of transcription from an infecting virus genome is a critical event and essential for subsequent virus replication, progeny assembly and onward transmission. However, the same virus genome is simultaneously sensed by the host cell as a \"pathogen-associated molecular pattern\". This results in the activation of numerous cellular restriction processes to limit virus transcription and replication, as well as, stimulating anti-viral processes in surrounding cells. To understand the critical dynamics of these opposing processes, I will exploit innovative new techniques in bio-orthogonal chemistry and single molecule RNA analysis to investigate a model DNA virus, herpes simplex virus (HSV), at single cell and single genome level.  Using these techniques in relevant cell models, together with knock-outs in key cell DNA sensors and virus mutants, I aim to understand the processes that operate at the earliest stages of infection, the precise importance and role(s) of various host DNA sensors and viral antagonists, and identify novel restriction factors and associated mechanisms of viral suppression. From high resolution and quantitative investigation of these events, I aim to establish new insight into the early innate immune response and contribute to the development of novel anti-viral therapies.\n","plannedDates":[{"endDate":"2023-10-04T00:00:00+00:00","startDate":"2020-10-05T00:00:00+00:00","startDateDateOnly":"2020-10-05","endDateDateOnly":"2023-10-04"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Kerina Naran","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Naran","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Spatiotemporal host and viral transcriptomics, host restriction and DNA sensing at single cell and single molecule resolution During the earliest stages of infection, the initiation of transcription from an infecting virus genome is a critical event and essential for subsequent virus replication, progeny assembly and onward transmission. However, the same virus genome is simultaneously sensed by the host cell as a \"pathogen-associated molecular pattern\". This results in the activation of numerous cellular restriction processes to limit virus transcription and replication, as well as, stimulating anti-viral processes in surrounding cells. To understand the critical dynamics of these opposing processes, I will exploit innovative new techniques in bio-orthogonal chemistry and single molecule RNA analysis to investigate a model DNA virus, herpes simplex virus (HSV), at single cell and single genome level.  Using these techniques in relevant cell models, together with knock-outs in key cell DNA sensors and virus mutants, I aim to understand the processes that operate at the earliest stages of infection, the precise importance and role(s) of various host DNA sensors and viral antagonists, and identify novel restriction factors and associated mechanisms of viral suppression. From high resolution and quantitative investigation of these events, I aim to establish new insight into the early innate immune response and contribute to the development of novel anti-viral therapies.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","DNA, Viral","Herpes Simplex","Herpesvirus 1, Human","Host-Pathogen Interactions","Humans","Immunity, Innate","Simplexvirus","Single-Cell Analysis","Virus Replication"]}
{"id":"360G-Wellcome-222301_Z_21_Z","title":"Mechanisms of CD4+ T Cell Dysfunction During HTLV-1  Infection","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222301/Z/21/Z","description":"Human T-cell Lymphotropic Virus type-1 (HTLV-1) infects 5-10 million people worldwide. The majority of people infected remain asymptomatic carriers (ACs), while 2-6% of those infected develop adult T-cell leukaemia and another 2-3% go on to develop chronic inflammatory diseases including HTLV-1 associated myelopathy (HAM). CD4+ T cells carry 95% of the HTLV-1 proviral burden. While CD4+ T cell dysfunction has been implicated in HAM pathogenesis, the mechanism of tissue damage is still unclear. Limited research has been done on the HTLV-1-specific CD4+ T cell immune response and little is known about CD4+ T cell dysfunction during chronic viral infections. The overall aim of this project is the identification and deep phenotypical and functional characterisation of live HTLV-1 specific CD4+ T cells in healthy individuals, ACs and HAM patients. We have optimised an ex vivo assay to identify and isolate live HTLV-1-specific CD4+ T cells. The results obtained in this project will have implications for vaccination approaches against HTLV-1 and for the development of strategies that could reduce inflammation and control disease, as well as providing mechanistic insights into HAM immunopathology.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Allison Maher","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Maher","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mechanisms of CD4+ T Cell Dysfunction During HTLV-1  Infection Human T-cell Lymphotropic Virus type-1 (HTLV-1) infects 5-10 million people worldwide. The majority of people infected remain asymptomatic carriers (ACs), while 2-6% of those infected develop adult T-cell leukaemia and another 2-3% go on to develop chronic inflammatory diseases including HTLV-1 associated myelopathy (HAM). CD4+ T cells carry 95% of the HTLV-1 proviral burden. While CD4+ T cell dysfunction has been implicated in HAM pathogenesis, the mechanism of tissue damage is still unclear. Limited research has been done on the HTLV-1-specific CD4+ T cell immune response and little is known about CD4+ T cell dysfunction during chronic viral infections. The overall aim of this project is the identification and deep phenotypical and functional characterisation of live HTLV-1 specific CD4+ T cells in healthy individuals, ACs and HAM patients. We have optimised an ex vivo assay to identify and isolate live HTLV-1-specific CD4+ T cells. The results obtained in this project will have implications for vaccination approaches against HTLV-1 and for the development of strategies that could reduce inflammation and control disease, as well as providing mechanistic insights into HAM immunopathology.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adult","CD4-Positive T-Lymphocytes","Carrier State","HTLV-I Infections","Human T-lymphotropic virus 1","Humans"]}
{"id":"360G-Wellcome-222300_Z_20_Z","title":"Regional Hub to Provide Scientific and Technical Support on Evidence-Informed Decision-Making for Vaccines in the WHO AFRO region","Region":"International","currency":"GBP","awardDate":"2020-12-31T00:00:00+00:00","Internal ID":"222300/Z/20/Z","description":"In the WHO AFRO, there is a need for sustainable mechanisms to provide scientific and technical EIDM support for vaccines and immunisation. We propose to establish a Regional Scientific Hub (RSH) to support NITAGs with EIDM. The RSH\u2019s mission is to enable NITAGs in the WHO AFRO to strengthen EIDM with respect to vaccines and immunisation practices. The RSH will offer the EIDM support to NITAGs in close collaboration with the WHO. Public health professional members working within immunisation programmes, technical partners and other health groups will also be supported by the RSH. The support provided by RSH will strengthen the effectiveness of African NITAGs, resulting to an enhanced access to existing and new vaccines in the region.\n\nThrough the provision of the EIDM support, the RSH key goals are:\n- Enhance access and use of EIDM resources and tools by members of NITAGs\n- Empower NITAGs to produce timely and independent evidence-based recommendations that inform national decisions on vaccines \n- Foster an increased national ownership of immunisation programmes in the region.\n- Accelerate the strengthening of national immunisation programmes\n\nAchieving these goals will result to increased immunisation rates and improved introduction of new vaccines in the WHO AFRO.\n","plannedDates":[{"endDate":"2025-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2025-12-31"}],"amountAwarded":4575696,"Financial Year":"2020/21","Lead Applicant":"Dr Benjamin Kagina","grantProgramme":[{"title":"Discretionary Award - Vaccines","title_keyword":"Discretionary Award - Vaccines"}],"Applicant Surname":"Kagina","Partnership Value":4575696,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Prof Gregory Hussey, Prof Rudzani Muloiwa","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cape-Town","name":"University of Cape Town","addressCountry":"South Africa","id_and_name":"[\"University of Cape Town\", \"360G-Wellcome-ORG:University-of-Cape-Town\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cape-Town","name":"University of Cape Town"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Regional Hub to Provide Scientific and Technical Support on Evidence-Informed Decision-Making for Vaccines in the WHO AFRO region In the WHO AFRO, there is a need for sustainable mechanisms to provide scientific and technical EIDM support for vaccines and immunisation. We propose to establish a Regional Scientific Hub (RSH) to support NITAGs with EIDM. The RSH\u2019s mission is to enable NITAGs in the WHO AFRO to strengthen EIDM with respect to vaccines and immunisation practices. The RSH will offer the EIDM support to NITAGs in close collaboration with the WHO. Public health professional members working within immunisation programmes, technical partners and other health groups will also be supported by the RSH. The support provided by RSH will strengthen the effectiveness of African NITAGs, resulting to an enhanced access to existing and new vaccines in the region.\n\nThrough the provision of the EIDM support, the RSH key goals are:\n- Enhance access and use of EIDM resources and tools by members of NITAGs\n- Empower NITAGs to produce timely and independent evidence-based recommendations that inform national decisions on vaccines \n- Foster an increased national ownership of immunisation programmes in the region.\n- Accelerate the strengthening of national immunisation programmes\n\nAchieving these goals will result to increased immunisation rates and improved introduction of new vaccines in the WHO AFRO.\n","awardDateDateOnly":"2020-12-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa","Decision Making","Humans","Immunization","Immunization Programs","Vaccination","Vaccines"]}
{"id":"360G-Wellcome-222299_Z_20_Z","title":"Development of Target Product Profiles for Snake Antivenom Products","Region":"International","currency":"GBP","awardDate":"2021-01-29T00:00:00+00:00","Internal ID":"222299/Z/20/Z","description":"Antivenoms are bespoke biologicals that have been the mainstay of snakebite treatment for 125 years. Requirements for production, safety and efficacy vary across regulatory environments. Shortages of effective antivenoms have emerged as important public health issues, particularly in Sub-Saharan Africa. The variability of current products in this market present substantial challenges. WHO is exploring a pathway for prequalification of antivenoms and identified a need to develop target product profiles (TPPs) to support optimisation of current and emerging products. TPPs can play a central role in the drug discovery and development process towards desired product characteristics, including access, equity and affordability considerations. At present, there are no available public-interest TPPs for snake antivenoms. We will develop public-interest WHO TPPs with preferred and minimally acceptable profiles for antivenom therapeutics, with an initial focus on Sub-Saharan Africa. The work will be a collaboration between WHO and DNDi following the 2018 WHO TPP Generic Methodology. The resultant WHO TPPs will be widely shared through diverse communication channels and publications, and listed in the WHO Health Product Profile Directory. TPPs will assist product standardization and guide more targeted research and development of antivenoms. \n","plannedDates":[{"endDate":"2023-02-03T00:00:00+00:00","startDate":"2021-05-04T00:00:00+00:00","startDateDateOnly":"2021-05-04","endDateDateOnly":"2023-02-03"}],"amountAwarded":338472,"Financial Year":"2020/21","Lead Applicant":"Dr Bernadette Abela-Ridder","grantProgramme":[{"title":"Discretionary Award - Snakebite","title_keyword":"Discretionary Award - Snakebite"}],"Applicant Surname":"Abela-Ridder","Partnership Value":338472,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:World-Health-Organization-Switzerland","name":"World Health Organization, Switzerland","addressCountry":"Switzerland","id_and_name":"[\"World Health Organization, Switzerland\", \"360G-Wellcome-ORG:World-Health-Organization-Switzerland\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:World-Health-Organization-Switzerland","name":"World Health Organization, Switzerland"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Development of Target Product Profiles for Snake Antivenom Products Antivenoms are bespoke biologicals that have been the mainstay of snakebite treatment for 125 years. Requirements for production, safety and efficacy vary across regulatory environments. Shortages of effective antivenoms have emerged as important public health issues, particularly in Sub-Saharan Africa. The variability of current products in this market present substantial challenges. WHO is exploring a pathway for prequalification of antivenoms and identified a need to develop target product profiles (TPPs) to support optimisation of current and emerging products. TPPs can play a central role in the drug discovery and development process towards desired product characteristics, including access, equity and affordability considerations. At present, there are no available public-interest TPPs for snake antivenoms. We will develop public-interest WHO TPPs with preferred and minimally acceptable profiles for antivenom therapeutics, with an initial focus on Sub-Saharan Africa. The work will be a collaboration between WHO and DNDi following the 2018 WHO TPP Generic Methodology. The resultant WHO TPPs will be widely shared through diverse communication channels and publications, and listed in the WHO Health Product Profile Directory. TPPs will assist product standardization and guide more targeted research and development of antivenoms. \n","awardDateDateOnly":"2021-01-29","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa South of the Sahara","Antivenins","Humans","Snake Bites"]}
{"id":"360G-Wellcome-222298_Z_20_Z","title":"Open Access Award 2020/21","Region":"North East","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222298/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":12883,"Financial Year":"2020/21","Lead Applicant":"Prof Stuart Corbridge","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Corbridge","Partnership Value":12883,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Durham","name":"University of Durham","addressCountry":"United Kingdom","id_and_name":"[\"University of Durham\", \"360G-Wellcome-ORG:University-of-Durham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Durham","name":"University of Durham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222297_Z_20_Z","title":"Open Access Award 2020/21","Region":"East of England","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222297/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2021-12-31"}],"amountAwarded":16190,"Financial Year":"2020/21","Lead Applicant":"Prof Wolf Reik","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Reik","Partnership Value":16190,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Babraham-Institute","name":"Babraham Institute","addressCountry":"United Kingdom","id_and_name":"[\"Babraham Institute\", \"360G-Wellcome-ORG:Babraham-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Babraham-Institute","name":"Babraham Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222296_Z_20_Z","title":"Open Access Award 2020/21","Region":"South East","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222296/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":13151,"Financial Year":"2020/21","Lead Applicant":"Prof Bryan Charleston","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Charleston","Partnership Value":13151,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:The-Pirbright-Institute","name":"The Pirbright Institute","addressCountry":"United Kingdom","id_and_name":"[\"The Pirbright Institute\", \"360G-Wellcome-ORG:The-Pirbright-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:The-Pirbright-Institute","name":"The Pirbright Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222295_Z_20_Z","title":"Open Access Award 2020/21","Region":"Greater London","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222295/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":99635,"Financial Year":"2020/21","Lead Applicant":"Sir Paul Nurse","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Nurse","Partnership Value":99635,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:The-Francis-Crick-Institute","name":"The Francis Crick Institute","addressCountry":"United Kingdom","id_and_name":"[\"The Francis Crick Institute\", \"360G-Wellcome-ORG:The-Francis-Crick-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:The-Francis-Crick-Institute","name":"The Francis Crick Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222294_Z_20_Z","title":"Open Access Award 2020/21","Region":"East of England","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222294/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":18877,"Financial Year":"2020/21","Lead Applicant":"Prof David Richardson","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Richardson","Partnership Value":18877,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-East-Anglia","name":"University of East Anglia","addressCountry":"United Kingdom","id_and_name":"[\"University of East Anglia\", \"360G-Wellcome-ORG:University-of-East-Anglia\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-East-Anglia","name":"University of East Anglia"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222292_Z_20_Z","title":"Integration of context and task rules by the nucleus reuniens.","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222292/Z/20/Z","description":"Deciding the best way to behave is often dependent on where you are. For example, cheering loudly when someone scores a goal is a good way to behave if you are watching a football match in the pub, but not if you are watching it on your phone in the library.\n\nThe ability to tell where you are is governed by a part of the brain called the hippocampus, while deciding the most appropriate behaviour is governed by the prefrontal cortex. By communicating intricately with each other, it is proposed that these regions allow you to modify behaviour based on your location. However, the hippocampus and prefrontal cortex are not connected to each other, and therefore we do not understand how they communicate so effectively.\n\nIn this proposal we will investigate that idea that this communication occurs through a region called the nucleus reuniens. We will investigate how this region connects with both prefrontal cortex and hippocampus; we will carry out computational modelling to investigate how this communication might occur; and then carry out behavioural experiments that will allow us to directly test how neurons in the nucleus reuniens allow the modification of behaviour based on where we are.\n","plannedDates":[{"endDate":"2023-09-13T00:00:00+00:00","startDate":"2020-09-14T00:00:00+00:00","startDateDateOnly":"2020-09-14","endDateDateOnly":"2023-09-13"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Jessica Passlack","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Passlack","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Integration of context and task rules by the nucleus reuniens. Deciding the best way to behave is often dependent on where you are. For example, cheering loudly when someone scores a goal is a good way to behave if you are watching a football match in the pub, but not if you are watching it on your phone in the library.\n\nThe ability to tell where you are is governed by a part of the brain called the hippocampus, while deciding the most appropriate behaviour is governed by the prefrontal cortex. By communicating intricately with each other, it is proposed that these regions allow you to modify behaviour based on your location. However, the hippocampus and prefrontal cortex are not connected to each other, and therefore we do not understand how they communicate so effectively.\n\nIn this proposal we will investigate that idea that this communication occurs through a region called the nucleus reuniens. We will investigate how this region connects with both prefrontal cortex and hippocampus; we will carry out computational modelling to investigate how this communication might occur; and then carry out behavioural experiments that will allow us to directly test how neurons in the nucleus reuniens allow the modification of behaviour based on where we are.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Communication","Hippocampus","Neurons","Prefrontal Cortex"]}
{"id":"360G-Wellcome-222291_Z_20_Z","title":"Open Access Award 2020/21","Region":"Greater London","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222291/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":35181,"Financial Year":"2020/21","Lead Applicant":"Prof Willem Hanekom","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Hanekom","Partnership Value":35181,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222290_Z_20_Z","title":"Open Access Award 2020/21","Region":"North West","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222290/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":25084,"Financial Year":"2020/21","Lead Applicant":"Prof Stephen Gordon","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Gordon","Partnership Value":25084,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"Liverpool School of Tropical Medicine\", \"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222289_Z_20_Z","title":"Open Access Award 2020/21","Region":"South East","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222289/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":68783,"Financial Year":"2020/21","Lead Applicant":"Prof Guy Thwaites","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Thwaites","Partnership Value":68783,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222288_Z_20_Z","title":"Open Access Award 2020/21","Region":"South East","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222288/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":75506,"Financial Year":"2020/21","Lead Applicant":"Prof Nicholas Day","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Day","Partnership Value":75506,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222287_Z_20_Z","title":"Open Access Award 2020/21","Region":"South East","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222287/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":109200,"Financial Year":"2020/21","Lead Applicant":"Prof Philip Bejon","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Bejon","Partnership Value":109200,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222286_Z_20_Z","title":"Investigations into assembly, egress and virus-host interactions of Oropouche Virus","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222286/Z/20/Z","description":"Tri-segmented bunyaviruses, which includes Rift valley fever virus and Oropouche virus (OROV), are responsible for a variety of human diseases ranging from self-limiting symptoms such as acute febrile illness, to lethal encephalitis and haemorrhagic fever. OROV is the first example of a virus shown to recruit endosomal sorting complex required for transport (ESCRT) components to virus assembly sites in the Golgi, through unclear mechanisms. During this project, I will develop virus-like particle assays to determine whether ESCRT recruitment is conserved across representative tri-segmented bunyavirus families. Once this has been established, I will investigate the molecular mechanisms that drive ESCRT recruitment to sites of bunyavirus assembly. I will do this by employing a range of proteomic approaches, that will utilise exogenously expressed bunyavirus envelope glycoproteins to identify potential interaction partners that are involved in ESCRT recruitment. Finally, I will conduct experiments using live OROV in collaborative research trips to Brazil, to understand how the virus changes the proteome of the cell during infection using a variety OROV mutants. These studies will elucidate a potentially novel mechanism of ESCRT recruitment during virus assembly and provide detailed understanding of bunyavirus-host interactions. Such new insights into bunyavirus infections may aid in development of antivirals.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Jake Barker","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Barker","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigations into assembly, egress and virus-host interactions of Oropouche Virus Tri-segmented bunyaviruses, which includes Rift valley fever virus and Oropouche virus (OROV), are responsible for a variety of human diseases ranging from self-limiting symptoms such as acute febrile illness, to lethal encephalitis and haemorrhagic fever. OROV is the first example of a virus shown to recruit endosomal sorting complex required for transport (ESCRT) components to virus assembly sites in the Golgi, through unclear mechanisms. During this project, I will develop virus-like particle assays to determine whether ESCRT recruitment is conserved across representative tri-segmented bunyavirus families. Once this has been established, I will investigate the molecular mechanisms that drive ESCRT recruitment to sites of bunyavirus assembly. I will do this by employing a range of proteomic approaches, that will utilise exogenously expressed bunyavirus envelope glycoproteins to identify potential interaction partners that are involved in ESCRT recruitment. Finally, I will conduct experiments using live OROV in collaborative research trips to Brazil, to understand how the virus changes the proteome of the cell during infection using a variety OROV mutants. These studies will elucidate a potentially novel mechanism of ESCRT recruitment during virus assembly and provide detailed understanding of bunyavirus-host interactions. Such new insights into bunyavirus infections may aid in development of antivirals.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Endosomes","Host-Pathogen Interactions","Humans","Proteomics","Virus Internalization","Virus Release"]}
{"id":"360G-Wellcome-222285_Z_20_Z","title":"Open Access Award 2020/21","Region":"East Midlands","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222285/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":23592,"Financial Year":"2020/21","Lead Applicant":"Prof Nishan Canagarajah","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Canagarajah","Partnership Value":23592,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leicester","name":"University of Leicester","addressCountry":"United Kingdom","id_and_name":"[\"University of Leicester\", \"360G-Wellcome-ORG:University-of-Leicester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leicester","name":"University of Leicester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222284_Z_20_Z","title":"Open Access Award 2020/21","Region":"South East","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222284/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":29873,"Financial Year":"2020/21","Lead Applicant":"Prof Mark Smith","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Smith","Partnership Value":29873,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Southampton","name":"University of Southampton","addressCountry":"United Kingdom","id_and_name":"[\"University of Southampton\", \"360G-Wellcome-ORG:University-of-Southampton\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Southampton","name":"University of Southampton"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222283_Z_20_Z","title":"Open Access Award 2020/21","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222283/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":50751,"Financial Year":"2020/21","Lead Applicant":"Prof Simone Buitendijk","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Buitendijk","Partnership Value":50751,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds","addressCountry":"United Kingdom","id_and_name":"[\"University of Leeds\", \"360G-Wellcome-ORG:University-of-Leeds\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222282_Z_20_Z","title":"Open Access Award 2020/21","Region":"Scotland","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222282/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":202536,"Financial Year":"2020/21","Lead Applicant":"Prof David Maguire","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Maguire","Partnership Value":202536,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee","addressCountry":"United Kingdom","id_and_name":"[\"University of Dundee\", \"360G-Wellcome-ORG:University-of-Dundee\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222280_Z_20_Z","title":"The mechanical regulation of chemical signaling in axon pathfinding in the developing Xenopus laevis brain ","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222280/Z/20/Z","description":"During nervous system development, neurons extend their axons over long distances to predefined targets. Research from the last decade has revealed a plethora of chemical signals that are involved in instructing axon guidance. However, it is now becoming increasingly evident that axons also respond to the mechanical environment that they grow in and this affects axon guidance. Moreover, crosstalk occurs between chemical and mechanical signalling. Thus, a holistic understanding of axon guidance would involve understanding both chemical and mechanical guidance cues and the crosstalk between them. A variety of chemical signalling cues which mediate attraction or repulsion are known to regulate axon pathfinding. These include Slits, Semaphorins, Netrins and Ephrins. However, chemical guidance cues do not act alone. The mechanical environment that the axons grow in, also influences axon pathfinding. One of the ways axons respond to the mechanical environment is through mechanosensitive ion channels (e.g. Piezo1). My PhD project aims at exploring the crosstalk between mechanical and chemical signalling in axon pathfinding, using the optic tract (OT) of Xenopus laevis as a model system.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Sudipta Mukherjee","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Mukherjee","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The mechanical regulation of chemical signaling in axon pathfinding in the developing Xenopus laevis brain  During nervous system development, neurons extend their axons over long distances to predefined targets. Research from the last decade has revealed a plethora of chemical signals that are involved in instructing axon guidance. However, it is now becoming increasingly evident that axons also respond to the mechanical environment that they grow in and this affects axon guidance. Moreover, crosstalk occurs between chemical and mechanical signalling. Thus, a holistic understanding of axon guidance would involve understanding both chemical and mechanical guidance cues and the crosstalk between them. A variety of chemical signalling cues which mediate attraction or repulsion are known to regulate axon pathfinding. These include Slits, Semaphorins, Netrins and Ephrins. However, chemical guidance cues do not act alone. The mechanical environment that the axons grow in, also influences axon pathfinding. One of the ways axons respond to the mechanical environment is through mechanosensitive ion channels (e.g. Piezo1). My PhD project aims at exploring the crosstalk between mechanical and chemical signalling in axon pathfinding, using the optic tract (OT) of Xenopus laevis as a model system.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Axon Guidance","Axons","Ion Channels","Mechanotransduction, Cellular","Signal Transduction","Xenopus Proteins","Xenopus laevis"]}
{"id":"360G-Wellcome-222279_Z_20_Z","title":"Development and Evolution of Cichlid Pigmentation","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222279/Z/20/Z","description":"The cichlid fish in the African Great Lakes are incredibly diverse despite being genetically very similar to each other. We will study the development of colour pattern in Astatotilapia calliptera, which consist of arrangements of specialised colour-bearing cells, chromatophores. We will focus on the variable circular markings on the fin known as egg-spots, as these play a role in reproductive behaviour and therefore have direct consequences for species evolution. Four genes have been identified as associated with variation in egg-spots number and colour in A. calliptera. We will use CRISPR-Cas9 to knock-out these genes to identify their effect on egg-spot development. We will also check whether the same genes are associated with egg-spot variation between different cichlid species. We will then model the interactions between chromatophores - these interactions affect the movement, differentiation, and death of chromatophores during development, affecting the resulting colouration. We will use this model to test which mechanisms the genes act through. Understanding how the slight genetic changes between cichlids affect embryo development and lead to such different appearances can help us understand the huge diversity of species we see today, and how the porcesses of embryo development and evolution affect each other.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Ms Bethan Clark","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Clark","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Development and Evolution of Cichlid Pigmentation The cichlid fish in the African Great Lakes are incredibly diverse despite being genetically very similar to each other. We will study the development of colour pattern in Astatotilapia calliptera, which consist of arrangements of specialised colour-bearing cells, chromatophores. We will focus on the variable circular markings on the fin known as egg-spots, as these play a role in reproductive behaviour and therefore have direct consequences for species evolution. Four genes have been identified as associated with variation in egg-spots number and colour in A. calliptera. We will use CRISPR-Cas9 to knock-out these genes to identify their effect on egg-spot development. We will also check whether the same genes are associated with egg-spot variation between different cichlid species. We will then model the interactions between chromatophores - these interactions affect the movement, differentiation, and death of chromatophores during development, affecting the resulting colouration. We will use this model to test which mechanisms the genes act through. Understanding how the slight genetic changes between cichlids affect embryo development and lead to such different appearances can help us understand the huge diversity of species we see today, and how the porcesses of embryo development and evolution affect each other.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animal Fins","Animals","Biological Evolution","CRISPR-Cas Systems","Cichlids","Lakes","Pigmentation"]}
{"id":"360G-Wellcome-222278_Z_20_Z","title":"Hunt for the vaccine","Region":"Greater London","currency":"GBP","awardDate":"2020-11-30T00:00:00+00:00","Internal ID":"222278/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2025-11-28T00:00:00+00:00","startDate":"2021-05-01T00:00:00+00:00","startDateDateOnly":"2021-05-01","endDateDateOnly":"2025-11-28"}],"amountAwarded":1911840,"Financial Year":"2020/21","Lead Applicant":"Miss Madeleine Turner","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Turner","Partnership Value":1911840,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Science-Museum","name":"Science Museum","addressCountry":"United Kingdom","id_and_name":"[\"Science Museum\", \"360G-Wellcome-ORG:Science-Museum\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Science-Museum","name":"Science Museum"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Hunt for the vaccine Not available","awardDateDateOnly":"2020-11-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Vaccination","Vaccines"]}
{"id":"360G-Wellcome-222276_Z_20_Z","title":"Chromatin state transitions during quiescence and reactivation of neural stem cells in Drosophila melanogaster","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222276/Z/20/Z","description":"In the adult brain, most cells that produce new neurons (neural stem cells) are found in an inactive state (quiescence). These cells can be awakened in response to various signals, including diet or injury. Importantly, active and inactive neural stem cells differ in the genes they express and the modifications present on histones, proteins that the DNA is wrapped around. Histone modifications play a crucial role in regulating gene expression. During my PhD project, I will examine these modifications in active and inactive neural stem cells in Drosophila, in which these cells are easy to identify and manipulate. Using Targeted DamID, a technique that makes it possible to identify protein-DNA interactions in vivo, I will profile the location of individual histone modifications neural stem cells and classify the chromatin in those cells into domains. I will use super-resolution microscopy to observe chromatin within the nuclei of neural stem cells. Finally, I will test the function of those genes that may be important for awakening neural stem cells or inducing them into the inactive state. Understanding the mechanisms that induce neural stem cell inactivity and reactivation can potentially give insights into new therapies for brain injury or neurodegenerative diseases.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Anna Malkowska","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Malkowska","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Chromatin state transitions during quiescence and reactivation of neural stem cells in Drosophila melanogaster In the adult brain, most cells that produce new neurons (neural stem cells) are found in an inactive state (quiescence). These cells can be awakened in response to various signals, including diet or injury. Importantly, active and inactive neural stem cells differ in the genes they express and the modifications present on histones, proteins that the DNA is wrapped around. Histone modifications play a crucial role in regulating gene expression. During my PhD project, I will examine these modifications in active and inactive neural stem cells in Drosophila, in which these cells are easy to identify and manipulate. Using Targeted DamID, a technique that makes it possible to identify protein-DNA interactions in vivo, I will profile the location of individual histone modifications neural stem cells and classify the chromatin in those cells into domains. I will use super-resolution microscopy to observe chromatin within the nuclei of neural stem cells. Finally, I will test the function of those genes that may be important for awakening neural stem cells or inducing them into the inactive state. Understanding the mechanisms that induce neural stem cell inactivity and reactivation can potentially give insights into new therapies for brain injury or neurodegenerative diseases.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Chromatin","Drosophila Proteins","Drosophila melanogaster","Histones","Neural Stem Cells"]}
{"id":"360G-Wellcome-222275_Z_20_Z","title":"Modelling bronchopulmonary dysplasia through human lung progenitor organoids and mouse xenotransplantation","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222275/Z/20/Z","description":"Bronchopulmonary dysplasia (BPD) is a chronic respiratory system disease with a particularly high incidence in preterm infants who receive mechanical ventilation and oxygen supplementation. BPD is characterized by less developed alveoli, the main gas exchange region. Clinical studies and animal experiments have identified hyperoxia exposure, ventilation trauma and genetic susceptibility as risk factors of BPD, though their effects on human alveolar development at a cellular level remain unknown. Based on the established progenitor organoid system derived from human embryonic lung tips, I aim to build an in vitro alveolar differentiation model and investigate the effects of BPD risk factors on this process. I will also use a mouse xenotransplantation model to assess the in vivo differentiation potential of human lung progenitors affected by BPD risk factors. These studies will help to delineate the impact of current respiration-supporting methods on human alveolar development. The elucidated cellular and molecular mechanisms can assist to reduce the risk and damage of BPD on preterm infants and improve long-term health conditions.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Ziqi Dong","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Dong","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Modelling bronchopulmonary dysplasia through human lung progenitor organoids and mouse xenotransplantation Bronchopulmonary dysplasia (BPD) is a chronic respiratory system disease with a particularly high incidence in preterm infants who receive mechanical ventilation and oxygen supplementation. BPD is characterized by less developed alveoli, the main gas exchange region. Clinical studies and animal experiments have identified hyperoxia exposure, ventilation trauma and genetic susceptibility as risk factors of BPD, though their effects on human alveolar development at a cellular level remain unknown. Based on the established progenitor organoid system derived from human embryonic lung tips, I aim to build an in vitro alveolar differentiation model and investigate the effects of BPD risk factors on this process. I will also use a mouse xenotransplantation model to assess the in vivo differentiation potential of human lung progenitors affected by BPD risk factors. These studies will help to delineate the impact of current respiration-supporting methods on human alveolar development. The elucidated cellular and molecular mechanisms can assist to reduce the risk and damage of BPD on preterm infants and improve long-term health conditions.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Bronchopulmonary Dysplasia","Cell Differentiation","Disease Models, Animal","Humans","Hyperoxia","Lung","Mice","Organoids","Pulmonary Alveoli"]}
{"id":"360G-Wellcome-222274_Z_20_Z","title":"Cellular Dynamics and Tissue Mechanics during Junctional Neurulation in Avian Embryos","Region":"East of England","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222274/Z/20/Z","description":"During early development, embryos begin to develop what will become the future brain and spinal cord in a process known as neurulation or neural tube formation. Errors in this process lead to common birth defects such as spina bifida and anencephaly, which can differ in type and severity based on location along the future spine. This process differs between the head and tail ends of an embryo, with the head rolling up from a flat sheet and the tail end forming a solid rod that hollows in humans and chick. Whilst much is known about these two disparate processes, the region where they join is poorly understood.\n\nWe aim to generate a better understanding of this junctional region, and the cellular and mechanical changes that govern its formation, through studying the wider cell movements and then focusing on mechanics and hydrostatic pressure differences. Using advanced microscopy of live and fixed tissues, we will assess cellular and tissue movements and use the data gathered to create a computerised physical model to predict tissue mechanics.\n\nThis work will provide new insights on the basic processes of neural tube formation and may also help understand the causes of some neural tube defects.\n","plannedDates":[{"endDate":"2023-10-04T00:00:00+00:00","startDate":"2020-10-05T00:00:00+00:00","startDateDateOnly":"2020-10-05","endDateDateOnly":"2023-10-04"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Lauren Moon","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Moon","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Cellular Dynamics and Tissue Mechanics during Junctional Neurulation in Avian Embryos During early development, embryos begin to develop what will become the future brain and spinal cord in a process known as neurulation or neural tube formation. Errors in this process lead to common birth defects such as spina bifida and anencephaly, which can differ in type and severity based on location along the future spine. This process differs between the head and tail ends of an embryo, with the head rolling up from a flat sheet and the tail end forming a solid rod that hollows in humans and chick. Whilst much is known about these two disparate processes, the region where they join is poorly understood.\n\nWe aim to generate a better understanding of this junctional region, and the cellular and mechanical changes that govern its formation, through studying the wider cell movements and then focusing on mechanics and hydrostatic pressure differences. Using advanced microscopy of live and fixed tissues, we will assess cellular and tissue movements and use the data gathered to create a computerised physical model to predict tissue mechanics.\n\nThis work will provide new insights on the basic processes of neural tube formation and may also help understand the causes of some neural tube defects.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Chick Embryo","Chickens","Hydrostatic Pressure","Neural Tube","Neural Tube Defects","Neurulation","Spinal Cord"]}
{"id":"360G-Wellcome-222272_Z_20_Z","title":"Delineating the unique functional contribution of the retrosplenial cortex in the hippocampal-diencephalic-cingulate network","Region":"Wales","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222272/Z/20/Z","description":"The retrosplenial (RSP) cortex  is a cortical area located behind the splenium, As a part of the hippocampal-diencephalic-cingulate network, it has been repeatedly implicated in episodic memory, spatial memory, and navigation. Pathologically, when damaged the RSP cortex produces both anterograde and retrograde amnesia. It is among the first regions to show neurodegeneration in Alzheimer\u2019s disease and Mild Cognitive Impairment. However, despite the region's clinical and behavioral significance, its unique functional contribution to hippocampal-dependent processes is poorly understood. To delineate the RSP cortex functions from that of other structures, I will use a combination of chemogenetic and optogenetic manipulations in rats, to examine behavioral effects. Disentangling the RSP cortex functions will not only elucidate the intrinsic processes underlying cognitive function, but also potentially provide a new target for the treatment of memory disorders.\n\n \n\n \n\n \n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Steliana Yanakieva","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Yanakieva","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University","addressCountry":"United Kingdom","id_and_name":"[\"Cardiff University\", \"360G-Wellcome-ORG:Cardiff-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Delineating the unique functional contribution of the retrosplenial cortex in the hippocampal-diencephalic-cingulate network The retrosplenial (RSP) cortex  is a cortical area located behind the splenium, As a part of the hippocampal-diencephalic-cingulate network, it has been repeatedly implicated in episodic memory, spatial memory, and navigation. Pathologically, when damaged the RSP cortex produces both anterograde and retrograde amnesia. It is among the first regions to show neurodegeneration in Alzheimer\u2019s disease and Mild Cognitive Impairment. However, despite the region's clinical and behavioral significance, its unique functional contribution to hippocampal-dependent processes is poorly understood. To delineate the RSP cortex functions from that of other structures, I will use a combination of chemogenetic and optogenetic manipulations in rats, to examine behavioral effects. Disentangling the RSP cortex functions will not only elucidate the intrinsic processes underlying cognitive function, but also potentially provide a new target for the treatment of memory disorders.\n\n \n\n \n\n \n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Alzheimer Disease","Animals","Cerebral Cortex","Gyrus Cinguli","Hippocampus","Optogenetics","Rats"]}
{"id":"360G-Wellcome-222268_Z_20_Z","title":"Using hierarchical models of habitual and goal-directed decision-making to understand compulsive behaviour","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222268/Z/20/Z","description":"Two systems govern human behaviour: the \u2018habitual\u2019 system tends to repeat actions were previously rewarding, and the \u2018goal-directed\u2019 system relies on an understanding of how the world works in choosing the best action. Whilst there is evidence that this is true for simple actions (e.g. \u2018eat cake\u2019, \u2018lock door\u2019), we do not know if it holds when applied to goals (a collection of actions that work towards a goal, e.g. \u2018start a business\u2019). My research aims to investigate how we choose which goals to pursue.\n\nTo test whether the two systems above apply to goals, I aim to develop a new cognitive task that involves choices between actions and choices between goals, and study how these choices are controlled by the brain. I will use a combination of behavioural, neuroimaging, and neurochemical approaches to this end. I also aim to investigate whether there are differences in how goals are chosen between healthy individuals and patients with compulsive disorders including addiction and obsessive-compulsive disorder.\n\nThe broader goal of my research is to understand how the brain optimises both short-term and long-term behaviour, and potentially inform clinical models of compulsive disorders.\n","plannedDates":[{"endDate":"2023-09-27T00:00:00+00:00","startDate":"2020-09-28T00:00:00+00:00","startDateDateOnly":"2020-09-28","endDateDateOnly":"2023-09-27"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Yumeya Yamamori","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Yamamori","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Using hierarchical models of habitual and goal-directed decision-making to understand compulsive behaviour Two systems govern human behaviour: the \u2018habitual\u2019 system tends to repeat actions were previously rewarding, and the \u2018goal-directed\u2019 system relies on an understanding of how the world works in choosing the best action. Whilst there is evidence that this is true for simple actions (e.g. \u2018eat cake\u2019, \u2018lock door\u2019), we do not know if it holds when applied to goals (a collection of actions that work towards a goal, e.g. \u2018start a business\u2019). My research aims to investigate how we choose which goals to pursue.\n\nTo test whether the two systems above apply to goals, I aim to develop a new cognitive task that involves choices between actions and choices between goals, and study how these choices are controlled by the brain. I will use a combination of behavioural, neuroimaging, and neurochemical approaches to this end. I also aim to investigate whether there are differences in how goals are chosen between healthy individuals and patients with compulsive disorders including addiction and obsessive-compulsive disorder.\n\nThe broader goal of my research is to understand how the brain optimises both short-term and long-term behaviour, and potentially inform clinical models of compulsive disorders.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adult","Brain","Decision Making","Goals","Humans","Obsessive-Compulsive Disorder","Reward"]}
{"id":"360G-Wellcome-222266_Z_20_Z","title":"The effect of dominance status on hypothalamic processing of social stimuli","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222266/Z/20/Z","description":"Social hierarchies are ubiquitous among animals. They ensure efficient allocation of resources such as food, shelter, and mates, and reduce the need for physical confrontations within a group. Recent research has uncovered how representations of social status are learned and encoded in the brain, specifically in cortical areas. These representations of social status inform which social behaviours are shown by animals at different levels of hierarchy. For instance, subordinates are more likely to exhibit social avoidance and defensive behaviours such as fleeing, and show more restraint when presented with rewards. Despite these findings, it remains unclear how cortical representations of social status affect downstream areas that are more closely linked to controlling status-specific behaviours. My PhD project will investigate how cortical representations of dominance status affect the processing of social stimuli in hypothalamic areas, and how this leads to altered social behaviour in dominant vs. subordinate males. This work will help explain how social status is translated into appropriate social behaviour by specific brain circuits, and how dysregulation of these processes might contribute to maladaptive behaviours.\n","plannedDates":[{"endDate":"2023-09-27T00:00:00+00:00","startDate":"2020-09-28T00:00:00+00:00","startDateDateOnly":"2020-09-28","endDateDateOnly":"2023-09-27"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Mr Neven Borak","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Borak","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The effect of dominance status on hypothalamic processing of social stimuli Social hierarchies are ubiquitous among animals. They ensure efficient allocation of resources such as food, shelter, and mates, and reduce the need for physical confrontations within a group. Recent research has uncovered how representations of social status are learned and encoded in the brain, specifically in cortical areas. These representations of social status inform which social behaviours are shown by animals at different levels of hierarchy. For instance, subordinates are more likely to exhibit social avoidance and defensive behaviours such as fleeing, and show more restraint when presented with rewards. Despite these findings, it remains unclear how cortical representations of social status affect downstream areas that are more closely linked to controlling status-specific behaviours. My PhD project will investigate how cortical representations of dominance status affect the processing of social stimuli in hypothalamic areas, and how this leads to altered social behaviour in dominant vs. subordinate males. This work will help explain how social status is translated into appropriate social behaviour by specific brain circuits, and how dysregulation of these processes might contribute to maladaptive behaviours.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Behavior, Animal","Brain","Hierarchy, Social","Hypothalamus","Male","Reward","Social Behavior","Social Dominance"]}
{"id":"360G-Wellcome-222264_Z_20_Z","title":"Investigating mRNA transport granule composition and transport dynamics in motor neurons","Region":"Greater London","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222264/Z/20/Z","description":"Neurons transport messenger RNA (mRNA) over long distances within RNA transport granules, which are made of one or more mRNAs coated by RNA binding proteins (RBPs). It is thought that such granules bind directly to motor proteins for transport, however, recent studies show that they can \u2018hitchhike\u2019 onto intracellular organelles for indirect mobilisation. The overall goal of my PhD is to uncover how these two distinct pathways are integrated to ensure coordinated transport along neuronal axons. Moreover, I will determine how these pathways are affected in motor neuron disease (MND). Specifically, I will focus on the RBP named Staufen, which is an important component for RNA granule assembly and transport, and which has been suggested to contribute to MND onset and progression.\n\nI aim to identify the mRNAs transported via either route under normal conditions and in MND. I will use a novel method in which proteins representing each transport pathway are modified by an enzyme that \"tags\" nearby proteins. Tagged proteins and associated mRNAs can thus be identified and used to investigate RNA granule composition associated with each transport pathway in healthy and diseased neurons.\n","plannedDates":[{"endDate":"2023-09-27T00:00:00+00:00","startDate":"2020-09-28T00:00:00+00:00","startDateDateOnly":"2020-09-28","endDateDateOnly":"2023-09-27"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Reem Abouward","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Abouward","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating mRNA transport granule composition and transport dynamics in motor neurons Neurons transport messenger RNA (mRNA) over long distances within RNA transport granules, which are made of one or more mRNAs coated by RNA binding proteins (RBPs). It is thought that such granules bind directly to motor proteins for transport, however, recent studies show that they can \u2018hitchhike\u2019 onto intracellular organelles for indirect mobilisation. The overall goal of my PhD is to uncover how these two distinct pathways are integrated to ensure coordinated transport along neuronal axons. Moreover, I will determine how these pathways are affected in motor neuron disease (MND). Specifically, I will focus on the RBP named Staufen, which is an important component for RNA granule assembly and transport, and which has been suggested to contribute to MND onset and progression.\n\nI aim to identify the mRNAs transported via either route under normal conditions and in MND. I will use a novel method in which proteins representing each transport pathway are modified by an enzyme that \"tags\" nearby proteins. Tagged proteins and associated mRNAs can thus be identified and used to investigate RNA granule composition associated with each transport pathway in healthy and diseased neurons.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Humans","Motor Neuron Disease","Motor Neurons","RNA, Messenger","RNA-Binding Proteins"]}
{"id":"360G-Wellcome-222259_Z_20_Z","title":"Investigating Alzheimer\u2019s Disease risk genes in Drosophila melanogaster","Region":"Wales","currency":"GBP","awardDate":"2021-06-30T00:00:00+00:00","Internal ID":"222259/Z/20/Z","description":"Alzheimer\u2019s Disease (AD) is the most common form of dementia and over the last 10 years many genetic mutations have been identified that alter an individuals risk of developing the disease. In my research I will be using Drosophila melanogaster (fruit flies) to investigate genetic contributions to AD. I will manipulate levels of specific genes within the fly brain and investigate how this, in turn, effects levels of other genes throughout the brain using a technique called RNA sequencing. To complement this analysis, I will also be investigating the effects of such manipulations on behavioural traits associated with human AD, such as sleep and memory disturbances. Generating a greater understanding of these newly discovered risk genes will hopefully aid the pursuit for a successful therapeutic target.\n","plannedDates":[{"endDate":"2023-09-23T00:00:00+00:00","startDate":"2020-09-24T00:00:00+00:00","startDateDateOnly":"2020-09-24","endDateDateOnly":"2023-09-23"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Miss Hannah Clarke","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Clarke","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University","addressCountry":"United Kingdom","id_and_name":"[\"Cardiff University\", \"360G-Wellcome-ORG:Cardiff-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating Alzheimer\u2019s Disease risk genes in Drosophila melanogaster Alzheimer\u2019s Disease (AD) is the most common form of dementia and over the last 10 years many genetic mutations have been identified that alter an individuals risk of developing the disease. In my research I will be using Drosophila melanogaster (fruit flies) to investigate genetic contributions to AD. I will manipulate levels of specific genes within the fly brain and investigate how this, in turn, effects levels of other genes throughout the brain using a technique called RNA sequencing. To complement this analysis, I will also be investigating the effects of such manipulations on behavioural traits associated with human AD, such as sleep and memory disturbances. Generating a greater understanding of these newly discovered risk genes will hopefully aid the pursuit for a successful therapeutic target.\n","awardDateDateOnly":"2021-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Alzheimer Disease","Animals","Brain","Disease Models, Animal","Drosophila melanogaster"]}
{"id":"360G-Wellcome-222258_Z_20_Z","title":"Open Access Award 2020/21","Region":"South West","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222258/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":44293,"Financial Year":"2020/21","Lead Applicant":"Prof Lisa Roberts","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Roberts","Partnership Value":44293,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Exeter","name":"University of Exeter","addressCountry":"United Kingdom","id_and_name":"[\"University of Exeter\", \"360G-Wellcome-ORG:University-of-Exeter\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Exeter","name":"University of Exeter"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222253_Z_20_Z","title":"Open Access Award 2020/21","Region":"Scotland","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222253/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":10849,"Financial Year":"2020/21","Lead Applicant":"Prof Sally Mapstone","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Mapstone","Partnership Value":10849,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-St-Andrews","name":"University of St Andrews","addressCountry":"United Kingdom","id_and_name":"[\"University of St Andrews\", \"360G-Wellcome-ORG:University-of-St-Andrews\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-St-Andrews","name":"University of St Andrews"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222252_Z_20_Z","title":"Open Access Award 2020/21","Region":"Scotland","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222252/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":10925,"Financial Year":"2020/21","Lead Applicant":"Prof Jim McDonald","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"McDonald","Partnership Value":10925,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Strathclyde","name":"University of Strathclyde","addressCountry":"United Kingdom","id_and_name":"[\"University of Strathclyde\", \"360G-Wellcome-ORG:University-of-Strathclyde\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Strathclyde","name":"University of Strathclyde"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222251_Z_20_Z","title":"Open Access Award 2020/21","Region":"West Midlands","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222251/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":13297,"Financial Year":"2020/21","Lead Applicant":"Prof Trevor McMillan","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"McMillan","Partnership Value":13297,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Keele-University","name":"Keele University","addressCountry":"United Kingdom","id_and_name":"[\"Keele University\", \"360G-Wellcome-ORG:Keele-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Keele-University","name":"Keele University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222250_Z_20_Z","title":"Open Access Award 2020/21","Region":"Scotland","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222250/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":15762,"Financial Year":"2020/21","Lead Applicant":"Prof George Boyne","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Boyne","Partnership Value":15762,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Aberdeen","name":"University of Aberdeen","addressCountry":"United Kingdom","id_and_name":"[\"University of Aberdeen\", \"360G-Wellcome-ORG:University-of-Aberdeen\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Aberdeen","name":"University of Aberdeen"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222249_Z_20_Z","title":"Open Access Award 2020/21","Region":"Northern Ireland","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222249/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":28684,"Financial Year":"2020/21","Lead Applicant":"Prof Ian Greer","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Greer","Partnership Value":28684,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Queens-University-Belfast","name":"Queen's University Belfast","addressCountry":"United Kingdom","id_and_name":"[\"Queen's University Belfast\", \"360G-Wellcome-ORG:Queens-University-Belfast\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Queens-University-Belfast","name":"Queen's University Belfast"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222248_Z_20_Z","title":"Open Access Award 2020/21","Region":"Greater London","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222248/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":31761,"Financial Year":"2020/21","Lead Applicant":"Prof David Latchman","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Latchman","Partnership Value":31761,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Birkbeck-University-of-London","name":"Birkbeck University of London","addressCountry":"United Kingdom","id_and_name":"[\"Birkbeck University of London\", \"360G-Wellcome-ORG:Birkbeck-University-of-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Birkbeck-University-of-London","name":"Birkbeck University of London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222247_Z_20_Z","title":"Open Access Award 2020/21","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222247/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-11-02T00:00:00+00:00","startDate":"2020-11-03T00:00:00+00:00","startDateDateOnly":"2020-11-03","endDateDateOnly":"2021-11-02"}],"amountAwarded":38763,"Financial Year":"2020/21","Lead Applicant":"Prof Charlie Jeffery","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Jeffery","Partnership Value":38763,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-York","name":"University of York","addressCountry":"United Kingdom","id_and_name":"[\"University of York\", \"360G-Wellcome-ORG:University-of-York\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-York","name":"University of York"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222246_Z_20_Z","title":"Open Access Award 2020/21","Region":"West Midlands","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222246/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":41401,"Financial Year":"2020/21","Lead Applicant":"Prof Stuart Croft","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Croft","Partnership Value":41401,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Warwick","name":"University of Warwick","addressCountry":"United Kingdom","id_and_name":"[\"University of Warwick\", \"360G-Wellcome-ORG:University-of-Warwick\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Warwick","name":"University of Warwick"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222245_Z_20_Z","title":"Open Access Award 2020/21","Region":"East Midlands","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222245/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":41779,"Financial Year":"2020/21","Lead Applicant":"Prof Shearer West","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"West","Partnership Value":41779,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Nottingham","name":"University of Nottingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Nottingham\", \"360G-Wellcome-ORG:University-of-Nottingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Nottingham","name":"University of Nottingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222244_Z_20_Z","title":"Open Access Award 2020/21","Region":"South East","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222244/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":49187,"Financial Year":"2020/21","Lead Applicant":"Prof Adam Tickell","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Tickell","Partnership Value":49187,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Sussex","name":"University of Sussex","addressCountry":"United Kingdom","id_and_name":"[\"University of Sussex\", \"360G-Wellcome-ORG:University-of-Sussex\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Sussex","name":"University of Sussex"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222242_Z_20_Z","title":"Open Access Award 2020/21","Region":"Greater London","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222242/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":53493,"Financial Year":"2020/21","Lead Applicant":"Prof Paul Workman","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Workman","Partnership Value":53493,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Institute-of-Cancer-Research","name":"Institute of Cancer Research","addressCountry":"United Kingdom","id_and_name":"[\"Institute of Cancer Research\", \"360G-Wellcome-ORG:Institute-of-Cancer-Research\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Institute-of-Cancer-Research","name":"Institute of Cancer Research"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222241_Z_20_Z","title":"Open Access Award 2020/21","Region":"North West","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222241/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":60404,"Financial Year":"2020/21","Lead Applicant":"Prof David Lalloo","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Lalloo","Partnership Value":60404,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"Liverpool School of Tropical Medicine\", \"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222240_Z_20_Z","title":"Open Access Award 2020/21","Region":"Greater London","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222240/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":64793,"Financial Year":"2020/21","Lead Applicant":"Prof Colin Bailey","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Bailey","Partnership Value":64793,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Queen-Mary-University-of-London","name":"Queen Mary University of London","addressCountry":"United Kingdom","id_and_name":"[\"Queen Mary University of London\", \"360G-Wellcome-ORG:Queen-Mary-University-of-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Queen-Mary-University-of-London","name":"Queen Mary University of London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222239_Z_20_Z","title":"Open Access Award 2020/21","Region":"Wales","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222239/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":68557,"Financial Year":"2020/21","Lead Applicant":"Prof Colin Riordan","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Riordan","Partnership Value":68557,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University","addressCountry":"United Kingdom","id_and_name":"[\"Cardiff University\", \"360G-Wellcome-ORG:Cardiff-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222238_Z_20_Z","title":"Open Access Award 2020/21","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222238/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":80459,"Financial Year":"2020/21","Lead Applicant":"Prof Koen Lamberts","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Lamberts","Partnership Value":80459,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield","addressCountry":"United Kingdom","id_and_name":"[\"University of Sheffield\", \"360G-Wellcome-ORG:University-of-Sheffield\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222237_Z_20_Z","title":"Open Access Award 2020/21","Region":"North West","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222237/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":80561,"Financial Year":"2020/21","Lead Applicant":"Prof Janet Beer","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Beer","Partnership Value":80561,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool","addressCountry":"United Kingdom","id_and_name":"[\"University of Liverpool\", \"360G-Wellcome-ORG:University-of-Liverpool\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222236_Z_20_Z","title":"Open Access Award 2020/21","Region":"West Midlands","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222236/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":94276,"Financial Year":"2020/21","Lead Applicant":"Sir David Eastwood","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Eastwood","Partnership Value":94276,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Birmingham\", \"360G-Wellcome-ORG:University-of-Birmingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222235_Z_20_Z","title":"Open Access Award 2020/21","Region":"North East","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222235/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":111364,"Financial Year":"2020/21","Lead Applicant":"Prof Chris Day","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Day","Partnership Value":111364,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Newcastle-University","name":"Newcastle University","addressCountry":"United Kingdom","id_and_name":"[\"Newcastle University\", \"360G-Wellcome-ORG:Newcastle-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Newcastle-University","name":"Newcastle University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222234_Z_20_Z","title":"Open Access Award 2020/21","Region":"Scotland","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222234/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":139146,"Financial Year":"2020/21","Lead Applicant":"Prof Anton Muscatelli","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Muscatelli","Partnership Value":139146,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow","addressCountry":"United Kingdom","id_and_name":"[\"University of Glasgow\", \"360G-Wellcome-ORG:University-of-Glasgow\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222233_Z_20_Z","title":"Open Access Award 2020/21","Region":"North West","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222233/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":171317,"Financial Year":"2020/21","Lead Applicant":"Prof Nancy Rothwell","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Rothwell","Partnership Value":171317,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222232_Z_20_Z","title":"Open Access Award 2020/21","Region":"South West","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222232/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":183060,"Financial Year":"2020/21","Lead Applicant":"Prof Hugh Brady","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Brady","Partnership Value":183060,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222231_Z_20_Z","title":"Open Access Award 2020/21","Region":"Greater London","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222231/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":204330,"Financial Year":"2020/21","Lead Applicant":"Prof Peter Piot","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Piot","Partnership Value":204330,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"London School of Hygiene & Tropical Medicine\", \"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222230_Z_20_Z","title":"Open Access Award 2020/21","Region":"Greater London","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222230/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":345206,"Financial Year":"2020/21","Lead Applicant":"Prof Edward Byrne","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Byrne","Partnership Value":345206,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222229_Z_20_Z","title":"Open Access Award 2020/21","Region":"Greater London","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222229/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":370755,"Financial Year":"2020/21","Lead Applicant":"Prof Alice Gast","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Gast","Partnership Value":370755,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222228_Z_20_Z","title":"Open Access Award 2020/21","Region":"Scotland","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222228/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":404392,"Financial Year":"2020/21","Lead Applicant":"Prof Peter Mathieson","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Mathieson","Partnership Value":404392,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222227_Z_20_Z","title":"Open Access Award 2020/21","Region":"Greater London","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222227/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":763249,"Financial Year":"2020/21","Lead Applicant":"Prof Michael Arthur","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Arthur","Partnership Value":763249,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222226_Z_20_Z","title":"Open Access Award 2020/21","Region":"East of England","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222226/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":787552,"Financial Year":"2020/21","Lead Applicant":"Prof Stephen Toope","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Toope","Partnership Value":787552,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222225_Z_20_Z","title":"Open Access Award 2020/21","Region":"South East","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"222225/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":1043556,"Financial Year":"2020/21","Lead Applicant":"Prof Louise Richardson","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Richardson","Partnership Value":1043556,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2020/21 Not available","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-222218_Z_20_Z","title":"Young People as Changemakers on Issues of Climate and Health","Region":"Greater London","currency":"GBP","awardDate":"2020-10-28T00:00:00+00:00","Internal ID":"222218/Z/20/Z","description":"Restless Development will identify, train and empower 20 Young Leaders (18-24) in Zimbabwe, working in pairs across 10 rural and urban communities in 2 districts, to develop evidence based solutions to address the impacts of global heating on health. These Young Leaders will bring unique perspectives from the communities in which they live and work, first using a youth-led research methodology to develop evidence on current levels of young people and their community\u2019s knowledge and understanding of global heating and health as interconnected issues, then using that evidence to conduct global heating and health advocacy work to develop community-based solutions. Acting as agents of change, Young Leaders will translate knowledge and research to their communities in order to improve the knowledge of the global heating and health related issues. By the end of the 12 month initiative, the project will have investigated and tested different methods young people can use to increase the understanding of the links between global heating and health, the subsequent impact on their communities, and identified local solutions to identified challenges. \n","plannedDates":[{"endDate":"2021-11-04T00:00:00+00:00","startDate":"2020-11-05T00:00:00+00:00","startDateDateOnly":"2020-11-05","endDateDateOnly":"2021-11-04"}],"amountAwarded":149995,"Financial Year":"2020/21","Lead Applicant":"Miss Sabina Basi","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Basi","Partnership Value":149995,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Restless-Development","name":"Restless Development","addressCountry":"United Kingdom","id_and_name":"[\"Restless Development\", \"360G-Wellcome-ORG:Restless-Development\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Restless-Development","name":"Restless Development"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Young People as Changemakers on Issues of Climate and Health Restless Development will identify, train and empower 20 Young Leaders (18-24) in Zimbabwe, working in pairs across 10 rural and urban communities in 2 districts, to develop evidence based solutions to address the impacts of global heating on health. These Young Leaders will bring unique perspectives from the communities in which they live and work, first using a youth-led research methodology to develop evidence on current levels of young people and their community\u2019s knowledge and understanding of global heating and health as interconnected issues, then using that evidence to conduct global heating and health advocacy work to develop community-based solutions. Acting as agents of change, Young Leaders will translate knowledge and research to their communities in order to improve the knowledge of the global heating and health related issues. By the end of the 12 month initiative, the project will have investigated and tested different methods young people can use to increase the understanding of the links between global heating and health, the subsequent impact on their communities, and identified local solutions to identified challenges. \n","awardDateDateOnly":"2020-10-28","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adolescent","Humans","Rural Population","Zimbabwe"]}
{"id":"360G-Wellcome-222217_Z_20_Z","title":"Health Policy Watch Reporting on Covid-19","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"222217/Z/20/Z","description":"Reliable, evidence-based media remains a key means of advancing public health literacy and bringing news, views and opinions from diverse regions of the world into the corridors of power. The vision driving Health Policy Watch, launched in 2019 as an open-access, non-profit health news service, is to create a new \"network paradigm\" that connects the dots between policy trends and realities in the global North and South. We provide coverage across 5 key themes, including: infectious diseases; non-communicable diseases; antimicrobial resistance; climate and environmental health; and health emergencies.  \n\nThe key objective of this proposal is to foster a more balanced- and \"solutions\"-oriented approach to health policy dialogue around issues and choices that are critical to effective response to the COVID-19 pandemic - and to the broader global health agenda in light of COVID-19 realities. \n\nInstitutional sustainability is a second key objective. To realize its public service mission, Health Policy Watch is committed to ensuring that all potential readers can access our content free of charge.  As we work, with modest resources, to build a diverse array of donors and collaborations to advance that mission, Wellcome Trust support would empower us to develop a more sustainable and robust funding portfolio.\n","plannedDates":[{"endDate":"2021-10-11T00:00:00+00:00","startDate":"2020-10-12T00:00:00+00:00","startDateDateOnly":"2020-10-12","endDateDateOnly":"2021-10-11"}],"amountAwarded":240730,"Financial Year":"2019/20","Lead Applicant":"Dr Carolyn Deere Birkbeck","grantProgramme":[{"title":"Discretionary Award - Policy ","title_keyword":"Discretionary Award - Policy "}],"Applicant Surname":"Deere Birkbeck","Partnership Value":240730,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Global-Policy-Reporting","name":"Global Policy Reporting","addressCountry":"Switzerland","id_and_name":"[\"Global Policy Reporting\", \"360G-Wellcome-ORG:Global-Policy-Reporting\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Global-Policy-Reporting","name":"Global Policy Reporting"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Health Policy Watch Reporting on Covid-19 Reliable, evidence-based media remains a key means of advancing public health literacy and bringing news, views and opinions from diverse regions of the world into the corridors of power. The vision driving Health Policy Watch, launched in 2019 as an open-access, non-profit health news service, is to create a new \"network paradigm\" that connects the dots between policy trends and realities in the global North and South. We provide coverage across 5 key themes, including: infectious diseases; non-communicable diseases; antimicrobial resistance; climate and environmental health; and health emergencies.  \n\nThe key objective of this proposal is to foster a more balanced- and \"solutions\"-oriented approach to health policy dialogue around issues and choices that are critical to effective response to the COVID-19 pandemic - and to the broader global health agenda in light of COVID-19 realities. \n\nInstitutional sustainability is a second key objective. To realize its public service mission, Health Policy Watch is committed to ensuring that all potential readers can access our content free of charge.  As we work, with modest resources, to build a diverse array of donors and collaborations to advance that mission, Wellcome Trust support would empower us to develop a more sustainable and robust funding portfolio.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Global Health","Health Policy","Humans","Mass Media","Policy Making","Public Health"]}
{"id":"360G-Wellcome-222215_Z_20_Z","title":"WHO Antivenom Stockpile Programme PHASE 1","Region":"International","currency":"GBP","awardDate":"2021-01-29T00:00:00+00:00","Internal ID":"222215/Z/20/Z","description":"Sub-Saharan Africa has a high snakebite burden, compounded by a lack of safe, effective and affordable treatments that are accessible to victims. Across seven East African countries (Ethiopia, South Sudan, Uganda, Kenya, Tanzania, Rwanda and Burundi) there are an estimated 89,940 (95% Confidence Interval: 74,511-105,385) cases of snakebite each year, while in seven West African nations (Cameroon, Nigeria, Chad, Togo, Benin, Ghana and Burkina Faso) there are 70,712 (95% CI: 58,348-84,791) cases annually. Access to snake antivenoms for the treatment of snakebite envenoming in sub-Saharan Africa has been declining since at least the 1970\u2019s and current data provided to WHO suggests that  \n","plannedDates":[{"endDate":"2022-09-28T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2022-09-28"}],"amountAwarded":1485631,"Financial Year":"2020/21","Lead Applicant":"Dr Bernadette Abela-Ridder","grantProgramme":[{"title":"Discretionary Award - Snakebite","title_keyword":"Discretionary Award - Snakebite"}],"Applicant Surname":"Abela-Ridder","Partnership Value":1485631,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:World-Health-Organization-Switzerland","name":"World Health Organization, Switzerland","addressCountry":"Switzerland","id_and_name":"[\"World Health Organization, Switzerland\", \"360G-Wellcome-ORG:World-Health-Organization-Switzerland\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:World-Health-Organization-Switzerland","name":"World Health Organization, Switzerland"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"WHO Antivenom Stockpile Programme PHASE 1 Sub-Saharan Africa has a high snakebite burden, compounded by a lack of safe, effective and affordable treatments that are accessible to victims. Across seven East African countries (Ethiopia, South Sudan, Uganda, Kenya, Tanzania, Rwanda and Burundi) there are an estimated 89,940 (95% Confidence Interval: 74,511-105,385) cases of snakebite each year, while in seven West African nations (Cameroon, Nigeria, Chad, Togo, Benin, Ghana and Burkina Faso) there are 70,712 (95% CI: 58,348-84,791) cases annually. Access to snake antivenoms for the treatment of snakebite envenoming in sub-Saharan Africa has been declining since at least the 1970\u2019s and current data provided to WHO suggests that  \n","awardDateDateOnly":"2021-01-29","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adult","Africa South of the Sahara","Africa, Eastern","Antivenins","Female","Humans","Male","Snake Bites"]}
{"id":"360G-Wellcome-222213_Z_20_Z","title":"Understanding the evolution of pathology after traumatic brain injury using advanced magnetic resonance imaging","Region":"East of England","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"222213/Z/20/Z","description":"Traumatic brain injuries result from falls, road traffic collisions, assaults or military activities. They are expected to affect every second person at some point in their lives and are a major cause of disability and death. Different people\u2019s brains seem to react differently to similar injuries. Some people recover whilst others continue to deteriorate even after the initial event, for example by developing early-onset dementia. We plan to use magnetic resonance images to study how the structure of the brain changes in the days to years after injury. The types of images we use (in particular diffusion tensor imaging) can reveal fine details that are invisible on conventional imaging. We will study approximately 1000 patients who had repeated scans from 72h to two years after injury, which is the largest database of its kind. Importantly, we will not assume that everyone\u2019s brain is the same but will strive to identify sub-types of response to injury. We will then compare how these structural changes relate to patients\u2019 symptoms and see if we can predict early after injury which recovery trajectory a patient is likely to follow.\n","plannedDates":[{"endDate":"2022-08-30T00:00:00+00:00","startDate":"2019-05-01T00:00:00+00:00","startDateDateOnly":"2019-05-01","endDateDateOnly":"2022-08-30"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Sophie Richter","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Richter","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding the evolution of pathology after traumatic brain injury using advanced magnetic resonance imaging Traumatic brain injuries result from falls, road traffic collisions, assaults or military activities. They are expected to affect every second person at some point in their lives and are a major cause of disability and death. Different people\u2019s brains seem to react differently to similar injuries. Some people recover whilst others continue to deteriorate even after the initial event, for example by developing early-onset dementia. We plan to use magnetic resonance images to study how the structure of the brain changes in the days to years after injury. The types of images we use (in particular diffusion tensor imaging) can reveal fine details that are invisible on conventional imaging. We will study approximately 1000 patients who had repeated scans from 72h to two years after injury, which is the largest database of its kind. Importantly, we will not assume that everyone\u2019s brain is the same but will strive to identify sub-types of response to injury. We will then compare how these structural changes relate to patients\u2019 symptoms and see if we can predict early after injury which recovery trajectory a patient is likely to follow.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Brain","Brain Injuries, Traumatic","Diffusion Tensor Imaging","Humans","Magnetic Resonance Imaging"]}
{"id":"360G-Wellcome-222203_Z_20_Z","title":"Ethics and British public health law, 1920-2020","Region":"Greater London","currency":"GBP","awardDate":"2021-01-19T00:00:00+00:00","Sponsor(s)":"Prof Kara Hanson","Internal ID":"222203/Z/20/Z","description":"This research will investigate the ethics of British public health over the period 1920-2020, through the lens of public health law. In so doing, it will develop the \u2018public health humanities\u2019 as a mode of designing and implementing interdisciplinary research in public health. My goals are to discover how the implicit and explicit ethical frameworks of public health law have changed over the period in question; to analyse how and why these changes came about; and to explore methods for investigating public health ethics from interdisciplinary perspectives. I will use documentary and archival sources to locate and interrogate moments of morally inflected controversy in public health law, and will work collaboratively with public health practitioners and researchers to explore novel methods of data generation and analysis. Attention to ethics and public health law in Britain 1920-2020 disrupts assumptions that ethics in this time and place has been neutral and unchanging, and examines relationships between shifting ethical frameworks and factors including the post-war welfare state and its subsequent roll-back, decolonisation, migration, epidemiology, HIV/AIDS, and bioethics. The project will historicise ethics, connect past and present, and provoke cross-disciplinary interrogation and integration, for the benefit of the humanities and public health alike.\n \n","plannedDates":[{"endDate":"2026-05-09T00:00:00+00:00","startDate":"2021-05-10T00:00:00+00:00","startDateDateOnly":"2021-05-10","endDateDateOnly":"2026-05-09"}],"amountAwarded":325774,"Financial Year":"2020/21","Lead Applicant":"Dr Janet Weston","grantProgramme":[{"title":"University Award in H&SS","title_keyword":"University Award in H&SS"}],"Applicant Surname":"Weston","Partnership Value":325774,"Approval Committee":"Medical Humanities Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"London School of Hygiene & Tropical Medicine\", \"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Ethics and British public health law, 1920-2020 This research will investigate the ethics of British public health over the period 1920-2020, through the lens of public health law. In so doing, it will develop the \u2018public health humanities\u2019 as a mode of designing and implementing interdisciplinary research in public health. My goals are to discover how the implicit and explicit ethical frameworks of public health law have changed over the period in question; to analyse how and why these changes came about; and to explore methods for investigating public health ethics from interdisciplinary perspectives. I will use documentary and archival sources to locate and interrogate moments of morally inflected controversy in public health law, and will work collaboratively with public health practitioners and researchers to explore novel methods of data generation and analysis. Attention to ethics and public health law in Britain 1920-2020 disrupts assumptions that ethics in this time and place has been neutral and unchanging, and examines relationships between shifting ethical frameworks and factors including the post-war welfare state and its subsequent roll-back, decolonisation, migration, epidemiology, HIV/AIDS, and bioethics. The project will historicise ethics, connect past and present, and provoke cross-disciplinary interrogation and integration, for the benefit of the humanities and public health alike.\n \n","awardDateDateOnly":"2021-01-19","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["History, 20th Century","Humans","Public Health","United Kingdom"]}
{"id":"360G-Wellcome-222199_Z_20_Z","title":"Mobilized, recruited, conscripted? Leveraging community health work, citizenship and public authority in northern Kenya","Region":"Scotland","currency":"GBP","awardDate":"2021-01-19T00:00:00+00:00","Sponsor(s)":"Dr Thomas Molony","Internal ID":"222199/Z/20/Z","description":"Who delivers health care, where and why? The COVID-19 pandemic has underscored stark global inequalities in answers to these questions. \u2018Community participation\u2019, an enduring pillar of interventions in the Global South, has been leveraged in response to COVID in Africa via Community Health Workers (CHWs). Key agencies who recruit Africa\u2019s army of Community Health Workers (CHWs) have declared them to be COVID\u2019s emerging \u2018first line of defence\u2019. This research will examine the structural factors that lead to the recruitment of CHWs and which contribute to the persistent undervaluing of CHWs\u2019 work in Kenya. The research will innovate in its combination of discourse analysis, informed by critical/feminist/postcolonial thought, with detailed ethnographic fieldwork in Kenya's marginalized north. The research will firstly provide a critical reading of the \u2018imperial remains\u2019 within CHW recruitment practices on the part of health agencies and INGOs. The research will secondly provide a historicized reading of (gendered) narratives regarding citizenship, public service and voluntarism in postcolonial Kenya. This research will then be brought into dialogue with detailed interviews with and ethnography of/by CHWs in Isiolo, northern Kenya, with implications for CHW policy but also for rethinking the desirability and justness of one of global health\u2019s core assumptions.\n","plannedDates":[{"endDate":"2024-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2024-03-31"}],"amountAwarded":263061,"Financial Year":"2020/21","Lead Applicant":"Dr Kathy Dodworth","grantProgramme":[{"title":"Research Fellowship in H&SS","title_keyword":"Research Fellowship in H&SS"}],"Applicant Surname":"Dodworth","Partnership Value":263061,"Approval Committee":"Social Science and Bioethics Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mobilized, recruited, conscripted? Leveraging community health work, citizenship and public authority in northern Kenya Who delivers health care, where and why? The COVID-19 pandemic has underscored stark global inequalities in answers to these questions. \u2018Community participation\u2019, an enduring pillar of interventions in the Global South, has been leveraged in response to COVID in Africa via Community Health Workers (CHWs). Key agencies who recruit Africa\u2019s army of Community Health Workers (CHWs) have declared them to be COVID\u2019s emerging \u2018first line of defence\u2019. This research will examine the structural factors that lead to the recruitment of CHWs and which contribute to the persistent undervaluing of CHWs\u2019 work in Kenya. The research will innovate in its combination of discourse analysis, informed by critical/feminist/postcolonial thought, with detailed ethnographic fieldwork in Kenya's marginalized north. The research will firstly provide a critical reading of the \u2018imperial remains\u2019 within CHW recruitment practices on the part of health agencies and INGOs. The research will secondly provide a historicized reading of (gendered) narratives regarding citizenship, public service and voluntarism in postcolonial Kenya. This research will then be brought into dialogue with detailed interviews with and ethnography of/by CHWs in Isiolo, northern Kenya, with implications for CHW policy but also for rethinking the desirability and justness of one of global health\u2019s core assumptions.\n","awardDateDateOnly":"2021-01-19","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anthropology, Cultural","Community Health Workers","Female","Humans","Kenya","Male"]}
{"id":"360G-Wellcome-222193_Z_20_Z","title":"Interactions between Cognitive Impairment & Transport in Urban Environments (IN-CITU)","Region":"North West","currency":"GBP","awardDate":"2021-01-19T00:00:00+00:00","Sponsor(s)":"Dr Andrew Balmer","Internal ID":"222193/Z/20/Z","description":"Novel social and cognitive science, approaching people and places as indivisible assemblages, challenges dementia research\u2019s traditional humanism (people as exceptional entities) and neuroreductionism (brains as cognitive supercomputers). However, these traditional ideas permeate current \"dementia-friendly\" strategies, positing that agentic persons inhabit inactive spaces. Resulting initiatives assume that architectural refinement will maximise individuals\u2019 intrinsic cognitive capacities, overlooking the complex distribution of cognition throughout evolving atmospheric spaces. They often lack user perspectives and sophisticated theoretical grounding. In response, I will combine cutting-edge scholarships to explore cognition-environment relations through a sensory ethnography of Manchester\u2019s public transport, a target for dementia-friendly initiatives. I will accompany 25 passengers with dementia, documenting the journeys through interviewing, fieldnotes, photography and mapping. Participants will capture photographs and videos for an exhibition across the transport network. The exceptionally rich dataset, comprised of audio-visual media, sensory ethnographic data and maps, will be made available to future researchers. The project will challenge outdated assumptions in dementia research and policy, developing proposals for improving each. It aligns with policy priorities and will propose service improvements in collaboration with key stakeholders. It will generate an unprecedented open-access dataset for analysing dementia-friendliness and cognition-environment relations, and pioneer methods for inclusive ecological dementia research.\n","plannedDates":[{"endDate":"2024-02-29T00:00:00+00:00","startDate":"2021-03-01T00:00:00+00:00","startDateDateOnly":"2021-03-01","endDateDateOnly":"2024-02-29"}],"amountAwarded":175664,"Financial Year":"2020/21","Lead Applicant":"Dr James Fletcher","grantProgramme":[{"title":"Research Fellowship in H&SS","title_keyword":"Research Fellowship in H&SS"}],"Applicant Surname":"Fletcher","Partnership Value":175664,"Approval Committee":"Social Science and Bioethics Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Interactions between Cognitive Impairment & Transport in Urban Environments (IN-CITU) Novel social and cognitive science, approaching people and places as indivisible assemblages, challenges dementia research\u2019s traditional humanism (people as exceptional entities) and neuroreductionism (brains as cognitive supercomputers). However, these traditional ideas permeate current \"dementia-friendly\" strategies, positing that agentic persons inhabit inactive spaces. Resulting initiatives assume that architectural refinement will maximise individuals\u2019 intrinsic cognitive capacities, overlooking the complex distribution of cognition throughout evolving atmospheric spaces. They often lack user perspectives and sophisticated theoretical grounding. In response, I will combine cutting-edge scholarships to explore cognition-environment relations through a sensory ethnography of Manchester\u2019s public transport, a target for dementia-friendly initiatives. I will accompany 25 passengers with dementia, documenting the journeys through interviewing, fieldnotes, photography and mapping. Participants will capture photographs and videos for an exhibition across the transport network. The exceptionally rich dataset, comprised of audio-visual media, sensory ethnographic data and maps, will be made available to future researchers. The project will challenge outdated assumptions in dementia research and policy, developing proposals for improving each. It aligns with policy priorities and will propose service improvements in collaboration with key stakeholders. It will generate an unprecedented open-access dataset for analysing dementia-friendliness and cognition-environment relations, and pioneer methods for inclusive ecological dementia research.\n","awardDateDateOnly":"2021-01-19","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anthropology, Cultural","Cognition","Dementia","Humans","Photography"]}
{"id":"360G-Wellcome-222192_Z_20_Z","title":"The Art of Colonial Medicine: Visual Cultures of Malaria in India, 1890-1940","Region":"South East","currency":"GBP","awardDate":"2021-01-19T00:00:00+00:00","Sponsor(s)":"Dr Rohan Deb Roy","Internal ID":"222192/Z/20/Z","description":"My project will investigate images (drawings, illustrations, and photographs) as central to scientific research into causes of the disease and the mechanisms of its spread in British India between 1890 and 1940. Despite Ronald Ross\u2019 own emphasis that his experiments on malaria were visual revelations, visual representations of malaria have remained neglected in historiography so far. I intend to explore how images informed research on malaria and influenced future inquiries into the development of tropical medicine and the processes of their institutionalisation. This project enriches the scholarship on malaria in colonial India by bringing into focus the importance of visuality in knowledge-making. This will facilitate an exploration of the power of images in strengthening, as well as shaping resistance to British imperialism; and also how medical visual culture gave meaning to human-animal relationships within an imperial context. In so doing, beginning with scientific images produced in the laboratory, I move into the domains of British administration and that of the vernacular reception, translation, and appropriation of the malarial iconography. By examining the interactions between the fields of arts and medical science, this project will be a major contribution to the historiographies of British colonial medicine and modern South Asia.\n","plannedDates":[{"endDate":"2024-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2024-08-31"}],"amountAwarded":161826,"Financial Year":"2020/21","Lead Applicant":"Dr Apurba Chatterjee","grantProgramme":[{"title":"Research Fellowship in H&SS","title_keyword":"Research Fellowship in H&SS"}],"Applicant Surname":"Chatterjee","Partnership Value":161826,"Approval Committee":"Medical Humanities Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Reading","name":"University of Reading","addressCountry":"United Kingdom","id_and_name":"[\"University of Reading\", \"360G-Wellcome-ORG:University-of-Reading\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Reading","name":"University of Reading"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The Art of Colonial Medicine: Visual Cultures of Malaria in India, 1890-1940 My project will investigate images (drawings, illustrations, and photographs) as central to scientific research into causes of the disease and the mechanisms of its spread in British India between 1890 and 1940. Despite Ronald Ross\u2019 own emphasis that his experiments on malaria were visual revelations, visual representations of malaria have remained neglected in historiography so far. I intend to explore how images informed research on malaria and influenced future inquiries into the development of tropical medicine and the processes of their institutionalisation. This project enriches the scholarship on malaria in colonial India by bringing into focus the importance of visuality in knowledge-making. This will facilitate an exploration of the power of images in strengthening, as well as shaping resistance to British imperialism; and also how medical visual culture gave meaning to human-animal relationships within an imperial context. In so doing, beginning with scientific images produced in the laboratory, I move into the domains of British administration and that of the vernacular reception, translation, and appropriation of the malarial iconography. By examining the interactions between the fields of arts and medical science, this project will be a major contribution to the historiographies of British colonial medicine and modern South Asia.\n","awardDateDateOnly":"2021-01-19","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","History, 20th Century","Humans","India","Malaria","United Kingdom"]}
{"id":"360G-Wellcome-222191_Z_20_Z","title":"The Child's Speech: speech therapy, stammering, and activism in Britain, 1906-2000","Region":"West Midlands","currency":"GBP","awardDate":"2021-01-19T00:00:00+00:00","Sponsor(s)":"Prof Mathew Thomson","Internal ID":"222191/Z/20/Z","description":"This project will produce a cultural and social history of speech therapy in twentieth-century Britain that is ambitious in seeking to account for the entwined relationship of speech therapy to stammering activism, not simply in a relationship of medical professional to patient. Municipalities employed speech therapists from c.1906 to \u2018correct\u2019 what (in contemporary language) were considered \u2018defects\u2019 of children\u2019s speech. Early therapists were often female, trained in drama-school elocution and only later became medicalised. Consequently, they were as marginalised as the disabled subjects they sought to \u2018treat\u2019. Conversely, individuals who stammered long pointed towards the uniqueness of their position and voice to militate for improved therapy. In short, this project allows an ambitious study that cuts across normally polarised voices of \u2018medical professional\u2019 and \u2018patient experience\u2019 to explore the boundaries of what encompasses \u2018the medical\u2019 itself: both as practices (elocution therapeutics and activism) and as theories (what \u2018stammering\u2019 meant). \u2018The Child\u2019s Speech\u2019 therefore offers a unique case study into the margins of disability studies which can point towards new frameworks for thinking about professionalisation; its relationship to competing, but also harmonising, forms of expertise, patient voice, experience and activism; and wider gender, race, class and disability dynamics within these.\n","plannedDates":[{"endDate":"2024-04-30T00:00:00+00:00","startDate":"2021-05-01T00:00:00+00:00","startDateDateOnly":"2021-05-01","endDateDateOnly":"2024-04-30"}],"amountAwarded":154510,"Financial Year":"2020/21","Lead Applicant":"Dr Andrew Burchell","grantProgramme":[{"title":"Research Fellowship in H&SS","title_keyword":"Research Fellowship in H&SS"}],"Applicant Surname":"Burchell","Partnership Value":154510,"Approval Committee":"Medical Humanities Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Warwick","name":"University of Warwick","addressCountry":"United Kingdom","id_and_name":"[\"University of Warwick\", \"360G-Wellcome-ORG:University-of-Warwick\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Warwick","name":"University of Warwick"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The Child's Speech: speech therapy, stammering, and activism in Britain, 1906-2000 This project will produce a cultural and social history of speech therapy in twentieth-century Britain that is ambitious in seeking to account for the entwined relationship of speech therapy to stammering activism, not simply in a relationship of medical professional to patient. Municipalities employed speech therapists from c.1906 to \u2018correct\u2019 what (in contemporary language) were considered \u2018defects\u2019 of children\u2019s speech. Early therapists were often female, trained in drama-school elocution and only later became medicalised. Consequently, they were as marginalised as the disabled subjects they sought to \u2018treat\u2019. Conversely, individuals who stammered long pointed towards the uniqueness of their position and voice to militate for improved therapy. In short, this project allows an ambitious study that cuts across normally polarised voices of \u2018medical professional\u2019 and \u2018patient experience\u2019 to explore the boundaries of what encompasses \u2018the medical\u2019 itself: both as practices (elocution therapeutics and activism) and as theories (what \u2018stammering\u2019 meant). \u2018The Child\u2019s Speech\u2019 therefore offers a unique case study into the margins of disability studies which can point towards new frameworks for thinking about professionalisation; its relationship to competing, but also harmonising, forms of expertise, patient voice, experience and activism; and wider gender, race, class and disability dynamics within these.\n","awardDateDateOnly":"2021-01-19","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Child","Female","Humans","Speech Therapy","United Kingdom"]}
{"id":"360G-Wellcome-222187_Z_20_Z","title":" Care, infrastructures and antiblackness: the making of biomedicine in a Sierra Leonean hospital ","Region":"North West","currency":"GBP","awardDate":"2021-01-19T00:00:00+00:00","Sponsor(s)":"Dr Andrew Davies","Internal ID":"222187/Z/20/Z","description":"The research project offers an in-depth analysis of the conflation between biomedical practice, care and antiblackness in the colonial wake. Using historical, geographic and ethnographic methods, it examines how the history of enslavement and colonialism is entangled with notions and practices of Western biomedical care and the spatial organisation of a postcolonial hospital. As a location for this study I have chosen Connaught Hospital in Freetown, Sierra Leone. Situated on Freetown's Northern coast between White Man's Bay and Susan's Bay, this was both the setting for mandatory quarantines for liberated slaves and the site of the British-built Colonial Hospital. Working with Sierra Leonean healthcare staff, I will examine the hold this violent past has on Sierra Leonean conceptions of care and trust in biomedicine. This allows me to 1) explore how biomedicine's conflation with antiblackness shapes biomedical encounters in postcolonial Sierra Leone and 2) examine how biomedical spaces and infrastructures perpetuate feelings of distrust and exclude other forms of care. In doing so I will 1) challenge the traditional geographical remit of Black Studies, 2) study how antiblackness weaves its way through medicine and care and 3) give Fanon's analyses of colonialism, racism and biomedicine a contemporary  &  geographic dimension.\n","plannedDates":[{"endDate":"2023-04-05T00:00:00+00:00","startDate":"2020-04-06T00:00:00+00:00","startDateDateOnly":"2020-04-06","endDateDateOnly":"2023-04-05"}],"amountAwarded":210087,"Financial Year":"2020/21","Lead Applicant":"Dr Lioba Hirsch","grantProgramme":[{"title":"Research Fellowship in H&SS","title_keyword":"Research Fellowship in H&SS"}],"Applicant Surname":"Hirsch","Partnership Value":210087,"Approval Committee":"Medical Humanities Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool","addressCountry":"United Kingdom","id_and_name":"[\"University of Liverpool\", \"360G-Wellcome-ORG:University-of-Liverpool\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool"}},"filename":"a001p00000xQ047AAC.json","title_and_description":" Care, infrastructures and antiblackness: the making of biomedicine in a Sierra Leonean hospital  The research project offers an in-depth analysis of the conflation between biomedical practice, care and antiblackness in the colonial wake. Using historical, geographic and ethnographic methods, it examines how the history of enslavement and colonialism is entangled with notions and practices of Western biomedical care and the spatial organisation of a postcolonial hospital. As a location for this study I have chosen Connaught Hospital in Freetown, Sierra Leone. Situated on Freetown's Northern coast between White Man's Bay and Susan's Bay, this was both the setting for mandatory quarantines for liberated slaves and the site of the British-built Colonial Hospital. Working with Sierra Leonean healthcare staff, I will examine the hold this violent past has on Sierra Leonean conceptions of care and trust in biomedicine. This allows me to 1) explore how biomedicine's conflation with antiblackness shapes biomedical encounters in postcolonial Sierra Leone and 2) examine how biomedical spaces and infrastructures perpetuate feelings of distrust and exclude other forms of care. In doing so I will 1) challenge the traditional geographical remit of Black Studies, 2) study how antiblackness weaves its way through medicine and care and 3) give Fanon's analyses of colonialism, racism and biomedicine a contemporary  &  geographic dimension.\n","awardDateDateOnly":"2021-01-19","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anthropology, Cultural","History, 20th Century","Humans","Racism","Sierra Leone","Trust"]}
{"id":"360G-Wellcome-222186_Z_20_Z","title":"Enabling Research Excellence by sharing between Diseases, Organisations and Regions","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"222186/Z/20/Z","description":"In low-income countries there remains a lack of internationally competitive research leaders. The Global Health Network has analysed the barriers and enablers to health research and show that typical approaches to capability building have not delivered long-term capabilities that foster internationally competitive teams. The Network has built a novel mechanism to address this which works across all types of study, disease areas and organisations to share know-how and deliver training, guidance and methods using a digital platform alongside local programmes. The success and impact that arise from this combination of cross-cutting knowledge exchange and research capability building together provide a strong research enabling platform. This active exchange of knowledge, tools and processes is increasing quality and driving efficiency in health research. The Network is driving better methods, new skills and supporting career development through the creation of active communities of practice. These capacity building, methodology research activities and delivery costs cannot be met by our project-specific funding for knowledge exchange, yet these elements deliver success and impact by bringing the research community together. This application is part of our long-term strategic development plan that sets out to further develop our unique and impactful approach for which we require consortia funding.\n","plannedDates":[{"endDate":"2021-10-31T00:00:00+00:00","startDate":"2020-11-01T00:00:00+00:00","startDateDateOnly":"2020-11-01","endDateDateOnly":"2021-10-31"}],"amountAwarded":250000,"Financial Year":"2019/20","Lead Applicant":"Prof Trudie Lang","grantProgramme":[{"title":"Discretionary Award - Policy ","title_keyword":"Discretionary Award - Policy "}],"Applicant Surname":"Lang","Partnership Value":250000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Enabling Research Excellence by sharing between Diseases, Organisations and Regions In low-income countries there remains a lack of internationally competitive research leaders. The Global Health Network has analysed the barriers and enablers to health research and show that typical approaches to capability building have not delivered long-term capabilities that foster internationally competitive teams. The Network has built a novel mechanism to address this which works across all types of study, disease areas and organisations to share know-how and deliver training, guidance and methods using a digital platform alongside local programmes. The success and impact that arise from this combination of cross-cutting knowledge exchange and research capability building together provide a strong research enabling platform. This active exchange of knowledge, tools and processes is increasing quality and driving efficiency in health research. The Network is driving better methods, new skills and supporting career development through the creation of active communities of practice. These capacity building, methodology research activities and delivery costs cannot be met by our project-specific funding for knowledge exchange, yet these elements deliver success and impact by bringing the research community together. This application is part of our long-term strategic development plan that sets out to further develop our unique and impactful approach for which we require consortia funding.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Capacity Building","Developing Countries","Financing, Organized","Global Health","Humans","Research Support as Topic"]}
{"id":"360G-Wellcome-222180_Z_20_Z","title":"The environmental sustainability of data-driven health research: a case-study of genomics and digital phenotyping in the UK","Region":"Greater London","currency":"GBP","awardDate":"2021-01-19T00:00:00+00:00","Sponsor(s)":"Prof Karen Glaser","Internal ID":"222180/Z/20/Z","description":"Data-driven health research, and the technologies it produces (DHRTs), are increasingly driving the UK health sector. DHRTs, which rely on advanced computing sciences and \u2018big data\u2019, have the potential to make a profound impact on society, and the pace of development is staggering. Equally, the databases, infrastructures, and software supporting DHRTs have important environmental and health impacts: their heavy energy requirements lead to high carbon dioxide emissions, and the reliance on minerals to develop their technological components can lead to unsustainable and/or toxic mineral extraction and e-waste disposal. While the environmental footprint of DHRTs may be considered unproblematic because of improvements in energy efficiency and the move to renewable energy, the speed of innovation is set to outpace the world\u2019s renewable energy sources, leading to increases in carbon emissions when other sectors are decreasing their energy use. Moreover, issues of unsustainable mineral extraction/e-waste disposal still remain. It is imperative that the environmental footprint of DHRTs is considered through responsible innovation that targets environmental sustainability. This project\u2019s aim is to use a UK perspective, qualitative case-study approach, that builds an empirical knowledge base that identifies the ethical, social and regulatory issues associated with DHRT\u2019s environmental impacts.\n","plannedDates":[{"endDate":"2026-08-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2026-08-31"}],"amountAwarded":246365,"Financial Year":"2020/21","Lead Applicant":"Dr Gabrielle Samuel","grantProgramme":[{"title":"Research Fellowship in H&SS","title_keyword":"Research Fellowship in H&SS"}],"Applicant Surname":"Samuel","Partnership Value":246365,"Approval Committee":"Social Science and Bioethics Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The environmental sustainability of data-driven health research: a case-study of genomics and digital phenotyping in the UK Data-driven health research, and the technologies it produces (DHRTs), are increasingly driving the UK health sector. DHRTs, which rely on advanced computing sciences and \u2018big data\u2019, have the potential to make a profound impact on society, and the pace of development is staggering. Equally, the databases, infrastructures, and software supporting DHRTs have important environmental and health impacts: their heavy energy requirements lead to high carbon dioxide emissions, and the reliance on minerals to develop their technological components can lead to unsustainable and/or toxic mineral extraction and e-waste disposal. While the environmental footprint of DHRTs may be considered unproblematic because of improvements in energy efficiency and the move to renewable energy, the speed of innovation is set to outpace the world\u2019s renewable energy sources, leading to increases in carbon emissions when other sectors are decreasing their energy use. Moreover, issues of unsustainable mineral extraction/e-waste disposal still remain. It is imperative that the environmental footprint of DHRTs is considered through responsible innovation that targets environmental sustainability. This project\u2019s aim is to use a UK perspective, qualitative case-study approach, that builds an empirical knowledge base that identifies the ethical, social and regulatory issues associated with DHRT\u2019s environmental impacts.\n","awardDateDateOnly":"2021-01-19","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Environment","Environmental Health","Genomics","Humans","Research","United Kingdom"]}
{"id":"360G-Wellcome-222177_Z_20_Z","title":"Multimorbidity and Knowledge Architectures: An Interdisciplinary Global Health Collaboration","Region":"Greater London","currency":"GBP","awardDate":"2021-01-19T00:00:00+00:00","Sponsor(s)":"Prof Clare Chandler","Internal ID":"222177/Z/20/Z","description":"As people live longer, the coexistence of multiple conditions in one individual \u2013 \u2018multimorbidity\u2019 \u2013 becomes more common. Scholars across the biomedical sciences have expressed concern that research, training and care systems remain organised along single-disease and single-organ-system lines and that new ways of producing knowledge about multimorbidity are needed. Medical anthropologists, with well-established strengths in illuminating and unsettling dominant frameworks, are ideally equipped to collaborate with biomedical scientists to articulate and respond to the challenge posed by multimorbidity. Using the analytic frame of \u2018epistemic infrastructures\u2019, referring here to the fragmented global assemblages through which knowledge about (multi)morbidity is produced and legitimised, I will investigate how individuals in different settings and communities of practice understand and engage with multimorbidity. Further, I will co-produce with them a conceptual framework for responding to this complex bio-social phenomenon. To achieve this, I propose a collaborative multi-site ethnographic study in global health institutions in the UK and research, training and care institutions in Zimbabwe, involving participant-observation, in-depth interviews and participatory methods. These activities, culminating in a symposium, will iteratively build the proposed framework. By involving biomedical researchers throughout, my research will be uniquely positioned to open new pathways to influence research, policy and care.\n","plannedDates":[{"endDate":"2024-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2024-03-31"}],"amountAwarded":276979,"Financial Year":"2020/21","Lead Applicant":"Dr Justin Dixon","grantProgramme":[{"title":"Research Fellowship in H&SS","title_keyword":"Research Fellowship in H&SS"}],"Applicant Surname":"Dixon","Partnership Value":276979,"Approval Committee":"Social Science and Bioethics Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"London School of Hygiene & Tropical Medicine\", \"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Multimorbidity and Knowledge Architectures: An Interdisciplinary Global Health Collaboration As people live longer, the coexistence of multiple conditions in one individual \u2013 \u2018multimorbidity\u2019 \u2013 becomes more common. Scholars across the biomedical sciences have expressed concern that research, training and care systems remain organised along single-disease and single-organ-system lines and that new ways of producing knowledge about multimorbidity are needed. Medical anthropologists, with well-established strengths in illuminating and unsettling dominant frameworks, are ideally equipped to collaborate with biomedical scientists to articulate and respond to the challenge posed by multimorbidity. Using the analytic frame of \u2018epistemic infrastructures\u2019, referring here to the fragmented global assemblages through which knowledge about (multi)morbidity is produced and legitimised, I will investigate how individuals in different settings and communities of practice understand and engage with multimorbidity. Further, I will co-produce with them a conceptual framework for responding to this complex bio-social phenomenon. To achieve this, I propose a collaborative multi-site ethnographic study in global health institutions in the UK and research, training and care institutions in Zimbabwe, involving participant-observation, in-depth interviews and participatory methods. These activities, culminating in a symposium, will iteratively build the proposed framework. By involving biomedical researchers throughout, my research will be uniquely positioned to open new pathways to influence research, policy and care.\n","awardDateDateOnly":"2021-01-19","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biomedical Research","Global Health","Humans","Multimorbidity","United Kingdom","Zimbabwe"]}
{"id":"360G-Wellcome-222175_Z_20_Z","title":"A Healthy Approach to Grief: The Emotional, Material, and Sensory History of Grief and Loss in Late-Georgian Britain, c. 1760-1830","Region":"East Midlands","currency":"GBP","awardDate":"2021-01-19T00:00:00+00:00","Sponsor(s)":"Prof Roey Sweet","Internal ID":"222175/Z/20/Z","description":"This project will produce a history of grief and loss in late-Georgian Britain (c.1760-1830) that re-evaluates current perceptions of grief as unhealthy, and will redress the imbalance in historical and literary studies that have focused overwhelmingly on assessments of bereavement, mourning and mortuary rituals. It will recover the full range of Georgian experiences of grief to show how understandings of grief extended far beyond the immediate emotional upheaval associated with death, encompassing much wider definitions than those we attribute to grief today. Grief awarded meaning to interpersonal relationships, offerering avenues for self-reflection and providing comfort during periods of separation. This project will apply historical and literary research techniques to a linguistic and material culture analysis of grief, and engage with research in psychology, sociology and philosophy. It will interrogate grief across three main themes: Sadness and Separation; Bereavement; Loss and Abandonment \u2013 which are embedded within acts of resilience, remembrance and recovery. The main goals of this project are (1). to investigate what it meant to grieve in late-Georgian Britain (2). to examine the relationship between grief, loss, comfort and well-being, and to (3). assess to what extent experiences of grief were regulated by conventions and mediated through socio-cultural codes.\n","plannedDates":[{"endDate":"2024-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2024-08-31"}],"amountAwarded":177775,"Financial Year":"2020/21","Lead Applicant":"Dr Helen Metcalfe","grantProgramme":[{"title":"Research Fellowship in H&SS","title_keyword":"Research Fellowship in H&SS"}],"Applicant Surname":"Metcalfe","Partnership Value":177775,"Approval Committee":"Medical Humanities Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leicester","name":"University of Leicester","addressCountry":"United Kingdom","id_and_name":"[\"University of Leicester\", \"360G-Wellcome-ORG:University-of-Leicester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leicester","name":"University of Leicester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A Healthy Approach to Grief: The Emotional, Material, and Sensory History of Grief and Loss in Late-Georgian Britain, c. 1760-1830 This project will produce a history of grief and loss in late-Georgian Britain (c.1760-1830) that re-evaluates current perceptions of grief as unhealthy, and will redress the imbalance in historical and literary studies that have focused overwhelmingly on assessments of bereavement, mourning and mortuary rituals. It will recover the full range of Georgian experiences of grief to show how understandings of grief extended far beyond the immediate emotional upheaval associated with death, encompassing much wider definitions than those we attribute to grief today. Grief awarded meaning to interpersonal relationships, offerering avenues for self-reflection and providing comfort during periods of separation. This project will apply historical and literary research techniques to a linguistic and material culture analysis of grief, and engage with research in psychology, sociology and philosophy. It will interrogate grief across three main themes: Sadness and Separation; Bereavement; Loss and Abandonment \u2013 which are embedded within acts of resilience, remembrance and recovery. The main goals of this project are (1). to investigate what it meant to grieve in late-Georgian Britain (2). to examine the relationship between grief, loss, comfort and well-being, and to (3). assess to what extent experiences of grief were regulated by conventions and mediated through socio-cultural codes.\n","awardDateDateOnly":"2021-01-19","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Attitude to Death","Bereavement","Grief","Humans","United Kingdom"]}
{"id":"360G-Wellcome-222164_Z_20_Z","title":"Global Health Trials Award \u2013 round 10 \u2013 2019/2020","Region":"South West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"222164/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":4483010,"Financial Year":"2019/20","Lead Applicant":"Mrs Jill Jones","grantProgramme":[{"title":"Joint Global Health Trials Award","title_keyword":"Joint Global Health Trials Award"}],"Partnership Name":"Joint global health trials","Applicant Surname":"Jones","Partnership Value":4483010,"Approval Committee":"Joint Global Health Trials Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:UKRI-MRC","name":"UKRI-MRC","addressCountry":"United Kingdom","id_and_name":"[\"UKRI-MRC\", \"360G-Wellcome-ORG:UKRI-MRC\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:UKRI-MRC","name":"UKRI-MRC"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Global Health Trials Award \u2013 round 10 \u2013 2019/2020 Not available","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Clinical Trials as Topic","Global Health","Humans","United States"]}
{"id":"360G-Wellcome-222163_Z_20_Z","title":"Renewal of WT funding for Centre for Macaques","Region":"International","currency":"GBP","awardDate":"2020-11-30T00:00:00+00:00","Internal ID":"222163/Z/20/Z","description":"Renewal of funding for Centre for Macaques (CfM) to August 2022\n","plannedDates":[{"endDate":"2022-08-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2022-08-31"}],"amountAwarded":350000,"Financial Year":"2020/21","Lead Applicant":"Dr Sara Wells","grantProgramme":[{"title":"Strategic Support: Science","title_keyword":"Strategic Support: Science"}],"Partnership Name":"Centre for Macaques (CFM)","Applicant Surname":"Wells","Partnership Value":350000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:UK-Research-and-Innovation","name":"UK Research and Innovation","addressCountry":"United Kingdom","id_and_name":"[\"UK Research and Innovation\", \"360G-Wellcome-ORG:UK-Research-and-Innovation\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:UK-Research-and-Innovation","name":"UK Research and Innovation"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Renewal of WT funding for Centre for Macaques Renewal of funding for Centre for Macaques (CfM) to August 2022\n","awardDateDateOnly":"2020-11-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","United States"]}
{"id":"360G-Wellcome-222157_Z_20_Z","title":"On  TReND: Mild Traumatic Brain Injury and the Contentious Reimagining of Alzheimer Disease-Related Dementias as Environmental Diseases","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2021-01-19T00:00:00+00:00","Sponsor(s)":"Prof Nathan Hughes","Internal ID":"222157/Z/20/Z","description":"There is a growing recognition that Alzheimer\u2019s-like dementias need to be understood in environmental, rather than simply genetic, terms. Head injury has been identified as one such environmental antecedent to dementia and a new class of dementias known as TReNDs \u2013 Traumatic brain injury Related NeuroDegenerative disorderS \u2013 has emerged. This recasting of Alzheimer\u2019s-like dementias as environmental conditions has significant implications for professions, patients, and publics and potentially transforms the classification, diagnosis, treatment, and regulation of neurodegeneration.\n\nThis project is based around a multi-sited ethnography, undertaken with scientists in molecular neuroscience; neuropathology; and sports science. Sitting at the intersection of medical sociology and Science and Technology Studies, the project asks:\n\nQ1: How does depicting Alzheimer\u2019s-related dementias as environmentally-induced change understandings of the classification, cause, and diagnosis of neurodegenerative disease?\n\nQ2: How is research into traumatic brain injury shaping novel therapeutic interventions for neurodegenerative diseases? What are the consequences for patients?\n\nQ3: How are regulations embedded into research on environmentally-induced dementias? What are the envisaged risks, regulations, and wider policy implications of this biomedical research?\n\nIn asking these questions, this project is amongst the first to empirically explore the societal and scientific implications of these emerging sciences of dementia.\n","plannedDates":[{"endDate":"2027-01-31T00:00:00+00:00","startDate":"2022-02-01T00:00:00+00:00","startDateDateOnly":"2022-02-01","endDateDateOnly":"2027-01-31"}],"amountAwarded":333089,"Financial Year":"2020/21","Lead Applicant":"Dr Gregory Hollin","grantProgramme":[{"title":"University Award in H&SS","title_keyword":"University Award in H&SS"}],"Applicant Surname":"Hollin","Partnership Value":333089,"Approval Committee":"Social Science and Bioethics Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield","addressCountry":"United Kingdom","id_and_name":"[\"University of Sheffield\", \"360G-Wellcome-ORG:University-of-Sheffield\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"On  TReND: Mild Traumatic Brain Injury and the Contentious Reimagining of Alzheimer Disease-Related Dementias as Environmental Diseases There is a growing recognition that Alzheimer\u2019s-like dementias need to be understood in environmental, rather than simply genetic, terms. Head injury has been identified as one such environmental antecedent to dementia and a new class of dementias known as TReNDs \u2013 Traumatic brain injury Related NeuroDegenerative disorderS \u2013 has emerged. This recasting of Alzheimer\u2019s-like dementias as environmental conditions has significant implications for professions, patients, and publics and potentially transforms the classification, diagnosis, treatment, and regulation of neurodegeneration.\n\nThis project is based around a multi-sited ethnography, undertaken with scientists in molecular neuroscience; neuropathology; and sports science. Sitting at the intersection of medical sociology and Science and Technology Studies, the project asks:\n\nQ1: How does depicting Alzheimer\u2019s-related dementias as environmentally-induced change understandings of the classification, cause, and diagnosis of neurodegenerative disease?\n\nQ2: How is research into traumatic brain injury shaping novel therapeutic interventions for neurodegenerative diseases? What are the consequences for patients?\n\nQ3: How are regulations embedded into research on environmentally-induced dementias? What are the envisaged risks, regulations, and wider policy implications of this biomedical research?\n\nIn asking these questions, this project is amongst the first to empirically explore the societal and scientific implications of these emerging sciences of dementia.\n","awardDateDateOnly":"2021-01-19","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Alzheimer Disease","Anthropology, Cultural","Brain Injuries, Traumatic","Dementia","Humans","Neurodegenerative Diseases"]}
{"id":"360G-Wellcome-222156_Z_20_Z","title":"ACORN 2.0 - A Clinically Oriented antimicrobial Resistance Network","Region":"South East","currency":"GBP","awardDate":"2020-12-31T00:00:00+00:00","Internal ID":"222156/Z/20/Z","description":"The ACORN project will establish a network of hospitals and clinical laboratories in Asia and Africa to implement efficient patient-focused antimicrobial resistance (AMR) surveillance. Network data will be used to determine AMR disease burden, risk factors, and patient and economic impacts for key clinical syndromes and associated pathogens.\n\nACORN will address the need for better systems for linked clinical and microbiology data analysis to enable clinicians and ministries of health to understand and respond to the locally and nationally relevant AMR challenges and to engage meaningfully with international surveillance efforts. ACORN will provide simple to use data collection, visualisation, and analysis tools along with a framework for sites to improve clinician utilisation of diagnostic microbiology resources. Targeted clinical and outcome data collection will enable local use of pathogen and antimicrobial susceptibility data, for example by identification of high-risk patients and for development of empiric treatment guidelines.\n\nGlobal AMR surveillance and mitigation endeavours are weakened as a result of limited active healthcare provider engagement via local data use. Project engagement efforts will focus on promotion of widespread adoption of ACORN, through collaborative links with key AMR stakeholders, to ensure that future global surveillance has meaning, from the ground up.\n\n \n","plannedDates":[{"endDate":"2024-09-28T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2024-09-28"}],"amountAwarded":3750237,"Financial Year":"2020/21","Lead Applicant":"Prof Paul Turner","grantProgramme":[{"title":"Discretionary award \u2013 DRI","title_keyword":"Discretionary award \u2013 DRI"}],"Applicant Surname":"Turner","Partnership Value":3750237,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Clare Ling, Dr Samuel Akech, Prof Elizabeth Ashley, Prof H Rogier van Doorn, Mrs Naomi Waithira, Prof Yoel Lubell, Dr Japheth Opintan, Prof Iruka Okeke, Dr Abhilasha Karkey, Dr Nantasit Luangasanatip, Dr Raph Hamers, Prof Nicholas Feasey","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"ACORN 2.0 - A Clinically Oriented antimicrobial Resistance Network The ACORN project will establish a network of hospitals and clinical laboratories in Asia and Africa to implement efficient patient-focused antimicrobial resistance (AMR) surveillance. Network data will be used to determine AMR disease burden, risk factors, and patient and economic impacts for key clinical syndromes and associated pathogens.\n\nACORN will address the need for better systems for linked clinical and microbiology data analysis to enable clinicians and ministries of health to understand and respond to the locally and nationally relevant AMR challenges and to engage meaningfully with international surveillance efforts. ACORN will provide simple to use data collection, visualisation, and analysis tools along with a framework for sites to improve clinician utilisation of diagnostic microbiology resources. Targeted clinical and outcome data collection will enable local use of pathogen and antimicrobial susceptibility data, for example by identification of high-risk patients and for development of empiric treatment guidelines.\n\nGlobal AMR surveillance and mitigation endeavours are weakened as a result of limited active healthcare provider engagement via local data use. Project engagement efforts will focus on promotion of widespread adoption of ACORN, through collaborative links with key AMR stakeholders, to ensure that future global surveillance has meaning, from the ground up.\n\n \n","awardDateDateOnly":"2020-12-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa","Anti-Bacterial Agents","Asia","Bacterial Infections","Drug Resistance, Bacterial","Global Health","Humans","Population Surveillance","Risk Factors"]}
{"id":"360G-Wellcome-222154_Z_20_Z","title":"A major barrier to innovation in treatment and care for people with psychosis in lowincome countries is the absence of rigorous epidemiological research into the aetiology, presentation, social context, associated physical health conditions and early course of psychosis.","Region":"Greater London","currency":"GBP","awardDate":"2020-10-19T00:00:00+00:00","Internal ID":"222154/Z/20/Z","description":"Through SCOPE, we will produce high quality, contextual evidence and use it to design\ninnovations in detection and treatment, to improve the lives of people living with\npsychosis in a low-income country.\nOur key goals are to:\n1. determine the rate of new cases of psychosis in rural and urban settings in\nEthiopia; identify possible risk factors for onset; and characterise the needs of\npeople with psychosis and the factors that affect early course and outcome.\n2. use this evidence to co-develop innovations to improve early detection and\noptimise the recovery of people with psychosis. The innovations will be\napplicable to rural, urban and homeless populations in Ethiopia, with potential\ngeneralisability to other low- and middle-income countries.\nWe will pilot test interventions, develop strategies to overcome implementation\nchallenges and identify key intervention components to inform adaptation for other\ncontexts.","plannedDates":[{"endDate":"2026-09-30T00:00:00+00:00","startDate":"2021-10-01T00:00:00+00:00","startDateDateOnly":"2021-10-01","endDateDateOnly":"2026-09-30"}],"amountAwarded":1382640,"Financial Year":"2020/21","Lead Applicant":"Dr Charlotte Hanlon","grantProgramme":[{"title":"Innovations Psychosis Flagship","title_keyword":"Innovations Psychosis Flagship"}],"Applicant Surname":"Hanlon","Partnership Value":1382640,"Approval Committee":"Science, Innovation and Translation Programme Advisory Group","Other Applicant(s)":"Prof Atalay Alem, Dr Abebaw Fekadu, Dr Alexander Cohen, Prof Craig Morgan, Prof Crick Lund, Prof Solomon Teferra, Dr Tessa Roberts","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A major barrier to innovation in treatment and care for people with psychosis in lowincome countries is the absence of rigorous epidemiological research into the aetiology, presentation, social context, associated physical health conditions and early course of psychosis. Through SCOPE, we will produce high quality, contextual evidence and use it to design\ninnovations in detection and treatment, to improve the lives of people living with\npsychosis in a low-income country.\nOur key goals are to:\n1. determine the rate of new cases of psychosis in rural and urban settings in\nEthiopia; identify possible risk factors for onset; and characterise the needs of\npeople with psychosis and the factors that affect early course and outcome.\n2. use this evidence to co-develop innovations to improve early detection and\noptimise the recovery of people with psychosis. The innovations will be\napplicable to rural, urban and homeless populations in Ethiopia, with potential\ngeneralisability to other low- and middle-income countries.\nWe will pilot test interventions, develop strategies to overcome implementation\nchallenges and identify key intervention components to inform adaptation for other\ncontexts.","awardDateDateOnly":"2020-10-19","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Developing Countries","Early Diagnosis","Early Medical Intervention","Ethiopia","Humans","Psychotic Disorders","Risk Factors","Urban Population"]}
{"id":"360G-Wellcome-222152_Z_20_Z","title":"Development of a S. Paratyphi A / S. Typhi bivalent vaccine through proof-of-concept (POC) in animals","Region":"International","currency":"GBP","awardDate":"2021-02-04T00:00:00+00:00","Internal ID":"222152/Z/20/Z","description":"Salmonella Typhi and Paratyphi A have a high incidence worldwide and coexist in many\nareas, especially in South and Southeast Asia. S. Typhi causes an estimated 12.5 million\ncases and 149,000 deaths and S. Paratyphi causes about 3 million cases and 19,000 deaths\nannually. There is urgent need for better and affordable vaccines against these infections.\nThe aim of this project is to develop a bivalent Typhi-Paratyphi A vaccine to prevent\nsystemic Salmonella infections and enteric fever. Specifically, we intend to identify a bivalent\nconjugate formulation, arrived through determination of optimal formulation  & \ncharacterization conditions, that induces equivalent or higher anti-OSP/Vi IgG titers than\nmonovalent OSP and Vi conjugate controls, and bactericidal activities against S. Typhi and\nS. Paratyphi A, with/without adjuvants.","plannedDates":[{"endDate":"2023-06-13T00:00:00+00:00","startDate":"2021-06-14T00:00:00+00:00","startDateDateOnly":"2021-06-14","endDateDateOnly":"2023-06-13"}],"amountAwarded":439472,"Financial Year":"2020/21","Lead Applicant":"Dr Manki Song","grantProgramme":[{"title":"Innovator Award","title_keyword":"Innovator Award"}],"Applicant Surname":"Song","Partnership Value":439472,"Approval Committee":"Innovator Awards Advisory Group","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:International-Vaccine-Institute","name":"International Vaccine Institute","addressCountry":"Korea, South","id_and_name":"[\"International Vaccine Institute\", \"360G-Wellcome-ORG:International-Vaccine-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:International-Vaccine-Institute","name":"International Vaccine Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Development of a S. Paratyphi A / S. Typhi bivalent vaccine through proof-of-concept (POC) in animals Salmonella Typhi and Paratyphi A have a high incidence worldwide and coexist in many\nareas, especially in South and Southeast Asia. S. Typhi causes an estimated 12.5 million\ncases and 149,000 deaths and S. Paratyphi causes about 3 million cases and 19,000 deaths\nannually. There is urgent need for better and affordable vaccines against these infections.\nThe aim of this project is to develop a bivalent Typhi-Paratyphi A vaccine to prevent\nsystemic Salmonella infections and enteric fever. Specifically, we intend to identify a bivalent\nconjugate formulation, arrived through determination of optimal formulation  & \ncharacterization conditions, that induces equivalent or higher anti-OSP/Vi IgG titers than\nmonovalent OSP and Vi conjugate controls, and bactericidal activities against S. Typhi and\nS. Paratyphi A, with/without adjuvants.","awardDateDateOnly":"2021-02-04","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Antibodies, Bacterial","Humans","Immunoglobulin G","Salmonella typhi","Typhoid Fever","Typhoid-Paratyphoid Vaccines"]}
{"id":"360G-Wellcome-222150_Z_20_Z","title":"Strengthening Joint Scientific & Political Actions for Global Health","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"222150/Z/20/Z","description":"The most pressing global health challenges of our time require strong partnerships for multi-stakeholder exchange and appropriate policy responses. Against this background, the World Health Summit would like to strengthen its collaboration with expert organizations such as Wellcome Trust, to make a greater contribution to policy-making in the field of global health research and strengthen scientific and political activity in Berlin and beyond in the spirit of the sustainable development goals.\n","plannedDates":[{"endDate":"2023-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2023-12-31"}],"amountAwarded":230048,"Financial Year":"2019/20","Lead Applicant":"Dr Joerg Heldmann","grantProgramme":[{"title":"Discretionary Award - Policy ","title_keyword":"Discretionary Award - Policy "}],"Applicant Surname":"Heldmann","Partnership Value":230048,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:World-Health-Summit","name":"World Health Summit","addressCountry":"Germany","id_and_name":"[\"World Health Summit\", \"360G-Wellcome-ORG:World-Health-Summit\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:World-Health-Summit","name":"World Health Summit"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Strengthening Joint Scientific & Political Actions for Global Health The most pressing global health challenges of our time require strong partnerships for multi-stakeholder exchange and appropriate policy responses. Against this background, the World Health Summit would like to strengthen its collaboration with expert organizations such as Wellcome Trust, to make a greater contribution to policy-making in the field of global health research and strengthen scientific and political activity in Berlin and beyond in the spirit of the sustainable development goals.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Global Health","Health Policy","Humans","International Cooperation","World Health Organization"]}
{"id":"360G-Wellcome-222149_Z_20_Z","title":"Health Security Activities of the Munich Security Conference 2020-2023","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"222149/Z/20/Z","description":"Building on the expertise and support provided by the Wellcome Trust in recent years, the MSC wishes to create a direct continuation of existing work, sustainably strengthen its global health dimension and expand its reach with additional activities in response to COVID-19 and beyond.\n\nDuring the MSC fiscal year 2020-2021 activities will include two follow-up Digital Conversations and various roundtables and side events within the scope of the 2021 Munich Security Conference, a 2021 Health Security Roundtable in Berlin and potentially a Health Security Roundtable on the sidelines of the MSC Core Group Meeting 2021 in Washington D.C.\n\nAdditionally, a Special Edition of the Munich Security Report, the \"Stability Report\" will address many current issues and challenges in global health security. As part of the grant proposal, the MSC will facilitate Wellcome Trust participation at the report launch and will give updates on report progress.\n\nEvents similar in number and design will take place in the fiscal years 2021-2022 and 2022-2023. Due to COVID-19, detailed plans will only be made at a later stage. The MSC will keep the Wellcome Trust up to date on its plans for new MSC health security activities as soon as they become available.\n","plannedDates":[{"endDate":"2023-05-31T00:00:00+00:00","startDate":"2020-12-01T00:00:00+00:00","startDateDateOnly":"2020-12-01","endDateDateOnly":"2023-05-31"}],"amountAwarded":341655,"Financial Year":"2019/20","Lead Applicant":"Mr Marcel Lewicki","grantProgramme":[{"title":"Discretionary Award - Policy ","title_keyword":"Discretionary Award - Policy "}],"Applicant Surname":"Lewicki","Partnership Value":341655,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Munich-Security-Conference","name":"Munich Security Conference","addressCountry":"Germany","id_and_name":"[\"Munich Security Conference\", \"360G-Wellcome-ORG:Munich-Security-Conference\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Munich-Security-Conference","name":"Munich Security Conference"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Health Security Activities of the Munich Security Conference 2020-2023 Building on the expertise and support provided by the Wellcome Trust in recent years, the MSC wishes to create a direct continuation of existing work, sustainably strengthen its global health dimension and expand its reach with additional activities in response to COVID-19 and beyond.\n\nDuring the MSC fiscal year 2020-2021 activities will include two follow-up Digital Conversations and various roundtables and side events within the scope of the 2021 Munich Security Conference, a 2021 Health Security Roundtable in Berlin and potentially a Health Security Roundtable on the sidelines of the MSC Core Group Meeting 2021 in Washington D.C.\n\nAdditionally, a Special Edition of the Munich Security Report, the \"Stability Report\" will address many current issues and challenges in global health security. As part of the grant proposal, the MSC will facilitate Wellcome Trust participation at the report launch and will give updates on report progress.\n\nEvents similar in number and design will take place in the fiscal years 2021-2022 and 2022-2023. Due to COVID-19, detailed plans will only be made at a later stage. The MSC will keep the Wellcome Trust up to date on its plans for new MSC health security activities as soon as they become available.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Congresses as Topic","Global Health","Humans"]}
{"id":"360G-Wellcome-222134_Z_20_Z","title":"TCR/BCR repertoire sequencing in the conjunctival associated lymphoid tissue from trachoma longitudinal studies","Region":"International","currency":"GBP","awardDate":"2020-11-24T00:00:00+00:00","Sponsor(s)":"Prof Blandina Mmbaga","Internal ID":"222134/Z/20/Z","description":"The primary aim of this study is to use next generation sequencing to investigate the T and B cell receptor repertoire in the conjunctival tissue in those susceptible to repeated ocular infection with Ct and those resistant despite similar exposures.\n\nRNA samples selected from archived conjunctival swab samples from a 4-year longitudinal study of children with progressing trachomatous scarring and non-progressing will be used. Sequences will be aligned to their germline V-, D-, and J-genes and assigned according to the IMGT/GENE-DB reference directory. The average length of CDR3 regions, as well as the frequency of shared CDR3s will be compared. The usage of specific V genes, families and their frequency will also be compared. Initial analysis will be conducted on 25 progressors and 25 non-progressors at the final time points.  Based on the results of the data obtained, a sufficient number of samples will be selected for further analysis from earlier timepoints in the cohort.\n\n\nThe project has the potential to contribute toward the evaluation and progression of current and future human clinical trials of Ct vaccines.\n","plannedDates":[{"endDate":"2024-02-29T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2024-02-29"}],"amountAwarded":120000,"Financial Year":"2020/21","Lead Applicant":"Mr Elias Mafuru","grantProgramme":[{"title":"International Masters Fellowship","title_keyword":"International Masters Fellowship"}],"Applicant Surname":"Mafuru","Partnership Value":120000,"Approval Committee":"International Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kilimanjaro-Clinical-Research-Institute","name":"Kilimanjaro Clinical Research Institute","addressCountry":"Tanzania","id_and_name":"[\"Kilimanjaro Clinical Research Institute\", \"360G-Wellcome-ORG:Kilimanjaro-Clinical-Research-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kilimanjaro-Clinical-Research-Institute","name":"Kilimanjaro Clinical Research Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"TCR/BCR repertoire sequencing in the conjunctival associated lymphoid tissue from trachoma longitudinal studies The primary aim of this study is to use next generation sequencing to investigate the T and B cell receptor repertoire in the conjunctival tissue in those susceptible to repeated ocular infection with Ct and those resistant despite similar exposures.\n\nRNA samples selected from archived conjunctival swab samples from a 4-year longitudinal study of children with progressing trachomatous scarring and non-progressing will be used. Sequences will be aligned to their germline V-, D-, and J-genes and assigned according to the IMGT/GENE-DB reference directory. The average length of CDR3 regions, as well as the frequency of shared CDR3s will be compared. The usage of specific V genes, families and their frequency will also be compared. Initial analysis will be conducted on 25 progressors and 25 non-progressors at the final time points.  Based on the results of the data obtained, a sufficient number of samples will be selected for further analysis from earlier timepoints in the cohort.\n\n\nThe project has the potential to contribute toward the evaluation and progression of current and future human clinical trials of Ct vaccines.\n","awardDateDateOnly":"2020-11-24","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["B-Lymphocytes","Child","Child, Preschool","Conjunctiva","Female","High-Throughput Nucleotide Sequencing","Humans","Infant","Longitudinal Studies","Male","Trachoma"]}
{"id":"360G-Wellcome-222133_Z_20_Z","title":"Healthy Brains Global Initiative start-up funding","Region":"Unknown","currency":"GBP","awardDate":"2020-11-30T00:00:00+00:00","Internal ID":"222133/Z/20/Z","description":"Healthy Brains Global Initiative (HBGI) is a collaboration of global leaders in neuroscience, policy, and financing working to improve the lives of those living with mental and neurological disorders and bend the unsustainable US$3 trillion global cost curve borne today by all countries.  HBGI is developing an umbrella set of financing mechanisms to leverage billions in financing and fuel an unprecedented increase in brain science breakthroughs.  We are currently in the mobilisation stage with a view to a formal launch in 2021. \n\nThe Co-Founders and Co-Chairs of the Board are Victor Dzau (National Academy of Medicine) and Garen Staglin (One Mind), and Brad Herbert is the interim CEO.  The Wellcome Trust is involved in multiple ways.  Ed Whiting is a member of HBGI\u2019s Interim Board, and Miranda Wolpert is Co-Chair of the Use of Proceeds Working Group and Andrew Welchman is also part of the group.\n\nWe value the expertise that the Wellcome Trust is providing to us and are requesting US$1.2 million to contribute to HBGI's running costs for the start-up phase.  This will fund us to design and launch a governance structure, determine the optimal use of proceeds, confirm metrics for ROI, and design and launch financing mechanisms.\n","plannedDates":[{"endDate":"2021-10-31T00:00:00+00:00","startDate":"2020-11-01T00:00:00+00:00","startDateDateOnly":"2020-11-01","endDateDateOnly":"2021-10-31"}],"amountAwarded":928074,"Financial Year":"2020/21","Lead Applicant":"Mr Brad Herbert","grantProgramme":[{"title":"Discretionary Award - Mental Health","title_keyword":"Discretionary Award - Mental Health"}],"Applicant Surname":"Herbert","Partnership Value":928074,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Healthy-Brains-Global-Initiative","name":"Healthy Brains Global Initiative","addressCountry":"United States","id_and_name":"[\"Healthy Brains Global Initiative\", \"360G-Wellcome-ORG:Healthy-Brains-Global-Initiative\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Healthy-Brains-Global-Initiative","name":"Healthy Brains Global Initiative"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Healthy Brains Global Initiative start-up funding Healthy Brains Global Initiative (HBGI) is a collaboration of global leaders in neuroscience, policy, and financing working to improve the lives of those living with mental and neurological disorders and bend the unsustainable US$3 trillion global cost curve borne today by all countries.  HBGI is developing an umbrella set of financing mechanisms to leverage billions in financing and fuel an unprecedented increase in brain science breakthroughs.  We are currently in the mobilisation stage with a view to a formal launch in 2021. \n\nThe Co-Founders and Co-Chairs of the Board are Victor Dzau (National Academy of Medicine) and Garen Staglin (One Mind), and Brad Herbert is the interim CEO.  The Wellcome Trust is involved in multiple ways.  Ed Whiting is a member of HBGI\u2019s Interim Board, and Miranda Wolpert is Co-Chair of the Use of Proceeds Working Group and Andrew Welchman is also part of the group.\n\nWe value the expertise that the Wellcome Trust is providing to us and are requesting US$1.2 million to contribute to HBGI's running costs for the start-up phase.  This will fund us to design and launch a governance structure, determine the optimal use of proceeds, confirm metrics for ROI, and design and launch financing mechanisms.\n","awardDateDateOnly":"2020-11-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Global Health","Humans","International Cooperation"]}
{"id":"360G-Wellcome-222125_Z_20_Z","title":"Enteric Pathogens and Post-discharge Outcomes among Children in sub-Saharan Africa and South Asia (The EPPO-SASA Study)","Region":"International","currency":"GBP","awardDate":"2020-11-24T00:00:00+00:00","Sponsor(s)":"Dr Samson Kinyanjui","Internal ID":"222125/Z/20/Z","description":"Enteric pathogens are a major cause of hospitalisation among children and are associated with diarrhoea, enteric dysfunction, dysbiosis, and increased risk of mortality and readmission especially in low- and middle-income countries. When admitted to hospital, treatment failure may occur despite following guidelines. Furthermore, carriage of pathogens or disturbance in the intestinal microbiome may be hospital-acquired and/or resistant to first-line antimicrobials potentially increasing the risk of readmission. I aim to determine whether molecular evidence of enteric pathogens and gut dysbiosis at hospital discharge, when children were judged as clinically well, is associated with readmission post-discharge among children across the nutritional stratum. This case-control study is nested within the completed CHAIN cohort study (six countries) that aims to characterise demographic, clinical, and social risk factors for mortality among children  \n","plannedDates":[{"endDate":"2024-01-30T00:00:00+00:00","startDate":"2021-08-02T00:00:00+00:00","startDateDateOnly":"2021-08-02","endDateDateOnly":"2024-01-30"}],"amountAwarded":97200,"Financial Year":"2020/21","Lead Applicant":"Mr Bonface Gichuki","grantProgramme":[{"title":"International Masters Fellowship","title_keyword":"International Masters Fellowship"}],"Applicant Surname":"Gichuki","Partnership Value":97200,"Approval Committee":"International Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kemri-Wellcome-Trust-Research-Programme","name":"Kemri-Wellcome Trust Research Programme","addressCountry":"Kenya","id_and_name":"[\"Kemri-Wellcome Trust Research Programme\", \"360G-Wellcome-ORG:Kemri-Wellcome-Trust-Research-Programme\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kemri-Wellcome-Trust-Research-Programme","name":"Kemri-Wellcome Trust Research Programme"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Enteric Pathogens and Post-discharge Outcomes among Children in sub-Saharan Africa and South Asia (The EPPO-SASA Study) Enteric pathogens are a major cause of hospitalisation among children and are associated with diarrhoea, enteric dysfunction, dysbiosis, and increased risk of mortality and readmission especially in low- and middle-income countries. When admitted to hospital, treatment failure may occur despite following guidelines. Furthermore, carriage of pathogens or disturbance in the intestinal microbiome may be hospital-acquired and/or resistant to first-line antimicrobials potentially increasing the risk of readmission. I aim to determine whether molecular evidence of enteric pathogens and gut dysbiosis at hospital discharge, when children were judged as clinically well, is associated with readmission post-discharge among children across the nutritional stratum. This case-control study is nested within the completed CHAIN cohort study (six countries) that aims to characterise demographic, clinical, and social risk factors for mortality among children  \n","awardDateDateOnly":"2020-11-24","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa South of the Sahara","Asia","Case-Control Studies","Child","Child, Preschool","Cohort Studies","Diarrhea","Female","Gastrointestinal Microbiome","Humans","Infant","Male","Nutritional Status","Patient Discharge","Patient Readmission","Risk Factors"]}
{"id":"360G-Wellcome-222125_A_20_Z","title":"Enteric Pathogens and Post-discharge Outcomes among Children in sub-Saharan Africa and South Asia (The EPPO-SASA Study)","Region":"East of England","currency":"GBP","awardDate":"2020-11-24T00:00:00+00:00","Internal ID":"222125/A/20/Z","description":"Enteric pathogens are a major cause of hospitalisation among children and are associated with diarrhoea, enteric dysfunction, dysbiosis, and increased risk of mortality and readmission especially in low- and middle-income countries. When admitted to hospital, treatment failure may occur despite following guidelines. Furthermore, carriage of pathogens or disturbance in the intestinal microbiome may be hospital-acquired and/or resistant to first-line antimicrobials potentially increasing the risk of readmission. I aim to determine whether molecular evidence of enteric pathogens and gut dysbiosis at hospital discharge, when children were judged as clinically well, is associated with readmission post-discharge among children across the nutritional stratum. This case-control study is nested within the completed CHAIN cohort study (six countries) that aims to characterise demographic, clinical, and social risk factors for mortality among children  \n","plannedDates":[{"endDate":"2024-02-29T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2024-02-29"}],"amountAwarded":22800,"Financial Year":"2020/21","Lead Applicant":"Dr Trevor Lawley","grantProgramme":[{"title":"International Masters Fellowship","title_keyword":"International Masters Fellowship"}],"Applicant Surname":"Lawley","Partnership Value":22800,"Approval Committee":"International Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Wellcome-Trust-Sanger-Institute","name":"Wellcome Trust Sanger Institute","addressCountry":"United Kingdom","id_and_name":"[\"Wellcome Trust Sanger Institute\", \"360G-Wellcome-ORG:Wellcome-Trust-Sanger-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Wellcome-Trust-Sanger-Institute","name":"Wellcome Trust Sanger Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Enteric Pathogens and Post-discharge Outcomes among Children in sub-Saharan Africa and South Asia (The EPPO-SASA Study) Enteric pathogens are a major cause of hospitalisation among children and are associated with diarrhoea, enteric dysfunction, dysbiosis, and increased risk of mortality and readmission especially in low- and middle-income countries. When admitted to hospital, treatment failure may occur despite following guidelines. Furthermore, carriage of pathogens or disturbance in the intestinal microbiome may be hospital-acquired and/or resistant to first-line antimicrobials potentially increasing the risk of readmission. I aim to determine whether molecular evidence of enteric pathogens and gut dysbiosis at hospital discharge, when children were judged as clinically well, is associated with readmission post-discharge among children across the nutritional stratum. This case-control study is nested within the completed CHAIN cohort study (six countries) that aims to characterise demographic, clinical, and social risk factors for mortality among children  \n","awardDateDateOnly":"2020-11-24","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa South of the Sahara","Asia","Case-Control Studies","Child","Child, Preschool","Cohort Studies","Diarrhea","Female","Gastrointestinal Microbiome","Humans","Infant","Male","Nutritional Status","Patient Discharge","Patient Readmission","Risk Factors"]}
{"id":"360G-Wellcome-222119_Z_20_Z","title":"Intra-host dengue virus genetic diversity among primary and secondary infections in Laos","Region":"South East","currency":"GBP","awardDate":"2020-11-24T00:00:00+00:00","Sponsor(s)":"Prof Elizabeth Ashley","Internal ID":"222119/Z/20/Z","description":"There are an estimated 100-400 million cases of dengue worldwide per year with the highest burden of disease in Asia. The virus (DENV) is a positive-sense single stranded RNA virus belonging to the genus Flavivirus. There are four serotypes: DENV1 to DENV4. Dengue virus RNA dependent RNA polymerase has no proof-reading activity, resulting in accumulation of mutations at each replication cycle.\nTherefore, within an infected individual, there is diversification of the DENV genome sequence leading to the presence of intra-host genetic variants (quasispecies), which may then lead, under selective pressure, to the emergence of a new strain of higher virulence. Previous findings suggested that immune pressure drives intra-host diversity.\nMy research will explore whether serotype-specific past immunity influences intra-host DENV genetic diversity during acute infection.\n\nObjectives:\n\n\n To describe intra host DENV genetic diversity in patients with primary and secondary infections\n To compare quasispecies profiles between primary and secondary infections\n To compare quasispecies profiles in secondary infections between two patient groups previously exposed to a different serotype.\n\n\n\nImpact :\nWe expect the findings of this project would permit a better understanding of processes leading to viral genetic variation, and could eventually be useful for improving viral surveillance systems and epidemic forecasting.\n","plannedDates":[{"endDate":"2024-03-03T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2024-03-03"}],"amountAwarded":120000,"Financial Year":"2020/21","Lead Applicant":"Dr Vilayouth Phimolsannusith","grantProgramme":[{"title":"International Masters Fellowship","title_keyword":"International Masters Fellowship"}],"Applicant Surname":"Phimolsannusith","Partnership Value":120000,"Approval Committee":"International Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Intra-host dengue virus genetic diversity among primary and secondary infections in Laos There are an estimated 100-400 million cases of dengue worldwide per year with the highest burden of disease in Asia. The virus (DENV) is a positive-sense single stranded RNA virus belonging to the genus Flavivirus. There are four serotypes: DENV1 to DENV4. Dengue virus RNA dependent RNA polymerase has no proof-reading activity, resulting in accumulation of mutations at each replication cycle.\nTherefore, within an infected individual, there is diversification of the DENV genome sequence leading to the presence of intra-host genetic variants (quasispecies), which may then lead, under selective pressure, to the emergence of a new strain of higher virulence. Previous findings suggested that immune pressure drives intra-host diversity.\nMy research will explore whether serotype-specific past immunity influences intra-host DENV genetic diversity during acute infection.\n\nObjectives:\n\n\n To describe intra host DENV genetic diversity in patients with primary and secondary infections\n To compare quasispecies profiles between primary and secondary infections\n To compare quasispecies profiles in secondary infections between two patient groups previously exposed to a different serotype.\n\n\n\nImpact :\nWe expect the findings of this project would permit a better understanding of processes leading to viral genetic variation, and could eventually be useful for improving viral surveillance systems and epidemic forecasting.\n","awardDateDateOnly":"2020-11-24","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aedes","Dengue","Dengue Virus","Genetic Variation","Genome, Viral","Humans","Phylogeny","RNA, Viral","Serogroup"]}
{"id":"360G-Wellcome-222112_Z_20_Z","title":"Incentivising pharmaceutical companies to improve equitable access to healthcare interventions","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"222112/Z/20/Z","description":"Equitable access is critical for maximising the impact of innovation and heavily depends on proactive actions by pharmaceutical companies, during and after the COVID-19 pandemic. In order to bring the pandemic to an end, achieve universal health coverage and protect the gains made on Sustainable Development Goal 3, the pharmaceutical industry will need to ensure that all scientific advancements benefit the maximum number of people, independent of the place they live or their ability to pay. The Access to Medicine Foundation (ATMF) has incentivised pharmaceutical company action to improve access to new innovations for more than a decade. By rewarding positive action, sharing best practices, and highlighting opportunities for change, the ATMF encourages companies to become willing partners to improve global access to their products. The ATMF will support Wellcome Trust\u2019s approach to equitable access to healthcare interventions through a combination of research and policy initiatives that will (a) incentivise pharmaceutical company action on COVID-19, (b) support global efforts to mainstream access principles during product development and (c) untap the potential of generic medicine manufacturers in expanding access to innovations in low- and middle-income countries. The request from the ATMF is for \u20ac471,750 (\u00a3425,000) from October 2020 to September 2021.\n","plannedDates":[{"endDate":"2021-10-07T00:00:00+00:00","startDate":"2020-10-08T00:00:00+00:00","startDateDateOnly":"2020-10-08","endDateDateOnly":"2021-10-07"}],"amountAwarded":419410,"Financial Year":"2019/20","Lead Applicant":"Dr Damiano de Felice","grantProgramme":[{"title":"Discretionary Award - Policy ","title_keyword":"Discretionary Award - Policy "}],"Applicant Surname":"de Felice","Partnership Value":419410,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Access-to-Medicine-Foundation","name":"Access to Medicine Foundation","addressCountry":"Netherlands","id_and_name":"[\"Access to Medicine Foundation\", \"360G-Wellcome-ORG:Access-to-Medicine-Foundation\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Access-to-Medicine-Foundation","name":"Access to Medicine Foundation"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Incentivising pharmaceutical companies to improve equitable access to healthcare interventions Equitable access is critical for maximising the impact of innovation and heavily depends on proactive actions by pharmaceutical companies, during and after the COVID-19 pandemic. In order to bring the pandemic to an end, achieve universal health coverage and protect the gains made on Sustainable Development Goal 3, the pharmaceutical industry will need to ensure that all scientific advancements benefit the maximum number of people, independent of the place they live or their ability to pay. The Access to Medicine Foundation (ATMF) has incentivised pharmaceutical company action to improve access to new innovations for more than a decade. By rewarding positive action, sharing best practices, and highlighting opportunities for change, the ATMF encourages companies to become willing partners to improve global access to their products. The ATMF will support Wellcome Trust\u2019s approach to equitable access to healthcare interventions through a combination of research and policy initiatives that will (a) incentivise pharmaceutical company action on COVID-19, (b) support global efforts to mainstream access principles during product development and (c) untap the potential of generic medicine manufacturers in expanding access to innovations in low- and middle-income countries. The request from the ATMF is for \u20ac471,750 (\u00a3425,000) from October 2020 to September 2021.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Developing Countries","Drug Industry","Drugs, Generic","Health Policy","Health Services Accessibility","Humans","Universal Health Insurance"]}
{"id":"360G-Wellcome-222111_Z_20_Z","title":"Novel image-guided therapeutics to improve surgical precision and loco-regional control in Neuroblastoma.","Region":"Greater London","currency":"GBP","awardDate":"2021-02-04T00:00:00+00:00","Internal ID":"222111/Z/20/Z","description":"Neuroblastoma (NB) is the most common extra-cranial solid cancer in children and contributes to 15% of childhood cancer deaths. Surgery to remove NB is often incomplete and poses high risks due to the significant involvement of vital organs and vessels.\nWe aim to develop a novel integrated surgical platform to eliminate cancer more efficiently and safely. With the synergistic use of highly innovative optical techniques, built around a core technology of using injectable probes, we aim to:\n1. Specifically, \"light up\" cancer to help the surgeon in differentiating tumour from vital organs (colour-coded surgery).\n2. Equip the surgeon with an innovative special scanner to chase small and non-visible cancer residuals.\n3. Kill any minimal residual cancer, left by the surgeon, using a new technology based on light.\nThis original approach has the potential to improve the effectiveness of surgery in eradicating solid paediatric and adult cancers, leading to better survival and fewer complications.","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2021-10-01T00:00:00+00:00","startDateDateOnly":"2021-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":519278,"Financial Year":"2020/21","Lead Applicant":"Mr Stefano Giuliani","grantProgramme":[{"title":"Innovator Award","title_keyword":"Innovator Award"}],"Applicant Surname":"Giuliani","Partnership Value":519278,"Approval Committee":"Innovator Awards Advisory Group","Other Applicant(s)":"Dr Gabriela Kramer-Marek, Prof Paul Beard, Prof John Anderson, Dr Olumide Ogunlade","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Novel image-guided therapeutics to improve surgical precision and loco-regional control in Neuroblastoma. Neuroblastoma (NB) is the most common extra-cranial solid cancer in children and contributes to 15% of childhood cancer deaths. Surgery to remove NB is often incomplete and poses high risks due to the significant involvement of vital organs and vessels.\nWe aim to develop a novel integrated surgical platform to eliminate cancer more efficiently and safely. With the synergistic use of highly innovative optical techniques, built around a core technology of using injectable probes, we aim to:\n1. Specifically, \"light up\" cancer to help the surgeon in differentiating tumour from vital organs (colour-coded surgery).\n2. Equip the surgeon with an innovative special scanner to chase small and non-visible cancer residuals.\n3. Kill any minimal residual cancer, left by the surgeon, using a new technology based on light.\nThis original approach has the potential to improve the effectiveness of surgery in eradicating solid paediatric and adult cancers, leading to better survival and fewer complications.","awardDateDateOnly":"2021-02-04","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Neuroblastoma"]}
{"id":"360G-Wellcome-222109_Z_20_Z","title":"Transitioning to a Zero Carbon Food System in Latin America","Region":"International","currency":"GBP","awardDate":"2020-11-30T00:00:00+00:00","Internal ID":"222109/Z/20/Z","description":"Wellcome Trust and IDRC will be supporting the building of an agenda for action on the transition to a zero-carbon food system in Latin America. This work will be conducted in parallel to the work conducted by the Rockefeller Foundation and IDRC in East Africa, which aims to \"improve the health and wellbeing of low-income and vulnerable populations who face the double burden of malnutrition and environmental threats like climate change\" (see annexed document for more information). The work conducted in both regions are part of a growing initiative entitled \"Catalysing change for healthy and sustainable food systems\", launched by the three institutions. The initiative will provide research grants to leading evidence builders in low- and middle-income countries (LMICs), with the aim of strengthening the contribution and engagement of LMIC research and civil society institutions in regional and global discussions about healthy and sustainable food systems.\n","plannedDates":[{"endDate":"2022-04-16T00:00:00+00:00","startDate":"2021-01-15T00:00:00+00:00","startDateDateOnly":"2021-01-15","endDateDateOnly":"2022-04-16"}],"amountAwarded":505090,"Financial Year":"2020/21","Lead Applicant":"Mr Greg Hallen","grantProgramme":[{"title":"Discretionary Award - OPOH","title_keyword":"Discretionary Award - OPOH"}],"Applicant Surname":"Hallen","Partnership Value":505090,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:International-Development-Research-Centre-Canada","name":"International Development Research Centre, Canada","addressCountry":"Canada","id_and_name":"[\"International Development Research Centre, Canada\", \"360G-Wellcome-ORG:International-Development-Research-Centre-Canada\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:International-Development-Research-Centre-Canada","name":"International Development Research Centre, Canada"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Transitioning to a Zero Carbon Food System in Latin America Wellcome Trust and IDRC will be supporting the building of an agenda for action on the transition to a zero-carbon food system in Latin America. This work will be conducted in parallel to the work conducted by the Rockefeller Foundation and IDRC in East Africa, which aims to \"improve the health and wellbeing of low-income and vulnerable populations who face the double burden of malnutrition and environmental threats like climate change\" (see annexed document for more information). The work conducted in both regions are part of a growing initiative entitled \"Catalysing change for healthy and sustainable food systems\", launched by the three institutions. The initiative will provide research grants to leading evidence builders in low- and middle-income countries (LMICs), with the aim of strengthening the contribution and engagement of LMIC research and civil society institutions in regional and global discussions about healthy and sustainable food systems.\n","awardDateDateOnly":"2020-11-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa","Climate Change","Developing Countries","Food Supply","Global Health","Humans","Latin America","Malnutrition"]}
{"id":"360G-Wellcome-222105_Z_20_Z","title":"Epidemic Inteligence: Understanding how returning migrant waves drive epidemic seeding and community transmission events in the South Asian context to inform epidemic preparedness","Region":"North West","currency":"GBP","awardDate":"2021-01-29T00:00:00+00:00","Internal ID":"222105/Z/20/Z","description":"Nepal, as for much of Asia, has high levels of labour migration, particularly to neighbouring India and the Middle East. The SARS-CoV-2 pandemic has caused a chaotic mass return migration event. While the government  has attempted to quarantine and test returning migrants the fragile infrastructure has been rapidly overwhelmed and repeated migration waves have occurred into remote rural areas.\n The  epidemic in Nepal is now entering the rapid escalation phase. Despite this surge, the government has been forced to raise the lockdown, imposed since March 24th, due to the economic and political consequences. There is limited understanding of the pattern and extent of transmission in this context due to limited and sporadic testing.\n\n\n Understand how return migration is influencing the epidemic dynamics in rural vs. urban contexts.\n Understand how the reported data from the core government testing system compares to estimated community prevalence dynamics to predict testing capacity gaps and refine future response.\n Determine sensitivity and specificity of GeneXpert Xpress testing using nasopharageal swabs or saliva against RT-PCR  for SARS CoV-2 infection.\n Sequence a cohort of 500 SARS CoV-2 samples to understand the patterns of repeated introduction, seeding and transmission occurring in rural and urban areas as the epidemic unfolds.\n\n","plannedDates":[{"endDate":"2022-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2022-03-31"}],"amountAwarded":639793,"Financial Year":"2020/21","Lead Applicant":"Dr Maxine Caws","grantProgramme":[{"title":"Coronavirus","title_keyword":"Coronavirus"}],"Partnership Name":"Wellcome-DFID Epidemic Preparedness","Applicant Surname":"Caws","Partnership Value":639793,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Buddha Basnyat, Dr Abhilasha Karkey, Dr Sameer Dixit","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"Liverpool School of Tropical Medicine\", \"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Epidemic Inteligence: Understanding how returning migrant waves drive epidemic seeding and community transmission events in the South Asian context to inform epidemic preparedness Nepal, as for much of Asia, has high levels of labour migration, particularly to neighbouring India and the Middle East. The SARS-CoV-2 pandemic has caused a chaotic mass return migration event. While the government  has attempted to quarantine and test returning migrants the fragile infrastructure has been rapidly overwhelmed and repeated migration waves have occurred into remote rural areas.\n The  epidemic in Nepal is now entering the rapid escalation phase. Despite this surge, the government has been forced to raise the lockdown, imposed since March 24th, due to the economic and political consequences. There is limited understanding of the pattern and extent of transmission in this context due to limited and sporadic testing.\n\n\n Understand how return migration is influencing the epidemic dynamics in rural vs. urban contexts.\n Understand how the reported data from the core government testing system compares to estimated community prevalence dynamics to predict testing capacity gaps and refine future response.\n Determine sensitivity and specificity of GeneXpert Xpress testing using nasopharageal swabs or saliva against RT-PCR  for SARS CoV-2 infection.\n Sequence a cohort of 500 SARS CoV-2 samples to understand the patterns of repeated introduction, seeding and transmission occurring in rural and urban areas as the epidemic unfolds.\n\n","awardDateDateOnly":"2021-01-29","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Asia","Epidemics","Humans","Nepal","Transients and Migrants"]}
{"id":"360G-Wellcome-222102_Z_20_Z","title":"Investigating the mechanisms involved in HIV infection and cerebral endothelial dysfunction in a 3D human brain neurovascular spheroid. ","Region":"Greater London","currency":"GBP","awardDate":"2020-12-08T00:00:00+00:00","Sponsor(s)":"Prof Henry Mwandumba, Prof Mark Marsh, Prof Patric Turowski, Prof Tom Solomon, Prof Daniel Cutler","Internal ID":"222102/Z/20/Z","description":"Despite successfully suppressing HIV infection with antiretroviral therapy (ART), cerebrovascular disease, including stroke and cognitive impairment, remains a dominant complication in this population. I have shown that HIV is a leading risk factor of stroke in the young and can contribute to 15-30% of overall stroke presentations in endemic regions. There is good evidence that atherogenesis is part of the mechanism. Chronic inflammation and antiretrovirals are amongst confounders that obscure delineating the exact pathway to atherogenesis. The Neurovascular Unit (NVU) which consists of the cerebrovascular endothelium supported by astrocytes and pericytes is pivotal to maintaining blood vessel function and impeding HIV to enter the brain. To date, scientific advancement has been limited by developing experimental systems that replicates the NVU in its normal environment.  My fellowship proposes to use a powerful new in vitro multicellular 3D model of the NVU, with blood brain barrier (BBB) properties similar to those found in vivo, to investigate how HIV crosses the BBB, establishes NVU infection, and triggers endothelial dysfunction, a precursor for atherogenesis. Finally, I will exploit an established cohort of HIV patients with ART and phenotyped for cerebrovascular disease in Malawi, to verify the mechanistic insights from my in vitro findings.\n","plannedDates":[{"endDate":"2025-02-04T00:00:00+00:00","startDate":"2021-02-05T00:00:00+00:00","startDateDateOnly":"2021-02-05","endDateDateOnly":"2025-02-04"}],"amountAwarded":777721,"Financial Year":"2020/21","Lead Applicant":"Dr Laura Benjamin","grantProgramme":[{"title":"Clinical Research Career Development Fellowship","title_keyword":"Clinical Research Career Development Fellowship"}],"Applicant Surname":"Benjamin","Partnership Value":777721,"Approval Committee":"Clinical Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the mechanisms involved in HIV infection and cerebral endothelial dysfunction in a 3D human brain neurovascular spheroid.  Despite successfully suppressing HIV infection with antiretroviral therapy (ART), cerebrovascular disease, including stroke and cognitive impairment, remains a dominant complication in this population. I have shown that HIV is a leading risk factor of stroke in the young and can contribute to 15-30% of overall stroke presentations in endemic regions. There is good evidence that atherogenesis is part of the mechanism. Chronic inflammation and antiretrovirals are amongst confounders that obscure delineating the exact pathway to atherogenesis. The Neurovascular Unit (NVU) which consists of the cerebrovascular endothelium supported by astrocytes and pericytes is pivotal to maintaining blood vessel function and impeding HIV to enter the brain. To date, scientific advancement has been limited by developing experimental systems that replicates the NVU in its normal environment.  My fellowship proposes to use a powerful new in vitro multicellular 3D model of the NVU, with blood brain barrier (BBB) properties similar to those found in vivo, to investigate how HIV crosses the BBB, establishes NVU infection, and triggers endothelial dysfunction, a precursor for atherogenesis. Finally, I will exploit an established cohort of HIV patients with ART and phenotyped for cerebrovascular disease in Malawi, to verify the mechanistic insights from my in vitro findings.\n","awardDateDateOnly":"2020-12-08","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Blood-Brain Barrier","Brain","Endothelial Cells","HIV Infections","Humans","Malawi"]}
{"id":"360G-Wellcome-222101_Z_20_Z","title":"Neuroinflammation and its role in precision physiotherapy for patients with entrapment neuropathies","Region":"South East","currency":"GBP","awardDate":"2020-12-08T00:00:00+00:00","Sponsor(s)":"Prof Kevin Talbot","Internal ID":"222101/Z/20/Z","description":"Entrapment neuropathies are the most common conditions causing nerve-related pain. Even though Physiotherapy is the recommended treatment, research suggests only modest benefits. A major road-block is the lack of adequate patient stratification. My fellowship will address this by investigating the role of neuroinflammation in precision physiotherapy. The key goals are to 1) characterise human neuroinflammation, 2) validate magnetic resonance neurography (MRN) as a non-invasive marker and 3) determine whether physiotherapeutic exercises (neurodynamics) can reduce neuroinflammation. I will use longitudinal cohorts of patients with carpal tunnel syndrome (CTS) and Morton\u2019s neuroma undergoing surgery as model systems with unparalleled access to injured tissues (e.g., nerve, skin, tenosynovium, blood). I will characterise neuroinflammation and its relationship to symptoms in these samples using gene/protein expression and histological analyses. By directly comparing MRN with histological findings, I will determine its validity as a non-invasive marker for neuroinflammation. I will then perform a mechanistic trial to investigate whether neurodynamic exercises reduce neuroinflammation by measuring MRN before and after exercises or control interventions in CTS patients. My project will provide novel biological insights into neuroinflammation, and may revolutionise its clinical detection. The development of precision physiotherapy has high potential to reduce patients\u2019 suffering and decrease healthcare costs.\n","plannedDates":[{"endDate":"2026-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2026-03-31"}],"amountAwarded":1194434,"Financial Year":"2020/21","Lead Applicant":"Dr Annina Schmid","grantProgramme":[{"title":"Clinical Research Career Development Fellowship","title_keyword":"Clinical Research Career Development Fellowship"}],"Applicant Surname":"Schmid","Partnership Value":1194434,"Approval Committee":"Clinical Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Neuroinflammation and its role in precision physiotherapy for patients with entrapment neuropathies Entrapment neuropathies are the most common conditions causing nerve-related pain. Even though Physiotherapy is the recommended treatment, research suggests only modest benefits. A major road-block is the lack of adequate patient stratification. My fellowship will address this by investigating the role of neuroinflammation in precision physiotherapy. The key goals are to 1) characterise human neuroinflammation, 2) validate magnetic resonance neurography (MRN) as a non-invasive marker and 3) determine whether physiotherapeutic exercises (neurodynamics) can reduce neuroinflammation. I will use longitudinal cohorts of patients with carpal tunnel syndrome (CTS) and Morton\u2019s neuroma undergoing surgery as model systems with unparalleled access to injured tissues (e.g., nerve, skin, tenosynovium, blood). I will characterise neuroinflammation and its relationship to symptoms in these samples using gene/protein expression and histological analyses. By directly comparing MRN with histological findings, I will determine its validity as a non-invasive marker for neuroinflammation. I will then perform a mechanistic trial to investigate whether neurodynamic exercises reduce neuroinflammation by measuring MRN before and after exercises or control interventions in CTS patients. My project will provide novel biological insights into neuroinflammation, and may revolutionise its clinical detection. The development of precision physiotherapy has high potential to reduce patients\u2019 suffering and decrease healthcare costs.\n","awardDateDateOnly":"2020-12-08","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Carpal Tunnel Syndrome","Exercise Therapy","Humans","Magnetic Resonance Imaging","Physical Therapy Modalities","Research Design"]}
{"id":"360G-Wellcome-222098_Z_20_Z","title":"Antibody gene variation and infectious disease susceptibility","Region":"Greater London","currency":"GBP","awardDate":"2020-12-08T00:00:00+00:00","Sponsor(s)":"Prof Julian Knight, Prof Shiranee Sriskandan, Dr Ronald Gregg","Internal ID":"222098/Z/20/Z","description":"Antibodies are fundamental to defence against a wide range of infectious agents and yet antibody responses vary markedly from individual to individual. Although the reasons for this remain unclear, there is strong reason to suspect a role for immunoglobulin gene regions, not least because these are amongst the most variable in the human genome. In earlier work, I linked the immunoglobulin heavy chain (IGH) locus to susceptibility to the most serious diseases caused by Streptococcus pyogenes, a major global health concern, and I now wish to determine the biological basis for this association. This proposal therefore aims to test my hypothesis that common genetic variation in this locus impacts antibody-mediated immunity to S.pyogenes in a manner that alters disease susceptibility. To do this, using an innovative high-throughput long-read sequencing approach, I will establish the extent and nature of germline IGH variation in children and adults with and without severe infection. I will then assess the relationship between IGH variation and antibody-mediated immunity as well as susceptibility to severe infection. Moving forward, I plan to use this approach to identify and prioritise antigens for rationale design of highly targeted vaccines and antibody-based therapeutics to combat a range of infectious diseases.\n","plannedDates":[{"endDate":"2025-05-03T00:00:00+00:00","startDate":"2021-08-04T00:00:00+00:00","startDateDateOnly":"2021-08-04","endDateDateOnly":"2025-05-03"}],"amountAwarded":658017,"Financial Year":"2020/21","Lead Applicant":"Dr Thomas Parks","grantProgramme":[{"title":"Clinical Research Career Development Fellowship","title_keyword":"Clinical Research Career Development Fellowship"}],"Applicant Surname":"Parks","Partnership Value":658017,"Approval Committee":"Clinical Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Antibody gene variation and infectious disease susceptibility Antibodies are fundamental to defence against a wide range of infectious agents and yet antibody responses vary markedly from individual to individual. Although the reasons for this remain unclear, there is strong reason to suspect a role for immunoglobulin gene regions, not least because these are amongst the most variable in the human genome. In earlier work, I linked the immunoglobulin heavy chain (IGH) locus to susceptibility to the most serious diseases caused by Streptococcus pyogenes, a major global health concern, and I now wish to determine the biological basis for this association. This proposal therefore aims to test my hypothesis that common genetic variation in this locus impacts antibody-mediated immunity to S.pyogenes in a manner that alters disease susceptibility. To do this, using an innovative high-throughput long-read sequencing approach, I will establish the extent and nature of germline IGH variation in children and adults with and without severe infection. I will then assess the relationship between IGH variation and antibody-mediated immunity as well as susceptibility to severe infection. Moving forward, I plan to use this approach to identify and prioritise antigens for rationale design of highly targeted vaccines and antibody-based therapeutics to combat a range of infectious diseases.\n","awardDateDateOnly":"2020-12-08","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Child","Genetic Predisposition to Disease","High-Throughput Nucleotide Sequencing","Humans","Streptococcal Vaccines","Streptococcus pyogenes"]}
{"id":"360G-Wellcome-222097_Z_20_Z","title":"The OpenSafely Research Platform","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"222097/Z/20/Z","description":"OpenSAFELY is a new secure analytics platform for electronic health records in the NHS, created to deliver urgent results during the global COVID-19 emergency. It is now successfully delivering analyses across more than 24 million patients\u2019 full pseudonymised primary care NHS records, with more to follow shortly. All our analytic software is open for security review, scientific review, and re-use. OpenSAFELY uses a new model for enhanced security and timely access to data: we don\u2019t transport large volumes of potentially disclosive pseudonymised patient data outside of the secure environments managed by the electronic health record software company; instead, trusted analysts can run large scale computation across live pseudonymised patient records inside the data centre of the electronic health records software company. This pragmatic and secure approach has allowed us to deliver our first analyses in just five weeks from project start.\n","plannedDates":[{"endDate":"2023-11-09T00:00:00+00:00","startDate":"2020-11-10T00:00:00+00:00","startDateDateOnly":"2020-11-10","endDateDateOnly":"2023-11-09"}],"amountAwarded":2277389,"Financial Year":"2019/20","Lead Applicant":"Dr Ben Goldacre","grantProgramme":[{"title":"Discretionary Award \u2013 DSH","title_keyword":"Discretionary Award \u2013 DSH"}],"Applicant Surname":"Goldacre","Partnership Value":2277389,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The OpenSafely Research Platform OpenSAFELY is a new secure analytics platform for electronic health records in the NHS, created to deliver urgent results during the global COVID-19 emergency. It is now successfully delivering analyses across more than 24 million patients\u2019 full pseudonymised primary care NHS records, with more to follow shortly. All our analytic software is open for security review, scientific review, and re-use. OpenSAFELY uses a new model for enhanced security and timely access to data: we don\u2019t transport large volumes of potentially disclosive pseudonymised patient data outside of the secure environments managed by the electronic health record software company; instead, trusted analysts can run large scale computation across live pseudonymised patient records inside the data centre of the electronic health records software company. This pragmatic and secure approach has allowed us to deliver our first analyses in just five weeks from project start.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Computer Security","Electronic Health Records","Humans","Software"]}
{"id":"360G-Wellcome-222077_Z_20_Z","title":"OKRE: Opening Knowledge across Research and Entertainment","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"222077/Z/20/Z","description":"The proposal outlines the request for funding to support the set-up, operation and activities of OKRE: Opening Knowledge across Research and Entertainment over five years.\n\nOKRE is a high-profile strategic initiative for working with the entertainment industries that has been developed in partnership with UKRI. OKRE enables Wellcome to build on the work it has done so far, to scale its impact and create a more sustainable transformation in the engagement of research with mass media.\n\nA gap was identified between research and entertainment sectors for a body akin to the Science Media Centre but designed to address the particular challenges of working with the entertainment industries. OKRE's business model has now been developed and the organisation has been registered with Companies House and the Charity Commission.\n\nWellcome is uniquely positioned to establish such a body. Funding enables OKRE to deliver core services in line with Wellcome's new strategic vision. OKRE's objects include promoting research, advancing education of the public and advancing the arts in social, scientific and health-related issues, as well as promoting the efficiency and effectiveness of charities. By sharing infrastructure costs with other funders, OKRE will enable Wellcome to scale the impact of its funding.\n","plannedDates":[{"endDate":"2025-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2025-12-31"}],"amountAwarded":2758611,"Financial Year":"2019/20","Lead Applicant":"Dr Iain Dodgeon","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Dodgeon","Partnership Value":2758611,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Opening-Knowledge-Across-Research-and-Entertainment-OKRE","name":"Opening Knowledge Across Research and Entertainment (OKRE)","addressCountry":"United Kingdom","id_and_name":"[\"Opening Knowledge Across Research and Entertainment (OKRE)\", \"360G-Wellcome-ORG:Opening-Knowledge-Across-Research-and-Entertainment-OKRE\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Opening-Knowledge-Across-Research-and-Entertainment-OKRE","name":"Opening Knowledge Across Research and Entertainment (OKRE)"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"OKRE: Opening Knowledge across Research and Entertainment The proposal outlines the request for funding to support the set-up, operation and activities of OKRE: Opening Knowledge across Research and Entertainment over five years.\n\nOKRE is a high-profile strategic initiative for working with the entertainment industries that has been developed in partnership with UKRI. OKRE enables Wellcome to build on the work it has done so far, to scale its impact and create a more sustainable transformation in the engagement of research with mass media.\n\nA gap was identified between research and entertainment sectors for a body akin to the Science Media Centre but designed to address the particular challenges of working with the entertainment industries. OKRE's business model has now been developed and the organisation has been registered with Companies House and the Charity Commission.\n\nWellcome is uniquely positioned to establish such a body. Funding enables OKRE to deliver core services in line with Wellcome's new strategic vision. OKRE's objects include promoting research, advancing education of the public and advancing the arts in social, scientific and health-related issues, as well as promoting the efficiency and effectiveness of charities. By sharing infrastructure costs with other funders, OKRE will enable Wellcome to scale the impact of its funding.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Information Dissemination","Mass Media","United Kingdom"]}
{"id":"360G-Wellcome-222076_Z_20_Z","title":"Wellcome Leap Inc. \u2013 Main Award","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"222076/Z/20/Z","description":"Wellcome Leap Inc. has been established by Wellcome as a US, wholly owned not for profit entity with the aim of delivering breakthroughs in human health and demonstrate seemingly impossible results on seemingly impossible timescales. This will be achieved through the creation of a small portfolio of goal focused Programmes selected based upon their potential to improve health globally rather than by their potential financial or commercial return.\n\n \n\n\nWellcome provides initial funding of $306.9M to Leap to cover their first 10 years of operation (although further funding may be provided over this 10 years). This funding will support Leap\u2019s operational costs and \u2018Programmatic costs\u2019 which will include (but not be limited to) the employment of Programme Directors to build and orchestrate large research programmes, subject matter advice and support to formulate a programme and the funding of sub-awardees to carry out research in pursuit of a programme goal.\n\n\nWellcome may provide further funding to Leap after 3 years of operation and it is anticipated that Leap will in time attract funding from third parties.    ","plannedDates":[{"endDate":"2030-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2030-09-30"}],"amountAwarded":248240718,"Financial Year":"2019/20","Lead Applicant":"Dr Regina Dugan","grantProgramme":[{"title":"Wellcome Leap Inc. ","title_keyword":"Wellcome Leap Inc. "}],"Applicant Surname":"Dugan","Partnership Value":248240718,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Wellcome-Leap-Inc","name":"Wellcome Leap Inc.","addressCountry":"United States","id_and_name":"[\"Wellcome Leap Inc.\", \"360G-Wellcome-ORG:Wellcome-Leap-Inc\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Wellcome-Leap-Inc","name":"Wellcome Leap Inc."}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Wellcome Leap Inc. \u2013 Main Award Wellcome Leap Inc. has been established by Wellcome as a US, wholly owned not for profit entity with the aim of delivering breakthroughs in human health and demonstrate seemingly impossible results on seemingly impossible timescales. This will be achieved through the creation of a small portfolio of goal focused Programmes selected based upon their potential to improve health globally rather than by their potential financial or commercial return.\n\n \n\n\nWellcome provides initial funding of $306.9M to Leap to cover their first 10 years of operation (although further funding may be provided over this 10 years). This funding will support Leap\u2019s operational costs and \u2018Programmatic costs\u2019 which will include (but not be limited to) the employment of Programme Directors to build and orchestrate large research programmes, subject matter advice and support to formulate a programme and the funding of sub-awardees to carry out research in pursuit of a programme goal.\n\n\nWellcome may provide further funding to Leap after 3 years of operation and it is anticipated that Leap will in time attract funding from third parties.    ","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Financing, Government","Financing, Organized","Humans","Research Support as Topic","United States"]}
{"id":"360G-Wellcome-222075_Z_20_Z","title":"Maternal and Infant Lactation pharmacoKinetics (MILK)","Region":"North West","currency":"GBP","awardDate":"2020-12-08T00:00:00+00:00","Sponsor(s)":"Dr Barbara Castelnuovo, Prof Saye Khoo, Prof Gary Maartens, Prof Mark Turner","Internal ID":"222075/Z/20/Z","description":"Worldwide many women require drug treatment during breastfeeding, but data surrounding transfer of drug from mother to breastfed infant are scarce and of very low quality. This fellowship will provide robust pharmacological data to inform evidence-based decision-making, through collaboration between University of Liverpool, UK; Infectious Diseases Institute, Makerere University, Uganda (IDI); and University of Cape Town, South Africa (UCT).\n\nThe drug exposure of infants of breastfeeding mothers requiring treatment for TB (drug-sensitive or drug-resistant), malaria and peri-partum infection, identified as local priorities, will be described. Intensive pharmacokinetic sampling of maternal plasma, breastmilk and infant blood will be undertaken. Bioanalysis will be done in the country of study, with capacity building at IDI supported by Liverpool and UCT. Consolidation of an integrated clinical and modelling approach for clinical pharmacology at IDI will ensure the generation of high-quality, robust data, and a sustainable group generating fresh ideas and proposals alongside the fellowship.\n\nSouth-north knowledge transfer will help define research priorities for the UK and build expertise in lactation pharmacology in Liverpool. Public engagement activities in both the UK and Uganda will communicate about study activities and harness the views and concerns of community members and healthcare workers about medication use in breastfeeding.\n","plannedDates":[{"endDate":"2025-02-28T00:00:00+00:00","startDate":"2021-03-01T00:00:00+00:00","startDateDateOnly":"2021-03-01","endDateDateOnly":"2025-02-28"}],"amountAwarded":1155073,"Financial Year":"2020/21","Lead Applicant":"Dr Catriona Waitt","grantProgramme":[{"title":"Clinical Research Career Development Fellowship","title_keyword":"Clinical Research Career Development Fellowship"}],"Applicant Surname":"Waitt","Partnership Value":1155073,"Approval Committee":"Clinical Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool","addressCountry":"United Kingdom","id_and_name":"[\"University of Liverpool\", \"360G-Wellcome-ORG:University-of-Liverpool\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Maternal and Infant Lactation pharmacoKinetics (MILK) Worldwide many women require drug treatment during breastfeeding, but data surrounding transfer of drug from mother to breastfed infant are scarce and of very low quality. This fellowship will provide robust pharmacological data to inform evidence-based decision-making, through collaboration between University of Liverpool, UK; Infectious Diseases Institute, Makerere University, Uganda (IDI); and University of Cape Town, South Africa (UCT).\n\nThe drug exposure of infants of breastfeeding mothers requiring treatment for TB (drug-sensitive or drug-resistant), malaria and peri-partum infection, identified as local priorities, will be described. Intensive pharmacokinetic sampling of maternal plasma, breastmilk and infant blood will be undertaken. Bioanalysis will be done in the country of study, with capacity building at IDI supported by Liverpool and UCT. Consolidation of an integrated clinical and modelling approach for clinical pharmacology at IDI will ensure the generation of high-quality, robust data, and a sustainable group generating fresh ideas and proposals alongside the fellowship.\n\nSouth-north knowledge transfer will help define research priorities for the UK and build expertise in lactation pharmacology in Liverpool. Public engagement activities in both the UK and Uganda will communicate about study activities and harness the views and concerns of community members and healthcare workers about medication use in breastfeeding.\n","awardDateDateOnly":"2020-12-08","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Breast Feeding","Female","Humans","Infant, Newborn","Lactation","Malaria","South Africa","Uganda","United Kingdom"]}
{"id":"360G-Wellcome-222071_Z_20_Z","title":"The predictive basis of intensity and loudness processing","Region":"North East","currency":"GBP","awardDate":"2020-12-08T00:00:00+00:00","Sponsor(s)":"Dr Matthew Howard, Prof Karl Friston, Prof Timothy Griffiths","Internal ID":"222071/Z/20/Z","description":"Generative models of perception, such as predictive coding, are mainstays of contemporary  neuroscience. Whilst there is abundant evidence and theory concerning what is predicted and when it is expected, little is known about how predictive models influence how strongly sensations are received (i.e. their intensity, or its perceptual counterparts such as loudness).\n\nThis proposal builds upon the handful of studies demonstrating the existence of predictive processing of intensity, and on my own published work demonstrating that pathological states of perception (i.e. tinnitus) can be understood, and objectified, as pervasive states of aberrant sensory predictions. Its goal is a clear picture of the function and neurobiological basis of predictive intensity processing, which might subsequently lead to diagnostic and therapeutic avenues for clinical disorders such as tinnitus, chronic pain and fibromyalgia.\n\nThe investigative approach is multifaceted, examining a range of hierarchical levels through a progression of paradigm complexity, and using complementary neuroimaging modalities, including electroencephalography (EEG), magnetoencephalography (MEG), electrocorticography (ECoG) and functional MRI. The predominant focus is auditory intensity (and loudness) in normal-hearing controls, with a subset of successful paradigms being run in clinical populations (to demonstrate the practical relevance of measures obtained), and in the somatosensory system (to demonstrate modality-independent commonalities).\n","plannedDates":[{"endDate":"2026-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2026-06-30"}],"amountAwarded":1148941,"Financial Year":"2020/21","Lead Applicant":"Dr William Sedley","grantProgramme":[{"title":"Clinical Research Career Development Fellowship","title_keyword":"Clinical Research Career Development Fellowship"}],"Applicant Surname":"Sedley","Partnership Value":1148941,"Approval Committee":"Clinical Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Newcastle-University","name":"Newcastle University","addressCountry":"United Kingdom","id_and_name":"[\"Newcastle University\", \"360G-Wellcome-ORG:Newcastle-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Newcastle-University","name":"Newcastle University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The predictive basis of intensity and loudness processing Generative models of perception, such as predictive coding, are mainstays of contemporary  neuroscience. Whilst there is abundant evidence and theory concerning what is predicted and when it is expected, little is known about how predictive models influence how strongly sensations are received (i.e. their intensity, or its perceptual counterparts such as loudness).\n\nThis proposal builds upon the handful of studies demonstrating the existence of predictive processing of intensity, and on my own published work demonstrating that pathological states of perception (i.e. tinnitus) can be understood, and objectified, as pervasive states of aberrant sensory predictions. Its goal is a clear picture of the function and neurobiological basis of predictive intensity processing, which might subsequently lead to diagnostic and therapeutic avenues for clinical disorders such as tinnitus, chronic pain and fibromyalgia.\n\nThe investigative approach is multifaceted, examining a range of hierarchical levels through a progression of paradigm complexity, and using complementary neuroimaging modalities, including electroencephalography (EEG), magnetoencephalography (MEG), electrocorticography (ECoG) and functional MRI. The predominant focus is auditory intensity (and loudness) in normal-hearing controls, with a subset of successful paradigms being run in clinical populations (to demonstrate the practical relevance of measures obtained), and in the somatosensory system (to demonstrate modality-independent commonalities).\n","awardDateDateOnly":"2020-12-08","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Auditory Perception","Brain","Electroencephalography","Fibromyalgia","Humans","Magnetoencephalography","Tinnitus"]}
{"id":"360G-Wellcome-222064_Z_20_Z","title":"Institutional Translation Partnership Awards \u2018The University of Bristol Translational Partnership Award 3","Region":"South West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"222064/Z/20/Z","description":"This University of Bristol-Wellcome Trust Translational Partnership Award (TPA) will build on the successes and insights gained from the past three years of our partnership to deliver a sustained, impactful change in our translational research and culture. Our ambition is to turn University research into real world solutions which transform our society, economy and health. In this award we will continue to try new things, disrupt the status quo and advance the way we support and accelerate translation by taking a bespoke, personalised approach, driving culture change to maximise the impact of our research. We will use this funding to work with researchers at all stages of the career pathway (PhD to Professor) to develop and realise their ambitions to translate their research through: - A Translational Research Hub to enable straightforward access to expertise and funding and facilitate engagement with non-academic partners - Proof of Concept and Translation Accelerator project funding to meet gaps in the translational funding pathway - Early Career Translational Fellowships to provide bespoke support for the most promising individuals and projects - Developing Innovation Networks with partner organisations in priority modalities and areas - Exploiting the translational platforms developed from our cutting-edge synthetic biology and informatics technologies in TPA1 and 2 - Providing training to researchers that embeds learning into practice through follow-up support and individualised action plans","plannedDates":[{"endDate":"2024-05-31T00:00:00+00:00","startDate":"2021-06-01T00:00:00+00:00","startDateDateOnly":"2021-06-01","endDateDateOnly":"2024-05-31"}],"amountAwarded":1800000,"Financial Year":"2019/20","Lead Applicant":"Prof Jeremy Tavar\u00e9","grantProgramme":[{"title":"Innovations Translational Partnership Award","title_keyword":"Innovations Translational Partnership Award"}],"Applicant Surname":"Tavar\u00e9","Partnership Value":1800000,"Approval Committee":"Science, Innovation and Translation Programme Advisory Group","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Institutional Translation Partnership Awards \u2018The University of Bristol Translational Partnership Award 3 This University of Bristol-Wellcome Trust Translational Partnership Award (TPA) will build on the successes and insights gained from the past three years of our partnership to deliver a sustained, impactful change in our translational research and culture. Our ambition is to turn University research into real world solutions which transform our society, economy and health. In this award we will continue to try new things, disrupt the status quo and advance the way we support and accelerate translation by taking a bespoke, personalised approach, driving culture change to maximise the impact of our research. We will use this funding to work with researchers at all stages of the career pathway (PhD to Professor) to develop and realise their ambitions to translate their research through: - A Translational Research Hub to enable straightforward access to expertise and funding and facilitate engagement with non-academic partners - Proof of Concept and Translation Accelerator project funding to meet gaps in the translational funding pathway - Early Career Translational Fellowships to provide bespoke support for the most promising individuals and projects - Developing Innovation Networks with partner organisations in priority modalities and areas - Exploiting the translational platforms developed from our cutting-edge synthetic biology and informatics technologies in TPA1 and 2 - Providing training to researchers that embeds learning into practice through follow-up support and individualised action plans","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","Research Support as Topic","Translational Medical Research"]}
{"id":"360G-Wellcome-222062_Z_20_Z","title":"Institutional Translation Partnership Awards \u2018The University of Cambridge Translational Partnership Award 3","Region":"East of England","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"222062/Z/20/Z","description":"The University of Cambridge will use the TPA funding to bridge the gap between discovery science and early stage translation of projects. The aim is to encourage and support basic scientists to realise the translational potential of their research by providing integrated facilitation for training, expert advice, funding and projects through creation of a virtual Therapeutic Hub, which supports the TPA within CATS. Our objectives are:\n- To provide a gateway for translation into the therapeutics sciences pipeline through the creation of a virtual therapeutic hub;\n- To facilitate early stage drug discovery and translational research\n- To develop a community of Translational Champions across the University who will provide opportunities for Departments/Institutes to develop their own translational strategies\n- To deliver training in early translation for research scientists and early career academics.","plannedDates":[{"endDate":"2024-04-30T00:00:00+00:00","startDate":"2021-05-01T00:00:00+00:00","startDateDateOnly":"2021-05-01","endDateDateOnly":"2024-04-30"}],"amountAwarded":2250000,"Financial Year":"2019/20","Lead Applicant":"Prof Andy Neely","grantProgramme":[{"title":"Innovations Translational Partnership Award","title_keyword":"Innovations Translational Partnership Award"}],"Applicant Surname":"Neely","Partnership Value":2250000,"Approval Committee":"Science, Innovation and Translation Programme Advisory Group","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Institutional Translation Partnership Awards \u2018The University of Cambridge Translational Partnership Award 3 The University of Cambridge will use the TPA funding to bridge the gap between discovery science and early stage translation of projects. The aim is to encourage and support basic scientists to realise the translational potential of their research by providing integrated facilitation for training, expert advice, funding and projects through creation of a virtual Therapeutic Hub, which supports the TPA within CATS. Our objectives are:\n- To provide a gateway for translation into the therapeutics sciences pipeline through the creation of a virtual therapeutic hub;\n- To facilitate early stage drug discovery and translational research\n- To develop a community of Translational Champions across the University who will provide opportunities for Departments/Institutes to develop their own translational strategies\n- To deliver training in early translation for research scientists and early career academics.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Drug Discovery","Humans","Research Personnel","Research Support as Topic","Translational Medical Research"]}
{"id":"360G-Wellcome-222061_Z_20_Z","title":"Innovations Translational Partnership Award (Manchester)","Region":"North West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"222061/Z/20/Z","description":"The University of Manchester will use the three-year Wellcome Translational Partnership\nAward (TPA) renewal to build on the successful initiatives launched and delivered through the\nfirst TPA and continue to grow the translational research culture and develop the translational\necosystem in Manchester. The TPA funding will be used to address four aims: 1) support\ntranslational research; 2) connect across disciplines; 3) innovate with industry; and 4) change\nthe culture by embedding translational research across the University. The Translational\nResearch Facilitators will continue to bring together a network of support, facilities and\nexpertise to build better links between science, technology and innovation, by removing\nbarriers between disciplines to make the pathway to translation quicker and easier. The TPA\nwill support translational research across all the stages of the translational pathway through\npump-priming funding schemes, training (particularly informatics), symposiums and\nworkshops, with a particular emphasis on new initiatives to support early career researchers.\nThe Translation Manchester Research Network (TMRN), established under the initial TPA,\nbrings together groups and organisations that exist to facilitate translational research across\nthe One Manchester health innovation ecosystem, making it the \u2018one-stop-shop\u2019 for\ntranslational research support. The TMRN will continue to play a key role in the delivery of the\ninitiatives set out in the TPA renewal. In addition, Innovation Labs will connect academics with\nindustry partners, and pump-prime new collaborations and innovation through seed corn\nfunding. The Research Connections Tool will enable researchers and clinicians to easily find\nappropriate collaborators across the University and our partner NHS trusts. To support\ndelivery of these new initiatives a Translational Research Support Officer and a Translational\nResearch Bioinformatician will be recruited into the Translation Manchester team.","plannedDates":[{"endDate":"2024-11-08T00:00:00+00:00","startDate":"2021-11-09T00:00:00+00:00","startDateDateOnly":"2021-11-09","endDateDateOnly":"2024-11-08"}],"amountAwarded":2397523,"Financial Year":"2019/20","Lead Applicant":"Prof Luke Georghiou","grantProgramme":[{"title":"Innovations Translational Partnership Award","title_keyword":"Innovations Translational Partnership Award"}],"Applicant Surname":"Georghiou","Partnership Value":2397523,"Approval Committee":"Science, Innovation and Translation Programme Advisory Group","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Innovations Translational Partnership Award (Manchester) The University of Manchester will use the three-year Wellcome Translational Partnership\nAward (TPA) renewal to build on the successful initiatives launched and delivered through the\nfirst TPA and continue to grow the translational research culture and develop the translational\necosystem in Manchester. The TPA funding will be used to address four aims: 1) support\ntranslational research; 2) connect across disciplines; 3) innovate with industry; and 4) change\nthe culture by embedding translational research across the University. The Translational\nResearch Facilitators will continue to bring together a network of support, facilities and\nexpertise to build better links between science, technology and innovation, by removing\nbarriers between disciplines to make the pathway to translation quicker and easier. The TPA\nwill support translational research across all the stages of the translational pathway through\npump-priming funding schemes, training (particularly informatics), symposiums and\nworkshops, with a particular emphasis on new initiatives to support early career researchers.\nThe Translation Manchester Research Network (TMRN), established under the initial TPA,\nbrings together groups and organisations that exist to facilitate translational research across\nthe One Manchester health innovation ecosystem, making it the \u2018one-stop-shop\u2019 for\ntranslational research support. The TMRN will continue to play a key role in the delivery of the\ninitiatives set out in the TPA renewal. In addition, Innovation Labs will connect academics with\nindustry partners, and pump-prime new collaborations and innovation through seed corn\nfunding. The Research Connections Tool will enable researchers and clinicians to easily find\nappropriate collaborators across the University and our partner NHS trusts. To support\ndelivery of these new initiatives a Translational Research Support Officer and a Translational\nResearch Bioinformatician will be recruited into the Translation Manchester team.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Cooperative Behavior","Humans","Research Personnel","Research Support as Topic","Translational Medical Research","United States"]}
{"id":"360G-Wellcome-222060_Z_20_Z","title":"Translational Partnerships Award: 3 Year Renewal","Region":"Scotland","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"222060/Z/20/Z","description":"Since 2018, the University of Edinburgh has been in receipt of a Wellcome Institutional\nTranslation Partnership Award which has now been renewed for a further three years. The\nambition of the partnership is to engage Wellcome Trust funded researchers and all of those\nworking within the Wellcome Trust scientific remit, to identify and develop early stage\ntranslational opportunities within their research. Edinburgh embedded its scheme within\nEdinburgh Innovations building a small focused team, including two Entrepreneurs-in-\nResidence with a successful commercial/translational background to nurture projects towards\ntranslation through leveraging future funding, industry collaborations or commercialisation plus\na dedicated Project Manager. Since inception, the program has engaged with hundreds of\nresearchers, providing mentoring and support.\nRenewal of the award will allow access to translational support and funding across the\nUniversity at scale. This will make beginning and navigating the translational journey for all\nresearchers easier and increase the diversity of the translational portfolio both in terms of\nthematic area and forms of impact.","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2021-10-01T00:00:00+00:00","startDateDateOnly":"2021-10-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":2401000,"Financial Year":"2019/20","Lead Applicant":"Prof Jonathan Seckl","grantProgramme":[{"title":"Innovations Translational Partnership Award","title_keyword":"Innovations Translational Partnership Award"}],"Applicant Surname":"Seckl","Partnership Value":2401000,"Approval Committee":"Science, Innovation and Translation Programme Advisory Group","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Translational Partnerships Award: 3 Year Renewal Since 2018, the University of Edinburgh has been in receipt of a Wellcome Institutional\nTranslation Partnership Award which has now been renewed for a further three years. The\nambition of the partnership is to engage Wellcome Trust funded researchers and all of those\nworking within the Wellcome Trust scientific remit, to identify and develop early stage\ntranslational opportunities within their research. Edinburgh embedded its scheme within\nEdinburgh Innovations building a small focused team, including two Entrepreneurs-in-\nResidence with a successful commercial/translational background to nurture projects towards\ntranslation through leveraging future funding, industry collaborations or commercialisation plus\na dedicated Project Manager. Since inception, the program has engaged with hundreds of\nresearchers, providing mentoring and support.\nRenewal of the award will allow access to translational support and funding across the\nUniversity at scale. This will make beginning and navigating the translational journey for all\nresearchers easier and increase the diversity of the translational portfolio both in terms of\nthematic area and forms of impact.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Cooperative Behavior","Humans","Research Personnel","Translational Medical Research","United States","Universities"]}
{"id":"360G-Wellcome-222057_Z_20_Z","title":"Outbreak Science Rapid PREreview \u2013 COVID-19 response","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"222057/Z/20/Z","description":"The coronavirus pandemic has led to an unprecedented uptake of preprints, with researchers from all over the globe collaborating and sharing information at record speeds. The Wellcome Trust-funded open source platform Outbreak Science Rapid PREreview (https://outbreaksci.prereview.org) launched by our team on January 1, 2020, is well-positioned to help provide rapid feedback and a help filter the high number of COVID-19 preprints for quality and potential impact. \n\nIn just a few months, the platform has reached about 500 users, 80 rapid reviews, and more than 230 requests for reviews, the majority of which are for COVID-19-related preprints. These numbers grow every day, and so do opportunities for collaborations with third-party sites and efforts that can increase the discoverability of the content and accessibility to the tool. \n\nTo leverage our platform and aid in tackling this pandemic, our team asks for financial support for the following activities and positions:\n\n\n \n Feature implementation and customization of our open API to make COVID-19-related content more discoverable via integration with third-party sites, such as preprint servers and research platforms;\n \n \n A full-time project manager to lead and coordinate the work. \n \n\n","plannedDates":[{"endDate":"2021-06-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-06-30"}],"amountAwarded":32419,"Financial Year":"2019/20","Lead Applicant":"Dr Daniela Saderi","grantProgramme":[{"title":"Discretionary Award - Open research","title_keyword":"Discretionary Award - Open research"}],"Applicant Surname":"Saderi","Partnership Value":32419,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Code-for-Science-and-Society","name":"Code for Science and Society","addressCountry":"United States","id_and_name":"[\"Code for Science and Society\", \"360G-Wellcome-ORG:Code-for-Science-and-Society\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Code-for-Science-and-Society","name":"Code for Science and Society"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Outbreak Science Rapid PREreview \u2013 COVID-19 response The coronavirus pandemic has led to an unprecedented uptake of preprints, with researchers from all over the globe collaborating and sharing information at record speeds. The Wellcome Trust-funded open source platform Outbreak Science Rapid PREreview (https://outbreaksci.prereview.org) launched by our team on January 1, 2020, is well-positioned to help provide rapid feedback and a help filter the high number of COVID-19 preprints for quality and potential impact. \n\nIn just a few months, the platform has reached about 500 users, 80 rapid reviews, and more than 230 requests for reviews, the majority of which are for COVID-19-related preprints. These numbers grow every day, and so do opportunities for collaborations with third-party sites and efforts that can increase the discoverability of the content and accessibility to the tool. \n\nTo leverage our platform and aid in tackling this pandemic, our team asks for financial support for the following activities and positions:\n\n\n \n Feature implementation and customization of our open API to make COVID-19-related content more discoverable via integration with third-party sites, such as preprint servers and research platforms;\n \n \n A full-time project manager to lead and coordinate the work. \n \n\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Coronavirus","Coronavirus Infections","Disease Outbreaks","Humans","Pandemics"]}
{"id":"360G-Wellcome-222056_Z_20_Z","title":"Designer biology to live image purine metabolism at single-cell resolution","Region":"East of England","currency":"GBP","awardDate":"2020-12-08T00:00:00+00:00","Sponsor(s)":"Prof Arthur Kaser, Dr Samie R Jaffrey","Internal ID":"222056/Z/20/Z","description":"I recently discovered the function of a previously uncharacterised gene, FAMIN, that is linked to Crohn\u2019s disease, leprosy and arthritis. A multifunctional purine enzyme, FAMIN is the pacesetter for purine recycling and hence determines cellular redox status, pH balance and energy production. Altogether, these control macrophage functions, such as bacterial killing and cytokine production. Importantly, my work has established this therapeutically targetable purine pathway as a direct driver of human inflammatory disease. However, further investigation of this pathway is currently limited by the inability to directly visualise and study purine metabolites in-situ, in real-time, and at single-cell resolution. Thus, the spatiotemporal dynamics of purine metabolism are mostly unknown. Assessing these dynamics will be crucial in understanding how purine dysfunction emerges in individual cells and can influence disease pathogenesis, for example through affecting redox state. Samie Jaffrey has pioneered technology that could overcome this hurdle. His group has generated programmable RNA-biosensors capable of live-imaging metabolites in single cells. I intend to learn these techniques and will engineer bespoke sensors for purine metabolites. I shall use these biosensors to dynamically track purine metabolism, and interrogate how environmental triggers can cause the purine dysfunction seen in numerous pathological contexts including chronic inflammatory diseases.\n","plannedDates":[{"endDate":"2025-04-11T00:00:00+00:00","startDate":"2021-04-12T00:00:00+00:00","startDateDateOnly":"2021-04-12","endDateDateOnly":"2025-04-11"}],"amountAwarded":811808,"Financial Year":"2020/21","Lead Applicant":"Dr Zaeem Cader","grantProgramme":[{"title":"Clinical Research Career Development Fellowship","title_keyword":"Clinical Research Career Development Fellowship"}],"Applicant Surname":"Cader","Partnership Value":811808,"Approval Committee":"Clinical Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Designer biology to live image purine metabolism at single-cell resolution I recently discovered the function of a previously uncharacterised gene, FAMIN, that is linked to Crohn\u2019s disease, leprosy and arthritis. A multifunctional purine enzyme, FAMIN is the pacesetter for purine recycling and hence determines cellular redox status, pH balance and energy production. Altogether, these control macrophage functions, such as bacterial killing and cytokine production. Importantly, my work has established this therapeutically targetable purine pathway as a direct driver of human inflammatory disease. However, further investigation of this pathway is currently limited by the inability to directly visualise and study purine metabolites in-situ, in real-time, and at single-cell resolution. Thus, the spatiotemporal dynamics of purine metabolism are mostly unknown. Assessing these dynamics will be crucial in understanding how purine dysfunction emerges in individual cells and can influence disease pathogenesis, for example through affecting redox state. Samie Jaffrey has pioneered technology that could overcome this hurdle. His group has generated programmable RNA-biosensors capable of live-imaging metabolites in single cells. I intend to learn these techniques and will engineer bespoke sensors for purine metabolites. I shall use these biosensors to dynamically track purine metabolism, and interrogate how environmental triggers can cause the purine dysfunction seen in numerous pathological contexts including chronic inflammatory diseases.\n","awardDateDateOnly":"2020-12-08","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biosensing Techniques","Humans","Oxidation-Reduction","Purines","Single-Cell Analysis"]}
{"id":"360G-Wellcome-222055_Z_20_Z","title":"Tackling Taboos: Co-creating startup solutions for under-served health issues","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"222055/Z/20/Z","description":"The early stages of health startups are science-rich environments that provide opportunities for the public to engage in health research and co-design new solutions. However, many user groups - especially those who are underserved by existing digital health solutions - are not empowered to engage with the research activities of startups. This is particularly evident for health issues considered \u2018taboo\u2019, such as incontinence, menopause, fertility, IBS, and mental ill-health. The result is a startup landscape that is overly focused on a narrow set of health issues and populations. \n\nThis project will launch a new programme of public engagement at Zinc, providing formal support and a structured programme to ~6 startups that are science-rich, dealing with taboo health issues, and committed to empowering underrepresented \u2018expert users\u2019. Working closely with specialist consultants, we will create opportunities for the public to contribute to, and learn about, health research and innovation. This work will advance the evidence-base for public engagement - in particular, our understanding of how founders and researchers can more effectively engage with publics underserved by digital health solutions. Longer-term, our aim is that this will lead to better integration of academic health research, public engagement, and commercial tech innovation.\n","plannedDates":[{"endDate":"2021-11-15T00:00:00+00:00","startDate":"2020-11-16T00:00:00+00:00","startDateDateOnly":"2020-11-16","endDateDateOnly":"2021-11-15"}],"amountAwarded":240000,"Financial Year":"2019/20","Lead Applicant":"Dr Rachel Carey","grantProgramme":[{"title":"Discretionary Award - Public Engagement","title_keyword":"Discretionary Award - Public Engagement"}],"Applicant Surname":"Carey","Partnership Value":240000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Zinc","name":"Zinc","addressCountry":"United Kingdom","id_and_name":"[\"Zinc\", \"360G-Wellcome-ORG:Zinc\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Zinc","name":"Zinc"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Tackling Taboos: Co-creating startup solutions for under-served health issues The early stages of health startups are science-rich environments that provide opportunities for the public to engage in health research and co-design new solutions. However, many user groups - especially those who are underserved by existing digital health solutions - are not empowered to engage with the research activities of startups. This is particularly evident for health issues considered \u2018taboo\u2019, such as incontinence, menopause, fertility, IBS, and mental ill-health. The result is a startup landscape that is overly focused on a narrow set of health issues and populations. \n\nThis project will launch a new programme of public engagement at Zinc, providing formal support and a structured programme to ~6 startups that are science-rich, dealing with taboo health issues, and committed to empowering underrepresented \u2018expert users\u2019. Working closely with specialist consultants, we will create opportunities for the public to contribute to, and learn about, health research and innovation. This work will advance the evidence-base for public engagement - in particular, our understanding of how founders and researchers can more effectively engage with publics underserved by digital health solutions. Longer-term, our aim is that this will lead to better integration of academic health research, public engagement, and commercial tech innovation.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans"]}
{"id":"360G-Wellcome-222053_Z_20_Z","title":"Healthy Food, Healthy Planet (Europe)","Region":"International","currency":"GBP","awardDate":"2020-10-28T00:00:00+00:00","Internal ID":"222053/Z/20/Z","description":"Healthy Food, Healthy Planet (Europe) (hereafter HFHP) is a collaboration of philanthropic and civil society organizations. Our goal is to support the formation of a movement across Europe advocating for a global food system compatible with climate, health, biodiversity, animal welfare, and just transition goals. \n\nTo execute a scoping strategy and facilitate scoping phase grantmaking of HFHP, ClimateWorks Foundation will establish a pooled fund with an option for aligned funding. The HFHP Fund has a target size of approximately USD $1 million, and will be managed by ClimateWorks. \n\nThe project will have two phases. The first phase will run from June to October 2020. It will culminate in an investment prospectus indicating opportunities for donors to support a European food movement. The second phase will run from October 2020 to July 2021 and will culminate in a strategic framework describing tactics for the movement. \n\nThe activities of both phases of HFHP will be overseen by a Project Lead who will design and execute consultative processes, work to ensure that research deployed and the materials produced reflect priorities of civil society, and incorporate learning from the research and consultative processes in the investment prospectus and the strategic framework.\n","plannedDates":[{"endDate":"2022-05-01T00:00:00+00:00","startDate":"2020-11-01T00:00:00+00:00","startDateDateOnly":"2020-11-01","endDateDateOnly":"2022-05-01"}],"amountAwarded":193379,"Financial Year":"2020/21","Lead Applicant":"Mr Avery Cohn","grantProgramme":[{"title":"Discretionary Award - OPOH","title_keyword":"Discretionary Award - OPOH"}],"Applicant Surname":"Cohn","Partnership Value":193379,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Climateworks-Foundation","name":"Climateworks Foundation","addressCountry":"United States","id_and_name":"[\"Climateworks Foundation\", \"360G-Wellcome-ORG:Climateworks-Foundation\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Climateworks-Foundation","name":"Climateworks Foundation"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Healthy Food, Healthy Planet (Europe) Healthy Food, Healthy Planet (Europe) (hereafter HFHP) is a collaboration of philanthropic and civil society organizations. Our goal is to support the formation of a movement across Europe advocating for a global food system compatible with climate, health, biodiversity, animal welfare, and just transition goals. \n\nTo execute a scoping strategy and facilitate scoping phase grantmaking of HFHP, ClimateWorks Foundation will establish a pooled fund with an option for aligned funding. The HFHP Fund has a target size of approximately USD $1 million, and will be managed by ClimateWorks. \n\nThe project will have two phases. The first phase will run from June to October 2020. It will culminate in an investment prospectus indicating opportunities for donors to support a European food movement. The second phase will run from October 2020 to July 2021 and will culminate in a strategic framework describing tactics for the movement. \n\nThe activities of both phases of HFHP will be overseen by a Project Lead who will design and execute consultative processes, work to ensure that research deployed and the materials produced reflect priorities of civil society, and incorporate learning from the research and consultative processes in the investment prospectus and the strategic framework.\n","awardDateDateOnly":"2020-10-28","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biodiversity","Europe","Food","Food Supply","Humans"]}
{"id":"360G-Wellcome-222052_Z_20_Z","title":"X-gene functions in spermatogonia, and their role in idiopathic and sex chromosome aneuploidy associated infertility.","Region":"Greater London","currency":"GBP","awardDate":"2020-12-08T00:00:00+00:00","Sponsor(s)":"Dr James Turner, Prof Fiona Watt","Internal ID":"222052/Z/20/Z","description":"The sex chromosomes underscore basic differences between males and females, and the X and Y chromosomes have specialized functions in the gonad and germ cells. Sex chromosome aneuploidies, i.e.  Klinefelter (XXY), Turner (XO) and double-Y (XYY) syndromes), form the largest group of chromosomal abnormalities and are associated with infertility. While recent studies have defined the mechanisms for germ cell loss in XO and XYY mice, Klinefelter syndrome (KS) infertility remains poorly understood. KS males experience an early spermatogonial block and germ cell loss initiates in utero. The early loss of gonadal function has significant long-term consequences.\n\nGametogenesis in males occurs throughout their lifespan and relies on germline (spermatogonial) stem cells (SSCs), differing with females. Recent work from our group has identified the concerted activity of gene networks in driving spermatogenesis, and unique regulation of X-linked genes during this process. We observe that a number of X-genes express specifically in SSCs. However, regulation of SSCs self-renewal vs. differentiation dynamics, and the functional importance of X-linked genes in this process, remain poorly understood. We aim to understand physiological gene regulatory networks functional in SSCs using a combination of single-cell methods, to explain how perturbation in X-gene dosage in SSCs may cause infertility.\n","plannedDates":[{"endDate":"2026-04-05T00:00:00+00:00","startDate":"2021-04-06T00:00:00+00:00","startDateDateOnly":"2021-04-06","endDateDateOnly":"2026-04-05"}],"amountAwarded":1588250,"Financial Year":"2020/21","Lead Applicant":"Dr Mahesh Sangrithi","grantProgramme":[{"title":"Clinical Research Career Development Fellowship","title_keyword":"Clinical Research Career Development Fellowship"}],"Applicant Surname":"Sangrithi","Partnership Value":1588250,"Approval Committee":"Clinical Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"X-gene functions in spermatogonia, and their role in idiopathic and sex chromosome aneuploidy associated infertility. The sex chromosomes underscore basic differences between males and females, and the X and Y chromosomes have specialized functions in the gonad and germ cells. Sex chromosome aneuploidies, i.e.  Klinefelter (XXY), Turner (XO) and double-Y (XYY) syndromes), form the largest group of chromosomal abnormalities and are associated with infertility. While recent studies have defined the mechanisms for germ cell loss in XO and XYY mice, Klinefelter syndrome (KS) infertility remains poorly understood. KS males experience an early spermatogonial block and germ cell loss initiates in utero. The early loss of gonadal function has significant long-term consequences.\n\nGametogenesis in males occurs throughout their lifespan and relies on germline (spermatogonial) stem cells (SSCs), differing with females. Recent work from our group has identified the concerted activity of gene networks in driving spermatogenesis, and unique regulation of X-linked genes during this process. We observe that a number of X-genes express specifically in SSCs. However, regulation of SSCs self-renewal vs. differentiation dynamics, and the functional importance of X-linked genes in this process, remain poorly understood. We aim to understand physiological gene regulatory networks functional in SSCs using a combination of single-cell methods, to explain how perturbation in X-gene dosage in SSCs may cause infertility.\n","awardDateDateOnly":"2020-12-08","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cell Differentiation","Female","Gene Regulatory Networks","Male","Mice","Spermatogenesis","Spermatogonia","Stem Cells"]}
{"id":"360G-Wellcome-222049_Z_20_Z","title":"Disorders of human pubertal timing","Region":"Greater London","currency":"GBP","awardDate":"2020-12-08T00:00:00+00:00","Sponsor(s)":"Prof Mark Caulfield, Prof Rebecca Oakey","Internal ID":"222049/Z/20/Z","description":"My proposal is focused on understanding the genetic basis, and consequently the pathophysiology, underpinning disordered human puberty.\n\nPubertal disorders are common, but associated with severe comorbidities. Delayed puberty presents a diagnostic challenge in adolescence, as conditions of gonadotropin deficiency and isolated delayed puberty display the same clinical and biochemical phenotype. However, correct management is vital because the former is associated with infertility and requires intensive reproductive therapy, whereas the latter is self-limiting but associated with a shortened reproductive lifespan. The biological mechanisms of precocious puberty, a condition associated with increased long-term cardiovascular and cancer risk and thus with significant impact on public health, remain similarly opaque. \n\nThe identification of causal genetic defects in disordered puberty allows interrogation of the key regulators of human puberty. \n\nI will use whole genome sequencing, comparative transcriptomics and methylomics studies in my large human cohort with disordered puberty, to define shared exonic and regulatory mutations resulting in delayed and precocious puberty. I aim to characterise the biological mechanisms underlying pubertal disorders through functional characterisation of novel genomic defects using cellular assays and animal models. These findings will ultimately translate to improved diagnostics, tailored therapeutic management and improved long-term outcomes for patients with disorders of puberty.\n","plannedDates":[{"endDate":"2025-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2025-08-31"}],"amountAwarded":611636,"Financial Year":"2020/21","Lead Applicant":"Dr Sasha Howard","grantProgramme":[{"title":"Clinical Research Career Development Fellowship","title_keyword":"Clinical Research Career Development Fellowship"}],"Applicant Surname":"Howard","Partnership Value":611636,"Approval Committee":"Clinical Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Queen-Mary-University-of-London","name":"Queen Mary University of London","addressCountry":"United Kingdom","id_and_name":"[\"Queen Mary University of London\", \"360G-Wellcome-ORG:Queen-Mary-University-of-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Queen-Mary-University-of-London","name":"Queen Mary University of London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Disorders of human pubertal timing My proposal is focused on understanding the genetic basis, and consequently the pathophysiology, underpinning disordered human puberty.\n\nPubertal disorders are common, but associated with severe comorbidities. Delayed puberty presents a diagnostic challenge in adolescence, as conditions of gonadotropin deficiency and isolated delayed puberty display the same clinical and biochemical phenotype. However, correct management is vital because the former is associated with infertility and requires intensive reproductive therapy, whereas the latter is self-limiting but associated with a shortened reproductive lifespan. The biological mechanisms of precocious puberty, a condition associated with increased long-term cardiovascular and cancer risk and thus with significant impact on public health, remain similarly opaque. \n\nThe identification of causal genetic defects in disordered puberty allows interrogation of the key regulators of human puberty. \n\nI will use whole genome sequencing, comparative transcriptomics and methylomics studies in my large human cohort with disordered puberty, to define shared exonic and regulatory mutations resulting in delayed and precocious puberty. I aim to characterise the biological mechanisms underlying pubertal disorders through functional characterisation of novel genomic defects using cellular assays and animal models. These findings will ultimately translate to improved diagnostics, tailored therapeutic management and improved long-term outcomes for patients with disorders of puberty.\n","awardDateDateOnly":"2020-12-08","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adolescent","Animals","Child","Female","Humans","Puberty","Puberty, Delayed","Puberty, Precocious","Sexual Maturation"]}
{"id":"360G-Wellcome-222048_Z_20_Z","title":"Enabling ISARIC Clinical Characterisation Protocol (CCP) roll out in LMICs","Region":"South East","currency":"GBP","awardDate":"2021-03-31T00:00:00+00:00","Internal ID":"222048/Z/20/Z","description":"By bringing GOARN Research and ISARIC partners together in the LMIC setting during COVID-19 we hope to strengthen the clinical, social science  and operational research response. \n\nAim: to support the roll out of the ISARIC WHO natural history protocol (known as the Clinical Characterisation Protocol - CCP) across LMICs: \n\nOverarching goals:  \n\n\n \n Support the roll out/uptake of the CCP across 5 countries per region, where feasible* (across four ISARIC regions of S America, Africa, S Asia  &  SE Asia).   \n \n\n\n\n \n Support the set up and running of local dynamic clinical data dashboards in at least 10 sites per ISARIC region \n \n\n\n\n \n Share the aggregate data with WHO to assist with providing a global picture on the incidence and presentation of moderate to severe cases across a representation of the LMICs to inform clinical management and public health planning and control.  \n \n\n\n\n \n Support the establishment of follow up modules and programmes for discharged hospitalised cases in 5 sites per region to evaluate longer term health impacts of COVID-19 on individual, health services and society to inform prevention and care planning.  \n \n\n\n \n\n*Brazil are in an intense first wave and reaching out to another 4 S. American countries would be challenging at the time of writing. \n","plannedDates":[{"endDate":"2022-11-28T00:00:00+00:00","startDate":"2021-06-01T00:00:00+00:00","startDateDateOnly":"2021-06-01","endDateDateOnly":"2022-11-28"}],"amountAwarded":340531,"Financial Year":"2020/21","Lead Applicant":"Dr Gail Carson","grantProgramme":[{"title":"Coronavirus","title_keyword":"Coronavirus"}],"Partnership Name":"Wellcome-DFID Epidemic Preparedness","Applicant Surname":"Carson","Partnership Value":340531,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Janice Caoili, Dr Muge Cevik, Dr Fernando Bozza, Dr John Amuasi, Dr Janet Scott, Prof Madiha Hashmi","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Enabling ISARIC Clinical Characterisation Protocol (CCP) roll out in LMICs By bringing GOARN Research and ISARIC partners together in the LMIC setting during COVID-19 we hope to strengthen the clinical, social science  and operational research response. \n\nAim: to support the roll out of the ISARIC WHO natural history protocol (known as the Clinical Characterisation Protocol - CCP) across LMICs: \n\nOverarching goals:  \n\n\n \n Support the roll out/uptake of the CCP across 5 countries per region, where feasible* (across four ISARIC regions of S America, Africa, S Asia  &  SE Asia).   \n \n\n\n\n \n Support the set up and running of local dynamic clinical data dashboards in at least 10 sites per ISARIC region \n \n\n\n\n \n Share the aggregate data with WHO to assist with providing a global picture on the incidence and presentation of moderate to severe cases across a representation of the LMICs to inform clinical management and public health planning and control.  \n \n\n\n\n \n Support the establishment of follow up modules and programmes for discharged hospitalised cases in 5 sites per region to evaluate longer term health impacts of COVID-19 on individual, health services and society to inform prevention and care planning.  \n \n\n\n \n\n*Brazil are in an intense first wave and reaching out to another 4 S. American countries would be challenging at the time of writing. \n","awardDateDateOnly":"2021-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Asia","Brazil","Humans","Research Design"]}
{"id":"360G-Wellcome-222047_Z_20_Z","title":"UNITE Global Summit: Virtual 2020","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"222047/Z/20/Z","description":"The Wellcome Trust Fund and UNITE collaborate to build the capacity of parliamentarians to advocate for the elimination of infectious diseases in their countries and around the world. Collaborations include activities designed to strengthen the exchange of evidence-based knowledge through dialogue and information sharing on infectious diseases, legislative processes and policymaking.\n\nThe UNITE Global Summit: Virtual 2020 will convene online on 7-8 September 2020. This event will bring together members of parliament from around the world in order to commit, inspire and empower policy makers towards the achievement of the UN Sustainable Development Goals over the next decade. Participants will work to develop a roadmap of clear policy actions to eliminate the threats posed by communicable diseases. This alignment of a common vision will culminate in the signing of UNITE\u2019s 2020 Declaration.\n\nWellcome Trust will play a key role in Panel Session 1: Epidemics \u2013 What are we learning from the global response to COVID-19, by co-sponsoring the UNITE Global Summit: Virtual 2020 with the Coalition for Epidemic Preparedness and Innovations (CEPI).\n","plannedDates":[{"endDate":"2020-10-20T00:00:00+00:00","startDate":"2020-08-20T00:00:00+00:00","startDateDateOnly":"2020-08-20","endDateDateOnly":"2020-10-20"}],"amountAwarded":2252,"Financial Year":"2019/20","Lead Applicant":"Mr Filipe Marques","grantProgramme":[{"title":"Discretionary Award - Policy ","title_keyword":"Discretionary Award - Policy "}],"Applicant Surname":"Marques","Partnership Value":2252,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:UNITE-Association-of-Parliamentarians-to-End-Infectious-Diseases","name":"UNITE - Association of Parliamentarians to End Infectious Diseases","addressCountry":"Portugal","id_and_name":"[\"UNITE - Association of Parliamentarians to End Infectious Diseases\", \"360G-Wellcome-ORG:UNITE-Association-of-Parliamentarians-to-End-Infectious-Diseases\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:UNITE-Association-of-Parliamentarians-to-End-Infectious-Diseases","name":"UNITE - Association of Parliamentarians to End Infectious Diseases"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"UNITE Global Summit: Virtual 2020 The Wellcome Trust Fund and UNITE collaborate to build the capacity of parliamentarians to advocate for the elimination of infectious diseases in their countries and around the world. Collaborations include activities designed to strengthen the exchange of evidence-based knowledge through dialogue and information sharing on infectious diseases, legislative processes and policymaking.\n\nThe UNITE Global Summit: Virtual 2020 will convene online on 7-8 September 2020. This event will bring together members of parliament from around the world in order to commit, inspire and empower policy makers towards the achievement of the UN Sustainable Development Goals over the next decade. Participants will work to develop a roadmap of clear policy actions to eliminate the threats posed by communicable diseases. This alignment of a common vision will culminate in the signing of UNITE\u2019s 2020 Declaration.\n\nWellcome Trust will play a key role in Panel Session 1: Epidemics \u2013 What are we learning from the global response to COVID-19, by co-sponsoring the UNITE Global Summit: Virtual 2020 with the Coalition for Epidemic Preparedness and Innovations (CEPI).\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Communicable Diseases","Epidemics","Global Health","Humans","Trust"]}
{"id":"360G-Wellcome-222044_Z_20_Z","title":"Full Value of Vaccines Assessment for invasive Non-Typhoidal Salmonella Vaccines","Region":"International","currency":"GBP","awardDate":"2020-12-31T00:00:00+00:00","Internal ID":"222044/Z/20/Z","description":"The need for vaccines against invasive non-typhoidal salmonella (iNTS) is now increasingly being recognized, but there is no iNTS vaccine available for use in humans. Several potential candidate vaccines against iNTS are being developed. Vaccine development considerations include a bivalent iNTS vaccine (Typhimurium and Enteritidis) or possibly a trivalent vaccine (Typhi/iNTS). Such financial investments not only need public-private partnerships, but also demand economic and public health justification. The World Health Organization (WHO) and other global partners have recently highlighted the need to justify investments in vaccines from a multi-stakeholder perspective.\nThe overall objective of this project is to develop a Full Value of Vaccine Assessment (FVVA) to understand the value of investment in an iNTS vaccine from a multi-stakeholder perspective. The long-term goal of this proposal is to pave the way for the development of a safe and efficacious iNTS vaccine, in-country licensure (marketing authorization in the country of manufacture), any necessary policy recommendations from the WHO Strategic Advisory Group of Experts (SAGE) on Immunization, WHO prequalification (PQ), Gavi financing, UNICEF purchasing and national technical advisory groups recommendations for vaccine use. This will be achieved as a joint IVI/WHO leadership and collaboration through a consensus process in partnership with multiple stakeholders.\"","plannedDates":[{"endDate":"2024-05-02T00:00:00+00:00","startDate":"2021-05-03T00:00:00+00:00","startDateDateOnly":"2021-05-03","endDateDateOnly":"2024-05-02"}],"amountAwarded":2283242,"Financial Year":"2020/21","Lead Applicant":"Dr Jerome Kim","grantProgramme":[{"title":"Innovations AIGH Enterics Flagship ","title_keyword":"Innovations AIGH Enterics Flagship "}],"Applicant Surname":"Kim","Partnership Value":2283242,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:International-Vaccine-Institute","name":"International Vaccine Institute","addressCountry":"Korea, South","id_and_name":"[\"International Vaccine Institute\", \"360G-Wellcome-ORG:International-Vaccine-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:International-Vaccine-Institute","name":"International Vaccine Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Full Value of Vaccines Assessment for invasive Non-Typhoidal Salmonella Vaccines The need for vaccines against invasive non-typhoidal salmonella (iNTS) is now increasingly being recognized, but there is no iNTS vaccine available for use in humans. Several potential candidate vaccines against iNTS are being developed. Vaccine development considerations include a bivalent iNTS vaccine (Typhimurium and Enteritidis) or possibly a trivalent vaccine (Typhi/iNTS). Such financial investments not only need public-private partnerships, but also demand economic and public health justification. The World Health Organization (WHO) and other global partners have recently highlighted the need to justify investments in vaccines from a multi-stakeholder perspective.\nThe overall objective of this project is to develop a Full Value of Vaccine Assessment (FVVA) to understand the value of investment in an iNTS vaccine from a multi-stakeholder perspective. The long-term goal of this proposal is to pave the way for the development of a safe and efficacious iNTS vaccine, in-country licensure (marketing authorization in the country of manufacture), any necessary policy recommendations from the WHO Strategic Advisory Group of Experts (SAGE) on Immunization, WHO prequalification (PQ), Gavi financing, UNICEF purchasing and national technical advisory groups recommendations for vaccine use. This will be achieved as a joint IVI/WHO leadership and collaboration through a consensus process in partnership with multiple stakeholders.\"","awardDateDateOnly":"2020-12-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Consensus","Humans","Immunization Programs","Public Health","Salmonella Infections","Salmonella Vaccines","World Health Organization"]}
{"id":"360G-Wellcome-222043_Z_20_Z","title":"Research on Research Institute \u2013 CWTS-Leiden Costs","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"222043/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2020-12-31T00:00:00+00:00","startDate":"2020-07-01T00:00:00+00:00","startDateDateOnly":"2020-07-01","endDateDateOnly":"2020-12-31"}],"amountAwarded":27393,"Financial Year":"2019/20","Lead Applicant":"Prof Sarah De Rijcke","grantProgramme":[{"title":"Research on Research Institute Grant ","title_keyword":"Research on Research Institute Grant "}],"Applicant Surname":"De Rijcke","Partnership Value":27393,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leiden","name":"University of Leiden","addressCountry":"Netherlands","id_and_name":"[\"University of Leiden\", \"360G-Wellcome-ORG:University-of-Leiden\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leiden","name":"University of Leiden"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Research on Research Institute \u2013 CWTS-Leiden Costs Not available","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biomedical Research","Humans"]}
{"id":"360G-Wellcome-222042_Z_20_Z","title":"afrimapr R building-blocks for the operational COVID-19 health response","Region":"North West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"222042/Z/20/Z","description":"We will develop software building-blocks to facilitate the use of operational health data in Africa to aid the COVID-19 response. The main gap the new work addresses is the use and re-use of health data in the immediate operational response to COVID-19. The project will run under the umbrella of afrimapr, an existing Wellcome Open Research Fund project improving the use of health research data. The project philosophy is the same: firstly to develop open-source R components to assist African data scientists in creating tools to address local issues, secondly to develop training resources and thirdly to promote them within African data communities. We have already started assessing, and improving access to, open-data on African health facility locations. This extension will allow us to continue working with new collaborators; healthsites.io and OpenStreetMap communities that collate and crowdsource health facility data. We will reach out to African data communities through DFID advisers to African ministries, national statistics institutes through the Global Statistical Service, and our networks and social media. Components for working with African health zones will also be developed. Increasing the use of open-access health data has the co-benefit of incentivizing improvements to the availability of the data themselves.   \n","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-11-01T00:00:00+00:00","startDateDateOnly":"2020-11-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":49903,"Financial Year":"2019/20","Lead Applicant":"Dr Andy South","grantProgramme":[{"title":"Discretionary Award - Open research","title_keyword":"Discretionary Award - Open research"}],"Applicant Surname":"South","Partnership Value":49903,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"Liverpool School of Tropical Medicine\", \"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"afrimapr R building-blocks for the operational COVID-19 health response We will develop software building-blocks to facilitate the use of operational health data in Africa to aid the COVID-19 response. The main gap the new work addresses is the use and re-use of health data in the immediate operational response to COVID-19. The project will run under the umbrella of afrimapr, an existing Wellcome Open Research Fund project improving the use of health research data. The project philosophy is the same: firstly to develop open-source R components to assist African data scientists in creating tools to address local issues, secondly to develop training resources and thirdly to promote them within African data communities. We have already started assessing, and improving access to, open-data on African health facility locations. This extension will allow us to continue working with new collaborators; healthsites.io and OpenStreetMap communities that collate and crowdsource health facility data. We will reach out to African data communities through DFID advisers to African ministries, national statistics institutes through the Global Statistical Service, and our networks and social media. Components for working with African health zones will also be developed. Increasing the use of open-access health data has the co-benefit of incentivizing improvements to the availability of the data themselves.   \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa","Biomedical Research","Crowdsourcing","Data Collection","Humans","Software"]}
{"id":"360G-Wellcome-222038_Z_20_Z","title":"A Rapid and Substantial Increase in Supplies of an Effective, Safe and Affordable Antivenom to sub-Saharan Africa","Region":"Wales","currency":"GBP","awardDate":"2021-04-30T00:00:00+00:00","Internal ID":"222038/Z/20/Z","description":"The project will be directed by MicroPharm and will include contributions by scientists at the Liverpool School of Tropical Medicine.  It is in direct response to the WHO's stated aim of reducing the mortality and morbidity of snake envenoming.  \n\nThe aim of the project is to re-establish supplies of Fav-Afrique in its current format as an equine F(ab\u2019)2 based antivenom suitable for the treatment of Category 1 venomous African snakes. Sanofi-Pasteur will continue to supply large pools of plasma from horses immunised with venoms from Echis, Bitis, Naja or Dendroaspis species respectively.  The manufacturing procedures will be modernised and simplified to increase yield and decrease cost.  Initial supplies will be available for clinical use in Africa by 2023.\n","plannedDates":[{"endDate":"2023-06-30T00:00:00+00:00","startDate":"2020-07-01T00:00:00+00:00","startDateDateOnly":"2020-07-01","endDateDateOnly":"2023-06-30"}],"amountAwarded":2965791,"Financial Year":"2020/21","Lead Applicant":"Prof John Landon","grantProgramme":[{"title":"Discretionary Award - Snakebite","title_keyword":"Discretionary Award - Snakebite"}],"Applicant Surname":"Landon","Partnership Value":2965791,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Rossen Donev, Dr Matthew Aldridge","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:MicroPharm-Limited","name":"MicroPharm Limited","addressCountry":"United Kingdom","id_and_name":"[\"MicroPharm Limited\", \"360G-Wellcome-ORG:MicroPharm-Limited\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:MicroPharm-Limited","name":"MicroPharm Limited"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A Rapid and Substantial Increase in Supplies of an Effective, Safe and Affordable Antivenom to sub-Saharan Africa The project will be directed by MicroPharm and will include contributions by scientists at the Liverpool School of Tropical Medicine.  It is in direct response to the WHO's stated aim of reducing the mortality and morbidity of snake envenoming.  \n\nThe aim of the project is to re-establish supplies of Fav-Afrique in its current format as an equine F(ab\u2019)2 based antivenom suitable for the treatment of Category 1 venomous African snakes. Sanofi-Pasteur will continue to supply large pools of plasma from horses immunised with venoms from Echis, Bitis, Naja or Dendroaspis species respectively.  The manufacturing procedures will be modernised and simplified to increase yield and decrease cost.  Initial supplies will be available for clinical use in Africa by 2023.\n","awardDateDateOnly":"2021-04-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Antivenins","Elapid Venoms","Horses","Snake Bites"]}
{"id":"360G-Wellcome-222020_Z_20_Z","title":"Longitudinal maternal and early life (neuro)immune mechanisms underlying neurodevelopmental and behavioural impairments in HIV-exposed uninfected children in a South African birth cohort","Region":"International","currency":"GBP","awardDate":"2020-11-24T00:00:00+00:00","Sponsor(s)":"Prof Dan Stein","Internal ID":"222020/Z/20/Z","description":"While prevention of mother-to-child transmission (PMTCT) success has resulted in the decline in paediatric HIV infection, the number of HIV-exposed uninfected (HEU) infants has rapidly risen. In 2018, the population of HEU children in sub-Saharan Africa was estimated to be 13.2 million. In utero exposure to HIV may exert detrimental influences on the intricate neurodevelopmental processes during the first five years of life, with long-lasting effects on cognitive performance and behaviour. Our understanding of the pathophysiological mechanisms that are involved in conferring risk for neurodevelopmental deficits due to HIV exposure remains limited.\n\nAltered neuroimmune regulation during pregnancy and early life may negatively affect neurodevelopment in children and in the context of maternal HIV infection may, in part, explain the delayed neurodevelopment observed in HEU children. However, the temporal regulation of neuroimmune markers during the critical period of the developing brain in HEU children remains unexplored. Importantly, it is also unknown at which stage (from in utero through to five years of age) the developing brain in children with HEU is affected. This study proposes to investigate longitudinally the association between maternal and infant neuroimmune function and brain development and neurodevelopmental outcomes in South African HEU children.\n","plannedDates":[{"endDate":"2026-02-28T00:00:00+00:00","startDate":"2021-03-01T00:00:00+00:00","startDateDateOnly":"2021-03-01","endDateDateOnly":"2026-02-28"}],"amountAwarded":580378,"Financial Year":"2020/21","Lead Applicant":"Dr Petrus Naude","grantProgramme":[{"title":"International Intermediate Fellowship","title_keyword":"International Intermediate Fellowship"}],"Applicant Surname":"Naude","Partnership Value":580378,"Approval Committee":"International Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cape-Town","name":"University of Cape Town","addressCountry":"South Africa","id_and_name":"[\"University of Cape Town\", \"360G-Wellcome-ORG:University-of-Cape-Town\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cape-Town","name":"University of Cape Town"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Longitudinal maternal and early life (neuro)immune mechanisms underlying neurodevelopmental and behavioural impairments in HIV-exposed uninfected children in a South African birth cohort While prevention of mother-to-child transmission (PMTCT) success has resulted in the decline in paediatric HIV infection, the number of HIV-exposed uninfected (HEU) infants has rapidly risen. In 2018, the population of HEU children in sub-Saharan Africa was estimated to be 13.2 million. In utero exposure to HIV may exert detrimental influences on the intricate neurodevelopmental processes during the first five years of life, with long-lasting effects on cognitive performance and behaviour. Our understanding of the pathophysiological mechanisms that are involved in conferring risk for neurodevelopmental deficits due to HIV exposure remains limited.\n\nAltered neuroimmune regulation during pregnancy and early life may negatively affect neurodevelopment in children and in the context of maternal HIV infection may, in part, explain the delayed neurodevelopment observed in HEU children. However, the temporal regulation of neuroimmune markers during the critical period of the developing brain in HEU children remains unexplored. Importantly, it is also unknown at which stage (from in utero through to five years of age) the developing brain in children with HEU is affected. This study proposes to investigate longitudinally the association between maternal and infant neuroimmune function and brain development and neurodevelopmental outcomes in South African HEU children.\n","awardDateDateOnly":"2020-11-24","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Brain","Child","Child Development","Child, Preschool","Cognition","Female","HIV Infections","Humans","Infant","Infant, Newborn","Infectious Disease Transmission, Vertical","Longitudinal Studies","Male","Neurodevelopmental Disorders","Pregnancy","Pregnancy Complications, Infectious","Prenatal Exposure Delayed Effects","South Africa"]}
{"id":"360G-Wellcome-222019_Z_20_Z","title":"Assessing the impact of a new class of insecticide treated net (Interceptor G2) on malaria vectors population dynamics, ecology and behaviours in the Cascades Region of Burkina Faso.","Region":"International","currency":"GBP","awardDate":"2020-11-24T00:00:00+00:00","Sponsor(s)":"Dr Adama Gansan\u00e9","Internal ID":"222019/Z/20/Z","description":"Long-Lasting Insecticide-Treated Nets (ITNs) are the most successful method for malaria vector control in Africa. Growing evidence indicates changes in mosquito vector biting and resting behaviours in several African settings where high ITN coverage has been achieved. These combined with growing resistance to pyrethroids, the insecticide class used in all nets, can reduce intervention success. This is the case in Burkina Faso where high outdoor biting and pyrethroid resistance is reducing the efficacy of standard ITNs. In response to this Burkina Faso, adopted the newly developed \u2018Next Generation Nets\u2019 in its 2019 mass distribution campaign, becoming the first country to deploy Interceptor G2 (IG2), a net combining a pyrethroid with chlorfenapyr, an insecticide that should be effective against pyrethroid-resistant vectors. However, my initial results from laboratory and semi-field studies on mosquitoes from the Cascades Region of Burkina Faso indicate much lower moralities with IG2 nets than expected from earlier trials raising concerns that local vectors may have already developed resistance to this insecticide class.  \nCombining field and laboratory works in the Cascades Region I will assess for chlorfenapyr-resistance, its potential mechanisms and the impact of IG2 on Anopheles gambiae s.l. demography, behaviours (resting and biting) and malaria transmission potential.\n \n","plannedDates":[{"endDate":"2024-04-30T00:00:00+00:00","startDate":"2021-05-01T00:00:00+00:00","startDateDateOnly":"2021-05-01","endDateDateOnly":"2024-04-30"}],"amountAwarded":149986,"Financial Year":"2020/21","Lead Applicant":"Dr Antoine Sanou","grantProgramme":[{"title":"International Training Fellowship","title_keyword":"International Training Fellowship"}],"Partnership Name":"NIHR/Wellcome Global health Partnership","Applicant Surname":"Sanou","Partnership Value":299969,"Approval Committee":"International Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Centre-National-de-Recherche-et-de-Formation-sur-le-Paludisme","name":"Centre National de Recherche et de Formation sur le Paludisme","addressCountry":"Burkina Faso","id_and_name":"[\"Centre National de Recherche et de Formation sur le Paludisme\", \"360G-Wellcome-ORG:Centre-National-de-Recherche-et-de-Formation-sur-le-Paludisme\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Centre-National-de-Recherche-et-de-Formation-sur-le-Paludisme","name":"Centre National de Recherche et de Formation sur le Paludisme"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Assessing the impact of a new class of insecticide treated net (Interceptor G2) on malaria vectors population dynamics, ecology and behaviours in the Cascades Region of Burkina Faso. Long-Lasting Insecticide-Treated Nets (ITNs) are the most successful method for malaria vector control in Africa. Growing evidence indicates changes in mosquito vector biting and resting behaviours in several African settings where high ITN coverage has been achieved. These combined with growing resistance to pyrethroids, the insecticide class used in all nets, can reduce intervention success. This is the case in Burkina Faso where high outdoor biting and pyrethroid resistance is reducing the efficacy of standard ITNs. In response to this Burkina Faso, adopted the newly developed \u2018Next Generation Nets\u2019 in its 2019 mass distribution campaign, becoming the first country to deploy Interceptor G2 (IG2), a net combining a pyrethroid with chlorfenapyr, an insecticide that should be effective against pyrethroid-resistant vectors. However, my initial results from laboratory and semi-field studies on mosquitoes from the Cascades Region of Burkina Faso indicate much lower moralities with IG2 nets than expected from earlier trials raising concerns that local vectors may have already developed resistance to this insecticide class.  \nCombining field and laboratory works in the Cascades Region I will assess for chlorfenapyr-resistance, its potential mechanisms and the impact of IG2 on Anopheles gambiae s.l. demography, behaviours (resting and biting) and malaria transmission potential.\n \n","awardDateDateOnly":"2020-11-24","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Anopheles","Burkina Faso","Humans","Insecticide Resistance","Insecticide-Treated Bednets","Insecticides","Malaria","Mosquito Control","Mosquito Vectors","Pyrethrins"]}
{"id":"360G-Wellcome-222011_Z_20_Z","title":"Optimising dosing of dihydroartemisinin-piperaquine for malaria preventive treatment in Malawian infants ","Region":"North West","currency":"GBP","awardDate":"2020-11-24T00:00:00+00:00","Sponsor(s)":"Prof Stephen Gordon","Internal ID":"222011/Z/20/Z","description":"The World Health Organisation recommends use of sulphadoxine-pyrimethamine (SP), administered with routine immunisation, for intermittent preventive treatment of malaria in infancy (IPTi) in areas of moderate to high transmission in sub-Saharan Africa. However, there is limited uptake of this recommendation and increasing resistance of malaria parasites to SP. Fortunately, another antimalarial drug, dihydroartemisinin-piperaquine (DP), has shown higher protective efficacy than SP. However, there is paucity of evidence to guide its optimal dosing in infants. Additionally, IPTi is usually given to infants born to women who received SP or DP for intermittent preventive treatment of malaria in pregnancy (IPTp). The impact of using DP for IPTp on subsequent metabolism and efficacy of DP in infancy is not well understood.\n\nIn this Fellowship, I will develop optimised dosing regimens of DP for IPTi by applying population pharmacokinetic-pharmacodynamic modelling techniques on data obtained from:\n \n\n\n Evaluating the pharmacokinetics, efficacy and safety of DP for IPTi, in a randomised-controlled trial, in infants born to Malawian women who received DP compared to SP for malaria prevention in pregnancy.\n Understanding age-related changes in piperaquine pharmacokinetics during infancy.\n\n\n\nThis work will provide the much-needed evidence to inform DP dosing for IPTi, when administered with routine immunisation.\n","plannedDates":[{"endDate":"2024-07-31T00:00:00+00:00","startDate":"2021-08-01T00:00:00+00:00","startDateDateOnly":"2021-08-01","endDateDateOnly":"2024-07-31"}],"amountAwarded":157795,"Financial Year":"2020/21","Lead Applicant":"Dr Clifford Banda","grantProgramme":[{"title":"International Training Fellowship","title_keyword":"International Training Fellowship"}],"Partnership Name":"NIHR/Wellcome Global health Partnership","Applicant Surname":"Banda","Partnership Value":315590,"Approval Committee":"International Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"Liverpool School of Tropical Medicine\", \"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Optimising dosing of dihydroartemisinin-piperaquine for malaria preventive treatment in Malawian infants  The World Health Organisation recommends use of sulphadoxine-pyrimethamine (SP), administered with routine immunisation, for intermittent preventive treatment of malaria in infancy (IPTi) in areas of moderate to high transmission in sub-Saharan Africa. However, there is limited uptake of this recommendation and increasing resistance of malaria parasites to SP. Fortunately, another antimalarial drug, dihydroartemisinin-piperaquine (DP), has shown higher protective efficacy than SP. However, there is paucity of evidence to guide its optimal dosing in infants. Additionally, IPTi is usually given to infants born to women who received SP or DP for intermittent preventive treatment of malaria in pregnancy (IPTp). The impact of using DP for IPTp on subsequent metabolism and efficacy of DP in infancy is not well understood.\n\nIn this Fellowship, I will develop optimised dosing regimens of DP for IPTi by applying population pharmacokinetic-pharmacodynamic modelling techniques on data obtained from:\n \n\n\n Evaluating the pharmacokinetics, efficacy and safety of DP for IPTi, in a randomised-controlled trial, in infants born to Malawian women who received DP compared to SP for malaria prevention in pregnancy.\n Understanding age-related changes in piperaquine pharmacokinetics during infancy.\n\n\n\nThis work will provide the much-needed evidence to inform DP dosing for IPTi, when administered with routine immunisation.\n","awardDateDateOnly":"2020-11-24","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Antimalarials","Artemisinins","Drug Combinations","Female","Humans","Infant","Infant, Newborn","Malaria","Malaria, Falciparum","Malawi","Male","Pregnancy","Pyrimethamine","Quinolines","Sulfadoxine"]}
{"id":"360G-Wellcome-222007_Z_20_Z","title":"Interactive play:  a strategy to improve nurturing care and movement behaviours for infants","Region":"International","currency":"GBP","awardDate":"2020-11-24T00:00:00+00:00","Sponsor(s)":"Prof Shane Norris","Internal ID":"222007/Z/20/Z","description":"The persistence of under- and over-nutrition, in conjunction with poor adherence to movement guidelines and lack of stimulation evident among South African children, is indicative of a generation being raised in an environment that is not conducive to optimum early childhood development. This perpetuates an intergenerational cycle of health inequality.\n\nNurturing care is essential for early childhood development, and relies on responsive and sensitive interactions between caregivers and infants. Considering the importance of caregiver-infant interaction, as well as of infant movement behaviours, I hypothesise that encouraging interactive play could improve childhood growth and developmental through both the biological pathways linked to infant movement, and nurturing care pathways that promote attachment and emotional development.\n\nThis study proposes to test this hypothesis by designing, implementing and testing the efficacy of an intervention that encourages interactive play during infancy. This study uses a novel objective assessments of interactive play, as well as rapid participant feedback tools and an adaptive intervention design to enhance behaviour change and therefore intervention adherence.\n \n","plannedDates":[{"endDate":"2024-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2024-06-30"}],"amountAwarded":152610,"Financial Year":"2020/21","Lead Applicant":"Dr Alessandra Prioreschi","grantProgramme":[{"title":"International Training Fellowship","title_keyword":"International Training Fellowship"}],"Partnership Name":"NIHR/Wellcome Global health Partnership","Applicant Surname":"Prioreschi","Partnership Value":305220,"Approval Committee":"International Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-the-Witwatersrand","name":"University of the Witwatersrand","addressCountry":"South Africa","id_and_name":"[\"University of the Witwatersrand\", \"360G-Wellcome-ORG:University-of-the-Witwatersrand\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-the-Witwatersrand","name":"University of the Witwatersrand"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Interactive play:  a strategy to improve nurturing care and movement behaviours for infants The persistence of under- and over-nutrition, in conjunction with poor adherence to movement guidelines and lack of stimulation evident among South African children, is indicative of a generation being raised in an environment that is not conducive to optimum early childhood development. This perpetuates an intergenerational cycle of health inequality.\n\nNurturing care is essential for early childhood development, and relies on responsive and sensitive interactions between caregivers and infants. Considering the importance of caregiver-infant interaction, as well as of infant movement behaviours, I hypothesise that encouraging interactive play could improve childhood growth and developmental through both the biological pathways linked to infant movement, and nurturing care pathways that promote attachment and emotional development.\n\nThis study proposes to test this hypothesis by designing, implementing and testing the efficacy of an intervention that encourages interactive play during infancy. This study uses a novel objective assessments of interactive play, as well as rapid participant feedback tools and an adaptive intervention design to enhance behaviour change and therefore intervention adherence.\n \n","awardDateDateOnly":"2020-11-24","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Caregivers","Child Development","Child, Preschool","Early Intervention, Educational","Female","Humans","Infant","Male","South Africa"]}
{"id":"360G-Wellcome-221998_Z_20_Z","title":"Investigating the prevalence, clinical consequences and associations of red blood cell alloimmunization among children with sickle cell disease in Kilifi Kenya ","Region":"International","currency":"GBP","awardDate":"2020-11-24T00:00:00+00:00","Sponsor(s)":"Prof Philip Bejon, Prof Russell Ware","Internal ID":"221998/Z/20/Z","description":"Sickle cell disease (SCD) is the most important genetic disorder in sub-Saharan Africa, where over 280,000 affected children are born every year. Although children with SCD represent only 1-2% of all births within the region, they receive between 10 and 25% of all the blood transfusions administered to children  \n\nMy fellowship has two main aims. First, I will describe the prevalence and consequences of alloimmunization among children attending the SCD clinic at Kilifi County Hospital in Kenya. Second, I will explore potential risk factors for the development of alloimmunization, including levels of inflammation within transfusion recipients and red blood cell genetic diversity in both donors and recipients.  By identifying risk factors that contribute to alloimmunization, I will contribute to the development of better strategies that reduce the chance of development of alloimmunization for the transfusion management of patients with SCD in Africa.\n","plannedDates":[{"endDate":"2026-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2026-08-31"}],"amountAwarded":574957,"Financial Year":"2020/21","Lead Applicant":"Dr Sophie Uyoga","grantProgramme":[{"title":"International Intermediate Fellowship","title_keyword":"International Intermediate Fellowship"}],"Applicant Surname":"Uyoga","Partnership Value":574957,"Approval Committee":"International Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kemri-Wellcome-Trust-Research-Programme","name":"Kemri-Wellcome Trust Research Programme","addressCountry":"Kenya","id_and_name":"[\"Kemri-Wellcome Trust Research Programme\", \"360G-Wellcome-ORG:Kemri-Wellcome-Trust-Research-Programme\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kemri-Wellcome-Trust-Research-Programme","name":"Kemri-Wellcome Trust Research Programme"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the prevalence, clinical consequences and associations of red blood cell alloimmunization among children with sickle cell disease in Kilifi Kenya  Sickle cell disease (SCD) is the most important genetic disorder in sub-Saharan Africa, where over 280,000 affected children are born every year. Although children with SCD represent only 1-2% of all births within the region, they receive between 10 and 25% of all the blood transfusions administered to children  \n\nMy fellowship has two main aims. First, I will describe the prevalence and consequences of alloimmunization among children attending the SCD clinic at Kilifi County Hospital in Kenya. Second, I will explore potential risk factors for the development of alloimmunization, including levels of inflammation within transfusion recipients and red blood cell genetic diversity in both donors and recipients.  By identifying risk factors that contribute to alloimmunization, I will contribute to the development of better strategies that reduce the chance of development of alloimmunization for the transfusion management of patients with SCD in Africa.\n","awardDateDateOnly":"2020-11-24","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anemia, Sickle Cell","Blood Transfusion","Child","Humans","Kenya","Prevalence","Risk Factors"]}
{"id":"360G-Wellcome-221997_Z_20_Z","title":"Enhancing growth and development among malnourished infants recovering from serious illness","Region":"International","currency":"GBP","awardDate":"2020-11-24T00:00:00+00:00","Sponsor(s)":"Prof Philip Bejon","Internal ID":"221997/Z/20/Z","description":"Globally, acute malnutrition affects 8.5 million infants under 6 months of age (u6m). Malnourished infants u6m are at elevated risk of death during admission and after discharge from hospital and of subsequent neurodevelopmental impairment. WHO nutritional rehabilitation guidelines for u6m focus on re-establishing exclusive breastfeeding (EBF) with discharge when consistent weight gain ( > 5g/kg/day) is achieved on breastmilk alone.  My pilot study examined breastfeeding peer supporters to facilitate guideline implementation among hospitalised malnourished infants.  We achieved 81% exclusive breastfeeding by discharge with 67% attaining the WHO recommended growth velocity on breastmilk alone. However, criteria for full nutritional recovery were generally not met 6 weeks after discharge. I now hypothesise that providing support during transition to home will improve nutritional recovery. In Phase 1 I will develop and pilot a breastfeeding support intervention among 30 recovering infants u6m. In Phase 2 I will apply a randomised controlled trial to evaluate effectiveness of the finalised intervention compared with standard care among 250 malnourished infants (4-12 weeks old) recovering from an illness. The primary outcome is growth (weight gain) assessed at age 6 months, with follow up to 12 months. Results will inform efforts to improve post-discharge management of recovering vulnerable infants u6m.\n","plannedDates":[{"endDate":"2027-01-31T00:00:00+00:00","startDate":"2022-02-01T00:00:00+00:00","startDateDateOnly":"2022-02-01","endDateDateOnly":"2027-01-31"}],"amountAwarded":347486,"Financial Year":"2020/21","Lead Applicant":"Dr Martha Mwangome","grantProgramme":[{"title":"International Intermediate Fellowship","title_keyword":"International Intermediate Fellowship"}],"Partnership Name":"NIHR/Wellcome Global health Partnership","Applicant Surname":"Mwangome","Partnership Value":694973,"Approval Committee":"International Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kemri-Wellcome-Trust-Research-Programme","name":"Kemri-Wellcome Trust Research Programme","addressCountry":"Kenya","id_and_name":"[\"Kemri-Wellcome Trust Research Programme\", \"360G-Wellcome-ORG:Kemri-Wellcome-Trust-Research-Programme\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kemri-Wellcome-Trust-Research-Programme","name":"Kemri-Wellcome Trust Research Programme"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Enhancing growth and development among malnourished infants recovering from serious illness Globally, acute malnutrition affects 8.5 million infants under 6 months of age (u6m). Malnourished infants u6m are at elevated risk of death during admission and after discharge from hospital and of subsequent neurodevelopmental impairment. WHO nutritional rehabilitation guidelines for u6m focus on re-establishing exclusive breastfeeding (EBF) with discharge when consistent weight gain ( > 5g/kg/day) is achieved on breastmilk alone.  My pilot study examined breastfeeding peer supporters to facilitate guideline implementation among hospitalised malnourished infants.  We achieved 81% exclusive breastfeeding by discharge with 67% attaining the WHO recommended growth velocity on breastmilk alone. However, criteria for full nutritional recovery were generally not met 6 weeks after discharge. I now hypothesise that providing support during transition to home will improve nutritional recovery. In Phase 1 I will develop and pilot a breastfeeding support intervention among 30 recovering infants u6m. In Phase 2 I will apply a randomised controlled trial to evaluate effectiveness of the finalised intervention compared with standard care among 250 malnourished infants (4-12 weeks old) recovering from an illness. The primary outcome is growth (weight gain) assessed at age 6 months, with follow up to 12 months. Results will inform efforts to improve post-discharge management of recovering vulnerable infants u6m.\n","awardDateDateOnly":"2020-11-24","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Breast Feeding","Child Development","Female","Humans","Infant","Malnutrition","Nutritional Status","Patient Discharge","Pilot Projects","Weight Gain"]}
{"id":"360G-Wellcome-221995_Z_20_Z","title":"Effects of intra-uterine HIV exposure on antibody functionality and B cell development","Region":"International","currency":"GBP","awardDate":"2020-11-24T00:00:00+00:00","Sponsor(s)":"Prof Valerie Mizrahi","Internal ID":"221995/Z/20/Z","description":"Approximately 30% of pregnant women in South Africa are HIV-infected resulting in over 300 000 infants exposed to HIV in utero every year. Rates of infectious mortality are reportedly higher among HIV-exposed uninfected infants (iHEU) compared to HIV-unexposed uninfected infants (iHUU). Studies evaluating the effects of maternal HIV infection on vaccine responses in their respective infants show that iHEU have similar antibody titres as those elicited in iHUU. These results imply efficacious vaccination in iHEU which contradicts the observed higher morbidity and mortality rates in iHEU. Therefore, I hypothesise that exposure to HIV in utero may impact the maturation of B cells leading to production of antibodies with poor Fc functions. Our preliminary analysis revealed altered B cell phenotypes across age in iHEU compared to iHUU. Therefore, in this study I aim to characterise B cell properties such as reduced somatic hypermutation for affinity maturation among iHEU using RNA-sequencing. Furthermore, I will analyse IgG Fc glycosylation that is associated with Fc-FcR affinity and Fc effector functions. Subsequently, I will develop in vitro models to measure antibody dependent cellular phagocytosis (ADCP) and cytotoxicity (ADCC) specific to early childhood vaccines.\n \n","plannedDates":[{"endDate":"2024-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2024-06-30"}],"amountAwarded":211407,"Financial Year":"2020/21","Lead Applicant":"Dr Sonwabile Dzanibe","grantProgramme":[{"title":"International Training Fellowship","title_keyword":"International Training Fellowship"}],"Applicant Surname":"Dzanibe","Partnership Value":211407,"Approval Committee":"International Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cape-Town","name":"University of Cape Town","addressCountry":"South Africa","id_and_name":"[\"University of Cape Town\", \"360G-Wellcome-ORG:University-of-Cape-Town\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cape-Town","name":"University of Cape Town"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Effects of intra-uterine HIV exposure on antibody functionality and B cell development Approximately 30% of pregnant women in South Africa are HIV-infected resulting in over 300 000 infants exposed to HIV in utero every year. Rates of infectious mortality are reportedly higher among HIV-exposed uninfected infants (iHEU) compared to HIV-unexposed uninfected infants (iHUU). Studies evaluating the effects of maternal HIV infection on vaccine responses in their respective infants show that iHEU have similar antibody titres as those elicited in iHUU. These results imply efficacious vaccination in iHEU which contradicts the observed higher morbidity and mortality rates in iHEU. Therefore, I hypothesise that exposure to HIV in utero may impact the maturation of B cells leading to production of antibodies with poor Fc functions. Our preliminary analysis revealed altered B cell phenotypes across age in iHEU compared to iHUU. Therefore, in this study I aim to characterise B cell properties such as reduced somatic hypermutation for affinity maturation among iHEU using RNA-sequencing. Furthermore, I will analyse IgG Fc glycosylation that is associated with Fc-FcR affinity and Fc effector functions. Subsequently, I will develop in vitro models to measure antibody dependent cellular phagocytosis (ADCP) and cytotoxicity (ADCC) specific to early childhood vaccines.\n \n","awardDateDateOnly":"2020-11-24","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Antibody-Dependent Cell Cytotoxicity","Female","Glycosylation","HIV Antibodies","HIV Infections","HIV-1","Humans","Infant","Pregnancy","Pregnancy Complications, Infectious","Receptors, Fc","South Africa"]}
{"id":"360G-Wellcome-221991_Z_20_Z","title":"Integrated primary eye care interventions in Ethiopia","Region":"Greater London","currency":"GBP","awardDate":"2020-11-24T00:00:00+00:00","Sponsor(s)":"Mr Dessalew Emaway, Prof Alison Grant","Internal ID":"221991/Z/20/Z","description":"Context: \nThere are 2.2 billion visually impaired people globally. About 90% of these live in low-and-middle- income countries, 80% have avoidable conditions, which are amenable to well-established cost- effective interventions. WHO is promoting Universal Eye Health through integration of Primary Eye Care (PEC) into Primary Health Care (PHC). However, there is little evidence how and what interventions work to effectively and sustainably integrate PEC services into PHC in low-income settings.\n\nProposed Research: \nThe following studies will be conducted in Ethiopia in four phases:\n\nPhase 1: Population-based cross-sectional studies to assess eye care need, inequalities, eye health-seeking behaviour and capabilities.\n\nPhase 2: Health System Preparedness Evaluation Study to assess the health system's capacity and gaps to deliver integrated PEC interventions.\n\nPhase 3: Intervention Development, informed by Phase 1  &  2, through Participatory Action Research (PAR) to develop contextually appropriate, feasible, community owned-and-led integrated  &  sustainable PEC services.\n\nPhase 4: Iterated testing and piloting of the identified PEC interventions both individually and as integrated package at community, health facility, and healthcare organisation level to identify a working PEC intervention that will inform scaled-up delivery of equitably accessible, quality, and sustainable PEC services integrated with PHC.\n","plannedDates":[{"endDate":"2026-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2026-08-31"}],"amountAwarded":467629,"Financial Year":"2020/21","Lead Applicant":"Dr Esmael Habtamu Ali","grantProgramme":[{"title":"International Intermediate Fellowship","title_keyword":"International Intermediate Fellowship"}],"Partnership Name":"NIHR/Wellcome Global health Partnership","Applicant Surname":"Ali","Partnership Value":935258,"Approval Committee":"International Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"London School of Hygiene & Tropical Medicine\", \"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Integrated primary eye care interventions in Ethiopia Context: \nThere are 2.2 billion visually impaired people globally. About 90% of these live in low-and-middle- income countries, 80% have avoidable conditions, which are amenable to well-established cost- effective interventions. WHO is promoting Universal Eye Health through integration of Primary Eye Care (PEC) into Primary Health Care (PHC). However, there is little evidence how and what interventions work to effectively and sustainably integrate PEC services into PHC in low-income settings.\n\nProposed Research: \nThe following studies will be conducted in Ethiopia in four phases:\n\nPhase 1: Population-based cross-sectional studies to assess eye care need, inequalities, eye health-seeking behaviour and capabilities.\n\nPhase 2: Health System Preparedness Evaluation Study to assess the health system's capacity and gaps to deliver integrated PEC interventions.\n\nPhase 3: Intervention Development, informed by Phase 1  &  2, through Participatory Action Research (PAR) to develop contextually appropriate, feasible, community owned-and-led integrated  &  sustainable PEC services.\n\nPhase 4: Iterated testing and piloting of the identified PEC interventions both individually and as integrated package at community, health facility, and healthcare organisation level to identify a working PEC intervention that will inform scaled-up delivery of equitably accessible, quality, and sustainable PEC services integrated with PHC.\n","awardDateDateOnly":"2020-11-24","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cross-Sectional Studies","Ethiopia","Health Services Research","Humans","Primary Health Care"]}
{"id":"360G-Wellcome-221989_Z_20_Z","title":"SARS-CoV-2 immunoepidemiology in Wellcome-funded urban and rural cohorts in Malawi : generating evidence to inform regional medium and long term decision making","Region":"Scotland","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221989/Z/20/Z","description":"General population serosurveillance in low-income Africa is fundamental to understanding the population exposure to SARS-CoV-2, to explain the observed epidemiology and to ensure that ongoing control measures in the region are proportionate and are not guided by observations from very different settings. Detailed longitudinal immunological studies of infected individuals will be key to determining the long-term strategy in managing COVID-19 in highly vulnerable African populations.\n\nUtilising the longitudinal urban and rural cohorts established by the Malawi Epidemiology and Intervention Research Unit, and supported by international and national expertise, we will undertake population immunoepidemiological surveillance to understand the trends in exposure and transmission of SARS-CoV-2, risk factors for SARS-CoV-2 infection and severe disease, as well as the proportion of asymptomatic or pauci-symptomatic infection in the population to enable an accurate estimate of infection fatality rate. Furthermore, we will recruit individuals with evidence of past SARS-CoV-2 infection to a nested cohort with 3-monthly sampling, to explore the magnitude and duration of antibody response and protective immunity in the Malawian population, and at the same time creating a biorepository for further in-depth virological and immunological studies.\n","plannedDates":[{"endDate":"2022-02-28T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2022-02-28"}],"amountAwarded":249544,"Financial Year":"2019/20","Lead Applicant":"Prof Amelia Crampin","grantProgramme":[{"title":"Strategic Support: Science","title_keyword":"Strategic Support: Science"}],"Applicant Surname":"Crampin","Partnership Value":249544,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Alison Price, Dr Antonia Ho, Dr Charles Mwansambo, Dr Chris Jewell, Dr Abena Amoah, Dr Jonathan Read, Dr Tonney Nyirenda, Dr Annie Chauma Mwale, Dr Peter MacPherson, Prof Nyovani Madise, Prof Victor Mwapasa","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow","addressCountry":"United Kingdom","id_and_name":"[\"University of Glasgow\", \"360G-Wellcome-ORG:University-of-Glasgow\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"SARS-CoV-2 immunoepidemiology in Wellcome-funded urban and rural cohorts in Malawi : generating evidence to inform regional medium and long term decision making General population serosurveillance in low-income Africa is fundamental to understanding the population exposure to SARS-CoV-2, to explain the observed epidemiology and to ensure that ongoing control measures in the region are proportionate and are not guided by observations from very different settings. Detailed longitudinal immunological studies of infected individuals will be key to determining the long-term strategy in managing COVID-19 in highly vulnerable African populations.\n\nUtilising the longitudinal urban and rural cohorts established by the Malawi Epidemiology and Intervention Research Unit, and supported by international and national expertise, we will undertake population immunoepidemiological surveillance to understand the trends in exposure and transmission of SARS-CoV-2, risk factors for SARS-CoV-2 infection and severe disease, as well as the proportion of asymptomatic or pauci-symptomatic infection in the population to enable an accurate estimate of infection fatality rate. Furthermore, we will recruit individuals with evidence of past SARS-CoV-2 infection to a nested cohort with 3-monthly sampling, to explore the magnitude and duration of antibody response and protective immunity in the Malawian population, and at the same time creating a biorepository for further in-depth virological and immunological studies.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Antibodies, Viral","Cohort Studies","Female","Humans","Longitudinal Studies","Malawi","Male","Risk Factors","Rural Population"]}
{"id":"360G-Wellcome-221988_Z_20_Z","title":"Shigella Vaccine Value Proposition","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221988/Z/20/Z","description":"Public Health Value Propositions, also called Full value Vaccine Assessments, are critical, evidence-based analyses conducted to ensure that efforts to develop new vaccines align with the needs, interests and capacity  of intended beneficiaries. We are developing a Shigella vaccine Value Proposition (svvp) to assess and possible enhance the probability that appropriate vaccines targeted at the diarrhoea-causing bacterium Shigella will be developed, produced, financed, widely recommended and adapted in low-middle income countries (LMICs)where it is endemic. The SVVP will inform late stage development investments in Shigella vaccine candidates. We are assessing and synthesizing relevant epidemiological, economic, policy regulatory and manufacturing aspects to address five broad questions and inform the SVVP.\n\n1. How strong is the evidence linking Shigella to stunting, and what would be the economic consequences of vaccine-induced reductions in stunting?\n\n2. What would be the projected impact on and cost effectiveness of the prevention of Shigellosis by effective vaccines?\n\n3. What is the potential demand for Shigella vaccines across different markets?\n\n4. What would be the optimal pathogen composition of a Shigella-containing combination vaccine potentially available in the near- or medium-term?\n\n5. From the perspectives of LMIC-level policy makers and other key stakeholder, what would be the perceived value of a shigella-containing vaccine?","plannedDates":[{"endDate":"2022-08-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2022-08-31"}],"amountAwarded":908761,"Financial Year":"2019/20","Lead Applicant":"Dr William Hausdorff","grantProgramme":[{"title":"Discretionary Award \u2013 Innovations","title_keyword":"Discretionary Award \u2013 Innovations"}],"Applicant Surname":"Hausdorff","Partnership Value":908761,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:PATH","name":"PATH","addressCountry":"United States","id_and_name":"[\"PATH\", \"360G-Wellcome-ORG:PATH\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:PATH","name":"PATH"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Shigella Vaccine Value Proposition Public Health Value Propositions, also called Full value Vaccine Assessments, are critical, evidence-based analyses conducted to ensure that efforts to develop new vaccines align with the needs, interests and capacity  of intended beneficiaries. We are developing a Shigella vaccine Value Proposition (svvp) to assess and possible enhance the probability that appropriate vaccines targeted at the diarrhoea-causing bacterium Shigella will be developed, produced, financed, widely recommended and adapted in low-middle income countries (LMICs)where it is endemic. The SVVP will inform late stage development investments in Shigella vaccine candidates. We are assessing and synthesizing relevant epidemiological, economic, policy regulatory and manufacturing aspects to address five broad questions and inform the SVVP.\n\n1. How strong is the evidence linking Shigella to stunting, and what would be the economic consequences of vaccine-induced reductions in stunting?\n\n2. What would be the projected impact on and cost effectiveness of the prevention of Shigellosis by effective vaccines?\n\n3. What is the potential demand for Shigella vaccines across different markets?\n\n4. What would be the optimal pathogen composition of a Shigella-containing combination vaccine potentially available in the near- or medium-term?\n\n5. From the perspectives of LMIC-level policy makers and other key stakeholder, what would be the perceived value of a shigella-containing vaccine?","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cost-Benefit Analysis","Developing Countries","Diarrhea","Dysentery, Bacillary","Humans","Public Health"]}
{"id":"360G-Wellcome-221986_Z_20_Z","title":"Sabin-Aspen September Convening on sustainable vaccine ecosystem","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221986/Z/20/Z","description":"The COVID-19 pandemic underscores the urgency and importance of vaccines and immunization to global health. There are significant and pressing scientific, technical and policy solutions needed to tackle the enormous challenges we face in a world with COVID-19. Bold thinking across disciplines, actionable recommendations and strong advocacy are all urgently needed to advance innovative ideas, overcome these hurdles and inform future programmatic work, in particular in light of the COVID pandemic. The goal of this project is to virtually convene The Sabin-Aspen Vaccine Science  &  Policy Group (Vaccine Group) in September 2020 to explore how the effort to accelerate the development of COVID-19 vaccines through ACT Accelerator and other initiatives can be harnessed to bring about a \"new normal\" for vaccine/vaccination ecosystem and ensure that vaccines for diseases with epidemic potential or those affecting low income populations are developed. The Sabin Vaccine Institute and the Aspen Institute, co-conveners of the Vaccine Group, will draft and disseminate a meeting report on the convening with principal findings and recommendations to inform program and policy planning.\n","plannedDates":[{"endDate":"2021-12-31T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-12-31"}],"amountAwarded":140190,"Financial Year":"2019/20","Lead Applicant":"Dr Bruce Gellin","grantProgramme":[{"title":"Discretionary Award - Vaccines","title_keyword":"Discretionary Award - Vaccines"}],"Applicant Surname":"Gellin","Partnership Value":140190,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Albert-B-Sabin-Vaccine-Institute-Inc","name":"Albert B. Sabin Vaccine Institute, Inc","addressCountry":"United States","id_and_name":"[\"Albert B. Sabin Vaccine Institute, Inc\", \"360G-Wellcome-ORG:Albert-B-Sabin-Vaccine-Institute-Inc\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Albert-B-Sabin-Vaccine-Institute-Inc","name":"Albert B. Sabin Vaccine Institute, Inc"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Sabin-Aspen September Convening on sustainable vaccine ecosystem The COVID-19 pandemic underscores the urgency and importance of vaccines and immunization to global health. There are significant and pressing scientific, technical and policy solutions needed to tackle the enormous challenges we face in a world with COVID-19. Bold thinking across disciplines, actionable recommendations and strong advocacy are all urgently needed to advance innovative ideas, overcome these hurdles and inform future programmatic work, in particular in light of the COVID pandemic. The goal of this project is to virtually convene The Sabin-Aspen Vaccine Science  &  Policy Group (Vaccine Group) in September 2020 to explore how the effort to accelerate the development of COVID-19 vaccines through ACT Accelerator and other initiatives can be harnessed to bring about a \"new normal\" for vaccine/vaccination ecosystem and ensure that vaccines for diseases with epidemic potential or those affecting low income populations are developed. The Sabin Vaccine Institute and the Aspen Institute, co-conveners of the Vaccine Group, will draft and disseminate a meeting report on the convening with principal findings and recommendations to inform program and policy planning.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Global Health","Health Policy","Humans","Immunization Programs","Pandemics","Vaccines"]}
{"id":"360G-Wellcome-221978_Z_20_Z","title":"TRANSCRIPTIONAL REGULATION OF SELF-RENEWAL IN HUMAN HAEMATOPOIETIC STEM CELLS","Region":"Greater London","currency":"GBP","awardDate":"2020-11-24T00:00:00+00:00","Sponsor(s)":"Prof Alison Lloyd","Internal ID":"221978/Z/20/Z","description":"Generation of functional HSC from pluripotent cells and robust HSC expansion in culture are limited by our incomplete understanding of the self-renewal process. My goal is to unveil the regulatory pathways that sustain HSC self-renewal, based on modulation of gene expression at pre- (chromatin modification) and co-transcriptional  (transcriptional elongation and RNA polymerase II pausing) levels and as directed by the metabolic state of the cell. I will carry out my scientific goals with the following aims:\n\n\n Determine the regulation of HSC self-renewal though modulation of transcriptional rate and RNA polymerase II activity.\n Understand the role of HSC metabolism and nutrient availability in the regulation of the HSC self-renewal gene regulation machinery.\n Modulate HSC transcriptional regulation to achieve successful HSC generation in culture.\n\n\nThese research avenues will lead to a better understanding of the molecular basis of self-renewal and will provide a foundation to improve the generation and expansion of engraftable human HSCs in culture, in order to fully exploit their potential for clinical applications. This work will expand our current knowledge of the HSC self-renewal process and provide new insights into the molecular features of stemness, with implications for other tissue stem cells and the cancer field.\n","plannedDates":[{"endDate":"2026-01-31T00:00:00+00:00","startDate":"2021-02-01T00:00:00+00:00","startDateDateOnly":"2021-02-01","endDateDateOnly":"2026-01-31"}],"amountAwarded":1535040,"Financial Year":"2020/21","Lead Applicant":"Dr Vincenzo Calvanese","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Calvanese","Partnership Value":1535040,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"TRANSCRIPTIONAL REGULATION OF SELF-RENEWAL IN HUMAN HAEMATOPOIETIC STEM CELLS Generation of functional HSC from pluripotent cells and robust HSC expansion in culture are limited by our incomplete understanding of the self-renewal process. My goal is to unveil the regulatory pathways that sustain HSC self-renewal, based on modulation of gene expression at pre- (chromatin modification) and co-transcriptional  (transcriptional elongation and RNA polymerase II pausing) levels and as directed by the metabolic state of the cell. I will carry out my scientific goals with the following aims:\n\n\n Determine the regulation of HSC self-renewal though modulation of transcriptional rate and RNA polymerase II activity.\n Understand the role of HSC metabolism and nutrient availability in the regulation of the HSC self-renewal gene regulation machinery.\n Modulate HSC transcriptional regulation to achieve successful HSC generation in culture.\n\n\nThese research avenues will lead to a better understanding of the molecular basis of self-renewal and will provide a foundation to improve the generation and expansion of engraftable human HSCs in culture, in order to fully exploit their potential for clinical applications. This work will expand our current knowledge of the HSC self-renewal process and provide new insights into the molecular features of stemness, with implications for other tissue stem cells and the cancer field.\n","awardDateDateOnly":"2020-11-24","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cell Self Renewal","Hematopoietic Stem Cells","Humans","Transcription, Genetic"]}
{"id":"360G-Wellcome-221963_Z_20_Z","title":"Socio-ecological dynamics of zoonotic and vector-borne diseases in changing landscapes: implications for surveillance and control","Region":"Scotland","currency":"GBP","awardDate":"2020-11-24T00:00:00+00:00","Sponsor(s)":"Prof Daniel Haydon, Prof Tock Chua","Internal ID":"221963/Z/20/Z","description":"Landscape changes disrupt infectious disease dynamics, requiring new approaches to characterise risks and prevent outbreaks. Focusing on emerging (Chikungunya, Zika) and epidemic (malaria, dengue) zoonotic and vector-borne diseases in Malaysia and the Philippines, I aim to design and evaluate enhanced surveillance systems linking health and environmental data to detect and prevent pathogen spillover and transmission. By developing novel models relating social and ecological processes across spatial and temporal scales, I will bridge critical gaps linking environmental change with human behaviour and health systems. Fine-scale studies of human mobility, behaviour and infection risks will be integrated within a large-scale experiment on tropical forest modification to understand how landscape change both interacts with and alters environmental factors (e.g. seasonality, biodiversity) and socioeconomic and biological factors (e.g. demography, mobility, immunity) to determine disease dynamics. Statistical and mathematical models will be used to explore factors across ecological settings, integrating routine surveillance data, population-based serological surveys and multitemporal Earth Observation data to reconstruct historical disease transmission over major environmental shifts. Predictive models will be designed to identify how future land use can reduce disease risks and how control programmes can use environmental data from new sources of real-time Earth Observation data to improve disease surveillance.\n","plannedDates":[{"endDate":"2026-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2026-03-31"}],"amountAwarded":1185742,"Financial Year":"2020/21","Lead Applicant":"Dr Kimberly Fornace","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Fornace","Partnership Value":1185742,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow","addressCountry":"United Kingdom","id_and_name":"[\"University of Glasgow\", \"360G-Wellcome-ORG:University-of-Glasgow\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Socio-ecological dynamics of zoonotic and vector-borne diseases in changing landscapes: implications for surveillance and control Landscape changes disrupt infectious disease dynamics, requiring new approaches to characterise risks and prevent outbreaks. Focusing on emerging (Chikungunya, Zika) and epidemic (malaria, dengue) zoonotic and vector-borne diseases in Malaysia and the Philippines, I aim to design and evaluate enhanced surveillance systems linking health and environmental data to detect and prevent pathogen spillover and transmission. By developing novel models relating social and ecological processes across spatial and temporal scales, I will bridge critical gaps linking environmental change with human behaviour and health systems. Fine-scale studies of human mobility, behaviour and infection risks will be integrated within a large-scale experiment on tropical forest modification to understand how landscape change both interacts with and alters environmental factors (e.g. seasonality, biodiversity) and socioeconomic and biological factors (e.g. demography, mobility, immunity) to determine disease dynamics. Statistical and mathematical models will be used to explore factors across ecological settings, integrating routine surveillance data, population-based serological surveys and multitemporal Earth Observation data to reconstruct historical disease transmission over major environmental shifts. Predictive models will be designed to identify how future land use can reduce disease risks and how control programmes can use environmental data from new sources of real-time Earth Observation data to improve disease surveillance.\n","awardDateDateOnly":"2020-11-24","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Chikungunya Fever","Dengue","Disease Outbreaks","Humans","Malaria","Malaysia","Models, Theoretical","Mosquito Vectors","Philippines","Zika Virus","Zika Virus Infection","Zoonoses"]}
{"id":"360G-Wellcome-221951_Z_20_Z","title":"Understanding non-coding genomic variation in neurological disorders","Region":"Greater London","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221951/Z/20/Z","description":"The vast majority of DNA is non-coding, repetitive, encompasses a significant proportion of disease risk and is divergent across populations. Major bottlenecks in the past restricted our understanding of this genomic region, including limited analysis techniques, inability to sequence large repetitive, homologous regions and the paucity of population control datasets. These restrictions have largely been overcome, and through early translation we have highlighted the importance of non-coding genomic factors with the identification of pathogenic recessive repeat expansions, homologous replicated regions and gene amplification events as major causes of neurological disease.\n\nThe overarching theme of this proposal is to investigate four large diverse neurology cohorts, where genome sequencing has explained less than one-third of cases. Initially, we will examine non-coding, short-read genome sequencing data using optimised and newly developed algorithms. Next, to overcome the limitations of short-read sequencing, we will apply and integrate long-read Oxford Nanopore genome sequencing and optical genome mapping to a range of neurological disease trios and paired brain and blood samples. Finally, we will comprehensively interpret and validate data, reannotate against diverse control genomes, compare disease-relevant transcriptome builds, interrogate collaborator cohorts and use transcriptome sequencing to inform on pathogenicity, identify mechanisms and pathways impacted by genetic vulnerability.\n","plannedDates":[{"endDate":"2027-01-21T00:00:00+00:00","startDate":"2022-01-22T00:00:00+00:00","startDateDateOnly":"2022-01-22","endDateDateOnly":"2027-01-21"}],"amountAwarded":2387230,"Financial Year":"2020/21","Lead Applicant":"Prof Henry Houlden","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Houlden","Partnership Value":2387230,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding non-coding genomic variation in neurological disorders The vast majority of DNA is non-coding, repetitive, encompasses a significant proportion of disease risk and is divergent across populations. Major bottlenecks in the past restricted our understanding of this genomic region, including limited analysis techniques, inability to sequence large repetitive, homologous regions and the paucity of population control datasets. These restrictions have largely been overcome, and through early translation we have highlighted the importance of non-coding genomic factors with the identification of pathogenic recessive repeat expansions, homologous replicated regions and gene amplification events as major causes of neurological disease.\n\nThe overarching theme of this proposal is to investigate four large diverse neurology cohorts, where genome sequencing has explained less than one-third of cases. Initially, we will examine non-coding, short-read genome sequencing data using optimised and newly developed algorithms. Next, to overcome the limitations of short-read sequencing, we will apply and integrate long-read Oxford Nanopore genome sequencing and optical genome mapping to a range of neurological disease trios and paired brain and blood samples. Finally, we will comprehensively interpret and validate data, reannotate against diverse control genomes, compare disease-relevant transcriptome builds, interrogate collaborator cohorts and use transcriptome sequencing to inform on pathogenicity, identify mechanisms and pathways impacted by genetic vulnerability.\n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Algorithms","Genome","Genome, Human","Genomics","High-Throughput Nucleotide Sequencing","Humans","Nervous System Diseases","Sequence Analysis, DNA","Whole Genome Sequencing"]}
{"id":"360G-Wellcome-221944_Z_20_Z","title":"Defining the molecular determinants required for Leishmania life cycle progression and virulence","Region":"Scotland","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221944/Z/20/Z","description":"Leishmania parasites cause a neglected disease on the WHO priority list. During their life cycle, these single-celled parasites must migrate through the sandfly (promastigotes), pre-adapt for mammalian infectivity (metacyclic promastigotes) and proliferate inside macrophages (amastigotes) while withstanding host immune defences. Adaptation to these radically different environments involves many changes, including metabolic and cell structure specialisations, ensuring survival and transmission. However, current understanding of these processes is disjointed and biased towards predicted/expected pathways. Half of Leishmania\u2019s protein-coding genes, including most unique to Leishmania, have no known or predicted function, (the \"dark genome\"), leaving potentially exploitable parasite biochemistry untapped in the search for new therapeutics. We aim to identify all major parasite pathogenicity factors.  We will determine a) the subcellular localisation of all proteins with poorly predicted function (~50% of the genome) and b) the fitness cost of gene deletion in each life cycle stage (100% of the genome). Integrative analysis of this deep dataset will identify key pathways in 1) organelle adaptation for an intracellular parasitic lifestyle and 2) host interaction, which we will then functionally dissect. This will identify virulence factors on a genome scale, determine the most important pathways required for parasitism and illuminate the \u2018dark genome\u2019.\n","plannedDates":[{"endDate":"2026-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2026-03-31"}],"amountAwarded":2298141,"Financial Year":"2020/21","Lead Applicant":"Dr Eva Gluenz","grantProgramme":[{"title":"Collaborative Award in Science","title_keyword":"Collaborative Award in Science"}],"Applicant Surname":"Gluenz","Partnership Value":2298141,"Approval Committee":"Science Interview Panel","Other Applicant(s)":"Prof Jeremy Mottram, Dr Jack Sunter","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow","addressCountry":"United Kingdom","id_and_name":"[\"University of Glasgow\", \"360G-Wellcome-ORG:University-of-Glasgow\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Defining the molecular determinants required for Leishmania life cycle progression and virulence Leishmania parasites cause a neglected disease on the WHO priority list. During their life cycle, these single-celled parasites must migrate through the sandfly (promastigotes), pre-adapt for mammalian infectivity (metacyclic promastigotes) and proliferate inside macrophages (amastigotes) while withstanding host immune defences. Adaptation to these radically different environments involves many changes, including metabolic and cell structure specialisations, ensuring survival and transmission. However, current understanding of these processes is disjointed and biased towards predicted/expected pathways. Half of Leishmania\u2019s protein-coding genes, including most unique to Leishmania, have no known or predicted function, (the \"dark genome\"), leaving potentially exploitable parasite biochemistry untapped in the search for new therapeutics. We aim to identify all major parasite pathogenicity factors.  We will determine a) the subcellular localisation of all proteins with poorly predicted function (~50% of the genome) and b) the fitness cost of gene deletion in each life cycle stage (100% of the genome). Integrative analysis of this deep dataset will identify key pathways in 1) organelle adaptation for an intracellular parasitic lifestyle and 2) host interaction, which we will then functionally dissect. This will identify virulence factors on a genome scale, determine the most important pathways required for parasitism and illuminate the \u2018dark genome\u2019.\n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Host-Parasite Interactions","Macrophages","Virulence"]}
{"id":"360G-Wellcome-221940_Z_20_Z","title":"ALIVE: Improving Adolescent mentaL health by reducing the Impact of poVErty","Region":"Greater London","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221940/Z/20/Z","description":"Depression and anxiety are leading contributors to the burden of disease among adolescents in low- and middle-income countries (LMIC), and they disproportionally affect adolescents living in poverty. Yet, the evidence base for interventions that effectively prevent depression and anxiety among adolescents living in poverty is weak. One major shortcoming is that interventions often fail to address poverty-related social determinants of mental health and neuropsychological consequences of poverty (such as impaired self-regulation). The aim of this study is to develop and pilot-test an intervention that equips adolescents with skills to escape poverty and strengthens self-regulation, thus preventing adolescent depression and anxiety in urban LMIC settings.The study objectives are to: (1) develop a theoretical model of the causal mechanisms linking poverty, self-regulation, and depression and anxiety among adolescents (age 10-19 years); (2) collaboratively develop a multi-component selective prevention intervention targeting self-regulation and skills for academic and employment success  among adolescents at high risk of developing depression or anxiety living in urban poverty in Colombia, Nepal and South Africa; (3) adapt and validate key instruments to measure eligibility, implementation, mediators, and outcomes of the intervention; and (4) undertake a 4-arm pilot randomized controlled trial of the selective prevention intervention in each site.\n","plannedDates":[{"endDate":"2026-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2026-06-30"}],"amountAwarded":2010416,"Financial Year":"2020/21","Lead Applicant":"Prof Crick Lund","grantProgramme":[{"title":"Collaborative Award in Science","title_keyword":"Collaborative Award in Science"}],"Partnership Name":"NIHR/Wellcome Global health Partnership","Applicant Surname":"Lund","Partnership Value":4020832,"Approval Committee":"Science Interview Panel","Other Applicant(s)":"Dr Brandon Kohrt, Dr Mark Jordans, Prof Lydia Krabbendam, Dr Tarun Dua, Mr Nagendra Luitel, Prof Mauricio Avendano","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"ALIVE: Improving Adolescent mentaL health by reducing the Impact of poVErty Depression and anxiety are leading contributors to the burden of disease among adolescents in low- and middle-income countries (LMIC), and they disproportionally affect adolescents living in poverty. Yet, the evidence base for interventions that effectively prevent depression and anxiety among adolescents living in poverty is weak. One major shortcoming is that interventions often fail to address poverty-related social determinants of mental health and neuropsychological consequences of poverty (such as impaired self-regulation). The aim of this study is to develop and pilot-test an intervention that equips adolescents with skills to escape poverty and strengthens self-regulation, thus preventing adolescent depression and anxiety in urban LMIC settings.The study objectives are to: (1) develop a theoretical model of the causal mechanisms linking poverty, self-regulation, and depression and anxiety among adolescents (age 10-19 years); (2) collaboratively develop a multi-component selective prevention intervention targeting self-regulation and skills for academic and employment success  among adolescents at high risk of developing depression or anxiety living in urban poverty in Colombia, Nepal and South Africa; (3) adapt and validate key instruments to measure eligibility, implementation, mediators, and outcomes of the intervention; and (4) undertake a 4-arm pilot randomized controlled trial of the selective prevention intervention in each site.\n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adolescent","Anxiety","Anxiety Disorders","Child","Colombia","Depression","Developing Countries","Female","Humans","Male","Nepal","Pilot Projects","Poverty","South Africa","Urban Population","Young Adult"]}
{"id":"360G-Wellcome-221936_Z_20_Z","title":"Plasticity of visual circuits","Region":"South East","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221936/Z/20/Z","description":"How does a circuit of neurons process sensory information?  And how is processing adjusted in relation to changes in the sensory environment or internal state of the animal? These questions will be investigated in larval zebrafish, where visual circuits and the behaviours they drive are altered in the context of\n\ni) changes in the visual environment, such as luminance or contrast,\nii) information arriving through chemical and mechanical senses,\niii) the internal state, such as arousal or satiety, and \niv) circadian mechanisms. \n\nTo investigate how visual processing is adjusted under these different conditions we will use larval zebrafish to image neural activity through the retina and brain of the behaving animal. Zebrafish generate distinct motor responses to stimuli of different contrasts, size and speed, allowing us to investigate the plasticity of computations directly linked to behaviour.\n\nOur guiding hypothesis is that the plasticity of visual circuits reflects use-dependent changes in synaptic strength and the actions of neuromodulators that reconfigure signal flow.  A comparison of computations carried out in different circuits will be key to identifying general mechanisms by which the brain adjusts sensory processing to the sensory environment and/or internal state of the animal.  \n\n \n","plannedDates":[{"endDate":"2027-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2027-08-31"}],"amountAwarded":2946454,"Financial Year":"2020/21","Lead Applicant":"Prof Leon Lagnado","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Lagnado","Partnership Value":2946454,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Sussex","name":"University of Sussex","addressCountry":"United Kingdom","id_and_name":"[\"University of Sussex\", \"360G-Wellcome-ORG:University-of-Sussex\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Sussex","name":"University of Sussex"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Plasticity of visual circuits How does a circuit of neurons process sensory information?  And how is processing adjusted in relation to changes in the sensory environment or internal state of the animal? These questions will be investigated in larval zebrafish, where visual circuits and the behaviours they drive are altered in the context of\n\ni) changes in the visual environment, such as luminance or contrast,\nii) information arriving through chemical and mechanical senses,\niii) the internal state, such as arousal or satiety, and \niv) circadian mechanisms. \n\nTo investigate how visual processing is adjusted under these different conditions we will use larval zebrafish to image neural activity through the retina and brain of the behaving animal. Zebrafish generate distinct motor responses to stimuli of different contrasts, size and speed, allowing us to investigate the plasticity of computations directly linked to behaviour.\n\nOur guiding hypothesis is that the plasticity of visual circuits reflects use-dependent changes in synaptic strength and the actions of neuromodulators that reconfigure signal flow.  A comparison of computations carried out in different circuits will be key to identifying general mechanisms by which the brain adjusts sensory processing to the sensory environment and/or internal state of the animal.  \n\n \n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Brain","Larva","Neuronal Plasticity","Photic Stimulation","Visual Pathways","Visual Perception","Zebrafish"]}
{"id":"360G-Wellcome-221934_Z_20_Z","title":"Epilepsy and neurodegeneration : disease mechanisms and early detection","Region":"Greater London","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221934/Z/20/Z","description":"Cognitive decline represents a significant and debilitating co-morbidity for patients with epilepsy which is poorly understood with an urgent clinical need for diagnostic, preventative and treatment strategies. Large epilepsy MRI datasets confirm progressive cortical atrophy and white matter abnormalities ; age-accelerated Tau protein accumulation has been reported in surgical resections, correlating with cognitive decline. We propose a comprehensive evaluation of mixed neurodegenerative processes integrating cross-sectional and longitudinal MRI, DWI, DCE-MRI and Tau-PETimaging with quantitative neuropathology  measurements of cortical, white mater atrophy and vascular pathology and pTau in resected surgical specimens in the context of cognitive impairment and genetic risk. We aim to characterise tau forms in surgical and post-mortem cohorts compared to Alzheimer's disease and other tauopathies. In prospective surgical cohorts, Tau-PET will be correlated with CSF markers, tissue levels using autoradiography and extent of cortical atrophy with high resolution in-vivo 7T and ex-vivo 9.4T MRI. In addition, cellular drivers for tau accumulation, as MTOR and seizure activity,  will be explored through human slice culture experiments with gene-expression analysis and the kinetics of tau incorporation through SILK studies and mass spectroscopy of tissues. These studies will elucidate pathomechanims of cognitive impairment, identify early disease-stage biomarkers enabling prediction and preventative strategies.\n","plannedDates":[{"endDate":"2026-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2026-03-31"}],"amountAwarded":2367251,"Financial Year":"2020/21","Lead Applicant":"Prof Maria Thom","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Thom","Partnership Value":2367251,"Approval Committee":"Science Interview Panel","Other Applicant(s)":"Prof Matthias Koepp","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Epilepsy and neurodegeneration : disease mechanisms and early detection Cognitive decline represents a significant and debilitating co-morbidity for patients with epilepsy which is poorly understood with an urgent clinical need for diagnostic, preventative and treatment strategies. Large epilepsy MRI datasets confirm progressive cortical atrophy and white matter abnormalities ; age-accelerated Tau protein accumulation has been reported in surgical resections, correlating with cognitive decline. We propose a comprehensive evaluation of mixed neurodegenerative processes integrating cross-sectional and longitudinal MRI, DWI, DCE-MRI and Tau-PETimaging with quantitative neuropathology  measurements of cortical, white mater atrophy and vascular pathology and pTau in resected surgical specimens in the context of cognitive impairment and genetic risk. We aim to characterise tau forms in surgical and post-mortem cohorts compared to Alzheimer's disease and other tauopathies. In prospective surgical cohorts, Tau-PET will be correlated with CSF markers, tissue levels using autoradiography and extent of cortical atrophy with high resolution in-vivo 7T and ex-vivo 9.4T MRI. In addition, cellular drivers for tau accumulation, as MTOR and seizure activity,  will be explored through human slice culture experiments with gene-expression analysis and the kinetics of tau incorporation through SILK studies and mass spectroscopy of tissues. These studies will elucidate pathomechanims of cognitive impairment, identify early disease-stage biomarkers enabling prediction and preventative strategies.\n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aged","Atrophy","Biomarkers","Cerebral Cortex","Cross-Sectional Studies","Female","Humans","Magnetic Resonance Imaging","Male","Positron-Emission Tomography","Tauopathies","tau Proteins"]}
{"id":"360G-Wellcome-221933_Z_20_Z","title":"A cross-species, cross-modal approach to computational neuroanatomy","Region":"South East","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221933/Z/20/Z","description":"In vivo methods for mapping brain connections are increasingly used in systems neuroscience but are yet to have significant clinical impact. We propose to develop new computational approaches that bridge information from precise but invasive methods in animals to enhance in vivo methods in humans. We translate this framework into clinical care in surgical patients:\n\nIn Aim 1, we will leverage a unique resource of macaque tracers currently being digitised. We will use state-of-the-art machine learning to automate quantification, and image processing for mapping histology to MRI, to produce a unique resource of macaque ground truth connectivity.\nIn Aim 2, we will develop computational approaches to enable macaque anatomical tracers, alongside multimodal MRI in macaques and humans, to be used to improve the accuracy of methods developed in humans.\nIn Aim 3, we will build end-to-end approaches for connectivity-based functional localisation, and deploy this as a tool to aid pre-surgical planning for localisation of subcortical targets in deep brain stimulation and for localisation of eloquent cortex in tumour surgery.\n \n","plannedDates":[{"endDate":"2026-01-31T00:00:00+00:00","startDate":"2021-02-01T00:00:00+00:00","startDateDateOnly":"2021-02-01","endDateDateOnly":"2026-01-31"}],"amountAwarded":1212397,"Financial Year":"2020/21","Lead Applicant":"Prof Saad Jbabdi","grantProgramme":[{"title":"Senior Research Fellowship","title_keyword":"Senior Research Fellowship"}],"Applicant Surname":"Jbabdi","Partnership Value":1212397,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A cross-species, cross-modal approach to computational neuroanatomy In vivo methods for mapping brain connections are increasingly used in systems neuroscience but are yet to have significant clinical impact. We propose to develop new computational approaches that bridge information from precise but invasive methods in animals to enhance in vivo methods in humans. We translate this framework into clinical care in surgical patients:\n\nIn Aim 1, we will leverage a unique resource of macaque tracers currently being digitised. We will use state-of-the-art machine learning to automate quantification, and image processing for mapping histology to MRI, to produce a unique resource of macaque ground truth connectivity.\nIn Aim 2, we will develop computational approaches to enable macaque anatomical tracers, alongside multimodal MRI in macaques and humans, to be used to improve the accuracy of methods developed in humans.\nIn Aim 3, we will build end-to-end approaches for connectivity-based functional localisation, and deploy this as a tool to aid pre-surgical planning for localisation of subcortical targets in deep brain stimulation and for localisation of eloquent cortex in tumour surgery.\n \n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Brain Mapping","Humans","Image Processing, Computer-Assisted","Macaca mulatta","Machine Learning","Magnetic Resonance Imaging"]}
{"id":"360G-Wellcome-221924_Z_20_Z","title":"Plasmid biology in human adapted pathogens","Region":"South East","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221924/Z/20/Z","description":"Plasmids are responsible for virulence and antimicrobial resistance in many bacteria. We will dissect fundamental mechanisms of plasmid maintenance in the obligate human pathogens, Shigella spp. and Neisseria gonorrhoeae, declared as high priority organisms by WHO/CDC. Toxin:antitoxin (TA) systems (addiction systems) are important for plasmid maintenance by eliminating bacteria failing to inherit a plasmid after cell division. For example, the VapBC TA system is essential for maintaining the 210kb Shigella virulence plasmid. Additionally, TA systems (including VapBC) are increasingly recognised for their role in antibiotic tolerance, often a precursor to resistance. Despite this, little is known of how plasmid maintenance is integrated with the bacterial host, and how TA systems are activated after plasmid loss/during tolerance. Combining our understanding of variation in VapBC and the VapC toxin target tRNAfMet with multidisciplinary approaches (mutagenesis/structural:function studies/single cell analysis), we will define mechanisms of TA system activation and the temporal dynamics of events following plasmid loss that culminate in cell death. We will examine the acquisition and maintenance of resistance plasmids in Shigella and N. gonorrhoeae, and the interactions between plasmids and their contribtion to tolerance and horizontal transfer.\n","plannedDates":[{"endDate":"2026-01-31T00:00:00+00:00","startDate":"2021-02-01T00:00:00+00:00","startDateDateOnly":"2021-02-01","endDateDateOnly":"2026-01-31"}],"amountAwarded":1969785,"Financial Year":"2020/21","Lead Applicant":"Prof Christoph Tang","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Tang","Partnership Value":1969785,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Plasmid biology in human adapted pathogens Plasmids are responsible for virulence and antimicrobial resistance in many bacteria. We will dissect fundamental mechanisms of plasmid maintenance in the obligate human pathogens, Shigella spp. and Neisseria gonorrhoeae, declared as high priority organisms by WHO/CDC. Toxin:antitoxin (TA) systems (addiction systems) are important for plasmid maintenance by eliminating bacteria failing to inherit a plasmid after cell division. For example, the VapBC TA system is essential for maintaining the 210kb Shigella virulence plasmid. Additionally, TA systems (including VapBC) are increasingly recognised for their role in antibiotic tolerance, often a precursor to resistance. Despite this, little is known of how plasmid maintenance is integrated with the bacterial host, and how TA systems are activated after plasmid loss/during tolerance. Combining our understanding of variation in VapBC and the VapC toxin target tRNAfMet with multidisciplinary approaches (mutagenesis/structural:function studies/single cell analysis), we will define mechanisms of TA system activation and the temporal dynamics of events following plasmid loss that culminate in cell death. We will examine the acquisition and maintenance of resistance plasmids in Shigella and N. gonorrhoeae, and the interactions between plasmids and their contribtion to tolerance and horizontal transfer.\n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anti-Bacterial Agents","Humans","Neisseria gonorrhoeae","Plasmids","Virulence"]}
{"id":"360G-Wellcome-221915_Z_20_Z","title":"Computational Modelling and Inference of Neurodegenerative Disease Propagation","Region":"Greater London","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221915/Z/20/Z","description":"This project uses computational modelling, machine learning, and big-data analysis to address key unknowns on the biology of neurodegenerative disease: when and where it starts; how it spreads over the brain (\"propagates\"); how it varies among diseases, subtypes, and individuals; how risk factors influence mechanisms. Current models linking imaging and other clinical data to propagation mechanisms are crude, and evaluation remains largely qualitative. The project introduces a powerful Bayesian inference framework, accounting for uncertainties throughout the data-processing pipeline, to enable robust evidence quantification of new and detailed computational models of disease propagation. The approach demands a rethink of contributing technologies. First, we unravel patient heterogeneity, which confounds propagation-model evaluation, through a new generation of data-driven disease progression models that identify fine-grained disease subtypes characterised by temporal trajectory of multi-modal biomarkers. Second, propagation models use brain connectome estimates and are confounded by high connection-error rates. We establish a new probabilistic connectomics paradigm that quantifies likelihoods of false positive and negative connections enabling models to mitigate their inevitable presence. We use the framework to provide the first truly quantitative evaluation of propagation models against state-of-the-art data sets leading to fundamental new insights on the mechanisms of pathology propagation in neurodegenerative diseases.\n","plannedDates":[{"endDate":"2026-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2026-03-31"}],"amountAwarded":1465345,"Financial Year":"2020/21","Lead Applicant":"Prof Daniel Alexander","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Alexander","Partnership Value":1465345,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Computational Modelling and Inference of Neurodegenerative Disease Propagation This project uses computational modelling, machine learning, and big-data analysis to address key unknowns on the biology of neurodegenerative disease: when and where it starts; how it spreads over the brain (\"propagates\"); how it varies among diseases, subtypes, and individuals; how risk factors influence mechanisms. Current models linking imaging and other clinical data to propagation mechanisms are crude, and evaluation remains largely qualitative. The project introduces a powerful Bayesian inference framework, accounting for uncertainties throughout the data-processing pipeline, to enable robust evidence quantification of new and detailed computational models of disease propagation. The approach demands a rethink of contributing technologies. First, we unravel patient heterogeneity, which confounds propagation-model evaluation, through a new generation of data-driven disease progression models that identify fine-grained disease subtypes characterised by temporal trajectory of multi-modal biomarkers. Second, propagation models use brain connectome estimates and are confounded by high connection-error rates. We establish a new probabilistic connectomics paradigm that quantifies likelihoods of false positive and negative connections enabling models to mitigate their inevitable presence. We use the framework to provide the first truly quantitative evaluation of propagation models against state-of-the-art data sets leading to fundamental new insights on the mechanisms of pathology propagation in neurodegenerative diseases.\n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Bayes Theorem","Biomarkers","Brain","Connectome","Disease Progression","Humans","Machine Learning","Neurodegenerative Diseases"]}
{"id":"360G-Wellcome-221914_Z_20_Z","title":"Molecular regulators of the alarmin IL-33 in health and disease","Region":"Scotland","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221914/Z/20/Z","description":"IL-33 is a critical cytokine in allergy, obesity, helminth infection, sepsis, and respiratory viral infection. Blockade of IL-33 (or its receptor, ST2) is currently being trialled in a range of allergic and inflammatory conditions, including Covid-19. The cytokine has a short half-life on release, but conversely has effects at distal sites and over long periods. Furthermore, innate immune cells in the intestine are poorly responsive to IL-33, but susceptibility to intestinal helminths is strongly controlled by IL-33. \n\nThis project will investigate:\n\n1) How, at a protein structural level, parasite proteins effectively block IL-33 responses. Determination of the effects on the parasite and host of blocking parasite modulation of the IL-33 pathway.\n\n2) What are the roles and targets of IL-33 released from the intestinal epithelium, both locally (in parasite infection) and systemically (in diet-induced obesity).\n\n3) The role of soluble IL-33 receptor in stabilisation of IL-33, and its effects at distal sites.\n\nTo achieve these aims will we will use structural biology, in vivo models of IL-33-dependent responses, creation of cell-specific ST2-deficient mouse strains, and generation of a soluble ST2-deficient mouse. Finally we will use human blood samples and three-dimensional culture methods to ensure translation of these findings to humans. \n","plannedDates":[{"endDate":"2026-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2026-06-30"}],"amountAwarded":1661908,"Financial Year":"2020/21","Lead Applicant":"Dr Henry McSorley","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"McSorley","Partnership Value":1661908,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee","addressCountry":"United Kingdom","id_and_name":"[\"University of Dundee\", \"360G-Wellcome-ORG:University-of-Dundee\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Molecular regulators of the alarmin IL-33 in health and disease IL-33 is a critical cytokine in allergy, obesity, helminth infection, sepsis, and respiratory viral infection. Blockade of IL-33 (or its receptor, ST2) is currently being trialled in a range of allergic and inflammatory conditions, including Covid-19. The cytokine has a short half-life on release, but conversely has effects at distal sites and over long periods. Furthermore, innate immune cells in the intestine are poorly responsive to IL-33, but susceptibility to intestinal helminths is strongly controlled by IL-33. \n\nThis project will investigate:\n\n1) How, at a protein structural level, parasite proteins effectively block IL-33 responses. Determination of the effects on the parasite and host of blocking parasite modulation of the IL-33 pathway.\n\n2) What are the roles and targets of IL-33 released from the intestinal epithelium, both locally (in parasite infection) and systemically (in diet-induced obesity).\n\n3) The role of soluble IL-33 receptor in stabilisation of IL-33, and its effects at distal sites.\n\nTo achieve these aims will we will use structural biology, in vivo models of IL-33-dependent responses, creation of cell-specific ST2-deficient mouse strains, and generation of a soluble ST2-deficient mouse. Finally we will use human blood samples and three-dimensional culture methods to ensure translation of these findings to humans. \n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Disease Models, Animal","Humans","Immunity, Innate","Interleukin-1 Receptor-Like 1 Protein","Interleukin-33","Intestinal Mucosa","Mice","Mice, Inbred C57BL","Mice, Knockout","Obesity"]}
{"id":"360G-Wellcome-221908_Z_20_Z","title":"The role of epithelial cell extrusion in asthma","Region":"Greater London","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221908/Z/20/Z","description":"Asthma is an airway inflammatory disease, defined by bronchoconstrictive attacks that can be life-threatening. The two essential tissue components of the bronchioles are the airway epithelium and the underlying smooth muscle. In asthma, the smooth muscle is remodelled and becomes hyper-responsive, leading to excessive contractility. We have shown that epithelia are exquisitely sensitive to mechanical forces. Cell crowding triggers cell extrusion, while stretching triggers cell division. We recently discovered that the asthmatic bronchoconstrictive attack, causes excess airway epithelial extrusion and damage, compromising the barrier function, leading to inflammation. We propose that in healthy lungs, epithelia and smooth muscle communicate with each other to ensure sufficient epithelial cells numbers, essential to a tight barrier. However, in asthma, excess epithelial extrusion signals smooth muscle remodeling, actuating further rounds of more intense bronchoconstriction. This feed-forward cycle could perpetuate asthma attacks. We believe that our mechanochemical and cell biological insight into asthma will reveal novel ways to prevent it. We will investigate this hypothesis by addressing the following questions:\n\n1) How are airways remodelled to cause an attack? \n2) Do epithelia regulate constriction? \n3) Does extrusion shed rhinovirus, yet trigger asthma attack\n","plannedDates":[{"endDate":"2026-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2026-03-31"}],"amountAwarded":1509343,"Financial Year":"2020/21","Lead Applicant":"Prof Jody Rosenblatt","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Rosenblatt","Partnership Value":1509343,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The role of epithelial cell extrusion in asthma Asthma is an airway inflammatory disease, defined by bronchoconstrictive attacks that can be life-threatening. The two essential tissue components of the bronchioles are the airway epithelium and the underlying smooth muscle. In asthma, the smooth muscle is remodelled and becomes hyper-responsive, leading to excessive contractility. We have shown that epithelia are exquisitely sensitive to mechanical forces. Cell crowding triggers cell extrusion, while stretching triggers cell division. We recently discovered that the asthmatic bronchoconstrictive attack, causes excess airway epithelial extrusion and damage, compromising the barrier function, leading to inflammation. We propose that in healthy lungs, epithelia and smooth muscle communicate with each other to ensure sufficient epithelial cells numbers, essential to a tight barrier. However, in asthma, excess epithelial extrusion signals smooth muscle remodeling, actuating further rounds of more intense bronchoconstriction. This feed-forward cycle could perpetuate asthma attacks. We believe that our mechanochemical and cell biological insight into asthma will reveal novel ways to prevent it. We will investigate this hypothesis by addressing the following questions:\n\n1) How are airways remodelled to cause an attack? \n2) Do epithelia regulate constriction? \n3) Does extrusion shed rhinovirus, yet trigger asthma attack\n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Airway Remodeling","Asthma","Bronchi","Epithelial Cells","Humans","Rhinovirus"]}
{"id":"360G-Wellcome-221892_Z_20_Z","title":"Molecular mechanisms of DNA synthesis by the human replisome","Region":"East of England","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221892/Z/20/Z","description":"Before mitosis, cells must make two accurate and complete copies of their genome, to ensure genetic stability across cellular generations. This challenging biochemical task requires complex molecular systems that duplicate chromosomal DNA and repair lesions that stall DNA synthesis. Sporadic or inherited defects in the cellular apparatus of genomic duplication cause genetic instability, which is responsible for developmental and degenerative pathologies and for cancer predisposition.\n\nOur knowledge of the molecular basis of eukaryotic DNA replication and related repair processes is incomplete, and this is especially true of genomic duplication in human cells, the most relevant to our health. Our proposal aims to provide a high-resolution view of the molecular mechanisms of DNA replication, using state-of-the-art biochemical and biophysical approaches. We will focus on components of the human replisome, the multi-protein assembly responsible for DNA synthesis in our cells.\n\nThere is intense medical interest in the molecular mechanisms responsible for genomic integrity and the rationale for the consequences of their occasional failure. In this respect, the work of our proposal is highly significant as it aims to deliver a comprehensive description in atomic detail of the complex and dynamic processes of DNA replication, when our genome is at its most vulnerable.\n","plannedDates":[{"endDate":"2026-05-31T00:00:00+00:00","startDate":"2021-06-01T00:00:00+00:00","startDateDateOnly":"2021-06-01","endDateDateOnly":"2026-05-31"}],"amountAwarded":1906940,"Financial Year":"2020/21","Lead Applicant":"Prof Luca Pellegrini","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Pellegrini","Partnership Value":1906940,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Molecular mechanisms of DNA synthesis by the human replisome Before mitosis, cells must make two accurate and complete copies of their genome, to ensure genetic stability across cellular generations. This challenging biochemical task requires complex molecular systems that duplicate chromosomal DNA and repair lesions that stall DNA synthesis. Sporadic or inherited defects in the cellular apparatus of genomic duplication cause genetic instability, which is responsible for developmental and degenerative pathologies and for cancer predisposition.\n\nOur knowledge of the molecular basis of eukaryotic DNA replication and related repair processes is incomplete, and this is especially true of genomic duplication in human cells, the most relevant to our health. Our proposal aims to provide a high-resolution view of the molecular mechanisms of DNA replication, using state-of-the-art biochemical and biophysical approaches. We will focus on components of the human replisome, the multi-protein assembly responsible for DNA synthesis in our cells.\n\nThere is intense medical interest in the molecular mechanisms responsible for genomic integrity and the rationale for the consequences of their occasional failure. In this respect, the work of our proposal is highly significant as it aims to deliver a comprehensive description in atomic detail of the complex and dynamic processes of DNA replication, when our genome is at its most vulnerable.\n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["DNA Replication","Genomic Instability","Humans"]}
{"id":"360G-Wellcome-221890_Z_20_Z","title":"Factors of biological ageing: does it all go together when it goes?","Region":"Scotland","currency":"GBP","awardDate":"2020-11-24T00:00:00+00:00","Sponsor(s)":"Prof Ian Deary","Internal ID":"221890/Z/20/Z","description":"Ageing-related cognitive decline carries a huge personal, societal, and financial cost. Understanding its underlying mechanisms with a view to ameliorating age-related cognitive decline is a huge challenge. It is essential to identify biomarkers of cognitive ageing and their potential determinants. Brain structural imaging markers in older age, their correspondence with proteomic and other biomarkers, and their potential determinants, are poorly characterised. Our understanding is informed by cross-sectional studies (which cannot fully reflect the dynamic within-person processes of ageing) and mainly univariate longitudinal data (i.e. describing how brain regions individually decline over time): most aspects of brain structure decline, on average.\n\nHowever, these approaches do not tell us whether there are important patterns of coordinated change, nor are they well-aligned with other levels of biological explanation. Such information could potentially aid stratification of risk and identification of important clusters of determinants of brain and cognitive ageing.\n\nI will apply cutting-edge factor-analytic methods to large longitudinal datasets to detect and validate patterns of correlated biological changes (brain structure, serum proteomic and DNA transcriptomic). I will test how these dimensions of ageing are associated with each other and with cognitive ageing, and use several techniques to ascertain their lifestyle, genetic and epigenetic predictors.\n","plannedDates":[{"endDate":"2026-04-30T00:00:00+00:00","startDate":"2021-05-01T00:00:00+00:00","startDateDateOnly":"2021-05-01","endDateDateOnly":"2026-04-30"}],"amountAwarded":886561,"Financial Year":"2020/21","Lead Applicant":"Dr Simon Cox","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Cox","Partnership Value":886561,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Factors of biological ageing: does it all go together when it goes? Ageing-related cognitive decline carries a huge personal, societal, and financial cost. Understanding its underlying mechanisms with a view to ameliorating age-related cognitive decline is a huge challenge. It is essential to identify biomarkers of cognitive ageing and their potential determinants. Brain structural imaging markers in older age, their correspondence with proteomic and other biomarkers, and their potential determinants, are poorly characterised. Our understanding is informed by cross-sectional studies (which cannot fully reflect the dynamic within-person processes of ageing) and mainly univariate longitudinal data (i.e. describing how brain regions individually decline over time): most aspects of brain structure decline, on average.\n\nHowever, these approaches do not tell us whether there are important patterns of coordinated change, nor are they well-aligned with other levels of biological explanation. Such information could potentially aid stratification of risk and identification of important clusters of determinants of brain and cognitive ageing.\n\nI will apply cutting-edge factor-analytic methods to large longitudinal datasets to detect and validate patterns of correlated biological changes (brain structure, serum proteomic and DNA transcriptomic). I will test how these dimensions of ageing are associated with each other and with cognitive ageing, and use several techniques to ascertain their lifestyle, genetic and epigenetic predictors.\n","awardDateDateOnly":"2020-11-24","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aged","Aging","Biomarkers","Brain","Cognitive Dysfunction","Cross-Sectional Studies","Humans","Longitudinal Studies","Proteomics"]}
{"id":"360G-Wellcome-221881_Z_20_Z","title":"Structural mechanism of genome acetylation and 3D folding","Region":"East Midlands","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221881/Z/20/Z","description":"Recent chromosome capture experiments have revealed a hierarchical 3D organisation of the genome ranging from Topologically Associating Domains (TADs) to larger-scale active, euchromatic and inactive, heterochromatic compartments. TADs arise through chromatin loop extrusion by cohesin/CTCF while compartments arise through epigenetic modification of the chromatin polymer. It has long been known that dynamic histone acetylation switches between repressive and permissive chromatin, a key event in transcriptional activation. We aim to capture cohesin in different structural states to understand how it is regulated and catalyses large-scale chromatin transactions. We also aim to understand the molecular mechanism behind acetylation-dependent activation of chromatin a reaction that is critical for the establishment of active euchromatin and may contribute to genome compartmentalisation and enhancer-promoter interaction. This proposal has the potential to transform our understanding the molecular mechanism behind two key reactions that contribute short- and long-range 3D genome architecture. It is possible that both mechanisms are interconnected and provide unifying principles to explain gene regulation with broad implications for health and disease.\n","plannedDates":[{"endDate":"2026-03-31T00:00:00+00:00","startDate":"2021-03-17T00:00:00+00:00","startDateDateOnly":"2021-03-17","endDateDateOnly":"2026-03-31"}],"amountAwarded":1551260,"Financial Year":"2020/21","Lead Applicant":"Prof Daniel Panne","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Panne","Partnership Value":1551260,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leicester","name":"University of Leicester","addressCountry":"United Kingdom","id_and_name":"[\"University of Leicester\", \"360G-Wellcome-ORG:University-of-Leicester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leicester","name":"University of Leicester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Structural mechanism of genome acetylation and 3D folding Recent chromosome capture experiments have revealed a hierarchical 3D organisation of the genome ranging from Topologically Associating Domains (TADs) to larger-scale active, euchromatic and inactive, heterochromatic compartments. TADs arise through chromatin loop extrusion by cohesin/CTCF while compartments arise through epigenetic modification of the chromatin polymer. It has long been known that dynamic histone acetylation switches between repressive and permissive chromatin, a key event in transcriptional activation. We aim to capture cohesin in different structural states to understand how it is regulated and catalyses large-scale chromatin transactions. We also aim to understand the molecular mechanism behind acetylation-dependent activation of chromatin a reaction that is critical for the establishment of active euchromatin and may contribute to genome compartmentalisation and enhancer-promoter interaction. This proposal has the potential to transform our understanding the molecular mechanism behind two key reactions that contribute short- and long-range 3D genome architecture. It is possible that both mechanisms are interconnected and provide unifying principles to explain gene regulation with broad implications for health and disease.\n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Acetylation","Animals","CCCTC-Binding Factor","Cell Cycle Proteins","Chromatin","Chromosomal Proteins, Non-Histone","Enhancer Elements, Genetic","Epigenesis, Genetic","Heterochromatin","Histones","Humans","Promoter Regions, Genetic"]}
{"id":"360G-Wellcome-221868_Z_20_Z","title":"Ringing the changes: how bacterial enzymes convert ribosomally-synthesised peptides into antibiotics","Region":"East of England","currency":"GBP","awardDate":"2020-11-24T00:00:00+00:00","Sponsor(s)":"Prof Dale Sanders","Internal ID":"221868/Z/20/Z","description":"The project aims to investigate the mechanism of peptide transformations carried out by YcaO enzymes and to use this knowledge to create novel antimicrobials.\n\nBacterial YcaO proteins are essential for the biosynthesis of multiple classes of peptide natural products through their ability to introduce important structural modifications including heterocycles, macrocycles, and thioamides. YcaO repurposing and swapping between different pathways offers exciting possibilities to create novel artificial peptides bearing such modifications. Despite much recent progress, we still do not really understand how these proteins work, and how their activities are coordinated within multisubunit enzyme complexes. I will use cryo-EM in combination with X-ray crystallography to solve the structures of YcaOs within their native complex assemblies trapped at different catalytic stages. In parallel, I will discover and characterise new YcaO proteins to further expand their known catalytic repertoire.\n\nFinally, the promiscuity of YcaOs allows for the production of large genetically encoded peptide antibiotic libraries. I will generate these by co-expressing randomised precursor genes along with modification systems. A high-throughput fluorescence-based version of a Waksman platform will be used for screening, where nano-sized \"Petri dishes\" (hydrogel beads) will be inoculated with both producer and reporter strains and sorted by FACS.\n","plannedDates":[{"endDate":"2026-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2026-08-31"}],"amountAwarded":1320618,"Financial Year":"2020/21","Lead Applicant":"Dr Dmitry Ghilarov","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Ghilarov","Partnership Value":1320618,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:John-Innes-Centre","name":"John Innes Centre","addressCountry":"United Kingdom","id_and_name":"[\"John Innes Centre\", \"360G-Wellcome-ORG:John-Innes-Centre\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:John-Innes-Centre","name":"John Innes Centre"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Ringing the changes: how bacterial enzymes convert ribosomally-synthesised peptides into antibiotics The project aims to investigate the mechanism of peptide transformations carried out by YcaO enzymes and to use this knowledge to create novel antimicrobials.\n\nBacterial YcaO proteins are essential for the biosynthesis of multiple classes of peptide natural products through their ability to introduce important structural modifications including heterocycles, macrocycles, and thioamides. YcaO repurposing and swapping between different pathways offers exciting possibilities to create novel artificial peptides bearing such modifications. Despite much recent progress, we still do not really understand how these proteins work, and how their activities are coordinated within multisubunit enzyme complexes. I will use cryo-EM in combination with X-ray crystallography to solve the structures of YcaOs within their native complex assemblies trapped at different catalytic stages. In parallel, I will discover and characterise new YcaO proteins to further expand their known catalytic repertoire.\n\nFinally, the promiscuity of YcaOs allows for the production of large genetically encoded peptide antibiotic libraries. I will generate these by co-expressing randomised precursor genes along with modification systems. A high-throughput fluorescence-based version of a Waksman platform will be used for screening, where nano-sized \"Petri dishes\" (hydrogel beads) will be inoculated with both producer and reporter strains and sorted by FACS.\n","awardDateDateOnly":"2020-11-24","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anti-Bacterial Agents","Bacteria","Biological Products","Cryoelectron Microscopy","Peptides","Ribosomes"]}
{"id":"360G-Wellcome-221857_Z_20_Z","title":"Targeting remodelling of lung stem and niche cells: lessons from regeneration to disease","Region":"East of England","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221857/Z/20/Z","description":"Lungs possess a remarkable regenerative capacity by dynamic multicellular responses following injury. However, chronic damage makes these responses persistent, leading to fibrosis. We will define the mechanisms by which productive regeneration programmes are diverted to disease remodelling, with the ultimate goal of uncovering therapeutic strategies that can treat or prevent lung fibrosis. \n\nWe recently identified Damage-Associated Transient Progenitors (DATPs), a functional mediator of alveolar stem cell differentiation, emerging during lung regeneration. Notably, chronic inflammation leads to accumulation of DATPs displaying defective differentiation, resulting in impaired alveolar regeneration. We aim to identify strategies to target DATPs in chronic injury by dissecting changes in them and their niche environments. Specifically, we will define (1) key DATP-niche interactions during different phases of regeneration, and how to these evolve during disease progression utilising a novel niche-labelling system; (2) transcriptional and epigenetic changes mediating damage-associated reprogramming following injury at single-cell resolutions, and key signalling modules conferring lineage flexibility of stem/niche cells; (3) conserved regenerative programmes and potential therapeutic targets in preclinical 3D human lung disease models we have developed. Our work will provide fundamental insights into defining the cellular and molecular basis of lung regeneration as well as identifying selective therapeutic targets in lung diseases.\n","plannedDates":[{"endDate":"2026-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2026-06-30"}],"amountAwarded":2107440,"Financial Year":"2020/21","Lead Applicant":"Dr Joo-Hyeon Lee","grantProgramme":[{"title":"Senior Research Fellowship","title_keyword":"Senior Research Fellowship"}],"Applicant Surname":"Lee","Partnership Value":2107440,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Targeting remodelling of lung stem and niche cells: lessons from regeneration to disease Lungs possess a remarkable regenerative capacity by dynamic multicellular responses following injury. However, chronic damage makes these responses persistent, leading to fibrosis. We will define the mechanisms by which productive regeneration programmes are diverted to disease remodelling, with the ultimate goal of uncovering therapeutic strategies that can treat or prevent lung fibrosis. \n\nWe recently identified Damage-Associated Transient Progenitors (DATPs), a functional mediator of alveolar stem cell differentiation, emerging during lung regeneration. Notably, chronic inflammation leads to accumulation of DATPs displaying defective differentiation, resulting in impaired alveolar regeneration. We aim to identify strategies to target DATPs in chronic injury by dissecting changes in them and their niche environments. Specifically, we will define (1) key DATP-niche interactions during different phases of regeneration, and how to these evolve during disease progression utilising a novel niche-labelling system; (2) transcriptional and epigenetic changes mediating damage-associated reprogramming following injury at single-cell resolutions, and key signalling modules conferring lineage flexibility of stem/niche cells; (3) conserved regenerative programmes and potential therapeutic targets in preclinical 3D human lung disease models we have developed. Our work will provide fundamental insights into defining the cellular and molecular basis of lung regeneration as well as identifying selective therapeutic targets in lung diseases.\n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cell Differentiation","Humans","Mice","Regeneration","Stem Cells"]}
{"id":"360G-Wellcome-221856_Z_20_Z","title":"Genetic approaches to studying early lineage specification in human embryos","Region":"East of England","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221856/Z/20/Z","description":"The goal of this proposal is to transform our understanding of the molecular mechanisms that control early human development. The mechanisms that regulate early cell fate decisions in human development remain poorly understood, despite their fundamental biological importance and wide-reaching clinical implications for understanding infertility, miscarriages, developmental disorders and therapeutic applications of stem cells. We seek to uncover when and how human embryonic epiblast cells are established and maintained, and to understand the molecular mechanisms that distinguish these pluripotent cells from extra-embryonic cells during embryogenesis. We will further develop pioneering methods to investigate gene function during human embryogenesis using CRISPR-Cas9-mediated genome editing, TRIM-Away protein depletion, constitutively active and kinase dead variants of proteins and small molecule inhibitors and activators. These approaches will enable us to directly test the function of genes involved in Hippo and TGFb signalling, and key transcription factors downstream of these pathways, which we hypothesize are involved in the first and second cell fate decisions, respectively. Altogether, we expect this program to make significant advances in our understanding of the molecular programs that shape early human embryogenesis, which has the potential to provide fundamental insights and to drive clinical translation.\n","plannedDates":[{"endDate":"2026-07-31T00:00:00+00:00","startDate":"2021-08-01T00:00:00+00:00","startDateDateOnly":"2021-08-01","endDateDateOnly":"2026-07-31"}],"amountAwarded":2064491,"Financial Year":"2020/21","Lead Applicant":"Prof Kathy Niakan","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Niakan","Partnership Value":2064491,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Genetic approaches to studying early lineage specification in human embryos The goal of this proposal is to transform our understanding of the molecular mechanisms that control early human development. The mechanisms that regulate early cell fate decisions in human development remain poorly understood, despite their fundamental biological importance and wide-reaching clinical implications for understanding infertility, miscarriages, developmental disorders and therapeutic applications of stem cells. We seek to uncover when and how human embryonic epiblast cells are established and maintained, and to understand the molecular mechanisms that distinguish these pluripotent cells from extra-embryonic cells during embryogenesis. We will further develop pioneering methods to investigate gene function during human embryogenesis using CRISPR-Cas9-mediated genome editing, TRIM-Away protein depletion, constitutively active and kinase dead variants of proteins and small molecule inhibitors and activators. These approaches will enable us to directly test the function of genes involved in Hippo and TGFb signalling, and key transcription factors downstream of these pathways, which we hypothesize are involved in the first and second cell fate decisions, respectively. Altogether, we expect this program to make significant advances in our understanding of the molecular programs that shape early human embryogenesis, which has the potential to provide fundamental insights and to drive clinical translation.\n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["CRISPR-Cas Systems","Embryonic Development","Gene Editing","Gene Expression Regulation, Developmental","Human Embryonic Stem Cells","Humans","Pluripotent Stem Cells","Signal Transduction"]}
{"id":"360G-Wellcome-221854_Z_20_Z","title":"Taking the long view: Identification of plasma protein biomarkers for dementia risk","Region":"Greater London","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221854/Z/20/Z","description":"The overarching goal of this collaborative project is to make a step change in knowledge of dementia biomarkers by focusing on plasma proteome. We hypothesize that plasma is biologically informative due to the presence of protein signals: imprints of subclinical dementia progression that can be identified via repeated proteomic profiling decades before clinical symptoms, providing novel candidate targets for preventative treatments.\n\nWe will use the largest plasma proteome platform currently available, with three aims, to (1) prospectively examine 4,993 plasma proteins in relation to subsequent accelerated cognitive decline and clinical dementia across multiple cohort studies; (2) determine whether the protein hits identified in aim 1 have a causal association with dementia, whether modifiable and druggable, using analysis stratified by time between protein measurement and dementia onset and Mendelian Randomization framework in relation to novel genome-wide, and druggable-genome arrays; and (3) examine whether proteins predicting dementia risk are imprints of risk factors for dementia.\n\nThe expected new outcomes include protein targets for drug development; improved identification of potentially modifiable lifestyle risks; dementia trials surrogate outcomes; improved diagnostic markers, plus data resource for future in-depth research on the multisystem aetiology of dementias and proteomics of a range of major diseases beyond dementia\n \n","plannedDates":[{"endDate":"2026-01-31T00:00:00+00:00","startDate":"2021-02-01T00:00:00+00:00","startDateDateOnly":"2021-02-01","endDateDateOnly":"2026-01-31"}],"amountAwarded":4161648,"Financial Year":"2020/21","Lead Applicant":"Prof Mika Kivimaki","grantProgramme":[{"title":"Collaborative Award in Science","title_keyword":"Collaborative Award in Science"}],"Applicant Surname":"Kivimaki","Partnership Value":4161648,"Approval Committee":"Science Interview Panel","Other Applicant(s)":"Dr Sudha Seshadri, Dr Rebecca Gottesman, Prof Aroon Hingorani, Prof Gill Livingston, Prof Eric Brunner, Prof Archana Singh-Manoux","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Taking the long view: Identification of plasma protein biomarkers for dementia risk The overarching goal of this collaborative project is to make a step change in knowledge of dementia biomarkers by focusing on plasma proteome. We hypothesize that plasma is biologically informative due to the presence of protein signals: imprints of subclinical dementia progression that can be identified via repeated proteomic profiling decades before clinical symptoms, providing novel candidate targets for preventative treatments.\n\nWe will use the largest plasma proteome platform currently available, with three aims, to (1) prospectively examine 4,993 plasma proteins in relation to subsequent accelerated cognitive decline and clinical dementia across multiple cohort studies; (2) determine whether the protein hits identified in aim 1 have a causal association with dementia, whether modifiable and druggable, using analysis stratified by time between protein measurement and dementia onset and Mendelian Randomization framework in relation to novel genome-wide, and druggable-genome arrays; and (3) examine whether proteins predicting dementia risk are imprints of risk factors for dementia.\n\nThe expected new outcomes include protein targets for drug development; improved identification of potentially modifiable lifestyle risks; dementia trials surrogate outcomes; improved diagnostic markers, plus data resource for future in-depth research on the multisystem aetiology of dementias and proteomics of a range of major diseases beyond dementia\n \n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biomarkers","Blood Proteins","Dementia","Humans","Mendelian Randomization Analysis","Proteome","Proteomics","Risk Factors"]}
{"id":"360G-Wellcome-221841_Z_20_Z","title":"Dis-Ease","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221841/Z/20/Z","description":"Declaring \"war on disease\" affects how we treat sick people, how we define the \"public\" in public health, and how we respond to real-world pandemics.. This was demonstrated vividly during the COVID-19 crisis, when these declarations of war initiated militarized states of emergency, prompted border lockdowns, and refreshed old fears about \"foreign\" pathogens. But why was this public health crisis being treated as a national security issue? What else does this metaphor do in the world? And what if it weren't a war?\n\nTo answer those questions, the feature-length documentary \"Dis-Ease\" retraces the origin and evolution of our \"war on disease\" through the history, philosophy, culture, and pop-cultural imaginaries of medicine. It is constructed around particular episodes in the history of human encounters with epidemic, endemic, and pandemic diseases, including plague, malaria, cholera, tuberculosis, influenza, HIV/AIDS, and COVID-19. By examining the cultural history that runs alongside the growing scientific understanding of these diseases over time, DIS-EASE looks to understand how pandemic preparedness became framed as biodefense, and how that has contributed to the present crisis. And it proposes alternatives for the future.\n","plannedDates":[{"endDate":"2022-02-14T00:00:00+00:00","startDate":"2020-10-15T00:00:00+00:00","startDateDateOnly":"2020-10-15","endDateDateOnly":"2022-02-14"}],"amountAwarded":45714,"Financial Year":"2019/20","Lead Applicant":"Ms Mariam Ghani","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Ghani","Partnership Value":45714,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Indexical-Films-LLC","name":"Indexical Films LLC","addressCountry":"United States","id_and_name":"[\"Indexical Films LLC\", \"360G-Wellcome-ORG:Indexical-Films-LLC\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Indexical-Films-LLC","name":"Indexical Films LLC"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Dis-Ease Declaring \"war on disease\" affects how we treat sick people, how we define the \"public\" in public health, and how we respond to real-world pandemics.. This was demonstrated vividly during the COVID-19 crisis, when these declarations of war initiated militarized states of emergency, prompted border lockdowns, and refreshed old fears about \"foreign\" pathogens. But why was this public health crisis being treated as a national security issue? What else does this metaphor do in the world? And what if it weren't a war?\n\nTo answer those questions, the feature-length documentary \"Dis-Ease\" retraces the origin and evolution of our \"war on disease\" through the history, philosophy, culture, and pop-cultural imaginaries of medicine. It is constructed around particular episodes in the history of human encounters with epidemic, endemic, and pandemic diseases, including plague, malaria, cholera, tuberculosis, influenza, HIV/AIDS, and COVID-19. By examining the cultural history that runs alongside the growing scientific understanding of these diseases over time, DIS-EASE looks to understand how pandemic preparedness became framed as biodefense, and how that has contributed to the present crisis. And it proposes alternatives for the future.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Communicable Diseases","History, 20th Century","Humans","Pandemics","Public Health"]}
{"id":"360G-Wellcome-221826_Z_20_Z","title":"Maladaptive thinking patterns in depression","Region":"Greater London","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221826/Z/20/Z","description":"Depression is amongst the most burdensome disorders world-wide because it is a common disorder with frequent relapses. Relapse risk is increased by maladaptive thinking patterns such as rumination and helplessness, and by antidepressant discontinuation, which in turn increases maladaptive thinking patterns.\n\nMaladaptive thinking patterns shape emotions and are influenced by emotions. However, we do not know the neurobiological mechanisms underlying these interactions. First, I propose to study this by measuring maladaptive thinking patterns directly using a decoding approach to magnetoencephalography (MEG). MEG decoding reveals fast sequences of stimulus representations during tasks. These sequences can then be compared to computational models to understand the algorithms the brain uses to prioritize information processing.\n\nMaladaptive thinking patterns are targeted by psychotherapeutic interventions and are sensitive to serotonergic manipulations.  I will examine how psychotherapeutic interventions influence the interaction between thoughts and emotions, and how an acute reduction in serotonin through tryptophan depletion affects them. The latter study will be performed in remitted depression and allow us to test whether the mechanisms are involved in subsequent relapses.\n\nOverall, I aim to provide a comprehensive account of how objectively-measured thought processes relate to emotions and to the prevention of depression relapses.\n","plannedDates":[{"endDate":"2027-01-17T00:00:00+00:00","startDate":"2021-01-18T00:00:00+00:00","startDateDateOnly":"2021-01-18","endDateDateOnly":"2027-01-17"}],"amountAwarded":1181059,"Financial Year":"2020/21","Lead Applicant":"Dr Quentin Huys","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Huys","Partnership Value":1181059,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Maladaptive thinking patterns in depression Depression is amongst the most burdensome disorders world-wide because it is a common disorder with frequent relapses. Relapse risk is increased by maladaptive thinking patterns such as rumination and helplessness, and by antidepressant discontinuation, which in turn increases maladaptive thinking patterns.\n\nMaladaptive thinking patterns shape emotions and are influenced by emotions. However, we do not know the neurobiological mechanisms underlying these interactions. First, I propose to study this by measuring maladaptive thinking patterns directly using a decoding approach to magnetoencephalography (MEG). MEG decoding reveals fast sequences of stimulus representations during tasks. These sequences can then be compared to computational models to understand the algorithms the brain uses to prioritize information processing.\n\nMaladaptive thinking patterns are targeted by psychotherapeutic interventions and are sensitive to serotonergic manipulations.  I will examine how psychotherapeutic interventions influence the interaction between thoughts and emotions, and how an acute reduction in serotonin through tryptophan depletion affects them. The latter study will be performed in remitted depression and allow us to test whether the mechanisms are involved in subsequent relapses.\n\nOverall, I aim to provide a comprehensive account of how objectively-measured thought processes relate to emotions and to the prevention of depression relapses.\n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Brain","Depression","Depressive Disorder, Major","Emotions","Humans","Magnetoencephalography","Thinking","Tryptophan"]}
{"id":"360G-Wellcome-221824_Z_20_Z","title":"TDP-43 Misregulation in neurodegeneration","Region":"Greater London","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221824/Z/20/Z","description":"TDP-43 is a conserved RNA binding protein central to the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). TDP-43 normally autoregulates its expression by binding to the 3\u2019UTR of its cognate transcript. We have linked disrupted TDP-43 autoregulation to disease, showing that disease-linked TDP-43 missense mutations disturb TDP-43 autoregulation causing a gain of function, finding that ALS patients harbour non-coding variants in the 5\u2019 and 3\u2019UTRs of TDP-43 that could disturb TDP-43 expression and observing that TDP-43 misregulation in mice causes selective brain atrophy reminiscent of human ALS-FTD. We will follow these leads to understand the causes and consequences of TDP-43 misregulation and elucidate therapeutic targets and biomarkers for ALS-FTD. Specifically, we will dissect the TDP-43 autoregulation protein interactome in wild-type and TDP-43 missense mutant cells by performing in-cell protein-RNA interaction studies and native mass spectrometry. To determine the significance of ALS-linked UTR variants in regulating TDP-43 expression we will perform an in-vitro CRISPR/Cas9 mutagenesis screen with parallel genomic and transcriptomic sequencing. To understand how TDP-43 misregulation causes regional and cell type-specific neurodegeneration we will use in situ sequencing of mouse brain sections to obtain transcriptomic information with single cell resolution.\n \n","plannedDates":[{"endDate":"2026-02-28T00:00:00+00:00","startDate":"2021-03-01T00:00:00+00:00","startDateDateOnly":"2021-03-01","endDateDateOnly":"2026-02-28"}],"amountAwarded":1973118,"Financial Year":"2020/21","Lead Applicant":"Dr Jemeen Sreedharan","grantProgramme":[{"title":"Senior Research Fellowship","title_keyword":"Senior Research Fellowship"}],"Applicant Surname":"Sreedharan","Partnership Value":1973118,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"TDP-43 Misregulation in neurodegeneration TDP-43 is a conserved RNA binding protein central to the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). TDP-43 normally autoregulates its expression by binding to the 3\u2019UTR of its cognate transcript. We have linked disrupted TDP-43 autoregulation to disease, showing that disease-linked TDP-43 missense mutations disturb TDP-43 autoregulation causing a gain of function, finding that ALS patients harbour non-coding variants in the 5\u2019 and 3\u2019UTRs of TDP-43 that could disturb TDP-43 expression and observing that TDP-43 misregulation in mice causes selective brain atrophy reminiscent of human ALS-FTD. We will follow these leads to understand the causes and consequences of TDP-43 misregulation and elucidate therapeutic targets and biomarkers for ALS-FTD. Specifically, we will dissect the TDP-43 autoregulation protein interactome in wild-type and TDP-43 missense mutant cells by performing in-cell protein-RNA interaction studies and native mass spectrometry. To determine the significance of ALS-linked UTR variants in regulating TDP-43 expression we will perform an in-vitro CRISPR/Cas9 mutagenesis screen with parallel genomic and transcriptomic sequencing. To understand how TDP-43 misregulation causes regional and cell type-specific neurodegeneration we will use in situ sequencing of mouse brain sections to obtain transcriptomic information with single cell resolution.\n \n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Amyotrophic Lateral Sclerosis","Animals","Brain","DNA-Binding Proteins","Frontotemporal Dementia","Humans","Mice","Mice, Transgenic","Transcriptome"]}
{"id":"360G-Wellcome-221824_A_20_Z","title":"TDP-43 Misregulation in neurodegeneration","Region":"East of England","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221824/A/20/Z","description":"TDP-43 is a conserved RNA binding protein central to the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). TDP-43 normally autoregulates its expression by binding to the 3\u2019UTR of its cognate transcript. We have linked disrupted TDP-43 autoregulation to disease, showing that disease-linked TDP-43 missense mutations disturb TDP-43 autoregulation causing a gain of function, finding that ALS patients harbour non-coding variants in the 5\u2019 and 3\u2019UTRs of TDP-43 that could disturb TDP-43 expression and observing that TDP-43 misregulation in mice causes selective brain atrophy reminiscent of human ALS-FTD. We will follow these leads to understand the causes and consequences of TDP-43 misregulation and elucidate therapeutic targets and biomarkers for ALS-FTD. Specifically, we will dissect the TDP-43 autoregulation protein interactome in wild-type and TDP-43 missense mutant cells by performing in-cell protein-RNA interaction studies and native mass spectrometry. To determine the significance of ALS-linked UTR variants in regulating TDP-43 expression we will perform an in-vitro CRISPR/Cas9 mutagenesis screen with parallel genomic and transcriptomic sequencing. To understand how TDP-43 misregulation causes regional and cell type-specific neurodegeneration we will use in situ sequencing of mouse brain sections to obtain transcriptomic information with single cell resolution.\n \n","plannedDates":[{"endDate":"2026-02-28T00:00:00+00:00","startDate":"2021-03-01T00:00:00+00:00","startDateDateOnly":"2021-03-01","endDateDateOnly":"2026-02-28"}],"amountAwarded":0,"Financial Year":"2020/21","Lead Applicant":"Dr Jemeen Sreedharan","grantProgramme":[{"title":"Sanger Resource Collaboration","title_keyword":"Sanger Resource Collaboration"}],"Applicant Surname":"Sreedharan","Partnership Value":0,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Wellcome-Trust-Sanger-Institute","name":"Wellcome Trust Sanger Institute","addressCountry":"United Kingdom","id_and_name":"[\"Wellcome Trust Sanger Institute\", \"360G-Wellcome-ORG:Wellcome-Trust-Sanger-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Wellcome-Trust-Sanger-Institute","name":"Wellcome Trust Sanger Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"TDP-43 Misregulation in neurodegeneration TDP-43 is a conserved RNA binding protein central to the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). TDP-43 normally autoregulates its expression by binding to the 3\u2019UTR of its cognate transcript. We have linked disrupted TDP-43 autoregulation to disease, showing that disease-linked TDP-43 missense mutations disturb TDP-43 autoregulation causing a gain of function, finding that ALS patients harbour non-coding variants in the 5\u2019 and 3\u2019UTRs of TDP-43 that could disturb TDP-43 expression and observing that TDP-43 misregulation in mice causes selective brain atrophy reminiscent of human ALS-FTD. We will follow these leads to understand the causes and consequences of TDP-43 misregulation and elucidate therapeutic targets and biomarkers for ALS-FTD. Specifically, we will dissect the TDP-43 autoregulation protein interactome in wild-type and TDP-43 missense mutant cells by performing in-cell protein-RNA interaction studies and native mass spectrometry. To determine the significance of ALS-linked UTR variants in regulating TDP-43 expression we will perform an in-vitro CRISPR/Cas9 mutagenesis screen with parallel genomic and transcriptomic sequencing. To understand how TDP-43 misregulation causes regional and cell type-specific neurodegeneration we will use in situ sequencing of mouse brain sections to obtain transcriptomic information with single cell resolution.\n \n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Amyotrophic Lateral Sclerosis","Animals","Brain","DNA-Binding Proteins","Frontotemporal Dementia","Humans","Mice","Mice, Transgenic","Transcriptome"]}
{"id":"360G-Wellcome-221818_Z_20_Z","title":"Structure, mechanism and dynamics of recoding in viral infection","Region":"South East","currency":"GBP","awardDate":"2020-11-24T00:00:00+00:00","Sponsor(s)":"Prof Francis Barr","Internal ID":"221818/Z/20/Z","description":"Many RNA viruses (e.g. SARS-CoV-2, HIV-1) have evolved ways of reprogramming translation to expand the coding capacity of their small genomes. \u2018Recoding\u2019 events such as -1 frameshifting, stop codon read-through and StopGo peptide release are necessary for viral replication, producing viral proteins in optimal ratios for efficient assembly. Recoding is regulated by a complex interplay between the elongating ribosome, cis-acting elements in the mRNA or nascent peptide, and trans-acting protein factors. Elucidating the structural basis of recoding is essential to understand viral pathogenesis. However, classical biochemical approaches cannot accurately capture kinetics or per-ribosome heterogeneity, making it difficult to define a window of opportunity for structure determination. Recent technological advances allow single-molecule fluorescent imaging of translation in real-time. I will apply these methods to study recoding in vitro and in live cells, starting with -1 frameshifting in SARS-CoV-2, HIV-1 and EMCV, which utilise topologically-distinct stimulatory elements. I will determine the structure of key ribosomal states by time-resolved cryo-EM, and investigate the structure and stability of stimulatory elements using crystallography, single molecule FRET and optical tweezers. Longer-term, this approach will be applied to investigate other recoding events, thus revealing universal and case-specific mechanistic principles, and highlighting new avenues for therapeutic intervention. \n","plannedDates":[{"endDate":"2026-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2026-03-31"}],"amountAwarded":1334770,"Financial Year":"2020/21","Lead Applicant":"Dr Chris Hill","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Hill","Partnership Value":1334770,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Structure, mechanism and dynamics of recoding in viral infection Many RNA viruses (e.g. SARS-CoV-2, HIV-1) have evolved ways of reprogramming translation to expand the coding capacity of their small genomes. \u2018Recoding\u2019 events such as -1 frameshifting, stop codon read-through and StopGo peptide release are necessary for viral replication, producing viral proteins in optimal ratios for efficient assembly. Recoding is regulated by a complex interplay between the elongating ribosome, cis-acting elements in the mRNA or nascent peptide, and trans-acting protein factors. Elucidating the structural basis of recoding is essential to understand viral pathogenesis. However, classical biochemical approaches cannot accurately capture kinetics or per-ribosome heterogeneity, making it difficult to define a window of opportunity for structure determination. Recent technological advances allow single-molecule fluorescent imaging of translation in real-time. I will apply these methods to study recoding in vitro and in live cells, starting with -1 frameshifting in SARS-CoV-2, HIV-1 and EMCV, which utilise topologically-distinct stimulatory elements. I will determine the structure of key ribosomal states by time-resolved cryo-EM, and investigate the structure and stability of stimulatory elements using crystallography, single molecule FRET and optical tweezers. Longer-term, this approach will be applied to investigate other recoding events, thus revealing universal and case-specific mechanistic principles, and highlighting new avenues for therapeutic intervention. \n","awardDateDateOnly":"2020-11-24","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cryoelectron Microscopy","Crystallography, X-Ray","HIV-1","Humans","Models, Molecular","Nucleic Acid Conformation","Protein Biosynthesis","RNA, Viral"]}
{"id":"360G-Wellcome-221817_Z_20_Z","title":"Exploring the role of glypicans in modulating morphogen signalling and stem cell dynamics","Region":"East of England","currency":"GBP","awardDate":"2020-11-24T00:00:00+00:00","Sponsor(s)":"Prof Wolf Reik","Internal ID":"221817/Z/20/Z","description":"Wnt and Hedgehog signalling regulate intestinal stem cell dynamics to ensure intestinal renewal, function and integrity is maintained. The activation of these two pathways involves crosstalk and communication between the mesenchymal and epithelial layers of the intestine. However, a puzzling conundrum is that both Wnt and Hedgehog carry hydrophobic lipid moieties that are required for receptor binding and signalling but that also hinder their solubility and diffusion and hence ability to move between intestinal cells. In Drosophila, the glypican Dally-like protein (Dlp), which possess a lipid binding pocket, binds and shields the lipid moiety of Wnts to aid transport. Dlp is also essential for initiating Hedgehog signalling but its precise mechanism of action is unknown. I will determine if Dlp also binds the lipid moieties of Hedgehog and what such binding means for Hedgehog solubility, transport and receptor engagement. I will determine if mammalian homologues of Dlp also bind the lipid moieties of Wnt and Hedgehog to regulate their activity and whether they are required in the mouse intestine for Wnt and Hedgehog signalling to orchestrate stem cell dynamics. A deep understanding of how glypicans modulate Wnt and Hedgehog signalling will answer major questions in developmental and stem cell biology.\n \n","plannedDates":[{"endDate":"2026-07-04T00:00:00+00:00","startDate":"2021-07-05T00:00:00+00:00","startDateDateOnly":"2021-07-05","endDateDateOnly":"2026-07-04"}],"amountAwarded":1110044,"Financial Year":"2020/21","Lead Applicant":"Dr Ian McGough","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"McGough","Partnership Value":1110044,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Babraham-Institute","name":"Babraham Institute","addressCountry":"United Kingdom","id_and_name":"[\"Babraham Institute\", \"360G-Wellcome-ORG:Babraham-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Babraham-Institute","name":"Babraham Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Exploring the role of glypicans in modulating morphogen signalling and stem cell dynamics Wnt and Hedgehog signalling regulate intestinal stem cell dynamics to ensure intestinal renewal, function and integrity is maintained. The activation of these two pathways involves crosstalk and communication between the mesenchymal and epithelial layers of the intestine. However, a puzzling conundrum is that both Wnt and Hedgehog carry hydrophobic lipid moieties that are required for receptor binding and signalling but that also hinder their solubility and diffusion and hence ability to move between intestinal cells. In Drosophila, the glypican Dally-like protein (Dlp), which possess a lipid binding pocket, binds and shields the lipid moiety of Wnts to aid transport. Dlp is also essential for initiating Hedgehog signalling but its precise mechanism of action is unknown. I will determine if Dlp also binds the lipid moieties of Hedgehog and what such binding means for Hedgehog solubility, transport and receptor engagement. I will determine if mammalian homologues of Dlp also bind the lipid moieties of Wnt and Hedgehog to regulate their activity and whether they are required in the mouse intestine for Wnt and Hedgehog signalling to orchestrate stem cell dynamics. A deep understanding of how glypicans modulate Wnt and Hedgehog signalling will answer major questions in developmental and stem cell biology.\n \n","awardDateDateOnly":"2020-11-24","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Drosophila Proteins","Hedgehog Proteins","Mice","Signal Transduction","Wnt Proteins","Wnt Signaling Pathway"]}
{"id":"360G-Wellcome-221807_Z_20_Z","title":"Probing cellular heterogeneity in the pancreatic microenvironment","Region":"Greater London","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221807/Z/20/Z","description":"The overarching goal of this proposal is to elucidate the functional diversity of the pancreatic mesenchymal lineage. In embryonic tissues, epithelial progenitors receive paracrine signals from the surrounding mesenchymal niche, which can modulate their ability to proliferate and differentiate. The pancreas consists of a variety of specialized epithelial cells, including endocrine and acinar cells, surrounded by a poorly defined heterogeneous mesenchyme. We hypothesise that different mesenchymal lineages define local instructive microenvironments, including cell\u2013cell crosstalk, ECM and signalling molecules, which eventually trigger distinct differentiation programmes from pancreatic progenitors. Sc-RNA-sequencing has generated a transcriptional map of the pancreatic mesenchyme in the mouse embryo. Here, we will unravel the spatial architecture of the identified mesenchymal cell states, linking their position to emerging pancreatic cell identities. Next, we will assess if mesenchymal lineages with a distinct spatial address underlie unique niche regulatory functions, promoting acinar or beta-cell differentiation. Finally, we will study the organisation and function of the identified niche microenvironment(s) in human tissue and pluripotent stem cells. The proposed programme will yield novel insight into pancreas biology and will set the stage for manipulating combinatorial pancreatic niches - an important step towards engineering functional beta-cells for regenerative medicine applications.\n","plannedDates":[{"endDate":"2026-09-30T00:00:00+00:00","startDate":"2021-10-01T00:00:00+00:00","startDateDateOnly":"2021-10-01","endDateDateOnly":"2026-09-30"}],"amountAwarded":1490731,"Financial Year":"2020/21","Lead Applicant":"Dr Francesca Spagnoli","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Spagnoli","Partnership Value":1490731,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Probing cellular heterogeneity in the pancreatic microenvironment The overarching goal of this proposal is to elucidate the functional diversity of the pancreatic mesenchymal lineage. In embryonic tissues, epithelial progenitors receive paracrine signals from the surrounding mesenchymal niche, which can modulate their ability to proliferate and differentiate. The pancreas consists of a variety of specialized epithelial cells, including endocrine and acinar cells, surrounded by a poorly defined heterogeneous mesenchyme. We hypothesise that different mesenchymal lineages define local instructive microenvironments, including cell\u2013cell crosstalk, ECM and signalling molecules, which eventually trigger distinct differentiation programmes from pancreatic progenitors. Sc-RNA-sequencing has generated a transcriptional map of the pancreatic mesenchyme in the mouse embryo. Here, we will unravel the spatial architecture of the identified mesenchymal cell states, linking their position to emerging pancreatic cell identities. Next, we will assess if mesenchymal lineages with a distinct spatial address underlie unique niche regulatory functions, promoting acinar or beta-cell differentiation. Finally, we will study the organisation and function of the identified niche microenvironment(s) in human tissue and pluripotent stem cells. The proposed programme will yield novel insight into pancreas biology and will set the stage for manipulating combinatorial pancreatic niches - an important step towards engineering functional beta-cells for regenerative medicine applications.\n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cell Differentiation","Cell Lineage","Humans","Mice","Pancreas","Stem Cell Niche"]}
{"id":"360G-Wellcome-221805_Z_20_Z","title":"Novel multi-nuclear magnetic resonance spectroscopy approaches for the sensitive and robust assessment of human cardiac energetics","Region":"South East","currency":"GBP","awardDate":"2020-11-24T00:00:00+00:00","Sponsor(s)":"Prof Stefan Neubauer","Internal ID":"221805/Z/20/Z","description":"Altered cardiac metabolism is now recognized as an important component of many cardiovascular diseases, including heart failure. Accurate assessment of cellular energetics promises significantly better disease staging and treatment monitoring in such conditions. Current non-invasive techniques based on magnetic resonance spectroscopy (MRS) are not precise enough to reliably define cardiac energetics in individual patients.\n\nIn this fellowship, I will develop new highly-sensitive MRS techniques for complete cardiac energetics assessment at 7T. The main goals of this research are:\n\n \n\n\n To establish a robust, patient-specific platform for cardiac energetics quantification, by developing novel approaches to overcome a range of technical challenges associated with 31P-MRS;\n To develop advanced methods that will allow for complete assessment of cardiac energetics, including quantification of Gibbs free energy of adenosine-triphosphate (ATP) hydrolysis (deltaG), and of complete myocardial ATP fluxes;\n To demonstrate the sensitivity of these novel methods to measure impairments in total cardiac ATP dynamics in patients with type II diabetes and to detect changes in cellular energetics that accompany the transition to heart failure.\n\n\n \n\nThese new measures will help provide unique insight into the pathophysiology of the failing heart and will be applicable in future studies monitoring novel metabolic therapies in cardiovascular disorders.\n","plannedDates":[{"endDate":"2026-04-30T00:00:00+00:00","startDate":"2021-05-01T00:00:00+00:00","startDateDateOnly":"2021-05-01","endDateDateOnly":"2026-04-30"}],"amountAwarded":993004,"Financial Year":"2020/21","Lead Applicant":"Dr Ladislav Valkovic","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Valkovic","Partnership Value":993004,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Novel multi-nuclear magnetic resonance spectroscopy approaches for the sensitive and robust assessment of human cardiac energetics Altered cardiac metabolism is now recognized as an important component of many cardiovascular diseases, including heart failure. Accurate assessment of cellular energetics promises significantly better disease staging and treatment monitoring in such conditions. Current non-invasive techniques based on magnetic resonance spectroscopy (MRS) are not precise enough to reliably define cardiac energetics in individual patients.\n\nIn this fellowship, I will develop new highly-sensitive MRS techniques for complete cardiac energetics assessment at 7T. The main goals of this research are:\n\n \n\n\n To establish a robust, patient-specific platform for cardiac energetics quantification, by developing novel approaches to overcome a range of technical challenges associated with 31P-MRS;\n To develop advanced methods that will allow for complete assessment of cardiac energetics, including quantification of Gibbs free energy of adenosine-triphosphate (ATP) hydrolysis (deltaG), and of complete myocardial ATP fluxes;\n To demonstrate the sensitivity of these novel methods to measure impairments in total cardiac ATP dynamics in patients with type II diabetes and to detect changes in cellular energetics that accompany the transition to heart failure.\n\n\n \n\nThese new measures will help provide unique insight into the pathophysiology of the failing heart and will be applicable in future studies monitoring novel metabolic therapies in cardiovascular disorders.\n","awardDateDateOnly":"2020-11-24","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adenosine Triphosphate","Diabetes Mellitus, Type 2","Energy Metabolism","Heart Failure","Humans","Magnetic Resonance Spectroscopy"]}
{"id":"360G-Wellcome-221803_Z_20_Z","title":"Unravelling the molecular mechanisms of invasive pneumococcal disease","Region":"Greater London","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221803/Z/20/Z","description":"Invasive pneumococcal disease causes over a million deaths per year worldwide, particularly in sub-Saharan Africa. Streptococcus pneumoniae strains vary considerably in virulence, but the reasons for this are unclear. Capsular serotype 1 strains are particularly invasive and cause a major proportion of severe infections, including meningitis, but are poorly studied, partly because they have been genetically intractable. We want to understand why serotype 1 strains are highly invasive, and to identify mechanisms that distinguish aggressive S. pneumoniae strains from less aggressive variants. Furthermore, a low-cost serotype 1 vaccine is urgently needed, especially in sub-Saharan Africa. In this project, we will combine and exploit (i) recently-developed in vitro and in vivo infection models, (ii) bacterial RNAseq data (including our data obtained from cerebral spinal fluid from Malawian meningitis patients) and (iii) our methodologies for mutating serotype 1 strains, to identify and characterise the roles of multiple novel genetic determinants important for the pathogenesis of invasive S. pneumoniae infections. We will also characterise in detail the zwitterionic capsular polysaccharide that defines serotype 1 strains and assess its role in pathogenesis. Finally, we will exploit Protein Glycan Coupling Technology (pioneered by the applicants) to produce a much-needed and affordable glycoconjugate serotype 1 vaccine.\n","plannedDates":[{"endDate":"2026-02-28T00:00:00+00:00","startDate":"2021-03-01T00:00:00+00:00","startDateDateOnly":"2021-03-01","endDateDateOnly":"2026-02-28"}],"amountAwarded":1904154,"Financial Year":"2020/21","Lead Applicant":"Prof Brendan Wren","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Wren","Partnership Value":1904154,"Approval Committee":"Science Interview Panel","Other Applicant(s)":"Prof Jeremy Brown","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"London School of Hygiene & Tropical Medicine\", \"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Unravelling the molecular mechanisms of invasive pneumococcal disease Invasive pneumococcal disease causes over a million deaths per year worldwide, particularly in sub-Saharan Africa. Streptococcus pneumoniae strains vary considerably in virulence, but the reasons for this are unclear. Capsular serotype 1 strains are particularly invasive and cause a major proportion of severe infections, including meningitis, but are poorly studied, partly because they have been genetically intractable. We want to understand why serotype 1 strains are highly invasive, and to identify mechanisms that distinguish aggressive S. pneumoniae strains from less aggressive variants. Furthermore, a low-cost serotype 1 vaccine is urgently needed, especially in sub-Saharan Africa. In this project, we will combine and exploit (i) recently-developed in vitro and in vivo infection models, (ii) bacterial RNAseq data (including our data obtained from cerebral spinal fluid from Malawian meningitis patients) and (iii) our methodologies for mutating serotype 1 strains, to identify and characterise the roles of multiple novel genetic determinants important for the pathogenesis of invasive S. pneumoniae infections. We will also characterise in detail the zwitterionic capsular polysaccharide that defines serotype 1 strains and assess its role in pathogenesis. Finally, we will exploit Protein Glycan Coupling Technology (pioneered by the applicants) to produce a much-needed and affordable glycoconjugate serotype 1 vaccine.\n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Bacterial Capsules","Disease Models, Animal","Humans","Meningitis, Pneumococcal","Mice","Pneumococcal Infections","Polysaccharides, Bacterial","Serogroup","Serotyping","Streptococcus pneumoniae"]}
{"id":"360G-Wellcome-221795_Z_20_Z","title":"Targeting membrane proteins in their native environments - Mass spectrometry meets cell biology ","Region":"South East","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221795/Z/20/Z","description":"The overarching goal of my research is to understand the relationship between membrane proteins and their lipid surroundings. This is important since many membrane proteins are unable to retain their structure and function when extracted from their native environment and reconstituted into a membrane mimetic. Dynamic proteins, for example G-protein coupled receptors, solute carriers and sigma receptors, are intimately connected to their membrane environments and prone to loss of function and activity in detergent micelles.  To overcome this disconnect we will develop and apply our mass spectrometry approaches to examine dynamic drug targets within their membrane context. Our key goals will be to challenge these receptors and transporters with agonists, antagonists, inhibitors and lipids effectively in situ. Examples include solute carriers which during tumour progression respond to the need for an altered metabolism by increasing expression. Analogous methods will be used to uncover the targets of mitochondrial and lysosomal therapies.  Many of our research themes converge on consequences of the COVID-19 pandemic.  While this remains an area of intense scientific scrutiny we will focus on the less-studied receptors and \u2018infection enhancers\u2019, and contribute to understanding the roles of lipids in the endocytosis and viral recognition pathways.  \n \n \n \n \n","plannedDates":[{"endDate":"2026-07-31T00:00:00+00:00","startDate":"2021-08-01T00:00:00+00:00","startDateDateOnly":"2021-08-01","endDateDateOnly":"2026-07-31"}],"amountAwarded":2188451,"Financial Year":"2020/21","Lead Applicant":"Prof Dame Carol Robinson","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Robinson","Partnership Value":2188451,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Targeting membrane proteins in their native environments - Mass spectrometry meets cell biology  The overarching goal of my research is to understand the relationship between membrane proteins and their lipid surroundings. This is important since many membrane proteins are unable to retain their structure and function when extracted from their native environment and reconstituted into a membrane mimetic. Dynamic proteins, for example G-protein coupled receptors, solute carriers and sigma receptors, are intimately connected to their membrane environments and prone to loss of function and activity in detergent micelles.  To overcome this disconnect we will develop and apply our mass spectrometry approaches to examine dynamic drug targets within their membrane context. Our key goals will be to challenge these receptors and transporters with agonists, antagonists, inhibitors and lipids effectively in situ. Examples include solute carriers which during tumour progression respond to the need for an altered metabolism by increasing expression. Analogous methods will be used to uncover the targets of mitochondrial and lysosomal therapies.  Many of our research themes converge on consequences of the COVID-19 pandemic.  While this remains an area of intense scientific scrutiny we will focus on the less-studied receptors and \u2018infection enhancers\u2019, and contribute to understanding the roles of lipids in the endocytosis and viral recognition pathways.  \n \n \n \n \n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Humans","Mass Spectrometry"]}
{"id":"360G-Wellcome-221794_Z_20_Z","title":"Distributed brain systems for motivation and action","Region":"South East","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221794/Z/20/Z","description":"The overarching aim is to understand the neural mechanisms of learning, decision-making, and motivation in humans. We will examine how they emerge from distributed patterns of activity across networks of subcortical nuclei such as the basal forebrain and dorsal raphe nucleus. While we know about such subcortical areas from animal studies, they have been under-investigated in humans. New imaging and uni- and multivariate analysis methods now make it possible to examine the distributed patterns of activity that arise in these areas. We have recently shown that we can record from these areas of the human brain using ultra high field magnetic resonance imaging. In addition, we know that these nuclei interact with cortical areas, especially in orbitofrontal, anterior cingulate, and insula cortex (regions that are especially prominent in humans and other primates).  We aim to record from both cortical and subcortical areas and to understand how they interact during learning, decision making, and motivation. The final aim is to assess whether new ultrasound stimulation tools that make it possible to alter neural activity in a minimally invasive manner even in brain areas far from the surface can be used to manipulate brain activity in these circuits in humans.\n","plannedDates":[{"endDate":"2026-09-30T00:00:00+00:00","startDate":"2021-10-01T00:00:00+00:00","startDateDateOnly":"2021-10-01","endDateDateOnly":"2026-09-30"}],"amountAwarded":2336909,"Financial Year":"2020/21","Lead Applicant":"Prof Matthew Rushworth","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Rushworth","Partnership Value":2336909,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Distributed brain systems for motivation and action The overarching aim is to understand the neural mechanisms of learning, decision-making, and motivation in humans. We will examine how they emerge from distributed patterns of activity across networks of subcortical nuclei such as the basal forebrain and dorsal raphe nucleus. While we know about such subcortical areas from animal studies, they have been under-investigated in humans. New imaging and uni- and multivariate analysis methods now make it possible to examine the distributed patterns of activity that arise in these areas. We have recently shown that we can record from these areas of the human brain using ultra high field magnetic resonance imaging. In addition, we know that these nuclei interact with cortical areas, especially in orbitofrontal, anterior cingulate, and insula cortex (regions that are especially prominent in humans and other primates).  We aim to record from both cortical and subcortical areas and to understand how they interact during learning, decision making, and motivation. The final aim is to assess whether new ultrasound stimulation tools that make it possible to alter neural activity in a minimally invasive manner even in brain areas far from the surface can be used to manipulate brain activity in these circuits in humans.\n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adult","Brain Mapping","Cerebral Cortex","Decision Making","Gyrus Cinguli","Humans","Magnetic Resonance Imaging","Motivation","Reward"]}
{"id":"360G-Wellcome-221790_Z_20_Z","title":"Children and Young People's Participatory Research and Communication for Change","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221790/Z/20/Z","description":"Aligned with Wellcome\u2019s commitment to leveraging public partnership \u2013 throughout the cycles of response, recovery and resilience/sustainable preparedness \u2013 to inform research, create trusted research, and increase the access and use of research more equitably across communities, this project will (1) Fill a current gap in children and young people (CYP) insights around Covid-19 and other issues of health and science related research, (2) Equip young people with participatory research and multi-media production skills, and (3) Develop a scaleable participatory model of research and communication for change.\n\nTo achieve this, UNICEF C4D, a leader in using communication strategies to empower CYP as critical actors in research and development, will partner with innovative multi-media platforms -- inclusive of video, community radio, and mobile-based platforms -- to facilitate CYP-led cross-country surveying, personal stories (via video), in-depth interviews (with/by CYP), and deliberative dialogues (via community radio, video and mobile-based platforms), that will uncover CYP needs, behaviours and experiences with COVID-19 and other priority health and science challenges. UNICEF and its partners will develop a replicable model and partnership base for CYP-led research and engagement to influence social and behaviour change to support future joint research engagement to inform policy and programmatic decision making.\n","plannedDates":[{"endDate":"2021-11-30T00:00:00+00:00","startDate":"2020-12-01T00:00:00+00:00","startDateDateOnly":"2020-12-01","endDateDateOnly":"2021-11-30"}],"amountAwarded":239027,"Financial Year":"2019/20","Lead Applicant":"Dr Kerida McDonald","grantProgramme":[{"title":"Discretionary Award - Public Engagement","title_keyword":"Discretionary Award - Public Engagement"}],"Applicant Surname":"McDonald","Partnership Value":239027,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:UNICEF-UK","name":"UNICEF UK","addressCountry":"United Kingdom","id_and_name":"[\"UNICEF UK\", \"360G-Wellcome-ORG:UNICEF-UK\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:UNICEF-UK","name":"UNICEF UK"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Children and Young People's Participatory Research and Communication for Change Aligned with Wellcome\u2019s commitment to leveraging public partnership \u2013 throughout the cycles of response, recovery and resilience/sustainable preparedness \u2013 to inform research, create trusted research, and increase the access and use of research more equitably across communities, this project will (1) Fill a current gap in children and young people (CYP) insights around Covid-19 and other issues of health and science related research, (2) Equip young people with participatory research and multi-media production skills, and (3) Develop a scaleable participatory model of research and communication for change.\n\nTo achieve this, UNICEF C4D, a leader in using communication strategies to empower CYP as critical actors in research and development, will partner with innovative multi-media platforms -- inclusive of video, community radio, and mobile-based platforms -- to facilitate CYP-led cross-country surveying, personal stories (via video), in-depth interviews (with/by CYP), and deliberative dialogues (via community radio, video and mobile-based platforms), that will uncover CYP needs, behaviours and experiences with COVID-19 and other priority health and science challenges. UNICEF and its partners will develop a replicable model and partnership base for CYP-led research and engagement to influence social and behaviour change to support future joint research engagement to inform policy and programmatic decision making.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adolescent","Child","Communication","Community Participation","Community-Based Participatory Research","Humans"]}
{"id":"360G-Wellcome-221786_Z_20_Z","title":"Understanding Chemotaxis Towards Self-Generated Gradients Using Computational Models, Model Organisms and T cells","Region":"Scotland","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221786/Z/20/Z","description":"Cell migration is essential to processes throughout biology, especially embryonic development and immune function. Migration must be steered to be physiologically effective. Steering cues are not well understood; we know a lot about how cells interpret them, but relatively little about how they are generated.\nThe basic premise of this work is that the cells often generate their own cues, by breaking down attractants that are widely present (and thus initially give no steering information) into local gradients. Attractant breakdown and migration happen simultaneously. This mechanism - chemotaxis up self-generated gradients (SGGs) - is hard to dissect because it is complex, and based on positive feedback loops. We therefore propose a four-pronged, iterative approach, in which we combine less challenging components to create an understanding of the underlying biology.\nKey goals are:\n(1) explore possible mechanisms and new extensions using computational models;\n(2) test outcomes using chemotactic Dictyostelium in custom microfluidic devices;\n(3) verify these data by establishing cultured T cells chemotaxing to CCL19 as a model SGG;\n(4) combine findings from parts 1-3 to make a 3D, SGG-based model of a lymph node.\nTogether they will illuminate chemotactic steering in general, by focussing on one physiologically important system.\n","plannedDates":[{"endDate":"2026-04-30T00:00:00+00:00","startDate":"2021-05-01T00:00:00+00:00","startDateDateOnly":"2021-05-01","endDateDateOnly":"2026-04-30"}],"amountAwarded":1492837,"Financial Year":"2020/21","Lead Applicant":"Prof Robert Insall","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Insall","Partnership Value":1492837,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow","addressCountry":"United Kingdom","id_and_name":"[\"University of Glasgow\", \"360G-Wellcome-ORG:University-of-Glasgow\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding Chemotaxis Towards Self-Generated Gradients Using Computational Models, Model Organisms and T cells Cell migration is essential to processes throughout biology, especially embryonic development and immune function. Migration must be steered to be physiologically effective. Steering cues are not well understood; we know a lot about how cells interpret them, but relatively little about how they are generated.\nThe basic premise of this work is that the cells often generate their own cues, by breaking down attractants that are widely present (and thus initially give no steering information) into local gradients. Attractant breakdown and migration happen simultaneously. This mechanism - chemotaxis up self-generated gradients (SGGs) - is hard to dissect because it is complex, and based on positive feedback loops. We therefore propose a four-pronged, iterative approach, in which we combine less challenging components to create an understanding of the underlying biology.\nKey goals are:\n(1) explore possible mechanisms and new extensions using computational models;\n(2) test outcomes using chemotactic Dictyostelium in custom microfluidic devices;\n(3) verify these data by establishing cultured T cells chemotaxing to CCL19 as a model SGG;\n(4) combine findings from parts 1-3 to make a 3D, SGG-based model of a lymph node.\nTogether they will illuminate chemotactic steering in general, by focussing on one physiologically important system.\n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cell Movement","Chemotactic Factors","Chemotaxis","Computer Simulation","Dictyostelium","Microfluidics","Models, Biological"]}
{"id":"360G-Wellcome-221784_Z_20_Z","title":"Conformational Surveillance of signalling proteins in the plasma membrane","Region":"South West","currency":"GBP","awardDate":"2020-11-24T00:00:00+00:00","Sponsor(s)":"Prof Catherine Nobes","Internal ID":"221784/Z/20/Z","description":"The distinct activities of polytopic channels, transporters and receptors are essential for cell signalling in response to external stimuli, and their dysfunction is frequently associated with disease. My research has revealed that these plasma membrane proteins undergo Conformational Surveillance by intramembrane proteases: their distinct conformations are recognised and subsequently downregulated by transmembrane domain cleavage. Substrates have never been identified for many intramembrane proteases; I propose this is largely due to a previous lack of systematic screening approaches, and that proteins with more than one transmembrane domain have not been fully explored as substrates.\n\nThe overarching aim in this fellowship is to discover the mechanisms that underpin Conformational Surveillance, and to reveal its full repertoire of functions. \n\nMy four main goals are:\n\n1) to explore newly identified examples of Conformational Surveillance;\n2) to examine whether intramembrane proteases of different families share this molecular activity;\n3) to understand the mechanistic coupling of intramembrane proteolysis and lysosomal degradation;\n4) to investigate Conformational Surveillance in neurons, where many intramembrane proteases are highly expressed.\n\nOverall, this research programme will shed light on a potentially widespread yet overlooked branch of cell surface proteostasis. \n","plannedDates":[{"endDate":"2026-02-28T00:00:00+00:00","startDate":"2021-03-01T00:00:00+00:00","startDateDateOnly":"2021-03-01","endDateDateOnly":"2026-02-28"}],"amountAwarded":1091843,"Financial Year":"2020/21","Lead Applicant":"Dr Adam Grieve","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Grieve","Partnership Value":1091843,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Conformational Surveillance of signalling proteins in the plasma membrane The distinct activities of polytopic channels, transporters and receptors are essential for cell signalling in response to external stimuli, and their dysfunction is frequently associated with disease. My research has revealed that these plasma membrane proteins undergo Conformational Surveillance by intramembrane proteases: their distinct conformations are recognised and subsequently downregulated by transmembrane domain cleavage. Substrates have never been identified for many intramembrane proteases; I propose this is largely due to a previous lack of systematic screening approaches, and that proteins with more than one transmembrane domain have not been fully explored as substrates.\n\nThe overarching aim in this fellowship is to discover the mechanisms that underpin Conformational Surveillance, and to reveal its full repertoire of functions. \n\nMy four main goals are:\n\n1) to explore newly identified examples of Conformational Surveillance;\n2) to examine whether intramembrane proteases of different families share this molecular activity;\n3) to understand the mechanistic coupling of intramembrane proteolysis and lysosomal degradation;\n4) to investigate Conformational Surveillance in neurons, where many intramembrane proteases are highly expressed.\n\nOverall, this research programme will shed light on a potentially widespread yet overlooked branch of cell surface proteostasis. \n","awardDateDateOnly":"2020-11-24","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cell Membrane","Humans","Lysosomes","Membrane Proteins","Neurons","Protein Conformation","Proteolysis"]}
{"id":"360G-Wellcome-221782_Z_20_Z","title":"The molecular aetiology of central obesity: moving from variant to function using large-scale data-driven approaches.","Region":"South East","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221782/Z/20/Z","description":"Central obesity is a leading contributing cause of illness and death across the world. Currently available strategies for prevention and treatment of this condition are manifestly inadequate. The research proposed here aims to identify fundamental processes involved in the development of central obesity. I plan to harness the power of human genetics, fused with deep molecular characterisation of the adipocytes to generate novel insights into the biology of central obesity. This \u2018multi-omics\u2019 approach will provide the basis for more effective preventative and therapeutic approaches that reduce the burden of central obesity and associated disease.\n\n \n","plannedDates":[{"endDate":"2026-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2026-03-31"}],"amountAwarded":2059266,"Financial Year":"2020/21","Lead Applicant":"Prof Cecilia Lindgren","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Lindgren","Partnership Value":2059266,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The molecular aetiology of central obesity: moving from variant to function using large-scale data-driven approaches. Central obesity is a leading contributing cause of illness and death across the world. Currently available strategies for prevention and treatment of this condition are manifestly inadequate. The research proposed here aims to identify fundamental processes involved in the development of central obesity. I plan to harness the power of human genetics, fused with deep molecular characterisation of the adipocytes to generate novel insights into the biology of central obesity. This \u2018multi-omics\u2019 approach will provide the basis for more effective preventative and therapeutic approaches that reduce the burden of central obesity and associated disease.\n\n \n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adipocytes","Animals","Humans","Obesity"]}
{"id":"360G-Wellcome-221776_Z_20_Z","title":"CTP switches in bacterial chromosome segregation and physiology: structures, functions, and mechanisms","Region":"East of England","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221776/Z/20/Z","description":"ATP and GTP switches are extensively used to control conformations and functions of proteins in a wide range of biological processes. However, CTP switches have rarely been found in biology. Recent work from our laboratory and others has shown that ParB is a founding member of a CTPase protein family that uses a CTP switch to regulate bacterial chromosome segregation. We hypothesize that CTP switches are currently unappreciated and may be widespread. In the proposed work we will exploit the tripartite ParABS system from Caulobacter crescentus to elucidate the structure, function, and mechanism of the CTP switch that ensures faithful chromosome segregation. Next, we will investigate how other CTP switches regulate membrane association and gene expression by employing Noc and KorB (proteins crucial for chromosome integrity and plasmid transmission, respectively) as models. Lastly, we will  identify and characterize other CTP switch proteins in C.crescentus and systematically discover putative CTP-binding/CTPase proteins across all sequenced bacterial genomes. Altogether, this work will provide fundamental knowledge on the mechanism and evolution of CTP switches and open new and unexpected horizons in numerous fields beyond bacterial chromosome segregation. Moreover, our immediate research on plasmid/chromosome segregation and transmission may inform strategies to combat plasmid-borne antibiotic resistance.\n","plannedDates":[{"endDate":"2026-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2026-06-30"}],"amountAwarded":1271158,"Financial Year":"2020/21","Lead Applicant":"Dr Tung Le","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Le","Partnership Value":1271158,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:John-Innes-Centre","name":"John Innes Centre","addressCountry":"United Kingdom","id_and_name":"[\"John Innes Centre\", \"360G-Wellcome-ORG:John-Innes-Centre\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:John-Innes-Centre","name":"John Innes Centre"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"CTP switches in bacterial chromosome segregation and physiology: structures, functions, and mechanisms ATP and GTP switches are extensively used to control conformations and functions of proteins in a wide range of biological processes. However, CTP switches have rarely been found in biology. Recent work from our laboratory and others has shown that ParB is a founding member of a CTPase protein family that uses a CTP switch to regulate bacterial chromosome segregation. We hypothesize that CTP switches are currently unappreciated and may be widespread. In the proposed work we will exploit the tripartite ParABS system from Caulobacter crescentus to elucidate the structure, function, and mechanism of the CTP switch that ensures faithful chromosome segregation. Next, we will investigate how other CTP switches regulate membrane association and gene expression by employing Noc and KorB (proteins crucial for chromosome integrity and plasmid transmission, respectively) as models. Lastly, we will  identify and characterize other CTP switch proteins in C.crescentus and systematically discover putative CTP-binding/CTPase proteins across all sequenced bacterial genomes. Altogether, this work will provide fundamental knowledge on the mechanism and evolution of CTP switches and open new and unexpected horizons in numerous fields beyond bacterial chromosome segregation. Moreover, our immediate research on plasmid/chromosome segregation and transmission may inform strategies to combat plasmid-borne antibiotic resistance.\n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Bacterial Proteins","Caulobacter crescentus","Chromosome Segregation","Chromosomes, Bacterial","Plasmids"]}
{"id":"360G-Wellcome-221774_Z_20_Z","title":"Preconception to pOst-partum study of cardiometabolic health in Primigravid PregnancY:  POPPY ","Region":"East of England","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221774/Z/20/Z","description":"The clinical manifestations of placental dysfunction include pre-eclampsia, gestational hypertension and fetal growth restriction. Women who experience placental dysfunction have a two-fold risk of cardiovascular disease (CVD) and diabetes in later life compared to women with uncomplicated pregnancies. However, it is unclear whether placental syndromes have a direct adverse effect on cardiometabolic health, whether a healthy pregnancy is protective, or whether women who experience a placental syndrome simply had poorer cardiometabolic health prior to pregnancy. If placental syndromes do lead to CVD and diabetes independently of established cardiometabolic risk factors (e.g. by causing end organ damage), a focus on CVD/diabetes prevention in this high-risk group of women is likely to reduce the burden of these diseases. Conversely, if pre-pregnancy factors are more important, improving cardiometabolic health in young women prior to conception is key and could reduce the incidence of placental syndromes. We plan to assess cardiometabolic risk factors and validated intermediate phenotypes of CVD/diabetes before conception, during pregnancy, and post-partum to determine whether placental syndromes affect post-partum maternal cardiometabolic health independently of pre-conception cardiometabolic health. This will help to determine the optimal timing and nature of prevention strategies to reduce the burden of diabetes/CVD in women, in future trials.\n","plannedDates":[{"endDate":"2026-05-31T00:00:00+00:00","startDate":"2021-06-01T00:00:00+00:00","startDateDateOnly":"2021-06-01","endDateDateOnly":"2026-05-31"}],"amountAwarded":4079159,"Financial Year":"2020/21","Lead Applicant":"Prof Ian Wilkinson","grantProgramme":[{"title":"Collaborative Award in Science","title_keyword":"Collaborative Award in Science"}],"Applicant Surname":"Wilkinson","Partnership Value":4079159,"Approval Committee":"Science Interview Panel","Other Applicant(s)":"Prof Abigail Fraser, Prof Christian Delles, Dr Carmel McEniery, Prof Kate Tilling, Prof Lucilla Poston, Prof Alun Hughes, Prof Christoph Lees, Prof Asma Khalil","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Preconception to pOst-partum study of cardiometabolic health in Primigravid PregnancY:  POPPY  The clinical manifestations of placental dysfunction include pre-eclampsia, gestational hypertension and fetal growth restriction. Women who experience placental dysfunction have a two-fold risk of cardiovascular disease (CVD) and diabetes in later life compared to women with uncomplicated pregnancies. However, it is unclear whether placental syndromes have a direct adverse effect on cardiometabolic health, whether a healthy pregnancy is protective, or whether women who experience a placental syndrome simply had poorer cardiometabolic health prior to pregnancy. If placental syndromes do lead to CVD and diabetes independently of established cardiometabolic risk factors (e.g. by causing end organ damage), a focus on CVD/diabetes prevention in this high-risk group of women is likely to reduce the burden of these diseases. Conversely, if pre-pregnancy factors are more important, improving cardiometabolic health in young women prior to conception is key and could reduce the incidence of placental syndromes. We plan to assess cardiometabolic risk factors and validated intermediate phenotypes of CVD/diabetes before conception, during pregnancy, and post-partum to determine whether placental syndromes affect post-partum maternal cardiometabolic health independently of pre-conception cardiometabolic health. This will help to determine the optimal timing and nature of prevention strategies to reduce the burden of diabetes/CVD in women, in future trials.\n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adult","Cardiovascular Diseases","Diabetes Mellitus","Female","Humans","Placenta","Pregnancy","Risk Factors"]}
{"id":"360G-Wellcome-221769_Z_20_Z","title":"Determining the limits for reversing hearing loss","Region":"Greater London","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221769/Z/20/Z","description":"Progressive hearing loss is very common but there are no medical treatments to slow down or reverse it. Histopathological reports suggest three main sites of lesion in the cochlea can be involved: sensory hair cells; synapses of hair cells with cochlear neurons; and the stria vascularis which produces a potassium-rich fluid with an endocochlear potential of +100mV that is essential for hair cell sensitivity. This research has three goals that will provide the scientific underpinning for development of new treatments for hearing loss. Firstly, we will investigate whether hearing loss in each of the three pathological categories can be reversed and hearing improved. Secondly, the research will determine what the limiting factors to reversal of hearing loss are and how these define the critical period for intervention. Thirdly, we will develop new diagnostic tools to distinguish the three sites of lesion using objective measures of auditory responses, to establish the underlying pathological contributions to hearing loss in an individual, and hence determine the optimum treatment. To achieve these goals, we will use mouse mutants with well-characterised cochlear pathology as examples of each site of lesion, and a new approach to reactivating a mutant gene after the onset of hearing loss.\n","plannedDates":[{"endDate":"2026-02-28T00:00:00+00:00","startDate":"2021-03-01T00:00:00+00:00","startDateDateOnly":"2021-03-01","endDateDateOnly":"2026-02-28"}],"amountAwarded":1947704,"Financial Year":"2020/21","Lead Applicant":"Prof Karen Steel","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Steel","Partnership Value":1947704,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Determining the limits for reversing hearing loss Progressive hearing loss is very common but there are no medical treatments to slow down or reverse it. Histopathological reports suggest three main sites of lesion in the cochlea can be involved: sensory hair cells; synapses of hair cells with cochlear neurons; and the stria vascularis which produces a potassium-rich fluid with an endocochlear potential of +100mV that is essential for hair cell sensitivity. This research has three goals that will provide the scientific underpinning for development of new treatments for hearing loss. Firstly, we will investigate whether hearing loss in each of the three pathological categories can be reversed and hearing improved. Secondly, the research will determine what the limiting factors to reversal of hearing loss are and how these define the critical period for intervention. Thirdly, we will develop new diagnostic tools to distinguish the three sites of lesion using objective measures of auditory responses, to establish the underlying pathological contributions to hearing loss in an individual, and hence determine the optimum treatment. To achieve these goals, we will use mouse mutants with well-characterised cochlear pathology as examples of each site of lesion, and a new approach to reactivating a mutant gene after the onset of hearing loss.\n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cochlea","Disease Models, Animal","Hair Cells, Auditory","Hearing Loss","Mice","Mutation"]}
{"id":"360G-Wellcome-221761_Z_20_Z","title":"The mechanism of recombination and its impacts on human mutation and disease","Region":"South East","currency":"GBP","awardDate":"2020-11-24T00:00:00+00:00","Sponsor(s)":"Prof John Todd","Internal ID":"221761/Z/20/Z","description":" \n\n \n\nMeiotic recombination is essential for creation of haploid gametes. Errors in this process cause miscarriage, infertility, and developmental disorders. Recombination proceeds via repair of programmed DNA breaks; however, the molecular mechanisms ensuring their repair are not well understood. My work reveals that these breaks are a significant mutagenic force, leading to de novo mutations (DNMs) in 1 in 3 sperm and 1 in 13 eggs. My proposed research will harness cutting-edge experiments in genetically-engineered mouse models to generate novel data and will further leverage existing population-scale human genetic and phenotypic data. I will integrate these data through sophisticated statistical analyses to answer the following questions:\n\n \n\n\n What are the properties, causes and impacts of recombination-associated mutations on human health? I will characterize these mutations comprehensively in humans and infer their molecular causes. I will investigate their impact on common and rare diseases.\n What is the mechanism of break repair in recombination? I will build on my recent work and interrogate meiotic break repair through specialised experimental assays on key proteins in genetically-engineered mice.\n What is the mechanism of mutagenesis? I will characterize the impact of pathways that are identified above as causal by disrupting them in genetically-engineered mice.\n\n\n \n","plannedDates":[{"endDate":"2026-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2026-03-31"}],"amountAwarded":1121260,"Financial Year":"2020/21","Lead Applicant":"Dr Anjali Hinch","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Hinch","Partnership Value":1121260,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The mechanism of recombination and its impacts on human mutation and disease  \n\n \n\nMeiotic recombination is essential for creation of haploid gametes. Errors in this process cause miscarriage, infertility, and developmental disorders. Recombination proceeds via repair of programmed DNA breaks; however, the molecular mechanisms ensuring their repair are not well understood. My work reveals that these breaks are a significant mutagenic force, leading to de novo mutations (DNMs) in 1 in 3 sperm and 1 in 13 eggs. My proposed research will harness cutting-edge experiments in genetically-engineered mouse models to generate novel data and will further leverage existing population-scale human genetic and phenotypic data. I will integrate these data through sophisticated statistical analyses to answer the following questions:\n\n \n\n\n What are the properties, causes and impacts of recombination-associated mutations on human health? I will characterize these mutations comprehensively in humans and infer their molecular causes. I will investigate their impact on common and rare diseases.\n What is the mechanism of break repair in recombination? I will build on my recent work and interrogate meiotic break repair through specialised experimental assays on key proteins in genetically-engineered mice.\n What is the mechanism of mutagenesis? I will characterize the impact of pathways that are identified above as causal by disrupting them in genetically-engineered mice.\n\n\n \n","awardDateDateOnly":"2020-11-24","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Female","Humans","Male","Meiosis","Mice","Spermatozoa"]}
{"id":"360G-Wellcome-221750_Z_20_Z","title":"PlanetDivoc91","Region":"North West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221750/Z/20/Z","description":"A 9-part digital comic for young adults (YA) aged 16-25 providing an alternative, character-based narrative about a pandemic. Co-created with young adults from across the globe, multidisciplinary researchers and experts, renowned comic writers and artists, PlanetDivoc91 offers audiences diverse perspectives on how to make sense of a pandemic. It connects and empowers YA - whose voices have been marginal in the COVID crisis - to be heard in current and future pandemic research and policy. This proposal builds on work already started in the UK and internationally, to extend in greater depth globally, particularly in India and South Africa (SA). ","plannedDates":[{"endDate":"2021-05-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2021-05-31"}],"amountAwarded":149993,"Financial Year":"2019/20","Lead Applicant":"Dr Bella Starling","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Starling","Partnership Value":149993,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"PlanetDivoc91 A 9-part digital comic for young adults (YA) aged 16-25 providing an alternative, character-based narrative about a pandemic. Co-created with young adults from across the globe, multidisciplinary researchers and experts, renowned comic writers and artists, PlanetDivoc91 offers audiences diverse perspectives on how to make sense of a pandemic. It connects and empowers YA - whose voices have been marginal in the COVID crisis - to be heard in current and future pandemic research and policy. This proposal builds on work already started in the UK and internationally, to extend in greater depth globally, particularly in India and South Africa (SA). ","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adolescent","Humans","India","South Africa","Young Adult"]}
{"id":"360G-Wellcome-221749_Z_20_Z","title":"The dynamics of cell entry and genome replication in a model complex virus","Region":"Greater London","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221749/Z/20/Z","description":"Bluetongue virus (BTV), a complex non-enveloped virus with a genome of ten double-stranded RNA segments, is an important pathogen and model for many similar large non-enveloped viruses (including the medically important rotaviruses). Previous studies have provided a well-understood replication cycle, a large range of research reagents and many novel assay systems, all complemented by high resolution atomic structures of many viral proteins. Notably, the recent structure of the viral polymerase in situ, a critical point of replication, has provided a unique opportunity to investigate many details involved in the virus life cycle. To achieve this we will will use state-of-the-art techniques such as cryoEM, cryo-ET, FCS and FRET in addition to our established in vitro and in vivo assays to determine how BTV entry to the cell causes the polymerase to initiate genome transcription from the 10 genomic dsRNAs and how this process differs from the later process of genome replication which follows the packaging of RNA during assembly. We will define how these processes link to the maturation of newly assembled virus particles and their exit from the cell. Our findings will have the potential to develop laboratory data to translational applications in future design of antiviral and vaccines.\n","plannedDates":[{"endDate":"2026-05-31T00:00:00+00:00","startDate":"2021-06-01T00:00:00+00:00","startDateDateOnly":"2021-06-01","endDateDateOnly":"2026-05-31"}],"amountAwarded":1793281,"Financial Year":"2020/21","Lead Applicant":"Prof Polly Roy","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Roy","Partnership Value":1793281,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"London School of Hygiene & Tropical Medicine\", \"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The dynamics of cell entry and genome replication in a model complex virus Bluetongue virus (BTV), a complex non-enveloped virus with a genome of ten double-stranded RNA segments, is an important pathogen and model for many similar large non-enveloped viruses (including the medically important rotaviruses). Previous studies have provided a well-understood replication cycle, a large range of research reagents and many novel assay systems, all complemented by high resolution atomic structures of many viral proteins. Notably, the recent structure of the viral polymerase in situ, a critical point of replication, has provided a unique opportunity to investigate many details involved in the virus life cycle. To achieve this we will will use state-of-the-art techniques such as cryoEM, cryo-ET, FCS and FRET in addition to our established in vitro and in vivo assays to determine how BTV entry to the cell causes the polymerase to initiate genome transcription from the 10 genomic dsRNAs and how this process differs from the later process of genome replication which follows the packaging of RNA during assembly. We will define how these processes link to the maturation of newly assembled virus particles and their exit from the cell. Our findings will have the potential to develop laboratory data to translational applications in future design of antiviral and vaccines.\n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Bluetongue virus","Cell Line","Cryoelectron Microscopy","Fluorescence Resonance Energy Transfer","Genome, Viral","RNA, Double-Stranded","RNA, Viral","Virus Replication"]}
{"id":"360G-Wellcome-221745_Z_20_Z","title":"Understanding the interaction between human milk oligosaccharides and the gut microbiome in preterm infant health and disease","Region":"North East","currency":"GBP","awardDate":"2020-11-24T00:00:00+00:00","Sponsor(s)":"Prof Jonathan Higgins","Internal ID":"221745/Z/20/Z","description":"Necrotising enterocolitis (NEC) is a leading cause of death in babies born extremely preterm. NEC infants generally have increased gram-negative bacteria compared to matched controls, potentially resulting in an LPS-stimulated increase in TLR4 and inflammatory cytokines in the intestinal epithelium, ultimately leading to the breakdown of epithelial integrity and necrosis. My recent work has shown that human milk oligosaccharides (HMOs) promote the establishment of a protective microbiome in the infant gut, which is associated with reduced risk of NEC.\n\nThis project will identify specific HMOs and bacteria that promote gut health and reduce NEC in preterm infants. The project will take advantage of a host-microbe model system I have recently developed. This will provide new insights into NEC pathogenesis, potentially leading to the development or refinement of therapeutics. I will achieve this by answering four critical questions:\n\n1.    What specific HMOs and microbial species are associated with NEC or gut health?\n2.    Do HMOs directly influence the epithelial integrity and inflammation observed in NEC?\n3.    How do specific bacterial species interact with the preterm intestinal epithelium?\n4.    Can a combination of HMO (prebiotic) and bacteria (probiotic) promote gut health and protect against NEC?\n","plannedDates":[{"endDate":"2026-07-31T00:00:00+00:00","startDate":"2021-08-01T00:00:00+00:00","startDateDateOnly":"2021-08-01","endDateDateOnly":"2026-07-31"}],"amountAwarded":1136115,"Financial Year":"2020/21","Lead Applicant":"Dr Christopher Stewart","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Stewart","Partnership Value":1136115,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Newcastle-University","name":"Newcastle University","addressCountry":"United Kingdom","id_and_name":"[\"Newcastle University\", \"360G-Wellcome-ORG:Newcastle-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Newcastle-University","name":"Newcastle University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding the interaction between human milk oligosaccharides and the gut microbiome in preterm infant health and disease Necrotising enterocolitis (NEC) is a leading cause of death in babies born extremely preterm. NEC infants generally have increased gram-negative bacteria compared to matched controls, potentially resulting in an LPS-stimulated increase in TLR4 and inflammatory cytokines in the intestinal epithelium, ultimately leading to the breakdown of epithelial integrity and necrosis. My recent work has shown that human milk oligosaccharides (HMOs) promote the establishment of a protective microbiome in the infant gut, which is associated with reduced risk of NEC.\n\nThis project will identify specific HMOs and bacteria that promote gut health and reduce NEC in preterm infants. The project will take advantage of a host-microbe model system I have recently developed. This will provide new insights into NEC pathogenesis, potentially leading to the development or refinement of therapeutics. I will achieve this by answering four critical questions:\n\n1.    What specific HMOs and microbial species are associated with NEC or gut health?\n2.    Do HMOs directly influence the epithelial integrity and inflammation observed in NEC?\n3.    How do specific bacterial species interact with the preterm intestinal epithelium?\n4.    Can a combination of HMO (prebiotic) and bacteria (probiotic) promote gut health and protect against NEC?\n","awardDateDateOnly":"2020-11-24","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Enterocolitis, Necrotizing","Gastrointestinal Microbiome","Humans","Infant, Newborn","Infant, Premature","Milk, Human","Oligosaccharides","Prebiotics"]}
{"id":"360G-Wellcome-221737_Z_20_Z","title":"Contribution of the miRNA-interferon interaction to human disease","Region":"Scotland","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221737/Z/20/Z","description":"The type I interferon (IFN) response is the major antiviral pathway in mammals but needs to be tightly regulated to ensure effective defence against viruses whilst avoiding the negative consequences of their overproduction, resulting in autoimmune and autoinflammatory diseases.\nI have recently demonstrated a central role for microRNAs (miRNAs) in maintaining optimal IFN levels, and conversely, that IFNs are important regulators of miRNA expression. These results led me to hypothesise that there is a tight interaction between the IFN and miRNA pathways, which contributes to specific traits of human diseases where one component of this interaction is altered.\nSupporting this hypothesis, our unpublished results show that diseases characterised by altered miRNA expression, such as 22q11.2DS, exhibit a dysregulated IFN response. Vice versa, diseases characterised by an abnormal IFN response, such as systemic lupus erythematosus, display altered miRNA levels. I aim to identify the mechanisms by which the miRNA biogenesis and IFN pathways interact and study the role of this interaction in diseases where the IFN or miRNA biogenesis pathways are altered. These results will provide a mechanistic perspective to some of the common but unexplained traits presented in these diseases and provide novel targets for intervention strategies.\n \n","plannedDates":[{"endDate":"2026-01-31T00:00:00+00:00","startDate":"2021-02-01T00:00:00+00:00","startDateDateOnly":"2021-02-01","endDateDateOnly":"2026-01-31"}],"amountAwarded":1827981,"Financial Year":"2020/21","Lead Applicant":"Dr Sara Macias","grantProgramme":[{"title":"Senior Research Fellowship","title_keyword":"Senior Research Fellowship"}],"Applicant Surname":"Macias","Partnership Value":1827981,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Contribution of the miRNA-interferon interaction to human disease The type I interferon (IFN) response is the major antiviral pathway in mammals but needs to be tightly regulated to ensure effective defence against viruses whilst avoiding the negative consequences of their overproduction, resulting in autoimmune and autoinflammatory diseases.\nI have recently demonstrated a central role for microRNAs (miRNAs) in maintaining optimal IFN levels, and conversely, that IFNs are important regulators of miRNA expression. These results led me to hypothesise that there is a tight interaction between the IFN and miRNA pathways, which contributes to specific traits of human diseases where one component of this interaction is altered.\nSupporting this hypothesis, our unpublished results show that diseases characterised by altered miRNA expression, such as 22q11.2DS, exhibit a dysregulated IFN response. Vice versa, diseases characterised by an abnormal IFN response, such as systemic lupus erythematosus, display altered miRNA levels. I aim to identify the mechanisms by which the miRNA biogenesis and IFN pathways interact and study the role of this interaction in diseases where the IFN or miRNA biogenesis pathways are altered. These results will provide a mechanistic perspective to some of the common but unexplained traits presented in these diseases and provide novel targets for intervention strategies.\n \n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Interferon Type I","MicroRNAs"]}
{"id":"360G-Wellcome-221725_Z_20_Z","title":"Exploring innate-like and adaptive gamma delta T cell paradigms in health and disease","Region":"West Midlands","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221725/Z/20/Z","description":"gammadelta T-cells have been retained in vertebrates for ~500million years, and are of increasing therapeutic interest, but their mode of ligand recognition and immunological niche has remained largely mysterious. Here we build on the emergence of parallel innate-like and adaptive human gammadelta T-cell paradigms to address unresolved \u2018keystone\u2019 questions in gammadelta T-cell biology. Firstly, we will exploit multidisciplinary approaches to explore the diversity of innate-like and adaptive gammadelta biology in different tissues, their coordination with other immune responses, and how these change in disease states such as inflammation and cancer. Secondly, we will identify molecular targets of gammadelta-TCRs from innate-like subsets and structurally characterise their TCR/ligand interactions and cellular/molecular recognition mechanisms, focussing significantly on the strong emergence of Butyrophilin family molecules as critical TCR-ligands for such populations. Thirdly we will exploit cytomegalovirus infection as a unique human model to identify novel ligands for antigen-experienced adaptive-like gammadelta T-cell subsets. Finally, we will develop and apply new methodology to image and phenotype distinct human gammadelta T-cell subsets in solid tissues, using multispectral immunofluorescence and digital spatial profiling. This programme should help revolutionise our understanding of gammadelta T-cells, and provide a solid foundation for ongoing efforts to therapeutically harness the gammadelta T-cell compartment.\n","plannedDates":[{"endDate":"2026-02-28T00:00:00+00:00","startDate":"2021-03-01T00:00:00+00:00","startDateDateOnly":"2021-03-01","endDateDateOnly":"2026-02-28"}],"amountAwarded":2051884,"Financial Year":"2020/21","Lead Applicant":"Prof Benjamin Willcox","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Willcox","Partnership Value":2051884,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Birmingham\", \"360G-Wellcome-ORG:University-of-Birmingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Exploring innate-like and adaptive gamma delta T cell paradigms in health and disease gammadelta T-cells have been retained in vertebrates for ~500million years, and are of increasing therapeutic interest, but their mode of ligand recognition and immunological niche has remained largely mysterious. Here we build on the emergence of parallel innate-like and adaptive human gammadelta T-cell paradigms to address unresolved \u2018keystone\u2019 questions in gammadelta T-cell biology. Firstly, we will exploit multidisciplinary approaches to explore the diversity of innate-like and adaptive gammadelta biology in different tissues, their coordination with other immune responses, and how these change in disease states such as inflammation and cancer. Secondly, we will identify molecular targets of gammadelta-TCRs from innate-like subsets and structurally characterise their TCR/ligand interactions and cellular/molecular recognition mechanisms, focussing significantly on the strong emergence of Butyrophilin family molecules as critical TCR-ligands for such populations. Thirdly we will exploit cytomegalovirus infection as a unique human model to identify novel ligands for antigen-experienced adaptive-like gammadelta T-cell subsets. Finally, we will develop and apply new methodology to image and phenotype distinct human gammadelta T-cell subsets in solid tissues, using multispectral immunofluorescence and digital spatial profiling. This programme should help revolutionise our understanding of gammadelta T-cells, and provide a solid foundation for ongoing efforts to therapeutically harness the gammadelta T-cell compartment.\n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adaptive Immunity","Cytomegalovirus","Cytomegalovirus Infections","Humans","Immunity, Innate","Ligands","Receptors, Antigen, T-Cell","T-Lymphocytes"]}
{"id":"360G-Wellcome-221719_Z_20_Z","title":"A collaborative platform and network for responsive infectious diseases bioethics research","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221719/Z/20/Z","description":"We seek to establish a research network and collaborative platform for rapidly identifying and analysing ethical and policy issues arising in infectious disease treatment, research, response, and preparedness, and engaging in research on the profound ethical challenges presented by infectious diseases across the globe.  The platform and network will provide real-time ethics and policy support, create a mechanism for collaborative responsive research as well as forward-looking projects with longer timeframes and engaging with crucial stakeholders from across high-resource and LMICs, all focusing on the critically important area of infectious disease and global health bioethics.  In addition to being responsive to the needs as identified by the network, we expect the platform and network to be available to respond to needs identified by the WHO Public Health Emergency Ethics Preparedness and Response (PHEEPR) Network and other global bioethics efforts. The Platform and Network will be structured into two related and overlapping sets of activities, which will complement and build on each other. These will comprise: an Infectious Disease Ethics Forum for discussion of emerging ethical issues, a Collaborative Network to identify important issues for policy response and research; and, a programme of global health ethics research focusing on infectious disease. \n \n","plannedDates":[{"endDate":"2024-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2024-12-31"}],"amountAwarded":1999436,"Financial Year":"2019/20","Lead Applicant":"Prof Michael Parker","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Parker","Partnership Value":1999436,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Prof Jeffrey Kahn","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A collaborative platform and network for responsive infectious diseases bioethics research We seek to establish a research network and collaborative platform for rapidly identifying and analysing ethical and policy issues arising in infectious disease treatment, research, response, and preparedness, and engaging in research on the profound ethical challenges presented by infectious diseases across the globe.  The platform and network will provide real-time ethics and policy support, create a mechanism for collaborative responsive research as well as forward-looking projects with longer timeframes and engaging with crucial stakeholders from across high-resource and LMICs, all focusing on the critically important area of infectious disease and global health bioethics.  In addition to being responsive to the needs as identified by the network, we expect the platform and network to be available to respond to needs identified by the WHO Public Health Emergency Ethics Preparedness and Response (PHEEPR) Network and other global bioethics efforts. The Platform and Network will be structured into two related and overlapping sets of activities, which will complement and build on each other. These will comprise: an Infectious Disease Ethics Forum for discussion of emerging ethical issues, a Collaborative Network to identify important issues for policy response and research; and, a programme of global health ethics research focusing on infectious disease. \n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Bioethics","Biomedical Research","Communicable Diseases","Cooperative Behavior","Global Health","Humans","Public Health"]}
{"id":"360G-Wellcome-221717_Z_20_Z","title":"Quorum sensing in African trypanosomes","Region":"Scotland","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221717/Z/20/Z","description":"Trypanosomes undergo development in both their mammalian host and in the tsetse fly to optimise their disease spread. In mammals, the parasites use quorum sensing (QS) to control their virulence and prepare for tsetse uptake through the generation of arrested stumpy forms, which are found in Trypanosoma brucei but not other African trypanosome species (namely, Trypanosoma congolense or Trypanosoma vivax). We recently discovered that oligopeptide signals can drive QS in Trypanosoma brucei, this activating a signal transduction cascade, some components of which we have already identified. We will now explore how the external signal connects to the identified signalling cascade to drive the differentiation response and how this is disrupted in laboratory-selected and naturally occurring trypanosomes that show reduced QS (so-called 'monomorphs'). We will also compare the distinct mechanisms used by different trypanosome species to prepare for transmission to tsetse flies. This will include characterisation of a cryptic 'stumpy like' stage in T. congolense and its developmental loss of the adherence phenotype characteristic of that species. Our research questions are:\n\n \n\n\n How do trypanosomes generate, detect and transduce external QS signals?\n How is QS lost in laboratory and natural parasite populations?\n How do different trypanosome species prepare for transmission?\n\n","plannedDates":[{"endDate":"2026-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2026-06-30"}],"amountAwarded":2488909,"Financial Year":"2020/21","Lead Applicant":"Prof Keith Matthews","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Matthews","Partnership Value":2488909,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Quorum sensing in African trypanosomes Trypanosomes undergo development in both their mammalian host and in the tsetse fly to optimise their disease spread. In mammals, the parasites use quorum sensing (QS) to control their virulence and prepare for tsetse uptake through the generation of arrested stumpy forms, which are found in Trypanosoma brucei but not other African trypanosome species (namely, Trypanosoma congolense or Trypanosoma vivax). We recently discovered that oligopeptide signals can drive QS in Trypanosoma brucei, this activating a signal transduction cascade, some components of which we have already identified. We will now explore how the external signal connects to the identified signalling cascade to drive the differentiation response and how this is disrupted in laboratory-selected and naturally occurring trypanosomes that show reduced QS (so-called 'monomorphs'). We will also compare the distinct mechanisms used by different trypanosome species to prepare for transmission to tsetse flies. This will include characterisation of a cryptic 'stumpy like' stage in T. congolense and its developmental loss of the adherence phenotype characteristic of that species. Our research questions are:\n\n \n\n\n How do trypanosomes generate, detect and transduce external QS signals?\n How is QS lost in laboratory and natural parasite populations?\n How do different trypanosome species prepare for transmission?\n\n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Host-Parasite Interactions","Quorum Sensing","Signal Transduction","Trypanosoma brucei brucei","Trypanosomiasis, African","Tsetse Flies"]}
{"id":"360G-Wellcome-221716_Z_20_Z","title":"Developing the next generation of anti-venoms to improve management of cobra poisonings in low and middle incoming countries","Region":"International","currency":"GBP","awardDate":"2020-10-06T00:00:00+00:00","Internal ID":"221716/Z/20/Z","description":"We propose a different approach to antivenoms, based on recombinant nanobodies (Nbs), targeting the lethal cobra toxins, to reduce morbidity and mortality. Nbs have a high affinity for selected epitopes, allowing rapid recognition of antigens even if bound to cholinergic receptors, combined with a capacity to dislocate neurotoxin from the receptor. \nThis COBRA-NGaV project brings together research teams with extensive experience in venomics and antivenomics to provide the proof-of-concept (PoC) for cobra toxin-specific Nb candidates as a novel generation of antivenoms and to address the dual obstacle to neutralise cobra toxins: weak immunogenicity and fast diffusion.\nPreliminary results have been obtained so far: i) strong and specific responses were elicited in dromedaries immunised against the toxic fractions of N. legionis, N. haje and N. oxiana; ii) phage display screenings were adopted to rescue strong Nb binders specific towards relevant N. l., N. h. and N. o. toxins; iii) several clusters of Nb sequences specifically binding cobra toxins have been identified.\nHerein, Nb selections and combinations for optimal synergic effects and best cross-species performances will be generated. Best-in-class candidates will be tested in a pre-clinical study in mice and sheep according to GMP rules. Cost effectiveness will be established.\n","plannedDates":[{"endDate":"2024-01-06T00:00:00+00:00","startDate":"2021-01-07T00:00:00+00:00","startDateDateOnly":"2021-01-07","endDateDateOnly":"2024-01-06"}],"amountAwarded":1197348,"Financial Year":"2020/21","Lead Applicant":"Prof Balkiss Bouhaouala-Zahar","grantProgramme":[{"title":"Snakebite Grant \u2013 Next Generation Treatments","title_keyword":"Snakebite Grant \u2013 Next Generation Treatments"}],"Applicant Surname":"Bouhaouala-Zahar","Partnership Value":1197348,"Approval Committee":"Snakebite Advisory Panel (one-off committee)","Other Applicant(s)":"Dr Delavar Shahbazzadeh, Dr Pierre Lafaye, Dr Salma Djilani, Prof Mohamed HAMMADI","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Institut-Pasteur-de-Tunis","name":"Institut Pasteur de Tunis","addressCountry":"Tunisia","id_and_name":"[\"Institut Pasteur de Tunis\", \"360G-Wellcome-ORG:Institut-Pasteur-de-Tunis\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Institut-Pasteur-de-Tunis","name":"Institut Pasteur de Tunis"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Developing the next generation of anti-venoms to improve management of cobra poisonings in low and middle incoming countries We propose a different approach to antivenoms, based on recombinant nanobodies (Nbs), targeting the lethal cobra toxins, to reduce morbidity and mortality. Nbs have a high affinity for selected epitopes, allowing rapid recognition of antigens even if bound to cholinergic receptors, combined with a capacity to dislocate neurotoxin from the receptor. \nThis COBRA-NGaV project brings together research teams with extensive experience in venomics and antivenomics to provide the proof-of-concept (PoC) for cobra toxin-specific Nb candidates as a novel generation of antivenoms and to address the dual obstacle to neutralise cobra toxins: weak immunogenicity and fast diffusion.\nPreliminary results have been obtained so far: i) strong and specific responses were elicited in dromedaries immunised against the toxic fractions of N. legionis, N. haje and N. oxiana; ii) phage display screenings were adopted to rescue strong Nb binders specific towards relevant N. l., N. h. and N. o. toxins; iii) several clusters of Nb sequences specifically binding cobra toxins have been identified.\nHerein, Nb selections and combinations for optimal synergic effects and best cross-species performances will be generated. Best-in-class candidates will be tested in a pre-clinical study in mice and sheep according to GMP rules. Cost effectiveness will be established.\n","awardDateDateOnly":"2020-10-06","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Antivenins","Mice","Recombinant Proteins","Sheep","Single-Chain Antibodies","Single-Domain Antibodies"]}
{"id":"360G-Wellcome-221712_Z_20_Z","title":"Discovery and early translation of small molecule toxin inhibitors for use as broadly effective, inexpensive, oral, prehospital snakebite treatments","Region":"North West","currency":"GBP","awardDate":"2020-10-06T00:00:00+00:00","Internal ID":"221712/Z/20/Z","description":"Small molecule toxin inhibitors offer great potential to rapidly deliver inexpensive, safe and efficacious oral interventions in the community soon after a snakebite, prior to subsequent admission to a healthcare facility. Despite such promise, only a handful of toxin inhibitors have been robustly explored to date. We redress this here by expanding the chemical space available for snakebite treatments by employing a comprehensive drug discovery approach. Using toxin-specific assays, we will screen diverse compound libraries ( > 50,000 molecules), including using the Human Pharmacopoeia and Phase-1 approved molecules in a repurposing approach, for hits that demonstrate broad toxin family neutralisation. Thereafter, we will rationally identify lead series by defining the toxin-specificity, kinetics, phenotypic potency and medicinal chemistry characteristics of hits, before performing murine preclinical efficacy and pharmacokinetic experiments to rationally define oral dosage regimens of lead candidates capable of achieving systemic inhibitory concentrations throughout a snakebite treatment period. Finally, we will evaluate therapeutic combinations of lead candidates by performing dose optimisation via PK/PD modelling, and preclinical efficacy and drug-drug interactions studies. This comprehensive drug discovery pipeline will deliver a portfolio of lead candidates (and numerous backups) ready for translation into clinical studies to assess their tolerability and efficacy as next-generation snakebite therapeutics.\n","plannedDates":[{"endDate":"2025-03-31T00:00:00+00:00","startDate":"2021-02-16T00:00:00+00:00","startDateDateOnly":"2021-02-16","endDateDateOnly":"2025-03-31"}],"amountAwarded":2621953,"Financial Year":"2020/21","Lead Applicant":"Dr Nicholas Casewell","grantProgramme":[{"title":"Snakebite Grant \u2013 Next Generation Treatments","title_keyword":"Snakebite Grant \u2013 Next Generation Treatments"}],"Applicant Surname":"Casewell","Partnership Value":2621953,"Approval Committee":"Snakebite Advisory Panel (one-off committee)","Other Applicant(s)":"Dr Jeroen Kool, Prof Stephen Ward, Prof Paul O'Neill, Prof Robert Harrison, Prof Neil Berry","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"Liverpool School of Tropical Medicine\", \"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Discovery and early translation of small molecule toxin inhibitors for use as broadly effective, inexpensive, oral, prehospital snakebite treatments Small molecule toxin inhibitors offer great potential to rapidly deliver inexpensive, safe and efficacious oral interventions in the community soon after a snakebite, prior to subsequent admission to a healthcare facility. Despite such promise, only a handful of toxin inhibitors have been robustly explored to date. We redress this here by expanding the chemical space available for snakebite treatments by employing a comprehensive drug discovery approach. Using toxin-specific assays, we will screen diverse compound libraries ( > 50,000 molecules), including using the Human Pharmacopoeia and Phase-1 approved molecules in a repurposing approach, for hits that demonstrate broad toxin family neutralisation. Thereafter, we will rationally identify lead series by defining the toxin-specificity, kinetics, phenotypic potency and medicinal chemistry characteristics of hits, before performing murine preclinical efficacy and pharmacokinetic experiments to rationally define oral dosage regimens of lead candidates capable of achieving systemic inhibitory concentrations throughout a snakebite treatment period. Finally, we will evaluate therapeutic combinations of lead candidates by performing dose optimisation via PK/PD modelling, and preclinical efficacy and drug-drug interactions studies. This comprehensive drug discovery pipeline will deliver a portfolio of lead candidates (and numerous backups) ready for translation into clinical studies to assess their tolerability and efficacy as next-generation snakebite therapeutics.\n","awardDateDateOnly":"2020-10-06","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Administration, Oral","Animals","Drug Discovery","Humans","Mice","Small Molecule Libraries"]}
{"id":"360G-Wellcome-221710_Z_20_Z","title":"Design, selection and validation of nicotinic acetylcholine receptor mimicking molecules as novel \u2018decoy receptor\u2019 therapies for treating snakebite","Region":"International","currency":"GBP","awardDate":"2020-10-06T00:00:00+00:00","Internal ID":"221710/Z/20/Z","description":"One of the most common lethal snakebite pathologies is neurotoxicity, which is the result of neurotoxins blocking nerve transmission, commonly via interaction with nicotinic acetylcholine receptors (nAChRs). Here we will use molecules that mimic the structural components of nAChRs that are important for toxin binding to generically inhibit the functional activity of venom neurotoxins. Our pilot data demonstrates that such \u2018decoy receptors\u2019 offer great potential to generically neutralise venom neurotoxins irrespective of snake species (unlike antivenom).\n\nWe will use structural and informatic guided approaches to rationally design a panel of acetylcholine receptor binding proteins, nAChR ligand binding domains, and peptide mimotopes, before measuring their binding affinity to venom neurotoxins. We will then identify the toxins they capture using analytical approaches, before demonstrating that they effectively prevent binding to nAChRs. Thereafter, we will use in vivo efficacy studies to robustly assess whether mixtures of lead decoy receptors protect mice from venom lethality, as either solo or adjunct therapies.\n\nWe anticipate that our inhibitory mixtures will exhibit superiority over antivenom by neutralising neurotoxins irrespective of the snake species and at lower therapeutic doses. This project therefore has the potential to generate a single, generic, eminently translatable therapy for treating neurotoxic snakebites worldwide.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":1194565,"Financial Year":"2020/21","Lead Applicant":"Prof Chris Ulens","grantProgramme":[{"title":"Snakebite Grant \u2013 Next Generation Treatments","title_keyword":"Snakebite Grant \u2013 Next Generation Treatments"}],"Applicant Surname":"Ulens","Partnership Value":1194565,"Approval Committee":"Snakebite Advisory Panel (one-off committee)","Other Applicant(s)":"Dr Jeroen Kool, Dr Nicholas Casewell","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Katholieke-Universiteit-Leuven","name":"Katholieke Universiteit Leuven","addressCountry":"Belgium","id_and_name":"[\"Katholieke Universiteit Leuven\", \"360G-Wellcome-ORG:Katholieke-Universiteit-Leuven\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Katholieke-Universiteit-Leuven","name":"Katholieke Universiteit Leuven"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Design, selection and validation of nicotinic acetylcholine receptor mimicking molecules as novel \u2018decoy receptor\u2019 therapies for treating snakebite One of the most common lethal snakebite pathologies is neurotoxicity, which is the result of neurotoxins blocking nerve transmission, commonly via interaction with nicotinic acetylcholine receptors (nAChRs). Here we will use molecules that mimic the structural components of nAChRs that are important for toxin binding to generically inhibit the functional activity of venom neurotoxins. Our pilot data demonstrates that such \u2018decoy receptors\u2019 offer great potential to generically neutralise venom neurotoxins irrespective of snake species (unlike antivenom).\n\nWe will use structural and informatic guided approaches to rationally design a panel of acetylcholine receptor binding proteins, nAChR ligand binding domains, and peptide mimotopes, before measuring their binding affinity to venom neurotoxins. We will then identify the toxins they capture using analytical approaches, before demonstrating that they effectively prevent binding to nAChRs. Thereafter, we will use in vivo efficacy studies to robustly assess whether mixtures of lead decoy receptors protect mice from venom lethality, as either solo or adjunct therapies.\n\nWe anticipate that our inhibitory mixtures will exhibit superiority over antivenom by neutralising neurotoxins irrespective of the snake species and at lower therapeutic doses. This project therefore has the potential to generate a single, generic, eminently translatable therapy for treating neurotoxic snakebites worldwide.\n","awardDateDateOnly":"2020-10-06","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Humans","Mice","Nicotinic Antagonists","Receptors, Nicotinic","Snake Bites"]}
{"id":"360G-Wellcome-221708_Z_20_Z","title":"Novel platforms to develop polyspecifically-effective, safe, affordable and thermostable monoclonal camelid VHH nanobodies to treat snake venom-induced necrosis in India and sub-Saharan Africa","Region":"North West","currency":"GBP","awardDate":"2020-10-06T00:00:00+00:00","Internal ID":"221708/Z/20/Z","description":"400,000 tropical snakebite victims require, every year, life-saving surgical debridement/amputation because there is no medicine to treat the disabling, income-depleting effects of snake venom-induced necrosis. A new therapy is urgently needed to prevent the severe health and socioeconomic consequences upon already-impoverished victims and health facilities.\n\nOur evidence-underpinned hypothesis is that rationally-selected recombinant, humanised camelid VHH targeting necrosis-inducing venom toxins (NITs) will possess the efficacy, rapid in-tissue distribution, safety, thermostability, affordability and large scale production characteristics appropriate for future development of a community-dispensed therapy \u2013 a paradigm shift in the clinical management of venom-induced necrosis to reduce morbidity. \n\nTo achieve this for Africa and India, our partners bring new approaches, platforms and all required resources to select candidate recombinant NIT-specific monoclonal VHH from (i) B cells of NIT-immunised camels and (ii) a synthetic VHH library - complementary approaches maximising likely success. \n\nDeploying sequential in vitro, ex vivo human skin and mouse in vivo assays of venom-induced necrosis enables down-selection of the most efficacious, thermostable recombinant VHH. \u2018Humanising\u2019 the latter donates the key safety criterion. E.coli expression enables inexpensive and large-scale production of humanised VHH. These therapy-characteristics and the vast panAfrica/India need, provide economy-of-scale production incentives for future manufacturing partners.    \n","plannedDates":[{"endDate":"2025-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2025-03-31"}],"amountAwarded":3032561,"Financial Year":"2020/21","Lead Applicant":"Prof Robert Harrison","grantProgramme":[{"title":"Snakebite Grant \u2013 Next Generation Treatments","title_keyword":"Snakebite Grant \u2013 Next Generation Treatments"}],"Applicant Surname":"Harrison","Partnership Value":3032561,"Approval Committee":"Snakebite Advisory Panel (one-off committee)","Other Applicant(s)":"Dr Devin Sok, Dr George Oluoch, Dr Kartik Sunagar, Dr Nicholas Casewell, Prof Christiane Berger-Schaffitzel, Prof Imre Berger","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"Liverpool School of Tropical Medicine\", \"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Novel platforms to develop polyspecifically-effective, safe, affordable and thermostable monoclonal camelid VHH nanobodies to treat snake venom-induced necrosis in India and sub-Saharan Africa 400,000 tropical snakebite victims require, every year, life-saving surgical debridement/amputation because there is no medicine to treat the disabling, income-depleting effects of snake venom-induced necrosis. A new therapy is urgently needed to prevent the severe health and socioeconomic consequences upon already-impoverished victims and health facilities.\n\nOur evidence-underpinned hypothesis is that rationally-selected recombinant, humanised camelid VHH targeting necrosis-inducing venom toxins (NITs) will possess the efficacy, rapid in-tissue distribution, safety, thermostability, affordability and large scale production characteristics appropriate for future development of a community-dispensed therapy \u2013 a paradigm shift in the clinical management of venom-induced necrosis to reduce morbidity. \n\nTo achieve this for Africa and India, our partners bring new approaches, platforms and all required resources to select candidate recombinant NIT-specific monoclonal VHH from (i) B cells of NIT-immunised camels and (ii) a synthetic VHH library - complementary approaches maximising likely success. \n\nDeploying sequential in vitro, ex vivo human skin and mouse in vivo assays of venom-induced necrosis enables down-selection of the most efficacious, thermostable recombinant VHH. \u2018Humanising\u2019 the latter donates the key safety criterion. E.coli expression enables inexpensive and large-scale production of humanised VHH. These therapy-characteristics and the vast panAfrica/India need, provide economy-of-scale production incentives for future manufacturing partners.    \n","awardDateDateOnly":"2020-10-06","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Antivenins","Humans","India","Mice","Recombinant Proteins","Single-Domain Antibodies"]}
{"id":"360G-Wellcome-221705_Z_20_Z","title":"Antibody Discovery and Development Against Non-Immunogenic Snake Venom Toxins ","Region":"International","currency":"GBP","awardDate":"2020-10-06T00:00:00+00:00","Internal ID":"221705/Z/20/Z","description":"This proposal aims to ultimately reduce global levels of morbidity and mortality from snakebite envenoming by discovering and developing antibodies that can neutralize the low molecular weight snake venom toxins \u2013 key contributors to the disease. These non-immunogenic toxins are poorly neutralized by currently available antivenoms produced by animal derived immunizations. This proposed project will discover neutralizing antibodies through immunization experiments using rationally designed immunogens and select for high-affinity antibodies via synthetic libraries using recombinant toxins.\n","plannedDates":[{"endDate":"2024-06-08T00:00:00+00:00","startDate":"2021-06-09T00:00:00+00:00","startDateDateOnly":"2021-06-09","endDateDateOnly":"2024-06-08"}],"amountAwarded":2734121,"Financial Year":"2020/21","Lead Applicant":"Dr Joseph Jardine","grantProgramme":[{"title":"Snakebite Grant \u2013 Next Generation Treatments","title_keyword":"Snakebite Grant \u2013 Next Generation Treatments"}],"Applicant Surname":"Jardine","Partnership Value":2734121,"Approval Committee":"Snakebite Advisory Panel (one-off committee)","Other Applicant(s)":"Dr Kartik Sunagar","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:International-AIDS-Vaccine-Initiative","name":"International AIDS Vaccine Initiative","addressCountry":"United States","id_and_name":"[\"International AIDS Vaccine Initiative\", \"360G-Wellcome-ORG:International-AIDS-Vaccine-Initiative\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:International-AIDS-Vaccine-Initiative","name":"International AIDS Vaccine Initiative"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Antibody Discovery and Development Against Non-Immunogenic Snake Venom Toxins  This proposal aims to ultimately reduce global levels of morbidity and mortality from snakebite envenoming by discovering and developing antibodies that can neutralize the low molecular weight snake venom toxins \u2013 key contributors to the disease. These non-immunogenic toxins are poorly neutralized by currently available antivenoms produced by animal derived immunizations. This proposed project will discover neutralizing antibodies through immunization experiments using rationally designed immunogens and select for high-affinity antibodies via synthetic libraries using recombinant toxins.\n","awardDateDateOnly":"2020-10-06","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Antibodies, Neutralizing","Antivenins","Neutralization Tests"]}
{"id":"360G-Wellcome-221703_Z_20_Z","title":"Black Health and the Humanities","Region":"South West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221703/Z/20/Z","description":"The project will establish an interdisciplinary network of researchers with the aim of investigating and bringing to light perspectives from the Black humanities on Black health and wellbeing. Led by the Centre for Black Humanities at the University of Bristol, the project will consist of a series of video conferenced online workshops, symposiums and events, which will: a) create a community of scholars whose research concerns how Black writers, intellectuals, artists, activists and theorists have creatively and critically addressed the psychological and physiological health of black people across the twentieth and twenty-first centuries; b) explore how research in Black humanities might intervene in the current racialized landscape of medicine and health; c) train and develop a new generation of ECR scholars in the theories and methods of Black studies and the medical humanities and in how they insect.\n \n","plannedDates":[{"endDate":"2022-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2022-09-30"}],"amountAwarded":191745,"Financial Year":"2019/20","Lead Applicant":"Dr Josie Gill","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Gill","Partnership Value":191745,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Black Health and the Humanities The project will establish an interdisciplinary network of researchers with the aim of investigating and bringing to light perspectives from the Black humanities on Black health and wellbeing. Led by the Centre for Black Humanities at the University of Bristol, the project will consist of a series of video conferenced online workshops, symposiums and events, which will: a) create a community of scholars whose research concerns how Black writers, intellectuals, artists, activists and theorists have creatively and critically addressed the psychological and physiological health of black people across the twentieth and twenty-first centuries; b) explore how research in Black humanities might intervene in the current racialized landscape of medicine and health; c) train and develop a new generation of ECR scholars in the theories and methods of Black studies and the medical humanities and in how they insect.\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["African Americans","Congresses as Topic","History, 20th Century","Humanities","Humans","Racism"]}
{"id":"360G-Wellcome-221702_Z_20_Z","title":"Recombinant snakebite antivenom for sub-Saharan Africa","Region":"International","currency":"GBP","awardDate":"2020-10-06T00:00:00+00:00","Internal ID":"221702/Z/20/Z","description":"Sub-Saharan Africa (sSA) is heavily burdened by snakebite envenoming. Existing antivenoms are scarce and many have suboptimal therapeutic properties. To improve snakebite envenoming therapy, the application of carefully designed mixtures of fully human monoclonal immunoglobulin G (IgG) antibodies for systemic and nanobodies for locally acting toxins poses as not only a therapeutically promising, but also scientifically feasible solution. Therefore, taking advantage of our well-established discovery pipelines and expertise in working with oligoclonal and broadly-neutralizing antibodies against toxins, we will develop a broad-spectrum (polyvalent) recombinant antivenom for sSA. The project will focus on the following technical goals that we believe have a potential to deliver measurable societal and humanitarian health impact: 1) The identification and isolation of all medically relevant snake venom toxins that need to be neutralized by a recombinant antivenom for sSA and 2) the discovery of a well-characterized panel of broadly-neutralizing IgGs and nanobodies that can neutralize all medically relevant systemically-acting and deep tissue penetrating toxins found in the 24 medically most relevant snake species from this region. Combined, these efforts will create a substantial shift in snakebite envenoming therapy and will enable the clinical development of improved, low-cost, and quality-assured snakebite therapeutics for victims in sSA.\n","plannedDates":[{"endDate":"2026-02-28T00:00:00+00:00","startDate":"2021-03-01T00:00:00+00:00","startDateDateOnly":"2021-03-01","endDateDateOnly":"2026-02-28"}],"amountAwarded":3081450,"Financial Year":"2020/21","Lead Applicant":"Dr Andreas Laustsen","grantProgramme":[{"title":"Snakebite Grant \u2013 Next Generation Treatments","title_keyword":"Snakebite Grant \u2013 Next Generation Treatments"}],"Applicant Surname":"Laustsen","Partnership Value":3081450,"Approval Committee":"Snakebite Advisory Panel (one-off committee)","Other Applicant(s)":"Dr John McCafferty","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Technical-University-of-Denmark","name":"Technical University of Denmark","addressCountry":"Denmark","id_and_name":"[\"Technical University of Denmark\", \"360G-Wellcome-ORG:Technical-University-of-Denmark\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Technical-University-of-Denmark","name":"Technical University of Denmark"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Recombinant snakebite antivenom for sub-Saharan Africa Sub-Saharan Africa (sSA) is heavily burdened by snakebite envenoming. Existing antivenoms are scarce and many have suboptimal therapeutic properties. To improve snakebite envenoming therapy, the application of carefully designed mixtures of fully human monoclonal immunoglobulin G (IgG) antibodies for systemic and nanobodies for locally acting toxins poses as not only a therapeutically promising, but also scientifically feasible solution. Therefore, taking advantage of our well-established discovery pipelines and expertise in working with oligoclonal and broadly-neutralizing antibodies against toxins, we will develop a broad-spectrum (polyvalent) recombinant antivenom for sSA. The project will focus on the following technical goals that we believe have a potential to deliver measurable societal and humanitarian health impact: 1) The identification and isolation of all medically relevant snake venom toxins that need to be neutralized by a recombinant antivenom for sSA and 2) the discovery of a well-characterized panel of broadly-neutralizing IgGs and nanobodies that can neutralize all medically relevant systemically-acting and deep tissue penetrating toxins found in the 24 medically most relevant snake species from this region. Combined, these efforts will create a substantial shift in snakebite envenoming therapy and will enable the clinical development of improved, low-cost, and quality-assured snakebite therapeutics for victims in sSA.\n","awardDateDateOnly":"2020-10-06","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa South of the Sahara","Animals","Antibodies, Monoclonal","Antibodies, Neutralizing","Antivenins","Humans","Neutralization Tests","Snake Bites"]}
{"id":"360G-Wellcome-221699_Z_20_Z","title":"Neutrophils re-entering the circulation from a primary site of inflammation:  Physiological or pathological?","Region":"Greater London","currency":"GBP","awardDate":"2020-12-01T00:00:00+00:00","Internal ID":"221699/Z/20/Z","description":"Neutrophils contribute to the killing and clearance of pathogens as well as initiate inflammation resolution and tissue repair processes. Furthermore, the established phenotypic and functional diversity of neutrophils have markedly extended the physiological and pathological roles of these myeloid cells. Building on the developing concept of neutrophil heterogeneity in disease settings, and significant mechanistic and pathophysiological data from the applicant, the present project aims to acquire an in-depth understanding of one population of disease-inducing neutrophils, namely neutrophils that have exhibited reverse transendothelial cells migration (rTEM). This phenomenon describes cells that initiate diapedesis, engage with endothelial cell (EC) junctions but then exhibit retrograde motility and re-enter the vascular lumen. Crucially, we have ample evidence that rTEM bestows an activation state on neutrophils in vivo, and that rTEM neutrophils are aligned with remote organ damage. Thus, exploiting recent technological advancements and capabilities, the current proposal aims to gain an in-depth understanding of the prevalence, molecular signature and pathogenic role of this \"subset\" of neutrophils, most notably in ageing. Furthermore, hypothesizing that the activation state of rTEM neutrophils maybe beneficial for the host, the project will for the first time explore the potential protective, and thus physiological, role of rTEM neutrophils against pathogens.\n","plannedDates":[{"endDate":"2027-01-09T00:00:00+00:00","startDate":"2022-01-10T00:00:00+00:00","startDateDateOnly":"2022-01-10","endDateDateOnly":"2027-01-09"}],"amountAwarded":1964639,"Financial Year":"2020/21","Lead Applicant":"Prof Sussan Nourshargh","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Nourshargh","Partnership Value":1964639,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Queen-Mary-University-of-London","name":"Queen Mary University of London","addressCountry":"United Kingdom","id_and_name":"[\"Queen Mary University of London\", \"360G-Wellcome-ORG:Queen-Mary-University-of-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Queen-Mary-University-of-London","name":"Queen Mary University of London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Neutrophils re-entering the circulation from a primary site of inflammation:  Physiological or pathological? Neutrophils contribute to the killing and clearance of pathogens as well as initiate inflammation resolution and tissue repair processes. Furthermore, the established phenotypic and functional diversity of neutrophils have markedly extended the physiological and pathological roles of these myeloid cells. Building on the developing concept of neutrophil heterogeneity in disease settings, and significant mechanistic and pathophysiological data from the applicant, the present project aims to acquire an in-depth understanding of one population of disease-inducing neutrophils, namely neutrophils that have exhibited reverse transendothelial cells migration (rTEM). This phenomenon describes cells that initiate diapedesis, engage with endothelial cell (EC) junctions but then exhibit retrograde motility and re-enter the vascular lumen. Crucially, we have ample evidence that rTEM bestows an activation state on neutrophils in vivo, and that rTEM neutrophils are aligned with remote organ damage. Thus, exploiting recent technological advancements and capabilities, the current proposal aims to gain an in-depth understanding of the prevalence, molecular signature and pathogenic role of this \"subset\" of neutrophils, most notably in ageing. Furthermore, hypothesizing that the activation state of rTEM neutrophils maybe beneficial for the host, the project will for the first time explore the potential protective, and thus physiological, role of rTEM neutrophils against pathogens.\n","awardDateDateOnly":"2020-12-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cell Movement","Endothelial Cells","Humans","Mice","Neutrophils","Transendothelial and Transepithelial Migration"]}
{"id":"360G-Wellcome-221698_Z_20_Z","title":"M72 Phase 2 Trial: Safety & Immunogenicity in People Living with HIV","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221698/Z/20/Z","description":"The aim of this proposal is to obtain co-funding from the Wellcome Trust for a Phase 2 safety and immunogenicity trial of the M72/AS01E investigational vaccine. This Phase 2 trial in people living with HIV (PLHIV) is conducted to support inclusion of PLHIV in a following pivotal Phase 3 VE trial and to thus enable public health use of the vaccine in PLHIV should the Phase 2 and Phase 3 data support its use. PLHIV are at high risk for TB disease and deaths, and an estimated 251,000 of 1,450,000 deaths from tuberculosis in 2018 occurred in PLHIV.\n\nThe key deliverables of the full program (Phase 2 and 3) are:\n\n\n Advance technical and clinical development of the M72/AS01E candidate vaccine from Phase 2b through Phase 3 (including Mtb uninfected and HIV-positive populations) and prepare for licensure\n Identify a marketing authorization holder willing and capable to file the licensure application(s) and manufacture global product supply and to ensure global access to the vaccine\n Aim for initial registration in South Africa to enable Phase 4 impact studies (outside the scope of this proposal) that generate robust effectiveness data for the prevention of TB in children and adults\n\n","plannedDates":[{"endDate":"2022-11-15T00:00:00+00:00","startDate":"2020-11-16T00:00:00+00:00","startDateDateOnly":"2020-11-16","endDateDateOnly":"2022-11-15"}],"amountAwarded":2352590,"Financial Year":"2019/20","Lead Applicant":"Dr Alexander Schmidt","grantProgramme":[{"title":"Discretionary Award \u2013 Directorate","title_keyword":"Discretionary Award \u2013 Directorate"}],"Applicant Surname":"Schmidt","Partnership Value":2352590,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Gates-Medical-Research-Institute","name":"Gates Medical Research Institute","addressCountry":"United States","id_and_name":"[\"Gates Medical Research Institute\", \"360G-Wellcome-ORG:Gates-Medical-Research-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Gates-Medical-Research-Institute","name":"Gates Medical Research Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"M72 Phase 2 Trial: Safety & Immunogenicity in People Living with HIV The aim of this proposal is to obtain co-funding from the Wellcome Trust for a Phase 2 safety and immunogenicity trial of the M72/AS01E investigational vaccine. This Phase 2 trial in people living with HIV (PLHIV) is conducted to support inclusion of PLHIV in a following pivotal Phase 3 VE trial and to thus enable public health use of the vaccine in PLHIV should the Phase 2 and Phase 3 data support its use. PLHIV are at high risk for TB disease and deaths, and an estimated 251,000 of 1,450,000 deaths from tuberculosis in 2018 occurred in PLHIV.\n\nThe key deliverables of the full program (Phase 2 and 3) are:\n\n\n Advance technical and clinical development of the M72/AS01E candidate vaccine from Phase 2b through Phase 3 (including Mtb uninfected and HIV-positive populations) and prepare for licensure\n Identify a marketing authorization holder willing and capable to file the licensure application(s) and manufacture global product supply and to ensure global access to the vaccine\n Aim for initial registration in South Africa to enable Phase 4 impact studies (outside the scope of this proposal) that generate robust effectiveness data for the prevention of TB in children and adults\n\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["AIDS Vaccines","Child","Clinical Trials as Topic","HIV Infections","Humans","South Africa","Tuberculosis","Tuberculosis Vaccines"]}
{"id":"360G-Wellcome-221690_Z_20_Z","title":"Myocardial energy starvation and ketone metabolism in patients with type 2 diabetes","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2020-12-08T00:00:00+00:00","Sponsor(s)":"Prof David Beech, Prof Sven Plein","Internal ID":"221690/Z/20/Z","description":"Patients with type 2 diabetes(T2D) are \u2018cardiac energy-deficient\u2019 and this deficiency contributes to their excess heart failure(HF) risk. The key mechanisms for cardiac energy deficiency are reduced myocardial blood flow, loss of metabolic flexibility over the choice of energy fuels and mitochondrial dysfunction. The contribution of these changes to the development of HF has not been systematically studied.Recent studies have highlighted the potential role of ketone bodies as a significant fuel source, and suggested an association between mild ketosis and improved clinical outcome in T2D.\n\nTwo work packages will be performed. Work-package1 aims to: \n\n\n Elucidate the mechanisms of the energy-starved state of the heart in diabetes; \n Determine how alterations of cardiac energy metabolism differ between prediabetes, T2D, and concomitant T2D and HF;\n Determine if ketones induce a differential response in mitochondrial respiration and whether this differential response varies along the continuum of diabetic heart disease.\n\n\nData will be acquired from patients undergoing aortic valve surgery for comprehensive assessments including: cardiovascular magnetic resonance imaging and spectroscopy; coronary sinus sampling studies; high resolution respirometry and liquid chromatography-triple quadrupole-mass spectrometry metabolomics from heart samples. \n\nWork-package 2 will explore the impact of ketone infusion on cardiac energy generation and contractile function in T2D patients.\n \n","plannedDates":[{"endDate":"2025-02-28T00:00:00+00:00","startDate":"2021-03-01T00:00:00+00:00","startDateDateOnly":"2021-03-01","endDateDateOnly":"2025-02-28"}],"amountAwarded":807333,"Financial Year":"2020/21","Lead Applicant":"Dr Eylem Levelt","grantProgramme":[{"title":"Clinical Research Career Development Fellowship","title_keyword":"Clinical Research Career Development Fellowship"}],"Applicant Surname":"Levelt","Partnership Value":807333,"Approval Committee":"Clinical Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds","addressCountry":"United Kingdom","id_and_name":"[\"University of Leeds\", \"360G-Wellcome-ORG:University-of-Leeds\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Myocardial energy starvation and ketone metabolism in patients with type 2 diabetes Patients with type 2 diabetes(T2D) are \u2018cardiac energy-deficient\u2019 and this deficiency contributes to their excess heart failure(HF) risk. The key mechanisms for cardiac energy deficiency are reduced myocardial blood flow, loss of metabolic flexibility over the choice of energy fuels and mitochondrial dysfunction. The contribution of these changes to the development of HF has not been systematically studied.Recent studies have highlighted the potential role of ketone bodies as a significant fuel source, and suggested an association between mild ketosis and improved clinical outcome in T2D.\n\nTwo work packages will be performed. Work-package1 aims to: \n\n\n Elucidate the mechanisms of the energy-starved state of the heart in diabetes; \n Determine how alterations of cardiac energy metabolism differ between prediabetes, T2D, and concomitant T2D and HF;\n Determine if ketones induce a differential response in mitochondrial respiration and whether this differential response varies along the continuum of diabetic heart disease.\n\n\nData will be acquired from patients undergoing aortic valve surgery for comprehensive assessments including: cardiovascular magnetic resonance imaging and spectroscopy; coronary sinus sampling studies; high resolution respirometry and liquid chromatography-triple quadrupole-mass spectrometry metabolomics from heart samples. \n\nWork-package 2 will explore the impact of ketone infusion on cardiac energy generation and contractile function in T2D patients.\n \n","awardDateDateOnly":"2020-12-08","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Diabetes Mellitus, Type 2","Energy Metabolism","Heart","Heart Failure","Humans","Ketone Bodies","Ketones","Prediabetic State"]}
{"id":"360G-Wellcome-221688_Z_20_Z","title":"The Impact of Mass Oral Cholera Vaccination in Uvira, South Kivu, Democratic Republic of the Congo","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221688/Z/20/Z","description":"In this study co-funded by Wellcome and Gavi, the aim is to study the impact of mass\ncholera vaccination in Uvira, DR Congo through a multifaceted approach aimed at estimating\nchanges in clinical disease incidence, infection rates, and the type and frequency of\noccurrence of toxigenic V. cholerae in the environment. Successful completion of this project\nwill provide critical insights into the impact that mass OCV campaigns can have on human\nhealth while at the same time providing a new understanding of the epidemiology of cholera\nin this hyper-endemic setting. Our specific objectives are:\nObjective 1: To enhance the cholera surveillance system in Uvira, South Kivu, DR Congo in\norder to estimate the impact of mass vaccination on lab-confirmed cholera incidence and\nmortality.\nObjective 2: To conduct serial cross-sectional serosurveys after vaccination to estimate the\nseroincidence of V. cholerae infection in Uvira over time and contextualize the primary\nresults based on clinical cholera cases.\nObjective 3: To use phenotypic and molecular methods to describe the changes in the V.\ncholerae population after vaccination in both human and environmental samples in Uvira.\nObjective 4: To use phenotypic and molecular methods to describe the changes in the V.\ncholerae population after vaccination in both human and environmental samples in Uvira.","plannedDates":[{"endDate":"2026-06-30T00:00:00+00:00","startDate":"2020-06-22T00:00:00+00:00","startDateDateOnly":"2020-06-22","endDateDateOnly":"2026-06-30"}],"amountAwarded":1521343,"Financial Year":"2019/20","Lead Applicant":"Dr Andrew Azman","grantProgramme":[{"title":"Innovations AIGH Enterics Flagship ","title_keyword":"Innovations AIGH Enterics Flagship "}],"Partnership Name":"Wellcome/GAVI Innovations Enterics Flagship","Applicant Surname":"Azman","Partnership Value":1521344,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Johns-Hopkins-University","name":"Johns Hopkins University","addressCountry":"United States","id_and_name":"[\"Johns Hopkins University\", \"360G-Wellcome-ORG:Johns-Hopkins-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Johns-Hopkins-University","name":"Johns Hopkins University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The Impact of Mass Oral Cholera Vaccination in Uvira, South Kivu, Democratic Republic of the Congo In this study co-funded by Wellcome and Gavi, the aim is to study the impact of mass\ncholera vaccination in Uvira, DR Congo through a multifaceted approach aimed at estimating\nchanges in clinical disease incidence, infection rates, and the type and frequency of\noccurrence of toxigenic V. cholerae in the environment. Successful completion of this project\nwill provide critical insights into the impact that mass OCV campaigns can have on human\nhealth while at the same time providing a new understanding of the epidemiology of cholera\nin this hyper-endemic setting. Our specific objectives are:\nObjective 1: To enhance the cholera surveillance system in Uvira, South Kivu, DR Congo in\norder to estimate the impact of mass vaccination on lab-confirmed cholera incidence and\nmortality.\nObjective 2: To conduct serial cross-sectional serosurveys after vaccination to estimate the\nseroincidence of V. cholerae infection in Uvira over time and contextualize the primary\nresults based on clinical cholera cases.\nObjective 3: To use phenotypic and molecular methods to describe the changes in the V.\ncholerae population after vaccination in both human and environmental samples in Uvira.\nObjective 4: To use phenotypic and molecular methods to describe the changes in the V.\ncholerae population after vaccination in both human and environmental samples in Uvira.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Child","Child, Preschool","Cholera","Cross-Sectional Studies","Democratic Republic of the Congo","Humans","Incidence","Seroepidemiologic Studies","Serogroup","Vaccination"]}
{"id":"360G-Wellcome-221685_Z_20_Z","title":"Health communication research","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221685/Z/20/Z","description":"Air pollution is a global health emergency. Outdoor air pollution causes 4.2 million premature deaths every year and 90% of these deaths happen in low- and middle-income countries. Additionally, air pollution has significant overlaps with climate change, both being caused in large part by the combustion of fossil fuels. While the link between air pollution and climate change isn\u2019t always straightforward, smart solutions can ensure a win-win.\n\nA survey commissioned by the Clean Air Fund (CAF) found that health professionals are the most trusted spokespeople on air pollution in all countries.[1] Consequently, there is an important opportunity to encourage real change if the health sector could be engaged as spokespeople to reduce air pollution, which has been further strengthened by COVID-19.\n\nIn this application we propose research on communications strategies that spur action on air pollution by healthcare practitioners. CAF is already funding such work in UK, India and at a global level. Additional support would add Bangladesh, Mexico and Ethiopia. Outputs include strategic recommendations for communicating on air pollution in the respective countries, as well as a database with existing campaigns and their effectiveness.\n\n \n\n[1] Research carried out in May 2020 in the UK, India, Poland, Bulgaria and Nigeria.\n","plannedDates":[{"endDate":"2020-12-21T00:00:00+00:00","startDate":"2020-07-22T00:00:00+00:00","startDateDateOnly":"2020-07-22","endDateDateOnly":"2020-12-21"}],"amountAwarded":232758,"Financial Year":"2019/20","Lead Applicant":"Ms Saskia Heijnen","grantProgramme":[{"title":"Discretionary Award - OPOH","title_keyword":"Discretionary Award - OPOH"}],"Applicant Surname":"Heijnen","Partnership Value":232758,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Clean-Air-Fund","name":"Clean Air Fund","addressCountry":"United Kingdom","id_and_name":"[\"Clean Air Fund\", \"360G-Wellcome-ORG:Clean-Air-Fund\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Clean-Air-Fund","name":"Clean Air Fund"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Health communication research Air pollution is a global health emergency. Outdoor air pollution causes 4.2 million premature deaths every year and 90% of these deaths happen in low- and middle-income countries. Additionally, air pollution has significant overlaps with climate change, both being caused in large part by the combustion of fossil fuels. While the link between air pollution and climate change isn\u2019t always straightforward, smart solutions can ensure a win-win.\n\nA survey commissioned by the Clean Air Fund (CAF) found that health professionals are the most trusted spokespeople on air pollution in all countries.[1] Consequently, there is an important opportunity to encourage real change if the health sector could be engaged as spokespeople to reduce air pollution, which has been further strengthened by COVID-19.\n\nIn this application we propose research on communications strategies that spur action on air pollution by healthcare practitioners. CAF is already funding such work in UK, India and at a global level. Additional support would add Bangladesh, Mexico and Ethiopia. Outputs include strategic recommendations for communicating on air pollution in the respective countries, as well as a database with existing campaigns and their effectiveness.\n\n \n\n[1] Research carried out in May 2020 in the UK, India, Poland, Bulgaria and Nigeria.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Air Pollution","Bangladesh","Climate Change","Developing Countries","Ethiopia","Global Health","Health Personnel","Humans","India","Mexico","Nigeria","Poland","United Kingdom"]}
{"id":"360G-Wellcome-221683_Z_20_Z","title":"Designing a Preparedness Model for the Future of Open Scholarship","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221683/Z/20/Z","description":"Over the next 12-18 months, leading structures relied on to conduct, publish and disseminate scholarly research are at risk of collapse. \n\nOne leading use case to illustrate the current reality as it unfolds, and how it will affect scholarly research communications is the impact on university and scholar led presses, and the risks that presents to the creation of scholarly monographs.  \n\nUniversity presses are collectively facing unprecedented deficits and sales shortfalls for print books this year. Budget constraints at the library level may well directly affect the sale of scholarly monographs as well as subsidies and subventions.\n\nTo address this potential threat to scholarship, we are launching a cross-institutional research effort to address pending infrastructure consolidation and collapse across the ecosystem, identifying the opportunities, leverage points, costs and approaches that could be employed. \n\nThe project sets out to deliver the following: \n\n\n \n Cost-benefit analyses to enable faster, more informed decision making in support of open scholarship;\n \n \n Criteria for assessing solutions in service of the academy;\n \n \n Actionable recommendations and guidance for budget owners;\n \n \n Actionable recommendations and models for projects to operate sustainably;\n \n \n Scenario planning for 6, 12, and 18+ months outlooks;\n \n \n A collective model for stewardship, cost-sharing, and risk pooling.\n \n\n","plannedDates":[{"endDate":"2021-06-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-06-30"}],"amountAwarded":30476,"Financial Year":"2019/20","Lead Applicant":"Ms Kaitlin Thaney","grantProgramme":[{"title":"Discretionary Award - Open research","title_keyword":"Discretionary Award - Open research"}],"Applicant Surname":"Thaney","Partnership Value":30476,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Code-for-Science-and-Society","name":"Code for Science and Society","addressCountry":"United States","id_and_name":"[\"Code for Science and Society\", \"360G-Wellcome-ORG:Code-for-Science-and-Society\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Code-for-Science-and-Society","name":"Code for Science and Society"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Designing a Preparedness Model for the Future of Open Scholarship Over the next 12-18 months, leading structures relied on to conduct, publish and disseminate scholarly research are at risk of collapse. \n\nOne leading use case to illustrate the current reality as it unfolds, and how it will affect scholarly research communications is the impact on university and scholar led presses, and the risks that presents to the creation of scholarly monographs.  \n\nUniversity presses are collectively facing unprecedented deficits and sales shortfalls for print books this year. Budget constraints at the library level may well directly affect the sale of scholarly monographs as well as subsidies and subventions.\n\nTo address this potential threat to scholarship, we are launching a cross-institutional research effort to address pending infrastructure consolidation and collapse across the ecosystem, identifying the opportunities, leverage points, costs and approaches that could be employed. \n\nThe project sets out to deliver the following: \n\n\n \n Cost-benefit analyses to enable faster, more informed decision making in support of open scholarship;\n \n \n Criteria for assessing solutions in service of the academy;\n \n \n Actionable recommendations and guidance for budget owners;\n \n \n Actionable recommendations and models for projects to operate sustainably;\n \n \n Scenario planning for 6, 12, and 18+ months outlooks;\n \n \n A collective model for stewardship, cost-sharing, and risk pooling.\n \n\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Budgets","Cost-Benefit Analysis","Research Support as Topic","Universities"]}
{"id":"360G-Wellcome-221681_Z_20_Z","title":"Elucidating the structure and function of the divergent and essential cytochrome bc1 complex in apicomplexan parasites","Region":"Scotland","currency":"GBP","awardDate":"2020-11-11T00:00:00+00:00","Sponsor(s)":"Dr Alexey Amunts, Dr Lilach Sheiner","Internal ID":"221681/Z/20/Z","description":"Apicomplexan parasites, which include Toxoplasma and Plasmodium, cause deadly human diseases, such as toxoplasmosis and malaria. Understanding their divergent cell biology could inform strategies to combat them. The apicomplexan mitochondrial electron transport chain (mETC) is essential for their survival and transmission, and highly divergent from the human mETC. Cytochrome bc1 is an mETC protein-complex that is essential, and a key target for drugs, like atovaquone. Yet its composition is unknown, and the mechanism of function and inhibition poorly understood. I propose to investigate how the cytochrome bc1 complex functions and interacts with inhibitors.\n\nUsing Toxoplasma as a model, I will uncover the role of my newly discovered apicomplexan cytochrome bc1 subunits, and decipher the role of respiratory super-complex formation, in parasite energy metabolism and survival. Using cryo-EM technology I will solve this complex\u2019s structure to elucidate its mechanism of action, highlighting key differences with the human complex, and understand the way inhibitors disrupt the electron flow essential for energy conversion.\n\nThese studies will provide a mechanistic understanding of the essential apicomplexan cytochrome bc1 complex and how inhibitors stop its function. This work will fill a critical gap in our knowledge of fundamental parasite cell biology, and likely inform drug discovery.\n","plannedDates":[{"endDate":"2024-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2024-12-31"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Andrew Maclean","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Maclean","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow","addressCountry":"United Kingdom","id_and_name":"[\"University of Glasgow\", \"360G-Wellcome-ORG:University-of-Glasgow\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Elucidating the structure and function of the divergent and essential cytochrome bc1 complex in apicomplexan parasites Apicomplexan parasites, which include Toxoplasma and Plasmodium, cause deadly human diseases, such as toxoplasmosis and malaria. Understanding their divergent cell biology could inform strategies to combat them. The apicomplexan mitochondrial electron transport chain (mETC) is essential for their survival and transmission, and highly divergent from the human mETC. Cytochrome bc1 is an mETC protein-complex that is essential, and a key target for drugs, like atovaquone. Yet its composition is unknown, and the mechanism of function and inhibition poorly understood. I propose to investigate how the cytochrome bc1 complex functions and interacts with inhibitors.\n\nUsing Toxoplasma as a model, I will uncover the role of my newly discovered apicomplexan cytochrome bc1 subunits, and decipher the role of respiratory super-complex formation, in parasite energy metabolism and survival. Using cryo-EM technology I will solve this complex\u2019s structure to elucidate its mechanism of action, highlighting key differences with the human complex, and understand the way inhibitors disrupt the electron flow essential for energy conversion.\n\nThese studies will provide a mechanistic understanding of the essential apicomplexan cytochrome bc1 complex and how inhibitors stop its function. This work will fill a critical gap in our knowledge of fundamental parasite cell biology, and likely inform drug discovery.\n","awardDateDateOnly":"2020-11-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cryoelectron Microscopy","Cytochromes b","Humans","Mitochondria","Protozoan Proteins"]}
{"id":"360G-Wellcome-221680_Z_20_Z","title":"Genomic epidemiology of acute respiratory distress syndrome and fibrosis in patients with COVID-19","Region":"East Midlands","currency":"GBP","awardDate":"2020-11-11T00:00:00+00:00","Sponsor(s)":"Prof Louise Wain, Prof Martin Tobin","Internal ID":"221680/Z/20/Z","description":"COVID-19 is an infectious respiratory disease with a global devastating health impact. Genetic and environmental factors influence COVID-19 susceptibility and outcomes, including the development of acute respiratory distress syndrome (ARDS) and pulmonary fibrosis. These lung pathologies have a high mortality and there are no specific treatment options or effective prognostic methods for patients. Therefore, there is an urgent need to identify effective biomarkers of disease prognosis. The aim of this research is to perform a genomic epidemiology study of ARDS and pulmonary fibrosis in patients with COVID-19. For that purpose, we will perform genetic overlap studies that will include genetic correlation analyses, polygenic risk score approaches, and assessments of overlap of individual genetic variants, followed by fine mapping studies, bioinformatic approaches to identify the likely causal genes, and further experiments to evaluate their role in disease and their potential as drug targets. Results of these analyses will allow us to identify novel genetic risk factors and to develop risk prediction models, which could enhance COVID-19 patient stratification for those at increased risk of lung sequela. Furthermore, the project will reveal novel therapeutic strategies, which would translate into improved and more personalised clinical care for patients at risk of lung fibrosis.\n","plannedDates":[{"endDate":"2025-04-06T00:00:00+00:00","startDate":"2021-04-07T00:00:00+00:00","startDateDateOnly":"2021-04-07","endDateDateOnly":"2025-04-06"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Beatriz Guill\u00e9n Gu\u00edo","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Guill\u00e9n Gu\u00edo","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leicester","name":"University of Leicester","addressCountry":"United Kingdom","id_and_name":"[\"University of Leicester\", \"360G-Wellcome-ORG:University-of-Leicester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leicester","name":"University of Leicester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Genomic epidemiology of acute respiratory distress syndrome and fibrosis in patients with COVID-19 COVID-19 is an infectious respiratory disease with a global devastating health impact. Genetic and environmental factors influence COVID-19 susceptibility and outcomes, including the development of acute respiratory distress syndrome (ARDS) and pulmonary fibrosis. These lung pathologies have a high mortality and there are no specific treatment options or effective prognostic methods for patients. Therefore, there is an urgent need to identify effective biomarkers of disease prognosis. The aim of this research is to perform a genomic epidemiology study of ARDS and pulmonary fibrosis in patients with COVID-19. For that purpose, we will perform genetic overlap studies that will include genetic correlation analyses, polygenic risk score approaches, and assessments of overlap of individual genetic variants, followed by fine mapping studies, bioinformatic approaches to identify the likely causal genes, and further experiments to evaluate their role in disease and their potential as drug targets. Results of these analyses will allow us to identify novel genetic risk factors and to develop risk prediction models, which could enhance COVID-19 patient stratification for those at increased risk of lung sequela. Furthermore, the project will reveal novel therapeutic strategies, which would translate into improved and more personalised clinical care for patients at risk of lung fibrosis.\n","awardDateDateOnly":"2020-11-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Genetic Predisposition to Disease","Humans","Prognosis","Respiratory Distress Syndrome","Risk Factors"]}
{"id":"360G-Wellcome-221678_Z_20_Z","title":"Extracellular polycation signalling in alveolar and systemic inflammation","Region":"North East","currency":"GBP","awardDate":"2020-11-11T00:00:00+00:00","Sponsor(s)":"Prof John Simpson","Internal ID":"221678/Z/20/Z","description":"Critically ill patients with pneumonia often have impaired neutrophil function and disruption of alveolar-capillary barrier integrity. During inflammation, excessive polycation generation activates the calcium-sensing receptor (CaSR), which can potentially compromise neutrophil function and barrier integrity. My over-arching hypothesis is that, during critical illness, CaSR, activated by polycations, mediates impairment of neutrophil, alveolar epithelial and pulmonary endothelial function, leading to reduced bacterial clearance and disruption of alveolar-capillary barrier.\n\nTo test the hypothesis, I shall use a range of complementary methods to (a) assess the effect of positive and negative allosteric CaSR modulators and polycations on a range of functions in neutrophils and monocytes from critically ill patients at high risk of developing nosocomial infection; (b) isolate human primary alveolar epithelial cells and culture primary human pulmonary microvascular endothelial cells, and assess the effect of CaSR modulators on barrier function, inflammatory signatures, and antimicrobial functions; (c) perform the first temporal assessment of CaSR expression (and effect of CaSR inhibition) in extravasated neutrophils and alveolar macrophages from human healthy volunteers receiving inhaled lipopolysaccharide (LPS) or control; and (d) create neutrophil-specific CaSR knockout mice, assessing the influence of neutrophil CaSR on the natural history of acute pulmonary infection, inflammation, and alveolar-capillary barrier disruption.\n","plannedDates":[{"endDate":"2025-03-17T00:00:00+00:00","startDate":"2021-02-01T00:00:00+00:00","startDateDateOnly":"2021-02-01","endDateDateOnly":"2025-03-17"}],"amountAwarded":458214,"Financial Year":"2020/21","Lead Applicant":"Dr Polina Yarova","grantProgramme":[{"title":"Career Re-Entry Fellowship","title_keyword":"Career Re-Entry Fellowship"}],"Applicant Surname":"Yarova","Partnership Value":458214,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Newcastle-University","name":"Newcastle University","addressCountry":"United Kingdom","id_and_name":"[\"Newcastle University\", \"360G-Wellcome-ORG:Newcastle-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Newcastle-University","name":"Newcastle University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Extracellular polycation signalling in alveolar and systemic inflammation Critically ill patients with pneumonia often have impaired neutrophil function and disruption of alveolar-capillary barrier integrity. During inflammation, excessive polycation generation activates the calcium-sensing receptor (CaSR), which can potentially compromise neutrophil function and barrier integrity. My over-arching hypothesis is that, during critical illness, CaSR, activated by polycations, mediates impairment of neutrophil, alveolar epithelial and pulmonary endothelial function, leading to reduced bacterial clearance and disruption of alveolar-capillary barrier.\n\nTo test the hypothesis, I shall use a range of complementary methods to (a) assess the effect of positive and negative allosteric CaSR modulators and polycations on a range of functions in neutrophils and monocytes from critically ill patients at high risk of developing nosocomial infection; (b) isolate human primary alveolar epithelial cells and culture primary human pulmonary microvascular endothelial cells, and assess the effect of CaSR modulators on barrier function, inflammatory signatures, and antimicrobial functions; (c) perform the first temporal assessment of CaSR expression (and effect of CaSR inhibition) in extravasated neutrophils and alveolar macrophages from human healthy volunteers receiving inhaled lipopolysaccharide (LPS) or control; and (d) create neutrophil-specific CaSR knockout mice, assessing the influence of neutrophil CaSR on the natural history of acute pulmonary infection, inflammation, and alveolar-capillary barrier disruption.\n","awardDateDateOnly":"2020-11-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Endothelial Cells","Humans","Lipopolysaccharides","Macrophages, Alveolar","Mice","Mice, Knockout","Neutrophils","Receptors, Calcium-Sensing"]}
{"id":"360G-Wellcome-221674_Z_20_Z","title":"Mapping sensory-motor cerebellar circuits for adaptive behaviour","Region":"Greater London","currency":"GBP","awardDate":"2020-11-11T00:00:00+00:00","Sponsor(s)":"Prof Liqun Luo, Prof Michael Hausser","Internal ID":"221674/Z/20/Z","description":"The cerebellar cortex is thought to form predictive associations between sensory inputs and motor commands: animals leverage these associations to coordinate and adapt movements to contextual changes in the environment. This sensory-motor control depends on Purkinje neurons, each of which receives sensory, motor and cognitive signals from one climbing fibre as well as thousands of parallel fibres, the axons of granule cells. Despite years of anatomical work, cerebellar sensory-motor representations have not been mapped at the cellular scale; similarly, the functional circuit connectivity underlying sensory-motor integration remains unexplored.\n\nTo reveal the functional architecture of the mouse cerebellar cortex, I propose to use rabies monosynaptic tracing to map and functionally characterise the presynaptic ensemble of individual Purkinje neurons. I will validate my functional connectomics strategy with electron microscopy and elucidate whether the anatomical organisation of presynaptic circuits converging on Purkinje neurons is modular or random (Aim1). Then, I will harness functional imaging and optogenetics to map the topography of cortico-cerebellar representations, and discover whether Purkinje neurons pool inputs from related sensory-motor presynaptic modules (Aim2). Finally I will train mice in a sensory-guided forelimb task, and ascertain how these circuits are engaged by sensory-motor events, and their timing, during adaptive behaviour (Aim3).\n \n","plannedDates":[{"endDate":"2025-01-03T00:00:00+00:00","startDate":"2021-01-04T00:00:00+00:00","startDateDateOnly":"2021-01-04","endDateDateOnly":"2025-01-03"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr L. Federico Rossi","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Rossi","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mapping sensory-motor cerebellar circuits for adaptive behaviour The cerebellar cortex is thought to form predictive associations between sensory inputs and motor commands: animals leverage these associations to coordinate and adapt movements to contextual changes in the environment. This sensory-motor control depends on Purkinje neurons, each of which receives sensory, motor and cognitive signals from one climbing fibre as well as thousands of parallel fibres, the axons of granule cells. Despite years of anatomical work, cerebellar sensory-motor representations have not been mapped at the cellular scale; similarly, the functional circuit connectivity underlying sensory-motor integration remains unexplored.\n\nTo reveal the functional architecture of the mouse cerebellar cortex, I propose to use rabies monosynaptic tracing to map and functionally characterise the presynaptic ensemble of individual Purkinje neurons. I will validate my functional connectomics strategy with electron microscopy and elucidate whether the anatomical organisation of presynaptic circuits converging on Purkinje neurons is modular or random (Aim1). Then, I will harness functional imaging and optogenetics to map the topography of cortico-cerebellar representations, and discover whether Purkinje neurons pool inputs from related sensory-motor presynaptic modules (Aim2). Finally I will train mice in a sensory-guided forelimb task, and ascertain how these circuits are engaged by sensory-motor events, and their timing, during adaptive behaviour (Aim3).\n \n","awardDateDateOnly":"2020-11-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Connectome","Mice","Neural Pathways","Optogenetics","Purkinje Cells"]}
{"id":"360G-Wellcome-221663_Z_20_Z","title":"Determining the role of inter-kingdom interactions in the evolution of antimicrobial resistance ","Region":"North West","currency":"GBP","awardDate":"2020-11-11T00:00:00+00:00","Sponsor(s)":"Dr Michael Bromley, Dr Chris Knight","Internal ID":"221663/Z/20/Z","description":"Polymicrobial infections consisting of Aspergillus fumigatus and Pseudomonas aeruginosa are associated with poorer patient outcomes and are often much harder to treat. There are a very limited number of drugs available to treat fungal infections, and both bacterial and fungal resistance is rapidly spreading in environmental and clinical settings. Determining the effect of inter-kingdom interactions between these pathogens upon the evolution of antimicrobial resistance is vital for the treatment of polymicrobial infections.\n\nMultispecies biofilms caused by coinfection of these two key respiratory pathogens create a physical barrier preventing drug penetration leading to protection from antimicrobial treatment. However, we understand very little about how competitive interactions within such communities can alter the mutational drivers of resistance or how coexistence changes the pleiotropic fitness costs associated with resistance. The aim of the project is to understand how coexistence and competition between A. fumigatus and P. aeruginosa alters the rate of resistance evolution in the presence and absence of antimicrobial treatment and how interactions change the fitness landscape of resistant mutants within both species.\n\nUnderstanding the drivers of resistance in polymicrobial communities may increase our ability to predict resistance evolution and aid the design therapeutic of strategies that limit the emergence of resistance.\n","plannedDates":[{"endDate":"2025-04-04T00:00:00+00:00","startDate":"2021-04-05T00:00:00+00:00","startDateDateOnly":"2021-04-05","endDateDateOnly":"2025-04-04"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Michael Bottery","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Bottery","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Determining the role of inter-kingdom interactions in the evolution of antimicrobial resistance  Polymicrobial infections consisting of Aspergillus fumigatus and Pseudomonas aeruginosa are associated with poorer patient outcomes and are often much harder to treat. There are a very limited number of drugs available to treat fungal infections, and both bacterial and fungal resistance is rapidly spreading in environmental and clinical settings. Determining the effect of inter-kingdom interactions between these pathogens upon the evolution of antimicrobial resistance is vital for the treatment of polymicrobial infections.\n\nMultispecies biofilms caused by coinfection of these two key respiratory pathogens create a physical barrier preventing drug penetration leading to protection from antimicrobial treatment. However, we understand very little about how competitive interactions within such communities can alter the mutational drivers of resistance or how coexistence changes the pleiotropic fitness costs associated with resistance. The aim of the project is to understand how coexistence and competition between A. fumigatus and P. aeruginosa alters the rate of resistance evolution in the presence and absence of antimicrobial treatment and how interactions change the fitness landscape of resistant mutants within both species.\n\nUnderstanding the drivers of resistance in polymicrobial communities may increase our ability to predict resistance evolution and aid the design therapeutic of strategies that limit the emergence of resistance.\n","awardDateDateOnly":"2020-11-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aspergillus fumigatus","Biofilms","Biological Evolution","Drug Resistance, Fungal","Microbial Interactions","Mutation","Pseudomonas aeruginosa"]}
{"id":"360G-Wellcome-221657_Z_20_Z","title":"Dopaminergic reorganisation of cross-region neural communication","Region":"Greater London","currency":"GBP","awardDate":"2020-11-11T00:00:00+00:00","Sponsor(s)":"Prof Kenneth Harris, Prof Matteo Carandini, Prof Ilana Witten","Internal ID":"221657/Z/20/Z","description":"Dopamine (DA) neurons in the ventral tegmental area (VTA) are thought to provide a reinforcement signal that is essential for learning. Despite recent advances, how VTA-DA neurons coordinate and modulate communication and synaptic plasticity across brain regions to drive behavior is still an open question. We hypothesise that 1) DA enhances communication of behaviorally relevant information across cortex and striatum and 2) the content of the information varies across corticostriatal regions. To test this model, we propose an ambitious research program in mice, using state-of-the-art in vivo electrophysiology, optogenetics, neuropharmacology and computational techniques. First, we will use high density in vivo electrophysiology (Neuropixels) to record neural activity across different corticostriatal regions, while optogenetically manipulating VTA-DA neurons in mice performing a visuospatial decision-making task. We will then use advanced computational methods to examine how and what information is communicated across corticostriatal regions, and how this process is modulated by DA. Finally, we will causally evaluate how DA mediated changes in cross-region communication depend on the receptor, synapses and the neuronal populations involved. In conclusion, we propose a comprehensive study of how DA modulates cross-region communication to drive behavior, providing a needed bridge between our systems and synaptic level understanding of VTA-DA.\n","plannedDates":[{"endDate":"2025-04-30T00:00:00+00:00","startDate":"2021-05-01T00:00:00+00:00","startDateDateOnly":"2021-05-01","endDateDateOnly":"2025-04-30"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Alejandro Pan Vazquez","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Pan Vazquez","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Dopaminergic reorganisation of cross-region neural communication Dopamine (DA) neurons in the ventral tegmental area (VTA) are thought to provide a reinforcement signal that is essential for learning. Despite recent advances, how VTA-DA neurons coordinate and modulate communication and synaptic plasticity across brain regions to drive behavior is still an open question. We hypothesise that 1) DA enhances communication of behaviorally relevant information across cortex and striatum and 2) the content of the information varies across corticostriatal regions. To test this model, we propose an ambitious research program in mice, using state-of-the-art in vivo electrophysiology, optogenetics, neuropharmacology and computational techniques. First, we will use high density in vivo electrophysiology (Neuropixels) to record neural activity across different corticostriatal regions, while optogenetically manipulating VTA-DA neurons in mice performing a visuospatial decision-making task. We will then use advanced computational methods to examine how and what information is communicated across corticostriatal regions, and how this process is modulated by DA. Finally, we will causally evaluate how DA mediated changes in cross-region communication depend on the receptor, synapses and the neuronal populations involved. In conclusion, we propose a comprehensive study of how DA modulates cross-region communication to drive behavior, providing a needed bridge between our systems and synaptic level understanding of VTA-DA.\n","awardDateDateOnly":"2020-11-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Decision Making","Dopamine","Dopaminergic Neurons","Mice","Optogenetics","Ventral Tegmental Area"]}
{"id":"360G-Wellcome-221651_Z_20_Z","title":"A genomics approach to unravelling the link between steroid hormone dysregulation and cardio-metabolic disease","Region":"South East","currency":"GBP","awardDate":"2020-11-11T00:00:00+00:00","Sponsor(s)":"Dr Claudia Langenberg, Prof Cecilia Lindgren, Prof Wiebke Arlt, Dr Hilary Finucane","Internal ID":"221651/Z/20/Z","description":"Steroid hormone dysregulation has been linked to nearly all leading causes of death, notably cardio-metabolic diseases. Despite this, the aetiological contribution of steroid hormones to such disease is poorly understood and its potential as a therapeutic target remains largely unexplored. To fill this gap, I seek to pioneer a new aetiological understanding of steroid hormone dysregulation and its health consequences through multiple complementary data-driven approaches. I will do the following:\n\n\n Identify the genomic basis of steroid regulation through large-scale genetic studies of steroid hormones, steroidogenic enzymes, and regulating peptides.\n Pinpoint the tissues, genes and biological mechanisms involved in steroid dysregulation in men and women, through the vertical integration of genetics with tissue-specific molecular trait data. As part of this, I will set up an omics atlas of the adrenal gland and the ovary.\n \n Map out the metabolic and regulatory relationships between steroid hormones and related traits through the identification of genetically determined multi-dimensional steroid traits.\n \n Conduct a genomics-driven identification of new therapeutic pathways and protein targets to correct disease-causing steroid imbalances. \n\n\nIn short, this research agenda will not only uncover the aetiological pathways linking the steroid endocrine system to cardio-metabolic disease, but also instigate novel treatment strategies.\n","plannedDates":[{"endDate":"2025-01-03T00:00:00+00:00","startDate":"2021-01-04T00:00:00+00:00","startDateDateOnly":"2021-01-04","endDateDateOnly":"2025-01-03"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Laura Wittemans","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Wittemans","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A genomics approach to unravelling the link between steroid hormone dysregulation and cardio-metabolic disease Steroid hormone dysregulation has been linked to nearly all leading causes of death, notably cardio-metabolic diseases. Despite this, the aetiological contribution of steroid hormones to such disease is poorly understood and its potential as a therapeutic target remains largely unexplored. To fill this gap, I seek to pioneer a new aetiological understanding of steroid hormone dysregulation and its health consequences through multiple complementary data-driven approaches. I will do the following:\n\n\n Identify the genomic basis of steroid regulation through large-scale genetic studies of steroid hormones, steroidogenic enzymes, and regulating peptides.\n Pinpoint the tissues, genes and biological mechanisms involved in steroid dysregulation in men and women, through the vertical integration of genetics with tissue-specific molecular trait data. As part of this, I will set up an omics atlas of the adrenal gland and the ovary.\n \n Map out the metabolic and regulatory relationships between steroid hormones and related traits through the identification of genetically determined multi-dimensional steroid traits.\n \n Conduct a genomics-driven identification of new therapeutic pathways and protein targets to correct disease-causing steroid imbalances. \n\n\nIn short, this research agenda will not only uncover the aetiological pathways linking the steroid endocrine system to cardio-metabolic disease, but also instigate novel treatment strategies.\n","awardDateDateOnly":"2020-11-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Female","Genomics","Humans","Metabolic Networks and Pathways","Ovary","Steroids"]}
{"id":"360G-Wellcome-221650_Z_20_Z","title":"Development of novel computational approaches for human cardiac mapping data - Improving understanding and treatment of atrial fibrillation  ","Region":"West Midlands","currency":"GBP","awardDate":"2020-11-11T00:00:00+00:00","Sponsor(s)":"Dr Martin Bishop, Dr Davor Pavlovic, Prof Igor Efimov","Internal ID":"221650/Z/20/Z","description":"Cardiac arrhythmias are a common pathway for multiple cardiovascular diseases, the leading cause of death in the world. Ablation of cardiac arrhythmias is a recommended and common treatment option for arrhythmia patients, but success rates are poor. Cardiac electroanatomical mapping systems (EAMs) are used to identify ablation targets. EAMs generate a wealth of raw data that is ideal for developing algorithms to tailor treatments to an individual patients\u2019 pathophysiology and improve treatment options. However, no platform exists for developing and testing algorithms.\n\nSpecific groups have developed closed-source software to identify ablation targets however, these results have not been widely reproducible. There is an acute need for an open-source and cross-vendor EAM analysis software to facilitate sharing methods, increase rigor and transparency and increase access to advanced processing tools.\n\nI will develop expandable open-source software for analysis of EAM data. I will incorporate established and novel analysis methodologies, including machine learning approaches. Algorithms will be robustly validated using clinical, pre-clinical and in silico datasets. The software I will develop will enable myself and others to utilise routinely collected clinical data, to better treat cardiac arrhythmia. I will apply these approaches to identify mechanistic drives of atrial fibrillation as an exemplar application.\n","plannedDates":[{"endDate":"2025-04-30T00:00:00+00:00","startDate":"2021-05-01T00:00:00+00:00","startDateDateOnly":"2021-05-01","endDateDateOnly":"2025-04-30"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Christopher O'Shea","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"O'Shea","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Birmingham\", \"360G-Wellcome-ORG:University-of-Birmingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Development of novel computational approaches for human cardiac mapping data - Improving understanding and treatment of atrial fibrillation   Cardiac arrhythmias are a common pathway for multiple cardiovascular diseases, the leading cause of death in the world. Ablation of cardiac arrhythmias is a recommended and common treatment option for arrhythmia patients, but success rates are poor. Cardiac electroanatomical mapping systems (EAMs) are used to identify ablation targets. EAMs generate a wealth of raw data that is ideal for developing algorithms to tailor treatments to an individual patients\u2019 pathophysiology and improve treatment options. However, no platform exists for developing and testing algorithms.\n\nSpecific groups have developed closed-source software to identify ablation targets however, these results have not been widely reproducible. There is an acute need for an open-source and cross-vendor EAM analysis software to facilitate sharing methods, increase rigor and transparency and increase access to advanced processing tools.\n\nI will develop expandable open-source software for analysis of EAM data. I will incorporate established and novel analysis methodologies, including machine learning approaches. Algorithms will be robustly validated using clinical, pre-clinical and in silico datasets. The software I will develop will enable myself and others to utilise routinely collected clinical data, to better treat cardiac arrhythmia. I will apply these approaches to identify mechanistic drives of atrial fibrillation as an exemplar application.\n","awardDateDateOnly":"2020-11-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Algorithms","Arrhythmias, Cardiac","Atrial Fibrillation","Catheter Ablation","Electrophysiologic Techniques, Cardiac","Humans","Machine Learning","Software"]}
{"id":"360G-Wellcome-221648_Z_20_Z","title":"Enhancing and refining the GHIAA MAPGuide","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221648/Z/20/Z","description":"GHIAA started the process of transforming its \u2018paper\u2019 Master Alliance Provisions Guide (MAPGuide) into an online resource in autumn 2019. Using Wellcome\u2019s funding, GHIAA has made significant progress towards developing an intuitive, user-friendly tool, and a robust online platform to support future growth.\n\nThe development process began with creating a prototype MAPGuide tool and conducting initial stakeholder consultations in January and February 2020. These consultations provided vital input on adjustments needed to improve the user experience with the online tool. Driven by that input, GHIAA has recently completed significant improvements to the beta version of the MAPGuide.\n\nDuring additional consultations in June 2020, stakeholders provided encouraging and constructive feedback on the improvements to the features and functionality of the MAPGuide. The next step in the development process is a public launch, targeted for early August 2020.\n\nGHIAA is seeking further funding from Wellcome to:\n\n\n Conduct additional consultations for wider stakeholder groups over the rest of 2020\n Make additional improvements based on feedback identified through consultations and user surveys after rollout\n Conduct targeted workshops on potential future features and improvements\n Conduct a consultative process to advance the Global Health Transactions Glossary\n Develop additional content, features and supporting tools for the MAPGuide\n\n","plannedDates":[{"endDate":"2021-06-30T00:00:00+00:00","startDate":"2020-08-24T00:00:00+00:00","startDateDateOnly":"2020-08-24","endDateDateOnly":"2021-06-30"}],"amountAwarded":52264,"Financial Year":"2019/20","Lead Applicant":"Prof Julia Barnes-Weise","grantProgramme":[{"title":"Discretionary Award - Policy ","title_keyword":"Discretionary Award - Policy "}],"Applicant Surname":"Barnes-Weise","Partnership Value":52264,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Global-Healthcare-Innovation-Alliance-Accelerator","name":"Global Healthcare Innovation Alliance Accelerator","addressCountry":"United States","id_and_name":"[\"Global Healthcare Innovation Alliance Accelerator\", \"360G-Wellcome-ORG:Global-Healthcare-Innovation-Alliance-Accelerator\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Global-Healthcare-Innovation-Alliance-Accelerator","name":"Global Healthcare Innovation Alliance Accelerator"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Enhancing and refining the GHIAA MAPGuide GHIAA started the process of transforming its \u2018paper\u2019 Master Alliance Provisions Guide (MAPGuide) into an online resource in autumn 2019. Using Wellcome\u2019s funding, GHIAA has made significant progress towards developing an intuitive, user-friendly tool, and a robust online platform to support future growth.\n\nThe development process began with creating a prototype MAPGuide tool and conducting initial stakeholder consultations in January and February 2020. These consultations provided vital input on adjustments needed to improve the user experience with the online tool. Driven by that input, GHIAA has recently completed significant improvements to the beta version of the MAPGuide.\n\nDuring additional consultations in June 2020, stakeholders provided encouraging and constructive feedback on the improvements to the features and functionality of the MAPGuide. The next step in the development process is a public launch, targeted for early August 2020.\n\nGHIAA is seeking further funding from Wellcome to:\n\n\n Conduct additional consultations for wider stakeholder groups over the rest of 2020\n Make additional improvements based on feedback identified through consultations and user surveys after rollout\n Conduct targeted workshops on potential future features and improvements\n Conduct a consultative process to advance the Global Health Transactions Glossary\n Develop additional content, features and supporting tools for the MAPGuide\n\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Internet"]}
{"id":"360G-Wellcome-221647_Z_20_Z","title":"Intravital imaging as a platform for screening checkpoint and focal adhesion kinase inhibitors as potential treatment for cancer metastasis","Region":"Scotland","currency":"GBP","awardDate":"2020-11-11T00:00:00+00:00","Sponsor(s)":"Dr David Entenberg, Prof Valerie Brunton","Internal ID":"221647/Z/20/Z","description":"Despite new developments in treatment, cancer remains the second leading cause of death worldwide. Breast cancer is the most common cancer within the UK, with death generally caused by the formation of metastasis. I intend to investigate the hypothesis that immune responses at the metastatic site determine the long-term outcome of therapy.\n\nI will compare immune responses at the primary and metastatic sites upon administration of checkpoint inhibitors that have different clinical success rates. Flow cytometry and t-SNE analysis will provide insight into the affected cell populations and timings.  I will then utilise newly developed intravital imaging technologies to visualise immune responses in vivo at multiple cancer sites. I will measure cytotoxic cell activity and tumour cell death as indicators for anti-cancer response. Further, I will examine the ability of a combination of checkpoint inhibitor and focal adhesion kinase inhibitor to fully eradicate tumour cells. An inhibitor will be fluorescently tagged to study its access to tissue and interaction with immune cells dependent on combination therapy.\n\nThe proposed research will help to elucidate the role of immunotherapy on the metastatic foci and will provide the first insights into the benefit and limitations of combination therapy on secondary site immune responses.\n","plannedDates":[{"endDate":"2025-04-30T00:00:00+00:00","startDate":"2021-05-01T00:00:00+00:00","startDateDateOnly":"2021-05-01","endDateDateOnly":"2025-04-30"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Miss Nicole Barth","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Barth","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Intravital imaging as a platform for screening checkpoint and focal adhesion kinase inhibitors as potential treatment for cancer metastasis Despite new developments in treatment, cancer remains the second leading cause of death worldwide. Breast cancer is the most common cancer within the UK, with death generally caused by the formation of metastasis. I intend to investigate the hypothesis that immune responses at the metastatic site determine the long-term outcome of therapy.\n\nI will compare immune responses at the primary and metastatic sites upon administration of checkpoint inhibitors that have different clinical success rates. Flow cytometry and t-SNE analysis will provide insight into the affected cell populations and timings.  I will then utilise newly developed intravital imaging technologies to visualise immune responses in vivo at multiple cancer sites. I will measure cytotoxic cell activity and tumour cell death as indicators for anti-cancer response. Further, I will examine the ability of a combination of checkpoint inhibitor and focal adhesion kinase inhibitor to fully eradicate tumour cells. An inhibitor will be fluorescently tagged to study its access to tissue and interaction with immune cells dependent on combination therapy.\n\nThe proposed research will help to elucidate the role of immunotherapy on the metastatic foci and will provide the first insights into the benefit and limitations of combination therapy on secondary site immune responses.\n","awardDateDateOnly":"2020-11-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Humans","Immunotherapy","Neoplasm Metastasis"]}
{"id":"360G-Wellcome-221640_Z_20_Z","title":"Molecular basis of parasite-induced disruption of host circadian outputs ","Region":"Scotland","currency":"GBP","awardDate":"2020-11-11T00:00:00+00:00","Sponsor(s)":"Prof Annette MacLeod, Prof Luis De Lecea","Internal ID":"221640/Z/20/Z","description":"Sleep/wake cycles are arguably the most important circadian behavioural output controlling many aspects of animal physiology. However, some infections induce disruptions to these cycles, leading to pathology. Sleeping sickness is an infection caused by the African trypanosome Trypanosoma brucei. One of the most puzzling symptoms of this disease is the profound alteration in sleep patterns, which is now recognised as circadian disorder. This disease provides an ideal framework to study how pathogens disrupt host circadian behaviour. \nI will use single-cell transcriptomics to profile the responses of key hypothalamic nuclei controlling circadian behaviour during infection. I will also characterise the population of parasites residing in the brain compared to bloodstream parasites to identify mechanisms of glial activation, neuroinflammation, and parasite survival in the CNS. These outputs will provide novel and unprecedented insights into the host-pathogen interactions in the hypothalamus that lead to disruptions of sleeping patterns. \nMy ultimate aim is to understand how pathogens interfere with the function of the central nervous system leading to changes in physiology and behaviour. The outcomes of my fellowship will provide a new understanding of infection-induced circadian disorders and will reveal factors that can be exploited for intervention and treatment of infections affecting the brain.\n","plannedDates":[{"endDate":"2025-01-31T00:00:00+00:00","startDate":"2021-02-01T00:00:00+00:00","startDateDateOnly":"2021-02-01","endDateDateOnly":"2025-01-31"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Juan Quintana Alcala","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Quintana Alcala","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow","addressCountry":"United Kingdom","id_and_name":"[\"University of Glasgow\", \"360G-Wellcome-ORG:University-of-Glasgow\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Molecular basis of parasite-induced disruption of host circadian outputs  Sleep/wake cycles are arguably the most important circadian behavioural output controlling many aspects of animal physiology. However, some infections induce disruptions to these cycles, leading to pathology. Sleeping sickness is an infection caused by the African trypanosome Trypanosoma brucei. One of the most puzzling symptoms of this disease is the profound alteration in sleep patterns, which is now recognised as circadian disorder. This disease provides an ideal framework to study how pathogens disrupt host circadian behaviour. \nI will use single-cell transcriptomics to profile the responses of key hypothalamic nuclei controlling circadian behaviour during infection. I will also characterise the population of parasites residing in the brain compared to bloodstream parasites to identify mechanisms of glial activation, neuroinflammation, and parasite survival in the CNS. These outputs will provide novel and unprecedented insights into the host-pathogen interactions in the hypothalamus that lead to disruptions of sleeping patterns. \nMy ultimate aim is to understand how pathogens interfere with the function of the central nervous system leading to changes in physiology and behaviour. The outcomes of my fellowship will provide a new understanding of infection-induced circadian disorders and will reveal factors that can be exploited for intervention and treatment of infections affecting the brain.\n","awardDateDateOnly":"2020-11-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Brain","Circadian Rhythm","Humans","Hypothalamus","Single-Cell Analysis","Trypanosomiasis, African"]}
{"id":"360G-Wellcome-221638_Z_20_Z","title":"Using multimodal normative modelling to predict clinical outcomes in early psychosis","Region":"Greater London","currency":"GBP","awardDate":"2020-11-11T00:00:00+00:00","Sponsor(s)":"Dr Andre Marquand, Prof Andrea Mechelli, Dr Ferath Kherif, Dr M Jorge Cardoso, Dr Vince Calhoun, Prof Philip McGuire","Internal ID":"221638/Z/20/Z","description":"Individuals at the early stages of psychosis already suffer from neuroanatomical, neurofunctional and neurocognitive alterations. However, it is not clear how these alterations interact with each other and, more importantly, how this interaction may help predict who will become unwell. The aim of the proposed study is to uncover previously hidden relationships between brain anatomy, function and cognition that can improve our understanding of the first signs of the illness and help predict illness trajectory at the individual level. This will be achieved by triangulating, for the first time, data fusion, machine learning and a unique longitudinal dataset of individuals at the prodromal stage or with a recent first episode of psychosis. This combination of methods will allow me to address three main objectives: 1) identify previously unknown relationships between anatomy, function and cognition in healthy individuals; 2) develop a model that captures the normative pattern of these hidden relationships and determine by how much each patient deviates from this pattern; 3) use these deviations to predict each patient\u2019s longitudinal clinical outcomes. I will also develop an open access tool that allows non-expert researchers to perform data fusion on their own data. Keywords: psychosis, data fusion, machine learning, outcome prediction.\n","plannedDates":[{"endDate":"2025-07-14T00:00:00+00:00","startDate":"2021-07-15T00:00:00+00:00","startDateDateOnly":"2021-07-15","endDateDateOnly":"2025-07-14"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Ms Sandra Vieira","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Vieira","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Using multimodal normative modelling to predict clinical outcomes in early psychosis Individuals at the early stages of psychosis already suffer from neuroanatomical, neurofunctional and neurocognitive alterations. However, it is not clear how these alterations interact with each other and, more importantly, how this interaction may help predict who will become unwell. The aim of the proposed study is to uncover previously hidden relationships between brain anatomy, function and cognition that can improve our understanding of the first signs of the illness and help predict illness trajectory at the individual level. This will be achieved by triangulating, for the first time, data fusion, machine learning and a unique longitudinal dataset of individuals at the prodromal stage or with a recent first episode of psychosis. This combination of methods will allow me to address three main objectives: 1) identify previously unknown relationships between anatomy, function and cognition in healthy individuals; 2) develop a model that captures the normative pattern of these hidden relationships and determine by how much each patient deviates from this pattern; 3) use these deviations to predict each patient\u2019s longitudinal clinical outcomes. I will also develop an open access tool that allows non-expert researchers to perform data fusion on their own data. Keywords: psychosis, data fusion, machine learning, outcome prediction.\n","awardDateDateOnly":"2020-11-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Brain","Female","Humans","Longitudinal Studies","Machine Learning","Psychotic Disorders","Young Adult"]}
{"id":"360G-Wellcome-221634_Z_20_Z","title":"Investigating the role of gut macrophages in mediating alpha-synuclein pathology in Parkinson\u2019s disease","Region":"Greater London","currency":"GBP","awardDate":"2020-11-11T00:00:00+00:00","Sponsor(s)":"Dr Soyon Hong, Prof Tim Bartels","Internal ID":"221634/Z/20/Z","description":"The gut-brain axis is at the heart of Parkinson\u2019s disease (PD) etiology. Pathological alpha-synuclein accumulates early in the gut, potentially affecting the enteric nervous system (ENS) and spreads to the brain. However, we lack insights into how pathological alpha-synuclein affects ENS integrity and cellular mediators underlying their spread. Here, I propose to study the role of a unique subset of gut macrophages (gMacs), the ENS-gMacs, that coordinate neuronal function in their unique ENS niche. I hypothesize that ENS-gMacs critically dependent on LRRK2 for alpha-synuclein clearance. LRRK2 is a risk factor for PD, regulates alpha-synuclein clearance in macrophages and is highly enriched in ENS-gMacs compared to microglia and neurons. First, using state-of-the-art single cell RNA and in-situ sequencing techniques I will examine how ENS-gMacs and microglia become dysfunctional in PD mouse models. Second, using in vivo and in vitro tools, I will dissect whether mutant LRRK2 signaling in ENS-gMacs affects neuronal function and survival upon PD patient-derived pathological alpha-synuclein. Finally, I will investigate how ENS-gMacs contribute to alpha-synuclein pathology and spread. Insights obtained will create new avenues to study neuroimmune pathways along gut-brain axis for the future, as well as novel targets for early therapeutic interventions in PD. \n","plannedDates":[{"endDate":"2024-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2024-12-31"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Sebastiaan De Schepper","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"De Schepper","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the role of gut macrophages in mediating alpha-synuclein pathology in Parkinson\u2019s disease The gut-brain axis is at the heart of Parkinson\u2019s disease (PD) etiology. Pathological alpha-synuclein accumulates early in the gut, potentially affecting the enteric nervous system (ENS) and spreads to the brain. However, we lack insights into how pathological alpha-synuclein affects ENS integrity and cellular mediators underlying their spread. Here, I propose to study the role of a unique subset of gut macrophages (gMacs), the ENS-gMacs, that coordinate neuronal function in their unique ENS niche. I hypothesize that ENS-gMacs critically dependent on LRRK2 for alpha-synuclein clearance. LRRK2 is a risk factor for PD, regulates alpha-synuclein clearance in macrophages and is highly enriched in ENS-gMacs compared to microglia and neurons. First, using state-of-the-art single cell RNA and in-situ sequencing techniques I will examine how ENS-gMacs and microglia become dysfunctional in PD mouse models. Second, using in vivo and in vitro tools, I will dissect whether mutant LRRK2 signaling in ENS-gMacs affects neuronal function and survival upon PD patient-derived pathological alpha-synuclein. Finally, I will investigate how ENS-gMacs contribute to alpha-synuclein pathology and spread. Insights obtained will create new avenues to study neuroimmune pathways along gut-brain axis for the future, as well as novel targets for early therapeutic interventions in PD. \n","awardDateDateOnly":"2020-11-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Enteric Nervous System","Humans","Leucine-Rich Repeat Serine-Threonine Protein Kinase-2","Macrophages","Mice","Mice, Inbred C57BL","Microglia","Neurons","Parkinson Disease","alpha-Synuclein"]}
{"id":"360G-Wellcome-221617_Z_20_Z","title":"Developing small molecules as a neurosteroid replacement strategy for treating postpartum psychosis","Region":"Wales","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221617/Z/20/Z","description":"After giving birth, some women have the rapid onset of a severe mental health condition, postpartum psychosis, with mood symptoms, hallucinations and delusions. Postpartum psychosis is a medical emergency due to the risk to both mother and child. During pregnancy there is an increase in circulating hormones called neurosteroids and these enter the brain and change the function of proteins called GABA-A receptors. In order to adapt, the brain reduces the amount of these proteins but following the rapid drop of neurosteroids after birth, the GABA-A receptors cannot recover to their pre-pregnancy levels quickly enough and therefore normal brain function is compromised, triggering postpartum psychosis. Our aim is to identify a synthetic neuroactive steroid that can compensate for the postpartum loss of natural neurosteroids and thereby reduce the symptoms in affected mothers and also prevent episodes in women at high risk. This will be of enormous benefit to women and their families.","plannedDates":[{"endDate":"2023-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2023-03-31"}],"amountAwarded":503102,"Financial Year":"2019/20","Lead Applicant":"Prof John Atack","grantProgramme":[{"title":"Innovator Award","title_keyword":"Innovator Award"}],"Applicant Surname":"Atack","Partnership Value":503102,"Approval Committee":"Innovator Awards Advisory Group","Other Applicant(s)":"Prof Jeremy Lambert, Dr Stephen Martin, Prof Simon Ward","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University","addressCountry":"United Kingdom","id_and_name":"[\"Cardiff University\", \"360G-Wellcome-ORG:Cardiff-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Developing small molecules as a neurosteroid replacement strategy for treating postpartum psychosis After giving birth, some women have the rapid onset of a severe mental health condition, postpartum psychosis, with mood symptoms, hallucinations and delusions. Postpartum psychosis is a medical emergency due to the risk to both mother and child. During pregnancy there is an increase in circulating hormones called neurosteroids and these enter the brain and change the function of proteins called GABA-A receptors. In order to adapt, the brain reduces the amount of these proteins but following the rapid drop of neurosteroids after birth, the GABA-A receptors cannot recover to their pre-pregnancy levels quickly enough and therefore normal brain function is compromised, triggering postpartum psychosis. Our aim is to identify a synthetic neuroactive steroid that can compensate for the postpartum loss of natural neurosteroids and thereby reduce the symptoms in affected mothers and also prevent episodes in women at high risk. This will be of enormous benefit to women and their families.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Depression, Postpartum","Female","Humans","Neurotransmitter Agents","Postpartum Period","Pregnancy","Pregnanolone","Psychotic Disorders","Steroids"]}
{"id":"360G-Wellcome-221616_Z_20_Z","title":"Public involvement to shape policies and solutions on antimicrobial resistance","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221616/Z/20/Z","description":"To address the problem of antimicrobial resistance (AMR) in Thailand, the Thai government produced the \"Thailand National Strategic Action Plan on Antimicrobial Resistance 2017-2021\" (TNSAP). While public engagement sits at the heart of the TNSAP, Thai campaigns so far have predominantly focused on raising awareness through educational materials and events like the annual AMR Week, but less on patient and public involvement in shaping the national AMR response. In our project, we will bring together adult audiences (e.g. patients, consumers, young professionals), non-governmental organisation representatives, AMR researchers and national policy makers to co-create an AMR stakeholder map, an AMR engagement strategy, and context-specific solutions to reduce the burden of AMR. The project will be implemented over 18 months, employing Wellcome\u2019s Responsive Dialogues approach to design and implement a combination of in-person regional Conversations and nation-wide virtual Conversations. Our main outcomes are (1) improved understanding and engagement with the issue of AMR among adult Thai communities (2) changes in the national AMR policy to include context-specific solutions and (3) improved understanding about the implementation of Wellcome\u2019s \u2018Responsive Dialogues\u2019 toolkit in Thailand. Our project will be integrated into the activities implemented within the current TNSAP and inform the next TNSAP .\n \n","plannedDates":[{"endDate":"2022-03-31T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2022-03-31"}],"amountAwarded":230515,"Financial Year":"2019/20","Lead Applicant":"Prof Phaik Yeong Cheah","grantProgramme":[{"title":"Discretionary Award - Public Engagement","title_keyword":"Discretionary Award - Public Engagement"}],"Applicant Surname":"Cheah","Partnership Value":230515,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Public involvement to shape policies and solutions on antimicrobial resistance To address the problem of antimicrobial resistance (AMR) in Thailand, the Thai government produced the \"Thailand National Strategic Action Plan on Antimicrobial Resistance 2017-2021\" (TNSAP). While public engagement sits at the heart of the TNSAP, Thai campaigns so far have predominantly focused on raising awareness through educational materials and events like the annual AMR Week, but less on patient and public involvement in shaping the national AMR response. In our project, we will bring together adult audiences (e.g. patients, consumers, young professionals), non-governmental organisation representatives, AMR researchers and national policy makers to co-create an AMR stakeholder map, an AMR engagement strategy, and context-specific solutions to reduce the burden of AMR. The project will be implemented over 18 months, employing Wellcome\u2019s Responsive Dialogues approach to design and implement a combination of in-person regional Conversations and nation-wide virtual Conversations. Our main outcomes are (1) improved understanding and engagement with the issue of AMR among adult Thai communities (2) changes in the national AMR policy to include context-specific solutions and (3) improved understanding about the implementation of Wellcome\u2019s \u2018Responsive Dialogues\u2019 toolkit in Thailand. Our project will be integrated into the activities implemented within the current TNSAP and inform the next TNSAP .\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Drug Resistance, Bacterial","Drug Resistance, Microbial","Health Policy","Humans","Thailand"]}
{"id":"360G-Wellcome-221612_Z_20_Z","title":"Understanding the mechanisms of multimodal communication in deaf children with cochlear implants","Region":"Greater London","currency":"GBP","awardDate":"2020-11-11T00:00:00+00:00","Sponsor(s)":"Prof Jason Barton, Prof Mairead MacSweeney","Internal ID":"221612/Z/20/Z","description":"Children develop and interact in complex, multimodal environments. I will investigate how deaf children with cochlear implant (CIs) integrate visual information from the talker\u2019s face to supplement sound.\n\nThis is important because CIs provide a degraded sound that lacks pitch and much affective information, placing high cognitive demand on the developing brain and increasing reliance on visual information and audio-visual integration.\n\nI will conduct experiments comparing adolescents with early-onset deafness and bilateral CIs to hearing controls. Eye tracking will be used to understand allocation of visual attention during word and emotion perception and the interaction between these processes. Visual evoked potentials will be measured using electroencephalography to understand the efficiency of cortical processing during visual perception.  Psychophysics and pupillometry will be combined to estimate the benefit gained from audio-visual speech integration and the impact on cognitive effort. Functional near-infrared spectroscopy will enable cortical imaging of CI users without interference from CI-generated artefacts. Correlations between activity in temporal and occipital cortices will be examined to understand audio-visual cortical connectivity and to specify mechanisms of audio-visual integration.\n\nThis work will enable us to better understand the role for visual cues in augmenting current auditory-only rehabilitative interventions to help deaf children communicate effectively.\n","plannedDates":[{"endDate":"2025-02-28T00:00:00+00:00","startDate":"2021-03-01T00:00:00+00:00","startDateDateOnly":"2021-03-01","endDateDateOnly":"2025-02-28"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Carly Anderson","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Anderson","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding the mechanisms of multimodal communication in deaf children with cochlear implants Children develop and interact in complex, multimodal environments. I will investigate how deaf children with cochlear implant (CIs) integrate visual information from the talker\u2019s face to supplement sound.\n\nThis is important because CIs provide a degraded sound that lacks pitch and much affective information, placing high cognitive demand on the developing brain and increasing reliance on visual information and audio-visual integration.\n\nI will conduct experiments comparing adolescents with early-onset deafness and bilateral CIs to hearing controls. Eye tracking will be used to understand allocation of visual attention during word and emotion perception and the interaction between these processes. Visual evoked potentials will be measured using electroencephalography to understand the efficiency of cortical processing during visual perception.  Psychophysics and pupillometry will be combined to estimate the benefit gained from audio-visual speech integration and the impact on cognitive effort. Functional near-infrared spectroscopy will enable cortical imaging of CI users without interference from CI-generated artefacts. Correlations between activity in temporal and occipital cortices will be examined to understand audio-visual cortical connectivity and to specify mechanisms of audio-visual integration.\n\nThis work will enable us to better understand the role for visual cues in augmenting current auditory-only rehabilitative interventions to help deaf children communicate effectively.\n","awardDateDateOnly":"2020-11-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adolescent","Attention","Child","Cochlear Implants","Deafness","Electroencephalography","Evoked Potentials, Visual","Female","Humans","Male","Photic Stimulation","Spectroscopy, Near-Infrared","Speech Perception","Visual Perception"]}
{"id":"360G-Wellcome-221610_Z_20_Z","title":"The contribution of spinal inhibitory circuits to aberrant excitability in Amyotrophic Lateral Sclerosis","Region":"Greater London","currency":"GBP","awardDate":"2020-11-11T00:00:00+00:00","Sponsor(s)":"Prof Robert Brownstone, Dr Claire Meehan, Prof Ole Kiehn","Internal ID":"221610/Z/20/Z","description":"Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease targeting motoneurons, leading to paresis and death. Changes in spinal microcircuits have been suggested to be part of an early homeostatic response to preserve motor output, possibly involving substantial alterations at the level of premotor synapses. Supported by solid preliminary data, I hypothesize that changes in these circuits precede motoneuron degeneration, and thus propose to address these aims: (1) define early disruptions in connectivity to motoneurons in ALS and (2) determine the genetic profile of these abnormalities. I will characterize well-known spinal synaptic pathways such as Ia excitation, disynaptic reciprocal inhibition and pre-synaptic inhibition in wildtype mice and 2 different models of ALS (SOD1G93A and TDP-43-A315T). I will do this both in vitro, by using a novel isolated mature mouse spinal cord preparation, and in vivo by performing intracellular recordings of motoneurons and EMG recordings with chronically implanted multielectrode arrays. These experiments will be complemented with transcriptomic analysis using single-cell patch seq and laser capture microscopy to reveal if changes in specific spinal microcircuits are accompanied by changes in expression profile of motoneurons and interneurons. This project will reveal if early degeneration in ALS results in generalized circuit impairment.\n","plannedDates":[{"endDate":"2025-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2025-03-31"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Filipe do Nascimento Xavier Fernandes","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"do Nascimento Xavier Fernandes","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The contribution of spinal inhibitory circuits to aberrant excitability in Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease targeting motoneurons, leading to paresis and death. Changes in spinal microcircuits have been suggested to be part of an early homeostatic response to preserve motor output, possibly involving substantial alterations at the level of premotor synapses. Supported by solid preliminary data, I hypothesize that changes in these circuits precede motoneuron degeneration, and thus propose to address these aims: (1) define early disruptions in connectivity to motoneurons in ALS and (2) determine the genetic profile of these abnormalities. I will characterize well-known spinal synaptic pathways such as Ia excitation, disynaptic reciprocal inhibition and pre-synaptic inhibition in wildtype mice and 2 different models of ALS (SOD1G93A and TDP-43-A315T). I will do this both in vitro, by using a novel isolated mature mouse spinal cord preparation, and in vivo by performing intracellular recordings of motoneurons and EMG recordings with chronically implanted multielectrode arrays. These experiments will be complemented with transcriptomic analysis using single-cell patch seq and laser capture microscopy to reveal if changes in specific spinal microcircuits are accompanied by changes in expression profile of motoneurons and interneurons. This project will reveal if early degeneration in ALS results in generalized circuit impairment.\n","awardDateDateOnly":"2020-11-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Amyotrophic Lateral Sclerosis","Animals","Mice","Mice, Transgenic","Motor Neurons","Spinal Cord","Superoxide Dismutase-1","Synapses","Synaptic Transmission"]}
{"id":"360G-Wellcome-221607_Z_20_Z","title":"Don't sugarcoat it: understanding and targeting glycosylation changes in pancreatic and liver cancers","Region":"Scotland","currency":"GBP","awardDate":"2020-11-11T00:00:00+00:00","Sponsor(s)":"Prof Kevin Ryan, Prof Stuart Haslam","Internal ID":"221607/Z/20/Z","description":"Pancreatic ductal adenocarcinoma (PDAC) and hepatocellular carcinoma (HCC) are leading causes of cancer-related deaths. Despite knowing these cancers\u2019 driver mutations, there are no effective therapies. A universal yet understudied feature of both PDAC and HCC is their aberrant glycosylation. Glycosylated serum proteins act as clinical biomarkers, but it is unknown how altered glycosylation \u2013 driven by gene expression changes and mutations of glycosyltransferases/glycosidases \u2013 contributes to disease progression.\n\nFirst, I propose to establish a new HCC mouse model combining genetic alterations with chronic alcohol consumption, a major risk factor. Second, I will systematically uncover the glycosylation changes in primary cells of this new HCC model and established PDAC models using unbiased mass spectrometry-based glycomics and lectin microarrays. By applying glycobiological techniques to this setting, I will bring together two hitherto disparate research fields. Third, based on these data, I will manipulate the glycosyltransferases/glycosidases most likely responsible for the glycosylation changes and examine disease progression, yielding new targetable oncogenes. In parallel, based on preliminary data, I will investigate the tumour suppressive mechanism of the fucosidase FUCA1 in mouse models of PDAC and HCC, using glycomics as a starting point. Finally, I will validate my findings in human PDAC and HCC samples.\n","plannedDates":[{"endDate":"2025-01-04T00:00:00+00:00","startDate":"2021-01-05T00:00:00+00:00","startDateDateOnly":"2021-01-05","endDateDateOnly":"2025-01-04"}],"amountAwarded":300000,"Financial Year":"2020/21","Lead Applicant":"Dr Victoria Wang","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Wang","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Beatson-Institute-for-Cancer-Research","name":"Beatson Institute for Cancer Research","addressCountry":"United Kingdom","id_and_name":"[\"Beatson Institute for Cancer Research\", \"360G-Wellcome-ORG:Beatson-Institute-for-Cancer-Research\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Beatson-Institute-for-Cancer-Research","name":"Beatson Institute for Cancer Research"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Don't sugarcoat it: understanding and targeting glycosylation changes in pancreatic and liver cancers Pancreatic ductal adenocarcinoma (PDAC) and hepatocellular carcinoma (HCC) are leading causes of cancer-related deaths. Despite knowing these cancers\u2019 driver mutations, there are no effective therapies. A universal yet understudied feature of both PDAC and HCC is their aberrant glycosylation. Glycosylated serum proteins act as clinical biomarkers, but it is unknown how altered glycosylation \u2013 driven by gene expression changes and mutations of glycosyltransferases/glycosidases \u2013 contributes to disease progression.\n\nFirst, I propose to establish a new HCC mouse model combining genetic alterations with chronic alcohol consumption, a major risk factor. Second, I will systematically uncover the glycosylation changes in primary cells of this new HCC model and established PDAC models using unbiased mass spectrometry-based glycomics and lectin microarrays. By applying glycobiological techniques to this setting, I will bring together two hitherto disparate research fields. Third, based on these data, I will manipulate the glycosyltransferases/glycosidases most likely responsible for the glycosylation changes and examine disease progression, yielding new targetable oncogenes. In parallel, based on preliminary data, I will investigate the tumour suppressive mechanism of the fucosidase FUCA1 in mouse models of PDAC and HCC, using glycomics as a starting point. Finally, I will validate my findings in human PDAC and HCC samples.\n","awardDateDateOnly":"2020-11-11","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Carcinoma, Hepatocellular","Disease Models, Animal","Disease Progression","Glycosylation","Humans","Liver Neoplasms","Mice","Mutation","Pancreatic Neoplasms"]}
{"id":"360G-Wellcome-221566_Z_20_Z","title":"A Unit for Health Evidence and Policy in Laos","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221566/Z/20/Z","description":"There is a need to build capacity and improve evidence-informed decision-making concerning resource allocation and priority-setting in health in low- and middle-income countries, such as Laos. This kind of capacity building and institutional strengthening is all the more important in an era of aid transitions and uncertainty related to the current COVID-19 pandemic, to enable Laos to continue progressing towards Universal Health Coverage.\nWe propose the creation of a Unit for Health Evidence and Policy (UHEP)  based in the University of Health Sciences in Vientiane, to enhance the use of research evidence to inform policy. UHEP will focus on health technology assessment (HTA) as a tool to enable priority-setting.\nWe aim to complete four main activities for this pilot project over one year.\n\n\n Situational analysis of the Lao health policy context including stakeholder mapping\n Training of Lao researchers and policy makers in HTA and on synthesis and use of research evidence (includes funding for one MSc student)\n Development of a roadmap for institutionalisation of rational priority setting in health policy development in Laos\n Selection and implementation of a pilot HTA project\n\n\nAt the end of this year UHEP will be established as a government technical partner for HTA in Laos\n","plannedDates":[{"endDate":"2021-11-15T00:00:00+00:00","startDate":"2020-11-16T00:00:00+00:00","startDateDateOnly":"2020-11-16","endDateDateOnly":"2021-11-15"}],"amountAwarded":50000,"Financial Year":"2019/20","Lead Applicant":"Dr Mayfong Mayxay","grantProgramme":[{"title":"Discretionary Award - Policy ","title_keyword":"Discretionary Award - Policy "}],"Partnership Name":"NIHR/Wellcome Global health Partnership","Applicant Surname":"Mayxay","Partnership Value":100000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A Unit for Health Evidence and Policy in Laos There is a need to build capacity and improve evidence-informed decision-making concerning resource allocation and priority-setting in health in low- and middle-income countries, such as Laos. This kind of capacity building and institutional strengthening is all the more important in an era of aid transitions and uncertainty related to the current COVID-19 pandemic, to enable Laos to continue progressing towards Universal Health Coverage.\nWe propose the creation of a Unit for Health Evidence and Policy (UHEP)  based in the University of Health Sciences in Vientiane, to enhance the use of research evidence to inform policy. UHEP will focus on health technology assessment (HTA) as a tool to enable priority-setting.\nWe aim to complete four main activities for this pilot project over one year.\n\n\n Situational analysis of the Lao health policy context including stakeholder mapping\n Training of Lao researchers and policy makers in HTA and on synthesis and use of research evidence (includes funding for one MSc student)\n Development of a roadmap for institutionalisation of rational priority setting in health policy development in Laos\n Selection and implementation of a pilot HTA project\n\n\nAt the end of this year UHEP will be established as a government technical partner for HTA in Laos\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Capacity Building","Evidence-Based Practice","Health Policy","Health Priorities","Humans","Laos","Pilot Projects"]}
{"id":"360G-Wellcome-221565_Z_20_Z","title":"OA Switchboard 2020","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221565/Z/20/Z","description":"Throughout 2020, a project is run to prepare for the OA Switchboard (a collaboratively developed and community run open source solution) to go live as an operational solution. The OA Switchboard provides essential infrastructure and back office services to facilitate the fulfilment of open access strategies across business models, policies and agreements via: 1. communication standards (\u2018metadata\u2019); 2. technical solutions (\u2018hub\u2019); 3. standardised real-time monitoring and reporting.\n\nThe essence of the problems it aims to address as a priority:\n\n\n It is complicated/cumbersome to find out how to get the service charges for a certain OA publication settled, and to prepare for (enable) such financial settlement\n It is a challenge to monitor funds and track spending in real time\n\n\nIn the current situation, enabling open access to scholarship has never been more pressing. Supporting the OA Switchboard is investing in open source infrastructure that will ensure that transformational change to open access can be achieved by all publishers, whilst reducing complexity for funders, institutions and researchers. It will also work alongside and strengthen other initiatives that the Wellcome Trust is supporting in this space, specifically in realising the synergies of interlinking the Journal Checker Tool and the OA Switchboard.\n","plannedDates":[{"endDate":"2021-12-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2021-12-31"}],"amountAwarded":22524,"Financial Year":"2019/20","Lead Applicant":"Ms Claire Redhead","grantProgramme":[{"title":"Discretionary Award - Open research","title_keyword":"Discretionary Award - Open research"}],"Applicant Surname":"Redhead","Partnership Value":22524,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Open-Access-Scholarly-Publishers-Association-OASPA","name":"Open Access Scholarly Publishers Association (OASPA)","addressCountry":"Netherlands","id_and_name":"[\"Open Access Scholarly Publishers Association (OASPA)\", \"360G-Wellcome-ORG:Open-Access-Scholarly-Publishers-Association-OASPA\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Open-Access-Scholarly-Publishers-Association-OASPA","name":"Open Access Scholarly Publishers Association (OASPA)"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"OA Switchboard 2020 Throughout 2020, a project is run to prepare for the OA Switchboard (a collaboratively developed and community run open source solution) to go live as an operational solution. The OA Switchboard provides essential infrastructure and back office services to facilitate the fulfilment of open access strategies across business models, policies and agreements via: 1. communication standards (\u2018metadata\u2019); 2. technical solutions (\u2018hub\u2019); 3. standardised real-time monitoring and reporting.\n\nThe essence of the problems it aims to address as a priority:\n\n\n It is complicated/cumbersome to find out how to get the service charges for a certain OA publication settled, and to prepare for (enable) such financial settlement\n It is a challenge to monitor funds and track spending in real time\n\n\nIn the current situation, enabling open access to scholarship has never been more pressing. Supporting the OA Switchboard is investing in open source infrastructure that will ensure that transformational change to open access can be achieved by all publishers, whilst reducing complexity for funders, institutions and researchers. It will also work alongside and strengthen other initiatives that the Wellcome Trust is supporting in this space, specifically in realising the synergies of interlinking the Journal Checker Tool and the OA Switchboard.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":[]}
{"id":"360G-Wellcome-221564_Z_20_Z","title":"Meat Your Persona","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221564/Z/20/Z","description":"Meat Your Persona will further the public\u2019s understanding of the connection between their meat consumption and its environmental and health impacts and will empower them with accessible information and tools to make better informed choices about their consumption. \n\nBuilding on the successful pilot (https://www.youtube.com/watch?v=QbHb4ap39nw), we propose a national tour, taking Meat Your Persona to audiences at urban and suburban shopping centres and community hubs. Our goal is to reach those with low science capital who are disconnected from the current conversation. In particular we will target Brexit-voting men outside London who are the most likely to eat the most meat and to not connect meat consumption with health and environmental impacts.  \n\nWe will capitalise on renewed public interest in evidence, using creative design methods to convey key facts from the LEAP research so that people are able to make better informed choices. We will actively signpost people to a purpose-built website where they can receive evidence-based support to reduce their meat consumption. The project will be evaluated independently to see if we have achieved our three goals: to drive behaviour change, build public trust in science and inform research through advancing the public conversation.\n","plannedDates":[{"endDate":"2022-01-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2022-01-30"}],"amountAwarded":222683,"Financial Year":"2019/20","Lead Applicant":"Prof Susan Jebb","grantProgramme":[{"title":"Discretionary Award - Public Engagement","title_keyword":"Discretionary Award - Public Engagement"}],"Applicant Surname":"Jebb","Partnership Value":222683,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Meat Your Persona Meat Your Persona will further the public\u2019s understanding of the connection between their meat consumption and its environmental and health impacts and will empower them with accessible information and tools to make better informed choices about their consumption. \n\nBuilding on the successful pilot (https://www.youtube.com/watch?v=QbHb4ap39nw), we propose a national tour, taking Meat Your Persona to audiences at urban and suburban shopping centres and community hubs. Our goal is to reach those with low science capital who are disconnected from the current conversation. In particular we will target Brexit-voting men outside London who are the most likely to eat the most meat and to not connect meat consumption with health and environmental impacts.  \n\nWe will capitalise on renewed public interest in evidence, using creative design methods to convey key facts from the LEAP research so that people are able to make better informed choices. We will actively signpost people to a purpose-built website where they can receive evidence-based support to reduce their meat consumption. The project will be evaluated independently to see if we have achieved our three goals: to drive behaviour change, build public trust in science and inform research through advancing the public conversation.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Health Promotion","Humans","London","Meat","Pilot Projects","United Kingdom"]}
{"id":"360G-Wellcome-221563_A_20_Z","title":"Global Goal: Unite for Our Future","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221563/A/20/Z","description":"Global Citizen and the European Commission ran a campaign, Global Goal: Unite for Our Future, with the aim of ensuring that everywhere in the world, those who need them have access to COVID-19 tests, treatments, and vaccines. The campaign also sought to lessen the impact of COVID-19 on the world\u2019s most vulnerable people, ensuring they still have access to education, clean water, and more.\nThe campaign, launched under the patronage of European Commission President Ursula von der Leyen, focused on the development of tools to tackle COVID-19, and ensuring that these tools are available to all communities equally, as well as mitigating the impacts of COVID-19 on those living in poverty.","plannedDates":[{"endDate":"2020-08-28T00:00:00+00:00","startDate":"2020-05-28T00:00:00+00:00","startDateDateOnly":"2020-05-28","endDateDateOnly":"2020-08-28"}],"amountAwarded":800000,"Financial Year":"2019/20","Lead Applicant":"Mr Nikola Ivezaj","grantProgramme":[{"title":"Discretionary Award - Policy ","title_keyword":"Discretionary Award - Policy "}],"Applicant Surname":"Ivezaj","Partnership Value":800000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Global-Poverty-Project-Inc","name":"Global Poverty Project Inc","addressCountry":"United States","id_and_name":"[\"Global Poverty Project Inc\", \"360G-Wellcome-ORG:Global-Poverty-Project-Inc\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Global-Poverty-Project-Inc","name":"Global Poverty Project Inc"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Global Goal: Unite for Our Future Global Citizen and the European Commission ran a campaign, Global Goal: Unite for Our Future, with the aim of ensuring that everywhere in the world, those who need them have access to COVID-19 tests, treatments, and vaccines. The campaign also sought to lessen the impact of COVID-19 on the world\u2019s most vulnerable people, ensuring they still have access to education, clean water, and more.\nThe campaign, launched under the patronage of European Commission President Ursula von der Leyen, focused on the development of tools to tackle COVID-19, and ensuring that these tools are available to all communities equally, as well as mitigating the impacts of COVID-19 on those living in poverty.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Global Health","Goals","Health Promotion","Humans","Poverty","Vulnerable Populations"]}
{"id":"360G-Wellcome-221559_Z_20_Z","title":"Epidemics Ethics","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221559/Z/20/Z","description":"With this proposal we seek to establish a global community of bioethicists (to be known as 'Epidemics Ethics') combined with a range of online resources and activities together capable of providing real-time, contextually appropriate support to assist researchers, policy-makers, communities, and responders in identifying, analysing and addressing ethical issues arising in the context of global health emergencies. Epidemics Ethics will complement the newly established Public Health Emergency Preparedness and Response Ethics Network (PHEPREN) by providing: timely responses to ethical problems, access to networks of experts, an array of online resources including seminars, workshops, blogs, and ethics briefings on issues of current concern. A key aim of Epidemics Ethics will be to support the establishment of fair, collaborative partnerships to enable ethics research to be conducted by ethics scholars in low and middle-income countries in the context of broader supportive international collaborations. With this in mind, capacity building will be a key focus. \n","plannedDates":[{"endDate":"2023-08-30T00:00:00+00:00","startDate":"2020-08-31T00:00:00+00:00","startDateDateOnly":"2020-08-31","endDateDateOnly":"2023-08-30"}],"amountAwarded":283840,"Financial Year":"2019/20","Lead Applicant":"Prof Michael Parker","grantProgramme":[{"title":"Coronavirus","title_keyword":"Coronavirus"}],"Partnership Name":"Wellcome-DFID Epidemic Preparedness","Applicant Surname":"Parker","Partnership Value":567681,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Epidemics Ethics With this proposal we seek to establish a global community of bioethicists (to be known as 'Epidemics Ethics') combined with a range of online resources and activities together capable of providing real-time, contextually appropriate support to assist researchers, policy-makers, communities, and responders in identifying, analysing and addressing ethical issues arising in the context of global health emergencies. Epidemics Ethics will complement the newly established Public Health Emergency Preparedness and Response Ethics Network (PHEPREN) by providing: timely responses to ethical problems, access to networks of experts, an array of online resources including seminars, workshops, blogs, and ethics briefings on issues of current concern. A key aim of Epidemics Ethics will be to support the establishment of fair, collaborative partnerships to enable ethics research to be conducted by ethics scholars in low and middle-income countries in the context of broader supportive international collaborations. With this in mind, capacity building will be a key focus. \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Capacity Building","Disease Outbreaks","Emergencies","Ethics, Research","Global Health","Humans","International Cooperation","Internationality","Public Health"]}
{"id":"360G-Wellcome-221558_Z_20_Z","title":"Full text COVID-19 preprints in Europe PMC","Region":"East of England","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221558/Z/20/Z","description":"In this pandemic, researchers have responded by publishing results rapidly, often through preprints. In fact, about half of the publications in Europe PMC on COVID-19 are preprints rather than peer-reviewed journal articles. Currently, the full text of these preprints are scattered as PDFs on preprint servers, or, available as a non-standard set of documents for machine learning purposes. This proposal is about making the full text of COVID-19 preprints available on Europe PMC, a large and sustainable life sciences archive, for reading and reuse via a standard XML format, alongside peer-reviewed full text articles. Being able to easily search and read preprint full text on a site already frequented by millions of users a month, means that they will be significantly more discoverable by people, and will be able to make use of existing infrastructure to integrate into the typical ecosystem of publications - for example, linking to related data - as well as being more open to scrutiny. This will accelerate scientific research on COVID-19, provide an opportunity to build new open and rapid publication systems, and form a corpus for future history of science research. \n","plannedDates":[{"endDate":"2022-07-17T00:00:00+00:00","startDate":"2020-08-18T00:00:00+00:00","startDateDateOnly":"2020-08-18","endDateDateOnly":"2022-07-17"}],"amountAwarded":324364,"Financial Year":"2019/20","Lead Applicant":"Dr Johanna McEntyre","grantProgramme":[{"title":"Discretionary Award - Open research","title_keyword":"Discretionary Award - Open research"}],"Partnership Name":"Europe Pubmed Central","Applicant Surname":"McEntyre","Partnership Value":404364,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:European-Bioinformatics-Institute","name":"European Bioinformatics Institute","addressCountry":"United Kingdom","id_and_name":"[\"European Bioinformatics Institute\", \"360G-Wellcome-ORG:European-Bioinformatics-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:European-Bioinformatics-Institute","name":"European Bioinformatics Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Full text COVID-19 preprints in Europe PMC In this pandemic, researchers have responded by publishing results rapidly, often through preprints. In fact, about half of the publications in Europe PMC on COVID-19 are preprints rather than peer-reviewed journal articles. Currently, the full text of these preprints are scattered as PDFs on preprint servers, or, available as a non-standard set of documents for machine learning purposes. This proposal is about making the full text of COVID-19 preprints available on Europe PMC, a large and sustainable life sciences archive, for reading and reuse via a standard XML format, alongside peer-reviewed full text articles. Being able to easily search and read preprint full text on a site already frequented by millions of users a month, means that they will be significantly more discoverable by people, and will be able to make use of existing infrastructure to integrate into the typical ecosystem of publications - for example, linking to related data - as well as being more open to scrutiny. This will accelerate scientific research on COVID-19, provide an opportunity to build new open and rapid publication systems, and form a corpus for future history of science research. \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Europe","Humans","Publications","Publishing"]}
{"id":"360G-Wellcome-221556_Z_20_Z","title":"COVER","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221556/Z/20/Z","description":"With the rapid development of candidate vaccines for COVID-19, this project will identify and provide guidance on a range ethical issues arising in the development and deployment of COVID-19 vaccines. Over the next six months, the COVER project will concentrate on the ethics of vaccine research and development\u2014including phase 3 trial design and equitable inclusion of special populations in the research agenda, with a particular focus on pregnant women as well as population groups that have or likely will experience disproportionate burden from COVID-19. This project will also conduct formative landscaping work on the ethical challenges and tradeoffs in the allocation and deployment of vaccines, both globally and within nations. This work will lay the groundwork for normative guidance and mathematical models to best inform policymaking once efficacious vaccines become available for wider use, with explicit consideration and assessment of how various approaches will not only impact the trajectory of the COVID-19 pandemic overall, but also how the benefits of vaccination will be fairly distributed across different population subgroups. In addition, the COVER project will begin to address ethical issues of COVID-19 vaccine development and deployment specific to Africa, with a concentrated body of work in Nigeria.\n","plannedDates":[{"endDate":"2021-09-02T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2021-09-02"}],"amountAwarded":198817,"Financial Year":"2019/20","Lead Applicant":"Prof Ruth Faden","grantProgramme":[{"title":"Coronavirus","title_keyword":"Coronavirus"}],"Applicant Surname":"Faden","Partnership Value":198817,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Johns-Hopkins-University","name":"Johns Hopkins University","addressCountry":"United States","id_and_name":"[\"Johns Hopkins University\", \"360G-Wellcome-ORG:Johns-Hopkins-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Johns-Hopkins-University","name":"Johns Hopkins University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"COVER With the rapid development of candidate vaccines for COVID-19, this project will identify and provide guidance on a range ethical issues arising in the development and deployment of COVID-19 vaccines. Over the next six months, the COVER project will concentrate on the ethics of vaccine research and development\u2014including phase 3 trial design and equitable inclusion of special populations in the research agenda, with a particular focus on pregnant women as well as population groups that have or likely will experience disproportionate burden from COVID-19. This project will also conduct formative landscaping work on the ethical challenges and tradeoffs in the allocation and deployment of vaccines, both globally and within nations. This work will lay the groundwork for normative guidance and mathematical models to best inform policymaking once efficacious vaccines become available for wider use, with explicit consideration and assessment of how various approaches will not only impact the trajectory of the COVID-19 pandemic overall, but also how the benefits of vaccination will be fairly distributed across different population subgroups. In addition, the COVER project will begin to address ethical issues of COVID-19 vaccine development and deployment specific to Africa, with a concentrated body of work in Nigeria.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa","Africa South of the Sahara","Biomedical Research","Female","Humans","Immunization Programs","Nigeria","Pregnancy","Research Design","Vaccination","Vaccines"]}
{"id":"360G-Wellcome-221553_Z_20_Z","title":"The benefits of decarbonised electricity generation in cities  ","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221553/Z/20/Z","description":"While prior national level and regional studies have evaluated the contribution of coal combustion on air quality-related health impacts at the national or regional level, a concrete understanding of how coal combustion impacts urban populations can make a strong case for the rapid phase-out of coal-fired electricity generation in cities around the world.\n\nProject aims:\n\n(1) demonstrate a strong urban case for a rapid-phase out of coal-fired electricity generation; and (2) utilise the research results for an effective advocacy and communications campaign at COP26.  In the research project, C40 will estimate the contribution of coal combustion for C40 city electricity generation to global GHG emissions, to air quality-related health burdens in C40 cities, to COVID-19-related health impacts as well as analyse the economic benefits of different coal phase-out scenarios by looking at: (1) the economic value of improved health associated with reduced coal combustion for electricity generation in C40 cities; and (2) the number of net jobs that are generated with a switch from coal combustion to clean energy.\n \n\n \n","plannedDates":[{"endDate":"2021-12-31T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-12-31"}],"amountAwarded":233652,"Financial Year":"2019/20","Lead Applicant":"Mr Markus Berensson","grantProgramme":[{"title":"Discretionary Award - OPOH","title_keyword":"Discretionary Award - OPOH"}],"Applicant Surname":"Berensson","Partnership Value":233652,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:C40-Cities","name":"C40 Cities","addressCountry":"United States","id_and_name":"[\"C40 Cities\", \"360G-Wellcome-ORG:C40-Cities\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:C40-Cities","name":"C40 Cities"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The benefits of decarbonised electricity generation in cities   While prior national level and regional studies have evaluated the contribution of coal combustion on air quality-related health impacts at the national or regional level, a concrete understanding of how coal combustion impacts urban populations can make a strong case for the rapid phase-out of coal-fired electricity generation in cities around the world.\n\nProject aims:\n\n(1) demonstrate a strong urban case for a rapid-phase out of coal-fired electricity generation; and (2) utilise the research results for an effective advocacy and communications campaign at COP26.  In the research project, C40 will estimate the contribution of coal combustion for C40 city electricity generation to global GHG emissions, to air quality-related health burdens in C40 cities, to COVID-19-related health impacts as well as analyse the economic benefits of different coal phase-out scenarios by looking at: (1) the economic value of improved health associated with reduced coal combustion for electricity generation in C40 cities; and (2) the number of net jobs that are generated with a switch from coal combustion to clean energy.\n \n\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Air Pollutants","Air Pollution","Cities","Coal","Electricity","Power Plants"]}
{"id":"360G-Wellcome-221551_Z_20_Z","title":"Resilience and Digital Engagement in the time of Coronavirus. ASDC Proposal for A National Support Programme for UK Science Centres","Region":"South West","currency":"GBP","awardDate":"2019-10-23T00:00:00+00:00","Internal ID":"221551/Z/20/Z","description":"The Vision: To support the UK Science and Discovery Centres in response to Coronavirus, by creating and delivering a National Resilience Programme accessible by all UK charitable Science Centres, and to further support the sector through a Leadership and knowledge exchange programme, and a Digital Resilience Programme working with Communities across the UK.\n\nThe Mission: To develop and deliver a National Resilience Programme to enhance Resilience of UK Science Centres during this time of restrictions due to Coronavirus and to ensure this is adaptable to what is needed by Science Centres and remains relevant across 2020 and 2021. To select 15 UK Science Centres and grant-fund these as part of a National Digital Resilience Programme to engage, inspire and involve under-represented children, families and communities with STEM and to raise the profile of the UK Science Centres over the coming year.","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":77632,"Financial Year":"2019/20","Lead Applicant":"Ms Shaaron Leverment","grantProgramme":[{"title":"Discretionary Award - Public Engagement","title_keyword":"Discretionary Award - Public Engagement"}],"Partnership Name":"WT/BEIS Inspiring Science","Applicant Surname":"Leverment","Partnership Value":241095,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:UK-Association-for-Science-and-Discovery-Centres-ASDC","name":"UK Association for Science and Discovery Centres (ASDC)","addressCountry":"United Kingdom","id_and_name":"[\"UK Association for Science and Discovery Centres (ASDC)\", \"360G-Wellcome-ORG:UK-Association-for-Science-and-Discovery-Centres-ASDC\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:UK-Association-for-Science-and-Discovery-Centres-ASDC","name":"UK Association for Science and Discovery Centres (ASDC)"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Resilience and Digital Engagement in the time of Coronavirus. ASDC Proposal for A National Support Programme for UK Science Centres The Vision: To support the UK Science and Discovery Centres in response to Coronavirus, by creating and delivering a National Resilience Programme accessible by all UK charitable Science Centres, and to further support the sector through a Leadership and knowledge exchange programme, and a Digital Resilience Programme working with Communities across the UK.\n\nThe Mission: To develop and deliver a National Resilience Programme to enhance Resilience of UK Science Centres during this time of restrictions due to Coronavirus and to ensure this is adaptable to what is needed by Science Centres and remains relevant across 2020 and 2021. To select 15 UK Science Centres and grant-fund these as part of a National Digital Resilience Programme to engage, inspire and involve under-represented children, families and communities with STEM and to raise the profile of the UK Science Centres over the coming year.","awardDateDateOnly":"2019-10-23","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Coronavirus","Humans","Leadership","United Kingdom"]}
{"id":"360G-Wellcome-221548_Z_20_Z","title":"A modern cryo-EM instrument for biological samples at Imperial College London","Region":"Greater London","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221548/Z/20/Z","description":"The Centre for Structural Biology at Imperial College London includes a heavily-used electron microscopy facility on the South Kensington campus that features four electron microscopes for single particle and tomographic analysis of biological samples. A large and rapidly-growing Imperial- and London-based user community spanning molecular biology, chemical biology, and drug development, uses these instruments for sample screening, optimisation, and data collection. These instruments, however, are all based on 20+ year-old archetype, resulting in rising maintenance costs and risk become irreparable any day due to inability to source replacement parts. These machines are also bottlenecks, incapable of providing high-throughput screening, optimisation, and data collection needed to feed high-resolution data collection instruments such as Titan Krioses accessible at various UK-based facilities. Our community is in urgent need of a contemporary electron microscope such as a Talos Arctica capable of both single particle and tomography cryoEM, equipped with technology for rapid screening and optimisation and compatibility with Krios sample handling. The instrument will be embedded and managed within the CSB EM facility and accessible by all CSB users on an hourly user rate basis to guarantee full cost recovery, a company-based service contract, and long-term sustainability.\n","plannedDates":[{"endDate":"2025-09-20T00:00:00+00:00","startDate":"2020-09-21T00:00:00+00:00","startDateDateOnly":"2020-09-21","endDateDateOnly":"2025-09-20"}],"amountAwarded":997614,"Financial Year":"2019/20","Lead Applicant":"Prof Thomas Meier","grantProgramme":[{"title":"Multi-User Equipment Grant","title_keyword":"Multi-User Equipment Grant"}],"Applicant Surname":"Meier","Partnership Value":997614,"Approval Committee":"Multi-User Equipment and Technology Development Committee","Other Applicant(s)":"Dr Harry Low, Dr Tiago Costa, Prof Xiaodong Zhang, Dr Alfonso De Simone, Dr Christopher Aylett, Dr Morgan Beeby, Prof Dale Wigley, Dr Doryen Bubeck, Prof Christian Speck","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A modern cryo-EM instrument for biological samples at Imperial College London The Centre for Structural Biology at Imperial College London includes a heavily-used electron microscopy facility on the South Kensington campus that features four electron microscopes for single particle and tomographic analysis of biological samples. A large and rapidly-growing Imperial- and London-based user community spanning molecular biology, chemical biology, and drug development, uses these instruments for sample screening, optimisation, and data collection. These instruments, however, are all based on 20+ year-old archetype, resulting in rising maintenance costs and risk become irreparable any day due to inability to source replacement parts. These machines are also bottlenecks, incapable of providing high-throughput screening, optimisation, and data collection needed to feed high-resolution data collection instruments such as Titan Krioses accessible at various UK-based facilities. Our community is in urgent need of a contemporary electron microscope such as a Talos Arctica capable of both single particle and tomography cryoEM, equipped with technology for rapid screening and optimisation and compatibility with Krios sample handling. The instrument will be embedded and managed within the CSB EM facility and accessible by all CSB users on an hourly user rate basis to guarantee full cost recovery, a company-based service contract, and long-term sustainability.\n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cryoelectron Microscopy","Electron Microscope Tomography","London","Specimen Handling"]}
{"id":"360G-Wellcome-221546_Z_20_Z","title":"Accelerating analysis of viruses, vesicles and nanoparticles with nanoscale flow cytometry","Region":"Greater London","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221546/Z/20/Z","description":"Multiparameter analysis of nanoscale entities such as viruses, nanoparticles and extracellular vesicles is restricted by the limited resolution of standard flow cytometers. Both the nanoparticle and extracellular vesicle fields are rapidly growing in the academic and commercial setting.\n\nWe are applying for a state-of-the-art dual-laser Flow NanoAnalyzer (model U30) from NanoFCM, as well as five years discounted servicing and support. The Flow NanoAnalyzer (FNA) is an innovative flow cytometer which has been specifically engineered to surpass the nanoparticle detection limitations of current commercial flow cytometers. In particular, the FNA enables detection of nanomaterials, nano-drug delivery systems, bacteria, viruses, cell organelles (e.g. mitochondria) and extracellular vesicles (e.g. exosomes and microvesicles) within a size range of 7-1000nm. The FNA is equipped with one highly sensitive side scatter channel, a 488 nm laser, a 638 nm laser and three single-photon counting module (SPCM) detectors (525/40 nm, 580/40 nm and  > 650 nm) to enable multi-colour/parameter experiments.\n\nThe FNA only recently launched in the UK (April 2019). Therefore, if funded, Imperial will become one of the first UK (and potentially European) universities to have this machine. This will attract significant interest from UK, as well as, international academic and industrial collaborators or users.\n","plannedDates":[{"endDate":"2025-10-31T00:00:00+00:00","startDate":"2020-11-01T00:00:00+00:00","startDateDateOnly":"2020-11-01","endDateDateOnly":"2025-10-31"}],"amountAwarded":172500,"Financial Year":"2019/20","Lead Applicant":"Dr Beth Holder","grantProgramme":[{"title":"Multi-User Equipment Grant","title_keyword":"Multi-User Equipment Grant"}],"Applicant Surname":"Holder","Partnership Value":172500,"Approval Committee":"Multi-User Equipment and Technology Development Committee","Other Applicant(s)":"Dr Richard Kelwick","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Accelerating analysis of viruses, vesicles and nanoparticles with nanoscale flow cytometry Multiparameter analysis of nanoscale entities such as viruses, nanoparticles and extracellular vesicles is restricted by the limited resolution of standard flow cytometers. Both the nanoparticle and extracellular vesicle fields are rapidly growing in the academic and commercial setting.\n\nWe are applying for a state-of-the-art dual-laser Flow NanoAnalyzer (model U30) from NanoFCM, as well as five years discounted servicing and support. The Flow NanoAnalyzer (FNA) is an innovative flow cytometer which has been specifically engineered to surpass the nanoparticle detection limitations of current commercial flow cytometers. In particular, the FNA enables detection of nanomaterials, nano-drug delivery systems, bacteria, viruses, cell organelles (e.g. mitochondria) and extracellular vesicles (e.g. exosomes and microvesicles) within a size range of 7-1000nm. The FNA is equipped with one highly sensitive side scatter channel, a 488 nm laser, a 638 nm laser and three single-photon counting module (SPCM) detectors (525/40 nm, 580/40 nm and  > 650 nm) to enable multi-colour/parameter experiments.\n\nThe FNA only recently launched in the UK (April 2019). Therefore, if funded, Imperial will become one of the first UK (and potentially European) universities to have this machine. This will attract significant interest from UK, as well as, international academic and industrial collaborators or users.\n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Extracellular Vesicles","Flow Cytometry","Humans","Lasers","Nanoparticles"]}
{"id":"360G-Wellcome-221544_Z_20_Z","title":"State of the art MEG-TRIUX-neo for advancing multi-modal neuroimaging techniques in Scotland","Region":"Scotland","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221544/Z/20/Z","description":"Magnetoencephalography (MEG) is an advanced technology using super-conducting quantum interference devices (SQUIDs) for measuring the tiny magnetic fields produced by the coherent electrical activity in groups of neurons. MEG is the only neuroimaging technology that enables non-invasive recordings with both excellent temporal and good anatomical resolutions. Such spatiotemporal accuracy is instrumental for discovering the mechanisms underlying mental functions and deficits in healthy and impaired brains.\n\nWe seek Wellcome Trust funding to replace our 12-year old MEG system with a state-of-the-art TRIUX-neo from MEGIN Ltd. The TRIUX-neo is an ultra-sensitive system based on new technology that combines MEG recordings with high-density EEG, online head-motion tracking and a helium recycling mechanism now essential with worldwide helium shortage.\n\nWith the TRIUX-neo, our multi-user MEG group (with significant Wellcome Trust funding, Investigator, Innovator, Seed and Sir Henry Wellcome Fellowship) will keep enhancing its cutting-edge, unique, cohesive and collaborative research and pioneer new methods and techniques across our extensive platform of in-house imaging facilities (i.e. EEG, MEG, NIRS, 3/7T fMRI).\n\nKey MEG innovations will focus on understanding brain network dynamics and oscillations in health and disease, using information theory and advanced network analyses and unique data fusion of EEG and 3/7TfMRI and neurostimulation (TMS, tES).\n","plannedDates":[{"endDate":"2026-03-28T00:00:00+00:00","startDate":"2021-03-29T00:00:00+00:00","startDateDateOnly":"2021-03-29","endDateDateOnly":"2026-03-28"}],"amountAwarded":1000000,"Financial Year":"2019/20","Lead Applicant":"Prof Philippe Schyns","grantProgramme":[{"title":"Multi-User Equipment Grant","title_keyword":"Multi-User Equipment Grant"}],"Applicant Surname":"Schyns","Partnership Value":1000000,"Approval Committee":"Multi-User Equipment and Technology Development Committee","Other Applicant(s)":"Dr Marios Philiastides, Dr Robin Ince, Prof Peter Uhlhaas, Prof Satu Palva, Prof Gregor Thut, Prof J. Matias Palva","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow","addressCountry":"United Kingdom","id_and_name":"[\"University of Glasgow\", \"360G-Wellcome-ORG:University-of-Glasgow\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"State of the art MEG-TRIUX-neo for advancing multi-modal neuroimaging techniques in Scotland Magnetoencephalography (MEG) is an advanced technology using super-conducting quantum interference devices (SQUIDs) for measuring the tiny magnetic fields produced by the coherent electrical activity in groups of neurons. MEG is the only neuroimaging technology that enables non-invasive recordings with both excellent temporal and good anatomical resolutions. Such spatiotemporal accuracy is instrumental for discovering the mechanisms underlying mental functions and deficits in healthy and impaired brains.\n\nWe seek Wellcome Trust funding to replace our 12-year old MEG system with a state-of-the-art TRIUX-neo from MEGIN Ltd. The TRIUX-neo is an ultra-sensitive system based on new technology that combines MEG recordings with high-density EEG, online head-motion tracking and a helium recycling mechanism now essential with worldwide helium shortage.\n\nWith the TRIUX-neo, our multi-user MEG group (with significant Wellcome Trust funding, Investigator, Innovator, Seed and Sir Henry Wellcome Fellowship) will keep enhancing its cutting-edge, unique, cohesive and collaborative research and pioneer new methods and techniques across our extensive platform of in-house imaging facilities (i.e. EEG, MEG, NIRS, 3/7T fMRI).\n\nKey MEG innovations will focus on understanding brain network dynamics and oscillations in health and disease, using information theory and advanced network analyses and unique data fusion of EEG and 3/7TfMRI and neurostimulation (TMS, tES).\n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Brain","Brain Mapping","Electroencephalography","Humans","Magnetic Resonance Imaging","Magnetoencephalography"]}
{"id":"360G-Wellcome-221543_Z_20_Z","title":"Strategic upgrade of crystal monitoring and optimisation equipment at ISMB, as critical infrastructure for structural biology and biochemistry","Region":"Greater London","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221543/Z/20/Z","description":"ISMB (Birkbeck/UCL) is renowned for its research in structural biology, successfully combining X-ray crystallography and electron microscopy and supporting users from a wider scientific community. The current set up for crystallisation includes a nanoliter liquid handler (Mosquito, SPT Labtech), an old Perkin-Elmer liquid handling robot for sample optimisation and an outdated Minstrel/Rigaku automated imaging suite. Recent crystallography beamline technological developments at high-end synchrotrons have pushed the boundaries of data collection and reduced the usable size of crystals down to a few microns. However, our current instrumentation does not allow us to take full advantage of these new technologies since refinement of crystallisation conditions, and monitoring of \u2018microcrystals\u2019 growth, cannot be managed by our outdated equipment. Moreover, two of the existing instruments are no longer supported by authorized services.\n\nTherefore, we are requesting the purchase of a new state-of-the-art \u2018imaging hotel\u2019 (UVEXps, swissci) and liquid handler (Dragonfly, SPT Labtech). Specifically, we propose to purchase a microliter liquid handler for optimisation of crystallisation conditions and a high-resolution crystal imaging system for storage, monitoring, imaging and detection of protein crystals. The two instruments will complement the existing liquid handler (Mosquito), while offering more flexibility to all users by remote access.\n","plannedDates":[{"endDate":"2025-11-07T00:00:00+00:00","startDate":"2020-11-08T00:00:00+00:00","startDateDateOnly":"2020-11-08","endDateDateOnly":"2025-11-07"}],"amountAwarded":232273,"Financial Year":"2019/20","Lead Applicant":"Prof Gabriel Waksman","grantProgramme":[{"title":"Multi-User Equipment Grant","title_keyword":"Multi-User Equipment Grant"}],"Applicant Surname":"Waksman","Partnership Value":232273,"Approval Committee":"Multi-User Equipment and Technology Development Committee","Other Applicant(s)":"Dr Matthew Gold, Prof Gregory Towers, Dr Anthony Roberts, Dr Nikos Pinotsis, Prof Snezana Djordjevic, Prof Finn Werner, Prof Trevor Smart, Prof Bonnie Wallace, Prof Frances Brodsky","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Birkbeck-University-of-London","name":"Birkbeck University of London","addressCountry":"United Kingdom","id_and_name":"[\"Birkbeck University of London\", \"360G-Wellcome-ORG:Birkbeck-University-of-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Birkbeck-University-of-London","name":"Birkbeck University of London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Strategic upgrade of crystal monitoring and optimisation equipment at ISMB, as critical infrastructure for structural biology and biochemistry ISMB (Birkbeck/UCL) is renowned for its research in structural biology, successfully combining X-ray crystallography and electron microscopy and supporting users from a wider scientific community. The current set up for crystallisation includes a nanoliter liquid handler (Mosquito, SPT Labtech), an old Perkin-Elmer liquid handling robot for sample optimisation and an outdated Minstrel/Rigaku automated imaging suite. Recent crystallography beamline technological developments at high-end synchrotrons have pushed the boundaries of data collection and reduced the usable size of crystals down to a few microns. However, our current instrumentation does not allow us to take full advantage of these new technologies since refinement of crystallisation conditions, and monitoring of \u2018microcrystals\u2019 growth, cannot be managed by our outdated equipment. Moreover, two of the existing instruments are no longer supported by authorized services.\n\nTherefore, we are requesting the purchase of a new state-of-the-art \u2018imaging hotel\u2019 (UVEXps, swissci) and liquid handler (Dragonfly, SPT Labtech). Specifically, we propose to purchase a microliter liquid handler for optimisation of crystallisation conditions and a high-resolution crystal imaging system for storage, monitoring, imaging and detection of protein crystals. The two instruments will complement the existing liquid handler (Mosquito), while offering more flexibility to all users by remote access.\n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Crystallization","Crystallography, X-Ray","Culicidae","Mosquito Control","Robotics"]}
{"id":"360G-Wellcome-221542_Z_20_Z","title":"Focussing on biomedical discovery in the North-East of England: A high-throughput/high-content live imaging system for cells, tissues and small model organisms","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221542/Z/20/Z","description":"The Flow Cytometry  &  Imaging Facility, Leeds Institute of Medical Research, needs to expand capability and capacity for live cell and high content imaging (HCI) to serve the local and wider scientific community. We request part-funding of a LIPSI high content/multichannel live-cell imager with environmental control (Nikon Instruments UK Ltd). The acquisition of a state-of-the-art LIPSI will replace our obsolete Operetta and Incucyte instruments and will transform our Facility by allowing fully integrated, automated, high-throughput, and high-content/live-cell imaging. The system allows very rapid epifluorescence (six simultaneous fluorescence channels), chromogenic and DIC acquisitions whilst running multiple time-lapse assays with sampling rates up to 60fps. This allows imaging of long-term live-cell 2D/3D cell cultures, tissue sections, small model organisms or rapid HCI of fixed cells. For increased throughput, the LIPSI includes motorised stage, robotic handler and environmentally-controlled plate-holder. This enables streamlined automated processing of multiplexed long-term live cell functional assays, with complex imaging schedules in both hypoxic and normoxic environments for up to 20 plates. Standard acquisitions comprise multichannel, time-lapse, multiple-positions, z-stacks, large images and multidimensional imaging using standard plastic or glass SBS plate, dish and slide formats used within the Facility.\n","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":162283,"Financial Year":"2019/20","Lead Applicant":"Prof Colin Johnson","grantProgramme":[{"title":"Multi-User Equipment Grant","title_keyword":"Multi-User Equipment Grant"}],"Applicant Surname":"Johnson","Partnership Value":162283,"Approval Committee":"Multi-User Equipment and Technology Development Committee","Other Applicant(s)":"Prof Susan Burchill, Prof Robert Ari\u00ebns, Dr Jacquelyn Bond, Dr Patricija van Oosten-Hawle, Prof Andrew Wilson, Prof Michelle Peckham, Prof Nikita Gamper","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds","addressCountry":"United Kingdom","id_and_name":"[\"University of Leeds\", \"360G-Wellcome-ORG:University-of-Leeds\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Focussing on biomedical discovery in the North-East of England: A high-throughput/high-content live imaging system for cells, tissues and small model organisms The Flow Cytometry  &  Imaging Facility, Leeds Institute of Medical Research, needs to expand capability and capacity for live cell and high content imaging (HCI) to serve the local and wider scientific community. We request part-funding of a LIPSI high content/multichannel live-cell imager with environmental control (Nikon Instruments UK Ltd). The acquisition of a state-of-the-art LIPSI will replace our obsolete Operetta and Incucyte instruments and will transform our Facility by allowing fully integrated, automated, high-throughput, and high-content/live-cell imaging. The system allows very rapid epifluorescence (six simultaneous fluorescence channels), chromogenic and DIC acquisitions whilst running multiple time-lapse assays with sampling rates up to 60fps. This allows imaging of long-term live-cell 2D/3D cell cultures, tissue sections, small model organisms or rapid HCI of fixed cells. For increased throughput, the LIPSI includes motorised stage, robotic handler and environmentally-controlled plate-holder. This enables streamlined automated processing of multiplexed long-term live cell functional assays, with complex imaging schedules in both hypoxic and normoxic environments for up to 20 plates. Standard acquisitions comprise multichannel, time-lapse, multiple-positions, z-stacks, large images and multidimensional imaging using standard plastic or glass SBS plate, dish and slide formats used within the Facility.\n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Flow Cytometry","High-Throughput Screening Assays","Humans","Image Processing, Computer-Assisted","Robotics","Time-Lapse Imaging"]}
{"id":"360G-Wellcome-221539_Z_20_Z","title":"LASCOPE extension","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221539/Z/20/Z","description":"The \"Lassa fever Clinical Course and Prognostic factors (LASCOPE)\" project is a prospective cohort study of patients with acute symptomatic Lassa fever (LF) hospitalized in dedicated treatment centers in Nigeria. The patients have access, free of charge, to reliable molecular diagnosis of LF, ribavirin therapy and an improved standard of supportive care including renal replacement therapy. This study aims at producing up to date data on LF disease presentation and course, management, outcomes and factors associated to fatality. The data produced by the LASCOPE study will inform the design of future trials evaluating innovative therapeutic strategies for LF, as well as the development of updated guidelines for the management of patients with LF. Lastly, this project will contribute to the development of clinical research capacities in the participating sites and put them in position to conduct future therapeutic and vaccine trials for LF.\n","plannedDates":[{"endDate":"2020-09-14T00:00:00+00:00","startDate":"2020-06-15T00:00:00+00:00","startDateDateOnly":"2020-06-15","endDateDateOnly":"2020-09-14"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Prof Peter Horby","grantProgramme":[{"title":"DFID-Wellcome Epidemic Preparedness Grant","title_keyword":"DFID-Wellcome Epidemic Preparedness Grant"}],"Partnership Name":"Wellcome-DFID Epidemic Preparedness","Applicant Surname":"Horby","Partnership Value":129995,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"LASCOPE extension The \"Lassa fever Clinical Course and Prognostic factors (LASCOPE)\" project is a prospective cohort study of patients with acute symptomatic Lassa fever (LF) hospitalized in dedicated treatment centers in Nigeria. The patients have access, free of charge, to reliable molecular diagnosis of LF, ribavirin therapy and an improved standard of supportive care including renal replacement therapy. This study aims at producing up to date data on LF disease presentation and course, management, outcomes and factors associated to fatality. The data produced by the LASCOPE study will inform the design of future trials evaluating innovative therapeutic strategies for LF, as well as the development of updated guidelines for the management of patients with LF. Lastly, this project will contribute to the development of clinical research capacities in the participating sites and put them in position to conduct future therapeutic and vaccine trials for LF.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Acute Disease","Clinical Trials as Topic","Humans","Lassa Fever","Lassa virus","Nigeria","Prospective Studies","Research Design","Ribavirin","Treatment Outcome"]}
{"id":"360G-Wellcome-221538_Z_20_Z","title":"Live cell imaging capability for research on pathogenic viruses","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221538/Z/20/Z","description":"We request a 75% contribution to purchase two IncuCyte S3 Live-Cell Analysis Systems, together with archive data storage capacity (\u00a3189,485). These instruments are designed to acquire real-time growth, migration, morphology, phenotypic and gene expression data from virus-infected cells in microplates.  They will be located in newly-opened Biological Safety Level 3 (BSL3) and BSL2 laboratories, transforming existing capacity for real-time analysis of virus-infected cells and enabling ambitious plans for expansion of virology research.  The overall aims of the research supported by these instruments are: 1) to understand the molecular mechanisms by which viruses enter cells, replicate their genomes and assemble into infectious virions, and 2) to drive early-stage development of new anti-viral therapeutics (eg screening compound libraries).  The IncuCyte instruments will facilitate both work streams. They will be housed in standard cell culture incubators and can be remote controlled allowing the analysis of cell parameters over time safely without disturbance.  In order to effectively train users, provide technical advice, oversee usage and manage the instruments, we also request funding for 10% of the salary of the current BSL2/BSL3 laboratory manager, and 5% of the BioImaging facility support scientist over 5 years (\u00a331,390).\n","plannedDates":[{"endDate":"2026-01-03T00:00:00+00:00","startDate":"2021-01-04T00:00:00+00:00","startDateDateOnly":"2021-01-04","endDateDateOnly":"2026-01-03"}],"amountAwarded":189485,"Financial Year":"2019/20","Lead Applicant":"Prof Mark Harris","grantProgramme":[{"title":"Multi-User Equipment Grant","title_keyword":"Multi-User Equipment Grant"}],"Applicant Surname":"Harris","Partnership Value":189485,"Approval Committee":"Multi-User Equipment and Technology Development Committee","Other Applicant(s)":"Dr Jamel Mankouri, Prof Nicola Stonehouse, Dr Andrew Tuplin, Dr John Barr, Dr Juan Fontana Jordan de Urries, Prof Adrian Whitehouse, Prof Andrew Macdonald, Dr Morgan Herod, Prof Peter Stockley","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds","addressCountry":"United Kingdom","id_and_name":"[\"University of Leeds\", \"360G-Wellcome-ORG:University-of-Leeds\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Live cell imaging capability for research on pathogenic viruses We request a 75% contribution to purchase two IncuCyte S3 Live-Cell Analysis Systems, together with archive data storage capacity (\u00a3189,485). These instruments are designed to acquire real-time growth, migration, morphology, phenotypic and gene expression data from virus-infected cells in microplates.  They will be located in newly-opened Biological Safety Level 3 (BSL3) and BSL2 laboratories, transforming existing capacity for real-time analysis of virus-infected cells and enabling ambitious plans for expansion of virology research.  The overall aims of the research supported by these instruments are: 1) to understand the molecular mechanisms by which viruses enter cells, replicate their genomes and assemble into infectious virions, and 2) to drive early-stage development of new anti-viral therapeutics (eg screening compound libraries).  The IncuCyte instruments will facilitate both work streams. They will be housed in standard cell culture incubators and can be remote controlled allowing the analysis of cell parameters over time safely without disturbance.  In order to effectively train users, provide technical advice, oversee usage and manage the instruments, we also request funding for 10% of the salary of the current BSL2/BSL3 laboratory manager, and 5% of the BioImaging facility support scientist over 5 years (\u00a331,390).\n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans"]}
{"id":"360G-Wellcome-221531_Z_20_Z","title":"Use of CGD to address DRIs in Kenya","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221531/Z/20/Z","description":"Global action to tackle AMR is insufficient because public engagement on AMR is limited[1]. CGD[2] can help close this gap and help communities and decision-makers take collective action on AMR.\n\nThis project will apply CGD methods in three Kenyan counties over 14 months to empower communities, health-workers, researchers and policymakers to generate and use data on AMR. A robust scoping phase will involve stakeholder consultations to tailor CGD methods and engagement mechanisms to the local contexts. The project will have three tracks:  \n\n\n Data to Empower: engaging citizens to better understand AMR related behavior and perceptions, and empowering citizens with objective and contextually relevant information \n Data to Give Direction: using CGD to empower citizens to change behaviors, fill evidence gaps for the research community, and support health policy decision-making,  \n Advocacy on CGD: encouraging researchers and policymakers to incorporate CGD as an important source of evidence for more holistic AMR policies\n\n\n[1] https://wellcome.ac.uk/reports/reframing-antimicrobial-resistance-antibiotic-resistance\n\n[2] CGD is \u2018data that people or their organisations produce to directly monitor, demand or drive change on issues that affect them. It is actively given by citizens, providing direct representations of their perspectives and an alternative to datasets collected by governments or international institutions\u2019\n","plannedDates":[{"endDate":"2021-10-03T00:00:00+00:00","startDate":"2020-08-03T00:00:00+00:00","startDateDateOnly":"2020-08-03","endDateDateOnly":"2021-10-03"}],"amountAwarded":602803,"Financial Year":"2019/20","Lead Applicant":"Ms Jenna Slotin","grantProgramme":[{"title":"Discretionary Award - Public Engagement","title_keyword":"Discretionary Award - Public Engagement"}],"Applicant Surname":"Slotin","Partnership Value":602803,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:The-United-Nations-Foundation","name":"The United Nations Foundation","addressCountry":"United States","id_and_name":"[\"The United Nations Foundation\", \"360G-Wellcome-ORG:The-United-Nations-Foundation\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:The-United-Nations-Foundation","name":"The United Nations Foundation"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Use of CGD to address DRIs in Kenya Global action to tackle AMR is insufficient because public engagement on AMR is limited[1]. CGD[2] can help close this gap and help communities and decision-makers take collective action on AMR.\n\nThis project will apply CGD methods in three Kenyan counties over 14 months to empower communities, health-workers, researchers and policymakers to generate and use data on AMR. A robust scoping phase will involve stakeholder consultations to tailor CGD methods and engagement mechanisms to the local contexts. The project will have three tracks:  \n\n\n Data to Empower: engaging citizens to better understand AMR related behavior and perceptions, and empowering citizens with objective and contextually relevant information \n Data to Give Direction: using CGD to empower citizens to change behaviors, fill evidence gaps for the research community, and support health policy decision-making,  \n Advocacy on CGD: encouraging researchers and policymakers to incorporate CGD as an important source of evidence for more holistic AMR policies\n\n\n[1] https://wellcome.ac.uk/reports/reframing-antimicrobial-resistance-antibiotic-resistance\n\n[2] CGD is \u2018data that people or their organisations produce to directly monitor, demand or drive change on issues that affect them. It is actively given by citizens, providing direct representations of their perspectives and an alternative to datasets collected by governments or international institutions\u2019\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Health Policy","Humans","Kenya"]}
{"id":"360G-Wellcome-221529_Z_20_Z","title":"Provision of multi-parameter fluorescence-activated cell sorting for functional and genomic analysis of immune cells","Region":"Greater London","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221529/Z/20/Z","description":"This application is for the purchase of a BD Aria-Fusion fluorescence activated cell sorter.  The instrument performs high-speed multi-parameter sorting, allowing isolation of rare cell subsets and supporting single-cell genetic and functional analyses. It will enable scientists at the UCL Institute of Immunity and Transplantation (IIT) to be at the forefront of studies of the patho-physiology of the human immune system and responses to disease treatments. \n\nThis state-of-the-art sorter is essential to allow us to maintain a cutting edge flow-cytometry core facility in the newly constructed Pears building, which will house the IIT from late 2020.  The Pears building is a \u00a361 million joint project between UCL and the Royal Free NHS Foundation Trust to create a world-leading centre for disease-focused immunology research. The building will accommodate some 20 research groups comprising approximately 200 scientists.  The translational immunology programs of the IIT include mechanistic studies in animal models, genetic and functional analyses of the human immune system, high-dimensional analysis of clinical samples and the monitoring of patients participating in novel immunotherapy trials. The technical capability of the FACS-Aria-Fusion is therefore required to support a wide variety of cutting-edge research programs in infection and immunity.\n","plannedDates":[{"endDate":"2025-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2025-12-31"}],"amountAwarded":271222,"Financial Year":"2019/20","Lead Applicant":"Prof David Sansom","grantProgramme":[{"title":"Multi-User Equipment Grant","title_keyword":"Multi-User Equipment Grant"}],"Applicant Surname":"Sansom","Partnership Value":271222,"Approval Committee":"Multi-User Equipment and Technology Development Committee","Other Applicant(s)":"Dr Benedict Seddon, Prof Lucy Walker, Prof Claudia Mauri, Prof Emma Morris, Prof Paul Griffiths, Dr Joe Grove, Prof Benjamin Chain, Prof Mala Maini","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Provision of multi-parameter fluorescence-activated cell sorting for functional and genomic analysis of immune cells This application is for the purchase of a BD Aria-Fusion fluorescence activated cell sorter.  The instrument performs high-speed multi-parameter sorting, allowing isolation of rare cell subsets and supporting single-cell genetic and functional analyses. It will enable scientists at the UCL Institute of Immunity and Transplantation (IIT) to be at the forefront of studies of the patho-physiology of the human immune system and responses to disease treatments. \n\nThis state-of-the-art sorter is essential to allow us to maintain a cutting edge flow-cytometry core facility in the newly constructed Pears building, which will house the IIT from late 2020.  The Pears building is a \u00a361 million joint project between UCL and the Royal Free NHS Foundation Trust to create a world-leading centre for disease-focused immunology research. The building will accommodate some 20 research groups comprising approximately 200 scientists.  The translational immunology programs of the IIT include mechanistic studies in animal models, genetic and functional analyses of the human immune system, high-dimensional analysis of clinical samples and the monitoring of patients participating in novel immunotherapy trials. The technical capability of the FACS-Aria-Fusion is therefore required to support a wide variety of cutting-edge research programs in infection and immunity.\n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Flow Cytometry","Humans"]}
{"id":"360G-Wellcome-221524_Z_20_Z","title":"State of the art direct electron detection at the Astbury Biostructure Laboratory","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221524/Z/20/Z","description":"The Astbury Biostructure Laboratory, was established in 2015 with University of Leeds investment, and a Wellcome multi-user equipment award, allowing us to install two Titan Krios microscopes (2016). In just three years, we have established an international reputation for excellence in cryoEM, and a buoyant user base that means our facility is already operating at capacity. We request funds to upgrade our microscopes, aiming to increase data acquisition rates, whilst improving data quality, allowing us to shorten session lengths, increase sample throughput, and introduce new methodologies.\n\nUpgrades will include:\n1. A ThermoFisher Falcon-4EC camera on Krios#1\n2. A Gatan Bioquantum K3 on Krios#2\n3. Aberration-Free/Fringe Free Imaging Systems (both microscopes)\n4. EPU-D software for electron diffraction (Krios#1)\n5. Whole-system maintenance contract extensions to 5 years from installation.\n\nWe anticipate a 5-8x improvement in data acquisition, empowering users to drive more challenging biological and biomedical discovery. We will be able to determine new high-resolution structures and integrate them into their cellular/tissue context, helping us to understand the molecular basis of diseases such as infections, cardiovascular disease, degeneration and cancer.\n\nWe request \u00a31m from Wellcome, with a University capital contribution of \u00a3325k, plus salary costs, Giving a total project cost of ~\u00a32.13m.\n","plannedDates":[{"endDate":"2026-01-03T00:00:00+00:00","startDate":"2021-01-04T00:00:00+00:00","startDateDateOnly":"2021-01-04","endDateDateOnly":"2026-01-03"}],"amountAwarded":1000000,"Financial Year":"2019/20","Lead Applicant":"Prof Neil Ranson","grantProgramme":[{"title":"Multi-User Equipment Grant","title_keyword":"Multi-User Equipment Grant"}],"Applicant Surname":"Ranson","Partnership Value":1000000,"Approval Committee":"Multi-User Equipment and Technology Development Committee","Other Applicant(s)":"Dr Elton Zeqiraj, Prof Mark Kearney, Prof Peter Stockley, Dr Stephen Muench, Prof Fiona Meldrum, Prof Sheena Radford, Dr Juan Fontana Jordan de Urries, Dr Rebecca Thompson, Prof Richard Bayliss","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds","addressCountry":"United Kingdom","id_and_name":"[\"University of Leeds\", \"360G-Wellcome-ORG:University-of-Leeds\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"State of the art direct electron detection at the Astbury Biostructure Laboratory The Astbury Biostructure Laboratory, was established in 2015 with University of Leeds investment, and a Wellcome multi-user equipment award, allowing us to install two Titan Krios microscopes (2016). In just three years, we have established an international reputation for excellence in cryoEM, and a buoyant user base that means our facility is already operating at capacity. We request funds to upgrade our microscopes, aiming to increase data acquisition rates, whilst improving data quality, allowing us to shorten session lengths, increase sample throughput, and introduce new methodologies.\n\nUpgrades will include:\n1. A ThermoFisher Falcon-4EC camera on Krios#1\n2. A Gatan Bioquantum K3 on Krios#2\n3. Aberration-Free/Fringe Free Imaging Systems (both microscopes)\n4. EPU-D software for electron diffraction (Krios#1)\n5. Whole-system maintenance contract extensions to 5 years from installation.\n\nWe anticipate a 5-8x improvement in data acquisition, empowering users to drive more challenging biological and biomedical discovery. We will be able to determine new high-resolution structures and integrate them into their cellular/tissue context, helping us to understand the molecular basis of diseases such as infections, cardiovascular disease, degeneration and cancer.\n\nWe request \u00a31m from Wellcome, with a University capital contribution of \u00a3325k, plus salary costs, Giving a total project cost of ~\u00a32.13m.\n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cryoelectron Microscopy","Software"]}
{"id":"360G-Wellcome-221523_Z_20_Z","title":"Europe PMC 2021-2026","Region":"East of England","currency":"GBP","awardDate":"2020-12-31T00:00:00+00:00","Internal ID":"221523/Z/20/Z","description":"In the next five years, the necessity for open science to solve global challenges will become increasingly apparent, and the need for Europe PMC as a critical piece of infrastructure will crystallise in the minds and usage patterns of researchers. The world of scientific publishing will undergo major changes, as routes for rapid and transparent publishing emerge, and efforts such as Plan S push towards universal open access. Europe PMC will support these goals by aggregating millions of articles and making them widely available. With a leading role in preprint aggregation and standards development, Europe PMC will be the go-to resource for searching life sciences literature from publication through review, revision, and citation. Publications at all stages need to be grounded in unambiguous links to supporting data, authors and reviewers, funding, and institutions, to build transparency and trust in the content; building these links will be a major direction for Europe PMC. Finally, transformative change in content search and retrieval will come from the development of AI methods that work on open access full text, encouraged by the Europe PMC platform for text and data mining, as well as the demonstration of machine learning benefits in user interfaces.\n","plannedDates":[{"endDate":"2026-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2026-03-31"}],"amountAwarded":1418660,"Financial Year":"2020/21","Lead Applicant":"Dr Johanna McEntyre","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Partnership Name":"Europe Pubmed Central","Applicant Surname":"McEntyre","Partnership Value":6515000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:European-Bioinformatics-Institute","name":"European Bioinformatics Institute","addressCountry":"United Kingdom","id_and_name":"[\"European Bioinformatics Institute\", \"360G-Wellcome-ORG:European-Bioinformatics-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:European-Bioinformatics-Institute","name":"European Bioinformatics Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Europe PMC 2021-2026 In the next five years, the necessity for open science to solve global challenges will become increasingly apparent, and the need for Europe PMC as a critical piece of infrastructure will crystallise in the minds and usage patterns of researchers. The world of scientific publishing will undergo major changes, as routes for rapid and transparent publishing emerge, and efforts such as Plan S push towards universal open access. Europe PMC will support these goals by aggregating millions of articles and making them widely available. With a leading role in preprint aggregation and standards development, Europe PMC will be the go-to resource for searching life sciences literature from publication through review, revision, and citation. Publications at all stages need to be grounded in unambiguous links to supporting data, authors and reviewers, funding, and institutions, to build transparency and trust in the content; building these links will be a major direction for Europe PMC. Finally, transformative change in content search and retrieval will come from the development of AI methods that work on open access full text, encouraged by the Europe PMC platform for text and data mining, as well as the demonstration of machine learning benefits in user interfaces.\n","awardDateDateOnly":"2020-12-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Europe"]}
{"id":"360G-Wellcome-221522_Z_20_Z","title":"Three Photon Microscopy Suite","Region":"Greater London","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221522/Z/20/Z","description":"We propose the establishment of a dedicated facility for three-photon live imaging of deep tissue. This will comprise a dedicated multiphoton microscope (Scientifica Hyperscope or similar) with optical components anti-reflectance coated for long-wavelength light (up to 1700 nm) for three photon imaging, together with a suitable laser excitation source. Funding is requested for a high power ultrafast laser (Amplitude Systems Satsuma 40/40 or similar) producing up to 40W at 1030nm, pumping an Optical Parametric Amplifier (APE/Amplitude Mango SP or similar) to produce 1150-1700 nm light at a 2 MHz repetition rate, optimised for three photon excitation of both green and red fluorophores. The microscope will be mounted on a single large antivibration table. The three-photon microscope will be installed in a Home-Office designated small animal imaging suite.  A dedicated facility manager (with substantial expertise of in vivo multiphoton imaging including biomedical optics), will run the facility, ensuring continued high imaging performance, and maximising effective and collaborative use of the facility. The imaging suite will provide a unique capability for deep tissue imaging by Wellcome Trust funded researchers across a range of biomedical application areas, including neuroscience, cardiology, stem cell biology and respiratory physiology. \n \n","plannedDates":[{"endDate":"2026-01-31T00:00:00+00:00","startDate":"2021-02-01T00:00:00+00:00","startDateDateOnly":"2021-02-01","endDateDateOnly":"2026-01-31"}],"amountAwarded":517128,"Financial Year":"2019/20","Lead Applicant":"Prof Simon Schultz","grantProgramme":[{"title":"Multi-User Equipment Grant","title_keyword":"Multi-User Equipment Grant"}],"Applicant Surname":"Schultz","Partnership Value":517128,"Approval Committee":"Multi-User Equipment and Technology Development Committee","Other Applicant(s)":"Dr Andrei Kozlov, Prof Cristina Lo Celso, Prof Molly Stevens, Dr Julien Vermot, Prof Clare Lloyd, Dr Amanda Foust, Dr Christopher Rowlands","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Three Photon Microscopy Suite We propose the establishment of a dedicated facility for three-photon live imaging of deep tissue. This will comprise a dedicated multiphoton microscope (Scientifica Hyperscope or similar) with optical components anti-reflectance coated for long-wavelength light (up to 1700 nm) for three photon imaging, together with a suitable laser excitation source. Funding is requested for a high power ultrafast laser (Amplitude Systems Satsuma 40/40 or similar) producing up to 40W at 1030nm, pumping an Optical Parametric Amplifier (APE/Amplitude Mango SP or similar) to produce 1150-1700 nm light at a 2 MHz repetition rate, optimised for three photon excitation of both green and red fluorophores. The microscope will be mounted on a single large antivibration table. The three-photon microscope will be installed in a Home-Office designated small animal imaging suite.  A dedicated facility manager (with substantial expertise of in vivo multiphoton imaging including biomedical optics), will run the facility, ensuring continued high imaging performance, and maximising effective and collaborative use of the facility. The imaging suite will provide a unique capability for deep tissue imaging by Wellcome Trust funded researchers across a range of biomedical application areas, including neuroscience, cardiology, stem cell biology and respiratory physiology. \n \n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Lasers","Mice","Microscopy","Microscopy, Fluorescence, Multiphoton","Photons"]}
{"id":"360G-Wellcome-221521_Z_20_Z","title":"Expanding the proteomics and establishing top-down capabilities for the UCL Mass Spectrometry Science Technology Platform.","Region":"Greater London","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221521/Z/20/Z","description":"The requested equipment is the ThermoFisher Orbitrap Eclipse Tribrid Mass Spectrometer with an Ultimate3000 LC system. This new instrument is designed for high-end proteomics, top-down protein characterisation, and crosslinking analysis and is equipped with the latest Orbitrap analyser, which offers higher resolution, sensitivity and acquisition rates compared to previous Orbitraps.\n\nThese features result in improvements to both limit of detection and quantification of peptides, ultimately leading to enhanced quantitative proteomics and crosslinking analysis.\n\nIts atypical geometry allows multistage fragmentation of ions (MSn), which is necessary for multiplexed proteomics experiments and for advanced crosslinking analyses using cleavable crosslinkers. Combined with a novel in-built real-time search algorithm, fragment ions of interest e.g. crosslinked peptides can be preferentially selected, further increasing the depth of analysis. The Eclipse is also capable of top-down proteomics experiments which is an ideal method for the study of proteoforms and labile post-translational modifications.\n\nWe will use the Eclipse to study the biological processes underpinning viral secondary envelopment, type 2 diabetes, cell responses to protein misfolding and cell competition; these studies are challenging due to the low amounts of sample available. The sensitivity and robustness in protein quantitation provided by the requested instrument will be key for their success.\n","plannedDates":[{"endDate":"2025-10-31T00:00:00+00:00","startDate":"2020-11-01T00:00:00+00:00","startDateDateOnly":"2020-11-01","endDateDateOnly":"2025-10-31"}],"amountAwarded":674756,"Financial Year":"2019/20","Lead Applicant":"Prof Konstantinos Thalassinos","grantProgramme":[{"title":"Multi-User Equipment Grant","title_keyword":"Multi-User Equipment Grant"}],"Applicant Surname":"Thalassinos","Partnership Value":674756,"Approval Committee":"Multi-User Equipment and Technology Development Committee","Other Applicant(s)":"Prof Daniel Raleigh, Prof Sarah Tabrizi, Prof Giampietro Schiavo, Dr Alan Lowe, Prof Frances Brodsky, Prof Michael Cheetham","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Expanding the proteomics and establishing top-down capabilities for the UCL Mass Spectrometry Science Technology Platform. The requested equipment is the ThermoFisher Orbitrap Eclipse Tribrid Mass Spectrometer with an Ultimate3000 LC system. This new instrument is designed for high-end proteomics, top-down protein characterisation, and crosslinking analysis and is equipped with the latest Orbitrap analyser, which offers higher resolution, sensitivity and acquisition rates compared to previous Orbitraps.\n\nThese features result in improvements to both limit of detection and quantification of peptides, ultimately leading to enhanced quantitative proteomics and crosslinking analysis.\n\nIts atypical geometry allows multistage fragmentation of ions (MSn), which is necessary for multiplexed proteomics experiments and for advanced crosslinking analyses using cleavable crosslinkers. Combined with a novel in-built real-time search algorithm, fragment ions of interest e.g. crosslinked peptides can be preferentially selected, further increasing the depth of analysis. The Eclipse is also capable of top-down proteomics experiments which is an ideal method for the study of proteoforms and labile post-translational modifications.\n\nWe will use the Eclipse to study the biological processes underpinning viral secondary envelopment, type 2 diabetes, cell responses to protein misfolding and cell competition; these studies are challenging due to the low amounts of sample available. The sensitivity and robustness in protein quantitation provided by the requested instrument will be key for their success.\n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cross-Linking Reagents","Diabetes Mellitus, Type 2","Humans","Mass Spectrometry","Peptides","Proteomics"]}
{"id":"360G-Wellcome-221520_Z_20_Z","title":"Advanced protein crystallography imaging system ","Region":"South East","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221520/Z/20/Z","description":"Protein crystallisation continues to play a central role in structural biology as the foundation for determining the atomic structures of macromolecules, understanding disease mechanisms, vaccine design and drug discovery. Several challenges remain, including crystallisation of multiprotein complexes, membrane proteins and time-resolved studies from systems directly engaged in catalysis, cell signalling, and ion movement. Studying different levels of structural complexity and dynamics is essential to understand protein function in health and disease. Technical developments are contributing to progress in these areas, including X-Ray Free Electron Lasers (XFELs) and Serial Synchrotron (SFX) data collection, coupled with advances in crystal imaging, which enable researchers to identify microcrystals that were previously not detectable with older instrumentation. This proposal builds on these advances through the acquisition of cutting-edge instrumentation for protein crystallisation, including advanced UV and multi fluorescence imaging optics and lipid cubic phase fluorescence after photobleaching (LCP FRAP) systems, which will provide access to, and development of, novel methods to detect and grow protein crystals of challenging multiprotein systems. A new multiuser protein crystallisation facility, centred in Oxford Biochemistry, but incorporating several stakeholders from across the wider University research community, will provide access and training.\n \n","plannedDates":[{"endDate":"2025-10-31T00:00:00+00:00","startDate":"2020-11-01T00:00:00+00:00","startDateDateOnly":"2020-11-01","endDateDateOnly":"2025-10-31"}],"amountAwarded":369413,"Financial Year":"2019/20","Lead Applicant":"Prof Simon Newstead","grantProgramme":[{"title":"Multi-User Equipment Grant","title_keyword":"Multi-User Equipment Grant"}],"Applicant Surname":"Newstead","Partnership Value":369413,"Approval Committee":"Multi-User Equipment and Technology Development Committee","Other Applicant(s)":"Dr Paul Elliott, Prof Elena Seiradake, Prof Maike Bublitz, Dr Bungo Akiyoshi, Prof Colin Kleanthous, Dr Ivan Ahel, Prof Elspeth Garman, Prof Christopher Schofield, Prof Matthew Higgins","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Advanced protein crystallography imaging system  Protein crystallisation continues to play a central role in structural biology as the foundation for determining the atomic structures of macromolecules, understanding disease mechanisms, vaccine design and drug discovery. Several challenges remain, including crystallisation of multiprotein complexes, membrane proteins and time-resolved studies from systems directly engaged in catalysis, cell signalling, and ion movement. Studying different levels of structural complexity and dynamics is essential to understand protein function in health and disease. Technical developments are contributing to progress in these areas, including X-Ray Free Electron Lasers (XFELs) and Serial Synchrotron (SFX) data collection, coupled with advances in crystal imaging, which enable researchers to identify microcrystals that were previously not detectable with older instrumentation. This proposal builds on these advances through the acquisition of cutting-edge instrumentation for protein crystallisation, including advanced UV and multi fluorescence imaging optics and lipid cubic phase fluorescence after photobleaching (LCP FRAP) systems, which will provide access to, and development of, novel methods to detect and grow protein crystals of challenging multiprotein systems. A new multiuser protein crystallisation facility, centred in Oxford Biochemistry, but incorporating several stakeholders from across the wider University research community, will provide access and training.\n \n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Crystallization","Crystallography, X-Ray","Proteins","Synchrotrons"]}
{"id":"360G-Wellcome-221514_Z_20_Z","title":"OX79 Coronavirus Record Linkage Project - QResearch-ICNARC COVID-19 Collaboration:","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221514/Z/20/Z","description":"This project will undertake large scale data linkage between critical and primary care and\nPublic Health England to investigate the effects of routine medications and patient\ncomorbidities on the outcomes from COVID-19 disease.\nAssessing the effects of routine medications on COVID-19 disease is important for two\nreasons. Firstly, some medications have been suggested to make the disease worse. As a\nresult, patients and clinicians are unclear about whether they should be continued. Secondly,\nsome routine drugs may treat or lessen the effects of infection. Establishing whether peopleon particular drugs are less likely to get severe infection will help researchers find treatments\nfor the disease.\nIdentifying what types of patient are prone to get severe disease and how long term conditions\naffect outcomes will help provide advice and target interventions to the right people.\nUndertaking these objectives will allow us to develop a platform linking all the patients in the\nprimary care database to all the Public Health England COVID-19 tests undertaken and all the\npatients admitted to an Intensive Care Unit. This platform will allow detailed assessment of the\ncourse of patients during the COVID-19 outbreak, including assessment of the effects on health\nfor patients without COVID-19 disease.\nThis platform will also enable studies investigating health, medication and health resource use\nbefore and after critical illness, accelerating development of a long term rich research resource.","plannedDates":[{"endDate":"2021-08-31T00:00:00+00:00","startDate":"2020-07-13T00:00:00+00:00","startDateDateOnly":"2020-07-13","endDateDateOnly":"2021-08-31"}],"amountAwarded":245691,"Financial Year":"2019/20","Lead Applicant":"Prof Julia Hippisley-Cox","grantProgramme":[{"title":"Discretionary Award \u2013 Innovations","title_keyword":"Discretionary Award \u2013 Innovations"}],"Applicant Surname":"Hippisley-Cox","Partnership Value":245691,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Prof Peter Watkinson","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"OX79 Coronavirus Record Linkage Project - QResearch-ICNARC COVID-19 Collaboration: This project will undertake large scale data linkage between critical and primary care and\nPublic Health England to investigate the effects of routine medications and patient\ncomorbidities on the outcomes from COVID-19 disease.\nAssessing the effects of routine medications on COVID-19 disease is important for two\nreasons. Firstly, some medications have been suggested to make the disease worse. As a\nresult, patients and clinicians are unclear about whether they should be continued. Secondly,\nsome routine drugs may treat or lessen the effects of infection. Establishing whether peopleon particular drugs are less likely to get severe infection will help researchers find treatments\nfor the disease.\nIdentifying what types of patient are prone to get severe disease and how long term conditions\naffect outcomes will help provide advice and target interventions to the right people.\nUndertaking these objectives will allow us to develop a platform linking all the patients in the\nprimary care database to all the Public Health England COVID-19 tests undertaken and all the\npatients admitted to an Intensive Care Unit. This platform will allow detailed assessment of the\ncourse of patients during the COVID-19 outbreak, including assessment of the effects on health\nfor patients without COVID-19 disease.\nThis platform will also enable studies investigating health, medication and health resource use\nbefore and after critical illness, accelerating development of a long term rich research resource.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Coronavirus Infections","England","Humans","Intensive Care Units","Primary Health Care"]}
{"id":"360G-Wellcome-221513_Z_20_Z","title":"UK contribution to development of a GDPR Code of Conduct","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221513/Z/20/Z","description":"\n Make a clear case for and facilitate UK involvement in the joint action with UK and EU stakeholders.\n Act as a secretariat to support the UK partner in the joint action.\n Prepare contingency plans for maintaining an influence in the absence of UK representation in the Joint Action.\n Gather a body of evidence of NHS and UK expertise on data processing in the health sector to contribute to the European Code of Conduct\n Maintain regular updates and briefings on the scope and objectives of the GPDR code of conduct, to maximise UK preparedness.\n Follow progress of Europe\u2019s data strategy, the European health data space and the development of a legislative proposal on Artificial Intelligence, using the same UK stakeholder group to feed in expertise where possible and provide intelligence and updates on possible implications for the health sector.\n\n","plannedDates":[{"endDate":"2021-05-18T00:00:00+00:00","startDate":"2020-05-18T00:00:00+00:00","startDateDateOnly":"2020-05-18","endDateDateOnly":"2021-05-18"}],"amountAwarded":57800,"Financial Year":"2019/20","Lead Applicant":"Dr Layla McCay","grantProgramme":[{"title":"Discretionary Award - Policy ","title_keyword":"Discretionary Award - Policy "}],"Applicant Surname":"McCay","Partnership Value":57800,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:NHS-Confederation","name":"NHS Confederation","addressCountry":"United Kingdom","id_and_name":"[\"NHS Confederation\", \"360G-Wellcome-ORG:NHS-Confederation\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:NHS-Confederation","name":"NHS Confederation"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"UK contribution to development of a GDPR Code of Conduct \n Make a clear case for and facilitate UK involvement in the joint action with UK and EU stakeholders.\n Act as a secretariat to support the UK partner in the joint action.\n Prepare contingency plans for maintaining an influence in the absence of UK representation in the Joint Action.\n Gather a body of evidence of NHS and UK expertise on data processing in the health sector to contribute to the European Code of Conduct\n Maintain regular updates and briefings on the scope and objectives of the GPDR code of conduct, to maximise UK preparedness.\n Follow progress of Europe\u2019s data strategy, the European health data space and the development of a legislative proposal on Artificial Intelligence, using the same UK stakeholder group to feed in expertise where possible and provide intelligence and updates on possible implications for the health sector.\n\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Europe","European Union","Humans","State Medicine","United Kingdom"]}
{"id":"360G-Wellcome-221510_Z_20_Z","title":"Transparent Peer Review for Open Science and Research Assessment","Region":"International","currency":"GBP","awardDate":"2020-06-04T00:00:00+00:00","Internal ID":"221510/Z/20/Z","description":"A scaleable, interoperable mechanism to establish transparent peer review in scientific journals and preprints as a standard optimized for the browsing, interpretation and assessment of research papers and preprints. The proposed tools and standards will allow inclusion of peer review formally in research assessment by funders and research institutions.\n","plannedDates":[{"endDate":"2023-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2023-08-31"}],"amountAwarded":89973,"Financial Year":"2019/20","Lead Applicant":"Dr Bernd Pulverer","grantProgramme":[{"title":"Learned Society Curation Awards","title_keyword":"Learned Society Curation Awards"}],"Partnership Name":"Wellcome \u2013 HHMI Learned Society Curation Awards","Applicant Surname":"Pulverer","Partnership Value":179945,"Approval Committee":"Learned Society Curation Awards Expert Review Group","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:European-Molecular-Biology-Organization","name":"European Molecular Biology Organization","addressCountry":"Germany","id_and_name":"[\"European Molecular Biology Organization\", \"360G-Wellcome-ORG:European-Molecular-Biology-Organization\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:European-Molecular-Biology-Organization","name":"European Molecular Biology Organization"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Transparent Peer Review for Open Science and Research Assessment A scaleable, interoperable mechanism to establish transparent peer review in scientific journals and preprints as a standard optimized for the browsing, interpretation and assessment of research papers and preprints. The proposed tools and standards will allow inclusion of peer review formally in research assessment by funders and research institutions.\n","awardDateDateOnly":"2020-06-04","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Peer Review","Peer Review, Research"]}
{"id":"360G-Wellcome-221508_Z_20_Z","title":"Spectral Flow Cytometry (SFC) for profiling single cells of the immune system in health and disease","Region":"North East","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221508/Z/20/Z","description":"Multi-dimensional single cell analysis using cytometry technologies is one of the most significant contributors to our understanding of complex cellular compartments such as the immune system.  In recent years we have seen an explosion of new technologies and methodologies that have expanded the number of parameters per cell such as scRNA-seq, but we have suffered from an inverse correlation with scalability and throughput due to significant associated costs.  Our goal is to successfully introduce Spectral Flow Cytometry (SFC) as a new, sensitive, scalable and future proof multi-dimensional single cell phenotyping technology to the vibrant, multi-user core facility.  We will use the immense capabilities of SFC to understand rare immune-deficiencies (Hambleton); decode the developing blood and immune system (Haniffa); dissect the role of macrophages in inflammatory disease through somatic mutation analysis (Collin); unravel molecular processes in host-pathogen interactions that dictate immune responses (Trost); understand more about Giant Cell Arteritis (Reynolds), anti-viral responses (Duncan), immune surveillance of liver cancer (Wilson) and the control/relapse of Rheumatoid Arthritis (Pratt).  We will also address fundamental questions about the technology and methodology itself through expanding the parameter set using probes and label free measurements based on auto-fluorescence (Filby) as well as develop analytical tools (Rico).\n","plannedDates":[{"endDate":"2021-11-01T00:00:00+00:00","startDate":"2020-11-02T00:00:00+00:00","startDateDateOnly":"2020-11-02","endDateDateOnly":"2021-11-01"}],"amountAwarded":367500,"Financial Year":"2019/20","Lead Applicant":"Dr Andrew Filby","grantProgramme":[{"title":"Multi-User Equipment Grant","title_keyword":"Multi-User Equipment Grant"}],"Applicant Surname":"Filby","Partnership Value":367500,"Approval Committee":"Multi-User Equipment and Technology Development Committee","Other Applicant(s)":"Dr Arthur Pratt, Dr Caroline Wilson, Prof Matthew Collin, Prof Muzlifah Haniffa, Prof Matthias Trost, Prof Sophie Hambleton, Dr Christopher Duncan, Dr Daniel Rico, Dr Gary Reynolds","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Newcastle-University","name":"Newcastle University","addressCountry":"United Kingdom","id_and_name":"[\"Newcastle University\", \"360G-Wellcome-ORG:Newcastle-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Newcastle-University","name":"Newcastle University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Spectral Flow Cytometry (SFC) for profiling single cells of the immune system in health and disease Multi-dimensional single cell analysis using cytometry technologies is one of the most significant contributors to our understanding of complex cellular compartments such as the immune system.  In recent years we have seen an explosion of new technologies and methodologies that have expanded the number of parameters per cell such as scRNA-seq, but we have suffered from an inverse correlation with scalability and throughput due to significant associated costs.  Our goal is to successfully introduce Spectral Flow Cytometry (SFC) as a new, sensitive, scalable and future proof multi-dimensional single cell phenotyping technology to the vibrant, multi-user core facility.  We will use the immense capabilities of SFC to understand rare immune-deficiencies (Hambleton); decode the developing blood and immune system (Haniffa); dissect the role of macrophages in inflammatory disease through somatic mutation analysis (Collin); unravel molecular processes in host-pathogen interactions that dictate immune responses (Trost); understand more about Giant Cell Arteritis (Reynolds), anti-viral responses (Duncan), immune surveillance of liver cancer (Wilson) and the control/relapse of Rheumatoid Arthritis (Pratt).  We will also address fundamental questions about the technology and methodology itself through expanding the parameter set using probes and label free measurements based on auto-fluorescence (Filby) as well as develop analytical tools (Rico).\n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Arthritis, Rheumatoid","Flow Cytometry","Humans","Macrophages","Single-Cell Analysis"]}
{"id":"360G-Wellcome-221507_Z_20_Z","title":"Improving mental health for marginalised groups at Oxford's Wellcome Centres","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221507/Z/20/Z","description":"\nThis proposal will address the intersection of mental health and Equality, Diversity  &  Inclusion (EDI) within Oxford\u2019s three Wellcome Centres. Mental health concerns permeate a broad range of challenges relevant to EDI, including social exclusion, chronic illness and disability, and minoritised populations (detailed below) that are disproportionately affected by mental ill-health.\n\nBy identifying specific mental health challenges that different groups face, we can improve equality. Through normalisation of discussions around mental health in the workplace, and building an appreciation for how these issues affect people differently, we foster inclusion. If we can recruit and retain a broader range of researchers further into their careers, we improve diversity, and therefore our science. An increasingly inclusive, fair and kind research culture will lower the risk of mental ill-health for all our team and staff members within the high-impact but high-pressure academic environment.\n\nOur specific objectives are to:\n(i)  Conduct an in-depth, expert review of mental health as it relates to EDI within our Centre work environments.\n(ii)  Implement recommendations arising from this review relating to policies, communication and practices.\n(iii)  Build a broad, cross-Centre programme promoting positive research change around mental health and EDI.\n \n","plannedDates":[{"endDate":"2023-05-03T00:00:00+00:00","startDate":"2021-05-04T00:00:00+00:00","startDateDateOnly":"2021-05-04","endDateDateOnly":"2023-05-03"}],"amountAwarded":77068,"Financial Year":"2019/20","Lead Applicant":"Prof Heidi Johansen-Berg","grantProgramme":[{"title":"Discretionary Award - Diversity and Inclusion","title_keyword":"Discretionary Award - Diversity and Inclusion"}],"Applicant Surname":"Johansen-Berg","Partnership Value":77068,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Improving mental health for marginalised groups at Oxford's Wellcome Centres \nThis proposal will address the intersection of mental health and Equality, Diversity  &  Inclusion (EDI) within Oxford\u2019s three Wellcome Centres. Mental health concerns permeate a broad range of challenges relevant to EDI, including social exclusion, chronic illness and disability, and minoritised populations (detailed below) that are disproportionately affected by mental ill-health.\n\nBy identifying specific mental health challenges that different groups face, we can improve equality. Through normalisation of discussions around mental health in the workplace, and building an appreciation for how these issues affect people differently, we foster inclusion. If we can recruit and retain a broader range of researchers further into their careers, we improve diversity, and therefore our science. An increasingly inclusive, fair and kind research culture will lower the risk of mental ill-health for all our team and staff members within the high-impact but high-pressure academic environment.\n\nOur specific objectives are to:\n(i)  Conduct an in-depth, expert review of mental health as it relates to EDI within our Centre work environments.\n(ii)  Implement recommendations arising from this review relating to policies, communication and practices.\n(iii)  Build a broad, cross-Centre programme promoting positive research change around mental health and EDI.\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Mental Disorders","Mental Health","Workplace"]}
{"id":"360G-Wellcome-221503_Z_20_Z","title":"An Ethical Framework for WHO EVIPNet Policy Dialogues","Region":"Greater London","currency":"GBP","awardDate":"2020-06-18T00:00:00+00:00","Internal ID":"221503/Z/20/Z","description":"This research project will develop a framework for systematically incorporating ethical values into WHO Evidence Informed Policy Network (EVIPNet) Europe policy dialogues. Although ethical values are central to the appraisal of evidence and deliberation that is involved in policy dialogues, there is currently no explicit guidance for facilitators or participants on how to identity, define, interpret and evaluate key ethical values, nor how to recognise and work towards resolving tensions between different values. Explicit consideration of ethical values in this context is essential to the accountability and legitimacy of policy dialogues in the health policy decision-making process. Without it, discussions and decisions risk being shaped by unacknowledged and potentially unfounded assumptions, and risk recommending policy solutions which do not adequately take into account their moral and social costs and benefits. My project will aim to identify and evaluate the major existing accounts of moral reasoning for complex, real world deliberative contexts, and to develop and defend a model which is appropriate for policy dialogues. Policy dialogues are highly pragmatic tools which do not seek to pre-determine the values, knowledge and reasoning that participants bring to the table, and an ethical framework for this context must be similarly inclusive and pragmatic. \n","plannedDates":[{"endDate":"2021-10-09T00:00:00+00:00","startDate":"2021-04-11T00:00:00+00:00","startDateDateOnly":"2021-04-11","endDateDateOnly":"2021-10-09"}],"amountAwarded":39193,"Financial Year":"2019/20","Lead Applicant":"Dr Polly Mitchell","grantProgramme":[{"title":"WT/POST Fellowship","title_keyword":"WT/POST Fellowship"}],"Applicant Surname":"Mitchell","Partnership Value":39193,"Approval Committee":"Secondment Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"An Ethical Framework for WHO EVIPNet Policy Dialogues This research project will develop a framework for systematically incorporating ethical values into WHO Evidence Informed Policy Network (EVIPNet) Europe policy dialogues. Although ethical values are central to the appraisal of evidence and deliberation that is involved in policy dialogues, there is currently no explicit guidance for facilitators or participants on how to identity, define, interpret and evaluate key ethical values, nor how to recognise and work towards resolving tensions between different values. Explicit consideration of ethical values in this context is essential to the accountability and legitimacy of policy dialogues in the health policy decision-making process. Without it, discussions and decisions risk being shaped by unacknowledged and potentially unfounded assumptions, and risk recommending policy solutions which do not adequately take into account their moral and social costs and benefits. My project will aim to identify and evaluate the major existing accounts of moral reasoning for complex, real world deliberative contexts, and to develop and defend a model which is appropriate for policy dialogues. Policy dialogues are highly pragmatic tools which do not seek to pre-determine the values, knowledge and reasoning that participants bring to the table, and an ethical framework for this context must be similarly inclusive and pragmatic. \n","awardDateDateOnly":"2020-06-18","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Decision Making","Europe","Evidence-Based Medicine","Health Policy","Humans","Morals","Policy Making"]}
{"id":"360G-Wellcome-221495_Z_20_Z","title":"The role of research and reflection in third sector responses to complex and fast-changing contexts: Using action learning methodologies to examine responses to supporting people with complex needs during Covid-19 and implications for future practice","Region":"South West","currency":"GBP","awardDate":"2020-06-18T00:00:00+00:00","Internal ID":"221495/Z/20/Z","description":"There is a growing recognition within public and third sector organisations that outcomes-based commissioning and management ignores the complexity (at an individual, organisational and systems level) in which services operate. Some in the sector are experimenting with more developmental, collaborative, place-based approaches. However strategic development has recently been disrupted by Covid-19, which has forced services to change overnight whilst increasing support needs within communities.\n\nThis project will analyse the ways in which community organisations have evolved during the crisis, and identify implications for future practice, not only in terms of service delivery models but also change processes and evaluation methods.\n\nCoLab is a cross-sector \u2018wellbeing hub\u2019 hosting 30 organisations from community, social enterprise and public sectors supporting people with complex needs (e.g. homelessness, mental ill-health). As an embedded researcher I will work with staff and users as co-researchers, drawing on research tools from different methodological approaches (e.g. participatory action research, ethnography, developmental evaluation) to explore their experiences of using, delivering and adapting services in a rapidly changing context.\n\nKey goals include producing recommendations for service development, identifying appropriate research methods to sustain an \u2018action research\u2019 culture moving forward, and sharing learning more widely within the sector and related academic fields.\n","plannedDates":[{"endDate":"2021-09-06T00:00:00+00:00","startDate":"2020-09-07T00:00:00+00:00","startDateDateOnly":"2020-09-07","endDateDateOnly":"2021-09-06"}],"amountAwarded":23143,"Financial Year":"2019/20","Lead Applicant":"Ms Lorraine Hansford","grantProgramme":[{"title":"WT/POST Fellowship","title_keyword":"WT/POST Fellowship"}],"Applicant Surname":"Hansford","Partnership Value":23143,"Approval Committee":"Secondment Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Exeter","name":"University of Exeter","addressCountry":"United Kingdom","id_and_name":"[\"University of Exeter\", \"360G-Wellcome-ORG:University-of-Exeter\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Exeter","name":"University of Exeter"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The role of research and reflection in third sector responses to complex and fast-changing contexts: Using action learning methodologies to examine responses to supporting people with complex needs during Covid-19 and implications for future practice There is a growing recognition within public and third sector organisations that outcomes-based commissioning and management ignores the complexity (at an individual, organisational and systems level) in which services operate. Some in the sector are experimenting with more developmental, collaborative, place-based approaches. However strategic development has recently been disrupted by Covid-19, which has forced services to change overnight whilst increasing support needs within communities.\n\nThis project will analyse the ways in which community organisations have evolved during the crisis, and identify implications for future practice, not only in terms of service delivery models but also change processes and evaluation methods.\n\nCoLab is a cross-sector \u2018wellbeing hub\u2019 hosting 30 organisations from community, social enterprise and public sectors supporting people with complex needs (e.g. homelessness, mental ill-health). As an embedded researcher I will work with staff and users as co-researchers, drawing on research tools from different methodological approaches (e.g. participatory action research, ethnography, developmental evaluation) to explore their experiences of using, delivering and adapting services in a rapidly changing context.\n\nKey goals include producing recommendations for service development, identifying appropriate research methods to sustain an \u2018action research\u2019 culture moving forward, and sharing learning more widely within the sector and related academic fields.\n","awardDateDateOnly":"2020-06-18","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans"]}
{"id":"360G-Wellcome-221493_Z_20_Z","title":"Scottish Public Health in the National Library of Scotland\u2019s Moving Image Archives ","Region":"Scotland","currency":"GBP","awardDate":"2020-06-18T00:00:00+00:00","Internal ID":"221493/Z/20/Z","description":"Initiatives such as \u2018The NHS at 70\u2019 show strong public interest in the histories of public health in the UK. Such discussions have particular resonances in Scotland with the country\u2019s reputation for poor public health and devolved responsibilities for healthcare. During my secondment, I will research the representation of hospitals, institutions of care and healthcare professions in Scotland, as found in the National Library of Scotland\u2019s Moving Image Archive. The collections include documentaries, promotional and public information films, amateur works and newsreels, from the 1890s to the present day. My project will involve researching, contextualising and connecting key recordings to create appropriate narratives about public health in Scotland. I will research the histories and legacies of key Scottish institutions represented in the archive (such as East Fortune Sanatorium for tuberculosis patients, the innovative \u2018therapy communities\u2019 at Dingleton Hospital and \u2018modern\u2019 institutions such as Glasgow\u2019s Stobie Hospital), situating this within a larger context of changing attitudes and policy about health and healthcare professions. I will create a curated interactive package, including clips and additional written information, for display at the Kelvin Hall premises.\n\n \n","plannedDates":[{"endDate":"2021-07-19T00:00:00+00:00","startDate":"2021-04-19T00:00:00+00:00","startDateDateOnly":"2021-04-19","endDateDateOnly":"2021-07-19"}],"amountAwarded":6181,"Financial Year":"2019/20","Lead Applicant":"Ms Sarah Spence","grantProgramme":[{"title":"WT/POST Fellowship","title_keyword":"WT/POST Fellowship"}],"Applicant Surname":"Spence","Partnership Value":6181,"Approval Committee":"Secondment Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow","addressCountry":"United Kingdom","id_and_name":"[\"University of Glasgow\", \"360G-Wellcome-ORG:University-of-Glasgow\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Scottish Public Health in the National Library of Scotland\u2019s Moving Image Archives  Initiatives such as \u2018The NHS at 70\u2019 show strong public interest in the histories of public health in the UK. Such discussions have particular resonances in Scotland with the country\u2019s reputation for poor public health and devolved responsibilities for healthcare. During my secondment, I will research the representation of hospitals, institutions of care and healthcare professions in Scotland, as found in the National Library of Scotland\u2019s Moving Image Archive. The collections include documentaries, promotional and public information films, amateur works and newsreels, from the 1890s to the present day. My project will involve researching, contextualising and connecting key recordings to create appropriate narratives about public health in Scotland. I will research the histories and legacies of key Scottish institutions represented in the archive (such as East Fortune Sanatorium for tuberculosis patients, the innovative \u2018therapy communities\u2019 at Dingleton Hospital and \u2018modern\u2019 institutions such as Glasgow\u2019s Stobie Hospital), situating this within a larger context of changing attitudes and policy about health and healthcare professions. I will create a curated interactive package, including clips and additional written information, for display at the Kelvin Hall premises.\n\n \n","awardDateDateOnly":"2020-06-18","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Public Health","Scotland"]}
{"id":"360G-Wellcome-221483_Z_20_Z","title":"Antimicrobial Resistant Enterobacteriaceae: Dairy production systems as potential sources of infection for humans in Kenya","Region":"International","currency":"GBP","awardDate":"2020-06-16T00:00:00+00:00","Sponsor(s)":"Dr Arshnee Moodley","Internal ID":"221483/Z/20/Z","description":"Antimicrobial resistance (AMR) is a global health threat, associated with increased morbidity, mortality, and financial costs.  Identifying the potential reservoirs of antibiotic resistance and resistance mechanisms is an important task to tackle AMR.  Klebsiella pneumoniae and Escherichia coli which can cause severe and often fatal infections such as septicemia and pneumonia are among the identified priority antimicrobial-resistant pathogens by the World Health Organization in 2017. Cephalosporins and Carbapenems are considered critically important antibiotics in the treatment of Gram-negative infections however their resistance has been reported in clinical settings.\nThe contribution of livestock as potential reservoirs and source of resistance genes to humans, which can be acquired by direct contact or through the environment and food-chain in Kenya is not known.\nThis study will investigate antibiotic usage, knowledge and practices amongst farmers and levels of AMR in different cattle dairy production systems to give an insight to Antimicrobial Usage and AMR, in particular focusing on the carriage of Cephalosporins and Carbapenem-resistant  Enterobacteriaceae (E. coli and K. pneumoniae). Moreover, we will investigate the genetic determinants conferring resistance and mobile genetic elements harboring resistant genes. Additional information on AMR would aid further research focused on combating AMR in developing countries. \n","plannedDates":[{"endDate":"2024-03-31T00:00:00+00:00","startDate":"2021-06-30T00:00:00+00:00","startDateDateOnly":"2021-06-30","endDateDateOnly":"2024-03-31"}],"amountAwarded":60000,"Financial Year":"2019/20","Lead Applicant":"Ms Lydiah Kisoo","grantProgramme":[{"title":"International Masters Fellowship","title_keyword":"International Masters Fellowship"}],"Partnership Name":"NIHR/Wellcome Global health Partnership","Applicant Surname":"Kisoo","Partnership Value":120000,"Approval Committee":"International Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:International-Livestock-Research-Institute-Kenya","name":"International Livestock Research Institute, Kenya","addressCountry":"Kenya","id_and_name":"[\"International Livestock Research Institute, Kenya\", \"360G-Wellcome-ORG:International-Livestock-Research-Institute-Kenya\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:International-Livestock-Research-Institute-Kenya","name":"International Livestock Research Institute, Kenya"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Antimicrobial Resistant Enterobacteriaceae: Dairy production systems as potential sources of infection for humans in Kenya Antimicrobial resistance (AMR) is a global health threat, associated with increased morbidity, mortality, and financial costs.  Identifying the potential reservoirs of antibiotic resistance and resistance mechanisms is an important task to tackle AMR.  Klebsiella pneumoniae and Escherichia coli which can cause severe and often fatal infections such as septicemia and pneumonia are among the identified priority antimicrobial-resistant pathogens by the World Health Organization in 2017. Cephalosporins and Carbapenems are considered critically important antibiotics in the treatment of Gram-negative infections however their resistance has been reported in clinical settings.\nThe contribution of livestock as potential reservoirs and source of resistance genes to humans, which can be acquired by direct contact or through the environment and food-chain in Kenya is not known.\nThis study will investigate antibiotic usage, knowledge and practices amongst farmers and levels of AMR in different cattle dairy production systems to give an insight to Antimicrobial Usage and AMR, in particular focusing on the carriage of Cephalosporins and Carbapenem-resistant  Enterobacteriaceae (E. coli and K. pneumoniae). Moreover, we will investigate the genetic determinants conferring resistance and mobile genetic elements harboring resistant genes. Additional information on AMR would aid further research focused on combating AMR in developing countries. \n","awardDateDateOnly":"2020-06-16","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Anti-Bacterial Agents","Cattle","Cattle Diseases","Dairying","Drug Resistance, Bacterial","Escherichia coli","Escherichia coli Infections","Farmers","Kenya"]}
{"id":"360G-Wellcome-221474_Z_20_Z","title":"A life course approach to measure thriving places","Region":"South West","currency":"GBP","awardDate":"2020-06-18T00:00:00+00:00","Internal ID":"221474/Z/20/Z","description":"The overarching aim of this project is to provide theoretical and measurement expertise in the economics of health and wellbeing into the work of a UK-based charity, Centre for Thriving Places, and specifically, their Thriving Places Index (TPI). More specifically, this project will be developing a better understanding of the key indicators that influence the wellbeing of individuals at different stages of the life course. Currently the TPI is summarised at the local authority level in England and Wales and is arranged into three headline elements: Local Conditions for wellbeing, Equality and Sustainability. This project will seek to inform how reflective TPI is of different population groups wellbeing at different stages of the life course, looking at wellbeing in younger and older population groups in particular. Specifically, this research project will focus of wellbeing at different stages of the lifecourse based on the indicators that feed into the TPI. The Centre for Thriving Places would use the work from this secondment to better inform local authority decision-making targeted as specific populations in their community. For instance, different public health policy responses may be required depending on the age profile of diverse local authority populations.\n","plannedDates":[{"endDate":"2021-04-18T00:00:00+00:00","startDate":"2020-10-19T00:00:00+00:00","startDateDateOnly":"2020-10-19","endDateDateOnly":"2021-04-18"}],"amountAwarded":35349,"Financial Year":"2019/20","Lead Applicant":"Dr Paul Mitchell","grantProgramme":[{"title":"WT/POST Fellowship","title_keyword":"WT/POST Fellowship"}],"Applicant Surname":"Mitchell","Partnership Value":35349,"Approval Committee":"Secondment Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A life course approach to measure thriving places The overarching aim of this project is to provide theoretical and measurement expertise in the economics of health and wellbeing into the work of a UK-based charity, Centre for Thriving Places, and specifically, their Thriving Places Index (TPI). More specifically, this project will be developing a better understanding of the key indicators that influence the wellbeing of individuals at different stages of the life course. Currently the TPI is summarised at the local authority level in England and Wales and is arranged into three headline elements: Local Conditions for wellbeing, Equality and Sustainability. This project will seek to inform how reflective TPI is of different population groups wellbeing at different stages of the life course, looking at wellbeing in younger and older population groups in particular. Specifically, this research project will focus of wellbeing at different stages of the lifecourse based on the indicators that feed into the TPI. The Centre for Thriving Places would use the work from this secondment to better inform local authority decision-making targeted as specific populations in their community. For instance, different public health policy responses may be required depending on the age profile of diverse local authority populations.\n","awardDateDateOnly":"2020-06-18","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aged","England","Health Status","Humans","United Kingdom","Wales"]}
{"id":"360G-Wellcome-221471_Z_20_Z","title":"Mismatches in Poverty Indices Over Time","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2020-06-18T00:00:00+00:00","Internal ID":"221471/Z/20/Z","description":"Alternative indices of poverty may classify different individuals as being \u2018poor\u2019; these mismatches are problematic for charities and policy makers who aim to identify and reduce poverty. I will compare mismatches in poverty indices by considering distributional changes over time amongst different groups in the population. The analysis follows from Meyer and Sullivan (2008), who identify changes over time in consumption and income poverty in the USA. I will extend their analysis to the development context; using the Uganda National Panel Survey dataset (n≈3,000) multiple poverty measures will be constructed at the household-level, across the period 2009-2016. By focusing on distributional changes over time, mismatches between these measures can be identified, providing insights for policy makers trying to identify poverty trends. By disaggregating these measures a more in-depth analysis on the attributes of well-being, rather than aggregate summary statistics, will be conducted. Utilising a panel structure to follow individual households over time will allow for insights into potential causes of declines in well-being and the consequences of volatility. The paper will provide a methodological contribution to poverty analysis in the developing world, and offer policy relevant analysis of poverty in Uganda.\n\nKeywords: Poverty Mismatches, Development Economics, Distributional Effects\n","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":14673,"Financial Year":"2019/20","Lead Applicant":"Dr Matthew Robson","grantProgramme":[{"title":"WT/POST Fellowship","title_keyword":"WT/POST Fellowship"}],"Applicant Surname":"Robson","Partnership Value":14673,"Approval Committee":"Secondment Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-York","name":"University of York","addressCountry":"United Kingdom","id_and_name":"[\"University of York\", \"360G-Wellcome-ORG:University-of-York\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-York","name":"University of York"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mismatches in Poverty Indices Over Time Alternative indices of poverty may classify different individuals as being \u2018poor\u2019; these mismatches are problematic for charities and policy makers who aim to identify and reduce poverty. I will compare mismatches in poverty indices by considering distributional changes over time amongst different groups in the population. The analysis follows from Meyer and Sullivan (2008), who identify changes over time in consumption and income poverty in the USA. I will extend their analysis to the development context; using the Uganda National Panel Survey dataset (n≈3,000) multiple poverty measures will be constructed at the household-level, across the period 2009-2016. By focusing on distributional changes over time, mismatches between these measures can be identified, providing insights for policy makers trying to identify poverty trends. By disaggregating these measures a more in-depth analysis on the attributes of well-being, rather than aggregate summary statistics, will be conducted. Utilising a panel structure to follow individual households over time will allow for insights into potential causes of declines in well-being and the consequences of volatility. The paper will provide a methodological contribution to poverty analysis in the developing world, and offer policy relevant analysis of poverty in Uganda.\n\nKeywords: Poverty Mismatches, Development Economics, Distributional Effects\n","awardDateDateOnly":"2020-06-18","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Family Characteristics","Humans","Poverty","Socioeconomic Factors","Uganda","United States"]}
{"id":"360G-Wellcome-221465_Z_20_Z","title":"A pilot study of a culturally appropriate hospital-based pulmonary rehabilitation programme among adults with functionally limiting chronic respiratory diseases in Malawi","Region":"North West","currency":"GBP","awardDate":"2020-06-16T00:00:00+00:00","Sponsor(s)":"Prof Stephen Gordon","Internal ID":"221465/Z/20/Z","description":"Malawi suffers a substantial burden of chronic respiratory diseases (CRDs) which causes significant morbidity and loss of economic productivity, and affects patients, families and health systems alike. CRDs are a major risk factor for Coronavirus Disease 2019 (COVID-19). Pharmacotherapy for CRDs is of limited benefit and costly. Its rational use could be complemented by non-pharmacologic treatments. For chronic obstructive pulmonary disease, pulmonary rehabilitation (PR) is well established as highly effective intervention which improves symptoms, quality of life and survival. PR is comprehensive package of interventions including exercise training. PR is now sufficiently understood to obviate further randomized trials in High Income Countries (HICs). However, given the design and delivery of programmes should be adapted to patient groups and context, high-quality data are needed outside HICs. My pilot study will determine feasibility and acceptability of PR in Malawi. Specifically, I will: (1) co-design, with service users and stakeholders, a locally appropriate PR program for patients with functionally limiting CRDs in Malawi, (2) examine lung function, exercise capacity and health status of participants before and after their participation in a PR program, and (3) examine participants\u2019 levels of attendance, participation and adherence to the programme.\n\nKeywords: chronic respiratory diseases, pulmonary rehabilitation, Malawi\n \n","plannedDates":[{"endDate":"2023-03-09T00:00:00+00:00","startDate":"2020-09-10T00:00:00+00:00","startDateDateOnly":"2020-09-10","endDateDateOnly":"2023-03-09"}],"amountAwarded":60000,"Financial Year":"2019/20","Lead Applicant":"Mr Fanuel Bickton","grantProgramme":[{"title":"International Masters Fellowship","title_keyword":"International Masters Fellowship"}],"Partnership Name":"NIHR/Wellcome Global health Partnership","Applicant Surname":"Bickton","Partnership Value":120000,"Approval Committee":"International Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"Liverpool School of Tropical Medicine\", \"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A pilot study of a culturally appropriate hospital-based pulmonary rehabilitation programme among adults with functionally limiting chronic respiratory diseases in Malawi Malawi suffers a substantial burden of chronic respiratory diseases (CRDs) which causes significant morbidity and loss of economic productivity, and affects patients, families and health systems alike. CRDs are a major risk factor for Coronavirus Disease 2019 (COVID-19). Pharmacotherapy for CRDs is of limited benefit and costly. Its rational use could be complemented by non-pharmacologic treatments. For chronic obstructive pulmonary disease, pulmonary rehabilitation (PR) is well established as highly effective intervention which improves symptoms, quality of life and survival. PR is comprehensive package of interventions including exercise training. PR is now sufficiently understood to obviate further randomized trials in High Income Countries (HICs). However, given the design and delivery of programmes should be adapted to patient groups and context, high-quality data are needed outside HICs. My pilot study will determine feasibility and acceptability of PR in Malawi. Specifically, I will: (1) co-design, with service users and stakeholders, a locally appropriate PR program for patients with functionally limiting CRDs in Malawi, (2) examine lung function, exercise capacity and health status of participants before and after their participation in a PR program, and (3) examine participants\u2019 levels of attendance, participation and adherence to the programme.\n\nKeywords: chronic respiratory diseases, pulmonary rehabilitation, Malawi\n \n","awardDateDateOnly":"2020-06-16","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Chronic Disease","Humans","Malawi","Pilot Projects","Pulmonary Disease, Chronic Obstructive","Quality of Life"]}
{"id":"360G-Wellcome-221457_Z_20_Z","title":"London as a Fast Track City: ending HIV by 2030","Region":"South East","currency":"GBP","awardDate":"2020-06-18T00:00:00+00:00","Internal ID":"221457/Z/20/Z","description":"Fast Track Cities (FTC) is a multi-partner initiative aimed at addressing the challenge that cities bear a large share of the global HIV burden. London signed up to FTC in 2018 with the aim of eliminating HIV from the capital by 2030. The Healthy London Partnership (HLP) is the delivering organisation for London, bringing together representatives from Public Health England, NHS England, the Mayor of London and the London Councils. The aim of this fellowship is to work closely with HLP and support translation of the global goals of the FTC programme into the local context of London-specific initiatives, which include: funding and facilitating a quality improvement collaborative to increase HIV testing, access to HIV care and support for people living with HIV; and developing strategies to end HIV-related stigma. This project builds on my HIV social science research and on the extensive work on complexity in healthcare by our Oxford team, including current Medical Research Council and Wellcome Trust funded projects on context and complexity in health interventions. I plan to increase synergy between methodological research (Oxford) and gain experience of the translation of city-wide HIV policies and interventions through to implementation activities (HLP), with benefits to both partners.\n","plannedDates":[{"endDate":"2021-07-31T00:00:00+00:00","startDate":"2020-11-01T00:00:00+00:00","startDateDateOnly":"2020-11-01","endDateDateOnly":"2021-07-31"}],"amountAwarded":17912,"Financial Year":"2019/20","Lead Applicant":"Dr Sara Paparini","grantProgramme":[{"title":"WT/POST Fellowship","title_keyword":"WT/POST Fellowship"}],"Applicant Surname":"Paparini","Partnership Value":17912,"Approval Committee":"Secondment Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"London as a Fast Track City: ending HIV by 2030 Fast Track Cities (FTC) is a multi-partner initiative aimed at addressing the challenge that cities bear a large share of the global HIV burden. London signed up to FTC in 2018 with the aim of eliminating HIV from the capital by 2030. The Healthy London Partnership (HLP) is the delivering organisation for London, bringing together representatives from Public Health England, NHS England, the Mayor of London and the London Councils. The aim of this fellowship is to work closely with HLP and support translation of the global goals of the FTC programme into the local context of London-specific initiatives, which include: funding and facilitating a quality improvement collaborative to increase HIV testing, access to HIV care and support for people living with HIV; and developing strategies to end HIV-related stigma. This project builds on my HIV social science research and on the extensive work on complexity in healthcare by our Oxford team, including current Medical Research Council and Wellcome Trust funded projects on context and complexity in health interventions. I plan to increase synergy between methodological research (Oxford) and gain experience of the translation of city-wide HIV policies and interventions through to implementation activities (HLP), with benefits to both partners.\n","awardDateDateOnly":"2020-06-18","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cities","England","HIV Infections","Health Policy","Humans","London","Social Stigma"]}
{"id":"360G-Wellcome-221455_Z_20_Z","title":"Ethics, youth mental health, and infectious disease outbreaks ","Region":"South East","currency":"GBP","awardDate":"2020-06-18T00:00:00+00:00","Internal ID":"221455/Z/20/Z","description":"To control the spread of the 2019 coronavirus disease (COVID-19) outbreak governments around the world have introduced public health measures including social distancing, isolation, and quarantine. This has created conflicts between competing ethical values, particularly protecting the publics\u2019 health and safety v. respecting individuals\u2019 liberty and preferences.  \n\nConcerns have been raised about the impact of currently-implemented measures on people\u2019s mental health. Children and young people may be affected in unique ways, due to their younger age and specific role in society. Yet, their mental health needs may be easily overlooked when professional care is devoted to those who are in most immediate need, i.e. the immunocompromised and the elderly.\n\nThe aim of this project is to conduct a systematic review of the evidence on the impact of social distancing, isolation, and quarantine on young people\u2019s mental health and wellbeing, and to interpret it in light of the ethics literature on public health emergencies. This work will be used to develop a UNICEF working paper focused on ethically-robust policy recommendations, so that public health measures that will be implemented in future infectious disease outbreaks are mindful of children\u2019s mental health needs. \n\nChildren, young people, COVID-19, mental health, ethics, UNICEF, systematic review\n","plannedDates":[{"endDate":"2021-04-18T00:00:00+00:00","startDate":"2020-10-19T00:00:00+00:00","startDateDateOnly":"2020-10-19","endDateDateOnly":"2021-04-18"}],"amountAwarded":16413,"Financial Year":"2019/20","Lead Applicant":"Ms Arianna Manzini","grantProgramme":[{"title":"WT/POST Fellowship","title_keyword":"WT/POST Fellowship"}],"Applicant Surname":"Manzini","Partnership Value":16413,"Approval Committee":"Secondment Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Ethics, youth mental health, and infectious disease outbreaks  To control the spread of the 2019 coronavirus disease (COVID-19) outbreak governments around the world have introduced public health measures including social distancing, isolation, and quarantine. This has created conflicts between competing ethical values, particularly protecting the publics\u2019 health and safety v. respecting individuals\u2019 liberty and preferences.  \n\nConcerns have been raised about the impact of currently-implemented measures on people\u2019s mental health. Children and young people may be affected in unique ways, due to their younger age and specific role in society. Yet, their mental health needs may be easily overlooked when professional care is devoted to those who are in most immediate need, i.e. the immunocompromised and the elderly.\n\nThe aim of this project is to conduct a systematic review of the evidence on the impact of social distancing, isolation, and quarantine on young people\u2019s mental health and wellbeing, and to interpret it in light of the ethics literature on public health emergencies. This work will be used to develop a UNICEF working paper focused on ethically-robust policy recommendations, so that public health measures that will be implemented in future infectious disease outbreaks are mindful of children\u2019s mental health needs. \n\nChildren, young people, COVID-19, mental health, ethics, UNICEF, systematic review\n","awardDateDateOnly":"2020-06-18","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adolescent","Child","Coronavirus Infections","Disease Outbreaks","Humans","Mental Health","Public Health"]}
{"id":"360G-Wellcome-221454_Z_20_Z","title":"Estimating the health co-benefits from climate action ","Region":"Greater London","currency":"GBP","awardDate":"2020-06-18T00:00:00+00:00","Internal ID":"221454/Z/20/Z","description":"There is evidence that the global value of health co-benefits that result from climate action, are greater than the financial costs of mitigation measures around climate change. However, policy decisions at national and sub-national levels seldom reflect a connection with these global assessments. The World Health Organisation (WHO) has recognised this as an area of priority, and over the course of 2020-21 are committed to work with Health Economists to provide economic evidence that can be integrated into national level considerations, and specific policy measures for climate change.\n\nAs a Health Economist, I will work with the Department of Environment, Climate Change and Health at WHO headquarters, to support the generation of reliable country-level estimates of potential health gains and savings from national climate mitigation commitments of member countries. I will use mixed methods in my research, including cost-benefit analysis for feasible interventions and policy analysis to appreciate successful policies in neighbouring countries. The outputs of my work, which will highlight the health implications of climate change for policy-makers within and outside the health sector, will include a policy report highlighting country level health benefits due to reduced emissions, as well as a paper for submission to an academic journal.\n","plannedDates":[{"endDate":"2021-07-05T00:00:00+00:00","startDate":"2021-01-05T00:00:00+00:00","startDateDateOnly":"2021-01-05","endDateDateOnly":"2021-07-05"}],"amountAwarded":15224,"Financial Year":"2019/20","Lead Applicant":"Ms Nikita Arora","grantProgramme":[{"title":"WT/POST Fellowship","title_keyword":"WT/POST Fellowship"}],"Applicant Surname":"Arora","Partnership Value":15224,"Approval Committee":"Secondment Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"London School of Hygiene & Tropical Medicine\", \"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Estimating the health co-benefits from climate action  There is evidence that the global value of health co-benefits that result from climate action, are greater than the financial costs of mitigation measures around climate change. However, policy decisions at national and sub-national levels seldom reflect a connection with these global assessments. The World Health Organisation (WHO) has recognised this as an area of priority, and over the course of 2020-21 are committed to work with Health Economists to provide economic evidence that can be integrated into national level considerations, and specific policy measures for climate change.\n\nAs a Health Economist, I will work with the Department of Environment, Climate Change and Health at WHO headquarters, to support the generation of reliable country-level estimates of potential health gains and savings from national climate mitigation commitments of member countries. I will use mixed methods in my research, including cost-benefit analysis for feasible interventions and policy analysis to appreciate successful policies in neighbouring countries. The outputs of my work, which will highlight the health implications of climate change for policy-makers within and outside the health sector, will include a policy report highlighting country level health benefits due to reduced emissions, as well as a paper for submission to an academic journal.\n","awardDateDateOnly":"2020-06-18","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Climate Change","Cost-Benefit Analysis","Global Health","Health Policy","Humans","World Health Organization"]}
{"id":"360G-Wellcome-221451_Z_20_Z","title":"Beyond the journal: a Microbiology Society open research platform","Region":"Greater London","currency":"GBP","awardDate":"2020-06-04T00:00:00+00:00","Internal ID":"221451/Z/20/Z","description":"This project aims to convert one of our journals, Access Microbiology, into an Open Research Platform (ORP), offering greater peer review transparency and fast-tracking the communication of valuable research, maximising potential for impact and influence.\n\nAt submission, articles will be made available on microbiologyresearch.org with a DOI, with clear links to open data, methods, and code, and accompanied by the reports from the machine learning review tools (e.g. Statcheck). Peer review will be transparent, and a version history maintained from preprint to Version of Record.\n\nMany societies are seeking new ways to serve their communities but are reluctant to adopt the pre-existing F1000 ORP software. This may be because they wish to maintain a single portal for access to all the work they publish; they are reluctant to enter into a publishing agreement with a commercial player; or they are concerned that the concept may not be embraced by their communities. Through this project, we hope to prove that an ORP can be provided using software in common use by publishers of all types, and that self-publishing societies can set up such a platform independently. We also hope to provide a financial model that proves ORPs can be financially self-sustaining.\n","plannedDates":[{"endDate":"2021-07-01T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2021-07-01"}],"amountAwarded":62082,"Financial Year":"2019/20","Lead Applicant":"Mr Justin Clark","grantProgramme":[{"title":"Learned Society Curation Awards","title_keyword":"Learned Society Curation Awards"}],"Partnership Name":"Wellcome \u2013 HHMI Learned Society Curation Awards","Applicant Surname":"Clark","Partnership Value":124163,"Approval Committee":"Learned Society Curation Awards Expert Review Group","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Microbiology-Society","name":"Microbiology Society","addressCountry":"United Kingdom","id_and_name":"[\"Microbiology Society\", \"360G-Wellcome-ORG:Microbiology-Society\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Microbiology-Society","name":"Microbiology Society"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Beyond the journal: a Microbiology Society open research platform This project aims to convert one of our journals, Access Microbiology, into an Open Research Platform (ORP), offering greater peer review transparency and fast-tracking the communication of valuable research, maximising potential for impact and influence.\n\nAt submission, articles will be made available on microbiologyresearch.org with a DOI, with clear links to open data, methods, and code, and accompanied by the reports from the machine learning review tools (e.g. Statcheck). Peer review will be transparent, and a version history maintained from preprint to Version of Record.\n\nMany societies are seeking new ways to serve their communities but are reluctant to adopt the pre-existing F1000 ORP software. This may be because they wish to maintain a single portal for access to all the work they publish; they are reluctant to enter into a publishing agreement with a commercial player; or they are concerned that the concept may not be embraced by their communities. Through this project, we hope to prove that an ORP can be provided using software in common use by publishers of all types, and that self-publishing societies can set up such a platform independently. We also hope to provide a financial model that proves ORPs can be financially self-sustaining.\n","awardDateDateOnly":"2020-06-04","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Machine Learning","Peer Review, Research","Publishing","Software"]}
{"id":"360G-Wellcome-221441_Z_20_Z","title":"Tools to Highlight Impact and Aid Curation of Scholarly Outputs","Region":"International","currency":"GBP","awardDate":"2020-06-04T00:00:00+00:00","Internal ID":"221441/Z/20/Z","description":"The proliferation of scholarly content and implementation of transparent peer review are creating challenges for readers and evaluators to assess research significance and review outcomes, and for journals to curate field-specific content. We propose controlled experiments in which we test the utility of badges and impact statements to signal the significance of articles published by the American Society for Cell Biology (ASCB) in its research journal, Molecular Biology of the Cell (MBoC). We will devise badges that alert readers to article attributes such as new concept, broadly relevant, technical advance, teaching resource, etc. We will also experiment with new peer review processes, including a streamlined process designed to concisely identify points of significance and key issues, and one in which authors, reviewers, and editors work together to craft concise impact statements for display on articles. The effects of these innovations will be assessed relative to traditional practices by comparing article-level metrics including article views, downloads, and Altmetrics attention scores and by surveys. We will then use these innovations and the expertise of ASCB members, including early career scientists, to curate preprints and articles in other venues with the goal of providing standard, portable tools for use by other publishers. \n","plannedDates":[{"endDate":"2022-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2022-09-30"}],"amountAwarded":82906,"Financial Year":"2019/20","Lead Applicant":"Ms Thea Clarke","grantProgramme":[{"title":"Learned Society Curation Awards","title_keyword":"Learned Society Curation Awards"}],"Partnership Name":"Wellcome \u2013 HHMI Learned Society Curation Awards","Applicant Surname":"Clarke","Partnership Value":165812,"Approval Committee":"Learned Society Curation Awards Expert Review Group","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:American-Society-for-Cell-Biology","name":"American Society for Cell Biology","addressCountry":"United States","id_and_name":"[\"American Society for Cell Biology\", \"360G-Wellcome-ORG:American-Society-for-Cell-Biology\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:American-Society-for-Cell-Biology","name":"American Society for Cell Biology"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Tools to Highlight Impact and Aid Curation of Scholarly Outputs The proliferation of scholarly content and implementation of transparent peer review are creating challenges for readers and evaluators to assess research significance and review outcomes, and for journals to curate field-specific content. We propose controlled experiments in which we test the utility of badges and impact statements to signal the significance of articles published by the American Society for Cell Biology (ASCB) in its research journal, Molecular Biology of the Cell (MBoC). We will devise badges that alert readers to article attributes such as new concept, broadly relevant, technical advance, teaching resource, etc. We will also experiment with new peer review processes, including a streamlined process designed to concisely identify points of significance and key issues, and one in which authors, reviewers, and editors work together to craft concise impact statements for display on articles. The effects of these innovations will be assessed relative to traditional practices by comparing article-level metrics including article views, downloads, and Altmetrics attention scores and by surveys. We will then use these innovations and the expertise of ASCB members, including early career scientists, to curate preprints and articles in other venues with the goal of providing standard, portable tools for use by other publishers. \n","awardDateDateOnly":"2020-06-04","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Peer Review, Research"]}
{"id":"360G-Wellcome-221440_Z_20_Z","title":"AMR Newsletter and matching AMR.Solutions website","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221440/Z/20/Z","description":"Starting February 2017, the insight from a significant amount of the Wellcome Trust-supported Expert-in-Residence work done by the applicant in support of the R & D efforts of the AMR community has been translated into a newsletter and a mirroring blogpost website. This content has come from attending key meetings (Dr. Rex is often asked to present, chair, and/or serve on program committees), authoring papers, and engagement (ad hoc email, TCs, and/or face-to-face meetings with key members of the developer community.\n\n \n\nWellcome Trust supported this work 2017-2019 through hourly billing and expense reimbursement. It is now proposed this support be converted to a fixed-term grant with consideration of the possibility of extensions of the grant if / as the DRI program progresses\n\n \n\nThe grant funds would be used to transformation and grow the project in 3 ways:\n\n\n Website upgrade for improved analytics and visual quality.\n Audience growth beyond R & D to the disciplines as finance, corporate leadership, and media relations, all of whom are key to success in this area.\n Social media outreach by maintaining the core USP while making use of Twitter, Facebook, Instagram, and LinkedIn to reach more deeply into the audience of those working in antibiotic R & D.\n\n","plannedDates":[{"endDate":"2022-02-28T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2022-02-28"}],"amountAwarded":155243,"Financial Year":"2019/20","Lead Applicant":"Dr John Rex","grantProgramme":[{"title":"Discretionary award \u2013 DRI","title_keyword":"Discretionary award \u2013 DRI"}],"Applicant Surname":"Rex","Partnership Value":155243,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Rex-Life-Sciences-LLC","name":"Rex Life Sciences LLC","addressCountry":"United States","id_and_name":"[\"Rex Life Sciences LLC\", \"360G-Wellcome-ORG:Rex-Life-Sciences-LLC\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Rex-Life-Sciences-LLC","name":"Rex Life Sciences LLC"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"AMR Newsletter and matching AMR.Solutions website Starting February 2017, the insight from a significant amount of the Wellcome Trust-supported Expert-in-Residence work done by the applicant in support of the R & D efforts of the AMR community has been translated into a newsletter and a mirroring blogpost website. This content has come from attending key meetings (Dr. Rex is often asked to present, chair, and/or serve on program committees), authoring papers, and engagement (ad hoc email, TCs, and/or face-to-face meetings with key members of the developer community.\n\n \n\nWellcome Trust supported this work 2017-2019 through hourly billing and expense reimbursement. It is now proposed this support be converted to a fixed-term grant with consideration of the possibility of extensions of the grant if / as the DRI program progresses\n\n \n\nThe grant funds would be used to transformation and grow the project in 3 ways:\n\n\n Website upgrade for improved analytics and visual quality.\n Audience growth beyond R & D to the disciplines as finance, corporate leadership, and media relations, all of whom are key to success in this area.\n Social media outreach by maintaining the core USP while making use of Twitter, Facebook, Instagram, and LinkedIn to reach more deeply into the audience of those working in antibiotic R & D.\n\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Blogging","Humans","Information Dissemination","Internet","Leadership","Social Media"]}
{"id":"360G-Wellcome-221437_Z_20_Z","title":"The AIDS Quilt and health activism","Region":"Greater London","currency":"GBP","awardDate":"2020-06-18T00:00:00+00:00","Internal ID":"221437/Z/20/Z","description":"The proposed project will support the Science Museum with idea development for a future exhibition on health activism through research in three interrelated areas. Firstly, knowledge will be built around the recently acquired quilt block #3 of the Dutch AIDS Quilt by gathering information about the NAMES Project Netherlands Foundation (donor of the quilt) and the 8 individuals commemorated in quilt block #3. Suitable parties will also be identified for interviews regarding the history of the quilt. The relationship between Amsterdam and London with regards to health activism and quilting will also be investigated. Secondly, by exploring the symbolism and materials used in the quilt block, the project seeks to understand the myriad of different purposes the quilt serves. Given that the quilt and its functions are tied up with an array of different emotions, the project also aims to study how quilt, affect and health activism are entangled. Relatedly, if the planned exhibition is conceived also as a form of activism, what role then might emotions play in the organisation of the exhibition? Lastly, the project will also examine contemporary forms of health activism so as to identify potential artefacts for collection and display by the museum.\n \n","plannedDates":[{"endDate":"2021-10-24T00:00:00+00:00","startDate":"2021-04-26T00:00:00+00:00","startDateDateOnly":"2021-04-26","endDateDateOnly":"2021-10-24"}],"amountAwarded":13629,"Financial Year":"2019/20","Lead Applicant":"Mr Bryan Lim","grantProgramme":[{"title":"WT/POST Fellowship","title_keyword":"WT/POST Fellowship"}],"Applicant Surname":"Lim","Partnership Value":13629,"Approval Committee":"Secondment Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Goldsmiths-University-of-London","name":"Goldsmiths, University of London","addressCountry":"United Kingdom","id_and_name":"[\"Goldsmiths, University of London\", \"360G-Wellcome-ORG:Goldsmiths-University-of-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Goldsmiths-University-of-London","name":"Goldsmiths, University of London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The AIDS Quilt and health activism The proposed project will support the Science Museum with idea development for a future exhibition on health activism through research in three interrelated areas. Firstly, knowledge will be built around the recently acquired quilt block #3 of the Dutch AIDS Quilt by gathering information about the NAMES Project Netherlands Foundation (donor of the quilt) and the 8 individuals commemorated in quilt block #3. Suitable parties will also be identified for interviews regarding the history of the quilt. The relationship between Amsterdam and London with regards to health activism and quilting will also be investigated. Secondly, by exploring the symbolism and materials used in the quilt block, the project seeks to understand the myriad of different purposes the quilt serves. Given that the quilt and its functions are tied up with an array of different emotions, the project also aims to study how quilt, affect and health activism are entangled. Relatedly, if the planned exhibition is conceived also as a form of activism, what role then might emotions play in the organisation of the exhibition? Lastly, the project will also examine contemporary forms of health activism so as to identify potential artefacts for collection and display by the museum.\n \n","awardDateDateOnly":"2020-06-18","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Emotions","Humans","London","Male","Museums","Netherlands","Qualitative Research"]}
{"id":"360G-Wellcome-221436_Z_20_Z","title":"Emerging research cultures: A study of the Wellcome Trust 2019 funding of PhD Networks ","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221436/Z/20/Z","description":"The Wellcome Trust 2019 PhD Programmes Call had two central criteria: scientific excellence and positive research culture. The call was unusual in the relative weight given to each of these criteria, and the open-ness to different understandings of research culture. It is important to understand the impacts of this intervention on the part of a major funder into research training. The aim of this study is to gain insights into the impact of this intervention, and into the development and implementation of measures to improve research culture. The study embraces the emergent nature of understandings of positive research that has distinguished this call from the outset. It adopts a dual approach: firstly it will support the formation of a community of practice, consisting of the funded programmes and the Wellcome Trust, as equal members; and secondly it will use the methods of participant action research to support iterative and reflective processes for understanding what positive research culture consists in, and what constitutes best practice. This dual approach serves as a framework for active observation, in which the lessons learned by the community of practice can be articulated and shared with other stakeholders, in the form of reports and publications.\n\n\n \n","plannedDates":[{"endDate":"2022-11-01T00:00:00+00:00","startDate":"2020-11-02T00:00:00+00:00","startDateDateOnly":"2020-11-02","endDateDateOnly":"2022-11-01"}],"amountAwarded":327745,"Financial Year":"2019/20","Lead Applicant":"Dr Annamaria Carusi","grantProgramme":[{"title":"Strategic Support: Science","title_keyword":"Strategic Support: Science"}],"Applicant Surname":"Carusi","Partnership Value":327745,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Interchange-Research-Limited","name":"Interchange Research Limited","addressCountry":"United Kingdom","id_and_name":"[\"Interchange Research Limited\", \"360G-Wellcome-ORG:Interchange-Research-Limited\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Interchange-Research-Limited","name":"Interchange Research Limited"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Emerging research cultures: A study of the Wellcome Trust 2019 funding of PhD Networks  The Wellcome Trust 2019 PhD Programmes Call had two central criteria: scientific excellence and positive research culture. The call was unusual in the relative weight given to each of these criteria, and the open-ness to different understandings of research culture. It is important to understand the impacts of this intervention on the part of a major funder into research training. The aim of this study is to gain insights into the impact of this intervention, and into the development and implementation of measures to improve research culture. The study embraces the emergent nature of understandings of positive research that has distinguished this call from the outset. It adopts a dual approach: firstly it will support the formation of a community of practice, consisting of the funded programmes and the Wellcome Trust, as equal members; and secondly it will use the methods of participant action research to support iterative and reflective processes for understanding what positive research culture consists in, and what constitutes best practice. This dual approach serves as a framework for active observation, in which the lessons learned by the community of practice can be articulated and shared with other stakeholders, in the form of reports and publications.\n\n\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biomedical Research","Humans","Trust"]}
{"id":"360G-Wellcome-221427_Z_20_Z","title":"Covid-19: How it is changing us","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221427/Z/20/Z","description":"This landmark research aims to understand in real time, and longitudinally, how Covid-19 is changing people\u2019s experience of community and levels of social protection in society. \n\nIt will specifically focus on the ways in which:\n\n\n \n Covid-19 is affecting and shaping the interactions between individuals in society and the effect on health, wellbeing, resilience, quality of life, and community \n \n \n digital is playing a role in community responses to the virus \n \n \n different measures to mitigate the virus changes the experience of community in a time of crisis\n \n \n individuals and communities relate to science, research and its role with respect to Covid-19\n \n\n\nThe aim of this project is to collect real-time information to inform policy makers and practitioners about how communities are responding to the pandemic, public health measures and other mitigation measures. It will also generate early insight into the potential longer-term impacts on both individuals\u2019 mental health and community wellbeing.\n\nTo understand how communities are experiencing Covid-19 across the UK, we will conduct a quantitative study with a nationally representative sample across the four nations. This will be supplemented by innovative digital ethnographic research which generates in-depth real time insight into the experiences of a diverse group of 100 adults.\n","plannedDates":[{"endDate":"2021-04-30T00:00:00+00:00","startDate":"2020-08-03T00:00:00+00:00","startDateDateOnly":"2020-08-03","endDateDateOnly":"2021-04-30"}],"amountAwarded":207999,"Financial Year":"2019/20","Lead Applicant":"Ms Helen Goulden","grantProgramme":[{"title":"Discretionary Award - Public Engagement","title_keyword":"Discretionary Award - Public Engagement"}],"Applicant Surname":"Goulden","Partnership Value":207999,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Young-Foundation","name":"Young Foundation","addressCountry":"United Kingdom","id_and_name":"[\"Young Foundation\", \"360G-Wellcome-ORG:Young-Foundation\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Young-Foundation","name":"Young Foundation"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Covid-19: How it is changing us This landmark research aims to understand in real time, and longitudinally, how Covid-19 is changing people\u2019s experience of community and levels of social protection in society. \n\nIt will specifically focus on the ways in which:\n\n\n \n Covid-19 is affecting and shaping the interactions between individuals in society and the effect on health, wellbeing, resilience, quality of life, and community \n \n \n digital is playing a role in community responses to the virus \n \n \n different measures to mitigate the virus changes the experience of community in a time of crisis\n \n \n individuals and communities relate to science, research and its role with respect to Covid-19\n \n\n\nThe aim of this project is to collect real-time information to inform policy makers and practitioners about how communities are responding to the pandemic, public health measures and other mitigation measures. It will also generate early insight into the potential longer-term impacts on both individuals\u2019 mental health and community wellbeing.\n\nTo understand how communities are experiencing Covid-19 across the UK, we will conduct a quantitative study with a nationally representative sample across the four nations. This will be supplemented by innovative digital ethnographic research which generates in-depth real time insight into the experiences of a diverse group of 100 adults.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Community Participation","Humans","Mental Health","Public Health","Quality of Life","United Kingdom"]}
{"id":"360G-Wellcome-221419_Z_20_Z","title":"Wellcome Trust support for CIDRAP \u2013 Antimicrobial Stewardship Project","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221419/Z/20/Z","description":"The CIDRAP Antimicrobial Stewardship Project (CIDRAP-ASP) was launched in July 2016 with the\ngoal of building an online international community focused on antimicrobial stewardship through\nvarious platforms and with content and ASP tools applicable to high, middle and low income\ncountries. CIDRAP-ASP has offered freely available, high-quality information and educational\nresources on antimicrobial stewardship practice, research, and policy. It features a dynamic,\ncontent-rich website designed to engage a diverse, international audience. This project capitalizes\non CIDRAP\u2019s existing internationally recognized expertise, infectious disease news and information\nsystem, website infrastructure, and strong national and international audiences.\nThrough our partnerships with subject matter experts, we provide a wealth of diverse resources for\npractitioners across the spectrum of human, animal, and environmental health to support their\nability to provide optimal care. CIDRAP-ASP generates deep, rich original content and aggregates\nthe most useful information from diverse perspectives and expertise.\nCIDRAP-ASP occupies a unique niche in the ecosystem of projects addressing antimicrobial\nresistance and stewardship because of the diversity of resources to which it provides access, and\nthe research and integrity with which it approaches nuanced and sometimes controversial topics.\n","plannedDates":[{"endDate":"2022-10-05T00:00:00+00:00","startDate":"2020-10-06T00:00:00+00:00","startDateDateOnly":"2020-10-06","endDateDateOnly":"2022-10-05"}],"amountAwarded":955118,"Financial Year":"2019/20","Lead Applicant":"Prof Michael Osterholm","grantProgramme":[{"title":"Discretionary award \u2013 DRI","title_keyword":"Discretionary award \u2013 DRI"}],"Applicant Surname":"Osterholm","Partnership Value":955118,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Kristine Moore","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Minnesota","name":"University of Minnesota","addressCountry":"United States","id_and_name":"[\"University of Minnesota\", \"360G-Wellcome-ORG:University-of-Minnesota\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Minnesota","name":"University of Minnesota"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Wellcome Trust support for CIDRAP \u2013 Antimicrobial Stewardship Project The CIDRAP Antimicrobial Stewardship Project (CIDRAP-ASP) was launched in July 2016 with the\ngoal of building an online international community focused on antimicrobial stewardship through\nvarious platforms and with content and ASP tools applicable to high, middle and low income\ncountries. CIDRAP-ASP has offered freely available, high-quality information and educational\nresources on antimicrobial stewardship practice, research, and policy. It features a dynamic,\ncontent-rich website designed to engage a diverse, international audience. This project capitalizes\non CIDRAP\u2019s existing internationally recognized expertise, infectious disease news and information\nsystem, website infrastructure, and strong national and international audiences.\nThrough our partnerships with subject matter experts, we provide a wealth of diverse resources for\npractitioners across the spectrum of human, animal, and environmental health to support their\nability to provide optimal care. CIDRAP-ASP generates deep, rich original content and aggregates\nthe most useful information from diverse perspectives and expertise.\nCIDRAP-ASP occupies a unique niche in the ecosystem of projects addressing antimicrobial\nresistance and stewardship because of the diversity of resources to which it provides access, and\nthe research and integrity with which it approaches nuanced and sometimes controversial topics.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Antimicrobial Stewardship","Global Health","Humans","Internet"]}
{"id":"360G-Wellcome-221418_Z_20_Z","title":"Evolution of Burkholderia pseudomallei antibiotic synthesis and resistance genes","Region":"South East","currency":"GBP","awardDate":"2020-06-16T00:00:00+00:00","Sponsor(s)":"Prof Nicholas Day","Internal ID":"221418/Z/20/Z","description":"Burkholderia pseudomallei (Bp) is a Gram-negative environmental bacterial pathogen. It causes melioidosis, a deadly infectious disease endemic in tropical and subtropical countries. Despite an increase in prevention efforts, the mortality rate of human melioidosis is still high. Bp is intrinsically resistant to several classes of antibiotics, which limits treatment options. The bacterium also synthesises antibiotics primarily to compete against other organisms in its soil habitats. I am testing the hypothesis that antibiotic resistance in Bp is either evolved as a self-protection mechanism against the antibiotics produced by itself, or interspecific competition or both. Using a dataset of 2,500 whole-genome sequences of Bp, I propose to mine the genes involved in the antibiotic synthesis, antibiotic resistance and their associated mobile genetic elements, thereby creating the first comprehensive antibiotic resistance and synthesis database for Bp. Long read sequencing will be employed to aid further identification of mobile genetic elements which will help determine the route of acquisition of these genes. I will use several bioinformatics methods to test the co-inherited patterns of antibiotic synthesis and resistance genes, their evolutionary stability and their mobility. Together, this will provide new ecological insights into antibiotic synthesis and resistance mechanisms in Bp and other bacteria.\n","plannedDates":[{"endDate":"2023-02-28T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2023-02-28"}],"amountAwarded":120000,"Financial Year":"2019/20","Lead Applicant":"Miss Chalita Chomkatekaew","grantProgramme":[{"title":"International Masters Fellowship","title_keyword":"International Masters Fellowship"}],"Applicant Surname":"Chomkatekaew","Partnership Value":120000,"Approval Committee":"International Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Evolution of Burkholderia pseudomallei antibiotic synthesis and resistance genes Burkholderia pseudomallei (Bp) is a Gram-negative environmental bacterial pathogen. It causes melioidosis, a deadly infectious disease endemic in tropical and subtropical countries. Despite an increase in prevention efforts, the mortality rate of human melioidosis is still high. Bp is intrinsically resistant to several classes of antibiotics, which limits treatment options. The bacterium also synthesises antibiotics primarily to compete against other organisms in its soil habitats. I am testing the hypothesis that antibiotic resistance in Bp is either evolved as a self-protection mechanism against the antibiotics produced by itself, or interspecific competition or both. Using a dataset of 2,500 whole-genome sequences of Bp, I propose to mine the genes involved in the antibiotic synthesis, antibiotic resistance and their associated mobile genetic elements, thereby creating the first comprehensive antibiotic resistance and synthesis database for Bp. Long read sequencing will be employed to aid further identification of mobile genetic elements which will help determine the route of acquisition of these genes. I will use several bioinformatics methods to test the co-inherited patterns of antibiotic synthesis and resistance genes, their evolutionary stability and their mobility. Together, this will provide new ecological insights into antibiotic synthesis and resistance mechanisms in Bp and other bacteria.\n","awardDateDateOnly":"2020-06-16","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anti-Bacterial Agents","Burkholderia pseudomallei","Computational Biology","Drug Resistance, Bacterial","Evolution, Molecular","Genome, Bacterial","Humans","Melioidosis"]}
{"id":"360G-Wellcome-221410_Z_20_Z","title":"Enabling research uptake through integrating networks and communities of practice","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221410/Z/20/Z","description":"Findings from health research should be translated into recommendations that can be implemented within policy and practice if research is to deliver its maximum impact and ability to change health outcomes. Currently research \u2018success\u2019 typically concludes with the publishing of papers in high impact journals with less attention to how, and indeed whether, those findings are made visible and accessible to those tasked with decision making that should be changing their practice on the basis of these new findings. Compounding this is the current difficulty for these practice and policy decision-makers to easily be made aware, find, access and synthesise new research recommendations. The Global Health Network seeks to address this by bringing researchers and decision makers together to find new tools and mechanisms for researchers to present their outcomes as recommendations that can be readily discoverable and put into practice. This proposal will firstly, establish a community of practice for researchers and decision-makers to share knowledge and develop resources, processes and mechanisms that can support turning results into discoverable, practical and usable recommendations. Secondly, to deliver an advanced digital database which enables rapid synthesis of the available research recommendations to drive improvements in uptake. \n","plannedDates":[{"endDate":"2022-10-04T00:00:00+00:00","startDate":"2020-10-05T00:00:00+00:00","startDateDateOnly":"2020-10-05","endDateDateOnly":"2022-10-04"}],"amountAwarded":142915,"Financial Year":"2019/20","Lead Applicant":"Prof Trudie Lang","grantProgramme":[{"title":"Discretionary Award - Policy ","title_keyword":"Discretionary Award - Policy "}],"Partnership Name":"NIHR/Wellcome Global health Partnership","Applicant Surname":"Lang","Partnership Value":285830,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Enabling research uptake through integrating networks and communities of practice Findings from health research should be translated into recommendations that can be implemented within policy and practice if research is to deliver its maximum impact and ability to change health outcomes. Currently research \u2018success\u2019 typically concludes with the publishing of papers in high impact journals with less attention to how, and indeed whether, those findings are made visible and accessible to those tasked with decision making that should be changing their practice on the basis of these new findings. Compounding this is the current difficulty for these practice and policy decision-makers to easily be made aware, find, access and synthesise new research recommendations. The Global Health Network seeks to address this by bringing researchers and decision makers together to find new tools and mechanisms for researchers to present their outcomes as recommendations that can be readily discoverable and put into practice. This proposal will firstly, establish a community of practice for researchers and decision-makers to share knowledge and develop resources, processes and mechanisms that can support turning results into discoverable, practical and usable recommendations. Secondly, to deliver an advanced digital database which enables rapid synthesis of the available research recommendations to drive improvements in uptake. \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Global Health","Health Policy","Humans","Policy Making"]}
{"id":"360G-Wellcome-221409_Z_20_Z","title":"Collecting and curating the material culture of contemporary women's bodies","Region":"East of England","currency":"GBP","awardDate":"2020-06-18T00:00:00+00:00","Internal ID":"221409/Z/20/Z","description":"This project investigates the function and value of material culture associated with contemporary women\u2019s experiences of health, such as menstruation, fertility and contraception. Drawing on recent work in LGBTQ+ and health activism, I will systematically research related objects in the Science Museum\u2019s collection, share my findings through the museum\u2019s online public engagement networks, identify further areas for collecting, and create a collecting proposal for consumer products designed to control, restore or facilitate bodily functions. This project asks four questions: What is the material culture of contemporary women\u2019s experiences with health, and how does it fit into museum collections? What types of objects should be collected to represent the contemporary material culture of this theme? How can these objects be used in public engagement work in the present and the future? How can they be used to support ongoing efforts to break cultural taboos about women\u2019s health and bodies in the context of museums? An analysis of these objects and their collection will shed light on their historical significance and reveal new ways that they might be used to highlight experiences of women\u2019s health and medicine in the past, present and future.\n","plannedDates":[{"endDate":"2021-10-29T00:00:00+00:00","startDate":"2021-05-01T00:00:00+00:00","startDateDateOnly":"2021-05-01","endDateDateOnly":"2021-10-29"}],"amountAwarded":15521,"Financial Year":"2019/20","Lead Applicant":"Miss Rhianna Elliott","grantProgramme":[{"title":"WT/POST Fellowship","title_keyword":"WT/POST Fellowship"}],"Applicant Surname":"Elliott","Partnership Value":15521,"Approval Committee":"Secondment Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Collecting and curating the material culture of contemporary women's bodies This project investigates the function and value of material culture associated with contemporary women\u2019s experiences of health, such as menstruation, fertility and contraception. Drawing on recent work in LGBTQ+ and health activism, I will systematically research related objects in the Science Museum\u2019s collection, share my findings through the museum\u2019s online public engagement networks, identify further areas for collecting, and create a collecting proposal for consumer products designed to control, restore or facilitate bodily functions. This project asks four questions: What is the material culture of contemporary women\u2019s experiences with health, and how does it fit into museum collections? What types of objects should be collected to represent the contemporary material culture of this theme? How can these objects be used in public engagement work in the present and the future? How can they be used to support ongoing efforts to break cultural taboos about women\u2019s health and bodies in the context of museums? An analysis of these objects and their collection will shed light on their historical significance and reveal new ways that they might be used to highlight experiences of women\u2019s health and medicine in the past, present and future.\n","awardDateDateOnly":"2020-06-18","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Female","Humans","Museums","Women's Health"]}
{"id":"360G-Wellcome-221407_Z_20_Z","title":"Western Kenya integrated COVID19 response leveraging community health strategy, youth and technology to flatten the curve and improve COVID19 case detection, isolation and management in Western Kenya","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221407/Z/20/Z","description":"To respond to the COVID19 pandemic, we will be deploying community health workers, equipped with mobile technology, and accompanied by youth to visit households door to door to screen for symptoms of COVID19, isolate, test, and manage suspected cases of COVID19. The community health workers and youth will educate households about preventive measures including frequent handwashing and home management of mild cases. Simultaneously, we will work with nurses, doctors, and clinical officers, to test and treat more severe cases of COVID19 in health facilities. Our goals are to visit every household in Siaya county covering a population of close to 1 million, and to train and support health workers working in the 32 health facilities in Siaya.\"","plannedDates":[{"endDate":"2021-07-30T00:00:00+00:00","startDate":"2020-05-18T00:00:00+00:00","startDateDateOnly":"2020-05-18","endDateDateOnly":"2021-07-30"}],"amountAwarded":349617,"Financial Year":"2019/20","Lead Applicant":"Dr Neema Kaseje","grantProgramme":[{"title":"Discretionary Award \u2013 Innovations","title_keyword":"Discretionary Award \u2013 Innovations"}],"Applicant Surname":"Kaseje","Partnership Value":349617,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Surgical-Systems-Research-Group","name":"Surgical Systems Research Group","addressCountry":"Kenya","id_and_name":"[\"Surgical Systems Research Group\", \"360G-Wellcome-ORG:Surgical-Systems-Research-Group\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Surgical-Systems-Research-Group","name":"Surgical Systems Research Group"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Western Kenya integrated COVID19 response leveraging community health strategy, youth and technology to flatten the curve and improve COVID19 case detection, isolation and management in Western Kenya To respond to the COVID19 pandemic, we will be deploying community health workers, equipped with mobile technology, and accompanied by youth to visit households door to door to screen for symptoms of COVID19, isolate, test, and manage suspected cases of COVID19. The community health workers and youth will educate households about preventive measures including frequent handwashing and home management of mild cases. Simultaneously, we will work with nurses, doctors, and clinical officers, to test and treat more severe cases of COVID19 in health facilities. Our goals are to visit every household in Siaya county covering a population of close to 1 million, and to train and support health workers working in the 32 health facilities in Siaya.\"","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adolescent","Community Health Workers","Humans","Kenya"]}
{"id":"360G-Wellcome-221406_Z_20_Z","title":"Highlight It: A Public Information Campaign around the Coronavirus","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221406/Z/20/Z","description":"This project will ensure as many people as possible have access to straightforward, clear information, that quickly responds to the questions and confusion people have about the coronavirus and the ways in which it is impacting their own lives and those they love. In order to reach millions of people around the world, the project will create high quality, embeddable content that newsrooms, platforms, health authorities, government bodies can all share with their audiences. It will also galvanise engaged citizens, who want to help, by creating an 'army' of 'Information Volunteers' who can take the same content and push it out to their own networks, whether that's via WhatsApp groups, Facebook communities, or family email chains. This crisis has demonstrated that there is no time or resource for duplication. By sharing efforts to monitor trending misinformation, collect real-time questions and areas of confusion from the public, and centralizing the output of shareable 'cards' that respond to these rumours and questions, it will help over-stretched newsrooms and communication departments, and provide concerned citizens with a role to play during a time where they want to help their communities.\n","plannedDates":[{"endDate":"2021-07-20T00:00:00+00:00","startDate":"2021-01-18T00:00:00+00:00","startDateDateOnly":"2021-01-18","endDateDateOnly":"2021-07-20"}],"amountAwarded":249200,"Financial Year":"2019/20","Lead Applicant":"Dr Claire Wardle","grantProgramme":[{"title":"Discretionary Award - Public Engagement","title_keyword":"Discretionary Award - Public Engagement"}],"Applicant Surname":"Wardle","Partnership Value":249200,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:First-Draft","name":"First Draft","addressCountry":"United Kingdom","id_and_name":"[\"First Draft\", \"360G-Wellcome-ORG:First-Draft\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:First-Draft","name":"First Draft"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Highlight It: A Public Information Campaign around the Coronavirus This project will ensure as many people as possible have access to straightforward, clear information, that quickly responds to the questions and confusion people have about the coronavirus and the ways in which it is impacting their own lives and those they love. In order to reach millions of people around the world, the project will create high quality, embeddable content that newsrooms, platforms, health authorities, government bodies can all share with their audiences. It will also galvanise engaged citizens, who want to help, by creating an 'army' of 'Information Volunteers' who can take the same content and push it out to their own networks, whether that's via WhatsApp groups, Facebook communities, or family email chains. This crisis has demonstrated that there is no time or resource for duplication. By sharing efforts to monitor trending misinformation, collect real-time questions and areas of confusion from the public, and centralizing the output of shareable 'cards' that respond to these rumours and questions, it will help over-stretched newsrooms and communication departments, and provide concerned citizens with a role to play during a time where they want to help their communities.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Communication","Humans","Information Dissemination"]}
{"id":"360G-Wellcome-221401_Z_20_Z","title":"Single Cell Expression Atlas","Region":"East of England","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221401/Z/20/Z","description":"Single Cell Expression Atlas (https://www.ebi.ac.uk/gxa/sc) is an open science resource that offers powerful searches for a gene expression data in different cell types, across tissues, species and conditions. Since its launch in May 2018, the Single Cell Expression Atlas has annotated and reanalysed 132 single cell RNA-Seq (scRNA-Seq) experiments across 12 different species that can be searched and visualised through its web interfaces. The SCEA is unique in that it reprocesses raw scRNA-Seq data in a standardised way. This proposal aims to keep up with the rapid technology development, expand the resource with new data modalities, continue expanding the species coverage and cross-species mapping  and expand the functionality of the resource. In particular, we will integrate single cell data sets from spatial and in-situ transcriptomics technologies, as well as emerging single cell omics protocols. Additionally, we will expand the types of analyses performed to facilitate study integration, cell type discovery and annotation. Finally, we will develop anatomograms at the organ, tissue and cell type level to enable intuitive interpretation of the experimental results and easily integrate the different types of data on the user interface.\n \n","plannedDates":[{"endDate":"2026-01-03T00:00:00+00:00","startDate":"2021-01-04T00:00:00+00:00","startDateDateOnly":"2021-01-04","endDateDateOnly":"2026-01-03"}],"amountAwarded":1560990,"Financial Year":"2019/20","Lead Applicant":"Dr Irene Papatheodorou","grantProgramme":[{"title":"Biomedical Resources Grant","title_keyword":"Biomedical Resources Grant"}],"Applicant Surname":"Papatheodorou","Partnership Value":1560990,"Approval Committee":"Biomedical Resource Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:European-Bioinformatics-Institute","name":"European Bioinformatics Institute","addressCountry":"United Kingdom","id_and_name":"[\"European Bioinformatics Institute\", \"360G-Wellcome-ORG:European-Bioinformatics-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:European-Bioinformatics-Institute","name":"European Bioinformatics Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Single Cell Expression Atlas Single Cell Expression Atlas (https://www.ebi.ac.uk/gxa/sc) is an open science resource that offers powerful searches for a gene expression data in different cell types, across tissues, species and conditions. Since its launch in May 2018, the Single Cell Expression Atlas has annotated and reanalysed 132 single cell RNA-Seq (scRNA-Seq) experiments across 12 different species that can be searched and visualised through its web interfaces. The SCEA is unique in that it reprocesses raw scRNA-Seq data in a standardised way. This proposal aims to keep up with the rapid technology development, expand the resource with new data modalities, continue expanding the species coverage and cross-species mapping  and expand the functionality of the resource. In particular, we will integrate single cell data sets from spatial and in-situ transcriptomics technologies, as well as emerging single cell omics protocols. Additionally, we will expand the types of analyses performed to facilitate study integration, cell type discovery and annotation. Finally, we will develop anatomograms at the organ, tissue and cell type level to enable intuitive interpretation of the experimental results and easily integrate the different types of data on the user interface.\n \n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Gene Expression Profiling","Humans","Mice","Sequence Analysis, RNA","Single-Cell Analysis","Software","Transcriptome","User-Computer Interface"]}
{"id":"360G-Wellcome-221400_Z_20_Z","title":"COVID-Mind: Mental Health during Covid-19","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221400/Z/20/Z","description":"This proposal is for the establishment of an international mental health research network for Covid-19 and the running of a UK mixed-methods mental health study. \n\n \n\nThe proposed network will have three core aims:\n\n\n \n \n  \n  \n   \n   \n    To support the establishment of high-quality longitudinal studies in countries internationally exploring the effects of Covid-19 on mental health\n    To enable international collaboration in longitudinal data analysis to understand cross-cultural differences in the mental health effects of Covid-19\n    To catalogue and disseminate other quantitative and qualitative mental health research on Covid-19\n   \n   \n  \n  \n \n \n\n\n \n\nWe will also lead a large-scale UK concurrent mixed methods study comprising a longitudinal study and a qualitative interview study to provide high quality, rigorous scientific data on the mental health impact of Covid-19 in the UK. This study is already underway and has 5 core aims:\n\n\n To understand the psychological and social impact of Covid-19\n To map how the psychosocial impact evolves over time as social isolation measures get stricter and once measures are relaxed\n To ascertain which groups are at greatest risk of adverse effects on their mental health\n To explore the interaction between psychosocial impact and adherence to healthy and protective behaviours\n To identify activities during isolation that could buffer against adverse effects\n\n","plannedDates":[{"endDate":"2022-05-31T00:00:00+00:00","startDate":"2020-06-01T00:00:00+00:00","startDateDateOnly":"2020-06-01","endDateDateOnly":"2022-05-31"}],"amountAwarded":411826,"Financial Year":"2019/20","Lead Applicant":"Dr Daisy Fancourt","grantProgramme":[{"title":"Discretionary Award - Mental Health","title_keyword":"Discretionary Award - Mental Health"}],"Applicant Surname":"Fancourt","Partnership Value":411826,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"COVID-Mind: Mental Health during Covid-19 This proposal is for the establishment of an international mental health research network for Covid-19 and the running of a UK mixed-methods mental health study. \n\n \n\nThe proposed network will have three core aims:\n\n\n \n \n  \n  \n   \n   \n    To support the establishment of high-quality longitudinal studies in countries internationally exploring the effects of Covid-19 on mental health\n    To enable international collaboration in longitudinal data analysis to understand cross-cultural differences in the mental health effects of Covid-19\n    To catalogue and disseminate other quantitative and qualitative mental health research on Covid-19\n   \n   \n  \n  \n \n \n\n\n \n\nWe will also lead a large-scale UK concurrent mixed methods study comprising a longitudinal study and a qualitative interview study to provide high quality, rigorous scientific data on the mental health impact of Covid-19 in the UK. This study is already underway and has 5 core aims:\n\n\n To understand the psychological and social impact of Covid-19\n To map how the psychosocial impact evolves over time as social isolation measures get stricter and once measures are relaxed\n To ascertain which groups are at greatest risk of adverse effects on their mental health\n To explore the interaction between psychosocial impact and adherence to healthy and protective behaviours\n To identify activities during isolation that could buffer against adverse effects\n\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Female","Humans","Longitudinal Studies","Male","Mental Health","Qualitative Research","Social Isolation","United Kingdom"]}
{"id":"360G-Wellcome-221395_Z_20_Z","title":"Undaunted: minority mental health activism and archives","Region":"Greater London","currency":"GBP","awardDate":"2020-05-14T00:00:00+00:00","Internal ID":"221395/Z/20/Z","description":"The project has three central activities.\n\nOne: Access. Cataloguing the papers of Melba Wilson OBE (fl. 1965-2010). Wilson\u2019s career included leading national and regional mental health programmes, policy units and services, specifically with a focus on minority ethnicity people.\n\nTwo: New descriptive practice. The cataloguing of Wilson\u2019s papers will be used as a springboard into new approaches around cataloguing and dissemination of archival sources.\n\nThree: Collections development. Scoping hidden histories of activism in the intersection of race and mental health, including the histories/ archives of organisations such as Ipamo (1995-1998) a Lambeth based Black mental health initiative, and the Afiya Trust (founded 1997) a national charity that works to reduce inequalities in health and social care provision.\n\nSupporting these three strands is our collaborative studentship with the University of Roehampton, and a programme of public engagement to disseminate the outputs of the project and to ensure a wider impact of the project outcomes.\n\nThe key outcomes of the project are:\n\n\n Enhancing the resources available in this field of research.\n Creating new opportunities for discursive research.\n Making a lasting change to the availability and range of minority mental health archive collections.\n Innovating in the field of archival practice.\n\n","plannedDates":[{"endDate":"2022-01-09T00:00:00+00:00","startDate":"2021-04-12T00:00:00+00:00","startDateDateOnly":"2021-04-12","endDateDateOnly":"2022-01-09"}],"amountAwarded":63753,"Financial Year":"2019/20","Lead Applicant":"Ms Arike Oke","grantProgramme":[{"title":"Research Resources Award","title_keyword":"Research Resources Award"}],"Applicant Surname":"Oke","Partnership Value":63753,"Approval Committee":"Research Resources Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Black-Cultural-Archives","name":"Black Cultural Archives","addressCountry":"United Kingdom","id_and_name":"[\"Black Cultural Archives\", \"360G-Wellcome-ORG:Black-Cultural-Archives\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Black-Cultural-Archives","name":"Black Cultural Archives"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Undaunted: minority mental health activism and archives The project has three central activities.\n\nOne: Access. Cataloguing the papers of Melba Wilson OBE (fl. 1965-2010). Wilson\u2019s career included leading national and regional mental health programmes, policy units and services, specifically with a focus on minority ethnicity people.\n\nTwo: New descriptive practice. The cataloguing of Wilson\u2019s papers will be used as a springboard into new approaches around cataloguing and dissemination of archival sources.\n\nThree: Collections development. Scoping hidden histories of activism in the intersection of race and mental health, including the histories/ archives of organisations such as Ipamo (1995-1998) a Lambeth based Black mental health initiative, and the Afiya Trust (founded 1997) a national charity that works to reduce inequalities in health and social care provision.\n\nSupporting these three strands is our collaborative studentship with the University of Roehampton, and a programme of public engagement to disseminate the outputs of the project and to ensure a wider impact of the project outcomes.\n\nThe key outcomes of the project are:\n\n\n Enhancing the resources available in this field of research.\n Creating new opportunities for discursive research.\n Making a lasting change to the availability and range of minority mental health archive collections.\n Innovating in the field of archival practice.\n\n","awardDateDateOnly":"2020-05-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Mental Health","Mental Health Services","Minority Groups","Universities"]}
{"id":"360G-Wellcome-221393_Z_20_Z","title":"Mining the Past","Region":"West Midlands","currency":"GBP","awardDate":"2020-05-14T00:00:00+00:00","Internal ID":"221393/Z/20/Z","description":"This is a project to conserve, catalogue and exploit the archives of the National Union of Mineworkers (NUM). It presents the opportunity to develop a nationally significant archive for occupational and industrial health at the MRC and a Midlands network for coal related archive collections. The NUM records are currently held in poor conditions at the union\u2019s headquarters in Barnsley. The project involves the removal of the archives to professional conservation facilities for drying and cleaning prior to storage at the MRC. It includes the sorting and cataloguing of the collection for research use as well as a public engagement programme. The project will:\n\n\n Remove the collection to Harwells for conservation treatment\n Re-box, sort and summarise the collection for immediate access and use in promotional activities\n File/item list the collection for full online catalogue access\n Select and digitise items for research, teaching and exhibitions.\n Develop a project website\n Co-host seminars with the Centre for the History of Medicine (Warwick) on coal, industry and health\n Develop a Midlands network of coal related archive collections for future collaboration, education and outreach activities\n Use the NUM archive as a focus for the development of a national industrial health and welfare archive \n\n","plannedDates":[{"endDate":"2023-10-31T00:00:00+00:00","startDate":"2020-11-01T00:00:00+00:00","startDateDateOnly":"2020-11-01","endDateDateOnly":"2023-10-31"}],"amountAwarded":326594,"Financial Year":"2019/20","Lead Applicant":"Ms Helen Ford","grantProgramme":[{"title":"Research Resources Award","title_keyword":"Research Resources Award"}],"Applicant Surname":"Ford","Partnership Value":326594,"Approval Committee":"Research Resources Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Warwick","name":"University of Warwick","addressCountry":"United Kingdom","id_and_name":"[\"University of Warwick\", \"360G-Wellcome-ORG:University-of-Warwick\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Warwick","name":"University of Warwick"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mining the Past This is a project to conserve, catalogue and exploit the archives of the National Union of Mineworkers (NUM). It presents the opportunity to develop a nationally significant archive for occupational and industrial health at the MRC and a Midlands network for coal related archive collections. The NUM records are currently held in poor conditions at the union\u2019s headquarters in Barnsley. The project involves the removal of the archives to professional conservation facilities for drying and cleaning prior to storage at the MRC. It includes the sorting and cataloguing of the collection for research use as well as a public engagement programme. The project will:\n\n\n Remove the collection to Harwells for conservation treatment\n Re-box, sort and summarise the collection for immediate access and use in promotional activities\n File/item list the collection for full online catalogue access\n Select and digitise items for research, teaching and exhibitions.\n Develop a project website\n Co-host seminars with the Centre for the History of Medicine (Warwick) on coal, industry and health\n Develop a Midlands network of coal related archive collections for future collaboration, education and outreach activities\n Use the NUM archive as a focus for the development of a national industrial health and welfare archive \n\n","awardDateDateOnly":"2020-05-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Coal Mining","Humans","Industry","Mining","Occupational Health"]}
{"id":"360G-Wellcome-221390_Z_20_Z","title":"Academy of Medical Sciences: Breaking Boundaries","Region":"Greater London","currency":"GBP","awardDate":"2020-09-01T00:00:00+00:00","Internal ID":"221390/Z/20/Z","description":"The Academy of Medical Sciences\u2019 mission is to advance biomedical and health research and its translation into benefits for society. The vision set out in this proposal is central to our strategy to create a diverse workforce of researchers to advance scientific discovery and to generate and optimise improvements in health. \n\nDrawing on our strengths of breadth, connectivity and unparalleled career support activities, over the next five years we will:\n\n\n Support researchers\u2019 transition to independence by enhancing our Starter Grants for Clinical Lecturers and Springboard for Biomedical Researchers schemes\n Promote health innovation with new programmes that support greater cross-disciplinary and pan-sector connectivity and collaboration by researchers\n\n\n\nThis proposal will enable us deliver a platform of cohesive, innovative activities that enhance research career pathways and achieve wider positive impacts on diversity and research culture. Our proven track record in galvanising action across the sector and leveraging further funding will drive greater coordination and effort across the UK\u2019s university, healthcare and industry sectors.\n\nIn five years\u2019 time we will have created mechanisms and a regional infrastructure that will equip and support cohorts of excellent researchers and future leaders to work collaboratively and proactively in addressing societal health challenges. \n\n \n","plannedDates":[{"endDate":"2025-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2025-12-31"}],"amountAwarded":15653620,"Financial Year":"2020/21","Lead Applicant":"Mr Simon Denegri","grantProgramme":[{"title":"AMS Partnership Scheme","title_keyword":"AMS Partnership Scheme"}],"Applicant Surname":"Denegri","Partnership Value":15653620,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Academy-of-Medical-Sciences","name":"Academy of Medical Sciences","addressCountry":"United Kingdom","id_and_name":"[\"Academy of Medical Sciences\", \"360G-Wellcome-ORG:Academy-of-Medical-Sciences\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Academy-of-Medical-Sciences","name":"Academy of Medical Sciences"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Academy of Medical Sciences: Breaking Boundaries The Academy of Medical Sciences\u2019 mission is to advance biomedical and health research and its translation into benefits for society. The vision set out in this proposal is central to our strategy to create a diverse workforce of researchers to advance scientific discovery and to generate and optimise improvements in health. \n\nDrawing on our strengths of breadth, connectivity and unparalleled career support activities, over the next five years we will:\n\n\n Support researchers\u2019 transition to independence by enhancing our Starter Grants for Clinical Lecturers and Springboard for Biomedical Researchers schemes\n Promote health innovation with new programmes that support greater cross-disciplinary and pan-sector connectivity and collaboration by researchers\n\n\n\nThis proposal will enable us deliver a platform of cohesive, innovative activities that enhance research career pathways and achieve wider positive impacts on diversity and research culture. Our proven track record in galvanising action across the sector and leveraging further funding will drive greater coordination and effort across the UK\u2019s university, healthcare and industry sectors.\n\nIn five years\u2019 time we will have created mechanisms and a regional infrastructure that will equip and support cohorts of excellent researchers and future leaders to work collaboratively and proactively in addressing societal health challenges. \n\n \n","awardDateDateOnly":"2020-09-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biomedical Research","Humans","Research Personnel"]}
{"id":"360G-Wellcome-221389_Z_20_Z","title":"Empowering Technology? Issues of Access in Digital Primary Care ","Region":"West Midlands","currency":"GBP","awardDate":"2020-06-18T00:00:00+00:00","Internal ID":"221389/Z/20/Z","description":"In 2019, the NHS Long Term Plan and GP Contract committed doctors to making online their default patient access point by 2023. The widely used NHS app and web-based appointment and repeat prescription systems will be updated to facilitate, e.g. video consultation and remote monitoring. England's provider, NHS Digital, claims these changes will increase capacity and cut costs by reducing physical attendance. Many consumer champions and academic experts have questioned the lack of independent evaluations of the technology, and stress the likelihood that privileging digital access will exacerbate existing healthcare inequalities. The expedited roll-out of these technologies required by the current COVID-19 crisis may heighten such concerns by evidencing a 'digital divide'.\n\nA rapid review will bring together current research from academia, the public sector, industry, and third sector. This will demonstrate the current state of digitisation and each group's specific concerns and interests in implementation. Interviews will then concentrate on areas of consensus surrounding best practice, establishing several case studies of leadership. \n\nFor policymakers, it will set out possible solutions for avoiding the exclusion of patients from specific age, income, or ethnic backgrounds; and draw attention to the possibilities for partnership by highlighting shared interests across stakeholding groups. \n","plannedDates":[{"endDate":"2021-01-18T00:00:00+00:00","startDate":"2020-10-19T00:00:00+00:00","startDateDateOnly":"2020-10-19","endDateDateOnly":"2021-01-18"}],"amountAwarded":7625,"Financial Year":"2019/20","Lead Applicant":"Mr Edward DeVane","grantProgramme":[{"title":"WT/POST Fellowship","title_keyword":"WT/POST Fellowship"}],"Applicant Surname":"DeVane","Partnership Value":7625,"Approval Committee":"Secondment Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Warwick","name":"University of Warwick","addressCountry":"United Kingdom","id_and_name":"[\"University of Warwick\", \"360G-Wellcome-ORG:University-of-Warwick\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Warwick","name":"University of Warwick"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Empowering Technology? Issues of Access in Digital Primary Care  In 2019, the NHS Long Term Plan and GP Contract committed doctors to making online their default patient access point by 2023. The widely used NHS app and web-based appointment and repeat prescription systems will be updated to facilitate, e.g. video consultation and remote monitoring. England's provider, NHS Digital, claims these changes will increase capacity and cut costs by reducing physical attendance. Many consumer champions and academic experts have questioned the lack of independent evaluations of the technology, and stress the likelihood that privileging digital access will exacerbate existing healthcare inequalities. The expedited roll-out of these technologies required by the current COVID-19 crisis may heighten such concerns by evidencing a 'digital divide'.\n\nA rapid review will bring together current research from academia, the public sector, industry, and third sector. This will demonstrate the current state of digitisation and each group's specific concerns and interests in implementation. Interviews will then concentrate on areas of consensus surrounding best practice, establishing several case studies of leadership. \n\nFor policymakers, it will set out possible solutions for avoiding the exclusion of patients from specific age, income, or ethnic backgrounds; and draw attention to the possibilities for partnership by highlighting shared interests across stakeholding groups. \n","awardDateDateOnly":"2020-06-18","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["England","Health Services Accessibility","Humans","Internet","Primary Health Care","State Medicine","Telemedicine"]}
{"id":"360G-Wellcome-221387_Z_20_Z","title":"Rediscovering Harold Bridger: his life, work and legacy. ","Region":"Greater London","currency":"GBP","awardDate":"2020-05-14T00:00:00+00:00","Internal ID":"221387/Z/20/Z","description":"Since 1989 the Planned Environment Therapy Archives have been unique in their remit to capture and preserve the records of therapeutic communities and care.\n\nIn 2002 the Archives acquired the papers of the psychoanalyst Harold Bridger. The collection spans the whole of Bridger\u2019s career, from his pioneering work as the Commanding Officer at the Second Northfield Experiment, through his role as a founding member of the Tavistock Institute of Human Relations, and on to his groundbreaking work concerning team dynamics in the workplace.\n\nBridger\u2019s papers have enormous research potential in the fields of psychiatry, psychology and sociology as well as the history of medicine, economics and social reform.\n\nThe project will look to address the under-use of Bridger\u2019s Archive by cataloguing the collection to international standards, identifying and carrying out preservation work, and promoting the collection.\n\nTo achieve this, a Project Archivist will be appointed to appraise, arrange and describe the materials. During the project, the post holder will carry out basic preservation to support long term use of the collection, and will oversee the digitisation of obsolete media. The Project Archivist will promote the collection by creating a network of stakeholders and attending relevant conferences and events.\n","plannedDates":[{"endDate":"2022-05-22T00:00:00+00:00","startDate":"2020-11-22T00:00:00+00:00","startDateDateOnly":"2020-11-22","endDateDateOnly":"2022-05-22"}],"amountAwarded":52532,"Financial Year":"2019/20","Lead Applicant":"Mrs Debra Doggett","grantProgramme":[{"title":"Research Resources Award","title_keyword":"Research Resources Award"}],"Applicant Surname":"Doggett","Partnership Value":52532,"Approval Committee":"Research Resources Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:The-Mulberry-Bush-Organisation","name":"The Mulberry Bush Organisation","addressCountry":"United Kingdom","id_and_name":"[\"The Mulberry Bush Organisation\", \"360G-Wellcome-ORG:The-Mulberry-Bush-Organisation\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:The-Mulberry-Bush-Organisation","name":"The Mulberry Bush Organisation"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Rediscovering Harold Bridger: his life, work and legacy.  Since 1989 the Planned Environment Therapy Archives have been unique in their remit to capture and preserve the records of therapeutic communities and care.\n\nIn 2002 the Archives acquired the papers of the psychoanalyst Harold Bridger. The collection spans the whole of Bridger\u2019s career, from his pioneering work as the Commanding Officer at the Second Northfield Experiment, through his role as a founding member of the Tavistock Institute of Human Relations, and on to his groundbreaking work concerning team dynamics in the workplace.\n\nBridger\u2019s papers have enormous research potential in the fields of psychiatry, psychology and sociology as well as the history of medicine, economics and social reform.\n\nThe project will look to address the under-use of Bridger\u2019s Archive by cataloguing the collection to international standards, identifying and carrying out preservation work, and promoting the collection.\n\nTo achieve this, a Project Archivist will be appointed to appraise, arrange and describe the materials. During the project, the post holder will carry out basic preservation to support long term use of the collection, and will oversee the digitisation of obsolete media. The Project Archivist will promote the collection by creating a network of stakeholders and attending relevant conferences and events.\n","awardDateDateOnly":"2020-05-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["History, 20th Century","History, 21st Century","Humans","Psychiatry"]}
{"id":"360G-Wellcome-221386_Z_20_Z","title":"AFRICA CDC RESPONSE TO COVID-19 PANDEMIC","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221386/Z/20/Z","description":"The African Union, Africa CDC, in collaboration with WHO on Febraury 22nd, 2020 convened an emergency meeting of all 55 ministers of health to discuss the COVID-19 pandemic. At the end of the meeting, they agreed on a continent-wide strategy for COVID-19 that will allow for greater coordination, collaboration, cooperation and communication. The strategy focuses on six major technical areas and is implemented through and endorsed Africa Coronavirus Task Force (AFCOR). As of 15 March 2020, over 26 countries have reported greater than 250 cases. In Africa, the primary strategy for COVID-19, therefore, is based on limiting transmission and minimizing harm. Delaying and diminishing the peak of outbreaks can help health systems better manage the surge of patients and communities better adapt to the disruption of social, cultural, and economic activities. In order to compliment WHO\u2019s efforts to respond to COVID-19, Africa CDC is uniquely positioned to support Member States through its presence within the African Union, the highest political body in Africa, and its five Regional Collaborating Centers. The primary challenge now is executing these tactics in a continent that is large, diverse, and at high risk of social and economic disruption from a pandemic. \n","plannedDates":[{"endDate":"2021-04-10T00:00:00+00:00","startDate":"2020-04-10T00:00:00+00:00","startDateDateOnly":"2020-04-10","endDateDateOnly":"2021-04-10"}],"amountAwarded":1000000,"Financial Year":"2019/20","Lead Applicant":"Dr Amadou Sall","grantProgramme":[{"title":"Coronavirus","title_keyword":"Coronavirus"}],"Partnership Name":"Wellcome-DFID Epidemic Preparedness","Applicant Surname":"Sall","Partnership Value":2000000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Institut-Pasteur-de-Dakar","name":"Institut Pasteur de Dakar","addressCountry":"Senegal","id_and_name":"[\"Institut Pasteur de Dakar\", \"360G-Wellcome-ORG:Institut-Pasteur-de-Dakar\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Institut-Pasteur-de-Dakar","name":"Institut Pasteur de Dakar"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"AFRICA CDC RESPONSE TO COVID-19 PANDEMIC The African Union, Africa CDC, in collaboration with WHO on Febraury 22nd, 2020 convened an emergency meeting of all 55 ministers of health to discuss the COVID-19 pandemic. At the end of the meeting, they agreed on a continent-wide strategy for COVID-19 that will allow for greater coordination, collaboration, cooperation and communication. The strategy focuses on six major technical areas and is implemented through and endorsed Africa Coronavirus Task Force (AFCOR). As of 15 March 2020, over 26 countries have reported greater than 250 cases. In Africa, the primary strategy for COVID-19, therefore, is based on limiting transmission and minimizing harm. Delaying and diminishing the peak of outbreaks can help health systems better manage the surge of patients and communities better adapt to the disruption of social, cultural, and economic activities. In order to compliment WHO\u2019s efforts to respond to COVID-19, Africa CDC is uniquely positioned to support Member States through its presence within the African Union, the highest political body in Africa, and its five Regional Collaborating Centers. The primary challenge now is executing these tactics in a continent that is large, diverse, and at high risk of social and economic disruption from a pandemic. \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa","Centers for Disease Control and Prevention, U.S.","Coronavirus Infections","Disease Outbreaks","Global Health","Humans","International Cooperation","Pandemics","United States"]}
{"id":"360G-Wellcome-221384_Z_20_Z","title":"Womens Aid Federation England Archive 1974-2020","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2020-05-14T00:00:00+00:00","Internal ID":"221384/Z/20/Z","description":"Women\u2019s Aid Federation England (WAFE) is the national coordinating body for all local and domestic violence services, including refuges in England. It provides information, training and resources to these services as well as to other agencies. It monitors the experiences of and the provision for women and children suffering abuse. It lobbies, advocates and campaigns throughout England.\n\nThe archive encapsulates the broad spectrum of its work. Growing out of the Women\u2019s Liberation Movement in 1974 the organisation moved in twenty years from being one which met with aggression from the police to one which was highly regarded for its knowledge and research. The organisation marks its 50th year in 2024. WAFE is working in collaboration with the University of Leeds Special Collections and the Feminist Archive North (FAN) to safeguard the historical record and make it accessible for research.  Collection, appraisal, documentation and preservation will ensure the collection is publicly available before this milestone year. New research collaborations will become active, learning resources will be created, and knowledge of WAFE's activity and significance will be shared and exchanged. The collection has interdisciplinary research significance and is a major resource for WAFEs own understanding of its contribution to health and society.\n","plannedDates":[{"endDate":"2024-01-31T00:00:00+00:00","startDate":"2021-05-01T00:00:00+00:00","startDateDateOnly":"2021-05-01","endDateDateOnly":"2024-01-31"}],"amountAwarded":209931,"Financial Year":"2019/20","Lead Applicant":"Ms Joanne Fitton","grantProgramme":[{"title":"Research Resources Award","title_keyword":"Research Resources Award"}],"Applicant Surname":"Fitton","Partnership Value":209931,"Approval Committee":"Research Resources Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds","addressCountry":"United Kingdom","id_and_name":"[\"University of Leeds\", \"360G-Wellcome-ORG:University-of-Leeds\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Womens Aid Federation England Archive 1974-2020 Women\u2019s Aid Federation England (WAFE) is the national coordinating body for all local and domestic violence services, including refuges in England. It provides information, training and resources to these services as well as to other agencies. It monitors the experiences of and the provision for women and children suffering abuse. It lobbies, advocates and campaigns throughout England.\n\nThe archive encapsulates the broad spectrum of its work. Growing out of the Women\u2019s Liberation Movement in 1974 the organisation moved in twenty years from being one which met with aggression from the police to one which was highly regarded for its knowledge and research. The organisation marks its 50th year in 2024. WAFE is working in collaboration with the University of Leeds Special Collections and the Feminist Archive North (FAN) to safeguard the historical record and make it accessible for research.  Collection, appraisal, documentation and preservation will ensure the collection is publicly available before this milestone year. New research collaborations will become active, learning resources will be created, and knowledge of WAFE's activity and significance will be shared and exchanged. The collection has interdisciplinary research significance and is a major resource for WAFEs own understanding of its contribution to health and society.\n","awardDateDateOnly":"2020-05-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Domestic Violence","England","Female","Humans","Women's Health"]}
{"id":"360G-Wellcome-221383_Z_20_Z","title":"Enhancing Research Uptake and Policy Engagement in the DELTAS Programme ","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221383/Z/20/Z","description":"Enhance DELTAS  is a programme led by the African Institute for Development Policy (AFIDEP) to provide research uptake and policy engagement support to awardees of the Developing Excellence in Leadership, Training and Science (DELTAS) Africa initiative, led by the African Academy of Sciences. Enhance DELTAS  will work with the first and second DELTAS Africa programmes to develop the capacity of individuals, support DELTAS institutions in creating enabling environments for policy engagement and research uptake, facilitate interaction between researchers and policymakers, and contribute to the field of Evidence Informed Decision-Making through peer reviewed publications. The programme will use face-to-face workshops, online self-learning materials including videos, interactive webinars, toolkits, and talks by policymakers. The programme will be underpinned by a robust monitoring, evaluation, and learning framework so that the programme can be continually improved, the changes as a result of the programme can be assessed, and the knowledge from implementing the programme can be shared with the EIDM community. \n \n","plannedDates":[{"endDate":"2021-05-31T00:00:00+00:00","startDate":"2020-07-01T00:00:00+00:00","startDateDateOnly":"2020-07-01","endDateDateOnly":"2021-05-31"}],"amountAwarded":147311,"Financial Year":"2019/20","Lead Applicant":"Prof Nyovani Madise","grantProgramme":[{"title":"Discretionary Award - REiAA","title_keyword":"Discretionary Award - REiAA"}],"Applicant Surname":"Madise","Partnership Value":147311,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:African-Institute-for-Development-Policy","name":"African Institute for Development Policy","addressCountry":"Kenya","id_and_name":"[\"African Institute for Development Policy\", \"360G-Wellcome-ORG:African-Institute-for-Development-Policy\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:African-Institute-for-Development-Policy","name":"African Institute for Development Policy"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Enhancing Research Uptake and Policy Engagement in the DELTAS Programme  Enhance DELTAS  is a programme led by the African Institute for Development Policy (AFIDEP) to provide research uptake and policy engagement support to awardees of the Developing Excellence in Leadership, Training and Science (DELTAS) Africa initiative, led by the African Academy of Sciences. Enhance DELTAS  will work with the first and second DELTAS Africa programmes to develop the capacity of individuals, support DELTAS institutions in creating enabling environments for policy engagement and research uptake, facilitate interaction between researchers and policymakers, and contribute to the field of Evidence Informed Decision-Making through peer reviewed publications. The programme will use face-to-face workshops, online self-learning materials including videos, interactive webinars, toolkits, and talks by policymakers. The programme will be underpinned by a robust monitoring, evaluation, and learning framework so that the programme can be continually improved, the changes as a result of the programme can be assessed, and the knowledge from implementing the programme can be shared with the EIDM community. \n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa","Capacity Building","Health Policy","Humans","Leadership","Policy Making","Program Development","Program Evaluation"]}
{"id":"360G-Wellcome-221380_Z_20_Z","title":"Positive history: preserving the archives of HIV/AIDS: care and testimony","Region":"Greater London","currency":"GBP","awardDate":"2020-05-14T00:00:00+00:00","Internal ID":"221380/Z/20/Z","description":"The aim of this project is to make accessible for research three recently acquired archive collections held by London Metropolitan Archives which together illuminate two important threads of the AIDS crisis of the 1980s and its aftermath: pioneering medical treatment, care and support; and lived experience of not only those diagnosed with HIV/AIDS, but their carers, partners, relatives and friends. They comprise: Mildmay Hospital archive including 4000 patient case files; 103 interviews of people with AIDS, their families, partners and carers, filmed by the  AIDS Since the 80s project; and the archive of peer-led support charity Positively UK (formerly Positively Women). The key outcomes will be: freely available online catalogues to item level of all three archives; a research database of key information extracted from the Mildmay Hospital case files, and full digital access to the 150 hours of filmed interviews supported by time-coded summaries, transcriptions and captioning. The archives, and the areas they inform such as the history of sexuality, science and medicine, as well as social and cultural change, and the methodologies used to make them discoverable, will be promoted through a conference, two professional skill-sharing events and two film-screenings, building on existing demonstrable interest in these archives.\n \n","plannedDates":[{"endDate":"2022-03-31T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2022-03-31"}],"amountAwarded":154842,"Financial Year":"2019/20","Lead Applicant":"Mrs Philippa Smith","grantProgramme":[{"title":"Research Resources Award","title_keyword":"Research Resources Award"}],"Applicant Surname":"Smith","Partnership Value":154842,"Approval Committee":"Research Resources Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:London-Metropolitan-Archives","name":"London Metropolitan Archives","addressCountry":"United Kingdom","id_and_name":"[\"London Metropolitan Archives\", \"360G-Wellcome-ORG:London-Metropolitan-Archives\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:London-Metropolitan-Archives","name":"London Metropolitan Archives"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Positive history: preserving the archives of HIV/AIDS: care and testimony The aim of this project is to make accessible for research three recently acquired archive collections held by London Metropolitan Archives which together illuminate two important threads of the AIDS crisis of the 1980s and its aftermath: pioneering medical treatment, care and support; and lived experience of not only those diagnosed with HIV/AIDS, but their carers, partners, relatives and friends. They comprise: Mildmay Hospital archive including 4000 patient case files; 103 interviews of people with AIDS, their families, partners and carers, filmed by the  AIDS Since the 80s project; and the archive of peer-led support charity Positively UK (formerly Positively Women). The key outcomes will be: freely available online catalogues to item level of all three archives; a research database of key information extracted from the Mildmay Hospital case files, and full digital access to the 150 hours of filmed interviews supported by time-coded summaries, transcriptions and captioning. The archives, and the areas they inform such as the history of sexuality, science and medicine, as well as social and cultural change, and the methodologies used to make them discoverable, will be promoted through a conference, two professional skill-sharing events and two film-screenings, building on existing demonstrable interest in these archives.\n \n","awardDateDateOnly":"2020-05-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Acquired Immunodeficiency Syndrome","Caregivers","HIV Infections","History, 20th Century","Humans","London"]}
{"id":"360G-Wellcome-221377_Z_20_Z","title":"Funding of Covid-19 R&D Priorities in Africa","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221377/Z/20/Z","description":"Success against the Covid-19 pandemic requires a transdisciplinary approach incorporating social sciences and humanities, economic research and health systems research. It also requires access to funding. The African Academy of Sciences (AAS), through its hosted AESA Platform, acts as Secretariat for this Fund for Covid-19 R & D priorities in Africa. This Fund is seeking proposals against identified priorities; coordinating a network of researchers working on Covid-19 R & D to build a clinical research and trials platform for Africa; and taking a longer-term view to address pandemic preparedness in research actions.  \n\nThe Fund is open to multiple priority areas for research and development, including:\n\n\n Epidemiological studies\n\n\nStudies to define disease severity and susceptibility of particularly groups at high risk of severe infection; the role of different age groups in transmission; the impact of control and mitigation measures; and to predict the most effective interventions.\n\n\n Clinical management\n\n\nStudies to define the natural history of Covid-19 infection including the identification of prognostic factors for severe disease and the identification of vulnerable groups; and studies to improve the clinical outcome of Covid-19, including strategies to improve the processes of care.\n\n\n Infection prevention and control\n\n\nStudies to assess the effectiveness, in both healthcare and community settings, of movement control strategies in preventing secondary transmission and of personal protective equipment in reducing the risk of transmission.\n\n\n Candidate vaccines, diagnostics and therapeutics\n\n\nClinical trials of potential treatments and preventative strategies, facilitated by the recent AESA programme launched as the Clinical Trials Community online platform.\n\n\n Ethical considerations for research\n\n\nStudies on culturally appropriate approaches to the ethical, social and legal issues prevalent in emergency situations, such as presented by Covid-19.\n\n\n Social sciences in a pandemic response\n\n\nEngagement to bring community voices to decision-making processes, to understand non-intended consequences of pandemic-control decisions and to understand contextual vulnerability; and studies to mitigate impacts of the socio-economic and political externalities of Covid-19.","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":548031,"Financial Year":"2019/20","Lead Applicant":"Dr Thomas Kariuki","grantProgramme":[{"title":"AAS Africa Platform (AESA)","title_keyword":"AAS Africa Platform (AESA)"}],"Applicant Surname":"Kariuki","Partnership Value":548031,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:African-Academy-of-Sciences","name":"African Academy of Sciences","addressCountry":"Kenya","id_and_name":"[\"African Academy of Sciences\", \"360G-Wellcome-ORG:African-Academy-of-Sciences\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:African-Academy-of-Sciences","name":"African Academy of Sciences"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Funding of Covid-19 R&D Priorities in Africa Success against the Covid-19 pandemic requires a transdisciplinary approach incorporating social sciences and humanities, economic research and health systems research. It also requires access to funding. The African Academy of Sciences (AAS), through its hosted AESA Platform, acts as Secretariat for this Fund for Covid-19 R & D priorities in Africa. This Fund is seeking proposals against identified priorities; coordinating a network of researchers working on Covid-19 R & D to build a clinical research and trials platform for Africa; and taking a longer-term view to address pandemic preparedness in research actions.  \n\nThe Fund is open to multiple priority areas for research and development, including:\n\n\n Epidemiological studies\n\n\nStudies to define disease severity and susceptibility of particularly groups at high risk of severe infection; the role of different age groups in transmission; the impact of control and mitigation measures; and to predict the most effective interventions.\n\n\n Clinical management\n\n\nStudies to define the natural history of Covid-19 infection including the identification of prognostic factors for severe disease and the identification of vulnerable groups; and studies to improve the clinical outcome of Covid-19, including strategies to improve the processes of care.\n\n\n Infection prevention and control\n\n\nStudies to assess the effectiveness, in both healthcare and community settings, of movement control strategies in preventing secondary transmission and of personal protective equipment in reducing the risk of transmission.\n\n\n Candidate vaccines, diagnostics and therapeutics\n\n\nClinical trials of potential treatments and preventative strategies, facilitated by the recent AESA programme launched as the Clinical Trials Community online platform.\n\n\n Ethical considerations for research\n\n\nStudies on culturally appropriate approaches to the ethical, social and legal issues prevalent in emergency situations, such as presented by Covid-19.\n\n\n Social sciences in a pandemic response\n\n\nEngagement to bring community voices to decision-making processes, to understand non-intended consequences of pandemic-control decisions and to understand contextual vulnerability; and studies to mitigate impacts of the socio-economic and political externalities of Covid-19.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa","Biomedical Research","Humans"]}
{"id":"360G-Wellcome-221376_Z_20_Z","title":"Preparing to Scale Oxitec\u2019s 2nd Generation Aedes aegypti Technology in Resource-limited, Dengue-prone Urban Settings","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221376/Z/20/Z","description":"Human diseases that are transmitted by the Aedes genus of mosquitoes are\nincreasing rapidly, diseases such as Zika, dengue, chikungunya and yellow fever.\nRecent estimates suggest that today around half the world\u2019s population are at daily\nrisk of infection, the vast majority by a single mosquito species, Aedes aegypti.\nOxitec\u2019s have developed a ground-breaking biological approach to control this vector\nusing safe, non-biting male mosquitoes (\"OX5034-E\"). Our male-only mosquitoes\ncarry a self-limiting gene, which means that when they mate with wild females,\noffspring inherit a copy of this gene that prevents females from surviving to\nadulthood. The genetic mechanism that prevents females from surviving also enables\ndeployment of our safe, non-toxic, non-biting male Aedes aegypti via egg packets in\nsmall recyclable boxes filled with water.\nThis project will fund the final stages of tailoring Oxitec\u2019s \"just-add-water\" vectorcontrol\ndevice into a sustainable and scalable Aedes aegypti control solution. We\nwill be optimising the OX5034-E device and developing customised digital tools to\nsupport the wide-spread deployment of this technology, particularly in low-income\ncommunities that so often require it most.\nThe project\u2019s three primary goals to accomplish this are:\n- Developing new methods for scalable and rapid deployment of OX5034-E\ndevices in dengue-prone settings.\n- Demonstrating OX5034-E\u2019s ability to integrate with traditional Aedes aegypti\ncontrol programs used by resource-limited governments and communities.\n- Completing the supporting online and mobile platform to help future end-users\nmanage the planning and deployment of OX5034-E.\nWe will provide immediate benefits by delivering a two-year Aedes control program\nin a dengue-impacted city in Brazil, but importantly our project is destined to deliver\nimpact at a global scale. In the years to come we anticipate saving thousands of lives,\nand positively impacting the livelihoods of many millions of people who currently live\nunder the near constant threat of this invasive and dangerous vector.","plannedDates":[{"endDate":"2023-09-27T00:00:00+00:00","startDate":"2021-03-31T00:00:00+00:00","startDateDateOnly":"2021-03-31","endDateDateOnly":"2023-09-27"}],"amountAwarded":4916005,"Financial Year":"2019/20","Lead Applicant":"Dr Kevin Gorman","grantProgramme":[{"title":"Innovations Priority Project","title_keyword":"Innovations Priority Project"}],"Applicant Surname":"Gorman","Partnership Value":4916005,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Mr Grey Frandsen","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Oxitec-Limited","name":"Oxitec Limited","addressCountry":"United Kingdom","id_and_name":"[\"Oxitec Limited\", \"360G-Wellcome-ORG:Oxitec-Limited\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Oxitec-Limited","name":"Oxitec Limited"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Preparing to Scale Oxitec\u2019s 2nd Generation Aedes aegypti Technology in Resource-limited, Dengue-prone Urban Settings Human diseases that are transmitted by the Aedes genus of mosquitoes are\nincreasing rapidly, diseases such as Zika, dengue, chikungunya and yellow fever.\nRecent estimates suggest that today around half the world\u2019s population are at daily\nrisk of infection, the vast majority by a single mosquito species, Aedes aegypti.\nOxitec\u2019s have developed a ground-breaking biological approach to control this vector\nusing safe, non-biting male mosquitoes (\"OX5034-E\"). Our male-only mosquitoes\ncarry a self-limiting gene, which means that when they mate with wild females,\noffspring inherit a copy of this gene that prevents females from surviving to\nadulthood. The genetic mechanism that prevents females from surviving also enables\ndeployment of our safe, non-toxic, non-biting male Aedes aegypti via egg packets in\nsmall recyclable boxes filled with water.\nThis project will fund the final stages of tailoring Oxitec\u2019s \"just-add-water\" vectorcontrol\ndevice into a sustainable and scalable Aedes aegypti control solution. We\nwill be optimising the OX5034-E device and developing customised digital tools to\nsupport the wide-spread deployment of this technology, particularly in low-income\ncommunities that so often require it most.\nThe project\u2019s three primary goals to accomplish this are:\n- Developing new methods for scalable and rapid deployment of OX5034-E\ndevices in dengue-prone settings.\n- Demonstrating OX5034-E\u2019s ability to integrate with traditional Aedes aegypti\ncontrol programs used by resource-limited governments and communities.\n- Completing the supporting online and mobile platform to help future end-users\nmanage the planning and deployment of OX5034-E.\nWe will provide immediate benefits by delivering a two-year Aedes control program\nin a dengue-impacted city in Brazil, but importantly our project is destined to deliver\nimpact at a global scale. In the years to come we anticipate saving thousands of lives,\nand positively impacting the livelihoods of many millions of people who currently live\nunder the near constant threat of this invasive and dangerous vector.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aedes","Animals","Brazil","Dengue","Dengue Virus","Female","Humans","Male","Mosquito Control","Mosquito Vectors","Zika Virus Infection"]}
{"id":"360G-Wellcome-221372_Z_20_Z","title":"A Biorepository for Research in Child Health","Region":"International","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221372/Z/20/Z","description":"We propose to create an African biorepository and linked comprehensive database to support cross-disciplinary research that advances child health. The biorepository will consolidate  > 527,000 samples and data from three ongoing large population-based studies: (i) Drakenstein Child Health Study, a birth cohort with samples from parents, children and the environment collected antenatally through childhood; (ii) paediatric tuberculosis studies with samples longitudinally collected over 15 years; and (iii) Cape Town Adolescent Antiretroviral Cohort, a study of HIV-infected adolescents on antiretroviral-therapy and uninfected controls investigating development and determinants of chronic disease. Ongoing prospective data and sample collection for the next 5 years, in these and other child health studies, will substantially grow this facility ( > 732,000 samples). The facility will support several Wellcome Trust grantees and serve as a platform for cross-disciplinary research, linking metadata and samples to different databases (demographic, clinical, radiological, microbiological, genetic, transcriptomic, environmental, immunological, psychosocial). A key focus is on infectious exposures and development of non-communicable diseases, key priorities in African health. A web interface will be created for investigators to access samples or datasets. This resource will be invaluable for current and future collaborative research to advance child health and to provide African-specific data and samples.\n","plannedDates":[{"endDate":"2026-05-31T00:00:00+00:00","startDate":"2021-06-01T00:00:00+00:00","startDateDateOnly":"2021-06-01","endDateDateOnly":"2026-05-31"}],"amountAwarded":1504262,"Financial Year":"2019/20","Lead Applicant":"Prof Heather Zar","grantProgramme":[{"title":"Biomedical Resources Grant","title_keyword":"Biomedical Resources Grant"}],"Applicant Surname":"Zar","Partnership Value":1504262,"Approval Committee":"Biomedical Resource Committee","Other Applicant(s)":"Dr Liz Goddard, Prof Francesca Little, Prof Landon Myer, Prof Mark Nicol","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cape-Town-Lung-Institute","name":"University of Cape Town Lung Institute","addressCountry":"South Africa","id_and_name":"[\"University of Cape Town Lung Institute\", \"360G-Wellcome-ORG:University-of-Cape-Town-Lung-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cape-Town-Lung-Institute","name":"University of Cape Town Lung Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A Biorepository for Research in Child Health We propose to create an African biorepository and linked comprehensive database to support cross-disciplinary research that advances child health. The biorepository will consolidate  > 527,000 samples and data from three ongoing large population-based studies: (i) Drakenstein Child Health Study, a birth cohort with samples from parents, children and the environment collected antenatally through childhood; (ii) paediatric tuberculosis studies with samples longitudinally collected over 15 years; and (iii) Cape Town Adolescent Antiretroviral Cohort, a study of HIV-infected adolescents on antiretroviral-therapy and uninfected controls investigating development and determinants of chronic disease. Ongoing prospective data and sample collection for the next 5 years, in these and other child health studies, will substantially grow this facility ( > 732,000 samples). The facility will support several Wellcome Trust grantees and serve as a platform for cross-disciplinary research, linking metadata and samples to different databases (demographic, clinical, radiological, microbiological, genetic, transcriptomic, environmental, immunological, psychosocial). A key focus is on infectious exposures and development of non-communicable diseases, key priorities in African health. A web interface will be created for investigators to access samples or datasets. This resource will be invaluable for current and future collaborative research to advance child health and to provide African-specific data and samples.\n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adolescent","Africa","Biomedical Research","Child","Child Health","Child, Preschool","Female","HIV Infections","Humans","Prospective Studies","Research Design","Tuberculosis"]}
{"id":"360G-Wellcome-221371_Z_20_Z","title":"A2O - Transforming EMPIAR into an Essential Resource for EM Data Spanning Scales from Atoms to Organisms","Region":"East of England","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221371/Z/20/Z","description":"The Electron Microscopy Public Image Archive (EMPIAR) was developed following consultations with the cryo-EM community highlighting the pressing need for public dissemination of image data underpinning cryo-EM structures. Since 2014, EMPIAR has quickly grown in volume (286 entries; 284 terabytes as of 01/04/2020) and established its role and value for the community ( > 180 EMPIAR citations). Its remit now includes micro-crystal electron diffraction (microED), soft-X-ray tomography (SXT), and volume-EM (including Focused Ion Beam and Serial Block-Face SEM) data. The main goals of this grant are to streamline and facilitate the deposition process (encouraging deposition and improving quality and quantity of deposited information) and to enhance and facilitate data reuse. All hardware and IT infrastructure will be provided by EMBL-EBI.\n\nSpecific aims:\n\n\n \n Fully support deposition of volume-EM data;\n \n \n Support handling large (tissue- and organism-level) 3D-volumes by pump-priming EMPIAR with flagship connectomics and non-connectomics datasets;\n \n \n Enable efficient and interactive reuse of large 3D-volumes by supporting multiscale imaging formats;\n \n \n Facilitate potential mandatory deposition by simplifying the deposition workflow and enhancing data reuse;\n \n \n Improve support for correlative imaging data, working with stakeholder communities and the EMBL-EBI BioImage Archive;\n \n \n Prepare for rapid growth of data volumes by evaluating and implementing data-compression methods.\n \n\n","plannedDates":[{"endDate":"2026-02-28T00:00:00+00:00","startDate":"2021-03-01T00:00:00+00:00","startDateDateOnly":"2021-03-01","endDateDateOnly":"2026-02-28"}],"amountAwarded":1476141,"Financial Year":"2019/20","Lead Applicant":"Dr Ardan Patwardhan","grantProgramme":[{"title":"Biomedical Resources Grant","title_keyword":"Biomedical Resources Grant"}],"Applicant Surname":"Patwardhan","Partnership Value":1476141,"Approval Committee":"Biomedical Resource Committee","Other Applicant(s)":"Prof Gerard Kleywegt","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:European-Bioinformatics-Institute","name":"European Bioinformatics Institute","addressCountry":"United Kingdom","id_and_name":"[\"European Bioinformatics Institute\", \"360G-Wellcome-ORG:European-Bioinformatics-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:European-Bioinformatics-Institute","name":"European Bioinformatics Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A2O - Transforming EMPIAR into an Essential Resource for EM Data Spanning Scales from Atoms to Organisms The Electron Microscopy Public Image Archive (EMPIAR) was developed following consultations with the cryo-EM community highlighting the pressing need for public dissemination of image data underpinning cryo-EM structures. Since 2014, EMPIAR has quickly grown in volume (286 entries; 284 terabytes as of 01/04/2020) and established its role and value for the community ( > 180 EMPIAR citations). Its remit now includes micro-crystal electron diffraction (microED), soft-X-ray tomography (SXT), and volume-EM (including Focused Ion Beam and Serial Block-Face SEM) data. The main goals of this grant are to streamline and facilitate the deposition process (encouraging deposition and improving quality and quantity of deposited information) and to enhance and facilitate data reuse. All hardware and IT infrastructure will be provided by EMBL-EBI.\n\nSpecific aims:\n\n\n \n Fully support deposition of volume-EM data;\n \n \n Support handling large (tissue- and organism-level) 3D-volumes by pump-priming EMPIAR with flagship connectomics and non-connectomics datasets;\n \n \n Enable efficient and interactive reuse of large 3D-volumes by supporting multiscale imaging formats;\n \n \n Facilitate potential mandatory deposition by simplifying the deposition workflow and enhancing data reuse;\n \n \n Improve support for correlative imaging data, working with stakeholder communities and the EMBL-EBI BioImage Archive;\n \n \n Prepare for rapid growth of data volumes by evaluating and implementing data-compression methods.\n \n\n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cryoelectron Microscopy","Electron Microscope Tomography","Imaging, Three-Dimensional"]}
{"id":"360G-Wellcome-221368_Z_20_Z","title":"Schistosome and Snail Resource (SSR); supporting global schistosomiasis research ","Region":"Greater London","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221368/Z/20/Z","description":"Schistosomes, transmitted by freshwater snails, infect  > 200 million people in low/middle-income countries, particularly sub-Saharan Africa. While substantial advances have been made in the control of human schistosomiasis, the diversity and complexity of schistosomes and their specific fresh-water snail hosts warrants fundamental research requiring lifecycles and live material. Without the availability of Schistosoma lifecycles, future research faces substantial obstacles; currently very few labs are able to maintain the parasites and/or the snail hosts and current long-term cultures lack the genetic heterogeneity observed in natural populations. Our proposal is for the creation of a Schistosome and Snail Resource (SSR), maintaining live material and lifecycles that are currently limited or that do not exist elsewhere. The SSR will provide access to 1) the \"standard/model\" Schistosoma and snail species; 2) key African Schistosoma species/strains; 3) cultures of diverse snail vectors, enhancing current research and capacity while enabling new research avenues. Our historical expertise in establishing and maintaining unique schistosome and snail isolates from different endemic settings, together with our state-of-the-art snail facility (NHM) and LSHTM rodent facility will facilitate the development of the resource. The SSR will add considerable value by facilitating priority research needed to support schistosomiasis control and elimination. \n \n","plannedDates":[{"endDate":"2025-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2025-12-31"}],"amountAwarded":1132223,"Financial Year":"2019/20","Lead Applicant":"Dr Bonnie Webster","grantProgramme":[{"title":"Biomedical Resources Grant","title_keyword":"Biomedical Resources Grant"}],"Applicant Surname":"Webster","Partnership Value":1132223,"Approval Committee":"Biomedical Resource Committee","Other Applicant(s)":"Dr Aidan Emery, Dr Amaya Bustinduy","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Natural-History-Museum","name":"Natural History Museum","addressCountry":"United Kingdom","id_and_name":"[\"Natural History Museum\", \"360G-Wellcome-ORG:Natural-History-Museum\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Natural-History-Museum","name":"Natural History Museum"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Schistosome and Snail Resource (SSR); supporting global schistosomiasis research  Schistosomes, transmitted by freshwater snails, infect  > 200 million people in low/middle-income countries, particularly sub-Saharan Africa. While substantial advances have been made in the control of human schistosomiasis, the diversity and complexity of schistosomes and their specific fresh-water snail hosts warrants fundamental research requiring lifecycles and live material. Without the availability of Schistosoma lifecycles, future research faces substantial obstacles; currently very few labs are able to maintain the parasites and/or the snail hosts and current long-term cultures lack the genetic heterogeneity observed in natural populations. Our proposal is for the creation of a Schistosome and Snail Resource (SSR), maintaining live material and lifecycles that are currently limited or that do not exist elsewhere. The SSR will provide access to 1) the \"standard/model\" Schistosoma and snail species; 2) key African Schistosoma species/strains; 3) cultures of diverse snail vectors, enhancing current research and capacity while enabling new research avenues. Our historical expertise in establishing and maintaining unique schistosome and snail isolates from different endemic settings, together with our state-of-the-art snail facility (NHM) and LSHTM rodent facility will facilitate the development of the resource. The SSR will add considerable value by facilitating priority research needed to support schistosomiasis control and elimination. \n \n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Humans","Rats","Rodentia","Schistosoma","Schistosomiasis","Snails"]}
{"id":"360G-Wellcome-221367_Z_20_Z","title":"A multi-contrast X-ray nanoscope for multidisciplinary research","Region":"Greater London","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221367/Z/20/Z","description":"We are seeking to acquire the resources to develop a unique X-ray 3D nanoscope. We will need: custom-source, isolation, manipulators, custom-detector, radiation-safe enclosure, two PDRAs (hardware- and software-focussed) and 1year system engineer for the transition to the long-term maintenance/management of the instrument.\n\nWe plan to build a nano-resolution multi-contrast 3D scanner with transformative potential across diverse disciplines, including cellular structural biology, pathology, musculoskeletal and respiratory medicine, tissue engineering and child health.\n\nThis will create a multi-user tool, benefitting researchers across multiple specialties. The simultaneous attainment of nano-scale resolution, unprecedented scale range (six orders of magnitude,5cm/50nm), multi-contrasts and a wide energy range will make the X-ray nanoscope proposed here a unique non-destructive 3D imaging tool.\n\nIts key advancements will be ultra-high-resolution zoom-ins on intact samples, whose entire structure is measured at a lower resolution, combined with multi-contrast modes arising from phase effects. A simple analogy of this new X-ray tomography paradigm is the way we navigate digital maps. We use coarse resolution at large scales, blowing-up in precise locations of interest. Both capabilities must be concurrently present: it would not be useful to navigate large areas at highest resolution (lost in space) and having only coarse resolution would lack invaluable insights.\n","plannedDates":[{"endDate":"2026-04-25T00:00:00+00:00","startDate":"2021-04-26T00:00:00+00:00","startDateDateOnly":"2021-04-26","endDateDateOnly":"2026-04-25"}],"amountAwarded":1288017,"Financial Year":"2019/20","Lead Applicant":"Dr Marco Endrizzi","grantProgramme":[{"title":"Technology Development Grant","title_keyword":"Technology Development Grant"}],"Applicant Surname":"Endrizzi","Partnership Value":1288017,"Approval Committee":"Biomedical Resource Committee","Other Applicant(s)":"Dr Charlotte Hagen, Prof Mark Lythgoe, Prof Rachel Chambers, Dr Anna Franz, Dr Joseph Jacob, Prof Alessandro Olivo, Prof Mariya Moosajee, Prof Paolo De Coppi, Prof Peter Lee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A multi-contrast X-ray nanoscope for multidisciplinary research We are seeking to acquire the resources to develop a unique X-ray 3D nanoscope. We will need: custom-source, isolation, manipulators, custom-detector, radiation-safe enclosure, two PDRAs (hardware- and software-focussed) and 1year system engineer for the transition to the long-term maintenance/management of the instrument.\n\nWe plan to build a nano-resolution multi-contrast 3D scanner with transformative potential across diverse disciplines, including cellular structural biology, pathology, musculoskeletal and respiratory medicine, tissue engineering and child health.\n\nThis will create a multi-user tool, benefitting researchers across multiple specialties. The simultaneous attainment of nano-scale resolution, unprecedented scale range (six orders of magnitude,5cm/50nm), multi-contrasts and a wide energy range will make the X-ray nanoscope proposed here a unique non-destructive 3D imaging tool.\n\nIts key advancements will be ultra-high-resolution zoom-ins on intact samples, whose entire structure is measured at a lower resolution, combined with multi-contrast modes arising from phase effects. A simple analogy of this new X-ray tomography paradigm is the way we navigate digital maps. We use coarse resolution at large scales, blowing-up in precise locations of interest. Both capabilities must be concurrently present: it would not be useful to navigate large areas at highest resolution (lost in space) and having only coarse resolution would lack invaluable insights.\n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Imaging, Three-Dimensional","Software","Tomography, X-Ray Computed","X-Rays"]}
{"id":"360G-Wellcome-221363_Z_20_Z","title":"Transmission facility for human malaria parasites","Region":"Greater London","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221363/Z/20/Z","description":"\nWe will establish a facility for the transmission of human malaria parasites to the mosquito vector and onwards to humanized mice that is open to all members of the research community. Owing to the difficulty in transmission of human malaria parasites in laboratory settings, only few facilities exist where this can be achieved consistently. The three UK facilities capable of this are not open facilities, and none have established the humanized mouse model for investigating the liver stage of the parasite. Notably, this facility will enable the investigation of transmission-blocking compounds, malaria vaccine development, basic research into the interaction of the parasite with the mosquito host and the mammalian liver using a humanized mouse model, the effect of insecticides on the transmission of parasites by insecticide-resistant mosquitoes, the trial of specific genetic modifications of mosquitoes, genetic crosses of malaria parasites and many other investigations. This will make available avenues of research that are currently out of reach for most members of the research community and support the acceleration of new and innovative interventions to halt the spread of malaria. \n \n","plannedDates":[{"endDate":"2025-10-30T00:00:00+00:00","startDate":"2020-10-31T00:00:00+00:00","startDateDateOnly":"2020-10-31","endDateDateOnly":"2025-10-30"}],"amountAwarded":845715,"Financial Year":"2019/20","Lead Applicant":"Prof Chris Drakeley","grantProgramme":[{"title":"Biomedical Resources Grant","title_keyword":"Biomedical Resources Grant"}],"Applicant Surname":"Drakeley","Partnership Value":845715,"Approval Committee":"Biomedical Resource Committee","Other Applicant(s)":"Dr Johannes Dessens, Prof David Baker, Dr Colin Sutherland, Dr Paul Bowyer, Prof James Logan","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"London School of Hygiene & Tropical Medicine\", \"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Transmission facility for human malaria parasites \nWe will establish a facility for the transmission of human malaria parasites to the mosquito vector and onwards to humanized mice that is open to all members of the research community. Owing to the difficulty in transmission of human malaria parasites in laboratory settings, only few facilities exist where this can be achieved consistently. The three UK facilities capable of this are not open facilities, and none have established the humanized mouse model for investigating the liver stage of the parasite. Notably, this facility will enable the investigation of transmission-blocking compounds, malaria vaccine development, basic research into the interaction of the parasite with the mosquito host and the mammalian liver using a humanized mouse model, the effect of insecticides on the transmission of parasites by insecticide-resistant mosquitoes, the trial of specific genetic modifications of mosquitoes, genetic crosses of malaria parasites and many other investigations. This will make available avenues of research that are currently out of reach for most members of the research community and support the acceleration of new and innovative interventions to halt the spread of malaria. \n \n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Disease Models, Animal","Humans","Malaria","Malaria Vaccines","Mice"]}
{"id":"360G-Wellcome-221362_Z_20_Z","title":"EAT Foundation Wellcome Support","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221362/Z/20/Z","description":"Summary\n\nEAT is pleased to submit this request for a continuation of Wellcome\u2019s support for EAT knowledge engagement and communications activities. A critical assessment of the economics of food and land used systems was identified as a critical knowledge gap to further progress on transitions to healthy and sustainable food and land use system. In collaboration with SISTEMIQ, FOLU, and PIK, we are pleased to share our comprehensive proposal for the Food System Economics Commission building on the foundational work of the EAT-Lancet Commission, and FOLU\u2019s Growing Better report. \n\nSecond, while EAT has had to cancel the 2020 version of the EAT Stockholm Food Forum, the Communications team has very rapidly pivoted and begun to develop an online version of the Forum, EAT at Home. This virtual forum is a multi-month digital food festival experience, designed to spotlight leading science, planetary health chefs, business solutions, dynamic dialogs and debates, cooking demos and more in an interactive and accessible format that will build and continue momentum on food transition, while greatly increasing the diversity of voices that EAT is able to feature and engage.\n\nThird, EAT thanks Wellcome for its continued support, including to core institutional functions. \n","plannedDates":[{"endDate":"2023-05-31T00:00:00+00:00","startDate":"2020-06-01T00:00:00+00:00","startDateDateOnly":"2020-06-01","endDateDateOnly":"2023-05-31"}],"amountAwarded":1001596,"Financial Year":"2019/20","Lead Applicant":"Dr Fabrice DeClerck","grantProgramme":[{"title":"Discretionary Award - OPOH","title_keyword":"Discretionary Award - OPOH"}],"Applicant Surname":"DeClerck","Partnership Value":1001596,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:EAT-Foundation","name":"EAT Foundation","addressCountry":"Norway","id_and_name":"[\"EAT Foundation\", \"360G-Wellcome-ORG:EAT-Foundation\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:EAT-Foundation","name":"EAT Foundation"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"EAT Foundation Wellcome Support Summary\n\nEAT is pleased to submit this request for a continuation of Wellcome\u2019s support for EAT knowledge engagement and communications activities. A critical assessment of the economics of food and land used systems was identified as a critical knowledge gap to further progress on transitions to healthy and sustainable food and land use system. In collaboration with SISTEMIQ, FOLU, and PIK, we are pleased to share our comprehensive proposal for the Food System Economics Commission building on the foundational work of the EAT-Lancet Commission, and FOLU\u2019s Growing Better report. \n\nSecond, while EAT has had to cancel the 2020 version of the EAT Stockholm Food Forum, the Communications team has very rapidly pivoted and begun to develop an online version of the Forum, EAT at Home. This virtual forum is a multi-month digital food festival experience, designed to spotlight leading science, planetary health chefs, business solutions, dynamic dialogs and debates, cooking demos and more in an interactive and accessible format that will build and continue momentum on food transition, while greatly increasing the diversity of voices that EAT is able to feature and engage.\n\nThird, EAT thanks Wellcome for its continued support, including to core institutional functions. \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cooking","Food Supply","Humans"]}
{"id":"360G-Wellcome-221361_Z_20_Z","title":"Next Generation Data Formats for BioImaging","Region":"Scotland","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221361/Z/20/Z","description":"Bioimaging measures the structure, constitution and dynamics of molecules, cells, tissues and organisms in biological systems. Data are often GBytes or Tbytes in size, cover space, time and other dimensions, include complex metadata that describe experimental setups, acquisition parameters and analytic outputs and are stored in 100s of different proprietary file formats. The scale and complexity of these data are a consistent, unsolved block to researchers making their bioimaging data public and FAIR, despite the fact that open data sharing and publication are mandated by the Wellcome and many other funding agencies. \n\nOME is a globally recognised, open source bioimage data specification and software project (https://www.openmicroscopy.org). Since 2002, OME's OME-TIFF file format and Bio-Formats file translation library have served as the global de facto standard for accessing bioimage data, but the capabilities of these tools will soon be surpassed by the growing volume and complexity of bioimaging datasets. We propose to build next generation bioimage file formats, flexible data models, data linkages and transfer tools to serve the needs of the rapidly evolving bioimaging community and feed new public data repositories and databases. The software will be liberally licensed to allow adoption across the research and industrial bioimaging communities.  \n","plannedDates":[{"endDate":"2024-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2024-03-31"}],"amountAwarded":1282716,"Financial Year":"2019/20","Lead Applicant":"Prof Jason Swedlow","grantProgramme":[{"title":"Technology Development Grant","title_keyword":"Technology Development Grant"}],"Applicant Surname":"Swedlow","Partnership Value":1282716,"Approval Committee":"Biomedical Resource Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee","addressCountry":"United Kingdom","id_and_name":"[\"University of Dundee\", \"360G-Wellcome-ORG:University-of-Dundee\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Next Generation Data Formats for BioImaging Bioimaging measures the structure, constitution and dynamics of molecules, cells, tissues and organisms in biological systems. Data are often GBytes or Tbytes in size, cover space, time and other dimensions, include complex metadata that describe experimental setups, acquisition parameters and analytic outputs and are stored in 100s of different proprietary file formats. The scale and complexity of these data are a consistent, unsolved block to researchers making their bioimaging data public and FAIR, despite the fact that open data sharing and publication are mandated by the Wellcome and many other funding agencies. \n\nOME is a globally recognised, open source bioimage data specification and software project (https://www.openmicroscopy.org). Since 2002, OME's OME-TIFF file format and Bio-Formats file translation library have served as the global de facto standard for accessing bioimage data, but the capabilities of these tools will soon be surpassed by the growing volume and complexity of bioimaging datasets. We propose to build next generation bioimage file formats, flexible data models, data linkages and transfer tools to serve the needs of the rapidly evolving bioimaging community and feed new public data repositories and databases. The software will be liberally licensed to allow adoption across the research and industrial bioimaging communities.  \n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Databases, Factual","Information Dissemination","Metadata","Software"]}
{"id":"360G-Wellcome-221360_Z_20_Z","title":"Next generation atomic force microscopy for solving problems in biomedicine","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221360/Z/20/Z","description":"AFM has unique capabilities for understanding life, and is able to image living systems in their native state under physiological conditions with molecular resolution. However, technologically, it is where EM was in the 1990s \u2013 far from delivering its theoretical potential when imaging biology. By understanding the physical principles of the technique and systematically optimising the instrumentation, the potential of EM has been unleashed in recent years. We aim to drive a similar \"resolution revolution\" in AFM, developing an instrument that can:\n\n\n Image functioning biological molecules in intact systems, including living cells, without perturbing their function or structure.\n Obtain these images with sufficient resolution to identify biomolecules by their topography.\n Accurately measure the organisation of biological molecules in complex, native samples.\n\n\nWe will do this by targeting fundamental weaknesses in AFM technology:\n\n\n Reducing the thermal noise of the cantilever by producing smaller and softer cantilevers, and a microscope that can use them, reducing the imaging force 10-100x compared to the current state-of-the-art.\n Reducing positioning noise and drift by developing a hierarchical, interferometric closed-loop scanner that reduces noise by  > 10x and drift by 100-1000x compared to the current state-of-the-art, providing traceably accurate measurements of size and position.\n\n","plannedDates":[{"endDate":"2025-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2025-12-31"}],"amountAwarded":635056,"Financial Year":"2019/20","Lead Applicant":"Prof Jamie Hobbs","grantProgramme":[{"title":"Technology Development Grant","title_keyword":"Technology Development Grant"}],"Applicant Surname":"Hobbs","Partnership Value":635056,"Approval Committee":"Biomedical Resource Committee","Other Applicant(s)":"Dr Nic Mullin","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield","addressCountry":"United Kingdom","id_and_name":"[\"University of Sheffield\", \"360G-Wellcome-ORG:University-of-Sheffield\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Next generation atomic force microscopy for solving problems in biomedicine AFM has unique capabilities for understanding life, and is able to image living systems in their native state under physiological conditions with molecular resolution. However, technologically, it is where EM was in the 1990s \u2013 far from delivering its theoretical potential when imaging biology. By understanding the physical principles of the technique and systematically optimising the instrumentation, the potential of EM has been unleashed in recent years. We aim to drive a similar \"resolution revolution\" in AFM, developing an instrument that can:\n\n\n Image functioning biological molecules in intact systems, including living cells, without perturbing their function or structure.\n Obtain these images with sufficient resolution to identify biomolecules by their topography.\n Accurately measure the organisation of biological molecules in complex, native samples.\n\n\nWe will do this by targeting fundamental weaknesses in AFM technology:\n\n\n Reducing the thermal noise of the cantilever by producing smaller and softer cantilevers, and a microscope that can use them, reducing the imaging force 10-100x compared to the current state-of-the-art.\n Reducing positioning noise and drift by developing a hierarchical, interferometric closed-loop scanner that reduces noise by  > 10x and drift by 100-1000x compared to the current state-of-the-art, providing traceably accurate measurements of size and position.\n\n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Image Processing, Computer-Assisted","Microscopy","Microscopy, Atomic Force"]}
{"id":"360G-Wellcome-221350_Z_20_Z","title":"Epidemiological modelling to support the global COVID-19 response: How to mitigate impact in low-income and crisis-affected settings","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221350/Z/20/Z","description":"The current COVID-19 pandemic is the greatest threat posed by a respiratory virus since 1918 H1N1 influenza pandemic. To date, the majority of epidemiological modelling analyses have focussed on High Income Countries (HICs). However, there is an equivalent need for models appropriate to Low- and Middle-Income Countries (LMICs) that comprise 85% of the world\u2019s population and have differing demographics and behaviours that are not captured by existing models. To address this, we will use a model of SARS-CoV-2 transmission to forecast epidemics and healthcare needs in LMICs, explore the potential impact of proposed interventions and estimate their impact in real-time. It will be fit to individual country surveillance data to support estimation of the reproduction number and projections will be made of the potential impact of alternative mitigation and suppression strategies, including household quarantine and social distancing, both generally and in vulnerable populations. The fit of the model to COVID-19 case count and mortality data collected after the implementation of various interventions will be used in real-time to evaluate their effectiveness in individual LMIC countries and the criteria for lifting of social distancing measures explored using the best fit model.  \n\n \n","plannedDates":[{"endDate":"2020-10-31T00:00:00+00:00","startDate":"2020-04-16T00:00:00+00:00","startDateDateOnly":"2020-04-16","endDateDateOnly":"2020-10-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Patrick Walker","grantProgramme":[{"title":"Coronavirus","title_keyword":"Coronavirus"}],"Partnership Name":"Wellcome-DFID Epidemic Preparedness","Applicant Surname":"Walker","Partnership Value":96664,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Prof Azra Ghani, Prof Neil Ferguson, Prof Nicholas Grassly","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Epidemiological modelling to support the global COVID-19 response: How to mitigate impact in low-income and crisis-affected settings The current COVID-19 pandemic is the greatest threat posed by a respiratory virus since 1918 H1N1 influenza pandemic. To date, the majority of epidemiological modelling analyses have focussed on High Income Countries (HICs). However, there is an equivalent need for models appropriate to Low- and Middle-Income Countries (LMICs) that comprise 85% of the world\u2019s population and have differing demographics and behaviours that are not captured by existing models. To address this, we will use a model of SARS-CoV-2 transmission to forecast epidemics and healthcare needs in LMICs, explore the potential impact of proposed interventions and estimate their impact in real-time. It will be fit to individual country surveillance data to support estimation of the reproduction number and projections will be made of the potential impact of alternative mitigation and suppression strategies, including household quarantine and social distancing, both generally and in vulnerable populations. The fit of the model to COVID-19 case count and mortality data collected after the implementation of various interventions will be used in real-time to evaluate their effectiveness in individual LMIC countries and the criteria for lifting of social distancing measures explored using the best fit model.  \n\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Income","Influenza A Virus, H1N1 Subtype","Influenza, Human","Models, Theoretical","Pandemics","Poverty"]}
{"id":"360G-Wellcome-221349_Z_20_Z","title":"Photonic hyperspectral no-label spotter (PHENOSPOT)","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221349/Z/20/Z","description":"A comprehensive understanding of communication in both healthy and diseased cells requires new tools to quantify the spatial distribution, onset and rate of protein secretion. To address this challenge, we will develop an in vitro technology that maps the three-dimensional (x, y, time) distribution of multiple cell-secreted molecules, such as chemokines, hormones, and cytokines, with single cell resolution. This technology allows to better characterise the heterogeneity of cell populations in response to stimuli and to define mechanisms of inter-cellular communication. Our innovation exploits the sensitivity of optical resonances to map the secretion of specific proteins without the need for a labelled antibody. Critically, and in contrast to competing technologies, such label-free approaches enable protein detection in real time. The photonic sensor can be fabricated at low-cost and can be integrated into standard commercial microscopes rendering the technology widely applicable. We have already demonstrated the technology and will now optimise its performance, develop its capability to detect at least 3 different types of proteins in parallel and work with a commercial partner to develop a system compatible with a laboratory-standard inverted microscope. We will engage with the community through exemplar projects that span infection and immunity, cancer, haematology and vaccinology.\n \n","plannedDates":[{"endDate":"2025-04-30T00:00:00+00:00","startDate":"2021-05-01T00:00:00+00:00","startDateDateOnly":"2021-05-01","endDateDateOnly":"2025-04-30"}],"amountAwarded":983193,"Financial Year":"2019/20","Lead Applicant":"Prof Thomas Krauss","grantProgramme":[{"title":"Technology Development Grant","title_keyword":"Technology Development Grant"}],"Applicant Surname":"Krauss","Partnership Value":983193,"Approval Committee":"Biomedical Resource Committee","Other Applicant(s)":"Dr David Kent, Prof Jennifer Southgate, Dr Peter O'Toole, Prof Ian Hitchcock, Prof Paul Kaye, Dr Steven Johnson","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-York","name":"University of York","addressCountry":"United Kingdom","id_and_name":"[\"University of York\", \"360G-Wellcome-ORG:University-of-York\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-York","name":"University of York"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Photonic hyperspectral no-label spotter (PHENOSPOT) A comprehensive understanding of communication in both healthy and diseased cells requires new tools to quantify the spatial distribution, onset and rate of protein secretion. To address this challenge, we will develop an in vitro technology that maps the three-dimensional (x, y, time) distribution of multiple cell-secreted molecules, such as chemokines, hormones, and cytokines, with single cell resolution. This technology allows to better characterise the heterogeneity of cell populations in response to stimuli and to define mechanisms of inter-cellular communication. Our innovation exploits the sensitivity of optical resonances to map the secretion of specific proteins without the need for a labelled antibody. Critically, and in contrast to competing technologies, such label-free approaches enable protein detection in real time. The photonic sensor can be fabricated at low-cost and can be integrated into standard commercial microscopes rendering the technology widely applicable. We have already demonstrated the technology and will now optimise its performance, develop its capability to detect at least 3 different types of proteins in parallel and work with a commercial partner to develop a system compatible with a laboratory-standard inverted microscope. We will engage with the community through exemplar projects that span infection and immunity, cancer, haematology and vaccinology.\n \n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Photons"]}
{"id":"360G-Wellcome-221348_Z_20_Z","title":"TyVOID","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221348/Z/20/Z","description":"This study will: assess the change of medium-term efficacy of the new Typhoid Conju-gate Vaccine (TCV) in children, by comparing the relative risk of typhoid in those initially vaccinated in 2017/2018 with later cohorts vaccinated in 2020 and 2021; assess the de-cline in individual-level immunity 3-5 years after vaccination; measure ongoing popula-tion-level impact against typhoid fever in the community. The data collected will help identify correlates of medium-term protection; inform the need for, timing of and potential cost-effectiveness of adding booster doses to vaccine schedules; permit the develop-ment of a mathematical model to predict future impact of typhoid vaccination in two en-demic settings.","plannedDates":[{"endDate":"2023-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2023-12-31"}],"amountAwarded":2158322,"Financial Year":"2019/20","Lead Applicant":"Prof Andrew Pollard","grantProgramme":[{"title":"Innovations AIGH Enterics Flagship ","title_keyword":"Innovations AIGH Enterics Flagship "}],"Applicant Surname":"Pollard","Partnership Value":2158322,"Approval Committee":"Science, Innovation and Translation Programme Advisory Group","Other Applicant(s)":"Dr Firdausi Qadri, Prof John Clemens, Dr Kathy Neuzil, Dr Virginia Pitzer, Dr Xinxue Liu, Prof Shrijana Shrestha, Dr Buddha Basnyat, Dr Katherine Theiss-Nyland, Dr Merryn Voysey","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"TyVOID This study will: assess the change of medium-term efficacy of the new Typhoid Conju-gate Vaccine (TCV) in children, by comparing the relative risk of typhoid in those initially vaccinated in 2017/2018 with later cohorts vaccinated in 2020 and 2021; assess the de-cline in individual-level immunity 3-5 years after vaccination; measure ongoing popula-tion-level impact against typhoid fever in the community. The data collected will help identify correlates of medium-term protection; inform the need for, timing of and potential cost-effectiveness of adding booster doses to vaccine schedules; permit the develop-ment of a mathematical model to predict future impact of typhoid vaccination in two en-demic settings.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Child, Preschool","Humans","Infant","Models, Theoretical","Salmonella typhi","Typhoid Fever","Typhoid-Paratyphoid Vaccines","Vaccination"]}
{"id":"360G-Wellcome-221345_Z_20_Z","title":"RSTMH small grants for snakebite ","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221345/Z/20/Z","description":"For Wellcome Trust to contribute to the established RSTMH small grants programme to enable those early in their careers to conduct small research projects into the topic of snakebite. Our small grants are awards of up to \u00a35,000 including VAT and available to those early in their careers who are working in a field relevant to tropical medicine or global health e.g. doctors, nurses, academic researchers, NGO workers, health economists, social scientists. These grants typically represent the very first time someone has received funding in their own name, the first application form they have written, and the first time they have managed their own project,including a budget and reporting. The grant process is designed to be as straightforward as possible, for many applicants English is not often their first language. The application is made through our online portal and 2 referees, including their supervisor, must be provided. Snakebite is a topic of great importance to RSTMH given its high levels of death and disability. Though funding has increased in the topic there is a need to encourage early career interest and we feel the small grants present a way to do this, which is easy for Wellcome to benefit from.    \n","plannedDates":[{"endDate":"2020-10-05T00:00:00+00:00","startDate":"2020-05-18T00:00:00+00:00","startDateDateOnly":"2020-05-18","endDateDateOnly":"2020-10-05"}],"amountAwarded":55300,"Financial Year":"2019/20","Lead Applicant":"Ms Tamar Ghosh","grantProgramme":[{"title":"Discretionary Award - Snakebite","title_keyword":"Discretionary Award - Snakebite"}],"Applicant Surname":"Ghosh","Partnership Value":55300,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Royal-Society-of-Tropical-Medicine-and-Hygiene","name":"Royal Society of Tropical Medicine and Hygiene","addressCountry":"United Kingdom","id_and_name":"[\"Royal Society of Tropical Medicine and Hygiene\", \"360G-Wellcome-ORG:Royal-Society-of-Tropical-Medicine-and-Hygiene\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Royal-Society-of-Tropical-Medicine-and-Hygiene","name":"Royal Society of Tropical Medicine and Hygiene"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"RSTMH small grants for snakebite  For Wellcome Trust to contribute to the established RSTMH small grants programme to enable those early in their careers to conduct small research projects into the topic of snakebite. Our small grants are awards of up to \u00a35,000 including VAT and available to those early in their careers who are working in a field relevant to tropical medicine or global health e.g. doctors, nurses, academic researchers, NGO workers, health economists, social scientists. These grants typically represent the very first time someone has received funding in their own name, the first application form they have written, and the first time they have managed their own project,including a budget and reporting. The grant process is designed to be as straightforward as possible, for many applicants English is not often their first language. The application is made through our online portal and 2 referees, including their supervisor, must be provided. Snakebite is a topic of great importance to RSTMH given its high levels of death and disability. Though funding has increased in the topic there is a need to encourage early career interest and we feel the small grants present a way to do this, which is easy for Wellcome to benefit from.    \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Financing, Organized","Humans","Research Support as Topic"]}
{"id":"360G-Wellcome-221327_Z_20_Z","title":"3D-FunSites - a virtual encyclopaedia of protein functional sites for assessing variant impacts and drug repurposing  ","Region":"Greater London","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221327/Z/20/Z","description":"We will significantly expand CATH, widely used by biomedical researchers, and enhance its value for disease analyses. Data on disease-associated genetic variations is vastly increasing but to fully exploit it we must understand how the resulting residue mutations impact protein functional sites and therefore functions. We will use CATH to predict the impact of variants on diseases and drug responses, enabling personalised medicine.\n\nCATH-FunFams are functional sub-classifications of CATH evolutionary superfamilies and the only structural resource comprehensively linking variants, structure and vast sequence data for predicting functional sites accurately (FunSites). Close proximity of disease variants (residue mutations) to FunSites, in 3D, is a key indicator of pathogenicity.\n\nOur expanded CATH-FunFams and FunSites will enhance machine learning methods to predict functional impacts and drug responses/side effects, including for different genders and ethnicities.\n\nWe will:-\n\n1. Expand CATH-FunFams and FunSites  > 5-fold by adding sequence data from metagenomes.\n\n2. Expand CATH-FunSites further by integrating comprehensive data from PDBe-KB, PDBsum and VarSite.\n\n3. Develop machine-learning tools that exploit data from (1)  &  (2) to predict impacts of genetic variations in different populations.\n\n4. Integrate drug data into FunFams and develop tools to predict drug repurposing/side effects.\n\n5. Develop intuitive webpages reporting functional impacts/drug repurposing/toxicity.\n","plannedDates":[{"endDate":"2026-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2026-03-31"}],"amountAwarded":851128,"Financial Year":"2019/20","Lead Applicant":"Prof Christine Orengo","grantProgramme":[{"title":"Biomedical Resources Grant","title_keyword":"Biomedical Resources Grant"}],"Applicant Surname":"Orengo","Partnership Value":851128,"Approval Committee":"Biomedical Resource Committee","Other Applicant(s)":"Dr Sameer Velankar, Prof Janet Thornton, Prof Andrew Martin","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"3D-FunSites - a virtual encyclopaedia of protein functional sites for assessing variant impacts and drug repurposing   We will significantly expand CATH, widely used by biomedical researchers, and enhance its value for disease analyses. Data on disease-associated genetic variations is vastly increasing but to fully exploit it we must understand how the resulting residue mutations impact protein functional sites and therefore functions. We will use CATH to predict the impact of variants on diseases and drug responses, enabling personalised medicine.\n\nCATH-FunFams are functional sub-classifications of CATH evolutionary superfamilies and the only structural resource comprehensively linking variants, structure and vast sequence data for predicting functional sites accurately (FunSites). Close proximity of disease variants (residue mutations) to FunSites, in 3D, is a key indicator of pathogenicity.\n\nOur expanded CATH-FunFams and FunSites will enhance machine learning methods to predict functional impacts and drug responses/side effects, including for different genders and ethnicities.\n\nWe will:-\n\n1. Expand CATH-FunFams and FunSites  > 5-fold by adding sequence data from metagenomes.\n\n2. Expand CATH-FunSites further by integrating comprehensive data from PDBe-KB, PDBsum and VarSite.\n\n3. Develop machine-learning tools that exploit data from (1)  &  (2) to predict impacts of genetic variations in different populations.\n\n4. Integrate drug data into FunFams and develop tools to predict drug repurposing/side effects.\n\n5. Develop intuitive webpages reporting functional impacts/drug repurposing/toxicity.\n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Genetic Variation","Humans","Machine Learning","Proteins"]}
{"id":"360G-Wellcome-221321_Z_20_Z","title":"Connecting three worlds: socialism, medicine and global health after WWII","Region":"South West","currency":"GBP","awardDate":"2020-07-30T00:00:00+00:00","Internal ID":"221321/Z/20/Z","description":"The project pioneers a new history of global health that, for the first time, incorporates the socialist world - a constellation of countries in a fluctuating political, economic and military nexus distinct from the capitalist West. It identifies the particular health cultures produced by socialism (in all its variety) and explores the impact of socialist internationalism in co-producing global health in the 20th century. This project offers a radical new account that will not only transform our knowledge of historical processes, but will further our understanding of ideas, practices and processes that current global health structures have been built on.\n\nGlobal health histories are framed mainly through American, colonial and liberal perspectives. The omission of socialist contexts, however, distorts our understanding of what global health is. Although there was not one socialist template, diverse framings of socialist medicine played major roles in shaping and contesting global practices.\n\nA systematic analysis of socialist medicine and international health through global case studies integrates missing expert networks, political agendas, public health models and diplomatic agreements in global health history. This work, in turn, allows us to rethink concepts such as socialism, solidarity, development, socialist medical research and health provision.\n","plannedDates":[{"endDate":"2025-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2025-12-31"}],"amountAwarded":1560998,"Financial Year":"2019/20","Lead Applicant":"Dr Dora Vargha","grantProgramme":[{"title":"Collaborative Award in H&SS","title_keyword":"Collaborative Award in H&SS"}],"Applicant Surname":"Vargha","Partnership Value":1560998,"Approval Committee":"Humanities and Social Science Selection Panel","Other Applicant(s)":"Dr Edna Su\u00e1rez-D\u00edaz, Dr Sarah Marks","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Exeter","name":"University of Exeter","addressCountry":"United Kingdom","id_and_name":"[\"University of Exeter\", \"360G-Wellcome-ORG:University-of-Exeter\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Exeter","name":"University of Exeter"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Connecting three worlds: socialism, medicine and global health after WWII The project pioneers a new history of global health that, for the first time, incorporates the socialist world - a constellation of countries in a fluctuating political, economic and military nexus distinct from the capitalist West. It identifies the particular health cultures produced by socialism (in all its variety) and explores the impact of socialist internationalism in co-producing global health in the 20th century. This project offers a radical new account that will not only transform our knowledge of historical processes, but will further our understanding of ideas, practices and processes that current global health structures have been built on.\n\nGlobal health histories are framed mainly through American, colonial and liberal perspectives. The omission of socialist contexts, however, distorts our understanding of what global health is. Although there was not one socialist template, diverse framings of socialist medicine played major roles in shaping and contesting global practices.\n\nA systematic analysis of socialist medicine and international health through global case studies integrates missing expert networks, political agendas, public health models and diplomatic agreements in global health history. This work, in turn, allows us to rethink concepts such as socialism, solidarity, development, socialist medical research and health provision.\n","awardDateDateOnly":"2020-07-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Global Health","History, 19th Century","History, 20th Century","History, 21st Century","Humans","Politics"]}
{"id":"360G-Wellcome-221320_Z_20_Z","title":"InterPro and Pfam: Protein domains and families for biomedical research","Region":"East of England","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221320/Z/20/Z","description":"InterPro is a core protein data resource that amalgamates 13 protein family databases (including Pfam) to provide the definitive description and classification of protein domains and families. Various scientific communities rely on the range of annotations provided by InterPro and its member databases to acquire novel insights into the vast amounts of new DNA sequence data, enabling scientists to interpret experiments and design new ones based on annotations spanning complete genomes down to single residues. The past five years have witnessed a major increase in the scale of sequences, concomitant with the emergence of AI/ML approaches for unlocking the biological signals encoded within the data. This project will exploit these innovative approaches to enhance protein annotations and refine classifications through the incorporation of additional data types, along with the application of ML methods and organisation of the protein family data. We will integrate KOfams and AMRFinder into InterPro, while continuing to scale the InterPro/Pfam/HMMER resources to tackle billions of proteins. Cumulatively, these developments will accelerate biomedical research by facilitating scientists to decipher the effect of human mutations, understand drug interactions, combat antimicrobial resistance, and tackle emerging pathogens.\n","plannedDates":[{"endDate":"2026-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2026-03-31"}],"amountAwarded":1391682,"Financial Year":"2019/20","Lead Applicant":"Dr Alex Bateman","grantProgramme":[{"title":"Biomedical Resources Grant","title_keyword":"Biomedical Resources Grant"}],"Applicant Surname":"Bateman","Partnership Value":1391682,"Approval Committee":"Biomedical Resource Committee","Other Applicant(s)":"Dr Robert Finn","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:European-Bioinformatics-Institute","name":"European Bioinformatics Institute","addressCountry":"United Kingdom","id_and_name":"[\"European Bioinformatics Institute\", \"360G-Wellcome-ORG:European-Bioinformatics-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:European-Bioinformatics-Institute","name":"European Bioinformatics Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"InterPro and Pfam: Protein domains and families for biomedical research InterPro is a core protein data resource that amalgamates 13 protein family databases (including Pfam) to provide the definitive description and classification of protein domains and families. Various scientific communities rely on the range of annotations provided by InterPro and its member databases to acquire novel insights into the vast amounts of new DNA sequence data, enabling scientists to interpret experiments and design new ones based on annotations spanning complete genomes down to single residues. The past five years have witnessed a major increase in the scale of sequences, concomitant with the emergence of AI/ML approaches for unlocking the biological signals encoded within the data. This project will exploit these innovative approaches to enhance protein annotations and refine classifications through the incorporation of additional data types, along with the application of ML methods and organisation of the protein family data. We will integrate KOfams and AMRFinder into InterPro, while continuing to scale the InterPro/Pfam/HMMER resources to tackle billions of proteins. Cumulatively, these developments will accelerate biomedical research by facilitating scientists to decipher the effect of human mutations, understand drug interactions, combat antimicrobial resistance, and tackle emerging pathogens.\n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Databases, Genetic","Humans","Molecular Sequence Annotation","Proteins"]}
{"id":"360G-Wellcome-221311_Z_20_Z","title":" Clinical ApplicatioN of DEep Learning and Intelligent Vision in Radiology: CAN DELIVeR","Region":"Ireland","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221311/Z/20/Z","description":"The workload associated with medical imaging has greatly increased both in terms of volume and complexity in recent years. The amount of clinicians trained in expert interpretation of these data has however, failed to keep pace with demand. This project encompasses the application of Machine Learning to specific radiology use cases. Imaging with MRI is the cornerstone of surveillance of patients with MS and underpins decision making around initiation of and modifications to therapy Reporting these images is a significant proportion of the reporting time of our Neuroradiologists. Artificial Intelligence, and especially machine and deep learning have been proposed as a potential solution. Computer Science (CS) groups who aim to tackle these issues may fail  due to a lack of access to clinical insight and clinical data.  Furthermore clinical groups may lack the CS expertise. Presently in Ireland there is no framework for clinicians with medical imaging problems, which could potentially be solved with machine vision, to interact with computer scientists with the expertise to solve these problems. We intend to apply solutions using novel computer science techniques to clinical problems with a particular focus on the assessment of interval change between scan acquisitions.\n \n","plannedDates":[{"endDate":"2022-10-19T00:00:00+00:00","startDate":"2019-09-02T00:00:00+00:00","startDateDateOnly":"2019-09-02","endDateDateOnly":"2022-10-19"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Brendan Kelly","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Partnership Name":"SFI-HRB-Wellcome Trust partnership","Applicant Surname":"Kelly","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-Dublin","name":"University College Dublin","addressCountry":"Ireland","id_and_name":"[\"University College Dublin\", \"360G-Wellcome-ORG:University-College-Dublin\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-Dublin","name":"University College Dublin"}},"filename":"a001p00000xQ047AAC.json","title_and_description":" Clinical ApplicatioN of DEep Learning and Intelligent Vision in Radiology: CAN DELIVeR The workload associated with medical imaging has greatly increased both in terms of volume and complexity in recent years. The amount of clinicians trained in expert interpretation of these data has however, failed to keep pace with demand. This project encompasses the application of Machine Learning to specific radiology use cases. Imaging with MRI is the cornerstone of surveillance of patients with MS and underpins decision making around initiation of and modifications to therapy Reporting these images is a significant proportion of the reporting time of our Neuroradiologists. Artificial Intelligence, and especially machine and deep learning have been proposed as a potential solution. Computer Science (CS) groups who aim to tackle these issues may fail  due to a lack of access to clinical insight and clinical data.  Furthermore clinical groups may lack the CS expertise. Presently in Ireland there is no framework for clinicians with medical imaging problems, which could potentially be solved with machine vision, to interact with computer scientists with the expertise to solve these problems. We intend to apply solutions using novel computer science techniques to clinical problems with a particular focus on the assessment of interval change between scan acquisitions.\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Deep Learning","Diagnostic Imaging","Humans","Ireland","Machine Learning","Magnetic Resonance Imaging","Radiology","Radiology Information Systems"]}
{"id":"360G-Wellcome-221307_Z_20_Z","title":"Chloroquine/Hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221307/Z/20/Z","description":"There is no proven treatment, chemoprophylaxis or vaccine for COVID-19. This is the most serious pandemic emergency for 100 years. Healthcare workers are being affected disproportionately in the continuing epidemic threatening an imminent breakdown of health services. Chloroquine and hydroxychloroquine are safe and well-tolerated medications which can be taken for years without adverse effects.Both have significant antiviral activity against SARS-CoV-2 and there is emerging evidence from China and Europe of efficacy in treatment. Unfortunately there is also premature recommendation from countries such as India which now recommends low dose hydroxychloroquine for prophylaxis in health care workers. \n\nWe propose conducting a multi-centre, multi-country randomised, double blind, placebo controlled assessment of the prophylactic efficacy of chloroquine (Asia) or hydroxychloroquine (Europe) in preventing COVID-19 illness in at-risk healthcare workers and other frontline staff. At least 40,000 participants in Asia and Europe will be randomised 1:1 to receive chloroquine or hydroxychloroquine or a matched film coated placebo as daily prophylaxis for three months.  The study\u2019s objectives are the prevention of symptomatic coronavirus disease (COVID-19) and the attenuation of the clinical severity.\n","plannedDates":[{"endDate":"2022-03-27T00:00:00+00:00","startDate":"2020-03-28T00:00:00+00:00","startDateDateOnly":"2020-03-28","endDateDateOnly":"2022-03-27"}],"amountAwarded":6920135,"Financial Year":"2019/20","Lead Applicant":"Prof Sir Nicholas White","grantProgramme":[{"title":"Therapeutics Accelerator ","title_keyword":"Therapeutics Accelerator "}],"Applicant Surname":"White","Partnership Value":6920135,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Chloroquine/Hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV) There is no proven treatment, chemoprophylaxis or vaccine for COVID-19. This is the most serious pandemic emergency for 100 years. Healthcare workers are being affected disproportionately in the continuing epidemic threatening an imminent breakdown of health services. Chloroquine and hydroxychloroquine are safe and well-tolerated medications which can be taken for years without adverse effects.Both have significant antiviral activity against SARS-CoV-2 and there is emerging evidence from China and Europe of efficacy in treatment. Unfortunately there is also premature recommendation from countries such as India which now recommends low dose hydroxychloroquine for prophylaxis in health care workers. \n\nWe propose conducting a multi-centre, multi-country randomised, double blind, placebo controlled assessment of the prophylactic efficacy of chloroquine (Asia) or hydroxychloroquine (Europe) in preventing COVID-19 illness in at-risk healthcare workers and other frontline staff. At least 40,000 participants in Asia and Europe will be randomised 1:1 to receive chloroquine or hydroxychloroquine or a matched film coated placebo as daily prophylaxis for three months.  The study\u2019s objectives are the prevention of symptomatic coronavirus disease (COVID-19) and the attenuation of the clinical severity.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Antiviral Agents","China","Chloroquine","Double-Blind Method","Health Personnel","Humans"]}
{"id":"360G-Wellcome-221305_Z_20_Z","title":"Remaking One Health: Decolonial approaches to street dogs and rabies prevention in India","Region":"Scotland","currency":"GBP","awardDate":"2020-07-30T00:00:00+00:00","Internal ID":"221305/Z/20/Z","description":"This study investigates the biosocial conditions that frame the persistence of rabies as a public health concern in India to rethink One Health approaches in post-anthropocentric directions. Dog-mediated rabies in Asia and Africa is a priority in transnational public health, and One Health approaches have scientific consensus as being key to its prevention (WHO 2019). India has the highest burden of human rabies globally despite long-standing initiatives, including One Health, on rabies elimination. Our project addresses this impasse.\n\nChallenging the (post)colonial One Health conceptualisation of street dogs as out-of-place disease vectors, our analytical framework of multispecies cultures directs new inter-disciplinary attention to the lived experiences of human and nonhuman animal actors, and to multiple dimensions of people-street dog relations in urban and rural India. We will examine historical and contemporary transnational influences on dog-related public health agendas; public attitudes and knowledge; everyday interactions between people, dogs, and the biophysical environment; and institutional interventions to advance decolonial concepts and practices for healthy multispecies societies. Through this fresh approach to rabies, we will reframe how One Health is theorised and pursued, and reconfigure it to enable more equitable approaches to health in a world marked by multispecies risk and vulnerability.\n","plannedDates":[{"endDate":"2025-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2025-08-31"}],"amountAwarded":599638,"Financial Year":"2019/20","Lead Applicant":"Dr Krithika Srinivasan","grantProgramme":[{"title":"Collaborative Award in H&SS","title_keyword":"Collaborative Award in H&SS"}],"Applicant Surname":"Srinivasan","Partnership Value":599638,"Approval Committee":"Humanities and Social Science Selection Panel","Other Applicant(s)":"Dr Christopher Pearson, Associate Professor Daniel Ramp, Dr Tim Kurz","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Remaking One Health: Decolonial approaches to street dogs and rabies prevention in India This study investigates the biosocial conditions that frame the persistence of rabies as a public health concern in India to rethink One Health approaches in post-anthropocentric directions. Dog-mediated rabies in Asia and Africa is a priority in transnational public health, and One Health approaches have scientific consensus as being key to its prevention (WHO 2019). India has the highest burden of human rabies globally despite long-standing initiatives, including One Health, on rabies elimination. Our project addresses this impasse.\n\nChallenging the (post)colonial One Health conceptualisation of street dogs as out-of-place disease vectors, our analytical framework of multispecies cultures directs new inter-disciplinary attention to the lived experiences of human and nonhuman animal actors, and to multiple dimensions of people-street dog relations in urban and rural India. We will examine historical and contemporary transnational influences on dog-related public health agendas; public attitudes and knowledge; everyday interactions between people, dogs, and the biophysical environment; and institutional interventions to advance decolonial concepts and practices for healthy multispecies societies. Through this fresh approach to rabies, we will reframe how One Health is theorised and pursued, and reconfigure it to enable more equitable approaches to health in a world marked by multispecies risk and vulnerability.\n","awardDateDateOnly":"2020-07-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Dog Diseases","Dogs","Humans","India","Public Health","Rabies","Rabies Vaccines"]}
{"id":"360G-Wellcome-221305_C_20_Z","title":"Remaking One Health: Decolonial approaches to street dogs and rabies prevention in India","Region":"International","currency":"GBP","awardDate":"2020-07-30T00:00:00+00:00","Internal ID":"221305/C/20/Z","description":"This study investigates the biosocial conditions that frame the persistence of rabies as a public health concern in India to rethink One Health approaches in post-anthropocentric directions. Dog-mediated rabies in Asia and Africa is a priority in transnational public health, and One Health approaches have scientific consensus as being key to its prevention (WHO 2019). India has the highest burden of human rabies globally despite long-standing initiatives, including One Health, on rabies elimination. Our project addresses this impasse.\n\nChallenging the (post)colonial One Health conceptualisation of street dogs as out-of-place disease vectors, our analytical framework of multispecies cultures directs new inter-disciplinary attention to the lived experiences of human and nonhuman animal actors, and to multiple dimensions of people-street dog relations in urban and rural India. We will examine historical and contemporary transnational influences on dog-related public health agendas; public attitudes and knowledge; everyday interactions between people, dogs, and the biophysical environment; and institutional interventions to advance decolonial concepts and practices for healthy multispecies societies. Through this fresh approach to rabies, we will reframe how One Health is theorised and pursued, and reconfigure it to enable more equitable approaches to health in a world marked by multispecies risk and vulnerability.\n","plannedDates":[{"endDate":"2025-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2025-08-31"}],"amountAwarded":238110,"Financial Year":"2019/20","Lead Applicant":"Associate Professor Daniel Ramp","grantProgramme":[{"title":"Collaborative Award in H&SS","title_keyword":"Collaborative Award in H&SS"}],"Applicant Surname":"Ramp","Partnership Value":238110,"Approval Committee":"Humanities and Social Science Selection Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Technology-Sydney","name":"University of Technology, Sydney","addressCountry":"Australia","id_and_name":"[\"University of Technology, Sydney\", \"360G-Wellcome-ORG:University-of-Technology-Sydney\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Technology-Sydney","name":"University of Technology, Sydney"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Remaking One Health: Decolonial approaches to street dogs and rabies prevention in India This study investigates the biosocial conditions that frame the persistence of rabies as a public health concern in India to rethink One Health approaches in post-anthropocentric directions. Dog-mediated rabies in Asia and Africa is a priority in transnational public health, and One Health approaches have scientific consensus as being key to its prevention (WHO 2019). India has the highest burden of human rabies globally despite long-standing initiatives, including One Health, on rabies elimination. Our project addresses this impasse.\n\nChallenging the (post)colonial One Health conceptualisation of street dogs as out-of-place disease vectors, our analytical framework of multispecies cultures directs new inter-disciplinary attention to the lived experiences of human and nonhuman animal actors, and to multiple dimensions of people-street dog relations in urban and rural India. We will examine historical and contemporary transnational influences on dog-related public health agendas; public attitudes and knowledge; everyday interactions between people, dogs, and the biophysical environment; and institutional interventions to advance decolonial concepts and practices for healthy multispecies societies. Through this fresh approach to rabies, we will reframe how One Health is theorised and pursued, and reconfigure it to enable more equitable approaches to health in a world marked by multispecies risk and vulnerability.\n","awardDateDateOnly":"2020-07-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Dog Diseases","Dogs","Humans","India","Public Health","Rabies","Rabies Vaccines"]}
{"id":"360G-Wellcome-221305_B_20_Z","title":"Remaking One Health: Decolonial approaches to street dogs and rabies prevention in India","Region":"International","currency":"GBP","awardDate":"2020-07-30T00:00:00+00:00","Internal ID":"221305/B/20/Z","description":"This study investigates the biosocial conditions that frame the persistence of rabies as a public health concern in India to rethink One Health approaches in post-anthropocentric directions. Dog-mediated rabies in Asia and Africa is a priority in transnational public health, and One Health approaches have scientific consensus as being key to its prevention (WHO 2019). India has the highest burden of human rabies globally despite long-standing initiatives, including One Health, on rabies elimination. Our project addresses this impasse.\n\nChallenging the (post)colonial One Health conceptualisation of street dogs as out-of-place disease vectors, our analytical framework of multispecies cultures directs new inter-disciplinary attention to the lived experiences of human and nonhuman animal actors, and to multiple dimensions of people-street dog relations in urban and rural India. We will examine historical and contemporary transnational influences on dog-related public health agendas; public attitudes and knowledge; everyday interactions between people, dogs, and the biophysical environment; and institutional interventions to advance decolonial concepts and practices for healthy multispecies societies. Through this fresh approach to rabies, we will reframe how One Health is theorised and pursued, and reconfigure it to enable more equitable approaches to health in a world marked by multispecies risk and vulnerability.\n","plannedDates":[{"endDate":"2025-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2025-08-31"}],"amountAwarded":338768,"Financial Year":"2019/20","Lead Applicant":"Dr Tim Kurz","grantProgramme":[{"title":"Collaborative Award in H&SS","title_keyword":"Collaborative Award in H&SS"}],"Applicant Surname":"Kurz","Partnership Value":338768,"Approval Committee":"Humanities and Social Science Selection Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Western-Australia","name":"University of Western Australia","addressCountry":"Australia","id_and_name":"[\"University of Western Australia\", \"360G-Wellcome-ORG:University-of-Western-Australia\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Western-Australia","name":"University of Western Australia"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Remaking One Health: Decolonial approaches to street dogs and rabies prevention in India This study investigates the biosocial conditions that frame the persistence of rabies as a public health concern in India to rethink One Health approaches in post-anthropocentric directions. Dog-mediated rabies in Asia and Africa is a priority in transnational public health, and One Health approaches have scientific consensus as being key to its prevention (WHO 2019). India has the highest burden of human rabies globally despite long-standing initiatives, including One Health, on rabies elimination. Our project addresses this impasse.\n\nChallenging the (post)colonial One Health conceptualisation of street dogs as out-of-place disease vectors, our analytical framework of multispecies cultures directs new inter-disciplinary attention to the lived experiences of human and nonhuman animal actors, and to multiple dimensions of people-street dog relations in urban and rural India. We will examine historical and contemporary transnational influences on dog-related public health agendas; public attitudes and knowledge; everyday interactions between people, dogs, and the biophysical environment; and institutional interventions to advance decolonial concepts and practices for healthy multispecies societies. Through this fresh approach to rabies, we will reframe how One Health is theorised and pursued, and reconfigure it to enable more equitable approaches to health in a world marked by multispecies risk and vulnerability.\n","awardDateDateOnly":"2020-07-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Dog Diseases","Dogs","Humans","India","Public Health","Rabies","Rabies Vaccines"]}
{"id":"360G-Wellcome-221305_A_20_Z","title":"Remaking One Health: Decolonial approaches to street dogs and rabies prevention in India","Region":"North West","currency":"GBP","awardDate":"2020-07-30T00:00:00+00:00","Internal ID":"221305/A/20/Z","description":"This study investigates the biosocial conditions that frame the persistence of rabies as a public health concern in India to rethink One Health approaches in post-anthropocentric directions. Dog-mediated rabies in Asia and Africa is a priority in transnational public health, and One Health approaches have scientific consensus as being key to its prevention (WHO 2019). India has the highest burden of human rabies globally despite long-standing initiatives, including One Health, on rabies elimination. Our project addresses this impasse.\n\nChallenging the (post)colonial One Health conceptualisation of street dogs as out-of-place disease vectors, our analytical framework of multispecies cultures directs new inter-disciplinary attention to the lived experiences of human and nonhuman animal actors, and to multiple dimensions of people-street dog relations in urban and rural India. We will examine historical and contemporary transnational influences on dog-related public health agendas; public attitudes and knowledge; everyday interactions between people, dogs, and the biophysical environment; and institutional interventions to advance decolonial concepts and practices for healthy multispecies societies. Through this fresh approach to rabies, we will reframe how One Health is theorised and pursued, and reconfigure it to enable more equitable approaches to health in a world marked by multispecies risk and vulnerability.\n","plannedDates":[{"endDate":"2025-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2025-08-31"}],"amountAwarded":326834,"Financial Year":"2019/20","Lead Applicant":"Dr Christopher Pearson","grantProgramme":[{"title":"Collaborative Award in H&SS","title_keyword":"Collaborative Award in H&SS"}],"Applicant Surname":"Pearson","Partnership Value":326834,"Approval Committee":"Humanities and Social Science Selection Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool","addressCountry":"United Kingdom","id_and_name":"[\"University of Liverpool\", \"360G-Wellcome-ORG:University-of-Liverpool\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Remaking One Health: Decolonial approaches to street dogs and rabies prevention in India This study investigates the biosocial conditions that frame the persistence of rabies as a public health concern in India to rethink One Health approaches in post-anthropocentric directions. Dog-mediated rabies in Asia and Africa is a priority in transnational public health, and One Health approaches have scientific consensus as being key to its prevention (WHO 2019). India has the highest burden of human rabies globally despite long-standing initiatives, including One Health, on rabies elimination. Our project addresses this impasse.\n\nChallenging the (post)colonial One Health conceptualisation of street dogs as out-of-place disease vectors, our analytical framework of multispecies cultures directs new inter-disciplinary attention to the lived experiences of human and nonhuman animal actors, and to multiple dimensions of people-street dog relations in urban and rural India. We will examine historical and contemporary transnational influences on dog-related public health agendas; public attitudes and knowledge; everyday interactions between people, dogs, and the biophysical environment; and institutional interventions to advance decolonial concepts and practices for healthy multispecies societies. Through this fresh approach to rabies, we will reframe how One Health is theorised and pursued, and reconfigure it to enable more equitable approaches to health in a world marked by multispecies risk and vulnerability.\n","awardDateDateOnly":"2020-07-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Dog Diseases","Dogs","Humans","India","Public Health","Rabies","Rabies Vaccines"]}
{"id":"360G-Wellcome-221304_Z_20_Z","title":" An international dimension to the first Indian research management conference","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221304/Z/20/Z","description":"The DBT/Wellcome Trust India Alliance will shortly be organizing the first Conference for Indian Research Managers and Administrators (RMAs), as part of the ongoing India Research Management Initiative (IRMI). IRMI activities represent the foundational steps towards strengthening research ecosystems in India. The IRMI Annual Conference series is intended as a platform for Indian RMAs to share their work and perspectives with peers, for institutional and funder representatives to engage with the possibilities of Research Management in India, and for Indian RMAs to work together as a community of professionals. Work has begun on creating a structure for the 2020 Conference, which will include 60-80 RMAs, researchers and funder representatives from India. As the current pool of RMAs in India is small and relatively inexperienced, it will be beneficial to additionally include a small group of international RMAs, for presentations and interactions at the Conference. This is a request to the Wellcome Trust for funding the costs of attendance of international experts at the IRMI Annual Conference 2020.  \n","plannedDates":[{"endDate":"2021-05-31T00:00:00+00:00","startDate":"2020-06-01T00:00:00+00:00","startDateDateOnly":"2020-06-01","endDateDateOnly":"2021-05-31"}],"amountAwarded":21115,"Financial Year":"2019/20","Lead Applicant":"Dr Savita Ayyar","grantProgramme":[{"title":"Discretionary Award - REiAA","title_keyword":"Discretionary Award - REiAA"}],"Applicant Surname":"Ayyar","Partnership Value":21115,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Wellcome-Trust-dbt-India-Alliance","name":"Wellcome Trust/dbt India Alliance","addressCountry":"India","id_and_name":"[\"Wellcome Trust/dbt India Alliance\", \"360G-Wellcome-ORG:Wellcome-Trust-dbt-India-Alliance\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Wellcome-Trust-dbt-India-Alliance","name":"Wellcome Trust/dbt India Alliance"}},"filename":"a001p00000xQ047AAC.json","title_and_description":" An international dimension to the first Indian research management conference The DBT/Wellcome Trust India Alliance will shortly be organizing the first Conference for Indian Research Managers and Administrators (RMAs), as part of the ongoing India Research Management Initiative (IRMI). IRMI activities represent the foundational steps towards strengthening research ecosystems in India. The IRMI Annual Conference series is intended as a platform for Indian RMAs to share their work and perspectives with peers, for institutional and funder representatives to engage with the possibilities of Research Management in India, and for Indian RMAs to work together as a community of professionals. Work has begun on creating a structure for the 2020 Conference, which will include 60-80 RMAs, researchers and funder representatives from India. As the current pool of RMAs in India is small and relatively inexperienced, it will be beneficial to additionally include a small group of international RMAs, for presentations and interactions at the Conference. This is a request to the Wellcome Trust for funding the costs of attendance of international experts at the IRMI Annual Conference 2020.  \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","India"]}
{"id":"360G-Wellcome-221303_Z_20_Z","title":"Managing COVID-19 epidemics in low- to middle-income and crisis-affected settings: Epidemiological and economic evaluation","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221303/Z/20/Z","description":"The COVID-19 pandemic is rapidly escalating and poses a potentially catastrophic threat to low and middle-income countries (LMICs) as well as crisis-affected populations. To support evidence-based, real-time decision-making by countries, donors, humanitarian actors and other stakeholders, the London School of Hygiene and Tropical Medicine (LSHTM) hereby proposes a six-month multi-disciplinary project.\nThe project is built around three Workstreams: (1) Evaluation of the health, fiscal and macro-economic impact of response options; (2) Global analysis; and (3) Technical support to decision-makers and local researchers. Specific activities (and associated deliverables) include the following:\n\n\n Improve global data collation and capacity for economic analysis around COVID-19\n Evaluate the health and economic implications of COVID-19 response options using micro-economic models\n Quantify the macro-economic consequences of COVID-19 response options\n Predict the transmission and mortality of alternative shielding options for high-risk populations\n Provide a regular series of global COVID-19 health impact, resource needs and cost estimates\n Advise LMIC governments, donors and humanitarian actors on COVID-19 strategy\n Support technical guidance and coordination for humanitarian actors\n Support LMIC economists to provide local evidence on COVID-19 responses\n\n\nWe propose to undertake the above largely through desk-based work from London over a period of 6 months (Apr-Sep 2020).\n","plannedDates":[{"endDate":"2021-10-09T00:00:00+00:00","startDate":"2020-04-10T00:00:00+00:00","startDateDateOnly":"2020-04-10","endDateDateOnly":"2021-10-09"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Prof Francesco Checchi","grantProgramme":[{"title":"Coronavirus","title_keyword":"Coronavirus"}],"Partnership Name":"Wellcome-DFID Epidemic Preparedness","Applicant Surname":"Checchi","Partnership Value":184142,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Prof Mark Jit, Prof Anna Vassall","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"London School of Hygiene & Tropical Medicine\", \"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Managing COVID-19 epidemics in low- to middle-income and crisis-affected settings: Epidemiological and economic evaluation The COVID-19 pandemic is rapidly escalating and poses a potentially catastrophic threat to low and middle-income countries (LMICs) as well as crisis-affected populations. To support evidence-based, real-time decision-making by countries, donors, humanitarian actors and other stakeholders, the London School of Hygiene and Tropical Medicine (LSHTM) hereby proposes a six-month multi-disciplinary project.\nThe project is built around three Workstreams: (1) Evaluation of the health, fiscal and macro-economic impact of response options; (2) Global analysis; and (3) Technical support to decision-makers and local researchers. Specific activities (and associated deliverables) include the following:\n\n\n Improve global data collation and capacity for economic analysis around COVID-19\n Evaluate the health and economic implications of COVID-19 response options using micro-economic models\n Quantify the macro-economic consequences of COVID-19 response options\n Predict the transmission and mortality of alternative shielding options for high-risk populations\n Provide a regular series of global COVID-19 health impact, resource needs and cost estimates\n Advise LMIC governments, donors and humanitarian actors on COVID-19 strategy\n Support technical guidance and coordination for humanitarian actors\n Support LMIC economists to provide local evidence on COVID-19 responses\n\n\nWe propose to undertake the above largely through desk-based work from London over a period of 6 months (Apr-Sep 2020).\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Altruism","Developing Countries","Global Health","Humans","International Cooperation","London"]}
{"id":"360G-Wellcome-221302_Z_20_Z","title":"Academic DNA-Encoded Library Resource","Region":"North West","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221302/Z/20/Z","description":"Our goal is to enhance and accelerate the validation and translation of new drug targets identified by the UK academic biomedical research community. In order to achieve this we will establish a DNA-Encoded Library (DEL) screening resource that will provide cost-free and commitment-free access to high-throughput compound screening for academic research groups, by;\n\n1) Designing and preparing DNA-encoded libraries containing 5-10 million diverse and drug-like compounds, representing a unique resource for academic researchers. \n\n2) Utilising these libraries to undertake 40 target selections against novel protein targets for academic users, delivering validated hit compounds to  > 20 research groups by 2025. \n\n3) Developing a sustainable and expandable resource which will continue to deliver beyond the current funding period. \n\nDELs are an established screening approach that are utilised by the majority of large pharmaceutical companies. The technology allows for the rapid identification of ligands for a target protein with a very simple protocol compared to other screening approaches. Active compounds are identified by affinity selection of protein-binding compounds from libraries containing millions of different compounds that are each linked to a unique DNA sequence. The DNA tag allows for rapid and high-throughput deconvolution of the active compounds by next-generation sequencing. \n","plannedDates":[{"endDate":"2026-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2026-06-30"}],"amountAwarded":1559880,"Financial Year":"2019/20","Lead Applicant":"Dr Sam Butterworth","grantProgramme":[{"title":"Biomedical Resources Grant","title_keyword":"Biomedical Resources Grant"}],"Applicant Surname":"Butterworth","Partnership Value":1559880,"Approval Committee":"Biomedical Resource Committee","Other Applicant(s)":"Dr Andreas Brunschweiger, Dr Andrew Leach, Prof Martin Noble, Prof Michael Waring","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Academic DNA-Encoded Library Resource Our goal is to enhance and accelerate the validation and translation of new drug targets identified by the UK academic biomedical research community. In order to achieve this we will establish a DNA-Encoded Library (DEL) screening resource that will provide cost-free and commitment-free access to high-throughput compound screening for academic research groups, by;\n\n1) Designing and preparing DNA-encoded libraries containing 5-10 million diverse and drug-like compounds, representing a unique resource for academic researchers. \n\n2) Utilising these libraries to undertake 40 target selections against novel protein targets for academic users, delivering validated hit compounds to  > 20 research groups by 2025. \n\n3) Developing a sustainable and expandable resource which will continue to deliver beyond the current funding period. \n\nDELs are an established screening approach that are utilised by the majority of large pharmaceutical companies. The technology allows for the rapid identification of ligands for a target protein with a very simple protocol compared to other screening approaches. Active compounds are identified by affinity selection of protein-binding compounds from libraries containing millions of different compounds that are each linked to a unique DNA sequence. The DNA tag allows for rapid and high-throughput deconvolution of the active compounds by next-generation sequencing. \n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["DNA","Drug Discovery","Drug Evaluation, Preclinical","High-Throughput Nucleotide Sequencing","High-Throughput Screening Assays","Ligands","Proteins","Small Molecule Libraries"]}
{"id":"360G-Wellcome-221300_Z_20_Z","title":"A high-quality connectome of the complete female adult Drosophila central nervous system","Region":"East of England","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221300/Z/20/Z","description":"We previously proposed to generate a complete connectome for the adult male Drosophila central nervous system (CNS), comprising both brain and nerve cord. Capitalising on that investment, this discretionary award would allow us to deliver a second, high-quality, female connectome just one year later, at a fraction of the cost.\n\nThis would be the first full CNS connectome, bilaterally complete and with sensorimotor circuits intact, of an adult female animal with complex behaviours. It would immediately allow comparisons of neuronal number, morphology, and connectivity across 1) hemispheres (this animal), 2) sexes (with the male CNS), and 3) three same-sex individuals (with partial datasets FAFB and the hemibrain) and global estimates of intra-individual, inter-sex, and inter-individual variation.\n\nThe PIs will use this joint resource to investigate circuitry underlying sexually dimorphic  behaviours such as decision-making (e.g., mating receptivity and egg-laying), aggression, sensory integration and descending control of motor programmes, memory formation and recall, and sleep. We will make both datasets available with a range of analytic tools for use by the  > 200 labs studying Drosophila neurobiology worldwide. Moreover, we expect the technology and pipelines developed for obtaining and comparing these connectomes to facilitate future studies in other organisms, ultimately including humans.\n","plannedDates":[{"endDate":"2025-12-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2025-12-30"}],"amountAwarded":2636462,"Financial Year":"2019/20","Lead Applicant":"Dr Gregory Jefferis","grantProgramme":[{"title":"Strategic Support: Science","title_keyword":"Strategic Support: Science"}],"Applicant Surname":"Jefferis","Partnership Value":2636462,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Gwyneth Card, Dr Matthias Landgraf, Prof Scott Waddell, Prof Gerald Rubin","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A high-quality connectome of the complete female adult Drosophila central nervous system We previously proposed to generate a complete connectome for the adult male Drosophila central nervous system (CNS), comprising both brain and nerve cord. Capitalising on that investment, this discretionary award would allow us to deliver a second, high-quality, female connectome just one year later, at a fraction of the cost.\n\nThis would be the first full CNS connectome, bilaterally complete and with sensorimotor circuits intact, of an adult female animal with complex behaviours. It would immediately allow comparisons of neuronal number, morphology, and connectivity across 1) hemispheres (this animal), 2) sexes (with the male CNS), and 3) three same-sex individuals (with partial datasets FAFB and the hemibrain) and global estimates of intra-individual, inter-sex, and inter-individual variation.\n\nThe PIs will use this joint resource to investigate circuitry underlying sexually dimorphic  behaviours such as decision-making (e.g., mating receptivity and egg-laying), aggression, sensory integration and descending control of motor programmes, memory formation and recall, and sleep. We will make both datasets available with a range of analytic tools for use by the  > 200 labs studying Drosophila neurobiology worldwide. Moreover, we expect the technology and pipelines developed for obtaining and comparing these connectomes to facilitate future studies in other organisms, ultimately including humans.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Brain","Central Nervous System","Connectome","Drosophila","Drosophila melanogaster","Female","Male","Nerve Net","Sex Characteristics"]}
{"id":"360G-Wellcome-221299_Z_20_Z","title":"\u2018The Last Taboo of Motherhood?: Postnatal Mental Disorders in Twentieth-Century Britain\u2019","Region":"West Midlands","currency":"GBP","awardDate":"2020-07-30T00:00:00+00:00","Internal ID":"221299/Z/20/Z","description":"Around 1900 a new classificatory system appeared to eliminate puerperal insanity from the psychiatric canon. However, as this project will illuminate, far from disappearing from psychiatric practice, mental hospital admissions under this category actually increased, while maternal mental illness was frequently drawn on in constructing defence pleas in infanticide trials. Exploration of postnatal mental illness offers a superb opportunity to understand the relationship between psychiatric theory and practice across the twentieth century, how psychiatric categories were defined, understood and implemented, and how they both adapted to and helped create new service provisions and treatments. The project will also explore how broader social and cultural factors, including attitudes towards motherhood and women\u2019s changing status, especially in relation to their alleged bodily and reproductive autonomy, was reflected in interpretations of postnatal mental illness. Existing at the \u2018borderland\u2019 of psychiatry and obstetrics, the project will investigate the energetic and on-going debates on causality, that became increasingly complex with the involvement of an expanding range of health professionals and campaign organisations in the second half of the century. Finally the project will explore how public and media responses and the experiences of sufferers can enhance our understanding of postnatal mental illness in the past. \n \n","plannedDates":[{"endDate":"2024-05-31T00:00:00+00:00","startDate":"2021-06-01T00:00:00+00:00","startDateDateOnly":"2021-06-01","endDateDateOnly":"2024-05-31"}],"amountAwarded":398900,"Financial Year":"2019/20","Lead Applicant":"Prof Hilary Marland","grantProgramme":[{"title":"Investigator Award in H&SS","title_keyword":"Investigator Award in H&SS"}],"Applicant Surname":"Marland","Partnership Value":398900,"Approval Committee":"Humanities and Social Science Selection Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Warwick","name":"University of Warwick","addressCountry":"United Kingdom","id_and_name":"[\"University of Warwick\", \"360G-Wellcome-ORG:University-of-Warwick\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Warwick","name":"University of Warwick"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"\u2018The Last Taboo of Motherhood?: Postnatal Mental Disorders in Twentieth-Century Britain\u2019 Around 1900 a new classificatory system appeared to eliminate puerperal insanity from the psychiatric canon. However, as this project will illuminate, far from disappearing from psychiatric practice, mental hospital admissions under this category actually increased, while maternal mental illness was frequently drawn on in constructing defence pleas in infanticide trials. Exploration of postnatal mental illness offers a superb opportunity to understand the relationship between psychiatric theory and practice across the twentieth century, how psychiatric categories were defined, understood and implemented, and how they both adapted to and helped create new service provisions and treatments. The project will also explore how broader social and cultural factors, including attitudes towards motherhood and women\u2019s changing status, especially in relation to their alleged bodily and reproductive autonomy, was reflected in interpretations of postnatal mental illness. Existing at the \u2018borderland\u2019 of psychiatry and obstetrics, the project will investigate the energetic and on-going debates on causality, that became increasingly complex with the involvement of an expanding range of health professionals and campaign organisations in the second half of the century. Finally the project will explore how public and media responses and the experiences of sufferers can enhance our understanding of postnatal mental illness in the past. \n \n","awardDateDateOnly":"2020-07-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Female","History, 20th Century","Humans","Mental Disorders","Pregnancy","United Kingdom"]}
{"id":"360G-Wellcome-221297_Z_20_Z","title":"Research on Research Institute - Sheffield Costs","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221297/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2021-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2021-12-31"}],"amountAwarded":224392,"Financial Year":"2019/20","Lead Applicant":"Prof James Wilsdon","grantProgramme":[{"title":"Research on Research Institute Grant ","title_keyword":"Research on Research Institute Grant "}],"Applicant Surname":"Wilsdon","Partnership Value":224392,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield","addressCountry":"United Kingdom","id_and_name":"[\"University of Sheffield\", \"360G-Wellcome-ORG:University-of-Sheffield\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Research on Research Institute - Sheffield Costs Not available","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biomedical Research","Humans"]}
{"id":"360G-Wellcome-221295_Z_20_Z","title":"Enabling advance imaging of synaptic function in living males and females over the course of the life-span with Positron Emission Tomography (PET) ","Region":"Scotland","currency":"GBP","awardDate":"2020-07-09T00:00:00+00:00","Internal ID":"221295/Z/20/Z","description":"Synapses are damaged in over 130 different brain diseases and yet thus far there are no reliable ways to measure synaptic structure or function in vivo in a preclinical or clinical setting. The recent discovery of promising Positron Emission Tomography (PET) radiotracers for imaging synapses, by targeting the synaptic vesicle glycoprotein 2A (SV2A), has the potential to transform clinical diagnosis, neuropathology, drug development and treatment of multiple brain diseases. Two major bottlenecks to deliver on this promise are: (1) the unavailability of high-yield and high-molar activity [18F]MNI1126, the lead SV2A PET radiotracer; and (2) the lack of a quantitatively accurate and validated SV2A brain PET atlas during normal aging in rodent models. This project will generate synthetic routes and radiochemistry methods for efficient production of [18F]MNI1126, it will develop detailed template resources for quantitative analysis of SV2A PET signal in different brain regions over the course of natural aging in the rat and mouse, and it will validate SV2A PET in vivo outcomes at unprecedented scale and resolution using synaptome mapping technology. The development of SV2A PET technology proposed in this award will catapult the use of quantitative SV2A PET in many brain diseases in humans and model organisms. \n\n \n\n \n\n \n\n \n\n \n","plannedDates":[{"endDate":"2025-10-31T00:00:00+00:00","startDate":"2020-11-01T00:00:00+00:00","startDateDateOnly":"2020-11-01","endDateDateOnly":"2025-10-31"}],"amountAwarded":1062390,"Financial Year":"2019/20","Lead Applicant":"Dr Adriana Tavares","grantProgramme":[{"title":"Technology Development Grant","title_keyword":"Technology Development Grant"}],"Applicant Surname":"Tavares","Partnership Value":1062390,"Approval Committee":"Biomedical Resource Committee","Other Applicant(s)":"Dr Andrew Sutherland, Prof Seth Grant","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Enabling advance imaging of synaptic function in living males and females over the course of the life-span with Positron Emission Tomography (PET)  Synapses are damaged in over 130 different brain diseases and yet thus far there are no reliable ways to measure synaptic structure or function in vivo in a preclinical or clinical setting. The recent discovery of promising Positron Emission Tomography (PET) radiotracers for imaging synapses, by targeting the synaptic vesicle glycoprotein 2A (SV2A), has the potential to transform clinical diagnosis, neuropathology, drug development and treatment of multiple brain diseases. Two major bottlenecks to deliver on this promise are: (1) the unavailability of high-yield and high-molar activity [18F]MNI1126, the lead SV2A PET radiotracer; and (2) the lack of a quantitatively accurate and validated SV2A brain PET atlas during normal aging in rodent models. This project will generate synthetic routes and radiochemistry methods for efficient production of [18F]MNI1126, it will develop detailed template resources for quantitative analysis of SV2A PET signal in different brain regions over the course of natural aging in the rat and mouse, and it will validate SV2A PET in vivo outcomes at unprecedented scale and resolution using synaptome mapping technology. The development of SV2A PET technology proposed in this award will catapult the use of quantitative SV2A PET in many brain diseases in humans and model organisms. \n\n \n\n \n\n \n\n \n\n \n","awardDateDateOnly":"2020-07-09","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aging","Animals","Brain","Female","Male","Mice","Positron-Emission Tomography","Radiopharmaceuticals","Rats","Rats, Sprague-Dawley","Synapses"]}
{"id":"360G-Wellcome-221292_Z_20_Z","title":"Negotiation of  WT compliant transformative agreements with society publishers","Region":"South West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221292/Z/20/Z","description":"The core aim of this proposal is to further increase the number of transformative open access agreements in place with Society and smaller publishers to ensure that Wellcome Trust funded authors have maximum opportunity and ability to publish in compliance with the 2021 Wellcome Trust Open Access policy. \n\nThe proposal seeks funding for a one year extension to the negotiation and licensing activity currently led by licensing manager, Kathryn Spiller. This role is dedicated to achieving agreements that meet the requirements of Wellcome Trust's policy and targets the society publishers that over the last 3 years have received the most revenue via Wellcome Trust funding grants.\n\n \n","plannedDates":[{"endDate":"2022-05-31T00:00:00+00:00","startDate":"2020-05-07T00:00:00+00:00","startDateDateOnly":"2020-05-07","endDateDateOnly":"2022-05-31"}],"amountAwarded":52000,"Financial Year":"2019/20","Lead Applicant":"Ms Caren Milloy","grantProgramme":[{"title":"Discretionary Award - Open research","title_keyword":"Discretionary Award - Open research"}],"Applicant Surname":"Milloy","Partnership Value":52000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Jisc","name":"Jisc","addressCountry":"United Kingdom","id_and_name":"[\"Jisc\", \"360G-Wellcome-ORG:Jisc\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Jisc","name":"Jisc"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Negotiation of  WT compliant transformative agreements with society publishers The core aim of this proposal is to further increase the number of transformative open access agreements in place with Society and smaller publishers to ensure that Wellcome Trust funded authors have maximum opportunity and ability to publish in compliance with the 2021 Wellcome Trust Open Access policy. \n\nThe proposal seeks funding for a one year extension to the negotiation and licensing activity currently led by licensing manager, Kathryn Spiller. This role is dedicated to achieving agreements that meet the requirements of Wellcome Trust's policy and targets the society publishers that over the last 3 years have received the most revenue via Wellcome Trust funding grants.\n\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans"]}
{"id":"360G-Wellcome-221284_Z_20_Z","title":"Pathfinder Commission for Planetary Health and Prosperity","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221284/Z/20/Z","description":"We propose a global Commission to quantify evidence for national, regional and global actions that will be positive for health, the environment and the economy. It will draw on knowledge generated by other initiatives where relevant but will fill a major gap that is not currently addressed, namely the focus on human health as well as decarbonising economies. This will require identifying and assessing policies, technologies and interventions across a range of sectors including transport, food systems, cities, energy, industry and health systems. The Commission will fill a number of knowledge gaps that are impeding progress towards a healthy zero-carbon economy \u2013 namely which actions will have the largest multiple benefits for health, the environment and prosperity in particular contexts, and which implementation strategies should be employed for effective scale-up.  \n\nIn addition to synthesising and grading the evidence, the Commission will generate a framework for action in the form of practical guidelines targeted towards national and city governments, NGOs, civil society and the private sector. These guidelines will indicate how to assess which actions should be prioritised in particular contexts. It will also include a comprehensive influence strategy to be developed with partner organisations and a leading creative agency.\n","plannedDates":[{"endDate":"2022-07-31T00:00:00+00:00","startDate":"2020-08-01T00:00:00+00:00","startDateDateOnly":"2020-08-01","endDateDateOnly":"2022-07-31"}],"amountAwarded":1412289,"Financial Year":"2019/20","Lead Applicant":"Dr Rosemary Green","grantProgramme":[{"title":"Discretionary Award - OPOH","title_keyword":"Discretionary Award - OPOH"}],"Applicant Surname":"Green","Partnership Value":1412289,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Kris Murray","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"London School of Hygiene & Tropical Medicine\", \"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Pathfinder Commission for Planetary Health and Prosperity We propose a global Commission to quantify evidence for national, regional and global actions that will be positive for health, the environment and the economy. It will draw on knowledge generated by other initiatives where relevant but will fill a major gap that is not currently addressed, namely the focus on human health as well as decarbonising economies. This will require identifying and assessing policies, technologies and interventions across a range of sectors including transport, food systems, cities, energy, industry and health systems. The Commission will fill a number of knowledge gaps that are impeding progress towards a healthy zero-carbon economy \u2013 namely which actions will have the largest multiple benefits for health, the environment and prosperity in particular contexts, and which implementation strategies should be employed for effective scale-up.  \n\nIn addition to synthesising and grading the evidence, the Commission will generate a framework for action in the form of practical guidelines targeted towards national and city governments, NGOs, civil society and the private sector. These guidelines will indicate how to assess which actions should be prioritised in particular contexts. It will also include a comprehensive influence strategy to be developed with partner organisations and a leading creative agency.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cities","Conservation of Natural Resources","Global Health","Humans"]}
{"id":"360G-Wellcome-221283_Z_20_Z","title":"Equity & difference: Deconstructing gender in health research for women","Region":"South East","currency":"GBP","awardDate":"2020-07-30T00:00:00+00:00","Internal ID":"221283/Z/20/Z","description":"Despite policy changes and advocacy efforts to promote the inclusion of women as participants in research and to advance a global agenda of women\u2019s sexual reproductive health over the past two decades, women remain significantly underrepresented in biomedical research and its translational outputs beyond reproductive health. In this empirical ethics project, we will investigate the reasons why structural barriers to women\u2019s health improvements persist within the practices of research itself\u2014in how research is designed, conducted, and translated. More deeply, we will interrogate the role that implicit and explicit moral attitudes, beliefs and arguments play in making the case for a focus on women\u2019s and girl\u2019s health needs, and in the reactions to these priority-setting appeals in academic, policy, and social media domains. Taken together this work aims to make a significant contribution to evidence-based advocacy within biomedical research practice, transforming how researchers think and do research with and for women and girls.\n","plannedDates":[{"endDate":"2024-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2024-12-31"}],"amountAwarded":701588,"Financial Year":"2019/20","Lead Applicant":"Prof Maureen Kelley","grantProgramme":[{"title":"Investigator Award in H&SS","title_keyword":"Investigator Award in H&SS"}],"Applicant Surname":"Kelley","Partnership Value":701588,"Approval Committee":"Humanities and Social Science Selection Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Equity & difference: Deconstructing gender in health research for women Despite policy changes and advocacy efforts to promote the inclusion of women as participants in research and to advance a global agenda of women\u2019s sexual reproductive health over the past two decades, women remain significantly underrepresented in biomedical research and its translational outputs beyond reproductive health. In this empirical ethics project, we will investigate the reasons why structural barriers to women\u2019s health improvements persist within the practices of research itself\u2014in how research is designed, conducted, and translated. More deeply, we will interrogate the role that implicit and explicit moral attitudes, beliefs and arguments play in making the case for a focus on women\u2019s and girl\u2019s health needs, and in the reactions to these priority-setting appeals in academic, policy, and social media domains. Taken together this work aims to make a significant contribution to evidence-based advocacy within biomedical research practice, transforming how researchers think and do research with and for women and girls.\n","awardDateDateOnly":"2020-07-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biomedical Research","Female","Humans","Reproductive Health","Women's Health"]}
{"id":"360G-Wellcome-221273_Z_20_Z","title":"Addressing Infertility in Emergent Reproductive Markets: An Anthropology of Cross-Border Reproductive Care in Contemporary Central Asia","Region":"North West","currency":"GBP","awardDate":"2020-07-30T00:00:00+00:00","Internal ID":"221273/Z/20/Z","description":"In contemporary Kazakhstan, Kyrgyzstan and Tajikistan, involuntary childlessness is a source of immense social stigma, addressed through a heterogeneous therapeutic landscape including shrines and sacred sites, Soviet-era sanatoria, and newly-opened fertility clinics. Central Asian states are positioning themselves as international \u2018reprohubs\u2019 (Inhorn) offering fertility treatment within strict conjugal confines to growing Chinese, European and local markets for Assisted Reproductive Technologies (ARTs). This configuration has generated intense public debate about the ethics of medically assisted reproduction, specifically concerning the intensified movement of people, gametes and technologies across borders. Through a tripartite focus on sites of reproductive care, itineraries of reproductive assistance, and debates about the (bio)ethics of emergent reproductive technologies, this project will illuminate how different models and practices of reproductive care are debated and used by individuals and couples to address infertility in stratified and rapidly-marketizing medical landscapes. Immersive ethnographic fieldwork will reveal how biomedical interventions to address infertility are incorporated into wider repertoires of healing practices and will examine how ARTs appear as objects of policy intervention, legal regulation, and religious commentary in emerging reproductive markets. In so doing, it will advance our understanding of involuntary childlessness, therapeutic landscapes, and the social ramifications of both in the global South.\n \n","plannedDates":[{"endDate":"2026-01-31T00:00:00+00:00","startDate":"2022-02-01T00:00:00+00:00","startDateDateOnly":"2022-02-01","endDateDateOnly":"2026-01-31"}],"amountAwarded":648234,"Financial Year":"2019/20","Lead Applicant":"Dr Madeleine Reeves","grantProgramme":[{"title":"Investigator Award in H&SS","title_keyword":"Investigator Award in H&SS"}],"Applicant Surname":"Reeves","Partnership Value":648234,"Approval Committee":"Humanities and Social Science Selection Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Addressing Infertility in Emergent Reproductive Markets: An Anthropology of Cross-Border Reproductive Care in Contemporary Central Asia In contemporary Kazakhstan, Kyrgyzstan and Tajikistan, involuntary childlessness is a source of immense social stigma, addressed through a heterogeneous therapeutic landscape including shrines and sacred sites, Soviet-era sanatoria, and newly-opened fertility clinics. Central Asian states are positioning themselves as international \u2018reprohubs\u2019 (Inhorn) offering fertility treatment within strict conjugal confines to growing Chinese, European and local markets for Assisted Reproductive Technologies (ARTs). This configuration has generated intense public debate about the ethics of medically assisted reproduction, specifically concerning the intensified movement of people, gametes and technologies across borders. Through a tripartite focus on sites of reproductive care, itineraries of reproductive assistance, and debates about the (bio)ethics of emergent reproductive technologies, this project will illuminate how different models and practices of reproductive care are debated and used by individuals and couples to address infertility in stratified and rapidly-marketizing medical landscapes. Immersive ethnographic fieldwork will reveal how biomedical interventions to address infertility are incorporated into wider repertoires of healing practices and will examine how ARTs appear as objects of policy intervention, legal regulation, and religious commentary in emerging reproductive markets. In so doing, it will advance our understanding of involuntary childlessness, therapeutic landscapes, and the social ramifications of both in the global South.\n \n","awardDateDateOnly":"2020-07-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Asia","Female","Humans","Infertility","Islam","Religion and Medicine","Reproductive Techniques, Assisted","Social Stigma"]}
{"id":"360G-Wellcome-221269_Z_20_Z","title":"Maps of Malignancy: Epidemiologists and Cancer in Sub-Saharan Africa","Region":"Greater London","currency":"GBP","awardDate":"2020-07-30T00:00:00+00:00","Internal ID":"221269/Z/20/Z","description":"Epidemiological efforts to map cancer in sub-Saharan Africa have a long history, playing an important role in how the disease has been imagined in the region. In the late colonial and early postcolonial period, British and French doctors produced small-scale epidemiological maps to advance understandings of cancer aetiology and improve treatment strategies at home. More recently, global surveillance initiatives seeking to rationalise health policy and planning in Africa have generated political atlases of the continent with national cancer burdens.  \n\nThis project carries out an archival and ethnographic study of these epidemiological efforts to chart malignancy in sub-Saharan Africa over the past 70 years. It takes these cartographies of diseases as its object of study, examining their scientific, political and material conditions of possibility and analysing their influence on cancer imaginaries and healthcare policies in Africa. In doing so, the project aims to draw attention to the crucial role that epidemiological maps have played in the postcolonial history of biomedicine in Africa, while developing an innovative approach to epidemiological surveillance that highlights its socio-technical infrastructure and performative power. At the same time, the project also purports to move Africa out of the margins of the global history of cancer.\n\n \n","plannedDates":[{"endDate":"2025-07-31T00:00:00+00:00","startDate":"2021-08-01T00:00:00+00:00","startDateDateOnly":"2021-08-01","endDateDateOnly":"2025-07-31"}],"amountAwarded":650069,"Financial Year":"2019/20","Lead Applicant":"Dr David Reubi","grantProgramme":[{"title":"Investigator Award in H&SS","title_keyword":"Investigator Award in H&SS"}],"Applicant Surname":"Reubi","Partnership Value":650069,"Approval Committee":"ERG10 Medical Humanities, Investigator and Collaborative Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Maps of Malignancy: Epidemiologists and Cancer in Sub-Saharan Africa Epidemiological efforts to map cancer in sub-Saharan Africa have a long history, playing an important role in how the disease has been imagined in the region. In the late colonial and early postcolonial period, British and French doctors produced small-scale epidemiological maps to advance understandings of cancer aetiology and improve treatment strategies at home. More recently, global surveillance initiatives seeking to rationalise health policy and planning in Africa have generated political atlases of the continent with national cancer burdens.  \n\nThis project carries out an archival and ethnographic study of these epidemiological efforts to chart malignancy in sub-Saharan Africa over the past 70 years. It takes these cartographies of diseases as its object of study, examining their scientific, political and material conditions of possibility and analysing their influence on cancer imaginaries and healthcare policies in Africa. In doing so, the project aims to draw attention to the crucial role that epidemiological maps have played in the postcolonial history of biomedicine in Africa, while developing an innovative approach to epidemiological surveillance that highlights its socio-technical infrastructure and performative power. At the same time, the project also purports to move Africa out of the margins of the global history of cancer.\n\n \n","awardDateDateOnly":"2020-07-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa South of the Sahara","Global Health","Humans","Neoplasms"]}
{"id":"360G-Wellcome-221268_Z_20_Z","title":"Jamal Edwards Delve ","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221268/Z/20/Z","description":"Through workshops with mental health researchers, at our youth centres, young people will deconstruct hip-hop lyrics understanding how to link them to wider mental health issues and research.  The project will focus on empowering young people to investigate mental health experiences in the community and gather evidence on the mechanisms others have relied on to overcome their struggles with the aim of reinforcing young people\u2019s resilience and discovering, through peer-led research, accessible prosocial tools to combat deterioration in mental health. \n","plannedDates":[{"endDate":"2021-10-31T00:00:00+00:00","startDate":"2020-07-15T00:00:00+00:00","startDateDateOnly":"2020-07-15","endDateDateOnly":"2021-10-31"}],"amountAwarded":91887,"Financial Year":"2019/20","Lead Applicant":"Ms Yara Mirdad","grantProgramme":[{"title":"Discretionary Award - Public Engagement","title_keyword":"Discretionary Award - Public Engagement"}],"Applicant Surname":"Mirdad","Partnership Value":91887,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Jamal-Edwards-Delve","name":"Jamal Edwards Delve","addressCountry":"United Kingdom","id_and_name":"[\"Jamal Edwards Delve\", \"360G-Wellcome-ORG:Jamal-Edwards-Delve\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Jamal-Edwards-Delve","name":"Jamal Edwards Delve"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Jamal Edwards Delve  Through workshops with mental health researchers, at our youth centres, young people will deconstruct hip-hop lyrics understanding how to link them to wider mental health issues and research.  The project will focus on empowering young people to investigate mental health experiences in the community and gather evidence on the mechanisms others have relied on to overcome their struggles with the aim of reinforcing young people\u2019s resilience and discovering, through peer-led research, accessible prosocial tools to combat deterioration in mental health. \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adolescent","Humans","Male","Mental Health","Resilience, Psychological"]}
{"id":"360G-Wellcome-221267_Z_20_Z","title":"Human genome synthesis","Region":"East of England","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221267/Z/20/Z","description":"The ability to make any human genome would transform hypothesis driven investigations in diverse areas of biology, genetic-archaeology and biotechnologies.  However, there are currently no technologies for building human genomes. Moreover, there is a technological void between the state of the art in the creation of synthetic genomes and what will be required to enable the synthesis of human genomes.  The current challenge is therefore to bridge this void. The goal of this proposal is to bridge the technological void between the state of the art, which has enabled the synthesis of Mbp-scale microbial genomes, and the technologies that will be required to build a human genome, which is 3 orders of magnitude larger than any synthetic genome that has been created to date.  We will establish key technologies for human genome synthesis and exemplify these technologies through the synthesis of a recoded human chromosome.\n \n","plannedDates":[{"endDate":"2023-01-03T00:00:00+00:00","startDate":"2021-01-04T00:00:00+00:00","startDateDateOnly":"2021-01-04","endDateDateOnly":"2023-01-03"}],"amountAwarded":1899321,"Financial Year":"2019/20","Lead Applicant":"Prof Jason Chin","grantProgramme":[{"title":"Strategic Support: Science","title_keyword":"Strategic Support: Science"}],"Applicant Surname":"Chin","Partnership Value":1899321,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Prof Tom Ellis, Prof Yizhi Cai, Dr Julian Sale","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:MRC-Laboratory-of-Molecular-Biology","name":"MRC Laboratory of Molecular Biology","addressCountry":"United Kingdom","id_and_name":"[\"MRC Laboratory of Molecular Biology\", \"360G-Wellcome-ORG:MRC-Laboratory-of-Molecular-Biology\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:MRC-Laboratory-of-Molecular-Biology","name":"MRC Laboratory of Molecular Biology"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Human genome synthesis The ability to make any human genome would transform hypothesis driven investigations in diverse areas of biology, genetic-archaeology and biotechnologies.  However, there are currently no technologies for building human genomes. Moreover, there is a technological void between the state of the art in the creation of synthetic genomes and what will be required to enable the synthesis of human genomes.  The current challenge is therefore to bridge this void. The goal of this proposal is to bridge the technological void between the state of the art, which has enabled the synthesis of Mbp-scale microbial genomes, and the technologies that will be required to build a human genome, which is 3 orders of magnitude larger than any synthetic genome that has been created to date.  We will establish key technologies for human genome synthesis and exemplify these technologies through the synthesis of a recoded human chromosome.\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Genome, Bacterial","Genome, Human","Humans"]}
{"id":"360G-Wellcome-221266_Z_20_Z","title":"North and South: Regional Health Inequalities in England","Region":"North East","currency":"GBP","awardDate":"2020-07-30T00:00:00+00:00","Internal ID":"221266/Z/20/Z","description":"North and South: Regional Health Inequalities in England \n\nThe \u2018north-south health divide\u2019 in England is longstanding and persistent, documented both before and after the epidemiological transition. In the mid-19th century, life expectancies in northern cities were four years lower than in southern cities, and today, there is still a two-year difference in average life expectancy between the northern and southern regions.\n\nHowever, there has been no thorough academic study of regional health inequalities, so we know little about the temporality, aetiology, experience, representation or perception of the \u2018north-south health divide\u2019. This oversight is becoming even more pressing given emerging evidence that health inequalities are increasing and that the north is falling further behind.\n\nUsing a novel, mixed-method, intensive, multi-disciplinary approach, the North and South project will fill this gap by providing the definitive account of the \u2018north-south health divide\u2019 and regional inequalities in health in England \u2013 contextualised within the wider European experience.\n\nBy drawing on concepts, data and methods from geography, epidemiology, sociology, history, social policy and literary studies, the project will enhance our understanding of the \u2018north-south health divide\u2019; provide insights into how to close it; and advance the international health inequalities field empirically, methodologically, and conceptually.\n\n \n","plannedDates":[{"endDate":"2026-04-30T00:00:00+00:00","startDate":"2021-05-01T00:00:00+00:00","startDateDateOnly":"2021-05-01","endDateDateOnly":"2026-04-30"}],"amountAwarded":913683,"Financial Year":"2019/20","Lead Applicant":"Prof Clare Bambra","grantProgramme":[{"title":"Investigator Award in H&SS","title_keyword":"Investigator Award in H&SS"}],"Applicant Surname":"Bambra","Partnership Value":913683,"Approval Committee":"Humanities and Social Science Selection Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Newcastle-University","name":"Newcastle University","addressCountry":"United Kingdom","id_and_name":"[\"Newcastle University\", \"360G-Wellcome-ORG:Newcastle-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Newcastle-University","name":"Newcastle University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"North and South: Regional Health Inequalities in England North and South: Regional Health Inequalities in England \n\nThe \u2018north-south health divide\u2019 in England is longstanding and persistent, documented both before and after the epidemiological transition. In the mid-19th century, life expectancies in northern cities were four years lower than in southern cities, and today, there is still a two-year difference in average life expectancy between the northern and southern regions.\n\nHowever, there has been no thorough academic study of regional health inequalities, so we know little about the temporality, aetiology, experience, representation or perception of the \u2018north-south health divide\u2019. This oversight is becoming even more pressing given emerging evidence that health inequalities are increasing and that the north is falling further behind.\n\nUsing a novel, mixed-method, intensive, multi-disciplinary approach, the North and South project will fill this gap by providing the definitive account of the \u2018north-south health divide\u2019 and regional inequalities in health in England \u2013 contextualised within the wider European experience.\n\nBy drawing on concepts, data and methods from geography, epidemiology, sociology, history, social policy and literary studies, the project will enhance our understanding of the \u2018north-south health divide\u2019; provide insights into how to close it; and advance the international health inequalities field empirically, methodologically, and conceptually.\n\n \n","awardDateDateOnly":"2020-07-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cities","England","Health Status Disparities","Humans","Life Expectancy"]}
{"id":"360G-Wellcome-221255_Z_20_Z","title":"Prosthetic Embodiment: The lived experience of health, disability and medical technology from the 1970s the present.","Region":"North West","currency":"GBP","awardDate":"2020-07-21T00:00:00+00:00","Sponsor(s)":"Prof Pratik Chakrabarti","Internal ID":"221255/Z/20/Z","description":"Prosthetic Embodiment investigates what it means to live \u2013 and live well \u2013 with prostheses. Adopting a historical approach, informed by critical medical humanities and disability studies, and focusing on artificial legs and their users, this globally sensitive project will be the first to consider how the experience of prosthetic embodiment has changed, from the 1970s through to the present. For people to use and live healthy lives with prosthetic legs, collaboration with those who make and fit them is vital. Through an innovative combination of historical approaches and visual anthropology, this study explores the agency and materiality of users, health professionals and technologies, following the relations between them in terms of prosthetic design, fitting, use, and recycling. A central question to be investigated is how practicalities of lives and bodily experiences are negotiated and renegotiated as users learn to live with new prostheses, and once again when devices are recycled through charitable organisations to new users in the global south. Exploring the diverse embodiment of people with limb difference will reveal important insights into how prostheses create both new possibilities and unexpected constraints on day-to-day living, and the experience of disability and medical technology more generally.\n","plannedDates":[{"endDate":"2025-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2025-08-31"}],"amountAwarded":378655,"Financial Year":"2019/20","Lead Applicant":"Dr Neil Pemberton","grantProgramme":[{"title":"University Award in H&SS","title_keyword":"University Award in H&SS"}],"Applicant Surname":"Pemberton","Partnership Value":378655,"Approval Committee":"Medical Humanities Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Prosthetic Embodiment: The lived experience of health, disability and medical technology from the 1970s the present. Prosthetic Embodiment investigates what it means to live \u2013 and live well \u2013 with prostheses. Adopting a historical approach, informed by critical medical humanities and disability studies, and focusing on artificial legs and their users, this globally sensitive project will be the first to consider how the experience of prosthetic embodiment has changed, from the 1970s through to the present. For people to use and live healthy lives with prosthetic legs, collaboration with those who make and fit them is vital. Through an innovative combination of historical approaches and visual anthropology, this study explores the agency and materiality of users, health professionals and technologies, following the relations between them in terms of prosthetic design, fitting, use, and recycling. A central question to be investigated is how practicalities of lives and bodily experiences are negotiated and renegotiated as users learn to live with new prostheses, and once again when devices are recycled through charitable organisations to new users in the global south. Exploring the diverse embodiment of people with limb difference will reveal important insights into how prostheses create both new possibilities and unexpected constraints on day-to-day living, and the experience of disability and medical technology more generally.\n","awardDateDateOnly":"2020-07-21","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Artificial Limbs","Disabled Persons","Humans","Prostheses and Implants"]}
{"id":"360G-Wellcome-221252_Z_20_Z","title":"Alternative access schemes for pharmaceuticals: bypassing scrutiny?","Region":"East of England","currency":"GBP","awardDate":"2020-07-21T00:00:00+00:00","Sponsor(s)":"Dr Stuart Hogarth","Internal ID":"221252/Z/20/Z","description":"High prices of new medicines have led most European countries to set up health technology assessment (HTA): evidence-based processes that evaluate whether a drug\u2019s benefits outweigh its costs, before it receives public funding. Yet, increasingly, expensive new medicines bypass this scrutiny. Instead, they enter health systems through alternative access schemes: diverse provisions that provide patients with access to treatment that are not routinely funded \u2013 for example the English Cancer Drugs Fund or individual patient funding requests. As a result, some drugs, including notably expensive cancer medicines, are prescribed even though they never demonstrated their \"value for money\" in HTA, reaching up to 5% of pharmaceutical budgets in some countries. Despite evidence of their growing significance, there is little systematic research on alternative access schemes.\n\nThis project seeks to understand why alternative access schemes emerged, how decisions in these schemes are made, and what the policy implications are for patients and public finances. It systematises knowledge of this emerging phenomenon by providing an overview of alternative access schemes in Europe and a detailed analysis of their political economy in selected health systems. It will contribute to debates on affordability of new medicines.\n","plannedDates":[{"endDate":"2024-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2024-03-31"}],"amountAwarded":245249,"Financial Year":"2019/20","Lead Applicant":"Dr Olga Loblova","grantProgramme":[{"title":"Research Fellowship in H&SS","title_keyword":"Research Fellowship in H&SS"}],"Applicant Surname":"Loblova","Partnership Value":245249,"Approval Committee":"Social Science and Bioethics Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Alternative access schemes for pharmaceuticals: bypassing scrutiny? High prices of new medicines have led most European countries to set up health technology assessment (HTA): evidence-based processes that evaluate whether a drug\u2019s benefits outweigh its costs, before it receives public funding. Yet, increasingly, expensive new medicines bypass this scrutiny. Instead, they enter health systems through alternative access schemes: diverse provisions that provide patients with access to treatment that are not routinely funded \u2013 for example the English Cancer Drugs Fund or individual patient funding requests. As a result, some drugs, including notably expensive cancer medicines, are prescribed even though they never demonstrated their \"value for money\" in HTA, reaching up to 5% of pharmaceutical budgets in some countries. Despite evidence of their growing significance, there is little systematic research on alternative access schemes.\n\nThis project seeks to understand why alternative access schemes emerged, how decisions in these schemes are made, and what the policy implications are for patients and public finances. It systematises knowledge of this emerging phenomenon by providing an overview of alternative access schemes in Europe and a detailed analysis of their political economy in selected health systems. It will contribute to debates on affordability of new medicines.\n","awardDateDateOnly":"2020-07-21","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Decision Making","Drug Costs","Europe","Health Policy","Health Services Accessibility","Humans","Technology Assessment, Biomedical"]}
{"id":"360G-Wellcome-221221_Z_20_Z","title":"Culture as Medicine: Exploring future interventions for substance abuse treatment and prevention in South Africa","Region":"International","currency":"GBP","awardDate":"2020-05-06T00:00:00+00:00","Sponsor(s)":"Prof Susan Levine","Internal ID":"221221/Z/20/Z","description":"The research questions are - How has indigenous medicine responded to the substance abuse crisis in SA?  What might future interventions look like?\n \n\n\n An auto-ethnographic reflection on addiction and recovery, that seeks to deepen local understandings and narratives to include notions of historical trauma, dispossession and \u2018insecure attachment\u2019 to ancestors, nature and land. \n Working with indigenous health practitioners (IHPs), the research will explore indigenous medicine\u2019s response to the high levels of substance abuse in South Africa.  Drawing inspiration from indigenous-led treatment programmes in Canada, Peru and the United States, that fuse indigenous and biomedical approaches, future interventions will be explored with indigenous and allopathic health practitioners, researchers and people in recovery as co-researchers.\n The project will experiment with various research methods; introducing the notion of dreaming as a research method; story-telling; and indabas. We aim to collectively envision interventions that integrate ancient indigenous methods, biomedical/psychological approaches and technological tools. The research will be based in Cape Town but will include participants from all over South Africa.\n Public engagement methods will be decided collectively during indabas to tailor the dissemination of findings to the various communities needs, this could be through podcasts/community radio, web-based audio-visual material, community indabas, ceremonies and performances.  \n\n","plannedDates":[{"endDate":"2023-06-30T00:00:00+00:00","startDate":"2020-07-01T00:00:00+00:00","startDateDateOnly":"2020-07-01","endDateDateOnly":"2023-06-30"}],"amountAwarded":84054,"Financial Year":"2019/20","Lead Applicant":"Ms Ntsiki Mackay Anderson","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Mackay Anderson","Partnership Value":84054,"Approval Committee":"ERG10 Medical Humanities, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cape-Town","name":"University of Cape Town","addressCountry":"South Africa","id_and_name":"[\"University of Cape Town\", \"360G-Wellcome-ORG:University-of-Cape-Town\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cape-Town","name":"University of Cape Town"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Culture as Medicine: Exploring future interventions for substance abuse treatment and prevention in South Africa The research questions are - How has indigenous medicine responded to the substance abuse crisis in SA?  What might future interventions look like?\n \n\n\n An auto-ethnographic reflection on addiction and recovery, that seeks to deepen local understandings and narratives to include notions of historical trauma, dispossession and \u2018insecure attachment\u2019 to ancestors, nature and land. \n Working with indigenous health practitioners (IHPs), the research will explore indigenous medicine\u2019s response to the high levels of substance abuse in South Africa.  Drawing inspiration from indigenous-led treatment programmes in Canada, Peru and the United States, that fuse indigenous and biomedical approaches, future interventions will be explored with indigenous and allopathic health practitioners, researchers and people in recovery as co-researchers.\n The project will experiment with various research methods; introducing the notion of dreaming as a research method; story-telling; and indabas. We aim to collectively envision interventions that integrate ancient indigenous methods, biomedical/psychological approaches and technological tools. The research will be based in Cape Town but will include participants from all over South Africa.\n Public engagement methods will be decided collectively during indabas to tailor the dissemination of findings to the various communities needs, this could be through podcasts/community radio, web-based audio-visual material, community indabas, ceremonies and performances.  \n\n","awardDateDateOnly":"2020-05-06","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Canada","Health Services, Indigenous","Humans","Indians, North American","Indigenous Peoples","Research Design","South Africa","Substance-Related Disorders"]}
{"id":"360G-Wellcome-221220_Z_20_Z","title":"Best interests and sufficient benefit: The ethics of hard decisions in healthcare","Region":"South East","currency":"GBP","awardDate":"2020-07-21T00:00:00+00:00","Sponsor(s)":"Prof Julian Savulescu","Internal ID":"221220/Z/20/Z","description":"Patients\u2019 'best interests' are important in healthcare, but their use faces challenges:\n\n\n Resource allocation: As well as aggregate measurements like population health, healthcare resource allocation should be sensitive to individual patients' claims. The idea of best interests provides limited guidance here, since resource constraints mean we cannot promote everyone's best interests. \n\n\n\n Value disagreement: Caring for patients who cannot communicate preferences \u2013 including infants \u2013 often generates fundamental value disagreement between carers and medical professionals over their best interests.\n\n\nMy proposal explores whether a principle of sufficiency - the idea that it is particularly important to prevent people from being very badly off - can help. Sufficiency has received renewed attention in political philosophy; my research will build on recent theoretical advances, developing a theory that is responsive and applicable to practical challenges.\n\nGoals\n\n\n Systematically outline challenges to best interests and existing work on sufficiency;\n Generate a novel sufficiency-based approach that can be used in healthcare decisions;\n Consider challenges and develop recommendations for two related practical issues: resource allocation and the care of critically ill infants;\n Publish 12 peer-reviewed journal articles;\n Disseminate research findings via websites and public-engagement activity at Oxford;\n Host a workshop on the role of sufficiency in healthcare.\n\n","plannedDates":[{"endDate":"2024-07-31T00:00:00+00:00","startDate":"2021-08-01T00:00:00+00:00","startDateDateOnly":"2021-08-01","endDateDateOnly":"2024-07-31"}],"amountAwarded":174702,"Financial Year":"2019/20","Lead Applicant":"Dr Benjamin Davies","grantProgramme":[{"title":"Research Fellowship in H&SS","title_keyword":"Research Fellowship in H&SS"}],"Applicant Surname":"Davies","Partnership Value":174702,"Approval Committee":"Social Science and Bioethics Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Best interests and sufficient benefit: The ethics of hard decisions in healthcare Patients\u2019 'best interests' are important in healthcare, but their use faces challenges:\n\n\n Resource allocation: As well as aggregate measurements like population health, healthcare resource allocation should be sensitive to individual patients' claims. The idea of best interests provides limited guidance here, since resource constraints mean we cannot promote everyone's best interests. \n\n\n\n Value disagreement: Caring for patients who cannot communicate preferences \u2013 including infants \u2013 often generates fundamental value disagreement between carers and medical professionals over their best interests.\n\n\nMy proposal explores whether a principle of sufficiency - the idea that it is particularly important to prevent people from being very badly off - can help. Sufficiency has received renewed attention in political philosophy; my research will build on recent theoretical advances, developing a theory that is responsive and applicable to practical challenges.\n\nGoals\n\n\n Systematically outline challenges to best interests and existing work on sufficiency;\n Generate a novel sufficiency-based approach that can be used in healthcare decisions;\n Consider challenges and develop recommendations for two related practical issues: resource allocation and the care of critically ill infants;\n Publish 12 peer-reviewed journal articles;\n Disseminate research findings via websites and public-engagement activity at Oxford;\n Host a workshop on the role of sufficiency in healthcare.\n\n","awardDateDateOnly":"2020-07-21","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Decision Making","Health Care Rationing","Humans"]}
{"id":"360G-Wellcome-221213_Z_20_Z","title":"Positively Belonging in Peru?: Venezuelan Migrants with HIV/AIDS at the intersections of Pharmaceutical Citizenship, Biosocialities, Race and Biomedicine.","Region":"Greater London","currency":"GBP","awardDate":"2020-07-21T00:00:00+00:00","Sponsor(s)":"Prof Ibrahim Abubakar","Internal ID":"221213/Z/20/Z","description":"A recent, unprecedented influx of migrants to Peru means that roughly 3% of the country\u2019s population are now of Venezuelan origin, with an estimated 1,700+ living with HIV. The focus of this research will be the social, medical, and legal aspects of \u2018belonging\u2019 for migrants in situations of medical precarity. This will be achieved by exploring the processes whereby these refugees access HIV-related medical-care and legal-migratory status, integrate into the wider Peruvian community, and interact with a biomedical system troubled with intersections of race, racisms, and xenophobia at a transformative moment in the history of Peru with never-before-seen mass- immigration from a Caribbean to an Andean nation.\nIn order to address this focus, the key research goals will be to:\n\n\n Investigate how HIV-positive Venezuelans negotiate \u2018pharmaceutical citizenship\u2019 (citizenship dependent on pharmaceutical compliance (Ecks,2005)) and receipt of Anti-retroviral therapy (ART).\n Interrogate actual and potential integration into biosocial communities (social-kinship based upon shared bio-factors (Young,2016)) based upon HIV-positivity.\n Query the intersections of racism and biomedicine when seeking HIV/AIDS-related health care for migrants.\n\n\nResearch for this project will involve 18-months ethnographic fieldwork in Lima, Peru with migrants and stakeholders, and will transform our understandings of migrant health, race, and \u2018belonging\u2019.\n","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2021-10-01T00:00:00+00:00","startDateDateOnly":"2021-10-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":236313,"Financial Year":"2019/20","Lead Applicant":"Dr Rebecca Irons","grantProgramme":[{"title":"Research Fellowship in H&SS","title_keyword":"Research Fellowship in H&SS"}],"Applicant Surname":"Irons","Partnership Value":236313,"Approval Committee":"Medical Humanities Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Positively Belonging in Peru?: Venezuelan Migrants with HIV/AIDS at the intersections of Pharmaceutical Citizenship, Biosocialities, Race and Biomedicine. A recent, unprecedented influx of migrants to Peru means that roughly 3% of the country\u2019s population are now of Venezuelan origin, with an estimated 1,700+ living with HIV. The focus of this research will be the social, medical, and legal aspects of \u2018belonging\u2019 for migrants in situations of medical precarity. This will be achieved by exploring the processes whereby these refugees access HIV-related medical-care and legal-migratory status, integrate into the wider Peruvian community, and interact with a biomedical system troubled with intersections of race, racisms, and xenophobia at a transformative moment in the history of Peru with never-before-seen mass- immigration from a Caribbean to an Andean nation.\nIn order to address this focus, the key research goals will be to:\n\n\n Investigate how HIV-positive Venezuelans negotiate \u2018pharmaceutical citizenship\u2019 (citizenship dependent on pharmaceutical compliance (Ecks,2005)) and receipt of Anti-retroviral therapy (ART).\n Interrogate actual and potential integration into biosocial communities (social-kinship based upon shared bio-factors (Young,2016)) based upon HIV-positivity.\n Query the intersections of racism and biomedicine when seeking HIV/AIDS-related health care for migrants.\n\n\nResearch for this project will involve 18-months ethnographic fieldwork in Lima, Peru with migrants and stakeholders, and will transform our understandings of migrant health, race, and \u2018belonging\u2019.\n","awardDateDateOnly":"2020-07-21","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["HIV Infections","Health Services Accessibility","Humans","Peru","Racism","Refugees","Transients and Migrants"]}
{"id":"360G-Wellcome-221191_Z_20_Z","title":"Biovalue, hope, and translational science: The public impact of novel clinical trials for the treatment of Huntington\u2019s disease ","Region":"Scotland","currency":"GBP","awardDate":"2020-05-06T00:00:00+00:00","Sponsor(s)":"Prof Linda McKie","Internal ID":"221191/Z/20/Z","description":"This research examines the relationship between the biotechnology industry and consumers, to determine what effect(s) this relationship may have on the outcome of clinical trials. Despite regularly being referred to as the \u2018new genetics\u2019, there has been little substantive change over the past two decades in the ways we have studied social aspects of genetic testing. Studies are largely embedded in the dichotomy of \u2018consumption\u2019/\u2018production\u2019, treating 'patients'/'industry' as discrete categories in an unchangeable hierarchy. However, medical biotechnologies do not exist in a theoretical vacuum: they are continuously evolving products of social, political and economic endeavours, which have social, political and economic consequences. This research will follow the Phase 3 Study of RG6042 (previously IONIS-HTTRx), the first drug specifically targeting the mechanism responsible for HD, and a Phase 1 trial of a novel gene therapy. Methodology includes interviews, group interviews, and participant observation to determine how information moves and mutates, and how this effects medico-social pathways. Drawing on concepts of translational science, this research will examine how/when/why and to what effect 'scientific' knowledge is communicated among and between actors, and what effect this may have on the outcome of the trial for both participants and industry.\n","plannedDates":[{"endDate":"2023-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2023-08-31"}],"amountAwarded":85336,"Financial Year":"2019/20","Lead Applicant":"Ms Giorgia Kerr","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Kerr","Partnership Value":85336,"Approval Committee":"ERG11 Social Science and Bioethics, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Biovalue, hope, and translational science: The public impact of novel clinical trials for the treatment of Huntington\u2019s disease  This research examines the relationship between the biotechnology industry and consumers, to determine what effect(s) this relationship may have on the outcome of clinical trials. Despite regularly being referred to as the \u2018new genetics\u2019, there has been little substantive change over the past two decades in the ways we have studied social aspects of genetic testing. Studies are largely embedded in the dichotomy of \u2018consumption\u2019/\u2018production\u2019, treating 'patients'/'industry' as discrete categories in an unchangeable hierarchy. However, medical biotechnologies do not exist in a theoretical vacuum: they are continuously evolving products of social, political and economic endeavours, which have social, political and economic consequences. This research will follow the Phase 3 Study of RG6042 (previously IONIS-HTTRx), the first drug specifically targeting the mechanism responsible for HD, and a Phase 1 trial of a novel gene therapy. Methodology includes interviews, group interviews, and participant observation to determine how information moves and mutates, and how this effects medico-social pathways. Drawing on concepts of translational science, this research will examine how/when/why and to what effect 'scientific' knowledge is communicated among and between actors, and what effect this may have on the outcome of the trial for both participants and industry.\n","awardDateDateOnly":"2020-05-06","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Drug Industry","Genetic Testing","Genetic Therapy","Humans","Huntington Disease"]}
{"id":"360G-Wellcome-221176_Z_20_Z","title":"What is internet addiction: Re-thinking the digital and addiction in relation to each other","Region":"Greater London","currency":"GBP","awardDate":"2020-05-06T00:00:00+00:00","Sponsor(s)":"Dr Joanna Cook","Internal ID":"221176/Z/20/Z","description":"This proposal is for a year-long ethnography of an internet addiction rehabilitation centre in rural Washington State. It will develop an anthropological understanding of internet addiction, the study of which has so far been limited to neuroscience, psychology, and psychiatry. This will allow the cultural, social, and systemic background to the condition to be revealed.\n\nThe ethnography will be phenomenological, exploring the changes in the experience of space and time that rapid withdrawal from the digital causes \u2013 putting the living body at the centre of study. I will do this with the aim of establishing how use of the digital changes the experience of everyday life, explaining internet addiction through these changes. I will also ask whether the experience of extreme cases is shared by ordinary users.\n\nI will investigate whether the condition can be used to denaturalise the broader category of addiction, unpacking and challenging suppositions established in the study of addiction and mental health.\n\nAs well as generating new knowledge and raising awareness, I will assist in the formation of patient groups, as well as supporting charities and healthcare facilities dealing with the condition. I will also aim to persuade healthcare services to fully recognise the condition.\n","plannedDates":[{"endDate":"2023-09-27T00:00:00+00:00","startDate":"2020-09-28T00:00:00+00:00","startDateDateOnly":"2020-09-28","endDateDateOnly":"2023-09-27"}],"amountAwarded":114971,"Financial Year":"2019/20","Lead Applicant":"Mr Joseph Tulasiewicz","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Tulasiewicz","Partnership Value":114971,"Approval Committee":"ERG11 Social Science and Bioethics, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"What is internet addiction: Re-thinking the digital and addiction in relation to each other This proposal is for a year-long ethnography of an internet addiction rehabilitation centre in rural Washington State. It will develop an anthropological understanding of internet addiction, the study of which has so far been limited to neuroscience, psychology, and psychiatry. This will allow the cultural, social, and systemic background to the condition to be revealed.\n\nThe ethnography will be phenomenological, exploring the changes in the experience of space and time that rapid withdrawal from the digital causes \u2013 putting the living body at the centre of study. I will do this with the aim of establishing how use of the digital changes the experience of everyday life, explaining internet addiction through these changes. I will also ask whether the experience of extreme cases is shared by ordinary users.\n\nI will investigate whether the condition can be used to denaturalise the broader category of addiction, unpacking and challenging suppositions established in the study of addiction and mental health.\n\nAs well as generating new knowledge and raising awareness, I will assist in the formation of patient groups, as well as supporting charities and healthcare facilities dealing with the condition. I will also aim to persuade healthcare services to fully recognise the condition.\n","awardDateDateOnly":"2020-05-06","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anthropology, Cultural","Behavior, Addictive","Humans","Internet","Rural Population","Washington"]}
{"id":"360G-Wellcome-221168_Z_20_Z","title":"L\u00e6knir ok l\u00e6gb\u00f3k: Mediterranean remedies in Old Norse manuscripts, a comparative study and translation of medical practices","Region":"Greater London","currency":"GBP","awardDate":"2020-05-06T00:00:00+00:00","Sponsor(s)":"Prof Dr Jo Evans","Internal ID":"221168/Z/20/Z","description":"My research focuses on XIII-XV Old Norse medical treaties featuring classics and continental models, to assess the extent to which Mediterranean medical practices were assimilated and re-elabotared within the Old Norse framework to understand the cultural dialogue between medieval Scandinavia and the continent. I will provide annotated translation of remedies, herbaria and antidotes contained in manuscripts preserved in Copenhagen and Reykjav\u00edk, comparing them with their continental counterparts at the British Library, Cambridge and Oxford. Consequently, the nature and the usage of these texts as sources of healing will be problematised and I will challenge the obsolete term \"pseudoscientific\" used in scholarship to refer to medieval medical practices and elaborate a new interpretive frame of understanding. I will demonstrate that Old Norse participated to the cultural syncretism in the Middle Ages by assimilating the occurrence of Classics and continental medical knowledge in manuscript context. This will lead to study a materiality of practices which allowed for a physical impact on the body. My research will address the cultural biases that have greatly affected certain topics within Old Norse scholarship which have not been considered in a comparative perspective and have led to the study of Old Norse culture in isolation.\n","plannedDates":[{"endDate":"2024-01-10T00:00:00+00:00","startDate":"2021-01-11T00:00:00+00:00","startDateDateOnly":"2021-01-11","endDateDateOnly":"2024-01-10"}],"amountAwarded":98900,"Financial Year":"2019/20","Lead Applicant":"Ms Luthien Cangemi","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Cangemi","Partnership Value":98900,"Approval Committee":"ERG10 Medical Humanities, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"L\u00e6knir ok l\u00e6gb\u00f3k: Mediterranean remedies in Old Norse manuscripts, a comparative study and translation of medical practices My research focuses on XIII-XV Old Norse medical treaties featuring classics and continental models, to assess the extent to which Mediterranean medical practices were assimilated and re-elabotared within the Old Norse framework to understand the cultural dialogue between medieval Scandinavia and the continent. I will provide annotated translation of remedies, herbaria and antidotes contained in manuscripts preserved in Copenhagen and Reykjav\u00edk, comparing them with their continental counterparts at the British Library, Cambridge and Oxford. Consequently, the nature and the usage of these texts as sources of healing will be problematised and I will challenge the obsolete term \"pseudoscientific\" used in scholarship to refer to medieval medical practices and elaborate a new interpretive frame of understanding. I will demonstrate that Old Norse participated to the cultural syncretism in the Middle Ages by assimilating the occurrence of Classics and continental medical knowledge in manuscript context. This will lead to study a materiality of practices which allowed for a physical impact on the body. My research will address the cultural biases that have greatly affected certain topics within Old Norse scholarship which have not been considered in a comparative perspective and have led to the study of Old Norse culture in isolation.\n","awardDateDateOnly":"2020-05-06","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Archaeology","Culture","History, Ancient","History, Medieval","Humans","Paintings"]}
{"id":"360G-Wellcome-221160_Z_20_Z","title":"A Policy Evaluation of the Integration of Health and Social Care in Greater Manchester ","Region":"South East","currency":"GBP","awardDate":"2020-05-06T00:00:00+00:00","Sponsor(s)":"Dr Aaron Reeves","Internal ID":"221160/Z/20/Z","description":"This mixed-methods project will treat Greater Manchester\u2019s integrated budget in 2016 and the delayed roll-out of Integrated Care Systems across the country as a quasi-natural experiment.\n\nI will use a nested-analysis method with qualitative research and three \u2018diverse' cases studies will be chosen non-randomly to understand how each Local Care Organisation are specifying their policy delivery according to different population needs.\n\nThe hypotheses from the small-n analysis will then be tested by further large-n analyses. My research will use advanced methods in order to isolate causal effects of the intervention of integrated care in Greater Manchester. I will use synthetic control methods to create a synthetic counterfactual trend of Greater Manchester if it had much less developed health and social care integration. My synthetic control will be developed from weighted trends from other city-region combined authorities in England. This method is an alternative to traditional methods such as difference-in-differences.\n\nThis research is interested in the consequences of integrating healthcare at a city-region geography on population health outcomes, this project hopes to understand whether this policy trend is likely to induce new inequalities into the health system, tackle those already in place, or both.\n","plannedDates":[{"endDate":"2023-10-11T00:00:00+00:00","startDate":"2020-10-12T00:00:00+00:00","startDateDateOnly":"2020-10-12","endDateDateOnly":"2023-10-11"}],"amountAwarded":108868,"Financial Year":"2019/20","Lead Applicant":"Mr Benjamin Goodair","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Goodair","Partnership Value":108868,"Approval Committee":"ERG11 Social Science and Bioethics, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A Policy Evaluation of the Integration of Health and Social Care in Greater Manchester  This mixed-methods project will treat Greater Manchester\u2019s integrated budget in 2016 and the delayed roll-out of Integrated Care Systems across the country as a quasi-natural experiment.\n\nI will use a nested-analysis method with qualitative research and three \u2018diverse' cases studies will be chosen non-randomly to understand how each Local Care Organisation are specifying their policy delivery according to different population needs.\n\nThe hypotheses from the small-n analysis will then be tested by further large-n analyses. My research will use advanced methods in order to isolate causal effects of the intervention of integrated care in Greater Manchester. I will use synthetic control methods to create a synthetic counterfactual trend of Greater Manchester if it had much less developed health and social care integration. My synthetic control will be developed from weighted trends from other city-region combined authorities in England. This method is an alternative to traditional methods such as difference-in-differences.\n\nThis research is interested in the consequences of integrating healthcare at a city-region geography on population health outcomes, this project hopes to understand whether this policy trend is likely to induce new inequalities into the health system, tackle those already in place, or both.\n","awardDateDateOnly":"2020-05-06","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Delivery of Health Care","Delivery of Health Care, Integrated","England","Health Policy","Humans","Social Work"]}
{"id":"360G-Wellcome-221158_Z_20_Z","title":"Towards a History of the Female Body in British Colonial Punjab (1885-1947)","Region":"South East","currency":"GBP","awardDate":"2020-05-06T00:00:00+00:00","Sponsor(s)":"Dr Erica Charters","Internal ID":"221158/Z/20/Z","description":"I am invested in researching the history of the female body in British colonial Punjab from 1885 - 1947, as it lived and experienced British colonial medicine. I want to study the character of the relationship between British colonial medicine and the princely states of Punjab, and between biomedicine and religious nationalism, and the impact of these relationships on women\u2019s bodies, and their motility, mobility, and embodied subjectivity. I have located hitherto unutilised primary sources \u2013 women\u2019s magazines, journals, and quasi-medical magazines run by women written in Punjabi, and medical and administrative records of local women\u2019s hospitals in the six princely states of Punjab \u2013 in order to investigate the lives of Punjabi women who experienced the biomedical regime through practicing medicine or becoming patients. \n\nThrough the position and practices of women under investigation, I wish to question the conceptualisation of \u2018medicalisation\u2019 that has often been applied to understand the impact of biomedicine on societies such as India. I wish to understand women\u2019s decisions and choices during this period not only as representative of the medical-religious dichotomy or alliance, but also as representative of the impact biomedicine had on their experiences of their own bodies. \n\n \n","plannedDates":[{"endDate":"2023-10-14T00:00:00+00:00","startDate":"2020-10-15T00:00:00+00:00","startDateDateOnly":"2020-10-15","endDateDateOnly":"2023-10-14"}],"amountAwarded":72174,"Financial Year":"2019/20","Lead Applicant":"Mrs Nikita Arora","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Arora","Partnership Value":72174,"Approval Committee":"ERG10 Medical Humanities, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Towards a History of the Female Body in British Colonial Punjab (1885-1947) I am invested in researching the history of the female body in British colonial Punjab from 1885 - 1947, as it lived and experienced British colonial medicine. I want to study the character of the relationship between British colonial medicine and the princely states of Punjab, and between biomedicine and religious nationalism, and the impact of these relationships on women\u2019s bodies, and their motility, mobility, and embodied subjectivity. I have located hitherto unutilised primary sources \u2013 women\u2019s magazines, journals, and quasi-medical magazines run by women written in Punjabi, and medical and administrative records of local women\u2019s hospitals in the six princely states of Punjab \u2013 in order to investigate the lives of Punjabi women who experienced the biomedical regime through practicing medicine or becoming patients. \n\nThrough the position and practices of women under investigation, I wish to question the conceptualisation of \u2018medicalisation\u2019 that has often been applied to understand the impact of biomedicine on societies such as India. I wish to understand women\u2019s decisions and choices during this period not only as representative of the medical-religious dichotomy or alliance, but also as representative of the impact biomedicine had on their experiences of their own bodies. \n\n \n","awardDateDateOnly":"2020-05-06","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Colonialism","Female","History, 20th Century","Humans","India"]}
{"id":"360G-Wellcome-221155_Z_20_Z","title":"Mapping critical psychiatry: a transnational study of critical psychiatry\u2019s reception in Western Europe and the US, 1965-today","Region":"Greater London","currency":"GBP","awardDate":"2020-05-06T00:00:00+00:00","Sponsor(s)":"Prof Sonu Shamdasani","Internal ID":"221155/Z/20/Z","description":"The 1960s and 1970s marked a decisive change in the history of psychiatry critique, when in the UK, in Germany, and the US therapeutic communities and patients\u2019 collectives formed outside of psychiatric institutions. Some of them were guided by psychiatry reformists, for instance R. D. Laing, others were self-managed by psychiatric patients as a counter-reaction to existing psychiatric institutions.\n\nMy research pursues two main goals: first, to offer an understanding of critical psychiatry as an international counter-cultural network which circulated knowledge and subversive practices across national borders; second, to analyse how psychiatry critique became a powerful tool for patients to confront social marginalisation, lack of rights and isolation.\n\nBased on original oral history, archival sources, and literary sources, I will map out a transnational historiography of critical psychiatry that revises existing narratives within the limits of national borders. My project constitutes the first attempt to examine in depth the Philadelphia Association, the governing body of various housing projects for psychiatric patients in London, as well as it does justice to the under-researched critical psychiatry scenes in Germany and the US.\n\nIn sum, I will produce new perspectives on key historical developments that have lead up to critical psychiatry\u2019s contemporary significance.\n","plannedDates":[{"endDate":"2023-09-27T00:00:00+00:00","startDate":"2020-09-28T00:00:00+00:00","startDateDateOnly":"2020-09-28","endDateDateOnly":"2023-09-27"}],"amountAwarded":97554,"Financial Year":"2019/20","Lead Applicant":"Ms Janina Klement","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Klement","Partnership Value":97554,"Approval Committee":"ERG10 Medical Humanities, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mapping critical psychiatry: a transnational study of critical psychiatry\u2019s reception in Western Europe and the US, 1965-today The 1960s and 1970s marked a decisive change in the history of psychiatry critique, when in the UK, in Germany, and the US therapeutic communities and patients\u2019 collectives formed outside of psychiatric institutions. Some of them were guided by psychiatry reformists, for instance R. D. Laing, others were self-managed by psychiatric patients as a counter-reaction to existing psychiatric institutions.\n\nMy research pursues two main goals: first, to offer an understanding of critical psychiatry as an international counter-cultural network which circulated knowledge and subversive practices across national borders; second, to analyse how psychiatry critique became a powerful tool for patients to confront social marginalisation, lack of rights and isolation.\n\nBased on original oral history, archival sources, and literary sources, I will map out a transnational historiography of critical psychiatry that revises existing narratives within the limits of national borders. My project constitutes the first attempt to examine in depth the Philadelphia Association, the governing body of various housing projects for psychiatric patients in London, as well as it does justice to the under-researched critical psychiatry scenes in Germany and the US.\n\nIn sum, I will produce new perspectives on key historical developments that have lead up to critical psychiatry\u2019s contemporary significance.\n","awardDateDateOnly":"2020-05-06","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Europe","Germany","History, 20th Century","History, 21st Century","Humans","Mental Disorders","Psychiatry"]}
{"id":"360G-Wellcome-221152_Z_20_Z","title":"Changing minds: mapping out the bioethical dimensions of psychedelic-assisted psychotherapy","Region":"South East","currency":"GBP","awardDate":"2020-05-06T00:00:00+00:00","Sponsor(s)":"Dr Philip Burnet","Internal ID":"221152/Z/20/Z","description":"Psilocybin-assisted psychotherapy is likely to become a licensed treatment in the US within two years. However, clinically-relevant doses have a number of surprising \u2018side-effects\u2019: they can cause long-term changes to political values and personality, increase prosociality and aesthetic appreciation, and induce mystical experiences of long-lasting spiritual significance connected to changes in religious belief. These changes remain under-researched but challenge several ethical concepts, including authenticity and autonomy, beneficence, and informed consent. The project will begin by systematically reviewing the non-clinical changes reported in the empirical literature to develop a conceptual analysis of these changes within a medical ethics framework. In addition, the perspectives of patients and practitioners of psilocybin-assisted psychotherapy concerning these changes remain unknown, and they are not addressed either in the informed consent process or in therapist training manuals. As such, the project\u2019s second stage will use qualitative empirical methods to provide an account of their experiences and understanding of these changes. Together, the two elements of the project will demonstrate how psilocybin-assisted psychotherapy challenges orthodox conceptualisations of psychiatry, which marginalise spirituality and experiences of awe, as well as requiring policymakers such as NICE and their National Collaborating Centres to revise their approach to foreseen-but-unintended consequences of treatment.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":106077,"Financial Year":"2019/20","Lead Applicant":"Mr Edward Jacobs","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Jacobs","Partnership Value":106077,"Approval Committee":"ERG11 Social Science and Bioethics, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Changing minds: mapping out the bioethical dimensions of psychedelic-assisted psychotherapy Psilocybin-assisted psychotherapy is likely to become a licensed treatment in the US within two years. However, clinically-relevant doses have a number of surprising \u2018side-effects\u2019: they can cause long-term changes to political values and personality, increase prosociality and aesthetic appreciation, and induce mystical experiences of long-lasting spiritual significance connected to changes in religious belief. These changes remain under-researched but challenge several ethical concepts, including authenticity and autonomy, beneficence, and informed consent. The project will begin by systematically reviewing the non-clinical changes reported in the empirical literature to develop a conceptual analysis of these changes within a medical ethics framework. In addition, the perspectives of patients and practitioners of psilocybin-assisted psychotherapy concerning these changes remain unknown, and they are not addressed either in the informed consent process or in therapist training manuals. As such, the project\u2019s second stage will use qualitative empirical methods to provide an account of their experiences and understanding of these changes. Together, the two elements of the project will demonstrate how psilocybin-assisted psychotherapy challenges orthodox conceptualisations of psychiatry, which marginalise spirituality and experiences of awe, as well as requiring policymakers such as NICE and their National Collaborating Centres to revise their approach to foreseen-but-unintended consequences of treatment.\n","awardDateDateOnly":"2020-05-06","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Informed Consent","Morals","Psychotherapy","Religion and Medicine","Spirituality"]}
{"id":"360G-Wellcome-221141_Z_20_Z","title":"The Transparent Womb: Gestational Labour, Reproductive Technologies, and the Politics of Visual Culture","Region":"Greater London","currency":"GBP","awardDate":"2020-05-06T00:00:00+00:00","Sponsor(s)":"Prof Madeleine Ohl","Internal ID":"221141/Z/20/Z","description":"Particular reproductive technologies can make visible elements of the process of biological procreation, but this is not a neutral process. How these technologies see, and are themselves seen, influences the way reproduction itself is understood. Even within current feminist theorising, there is insufficient research into the role of visual cultures of reproductive technologies in the construction of cultural imaginaries surrounding biological reproduction.\n\nUsing social reproduction theory as a framework, this PhD will explore the gender politics of the visual representation of historical and emerging reproductive technologies, and investigate the cultural impact of this representation. It will use archival research (extending to advertising, product design, media coverage, and activist ephemera) to explore three case studies: 1. Conception \u2013 egg-freezing and IVF; 2. Gestation in process \u2013 from ultrasound to the artificial womb; 3. Political contexts \u2013 alternative feminist reproductive technologies.\n\nThe thesis will explore the gender (and racialised) politics of how historical and emerging reproductive technologies represent gestation, and how they themselves are visually represented. It will analyse the effect of this representation of reproductive technologies on the cultural imaginary, particularly in terms of its role in facilitating or prohibiting social recognition of gestation as a form of reproductive labour.\n","plannedDates":[{"endDate":"2023-09-15T00:00:00+00:00","startDate":"2020-09-16T00:00:00+00:00","startDateDateOnly":"2020-09-16","endDateDateOnly":"2023-09-15"}],"amountAwarded":93106,"Financial Year":"2019/20","Lead Applicant":"Ms Holly Isard","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Isard","Partnership Value":93106,"Approval Committee":"ERG10 Medical Humanities, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-West-London","name":"University of West London","addressCountry":"United Kingdom","id_and_name":"[\"University of West London\", \"360G-Wellcome-ORG:University-of-West-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-West-London","name":"University of West London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The Transparent Womb: Gestational Labour, Reproductive Technologies, and the Politics of Visual Culture Particular reproductive technologies can make visible elements of the process of biological procreation, but this is not a neutral process. How these technologies see, and are themselves seen, influences the way reproduction itself is understood. Even within current feminist theorising, there is insufficient research into the role of visual cultures of reproductive technologies in the construction of cultural imaginaries surrounding biological reproduction.\n\nUsing social reproduction theory as a framework, this PhD will explore the gender politics of the visual representation of historical and emerging reproductive technologies, and investigate the cultural impact of this representation. It will use archival research (extending to advertising, product design, media coverage, and activist ephemera) to explore three case studies: 1. Conception \u2013 egg-freezing and IVF; 2. Gestation in process \u2013 from ultrasound to the artificial womb; 3. Political contexts \u2013 alternative feminist reproductive technologies.\n\nThe thesis will explore the gender (and racialised) politics of how historical and emerging reproductive technologies represent gestation, and how they themselves are visually represented. It will analyse the effect of this representation of reproductive technologies on the cultural imaginary, particularly in terms of its role in facilitating or prohibiting social recognition of gestation as a form of reproductive labour.\n","awardDateDateOnly":"2020-05-06","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Female","Feminism","Gender Identity","History, 20th Century","Humans","Mass Media","Politics","Pregnancy","Reproduction"]}
{"id":"360G-Wellcome-221136_Z_20_Z","title":"Exploring Everyday Ethics in Palliative Care in China: A Qualitative Empirical Bioethics Study","Region":"South West","currency":"GBP","awardDate":"2020-05-06T00:00:00+00:00","Sponsor(s)":"Prof Richard Huxtable","Internal ID":"221136/Z/20/Z","description":"Existing research and training in palliative care ethics appear not to focus on, or be tailored to, practice in China. This research aims to fill these gaps by: first, identifying and exploring the ethical challenges Chinese healthcare professionals have confronted during their provision of palliative care; second, identifying the ethical training they have received and the extent to which they feel prepared to address relevant challenges; and, third, proposing changes, for example, to existing training in order to better equip these professionals. The significance of this research includes offering up-to-date knowledge of palliative care provision and relevant ethical training in China, assessing the utility of these training schemes and eventually making insightful suggestions.\n\nThis is an empirical bioethics project, which has three phases (mapping-framing-shaping). The mapping phase involves literature reviews. The framing phase involves qualitative research. The researcher plans to retrieve and thematically analyse empirical data via one-to-one semi-structured interviews. Considering the unique cultural and social background, the data collection will be undertaken in Mandarin in selected hospitals in China. The shaping phase then combines the previous theoretical and empirical findings, using an empirical bioethics methodology - reflexive balancing - with a view to making recommendations for future practice.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":173371,"Financial Year":"2019/20","Lead Applicant":"Miss Shengyu Zhao","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Zhao","Partnership Value":173371,"Approval Committee":"ERG11 Social Science and Bioethics, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Exploring Everyday Ethics in Palliative Care in China: A Qualitative Empirical Bioethics Study Existing research and training in palliative care ethics appear not to focus on, or be tailored to, practice in China. This research aims to fill these gaps by: first, identifying and exploring the ethical challenges Chinese healthcare professionals have confronted during their provision of palliative care; second, identifying the ethical training they have received and the extent to which they feel prepared to address relevant challenges; and, third, proposing changes, for example, to existing training in order to better equip these professionals. The significance of this research includes offering up-to-date knowledge of palliative care provision and relevant ethical training in China, assessing the utility of these training schemes and eventually making insightful suggestions.\n\nThis is an empirical bioethics project, which has three phases (mapping-framing-shaping). The mapping phase involves literature reviews. The framing phase involves qualitative research. The researcher plans to retrieve and thematically analyse empirical data via one-to-one semi-structured interviews. Considering the unique cultural and social background, the data collection will be undertaken in Mandarin in selected hospitals in China. The shaping phase then combines the previous theoretical and empirical findings, using an empirical bioethics methodology - reflexive balancing - with a view to making recommendations for future practice.\n","awardDateDateOnly":"2020-05-06","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Bioethics","China","Health Personnel","Humans","Interviews as Topic","Palliative Care","Qualitative Research"]}
{"id":"360G-Wellcome-221135_Z_20_Z","title":"Seroepidemiology in Africa for iNTS vaccine (SAiNTS)","Region":"North West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221135/Z/20/Z","description":"Invasive non-typhoidal\nSalmonella (iNTS) is estimated to cause 535,000 illnesses, 77,500 deaths, and the loss of\n4,263,500 disability-adjusted life years (DALY\u2019s) every year, with 86.7% of the global burden\nfalling in sub-Saharan Africa (sSA). The proposed SAiNTS study will work with the EU-funded\nVacc-iNTS consortium, and will complete a comprehensive rural community-based seroepidemiological\nstudy in a malarial area, measuring age-stratified exposure, susceptibility and\nnatural immunity to NTS, and leveraging multiple additional cohort datasets, with the\noverarching goals of:\n- Accelerating the clinical development of 3 new iNTS vaccines in early clinical\ndevelopment through phase 1 and phase 2a immunogenicity studies\n- Providing a model contributing to realistic assessments of the impact of iNTS\nvaccination in varying epidemiological settings across Africa.\nThe SAiNTS study, accordingly, has the following specific aims:\nAim 1: Develop a regression model for age-dependant, naturally acquired immunity against\niNTS disease (alphaLPS-IgG antibody and SBA) and compare to the age-stratified incidence of\nSalmonella enteric infections (eNTS).\nAim 2: Estimate a Correlate of Protection for invasive NTS, based on naturally acquired\nantibody levels and known age-stratified disease incidence.\nAim 3: Assess the effect of different iNTS risk factors on the age-dependent acquisition of\nnatural immunity, and how they might impact on estimated correlates of protection and iNTS\nvaccine impact in different scenarios.","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":599245,"Financial Year":"2019/20","Lead Applicant":"Prof Melita Gordon","grantProgramme":[{"title":"Innovations AIGH Enterics Flagship ","title_keyword":"Innovations AIGH Enterics Flagship "}],"Applicant Surname":"Gordon","Partnership Value":599245,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Tonney Nyirenda, Dr Marc Henrion, Prof Neil French","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool","addressCountry":"United Kingdom","id_and_name":"[\"University of Liverpool\", \"360G-Wellcome-ORG:University-of-Liverpool\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Seroepidemiology in Africa for iNTS vaccine (SAiNTS) Invasive non-typhoidal\nSalmonella (iNTS) is estimated to cause 535,000 illnesses, 77,500 deaths, and the loss of\n4,263,500 disability-adjusted life years (DALY\u2019s) every year, with 86.7% of the global burden\nfalling in sub-Saharan Africa (sSA). The proposed SAiNTS study will work with the EU-funded\nVacc-iNTS consortium, and will complete a comprehensive rural community-based seroepidemiological\nstudy in a malarial area, measuring age-stratified exposure, susceptibility and\nnatural immunity to NTS, and leveraging multiple additional cohort datasets, with the\noverarching goals of:\n- Accelerating the clinical development of 3 new iNTS vaccines in early clinical\ndevelopment through phase 1 and phase 2a immunogenicity studies\n- Providing a model contributing to realistic assessments of the impact of iNTS\nvaccination in varying epidemiological settings across Africa.\nThe SAiNTS study, accordingly, has the following specific aims:\nAim 1: Develop a regression model for age-dependant, naturally acquired immunity against\niNTS disease (alphaLPS-IgG antibody and SBA) and compare to the age-stratified incidence of\nSalmonella enteric infections (eNTS).\nAim 2: Estimate a Correlate of Protection for invasive NTS, based on naturally acquired\nantibody levels and known age-stratified disease incidence.\nAim 3: Assess the effect of different iNTS risk factors on the age-dependent acquisition of\nnatural immunity, and how they might impact on estimated correlates of protection and iNTS\nvaccine impact in different scenarios.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adolescent","Adult","Africa South of the Sahara","Aged, 80 and over","Child","Child, Preschool","Female","Humans","Immunoglobulin G","Incidence","Infant","Middle Aged","Risk Factors","Rural Population","Salmonella Infections","Salmonella Vaccines","Serogroup","Young Adult"]}
{"id":"360G-Wellcome-221121_Z_20_Z","title":"Living in a World of Voices: An Interdisciplinary Investigation of Non-Clinical Voice-Hearers in Context","Region":"North East","currency":"GBP","awardDate":"2020-05-06T00:00:00+00:00","Sponsor(s)":"Prof Richard Crisp","Internal ID":"221121/Z/20/Z","description":"A growing body of psychological research has identified a population of individuals who hear voices outside of the context of pathology. These \"non-clinical\" voice-hearers have been the subject of a variety of studies aimed at understanding their relationship with clinical voice-hearers. This research, which often relies on standardized psychological measures, fails to explore the broader context in which these experiences occur. Non-clinical participants are often recruited from spiritual communities who accept anomalous experiences and offer meaningful frameworks in which to understand them. The proposed research will address this gap in the literature.  Drawing on theory and methodology from anthropology, psychology, and philosophy this research will explore the ways in which the voice-hearing experiences of these individuals are shaped by the larger contexts of their lives. In particular it will seek to understand the ways in which community attitudes towards anomalous experience such as voice-hearing may impact appraisals of these experiences.  \n\n \n\n \n","plannedDates":[{"endDate":"2023-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2023-12-31"}],"amountAwarded":96988,"Financial Year":"2019/20","Lead Applicant":"Ms Ariel Swyer","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Swyer","Partnership Value":96988,"Approval Committee":"ERG10 Medical Humanities, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Durham","name":"University of Durham","addressCountry":"United Kingdom","id_and_name":"[\"University of Durham\", \"360G-Wellcome-ORG:University-of-Durham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Durham","name":"University of Durham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Living in a World of Voices: An Interdisciplinary Investigation of Non-Clinical Voice-Hearers in Context A growing body of psychological research has identified a population of individuals who hear voices outside of the context of pathology. These \"non-clinical\" voice-hearers have been the subject of a variety of studies aimed at understanding their relationship with clinical voice-hearers. This research, which often relies on standardized psychological measures, fails to explore the broader context in which these experiences occur. Non-clinical participants are often recruited from spiritual communities who accept anomalous experiences and offer meaningful frameworks in which to understand them. The proposed research will address this gap in the literature.  Drawing on theory and methodology from anthropology, psychology, and philosophy this research will explore the ways in which the voice-hearing experiences of these individuals are shaped by the larger contexts of their lives. In particular it will seek to understand the ways in which community attitudes towards anomalous experience such as voice-hearing may impact appraisals of these experiences.  \n\n \n\n \n","awardDateDateOnly":"2020-05-06","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Hallucinations","Humans"]}
{"id":"360G-Wellcome-221115_Z_20_Z","title":"The Doctrine of Signatures in Early Modern Medical Practice","Region":"East of England","currency":"GBP","awardDate":"2020-05-06T00:00:00+00:00","Sponsor(s)":"Dr Daniel Margocsy","Internal ID":"221115/Z/20/Z","description":"Early modern Paracelsian physicians, natural historians, chemists and lay practitioners were united in their belief that a plant\u2019s morphological resemblance to a human body part indicated its curative effect. My doctoral research will result in the first monograph to examine how the doctrine of signatures was applied, developed and transformed through medicinal and chymical practice in Germany and England. Through the exploration of personal archives, prescriptions and recipes, I will trace the formation and transmission of this doctrine among chymical physicians, apothecaries and domestic practitioners. I hope to connect histories of mystical philosophy and intellectual developments with recent works on the practices of healing and knowledge transmission. I hold that the doctrine of signatures was not a unified mystical theory once proposed and discredited by \"modern science\", as argued by philosophers and historians since Michel Foucault, William Ashworth, James Bono or Peter Harrison. Instead, it was a fluid, malleable set of ideas developing in conversation with humanistic learning, experiential knowledge and everyday practice, which survived well into the late seventeenth century. In this way, I hope to challenge the still-dominating narrative on the rise of modernity and scientific revolution.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":174156,"Financial Year":"2019/20","Lead Applicant":"Miss Xinyi Wen","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Wen","Partnership Value":174156,"Approval Committee":"ERG10 Medical Humanities, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The Doctrine of Signatures in Early Modern Medical Practice Early modern Paracelsian physicians, natural historians, chemists and lay practitioners were united in their belief that a plant\u2019s morphological resemblance to a human body part indicated its curative effect. My doctoral research will result in the first monograph to examine how the doctrine of signatures was applied, developed and transformed through medicinal and chymical practice in Germany and England. Through the exploration of personal archives, prescriptions and recipes, I will trace the formation and transmission of this doctrine among chymical physicians, apothecaries and domestic practitioners. I hope to connect histories of mystical philosophy and intellectual developments with recent works on the practices of healing and knowledge transmission. I hold that the doctrine of signatures was not a unified mystical theory once proposed and discredited by \"modern science\", as argued by philosophers and historians since Michel Foucault, William Ashworth, James Bono or Peter Harrison. Instead, it was a fluid, malleable set of ideas developing in conversation with humanistic learning, experiential knowledge and everyday practice, which survived well into the late seventeenth century. In this way, I hope to challenge the still-dominating narrative on the rise of modernity and scientific revolution.\n","awardDateDateOnly":"2020-05-06","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["England","Germany","History, 18th Century","History, 19th Century","History, 20th Century","Physicians"]}
{"id":"360G-Wellcome-221057_Z_20_Z","title":"Informality and the Right to Health: How informal networks shape access to water in the Makoko settlement","Region":"Greater London","currency":"GBP","awardDate":"2020-05-06T00:00:00+00:00","Sponsor(s)":"Prof Julio D\u00e1vila","Internal ID":"221057/Z/20/Z","description":"This interdisciplinary PhD explores how different stakeholders involved in water delivery affect access to water in the Makoko settlement in Lagos, and which implications this holds for socio-spatial health inequalities. In Lagos, vested interests behind public health agendas manifest through urban water insecurity while informal water networks emerged as a counter-narrative to public service absenteeism partly rooted in a colonial urban planning legacy. The main hypothesis is that the reproduction of power relations along socio-spatial gradients is facilitated by reinforced idioms of informality, aiming to justify the lack of water infrastructure and underservicing of specific low-income groups and thereby intrinsically re-producing the very informal networks that disrupt municipal water services and leading to a widening of the urban health gap. Methodologically, I will intersect statistical and geographical data with cognitive mapping, semi-narrative qualitative interviews and dwellers\u2019 self-report on health conditions. Further linking historical explanations for the water crisis to empirical data, my research strives to challenge orthodox development and planning discourses based on notions of an \"African exceptionalism\" vis-\u00e0-vis the \"European master narrative\" while contributing to the theoretical and empirical development of the \"right to health\" as a prerequisite for the \"right to the city\" and the universal human rights.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":111099,"Financial Year":"2019/20","Lead Applicant":"Ms Nura Ali","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Ali","Partnership Value":111099,"Approval Committee":"ERG11 Social Science and Bioethics, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Informality and the Right to Health: How informal networks shape access to water in the Makoko settlement This interdisciplinary PhD explores how different stakeholders involved in water delivery affect access to water in the Makoko settlement in Lagos, and which implications this holds for socio-spatial health inequalities. In Lagos, vested interests behind public health agendas manifest through urban water insecurity while informal water networks emerged as a counter-narrative to public service absenteeism partly rooted in a colonial urban planning legacy. The main hypothesis is that the reproduction of power relations along socio-spatial gradients is facilitated by reinforced idioms of informality, aiming to justify the lack of water infrastructure and underservicing of specific low-income groups and thereby intrinsically re-producing the very informal networks that disrupt municipal water services and leading to a widening of the urban health gap. Methodologically, I will intersect statistical and geographical data with cognitive mapping, semi-narrative qualitative interviews and dwellers\u2019 self-report on health conditions. Further linking historical explanations for the water crisis to empirical data, my research strives to challenge orthodox development and planning discourses based on notions of an \"African exceptionalism\" vis-\u00e0-vis the \"European master narrative\" while contributing to the theoretical and empirical development of the \"right to health\" as a prerequisite for the \"right to the city\" and the universal human rights.\n","awardDateDateOnly":"2020-05-06","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Human Rights","Humans","Water Supply"]}
{"id":"360G-Wellcome-221054_Z_20_Z","title":"Writing mental illness: narrative insurgency and experimental form in British and American women\u2019s writing from 1965","Region":"Scotland","currency":"GBP","awardDate":"2020-05-06T00:00:00+00:00","Sponsor(s)":"Dr Gavin Miller","Internal ID":"221054/Z/20/Z","description":"This thesis will consider experimental form in female-authored representations of mental illness in British and American writing, 1965-present. The narrative and formal experimentation of modern women\u2019s literature challenges both literary conventions and the valorisation of testimonial mimetic narratives about mental illness within the Medical Humanities. Previous study on the topic of women and madness focuses on the content of women\u2019s writing about mental illness more than their formal strategies, thus assessing their writing for its testimonial value rather than its literary sophistication. This thesis will locate illness, not as a metaphor or a device, but as an embodied state, which produces rich aesthetic possibilities and textual forms. It will investigate the opportunities that intermediality - images and non-standard typography - offers for challenging narrative homogeneity and how women writers have critiqued the narrative expectation of empathy in the context of mental health. Considering women\u2019s experimental literature as a genre, I will look at prose fiction, graphic novels, and zines. By comparing the relationships between activism and art, personal experience and experimental fiction, image and text in women's writing, this thesis will offer a fresh framework for approaching the representational politics of mental health across disciplines and within mental healthcare provision. \n","plannedDates":[{"endDate":"2023-11-06T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2023-11-06"}],"amountAwarded":84857,"Financial Year":"2019/20","Lead Applicant":"Ms Zoe Slater","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Slater","Partnership Value":84857,"Approval Committee":"ERG10 Medical Humanities, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow","addressCountry":"United Kingdom","id_and_name":"[\"University of Glasgow\", \"360G-Wellcome-ORG:University-of-Glasgow\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Writing mental illness: narrative insurgency and experimental form in British and American women\u2019s writing from 1965 This thesis will consider experimental form in female-authored representations of mental illness in British and American writing, 1965-present. The narrative and formal experimentation of modern women\u2019s literature challenges both literary conventions and the valorisation of testimonial mimetic narratives about mental illness within the Medical Humanities. Previous study on the topic of women and madness focuses on the content of women\u2019s writing about mental illness more than their formal strategies, thus assessing their writing for its testimonial value rather than its literary sophistication. This thesis will locate illness, not as a metaphor or a device, but as an embodied state, which produces rich aesthetic possibilities and textual forms. It will investigate the opportunities that intermediality - images and non-standard typography - offers for challenging narrative homogeneity and how women writers have critiqued the narrative expectation of empathy in the context of mental health. Considering women\u2019s experimental literature as a genre, I will look at prose fiction, graphic novels, and zines. By comparing the relationships between activism and art, personal experience and experimental fiction, image and text in women's writing, this thesis will offer a fresh framework for approaching the representational politics of mental health across disciplines and within mental healthcare provision. \n","awardDateDateOnly":"2020-05-06","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Empathy","Female","Humans","Mental Disorders","Metaphor","Narration","Writing"]}
{"id":"360G-Wellcome-221052_Z_20_Z","title":"Human Cell Atlas - development atlas extension","Region":"North East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221052/Z/20/Z","description":"We propose to generate an in-depth single cell and spatial atlas of embryos during late organogenesis, at 6/7 post conception weeks (PCW). This project will form a blueprint for a complete HCA development cell atlas, which will ultimately cover all accessible developmental stages week by week.  We will leverage genomics technologies to profile single cells from dissociated tissues and within intact tissue sections, and deploy cutting-edge computational methods to reconstruct, in silico, a three-dimensional atlas of the whole human embryo.  This work will significantly extend our existing WSSS-funded Development Cell Atlas research programme, which is focused on organ-based profiling.  Our reconstruction of a complete human embryo atlas will provide a blueprint for establishing high resolution molecular-based anatomical landmarks during human development, harmonizing developmental knowledge across species, and establishing a foundational resource with significant implications for developmental and childhood disorders, regenerative medicine and tissue engineering.  \n\n\n \n","plannedDates":[{"endDate":"2022-12-10T00:00:00+00:00","startDate":"2020-12-11T00:00:00+00:00","startDateDateOnly":"2020-12-11","endDateDateOnly":"2022-12-10"}],"amountAwarded":876884,"Financial Year":"2019/20","Lead Applicant":"Prof Muzlifah Haniffa","grantProgramme":[{"title":"Strategic Support: Science","title_keyword":"Strategic Support: Science"}],"Applicant Surname":"Haniffa","Partnership Value":876884,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Sam Behjati, Prof Neil Lawrence, Dr Kerstin Meyer, Prof Elizabeth Robertson, Dr Omer Bayraktar, Prof Berthold Gottgens, Dr John Marioni, Dr Sarah Teichmann","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Newcastle-University","name":"Newcastle University","addressCountry":"United Kingdom","id_and_name":"[\"Newcastle University\", \"360G-Wellcome-ORG:Newcastle-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Newcastle-University","name":"Newcastle University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Human Cell Atlas - development atlas extension We propose to generate an in-depth single cell and spatial atlas of embryos during late organogenesis, at 6/7 post conception weeks (PCW). This project will form a blueprint for a complete HCA development cell atlas, which will ultimately cover all accessible developmental stages week by week.  We will leverage genomics technologies to profile single cells from dissociated tissues and within intact tissue sections, and deploy cutting-edge computational methods to reconstruct, in silico, a three-dimensional atlas of the whole human embryo.  This work will significantly extend our existing WSSS-funded Development Cell Atlas research programme, which is focused on organ-based profiling.  Our reconstruction of a complete human embryo atlas will provide a blueprint for establishing high resolution molecular-based anatomical landmarks during human development, harmonizing developmental knowledge across species, and establishing a foundational resource with significant implications for developmental and childhood disorders, regenerative medicine and tissue engineering.  \n\n\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Atlases as Topic","Embryo, Mammalian","Humans","Tissue Engineering"]}
{"id":"360G-Wellcome-221052_E_20_Z","title":"Human Cell Atlas - development atlas extension","Region":"East of England","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221052/E/20/Z","description":"We propose to generate an in-depth single cell and spatial atlas of embryos during late organogenesis, at 6/7 post conception weeks (PCW). This project will form a blueprint for a complete HCA development cell atlas, which will ultimately cover all accessible developmental stages week by week.  We will leverage genomics technologies to profile single cells from dissociated tissues and within intact tissue sections, and deploy cutting-edge computational methods to reconstruct, in silico, a three-dimensional atlas of the whole human embryo.  This work will significantly extend our existing WSSS-funded Development Cell Atlas research programme, which is focused on organ-based profiling.  Our reconstruction of a complete human embryo atlas will provide a blueprint for establishing high resolution molecular-based anatomical landmarks during human development, harmonizing developmental knowledge across species, and establishing a foundational resource with significant implications for developmental and childhood disorders, regenerative medicine and tissue engineering.  \n\n\n \n","plannedDates":[{"endDate":"2022-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2022-08-31"}],"amountAwarded":2164882,"Financial Year":"2019/20","Lead Applicant":"Prof Muzlifah Haniffa","grantProgramme":[{"title":"Sanger Resource Collaboration","title_keyword":"Sanger Resource Collaboration"}],"Applicant Surname":"Haniffa","Partnership Value":2164882,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Omer Bayraktar, Dr Sam Behjati, Prof Neil Lawrence, Dr Kerstin Meyer, Prof Berthold Gottgens, Dr John Marioni, Dr Sarah Teichmann, Prof Elizabeth Robertson","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Wellcome-Trust-Sanger-Institute","name":"Wellcome Trust Sanger Institute","addressCountry":"United Kingdom","id_and_name":"[\"Wellcome Trust Sanger Institute\", \"360G-Wellcome-ORG:Wellcome-Trust-Sanger-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Wellcome-Trust-Sanger-Institute","name":"Wellcome Trust Sanger Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Human Cell Atlas - development atlas extension We propose to generate an in-depth single cell and spatial atlas of embryos during late organogenesis, at 6/7 post conception weeks (PCW). This project will form a blueprint for a complete HCA development cell atlas, which will ultimately cover all accessible developmental stages week by week.  We will leverage genomics technologies to profile single cells from dissociated tissues and within intact tissue sections, and deploy cutting-edge computational methods to reconstruct, in silico, a three-dimensional atlas of the whole human embryo.  This work will significantly extend our existing WSSS-funded Development Cell Atlas research programme, which is focused on organ-based profiling.  Our reconstruction of a complete human embryo atlas will provide a blueprint for establishing high resolution molecular-based anatomical landmarks during human development, harmonizing developmental knowledge across species, and establishing a foundational resource with significant implications for developmental and childhood disorders, regenerative medicine and tissue engineering.  \n\n\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Atlases as Topic","Embryo, Mammalian","Humans","Tissue Engineering"]}
{"id":"360G-Wellcome-221052_C_20_Z","title":"Human Cell Atlas - development atlas extension","Region":"East of England","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221052/C/20/Z","description":"We propose to generate an in-depth single cell and spatial atlas of embryos during late organogenesis, at 6/7 post conception weeks (PCW). This project will form a blueprint for a complete HCA development cell atlas, which will ultimately cover all accessible developmental stages week by week.  We will leverage genomics technologies to profile single cells from dissociated tissues and within intact tissue sections, and deploy cutting-edge computational methods to reconstruct, in silico, a three-dimensional atlas of the whole human embryo.  This work will significantly extend our existing WSSS-funded Development Cell Atlas research programme, which is focused on organ-based profiling.  Our reconstruction of a complete human embryo atlas will provide a blueprint for establishing high resolution molecular-based anatomical landmarks during human development, harmonizing developmental knowledge across species, and establishing a foundational resource with significant implications for developmental and childhood disorders, regenerative medicine and tissue engineering.  \n\n\n \n","plannedDates":[{"endDate":"2022-11-30T00:00:00+00:00","startDate":"2020-12-01T00:00:00+00:00","startDateDateOnly":"2020-12-01","endDateDateOnly":"2022-11-30"}],"amountAwarded":119697,"Financial Year":"2019/20","Lead Applicant":"Prof Berthold Gottgens","grantProgramme":[{"title":"Strategic Support: Science","title_keyword":"Strategic Support: Science"}],"Applicant Surname":"Gottgens","Partnership Value":119697,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr John Marioni, Dr Sam Behjati, Prof Neil Lawrence, Dr Kerstin Meyer, Prof Berthold Gottgens, Prof Elizabeth Robertson, Dr Sarah Teichmann, Dr Omer Bayraktar","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Human Cell Atlas - development atlas extension We propose to generate an in-depth single cell and spatial atlas of embryos during late organogenesis, at 6/7 post conception weeks (PCW). This project will form a blueprint for a complete HCA development cell atlas, which will ultimately cover all accessible developmental stages week by week.  We will leverage genomics technologies to profile single cells from dissociated tissues and within intact tissue sections, and deploy cutting-edge computational methods to reconstruct, in silico, a three-dimensional atlas of the whole human embryo.  This work will significantly extend our existing WSSS-funded Development Cell Atlas research programme, which is focused on organ-based profiling.  Our reconstruction of a complete human embryo atlas will provide a blueprint for establishing high resolution molecular-based anatomical landmarks during human development, harmonizing developmental knowledge across species, and establishing a foundational resource with significant implications for developmental and childhood disorders, regenerative medicine and tissue engineering.  \n\n\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Atlases as Topic","Embryo, Mammalian","Humans","Tissue Engineering"]}
{"id":"360G-Wellcome-221052_B_20_Z","title":"Human Cell Atlas - development atlas extension","Region":"East of England","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221052/B/20/Z","description":"We propose to generate an in-depth single cell and spatial atlas of embryos during late organogenesis, at 6/7 post conception weeks (PCW). This project will form a blueprint for a complete HCA development cell atlas, which will ultimately cover all accessible developmental stages week by week.  We will leverage genomics technologies to profile single cells from dissociated tissues and within intact tissue sections, and deploy cutting-edge computational methods to reconstruct, in silico, a three-dimensional atlas of the whole human embryo.  This work will significantly extend our existing WSSS-funded Development Cell Atlas research programme, which is focused on organ-based profiling.  Our reconstruction of a complete human embryo atlas will provide a blueprint for establishing high resolution molecular-based anatomical landmarks during human development, harmonizing developmental knowledge across species, and establishing a foundational resource with significant implications for developmental and childhood disorders, regenerative medicine and tissue engineering.  \n\n\n \n","plannedDates":[{"endDate":"2022-11-30T00:00:00+00:00","startDate":"2020-12-01T00:00:00+00:00","startDateDateOnly":"2020-12-01","endDateDateOnly":"2022-11-30"}],"amountAwarded":161121,"Financial Year":"2019/20","Lead Applicant":"Prof Neil Lawrence","grantProgramme":[{"title":"Strategic Support: Science","title_keyword":"Strategic Support: Science"}],"Applicant Surname":"Lawrence","Partnership Value":161121,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Sam Behjati, Dr Omer Bayraktar, Dr Sarah Teichmann, Prof Neil Lawrence, Dr John Marioni, Dr Kerstin Meyer, Prof Berthold Gottgens, Prof Elizabeth Robertson","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Human Cell Atlas - development atlas extension We propose to generate an in-depth single cell and spatial atlas of embryos during late organogenesis, at 6/7 post conception weeks (PCW). This project will form a blueprint for a complete HCA development cell atlas, which will ultimately cover all accessible developmental stages week by week.  We will leverage genomics technologies to profile single cells from dissociated tissues and within intact tissue sections, and deploy cutting-edge computational methods to reconstruct, in silico, a three-dimensional atlas of the whole human embryo.  This work will significantly extend our existing WSSS-funded Development Cell Atlas research programme, which is focused on organ-based profiling.  Our reconstruction of a complete human embryo atlas will provide a blueprint for establishing high resolution molecular-based anatomical landmarks during human development, harmonizing developmental knowledge across species, and establishing a foundational resource with significant implications for developmental and childhood disorders, regenerative medicine and tissue engineering.  \n\n\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Atlases as Topic","Embryo, Mammalian","Humans","Tissue Engineering"]}
{"id":"360G-Wellcome-221052_A_20_Z","title":"Human Cell Atlas - development atlas extension","Region":"East of England","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221052/A/20/Z","description":"We propose to generate an in-depth single cell and spatial atlas of embryos during late organogenesis, at 6/7 post conception weeks (PCW). This project will form a blueprint for a complete HCA development cell atlas, which will ultimately cover all accessible developmental stages week by week.  We will leverage genomics technologies to profile single cells from dissociated tissues and within intact tissue sections, and deploy cutting-edge computational methods to reconstruct, in silico, a three-dimensional atlas of the whole human embryo.  This work will significantly extend our existing WSSS-funded Development Cell Atlas research programme, which is focused on organ-based profiling.  Our reconstruction of a complete human embryo atlas will provide a blueprint for establishing high resolution molecular-based anatomical landmarks during human development, harmonizing developmental knowledge across species, and establishing a foundational resource with significant implications for developmental and childhood disorders, regenerative medicine and tissue engineering.  \n\n\n \n","plannedDates":[{"endDate":"2022-11-30T00:00:00+00:00","startDate":"2020-12-01T00:00:00+00:00","startDateDateOnly":"2020-12-01","endDateDateOnly":"2022-11-30"}],"amountAwarded":121985,"Financial Year":"2019/20","Lead Applicant":"Dr John Marioni","grantProgramme":[{"title":"Strategic Support: Science","title_keyword":"Strategic Support: Science"}],"Applicant Surname":"Marioni","Partnership Value":121985,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Kerstin Meyer, Dr Sarah Teichmann, Prof Berthold Gottgens, Dr John Marioni, Dr Omer Bayraktar, Dr Sam Behjati, Prof Neil Lawrence, Prof Elizabeth Robertson","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Human Cell Atlas - development atlas extension We propose to generate an in-depth single cell and spatial atlas of embryos during late organogenesis, at 6/7 post conception weeks (PCW). This project will form a blueprint for a complete HCA development cell atlas, which will ultimately cover all accessible developmental stages week by week.  We will leverage genomics technologies to profile single cells from dissociated tissues and within intact tissue sections, and deploy cutting-edge computational methods to reconstruct, in silico, a three-dimensional atlas of the whole human embryo.  This work will significantly extend our existing WSSS-funded Development Cell Atlas research programme, which is focused on organ-based profiling.  Our reconstruction of a complete human embryo atlas will provide a blueprint for establishing high resolution molecular-based anatomical landmarks during human development, harmonizing developmental knowledge across species, and establishing a foundational resource with significant implications for developmental and childhood disorders, regenerative medicine and tissue engineering.  \n\n\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Atlases as Topic","Embryo, Mammalian","Humans","Tissue Engineering"]}
{"id":"360G-Wellcome-221044_Z_20_Z","title":"The role of non-histone proteins in chromosome structure and function during mitosis","Region":"Scotland","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"221044/Z/20/Z","description":"I propose to study how a set of key proteins (condensins I/II, cohesin, Kif4A, topo IIalpha) mold the chromatin fibre into its characteristic rod-shaped helix of loops in mitosis. Using a transformative system allowing us to obtain cultures entering mitosis with near-perfect synchrony we will adopt an interdisciplinary approach involving genomics (Hi-C, Capture-C, cut & run), proteomics, crosslinking, microscopy and molecular modelling to resolve changes in chromatin fibre and chromosomal protein organisation on a minute-by-minute basis during mitotic entry. Using non-toxic synchrony methods plus acute (and reversible) protein depletion with auxin degrons, we will determine when, where, how and with whom these proteins act to shape mitotic chromosomes. Access to the single copy chicken Z chromosome with its unique-sequence centromere allows us unprecedented mapping of the chromatin folding and protein distribution at a vertebrate centromere during this process. Following our discovery that RNAs mediate assembly of the mitotic chromosome periphery compartment (MCPC) downstream of Ki-67, we will initiate a new research direction identifying the proteins and RNAs involved, and determining their functional significance for chromosome segregation. Lastly, we will optimise methods for isolating human artificial chromosomes (HACs), avoiding unwanted DNA rearrangements that endanger future synthetic genome efforts.\n","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":4000000,"Financial Year":"2019/20","Lead Applicant":"Prof William Earnshaw","grantProgramme":[{"title":"Principal Research Fellowship Renewal","title_keyword":"Principal Research Fellowship Renewal"}],"Applicant Surname":"Earnshaw","Partnership Value":4000000,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The role of non-histone proteins in chromosome structure and function during mitosis I propose to study how a set of key proteins (condensins I/II, cohesin, Kif4A, topo IIalpha) mold the chromatin fibre into its characteristic rod-shaped helix of loops in mitosis. Using a transformative system allowing us to obtain cultures entering mitosis with near-perfect synchrony we will adopt an interdisciplinary approach involving genomics (Hi-C, Capture-C, cut & run), proteomics, crosslinking, microscopy and molecular modelling to resolve changes in chromatin fibre and chromosomal protein organisation on a minute-by-minute basis during mitotic entry. Using non-toxic synchrony methods plus acute (and reversible) protein depletion with auxin degrons, we will determine when, where, how and with whom these proteins act to shape mitotic chromosomes. Access to the single copy chicken Z chromosome with its unique-sequence centromere allows us unprecedented mapping of the chromatin folding and protein distribution at a vertebrate centromere during this process. Following our discovery that RNAs mediate assembly of the mitotic chromosome periphery compartment (MCPC) downstream of Ki-67, we will initiate a new research direction identifying the proteins and RNAs involved, and determining their functional significance for chromosome segregation. Lastly, we will optimise methods for isolating human artificial chromosomes (HACs), avoiding unwanted DNA rearrangements that endanger future synthetic genome efforts.\n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adenosine Triphosphatases","Animals","Cell Line","Centromere","Chickens","Chromatin","Chromosomal Proteins, Non-Histone","Chromosome Segregation","DNA-Binding Proteins","Humans","Mitosis"]}
{"id":"360G-Wellcome-221038_Z_20_Z","title":"The ethics of tracking infectious disease transmission","Region":"South East","currency":"GBP","awardDate":"2020-07-21T00:00:00+00:00","Sponsor(s)":"Prof Michael Parker","Internal ID":"221038/Z/20/Z","description":"New \u2018pathogen sequencing technologies\u2019, which have the power to identify and describe infectious disease transmission networks, are transforming public health practice. They also raise practically important ethical questions (for example regarding privacy protection), as-well-as conceptual and normative questions concerning responsibility for disease transmission, blame and the obligations of various actors.\n\nThis empirical bioethics study will combine qualitative research with normative ethical analysis to develop an account of ethical practice in the use of technologies that can identify and describe infectious disease transmission networks.\n\nThis will be achieved by answering the following research question:\n\n\n What are expert and lay views on the potential social consequences and ethical risks of identifying transmission networks through the use of pathogen sequencing technologies?\n What ethical norms concerning transmission of infectious disease underpin these views?\n How do the concepts of personal responsibility, blame and obligation bear on the ethics of using pathogen technologies to identify and describe infectious disease transmission networks?\n What contextual factors influence ethical norms and ethical practice in this area?\n\n","plannedDates":[{"endDate":"2023-11-30T00:00:00+00:00","startDate":"2020-12-01T00:00:00+00:00","startDateDateOnly":"2020-12-01","endDateDateOnly":"2023-11-30"}],"amountAwarded":231432,"Financial Year":"2019/20","Lead Applicant":"Dr Stephanie Johnson","grantProgramme":[{"title":"Research Fellowship in H&SS","title_keyword":"Research Fellowship in H&SS"}],"Applicant Surname":"Johnson","Partnership Value":231432,"Approval Committee":"Social Science and Bioethics Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The ethics of tracking infectious disease transmission New \u2018pathogen sequencing technologies\u2019, which have the power to identify and describe infectious disease transmission networks, are transforming public health practice. They also raise practically important ethical questions (for example regarding privacy protection), as-well-as conceptual and normative questions concerning responsibility for disease transmission, blame and the obligations of various actors.\n\nThis empirical bioethics study will combine qualitative research with normative ethical analysis to develop an account of ethical practice in the use of technologies that can identify and describe infectious disease transmission networks.\n\nThis will be achieved by answering the following research question:\n\n\n What are expert and lay views on the potential social consequences and ethical risks of identifying transmission networks through the use of pathogen sequencing technologies?\n What ethical norms concerning transmission of infectious disease underpin these views?\n How do the concepts of personal responsibility, blame and obligation bear on the ethics of using pathogen technologies to identify and describe infectious disease transmission networks?\n What contextual factors influence ethical norms and ethical practice in this area?\n\n","awardDateDateOnly":"2020-07-21","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Confidentiality","Humans","Privacy","Public Health","Qualitative Research"]}
{"id":"360G-Wellcome-221034_Z_20_Z","title":"A health policy analysis of vaccine policy decisions in the Association of Southeast Asian Nations region to develop a framework to guide vaccine policy decisions: emergence of mandatory vaccine agendas, decision making process and influences. ","Region":"Greater London","currency":"GBP","awardDate":"2020-05-06T00:00:00+00:00","Sponsor(s)":"Prof Catherine Goodman","Internal ID":"221034/Z/20/Z","description":"Vaccine policy agendas, decision making process and influences to the decisions highly vary across countries. In recent years, mandatory vaccination policies have been introduced globally, to enforce specific vaccinations on target populations in a country. The policies pose various ethical and legal dilemmas that have been highly debated by academics, policy makers, and country citizens. Some studies have evaluated the policy impact on vaccine coverage and discussed ethics and perspectives of stakeholders. However, research has been geographically biased to Europe and United States; though the policies have been adopted globally, including among the member states of the Association of Southeast Asian Nations. Given the disparities in results and controversy of the policy, the policy decision-making on mandatory vaccinations have not been well understood. To fill this gap in research, this qualitative study will select two countries in ASEAN as cases, and apply policy theories to data collected through literature reviews and key-informant interviews. The study aims to understand the emergence of mandatory vaccinations in policy makers agenda and the actors involved, context of policy adoption and the process and influences of the policy decision. This study aims to develop a vaccine policy decision framework to guide future vaccine policies.\n","plannedDates":[{"endDate":"2023-11-18T00:00:00+00:00","startDate":"2020-09-21T00:00:00+00:00","startDateDateOnly":"2020-09-21","endDateDateOnly":"2023-11-18"}],"amountAwarded":147166,"Financial Year":"2019/20","Lead Applicant":"Mrs Aniqa Marshall","grantProgramme":[{"title":"PhD Studentship in H&SS","title_keyword":"PhD Studentship in H&SS"}],"Applicant Surname":"Marshall","Partnership Value":147166,"Approval Committee":"ERG11 Social Science and Bioethics, Early Career Awards","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"London School of Hygiene & Tropical Medicine\", \"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A health policy analysis of vaccine policy decisions in the Association of Southeast Asian Nations region to develop a framework to guide vaccine policy decisions: emergence of mandatory vaccine agendas, decision making process and influences.  Vaccine policy agendas, decision making process and influences to the decisions highly vary across countries. In recent years, mandatory vaccination policies have been introduced globally, to enforce specific vaccinations on target populations in a country. The policies pose various ethical and legal dilemmas that have been highly debated by academics, policy makers, and country citizens. Some studies have evaluated the policy impact on vaccine coverage and discussed ethics and perspectives of stakeholders. However, research has been geographically biased to Europe and United States; though the policies have been adopted globally, including among the member states of the Association of Southeast Asian Nations. Given the disparities in results and controversy of the policy, the policy decision-making on mandatory vaccinations have not been well understood. To fill this gap in research, this qualitative study will select two countries in ASEAN as cases, and apply policy theories to data collected through literature reviews and key-informant interviews. The study aims to understand the emergence of mandatory vaccinations in policy makers agenda and the actors involved, context of policy adoption and the process and influences of the policy decision. This study aims to develop a vaccine policy decision framework to guide future vaccine policies.\n","awardDateDateOnly":"2020-05-06","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Decision Making","Health Policy","Humans","Immunization Programs","Policy Making","Qualitative Research","Vaccination"]}
{"id":"360G-Wellcome-221021_Z_20_Z","title":"Understanding ethnic variations in the prevalence and experience of food insecurity, and its interaction with mental health: A mixed-methods longitudinal research programme","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2020-07-21T00:00:00+00:00","Sponsor(s)":"Prof Hilary Graham","Internal ID":"221021/Z/20/Z","description":"This Fellowship will explore the intersection of contemporary marginality, ethnicity and mental health through an integrative mixed methods study of the prevalence, causes, and lived experience of food insecurity in the UK.\n\nThe goals are to:\n\n\n understand variations in the prevalence and socio-demographic correlates of food insecurity, and its interaction with mental health, among UK ethnic groups\n understand how different ethnic groups conceptualise \u2018food insecurity\u2019 and how this shapes its interaction with their mental health\n understand ethnic variations in the lived experience of food insecurity, including food bank use, and its interaction with mental health\n theorise the nexus of marginality, ethnicity and health in post-industrial Britain\n provide a platform for mixed-methods, longitudinal analyses of food insecurity.\n\n\n\nThe Fellowship is composed of two interlinked studies, integrated within a new theoretical framework on contemporary marginality. Study 1 employs Qualitative Longitudinal Research methods (N=30) over two years to explore the experience of food insecurity, the contingent nature of ethnicity, and the interaction of food insecurity, ethnicity and mental health.\n\nStudy 2 will estimate the prevalence, socio-demographic correlates and mental health causes and consequences of food insecurity and food bank use among UK ethnic groups, using existing and commissioned national and local survey data.\n","plannedDates":[{"endDate":"2023-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2023-12-31"}],"amountAwarded":245971,"Financial Year":"2019/20","Lead Applicant":"Dr Madeleine Power","grantProgramme":[{"title":"Research Fellowship in H&SS","title_keyword":"Research Fellowship in H&SS"}],"Applicant Surname":"Power","Partnership Value":245971,"Approval Committee":"Social Science and Bioethics Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-York","name":"University of York","addressCountry":"United Kingdom","id_and_name":"[\"University of York\", \"360G-Wellcome-ORG:University-of-York\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-York","name":"University of York"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding ethnic variations in the prevalence and experience of food insecurity, and its interaction with mental health: A mixed-methods longitudinal research programme This Fellowship will explore the intersection of contemporary marginality, ethnicity and mental health through an integrative mixed methods study of the prevalence, causes, and lived experience of food insecurity in the UK.\n\nThe goals are to:\n\n\n understand variations in the prevalence and socio-demographic correlates of food insecurity, and its interaction with mental health, among UK ethnic groups\n understand how different ethnic groups conceptualise \u2018food insecurity\u2019 and how this shapes its interaction with their mental health\n understand ethnic variations in the lived experience of food insecurity, including food bank use, and its interaction with mental health\n theorise the nexus of marginality, ethnicity and health in post-industrial Britain\n provide a platform for mixed-methods, longitudinal analyses of food insecurity.\n\n\n\nThe Fellowship is composed of two interlinked studies, integrated within a new theoretical framework on contemporary marginality. Study 1 employs Qualitative Longitudinal Research methods (N=30) over two years to explore the experience of food insecurity, the contingent nature of ethnicity, and the interaction of food insecurity, ethnicity and mental health.\n\nStudy 2 will estimate the prevalence, socio-demographic correlates and mental health causes and consequences of food insecurity and food bank use among UK ethnic groups, using existing and commissioned national and local survey data.\n","awardDateDateOnly":"2020-07-21","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adult","Ethnic Groups","Female","Food Supply","Humans","Longitudinal Studies","Male","Mental Health","Middle Aged","Minority Groups","Prevalence","United Kingdom"]}
{"id":"360G-Wellcome-221013_Z_20_Z","title":"Serological studies to quantify SARS-CoV-2 population infection risk in Singapore, Hong Kong and Thailand","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221013/Z/20/Z","description":"We propose a prospective serological study to investigate the incidence of SARS-CoV-2 infection in the general population in three Asian settings: Singapore, Hong Kong and Thailand. The study will aim to measure the age-specific seroprevalence and incidence of SARS-CoV-2 infection at 3 time points, each 6 months apart. Age-specific incidence estimates will be applied to the census population to obtain numbers of infections in the population at each time point. These estimates will be compared with external data on COVID-19 hospitalisations and deaths in each setting, to calculate age-specific infection-hospitalisation and infection-fatality ratios. SARS-CoV-2 antibody kinetics will be defined by studying changes in antibody titres over time. Risk factors for infection will be studied by comparing SARS-CoV-2 seroconverters and non-seroconverters with respect to epidemiological exposures. This study will provide crucial information regarding population exposure and SARS-CoV-2 transmission dynamics, and will provide a complete picture of the relationship between clinically apparent and asymptomatic infections.\n","plannedDates":[{"endDate":"2022-07-31T00:00:00+00:00","startDate":"2020-08-01T00:00:00+00:00","startDateDateOnly":"2020-08-01","endDateDateOnly":"2022-07-31"}],"amountAwarded":399361,"Financial Year":"2019/20","Lead Applicant":"Dr Clarence Tam","grantProgramme":[{"title":"Coronavirus","title_keyword":"Coronavirus"}],"Partnership Name":"Wellcome-DFID Epidemic Preparedness","Applicant Surname":"Tam","Partnership Value":823390,"Approval Committee":"Epidemic Technical Advisory Panel","Other Applicant(s)":"Prof Benjamin Cowling, Dr Stefan Fernandez, Dr Chee Fu Yung, Dr Kathryn Anderson, Prof Lin-Fa Wang","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:National-University-of-Singapore","name":"National University of Singapore","addressCountry":"Singapore","id_and_name":"[\"National University of Singapore\", \"360G-Wellcome-ORG:National-University-of-Singapore\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:National-University-of-Singapore","name":"National University of Singapore"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Serological studies to quantify SARS-CoV-2 population infection risk in Singapore, Hong Kong and Thailand We propose a prospective serological study to investigate the incidence of SARS-CoV-2 infection in the general population in three Asian settings: Singapore, Hong Kong and Thailand. The study will aim to measure the age-specific seroprevalence and incidence of SARS-CoV-2 infection at 3 time points, each 6 months apart. Age-specific incidence estimates will be applied to the census population to obtain numbers of infections in the population at each time point. These estimates will be compared with external data on COVID-19 hospitalisations and deaths in each setting, to calculate age-specific infection-hospitalisation and infection-fatality ratios. SARS-CoV-2 antibody kinetics will be defined by studying changes in antibody titres over time. Risk factors for infection will be studied by comparing SARS-CoV-2 seroconverters and non-seroconverters with respect to epidemiological exposures. This study will provide crucial information regarding population exposure and SARS-CoV-2 transmission dynamics, and will provide a complete picture of the relationship between clinically apparent and asymptomatic infections.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adult","Asian Continental Ancestry Group","Female","Hong Kong","Humans","Incidence","Male","Middle Aged","Prospective Studies","Risk Factors","Seroepidemiologic Studies","Singapore","Thailand"]}
{"id":"360G-Wellcome-221012_Z_20_Z","title":"The African coaLition for Epidemic Research, Response and Training, Clinical Characterization Protocol (ALERRT CCP)","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221012/Z/20/Z","description":"As part of the response to the emergence of COVID-19, the World Health Organization Africa Regional Office is organizing various Infection Prevention and Control (IPC) and critical care training activities targeted at Low and Middle-Income countries (LMICs) in Africa. While the initiatives taken by WHO/AFRO are critical, training for research into the disease also needs to be targeted at the same LMICs, because being an Emerging Infectious Disease, we need to \"learn-as-we-go\". Clinical research on COVID-19 will have to be closely integrated with the IPC, clinical care, and epidemiological training activities, including use of the WHO First Few X (FFX) Cases and contact investigation protocol for COVID-19. ALERRT proposes to work closely with the WHO/AFRO and Africa CDC and existing networks and structures across Africa and globally to provide the fore-mentioned clinical research training and support. ALERRT is a member of the Global Federation - ISARIC, which has developed a Clinical Characterization protocol for COVID-19. This protocol been endorsed by the WHO and is currently being used in China and across the UK and Europe.Being already established and conducting activities in sub-Sahara Africa, the ALERRT network has the capacity to effectively implement the proposed project.\n","plannedDates":[{"endDate":"2022-08-12T00:00:00+00:00","startDate":"2020-08-13T00:00:00+00:00","startDateDateOnly":"2020-08-13","endDateDateOnly":"2022-08-12"}],"amountAwarded":1416424,"Financial Year":"2019/20","Lead Applicant":"Dr John Amuasi","grantProgramme":[{"title":"Coronavirus","title_keyword":"Coronavirus"}],"Partnership Name":"Wellcome-DFID Epidemic Preparedness","Applicant Surname":"Amuasi","Partnership Value":1416424,"Approval Committee":"Epidemic Technical Advisory Panel","Other Applicant(s)":"Dr Oumou Maiga-Ascofare, Dr Amadou Sall, Dr Tajudeen Raji, Dr Anani Badje, Dr Mathias Altmann, Dr Fabien Taieb, Dr Kenneth Baillie, Prof Peter Horby, Prof Souleymane Mboup","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kwame-Nkrumah-University-of-Science-and-Technology","name":"Kwame Nkrumah University of Science and Technology","addressCountry":"Ghana","id_and_name":"[\"Kwame Nkrumah University of Science and Technology\", \"360G-Wellcome-ORG:Kwame-Nkrumah-University-of-Science-and-Technology\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kwame-Nkrumah-University-of-Science-and-Technology","name":"Kwame Nkrumah University of Science and Technology"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The African coaLition for Epidemic Research, Response and Training, Clinical Characterization Protocol (ALERRT CCP) As part of the response to the emergence of COVID-19, the World Health Organization Africa Regional Office is organizing various Infection Prevention and Control (IPC) and critical care training activities targeted at Low and Middle-Income countries (LMICs) in Africa. While the initiatives taken by WHO/AFRO are critical, training for research into the disease also needs to be targeted at the same LMICs, because being an Emerging Infectious Disease, we need to \"learn-as-we-go\". Clinical research on COVID-19 will have to be closely integrated with the IPC, clinical care, and epidemiological training activities, including use of the WHO First Few X (FFX) Cases and contact investigation protocol for COVID-19. ALERRT proposes to work closely with the WHO/AFRO and Africa CDC and existing networks and structures across Africa and globally to provide the fore-mentioned clinical research training and support. ALERRT is a member of the Global Federation - ISARIC, which has developed a Clinical Characterization protocol for COVID-19. This protocol been endorsed by the WHO and is currently being used in China and across the UK and Europe.Being already established and conducting activities in sub-Sahara Africa, the ALERRT network has the capacity to effectively implement the proposed project.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa","Biomedical Research","China","Developing Countries","Humans","Infection Control","World Health Organization"]}
{"id":"360G-Wellcome-221003_Z_20_Z","title":"Characterization of SARS-CoV-2 transmission dynamics, clinical features and disease impact in South Africa, a setting with high HIV prevalence","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"221003/Z/20/Z","description":"Factors prevalent in Africa such as malnutrition, HIV, tuberculosis and limited access to healthcare, among others, may impact both transmission dynamics and disease progression associated with SARS-CoV-2 infection as well as the burden on the healthcare system and society.We aim to characterize key transmissibility and clinical features of and the antibody response to SARS-CoV-2 as well as to enhance surveillance for COVID-19, identify groups at increased risk of severe illness, estimate the disease burden of medically- and non-medically attended mild, severe-non-fatal and fatal illness and forecast the impact of the outbreak on the healthcare system and the society in South Africa. Particular emphasis will be given to HIV-infected individuals. The aims will be achieved through the implementation of shedding and household transmission studies, collection of sequential serum samples, enhanced facility-based (hospitals and clinics) surveillance among patients with mild and severerespiratory illness in well-established population-based surveillance sites where incidence can be calculated, and healthcare utilization and serological surveys in selected communities. In addition, digital surveillance (based on Google searches) will be used to complement virological surveillance and nowcasting and short-term forecasting (up to 4 weeks) will be implemented over the duration of the epidemic.\n","plannedDates":[{"endDate":"2022-06-30T00:00:00+00:00","startDate":"2020-07-01T00:00:00+00:00","startDateDateOnly":"2020-07-01","endDateDateOnly":"2022-06-30"}],"amountAwarded":2003681,"Financial Year":"2019/20","Lead Applicant":"Prof Cheryl Cohen","grantProgramme":[{"title":"Coronavirus","title_keyword":"Coronavirus"}],"Partnership Name":"Wellcome-DFID Epidemic Preparedness","Applicant Surname":"Cohen","Partnership Value":2003681,"Approval Committee":"Epidemic Technical Advisory Panel","Other Applicant(s)":"Prof Juliet Pulliam, Dr Jinal Bhiman, Prof Neil Martinson, Dr Cecile Viboud","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Wits-Health-Consortium-Pty-Ltd","name":"Wits Health Consortium (Pty) Ltd","addressCountry":"South Africa","id_and_name":"[\"Wits Health Consortium (Pty) Ltd\", \"360G-Wellcome-ORG:Wits-Health-Consortium-Pty-Ltd\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Wits-Health-Consortium-Pty-Ltd","name":"Wits Health Consortium (Pty) Ltd"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Characterization of SARS-CoV-2 transmission dynamics, clinical features and disease impact in South Africa, a setting with high HIV prevalence Factors prevalent in Africa such as malnutrition, HIV, tuberculosis and limited access to healthcare, among others, may impact both transmission dynamics and disease progression associated with SARS-CoV-2 infection as well as the burden on the healthcare system and society.We aim to characterize key transmissibility and clinical features of and the antibody response to SARS-CoV-2 as well as to enhance surveillance for COVID-19, identify groups at increased risk of severe illness, estimate the disease burden of medically- and non-medically attended mild, severe-non-fatal and fatal illness and forecast the impact of the outbreak on the healthcare system and the society in South Africa. Particular emphasis will be given to HIV-infected individuals. The aims will be achieved through the implementation of shedding and household transmission studies, collection of sequential serum samples, enhanced facility-based (hospitals and clinics) surveillance among patients with mild and severerespiratory illness in well-established population-based surveillance sites where incidence can be calculated, and healthcare utilization and serological surveys in selected communities. In addition, digital surveillance (based on Google searches) will be used to complement virological surveillance and nowcasting and short-term forecasting (up to 4 weeks) will be implemented over the duration of the epidemic.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Antibodies, Viral","Cost of Illness","Disease Outbreaks","HIV Infections","Humans","Incidence","Prevalence","South Africa"]}
{"id":"360G-Wellcome-220991_Z_20_Z","title":"Investigation of pre-existing immunity to coronaviruses; implications for immunopathology and pathophysiology of COVID-19 disease","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220991/Z/20/Z","description":"Background; It is unknown how prior exposure to commonly circulating human coronaviruses (HCoV) impacts immunity against highly-pathogenic species (SARS, SARS-CoV-2  &  MERS). There are limited data, across Europe, Asia and Africa, on the prevalence of infection and seroconversion against widely circulating and mildly symptomatic HCoVs (229E, NL63, OC43, and HKU1). There is a current supposition that antibody-dependent-enhancement (ADE) may play a role in the pathophysiology of COVID-19. ADE occurs when non-neutralizing antiviral proteins facilitate virus entry into host cells, leading to increased infectivity in the cells. In such cases, higher viremia has been measured and the clinical course of disease can be more severe. In preclinical animal models, immunopathology was observed after challenge following vaccination with some SARS vaccines. Therefore, concerns have been raised regarding the impact of immunopathology and ADE on prophylactic vaccination against SARS and possibly SARS-CoV-2.\n\nGoals: to perform detailed systems serology of pre-existing immunity, in children and adults, from the UK and Africa, towards novel and commonly circulating coronaviruses.\n\nImpact: These studies highlight the limited knowledge in the field and a need for a systematic approach to investigate cross-reactive humoral immunity against HCoV to  inform the immunopathology and pathophysiology of COVID-19.\n","plannedDates":[{"endDate":"2022-06-30T00:00:00+00:00","startDate":"2020-07-01T00:00:00+00:00","startDateDateOnly":"2020-07-01","endDateDateOnly":"2022-06-30"}],"amountAwarded":755818,"Financial Year":"2019/20","Lead Applicant":"Prof Teresa Lambe","grantProgramme":[{"title":"Coronavirus","title_keyword":"Coronavirus"}],"Partnership Name":"Wellcome-DFID Epidemic Preparedness","Applicant Surname":"Lambe","Partnership Value":1217834,"Approval Committee":"Epidemic Technical Advisory Panel","Other Applicant(s)":"Dr Jennifer Hill, Prof Adrian Hill, Prof Tandakha Dieye, Prof Katie Ewer, Dr Charles Agoti, Prof Andrew Pollard, Prof George Warimwe","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigation of pre-existing immunity to coronaviruses; implications for immunopathology and pathophysiology of COVID-19 disease Background; It is unknown how prior exposure to commonly circulating human coronaviruses (HCoV) impacts immunity against highly-pathogenic species (SARS, SARS-CoV-2  &  MERS). There are limited data, across Europe, Asia and Africa, on the prevalence of infection and seroconversion against widely circulating and mildly symptomatic HCoVs (229E, NL63, OC43, and HKU1). There is a current supposition that antibody-dependent-enhancement (ADE) may play a role in the pathophysiology of COVID-19. ADE occurs when non-neutralizing antiviral proteins facilitate virus entry into host cells, leading to increased infectivity in the cells. In such cases, higher viremia has been measured and the clinical course of disease can be more severe. In preclinical animal models, immunopathology was observed after challenge following vaccination with some SARS vaccines. Therefore, concerns have been raised regarding the impact of immunopathology and ADE on prophylactic vaccination against SARS and possibly SARS-CoV-2.\n\nGoals: to perform detailed systems serology of pre-existing immunity, in children and adults, from the UK and Africa, towards novel and commonly circulating coronaviruses.\n\nImpact: These studies highlight the limited knowledge in the field and a need for a systematic approach to investigate cross-reactive humoral immunity against HCoV to  inform the immunopathology and pathophysiology of COVID-19.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa","Animals","Antibodies, Viral","Coronavirus Infections","Cross Reactions","Humans","Immunity, Humoral","United Kingdom","Vaccination","Viral Vaccines"]}
{"id":"360G-Wellcome-220985_Z_20_Z","title":"COVID-19 Intervention Modelling for East Africa  (CIMEA)","Region":"West Midlands","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220985/Z/20/Z","description":"COVID-19 is a global threat to health, with many countries reporting extended outbreaks. To date 9 countries in Africa have recorded infection and it seems imminent that East Africa will have introductions and onward transmission. The SARS-CoV-2 virus (the aetiological agent of COVID-19) spreads rapidly (R0~2, serial interval about 1 week), and hence control will be difficult.  National plans for dealing with this public health emergency will benefit from predictions of the expected rate, distribution and extent of spread in countries throughout the region, and on the likely impact and feasibility of isolation and contact tracing interventions. We will support the emergency preparations through bespoke modelling, incorporating known demographic population structure, age-related contact patterns and existing mobile phone population movement data. In Uganda and Kenya we will collect epidemiological, genomic and behavioural data through health facility surveillance, household follow-up and contact studies to quantify uncertainties of SARS-CoV-2  virus epidemiology and contact patterns in well and unwell individuals. Results from the study will be rapidly communicated to the relevant authorities, and modelling code and analysis, and data including sequences, placed in the public domain in near real-time. This project could have lasting impact on the role of research in policy decisions.\n","plannedDates":[{"endDate":"2022-05-26T00:00:00+00:00","startDate":"2020-05-27T00:00:00+00:00","startDateDateOnly":"2020-05-27","endDateDateOnly":"2022-05-26"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Prof James Nokes","grantProgramme":[{"title":"Coronavirus","title_keyword":"Coronavirus"}],"Partnership Name":"Wellcome-DFID Epidemic Preparedness","Applicant Surname":"Nokes","Partnership Value":1030349,"Approval Committee":"Epidemic Technical Advisory Panel","Other Applicant(s)":"Prof Matthew Keeling, Prof Xavier Didelot, Dr George Githinji, Prof Matthew Cotten","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Warwick","name":"University of Warwick","addressCountry":"United Kingdom","id_and_name":"[\"University of Warwick\", \"360G-Wellcome-ORG:University-of-Warwick\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Warwick","name":"University of Warwick"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"COVID-19 Intervention Modelling for East Africa  (CIMEA) COVID-19 is a global threat to health, with many countries reporting extended outbreaks. To date 9 countries in Africa have recorded infection and it seems imminent that East Africa will have introductions and onward transmission. The SARS-CoV-2 virus (the aetiological agent of COVID-19) spreads rapidly (R0~2, serial interval about 1 week), and hence control will be difficult.  National plans for dealing with this public health emergency will benefit from predictions of the expected rate, distribution and extent of spread in countries throughout the region, and on the likely impact and feasibility of isolation and contact tracing interventions. We will support the emergency preparations through bespoke modelling, incorporating known demographic population structure, age-related contact patterns and existing mobile phone population movement data. In Uganda and Kenya we will collect epidemiological, genomic and behavioural data through health facility surveillance, household follow-up and contact studies to quantify uncertainties of SARS-CoV-2  virus epidemiology and contact patterns in well and unwell individuals. Results from the study will be rapidly communicated to the relevant authorities, and modelling code and analysis, and data including sequences, placed in the public domain in near real-time. This project could have lasting impact on the role of research in policy decisions.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adolescent","Adult","Africa","Cell Phone","Child","Disease Outbreaks","Epidemics","Female","Humans","Infant","Male","Middle Aged","Uganda","Young Adult"]}
{"id":"360G-Wellcome-220981_Z_20_Z","title":"A comprehensive study of immunopathogenesis of SARS-CoV-2 infection","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220981/Z/20/Z","description":"Since December 2019 the emergence of severe acute respiratory infections (COVID-19) in China, caused by the new coronavirus SARS-CoV-2, has posed a huge threat to global health with fatality rates up to 10% in elderly patients. Almost 100% of patients showed bilateral patchy shadows or ground glass opacity in their lungs by chest CT scans indicating acute lung injury (ALI). Therefore, understanding the underlying mechanism(s) of ALI induced by SARS-CoV-2 is very important to inform vaccine safety and immunotherapeutic strategies. In this proposal, we will investigate the host immune responses and their association with severity of ALI in patient samples and animal models. We will bring together a team of experts with complementary expertise including immunopathology in coronavirus infections, up-to-date lab technologies, and know-how to ensure the feasibility of this study with the following goals: \n1)    defining SARS-CoV-2 specific serum profiles (epitopes) using yeast display antigen library\n2)    determining antibody functions including antibody-dependent enhancement (ADE) vs neutralizing activities in vitro assays\n3)    studying T cell (CD4 and CD8) responses to whole SARS-CoV-2 genome\n4)    evaluating ALI in response to live SARS-CoV-2 infection with or without passive immunity (antibody or T cells) generated from vaccine candidates in a humanized mice model.\n","plannedDates":[{"endDate":"2022-05-04T00:00:00+00:00","startDate":"2020-05-05T00:00:00+00:00","startDateDateOnly":"2020-05-05","endDateDateOnly":"2022-05-04"}],"amountAwarded":864564,"Financial Year":"2019/20","Lead Applicant":"Prof Xiao-Ning Xu","grantProgramme":[{"title":"Coronavirus","title_keyword":"Coronavirus"}],"Partnership Name":"Wellcome-DFID Epidemic Preparedness","Applicant Surname":"Xu","Partnership Value":864564,"Approval Committee":"Epidemic Technical Advisory Panel","Other Applicant(s)":"Dr Nigel Temperton, Prof Kwok Yung Yuen, Prof Honglin Chen, Prof Zhiwei Chen, Dr Peter Kelleher, Prof Gavin Screaton","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A comprehensive study of immunopathogenesis of SARS-CoV-2 infection Since December 2019 the emergence of severe acute respiratory infections (COVID-19) in China, caused by the new coronavirus SARS-CoV-2, has posed a huge threat to global health with fatality rates up to 10% in elderly patients. Almost 100% of patients showed bilateral patchy shadows or ground glass opacity in their lungs by chest CT scans indicating acute lung injury (ALI). Therefore, understanding the underlying mechanism(s) of ALI induced by SARS-CoV-2 is very important to inform vaccine safety and immunotherapeutic strategies. In this proposal, we will investigate the host immune responses and their association with severity of ALI in patient samples and animal models. We will bring together a team of experts with complementary expertise including immunopathology in coronavirus infections, up-to-date lab technologies, and know-how to ensure the feasibility of this study with the following goals: \n1)    defining SARS-CoV-2 specific serum profiles (epitopes) using yeast display antigen library\n2)    determining antibody functions including antibody-dependent enhancement (ADE) vs neutralizing activities in vitro assays\n3)    studying T cell (CD4 and CD8) responses to whole SARS-CoV-2 genome\n4)    evaluating ALI in response to live SARS-CoV-2 infection with or without passive immunity (antibody or T cells) generated from vaccine candidates in a humanized mice model.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Antibodies, Neutralizing","Coronavirus Infections","Disease Models, Animal","Humans","Lung","Mice","Respiratory Tract Infections","SARS Virus","Severe Acute Respiratory Syndrome"]}
{"id":"360G-Wellcome-220977_Z_20_Z","title":"African COVID-19 Preparedness (AFRICO19)","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220977/Z/20/Z","description":"Our project, AFRICO19, will enhance capacity to understand SARS-CoV-2/hCoV-19 infection in three regions of Africa and globally. Building on existing infrastructures and collaborations we will create a network to share knowledge on next generation sequencing (NGS), including Oxford Nanopore Technology (MinION), coronavirus biology and COVID-19 disease control. Our consortium links three African sites combined with genomics and informatics support from the University of Glasgow to achieve the following key goals:\n1. Support East and West African capacities for rapid diagnosis and sequencing of SARS-CoV-2 to help with contact tracing and quarantine measures. Novel diagnostic tools optimized for this virus will be deployed. An African COVID-19 case definition will be refined using machine learning for identification of SARS-CoV-2 infections.\n2. Surveillance of SARS-CoV-2 will be performed in one cohort at each African site. This will use established cohorts to ensure that sampling begins quickly. A sampling plan optimized to detect initial moderate and severe cases followed by household contact tracing will be employed to obtain both mild to severe COVID-19 cases.\n3. Provide improved understanding of SARS-CoV-2 biology/evolution using machine learning and novel bioinformatics analyses. Our results will be shared via a real-time analysis platform using the newly developed CoV-GLUE resource.\n","plannedDates":[{"endDate":"2022-07-12T00:00:00+00:00","startDate":"2020-07-06T00:00:00+00:00","startDateDateOnly":"2020-07-06","endDateDateOnly":"2022-07-12"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Prof Matthew Cotten","grantProgramme":[{"title":"Coronavirus","title_keyword":"Coronavirus"}],"Partnership Name":"Wellcome-DFID Epidemic Preparedness","Applicant Surname":"Cotten","Partnership Value":646963,"Approval Committee":"Epidemic Technical Advisory Panel","Other Applicant(s)":"Prof David Robertson, Prof Martin Antonio, Prof James Nokes, Dr Ke Yuan","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"London School of Hygiene & Tropical Medicine\", \"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"African COVID-19 Preparedness (AFRICO19) Our project, AFRICO19, will enhance capacity to understand SARS-CoV-2/hCoV-19 infection in three regions of Africa and globally. Building on existing infrastructures and collaborations we will create a network to share knowledge on next generation sequencing (NGS), including Oxford Nanopore Technology (MinION), coronavirus biology and COVID-19 disease control. Our consortium links three African sites combined with genomics and informatics support from the University of Glasgow to achieve the following key goals:\n1. Support East and West African capacities for rapid diagnosis and sequencing of SARS-CoV-2 to help with contact tracing and quarantine measures. Novel diagnostic tools optimized for this virus will be deployed. An African COVID-19 case definition will be refined using machine learning for identification of SARS-CoV-2 infections.\n2. Surveillance of SARS-CoV-2 will be performed in one cohort at each African site. This will use established cohorts to ensure that sampling begins quickly. A sampling plan optimized to detect initial moderate and severe cases followed by household contact tracing will be employed to obtain both mild to severe COVID-19 cases.\n3. Provide improved understanding of SARS-CoV-2 biology/evolution using machine learning and novel bioinformatics analyses. Our results will be shared via a real-time analysis platform using the newly developed CoV-GLUE resource.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa","Computational Biology","Coronavirus Infections","High-Throughput Nucleotide Sequencing","Humans","Machine Learning"]}
{"id":"360G-Wellcome-220960_Z_20_Z","title":"Wellcome Leap Inc. \u2013 Interim award","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220960/Z/20/Z","description":"In early February 2020 Wellcome\u2019s BoG approved the appointment of Regina Dugan as CEO of the Wellcome Leap Fund (WLF), the relocation of the WLF\u2019s primary place of business to the U.S. and the creation of a U.S. not-for-profit entity within the Wellcome group (Leap US). This grant is a mobilisation fund to support the initial activities required for Leap US\u2019 set up and strategy development, prior to the awarding of full grant which will be administered upon BoG approving the CEO\u2019s strategy and business plan for the WLF.    ","plannedDates":[{"endDate":"2021-03-30T00:00:00+00:00","startDate":"2020-03-30T00:00:00+00:00","startDateDateOnly":"2020-03-30","endDateDateOnly":"2021-03-30"}],"amountAwarded":782901,"Financial Year":"2019/20","Lead Applicant":"Dr Regina Dugan","grantProgramme":[{"title":"Wellcome Leap Inc. ","title_keyword":"Wellcome Leap Inc. "}],"Applicant Surname":"Dugan","Partnership Value":782901,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Wellcome-Leap-Inc","name":"Wellcome Leap Inc.","addressCountry":"United States","id_and_name":"[\"Wellcome Leap Inc.\", \"360G-Wellcome-ORG:Wellcome-Leap-Inc\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Wellcome-Leap-Inc","name":"Wellcome Leap Inc."}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Wellcome Leap Inc. \u2013 Interim award In early February 2020 Wellcome\u2019s BoG approved the appointment of Regina Dugan as CEO of the Wellcome Leap Fund (WLF), the relocation of the WLF\u2019s primary place of business to the U.S. and the creation of a U.S. not-for-profit entity within the Wellcome group (Leap US). This grant is a mobilisation fund to support the initial activities required for Leap US\u2019 set up and strategy development, prior to the awarding of full grant which will be administered upon BoG approving the CEO\u2019s strategy and business plan for the WLF.    ","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","United States"]}
{"id":"360G-Wellcome-220953_Z_20_Z","title":"IHCC Development of 2020 Scientific Strategy and Long-term Plan","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220953/Z/20/Z","description":" \n\n\n \n  \n   \n   This proposal is for partial funding of the IHCC as it transitions from a nascent organization to a mature and sustainable one.  The IHCC\u2019s inaugural summit was funded by the Wellcome Trust, the NIH, and the Medical Research Council of the UK. Since, the NIH has provided support for both administration of the IHCC, its second and third summit and pilot work on the Atlas and scientific projects.  The funding period from June 2020-2021 will be one of organizational maturing, strategic planning, demonstration of feasibility of prioritized cross cohort projects and the development of a business plan. Funding from new industry members and from HIROs is anticipated for growth and sustainability.  The Wellcome Trusts\u2019 investment will be highly levered with NIH\u2019s investment and is key to allowing the IHCC to launch itself with a robust charter and organizational structure, a scientific plan an Atlas and data structure that will make the IHCC\u2019s assets accessible. Deliverables from this funding will be a) a strategic plan, b) a 4th ICS, c) completion of 3-5 pilot cross- cohort demonstration projects, and d) a compendium of opportunities for research across the globe, and e) formal engagement of funders toward a sustainable funding model.\n\n    \n   \n  \n \n\n","plannedDates":[{"endDate":"2021-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2021-09-30"}],"amountAwarded":399144,"Financial Year":"2019/20","Lead Applicant":"Prof Geoffrey Ginsburg","grantProgramme":[{"title":"Strategic Support: Science","title_keyword":"Strategic Support: Science"}],"Applicant Surname":"Ginsburg","Partnership Value":399144,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Global-Genomic-Medicine-Collaborative-G2MC","name":"Global Genomic Medicine Collaborative (G2MC)","addressCountry":"United States","id_and_name":"[\"Global Genomic Medicine Collaborative (G2MC)\", \"360G-Wellcome-ORG:Global-Genomic-Medicine-Collaborative-G2MC\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Global-Genomic-Medicine-Collaborative-G2MC","name":"Global Genomic Medicine Collaborative (G2MC)"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"IHCC Development of 2020 Scientific Strategy and Long-term Plan  \n\n\n \n  \n   \n   This proposal is for partial funding of the IHCC as it transitions from a nascent organization to a mature and sustainable one.  The IHCC\u2019s inaugural summit was funded by the Wellcome Trust, the NIH, and the Medical Research Council of the UK. Since, the NIH has provided support for both administration of the IHCC, its second and third summit and pilot work on the Atlas and scientific projects.  The funding period from June 2020-2021 will be one of organizational maturing, strategic planning, demonstration of feasibility of prioritized cross cohort projects and the development of a business plan. Funding from new industry members and from HIROs is anticipated for growth and sustainability.  The Wellcome Trusts\u2019 investment will be highly levered with NIH\u2019s investment and is key to allowing the IHCC to launch itself with a robust charter and organizational structure, a scientific plan an Atlas and data structure that will make the IHCC\u2019s assets accessible. Deliverables from this funding will be a) a strategic plan, b) a 4th ICS, c) completion of 3-5 pilot cross- cohort demonstration projects, and d) a compendium of opportunities for research across the globe, and e) formal engagement of funders toward a sustainable funding model.\n\n    \n   \n  \n \n\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Financial Management","Financing, Organized","Humans","Research Support as Topic","United Kingdom"]}
{"id":"360G-Wellcome-220949_Z_20_Z","title":"Core costs grant","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220949/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2020-06-19T00:00:00+00:00","startDate":"2020-03-19T00:00:00+00:00","startDateDateOnly":"2020-03-19","endDateDateOnly":"2020-06-19"}],"amountAwarded":50000,"Financial Year":"2019/20","Lead Applicant":"Ms Lauren Roberts","grantProgramme":[{"title":"Discretionary Award \u2013 Directorate","title_keyword":"Discretionary Award \u2013 Directorate"}],"Applicant Surname":"Roberts","Partnership Value":50000,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Jayne Spink","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Genetic-Alliance-UK","name":"Genetic Alliance UK","addressCountry":"United Kingdom","id_and_name":"[\"Genetic Alliance UK\", \"360G-Wellcome-ORG:Genetic-Alliance-UK\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Genetic-Alliance-UK","name":"Genetic Alliance UK"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Core costs grant Not available","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","United States"]}
{"id":"360G-Wellcome-220948_Z_20_Z","title":"Healthy Minds and Active Bodies: the promotion of health and wellbeing by UK youth movements","Region":"West Midlands","currency":"GBP","awardDate":"2020-05-14T00:00:00+00:00","Internal ID":"220948/Z/20/Z","description":"This 24-month project focuses on cataloguing and preserving the archives of two influential youth movements:\n\n\n The Young Men\u2019s Christian Association (YMCA)\n The Youth Hostels Association (YHA)\n\n\n\nBoth archives are held at the Cadbury Research Library, University of Birmingham.\n\nHealth and welfare of young people are guiding principles of these charities. Since their creation, both organisations have focused their activities on improving the mental and physical health of young people, with emphasis on working with those from disadvantaged backgrounds.\n\nThe YMCA archive comprises 978 boxes and the YHA archive comprises 405 boxes; all of which require detailed cataloguing in order to realise their full research potential. Both collections include minutes, reports, publications, photographs and ephemera. Material documents the work of both charities in improving young people\u2019s physical health, mental wellbeing, and general fitness.\n\nThe outcome of this project will be two fully searchable electronic catalogues which will enable access and reveal the full research potential of these internationally significant collections.\n\nEngagement activities with academics, researchers, students and members of the public will ensure that the collections are visible across a broad range of audiences.\n","plannedDates":[{"endDate":"2023-01-03T00:00:00+00:00","startDate":"2021-01-04T00:00:00+00:00","startDateDateOnly":"2021-01-04","endDateDateOnly":"2023-01-03"}],"amountAwarded":236339,"Financial Year":"2019/20","Lead Applicant":"Mr Mark Eccleston","grantProgramme":[{"title":"Research Resources Award","title_keyword":"Research Resources Award"}],"Applicant Surname":"Eccleston","Partnership Value":236339,"Approval Committee":"Research Resources Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Birmingham\", \"360G-Wellcome-ORG:University-of-Birmingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Healthy Minds and Active Bodies: the promotion of health and wellbeing by UK youth movements This 24-month project focuses on cataloguing and preserving the archives of two influential youth movements:\n\n\n The Young Men\u2019s Christian Association (YMCA)\n The Youth Hostels Association (YHA)\n\n\n\nBoth archives are held at the Cadbury Research Library, University of Birmingham.\n\nHealth and welfare of young people are guiding principles of these charities. Since their creation, both organisations have focused their activities on improving the mental and physical health of young people, with emphasis on working with those from disadvantaged backgrounds.\n\nThe YMCA archive comprises 978 boxes and the YHA archive comprises 405 boxes; all of which require detailed cataloguing in order to realise their full research potential. Both collections include minutes, reports, publications, photographs and ephemera. Material documents the work of both charities in improving young people\u2019s physical health, mental wellbeing, and general fitness.\n\nThe outcome of this project will be two fully searchable electronic catalogues which will enable access and reveal the full research potential of these internationally significant collections.\n\nEngagement activities with academics, researchers, students and members of the public will ensure that the collections are visible across a broad range of audiences.\n","awardDateDateOnly":"2020-05-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adolescent","Health Promotion","Humans","Male","Mental Health","United Kingdom","Young Adult"]}
{"id":"360G-Wellcome-220906_Z_20_Z","title":"Preventable axon degeneration in human disease","Region":"East of England","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220906/Z/20/Z","description":"Programmed axon degeneration (or Wallerian degeneration; WD) is a preventable and druggable mechanism of axon loss. WD is well-characterised in animals and highly conserved. Blocking WD alleviates axon loss and symptoms in multiple disease models, suggesting a common, downstream mechanism. Human data are essential to confirm the role of WD in specific human diseases, ensuring drugs under development are tested in highly-relevant disorders and patients. We reported mutations in rare human axonopathies that aberrantly activate WD, and lifelong rescue of a related mouse model. Our programme determines the wider involvement of WD in rare and common human disorders, specifically peripheral neuropathies and ALS, where axon degeneration is important. We use online resources (100,000 Genomes, Project MinE, UK Biobank, etc.) and targeted sequencing of well-phenotyped cohorts and test roles of gene variants in causation, risk and severity. We determine their functional impact using complementary human iPSC and mouse modelling and develop specific biomarkers of WD for clinical samples. This project will provide insight into pathogenic mechanisms and a firm platform for developing and testing therapeutics. Our team, a world leader in Wallerian degeneration and leading neurogeneticists in rare and common neuropathies and human iPSC modelling, is uniquely placed to deliver this.\n \n","plannedDates":[{"endDate":"2026-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2026-03-31"}],"amountAwarded":3640891,"Financial Year":"2019/20","Lead Applicant":"Prof Michael Coleman","grantProgramme":[{"title":"Collaborative Award in Science","title_keyword":"Collaborative Award in Science"}],"Applicant Surname":"Coleman","Partnership Value":3640891,"Approval Committee":"Science Interview Panel","Other Applicant(s)":"Prof Mary Reilly, Prof David Bennett, Prof Ahmet Hoke","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Preventable axon degeneration in human disease Programmed axon degeneration (or Wallerian degeneration; WD) is a preventable and druggable mechanism of axon loss. WD is well-characterised in animals and highly conserved. Blocking WD alleviates axon loss and symptoms in multiple disease models, suggesting a common, downstream mechanism. Human data are essential to confirm the role of WD in specific human diseases, ensuring drugs under development are tested in highly-relevant disorders and patients. We reported mutations in rare human axonopathies that aberrantly activate WD, and lifelong rescue of a related mouse model. Our programme determines the wider involvement of WD in rare and common human disorders, specifically peripheral neuropathies and ALS, where axon degeneration is important. We use online resources (100,000 Genomes, Project MinE, UK Biobank, etc.) and targeted sequencing of well-phenotyped cohorts and test roles of gene variants in causation, risk and severity. We determine their functional impact using complementary human iPSC and mouse modelling and develop specific biomarkers of WD for clinical samples. This project will provide insight into pathogenic mechanisms and a firm platform for developing and testing therapeutics. Our team, a world leader in Wallerian degeneration and leading neurogeneticists in rare and common neuropathies and human iPSC modelling, is uniquely placed to deliver this.\n \n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Amyotrophic Lateral Sclerosis","Animals","Axons","Disease Models, Animal","Humans","Induced Pluripotent Stem Cells","Mice","Mutation","Nerve Degeneration"]}
{"id":"360G-Wellcome-220900_Z_20_Z","title":"Informing strategies for malaria eradication: a combined epidemiological and economics approach","Region":"Greater London","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220900/Z/20/Z","description":"The last decade has witnessed substantial declines in the global burden of malaria; however, in recent years progress has stalled. We aim to combine a mathematical modelling framework with economic analyses to gain insight into the optimal global, regional and country strategies to achieve the ultimate aim of malaria eradication. Specifically:\n\n\n What is the optimal strategy to achieve malaria eradication? Should resources initially focus on high burden countries, elimination countries or a balance between these? How does this change as burden and transmission decline? How do competing aims in the short-term (e.g. the need to reduce morbidity and mortality) hamper achieving longer-term eradication aims?\n What is the trade-off between country priorities and regional and global strategies? How do competing national priorities determine regional and global success? What degree of international cooperation is needed and at what scale? What are the economic benefits and costs of co-operation to countries?\n How are strategies influenced by the wider political economy? How do competing priorities influencing national decision makers impact wider eradication efforts? How does weak governance and political constraints in national and international decision-making reduce the effectiveness of strategies?\n\n","plannedDates":[{"endDate":"2025-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2025-12-31"}],"amountAwarded":1409484,"Financial Year":"2019/20","Lead Applicant":"Prof Azra Ghani","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Ghani","Partnership Value":1409484,"Approval Committee":"Science Interview Panel","Other Applicant(s)":"Dr Katharina Hauck","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Informing strategies for malaria eradication: a combined epidemiological and economics approach The last decade has witnessed substantial declines in the global burden of malaria; however, in recent years progress has stalled. We aim to combine a mathematical modelling framework with economic analyses to gain insight into the optimal global, regional and country strategies to achieve the ultimate aim of malaria eradication. Specifically:\n\n\n What is the optimal strategy to achieve malaria eradication? Should resources initially focus on high burden countries, elimination countries or a balance between these? How does this change as burden and transmission decline? How do competing aims in the short-term (e.g. the need to reduce morbidity and mortality) hamper achieving longer-term eradication aims?\n What is the trade-off between country priorities and regional and global strategies? How do competing national priorities determine regional and global success? What degree of international cooperation is needed and at what scale? What are the economic benefits and costs of co-operation to countries?\n How are strategies influenced by the wider political economy? How do competing priorities influencing national decision makers impact wider eradication efforts? How does weak governance and political constraints in national and international decision-making reduce the effectiveness of strategies?\n\n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Disease Eradication","Global Health","Humans","Malaria","Models, Theoretical"]}
{"id":"360G-Wellcome-220895_Z_20_Z","title":"Lymphatic biology in kidney development, health and disease","Region":"Greater London","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220895/Z/20/Z","description":"The lymphatic vasculature is essential for health in vertebrates. Alongside roles in tissue fluid balance, cholesterol transport and immunomodulation, lymphatic vessels possess remarkable organotypicity, which underpins organ-specific lymphatic functions during embryonic development, health and disease.\n \nUsing the mammalian kidney as a model system, I will study two concepts responsible for the organotypicity of lymphatics: the cellular sources of lymphatic endothelial cells and molecular crosstalk between lymphatics and epithelia, a paradigm that may be applicable to other organs like lung and gut. I will focus on these processes in embryonic development, health and polycystic kidney disease (PKD); the most common genetic renal disorder, which features dysfunctional lymphatics. I will use several emerging technologies including high-resolution three-dimensional imaging, single-cell RNA sequencing, novel in vivo imaging modalities, targeted kidney delivery of therapeutics and computational modelling.\n\nThe insights arising from these experiments in this Investigator Award will enhance our understanding of lymphatic biology in kidney development, physiology and disease; areas in which the contribution of lymphatics is poorly understood. The findings will provide new directions and tools for understanding and manipulating lymphatic function in organogenesis, health and multiple disease processes.\n","plannedDates":[{"endDate":"2025-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2025-08-31"}],"amountAwarded":1555838,"Financial Year":"2019/20","Lead Applicant":"Prof David Long","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Long","Partnership Value":1555838,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Lymphatic biology in kidney development, health and disease The lymphatic vasculature is essential for health in vertebrates. Alongside roles in tissue fluid balance, cholesterol transport and immunomodulation, lymphatic vessels possess remarkable organotypicity, which underpins organ-specific lymphatic functions during embryonic development, health and disease.\n \nUsing the mammalian kidney as a model system, I will study two concepts responsible for the organotypicity of lymphatics: the cellular sources of lymphatic endothelial cells and molecular crosstalk between lymphatics and epithelia, a paradigm that may be applicable to other organs like lung and gut. I will focus on these processes in embryonic development, health and polycystic kidney disease (PKD); the most common genetic renal disorder, which features dysfunctional lymphatics. I will use several emerging technologies including high-resolution three-dimensional imaging, single-cell RNA sequencing, novel in vivo imaging modalities, targeted kidney delivery of therapeutics and computational modelling.\n\nThe insights arising from these experiments in this Investigator Award will enhance our understanding of lymphatic biology in kidney development, physiology and disease; areas in which the contribution of lymphatics is poorly understood. The findings will provide new directions and tools for understanding and manipulating lymphatic function in organogenesis, health and multiple disease processes.\n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Humans","Kidney","Lymph","Lymphatic Vessels","Mice","Organogenesis","Organoids","Single-Cell Analysis"]}
{"id":"360G-Wellcome-220887_Z_20_Z","title":"Rhomboid-like proteins: from molecular principles to pathophysiological significance","Region":"South East","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220887/Z/20/Z","description":"The goal of this proposal is to transform our understanding of both the molecular mechanisms and the pathophysiological roles of members of the rhomboid-like superfamily. At the mechanistic level, our long-term research into this group of polytopic membrane proteins has led us to the hypothesis that the core function of the rhomboid-like domain is specific TMD recognition of substrates (of the rhomboid intramembrane serine proteases) and clients (of the non-protease members of the clan). Using a structural and biochemical approach, we seek to understand the molecular details of how this specific recognition is achieved. \n\nBiologically, rhomboid-like proteins have many functions, but we still have little understanding of their role in mammals, particularly of the rhomboid proteases. Building on our mechanistic aims, we plan to break this log-jam by pioneering systematic methods of substrate identification. We already know that iRhoms, catalytically inactive homologues of rhomboids, regulate inflammation, growth factor signalling and, as we have recently discovered, tumour growth. We plan to further elucidate these roles, both at the level of fundamental cell biology but also with a goal to reveal their potential medical significance. By the end of this work we expect to know which rhomboid-like proteins are useful therapeutic targets.\n","plannedDates":[{"endDate":"2026-01-31T00:00:00+00:00","startDate":"2021-02-01T00:00:00+00:00","startDateDateOnly":"2021-02-01","endDateDateOnly":"2026-01-31"}],"amountAwarded":2276736,"Financial Year":"2019/20","Lead Applicant":"Prof Matthew Freeman","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Freeman","Partnership Value":2276736,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Rhomboid-like proteins: from molecular principles to pathophysiological significance The goal of this proposal is to transform our understanding of both the molecular mechanisms and the pathophysiological roles of members of the rhomboid-like superfamily. At the mechanistic level, our long-term research into this group of polytopic membrane proteins has led us to the hypothesis that the core function of the rhomboid-like domain is specific TMD recognition of substrates (of the rhomboid intramembrane serine proteases) and clients (of the non-protease members of the clan). Using a structural and biochemical approach, we seek to understand the molecular details of how this specific recognition is achieved. \n\nBiologically, rhomboid-like proteins have many functions, but we still have little understanding of their role in mammals, particularly of the rhomboid proteases. Building on our mechanistic aims, we plan to break this log-jam by pioneering systematic methods of substrate identification. We already know that iRhoms, catalytically inactive homologues of rhomboids, regulate inflammation, growth factor signalling and, as we have recently discovered, tumour growth. We plan to further elucidate these roles, both at the level of fundamental cell biology but also with a goal to reveal their potential medical significance. By the end of this work we expect to know which rhomboid-like proteins are useful therapeutic targets.\n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cell Membrane","Humans","Inflammation","Serine Endopeptidases","Signal Transduction","Substrate Specificity"]}
{"id":"360G-Wellcome-220886_Z_20_Z","title":"The development of neural circuits for episodic and general memories","Region":"Greater London","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220886/Z/20/Z","description":"This proposal aims to understand how neural networks for memory emerge during post-natal development, both during normal development and following early-life brain damage.\n\nEpisodic memories (memories of events and their spatio-temporal context), and generalised learning such as semantic memories (factual world-knowledge) are supported by different brain networks. Episodic memories are thought to be encoded initially by the hippocampus, whilst general knowledge would be extracted by integrating across experiences via hippocampus-neocortical interactions.\n\nHowever, the ontogenetic unfolding of memory runs counter to this framework. Early development is characterised by the rapid acquisition of general knowledge, despite amnesia for specific events. Furthermore, sustaining early-life hippocampal damage results in dense amnesia for specific episodes, but general learning is relatively preserved.\n\nWe aim to resolve this apparent paradox by studying neural circuit activity in vivo, in conjunction with behaviour, in developing rodents.\n\nOur goals are to:\n\n1) Understand the development of hippocampal mechanisms supporting the generation of memory traces of specific events;\n\n2) Understand the neural mechanisms that enable the association of items with their spatio-temporal context (episodic memory processing);\n\n3) Discover how neural coding for generalised knowledge emerges across cortical-hippocampal networks during normal development, and identify networks supporting preserved learning after early-life hippocampal damage.\n","plannedDates":[{"endDate":"2025-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2025-08-31"}],"amountAwarded":1636956,"Financial Year":"2019/20","Lead Applicant":"Dr Thomas Wills","grantProgramme":[{"title":"Senior Research Fellowship","title_keyword":"Senior Research Fellowship"}],"Applicant Surname":"Wills","Partnership Value":1636956,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The development of neural circuits for episodic and general memories This proposal aims to understand how neural networks for memory emerge during post-natal development, both during normal development and following early-life brain damage.\n\nEpisodic memories (memories of events and their spatio-temporal context), and generalised learning such as semantic memories (factual world-knowledge) are supported by different brain networks. Episodic memories are thought to be encoded initially by the hippocampus, whilst general knowledge would be extracted by integrating across experiences via hippocampus-neocortical interactions.\n\nHowever, the ontogenetic unfolding of memory runs counter to this framework. Early development is characterised by the rapid acquisition of general knowledge, despite amnesia for specific events. Furthermore, sustaining early-life hippocampal damage results in dense amnesia for specific episodes, but general learning is relatively preserved.\n\nWe aim to resolve this apparent paradox by studying neural circuit activity in vivo, in conjunction with behaviour, in developing rodents.\n\nOur goals are to:\n\n1) Understand the development of hippocampal mechanisms supporting the generation of memory traces of specific events;\n\n2) Understand the neural mechanisms that enable the association of items with their spatio-temporal context (episodic memory processing);\n\n3) Discover how neural coding for generalised knowledge emerges across cortical-hippocampal networks during normal development, and identify networks supporting preserved learning after early-life hippocampal damage.\n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Amnesia","Animals","Hippocampus","Learning","Memory","Memory, Episodic","Nerve Net","Rats, Long-Evans"]}
{"id":"360G-Wellcome-220885_Z_20_Z","title":"Population genomic analysis of HIV transmission fitness","Region":"Greater London","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220885/Z/20/Z","description":"This proposal concerns the identification of genetic polymorphisms which alter the fitness of Human Immunodeficiency Virus (HIV-1), the robust estimation of virus fitness, and the characterization of how polymorphisms influence replicative fitness within hosts versus transmission to new hosts. \n\nHIV evolves to evade the immune system, resist antiviral medications, and maximize its rate of replication within infected hosts. But at the epidemic level, natural selection promotes evolution of variants which are more transmissible. Natural selection within and between hosts can act in opposing directions, and evolutionary trends have been discerned from population based sampling of HIV such as a hypothetical transmission/virulence tradeoff.  Because HIV evolves at multiple scales, the fitness of a particular polymorphism should be characterized along multiple dimensions including its impact on replication within hosts and transmission to new hosts. We will develop a framework for characterizing genetic fitness along multiple dimensions by building on theory developed for estimating state-dependent speciation rates. These methods will be applied to several large population-based samples of whole-genome deep sequencing (WGDS) of HIV. The outcome of this analysis will be an unprecedentedly detailed characterization of how particular genetic substitutions influence HIV pathogenesis and transmission at the epidemic level. \n \n","plannedDates":[{"endDate":"2023-10-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2023-10-31"}],"amountAwarded":654391,"Financial Year":"2019/20","Lead Applicant":"Dr Erik Volz","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Volz","Partnership Value":654391,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Population genomic analysis of HIV transmission fitness This proposal concerns the identification of genetic polymorphisms which alter the fitness of Human Immunodeficiency Virus (HIV-1), the robust estimation of virus fitness, and the characterization of how polymorphisms influence replicative fitness within hosts versus transmission to new hosts. \n\nHIV evolves to evade the immune system, resist antiviral medications, and maximize its rate of replication within infected hosts. But at the epidemic level, natural selection promotes evolution of variants which are more transmissible. Natural selection within and between hosts can act in opposing directions, and evolutionary trends have been discerned from population based sampling of HIV such as a hypothetical transmission/virulence tradeoff.  Because HIV evolves at multiple scales, the fitness of a particular polymorphism should be characterized along multiple dimensions including its impact on replication within hosts and transmission to new hosts. We will develop a framework for characterizing genetic fitness along multiple dimensions by building on theory developed for estimating state-dependent speciation rates. These methods will be applied to several large population-based samples of whole-genome deep sequencing (WGDS) of HIV. The outcome of this analysis will be an unprecedentedly detailed characterization of how particular genetic substitutions influence HIV pathogenesis and transmission at the epidemic level. \n \n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Evolution, Molecular","HIV Infections","HIV-1","High-Throughput Nucleotide Sequencing","Humans","Models, Genetic","Polymorphism, Genetic","Selection, Genetic","Virus Replication"]}
{"id":"360G-Wellcome-220876_Z_20_Z","title":"Deciphering Bifidobacterium-diet-immune interactions in global infant populations ","Region":"International","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220876/Z/20/Z","description":"\u2018First contact\u2019 between Bifidobacterium and their infant host represents a critical developmental window.\n\nOur studies show that supplementation with Bifidobacterium isolates that metabolize breastmilk positively influences the preterm infant microbiota. We have also shown that: full-term infants have mini-bifidobacterial ecosystems that form dietary (breastmilk) cross-feeding networks; that geographically-separated infants harbour Bifidobacterium isolates with key differences in genomic content, and that particular Bifidobacterium genetic variants drive beneficial immune programming.\n\nBuilding on our established findings and preliminary data, bringing together global maternal-infant cohort samples and using integrated multi-disciplinary approaches, we will:\n\n\n Genetically characterise geographically distinct intra- and inter-infant Bifidobacterium populations\n Profile geographically divergent maternal breastmilk samples, link them to genetic and phenotypic variation in Bifidobacterium, and define novel breastmilk metabolism pathways.\n Determine how different Bifidobacterium communities influence immune responses, and how this relates to vaccine-related immunity.\n\n\nWe will significantly expand our fundamental knowledge by elucidating how Bifidobacterium species and genetic variants co-operate within an early-life diet (breastmilk) environment and define \u2018signatures\u2019 across different geographical regions. In a direct link to infant health, we will probe how these communities alter immune system development and vaccination responses. A fundamental understanding of these features will allow selection of Bifidobacterium-communities for next-stage translational projects.\n","plannedDates":[{"endDate":"2026-07-25T00:00:00+00:00","startDate":"2021-07-26T00:00:00+00:00","startDateDateOnly":"2021-07-26","endDateDateOnly":"2026-07-25"}],"amountAwarded":1666180,"Financial Year":"2019/20","Lead Applicant":"Dr Lindsay Hall","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Hall","Partnership Value":1666180,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Technical-University-of-Munich","name":"Technical University of Munich","addressCountry":"Germany","id_and_name":"[\"Technical University of Munich\", \"360G-Wellcome-ORG:Technical-University-of-Munich\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Technical-University-of-Munich","name":"Technical University of Munich"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Deciphering Bifidobacterium-diet-immune interactions in global infant populations  \u2018First contact\u2019 between Bifidobacterium and their infant host represents a critical developmental window.\n\nOur studies show that supplementation with Bifidobacterium isolates that metabolize breastmilk positively influences the preterm infant microbiota. We have also shown that: full-term infants have mini-bifidobacterial ecosystems that form dietary (breastmilk) cross-feeding networks; that geographically-separated infants harbour Bifidobacterium isolates with key differences in genomic content, and that particular Bifidobacterium genetic variants drive beneficial immune programming.\n\nBuilding on our established findings and preliminary data, bringing together global maternal-infant cohort samples and using integrated multi-disciplinary approaches, we will:\n\n\n Genetically characterise geographically distinct intra- and inter-infant Bifidobacterium populations\n Profile geographically divergent maternal breastmilk samples, link them to genetic and phenotypic variation in Bifidobacterium, and define novel breastmilk metabolism pathways.\n Determine how different Bifidobacterium communities influence immune responses, and how this relates to vaccine-related immunity.\n\n\nWe will significantly expand our fundamental knowledge by elucidating how Bifidobacterium species and genetic variants co-operate within an early-life diet (breastmilk) environment and define \u2018signatures\u2019 across different geographical regions. In a direct link to infant health, we will probe how these communities alter immune system development and vaccination responses. A fundamental understanding of these features will allow selection of Bifidobacterium-communities for next-stage translational projects.\n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Bifidobacterium","Breast Feeding","Diet","Female","Gastrointestinal Microbiome","Genetic Variation","Humans","Infant","Infant, Newborn","Milk, Human"]}
{"id":"360G-Wellcome-220875_Z_20_Z","title":"Defining \u2018clinically actionable\u2019 genetic mechanisms in atopic eczema risk and resolution","Region":"Scotland","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220875/Z/20/Z","description":"Atopic eczema is an itchy condition characterised by skin barrier dysfunction and inflammation. It frequently causes chronic morbidity, but a subset of cases enter long-term remission, demonstrating that resolution may be a tractable therapeutic aim.\nEczema is highly heritable. Null mutations in FLG are the strongest genetic risk and a locus on chr11q13.5, for which the nearest gene is EMSY, has a multiplicative effect. We have shown that EMSY is a transcriptional regulator in skin, controlling multiple aspect of barrier formation.\nWe will investigate molecular mechanisms at these two major risk loci: chr1q21.3 (FLG, FLG-AS1 and related genes) and chr11q13.5 (EMSY and LRRC32), aiming to define pathways contributing to eczema resolution. Findings will be tested in a well-characterised birth cohort (ALSPAC), to confirm clinical relevance.\nAnalyses of European cohorts (n > 25,000) show evidence of gene-environment interactions in eczema, but these findings require validation. We will use an optimised skin organoid model to investigate three environmental factors (tobacco smoke, wash-products and pet allergens) for which there is evidence of interaction with FLG genotype. Detailed functional and biochemical phenotyping will increase understanding of gene-environment interactions.\nThis work will inform eczema prevention strategies and characterise mechanisms contributing to eczema resolution, as future therapeutic targets.\n","plannedDates":[{"endDate":"2025-10-31T00:00:00+00:00","startDate":"2020-11-01T00:00:00+00:00","startDateDateOnly":"2020-11-01","endDateDateOnly":"2025-10-31"}],"amountAwarded":2258810,"Financial Year":"2019/20","Lead Applicant":"Prof Sara Brown","grantProgramme":[{"title":"Senior Research Fellowship Renewal","title_keyword":"Senior Research Fellowship Renewal"}],"Applicant Surname":"Brown","Partnership Value":2258810,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Defining \u2018clinically actionable\u2019 genetic mechanisms in atopic eczema risk and resolution Atopic eczema is an itchy condition characterised by skin barrier dysfunction and inflammation. It frequently causes chronic morbidity, but a subset of cases enter long-term remission, demonstrating that resolution may be a tractable therapeutic aim.\nEczema is highly heritable. Null mutations in FLG are the strongest genetic risk and a locus on chr11q13.5, for which the nearest gene is EMSY, has a multiplicative effect. We have shown that EMSY is a transcriptional regulator in skin, controlling multiple aspect of barrier formation.\nWe will investigate molecular mechanisms at these two major risk loci: chr1q21.3 (FLG, FLG-AS1 and related genes) and chr11q13.5 (EMSY and LRRC32), aiming to define pathways contributing to eczema resolution. Findings will be tested in a well-characterised birth cohort (ALSPAC), to confirm clinical relevance.\nAnalyses of European cohorts (n > 25,000) show evidence of gene-environment interactions in eczema, but these findings require validation. We will use an optimised skin organoid model to investigate three environmental factors (tobacco smoke, wash-products and pet allergens) for which there is evidence of interaction with FLG genotype. Detailed functional and biochemical phenotyping will increase understanding of gene-environment interactions.\nThis work will inform eczema prevention strategies and characterise mechanisms contributing to eczema resolution, as future therapeutic targets.\n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Dermatitis, Atopic","Eczema","Gene-Environment Interaction","Humans"]}
{"id":"360G-Wellcome-220872_Z_20_Z","title":"B cell activation in human GALT: drivers and consequences","Region":"Greater London","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220872/Z/20/Z","description":"We have identified bifurcation in human B cell development from shortly after bone marrow exit. B cells following one trajectory express high levels of IgM and have a gut-homing phenotype when in blood. They selectively migrate through gut and ultimately give rise to marginal zone B cells (MZB). The other branch expresses low levels of IgM and is systemic. All stages of the gut-homing branch are vastly depleted in the autoimmune disease lupus nephritis. \n\nWe will ask:\n1. What drives the lineage split that commits a subset of developing B cells to migrate into GALT, and how does this fail in lupus nephritis?\n2. What happens to MZB and their precursors in GALT?\n3. Do MZB emergent from GALT enter spleen and respond to further tissue specific cues?\n\nWe will apply cutting-edge technologies to identify the epigenetic marks and transcriptomes that reflect the key events in vivo and use these to compare pseudotime developmental sequences. We will merge deep single cell phenotype in tissues with paired transcriptomes of single cells in suspension to create a multidimensional map of events in GALT, and track subsequent clone evolution across tissues.\n\nThis understudied area of basic immunology is fundamental to good human health.\n","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":1374681,"Financial Year":"2019/20","Lead Applicant":"Prof Jo Spencer","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Spencer","Partnership Value":1374681,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"B cell activation in human GALT: drivers and consequences We have identified bifurcation in human B cell development from shortly after bone marrow exit. B cells following one trajectory express high levels of IgM and have a gut-homing phenotype when in blood. They selectively migrate through gut and ultimately give rise to marginal zone B cells (MZB). The other branch expresses low levels of IgM and is systemic. All stages of the gut-homing branch are vastly depleted in the autoimmune disease lupus nephritis. \n\nWe will ask:\n1. What drives the lineage split that commits a subset of developing B cells to migrate into GALT, and how does this fail in lupus nephritis?\n2. What happens to MZB and their precursors in GALT?\n3. Do MZB emergent from GALT enter spleen and respond to further tissue specific cues?\n\nWe will apply cutting-edge technologies to identify the epigenetic marks and transcriptomes that reflect the key events in vivo and use these to compare pseudotime developmental sequences. We will merge deep single cell phenotype in tissues with paired transcriptomes of single cells in suspension to create a multidimensional map of events in GALT, and track subsequent clone evolution across tissues.\n\nThis understudied area of basic immunology is fundamental to good human health.\n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","B-Lymphocytes","Epigenesis, Genetic","Humans","Immunoglobulin M","Lupus Nephritis","Mice","Single-Cell Analysis","Spleen","Transcriptome"]}
{"id":"360G-Wellcome-220870_Z_20_Z","title":"Controlling emergent Anopheles stephensi in Ethiopia and Sudan (CEASE)","Region":"North West","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220870/Z/20/Z","description":"Malaria is predominantly a rural disease in Africa and whilst urbanisation is occurring rapidly it was thought unlikely to lead to substantial increases in malaria transmission because Africa lacks an urban-adapted malaria vector. However, Anopheles stephensi, a common and efficient urban malaria vector in South Asia and the Persian Gulf, has recently been found in the Horn of Africa, including Ethiopia and Sudan and is associated with a rise in malaria in Djibouti. This prompted the WHO to call for urgent action to control the spread of the vector. This proposal brings together biologists, epidemiologists, mathematical and geostatistical modellers and medical anthropologists with the aim of preventing the spread of An. stephensi in Ethiopia and Sudan. The research will: (i) investigate the distribution, routes of introduction/reintroduction and spread of An. stephensi; (ii) quantify the importance of An. stephensi for malaria transmission and iii) evaluate multi-sectoral vector control strategies. This incredibly timely research will quantify the threat posed by An. stephensi in Ethiopia and Sudan and identify control measures to reduce populations and combat further spread in Africa. Historic examples (e.g. An. gambiae in Brazil) demonstrate that without prompt action, invasive species can become established with massive impacts on morbidity/mortality.\n","plannedDates":[{"endDate":"2024-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2024-12-31"}],"amountAwarded":1776461,"Financial Year":"2019/20","Lead Applicant":"Prof Martin Donnelly","grantProgramme":[{"title":"Collaborative Award in Science","title_keyword":"Collaborative Award in Science"}],"Partnership Name":"NIHR/Wellcome Global health Partnership","Applicant Surname":"Donnelly","Partnership Value":3552923,"Approval Committee":"Science Interview Panel","Other Applicant(s)":"Dr Luigi Sedda, Prof Koen Peeters, Dr Hmooda Kafy, Associate Professor Elfatih Malik, Dr Anne Wilson, Dr David Weetman, Prof Delenasaw Yewhalaw, Dr Endalamaw Belachew, Dr Thomas Churcher","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"Liverpool School of Tropical Medicine\", \"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Controlling emergent Anopheles stephensi in Ethiopia and Sudan (CEASE) Malaria is predominantly a rural disease in Africa and whilst urbanisation is occurring rapidly it was thought unlikely to lead to substantial increases in malaria transmission because Africa lacks an urban-adapted malaria vector. However, Anopheles stephensi, a common and efficient urban malaria vector in South Asia and the Persian Gulf, has recently been found in the Horn of Africa, including Ethiopia and Sudan and is associated with a rise in malaria in Djibouti. This prompted the WHO to call for urgent action to control the spread of the vector. This proposal brings together biologists, epidemiologists, mathematical and geostatistical modellers and medical anthropologists with the aim of preventing the spread of An. stephensi in Ethiopia and Sudan. The research will: (i) investigate the distribution, routes of introduction/reintroduction and spread of An. stephensi; (ii) quantify the importance of An. stephensi for malaria transmission and iii) evaluate multi-sectoral vector control strategies. This incredibly timely research will quantify the threat posed by An. stephensi in Ethiopia and Sudan and identify control measures to reduce populations and combat further spread in Africa. Historic examples (e.g. An. gambiae in Brazil) demonstrate that without prompt action, invasive species can become established with massive impacts on morbidity/mortality.\n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Anopheles","Ethiopia","Humans","Insect Vectors","Malaria","Mosquito Vectors","Sudan"]}
{"id":"360G-Wellcome-220866_Z_20_Z","title":"Treating hepatitis C in Pakistan. Strategies to avoid resistance to antiviral drugs","Region":"Greater London","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220866/Z/20/Z","description":"Hepatitis C infection can be cured by affordable drugs, leading to calls to expand treatment among the 70 million infected people worldwide. Many countries have initiated \u2018test and treat\u2019 programmes. e.g. India have reported treatment for ~40,000 patients in Punjab. However, 5-10% of infected people don\u2019t respond and may develop viral resistance and go on to develop liver cancer. Salvage regimens are often unaffordable/unavailable.\n\nWe will address the remaining questions in hepatitis C therapy. We will work in Pakistan where hepatitis C is highly endemic (4.8% sero-prevalence) with regions reaching sero-prevalences of 10-20% (hot-spots). We will link with the government HCV programme to determine the most effective treatment for people who don\u2019t respond to initial therapy. We will examine viral resistance in treatment failures to determine whether resistance dissemination is problematic and develop strategies to address it. We will determine whether some viruses are more oncogenic, allowing targeted surveillance. We will measure incident infection in the uninfected population (in hot-spot areas) and treated people, using modelling to determine what proportion of people must be cured to prevent disease recurrence. These data will inform the global elimination agenda and provide crucial data to develop optimised elimination programmes.\n \n","plannedDates":[{"endDate":"2025-01-03T00:00:00+00:00","startDate":"2021-01-04T00:00:00+00:00","startDateDateOnly":"2021-01-04","endDateDateOnly":"2025-01-03"}],"amountAwarded":1395744,"Financial Year":"2019/20","Lead Applicant":"Prof Graham Foster","grantProgramme":[{"title":"Collaborative Award in Science","title_keyword":"Collaborative Award in Science"}],"Partnership Name":"NIHR/Wellcome Global health Partnership","Applicant Surname":"Foster","Partnership Value":2791488,"Approval Committee":"Science Interview Panel","Other Applicant(s)":"Prof Saeed Hamid, Prof Eleanor Barnes, Prof Peter Vickerman, Prof Dr Saad Niaz","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Queen-Mary-University-of-London","name":"Queen Mary University of London","addressCountry":"United Kingdom","id_and_name":"[\"Queen Mary University of London\", \"360G-Wellcome-ORG:Queen-Mary-University-of-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Queen-Mary-University-of-London","name":"Queen Mary University of London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Treating hepatitis C in Pakistan. Strategies to avoid resistance to antiviral drugs Hepatitis C infection can be cured by affordable drugs, leading to calls to expand treatment among the 70 million infected people worldwide. Many countries have initiated \u2018test and treat\u2019 programmes. e.g. India have reported treatment for ~40,000 patients in Punjab. However, 5-10% of infected people don\u2019t respond and may develop viral resistance and go on to develop liver cancer. Salvage regimens are often unaffordable/unavailable.\n\nWe will address the remaining questions in hepatitis C therapy. We will work in Pakistan where hepatitis C is highly endemic (4.8% sero-prevalence) with regions reaching sero-prevalences of 10-20% (hot-spots). We will link with the government HCV programme to determine the most effective treatment for people who don\u2019t respond to initial therapy. We will examine viral resistance in treatment failures to determine whether resistance dissemination is problematic and develop strategies to address it. We will determine whether some viruses are more oncogenic, allowing targeted surveillance. We will measure incident infection in the uninfected population (in hot-spot areas) and treated people, using modelling to determine what proportion of people must be cured to prevent disease recurrence. These data will inform the global elimination agenda and provide crucial data to develop optimised elimination programmes.\n \n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Antiviral Agents","Drug Resistance, Viral","Hepacivirus","Hepatitis C","Humans","India","Pakistan"]}
{"id":"360G-Wellcome-220863_Z_20_Z","title":"Studying lentiviruses to understand mechanisms, regulation and consequences of nucleic acid sensing","Region":"Greater London","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220863/Z/20/Z","description":"I propose a new overarching hypothesis that innate immune sensing of nucleic acids, cell cycle regulation, and a hitherto unappreciated function of endogenous viral elements, contribute to an integrated system of regulating inflammatory responses to infection. Encouraged by preliminary data we will investigate the relationship between cell cycle and innate immune sensing by manipulating cell cycle and measuring responses to infection and relating expression of endogenous viral elements to cell cycle and their activation of nucleic acid sensing. We will also study the mechanisms of lentiviral Vpx/Vpr proteins taking molecular genetic and structural approaches to examine their enhancement of viral expression, manipulation of endogenous element expression and inhibition of innate immune signaling. We will also investigate the role of G3BP1 stress granules and their role in coordinating nucleic acid sensing with regulation of translation by PKR, mediated through cyclophilins. Overall our approach is to manipulate cellular pathways, for example cell division, and test sensing responses or manipulate virus and measure activation of sensing or viral inhibition of sensing. We expect to reveal mechanisms of nucleic acid sensing that can be tractably inhibited therapeutically and provide new mechanistic knowledge of inflammatory pathways broadly relevant to infectious and inflammatory diseases.\n \n","plannedDates":[{"endDate":"2025-11-30T00:00:00+00:00","startDate":"2020-12-01T00:00:00+00:00","startDateDateOnly":"2020-12-01","endDateDateOnly":"2025-11-30"}],"amountAwarded":1878714,"Financial Year":"2019/20","Lead Applicant":"Prof Gregory Towers","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Towers","Partnership Value":1878714,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Studying lentiviruses to understand mechanisms, regulation and consequences of nucleic acid sensing I propose a new overarching hypothesis that innate immune sensing of nucleic acids, cell cycle regulation, and a hitherto unappreciated function of endogenous viral elements, contribute to an integrated system of regulating inflammatory responses to infection. Encouraged by preliminary data we will investigate the relationship between cell cycle and innate immune sensing by manipulating cell cycle and measuring responses to infection and relating expression of endogenous viral elements to cell cycle and their activation of nucleic acid sensing. We will also study the mechanisms of lentiviral Vpx/Vpr proteins taking molecular genetic and structural approaches to examine their enhancement of viral expression, manipulation of endogenous element expression and inhibition of innate immune signaling. We will also investigate the role of G3BP1 stress granules and their role in coordinating nucleic acid sensing with regulation of translation by PKR, mediated through cyclophilins. Overall our approach is to manipulate cellular pathways, for example cell division, and test sensing responses or manipulate virus and measure activation of sensing or viral inhibition of sensing. We expect to reveal mechanisms of nucleic acid sensing that can be tractably inhibited therapeutically and provide new mechanistic knowledge of inflammatory pathways broadly relevant to infectious and inflammatory diseases.\n \n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["HEK293 Cells","Host-Pathogen Interactions","Humans","Immunity, Innate","Lentivirus","Nucleic Acids","Signal Transduction"]}
{"id":"360G-Wellcome-220861_Z_20_Z","title":"Roles of intron retention and splicing factors in axons","Region":"Greater London","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220861/Z/20/Z","description":"In recent years, RNA dynamics in axons and dendrites have arisen as central to neuronal maturation and maintenance of healthy neuronal connectivity. However, the functional roles of transported mRNAs and their binding proteins are scarcely understood. Some of the proteins associated to local mRNAs are splicing factors and spliceosome proteins.\nWe recently demonstrated that their axonal role is complex, as, in developing neurons in vivo, the splicing factor SFPQ and the U1 spliceosome protein snRNP70 locally control axonal shape and connectivity, through modulation of the local transcriptome. These findings open two essential questions: how are these splicing proteins shaping the transcriptome landscape locally and what is the molecular nature of the axonal interactions between specific mRNAs and these two proteins? \nMoreover, the recent findings of axonal and dendritic partially spliced mRNAs, retaining a single intron, open the additional question of the role(s) of intron-retaining transcripts in neurites and the possibility of direct functional interaction between retained introns and splicing proteins. \nWe propose to answer these essential questions, at cellular and molecular levels, using zebrafish developing neurons (in embryos and in culture) as experimental models.\n","plannedDates":[{"endDate":"2025-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2025-08-31"}],"amountAwarded":1690786,"Financial Year":"2019/20","Lead Applicant":"Prof Corinne Houart","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Houart","Partnership Value":1690786,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Roles of intron retention and splicing factors in axons In recent years, RNA dynamics in axons and dendrites have arisen as central to neuronal maturation and maintenance of healthy neuronal connectivity. However, the functional roles of transported mRNAs and their binding proteins are scarcely understood. Some of the proteins associated to local mRNAs are splicing factors and spliceosome proteins.\nWe recently demonstrated that their axonal role is complex, as, in developing neurons in vivo, the splicing factor SFPQ and the U1 spliceosome protein snRNP70 locally control axonal shape and connectivity, through modulation of the local transcriptome. These findings open two essential questions: how are these splicing proteins shaping the transcriptome landscape locally and what is the molecular nature of the axonal interactions between specific mRNAs and these two proteins? \nMoreover, the recent findings of axonal and dendritic partially spliced mRNAs, retaining a single intron, open the additional question of the role(s) of intron-retaining transcripts in neurites and the possibility of direct functional interaction between retained introns and splicing proteins. \nWe propose to answer these essential questions, at cellular and molecular levels, using zebrafish developing neurons (in embryos and in culture) as experimental models.\n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Alternative Splicing","Animals","Axons","Cells, Cultured","Introns","Neurons","RNA Splicing","RNA, Messenger","RNA-Binding Proteins","Zebrafish"]}
{"id":"360G-Wellcome-220857_Z_20_Z","title":"Exploiting genomic approaches to identify the environmental basis of depression","Region":"Scotland","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220857/Z/20/Z","description":"Despite major advances in our understanding of depression\u2019s genetic architecture, there remain major gaps in our understanding of its environmental risk factors that impede prevention. Using studies of both related and unrelated individuals, I will identify the genetic changes and behaviours in those individuals that lead to depression in those individuals, as well as in their relatives. I will compare these changes with the genetic signatures of lifestyle factors (e.g. obesity) and behaviours, such as smoking and alcohol consumption, to identify if they are environmental risk factors for depression. In a complimentary approach, I will measure epigenetic changes in DNA methylation associated with depression and its risk factors. I will use optimise these epigenetic measures to improve the prediction of depression and the measurement of its risk factors. Finally, I will optimise the prediction of depression and its risk factors by applying these findings to prospective longitudinal dataset where depression and environmental risk factors have been measured on multiple occasions. These studies will be used to refine the accuracy of each predictor and estimate how it would behave in unseen samples of individuals, in whom it may be applied for prevention in future studies. \n","plannedDates":[{"endDate":"2026-05-31T00:00:00+00:00","startDate":"2021-06-01T00:00:00+00:00","startDateDateOnly":"2021-06-01","endDateDateOnly":"2026-05-31"}],"amountAwarded":2530384,"Financial Year":"2019/20","Lead Applicant":"Prof Andrew McIntosh","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"McIntosh","Partnership Value":2530384,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Exploiting genomic approaches to identify the environmental basis of depression Despite major advances in our understanding of depression\u2019s genetic architecture, there remain major gaps in our understanding of its environmental risk factors that impede prevention. Using studies of both related and unrelated individuals, I will identify the genetic changes and behaviours in those individuals that lead to depression in those individuals, as well as in their relatives. I will compare these changes with the genetic signatures of lifestyle factors (e.g. obesity) and behaviours, such as smoking and alcohol consumption, to identify if they are environmental risk factors for depression. In a complimentary approach, I will measure epigenetic changes in DNA methylation associated with depression and its risk factors. I will use optimise these epigenetic measures to improve the prediction of depression and the measurement of its risk factors. Finally, I will optimise the prediction of depression and its risk factors by applying these findings to prospective longitudinal dataset where depression and environmental risk factors have been measured on multiple occasions. These studies will be used to refine the accuracy of each predictor and estimate how it would behave in unseen samples of individuals, in whom it may be applied for prevention in future studies. \n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["DNA Methylation","Depression","Epigenesis, Genetic","Genetic Predisposition to Disease","Humans","Longitudinal Studies","Prospective Studies","Risk Factors"]}
{"id":"360G-Wellcome-220818_Z_20_Z","title":"Hybridisation in urogenital schistosomiasis (HUGS): A multidisciplinary longitudinal population study revealing the transmission biology, epidemiological impact and clinical importance of Schistosoma haematobium-hybrids in Malawi","Region":"North West","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220818/Z/20/Z","description":"Our discovery of Schistosoma haematobium hybrids co-infecting Malawian children exposes critical knowledge gaps in WHO\u2019s preventive chemotherapy (PC) strategy for schistosomiasis. Our HUGS (hybridisation in urogenital schistosomiasis) study will generate robust evidence that best informs medical, veterinary and environmental sectors in schistosomiasis control and interruption of schistosome transmission. This 4-year multidisciplinary investigation will develop new molecular assays that quantify multihost transmission dynamics and zoonotic spill-overs. We will reveal which pre- or post-zygotic drivers facilitate saltatory hybrid evolution. HUGS is set out in four objectives [% allocation] that:\n\nObj-1 [25%]: Test if the proportion of hybrid co-infection is (non)uniform across two representative communities where S. haematobium-mattheei or S. haematobium-bovis occur, inclusive of household GPS mapping and identification of associated risk factors by questionnaire;\n\nObj-2 [45%]: Verify, in a 2-year longitudinal population follow-up study with annual PC, if the above proportions and spatial patterns of hybrid co-infection hold or alter in the two communities;\n \nObj-3 [15%]: Ascertain if there is any increased host morbidity (e.g. anaemia or urogenital disease) in hybrid co-infection(s) as measured by point-of-contact assays and portable ultrasonography;\n\nObj-4 [15%]: Reveal hybrid environmental transmission by malacological inspections, livestock tracking and abattoir surveillance, with advanced molecular typing of collected schistosome material.\n","plannedDates":[{"endDate":"2025-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2025-03-31"}],"amountAwarded":859476,"Financial Year":"2019/20","Lead Applicant":"Prof Russell Stothard","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Partnership Name":"NIHR/Wellcome Global health Partnership","Applicant Surname":"Stothard","Partnership Value":1718953,"Approval Committee":"Science Interview Panel","Other Applicant(s)":"Dr Janelisa Musaya","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"Liverpool School of Tropical Medicine\", \"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Hybridisation in urogenital schistosomiasis (HUGS): A multidisciplinary longitudinal population study revealing the transmission biology, epidemiological impact and clinical importance of Schistosoma haematobium-hybrids in Malawi Our discovery of Schistosoma haematobium hybrids co-infecting Malawian children exposes critical knowledge gaps in WHO\u2019s preventive chemotherapy (PC) strategy for schistosomiasis. Our HUGS (hybridisation in urogenital schistosomiasis) study will generate robust evidence that best informs medical, veterinary and environmental sectors in schistosomiasis control and interruption of schistosome transmission. This 4-year multidisciplinary investigation will develop new molecular assays that quantify multihost transmission dynamics and zoonotic spill-overs. We will reveal which pre- or post-zygotic drivers facilitate saltatory hybrid evolution. HUGS is set out in four objectives [% allocation] that:\n\nObj-1 [25%]: Test if the proportion of hybrid co-infection is (non)uniform across two representative communities where S. haematobium-mattheei or S. haematobium-bovis occur, inclusive of household GPS mapping and identification of associated risk factors by questionnaire;\n\nObj-2 [45%]: Verify, in a 2-year longitudinal population follow-up study with annual PC, if the above proportions and spatial patterns of hybrid co-infection hold or alter in the two communities;\n \nObj-3 [15%]: Ascertain if there is any increased host morbidity (e.g. anaemia or urogenital disease) in hybrid co-infection(s) as measured by point-of-contact assays and portable ultrasonography;\n\nObj-4 [15%]: Reveal hybrid environmental transmission by malacological inspections, livestock tracking and abattoir surveillance, with advanced molecular typing of collected schistosome material.\n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Female","Humans","Longitudinal Studies","Malawi","Male","Risk Factors","Schistosoma","Schistosoma haematobium","Schistosomiasis","Schistosomiasis haematobia"]}
{"id":"360G-Wellcome-220814_Z_20_Z","title":"Systematic discovery and analysis of novel molecular mechanisms in protein synthesis","Region":"East of England","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220814/Z/20/Z","description":"Protein synthesis is one of the most fundamental processes in all organisms. Due to the unique constraints under which RNA viruses evolve, non-canonical mechanisms are particularly prevalent in RNA virus gene expression. Thus, we are using viruses as a source for the discovery of novel gene expression strategies. We will leverage our expertise in computational biology to mine public transcriptomic datasets for 10000s of novel virus species, and use our expertise in virus comparative genomics and molecular biology to identify and characterize novel translational mechanisms. An important feature of the research strategy is close synergistic interaction between the bioinformaticians and experimentalists in my team, which allows us to efficiently investigate new discoveries.\n\nKey goals are to:\n\n \n\n\n \n Search ~120,000 RNA-Seq datasets for RNA virus-derived sequences from diverse host organisms from protists to mammals.\n \n \n Use comparative genomics to predict novel cases of non-canonical gene expression.\n \n \n Experimentally characterize the most interesting novel mechanisms.\n \n\n\n \n\nCharacterizing these exceptions to the rules of canonical translation will provide new insights into the mechanisms underlying protein synthesis, reveal new modes of cellular gene expression, and provide new tools for molecular biology research, biotechnology and synthetic biology. Thus the results will have broad applications in fundamental molecular biology.\n","plannedDates":[{"endDate":"2026-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2026-06-30"}],"amountAwarded":1628077,"Financial Year":"2019/20","Lead Applicant":"Dr Andrew Firth","grantProgramme":[{"title":"Senior Research Fellowship Renewal","title_keyword":"Senior Research Fellowship Renewal"}],"Applicant Surname":"Firth","Partnership Value":1628077,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Systematic discovery and analysis of novel molecular mechanisms in protein synthesis Protein synthesis is one of the most fundamental processes in all organisms. Due to the unique constraints under which RNA viruses evolve, non-canonical mechanisms are particularly prevalent in RNA virus gene expression. Thus, we are using viruses as a source for the discovery of novel gene expression strategies. We will leverage our expertise in computational biology to mine public transcriptomic datasets for 10000s of novel virus species, and use our expertise in virus comparative genomics and molecular biology to identify and characterize novel translational mechanisms. An important feature of the research strategy is close synergistic interaction between the bioinformaticians and experimentalists in my team, which allows us to efficiently investigate new discoveries.\n\nKey goals are to:\n\n \n\n\n \n Search ~120,000 RNA-Seq datasets for RNA virus-derived sequences from diverse host organisms from protists to mammals.\n \n \n Use comparative genomics to predict novel cases of non-canonical gene expression.\n \n \n Experimentally characterize the most interesting novel mechanisms.\n \n\n\n \n\nCharacterizing these exceptions to the rules of canonical translation will provide new insights into the mechanisms underlying protein synthesis, reveal new modes of cellular gene expression, and provide new tools for molecular biology research, biotechnology and synthetic biology. Thus the results will have broad applications in fundamental molecular biology.\n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Computational Biology","Humans","Protein Biosynthesis"]}
{"id":"360G-Wellcome-220810_Z_20_Z","title":"Alternative lengthening of telomeres: induction, maintenance and vulnerabilities","Region":"Greater London","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220810/Z/20/Z","description":"To maintain unlimited proliferative capacity, cancer cells must maintain their telomeres. ~85% of cancers achieve this by up-regulating telomerase, while the remaining ~15% of cancers employ the Alternative Lengthening of telomeres (ALT) pathway. Currently, there are no targeted treatments for ALT cancers, which have a poor prognosis and are universally aggressive. Insights into the mechanisms that promote/are essential for the ALT process may reveal vulnerabilities that could be exploited therapeutically. However, the lack of a cellular model that permits the induction of ALT has severely limited our ability to interrogate the underlying mechanisms. We have recently made a key discovery that Kaposi\u2019s Sarcoma Herpes Virus (KSHV) infection triggers the stable acquisition of ALT. In this application, we will exploit KSHV to identify the host and virally encoded factors that are critical for ALT induction. Using PICh to interrogate the proteomic composition of telomeres, we have identified 703 proteins that are specifically enriched at ALT telomeres. We will perform a \"703 ALT\" CRISPR dropout screens to identify genes that modulate/are essential in ALT cancer cells but are dispensable in normal cells. Our proposal will expand our understanding of the ALT process and may identify critical vulnerabilities, which could be targeted therapeutically.\n","plannedDates":[{"endDate":"2025-11-30T00:00:00+00:00","startDate":"2020-12-01T00:00:00+00:00","startDateDateOnly":"2020-12-01","endDateDateOnly":"2025-11-30"}],"amountAwarded":1882059,"Financial Year":"2019/20","Lead Applicant":"Dr Simon Boulton","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Boulton","Partnership Value":1882059,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:The-Francis-Crick-Institute","name":"The Francis Crick Institute","addressCountry":"United Kingdom","id_and_name":"[\"The Francis Crick Institute\", \"360G-Wellcome-ORG:The-Francis-Crick-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:The-Francis-Crick-Institute","name":"The Francis Crick Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Alternative lengthening of telomeres: induction, maintenance and vulnerabilities To maintain unlimited proliferative capacity, cancer cells must maintain their telomeres. ~85% of cancers achieve this by up-regulating telomerase, while the remaining ~15% of cancers employ the Alternative Lengthening of telomeres (ALT) pathway. Currently, there are no targeted treatments for ALT cancers, which have a poor prognosis and are universally aggressive. Insights into the mechanisms that promote/are essential for the ALT process may reveal vulnerabilities that could be exploited therapeutically. However, the lack of a cellular model that permits the induction of ALT has severely limited our ability to interrogate the underlying mechanisms. We have recently made a key discovery that Kaposi\u2019s Sarcoma Herpes Virus (KSHV) infection triggers the stable acquisition of ALT. In this application, we will exploit KSHV to identify the host and virally encoded factors that are critical for ALT induction. Using PICh to interrogate the proteomic composition of telomeres, we have identified 703 proteins that are specifically enriched at ALT telomeres. We will perform a \"703 ALT\" CRISPR dropout screens to identify genes that modulate/are essential in ALT cancer cells but are dispensable in normal cells. Our proposal will expand our understanding of the ALT process and may identify critical vulnerabilities, which could be targeted therapeutically.\n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["CRISPR-Cas Systems","Herpesvirus 8, Human","Humans","Proteomics","Sarcoma, Kaposi"]}
{"id":"360G-Wellcome-220808_Z_20_Z","title":"Genetic Code Compression and Expansion","Region":"East of England","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220808/Z/20/Z","description":"Genetic code expansion enables the site-specific, incorporation of non-canonical amino acids (ncAAs) into proteins, and has enabled diverse biological discoveries. Most experiments incorporate ncAAs in response to amber stop codons.  This strategy is limited to incorporating one type of ncAAs into a protein at a time, and there are no other natural blank codons that can be used for ncAA incorporation.\n\nWe synthesized a 4 Mb E. coli genome with a compressed genetic code, through the genome-wide substitution of three target codons by defined synonyms.  The resulting cell, Syn61, uses 61 codons to encode the 20 canonical amino acids.\n\nIn Aim 1 we address the limitations of genetic code expansion by encoding multiple distinct ncAAs in response to blank codons in Syn61. This dramatically expands the applications of ncAA incorporation.\n\nThe recoding of Syn61 was based on the prior identification of a synonymous codon compression scheme (a rule that defines which codons to remove and which codons to replace them with).  In Aim 2 and Aim 3 we systematically discover allowed synonymous codon compression schemes that we use to create deeply compressed synthetic genomes using accelerated genome synthesis methods. This creates more blank codons that may be reassigned to ncAAs.\n \n","plannedDates":[{"endDate":"2025-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2025-12-31"}],"amountAwarded":2769513,"Financial Year":"2019/20","Lead Applicant":"Prof Jason Chin","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Chin","Partnership Value":2769513,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:MRC-Laboratory-of-Molecular-Biology","name":"MRC Laboratory of Molecular Biology","addressCountry":"United Kingdom","id_and_name":"[\"MRC Laboratory of Molecular Biology\", \"360G-Wellcome-ORG:MRC-Laboratory-of-Molecular-Biology\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:MRC-Laboratory-of-Molecular-Biology","name":"MRC Laboratory of Molecular Biology"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Genetic Code Compression and Expansion Genetic code expansion enables the site-specific, incorporation of non-canonical amino acids (ncAAs) into proteins, and has enabled diverse biological discoveries. Most experiments incorporate ncAAs in response to amber stop codons.  This strategy is limited to incorporating one type of ncAAs into a protein at a time, and there are no other natural blank codons that can be used for ncAA incorporation.\n\nWe synthesized a 4 Mb E. coli genome with a compressed genetic code, through the genome-wide substitution of three target codons by defined synonyms.  The resulting cell, Syn61, uses 61 codons to encode the 20 canonical amino acids.\n\nIn Aim 1 we address the limitations of genetic code expansion by encoding multiple distinct ncAAs in response to blank codons in Syn61. This dramatically expands the applications of ncAA incorporation.\n\nThe recoding of Syn61 was based on the prior identification of a synonymous codon compression scheme (a rule that defines which codons to remove and which codons to replace them with).  In Aim 2 and Aim 3 we systematically discover allowed synonymous codon compression schemes that we use to create deeply compressed synthetic genomes using accelerated genome synthesis methods. This creates more blank codons that may be reassigned to ncAAs.\n \n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Amino Acids","Codon","Codon, Terminator","Escherichia coli","Escherichia coli Proteins","Genetic Code","Genome, Bacterial","Protein Biosynthesis"]}
{"id":"360G-Wellcome-220799_Z_20_Z","title":"Molecular mechanisms determining the polarised synaptic distribution and molecular function of the retrograde endocannabinoid signalling system","Region":"South West","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220799/Z/20/Z","description":"The endocannabinoid system (ECS) acts as a negative feedback mechanism to suppress excitatory and inhibitory synaptic transmission. This is critically important for a wide range of brain functions including appetite, pain, and cognition. Moreover, ECS dysfunction is implicated in multiple neuropathologies, and there is increasing scientific and public interest in drugs that target the ECS, including medical marijuana.\n\nThe molecular organisation of the ECS is highly unusual because, in reverse to other neurotransmitter systems, endocannabinoids are released from the postsynaptic membrane to activate receptors at the presynaptic membrane. Despite its importance, remarkably little is known about how the enzymes and receptors essential for ECS \u2018backwards\u2019 transmission are targeted to, and retained at, opposing sides of the synapse.\n\nFocusing on the primary cannabinoid receptor CB1R and the major endocannabinoid synthesising  enzyme diacylglycerol lipase alpha (DAGLalpha) as prototypic examples, we will investigate the protein interactions and pathways that determine the architecture and organisation of the ECS.\n\nOur goal is to define how the differentially polarised trafficking of ECS components to synapses is orchestrated.\n\nThis mechanistic knowledge of the ECS will advance understanding of neuronal protein polarisation and inform the design of future strategies to modulate ECS signalling for therapeutic benefit.\n \n","plannedDates":[{"endDate":"2026-01-31T00:00:00+00:00","startDate":"2021-02-01T00:00:00+00:00","startDateDateOnly":"2021-02-01","endDateDateOnly":"2026-01-31"}],"amountAwarded":1104076,"Financial Year":"2019/20","Lead Applicant":"Prof Jeremy Henley","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Henley","Partnership Value":1104076,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Molecular mechanisms determining the polarised synaptic distribution and molecular function of the retrograde endocannabinoid signalling system The endocannabinoid system (ECS) acts as a negative feedback mechanism to suppress excitatory and inhibitory synaptic transmission. This is critically important for a wide range of brain functions including appetite, pain, and cognition. Moreover, ECS dysfunction is implicated in multiple neuropathologies, and there is increasing scientific and public interest in drugs that target the ECS, including medical marijuana.\n\nThe molecular organisation of the ECS is highly unusual because, in reverse to other neurotransmitter systems, endocannabinoids are released from the postsynaptic membrane to activate receptors at the presynaptic membrane. Despite its importance, remarkably little is known about how the enzymes and receptors essential for ECS \u2018backwards\u2019 transmission are targeted to, and retained at, opposing sides of the synapse.\n\nFocusing on the primary cannabinoid receptor CB1R and the major endocannabinoid synthesising  enzyme diacylglycerol lipase alpha (DAGLalpha) as prototypic examples, we will investigate the protein interactions and pathways that determine the architecture and organisation of the ECS.\n\nOur goal is to define how the differentially polarised trafficking of ECS components to synapses is orchestrated.\n\nThis mechanistic knowledge of the ECS will advance understanding of neuronal protein polarisation and inform the design of future strategies to modulate ECS signalling for therapeutic benefit.\n \n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Endocannabinoids","Humans","Lipoprotein Lipase","Monoacylglycerol Lipases","Receptor, Cannabinoid, CB1","Signal Transduction","Synapses"]}
{"id":"360G-Wellcome-220797_Z_20_Z","title":"Erythrocyte invasion in malaria: molecular mechanism to precision therapeutics","Region":"South East","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220797/Z/20/Z","description":"Invasion of erythrocytes is one of the most critical steps in the life cycle of the malaria parasite. Prevent erythrocyte invasion, and we can prevent parasite growth, disease symptoms and transmission. \n\nEssential for erythrocyte invasion is the PfRCR complex of Plasmodium falciparum, consisting of PfRH5, PfCyRPA and PfRIPR. This proposal will use structural insights to guide experiments to understand the function of PfRCR in erythrocyte invasion, and to guide development of future vaccines and therapeutic antibodies. Over the next five years, I will:\n\n(i)        Determine structures of PfRCR and PfRIPR and understand whether complex formation is necessary for invasion.\n(ii)       Understand molecular mechanisms of the most invasion-neutralising human antibodies targeting PfRH5, PfCyRPA and PfRIPR.\n(iii)      Determine how PfRH5 induces calcium flux in erythrocytes.\n(iv)      Use structural insights to design improved therapeutic monoclonal antibodies and vaccine immunogens targeting PfRCR.\n\nThese studies will deepen our understanding of this critical event in erythrocyte invasion. They will reveal the human antibody response to PfRCR vaccination and use this insight to guide design of the malaria therapeutics of the future.\n","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":2105418,"Financial Year":"2019/20","Lead Applicant":"Prof Matthew Higgins","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Higgins","Partnership Value":2105418,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Erythrocyte invasion in malaria: molecular mechanism to precision therapeutics Invasion of erythrocytes is one of the most critical steps in the life cycle of the malaria parasite. Prevent erythrocyte invasion, and we can prevent parasite growth, disease symptoms and transmission. \n\nEssential for erythrocyte invasion is the PfRCR complex of Plasmodium falciparum, consisting of PfRH5, PfCyRPA and PfRIPR. This proposal will use structural insights to guide experiments to understand the function of PfRCR in erythrocyte invasion, and to guide development of future vaccines and therapeutic antibodies. Over the next five years, I will:\n\n(i)        Determine structures of PfRCR and PfRIPR and understand whether complex formation is necessary for invasion.\n(ii)       Understand molecular mechanisms of the most invasion-neutralising human antibodies targeting PfRH5, PfCyRPA and PfRIPR.\n(iii)      Determine how PfRH5 induces calcium flux in erythrocytes.\n(iv)      Use structural insights to design improved therapeutic monoclonal antibodies and vaccine immunogens targeting PfRCR.\n\nThese studies will deepen our understanding of this critical event in erythrocyte invasion. They will reveal the human antibody response to PfRCR vaccination and use this insight to guide design of the malaria therapeutics of the future.\n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Antibodies, Protozoan","Calcium","Erythrocytes","Humans","Malaria Vaccines","Malaria, Falciparum","Plasmodium falciparum","Protozoan Proteins"]}
{"id":"360G-Wellcome-220794_Z_20_Z","title":"Unconventional dynamics: turnover, structure and maintenance of the \u03b3\u03b4 T cell population in humans  ","Region":"Greater London","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220794/Z/20/Z","description":"For 500 million years, vertebrates have retained three distinct lymphocyte lineages bearing rearranged receptors\u2013 alphabeta T-cells, B-cells, and gammadelta T-cells - suggesting that each compartment is critical to host immunity. We have a good understanding of classical alphabeta T-cells and B-cells but our knowledge of \"unconventional\" gammadelta T-cells lags far behind. There has been a recent explosion of interest in the gammadelta population and considerable excitement around their therapeutic potential. This is motivated by their unique recognition capabilities, their enrichment at sites of pathogen entry, and potent antimicrobial/antiviral/antitumour activities. Previously assumed to sit at the interface of innate and adaptive immunity, recent work has shown that gammadelta T-cells can be divided into functionally-distinct innate-like and adaptive-like subsets. A knowledge of the dynamics that critically underpin such diverse populations is lacking, hindering fundamental understanding and therapeutic exploitation. We will investigate gammadelta T-cell dynamics in humans including quantification of in vivo lifespans, maintenance mechanisms (de novo production versus self-renewal), and repertoire dynamics relative to canonical adaptive (CD8) and innate-like (MAIT) populations. We will establish benchmark in vivo dynamic measurements for  \"innate\" and \"adaptive\" human gammadelta T-cell subsets, and generate the first quantitative models of the human gammadelta T-cell compartment.  \n\n \n\n \n","plannedDates":[{"endDate":"2025-07-19T00:00:00+00:00","startDate":"2021-07-20T00:00:00+00:00","startDateDateOnly":"2021-07-20","endDateDateOnly":"2025-07-19"}],"amountAwarded":1201563,"Financial Year":"2019/20","Lead Applicant":"Prof Becca Asquith","grantProgramme":[{"title":"Collaborative Award in Science","title_keyword":"Collaborative Award in Science"}],"Applicant Surname":"Asquith","Partnership Value":1201563,"Approval Committee":"Science Interview Panel","Other Applicant(s)":"Prof Derek Macallan, Prof Benjamin Willcox","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Unconventional dynamics: turnover, structure and maintenance of the \u03b3\u03b4 T cell population in humans   For 500 million years, vertebrates have retained three distinct lymphocyte lineages bearing rearranged receptors\u2013 alphabeta T-cells, B-cells, and gammadelta T-cells - suggesting that each compartment is critical to host immunity. We have a good understanding of classical alphabeta T-cells and B-cells but our knowledge of \"unconventional\" gammadelta T-cells lags far behind. There has been a recent explosion of interest in the gammadelta population and considerable excitement around their therapeutic potential. This is motivated by their unique recognition capabilities, their enrichment at sites of pathogen entry, and potent antimicrobial/antiviral/antitumour activities. Previously assumed to sit at the interface of innate and adaptive immunity, recent work has shown that gammadelta T-cells can be divided into functionally-distinct innate-like and adaptive-like subsets. A knowledge of the dynamics that critically underpin such diverse populations is lacking, hindering fundamental understanding and therapeutic exploitation. We will investigate gammadelta T-cell dynamics in humans including quantification of in vivo lifespans, maintenance mechanisms (de novo production versus self-renewal), and repertoire dynamics relative to canonical adaptive (CD8) and innate-like (MAIT) populations. We will establish benchmark in vivo dynamic measurements for  \"innate\" and \"adaptive\" human gammadelta T-cell subsets, and generate the first quantitative models of the human gammadelta T-cell compartment.  \n\n \n\n \n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adaptive Immunity","Animals","B-Lymphocytes","Humans"]}
{"id":"360G-Wellcome-220790_Z_20_Z","title":"Exploiting divergent biology of two fission yeasts to understand membrane function","Region":"Greater London","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220790/Z/20/Z","description":"Membrane function is fundamental to life. Deregulation of the membrane lipid repertoire has severe consequences for cellular and organismal fitness. Defining how lipid composition controls membrane organization and cellular physiology remains a major challenge in biology. Membrane lipid composition is subject to complex feedbacks and reflects the metabolic and regulatory capabilities of the specific experimental system. I propose to attack this problem by exploiting the natural divergence in membrane lipid composition between S. pombe and S. japonicus, two related genetically tractable fission yeasts with different lifestyles. I believe that our research program integrating comparative analyses and reverse engineering of cellular mechanisms with biophysics and systems approaches, provides an unmatched discovery platform capable of revealing the core principles that govern membrane organization and function. Our research will explain how changes in the architecture of glycerophospholipid fatty acyl tails affect membrane properties. It will provide insights into the organization and evolution of genetic networks regulating membrane homeostasis. Finally, it will test if acquisition of new lipid metabolic functionalities engenders diversification of cellular pathways and organismal physiology.\n \n","plannedDates":[{"endDate":"2026-07-04T00:00:00+00:00","startDate":"2021-07-05T00:00:00+00:00","startDateDateOnly":"2021-07-05","endDateDateOnly":"2026-07-04"}],"amountAwarded":1813347,"Financial Year":"2019/20","Lead Applicant":"Prof Snezhana Oliferenko","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Oliferenko","Partnership Value":1813347,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Exploiting divergent biology of two fission yeasts to understand membrane function Membrane function is fundamental to life. Deregulation of the membrane lipid repertoire has severe consequences for cellular and organismal fitness. Defining how lipid composition controls membrane organization and cellular physiology remains a major challenge in biology. Membrane lipid composition is subject to complex feedbacks and reflects the metabolic and regulatory capabilities of the specific experimental system. I propose to attack this problem by exploiting the natural divergence in membrane lipid composition between S. pombe and S. japonicus, two related genetically tractable fission yeasts with different lifestyles. I believe that our research program integrating comparative analyses and reverse engineering of cellular mechanisms with biophysics and systems approaches, provides an unmatched discovery platform capable of revealing the core principles that govern membrane organization and function. Our research will explain how changes in the architecture of glycerophospholipid fatty acyl tails affect membrane properties. It will provide insights into the organization and evolution of genetic networks regulating membrane homeostasis. Finally, it will test if acquisition of new lipid metabolic functionalities engenders diversification of cellular pathways and organismal physiology.\n \n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cell Membrane","Lipid Metabolism","Membrane Lipids","Schizosaccharomyces"]}
{"id":"360G-Wellcome-220788_Z_20_Z","title":"Engineering genomic features to better understand the molecular basis of immune mediated diseases and their treatment","Region":"East of England","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220788/Z/20/Z","description":"Genetic and transcriptional studies have demonstrated that shared aetiology between immune-mediated diseases (IMD) is reflected in shared patterns in both data types, and suggested new targets for treatment. However, the huge number of variants and genes measured mean that only a minority of potential information in these data has been harnessed, and disease prognosis and treatment success remains variable and unpredictable. My goal is to overcome this dimensional challenge by developing genomic feature engineering which exploits these shared patterns, to extract new insight from jointly analysing over a hundred existing datasets.\n\nI will generate summary features by tailoring dimension-reduction strategies and applying them to genetic and transcriptomic data from patients and cohorts with related traits measured. I will investigate how each feature contributes to rare and common IMD risk, and prognostic variability within diseases. I will correlate features with molecular measurements and clinical data to understand the gene products they represent, and the situations (cell type, disease state/subtype) in which they are relevant. Finally, through predictive modeling, I will explore the expected impact of targeting these gene products in different diseases and subtypes, to generate, and test, hypotheses about which targets might modify specific IMD activity or progression.\n\n \n","plannedDates":[{"endDate":"2026-01-31T00:00:00+00:00","startDate":"2021-02-01T00:00:00+00:00","startDateDateOnly":"2021-02-01","endDateDateOnly":"2026-01-31"}],"amountAwarded":1243595,"Financial Year":"2019/20","Lead Applicant":"Dr Chris Wallace","grantProgramme":[{"title":"Senior Research Fellowship Renewal","title_keyword":"Senior Research Fellowship Renewal"}],"Applicant Surname":"Wallace","Partnership Value":1243595,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Engineering genomic features to better understand the molecular basis of immune mediated diseases and their treatment Genetic and transcriptional studies have demonstrated that shared aetiology between immune-mediated diseases (IMD) is reflected in shared patterns in both data types, and suggested new targets for treatment. However, the huge number of variants and genes measured mean that only a minority of potential information in these data has been harnessed, and disease prognosis and treatment success remains variable and unpredictable. My goal is to overcome this dimensional challenge by developing genomic feature engineering which exploits these shared patterns, to extract new insight from jointly analysing over a hundred existing datasets.\n\nI will generate summary features by tailoring dimension-reduction strategies and applying them to genetic and transcriptomic data from patients and cohorts with related traits measured. I will investigate how each feature contributes to rare and common IMD risk, and prognostic variability within diseases. I will correlate features with molecular measurements and clinical data to understand the gene products they represent, and the situations (cell type, disease state/subtype) in which they are relevant. Finally, through predictive modeling, I will explore the expected impact of targeting these gene products in different diseases and subtypes, to generate, and test, hypotheses about which targets might modify specific IMD activity or progression.\n\n \n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Genomics","Humans"]}
{"id":"360G-Wellcome-220784_Z_20_Z","title":"Proteostasis and Autophagy in Immune Senescence","Region":"South East","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220784/Z/20/Z","description":"Lymphocyte function underpins effective immunity to infection and cancer, and is adversely affected by age in a process called immune senescence, a major obstacle to having a healthy lifespan. The cellular basis of T cell senescence is largely unknown. Maintaining proteostasis, regulated by protein synthesis and degradation, in the face of intrinsic and environmental insults is a key determinant of cellular and organismal lifespan. We will address the hypothesis that modulating the conserved degradation and recycling process known as autophagy, can restore immune responses in lymphocytes in the elderly. We have shown that autophagy prevents immune aging, and demonstrated a decline in autophagic flux in lymphocytes with age, and a global age-related decline of protein translation. But it is uncertain which of the synthesized and degraded proteins are most important. It is clear, however, that the induction of specific repair pathways, including autophagy, extends life and health span. We have uncovered a novel pathway that rejuvenates lymphocyte function by regulating autophagy translationally, which we intend now to fully characterize. Our goal is to identify potential therapeutic strategies for restoring health span in the elderly. This work will also address fundamental gaps in our understanding of the aging process.\n\n \n","plannedDates":[{"endDate":"2025-08-14T00:00:00+00:00","startDate":"2020-08-15T00:00:00+00:00","startDateDateOnly":"2020-08-15","endDateDateOnly":"2025-08-14"}],"amountAwarded":1789979,"Financial Year":"2019/20","Lead Applicant":"Prof Anna Katharina (Katja) Simon","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Simon","Partnership Value":1789979,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Proteostasis and Autophagy in Immune Senescence Lymphocyte function underpins effective immunity to infection and cancer, and is adversely affected by age in a process called immune senescence, a major obstacle to having a healthy lifespan. The cellular basis of T cell senescence is largely unknown. Maintaining proteostasis, regulated by protein synthesis and degradation, in the face of intrinsic and environmental insults is a key determinant of cellular and organismal lifespan. We will address the hypothesis that modulating the conserved degradation and recycling process known as autophagy, can restore immune responses in lymphocytes in the elderly. We have shown that autophagy prevents immune aging, and demonstrated a decline in autophagic flux in lymphocytes with age, and a global age-related decline of protein translation. But it is uncertain which of the synthesized and degraded proteins are most important. It is clear, however, that the induction of specific repair pathways, including autophagy, extends life and health span. We have uncovered a novel pathway that rejuvenates lymphocyte function by regulating autophagy translationally, which we intend now to fully characterize. Our goal is to identify potential therapeutic strategies for restoring health span in the elderly. This work will also address fundamental gaps in our understanding of the aging process.\n\n \n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aged","Aging","Animals","Autophagy","Cellular Senescence","Humans","Longevity","Lymphocytes"]}
{"id":"360G-Wellcome-220780_Z_20_Z","title":"Specialization of chromosome segregation mechanisms in meiosis","Region":"Scotland","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220780/Z/20/Z","description":"Meiosis generates gametes with half the parental genome through two consecutive chromosome segregation events, meiosis I and meiosis II. Meiotic errors are prevalent in humans, accounting for frequent miscarriages, birth defects and infertility, yet the mechanistic origins of these errors are undefined. Our vision is to discover the molecular basis of the adaptations that sort chromosomes into gametes during meiosis. We will exploit the tractability of yeast meiosis to overcome the limitations of protracted meiosis and scarcity of material in other systems, to address three complementary aims. First, we will determine the mechanism by which kinetochores suppress crossover recombination near centromeres during meiotic prophase, and the significance of this suppression for chromosome segregation. Second, we will reveal how sister kinetochores are specifically fused, and the surveillance machinery re-wired, to permit sister chromatid co-segregation only during meiosis I. Third, we will identify the modified cell cycle controls that drive two consecutive chromosome segregation events during meiosis and determine how these controls couple chromosome morphogenesis to gametogenesis. The molecular pathways we discover will provide a framework for identifying potential sources of meiotic errors in humans.\n","plannedDates":[{"endDate":"2026-02-28T00:00:00+00:00","startDate":"2021-03-01T00:00:00+00:00","startDateDateOnly":"2021-03-01","endDateDateOnly":"2026-02-28"}],"amountAwarded":2345878,"Financial Year":"2019/20","Lead Applicant":"Prof Adele Marston","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Marston","Partnership Value":2345878,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Specialization of chromosome segregation mechanisms in meiosis Meiosis generates gametes with half the parental genome through two consecutive chromosome segregation events, meiosis I and meiosis II. Meiotic errors are prevalent in humans, accounting for frequent miscarriages, birth defects and infertility, yet the mechanistic origins of these errors are undefined. Our vision is to discover the molecular basis of the adaptations that sort chromosomes into gametes during meiosis. We will exploit the tractability of yeast meiosis to overcome the limitations of protracted meiosis and scarcity of material in other systems, to address three complementary aims. First, we will determine the mechanism by which kinetochores suppress crossover recombination near centromeres during meiotic prophase, and the significance of this suppression for chromosome segregation. Second, we will reveal how sister kinetochores are specifically fused, and the surveillance machinery re-wired, to permit sister chromatid co-segregation only during meiosis I. Third, we will identify the modified cell cycle controls that drive two consecutive chromosome segregation events during meiosis and determine how these controls couple chromosome morphogenesis to gametogenesis. The molecular pathways we discover will provide a framework for identifying potential sources of meiotic errors in humans.\n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Centromere","Chromosome Segregation","Crossing Over, Genetic","Kinetochores","Meiosis","Recombination, Genetic"]}
{"id":"360G-Wellcome-220776_Z_20_Z","title":"Mechanism of cell-to-cell transmission of flaviviruses","Region":"South East","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220776/Z/20/Z","description":"This proposal will investigate the mechanism of cell-to-cell transmission and spread of flaviviruses using Dengue and Zika as model systems. We will therefore address a longstanding debate on how they exit from infected cells, and preferentially spread into specific cell types. Dengue and Zika are the two most prevalent flaviviruses worldwide, sharing significant overlap in their genome architecture and biology. Dengue infects  > 50 million people annually, causing severe pathologies. Zika too has emerged as a global threat with recent outbreaks linked to serious neuro-developmental complications in children and Guillain Barr\u00e9 syndrome in adults. No vaccines or therapeutics exist for these viruses, and our current understanding on mechanisms of their transmission and spread is severely limited.\n            Viral infections spread by overcoming multiple barriers to move from cell to cell. Viral progenies can move across extracellular space either as free particles via fluid phase diffusion, within vesicles, or by cell-cell contacts. To understand transmission, we will therefore address: (i) characteristics of the extracellular virus populations, (ii) whether multiple transmission routes exist (iii) whether the viral envelope is the primary determinant of transmissibility. This proposal builds on our previously published and ongoing studies on viral manipulation of autophagy for assembly and spread.\n","plannedDates":[{"endDate":"2025-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2025-12-31"}],"amountAwarded":1567546,"Financial Year":"2019/20","Lead Applicant":"Dr Sumana Sanyal","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Sanyal","Partnership Value":1567546,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mechanism of cell-to-cell transmission of flaviviruses This proposal will investigate the mechanism of cell-to-cell transmission and spread of flaviviruses using Dengue and Zika as model systems. We will therefore address a longstanding debate on how they exit from infected cells, and preferentially spread into specific cell types. Dengue and Zika are the two most prevalent flaviviruses worldwide, sharing significant overlap in their genome architecture and biology. Dengue infects  > 50 million people annually, causing severe pathologies. Zika too has emerged as a global threat with recent outbreaks linked to serious neuro-developmental complications in children and Guillain Barr\u00e9 syndrome in adults. No vaccines or therapeutics exist for these viruses, and our current understanding on mechanisms of their transmission and spread is severely limited.\n            Viral infections spread by overcoming multiple barriers to move from cell to cell. Viral progenies can move across extracellular space either as free particles via fluid phase diffusion, within vesicles, or by cell-cell contacts. To understand transmission, we will therefore address: (i) characteristics of the extracellular virus populations, (ii) whether multiple transmission routes exist (iii) whether the viral envelope is the primary determinant of transmissibility. This proposal builds on our previously published and ongoing studies on viral manipulation of autophagy for assembly and spread.\n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Dengue","Dengue Virus","Humans","Zika Virus","Zika Virus Infection"]}
{"id":"360G-Wellcome-220772_Z_20_Z","title":"Checkpoint control of T cell-B cell collaboration in the regulation of autoimmunity","Region":"Greater London","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220772/Z/20/Z","description":"Productive communication between T cells and B cells is vital for protective immunity, however dysregulation of this process can trigger autoimmunity.  Costimulatory checkpoints limit T cell help for B cells by controlling the differentiation of follicular helper T cells (Tfh), a cellular subset overrepresented in multiple autoimmune diseases. We have found that anti-CTLA-4 antibodies can trigger spontaneous Tfh differentiation in mice. Targeting CTLA-4 with checkpoint inhibitors in cancer patients may therefore induce Tfh, potentially relevant to the autoimmune side-effects seen with these treatments. Despite their escalating clinical burden, the cellular mechanisms underpinning checkpoint-inhibitor induced autoimmunity remain poorly understood.\n\nIn this proposal I will investigate the hypothesis that induction of Tfh responses is a general feature of autoimmunity, reflecting a loss of costimulatory (checkpoint) control. I will explore how CTLA-4 and PD-1 co-operate to regulate Tfh differentiation, and establish the consequence of a Tfh response for tissue autoimmunity. Insights will be drawn from autoimmune patients treated with CTLA-4-Ig, and cancer patients treated with CTLA-4 antibodies. Building on exciting preliminary data, I will determine whether Tfh populations have value in predicting outcomes in classical autoimmunity as well as in checkpoint-inhibitor induced disease.\n \n","plannedDates":[{"endDate":"2026-02-28T00:00:00+00:00","startDate":"2021-03-01T00:00:00+00:00","startDateDateOnly":"2021-03-01","endDateDateOnly":"2026-02-28"}],"amountAwarded":1900785,"Financial Year":"2019/20","Lead Applicant":"Prof Lucy Walker","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Walker","Partnership Value":1900785,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Checkpoint control of T cell-B cell collaboration in the regulation of autoimmunity Productive communication between T cells and B cells is vital for protective immunity, however dysregulation of this process can trigger autoimmunity.  Costimulatory checkpoints limit T cell help for B cells by controlling the differentiation of follicular helper T cells (Tfh), a cellular subset overrepresented in multiple autoimmune diseases. We have found that anti-CTLA-4 antibodies can trigger spontaneous Tfh differentiation in mice. Targeting CTLA-4 with checkpoint inhibitors in cancer patients may therefore induce Tfh, potentially relevant to the autoimmune side-effects seen with these treatments. Despite their escalating clinical burden, the cellular mechanisms underpinning checkpoint-inhibitor induced autoimmunity remain poorly understood.\n\nIn this proposal I will investigate the hypothesis that induction of Tfh responses is a general feature of autoimmunity, reflecting a loss of costimulatory (checkpoint) control. I will explore how CTLA-4 and PD-1 co-operate to regulate Tfh differentiation, and establish the consequence of a Tfh response for tissue autoimmunity. Insights will be drawn from autoimmune patients treated with CTLA-4-Ig, and cancer patients treated with CTLA-4 antibodies. Building on exciting preliminary data, I will determine whether Tfh populations have value in predicting outcomes in classical autoimmunity as well as in checkpoint-inhibitor induced disease.\n \n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Autoimmune Diseases","Autoimmunity","B-Lymphocytes","CTLA-4 Antigen","Humans","Mice","Neoplasms","Programmed Cell Death 1 Receptor","T-Lymphocytes, Helper-Inducer"]}
{"id":"360G-Wellcome-220772_A_20_Z","title":"Checkpoint control of T cell-B cell collaboration in the regulation of autoimmunity","Region":"East of England","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220772/A/20/Z","description":"Productive communication between T cells and B cells is vital for protective immunity, however dysregulation of this process can trigger autoimmunity.  Costimulatory checkpoints limit T cell help for B cells by controlling the differentiation of follicular helper T cells (Tfh), a cellular subset overrepresented in multiple autoimmune diseases. We have found that anti-CTLA-4 antibodies can trigger spontaneous Tfh differentiation in mice. Targeting CTLA-4 with checkpoint inhibitors in cancer patients may therefore induce Tfh, potentially relevant to the autoimmune side-effects seen with these treatments. Despite their escalating clinical burden, the cellular mechanisms underpinning checkpoint-inhibitor induced autoimmunity remain poorly understood.\n\nIn this proposal I will investigate the hypothesis that induction of Tfh responses is a general feature of autoimmunity, reflecting a loss of costimulatory (checkpoint) control. I will explore how CTLA-4 and PD-1 co-operate to regulate Tfh differentiation, and establish the consequence of a Tfh response for tissue autoimmunity. Insights will be drawn from autoimmune patients treated with CTLA-4-Ig, and cancer patients treated with CTLA-4 antibodies. Building on exciting preliminary data, I will determine whether Tfh populations have value in predicting outcomes in classical autoimmunity as well as in checkpoint-inhibitor induced disease.\n \n","plannedDates":[{"endDate":"2026-02-28T00:00:00+00:00","startDate":"2021-03-01T00:00:00+00:00","startDateDateOnly":"2021-03-01","endDateDateOnly":"2026-02-28"}],"amountAwarded":64000,"Financial Year":"2019/20","Lead Applicant":"Dr Sarah Teichmann","grantProgramme":[{"title":"Sanger Resource Collaboration","title_keyword":"Sanger Resource Collaboration"}],"Applicant Surname":"Teichmann","Partnership Value":64000,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Wellcome-Trust-Sanger-Institute","name":"Wellcome Trust Sanger Institute","addressCountry":"United Kingdom","id_and_name":"[\"Wellcome Trust Sanger Institute\", \"360G-Wellcome-ORG:Wellcome-Trust-Sanger-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Wellcome-Trust-Sanger-Institute","name":"Wellcome Trust Sanger Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Checkpoint control of T cell-B cell collaboration in the regulation of autoimmunity Productive communication between T cells and B cells is vital for protective immunity, however dysregulation of this process can trigger autoimmunity.  Costimulatory checkpoints limit T cell help for B cells by controlling the differentiation of follicular helper T cells (Tfh), a cellular subset overrepresented in multiple autoimmune diseases. We have found that anti-CTLA-4 antibodies can trigger spontaneous Tfh differentiation in mice. Targeting CTLA-4 with checkpoint inhibitors in cancer patients may therefore induce Tfh, potentially relevant to the autoimmune side-effects seen with these treatments. Despite their escalating clinical burden, the cellular mechanisms underpinning checkpoint-inhibitor induced autoimmunity remain poorly understood.\n\nIn this proposal I will investigate the hypothesis that induction of Tfh responses is a general feature of autoimmunity, reflecting a loss of costimulatory (checkpoint) control. I will explore how CTLA-4 and PD-1 co-operate to regulate Tfh differentiation, and establish the consequence of a Tfh response for tissue autoimmunity. Insights will be drawn from autoimmune patients treated with CTLA-4-Ig, and cancer patients treated with CTLA-4 antibodies. Building on exciting preliminary data, I will determine whether Tfh populations have value in predicting outcomes in classical autoimmunity as well as in checkpoint-inhibitor induced disease.\n \n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Autoimmune Diseases","Autoimmunity","B-Lymphocytes","CTLA-4 Antigen","Humans","Mice","Neoplasms","Programmed Cell Death 1 Receptor","T-Lymphocytes, Helper-Inducer"]}
{"id":"360G-Wellcome-220767_Z_20_Z","title":"Solastalgia - The impacts of Environmental Change on mental health ","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2020-10-01T00:00:00+00:00","Internal ID":"220767/Z/20/Z","description":"A two year exploration of Solastalgia - mental distress specifically caused by environmental change, defined as a land disease of \"place-based lived experience\". \n\nOur team is a global collective of artists, researchers, designers, conservationists, technologists and activists from fields including psychology, arts, sustainability, sociology, design and medicine. Through the Hub we will place lived experiences at the forefront of understanding Solastalgia. We will use human centred design, storytelling and creative media arts to deeply explore human experiences and relationships with the natural world as an alternative to the current dominant, data-driven discourses. \n\nThrough a network of global field stations, sited in critical landscapes, we will work closely with local and indegnous communities to understand and communicate their connection to land and their lived experiences of climate change.  Looking at Solastalgia through the lens of these communities we will together explore the complex, fragile relationship of psyche and land. \n\nThrough the Hub we will open up this urgent and timely discussion to multiple audiences. Incorporating diverse knowledge and perspectives, lived experiences that are complex and layered through storytelling and artistic approaches we will identify context-specific pathways towards a sustainable future.\n","plannedDates":[{"endDate":"2023-09-30T00:00:00+00:00","startDate":"2021-10-01T00:00:00+00:00","startDateDateOnly":"2021-10-01","endDateDateOnly":"2023-09-30"}],"amountAwarded":486720,"Financial Year":"2020/21","Lead Applicant":"Ms Victoria Pratt","grantProgramme":[{"title":"Interdisciplinary Hub","title_keyword":"Interdisciplinary Hub"}],"Applicant Surname":"Pratt","Partnership Value":486720,"Approval Committee":"The Hub Selection Panel","Other Applicant(s)":"Mrs Kaisa Ker\u00e4t\u00e4r, Dr Ayesha Ahmad, Ms Sheila Ghelani, Mr Romit Raj, Ms Babitha George","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Invisible-Flock-Co","name":"Invisible Flock Co","addressCountry":"United Kingdom","id_and_name":"[\"Invisible Flock Co\", \"360G-Wellcome-ORG:Invisible-Flock-Co\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Invisible-Flock-Co","name":"Invisible Flock Co"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Solastalgia - The impacts of Environmental Change on mental health  A two year exploration of Solastalgia - mental distress specifically caused by environmental change, defined as a land disease of \"place-based lived experience\". \n\nOur team is a global collective of artists, researchers, designers, conservationists, technologists and activists from fields including psychology, arts, sustainability, sociology, design and medicine. Through the Hub we will place lived experiences at the forefront of understanding Solastalgia. We will use human centred design, storytelling and creative media arts to deeply explore human experiences and relationships with the natural world as an alternative to the current dominant, data-driven discourses. \n\nThrough a network of global field stations, sited in critical landscapes, we will work closely with local and indegnous communities to understand and communicate their connection to land and their lived experiences of climate change.  Looking at Solastalgia through the lens of these communities we will together explore the complex, fragile relationship of psyche and land. \n\nThrough the Hub we will open up this urgent and timely discussion to multiple audiences. Incorporating diverse knowledge and perspectives, lived experiences that are complex and layered through storytelling and artistic approaches we will identify context-specific pathways towards a sustainable future.\n","awardDateDateOnly":"2020-10-01","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Climate Change","Humans","Mental Health"]}
{"id":"360G-Wellcome-220764_Z_20_Z","title":"Detecting and Excluding Coronavirus disease 2019 (COVID-19) at the Point of Need","Region":"East of England","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220764/Z/20/Z","description":"Rapid diagnostics have been identified by the WHO R & D Blueprint as a critical unmet need for the control of COVID-19 - particularly in the absence of a vaccine and proven antiviral agents. Our primary objective is to develop a low cost, high performance rapid test for the detection and exclusion of SARS-CoV-2, the causative virus of coronavirus disease 2019 (COVID-19).\n\nThe technology will be made available in line with the Global Access Policy for Gavi-eligible countries that are most vulnerable to onward transmission of COVID-19 and of limited detection due to insufficient laboratory capacity. The RDT will be appropriate for assembly and manufacture with multiple quality-assured partners to meet demand.\n","plannedDates":[{"endDate":"2021-12-31T00:00:00+00:00","startDate":"2020-03-05T00:00:00+00:00","startDateDateOnly":"2020-03-05","endDateDateOnly":"2021-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Joe Fitchett","grantProgramme":[{"title":"Coronavirus","title_keyword":"Coronavirus"}],"Partnership Name":"Wellcome-DFID Epidemic Preparedness","Applicant Surname":"Fitchett","Partnership Value":888104,"Approval Committee":"Epidemic Technical Advisory Panel","Other Applicant(s)":"Dr Amadou Sall, Dr Emily Adams, Prof Luis Cuevas, Prof Sanjeev Krishna","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Mologic-Ltd","name":"Mologic Ltd","addressCountry":"United Kingdom","id_and_name":"[\"Mologic Ltd\", \"360G-Wellcome-ORG:Mologic-Ltd\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Mologic-Ltd","name":"Mologic Ltd"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Detecting and Excluding Coronavirus disease 2019 (COVID-19) at the Point of Need Rapid diagnostics have been identified by the WHO R & D Blueprint as a critical unmet need for the control of COVID-19 - particularly in the absence of a vaccine and proven antiviral agents. Our primary objective is to develop a low cost, high performance rapid test for the detection and exclusion of SARS-CoV-2, the causative virus of coronavirus disease 2019 (COVID-19).\n\nThe technology will be made available in line with the Global Access Policy for Gavi-eligible countries that are most vulnerable to onward transmission of COVID-19 and of limited detection due to insufficient laboratory capacity. The RDT will be appropriate for assembly and manufacture with multiple quality-assured partners to meet demand.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Coronavirus Infections","Humans"]}
{"id":"360G-Wellcome-220759_Z_20_Z","title":"Sleep circuitry: linking homeostasis, sedation and stress","Region":"Greater London","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220759/Z/20/Z","description":"This proposal aims to understand:\n1) What circuitries sense the inexorable drive to sleep when we are sleep-deprived?  We will investigate if sleep need is sensed locally in the brain by a distributed circuit network that feeds into a central hub, the lateral hypothalamus, providing global restorative sleep. We have identified neurons in the mouse prefrontal cortex, preoptic hypothalamus, and ventral tegmental area (VTA) that sense sleep need and contribute to inducing sleep after sleep deprivation. Learning how responses to sleep deprivation are embedded in distributed sleep circuitry would explain how sleep homeostasis works at the circuit level.\n2) Do sedative drugs promote these restorative sleep pathways? How do two important drugs, propofol and dexmedetomidine, intervene in the sleep-homeostasis circuitry? We will search for cells that respond to sedatives to induce restorative  sleep without deleterious effects (hypothermia). Understanding this circuitry may identify new drug targets.\n3) What is the significance of sleep-promoting circuitry we have discovered in the basal ganglia and midbrain (globus pallidus to lateral habenula to VTA to lateral hypothalamus), which overlaps with circuitry that responds to aversive outcomes and stress? We will investigate if this basal ganglia-triggered sleep helps offline processing of negative experience.\n","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":2388796,"Financial Year":"2019/20","Lead Applicant":"Prof Nicholas Franks","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Franks","Partnership Value":2388796,"Approval Committee":"Science Interview Panel","Other Applicant(s)":"Prof William Wisden","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Sleep circuitry: linking homeostasis, sedation and stress This proposal aims to understand:\n1) What circuitries sense the inexorable drive to sleep when we are sleep-deprived?  We will investigate if sleep need is sensed locally in the brain by a distributed circuit network that feeds into a central hub, the lateral hypothalamus, providing global restorative sleep. We have identified neurons in the mouse prefrontal cortex, preoptic hypothalamus, and ventral tegmental area (VTA) that sense sleep need and contribute to inducing sleep after sleep deprivation. Learning how responses to sleep deprivation are embedded in distributed sleep circuitry would explain how sleep homeostasis works at the circuit level.\n2) Do sedative drugs promote these restorative sleep pathways? How do two important drugs, propofol and dexmedetomidine, intervene in the sleep-homeostasis circuitry? We will search for cells that respond to sedatives to induce restorative  sleep without deleterious effects (hypothermia). Understanding this circuitry may identify new drug targets.\n3) What is the significance of sleep-promoting circuitry we have discovered in the basal ganglia and midbrain (globus pallidus to lateral habenula to VTA to lateral hypothalamus), which overlaps with circuitry that responds to aversive outcomes and stress? We will investigate if this basal ganglia-triggered sleep helps offline processing of negative experience.\n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Homeostasis","Hypnotics and Sedatives","Hypothalamus","Mice","Mice, Inbred C57BL","Mice, Transgenic","Neurons","Prefrontal Cortex","Propofol","Sleep","Sleep Deprivation","Ventral Tegmental Area","Wakefulness"]}
{"id":"360G-Wellcome-220758_Z_20_Z","title":"MQ Strategy Implementation 2020/2021","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220758/Z/20/Z","description":"This grant will enable MQ to deliver two key activities in 2020/21: the implementation of our income generation strategy, and the development and delivery of the MQ Annual Mental Health Science Meeting 2021.\n\nMQ exists to \u2018create a world where mental illness is understood, effectively treated and one-day prevented\u2019. In 2019, MQ worked with the agency Open Creates to develop a new income generation strategy to deliver these ambitions - bringing the public and scientists together to fund ground-breaking mental health research, more quickly.\n\nWith the support of this grant, MQ will work with Open Creates to define and test priority research themes that align with the views of target audiences. Following identification of priority theme(s), MQ will then roll out activity to build public awareness, engage and grow a base of supporters, and raise funds for mental health research against a compelling research and organisational strategy.\n\nThis grant will also support MQ to work with the mental health science community and key supporters to develop and deliver a successful Mental Health Science Meeting in 2021, championing collaboration and knowledge sharing amongst researchers, and showcasing the potential of mental health science to excite and motivate our supporters and stakeholders.\n","plannedDates":[{"endDate":"2021-06-30T00:00:00+00:00","startDate":"2020-01-09T00:00:00+00:00","startDateDateOnly":"2020-01-09","endDateDateOnly":"2021-06-30"}],"amountAwarded":150000,"Financial Year":"2019/20","Lead Applicant":"Ms Emily Wheeler","grantProgramme":[{"title":"Discretionary Award - Mental Health","title_keyword":"Discretionary Award - Mental Health"}],"Applicant Surname":"Wheeler","Partnership Value":150000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:MQ-Transforming-Mental-Health","name":"MQ Transforming Mental Health","addressCountry":"United Kingdom","id_and_name":"[\"MQ Transforming Mental Health\", \"360G-Wellcome-ORG:MQ-Transforming-Mental-Health\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:MQ-Transforming-Mental-Health","name":"MQ Transforming Mental Health"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"MQ Strategy Implementation 2020/2021 This grant will enable MQ to deliver two key activities in 2020/21: the implementation of our income generation strategy, and the development and delivery of the MQ Annual Mental Health Science Meeting 2021.\n\nMQ exists to \u2018create a world where mental illness is understood, effectively treated and one-day prevented\u2019. In 2019, MQ worked with the agency Open Creates to develop a new income generation strategy to deliver these ambitions - bringing the public and scientists together to fund ground-breaking mental health research, more quickly.\n\nWith the support of this grant, MQ will work with Open Creates to define and test priority research themes that align with the views of target audiences. Following identification of priority theme(s), MQ will then roll out activity to build public awareness, engage and grow a base of supporters, and raise funds for mental health research against a compelling research and organisational strategy.\n\nThis grant will also support MQ to work with the mental health science community and key supporters to develop and deliver a successful Mental Health Science Meeting in 2021, championing collaboration and knowledge sharing amongst researchers, and showcasing the potential of mental health science to excite and motivate our supporters and stakeholders.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biomedical Research","Humans","Mental Disorders","Mental Health","Research Support as Topic"]}
{"id":"360G-Wellcome-220757_Z_20_Z","title":"Malawi-Liverpool-Wellcome Trust COVID-19 Epidemic Preparedness","Region":"North West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220757/Z/20/Z","description":"Malawi is at high risk of COVID-19 epidemic spread, the healthcare system is fragile and the population vulnerable to severe disease. This application proposes Malawi Liverpool Wellcome Trust Clinical Research Programme preparedness activities for epidemic COVID-19 disease. These are split into three work packages: 1) Diagnostic capacity and genomics surveillance; 2) Secondary care; 3) Epidemiology and control. Strategically, we have designed our activities to develop a platform for MLW to rapidly pivot into response mode to both support the healthcare system and deliver excellent research for current and future epidemic disease threats.\n\nKey goals for this proposal are:\n\n\n Provide diagnostic capability in Malawi for the COVID-19 epidemic\n Develop clinical and epidemiological tools to manage epidemic disease in Malawi\n\n","plannedDates":[{"endDate":"2021-07-19T00:00:00+00:00","startDate":"2020-03-20T00:00:00+00:00","startDateDateOnly":"2020-03-20","endDateDateOnly":"2021-07-19"}],"amountAwarded":124963,"Financial Year":"2019/20","Lead Applicant":"Dr Ben Morton","grantProgramme":[{"title":"Coronavirus","title_keyword":"Coronavirus"}],"Partnership Name":"Wellcome-DFID Epidemic Preparedness","Applicant Surname":"Morton","Partnership Value":249926,"Approval Committee":"Epidemic Technical Advisory Panel","Other Applicant(s)":"Prof Henry Mwandumba, Dr Jennifer Cornick, Dr Peter MacPherson, Prof Stephen Gordon","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"Liverpool School of Tropical Medicine\", \"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Malawi-Liverpool-Wellcome Trust COVID-19 Epidemic Preparedness Malawi is at high risk of COVID-19 epidemic spread, the healthcare system is fragile and the population vulnerable to severe disease. This application proposes Malawi Liverpool Wellcome Trust Clinical Research Programme preparedness activities for epidemic COVID-19 disease. These are split into three work packages: 1) Diagnostic capacity and genomics surveillance; 2) Secondary care; 3) Epidemiology and control. Strategically, we have designed our activities to develop a platform for MLW to rapidly pivot into response mode to both support the healthcare system and deliver excellent research for current and future epidemic disease threats.\n\nKey goals for this proposal are:\n\n\n Provide diagnostic capability in Malawi for the COVID-19 epidemic\n Develop clinical and epidemiological tools to manage epidemic disease in Malawi\n\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Epidemics","Humans","Malawi"]}
{"id":"360G-Wellcome-220755_Z_20_Z","title":"Does stroke impair immunological memory and increase infectious disease risk during the chronic phase of recovery","Region":"Scotland","currency":"GBP","awardDate":"2020-06-17T00:00:00+00:00","Sponsor(s)":"Prof Christopher Gregory","Internal ID":"220755/Z/20/Z","description":"Stroke patients are increasingly surviving long-term after the primary neurological insult. Post-stroke complications have thus rapidly become an area of unmet clinical need. Infection is a common and dangerous complication of stroke associated with increased death and disability. Stroke-induced immune suppression is associated with infection susceptibility, but the majority of studies have focused on short-term (hours to days) changes to immune function. My recent data show early reduced numbers of lymphocytes and dendritic cells in experimental and clinical settings. It is unknown whether this impacts adaptive immune function and immunological memory. Using experimental animal models and parallel analysis of population health data sets, key goals of this proposal are:\n\n1. To understand the extent and persistence of changes to adaptive immune cells after stroke and how this relates to infection susceptibility.\n2. To determine if previously generated adaptive immunological memory is lost after stroke.\n3. To determine if generation of new adaptive immunological memory is impaired after stroke.\n\nThis will generate understanding of the extent of adaptive immune memory deficits after stroke and the window of susceptibility in which stroke patients are vulnerable to infection and could result in new therapeutic approaches to reduce infection and improve long-term patient outcome. \n","plannedDates":[{"endDate":"2026-01-31T00:00:00+00:00","startDate":"2021-02-01T00:00:00+00:00","startDateDateOnly":"2021-02-01","endDateDateOnly":"2026-01-31"}],"amountAwarded":1016701,"Financial Year":"2019/20","Lead Applicant":"Dr Laura McCulloch","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"McCulloch","Partnership Value":1016701,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Does stroke impair immunological memory and increase infectious disease risk during the chronic phase of recovery Stroke patients are increasingly surviving long-term after the primary neurological insult. Post-stroke complications have thus rapidly become an area of unmet clinical need. Infection is a common and dangerous complication of stroke associated with increased death and disability. Stroke-induced immune suppression is associated with infection susceptibility, but the majority of studies have focused on short-term (hours to days) changes to immune function. My recent data show early reduced numbers of lymphocytes and dendritic cells in experimental and clinical settings. It is unknown whether this impacts adaptive immune function and immunological memory. Using experimental animal models and parallel analysis of population health data sets, key goals of this proposal are:\n\n1. To understand the extent and persistence of changes to adaptive immune cells after stroke and how this relates to infection susceptibility.\n2. To determine if previously generated adaptive immunological memory is lost after stroke.\n3. To determine if generation of new adaptive immunological memory is impaired after stroke.\n\nThis will generate understanding of the extent of adaptive immune memory deficits after stroke and the window of susceptibility in which stroke patients are vulnerable to infection and could result in new therapeutic approaches to reduce infection and improve long-term patient outcome. \n","awardDateDateOnly":"2020-06-17","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adaptive Immunity","Animals","Disease Models, Animal","Humans","Immunologic Memory","Stroke"]}
{"id":"360G-Wellcome-220752_Z_20_Z","title":"Decoding Genetic Studies from Pakistan - A Review of International, Regional and Local Guidelines and Compliance.","Region":"International","currency":"GBP","awardDate":"2020-03-02T00:00:00+00:00","Internal ID":"220752/Z/20/Z","description":"I conducted research for my Masters thesis to explore, identify and examine ethical guidelines available for genetic studies and to then analyse and describe the extent to which researchers in Pakistan, comply with existing ethical standards specified for genetic research. I report in my thesis that there are no guidelines for genetic research, gene therapy or gene editing in Pakistan. I also found some other patterns in the studies reviewed that I would like to present in the form of a publication in a peer reviewed journal as I feel they will provide a foundation of behavioural practises of researchers in Pakistan.\n\nI would also like to use the findings as a starting point to develop and propose guidelines for researchers for genetic research, gene therapy and gene editing in Pakistan. I want to propose guidelines that can be incorporated effectively into practise for which I will need to identify effective training, implementation and monitoring of the guidelines.\n\nKey goals:\n\n1. Develop a better understanding of the ethical review process of international collaborations in the UK\n\n2. Produce a draft of a paper for submission to a peer reviewed journal\n\n3. Propose an outline of guidelines for researchers in Pakistan\n","plannedDates":[{"endDate":"2021-11-01T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2021-11-01"}],"amountAwarded":4707,"Financial Year":"2019/20","Lead Applicant":"Dr Natasha Anwar","grantProgramme":[{"title":"Global Forum on Bioethics in Research","title_keyword":"Global Forum on Bioethics in Research"}],"Applicant Surname":"Anwar","Partnership Value":4707,"Approval Committee":"Global Forum on Bioethics in Research Fellowships Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:The-Aga-Khan-University-Pakistan","name":"The Aga Khan University, Pakistan","addressCountry":"Pakistan","id_and_name":"[\"The Aga Khan University, Pakistan\", \"360G-Wellcome-ORG:The-Aga-Khan-University-Pakistan\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:The-Aga-Khan-University-Pakistan","name":"The Aga Khan University, Pakistan"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Decoding Genetic Studies from Pakistan - A Review of International, Regional and Local Guidelines and Compliance. I conducted research for my Masters thesis to explore, identify and examine ethical guidelines available for genetic studies and to then analyse and describe the extent to which researchers in Pakistan, comply with existing ethical standards specified for genetic research. I report in my thesis that there are no guidelines for genetic research, gene therapy or gene editing in Pakistan. I also found some other patterns in the studies reviewed that I would like to present in the form of a publication in a peer reviewed journal as I feel they will provide a foundation of behavioural practises of researchers in Pakistan.\n\nI would also like to use the findings as a starting point to develop and propose guidelines for researchers for genetic research, gene therapy and gene editing in Pakistan. I want to propose guidelines that can be incorporated effectively into practise for which I will need to identify effective training, implementation and monitoring of the guidelines.\n\nKey goals:\n\n1. Develop a better understanding of the ethical review process of international collaborations in the UK\n\n2. Produce a draft of a paper for submission to a peer reviewed journal\n\n3. Propose an outline of guidelines for researchers in Pakistan\n","awardDateDateOnly":"2020-03-02","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biomedical Research","Ethics, Research","Genetic Therapy","Guidelines as Topic","Humans","Pakistan"]}
{"id":"360G-Wellcome-220749_Z_20_Z","title":"Asian Clinical Trial Network","Region":"International","currency":"GBP","awardDate":"2021-03-31T00:00:00+00:00","Internal ID":"220749/Z/20/Z","description":"Drug-resistant infections (DRIs) have recently been recognised as a major challenge by the G20 and the UN General Assembly, with a disproportionate impact on the people of Asia. Potential solutions will require multidisciplinary and multi-country collaboration in order to successfully address in terms of innovative discoveries, implementation of policies and roll-out and evaluation of the best evidence based clinical practices. \n\nThe current model of clinical research in low and middle-income countries (LMICs) is to fund individual clinical trials on an ad-hoc basis, with each trial requiring significant investment in research infrastructure and skills development in addition to the trial-specific costs. This model is inefficient scientifically, developmentally, and financially. \n\nIn response to the challenge of AMR, Wellcome plans to set up a pilot clinical trial network (CTN) in SEA. The CTN will significantly increase the quality and efficiency of clinical trials in the region, resulting in an improved understanding of DRI, improved treatment of those infections and an increase in the supply of new drugs to fight AMR. The support hub for this clinical trial network will be based in Singapore.\n \n","plannedDates":[{"endDate":"2024-02-09T00:00:00+00:00","startDate":"2021-02-10T00:00:00+00:00","startDateDateOnly":"2021-02-10","endDateDateOnly":"2024-02-09"}],"amountAwarded":1335301,"Financial Year":"2020/21","Lead Applicant":"Dr Li Yang Hsu","grantProgramme":[{"title":"Discretionary award \u2013 DRI","title_keyword":"Discretionary award \u2013 DRI"}],"Partnership Name":"Network for Clinical Research in Asia","Applicant Surname":"Hsu","Partnership Value":1335302,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:National-University-of-Singapore","name":"National University of Singapore","addressCountry":"Singapore","id_and_name":"[\"National University of Singapore\", \"360G-Wellcome-ORG:National-University-of-Singapore\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:National-University-of-Singapore","name":"National University of Singapore"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Asian Clinical Trial Network Drug-resistant infections (DRIs) have recently been recognised as a major challenge by the G20 and the UN General Assembly, with a disproportionate impact on the people of Asia. Potential solutions will require multidisciplinary and multi-country collaboration in order to successfully address in terms of innovative discoveries, implementation of policies and roll-out and evaluation of the best evidence based clinical practices. \n\nThe current model of clinical research in low and middle-income countries (LMICs) is to fund individual clinical trials on an ad-hoc basis, with each trial requiring significant investment in research infrastructure and skills development in addition to the trial-specific costs. This model is inefficient scientifically, developmentally, and financially. \n\nIn response to the challenge of AMR, Wellcome plans to set up a pilot clinical trial network (CTN) in SEA. The CTN will significantly increase the quality and efficiency of clinical trials in the region, resulting in an improved understanding of DRI, improved treatment of those infections and an increase in the supply of new drugs to fight AMR. The support hub for this clinical trial network will be based in Singapore.\n \n","awardDateDateOnly":"2021-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Asia","Clinical Trials as Topic","Developing Countries","Humans","Singapore"]}
{"id":"360G-Wellcome-220748_Z_20_Z","title":"Young European Takes on \u201cHealthy Lives and Well-Being for all\u201d","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220748/Z/20/Z","description":"The European Youth Parliament (EYP) is based on the idea that the great challenges of our time cannot be tackled on a national level alone, but need to be addressed multilaterally. Moreover, the EYP leverages a new generation of young changemakers to be part of the solution.\n\nAs the umbrella organisation of the EYP, the Schwarzkopf Foundation Young Europe is proposing a project that will bring various interconnections between \"Health\" and \"Politics\" to the forefront of debate among young people across Europe. The project will bring together young people from across Europe with decision-makers and experts, to debate today\u2019s pressing topics in the field of health, and to develop positions that will be shared with decision-makers and the public. Discussions will take place in a variety of formats and settings, constituting a broad consultation process that will aggregate \"young opinions\" from across Europe, which are then to be shared in close-up debates with decision-makers (especially in the context of Germany\u2019s EU Council presidency) - as well as with young peers, and the broader public.\n","plannedDates":[{"endDate":"2021-05-01T00:00:00+00:00","startDate":"2020-04-01T00:00:00+00:00","startDateDateOnly":"2020-04-01","endDateDateOnly":"2021-05-01"}],"amountAwarded":79890,"Financial Year":"2019/20","Lead Applicant":"Mr Lukas Fendel","grantProgramme":[{"title":"Discretionary Award - Policy ","title_keyword":"Discretionary Award - Policy "}],"Applicant Surname":"Fendel","Partnership Value":79890,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Schwarzkopf-Stiftung-Junges-Europa","name":"Schwarzkopf Stiftung Junges Europa","addressCountry":"Germany","id_and_name":"[\"Schwarzkopf Stiftung Junges Europa\", \"360G-Wellcome-ORG:Schwarzkopf-Stiftung-Junges-Europa\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Schwarzkopf-Stiftung-Junges-Europa","name":"Schwarzkopf Stiftung Junges Europa"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Young European Takes on \u201cHealthy Lives and Well-Being for all\u201d The European Youth Parliament (EYP) is based on the idea that the great challenges of our time cannot be tackled on a national level alone, but need to be addressed multilaterally. Moreover, the EYP leverages a new generation of young changemakers to be part of the solution.\n\nAs the umbrella organisation of the EYP, the Schwarzkopf Foundation Young Europe is proposing a project that will bring various interconnections between \"Health\" and \"Politics\" to the forefront of debate among young people across Europe. The project will bring together young people from across Europe with decision-makers and experts, to debate today\u2019s pressing topics in the field of health, and to develop positions that will be shared with decision-makers and the public. Discussions will take place in a variety of formats and settings, constituting a broad consultation process that will aggregate \"young opinions\" from across Europe, which are then to be shared in close-up debates with decision-makers (especially in the context of Germany\u2019s EU Council presidency) - as well as with young peers, and the broader public.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adolescent","Decision Making","Europe","European Union","Germany","Humans"]}
{"id":"360G-Wellcome-220747_Z_20_Z","title":"Defining optimal interventions for Perinatal Anxiety (PNA) in a general practice population: a mixed methods study.","Region":"West Midlands","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220747/Z/20/Z","description":"Background to the research problem \n\nPerinatal anxiety (PNA) is anxiety that occurs during pregnancy or up to twelve months postpartum. The global prevalence of PNA is estimated to be over 15% and at least as common as perinatal depression (PND).  PNA can adversely impact both mother and child. Whereas a significant amount of research has been conducted into PND; i in comparison there is very little work published that reviews PNA. The National Institute for Health and Clinical Excellence has recommended that further research is needed in order to develop psychological interventions to identify and treat moderate to severe anxiety disorders in pregnancy which is where my research intends to fill a vital gap. \n\nMy approach\n\nMy PhD aims to define optimal interventions for PNA. The PhD comprises of several parts including a systematic review of published literature, interviews with PNA stakeholders such as patients and professionals who deliver perinatal care with the final aim to co-develop an intervention for PNA with stakeholders.\n\nExpected impact of my work \n\nAfter development of an intervention I hope to secure funding after my PhD to test it. I hope that it may be recognised and recommended in clinical practice. \n","plannedDates":[{"endDate":"2022-12-08T00:00:00+00:00","startDate":"2019-09-30T00:00:00+00:00","startDateDateOnly":"2019-09-30","endDateDateOnly":"2022-12-08"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Victoria Silverwood","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Silverwood","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Keele-University","name":"Keele University","addressCountry":"United Kingdom","id_and_name":"[\"Keele University\", \"360G-Wellcome-ORG:Keele-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Keele-University","name":"Keele University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Defining optimal interventions for Perinatal Anxiety (PNA) in a general practice population: a mixed methods study. Background to the research problem \n\nPerinatal anxiety (PNA) is anxiety that occurs during pregnancy or up to twelve months postpartum. The global prevalence of PNA is estimated to be over 15% and at least as common as perinatal depression (PND).  PNA can adversely impact both mother and child. Whereas a significant amount of research has been conducted into PND; i in comparison there is very little work published that reviews PNA. The National Institute for Health and Clinical Excellence has recommended that further research is needed in order to develop psychological interventions to identify and treat moderate to severe anxiety disorders in pregnancy which is where my research intends to fill a vital gap. \n\nMy approach\n\nMy PhD aims to define optimal interventions for PNA. The PhD comprises of several parts including a systematic review of published literature, interviews with PNA stakeholders such as patients and professionals who deliver perinatal care with the final aim to co-develop an intervention for PNA with stakeholders.\n\nExpected impact of my work \n\nAfter development of an intervention I hope to secure funding after my PhD to test it. I hope that it may be recognised and recommended in clinical practice. \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anxiety","Anxiety Disorders","Female","Humans","Perinatal Care","Pregnancy"]}
{"id":"360G-Wellcome-220745_Z_20_Z","title":"GMCDP Archive Assessment and Collections Appraisal","Region":"North East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220745/Z/20/Z","description":"GMCDP\u2019s archive collection reveals the changing perspectives, language and attitudes towards disabled people that have occurred over recent decades. It highlights changes in medical practices, discussions and debates around bio-ethics and end of life issues, campaigns for independent living, the self-organisation of disabled people, development of disability culture, and the significant impact of wider health determinants.\n\n \n\nFollowing on from feedback on a previous application to Wellcome Trust, GMCDP recognises the need to have a more detailed, specialist assessment of our collection in order to be able to move forwarded to the next stage. GMCDP are therefore seeking to carry out an archivist assessment and collections appraisal of our archives, and will commission Janice Tullock Associates (archivist) and Sharon Oldale (conservator) to provide the following outcomes:\n\n\n Survey the collection to assess its needs.\n Assess the level of cataloguing the collection requires.\n Develop a statement of the significance of the collection.\n Provide a detailed report on findings, with recommendations.\n Develop a project plan for the cataloguing of the archive.\n Assess the level of archivist and specialist input required throughout the duration of the project.\n Conservation assessment and recommendations.\n\n","plannedDates":[{"endDate":"2020-04-05T00:00:00+00:00","startDate":"2020-03-05T00:00:00+00:00","startDateDateOnly":"2020-03-05","endDateDateOnly":"2020-04-05"}],"amountAwarded":6275,"Financial Year":"2019/20","Lead Applicant":"Miss Nicola McDonagh","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"McDonagh","Partnership Value":6275,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Greater-Manchester-Coalition-of-Disabled-People","name":"Greater Manchester Coalition of Disabled People","addressCountry":"United Kingdom","id_and_name":"[\"Greater Manchester Coalition of Disabled People\", \"360G-Wellcome-ORG:Greater-Manchester-Coalition-of-Disabled-People\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Greater-Manchester-Coalition-of-Disabled-People","name":"Greater Manchester Coalition of Disabled People"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"GMCDP Archive Assessment and Collections Appraisal GMCDP\u2019s archive collection reveals the changing perspectives, language and attitudes towards disabled people that have occurred over recent decades. It highlights changes in medical practices, discussions and debates around bio-ethics and end of life issues, campaigns for independent living, the self-organisation of disabled people, development of disability culture, and the significant impact of wider health determinants.\n\n \n\nFollowing on from feedback on a previous application to Wellcome Trust, GMCDP recognises the need to have a more detailed, specialist assessment of our collection in order to be able to move forwarded to the next stage. GMCDP are therefore seeking to carry out an archivist assessment and collections appraisal of our archives, and will commission Janice Tullock Associates (archivist) and Sharon Oldale (conservator) to provide the following outcomes:\n\n\n Survey the collection to assess its needs.\n Assess the level of cataloguing the collection requires.\n Develop a statement of the significance of the collection.\n Provide a detailed report on findings, with recommendations.\n Develop a project plan for the cataloguing of the archive.\n Assess the level of archivist and specialist input required throughout the duration of the project.\n Conservation assessment and recommendations.\n\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Disabled Persons","Humans","Surveys and Questionnaires"]}
{"id":"360G-Wellcome-220740_Z_20_Z","title":"Assessing the impact of genetic variation on chronic kidney disease in Africa","Region":"Greater London","currency":"GBP","awardDate":"2020-06-23T00:00:00+00:00","Sponsor(s)":"Prof Moffat Nyirenda, Prof Andrew Morris","Internal ID":"220740/Z/20/Z","description":"In sub-Saharan Africa, over 50 million people have chronic kidney disease (CKD) making Africa the continent with the highest burden of CKD in the world. With rapidly increasing urbanisation, trends towards unhealthy diets, obesity and increases in metabolic risk factors, the projected increase in the prevalence of CKD may be even greater in Africa than in other parts of the world.\n\nOver the past decade, genome-wide association studies have uncovered numerous genetic determinants of CKD in European and Asian ancestry populations. These studies have led to numerous novel findings, which are helping improve our understanding of factors and pathways affecting both normal and pathologic kidney function. However, to date, there is no known published GWAS of CKD in any continental African population.  \n\nKey goals include\n\n\n Conduct large-scale genomic studies of CKD in Africa which will potentially provide new opportunities to identify the biological determinants of CKD in individuals of African ancestry.\n Leverage the low linkage disequilibrium between genetic markers in African populations to conduct fine-mapping of novel and previously identified signals in the trans-ethnic meta-analysis.\n Develop a Polygenic Risk Score for CKD risk in Africa and assess whether cardiometabolic traits/diseases are causally related to the risk of CKD in Africans.\n\n","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":917588,"Financial Year":"2019/20","Lead Applicant":"Dr Segun Fatumo","grantProgramme":[{"title":"International Intermediate Fellowship","title_keyword":"International Intermediate Fellowship"}],"Applicant Surname":"Fatumo","Partnership Value":917588,"Approval Committee":"International Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"London School of Hygiene & Tropical Medicine\", \"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Assessing the impact of genetic variation on chronic kidney disease in Africa In sub-Saharan Africa, over 50 million people have chronic kidney disease (CKD) making Africa the continent with the highest burden of CKD in the world. With rapidly increasing urbanisation, trends towards unhealthy diets, obesity and increases in metabolic risk factors, the projected increase in the prevalence of CKD may be even greater in Africa than in other parts of the world.\n\nOver the past decade, genome-wide association studies have uncovered numerous genetic determinants of CKD in European and Asian ancestry populations. These studies have led to numerous novel findings, which are helping improve our understanding of factors and pathways affecting both normal and pathologic kidney function. However, to date, there is no known published GWAS of CKD in any continental African population.  \n\nKey goals include\n\n\n Conduct large-scale genomic studies of CKD in Africa which will potentially provide new opportunities to identify the biological determinants of CKD in individuals of African ancestry.\n Leverage the low linkage disequilibrium between genetic markers in African populations to conduct fine-mapping of novel and previously identified signals in the trans-ethnic meta-analysis.\n Develop a Polygenic Risk Score for CKD risk in Africa and assess whether cardiometabolic traits/diseases are causally related to the risk of CKD in Africans.\n\n","awardDateDateOnly":"2020-06-23","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["African Continental Ancestry Group","Cardiovascular Diseases","Genetic Predisposition to Disease","Genome-Wide Association Study","Humans","Multifactorial Inheritance","Polymorphism, Single Nucleotide","Renal Insufficiency, Chronic","Risk Factors"]}
{"id":"360G-Wellcome-220738_Z_20_Z","title":"Teacher Research Grant - Project Evaluation","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220738/Z/20/Z","description":"Not available","plannedDates":[{"endDate":"2022-02-18T00:00:00+00:00","startDate":"2020-01-20T00:00:00+00:00","startDateDateOnly":"2020-01-20","endDateDateOnly":"2022-02-18"}],"amountAwarded":176431,"Financial Year":"2019/20","Lead Applicant":"Dr Bronwen Maxwell","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Maxwell","Partnership Value":176431,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Sheffield-Hallam-University","name":"Sheffield Hallam University","addressCountry":"United Kingdom","id_and_name":"[\"Sheffield Hallam University\", \"360G-Wellcome-ORG:Sheffield-Hallam-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Sheffield-Hallam-University","name":"Sheffield Hallam University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Teacher Research Grant - Project Evaluation Not available","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Research"]}
{"id":"360G-Wellcome-220737_Z_20_Z","title":"Elucidating the mechanisms and functions of bacterial-derived mediators on Plasmodium falciparum. ","Region":"International","currency":"GBP","awardDate":"2020-06-23T00:00:00+00:00","Sponsor(s)":"Dr Lisa Ranford-Cartwright, Dr Samuel Dadzie","Internal ID":"220737/Z/20/Z","description":"Some bacteria species in the mosquito midgut demonstrate anti-Plasmodial effect independent of the mosquito immune system. Understanding this mechanism could help propose bacteria-mediated strategies for targeting and blocking transmission without producing transgenic bacteria. This project proposes to identify mosquito midgut bacteria that secrete anti-parasitic factors and investigate their variations in natural Anopheles mosquito populations. Mosquito stages of P. falciparum will be exposed to spent culture media of midgut bacteria species through in vitro and in vivo (using axenic mosquitoes) assays and developmental and functional parasite effects assessed by immunofluorescence microscopy. The biological significance of the bacteria secreted products will be confirmed by comparing with parasite exposure to bacteria cells. The natural prevalence of effective bacteria will be investigated in blood-fed field-caught Anopheles malaria vector species from areas of high and low malaria transmission using 16S sequencing. In addition, bacterial metabolites will be identified by LC MS/MS for further investigations into their mechanisms of cell activity. It is expected that results from this study will increase our knowledge in the biological role of specific bacteria in natural variations of vector competence and reveal bacterial products from mosquito microbiome that can be further explored for parasite transmission-blocking in the mosquitoes.\n","plannedDates":[{"endDate":"2026-01-31T00:00:00+00:00","startDate":"2021-02-01T00:00:00+00:00","startDateDateOnly":"2021-02-01","endDateDateOnly":"2026-01-31"}],"amountAwarded":613982,"Financial Year":"2019/20","Lead Applicant":"Dr Jewelna Akorli","grantProgramme":[{"title":"International Intermediate Fellowship","title_keyword":"International Intermediate Fellowship"}],"Applicant Surname":"Akorli","Partnership Value":613982,"Approval Committee":"International Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Noguchi-Memorial-Institute-for-Medical-Research","name":"Noguchi Memorial Institute for Medical Research","addressCountry":"Ghana","id_and_name":"[\"Noguchi Memorial Institute for Medical Research\", \"360G-Wellcome-ORG:Noguchi-Memorial-Institute-for-Medical-Research\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Noguchi-Memorial-Institute-for-Medical-Research","name":"Noguchi Memorial Institute for Medical Research"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Elucidating the mechanisms and functions of bacterial-derived mediators on Plasmodium falciparum.  Some bacteria species in the mosquito midgut demonstrate anti-Plasmodial effect independent of the mosquito immune system. Understanding this mechanism could help propose bacteria-mediated strategies for targeting and blocking transmission without producing transgenic bacteria. This project proposes to identify mosquito midgut bacteria that secrete anti-parasitic factors and investigate their variations in natural Anopheles mosquito populations. Mosquito stages of P. falciparum will be exposed to spent culture media of midgut bacteria species through in vitro and in vivo (using axenic mosquitoes) assays and developmental and functional parasite effects assessed by immunofluorescence microscopy. The biological significance of the bacteria secreted products will be confirmed by comparing with parasite exposure to bacteria cells. The natural prevalence of effective bacteria will be investigated in blood-fed field-caught Anopheles malaria vector species from areas of high and low malaria transmission using 16S sequencing. In addition, bacterial metabolites will be identified by LC MS/MS for further investigations into their mechanisms of cell activity. It is expected that results from this study will increase our knowledge in the biological role of specific bacteria in natural variations of vector competence and reveal bacterial products from mosquito microbiome that can be further explored for parasite transmission-blocking in the mosquitoes.\n","awardDateDateOnly":"2020-06-23","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Anopheles","Bacteria","Chromatography, Liquid","Gastrointestinal Microbiome","Malaria, Falciparum","Microbiota","Mosquito Vectors","Plasmodium falciparum"]}
{"id":"360G-Wellcome-220727_Z_20_Z","title":"The role of IDH mutation in liver cell plasticity and cancer","Region":"Scotland","currency":"GBP","awardDate":"2020-10-05T00:00:00+00:00","Sponsor(s)":"Prof Stephen Wigmore","Internal ID":"220727/Z/20/Z","description":"The application of next generation sequencing to bile duct cancers (cholangiocarcinoma) has revealed a subgroup with mutations in the Isocitrate Dehydrogenase (IDH1, IDH2) genes, which appear non-overlapping with other drivers including TP53 and KRAS and which are associated with relatively favourable, but still poor, clinical prognosis. IDH1/2 mutations result in neomorphic production of the oncometabolite 2-hydroxyglutarate (2HG), which causes cell toxicity, DNA hypermethylation, and repression of cellular differentiation. This project tests two hypotheses. First, it seeks to determine whether 2HG production can metabolically reprogramme liver cell identity, triggering a cell fate change from a hepatocyte to a biliary phenotype, thereby promoting the formation of cholangiocarcinoma. I will seek to define the cell populations in the liver in which IDH1 mutations occur in disease and use lineage tracing techniques to establish whether IDH1 mutation results in an increase in hepatic progenitor or ductal cells in vivo, as well as which cell types give rise to these ductular reactions. Second, I shall examine whether 2HG causes non-cell-autonomous local toxicity or inflammation, and determine whether this contributes to tumorigenesis. My results will elucidate fundamental mechanisms of biliary carcinogenesis and suggest the likely efficacy of targeted 2HG inhibition or, indeed, 2HG overexpression.\n","plannedDates":[{"endDate":"2025-08-03T00:00:00+00:00","startDate":"2021-08-04T00:00:00+00:00","startDateDateOnly":"2021-08-04","endDateDateOnly":"2025-08-03"}],"amountAwarded":709662,"Financial Year":"2020/21","Lead Applicant":"Miss Rachel Guest","grantProgramme":[{"title":"Clinical Research Career Development Fellowship","title_keyword":"Clinical Research Career Development Fellowship"}],"Applicant Surname":"Guest","Partnership Value":709662,"Approval Committee":"Clinical Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The role of IDH mutation in liver cell plasticity and cancer The application of next generation sequencing to bile duct cancers (cholangiocarcinoma) has revealed a subgroup with mutations in the Isocitrate Dehydrogenase (IDH1, IDH2) genes, which appear non-overlapping with other drivers including TP53 and KRAS and which are associated with relatively favourable, but still poor, clinical prognosis. IDH1/2 mutations result in neomorphic production of the oncometabolite 2-hydroxyglutarate (2HG), which causes cell toxicity, DNA hypermethylation, and repression of cellular differentiation. This project tests two hypotheses. First, it seeks to determine whether 2HG production can metabolically reprogramme liver cell identity, triggering a cell fate change from a hepatocyte to a biliary phenotype, thereby promoting the formation of cholangiocarcinoma. I will seek to define the cell populations in the liver in which IDH1 mutations occur in disease and use lineage tracing techniques to establish whether IDH1 mutation results in an increase in hepatic progenitor or ductal cells in vivo, as well as which cell types give rise to these ductular reactions. Second, I shall examine whether 2HG causes non-cell-autonomous local toxicity or inflammation, and determine whether this contributes to tumorigenesis. My results will elucidate fundamental mechanisms of biliary carcinogenesis and suggest the likely efficacy of targeted 2HG inhibition or, indeed, 2HG overexpression.\n","awardDateDateOnly":"2020-10-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Bile Duct Neoplasms","Carcinogenesis","Cell Lineage","Cholangiocarcinoma","Humans","Isocitrate Dehydrogenase","Liver Neoplasms","Mice","Mutation"]}
{"id":"360G-Wellcome-220725_Z_20_Z","title":"Decoding macrophage functional heterogeneity in the pathogenesis of Crohn's disease","Region":"Scotland","currency":"GBP","awardDate":"2020-10-05T00:00:00+00:00","Sponsor(s)":"Dr Gwo-Tzer Ho","Internal ID":"220725/Z/20/Z","description":"The accumulation of intestinal macrophages (iMphis) and presence of a distinct mononuclear phagocyte gene-expression profile, predict treatment failure and adverse clinical outcomes in Crohn's disease (CD). Preliminary scRNA-seq data demonstrates that a transcriptionally distinct iMphi subtype (CD-MPhi) accumulates in human and murine colitis, which I have prospectively validated. Unbiased CD-MPhi-epithelium, ligand-receptor interaction analyses reveals CD-MPhi derived activin signals to cognate receptors on colonic epithelium. CD-MPhis are the exclusive iMphi source of activin in mouse and humans, a TGF-beta superfamily member with cell-specific cytokine, growth and hormone effects. Activin administration to human colonic epithelium inhibits proliferation with a dose-dependent effect on cytokine, chemokine and pattern recognition gene expression. \n\nAims\n\n\n Define iMphi heterogeneity and dynamics in CD \n Interrogate the functional role of a novel pathogenic subset (CD-MPhi) in regulating intestinal inflammation\n Investigate CD-MPhi driven activin signalling as a therapeutic target for intestinal inflammation\n\n\n \n\nMethods\nUsing a novel, human, biopsy-based sampling approach, I will perform scRNA-seq of iMphis in newly diagnosed, treatment naive CD patients, with longitudinal, flow cytometry-based intestinal characterisation to reveal iMphi dynamics over time. Lastly, I will manipulate cell-specific activin-signalling in transgenic animals and primary human epithelium co-culture models to probe the mechanisms of activin-mediated epithelium dysfunction in CD.\n\n \n","plannedDates":[{"endDate":"2025-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2025-03-31"}],"amountAwarded":788449,"Financial Year":"2020/21","Lead Applicant":"Dr Gareth-Rhys Jones","grantProgramme":[{"title":"Clinical Research Career Development Fellowship","title_keyword":"Clinical Research Career Development Fellowship"}],"Applicant Surname":"Jones","Partnership Value":788449,"Approval Committee":"Clinical Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Decoding macrophage functional heterogeneity in the pathogenesis of Crohn's disease The accumulation of intestinal macrophages (iMphis) and presence of a distinct mononuclear phagocyte gene-expression profile, predict treatment failure and adverse clinical outcomes in Crohn's disease (CD). Preliminary scRNA-seq data demonstrates that a transcriptionally distinct iMphi subtype (CD-MPhi) accumulates in human and murine colitis, which I have prospectively validated. Unbiased CD-MPhi-epithelium, ligand-receptor interaction analyses reveals CD-MPhi derived activin signals to cognate receptors on colonic epithelium. CD-MPhis are the exclusive iMphi source of activin in mouse and humans, a TGF-beta superfamily member with cell-specific cytokine, growth and hormone effects. Activin administration to human colonic epithelium inhibits proliferation with a dose-dependent effect on cytokine, chemokine and pattern recognition gene expression. \n\nAims\n\n\n Define iMphi heterogeneity and dynamics in CD \n Interrogate the functional role of a novel pathogenic subset (CD-MPhi) in regulating intestinal inflammation\n Investigate CD-MPhi driven activin signalling as a therapeutic target for intestinal inflammation\n\n\n \n\nMethods\nUsing a novel, human, biopsy-based sampling approach, I will perform scRNA-seq of iMphis in newly diagnosed, treatment naive CD patients, with longitudinal, flow cytometry-based intestinal characterisation to reveal iMphi dynamics over time. Lastly, I will manipulate cell-specific activin-signalling in transgenic animals and primary human epithelium co-culture models to probe the mechanisms of activin-mediated epithelium dysfunction in CD.\n\n \n","awardDateDateOnly":"2020-10-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Activins","Animals","Colon","Crohn Disease","Humans","Intestinal Mucosa","Macrophages","Mice","Signal Transduction"]}
{"id":"360G-Wellcome-220720_Z_20_Z","title":"Impact of metabolic resistance to pyrethroids on the vectorial competence of the major African malaria vector Anopheles funestus","Region":"Misc","currency":"GBP","awardDate":"2020-06-23T00:00:00+00:00","Sponsor(s)":"Prof Charles Wondji, Prof Flobert Njiokou","Internal ID":"220720/Z/20/Z","description":"Insecticide resistance is threatening effectiveness of insecticide-based interventions to control malaria across Africa. However, the impact of this resistance on malaria transmission remains a matter of debate. It is not yet well established whether insecticide resistance, particularly metabolic resistance, in addition to allow survival to insecticide exposure, positively or negatively affect capacity of vectors to develop and transmit malaria parasites. Taking advantage of the recent designs of the first simple DNA-based assays allowing to track cytochrome P450- and glutathione-S-transferase mediated metabolic resistance in the major malaria vector Anopheles funestus, this project aims at establishing the impact of metabolic resistance on malaria transmission in Africa, to improve resistance management. More specifically, I will: Aim1) Investigate the influence of metabolic resistance on the development of P. falciparum in An. funestus using GST and P450 markers; Aim2) Characterize the transcriptomic changes accompanying P. falciparum infection in metabolic insecticide resistant An. funestus using RNAseq; Aim3) Investigate interactions between metabolic resistance and Plasmodium immune response genes in An. funestus using functional genomics (RNAi).\n\nThis project will benefit from the expertise gained during my Wellcome Trust Training Fellowship including the successful rearing and establishment of experimental infections of field An. funestus using natural P. falciparum isolates.\n","plannedDates":[{"endDate":"2025-11-30T00:00:00+00:00","startDate":"2020-12-01T00:00:00+00:00","startDateDateOnly":"2020-12-01","endDateDateOnly":"2025-11-30"}],"amountAwarded":695284,"Financial Year":"2019/20","Lead Applicant":"Dr Cyrille Ndo","grantProgramme":[{"title":"International Intermediate Fellowship","title_keyword":"International Intermediate Fellowship"}],"Applicant Surname":"Ndo","Partnership Value":695284,"Approval Committee":"International Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Centre-for-Research-in-Infectious-Diseases-CRID","name":"Centre for Research in Infectious Diseases (CRID)","addressCountry":"Cameroon","id_and_name":"[\"Centre for Research in Infectious Diseases (CRID)\", \"360G-Wellcome-ORG:Centre-for-Research-in-Infectious-Diseases-CRID\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Centre-for-Research-in-Infectious-Diseases-CRID","name":"Centre for Research in Infectious Diseases (CRID)"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Impact of metabolic resistance to pyrethroids on the vectorial competence of the major African malaria vector Anopheles funestus Insecticide resistance is threatening effectiveness of insecticide-based interventions to control malaria across Africa. However, the impact of this resistance on malaria transmission remains a matter of debate. It is not yet well established whether insecticide resistance, particularly metabolic resistance, in addition to allow survival to insecticide exposure, positively or negatively affect capacity of vectors to develop and transmit malaria parasites. Taking advantage of the recent designs of the first simple DNA-based assays allowing to track cytochrome P450- and glutathione-S-transferase mediated metabolic resistance in the major malaria vector Anopheles funestus, this project aims at establishing the impact of metabolic resistance on malaria transmission in Africa, to improve resistance management. More specifically, I will: Aim1) Investigate the influence of metabolic resistance on the development of P. falciparum in An. funestus using GST and P450 markers; Aim2) Characterize the transcriptomic changes accompanying P. falciparum infection in metabolic insecticide resistant An. funestus using RNAseq; Aim3) Investigate interactions between metabolic resistance and Plasmodium immune response genes in An. funestus using functional genomics (RNAi).\n\nThis project will benefit from the expertise gained during my Wellcome Trust Training Fellowship including the successful rearing and establishment of experimental infections of field An. funestus using natural P. falciparum isolates.\n","awardDateDateOnly":"2020-06-23","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Anopheles","Cytochrome P-450 Enzyme System","Gene Expression Profiling","Glutathione Transferase","Insect Proteins","Insecticide Resistance","Insecticides","Malaria","Mosquito Vectors","Plasmodium falciparum"]}
{"id":"360G-Wellcome-220717_Z_20_Z","title":"Intimate partner violence against women in low- and middle-income countries: associations with parenting practices and early childhood development.","Region":"International","currency":"GBP","awardDate":"2020-06-23T00:00:00+00:00","Sponsor(s)":"Prof Aluisio Barros","Internal ID":"220717/Z/20/Z","description":"The 2030 Agenda for Sustainable Development highlights the need to prevent and respond to violence against women and girls. It also affirms the need to invest in early childhood care for the promotion of sustainable development in low and middle-income (LMICs). Intimate partner violence (IPV) is one of the most common and extreme manifestations of gender inequality worldwide, and has a higher prevalence and more severe consequences for women and children living in LMICs. I aim to examine the association of IPV with parenting practices and early childhood development in LMICs. This will be done using data from nationally representative household surveys (DHS) carried out since 2010 in at least 10 LMICs, and a large population-based prospective cohort study in Brazil, following over 4,000 children born in 2015. A key objective of the project is to explore whether women´s mental health mediates the proposed associations, and the role of women\u2019s empowerment levels in the associations under study. The empirical evidence generated from this project will contribute to increasing visibility of the intergenerational consequences of IPV on children and provide guidance for the direction of global resources to prevent gender-based violence.\n","plannedDates":[{"endDate":"2024-02-28T00:00:00+00:00","startDate":"2021-03-01T00:00:00+00:00","startDateDateOnly":"2021-03-01","endDateDateOnly":"2024-02-28"}],"amountAwarded":103661,"Financial Year":"2019/20","Lead Applicant":"Ms Carolina de Vargas Nunes Coll","grantProgramme":[{"title":"International Training Fellowship","title_keyword":"International Training Fellowship"}],"Partnership Name":"NIHR/Wellcome Global health Partnership","Applicant Surname":"Coll","Partnership Value":207323,"Approval Committee":"International Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:ABRASCO","name":"ABRASCO","addressCountry":"Brazil","id_and_name":"[\"ABRASCO\", \"360G-Wellcome-ORG:ABRASCO\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:ABRASCO","name":"ABRASCO"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Intimate partner violence against women in low- and middle-income countries: associations with parenting practices and early childhood development. The 2030 Agenda for Sustainable Development highlights the need to prevent and respond to violence against women and girls. It also affirms the need to invest in early childhood care for the promotion of sustainable development in low and middle-income (LMICs). Intimate partner violence (IPV) is one of the most common and extreme manifestations of gender inequality worldwide, and has a higher prevalence and more severe consequences for women and children living in LMICs. I aim to examine the association of IPV with parenting practices and early childhood development in LMICs. This will be done using data from nationally representative household surveys (DHS) carried out since 2010 in at least 10 LMICs, and a large population-based prospective cohort study in Brazil, following over 4,000 children born in 2015. A key objective of the project is to explore whether women´s mental health mediates the proposed associations, and the role of women\u2019s empowerment levels in the associations under study. The empirical evidence generated from this project will contribute to increasing visibility of the intergenerational consequences of IPV on children and provide guidance for the direction of global resources to prevent gender-based violence.\n","awardDateDateOnly":"2020-06-23","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adolescent","Adult","Brazil","Child","Child Development","Child, Preschool","Female","Humans","Intimate Partner Violence","Male","Parenting","Poverty","Socioeconomic Factors"]}
{"id":"360G-Wellcome-220711_Z_20_Z","title":"Exploring the Role of MITOchondrial ImmunoMETAbolism in Neuroinflammation:  Mechanisms and New Targets for Progressive MS Treatment (MITO_META)","Region":"East of England","currency":"GBP","awardDate":"2020-10-05T00:00:00+00:00","Sponsor(s)":"Dr Stefano Pluchino","Internal ID":"220711/Z/20/Z","description":"People with progressive multiple sclerosis (P-MS) have substantial unmet clinical needs. While current therapies for MS are focused on manipulating the activity of the adaptive immune system, they have limited applicability for P-MS where a switch towards the chronic activation of innate immune cells, such as mononuclear phagocytes (MPs), occurs.\n\nMITO_META aims to test the hypothesis that the detrimental activation of MPs in P-MS is dependent on their mitochondrial metabolism and that targeting mitochondrial complex I (CI) activity in MPs will lead to novel therapeutic approaches for P-MS.\n\nTo achieve this aim, I will adopt a combination of animal models and post-mortem biological samples obtained from MS patients. I will initially use the experimental autoimmune encephalomyelitis (EAE) mouse model of MS to study the effect of removing Complex I from MPs during neuroinflammation (Aim 1). I will then analyse how the metabolism of MPs changes during neuroinflammation, and compare these findings to those obtained from post-mortem analysis of people with progressive MS (Aim 2).\n\nElucidating the role of mitochondrial function in MPs during chronic neuroinflammation will advance our understanding of P-MS and lead to new therapies to interfere with the progression of disability.\n","plannedDates":[{"endDate":"2023-10-31T00:00:00+00:00","startDate":"2020-11-01T00:00:00+00:00","startDateDateOnly":"2020-11-01","endDateDateOnly":"2023-10-31"}],"amountAwarded":446707,"Financial Year":"2020/21","Lead Applicant":"Dr Luca Peruzzotti-Jametti","grantProgramme":[{"title":"Clinical Research Career Development Fellowship","title_keyword":"Clinical Research Career Development Fellowship"}],"Applicant Surname":"Peruzzotti-Jametti","Partnership Value":446707,"Approval Committee":"Clinical Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Exploring the Role of MITOchondrial ImmunoMETAbolism in Neuroinflammation:  Mechanisms and New Targets for Progressive MS Treatment (MITO_META) People with progressive multiple sclerosis (P-MS) have substantial unmet clinical needs. While current therapies for MS are focused on manipulating the activity of the adaptive immune system, they have limited applicability for P-MS where a switch towards the chronic activation of innate immune cells, such as mononuclear phagocytes (MPs), occurs.\n\nMITO_META aims to test the hypothesis that the detrimental activation of MPs in P-MS is dependent on their mitochondrial metabolism and that targeting mitochondrial complex I (CI) activity in MPs will lead to novel therapeutic approaches for P-MS.\n\nTo achieve this aim, I will adopt a combination of animal models and post-mortem biological samples obtained from MS patients. I will initially use the experimental autoimmune encephalomyelitis (EAE) mouse model of MS to study the effect of removing Complex I from MPs during neuroinflammation (Aim 1). I will then analyse how the metabolism of MPs changes during neuroinflammation, and compare these findings to those obtained from post-mortem analysis of people with progressive MS (Aim 2).\n\nElucidating the role of mitochondrial function in MPs during chronic neuroinflammation will advance our understanding of P-MS and lead to new therapies to interfere with the progression of disability.\n","awardDateDateOnly":"2020-10-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Disease Models, Animal","Disease Progression","Encephalomyelitis, Autoimmune, Experimental","Humans","Inflammation","Mice","Mice, Inbred C57BL","Mitochondria","Multiple Sclerosis"]}
{"id":"360G-Wellcome-220708_Z_20_Z","title":"Modulation of astrocytic gap junction coupling in focal epilepsy","Region":"South East","currency":"GBP","awardDate":"2020-10-05T00:00:00+00:00","Sponsor(s)":"Prof Colin Akerman","Internal ID":"220708/Z/20/Z","description":"Understanding the mechanisms that underlie epileptogenesis is crucial for the development of new treatments. Recent evidence has implicated astrocytes as a key cell population in the aetiology of focal epilepsy. Astrocytic gap-junction networks perform vital functions in supporting neural activity, including the shuttling of essential metabolic fuels and the regulation of the extracellular ionic environment for neurons. The objective of this project is to understand the relationship between neuronal activity and astrocytic gap-junction coupling, and how this relationship may break down in epilepsy. This will build upon preliminary evidence that astrocytic gap-junctions can show rapid, activity-dependent changes, in a manner related to levels of neuronal activity. The work will use surgically-resected human brain tissue and mouse models in which it is possible to selectively manipulate defined cell types. There are three parallel research aims. First, glioma-associated brain tissue will be used as a test case to relate functional astrocytic gap-junction coupling and neuronal hyperexcitability in a human context. Second, in vivo optical studies in mouse will examine how epileptiform network activity influences dynamic astrocytic gap-junction coupling. And third, optogenetic and pharmacological strategies will be used to dissect the cellular mechanisms that mediate activity-dependent changes in astrocytic coupling.\n","plannedDates":[{"endDate":"2025-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2025-06-30"}],"amountAwarded":534185,"Financial Year":"2020/21","Lead Applicant":"Dr Alexandre Mathy","grantProgramme":[{"title":"Clinical Research Career Development Fellowship","title_keyword":"Clinical Research Career Development Fellowship"}],"Applicant Surname":"Mathy","Partnership Value":534185,"Approval Committee":"Clinical Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Modulation of astrocytic gap junction coupling in focal epilepsy Understanding the mechanisms that underlie epileptogenesis is crucial for the development of new treatments. Recent evidence has implicated astrocytes as a key cell population in the aetiology of focal epilepsy. Astrocytic gap-junction networks perform vital functions in supporting neural activity, including the shuttling of essential metabolic fuels and the regulation of the extracellular ionic environment for neurons. The objective of this project is to understand the relationship between neuronal activity and astrocytic gap-junction coupling, and how this relationship may break down in epilepsy. This will build upon preliminary evidence that astrocytic gap-junctions can show rapid, activity-dependent changes, in a manner related to levels of neuronal activity. The work will use surgically-resected human brain tissue and mouse models in which it is possible to selectively manipulate defined cell types. There are three parallel research aims. First, glioma-associated brain tissue will be used as a test case to relate functional astrocytic gap-junction coupling and neuronal hyperexcitability in a human context. Second, in vivo optical studies in mouse will examine how epileptiform network activity influences dynamic astrocytic gap-junction coupling. And third, optogenetic and pharmacological strategies will be used to dissect the cellular mechanisms that mediate activity-dependent changes in astrocytic coupling.\n","awardDateDateOnly":"2020-10-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Astrocytes","Brain","Epilepsy","Gap Junctions","Humans","Mice","Neurons","Optogenetics"]}
{"id":"360G-Wellcome-220706_Z_20_Z","title":"GENOME EDITING IN AFRICA: ISSUES ARISING FROM ETHICS, GOVERNANCE, AND ENGAGEMENT","Region":"International","currency":"GBP","awardDate":"2020-03-02T00:00:00+00:00","Internal ID":"220706/Z/20/Z","description":"The purpose of this proposal is to develop an African, Regional interdisciplinary forum on the ethics, governance, engagement and social acceptability of Genome Editing in Africa. In spite of the discussions on Genomics, most African countries are yet to adequately engage in the critical debate on the regulation and ethics of genome editing. It is pertinent to have collaborative partnerships to focus on prudent research-based advocacy, to ensure truly informed policy decision making on gene editing in Africa. The key goals of this proposal is to disseminate the key outcomes of the 2019 GFBR meeting on\" Genome Editing for Human Benefit: Ethics, Engagement and Governance\", and to develop a proposal to take the outcome of this meeting further so as to begin an African oriented discussion on genome editing from the perspective of Africans. There will also be a research paper to be published in a peer-reviewed journal. Also, the focus of this proposal is to have a two-day workshop  in Nigeria with key stakeholders from Africa discussing the ethical, governance and engagement issues relevant to Africa in Genome Editing that arose from the Singapore meeting.The meeting will promote collaborations between African Countries on the best practices in Genome Editing \n","plannedDates":[{"endDate":"2022-06-05T00:00:00+00:00","startDate":"2021-08-01T00:00:00+00:00","startDateDateOnly":"2021-08-01","endDateDateOnly":"2022-06-05"}],"amountAwarded":7340,"Financial Year":"2019/20","Lead Applicant":"Prof Simisola Akintola","grantProgramme":[{"title":"Global Forum on Bioethics in Research","title_keyword":"Global Forum on Bioethics in Research"}],"Applicant Surname":"Akintola","Partnership Value":7340,"Approval Committee":"Global Forum on Bioethics in Research Fellowships Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Ibadan","name":"University of Ibadan","addressCountry":"Nigeria","id_and_name":"[\"University of Ibadan\", \"360G-Wellcome-ORG:University-of-Ibadan\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Ibadan","name":"University of Ibadan"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"GENOME EDITING IN AFRICA: ISSUES ARISING FROM ETHICS, GOVERNANCE, AND ENGAGEMENT The purpose of this proposal is to develop an African, Regional interdisciplinary forum on the ethics, governance, engagement and social acceptability of Genome Editing in Africa. In spite of the discussions on Genomics, most African countries are yet to adequately engage in the critical debate on the regulation and ethics of genome editing. It is pertinent to have collaborative partnerships to focus on prudent research-based advocacy, to ensure truly informed policy decision making on gene editing in Africa. The key goals of this proposal is to disseminate the key outcomes of the 2019 GFBR meeting on\" Genome Editing for Human Benefit: Ethics, Engagement and Governance\", and to develop a proposal to take the outcome of this meeting further so as to begin an African oriented discussion on genome editing from the perspective of Africans. There will also be a research paper to be published in a peer-reviewed journal. Also, the focus of this proposal is to have a two-day workshop  in Nigeria with key stakeholders from Africa discussing the ethical, governance and engagement issues relevant to Africa in Genome Editing that arose from the Singapore meeting.The meeting will promote collaborations between African Countries on the best practices in Genome Editing \n","awardDateDateOnly":"2020-03-02","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa","Developing Countries","Gene Editing","Humans","Nigeria","Singapore"]}
{"id":"360G-Wellcome-220704_Z_20_Z","title":"Characterization of the phenotypic and transcriptional profiles of B cells that encode broadly neutralizing antibodies against HIV","Region":"International","currency":"GBP","awardDate":"2020-06-23T00:00:00+00:00","Sponsor(s)":"Prof Thumbi Ndung'u","Internal ID":"220704/Z/20/Z","description":"HIV induces B-cell defects that could impair the development of effective antibody responses, such as broadly neutralizing antibodies (bNAbs). However, some rare patients still develop anti-HIV bNAbs. Such responses can be mimicked with vaccines for protection against HIV. The B cells that develop breadth despite the ongoing HIV-induced immune defects could have unique profiles that enable their survival and functionality. The aim of this work is to characterize the transcriptional and phenotypic profiles of B cells that encode for anti-HIV bNAbs and their precursors/intermediates. I will use longitudinal clinical samples from well characterized HIV-infected individuals who have broadly neutralizing sera. I have already isolated a bNAb from this cohort by FACS-sorting of epitope specific memory B cells and cloning the immunoglobulin genes. I am currently isolating bNAbs from the other individuals. This will create a platform for subsequent characterization of the B cells that encode for the bNAbs. I will then characterize the phenotypic and transcriptional profiles of epitope specific memory B cells that encode for the bNAbs lineages using paired flow cytometry, cloning and single cell RNA-seq. This will reveal the profiles that, if induced with appropriate adjuvants, could promote elicitation of protective anti-HIV bNAbs after vaccination.\n","plannedDates":[{"endDate":"2023-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2023-08-31"}],"amountAwarded":241245,"Financial Year":"2019/20","Lead Applicant":"Dr Daniel Muema","grantProgramme":[{"title":"International Training Fellowship","title_keyword":"International Training Fellowship"}],"Applicant Surname":"Muema","Partnership Value":241245,"Approval Committee":"International Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Africa-Health-Research-Institute","name":"Africa Health Research Institute","addressCountry":"South Africa","id_and_name":"[\"Africa Health Research Institute\", \"360G-Wellcome-ORG:Africa-Health-Research-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Africa-Health-Research-Institute","name":"Africa Health Research Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Characterization of the phenotypic and transcriptional profiles of B cells that encode broadly neutralizing antibodies against HIV HIV induces B-cell defects that could impair the development of effective antibody responses, such as broadly neutralizing antibodies (bNAbs). However, some rare patients still develop anti-HIV bNAbs. Such responses can be mimicked with vaccines for protection against HIV. The B cells that develop breadth despite the ongoing HIV-induced immune defects could have unique profiles that enable their survival and functionality. The aim of this work is to characterize the transcriptional and phenotypic profiles of B cells that encode for anti-HIV bNAbs and their precursors/intermediates. I will use longitudinal clinical samples from well characterized HIV-infected individuals who have broadly neutralizing sera. I have already isolated a bNAb from this cohort by FACS-sorting of epitope specific memory B cells and cloning the immunoglobulin genes. I am currently isolating bNAbs from the other individuals. This will create a platform for subsequent characterization of the B cells that encode for the bNAbs. I will then characterize the phenotypic and transcriptional profiles of epitope specific memory B cells that encode for the bNAbs lineages using paired flow cytometry, cloning and single cell RNA-seq. This will reveal the profiles that, if induced with appropriate adjuvants, could promote elicitation of protective anti-HIV bNAbs after vaccination.\n","awardDateDateOnly":"2020-06-23","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["AIDS Vaccines","Antibodies, Neutralizing","B-Lymphocytes","Epitopes","HIV Antibodies","HIV Infections","HIV-1","Humans"]}
{"id":"360G-Wellcome-220703_Z_20_Z","title":"Novel Non-invasive Haemodynamic Methods in Heart Failure with Preserved Ejection Fraction","Region":"East of England","currency":"GBP","awardDate":"2020-10-05T00:00:00+00:00","Sponsor(s)":"Prof Wiliiam Fraser","Internal ID":"220703/Z/20/Z","description":"Heart failure with preserved ejection fraction (HFpEF) is prevalent, increasing and has a poor prognosis. Left ventricular (LV) haemodynamic assessment is needed to diagnose and manage patients with HFpEF. The reference method for it is an invasive study and is rarely done due to costs and risks. Doppler-derived velocity is used as a surrogate for LV pressure. However, because it is based on a number of assumptions, Doppler remains unreliable for detecting increased LV end-diastolic pressure (LVEDP). I have validated a four-dimensional flow cardiovascular magnetic resonance (4D flow CMR) acquisition which addresses issues with Doppler. I have further developed an accurate quantification method, which uniquely, measures intra-ventricular blood flow in 4D. Other advantages are that it does not require any additional hardware and has demonstrated superior associated with LVEDP. In this Fellowship, I will develop 4D flow techniques for an accurate assessment of LVEDP and pressure-volume loop in HFpEF. In addition, I will learn from and collaborate with the world-renowned clinicians, software/hardware engineers and modelling experts in academia and industry, to improve the method\u2019s accuracy and applicability. I will validate the method\u2019s accuracy and generate clinical data to support future clinical trials, clinical translation and patient benefit.\n","plannedDates":[{"endDate":"2025-02-01T00:00:00+00:00","startDate":"2021-02-02T00:00:00+00:00","startDateDateOnly":"2021-02-02","endDateDateOnly":"2025-02-01"}],"amountAwarded":717907,"Financial Year":"2020/21","Lead Applicant":"Dr Pankaj Garg","grantProgramme":[{"title":"Clinical Research Career Development Fellowship","title_keyword":"Clinical Research Career Development Fellowship"}],"Applicant Surname":"Garg","Partnership Value":717907,"Approval Committee":"Clinical Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-East-Anglia","name":"University of East Anglia","addressCountry":"United Kingdom","id_and_name":"[\"University of East Anglia\", \"360G-Wellcome-ORG:University-of-East-Anglia\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-East-Anglia","name":"University of East Anglia"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Novel Non-invasive Haemodynamic Methods in Heart Failure with Preserved Ejection Fraction Heart failure with preserved ejection fraction (HFpEF) is prevalent, increasing and has a poor prognosis. Left ventricular (LV) haemodynamic assessment is needed to diagnose and manage patients with HFpEF. The reference method for it is an invasive study and is rarely done due to costs and risks. Doppler-derived velocity is used as a surrogate for LV pressure. However, because it is based on a number of assumptions, Doppler remains unreliable for detecting increased LV end-diastolic pressure (LVEDP). I have validated a four-dimensional flow cardiovascular magnetic resonance (4D flow CMR) acquisition which addresses issues with Doppler. I have further developed an accurate quantification method, which uniquely, measures intra-ventricular blood flow in 4D. Other advantages are that it does not require any additional hardware and has demonstrated superior associated with LVEDP. In this Fellowship, I will develop 4D flow techniques for an accurate assessment of LVEDP and pressure-volume loop in HFpEF. In addition, I will learn from and collaborate with the world-renowned clinicians, software/hardware engineers and modelling experts in academia and industry, to improve the method\u2019s accuracy and applicability. I will validate the method\u2019s accuracy and generate clinical data to support future clinical trials, clinical translation and patient benefit.\n","awardDateDateOnly":"2020-10-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Blood Flow Velocity","Heart Failure","Heart Ventricles","Humans","Magnetic Resonance Imaging","Stroke Volume","Ventricular Function, Left"]}
{"id":"360G-Wellcome-220690_Z_20_Z","title":"Investigating antimicrobial susceptibility of Rickettsia typhi","Region":"South East","currency":"GBP","awardDate":"2020-06-23T00:00:00+00:00","Sponsor(s)":"Prof Elizabeth Ashley","Internal ID":"220690/Z/20/Z","description":"Rickettsia typhi is an obligate intracellular Gram-negative bacterium causing murine typhus. The disease is globally distributed but neglected. It is an important cause of acute febrile illness in Laos. Although murine typhus is treatable, a clinical trial by Newton P et al. (2019) suggested that azithromycin is inferior to doxycycline. However conventional antibiotic susceptibility testing was not performed to corroborate this finding since no methods exist. Therefore, there is a need to develop a highly sensitive qPCR method comparable with the gold standard method of the plaque assay to assess antimicrobial susceptibility of R. typhi isolates as well as investigation of the genetics and/or metabolism of this bacteria, and to correlate the findings with clinical response to treatment. To estimate the rickettsia clearance, we will characterise the R. typhi DNA load using qPCR in patients from a pilot study of  murine typhus patients receiving doxycycline or azithromycin. Moreover, optimised conditions for R. typhi growth including nutrient requirement for development of a host cell-free culture medium using R. montana as a model to simplify antibiotic susceptibility testing of this bacteria will be investigated. The proposed work will improve our understanding of appropriate murine typhus treatment in Laos.\n\n \n","plannedDates":[{"endDate":"2023-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2023-08-31"}],"amountAwarded":257984,"Financial Year":"2019/20","Lead Applicant":"Dr Weerawat Phuklia","grantProgramme":[{"title":"International Training Fellowship","title_keyword":"International Training Fellowship"}],"Applicant Surname":"Phuklia","Partnership Value":257984,"Approval Committee":"International Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating antimicrobial susceptibility of Rickettsia typhi Rickettsia typhi is an obligate intracellular Gram-negative bacterium causing murine typhus. The disease is globally distributed but neglected. It is an important cause of acute febrile illness in Laos. Although murine typhus is treatable, a clinical trial by Newton P et al. (2019) suggested that azithromycin is inferior to doxycycline. However conventional antibiotic susceptibility testing was not performed to corroborate this finding since no methods exist. Therefore, there is a need to develop a highly sensitive qPCR method comparable with the gold standard method of the plaque assay to assess antimicrobial susceptibility of R. typhi isolates as well as investigation of the genetics and/or metabolism of this bacteria, and to correlate the findings with clinical response to treatment. To estimate the rickettsia clearance, we will characterise the R. typhi DNA load using qPCR in patients from a pilot study of  murine typhus patients receiving doxycycline or azithromycin. Moreover, optimised conditions for R. typhi growth including nutrient requirement for development of a host cell-free culture medium using R. montana as a model to simplify antibiotic susceptibility testing of this bacteria will be investigated. The proposed work will improve our understanding of appropriate murine typhus treatment in Laos.\n\n \n","awardDateDateOnly":"2020-06-23","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Anti-Bacterial Agents","Azithromycin","DNA, Bacterial","Doxycycline","Humans","Mice","Pilot Projects","Real-Time Polymerase Chain Reaction","Rickettsia"]}
{"id":"360G-Wellcome-220684_Z_20_Z","title":"Intervention for Depression In underserved Geriatric Populations (INDIGO) ","Region":"International","currency":"GBP","awardDate":"2020-06-23T00:00:00+00:00","Sponsor(s)":"Prof Oye Gureje, Dr Stephanie Daley, Prof Jose Luis Ayuso Mateos","Internal ID":"220684/Z/20/Z","description":"Depression is a common and disabling condition among the rapidly growing population of older people in low- and middle-income countries (LMICs). The burden is particularly high among older Nigerians. Yet, there is a large unmet need for treatment, possibly in part because available care is inaccessible and not age-appropriate for the older person. In line with global priorities, as envisioned in the Sustainable Development Goals to leave no one behind in the provision of quality health care, there is a pressing need for an integrated model of community-based mental health care that encompasses health, social, and informal care for older people in LMICs. Building on prior considerable work by our group to scale-up mental health care with the aid of the W.H.O Mental Health Gap Action Programme Intervention Guide, we now wish to leverage on the e-version of the tool, by 1) adapting it for the care of older persons with late-life depression through a user driven iterative loop process in which contextual, socio-cultural and health factors in the lived experience of late-life depression are incorporated; and 2) testing, in a pilot hybrid (effectiveness-implementation) design, effectiveness, cost-effectiveness, and factors that may affect the delivery of the intervention in routine care.\n","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":292294,"Financial Year":"2019/20","Lead Applicant":"Dr Akin Ojagbemi","grantProgramme":[{"title":"International Intermediate Fellowship","title_keyword":"International Intermediate Fellowship"}],"Partnership Name":"NIHR/Wellcome Global health Partnership","Applicant Surname":"Ojagbemi","Partnership Value":584588,"Approval Committee":"International Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:College-of-Medicine-University-of-Ibadan","name":"College of Medicine, University of Ibadan","addressCountry":"Nigeria","id_and_name":"[\"College of Medicine, University of Ibadan\", \"360G-Wellcome-ORG:College-of-Medicine-University-of-Ibadan\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:College-of-Medicine-University-of-Ibadan","name":"College of Medicine, University of Ibadan"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Intervention for Depression In underserved Geriatric Populations (INDIGO)  Depression is a common and disabling condition among the rapidly growing population of older people in low- and middle-income countries (LMICs). The burden is particularly high among older Nigerians. Yet, there is a large unmet need for treatment, possibly in part because available care is inaccessible and not age-appropriate for the older person. In line with global priorities, as envisioned in the Sustainable Development Goals to leave no one behind in the provision of quality health care, there is a pressing need for an integrated model of community-based mental health care that encompasses health, social, and informal care for older people in LMICs. Building on prior considerable work by our group to scale-up mental health care with the aid of the W.H.O Mental Health Gap Action Programme Intervention Guide, we now wish to leverage on the e-version of the tool, by 1) adapting it for the care of older persons with late-life depression through a user driven iterative loop process in which contextual, socio-cultural and health factors in the lived experience of late-life depression are incorporated; and 2) testing, in a pilot hybrid (effectiveness-implementation) design, effectiveness, cost-effectiveness, and factors that may affect the delivery of the intervention in routine care.\n","awardDateDateOnly":"2020-06-23","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aged","Aged, 80 and over","Depression","Developing Countries","Geriatric Assessment","Humans","Male","Nigeria","Pilot Projects","Poverty"]}
{"id":"360G-Wellcome-220681_Z_20_Z","title":"Guys and St Thomas's Charity Partnership","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220681/Z/20/Z","description":"We are applying to Wellcome for a \u00a31.5M investment as match towards an overall \u00a33M+ programme that will test new ways of working to embed health research in our practice. \n\n\nThis will be split between two priority portfolio areas; Adolescent Mental Health (AMH) and Multiple Long-term Conditions (MLTCs) \nWe will explore 3 opportunity areas, these are: \n\n\n1. New models for generating and using public insight in research\n2. New models for creating impact through investment partnerships \n3. Accelerating our evidence \n\n\nThe work will be supported by research partnerships, a network of public engagement expertise and a partnership advisory group. We already have an existing relationship with KCL, with whom we currently run a \u00a31m+ MLTC research challenge fund in the MLTC programme, as well as our cornerstone investment into the Science Gallery London https://london.sciencegallery.com/.  We would also like to deepen our relationships with other academic institutions as part of this work.\n\nPlease see Partnership Plan for details. \n\nPlease see Partnership Slide Deck\n","plannedDates":[{"endDate":"2023-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2023-08-31"}],"amountAwarded":1499800,"Financial Year":"2019/20","Lead Applicant":"Ms Louise Mousseau","grantProgramme":[{"title":"Discretionary Award - Public Engagement","title_keyword":"Discretionary Award - Public Engagement"}],"Applicant Surname":"Mousseau","Partnership Value":1499800,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Ms Gabrielle Allen","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Guy\u2019s-and-St-Thomas\u2019-Charity","name":"Guy\u2019s and St Thomas\u2019 Charity","addressCountry":"United Kingdom","id_and_name":"[\"Guy\\u2019s and St Thomas\\u2019 Charity\", \"360G-Wellcome-ORG:Guy\\u2019s-and-St-Thomas\\u2019-Charity\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Guy\u2019s-and-St-Thomas\u2019-Charity","name":"Guy\u2019s and St Thomas\u2019 Charity"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Guys and St Thomas's Charity Partnership We are applying to Wellcome for a \u00a31.5M investment as match towards an overall \u00a33M+ programme that will test new ways of working to embed health research in our practice. \n\n\nThis will be split between two priority portfolio areas; Adolescent Mental Health (AMH) and Multiple Long-term Conditions (MLTCs) \nWe will explore 3 opportunity areas, these are: \n\n\n1. New models for generating and using public insight in research\n2. New models for creating impact through investment partnerships \n3. Accelerating our evidence \n\n\nThe work will be supported by research partnerships, a network of public engagement expertise and a partnership advisory group. We already have an existing relationship with KCL, with whom we currently run a \u00a31m+ MLTC research challenge fund in the MLTC programme, as well as our cornerstone investment into the Science Gallery London https://london.sciencegallery.com/.  We would also like to deepen our relationships with other academic institutions as part of this work.\n\nPlease see Partnership Plan for details. \n\nPlease see Partnership Slide Deck\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","London","Mental Health"]}
{"id":"360G-Wellcome-220680_Z_20_Z","title":"Cardiovascular disease in very low income sub-Saharan Africa: informing the response to an emerging epidemic","Region":"Greater London","currency":"GBP","awardDate":"2020-10-05T00:00:00+00:00","Sponsor(s)":"Prof Liam Smeeth","Internal ID":"220680/Z/20/Z","description":"I will improve understanding of key determinants and the incidence of cardiovascular disease in low-income sub-Saharan-Africa, capitalising on my expertise in stroke epidemiology in rural and urban Malawi and the research infrastructure across seven sub-Saharan-Africa population cohorts.\n\nInformation on the age- and sex-specific incidences of priority cardiovascular diseases is essential for health service planning in sub-Saharan-Africa. \"Traditional\" risk-factors (hypertension, type-2 diabetes and obesity) are highly prevalent and increasing in incidence and some, particular to low-income settings, such as chronic-infections, are not declining. The performance of diagnostic tools and risk prediction scores for cardiovascular disease developed in high-income settings need to be tested and adapted for use in low-income sub-Saharan-Africa.\n\nI will build on the urban/rural cohort in Malawi, extending community and clinic surveillance with population-level questionnaire-screening (followed by a diagnostic pathway in those with \"possible cardiovascular disease\") to estimate the true incidence of various cardiovascular diseases. I will also extend the follow-up for our seven African cohorts and use this harmonised dataset to estimate the relative contributions of key drivers of cardiovascular disease and assess the performance of existing cardiovascular disease risk prediction scores.\n\nThis work will inform the planning of evidence-based, health-systems responses and context-relevant, individual, and population-level interventions.\n","plannedDates":[{"endDate":"2025-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2025-06-30"}],"amountAwarded":1271351,"Financial Year":"2020/21","Lead Applicant":"Dr Alison Price","grantProgramme":[{"title":"Clinical Research Career Development Fellowship","title_keyword":"Clinical Research Career Development Fellowship"}],"Applicant Surname":"Price","Partnership Value":1271351,"Approval Committee":"Clinical Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"London School of Hygiene & Tropical Medicine\", \"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Cardiovascular disease in very low income sub-Saharan Africa: informing the response to an emerging epidemic I will improve understanding of key determinants and the incidence of cardiovascular disease in low-income sub-Saharan-Africa, capitalising on my expertise in stroke epidemiology in rural and urban Malawi and the research infrastructure across seven sub-Saharan-Africa population cohorts.\n\nInformation on the age- and sex-specific incidences of priority cardiovascular diseases is essential for health service planning in sub-Saharan-Africa. \"Traditional\" risk-factors (hypertension, type-2 diabetes and obesity) are highly prevalent and increasing in incidence and some, particular to low-income settings, such as chronic-infections, are not declining. The performance of diagnostic tools and risk prediction scores for cardiovascular disease developed in high-income settings need to be tested and adapted for use in low-income sub-Saharan-Africa.\n\nI will build on the urban/rural cohort in Malawi, extending community and clinic surveillance with population-level questionnaire-screening (followed by a diagnostic pathway in those with \"possible cardiovascular disease\") to estimate the true incidence of various cardiovascular diseases. I will also extend the follow-up for our seven African cohorts and use this harmonised dataset to estimate the relative contributions of key drivers of cardiovascular disease and assess the performance of existing cardiovascular disease risk prediction scores.\n\nThis work will inform the planning of evidence-based, health-systems responses and context-relevant, individual, and population-level interventions.\n","awardDateDateOnly":"2020-10-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adult","Africa South of the Sahara","Cardiovascular Diseases","Diabetes Mellitus, Type 2","Female","Humans","Incidence","Malawi","Male","Middle Aged","Poverty","Risk Factors"]}
{"id":"360G-Wellcome-220679_Z_20_Z","title":"Understanding and inducing immunity against rabies and Epstein Barr virus Class III fusion proteins","Region":"South East","currency":"GBP","awardDate":"2020-10-05T00:00:00+00:00","Sponsor(s)":"Prof Richard Cornall","Internal ID":"220679/Z/20/Z","description":"Viral fusion proteins are important targets for vaccine-induced neutralising antibody. Structure-guided design of such antigens in pre-fusion conformation has created leading vaccine candidates against viruses with Class I and II fusion proteins, such as respiratory syncytial virus and dengue virus. Use of pre-fusion stabilised Class III proteins for vaccination has not yet been reported, but these too are major vaccine targets for rabies virus and the herpesviruses (the gB proteins).\n\nI propose to build upon preliminary data demonstrating pre-fusion stabilisation of rabies glycoprotein. I will evaluate pre-fusion-stabilised immunogens for vaccines against rabies and a chosen herpesvirus, Epstein Barr virus (EBV). By isolating monoclonal antibodies against EBV gB, I will ascertain whether herpesvirus gB proteins contain pre-fusion-specific neutralising epitopes. In healthy EBV carriers, I will explore whether salivary EBV shedding can be used as a marker of immune control of virus reactivation, to dissect mechanisms of natural immunity, and to rapidly detect efficacy in future early-phase vaccine trials.\n\nA low-cost single-dose vaccine based on stabilised rabies glycoprotein could help reduce the 60,000 deaths due to rabies each year. An effective EBV vaccine could reduce the  > 100,000 deaths per year due to EBV-driven cancers and, many believe, could also prevent multiple sclerosis.\n","plannedDates":[{"endDate":"2025-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2025-12-31"}],"amountAwarded":1304625,"Financial Year":"2020/21","Lead Applicant":"Dr Alexander Douglas","grantProgramme":[{"title":"Clinical Research Career Development Fellowship","title_keyword":"Clinical Research Career Development Fellowship"}],"Applicant Surname":"Douglas","Partnership Value":1304625,"Approval Committee":"Clinical Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding and inducing immunity against rabies and Epstein Barr virus Class III fusion proteins Viral fusion proteins are important targets for vaccine-induced neutralising antibody. Structure-guided design of such antigens in pre-fusion conformation has created leading vaccine candidates against viruses with Class I and II fusion proteins, such as respiratory syncytial virus and dengue virus. Use of pre-fusion stabilised Class III proteins for vaccination has not yet been reported, but these too are major vaccine targets for rabies virus and the herpesviruses (the gB proteins).\n\nI propose to build upon preliminary data demonstrating pre-fusion stabilisation of rabies glycoprotein. I will evaluate pre-fusion-stabilised immunogens for vaccines against rabies and a chosen herpesvirus, Epstein Barr virus (EBV). By isolating monoclonal antibodies against EBV gB, I will ascertain whether herpesvirus gB proteins contain pre-fusion-specific neutralising epitopes. In healthy EBV carriers, I will explore whether salivary EBV shedding can be used as a marker of immune control of virus reactivation, to dissect mechanisms of natural immunity, and to rapidly detect efficacy in future early-phase vaccine trials.\n\nA low-cost single-dose vaccine based on stabilised rabies glycoprotein could help reduce the 60,000 deaths due to rabies each year. An effective EBV vaccine could reduce the  > 100,000 deaths per year due to EBV-driven cancers and, many believe, could also prevent multiple sclerosis.\n","awardDateDateOnly":"2020-10-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Antibodies, Neutralizing","Antibodies, Viral","Antigens, Viral","Herpesvirus 4, Human","Humans","Rabies","Rabies virus","Viral Envelope Proteins"]}
{"id":"360G-Wellcome-220671_Z_20_Z","title":"Effect of early-life nutrition and WASH interventions on the long-term health of Zimbabwean children","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220671/Z/20/Z","description":"Over 150 million children worldwide are particularly short for their age, and we say that these children are stunted. Stunted children have increased mortality and reduced intelligence, so stunting affects whole societies. Improving nutrition is currently the best intervention to reduce stunting, but typically only improves growth by a small amount. The first thousand days of life (up to the age of two years) are seen as a crucial period for child growth. The scientific community lacks complete understanding of how poor growth affects children at older ages, and what the impact of targeted nutrition or water/sanitation and hygiene (WASH) interventions is on the physical fitness and brain function of children.\n\n\nThis project will measure the long-term effects of stunting of children aged 6 years in Zimbabwe, some of whom received a targeted nutrition or WASH  intervention between 6-18 months. It will measure how they have grown together with their brain function, physical fitness and how much fat and lean mass they have. This data will give a complete picture of how well these children are functioning, and enable us to compare what the true impacts of the extra nutrition and/or WASH are.\n","plannedDates":[{"endDate":"2022-11-30T00:00:00+00:00","startDate":"2019-09-23T00:00:00+00:00","startDateDateOnly":"2019-09-23","endDateDateOnly":"2022-11-30"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Joseph Piper","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Piper","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Queen-Mary-University-of-London","name":"Queen Mary University of London","addressCountry":"United Kingdom","id_and_name":"[\"Queen Mary University of London\", \"360G-Wellcome-ORG:Queen-Mary-University-of-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Queen-Mary-University-of-London","name":"Queen Mary University of London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Effect of early-life nutrition and WASH interventions on the long-term health of Zimbabwean children Over 150 million children worldwide are particularly short for their age, and we say that these children are stunted. Stunted children have increased mortality and reduced intelligence, so stunting affects whole societies. Improving nutrition is currently the best intervention to reduce stunting, but typically only improves growth by a small amount. The first thousand days of life (up to the age of two years) are seen as a crucial period for child growth. The scientific community lacks complete understanding of how poor growth affects children at older ages, and what the impact of targeted nutrition or water/sanitation and hygiene (WASH) interventions is on the physical fitness and brain function of children.\n\n\nThis project will measure the long-term effects of stunting of children aged 6 years in Zimbabwe, some of whom received a targeted nutrition or WASH  intervention between 6-18 months. It will measure how they have grown together with their brain function, physical fitness and how much fat and lean mass they have. This data will give a complete picture of how well these children are functioning, and enable us to compare what the true impacts of the extra nutrition and/or WASH are.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Child","Child Development","Child Nutrition Disorders","Child Nutritional Physiological Phenomena","Child, Preschool","Growth Disorders","Humans","Hygiene","Infant","Male","Malnutrition","Nutritional Status","Sanitation","Zimbabwe"]}
{"id":"360G-Wellcome-220668_Z_20_Z","title":"Defining Causal Variants and Associated Genes in Polygenic Nephrolithiasis","Region":"South East","currency":"GBP","awardDate":"2020-10-05T00:00:00+00:00","Sponsor(s)":"Prof Freddie Hamdy","Internal ID":"220668/Z/20/Z","description":"Kidney stones, which are a major clinical and economic health burden, are commonly recurrent, and current stone prevention strategies are relatively ineffective. The renal tubular mechanisms underlying this disease are poorly understood, thereby limiting opportunities to develop novel therapies. Via a genome-wide association study (GWAS) we identified twenty genetic loci linked to kidney stone formation. However, the genes influenced by these loci remain to be elucidated. My goals are to: identify additional stone-associated loci by X chromosome and sex-specific GWAS studies; define biologically relevant renal cell types by identifying areas of accessible chromatin at relevant loci through single cell assays for transposase accessible chromatin (ATAC)-sequencing in renal tissue; determine causal GWAS-associated SNPs by examining local epigenetic modifications in relevant cell types via chromatin immunoprecipitation (ChIP)-sequencing; link causal SNPs to effector genes by determining the 3-dimensional chromatin landscape in relevant cell types through Next Generation Chromatin Conformation Capture; validate predicted genotype-phenotype associations in relevant cohorts; and elucidate the roles of effector genes in cellular function via in vitro studies. This research will provide new insights into tubular function and the molecular pathophysiology of renal stone disease and reveal new therapeutic targets for the prevention of kidney stone recurrence.\n","plannedDates":[{"endDate":"2026-08-03T00:00:00+00:00","startDate":"2021-08-04T00:00:00+00:00","startDateDateOnly":"2021-08-04","endDateDateOnly":"2026-08-03"}],"amountAwarded":590676,"Financial Year":"2020/21","Lead Applicant":"Dr Sarah Howles","grantProgramme":[{"title":"Clinical Research Career Development Fellowship","title_keyword":"Clinical Research Career Development Fellowship"}],"Applicant Surname":"Howles","Partnership Value":590676,"Approval Committee":"Clinical Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Defining Causal Variants and Associated Genes in Polygenic Nephrolithiasis Kidney stones, which are a major clinical and economic health burden, are commonly recurrent, and current stone prevention strategies are relatively ineffective. The renal tubular mechanisms underlying this disease are poorly understood, thereby limiting opportunities to develop novel therapies. Via a genome-wide association study (GWAS) we identified twenty genetic loci linked to kidney stone formation. However, the genes influenced by these loci remain to be elucidated. My goals are to: identify additional stone-associated loci by X chromosome and sex-specific GWAS studies; define biologically relevant renal cell types by identifying areas of accessible chromatin at relevant loci through single cell assays for transposase accessible chromatin (ATAC)-sequencing in renal tissue; determine causal GWAS-associated SNPs by examining local epigenetic modifications in relevant cell types via chromatin immunoprecipitation (ChIP)-sequencing; link causal SNPs to effector genes by determining the 3-dimensional chromatin landscape in relevant cell types through Next Generation Chromatin Conformation Capture; validate predicted genotype-phenotype associations in relevant cohorts; and elucidate the roles of effector genes in cellular function via in vitro studies. This research will provide new insights into tubular function and the molecular pathophysiology of renal stone disease and reveal new therapeutic targets for the prevention of kidney stone recurrence.\n","awardDateDateOnly":"2020-10-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Chromatin","Chromosomes, Human, X","Female","Genetic Predisposition to Disease","Genome-Wide Association Study","Humans","Kidney Calculi","Male","Polymorphism, Single Nucleotide"]}
{"id":"360G-Wellcome-220667_Z_20_Z","title":"Understanding the DNA Damage Driven Immune Response in Oesophageal Adenocarcinoma (OAC): Opportunities for Improved Stratification and Treatment","Region":"Northern Ireland","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220667/Z/20/Z","description":"Oesophageal cancer is the sixth most common cause of cancer death worldwide.  Even when treated with chemotherapy and surgery aiming to cure the disease, eight out of ten patients do not respond to chemotherapy and most patients relapse.\n\nWe have shown previously that genetic changes within the tumour can influence whether chemotherapy is effective.  We showed that a group of patients have tumours which respond better to chemotherapy than others.  This group is called \u2018DNA damage immune response (DDIR) positive\u2019. DDIR negative patients have worse outcomes. \n\nIn this project, we aim to use genetic information about DDIR positive patients who benefit from chemotherapy to improve outcomes for those who do not.  \n\nWe will initially analyse genetic information from 548 oesophageal tumours.   We will identify the most common genetic changes in patients who benefit from chemotherapy. We then plan to model these changes in the laboratory in oesophageal cancer cells which are relatively resistant to chemotherapy to find out if they respond. We will confirm our findings in a range of laboratory models.\n\nWe expect that the knowledge gained will play a role in identifying new combinations of treatment to improve response to chemotherapy in patients who currently have poor outcomes.\n","plannedDates":[{"endDate":"2022-08-06T00:00:00+00:00","startDate":"2019-08-07T00:00:00+00:00","startDateDateOnly":"2019-08-07","endDateDateOnly":"2022-08-06"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Anita Lavery","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Partnership Name":"SFI-HRB-Wellcome Trust partnership","Applicant Surname":"Lavery","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Queens-University-Belfast","name":"Queen's University Belfast","addressCountry":"United Kingdom","id_and_name":"[\"Queen's University Belfast\", \"360G-Wellcome-ORG:Queens-University-Belfast\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Queens-University-Belfast","name":"Queen's University Belfast"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding the DNA Damage Driven Immune Response in Oesophageal Adenocarcinoma (OAC): Opportunities for Improved Stratification and Treatment Oesophageal cancer is the sixth most common cause of cancer death worldwide.  Even when treated with chemotherapy and surgery aiming to cure the disease, eight out of ten patients do not respond to chemotherapy and most patients relapse.\n\nWe have shown previously that genetic changes within the tumour can influence whether chemotherapy is effective.  We showed that a group of patients have tumours which respond better to chemotherapy than others.  This group is called \u2018DNA damage immune response (DDIR) positive\u2019. DDIR negative patients have worse outcomes. \n\nIn this project, we aim to use genetic information about DDIR positive patients who benefit from chemotherapy to improve outcomes for those who do not.  \n\nWe will initially analyse genetic information from 548 oesophageal tumours.   We will identify the most common genetic changes in patients who benefit from chemotherapy. We then plan to model these changes in the laboratory in oesophageal cancer cells which are relatively resistant to chemotherapy to find out if they respond. We will confirm our findings in a range of laboratory models.\n\nWe expect that the knowledge gained will play a role in identifying new combinations of treatment to improve response to chemotherapy in patients who currently have poor outcomes.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adenocarcinoma","DNA Damage","Esophageal Neoplasms","Humans"]}
{"id":"360G-Wellcome-220666_Z_20_Z","title":"Radiotherapy-Related Adverse Cardiac Events In Lung Cancer","Region":"Northern Ireland","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220666/Z/20/Z","description":"The most important risk factor for lung cancer is smoking, which also causes cardiovascular disease. Due to other medical problems preventing surgery, or patient preference, many patients with lung cancer receive radiotherapy. Radiotherapy is high-dose X-rays and there are risks associated with this treatment, in particular to the heart. Little is known about why some patients\u2019 hearts appear more sensitive than others.\n\nThe purpose of the RACING research project is to discover how radiotherapy affects the heart and if radiotherapy heart damage can be predicted before treatment. Laboratory experiments will test how radiotherapy can affect the pump action of the heart, and which parts of the heart are most likely to malfunction, and the mechanism of damage. Patients who\u2019ve had radiotherapy previously will have their CT scans examined by advanced computer software to find clues that could help doctors avoid/reduce radiotherapy heart damage in future patients.\n","plannedDates":[{"endDate":"2022-08-05T00:00:00+00:00","startDate":"2019-08-06T00:00:00+00:00","startDateDateOnly":"2019-08-06","endDateDateOnly":"2022-08-05"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Gerard Walls","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Partnership Name":"SFI-HRB-Wellcome Trust partnership","Applicant Surname":"Walls","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Queens-University-Belfast","name":"Queen's University Belfast","addressCountry":"United Kingdom","id_and_name":"[\"Queen's University Belfast\", \"360G-Wellcome-ORG:Queens-University-Belfast\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Queens-University-Belfast","name":"Queen's University Belfast"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Radiotherapy-Related Adverse Cardiac Events In Lung Cancer The most important risk factor for lung cancer is smoking, which also causes cardiovascular disease. Due to other medical problems preventing surgery, or patient preference, many patients with lung cancer receive radiotherapy. Radiotherapy is high-dose X-rays and there are risks associated with this treatment, in particular to the heart. Little is known about why some patients\u2019 hearts appear more sensitive than others.\n\nThe purpose of the RACING research project is to discover how radiotherapy affects the heart and if radiotherapy heart damage can be predicted before treatment. Laboratory experiments will test how radiotherapy can affect the pump action of the heart, and which parts of the heart are most likely to malfunction, and the mechanism of damage. Patients who\u2019ve had radiotherapy previously will have their CT scans examined by advanced computer software to find clues that could help doctors avoid/reduce radiotherapy heart damage in future patients.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Heart","Humans","Lung Neoplasms","Radiation Injuries","Radiotherapy","Tomography, X-Ray Computed"]}
{"id":"360G-Wellcome-220664_Z_20_Z","title":"Accelerating Medicines Partnership in Schizophrenia","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220664/Z/20/Z","description":"Not Available","plannedDates":[{"endDate":"2025-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2025-08-31"}],"amountAwarded":1957254,"Financial Year":"2019/20","Lead Applicant":"Mr David Wholley","grantProgramme":[{"title":"Discretionary Award \u2013 Innovations","title_keyword":"Discretionary Award \u2013 Innovations"}],"Applicant Surname":"Wholley","Partnership Value":1957254,"Approval Committee":"Innovation Advisory Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Foundation-for-the-National-Institutes-of-Health","name":"Foundation for the National Institutes of Health","addressCountry":"United States","id_and_name":"[\"Foundation for the National Institutes of Health\", \"360G-Wellcome-ORG:Foundation-for-the-National-Institutes-of-Health\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Foundation-for-the-National-Institutes-of-Health","name":"Foundation for the National Institutes of Health"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Accelerating Medicines Partnership in Schizophrenia Not Available","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Schizophrenia"]}
{"id":"360G-Wellcome-220664_A_20_Z","title":"Accelerating Medicines Partnership in Schizophrenia","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220664/A/20/Z","description":"Not Available","plannedDates":[{"endDate":"2025-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2025-08-31"}],"amountAwarded":3914507,"Financial Year":"2019/20","Lead Applicant":"Mr David Wholley","grantProgramme":[{"title":"Discretionary Award \u2013 Innovations","title_keyword":"Discretionary Award \u2013 Innovations"}],"Applicant Surname":"Wholley","Partnership Value":3914507,"Approval Committee":"Innovation Advisory Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Foundation-for-the-National-Institutes-of-Health","name":"Foundation for the National Institutes of Health","addressCountry":"United States","id_and_name":"[\"Foundation for the National Institutes of Health\", \"360G-Wellcome-ORG:Foundation-for-the-National-Institutes-of-Health\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Foundation-for-the-National-Institutes-of-Health","name":"Foundation for the National Institutes of Health"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Accelerating Medicines Partnership in Schizophrenia Not Available","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Schizophrenia"]}
{"id":"360G-Wellcome-220661_Z_20_Z","title":"The effect of ageing on inflammation resolution and its causation in age-related immune dysfunction. ","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220661/Z/20/Z","description":"The immune system protects us from infection, however as we age it can weaken and even contribute to age-related diseases such as heart disease, cancer and arthritis. The exact reasons for this are not known, and new treatments could help us fight infection, treat age-related disease, and improve lifespan. This laboratory has discovered that one explanation may be that white blood cells cannot neutralise their targets at sites of infection properly, worsening the inflammatory response and causing excessive tissue damage. Another explanation may be that the management or oversight of the immune response seems to change with time. To examine these two ideas we plan to use a safe and effective model of skin infection in adults to look for subtle differences between the immune systems of young and elderly people, before and after local skin infections. If we find a cause for these differences, we will perform experiments in mice to see if they are a cause of age-related immune dysfunction. These results could then be used to design medications and further experiments to help improve the lives of patients with and without age-related disease.\n \n","plannedDates":[{"endDate":"2023-05-26T00:00:00+00:00","startDate":"2019-10-09T00:00:00+00:00","startDateDateOnly":"2019-10-09","endDateDateOnly":"2023-05-26"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr George Collins","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Collins","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The effect of ageing on inflammation resolution and its causation in age-related immune dysfunction.  The immune system protects us from infection, however as we age it can weaken and even contribute to age-related diseases such as heart disease, cancer and arthritis. The exact reasons for this are not known, and new treatments could help us fight infection, treat age-related disease, and improve lifespan. This laboratory has discovered that one explanation may be that white blood cells cannot neutralise their targets at sites of infection properly, worsening the inflammatory response and causing excessive tissue damage. Another explanation may be that the management or oversight of the immune response seems to change with time. To examine these two ideas we plan to use a safe and effective model of skin infection in adults to look for subtle differences between the immune systems of young and elderly people, before and after local skin infections. If we find a cause for these differences, we will perform experiments in mice to see if they are a cause of age-related immune dysfunction. These results could then be used to design medications and further experiments to help improve the lives of patients with and without age-related disease.\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aged","Aging","Animals","Disease Models, Animal","Humans","Infections","Mice","Skin"]}
{"id":"360G-Wellcome-220659_Z_20_Z","title":"Catatonia: Neuroimaging, Immunology and Psychopathology (CAT:NIP)","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220659/Z/20/Z","description":"Background:\n\nCatatonia is a severe psychiatric illness in which individuals have difficulties in moving and speaking. I aim to understand what brain changes occur during catatonia.\n\n \n\nApproach:\n\nPatients with catatonia are usually effectively treated using medications from the benzodiazepine class, which increase the activity of pathways relying on the neurotransmitter GABA. In addition, 88% of patients with a form of brain inflammation known as NMDA receptor encephalitis have catatonia, which suggests that the neurotransmitter glutamate might also be relevant.\n\n \n\nTo investigate the roles of these neurotransmitters, we have two main experiments:\n\n\n We will take blood samples from patients with catatonia to examine whether they have antibodies to cell surface components associated with GABA and glutamate transmission. We will use these blood samples to investigate whether any new antibodies or other proteins that bind to the brain or affect brain function can be found.\n We will conduct a form of brain scan called magnetic resonance spectroscopy on patients with catatonic features. This will allow us to examine the levels of GABA and glutamate in their brains and to compare these to other patients without catatonic features.\n\n\n \n\nImpact:\n\nWe hope to identify what causes catatonia in order to appropriately target future treatments\n","plannedDates":[{"endDate":"2023-11-05T00:00:00+00:00","startDate":"2019-12-04T00:00:00+00:00","startDateDateOnly":"2019-12-04","endDateDateOnly":"2023-11-05"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Jonathan Rogers","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Rogers","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Catatonia: Neuroimaging, Immunology and Psychopathology (CAT:NIP) Background:\n\nCatatonia is a severe psychiatric illness in which individuals have difficulties in moving and speaking. I aim to understand what brain changes occur during catatonia.\n\n \n\nApproach:\n\nPatients with catatonia are usually effectively treated using medications from the benzodiazepine class, which increase the activity of pathways relying on the neurotransmitter GABA. In addition, 88% of patients with a form of brain inflammation known as NMDA receptor encephalitis have catatonia, which suggests that the neurotransmitter glutamate might also be relevant.\n\n \n\nTo investigate the roles of these neurotransmitters, we have two main experiments:\n\n\n We will take blood samples from patients with catatonia to examine whether they have antibodies to cell surface components associated with GABA and glutamate transmission. We will use these blood samples to investigate whether any new antibodies or other proteins that bind to the brain or affect brain function can be found.\n We will conduct a form of brain scan called magnetic resonance spectroscopy on patients with catatonic features. This will allow us to examine the levels of GABA and glutamate in their brains and to compare these to other patients without catatonic features.\n\n\n \n\nImpact:\n\nWe hope to identify what causes catatonia in order to appropriately target future treatments\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Autoantibodies","Brain","Glutamic Acid","Humans","gamma-Aminobutyric Acid"]}
{"id":"360G-Wellcome-220658_Z_20_Z","title":"Optimising seasonal malaria chemoprevention and seasonal vaccination in childhood to address the resurgent malaria burden in Africa","Region":"Greater London","currency":"GBP","awardDate":"2020-06-17T00:00:00+00:00","Sponsor(s)":"Prof Liam Smeeth","Internal ID":"220658/Z/20/Z","description":"Almost half of the 435,000 malaria deaths each year occur in countries of the Sahel region of Africa, and the majority of these deaths occur during the three-four month rainy season. Monthly seasonal malaria chemoprevention (SMC) is highly effective in these areas, reducing malaria cases by 75-80% in trials, and malaria-specific mortality by 40-50% under programmatic conditions. However, malaria remains a leading cause of disease and death in several countries deploying SMC.  \n \nThe key goals are therefore to understand how to 1) maximise the impact of SMC as currently designed (e.g. by timing it more accurately in different areas), 2) modify the SMC strategy to make it more effective (e.g. by identifying the causes of severe malaria in the context of SMC), 3) use other control tools, including seasonally-targeted vaccination, alongside SMC and 4) understand how improving malaria prevention in childhood would affect naturally-acquired immunity.\n\nAnalysis of data from a comprehensive evaluation of SMC in 7 countries, an SMC trial in 20,000 children, and the first-ever trial of seasonally-targeted vaccination alongside SMC provides a unique opportunity to answer these questions. Mathematical models incorporating these results will enable malaria prevention packages to be optimised according to the local epidemiology.\n","plannedDates":[{"endDate":"2026-01-03T00:00:00+00:00","startDate":"2021-01-04T00:00:00+00:00","startDateDateOnly":"2021-01-04","endDateDateOnly":"2026-01-03"}],"amountAwarded":916159,"Financial Year":"2019/20","Lead Applicant":"Dr Matthew Cairns","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Cairns","Partnership Value":916159,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"London School of Hygiene & Tropical Medicine\", \"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Optimising seasonal malaria chemoprevention and seasonal vaccination in childhood to address the resurgent malaria burden in Africa Almost half of the 435,000 malaria deaths each year occur in countries of the Sahel region of Africa, and the majority of these deaths occur during the three-four month rainy season. Monthly seasonal malaria chemoprevention (SMC) is highly effective in these areas, reducing malaria cases by 75-80% in trials, and malaria-specific mortality by 40-50% under programmatic conditions. However, malaria remains a leading cause of disease and death in several countries deploying SMC.  \n \nThe key goals are therefore to understand how to 1) maximise the impact of SMC as currently designed (e.g. by timing it more accurately in different areas), 2) modify the SMC strategy to make it more effective (e.g. by identifying the causes of severe malaria in the context of SMC), 3) use other control tools, including seasonally-targeted vaccination, alongside SMC and 4) understand how improving malaria prevention in childhood would affect naturally-acquired immunity.\n\nAnalysis of data from a comprehensive evaluation of SMC in 7 countries, an SMC trial in 20,000 children, and the first-ever trial of seasonally-targeted vaccination alongside SMC provides a unique opportunity to answer these questions. Mathematical models incorporating these results will enable malaria prevention packages to be optimised according to the local epidemiology.\n","awardDateDateOnly":"2020-06-17","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa","Child, Preschool","Humans","Infant","Malaria","Malaria Vaccines","Seasons"]}
{"id":"360G-Wellcome-220656_Z_20_Z","title":"Defining the impact of androgens on macrophage function during endometrial tissue repair","Region":"Scotland","currency":"GBP","awardDate":"2020-06-17T00:00:00+00:00","Sponsor(s)":"Prof Christopher Gregory","Internal ID":"220656/Z/20/Z","description":"Macrophages are essential mediators of tissue repair but we lack fundamental knowledge about how they are regulated in the endometrium. Androgens regulate macrophage function in other tissue repair contexts but their role in endometrial repair has not been defined. This project will determine how macrophages are regulated in endometrial repair by assessing their turnover and phenotype and how this is affected by androgens by using a highly reproducible mouse model of endometrial repair that we have developed.\n\nThe key goals of this project are;\n\n\n to determine whether monocytes contribute to the endometrial macrophage function in repair,\n to define how androgens mediate intrinsic and extrinsic effects on endometrial macrophage function and\n to investigate how androgen excess alter macrophage function in aberrant repair.\n\n\nThis will be achieved by using fate-mapping techniques, transcriptomics analysis, multiparameter flow cytometry and immunohistochemistry combined with pharmacological and genetic approaches to modulate androgen action.\n\nThese studies will establish that macrophages are critical mediators of endometrial repair and modulation of their phenotype by androgens determines the balance between healthy and disordered tissue repair. These important insights will provide a platform for assessing macrophage AR as a potential therapeutic target in reproductive health.\n","plannedDates":[{"endDate":"2025-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2025-12-31"}],"amountAwarded":1163672,"Financial Year":"2019/20","Lead Applicant":"Dr Douglas Gibson","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Gibson","Partnership Value":1163672,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Defining the impact of androgens on macrophage function during endometrial tissue repair Macrophages are essential mediators of tissue repair but we lack fundamental knowledge about how they are regulated in the endometrium. Androgens regulate macrophage function in other tissue repair contexts but their role in endometrial repair has not been defined. This project will determine how macrophages are regulated in endometrial repair by assessing their turnover and phenotype and how this is affected by androgens by using a highly reproducible mouse model of endometrial repair that we have developed.\n\nThe key goals of this project are;\n\n\n to determine whether monocytes contribute to the endometrial macrophage function in repair,\n to define how androgens mediate intrinsic and extrinsic effects on endometrial macrophage function and\n to investigate how androgen excess alter macrophage function in aberrant repair.\n\n\nThis will be achieved by using fate-mapping techniques, transcriptomics analysis, multiparameter flow cytometry and immunohistochemistry combined with pharmacological and genetic approaches to modulate androgen action.\n\nThese studies will establish that macrophages are critical mediators of endometrial repair and modulation of their phenotype by androgens determines the balance between healthy and disordered tissue repair. These important insights will provide a platform for assessing macrophage AR as a potential therapeutic target in reproductive health.\n","awardDateDateOnly":"2020-06-17","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Androgens","Animals","Disease Models, Animal","Endometrium","Female","Macrophages","Mice","Receptors, Androgen"]}
{"id":"360G-Wellcome-220646_Z_20_Z","title":"crAssphages - the most abundant viruses of the human gut","Region":"Ireland","currency":"GBP","awardDate":"2020-06-17T00:00:00+00:00","Sponsor(s)":"Prof Paul Ross","Internal ID":"220646/Z/20/Z","description":"The recently discovered crAssphages are the most abundant group of viruses in the human body, reaching up to 20% of gut microbial DNA. They infect bacteria of the order Bacteroidales and demonstrate incredibly stable, sometimes years-long colonisation of the human gut. Our preliminary results, based on the first isolation of a crAss-like phage in culture, indicate that they use an unusual mechanism of infection that allows them to continuously co-exist with the bacterial host population at high levels. I hypothesize that bacterial interactions with their phage \u2018partners\u2019 is an essential aspect of microbiome functionality. The long term persistence of crAssphages in the human gut microbiome is an epitome of such phage-host interaction. My key research question is to provide a mechanistic and structural explanation of this interaction and gain insights into its significance for host physiology and overall microbiome structure. My research program consists of three specific aims: 1) developing methods for genetic manipulation with crAss-like phages; 2) using structural biology to get insights into mechanisms of phage-host interaction; 3) investigate persistence mechanism and its effect on community structure. Taken together these efforts should significantly advance our understanding of this new and elusive group of viruses in the human microbiome.\n","plannedDates":[{"endDate":"2025-11-22T00:00:00+00:00","startDate":"2020-11-23T00:00:00+00:00","startDateDateOnly":"2020-11-23","endDateDateOnly":"2025-11-22"}],"amountAwarded":413761,"Financial Year":"2019/20","Lead Applicant":"Dr Andrey Shkoporov","grantProgramme":[{"title":"Research Career Development Fellowship","title_keyword":"Research Career Development Fellowship"}],"Partnership Name":"SFI-HRB-Wellcome Trust partnership","Applicant Surname":"Shkoporov","Partnership Value":827523,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-Cork","name":"University College Cork","addressCountry":"Ireland","id_and_name":"[\"University College Cork\", \"360G-Wellcome-ORG:University-College-Cork\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-Cork","name":"University College Cork"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"crAssphages - the most abundant viruses of the human gut The recently discovered crAssphages are the most abundant group of viruses in the human body, reaching up to 20% of gut microbial DNA. They infect bacteria of the order Bacteroidales and demonstrate incredibly stable, sometimes years-long colonisation of the human gut. Our preliminary results, based on the first isolation of a crAss-like phage in culture, indicate that they use an unusual mechanism of infection that allows them to continuously co-exist with the bacterial host population at high levels. I hypothesize that bacterial interactions with their phage \u2018partners\u2019 is an essential aspect of microbiome functionality. The long term persistence of crAssphages in the human gut microbiome is an epitome of such phage-host interaction. My key research question is to provide a mechanistic and structural explanation of this interaction and gain insights into its significance for host physiology and overall microbiome structure. My research program consists of three specific aims: 1) developing methods for genetic manipulation with crAss-like phages; 2) using structural biology to get insights into mechanisms of phage-host interaction; 3) investigate persistence mechanism and its effect on community structure. Taken together these efforts should significantly advance our understanding of this new and elusive group of viruses in the human microbiome.\n","awardDateDateOnly":"2020-06-17","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Bacteria","Bacteriophages","Gastrointestinal Microbiome","Gastrointestinal Tract","Host-Pathogen Interactions","Humans"]}
{"id":"360G-Wellcome-220640_Z_20_Z","title":"Investigation of the role of the VWF-ADAMTS13 axis in the pathogenesis of sickle cell vasculopathy in children ","Region":"Ireland","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220640/Z/20/Z","description":"Sickle cell disease (SCD) is responsible for major global morbidity and mortality and more than 1,000 SCD children are born every day. Globally over half will die before five years of age and  \n\n\nA critical step in blood vessel blockage in SCD involves sickle red cells sticking to the blood vessel wall. Interestingly, evidence suggests a new role for the plasma clotting protein von Willebrand factor (VWF) in this process with increased VWF and reduced levels of ADAMTS13, the main protein responsible for breaking down VWF.\n\nThis study aims to define the molecular mechanisms underlying blood vessel blockage in SCD, including how VWF and abnormally large forms of VWF, influence paediatric SCD biology. We will specifically investigate the hypothesis that sickle red cell occlusion is promoted by a dysfunctional VWF-ADAMTS13 axis, leading to characteristic clinical complications. Novel findings from this research may inform future treatments to improve clinical outcomes.\n","plannedDates":[{"endDate":"2022-12-26T00:00:00+00:00","startDate":"2019-07-07T00:00:00+00:00","startDateDateOnly":"2019-07-07","endDateDateOnly":"2022-12-26"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Helen Fogarty","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Partnership Name":"SFI-HRB-Wellcome Trust partnership","Applicant Surname":"Fogarty","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Royal-College-of-Surgeons-in-Ireland","name":"Royal College of Surgeons in Ireland","addressCountry":"Ireland","id_and_name":"[\"Royal College of Surgeons in Ireland\", \"360G-Wellcome-ORG:Royal-College-of-Surgeons-in-Ireland\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Royal-College-of-Surgeons-in-Ireland","name":"Royal College of Surgeons in Ireland"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigation of the role of the VWF-ADAMTS13 axis in the pathogenesis of sickle cell vasculopathy in children  Sickle cell disease (SCD) is responsible for major global morbidity and mortality and more than 1,000 SCD children are born every day. Globally over half will die before five years of age and  \n\n\nA critical step in blood vessel blockage in SCD involves sickle red cells sticking to the blood vessel wall. Interestingly, evidence suggests a new role for the plasma clotting protein von Willebrand factor (VWF) in this process with increased VWF and reduced levels of ADAMTS13, the main protein responsible for breaking down VWF.\n\nThis study aims to define the molecular mechanisms underlying blood vessel blockage in SCD, including how VWF and abnormally large forms of VWF, influence paediatric SCD biology. We will specifically investigate the hypothesis that sickle red cell occlusion is promoted by a dysfunctional VWF-ADAMTS13 axis, leading to characteristic clinical complications. Novel findings from this research may inform future treatments to improve clinical outcomes.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["ADAMTS13 Protein","Anemia, Sickle Cell","Child","Humans","von Willebrand Factor"]}
{"id":"360G-Wellcome-220628_Z_20_Z","title":"Molecular basis of phase separation in viral replication and neurodegenerative disease","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2020-06-17T00:00:00+00:00","Sponsor(s)":"Prof Andrew Macdonald","Internal ID":"220628/Z/20/Z","description":"Membrane-less organelles (MLOs) are multicomponent structures that form by liquid-liquid phase separation (LLPS) of proteins/RNA. They play key roles in organising cells, signalling, stress and viral factory formation, whilst aberrant LLPS is associated with several neurodegenerative diseases (e.g. MND). MLOs are heterogeneous and dynamic, making it challenging to elucidate their composition, structure and biogenesis. New tools are urgently needed to study LLPS in vitro and in vivo to address fundamental questions of the molecular mechanism of LLPS, and to unravel how it contributes to homeostasis and disease. Here, I will develop a toolkit of MS-based methods to study LLPS, focussing on two systems: TDP-43, implicated in MND, and NSP2/NSP5, involved in Rotavirus viral factory formation. This will reveal new insights into the structure/dynamics of these proteins (which promote/suppress LLPS) and the protein-protein/RNA interactions which nucleate LLPS. I will study LLPS in vivo using, and developing, structural MS methods to reveal the proteins recruited into MLOs and the interactions mediating recruitment. This toolkit of MS methods, reinforced with biochemical/cellular/functional assays, will afford new mechanistic insights into two important systems, uncover new targets to combat neurodegeneration and viral infection, and open the door to revealing how LLPS controls many other cellular processes.\n","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":1196484,"Financial Year":"2019/20","Lead Applicant":"Dr Antonio Calabrese","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Calabrese","Partnership Value":1196484,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds","addressCountry":"United Kingdom","id_and_name":"[\"University of Leeds\", \"360G-Wellcome-ORG:University-of-Leeds\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leeds","name":"University of Leeds"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Molecular basis of phase separation in viral replication and neurodegenerative disease Membrane-less organelles (MLOs) are multicomponent structures that form by liquid-liquid phase separation (LLPS) of proteins/RNA. They play key roles in organising cells, signalling, stress and viral factory formation, whilst aberrant LLPS is associated with several neurodegenerative diseases (e.g. MND). MLOs are heterogeneous and dynamic, making it challenging to elucidate their composition, structure and biogenesis. New tools are urgently needed to study LLPS in vitro and in vivo to address fundamental questions of the molecular mechanism of LLPS, and to unravel how it contributes to homeostasis and disease. Here, I will develop a toolkit of MS-based methods to study LLPS, focussing on two systems: TDP-43, implicated in MND, and NSP2/NSP5, involved in Rotavirus viral factory formation. This will reveal new insights into the structure/dynamics of these proteins (which promote/suppress LLPS) and the protein-protein/RNA interactions which nucleate LLPS. I will study LLPS in vivo using, and developing, structural MS methods to reveal the proteins recruited into MLOs and the interactions mediating recruitment. This toolkit of MS methods, reinforced with biochemical/cellular/functional assays, will afford new mechanistic insights into two important systems, uncover new targets to combat neurodegeneration and viral infection, and open the door to revealing how LLPS controls many other cellular processes.\n","awardDateDateOnly":"2020-06-17","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cytoplasmic Granules","Humans","Organelles","RNA, Viral","Rotavirus","Viral Nonstructural Proteins","Viral Proteins"]}
{"id":"360G-Wellcome-220622_Z_20_Z","title":"Spatiotemporal single-cell multi-omics to unlock hair cell regeneration","Region":"Greater London","currency":"GBP","awardDate":"2020-06-17T00:00:00+00:00","Sponsor(s)":"Prof Jonathan Gale","Internal ID":"220622/Z/20/Z","description":"In humans, as with all mammals,, the loss of auditory sensory hair cells (HCs) is irreversible. However, different degrees of HC regeneration occur in vestibular sensory epithelia, at early developmental stages, or in non-mammalian species. HC regeneration results from division and/or trans-differentiation of neighbouring supporting cells (SCs). It is generally accepted that poor/absent HC regeneration relates to the differentiation state reached by SCs and HCs, but the mechanisms behind this are unknown.\nWhat dictates HC regeneration potential? Taking on a multi-layered approach, combining single-cell multi-omics, in-situ sequencing and transcriptional manipulations, I will study the vestibular utricle to evaluate the connection between maturation and HC regeneration potential. First, I will identify the cell/tissue level factors that interact during maturation to distinguish the mouse (marginally-regenerating) and chick (fully-regenerating) utricle. Second, I will study the regeneration trajectories of postnatal and adult mouse utricle to zoom-in on the factors driving the age-related decrease in regeneration potential. Finally, I will perform simultaneous transcriptional manipulation of identified targets aiming to overturn the poor HC regeneration of the adult mammalian utricle.\nMy research will generate unprecedented cell/tissue-level insight on the maturation and regeneration of sensory epithelia, identifying potential novel therapeutic avenues for recovery from pathological HC loss.\n","plannedDates":[{"endDate":"2026-08-31T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2026-08-31"}],"amountAwarded":1547266,"Financial Year":"2019/20","Lead Applicant":"Dr Marcela Lipovsek","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Lipovsek","Partnership Value":1547266,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Spatiotemporal single-cell multi-omics to unlock hair cell regeneration In humans, as with all mammals,, the loss of auditory sensory hair cells (HCs) is irreversible. However, different degrees of HC regeneration occur in vestibular sensory epithelia, at early developmental stages, or in non-mammalian species. HC regeneration results from division and/or trans-differentiation of neighbouring supporting cells (SCs). It is generally accepted that poor/absent HC regeneration relates to the differentiation state reached by SCs and HCs, but the mechanisms behind this are unknown.\nWhat dictates HC regeneration potential? Taking on a multi-layered approach, combining single-cell multi-omics, in-situ sequencing and transcriptional manipulations, I will study the vestibular utricle to evaluate the connection between maturation and HC regeneration potential. First, I will identify the cell/tissue level factors that interact during maturation to distinguish the mouse (marginally-regenerating) and chick (fully-regenerating) utricle. Second, I will study the regeneration trajectories of postnatal and adult mouse utricle to zoom-in on the factors driving the age-related decrease in regeneration potential. Finally, I will perform simultaneous transcriptional manipulation of identified targets aiming to overturn the poor HC regeneration of the adult mammalian utricle.\nMy research will generate unprecedented cell/tissue-level insight on the maturation and regeneration of sensory epithelia, identifying potential novel therapeutic avenues for recovery from pathological HC loss.\n","awardDateDateOnly":"2020-06-17","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aging","Animals","Chick Embryo","Gene Expression Regulation, Developmental","Hair Cells, Auditory","Mice","Regeneration","Saccule and Utricle","Single-Cell Analysis"]}
{"id":"360G-Wellcome-220620_Z_20_Z","title":"What makes a virus an intestinal pathogen?","Region":"East of England","currency":"GBP","awardDate":"2020-06-17T00:00:00+00:00","Sponsor(s)":"Prof Geoffrey Smith","Internal ID":"220620/Z/20/Z","description":"Enteric viruses are a major cause of mortality and morbidity in the young, the elderly, and the immunocompromised. Even after decades of research, it is still poorly understood why these viruses replicate particularly in the gastrointestinal tract and what triggers virus dissemination beyond the gut. Despite their worldwide prevalence, and recently emerged neuropathogenic strains, astroviruses represent one of the least studied groups of human RNA viruses, mainly due to difficulties with culturing and molecular manipulations.\n\nMy research will focus on understanding the molecular determinants of astrovirus infection \u2013 starting with basic replication mechanisms and moving towards physiologically relevant translational outputs. Key goals include:\n\n\n Characterisation of the viral RNA structure and replication strategy to understand their role during virus infection.\n Functional dissection of the astrovirus polyprotein processing strategy and its role in virus infection.\n Identification and assessing the importance of gut-specific determinants in virus infection.\n Identification of the molecular mechanisms responsible for neurovirulence.\n\n\n\nElucidation of the fundamental molecular biology of astroviruses underpins an understanding of their pathogenesis, both in the gut and in the central nervous system. It will also facilitate the development of vaccines and antiviral therapies, addressing an unmet need for young children in developing countries.\n","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":1065085,"Financial Year":"2019/20","Lead Applicant":"Dr Valeria Lulla","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Lulla","Partnership Value":1065085,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"What makes a virus an intestinal pathogen? Enteric viruses are a major cause of mortality and morbidity in the young, the elderly, and the immunocompromised. Even after decades of research, it is still poorly understood why these viruses replicate particularly in the gastrointestinal tract and what triggers virus dissemination beyond the gut. Despite their worldwide prevalence, and recently emerged neuropathogenic strains, astroviruses represent one of the least studied groups of human RNA viruses, mainly due to difficulties with culturing and molecular manipulations.\n\nMy research will focus on understanding the molecular determinants of astrovirus infection \u2013 starting with basic replication mechanisms and moving towards physiologically relevant translational outputs. Key goals include:\n\n\n Characterisation of the viral RNA structure and replication strategy to understand their role during virus infection.\n Functional dissection of the astrovirus polyprotein processing strategy and its role in virus infection.\n Identification and assessing the importance of gut-specific determinants in virus infection.\n Identification of the molecular mechanisms responsible for neurovirulence.\n\n\n\nElucidation of the fundamental molecular biology of astroviruses underpins an understanding of their pathogenesis, both in the gut and in the central nervous system. It will also facilitate the development of vaccines and antiviral therapies, addressing an unmet need for young children in developing countries.\n","awardDateDateOnly":"2020-06-17","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Astrocytes","Astroviridae Infections","Humans","Mamastrovirus","RNA, Viral"]}
{"id":"360G-Wellcome-220607_Z_20_Z","title":"Understanding how Salmonella interferes with the adaptive immune system","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220607/Z/20/Z","description":"Salmonella enterica is one of the four key causative agents of foodbourne diseases and each year it affects around 1 in 10 of the global population, according the World Health Organisation (World Health Organisation, n.d.). Salmonella enterica can cause a range of illness from a mild diarrhoeal illness to a widespread systemic infection known as typhoid fever. Successful clearance of the Salmonella bacteria from our bodies during an infection relies on part of immune system called the adaptive immune system. This part of our immune system not only produces a highly specific response but also provides long-lasting immunity. Salmonella has evolved to live within the hostile environment of our cells and is able to manipulate the host cell to aid its survival.  Recent work by the Holden Laboratory, Imperial College London, has shown that Salmonella produces a small protein, called SteD, that specifically interferes with a specific component of the adaptive immune system. Further work has identified two new genes required for SteD to function. In this project, I will establish how SteD hijacks these two proteins to disrupt the immune system.\n \n","plannedDates":[{"endDate":"2023-02-06T00:00:00+00:00","startDate":"2019-08-07T00:00:00+00:00","startDateDateOnly":"2019-08-07","endDateDateOnly":"2023-02-06"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Samkeliso Blundell","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Blundell","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding how Salmonella interferes with the adaptive immune system Salmonella enterica is one of the four key causative agents of foodbourne diseases and each year it affects around 1 in 10 of the global population, according the World Health Organisation (World Health Organisation, n.d.). Salmonella enterica can cause a range of illness from a mild diarrhoeal illness to a widespread systemic infection known as typhoid fever. Successful clearance of the Salmonella bacteria from our bodies during an infection relies on part of immune system called the adaptive immune system. This part of our immune system not only produces a highly specific response but also provides long-lasting immunity. Salmonella has evolved to live within the hostile environment of our cells and is able to manipulate the host cell to aid its survival.  Recent work by the Holden Laboratory, Imperial College London, has shown that Salmonella produces a small protein, called SteD, that specifically interferes with a specific component of the adaptive immune system. Further work has identified two new genes required for SteD to function. In this project, I will establish how SteD hijacks these two proteins to disrupt the immune system.\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adaptive Immunity","Animals","Humans","Salmonella","Salmonella Infections","Salmonella typhimurium"]}
{"id":"360G-Wellcome-220601_Z_20_Z","title":"Defining the decline in endogenous insulin secretion in type 1 diabetes diagnosed after 30 years of age.","Region":"South West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220601/Z/20/Z","description":"Type 1 diabetes is associated with loss of insulin release, which results in high blood sugars. In children and young adults this loss of insulin is known to happen quickly. After just a couple of years of having type 1 diabetes, most of this age group will make almost no insulin. Research is trying to find new treatments to slow down and even stop this insulin loss. Those developing type 1 diabetes after 30 years of age are rarely included in these trials- despite making up nearly half of all cases of type 1 diabetes. This is because, in this age group, the rate of insulin loss is unknown. Finding out this rate and factors that effect it is an important step towards including older individuals in trials.\n\n\nI also aim to test a new, simpler way of monitoring insulin loss by using a finger prick blood test.  This will hopefully make it possible to conduct research from home rather than in hospital. Together, the answers to these questions aim to make it easier to develop new treatments for type 1 diabetes, as these studies could recruit many more people, using a much simpler and cheaper measure of insulin loss.\n \n","plannedDates":[{"endDate":"2023-03-02T00:00:00+00:00","startDate":"2019-08-07T00:00:00+00:00","startDateDateOnly":"2019-08-07","endDateDateOnly":"2023-03-02"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Nicholas Thomas","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Thomas","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Exeter","name":"University of Exeter","addressCountry":"United Kingdom","id_and_name":"[\"University of Exeter\", \"360G-Wellcome-ORG:University-of-Exeter\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Exeter","name":"University of Exeter"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Defining the decline in endogenous insulin secretion in type 1 diabetes diagnosed after 30 years of age. Type 1 diabetes is associated with loss of insulin release, which results in high blood sugars. In children and young adults this loss of insulin is known to happen quickly. After just a couple of years of having type 1 diabetes, most of this age group will make almost no insulin. Research is trying to find new treatments to slow down and even stop this insulin loss. Those developing type 1 diabetes after 30 years of age are rarely included in these trials- despite making up nearly half of all cases of type 1 diabetes. This is because, in this age group, the rate of insulin loss is unknown. Finding out this rate and factors that effect it is an important step towards including older individuals in trials.\n\n\nI also aim to test a new, simpler way of monitoring insulin loss by using a finger prick blood test.  This will hopefully make it possible to conduct research from home rather than in hospital. Together, the answers to these questions aim to make it easier to develop new treatments for type 1 diabetes, as these studies could recruit many more people, using a much simpler and cheaper measure of insulin loss.\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adult","Diabetes Mellitus, Type 1","Humans","Hypoglycemic Agents","Insulin"]}
{"id":"360G-Wellcome-220600_Z_20_Z","title":"Clinical and molecular delineation of neurodevelopmental disease within genetically isolated communities.","Region":"South West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220600/Z/20/Z","description":"Inherited neurodevelopmental disorders affect brain development and function and occur as result of changes to the genetic code, which may be passed down through families. The causes of these disorders remain poorly understood, and they present an immense healthcare burden worldwide. This means that affected families may often undergo multiple investigations in search of a diagnosis.\nSome neurodevelopmental disorders, which are otherwise rare in the general population, may occur more commonly in certain communities such as the Amish and Palestinian populations. The unique genetic make-up of these communities makes it easier for scientists to identify the genetic causes of inherited neurodevelopmental disease, which in turn greatly aids scientific understanding of brain growth, development and function. This project aims to identify new genetic causes of human inherited neurodevelopmental disease within these community settings. Studying the biological function of these genes will help us understand more about human health and the medical problems which arise when the genes involved do not function properly. This knowledge is ultimately important to develop better treatments for these disorders. Crucially, this work will also provide diagnoses for patients and their families, not just in these communities, but also worldwide.\n","plannedDates":[{"endDate":"2022-12-21T00:00:00+00:00","startDate":"2019-08-01T00:00:00+00:00","startDateDateOnly":"2019-08-01","endDateDateOnly":"2022-12-21"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr James Fasham","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Fasham","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Exeter","name":"University of Exeter","addressCountry":"United Kingdom","id_and_name":"[\"University of Exeter\", \"360G-Wellcome-ORG:University-of-Exeter\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Exeter","name":"University of Exeter"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Clinical and molecular delineation of neurodevelopmental disease within genetically isolated communities. Inherited neurodevelopmental disorders affect brain development and function and occur as result of changes to the genetic code, which may be passed down through families. The causes of these disorders remain poorly understood, and they present an immense healthcare burden worldwide. This means that affected families may often undergo multiple investigations in search of a diagnosis.\nSome neurodevelopmental disorders, which are otherwise rare in the general population, may occur more commonly in certain communities such as the Amish and Palestinian populations. The unique genetic make-up of these communities makes it easier for scientists to identify the genetic causes of inherited neurodevelopmental disease, which in turn greatly aids scientific understanding of brain growth, development and function. This project aims to identify new genetic causes of human inherited neurodevelopmental disease within these community settings. Studying the biological function of these genes will help us understand more about human health and the medical problems which arise when the genes involved do not function properly. This knowledge is ultimately important to develop better treatments for these disorders. Crucially, this work will also provide diagnoses for patients and their families, not just in these communities, but also worldwide.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Genetic Predisposition to Disease","Humans","Neurodevelopmental Disorders"]}
{"id":"360G-Wellcome-220597_Z_20_Z","title":"Integration of kinases with membrane trafficking machinery","Region":"East of England","currency":"GBP","awardDate":"2020-06-17T00:00:00+00:00","Sponsor(s)":"Prof Julian Rayner","Internal ID":"220597/Z/20/Z","description":"Endocytosis is a highly dynamic process that determines the composition of the plasma membrane (PM). The dysfunction of endocytic pathways is a causal factor behind a number of human genetic diseases, and its dys-regulation can contribute to neurodegeneration. \n\nDespite the critical role that endocytosis plays in health and disease, surprisingly little is known about how it is regulated. A major potential regulation point is the dynamic phosphorylation of endocytic components by kinases. However, it is poorly understood which kinases (and phosphatases) control endocytosis and the PM proteome, even though they represent potential targets for disease-modifying therapies.  \n\nMy long-term vision is to understand the integration of protein kinases  within membrane-trafficking machinery. My starting focus is on the Numb-associated kinase family (NAK). NAKs were identified as a susceptibility factor in Parkinson\u2019s disease and neuropathic pain but the molecular mechanisms behind this are not clear.  \n\nI will elucidate the key cellular functions of NAKs: (1) which cellular processes and substrates are associated with NAKs (2) the consequences of their activity for cellular physiology and (3) the regulatory processes and interaction partners which govern NAK activity states.\n","plannedDates":[{"endDate":"2025-12-30T00:00:00+00:00","startDate":"2020-12-31T00:00:00+00:00","startDateDateOnly":"2020-12-31","endDateDateOnly":"2025-12-30"}],"amountAwarded":1178961,"Financial Year":"2019/20","Lead Applicant":"Dr Zuzana Kadlecova","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Kadlecova","Partnership Value":1178961,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Integration of kinases with membrane trafficking machinery Endocytosis is a highly dynamic process that determines the composition of the plasma membrane (PM). The dysfunction of endocytic pathways is a causal factor behind a number of human genetic diseases, and its dys-regulation can contribute to neurodegeneration. \n\nDespite the critical role that endocytosis plays in health and disease, surprisingly little is known about how it is regulated. A major potential regulation point is the dynamic phosphorylation of endocytic components by kinases. However, it is poorly understood which kinases (and phosphatases) control endocytosis and the PM proteome, even though they represent potential targets for disease-modifying therapies.  \n\nMy long-term vision is to understand the integration of protein kinases  within membrane-trafficking machinery. My starting focus is on the Numb-associated kinase family (NAK). NAKs were identified as a susceptibility factor in Parkinson\u2019s disease and neuropathic pain but the molecular mechanisms behind this are not clear.  \n\nI will elucidate the key cellular functions of NAKs: (1) which cellular processes and substrates are associated with NAKs (2) the consequences of their activity for cellular physiology and (3) the regulatory processes and interaction partners which govern NAK activity states.\n","awardDateDateOnly":"2020-06-17","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cell Membrane","Endocytosis","Humans","Parkinson Disease","Phosphorylation"]}
{"id":"360G-Wellcome-220596_Z_20_Z","title":"Discovering New Pathways of Preleukaemic Dysregulation from Single Cell Transcriptional and Chromatin Landscapes","Region":"East of England","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220596/Z/20/Z","description":"Blood stem cells ensure the constant supply of new blood cells throughout a person\u2019s lifetime.  The normal function of blood stem cells critically depends on the fine tuning of which genes should be active at any given time.  Moreover, a large number of leukaemias arise when this fine balance of gene activities is disturbed.  Through my research I want to answer the following questions:\n\n\n What are the mechanisms which regulate gene activities to ensure normal blood stem cell function? \n Can we identify new strategies to treat leukaemia by reversing the disturbed balance of gene activities?\n\n\nTo answer these questions, I plan to use a combination of experimental and computational approaches, in order to discover how individual regulator genes are connected to form complex networks that control normal blood cell differentiation, and also reveal how perturbation of these complex networks can cause leukaemia. \n\n \n\n \n","plannedDates":[{"endDate":"2023-12-25T00:00:00+00:00","startDate":"2019-12-31T00:00:00+00:00","startDateDateOnly":"2019-12-31","endDateDateOnly":"2023-12-25"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Katherine Sturgess","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Sturgess","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Discovering New Pathways of Preleukaemic Dysregulation from Single Cell Transcriptional and Chromatin Landscapes Blood stem cells ensure the constant supply of new blood cells throughout a person\u2019s lifetime.  The normal function of blood stem cells critically depends on the fine tuning of which genes should be active at any given time.  Moreover, a large number of leukaemias arise when this fine balance of gene activities is disturbed.  Through my research I want to answer the following questions:\n\n\n What are the mechanisms which regulate gene activities to ensure normal blood stem cell function? \n Can we identify new strategies to treat leukaemia by reversing the disturbed balance of gene activities?\n\n\nTo answer these questions, I plan to use a combination of experimental and computational approaches, in order to discover how individual regulator genes are connected to form complex networks that control normal blood cell differentiation, and also reveal how perturbation of these complex networks can cause leukaemia. \n\n \n\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cell Differentiation","Gene Regulatory Networks","Humans","Leukemia","Neoplastic Stem Cells"]}
{"id":"360G-Wellcome-220594_Z_20_Z","title":"Improving engraftment for cell therapy in cholangiopathies","Region":"Scotland","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220594/Z/20/Z","description":"The cholangiopathies are a group of diseases, which cause injury to the biliary system. The most prevalent of these are primary sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC), both of which frequently progress to cause hepatic failure.\n \nLiver transplant offers the only curative therapy for PSC and PBC however, there are a limited number of livers available and transplantation is associated with a significant risk of complications. Stem cell therapy has shown promise as an alternative treatment strategy, but delivery of cells to the biliary system is challenging.\n \nRecently it has become possible to create particles which target specific markers in tissues and cells. Particles designed to target the biliary system can be attached to the surface of stem cells, creating a method for stem cells to home to the biliary system, in the hope of improving cell delivery and treatment efficacy.\n \n","plannedDates":[{"endDate":"2023-02-02T00:00:00+00:00","startDate":"2019-08-05T00:00:00+00:00","startDateDateOnly":"2019-08-05","endDateDateOnly":"2023-02-02"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Mark Macmillan","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Macmillan","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Improving engraftment for cell therapy in cholangiopathies The cholangiopathies are a group of diseases, which cause injury to the biliary system. The most prevalent of these are primary sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC), both of which frequently progress to cause hepatic failure.\n \nLiver transplant offers the only curative therapy for PSC and PBC however, there are a limited number of livers available and transplantation is associated with a significant risk of complications. Stem cell therapy has shown promise as an alternative treatment strategy, but delivery of cells to the biliary system is challenging.\n \nRecently it has become possible to create particles which target specific markers in tissues and cells. Particles designed to target the biliary system can be attached to the surface of stem cells, creating a method for stem cells to home to the biliary system, in the hope of improving cell delivery and treatment efficacy.\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cholangitis, Sclerosing","Humans","Liver Transplantation","Stem Cell Transplantation","Stem Cells"]}
{"id":"360G-Wellcome-220593_Z_20_Z","title":"Measuring unmet need in sexual and reproductive health among women under the age of 25","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220593/Z/20/Z","description":"When designing and evaluating health policies, there is a particular challenge that often arises - how do we work out the number of people who need healthcare but haven\u2019t received it?  This is often referred to as \u2018unmet need\u2019.  Although a lot of data are collected regarding the use of healthcare services, by definition, the people who aren\u2019t receiving the services that they require do not contribute to these datasets.  My thesis will look at the concept of unmet need through the lens of sexual and reproductive health, attempting to ascertain whether we can calculate levels of unmet need across England using the data that we already have available.\n\nThrough this project I will attempt to calculate the number of women in England under the age of 25 who did not receive the sexual and reproductive healthcare that they needed between 2010 and 2020. I will then use financial data to work out whether this unmet need was greater in areas that had smaller budgets for sexual and reproductive health during this period.\n","plannedDates":[{"endDate":"2022-12-20T00:00:00+00:00","startDate":"2019-09-02T00:00:00+00:00","startDateDateOnly":"2019-09-02","endDateDateOnly":"2022-12-20"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Danielle Solomon","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Solomon","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Measuring unmet need in sexual and reproductive health among women under the age of 25 When designing and evaluating health policies, there is a particular challenge that often arises - how do we work out the number of people who need healthcare but haven\u2019t received it?  This is often referred to as \u2018unmet need\u2019.  Although a lot of data are collected regarding the use of healthcare services, by definition, the people who aren\u2019t receiving the services that they require do not contribute to these datasets.  My thesis will look at the concept of unmet need through the lens of sexual and reproductive health, attempting to ascertain whether we can calculate levels of unmet need across England using the data that we already have available.\n\nThrough this project I will attempt to calculate the number of women in England under the age of 25 who did not receive the sexual and reproductive healthcare that they needed between 2010 and 2020. I will then use financial data to work out whether this unmet need was greater in areas that had smaller budgets for sexual and reproductive health during this period.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adult","England","Female","Humans","Reproductive Health","Reproductive Health Services","Sexual Behavior","Sexual Health","State Medicine","Women's Health"]}
{"id":"360G-Wellcome-220592_Z_20_Z","title":"Novel labelling and tracking strategies to understand mesenchymal stem/stromal cell populations relevant to musculoskeletal regenerative therapy","Region":"East of England","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220592/Z/20/Z","description":"Bone marrow-derived MSCs can exert strong therapeutic effects in the musculoskeletal system and cell therapies have developed to regenerate and repair cartilage defects. However, our understanding of the biology of this heterogeneous group of cells is incomplete and there are still many hurdles to their wide application in the clinic.\n\nWe will use a combination of labelling techniques and novel cell markers developed in Cambridge to track labelled cells in vivo to determine their survival, engraftment and distribution. The biology of unlabelled and labelled MSCs will be studied in vitro to confirm that the labelling does not affect the cells\u2019 function. Labelled cells will be injected into a mouse knee (after creation of a cartilage defect) and repeated imaging will be used to track the distribution of these cells to study their biology in greater detail.\n\nWith the current focus on moving cell therapies to the clinic, in vivo tracking of these cells is critical in assessing their homing and proliferative potential over time. The novel genetic labelling strategies used will provide important information regarding graft behaviour in small animal models, offering both fast readouts of longitudinal cell survival and low costs per imaging study.\n","plannedDates":[{"endDate":"2023-05-15T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2023-05-15"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Matthew Seah","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Seah","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Novel labelling and tracking strategies to understand mesenchymal stem/stromal cell populations relevant to musculoskeletal regenerative therapy Bone marrow-derived MSCs can exert strong therapeutic effects in the musculoskeletal system and cell therapies have developed to regenerate and repair cartilage defects. However, our understanding of the biology of this heterogeneous group of cells is incomplete and there are still many hurdles to their wide application in the clinic.\n\nWe will use a combination of labelling techniques and novel cell markers developed in Cambridge to track labelled cells in vivo to determine their survival, engraftment and distribution. The biology of unlabelled and labelled MSCs will be studied in vitro to confirm that the labelling does not affect the cells\u2019 function. Labelled cells will be injected into a mouse knee (after creation of a cartilage defect) and repeated imaging will be used to track the distribution of these cells to study their biology in greater detail.\n\nWith the current focus on moving cell therapies to the clinic, in vivo tracking of these cells is critical in assessing their homing and proliferative potential over time. The novel genetic labelling strategies used will provide important information regarding graft behaviour in small animal models, offering both fast readouts of longitudinal cell survival and low costs per imaging study.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Mesenchymal Stem Cell Transplantation","Mesenchymal Stem Cells","Mice"]}
{"id":"360G-Wellcome-220591_Z_20_Z","title":"Continuing the Mental Health Agenda in 2020","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220591/Z/20/Z","description":"This proposal aims to sustain lasting activity on mental health advocacy.  The United GMH team will leverage support from Wellcome to mobilise partners, and the wider global mental health community, to maintain the momentum built since 2018 to raise mental health further up the global political agenda in 2020. We are requesting \u00a3250,000 from Wellcome to further this work. \n\nThis proposal plans activities covering four streams:\n\n\n \n Sustaining the work of the BluePrint Group including delivery of the Kenya face to face meeting and a second meeting later in the year (TBC Sept/Oct)\n \n \n Leading the BluePrint Group and the wider mental health community to design and undertake a comprehensive multi-stakeholder consultation and create and finalise an action plan to ensure the Global Mental Health Roadmap is delivered; starting with the engagement with key stakeholders at Davos and at the Speak Your Mind and BPG meetings in February\n \n \n Working with WHO to develop the advocacy strategy, consultation process and finalisation of their WHO Mental Health Action Plan\n \n \n Working to incorporate messaging around the need for more mental health research as part of UnitedGMH\u2019s research on broader advocacy\n \n\n","plannedDates":[{"endDate":"2020-10-31T00:00:00+00:00","startDate":"2020-01-01T00:00:00+00:00","startDateDateOnly":"2020-01-01","endDateDateOnly":"2020-10-31"}],"amountAwarded":250190,"Financial Year":"2019/20","Lead Applicant":"Ms Elisha London","grantProgramme":[{"title":"Discretionary Award - Mental Health","title_keyword":"Discretionary Award - Mental Health"}],"Applicant Surname":"London","Partnership Value":250190,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:United-for-Global-Mental-Health","name":"United for Global Mental Health","addressCountry":"United Kingdom","id_and_name":"[\"United for Global Mental Health\", \"360G-Wellcome-ORG:United-for-Global-Mental-Health\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:United-for-Global-Mental-Health","name":"United for Global Mental Health"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Continuing the Mental Health Agenda in 2020 This proposal aims to sustain lasting activity on mental health advocacy.  The United GMH team will leverage support from Wellcome to mobilise partners, and the wider global mental health community, to maintain the momentum built since 2018 to raise mental health further up the global political agenda in 2020. We are requesting \u00a3250,000 from Wellcome to further this work. \n\nThis proposal plans activities covering four streams:\n\n\n \n Sustaining the work of the BluePrint Group including delivery of the Kenya face to face meeting and a second meeting later in the year (TBC Sept/Oct)\n \n \n Leading the BluePrint Group and the wider mental health community to design and undertake a comprehensive multi-stakeholder consultation and create and finalise an action plan to ensure the Global Mental Health Roadmap is delivered; starting with the engagement with key stakeholders at Davos and at the Speak Your Mind and BPG meetings in February\n \n \n Working with WHO to develop the advocacy strategy, consultation process and finalisation of their WHO Mental Health Action Plan\n \n \n Working to incorporate messaging around the need for more mental health research as part of UnitedGMH\u2019s research on broader advocacy\n \n\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Global Health","Humans","Kenya","Mental Health","Patient Advocacy"]}
{"id":"360G-Wellcome-220589_Z_20_Z","title":"Investigating the contribution of gamma-delta T-cells to immunosurveillance of cancer and response to immunotherapy","Region":"Greater London","currency":"GBP","awardDate":"2020-10-05T00:00:00+00:00","Sponsor(s)":"Prof Adrian Hayday","Internal ID":"220589/Z/20/Z","description":"Gamma-delta T-cells are critical for protecting against carcinogenesis in mice but clinical associations have been equivocal and human trials of gamma-delta T-cell therapy have been disappointing.  Previous studies have been limited by unavailable technologies to describe these cells with sufficient granularity whilst clinical trials have largely focussed on the more numerous V-delta-2 subtype.  Using contemporary methods such as TCR-sequencing and ex vivo culture systems to extract gamma-delta T-cells from human tissues, we recently demonstrated that only certain subtypes of these cells, namely the V-delta-1 subtype, are associated with survival in triple-negative breast cancers.  \n\nThis proposal aims to extend our previous findings to a pan-cancer setting by mapping, with greater and necessary detail, these cells in melanoma, breast, lung and other cancers with a particular focus on V-delta subtyping, differential effector functions and cell regulatory axes.  Importantly, we will also map gamma-delta T-cell interactions with alpha-beta T-cells as these cells have been established as being critical to cancer immunosurveillance.  We will stratify our findings to clinical outcomes to build a novel reference human tumour gamma-delta T-cell atlas to guide ongoing translational efforts in adoptive gamma-delta T-cell therapy.  Hence, this proposal may lead to rapid translation into clinical benefit.\n","plannedDates":[{"endDate":"2025-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2025-08-31"}],"amountAwarded":698120,"Financial Year":"2020/21","Lead Applicant":"Dr Yin Wu","grantProgramme":[{"title":"Clinical Research Career Development Fellowship","title_keyword":"Clinical Research Career Development Fellowship"}],"Applicant Surname":"Wu","Partnership Value":698120,"Approval Committee":"Clinical Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the contribution of gamma-delta T-cells to immunosurveillance of cancer and response to immunotherapy Gamma-delta T-cells are critical for protecting against carcinogenesis in mice but clinical associations have been equivocal and human trials of gamma-delta T-cell therapy have been disappointing.  Previous studies have been limited by unavailable technologies to describe these cells with sufficient granularity whilst clinical trials have largely focussed on the more numerous V-delta-2 subtype.  Using contemporary methods such as TCR-sequencing and ex vivo culture systems to extract gamma-delta T-cells from human tissues, we recently demonstrated that only certain subtypes of these cells, namely the V-delta-1 subtype, are associated with survival in triple-negative breast cancers.  \n\nThis proposal aims to extend our previous findings to a pan-cancer setting by mapping, with greater and necessary detail, these cells in melanoma, breast, lung and other cancers with a particular focus on V-delta subtyping, differential effector functions and cell regulatory axes.  Importantly, we will also map gamma-delta T-cell interactions with alpha-beta T-cells as these cells have been established as being critical to cancer immunosurveillance.  We will stratify our findings to clinical outcomes to build a novel reference human tumour gamma-delta T-cell atlas to guide ongoing translational efforts in adoptive gamma-delta T-cell therapy.  Hence, this proposal may lead to rapid translation into clinical benefit.\n","awardDateDateOnly":"2020-10-05","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Female","Humans","Immunotherapy, Adoptive","Receptors, Antigen, T-Cell","T-Lymphocytes","Triple Negative Breast Neoplasms"]}
{"id":"360G-Wellcome-220587_Z_20_Z","title":"Understanding TB treatment response: a cross-disciplinary approach","Region":"Greater London","currency":"GBP","awardDate":"2020-06-17T00:00:00+00:00","Sponsor(s)":"Prof Ibrahim Abubakar","Internal ID":"220587/Z/20/Z","description":"Tuberculosis is the leading cause of death from infectious diseases and requires a long treatment. Various initiatives aim to develop shorter and more effective treatment. However, this is complicated by the (1) absence of a biomarker that can predict treatment response during early phases of treatment and; (2) interactions between drugs when given together which makes dose selection/optimisation difficult.\n\nMy aim is to address these shortcomings by, for the first time, studying relationships between pharmacology, microbiology and immunology markers, using data from patients with drug sensitive and multidrug resistant tuberculosis and statistical modelling. This will help developing a test that predicts cure during the first 2 months of treatment which can contribute to improved efficiency of clinical trials evaluating tuberculosis treatment. Secondly, I aim to characterise overall antimicrobial activity and emergence of persistence and resistance, whilst accounting for drug-drug interactions using an innovative combination of in-vitro kill-curve and hollow-fibre experiments, in-vivo pharmacokinetic data and statistical modelling. This will inform optimisation of tuberculosis treatment.\n\nI will undertake this work at University College London in collaboration with the University of Cape Town, South Africa, giving me access to a large and diverse tuberculosis patient population and state of the art laboratory facilities.\n","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":1113271,"Financial Year":"2019/20","Lead Applicant":"Dr Frank Kloprogge","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Kloprogge","Partnership Value":1113271,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding TB treatment response: a cross-disciplinary approach Tuberculosis is the leading cause of death from infectious diseases and requires a long treatment. Various initiatives aim to develop shorter and more effective treatment. However, this is complicated by the (1) absence of a biomarker that can predict treatment response during early phases of treatment and; (2) interactions between drugs when given together which makes dose selection/optimisation difficult.\n\nMy aim is to address these shortcomings by, for the first time, studying relationships between pharmacology, microbiology and immunology markers, using data from patients with drug sensitive and multidrug resistant tuberculosis and statistical modelling. This will help developing a test that predicts cure during the first 2 months of treatment which can contribute to improved efficiency of clinical trials evaluating tuberculosis treatment. Secondly, I aim to characterise overall antimicrobial activity and emergence of persistence and resistance, whilst accounting for drug-drug interactions using an innovative combination of in-vitro kill-curve and hollow-fibre experiments, in-vivo pharmacokinetic data and statistical modelling. This will inform optimisation of tuberculosis treatment.\n\nI will undertake this work at University College London in collaboration with the University of Cape Town, South Africa, giving me access to a large and diverse tuberculosis patient population and state of the art laboratory facilities.\n","awardDateDateOnly":"2020-06-17","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Antitubercular Agents","Humans","Mycobacterium tuberculosis","South Africa","Tuberculosis","Tuberculosis, Multidrug-Resistant"]}
{"id":"360G-Wellcome-220586_Z_20_Z","title":" Cellular and genetic landscape of transformed myeloproliferative neoplasms","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220586/Z/20/Z","description":"This research project aims to understand how a group of slow cancers of the bone marrow - myeloproliferative neoplasms (MPN) - accelerate into a rapid and incurable leukaemia - advanced-phase MPN. This happens in up to one fifth of all MPN cases. Current treatments can allay symptoms but do not cure advanced-phase MPN. Patients' responses are short-lived, followed by relapse and very poor survival lasting weeks or a few months. We urgently need to understand how MPN cells progress to aggressive leukaemia, why they are so resistant to current treatment, and whether there are surface markers on the diseased cells that we could target with new drug therapies.\n\nOur research draws on patient samples from a clinical trial called the Phazar study. This study examined patients with advanced-phase MPN, who received treatment with two drugs, ruxolitinib and azacytidine. About 40% responded to these drugs, but almost all subsequently relapsed. Using state-of-the-art technologies to examine these patient samples, we are seeking to understand the disease biology of this type of leukaemia, how it evolves from the more benign chronic phase, and why some patients respond to the current standard of care while others do not.\n","plannedDates":[{"endDate":"2022-12-15T00:00:00+00:00","startDate":"2019-08-05T00:00:00+00:00","startDateDateOnly":"2019-08-05","endDateDateOnly":"2022-12-15"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Charlotte Brierley","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Brierley","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":" Cellular and genetic landscape of transformed myeloproliferative neoplasms This research project aims to understand how a group of slow cancers of the bone marrow - myeloproliferative neoplasms (MPN) - accelerate into a rapid and incurable leukaemia - advanced-phase MPN. This happens in up to one fifth of all MPN cases. Current treatments can allay symptoms but do not cure advanced-phase MPN. Patients' responses are short-lived, followed by relapse and very poor survival lasting weeks or a few months. We urgently need to understand how MPN cells progress to aggressive leukaemia, why they are so resistant to current treatment, and whether there are surface markers on the diseased cells that we could target with new drug therapies.\n\nOur research draws on patient samples from a clinical trial called the Phazar study. This study examined patients with advanced-phase MPN, who received treatment with two drugs, ruxolitinib and azacytidine. About 40% responded to these drugs, but almost all subsequently relapsed. Using state-of-the-art technologies to examine these patient samples, we are seeking to understand the disease biology of this type of leukaemia, how it evolves from the more benign chronic phase, and why some patients respond to the current standard of care while others do not.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aged","Aged, 80 and over","Azacitidine","Bone Marrow","Female","Humans","Male","Middle Aged","Myeloproliferative Disorders","Pyrazoles"]}
{"id":"360G-Wellcome-220584_Z_20_Z","title":"Respiratory immune responses and their interaction in control of nasal colonization with Bordetella pertussis and Staphylococcus aureus in humans  ","Region":"Ireland","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220584/Z/20/Z","description":"This research study is designed to examine how the human immune system responds to different types of vaccines and to bacteria that commonly live in the nose, in particular Bordetella pertussis and Staphylococcus aureus. Infection with the bacteria Bordetella pertussis (\u2018B.pertussis\u2019) causes whooping cough. Vaccines are routinely given in childhood to prevent whooping cough. If you received routine childhood vaccinations you will have received one of two B.pertussis vaccines depending on your year of birth. This study aims to look at how the human immune system responds to different types of B.pertussis vaccines that are or were in routine use.  Another important bacteria which  may cause disease in humans is Staphylococcus aureus (\u2018S.aureus\u2019). Approximately 20-30% of healthy people carry these bacteria in their nose without it causing infection. This is called colonisation. However, in some people, infection with S.aureus can be potentially serious and require prompt  treatment. This study aims to look at the differences in how human immune system responds in people who are colonised with S.aureus and those who are not. It is hoped that this research will contribute to future work on vaccines that may benefit vulnerable patients susceptible to serious infections with both S.aureus and B.Pertussis.\n \n","plannedDates":[{"endDate":"2022-07-07T00:00:00+00:00","startDate":"2019-07-08T00:00:00+00:00","startDateDateOnly":"2019-07-08","endDateDateOnly":"2022-07-07"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Karen McCarthy","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Partnership Name":"SFI-HRB-Wellcome Trust partnership","Applicant Surname":"McCarthy","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Trinity-College-Dublin","name":"Trinity College Dublin","addressCountry":"Ireland","id_and_name":"[\"Trinity College Dublin\", \"360G-Wellcome-ORG:Trinity-College-Dublin\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Trinity-College-Dublin","name":"Trinity College Dublin"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Respiratory immune responses and their interaction in control of nasal colonization with Bordetella pertussis and Staphylococcus aureus in humans   This research study is designed to examine how the human immune system responds to different types of vaccines and to bacteria that commonly live in the nose, in particular Bordetella pertussis and Staphylococcus aureus. Infection with the bacteria Bordetella pertussis (\u2018B.pertussis\u2019) causes whooping cough. Vaccines are routinely given in childhood to prevent whooping cough. If you received routine childhood vaccinations you will have received one of two B.pertussis vaccines depending on your year of birth. This study aims to look at how the human immune system responds to different types of B.pertussis vaccines that are or were in routine use.  Another important bacteria which  may cause disease in humans is Staphylococcus aureus (\u2018S.aureus\u2019). Approximately 20-30% of healthy people carry these bacteria in their nose without it causing infection. This is called colonisation. However, in some people, infection with S.aureus can be potentially serious and require prompt  treatment. This study aims to look at the differences in how human immune system responds in people who are colonised with S.aureus and those who are not. It is hoped that this research will contribute to future work on vaccines that may benefit vulnerable patients susceptible to serious infections with both S.aureus and B.Pertussis.\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Bordetella pertussis","Humans","Nose","Staphylococcus aureus","Whooping Cough"]}
{"id":"360G-Wellcome-220582_Z_20_Z","title":"Novel genetic and neuroimaging biomarkers in the primary tauopathies","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220582/Z/20/Z","description":"Frontotemporal dementia (FTD) is a progressive and ultimately fatal disorder characterised by changes in behaviour, personality, language and occasonally movement, for which there is currently no cure. In the 45-65 year age range FTD has a similar prevalence to Alzheimer\u2019s Disease. Pathological studies suggest that abnormal proteins accumulate in vulnerable brain regions, and then spread along anatomical connections . Tau protein, which is also important in Alzheimer\u2019s disease pathogenesis, accounts for 40% of all cases of FTD. With potential therapeutic treatments targeting Tau on the horizon, there is an urgent need to develop biomarkers to correctly identify the underlying pathological protein in life, as well as well to monitor the effects of these treatments on disease progression.\n\nMy PhD aims to identify genetic risk factors that make particular regions of the brain vulnerable to tau pathology, and study how the disease progresses over time in the different subtypes (Picks Disease, MAPT mutations, Progressive Supranuclear Palsy and Cortico-Basal Degeneration).\n\nUnderstanding the influence of genetics on the neuro-anatomical vulnerability of the brain to tau pathology may provide not only biological insight into the onset and progression of these disorders, but also biomarkers to better stratify patients in future disease modifying clinical trials.\n","plannedDates":[{"endDate":"2022-11-26T00:00:00+00:00","startDate":"2019-08-27T00:00:00+00:00","startDateDateOnly":"2019-08-27","endDateDateOnly":"2022-11-26"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr William Scotton","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Scotton","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Novel genetic and neuroimaging biomarkers in the primary tauopathies Frontotemporal dementia (FTD) is a progressive and ultimately fatal disorder characterised by changes in behaviour, personality, language and occasonally movement, for which there is currently no cure. In the 45-65 year age range FTD has a similar prevalence to Alzheimer\u2019s Disease. Pathological studies suggest that abnormal proteins accumulate in vulnerable brain regions, and then spread along anatomical connections . Tau protein, which is also important in Alzheimer\u2019s disease pathogenesis, accounts for 40% of all cases of FTD. With potential therapeutic treatments targeting Tau on the horizon, there is an urgent need to develop biomarkers to correctly identify the underlying pathological protein in life, as well as well to monitor the effects of these treatments on disease progression.\n\nMy PhD aims to identify genetic risk factors that make particular regions of the brain vulnerable to tau pathology, and study how the disease progresses over time in the different subtypes (Picks Disease, MAPT mutations, Progressive Supranuclear Palsy and Cortico-Basal Degeneration).\n\nUnderstanding the influence of genetics on the neuro-anatomical vulnerability of the brain to tau pathology may provide not only biological insight into the onset and progression of these disorders, but also biomarkers to better stratify patients in future disease modifying clinical trials.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biomarkers","Brain","Disease Progression","Frontotemporal Dementia","Humans","Neuroimaging","Tauopathies","tau Proteins"]}
{"id":"360G-Wellcome-220581_Z_20_Z","title":"Mitochondrial Mechanisms And Therapeutics In Heart Transplantation","Region":"East of England","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220581/Z/20/Z","description":"Heart transplantation is the best available and life-saving treatment for end-stage heart failure. Unfortunately, there are far more patients in need of a heart transplant than there are suitable donor hearts and many patients die every year due to this shortage.\n\nWhen a heart is donated for transplantation, it can spend several hours outside the body without any oxygen supply, before it is transplanted into the recipient patient. During this period, a molecule called succinate builds up in cells. When the oxygen supply is restored to the heart, succinate is rapidly broken down, leading to injury and ultimately death of heart cells.\n\nWe will use mouse, pig and human hearts to explore the events that damage donor hearts. This will help confirm that what we have learned from animal experiments are relevant to humans. We have also developed drugs that prevent succinate from building up in heart cells, and may be able to reduce damage during transplantation. We will test whether these drugs are safe and effective in reducing succinate build up, reducing damage to heart cells and improving donor heart function after transplantation. This treatment could result in more donor hearts being available and ultimately save lives.\n","plannedDates":[{"endDate":"2023-05-02T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2023-05-02"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Margaret Huang","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Huang","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mitochondrial Mechanisms And Therapeutics In Heart Transplantation Heart transplantation is the best available and life-saving treatment for end-stage heart failure. Unfortunately, there are far more patients in need of a heart transplant than there are suitable donor hearts and many patients die every year due to this shortage.\n\nWhen a heart is donated for transplantation, it can spend several hours outside the body without any oxygen supply, before it is transplanted into the recipient patient. During this period, a molecule called succinate builds up in cells. When the oxygen supply is restored to the heart, succinate is rapidly broken down, leading to injury and ultimately death of heart cells.\n\nWe will use mouse, pig and human hearts to explore the events that damage donor hearts. This will help confirm that what we have learned from animal experiments are relevant to humans. We have also developed drugs that prevent succinate from building up in heart cells, and may be able to reduce damage during transplantation. We will test whether these drugs are safe and effective in reducing succinate build up, reducing damage to heart cells and improving donor heart function after transplantation. This treatment could result in more donor hearts being available and ultimately save lives.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Heart","Heart Transplantation","Humans","Mice","Swine"]}
{"id":"360G-Wellcome-220580_Z_20_Z","title":"Understanding the gene expression dynamics that regulate glioma stem cell transitions ","Region":"North West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220580/Z/20/Z","description":"It is believed that glioblastoma multiforme (GBM), the most aggressive form of adult primary brain cancer, arises from abnormal cells of origin (stem cells) in the brain known as glioma stem cells (GSCs). There is no cure for GBM.\n\nImportantly, GSCs can assume either an active or dormant state. Research suggests that GSCs in the dormant state are especially resistant to treatment and when made active again, result in deadly regrowth of cancer.\n\nFindings from my host laboratory suggest that such cell-state transitions are controlled by unique patterns of gene expression ('expression' being the process by which a gene is converted to its relevant protein) as opposed to genes simply being turned on or off.\n\nMy research will use cutting edge tools to label genes of interest with markers that give off a fluorescent glow. This will allow us to identify patterns of gene expression that causes changes in GSC states.\n\nIf this research is successful, future treatments could be developed to give doctors control over these cell states. For example, we might be able to prevent dormant cells from becoming re-activated. By doing so, we can hopefully change what is currently a deadly disease into a chronic manageable condition.\n","plannedDates":[{"endDate":"2022-10-01T00:00:00+00:00","startDate":"2019-10-02T00:00:00+00:00","startDateDateOnly":"2019-10-02","endDateDateOnly":"2022-10-01"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Richard Zhiming Fu","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Fu","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding the gene expression dynamics that regulate glioma stem cell transitions  It is believed that glioblastoma multiforme (GBM), the most aggressive form of adult primary brain cancer, arises from abnormal cells of origin (stem cells) in the brain known as glioma stem cells (GSCs). There is no cure for GBM.\n\nImportantly, GSCs can assume either an active or dormant state. Research suggests that GSCs in the dormant state are especially resistant to treatment and when made active again, result in deadly regrowth of cancer.\n\nFindings from my host laboratory suggest that such cell-state transitions are controlled by unique patterns of gene expression ('expression' being the process by which a gene is converted to its relevant protein) as opposed to genes simply being turned on or off.\n\nMy research will use cutting edge tools to label genes of interest with markers that give off a fluorescent glow. This will allow us to identify patterns of gene expression that causes changes in GSC states.\n\nIf this research is successful, future treatments could be developed to give doctors control over these cell states. For example, we might be able to prevent dormant cells from becoming re-activated. By doing so, we can hopefully change what is currently a deadly disease into a chronic manageable condition.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Brain Neoplasms","Glioblastoma","Glioma","Humans","Neoplastic Stem Cells"]}
{"id":"360G-Wellcome-220577_Z_20_Z","title":"The Impact of Intensive Medical and Surgical Control of Diabetes on Experimental Rodent Diabetic Kidney Disease.","Region":"Ireland","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220577/Z/20/Z","description":"Background:\n\nKidney disease affects 12 in every 100 people, most commonly due to diabetes. Kidney damage due to diabetes often persists despite treatment with the best available drugs. Most people with kidney damage from diabetes are overweight. Drug and surgical weight loss treatments help overweight people to lose more weight for longer periods of time, improve quality of life, and reduce the chance of dying. Helping people with diabetes to lose weight also slows kidney damage. How this happens remains poorly understood. \n\nApproach:\n\nWe will study kidney damage caused by diabetes in rats as they age. We will also treat rats with diabetic kidney damage with drug and surgical obesity treatments to better understand how weight loss protects kidney tissue. \n\nExpected Impact:\n\nWe will present our results at international scientific meetings and publish our results in scientific papers. We will present our results to patients attending our dedicated weight loss clinic for people with kidney disease, and involve patient stakeholders in planning future studies. Our studies may result in more people with diabetic kidney damage receiving weight loss treatments and may highlight important targets for new therapies for diabetic kidney damage.\n","plannedDates":[{"endDate":"2022-07-07T00:00:00+00:00","startDate":"2019-07-08T00:00:00+00:00","startDateDateOnly":"2019-07-08","endDateDateOnly":"2022-07-07"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr William Martin","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Partnership Name":"SFI-HRB-Wellcome Trust partnership","Applicant Surname":"Martin","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-Dublin","name":"University College Dublin","addressCountry":"Ireland","id_and_name":"[\"University College Dublin\", \"360G-Wellcome-ORG:University-College-Dublin\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-Dublin","name":"University College Dublin"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The Impact of Intensive Medical and Surgical Control of Diabetes on Experimental Rodent Diabetic Kidney Disease. Background:\n\nKidney disease affects 12 in every 100 people, most commonly due to diabetes. Kidney damage due to diabetes often persists despite treatment with the best available drugs. Most people with kidney damage from diabetes are overweight. Drug and surgical weight loss treatments help overweight people to lose more weight for longer periods of time, improve quality of life, and reduce the chance of dying. Helping people with diabetes to lose weight also slows kidney damage. How this happens remains poorly understood. \n\nApproach:\n\nWe will study kidney damage caused by diabetes in rats as they age. We will also treat rats with diabetic kidney damage with drug and surgical obesity treatments to better understand how weight loss protects kidney tissue. \n\nExpected Impact:\n\nWe will present our results at international scientific meetings and publish our results in scientific papers. We will present our results to patients attending our dedicated weight loss clinic for people with kidney disease, and involve patient stakeholders in planning future studies. Our studies may result in more people with diabetic kidney damage receiving weight loss treatments and may highlight important targets for new therapies for diabetic kidney damage.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Diabetic Nephropathies","Humans","Kidney","Obesity","Quality of Life","Rats","Weight Loss"]}
{"id":"360G-Wellcome-220576_Z_20_Z","title":"The Development and Optimization of Anti-CLEC12A Targeted Umbilical Cord Blood Derived CAR-NK Cells in Acute Myeloid Leukaemia.","Region":"Ireland","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220576/Z/20/Z","description":"Acute myeloid leukaemia (AML) is an aggressive form of blood cancer. Current chemotherapy-based treatments cure less than half of all patients with AML. In many cases a relapse occurs which is very difficult to treat effectively. \u2018Leukaemia stem cells\u2019 which resist the effects of chemotherapy are an important cause of AML relapse. New treatments which can target and destroy these cells may reduce the risk of relapse and increase cure rates.\n\nIn certain other forms of blood cancer new treatments called CAR-T cell therapies have been very effective. These treatments retrain a patient\u2019s immune cells (T-cells) to recognise cancer cells. These treatments are harder to develop for AML as it is difficult to identify a suitable target on the cells for immune attack. In this project we are developing a therapy using \u2018retrained\u2019 natural killer cells (CAR-NK cells) which recognise AML cells and leukaemia stem cells. The target for the CAR-NK cells is a protein called CLEC12A. We are also investigating ways of improving the ability of these CAR-NK cells to recognise and destroy leukaemia cells. One example of this is combining CAR-NK cells with medications or changing their genetic code to further boost their activity.\n","plannedDates":[{"endDate":"2022-07-07T00:00:00+00:00","startDate":"2019-07-08T00:00:00+00:00","startDateDateOnly":"2019-07-08","endDateDateOnly":"2022-07-07"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Mark Gurney","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Partnership Name":"SFI-HRB-Wellcome Trust partnership","Applicant Surname":"Gurney","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:National-University-of-Ireland-Galway","name":"National University of Ireland Galway","addressCountry":"Ireland","id_and_name":"[\"National University of Ireland Galway\", \"360G-Wellcome-ORG:National-University-of-Ireland-Galway\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:National-University-of-Ireland-Galway","name":"National University of Ireland Galway"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The Development and Optimization of Anti-CLEC12A Targeted Umbilical Cord Blood Derived CAR-NK Cells in Acute Myeloid Leukaemia. Acute myeloid leukaemia (AML) is an aggressive form of blood cancer. Current chemotherapy-based treatments cure less than half of all patients with AML. In many cases a relapse occurs which is very difficult to treat effectively. \u2018Leukaemia stem cells\u2019 which resist the effects of chemotherapy are an important cause of AML relapse. New treatments which can target and destroy these cells may reduce the risk of relapse and increase cure rates.\n\nIn certain other forms of blood cancer new treatments called CAR-T cell therapies have been very effective. These treatments retrain a patient\u2019s immune cells (T-cells) to recognise cancer cells. These treatments are harder to develop for AML as it is difficult to identify a suitable target on the cells for immune attack. In this project we are developing a therapy using \u2018retrained\u2019 natural killer cells (CAR-NK cells) which recognise AML cells and leukaemia stem cells. The target for the CAR-NK cells is a protein called CLEC12A. We are also investigating ways of improving the ability of these CAR-NK cells to recognise and destroy leukaemia cells. One example of this is combining CAR-NK cells with medications or changing their genetic code to further boost their activity.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Killer Cells, Natural","Leukemia, Myeloid, Acute"]}
{"id":"360G-Wellcome-220575_Z_20_Z","title":"Mapping the energetic pathways of the brain: Ultra-high-field MRI of cerebral oxygen and glucose utilisation","Region":"Wales","currency":"GBP","awardDate":"2020-06-17T00:00:00+00:00","Sponsor(s)":"Prof Peter Smowton","Internal ID":"220575/Z/20/Z","description":"Aerobic glycolysis (AG) plays a vital role in brain disease, development, and ageing. Elevated AG has been linked to axonal elongation and synaptogenesis in childhood, synaptic plasticity in adulthood, and is a hallmark of cancer. There is also evidence of a significant reduction in AG in older age and in neurodegeneration. The development of a non-invasive method for imaging AG has the potential for significant impact in basic neuroscience and clinical practice. For example, in cancer therapy, post-treatment mapping of AG is anticipated to be a sensitive measure for assessing recurrence and for the planning of salvage therapy.\n\n\nI propose to develop ultra-high field (7T) MRI methods to safely and non-invasively map aerobic glycolysis and tissue oxygen availability in the human brain, providing a new window into brain metabolism and metabolic dysfunction. The methods development involves two main paths. 1) Glucose labeled deuterium imaging to directly map cerebral AG. 2) Development of vascular imaging methods, including deuterium perfusion and blood volume imaging. The combination of these two methods will enable calculation of cerebral glucose metabolism, oxygen metabolism, and tissue oxygen availability. These methods will be validated experimentally using a controlled pharmacological modulation of aerobic glycolysis with sub-anaesthetic ketamine administration.\n","plannedDates":[{"endDate":"2026-01-12T00:00:00+00:00","startDate":"2021-01-13T00:00:00+00:00","startDateDateOnly":"2021-01-13","endDateDateOnly":"2026-01-12"}],"amountAwarded":1551810,"Financial Year":"2019/20","Lead Applicant":"Dr Michael Germuska","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Germuska","Partnership Value":1551810,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University","addressCountry":"United Kingdom","id_and_name":"[\"Cardiff University\", \"360G-Wellcome-ORG:Cardiff-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mapping the energetic pathways of the brain: Ultra-high-field MRI of cerebral oxygen and glucose utilisation Aerobic glycolysis (AG) plays a vital role in brain disease, development, and ageing. Elevated AG has been linked to axonal elongation and synaptogenesis in childhood, synaptic plasticity in adulthood, and is a hallmark of cancer. There is also evidence of a significant reduction in AG in older age and in neurodegeneration. The development of a non-invasive method for imaging AG has the potential for significant impact in basic neuroscience and clinical practice. For example, in cancer therapy, post-treatment mapping of AG is anticipated to be a sensitive measure for assessing recurrence and for the planning of salvage therapy.\n\n\nI propose to develop ultra-high field (7T) MRI methods to safely and non-invasively map aerobic glycolysis and tissue oxygen availability in the human brain, providing a new window into brain metabolism and metabolic dysfunction. The methods development involves two main paths. 1) Glucose labeled deuterium imaging to directly map cerebral AG. 2) Development of vascular imaging methods, including deuterium perfusion and blood volume imaging. The combination of these two methods will enable calculation of cerebral glucose metabolism, oxygen metabolism, and tissue oxygen availability. These methods will be validated experimentally using a controlled pharmacological modulation of aerobic glycolysis with sub-anaesthetic ketamine administration.\n","awardDateDateOnly":"2020-06-17","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Brain","Glucose","Glycolysis","Humans","Magnetic Resonance Imaging","Oxygen","Oxygen Consumption"]}
{"id":"360G-Wellcome-220574_Z_20_Z","title":"Trends in complications, morbidity and cause of death in diabetes patients in England","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220574/Z/20/Z","description":"Diabetes is a leading cause of mortality and morbidity in England, with significant impact upon individual patients,  and the NHS. Its significance is expected to increase in coming decades due to population ageing and obesity prevalence. Diabetes is associated with several sequelae including heart disease, stroke, and limb amputations, and more recently several cancers and dementia. Work in the US has identified an aggregate reduction in diabetes complications, particularly in vascular complications, with patients experiencing a more diverse range of complications with a growing proportional impact of non-CVD causes. How incidence of complications and mortality  has changed over the past two decades in England is unclear.\n\n\nThis research fellowships primary aim is to estimate trends in complications and outcomes in patients with type 2 diabetes in England 1998-2018. I will integrate large national datasets including the CPRD, a UK primary care database, linked to Hospital Episode Statistics, the National Cancer Registration and Analysis Service and death records and. Specifically, this fellowship will: 1. estimate trends in age-specific cause of death in patients with diabetes; 2. estimate trends in age-specific incidence of diabetes-related complications and health service-usage; 3. estimate trends in age-specific cancer incidence, survival and mortality in patients with diabetes. \n","plannedDates":[{"endDate":"2022-05-31T00:00:00+00:00","startDate":"2019-06-01T00:00:00+00:00","startDateDateOnly":"2019-06-01","endDateDateOnly":"2022-05-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Jonathan Pearson-Stuttard","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Pearson-Stuttard","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Trends in complications, morbidity and cause of death in diabetes patients in England Diabetes is a leading cause of mortality and morbidity in England, with significant impact upon individual patients,  and the NHS. Its significance is expected to increase in coming decades due to population ageing and obesity prevalence. Diabetes is associated with several sequelae including heart disease, stroke, and limb amputations, and more recently several cancers and dementia. Work in the US has identified an aggregate reduction in diabetes complications, particularly in vascular complications, with patients experiencing a more diverse range of complications with a growing proportional impact of non-CVD causes. How incidence of complications and mortality  has changed over the past two decades in England is unclear.\n\n\nThis research fellowships primary aim is to estimate trends in complications and outcomes in patients with type 2 diabetes in England 1998-2018. I will integrate large national datasets including the CPRD, a UK primary care database, linked to Hospital Episode Statistics, the National Cancer Registration and Analysis Service and death records and. Specifically, this fellowship will: 1. estimate trends in age-specific cause of death in patients with diabetes; 2. estimate trends in age-specific incidence of diabetes-related complications and health service-usage; 3. estimate trends in age-specific cancer incidence, survival and mortality in patients with diabetes. \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aged","Aged, 80 and over","Databases, Factual","Diabetes Mellitus, Type 2","England","Female","Humans","Incidence","Neoplasms","State Medicine"]}
{"id":"360G-Wellcome-220573_Z_20_Z","title":"Investigating the interplay between interleukin-11 (IL-11) and senescence in cardio-renal aging.","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220573/Z/20/Z","description":"As chronological age increases, even in the absence of disease, vital organs accumulate changes which cause them to function less efficiently. Impaired efficiency of organs such as the heart or kidney are particularly common in older people causing the development of symptoms and require medical attention or hospital admissions.\n\nCells accumulate damage to their DNA with age which causes these cells to enter a protective dormant state known as senescence. This prevents these cells from dividing and passing on the damaged DNA, however, senescent cells release molecules which cause neighbouring cells to produce scar tissue called fibrosis which impairs the efficiency of these organs. Interleukin-11 is one of these molecules which is known to cause fibrosis in multiple different diseases and blocking its effects reduces the amount of fibrosis. We plan to use treatments to block Interleukin-11 in ageing mice to identify the effect this has on the health of these mice and the amount of fibrotic tissue that they develop. We will also analyse the effects of senescent cells on the surrounding tissues to identify the benefit of treatments which specifically remove these cells or stop their contribution to scar formation.\n","plannedDates":[{"endDate":"2023-03-31T00:00:00+00:00","startDate":"2019-10-03T00:00:00+00:00","startDateDateOnly":"2019-10-03","endDateDateOnly":"2023-03-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Mark Sweeney","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Sweeney","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the interplay between interleukin-11 (IL-11) and senescence in cardio-renal aging. As chronological age increases, even in the absence of disease, vital organs accumulate changes which cause them to function less efficiently. Impaired efficiency of organs such as the heart or kidney are particularly common in older people causing the development of symptoms and require medical attention or hospital admissions.\n\nCells accumulate damage to their DNA with age which causes these cells to enter a protective dormant state known as senescence. This prevents these cells from dividing and passing on the damaged DNA, however, senescent cells release molecules which cause neighbouring cells to produce scar tissue called fibrosis which impairs the efficiency of these organs. Interleukin-11 is one of these molecules which is known to cause fibrosis in multiple different diseases and blocking its effects reduces the amount of fibrosis. We plan to use treatments to block Interleukin-11 in ageing mice to identify the effect this has on the health of these mice and the amount of fibrotic tissue that they develop. We will also analyse the effects of senescent cells on the surrounding tissues to identify the benefit of treatments which specifically remove these cells or stop their contribution to scar formation.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aging","Animals","Cellular Senescence","Cicatrix","Fibrosis","Mice"]}
{"id":"360G-Wellcome-220572_Z_20_Z","title":"Targeting oxidised low-density lipoprotein\u00a0in\u00a0atherosclerotic\u00a0plaque with\u00a0antibody-based constructs for imaging and therapeutics","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220572/Z/20/Z","description":"Background\n\nOxidised LDL (oxLDL) forms a significant component of fatty plaques, or atherosclerotic lesions, that accumulate in coronary artery disease and can cause heart attacks or strokes. We have recently developed an antibody to oxLDL, LO1,that can target atherosclerotic plaques.\n\nApproach\n\nI aim to harness LO1 and other antibody fragments for targeting of nanoparticles to atherosclerotic plaque. I will develop nanoparticles that are capable of carrying a drug, that will be released when it reaches its destination (i.e. the atherosclerotic plaque). I will produce varying designs with different drugs and targeting agents and aim to demonstrate effective delivery of the nanoparticles. I will test these nanoparticles in mouse models of atherosclerosis, as well as a newly developed original experimental model using an amputated human limb. I will then fill the nanoparticles with the drug and aim to demonstrate a beneficial effect.\n\nExpected Impact\n\nThe novel nanoparticles targeted to atherosclerotic plaque will provide a means of local delivery of drugs directly to diseased areas. This will permit much smaller drug doses to be used, with therefore fewer unwanted side effects. In addition, the drugs can be tailored to an individual, utilising the most suitable drug to treat each patient\u2019s atherosclerotic plaques.\n","plannedDates":[{"endDate":"2022-11-30T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-11-30"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Adam Hartley","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Hartley","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Targeting oxidised low-density lipoprotein\u00a0in\u00a0atherosclerotic\u00a0plaque with\u00a0antibody-based constructs for imaging and therapeutics Background\n\nOxidised LDL (oxLDL) forms a significant component of fatty plaques, or atherosclerotic lesions, that accumulate in coronary artery disease and can cause heart attacks or strokes. We have recently developed an antibody to oxLDL, LO1,that can target atherosclerotic plaques.\n\nApproach\n\nI aim to harness LO1 and other antibody fragments for targeting of nanoparticles to atherosclerotic plaque. I will develop nanoparticles that are capable of carrying a drug, that will be released when it reaches its destination (i.e. the atherosclerotic plaque). I will produce varying designs with different drugs and targeting agents and aim to demonstrate effective delivery of the nanoparticles. I will test these nanoparticles in mouse models of atherosclerosis, as well as a newly developed original experimental model using an amputated human limb. I will then fill the nanoparticles with the drug and aim to demonstrate a beneficial effect.\n\nExpected Impact\n\nThe novel nanoparticles targeted to atherosclerotic plaque will provide a means of local delivery of drugs directly to diseased areas. This will permit much smaller drug doses to be used, with therefore fewer unwanted side effects. In addition, the drugs can be tailored to an individual, utilising the most suitable drug to treat each patient\u2019s atherosclerotic plaques.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Atherosclerosis","Disease Models, Animal","Humans","Lipoproteins, LDL","Mice","Nanoparticles","Plaque, Atherosclerotic"]}
{"id":"360G-Wellcome-220566_Z_20_Z","title":"The role of enteropathy and systemic inflammation in severe acute malnutrition","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220566/Z/20/Z","description":"Being extremely underweight from lack of nutrition can lead to a condition called severe acute malnutrition (SAM). This can cause a number of problems including leaving children with thin and leaky guts. Children with SAM have a high chance of dying during hospital admission, and during the following year. The cause of this ongoing risk of death is unknown, but may be related to the changes in the child\u2019s intestines which can result in the immune system not working properly, including not being able to fight off new infections.\n\n\nFrom stored samples of a completed study of 200 children with SAM, I will look at different markers in the blood and stool to see how well the gut and the immune system are working, and see if these markers relate to the chances of the child dying or being\nreadmitted to hospital in the following year. After this I will look at some of these markers in a new trial that is looking at new medicines to improve the health of the gut in children with SAM. I will see if it also improves the markers of the immune system.\n","plannedDates":[{"endDate":"2022-11-30T00:00:00+00:00","startDate":"2019-09-02T00:00:00+00:00","startDateDateOnly":"2019-09-02","endDateDateOnly":"2022-11-30"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Jonathan Sturgeon","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Sturgeon","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"London School of Hygiene & Tropical Medicine\", \"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The role of enteropathy and systemic inflammation in severe acute malnutrition Being extremely underweight from lack of nutrition can lead to a condition called severe acute malnutrition (SAM). This can cause a number of problems including leaving children with thin and leaky guts. Children with SAM have a high chance of dying during hospital admission, and during the following year. The cause of this ongoing risk of death is unknown, but may be related to the changes in the child\u2019s intestines which can result in the immune system not working properly, including not being able to fight off new infections.\n\n\nFrom stored samples of a completed study of 200 children with SAM, I will look at different markers in the blood and stool to see how well the gut and the immune system are working, and see if these markers relate to the chances of the child dying or being\nreadmitted to hospital in the following year. After this I will look at some of these markers in a new trial that is looking at new medicines to improve the health of the gut in children with SAM. I will see if it also improves the markers of the immune system.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biomarkers","Child","Child Nutrition Disorders","Child, Preschool","Humans","Infant","Inflammation","Malnutrition","Severe Acute Malnutrition"]}
{"id":"360G-Wellcome-220565_Z_20_Z","title":"Vaccine-induced systemic and mucosal immunity to Bordetella pertussis in infancy: bringing B- and T-cell responses together","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220565/Z/20/Z","description":"Whooping cough, known as pertussis, is a serious infection, especially in infants. Two types of pertussis vaccine exist: whole-cell (wP) and acellular (aP). We now think that aP vaccines may not be as long-lasting or effective in preventing infection as wP vaccines, but the cause remains unknown. It may be due to differences in specific groups of cells in the immune system called T-helper cells. The type of T-helper cells found in animals and humans who have received wP- compared to aP-vaccines is better at preventing bacteria from being passed on. We still do not know enough about all the important T-helper cells involved and there is no data in very young children. My project is set within a larger study in The Gambia that is vaccinating babies with aP or wP vaccine. I will investigate T-helper cells activated by these vaccines and see how they may help other components of the infant\u2019s immune system. As well as taking blood samples, I will collect and analyse fluid from the infant\u2019s nose (where pertussis bacteria initially infect), to provide further insight into how these vaccines differ in their action. My findings will help to design better pertussis vaccines in the future. \n","plannedDates":[{"endDate":"2023-05-31T00:00:00+00:00","startDate":"2019-09-02T00:00:00+00:00","startDateDateOnly":"2019-09-02","endDateDateOnly":"2023-05-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Anja Saso","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Saso","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"London School of Hygiene & Tropical Medicine\", \"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Vaccine-induced systemic and mucosal immunity to Bordetella pertussis in infancy: bringing B- and T-cell responses together Whooping cough, known as pertussis, is a serious infection, especially in infants. Two types of pertussis vaccine exist: whole-cell (wP) and acellular (aP). We now think that aP vaccines may not be as long-lasting or effective in preventing infection as wP vaccines, but the cause remains unknown. It may be due to differences in specific groups of cells in the immune system called T-helper cells. The type of T-helper cells found in animals and humans who have received wP- compared to aP-vaccines is better at preventing bacteria from being passed on. We still do not know enough about all the important T-helper cells involved and there is no data in very young children. My project is set within a larger study in The Gambia that is vaccinating babies with aP or wP vaccine. I will investigate T-helper cells activated by these vaccines and see how they may help other components of the infant\u2019s immune system. As well as taking blood samples, I will collect and analyse fluid from the infant\u2019s nose (where pertussis bacteria initially infect), to provide further insight into how these vaccines differ in their action. My findings will help to design better pertussis vaccines in the future. \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Bordetella pertussis","Humans","Immunity, Mucosal","Infant","Pertussis Vaccine","Whooping Cough"]}
{"id":"360G-Wellcome-220564_Z_20_Z","title":"Computer Aided Screening for Tuberculosis in Low Resource Environments (CASTLE)","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220564/Z/20/Z","description":"TB is very common among people living with HIV (PLHIV) in who are unwell and require admission to hospital. However TB can be difficult to diagnose.  Digital chest X ray with computer-aided diagnosis (DCXR-CAD) and a urine test may help promptly diagnose TB.  \n\n\nAt a single hospital in Malawi, days of the week will be randomly assigned so that on some days patients with HIV coming into hospital will be offered a DCXR-CAD and urine test as well as usual care and on other days patients will be offered usual care only.  We will measure how many patients in each group die in hospital, how many start TB treatment, and how many patients have their TB diagnosis missed and therefore untreated by the time they leave hospital or die.\n\n\nAs part of this study a small number of patients will have enhanced laboratory tests for TB, monitoring of HIV severity, tests for other infectious diseases and tests of inflammatory markers.\n\n\nThe goal is to see if DCXR-CAD and urine testing reduces deaths among people with HIV who are in hospital, and to provide insight into what diseases are causing people with HIV to become unwell and need hospital admission.\n","plannedDates":[{"endDate":"2023-01-31T00:00:00+00:00","startDate":"2019-08-07T00:00:00+00:00","startDateDateOnly":"2019-08-07","endDateDateOnly":"2023-01-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Rachael Burke","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Burke","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"London School of Hygiene & Tropical Medicine\", \"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Computer Aided Screening for Tuberculosis in Low Resource Environments (CASTLE) TB is very common among people living with HIV (PLHIV) in who are unwell and require admission to hospital. However TB can be difficult to diagnose.  Digital chest X ray with computer-aided diagnosis (DCXR-CAD) and a urine test may help promptly diagnose TB.  \n\n\nAt a single hospital in Malawi, days of the week will be randomly assigned so that on some days patients with HIV coming into hospital will be offered a DCXR-CAD and urine test as well as usual care and on other days patients will be offered usual care only.  We will measure how many patients in each group die in hospital, how many start TB treatment, and how many patients have their TB diagnosis missed and therefore untreated by the time they leave hospital or die.\n\n\nAs part of this study a small number of patients will have enhanced laboratory tests for TB, monitoring of HIV severity, tests for other infectious diseases and tests of inflammatory markers.\n\n\nThe goal is to see if DCXR-CAD and urine testing reduces deaths among people with HIV who are in hospital, and to provide insight into what diseases are causing people with HIV to become unwell and need hospital admission.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["HIV Infections","Humans","Malawi","Mass Screening","Point-of-Care Systems","Radiography, Thoracic","Tuberculosis","Tuberculosis, Pulmonary"]}
{"id":"360G-Wellcome-220562_Z_20_Z","title":"Working memory impairment in temporal lobe epilepsy","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220562/Z/20/Z","description":"This project examines how temporal lobe epilepsy (TLE) disrupts specific memory processes, through the integrated study of behaviour, neurophysiology, and multi-modal imaging . This is important because, within the peak age group 60\u201390 years of developing TLE, up to 60% of individuals demonstrate objective memory dysfunction, before starting anti-seizure medication. At present, there are no specific treatment targets for this significant problem. \n\n\nTwo factors which are associated with memory problems in TLE are higher number of seizures and co-existing cerebrovascular disease. However, it remains unknown how these two factors impact memory, whether they interact, and whether they both act by disrupting function of the hippocampus- our memory organ. I plan to:\n\n\n use a novel cognitive task to assess how TLE perturbs two specific facets of memory that are known to be less efficient with ageing and Alzheimer\u2019s disease.\n establish the mechanistic contributions of electrical disruption and structural white matter abnormalities to memory impairment.\n\n\n \n\nThese cognitive processes, if affected, could explain memory deficits caused by acute and long-term effects of seizures. Ultimately, this project may help inform clinical assessment and guide specific management of sub-clinical seizure activity and vascular risk factors, to improve memory co-morbidity and quality of life in TLE.\n","plannedDates":[{"endDate":"2023-02-04T00:00:00+00:00","startDate":"2019-11-06T00:00:00+00:00","startDateDateOnly":"2019-11-06","endDateDateOnly":"2023-02-04"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Xin You Tai","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Tai","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Working memory impairment in temporal lobe epilepsy This project examines how temporal lobe epilepsy (TLE) disrupts specific memory processes, through the integrated study of behaviour, neurophysiology, and multi-modal imaging . This is important because, within the peak age group 60\u201390 years of developing TLE, up to 60% of individuals demonstrate objective memory dysfunction, before starting anti-seizure medication. At present, there are no specific treatment targets for this significant problem. \n\n\nTwo factors which are associated with memory problems in TLE are higher number of seizures and co-existing cerebrovascular disease. However, it remains unknown how these two factors impact memory, whether they interact, and whether they both act by disrupting function of the hippocampus- our memory organ. I plan to:\n\n\n use a novel cognitive task to assess how TLE perturbs two specific facets of memory that are known to be less efficient with ageing and Alzheimer\u2019s disease.\n establish the mechanistic contributions of electrical disruption and structural white matter abnormalities to memory impairment.\n\n\n \n\nThese cognitive processes, if affected, could explain memory deficits caused by acute and long-term effects of seizures. Ultimately, this project may help inform clinical assessment and guide specific management of sub-clinical seizure activity and vascular risk factors, to improve memory co-morbidity and quality of life in TLE.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aged","Epilepsy, Temporal Lobe","Female","Hippocampus","Humans","Male","Memory Disorders","Memory, Short-Term","Middle Aged"]}
{"id":"360G-Wellcome-220559_Z_20_Z","title":"Towards an Appropriate African Framework for Public Engagement with Human Genome Editing","Region":"Unknown","currency":"GBP","awardDate":"2020-03-02T00:00:00+00:00","Internal ID":"220559/Z/20/Z","description":"The novel biotechnology of the CRISPR-Cas9 method has certainly precipitated unprecedented interest as well as concern with regard to the scientific reality of human genome editing. This excitement and anxiety become even more acute in resource-limited settings where there is limited awareness and engagement between the experts in human genomics and gene editing and the public. Hence, there is an urgent need for effective public engagement. The purpose of my fellowship is to get vital mentorship in public engagement with human genome editing. My aim is to benchmark with best practice at NHGRI and work towards developing an appropriate African framework for public engagement with human genome editing. My visit will also be a unique opportunity for me to network and cultivate opportunities for north-south collaborative partnerships. Besides, the acquired knowledge and skills will greatly contribute towards Africa\u2019s capacity-building. I plan to effectively disseminate my work, including at least one publication in a reputable peer-reviewed journal. Thus my trip is in line with GFBR\u2019s goal of bringing together key stakeholders from developing and developed countries in addressing frontier bioethical concerns in research. It is also relevant to GFBR\u2019s goals of capacity-building and of fostering effective collaborative partnerships. \n \n","plannedDates":[{"endDate":"2021-07-29T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2021-07-29"}],"amountAwarded":7459,"Financial Year":"2019/20","Lead Applicant":"Dr Gerald Ssebunnya","grantProgramme":[{"title":"Global Forum on Bioethics in Research","title_keyword":"Global Forum on Bioethics in Research"}],"Applicant Surname":"Ssebunnya","Partnership Value":7459,"Approval Committee":"Global Forum on Bioethics in Research Fellowships Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:AD021D9D-DD18-4437-B301-AB4A012A5880","name":"No Organisation","addressCountry":"Unknown","id_and_name":"[\"No Organisation\", \"360G-Wellcome-ORG:AD021D9D-DD18-4437-B301-AB4A012A5880\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:AD021D9D-DD18-4437-B301-AB4A012A5880","name":"No Organisation"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Towards an Appropriate African Framework for Public Engagement with Human Genome Editing The novel biotechnology of the CRISPR-Cas9 method has certainly precipitated unprecedented interest as well as concern with regard to the scientific reality of human genome editing. This excitement and anxiety become even more acute in resource-limited settings where there is limited awareness and engagement between the experts in human genomics and gene editing and the public. Hence, there is an urgent need for effective public engagement. The purpose of my fellowship is to get vital mentorship in public engagement with human genome editing. My aim is to benchmark with best practice at NHGRI and work towards developing an appropriate African framework for public engagement with human genome editing. My visit will also be a unique opportunity for me to network and cultivate opportunities for north-south collaborative partnerships. Besides, the acquired knowledge and skills will greatly contribute towards Africa\u2019s capacity-building. I plan to effectively disseminate my work, including at least one publication in a reputable peer-reviewed journal. Thus my trip is in line with GFBR\u2019s goal of bringing together key stakeholders from developing and developed countries in addressing frontier bioethical concerns in research. It is also relevant to GFBR\u2019s goals of capacity-building and of fostering effective collaborative partnerships. \n \n","awardDateDateOnly":"2020-03-02","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa","CRISPR-Cas Systems","Clustered Regularly Interspaced Short Palindromic Repeats","Gene Editing","Humans"]}
{"id":"360G-Wellcome-220558_Z_20_Z","title":"Genetics and Epidemiology of Diabetic Retinopathy","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220558/Z/20/Z","description":"Background\nDiabetic eye disease, or diabetic retinopathy (DR), is a common complication of diabetes. 1.5 million people in the UK have DR of whom 140,000 have sight-threatening diabetic retinopathy (STDR). STDR is a leading cause of blindness in working age people, associated with lifetime costs of up to ~\u00a3237,000 per patient. It remains unclear why some patients with DR progress to STDR while others do not. Individuals with a family member who has STDR are more likely to develop STDR themselves, implying that genetics play an important role.\n\nMy approach\nMy study aims to determine what factors influence the development of STDR. Genetic, dietary and other lifestyle information gathered from  > 26,000 participants with diabetes in the UK Biobank and EPIC Norfolk projects will be linked with their eye records from the National Diabetic Eye Screening Programme. My analysis will then compare patients who have STDR with those who do not.\n\nExpected impact of my work\nUnderstanding the underlying genetics of STDR may reveal biological targets for new treatments. My findings could also help improve healthcare resource allocation by better predicting which patients with diabetes are at highest risk of developing STDR, based on their individual genetic and non-genetic risk factors.\n","plannedDates":[{"endDate":"2022-11-06T00:00:00+00:00","startDate":"2019-08-07T00:00:00+00:00","startDateDateOnly":"2019-08-07","endDateDateOnly":"2022-11-06"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Alasdair Warwick","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Warwick","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Genetics and Epidemiology of Diabetic Retinopathy Background\nDiabetic eye disease, or diabetic retinopathy (DR), is a common complication of diabetes. 1.5 million people in the UK have DR of whom 140,000 have sight-threatening diabetic retinopathy (STDR). STDR is a leading cause of blindness in working age people, associated with lifetime costs of up to ~\u00a3237,000 per patient. It remains unclear why some patients with DR progress to STDR while others do not. Individuals with a family member who has STDR are more likely to develop STDR themselves, implying that genetics play an important role.\n\nMy approach\nMy study aims to determine what factors influence the development of STDR. Genetic, dietary and other lifestyle information gathered from  > 26,000 participants with diabetes in the UK Biobank and EPIC Norfolk projects will be linked with their eye records from the National Diabetic Eye Screening Programme. My analysis will then compare patients who have STDR with those who do not.\n\nExpected impact of my work\nUnderstanding the underlying genetics of STDR may reveal biological targets for new treatments. My findings could also help improve healthcare resource allocation by better predicting which patients with diabetes are at highest risk of developing STDR, based on their individual genetic and non-genetic risk factors.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biological Specimen Banks","Diabetic Retinopathy","Humans","Life Style","Risk Factors","United Kingdom"]}
{"id":"360G-Wellcome-220557_Z_20_Z","title":"Barriers and enablers to the adoption of blood culture sampling recommendations","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220557/Z/20/Z","description":"Blood culture (BC), the core sample for antimicrobial resistance surveillance, is recommended to be sampled from all sepsis patients prior to administration of antibiotics. However, BC sampling rates are lower than recommended in both high-income countries (HICs) and low and middle-income countries (LMICs). Various barriers and enablers have been identified that impeded the adoption of BC sampling recommendations using different theories; however, a systematic review on this topic is not currently available.\n\n \n\nWe propose to conduct a systematic review to identify known barriers and enablers to the adoption of local and international BC sampling recommendations. We will use the theoretical domain framework (TDF), which has been developed by refining a wide range of theories, as a framework for synthesizing evidence on barriers and enablers. Findings will be stratified by HICs and LMICs. We will then conduct a survey study among medical doctors using face-to-face interviews and electronic questionnaires to explore generalizability of systematic review findings among medical doctors in Thailand, Viet Nam and Indonesia. All questionnaires (in Thai, Vietnamese, Indonesian and English) will also be made available online, and open for public participation.\n\n \n\nA systematic summary of the existing evidence can inform the development of interventions.\n","plannedDates":[{"endDate":"2021-11-01T00:00:00+00:00","startDate":"2020-05-01T00:00:00+00:00","startDateDateOnly":"2020-05-01","endDateDateOnly":"2021-11-01"}],"amountAwarded":100546,"Financial Year":"2019/20","Lead Applicant":"Dr Direk Limmathurotsakul","grantProgramme":[{"title":"Discretionary award \u2013 DRI","title_keyword":"Discretionary award \u2013 DRI"}],"Applicant Surname":"Limmathurotsakul","Partnership Value":100546,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Lou Atkins, Dr Raph Hamers, Prof H Rogier van Doorn","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Barriers and enablers to the adoption of blood culture sampling recommendations Blood culture (BC), the core sample for antimicrobial resistance surveillance, is recommended to be sampled from all sepsis patients prior to administration of antibiotics. However, BC sampling rates are lower than recommended in both high-income countries (HICs) and low and middle-income countries (LMICs). Various barriers and enablers have been identified that impeded the adoption of BC sampling recommendations using different theories; however, a systematic review on this topic is not currently available.\n\n \n\nWe propose to conduct a systematic review to identify known barriers and enablers to the adoption of local and international BC sampling recommendations. We will use the theoretical domain framework (TDF), which has been developed by refining a wide range of theories, as a framework for synthesizing evidence on barriers and enablers. Findings will be stratified by HICs and LMICs. We will then conduct a survey study among medical doctors using face-to-face interviews and electronic questionnaires to explore generalizability of systematic review findings among medical doctors in Thailand, Viet Nam and Indonesia. All questionnaires (in Thai, Vietnamese, Indonesian and English) will also be made available online, and open for public participation.\n\n \n\nA systematic summary of the existing evidence can inform the development of interventions.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Blood Culture","Humans","Indonesia","Sepsis","Surveys and Questionnaires","Thailand"]}
{"id":"360G-Wellcome-220555_Z_20_Z","title":"Engaging with Local Communities in Botswana: Understanding Cultural Values, Norms and Beliefs that may impact Genome-Editing Research in Botswana ","Region":"International","currency":"GBP","awardDate":"2020-03-02T00:00:00+00:00","Internal ID":"220555/Z/20/Z","description":"The continuous growth and recent technical advances that have improved the precision, cost and simplicity of new gene editing technologies such as Somatic and germline therapy have since given birth to new hope in the fight against the burden of disease such as HIV in developing countries (sources). Despite facing dis-proportionally higher prevalence HIV rates, communities in Botswana to our knowledge the technologies have not been tried hence Batswana remain understudied in gene editing research.  Therefore, I am proposing a study to engage with local communities to educate them about gene-editing technology research and collect their perspectives on how their cultural values norms and beliefs can have positive or negative implications on their benefiting from this technology.\n\n1. The overall goal of the project is to explore the perceptions of communities in Botswana regarding perceived and real social ethical issues (cultural values, norms and beliefs) surrounding gene-editing technologies regarding its use for health benefits?   \n\n2. The project also aims to empower communities with knowledge through education and engagement about gene-editing technology for better informed decisions in preparation for participation in gene-editing technologies as well as learning about its potential benefits, risks and use of genomics, gene-editing technologies.\n\n \n","plannedDates":[{"endDate":"2023-01-02T00:00:00+00:00","startDate":"2021-06-01T00:00:00+00:00","startDateDateOnly":"2021-06-01","endDateDateOnly":"2023-01-02"}],"amountAwarded":7469,"Financial Year":"2019/20","Lead Applicant":"Dr Setlhomo Koloi-Keaikitse","grantProgramme":[{"title":"Global Forum on Bioethics in Research","title_keyword":"Global Forum on Bioethics in Research"}],"Applicant Surname":"Koloi-Keaikitse","Partnership Value":7469,"Approval Committee":"Global Forum on Bioethics in Research Fellowships Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Botswana","name":"University of Botswana","addressCountry":"Botswana","id_and_name":"[\"University of Botswana\", \"360G-Wellcome-ORG:University-of-Botswana\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Botswana","name":"University of Botswana"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Engaging with Local Communities in Botswana: Understanding Cultural Values, Norms and Beliefs that may impact Genome-Editing Research in Botswana  The continuous growth and recent technical advances that have improved the precision, cost and simplicity of new gene editing technologies such as Somatic and germline therapy have since given birth to new hope in the fight against the burden of disease such as HIV in developing countries (sources). Despite facing dis-proportionally higher prevalence HIV rates, communities in Botswana to our knowledge the technologies have not been tried hence Batswana remain understudied in gene editing research.  Therefore, I am proposing a study to engage with local communities to educate them about gene-editing technology research and collect their perspectives on how their cultural values norms and beliefs can have positive or negative implications on their benefiting from this technology.\n\n1. The overall goal of the project is to explore the perceptions of communities in Botswana regarding perceived and real social ethical issues (cultural values, norms and beliefs) surrounding gene-editing technologies regarding its use for health benefits?   \n\n2. The project also aims to empower communities with knowledge through education and engagement about gene-editing technology for better informed decisions in preparation for participation in gene-editing technologies as well as learning about its potential benefits, risks and use of genomics, gene-editing technologies.\n\n \n","awardDateDateOnly":"2020-03-02","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Botswana","Culture","Developing Countries","Gene Editing","HIV Infections","Humans"]}
{"id":"360G-Wellcome-220554_Z_20_Z","title":"The potential role of IL-2 in preventing autoimmunity after alemtuzumab in multiple sclerosis","Region":"East of England","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220554/Z/20/Z","description":"Multiple sclerosis (MS) is a common autoimmune disease of young adults, in which the patient\u2019s own immune system attacks their brain and spinal cord, causing disability. Alemtuzumab is a highly effective treatment that depletes lymphocytes (cells that normally fight infection but some of which cause damage in MS).\n\nAfter treatment, the immune system returns without the MS-causing cells. However, in 40% of patients, as a consequence of treatment, the recovering immune system attacks another organ instead (e.g. the thyroid gland), limiting our use of alemtuzumab.\n\nThis complication partly results from an imbalance between self-reactive lymphocytes, and regulatory cells, which specialise in controlling the self-reactive lymphocytes. Boosting regulatory cell numbers after alemtuzumab could therefore prevent autoimmunity. Interleukin-2 (IL-2) is a naturally occurring substance shown to increase regulatory cell numbers and suppress autoimmune disease. \n\nUsing laboratory-based experiments, mouse studies and short dosing studies in patients, I will determine whether IL-2 can also increase regulatory cells after alemtuzumab treatment, hopefully providing evidence for a future clinical trial.\n\nPreventing post-treatment autoimmunity would represent an important advance in the management of MS, saving the NHS and patients considerable costs. The wider implication of my work is a general strategy for manipulating human immune reconstitution.\n","plannedDates":[{"endDate":"2022-11-29T00:00:00+00:00","startDate":"2019-08-30T00:00:00+00:00","startDateDateOnly":"2019-08-30","endDateDateOnly":"2022-11-29"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Zoya Georgieva","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Georgieva","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The potential role of IL-2 in preventing autoimmunity after alemtuzumab in multiple sclerosis Multiple sclerosis (MS) is a common autoimmune disease of young adults, in which the patient\u2019s own immune system attacks their brain and spinal cord, causing disability. Alemtuzumab is a highly effective treatment that depletes lymphocytes (cells that normally fight infection but some of which cause damage in MS).\n\nAfter treatment, the immune system returns without the MS-causing cells. However, in 40% of patients, as a consequence of treatment, the recovering immune system attacks another organ instead (e.g. the thyroid gland), limiting our use of alemtuzumab.\n\nThis complication partly results from an imbalance between self-reactive lymphocytes, and regulatory cells, which specialise in controlling the self-reactive lymphocytes. Boosting regulatory cell numbers after alemtuzumab could therefore prevent autoimmunity. Interleukin-2 (IL-2) is a naturally occurring substance shown to increase regulatory cell numbers and suppress autoimmune disease. \n\nUsing laboratory-based experiments, mouse studies and short dosing studies in patients, I will determine whether IL-2 can also increase regulatory cells after alemtuzumab treatment, hopefully providing evidence for a future clinical trial.\n\nPreventing post-treatment autoimmunity would represent an important advance in the management of MS, saving the NHS and patients considerable costs. The wider implication of my work is a general strategy for manipulating human immune reconstitution.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Alemtuzumab","Animals","Humans","Interleukin-2","Mice","Multiple Sclerosis"]}
{"id":"360G-Wellcome-220553_Z_20_Z","title":"Discovering the Genetic Basis of Epilepsies through Computational Analysis of Clinical Phenotype","Region":"North East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220553/Z/20/Z","description":"Background\nEpilepsy affects 1% of people and empirical treatment benefits only a third. Seizures and their treatments have serious health and socioeconomic consequences. Over a third of epilepsy is thought to arise from variation in the person\u2019s genetic code. However, currently we can only rarely identify what this is, a necessary step towards using it to improve treatment. Studying people grouped by the symptoms of their epilepsy has successfully defined, and discovered the genetic causes of distinctive but rare epilepsies such as Dravet Syndrome, facilitating research that has improved their treatment.\n\n\nApproach\nThe yield of large genetic studies of epilepsy is currently limited by the challenges of combining and interpreting vast quantities of complex information about participants' epilepsy symptoms. We will develop computational methods to make information about the symptoms of participants in Epi25 (the largest ever epilepsy study) more tractable. We will use these to identify new patterns of symptoms and their associated genetic causes.\n\n\nExpected Impact\nIdentifying new genetic causes of epilepsy could help to us to personalise the selection of existing treatments more successfully within a few years, and to design new, precise treatments based upon newly discovered mechanisms. Our methods may be applicable to other diseases.\n","plannedDates":[{"endDate":"2022-07-31T00:00:00+00:00","startDate":"2019-08-01T00:00:00+00:00","startDateDateOnly":"2019-08-01","endDateDateOnly":"2022-07-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr David Lewis-Smith","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Lewis-Smith","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Newcastle-University","name":"Newcastle University","addressCountry":"United Kingdom","id_and_name":"[\"Newcastle University\", \"360G-Wellcome-ORG:Newcastle-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Newcastle-University","name":"Newcastle University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Discovering the Genetic Basis of Epilepsies through Computational Analysis of Clinical Phenotype Background\nEpilepsy affects 1% of people and empirical treatment benefits only a third. Seizures and their treatments have serious health and socioeconomic consequences. Over a third of epilepsy is thought to arise from variation in the person\u2019s genetic code. However, currently we can only rarely identify what this is, a necessary step towards using it to improve treatment. Studying people grouped by the symptoms of their epilepsy has successfully defined, and discovered the genetic causes of distinctive but rare epilepsies such as Dravet Syndrome, facilitating research that has improved their treatment.\n\n\nApproach\nThe yield of large genetic studies of epilepsy is currently limited by the challenges of combining and interpreting vast quantities of complex information about participants' epilepsy symptoms. We will develop computational methods to make information about the symptoms of participants in Epi25 (the largest ever epilepsy study) more tractable. We will use these to identify new patterns of symptoms and their associated genetic causes.\n\n\nExpected Impact\nIdentifying new genetic causes of epilepsy could help to us to personalise the selection of existing treatments more successfully within a few years, and to design new, precise treatments based upon newly discovered mechanisms. Our methods may be applicable to other diseases.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Epilepsies, Myoclonic","Epilepsy","Humans"]}
{"id":"360G-Wellcome-220552_Z_20_Z","title":"Ethics of human genome editing from Islamic and Confucian perspectives","Region":"International","currency":"GBP","awardDate":"2020-03-02T00:00:00+00:00","Internal ID":"220552/Z/20/Z","description":"This project aims to explore Islamic and Confucian perspectives on ethical issues pertaining to human genome editing namely safety and efficacy of the technology, human dignity and rights, modifying God\u2019s creation, and human genetic enhancement.  It will identify the similarities and differences between both perspectives and highlight the common ethical principles that could be applied in assessing the permissibility of human genome editing technology. This project is a qualitative study that involve normative literature analysis and comparative analysis between Islamic and Confucian perspectives. Given that Islam and Confucianism are among the main ethical traditions in the world, findings from this project would help stakeholders in understanding both perspectives and formulating policies and guidelines regarding responsible research and use of human genome editing. It is hoped that it would encourage more cross-cultural studies that contribute to the global discussion on ethics of human genome editing.\n","plannedDates":[{"endDate":"2021-12-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2021-12-31"}],"amountAwarded":2118,"Financial Year":"2019/20","Lead Applicant":"Dr Noor Munirah Isa","grantProgramme":[{"title":"Global Forum on Bioethics in Research","title_keyword":"Global Forum on Bioethics in Research"}],"Applicant Surname":"Isa","Partnership Value":2118,"Approval Committee":"Global Forum on Bioethics in Research Fellowships Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Malaya","name":"University of Malaya","addressCountry":"Malaysia","id_and_name":"[\"University of Malaya\", \"360G-Wellcome-ORG:University-of-Malaya\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Malaya","name":"University of Malaya"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Ethics of human genome editing from Islamic and Confucian perspectives This project aims to explore Islamic and Confucian perspectives on ethical issues pertaining to human genome editing namely safety and efficacy of the technology, human dignity and rights, modifying God\u2019s creation, and human genetic enhancement.  It will identify the similarities and differences between both perspectives and highlight the common ethical principles that could be applied in assessing the permissibility of human genome editing technology. This project is a qualitative study that involve normative literature analysis and comparative analysis between Islamic and Confucian perspectives. Given that Islam and Confucianism are among the main ethical traditions in the world, findings from this project would help stakeholders in understanding both perspectives and formulating policies and guidelines regarding responsible research and use of human genome editing. It is hoped that it would encourage more cross-cultural studies that contribute to the global discussion on ethics of human genome editing.\n","awardDateDateOnly":"2020-03-02","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Gene Editing","Genome, Human","Humans"]}
{"id":"360G-Wellcome-220551_Z_20_Z","title":"Dietary management of type 2 diabetes in primary care","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220551/Z/20/Z","description":"It is possible to reverse type 2 diabetes - where people return to normal blood glucose control without medications - through significant weight loss, using total diet replacement programmes (\"soups and shakes\" diets). However, diets using real food may be more acceptable to some people, and potentially more sustainable. My recent study demonstrated that it was possible for nurses to support patients with obesity and type 2 diabetes to adopt a real-food low-carbohydrate diet, helping them lose weight and improve their blood glucose in the short term. However, it is not clear what effects these diets have on appetite (which influences whether they might work longer-term), and whether other patient groups may benefit.\n\nI will run an experimental study to investigate the effects of low-carbohydrate weight-loss diets on appetite in people with type 2 diabetes.  I will also run a pilot study to test if people with type 2 diabetes without obesity can adopt this low-carbohydrate diet, and whether this improves their blood glucose control.\n\nThese studies will inform the design of a full-scale trial testing whether low-carbohydrate weight-loss diets are effective for people with type 2 diabetes longer-term, and whether they should be recommended as part of routine care.\n","plannedDates":[{"endDate":"2022-10-13T00:00:00+00:00","startDate":"2019-10-14T00:00:00+00:00","startDateDateOnly":"2019-10-14","endDateDateOnly":"2022-10-13"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Elizabeth Morris","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Morris","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Dietary management of type 2 diabetes in primary care It is possible to reverse type 2 diabetes - where people return to normal blood glucose control without medications - through significant weight loss, using total diet replacement programmes (\"soups and shakes\" diets). However, diets using real food may be more acceptable to some people, and potentially more sustainable. My recent study demonstrated that it was possible for nurses to support patients with obesity and type 2 diabetes to adopt a real-food low-carbohydrate diet, helping them lose weight and improve their blood glucose in the short term. However, it is not clear what effects these diets have on appetite (which influences whether they might work longer-term), and whether other patient groups may benefit.\n\nI will run an experimental study to investigate the effects of low-carbohydrate weight-loss diets on appetite in people with type 2 diabetes.  I will also run a pilot study to test if people with type 2 diabetes without obesity can adopt this low-carbohydrate diet, and whether this improves their blood glucose control.\n\nThese studies will inform the design of a full-scale trial testing whether low-carbohydrate weight-loss diets are effective for people with type 2 diabetes longer-term, and whether they should be recommended as part of routine care.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adult","Diabetes Mellitus, Type 2","Diet, Carbohydrate-Restricted","Female","Humans","Middle Aged","Obesity","Pilot Projects","Research Design","Weight Loss"]}
{"id":"360G-Wellcome-220550_Z_20_Z","title":"Exploring the clonal determinants of T-cell anti-cancer and autoimmune responses after immune checkpoint blockade","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220550/Z/20/Z","description":"This research aims to improve our understanding of how an important immune cell, called a T cell, functions and changes when treated with a class drug called immune checkpoint blockers (ICBs). These drugs have been very successful in treating some forms of cancer - particularly skin cancers - but they don't work for everybody and some people suffer from severe side effects. \n\nWe will compare the T cells from patients with skin cancer with those from healthy volunteers. We will then analyse what happens to T cells when they are exposed to ICBs. First, we will look at which bits of DNA instructions they turn on and off . Second, we will look at which T cells are implicated in the autoimmune side effects with the objective of identifying which T cells drive these toxic responses.\n\nUltimately, this research will enable us to predict which patients are more likely to benefit from ICBs, and which are at higher risk of side effects, allowing patients and doctors to make better decisions about treatment . Also, by better understanding the autoimmune side-effects, we might gain insight into what goes wrong in many diseases caused by an over-active immune system.\n","plannedDates":[{"endDate":"2022-10-06T00:00:00+00:00","startDate":"2019-10-07T00:00:00+00:00","startDateDateOnly":"2019-10-07","endDateDateOnly":"2022-10-06"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Robert Watson","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Watson","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Exploring the clonal determinants of T-cell anti-cancer and autoimmune responses after immune checkpoint blockade This research aims to improve our understanding of how an important immune cell, called a T cell, functions and changes when treated with a class drug called immune checkpoint blockers (ICBs). These drugs have been very successful in treating some forms of cancer - particularly skin cancers - but they don't work for everybody and some people suffer from severe side effects. \n\nWe will compare the T cells from patients with skin cancer with those from healthy volunteers. We will then analyse what happens to T cells when they are exposed to ICBs. First, we will look at which bits of DNA instructions they turn on and off . Second, we will look at which T cells are implicated in the autoimmune side effects with the objective of identifying which T cells drive these toxic responses.\n\nUltimately, this research will enable us to predict which patients are more likely to benefit from ICBs, and which are at higher risk of side effects, allowing patients and doctors to make better decisions about treatment . Also, by better understanding the autoimmune side-effects, we might gain insight into what goes wrong in many diseases caused by an over-active immune system.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Skin Neoplasms","T-Lymphocytes"]}
{"id":"360G-Wellcome-220549_Z_20_Z","title":"Investigating the diversity and evolution of Hepatitis B virus using Nanopore whole genome sequencing","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220549/Z/20/Z","description":"BACKGROUND\n\nChronic Hepatitis B virus (HBV) infection is a global health threat affecting 290 million people, causing 800,000 deaths a year from liver cirrhosis and liver cancer. The United Nations has set elimination targets to be achieved by 2030, however, existing strategies will not enable this goal to be met. Viral genetic sequence is linked to treatment response and clinical outcome. Studying the genetic sequence of HBV therefore provides an avenue to improve elimination strategies.\n\nRecently, we have provided proof of principle that full-genome HBV sequences can be generated using the Nanopore platform. This method is ideal for studying viral diversity due to the long reads generated. I will use this method to study the diversity of HBV within and between hosts, capitalizing on well-established cohorts in South Africa and Uganda.\n\nAPPROACH\n\n1. To optimize Nanopore methods for HBV full genome deep sequencing\n\n2. To identify and characterise HBV strains circulating in sub-Saharan Africa\n\n3. To characterise the kinetics of HBV evolution\n\n4. To investigate the relationship between viral diversity and liver disease\n\nEXPECTED IMPACT\n\nThis information can potentially be used to improve prognostication, understand immune control,\n\noptimise drugs and vaccines, with the potential for high impact on global health.\n","plannedDates":[{"endDate":"2023-06-09T00:00:00+00:00","startDate":"2020-02-10T00:00:00+00:00","startDateDateOnly":"2020-02-10","endDateDateOnly":"2023-06-09"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Sheila Lumley","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Lumley","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the diversity and evolution of Hepatitis B virus using Nanopore whole genome sequencing BACKGROUND\n\nChronic Hepatitis B virus (HBV) infection is a global health threat affecting 290 million people, causing 800,000 deaths a year from liver cirrhosis and liver cancer. The United Nations has set elimination targets to be achieved by 2030, however, existing strategies will not enable this goal to be met. Viral genetic sequence is linked to treatment response and clinical outcome. Studying the genetic sequence of HBV therefore provides an avenue to improve elimination strategies.\n\nRecently, we have provided proof of principle that full-genome HBV sequences can be generated using the Nanopore platform. This method is ideal for studying viral diversity due to the long reads generated. I will use this method to study the diversity of HBV within and between hosts, capitalizing on well-established cohorts in South Africa and Uganda.\n\nAPPROACH\n\n1. To optimize Nanopore methods for HBV full genome deep sequencing\n\n2. To identify and characterise HBV strains circulating in sub-Saharan Africa\n\n3. To characterise the kinetics of HBV evolution\n\n4. To investigate the relationship between viral diversity and liver disease\n\nEXPECTED IMPACT\n\nThis information can potentially be used to improve prognostication, understand immune control,\n\noptimise drugs and vaccines, with the potential for high impact on global health.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["DNA, Viral","Genome, Viral","Hepatitis B","Hepatitis B virus","High-Throughput Nucleotide Sequencing","Humans","Nanopores","Sequence Analysis, DNA","South Africa","Uganda"]}
{"id":"360G-Wellcome-220548_Z_20_Z","title":"Optogenetics to model activity-dependent neurodegeneration in amyotrophic lateral sclerosis","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220548/Z/20/Z","description":"Amyotrophic lateral sclerosis (ALS) causes motor neurons, nerve cells which control voluntary movement, to die. The cause is not fully understood but likely involves an interplay between errors in our genetic code (mutations) and the environment.\n\nWith stem cell technology, patient skin cells can be transformed into motor neurons in the laboratory. Our group has used this technique to identify important disease-related changes. However, in the body, motor neurons are highly electrically active and undergo repetitive 'firing' to activate muscles. Therefore, a complete understanding of motor neuron vulnerability in ALS requires a model in which the activity of these cells can be controlled.\n\nIn this project I will generate motor neurons from patients with disease-causing mutations, and insert a genetically-engineered light-sensitive 'switch' to control activity using light. I will light-stimulate them, both in isolation and with muscle cells. We hypothesise that stimulation will mature the cells, making them more representative of motor neurons in ALS, which start dying in later life. We also hypothesize that stimulation will drive disease-relevant changes. This impact of this work will be a contribution to our understanding of the causes of ALS, and a novel model of disease for further study and testing possible treatments.\n","plannedDates":[{"endDate":"2022-10-31T00:00:00+00:00","startDate":"2019-10-13T00:00:00+00:00","startDateDateOnly":"2019-10-13","endDateDateOnly":"2022-10-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Lucy Farrimond","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Farrimond","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Optogenetics to model activity-dependent neurodegeneration in amyotrophic lateral sclerosis Amyotrophic lateral sclerosis (ALS) causes motor neurons, nerve cells which control voluntary movement, to die. The cause is not fully understood but likely involves an interplay between errors in our genetic code (mutations) and the environment.\n\nWith stem cell technology, patient skin cells can be transformed into motor neurons in the laboratory. Our group has used this technique to identify important disease-related changes. However, in the body, motor neurons are highly electrically active and undergo repetitive 'firing' to activate muscles. Therefore, a complete understanding of motor neuron vulnerability in ALS requires a model in which the activity of these cells can be controlled.\n\nIn this project I will generate motor neurons from patients with disease-causing mutations, and insert a genetically-engineered light-sensitive 'switch' to control activity using light. I will light-stimulate them, both in isolation and with muscle cells. We hypothesise that stimulation will mature the cells, making them more representative of motor neurons in ALS, which start dying in later life. We also hypothesize that stimulation will drive disease-relevant changes. This impact of this work will be a contribution to our understanding of the causes of ALS, and a novel model of disease for further study and testing possible treatments.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Amyotrophic Lateral Sclerosis","Animals","Humans","Motor Neurons","Mutation","Optogenetics"]}
{"id":"360G-Wellcome-220547_Z_20_Z","title":"A Critical Investigation of Gene Drive Technology ","Region":"International","currency":"GBP","awardDate":"2020-03-02T00:00:00+00:00","Internal ID":"220547/Z/20/Z","description":"There is established bio-ethical literature related to genomic research and technology, with this literature increasingly also focussing on gene drive technologies. While such questions are important, these questions often do not critically engage with how gene drive technologies interact with social, political and economic spheres. Furthermore, there is very limited critical discussion about these technologies from scholars situated in the global South, where some first field trials are set take place.  \n\nDuring this fellowship, I will work on a journal article for publication critically interrogating the social, political and economic dimensions of gene drive technology. This paper will focus on questions such as, why are the first field trials of  this controversial technologies organised in one of the poorest countries in the world, who actually benefits from such research, especially given the convergence of funding from Western governments, philanthropic funders, and the commercial agricultural sector, and what is the impact of these arrangements of local communities and governance structures where gene drive technologies have been proposed to be used. The publication will begin to articulate these kinds critical questions that must be engaged with, if we are to ensure gene drive technologies does not reproduce historic patterns of inequality.\n","plannedDates":[{"endDate":"2021-11-01T00:00:00+00:00","startDate":"2021-09-01T00:00:00+00:00","startDateDateOnly":"2021-09-01","endDateDateOnly":"2021-11-01"}],"amountAwarded":5841,"Financial Year":"2019/20","Lead Applicant":"Mr Marlyn Faure","grantProgramme":[{"title":"Global Forum on Bioethics in Research","title_keyword":"Global Forum on Bioethics in Research"}],"Applicant Surname":"Faure","Partnership Value":5841,"Approval Committee":"Global Forum on Bioethics in Research Fellowships Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cape-Town","name":"University of Cape Town","addressCountry":"South Africa","id_and_name":"[\"University of Cape Town\", \"360G-Wellcome-ORG:University-of-Cape-Town\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cape-Town","name":"University of Cape Town"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A Critical Investigation of Gene Drive Technology  There is established bio-ethical literature related to genomic research and technology, with this literature increasingly also focussing on gene drive technologies. While such questions are important, these questions often do not critically engage with how gene drive technologies interact with social, political and economic spheres. Furthermore, there is very limited critical discussion about these technologies from scholars situated in the global South, where some first field trials are set take place.  \n\nDuring this fellowship, I will work on a journal article for publication critically interrogating the social, political and economic dimensions of gene drive technology. This paper will focus on questions such as, why are the first field trials of  this controversial technologies organised in one of the poorest countries in the world, who actually benefits from such research, especially given the convergence of funding from Western governments, philanthropic funders, and the commercial agricultural sector, and what is the impact of these arrangements of local communities and governance structures where gene drive technologies have been proposed to be used. The publication will begin to articulate these kinds critical questions that must be engaged with, if we are to ensure gene drive technologies does not reproduce historic patterns of inequality.\n","awardDateDateOnly":"2020-03-02","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans"]}
{"id":"360G-Wellcome-220546_Z_20_Z","title":"THE GOVERNANCE FRAMEWORK OF GENOME RESEARCH IN MALAWI","Region":"Unknown","currency":"GBP","awardDate":"2020-03-02T00:00:00+00:00","Internal ID":"220546/Z/20/Z","description":"The main intention of this fellowship is to document the distinct ethical issues related to the use of genome research in eradicating Malaria. This will then result in identifying an ethical acceptable framework for genome editing that necessitates the progress of scientific research.  The following key goals are expected to be  met in the 6 week period.\n\n\n Review and document the National commission for science and technology NSCT regulations and guidelines in regards to genome  editing.\n Review the regulations, guidelines and policies used by ethics committees and regulators at McMaster and some sub-Saharan countries that incorporates genome editing for malaria eradication.\n     Establish and document evidence  that aid advocacy to implicating policies that are favorable for researchers to conduct genome research and at the same time beneficial for human health IN Malawi\n     Recommend ethical acceptable approaches   and frameworks that can address the ethical issues surrounding genome research\n\n","plannedDates":[{"endDate":"2021-07-31T00:00:00+00:00","startDate":"2020-07-09T00:00:00+00:00","startDateDateOnly":"2020-07-09","endDateDateOnly":"2021-07-31"}],"amountAwarded":7783,"Financial Year":"2019/20","Lead Applicant":"Mrs Ruby Ng'ong'ola","grantProgramme":[{"title":"Global Forum on Bioethics in Research","title_keyword":"Global Forum on Bioethics in Research"}],"Applicant Surname":"Ng'ong'ola","Partnership Value":7783,"Approval Committee":"Global Forum on Bioethics in Research Fellowships Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:590604F5-C9C4-484E-8B64-A99D010190C2","name":"No Organisation","addressCountry":"Unknown","id_and_name":"[\"No Organisation\", \"360G-Wellcome-ORG:590604F5-C9C4-484E-8B64-A99D010190C2\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:590604F5-C9C4-484E-8B64-A99D010190C2","name":"No Organisation"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"THE GOVERNANCE FRAMEWORK OF GENOME RESEARCH IN MALAWI The main intention of this fellowship is to document the distinct ethical issues related to the use of genome research in eradicating Malaria. This will then result in identifying an ethical acceptable framework for genome editing that necessitates the progress of scientific research.  The following key goals are expected to be  met in the 6 week period.\n\n\n Review and document the National commission for science and technology NSCT regulations and guidelines in regards to genome  editing.\n Review the regulations, guidelines and policies used by ethics committees and regulators at McMaster and some sub-Saharan countries that incorporates genome editing for malaria eradication.\n     Establish and document evidence  that aid advocacy to implicating policies that are favorable for researchers to conduct genome research and at the same time beneficial for human health IN Malawi\n     Recommend ethical acceptable approaches   and frameworks that can address the ethical issues surrounding genome research\n\n","awardDateDateOnly":"2020-03-02","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biomedical Research","Ethics, Research","Gene Editing","Humans","Malaria","Malawi"]}
{"id":"360G-Wellcome-220544_Z_20_Z","title":"The Global Alliance for Genomics and Health: Setting the Standards for Genomics and Health-Related Data Sharing","Region":"East of England","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220544/Z/20/Z","description":"The decreasing cost of genomic sequencing will yield millions of samples in the coming years from both research and healthcare. To make the most use of these data, the community must agree on common methods for collecting, storing, transferring, accessing, and analyzing data. \n\nThis proposal will support the Global Alliance for Genomics and Health (GA4GH; www.ga4gh.org) as it develops the standards and policies necessary for effective and responsible data sharing. With more than 1,000 active contributors working across more than 30 countries in the areas of healthcare, research, patient advocacy, life science, and information technology, this diverse organization enables broad sharing that transcends the boundaries of any single institution or country. \n\nWe envision a future in which the full suite of GA4GH standards enables all clinicians, geneticists, and researchers to search across the world\u2019s collective genomic data to reveal unanticipated gene-disease associations, make otherwise impossible drug-response predictions, and generally participate in genomics at a competitive pace\u2014regardless of their means or location. \n\nThe promise of genomic medicine lies at a crossroads that depends on community harmonization and will significantly enhance human health and medicine if we succeed. We believe GA4GH is necessary to that success. \n","plannedDates":[{"endDate":"2026-02-28T00:00:00+00:00","startDate":"2021-03-01T00:00:00+00:00","startDateDateOnly":"2021-03-01","endDateDateOnly":"2026-02-28"}],"amountAwarded":2499432,"Financial Year":"2019/20","Lead Applicant":"Prof Ewan Birney","grantProgramme":[{"title":"Strategic Support: Science","title_keyword":"Strategic Support: Science"}],"Applicant Surname":"Birney","Partnership Value":2499432,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Mr Peter Goodhand","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:European-Bioinformatics-Institute","name":"European Bioinformatics Institute","addressCountry":"United Kingdom","id_and_name":"[\"European Bioinformatics Institute\", \"360G-Wellcome-ORG:European-Bioinformatics-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:European-Bioinformatics-Institute","name":"European Bioinformatics Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The Global Alliance for Genomics and Health: Setting the Standards for Genomics and Health-Related Data Sharing The decreasing cost of genomic sequencing will yield millions of samples in the coming years from both research and healthcare. To make the most use of these data, the community must agree on common methods for collecting, storing, transferring, accessing, and analyzing data. \n\nThis proposal will support the Global Alliance for Genomics and Health (GA4GH; www.ga4gh.org) as it develops the standards and policies necessary for effective and responsible data sharing. With more than 1,000 active contributors working across more than 30 countries in the areas of healthcare, research, patient advocacy, life science, and information technology, this diverse organization enables broad sharing that transcends the boundaries of any single institution or country. \n\nWe envision a future in which the full suite of GA4GH standards enables all clinicians, geneticists, and researchers to search across the world\u2019s collective genomic data to reveal unanticipated gene-disease associations, make otherwise impossible drug-response predictions, and generally participate in genomics at a competitive pace\u2014regardless of their means or location. \n\nThe promise of genomic medicine lies at a crossroads that depends on community harmonization and will significantly enhance human health and medicine if we succeed. We believe GA4GH is necessary to that success. \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Genomics","Global Health","Humans","Information Dissemination"]}
{"id":"360G-Wellcome-220543_Z_20_Z","title":"A Single-cell approach to probing proximal TCR signalling and early transcription of cytotoxic T cells","Region":"East of England","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220543/Z/20/Z","description":"Cytotoxic T cells (\u2018killer cells\u2019) are a vital component of our immune system.  The human body is capable of mounting different responses to ensure defence against foreign invaders such as faulty cancerous cells, whilst protecting useful bodily cells from destruction.  Their \u2018killing\u2019 ability is the reason cytotoxic T cells are of great interest in the development of cancer treatments. However, more work is required if they can be harnessed as effective and yet safe therapies.  \n\nStudying cytotoxic T cells is difficult with conventional scientific methods, since our bodies are inherently designed to produce vast populations of T cells, each able to kill different infected or faulty cells.  The diversity and rapidity of these responses confer immunological advantages but make deciphering events on a per-cell basis perplexing.  This project proposes to use \u2018single-cell resolution\u2019 methods to study cytotoxic T cells. Mass cytometry and single-cell RNA sequencing are innovative techniques that are capable of simultaneously measuring multiple changes within each single-cell.  Together, these techniques will allow us to gain an in-depth understanding of the regulation of cytotoxic T cells, to improve and expand cancer immunotherapy.\n","plannedDates":[{"endDate":"2022-08-14T00:00:00+00:00","startDate":"2019-02-05T00:00:00+00:00","startDateDateOnly":"2019-02-05","endDateDateOnly":"2022-08-14"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Claire Ma","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Ma","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A Single-cell approach to probing proximal TCR signalling and early transcription of cytotoxic T cells Cytotoxic T cells (\u2018killer cells\u2019) are a vital component of our immune system.  The human body is capable of mounting different responses to ensure defence against foreign invaders such as faulty cancerous cells, whilst protecting useful bodily cells from destruction.  Their \u2018killing\u2019 ability is the reason cytotoxic T cells are of great interest in the development of cancer treatments. However, more work is required if they can be harnessed as effective and yet safe therapies.  \n\nStudying cytotoxic T cells is difficult with conventional scientific methods, since our bodies are inherently designed to produce vast populations of T cells, each able to kill different infected or faulty cells.  The diversity and rapidity of these responses confer immunological advantages but make deciphering events on a per-cell basis perplexing.  This project proposes to use \u2018single-cell resolution\u2019 methods to study cytotoxic T cells. Mass cytometry and single-cell RNA sequencing are innovative techniques that are capable of simultaneously measuring multiple changes within each single-cell.  Together, these techniques will allow us to gain an in-depth understanding of the regulation of cytotoxic T cells, to improve and expand cancer immunotherapy.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Immunotherapy","Sequence Analysis, RNA","Single-Cell Analysis","T-Lymphocytes, Cytotoxic"]}
{"id":"360G-Wellcome-220542_Z_20_Z","title":"Leveraging electronic health records for the design of improved care for older surgical patients","Region":"East of England","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220542/Z/20/Z","description":"With an ageing population, increasing numbers of older patients are presenting for surgery.  Those with other health problems who undergo major operations are more likely to develop complications and fail to make a full recovery.  The complexity of modern healthcare means that approaches used to design other complex systems (such as energy or aviation) are increasingly advocated to understand, design, and improve health systems. In our project we aim to explore how healthcare data can be used to supplement such an approach; to identify events and factors associated with older patients losing independence after surgery or suffering another complication (such as a heart attack) whilst in hospital.\n\nWe will firstly gain consensus on what defines a 'high-risk' patient by searching the literature and canvassing the opinion of healthcare professionals.  This information will inform the generation of a large, anonymised dataset, extracted from our hospital's electronic health record and use this to identify events, conditions, and factors that are associated with poor outcome after surgery.  In the final phase we will use these findings to explore, simulate, and design potential solutions to these identified problems with the hope of exploring the beneficial effects of such a solution in future work.  \n\n \n","plannedDates":[{"endDate":"2023-05-29T00:00:00+00:00","startDate":"2018-10-01T00:00:00+00:00","startDateDateOnly":"2018-10-01","endDateDateOnly":"2023-05-29"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Daniel Stubbs","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Stubbs","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Leveraging electronic health records for the design of improved care for older surgical patients With an ageing population, increasing numbers of older patients are presenting for surgery.  Those with other health problems who undergo major operations are more likely to develop complications and fail to make a full recovery.  The complexity of modern healthcare means that approaches used to design other complex systems (such as energy or aviation) are increasingly advocated to understand, design, and improve health systems. In our project we aim to explore how healthcare data can be used to supplement such an approach; to identify events and factors associated with older patients losing independence after surgery or suffering another complication (such as a heart attack) whilst in hospital.\n\nWe will firstly gain consensus on what defines a 'high-risk' patient by searching the literature and canvassing the opinion of healthcare professionals.  This information will inform the generation of a large, anonymised dataset, extracted from our hospital's electronic health record and use this to identify events, conditions, and factors that are associated with poor outcome after surgery.  In the final phase we will use these findings to explore, simulate, and design potential solutions to these identified problems with the hope of exploring the beneficial effects of such a solution in future work.  \n\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aged","Electronic Health Records","Humans"]}
{"id":"360G-Wellcome-220541_Z_20_Z","title":"Community and stakeholders perceptions towards human gene editing. An explorative study in Argentina","Region":"International","currency":"GBP","awardDate":"2020-03-02T00:00:00+00:00","Internal ID":"220541/Z/20/Z","description":"The project aims to develop a better understanding of the general public and various stakeholders views on human gene editing in Argentina. Focus group sessions will be conducted for an in-depth exploration and description of the general public, patients and members of REC attitudes and perceptions towards human gene editing.\n\nKey goals are:\n\n\n The findings of the project will contribute to strengthening the evidence on an unexplored topic in Latin America.\n The results will also serve as a basis for future research in Argentina and other Latin American countries.\n The information obtained will provide information to Ministry of Health policymakers for future policy.\n An academic paper for publication in a peer-review journal will be produced.\n Key actors in Latin American countries will be identified to facilitate the dissemination of the findings.\n A human gene editing workshop with experts for research participants to disseminate the findings of the project and to promote dialogue among stakeholders will be conducted.\n\n","plannedDates":[{"endDate":"2021-09-21T00:00:00+00:00","startDate":"2020-09-21T00:00:00+00:00","startDateDateOnly":"2020-09-21","endDateDateOnly":"2021-09-21"}],"amountAwarded":7790,"Financial Year":"2019/20","Lead Applicant":"Dr Ana Palmero","grantProgramme":[{"title":"Global Forum on Bioethics in Research","title_keyword":"Global Forum on Bioethics in Research"}],"Applicant Surname":"Palmero","Partnership Value":7790,"Approval Committee":"Global Forum on Bioethics in Research Fellowships Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Centro-De-Estudios-De-Estado-Y-Sociedad-Cedes","name":"Centro De Estudios De Estado Y Sociedad Cedes","addressCountry":"Argentina","id_and_name":"[\"Centro De Estudios De Estado Y Sociedad Cedes\", \"360G-Wellcome-ORG:Centro-De-Estudios-De-Estado-Y-Sociedad-Cedes\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Centro-De-Estudios-De-Estado-Y-Sociedad-Cedes","name":"Centro De Estudios De Estado Y Sociedad Cedes"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Community and stakeholders perceptions towards human gene editing. An explorative study in Argentina The project aims to develop a better understanding of the general public and various stakeholders views on human gene editing in Argentina. Focus group sessions will be conducted for an in-depth exploration and description of the general public, patients and members of REC attitudes and perceptions towards human gene editing.\n\nKey goals are:\n\n\n The findings of the project will contribute to strengthening the evidence on an unexplored topic in Latin America.\n The results will also serve as a basis for future research in Argentina and other Latin American countries.\n The information obtained will provide information to Ministry of Health policymakers for future policy.\n An academic paper for publication in a peer-review journal will be produced.\n Key actors in Latin American countries will be identified to facilitate the dissemination of the findings.\n A human gene editing workshop with experts for research participants to disseminate the findings of the project and to promote dialogue among stakeholders will be conducted.\n\n","awardDateDateOnly":"2020-03-02","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Argentina","Humans","Latin America","Stakeholder Participation"]}
{"id":"360G-Wellcome-220539_Z_20_Z","title":"The Wellcome Screenwriting Fellowship 2019","Region":"Unknown","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220539/Z/20/Z","description":"This is a prize for a Screenwriting Fellowship, awarded in collaboration with the BFI and Film4 in 2019","plannedDates":[{"endDate":"2021-01-01T00:00:00+00:00","startDate":"2020-01-01T00:00:00+00:00","startDateDateOnly":"2020-01-01","endDateDateOnly":"2021-01-01"}],"amountAwarded":30000,"Financial Year":"2019/20","Lead Applicant":"Ms Lucy Prebble","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Prebble","Partnership Value":30000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:D6E70B1C-D23F-49D9-B000-AB4A009D1D91","name":"No Organisation","addressCountry":"Unknown","id_and_name":"[\"No Organisation\", \"360G-Wellcome-ORG:D6E70B1C-D23F-49D9-B000-AB4A009D1D91\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:D6E70B1C-D23F-49D9-B000-AB4A009D1D91","name":"No Organisation"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The Wellcome Screenwriting Fellowship 2019 This is a prize for a Screenwriting Fellowship, awarded in collaboration with the BFI and Film4 in 2019","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Fellowships and Scholarships","Humans"]}
{"id":"360G-Wellcome-220538_Z_20_Z","title":"Building communication and trust in gene editing in human health","Region":"Unknown","currency":"GBP","awardDate":"2020-03-02T00:00:00+00:00","Internal ID":"220538/Z/20/Z","description":"To organize two meetings for the general public to raise awareness about gene editing in Argentina so they can be enriched with reliable information. The idea is to repeat the event held in Buenos Aires in 2018 that I presented in the Forum in Singapore 2019, in two different cities in Argentina: Santa Fe and Entre R\u00edos, in order to reach more people about the importance of this technology. A registration form will be available for the general public to sign up for the meetings.\n\nOn the other hand, Ana Palmero will apply to another Meeting Fellowship to organize a workshop to ask patients of gene therapies, which in the future could require treatment with gene editing, their opinion about the technique. This way, she will gather data.\n\nEven my project can be carried out independently, the idea is to work together to empower the workshop of Ana Palmero. The patients of the interest for the workshop will be invited to participate in the meetings in where they will receive information that will be able to use later in the workshop. An informed person, can elaborate better answers.\n\nThis way, two ministries of Argentina will work together: Science and Health\n","plannedDates":[{"endDate":"2021-04-30T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2021-04-30"}],"amountAwarded":5429,"Financial Year":"2019/20","Lead Applicant":"Mr Sebastian Barbosa","grantProgramme":[{"title":"Global Forum on Bioethics in Research","title_keyword":"Global Forum on Bioethics in Research"}],"Applicant Surname":"Barbosa","Partnership Value":5429,"Approval Committee":"Global Forum on Bioethics in Research Fellowships Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:07C53A41-E2D5-49D2-BDD3-AB4500E60444","name":"No Organisation","addressCountry":"Unknown","id_and_name":"[\"No Organisation\", \"360G-Wellcome-ORG:07C53A41-E2D5-49D2-BDD3-AB4500E60444\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:07C53A41-E2D5-49D2-BDD3-AB4500E60444","name":"No Organisation"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Building communication and trust in gene editing in human health To organize two meetings for the general public to raise awareness about gene editing in Argentina so they can be enriched with reliable information. The idea is to repeat the event held in Buenos Aires in 2018 that I presented in the Forum in Singapore 2019, in two different cities in Argentina: Santa Fe and Entre R\u00edos, in order to reach more people about the importance of this technology. A registration form will be available for the general public to sign up for the meetings.\n\nOn the other hand, Ana Palmero will apply to another Meeting Fellowship to organize a workshop to ask patients of gene therapies, which in the future could require treatment with gene editing, their opinion about the technique. This way, she will gather data.\n\nEven my project can be carried out independently, the idea is to work together to empower the workshop of Ana Palmero. The patients of the interest for the workshop will be invited to participate in the meetings in where they will receive information that will be able to use later in the workshop. An informed person, can elaborate better answers.\n\nThis way, two ministries of Argentina will work together: Science and Health\n","awardDateDateOnly":"2020-03-02","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Argentina","Gene Editing","Humans","Singapore"]}
{"id":"360G-Wellcome-220537_Z_20_Z","title":"An investigation of white matter fibre tract topology, connectivity and microstructure to uncover the ictogenic network in focal epilepsy","Region":"Wales","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220537/Z/20/Z","description":"Epilepsy is the most common serious neurological disorder and one-third of those affected continue to experience disabling seizures despite taking regular medications. It is thought that there are abnormal cortical areas in the brain that, together with the white matter connections that join them, form pathological circuits responsible for seizures. These circuits vary between subjects in their properties, location and spread. Modern medical imaging and other investigations do not fully detect the abnormal circuits, leaving the majority of patients unsuitable for surgery or vastly reducing their chances of seizure freedom post-operatively.\n\nUsing state-of-the-art imaging hardware and methodology I will obtain high quality brain scans of 20 patients with epilepsy. I will look at the multiple qualities that can tell us about the state of the brain connections, producing very detailed maps of abnormalities. I will then test contribution of these abnormalities by mathematically simulating seizures and comparing my simulations with the real seizure activity we record from the same patients. This will help us describe the circuits or give us information about how these circuits work.  \n\nMy approach will allow us better understand the exact mechanisms that drive epilepsy and may help develop better treatments for these patients.\n","plannedDates":[{"endDate":"2022-11-06T00:00:00+00:00","startDate":"2019-08-07T00:00:00+00:00","startDateDateOnly":"2019-08-07","endDateDateOnly":"2022-11-06"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Dmitri Sastin","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Sastin","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University","addressCountry":"United Kingdom","id_and_name":"[\"Cardiff University\", \"360G-Wellcome-ORG:Cardiff-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"An investigation of white matter fibre tract topology, connectivity and microstructure to uncover the ictogenic network in focal epilepsy Epilepsy is the most common serious neurological disorder and one-third of those affected continue to experience disabling seizures despite taking regular medications. It is thought that there are abnormal cortical areas in the brain that, together with the white matter connections that join them, form pathological circuits responsible for seizures. These circuits vary between subjects in their properties, location and spread. Modern medical imaging and other investigations do not fully detect the abnormal circuits, leaving the majority of patients unsuitable for surgery or vastly reducing their chances of seizure freedom post-operatively.\n\nUsing state-of-the-art imaging hardware and methodology I will obtain high quality brain scans of 20 patients with epilepsy. I will look at the multiple qualities that can tell us about the state of the brain connections, producing very detailed maps of abnormalities. I will then test contribution of these abnormalities by mathematically simulating seizures and comparing my simulations with the real seizure activity we record from the same patients. This will help us describe the circuits or give us information about how these circuits work.  \n\nMy approach will allow us better understand the exact mechanisms that drive epilepsy and may help develop better treatments for these patients.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Brain","Epilepsy","Humans","Magnetic Resonance Imaging","Models, Neurological","Neural Pathways","Seizures","White Matter"]}
{"id":"360G-Wellcome-220536_Z_20_Z","title":"The implementation of atrial fibrillation screening in primary care: a mixed-methods process evaluation of the SAFER trial","Region":"East of England","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220536/Z/20/Z","description":"In atrial fibrillation (AF), the heart beats irregularly. This may produce no symptoms but can cause stroke: 1 in 10 strokes occur in people who do not know that they have AF. Subsequently, there are calls for screening for AF but we first need information on whether screening reduces strokes and is cost-effective. The SAFER trial will study this by comparing the rates of stroke (and other conditions) in general practices that screen to those that do not.  Some practices will be given training to perform screening but how they implement it will affect whether screening improves health.\n\nI will review evidence for how practices can best implement screening. I will observe how practices implement AF screening by examining training, day-to-day running, consultations, communications, and interviewing staff. I will send quarterly surveys to practices that perform and do not perform screening to see how they differ. I will finally combine my research to discover how best to implement AF screening.\n\nMy results will guide practitioners and researchers on screening. It will help the trial run AF screening more successfully and explain the trial results more clearly. We can then recommend to screening agencies how AF screening programmes should be run.\n","plannedDates":[{"endDate":"2022-09-30T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-09-30"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Rakesh Modi","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Modi","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The implementation of atrial fibrillation screening in primary care: a mixed-methods process evaluation of the SAFER trial In atrial fibrillation (AF), the heart beats irregularly. This may produce no symptoms but can cause stroke: 1 in 10 strokes occur in people who do not know that they have AF. Subsequently, there are calls for screening for AF but we first need information on whether screening reduces strokes and is cost-effective. The SAFER trial will study this by comparing the rates of stroke (and other conditions) in general practices that screen to those that do not.  Some practices will be given training to perform screening but how they implement it will affect whether screening improves health.\n\nI will review evidence for how practices can best implement screening. I will observe how practices implement AF screening by examining training, day-to-day running, consultations, communications, and interviewing staff. I will send quarterly surveys to practices that perform and do not perform screening to see how they differ. I will finally combine my research to discover how best to implement AF screening.\n\nMy results will guide practitioners and researchers on screening. It will help the trial run AF screening more successfully and explain the trial results more clearly. We can then recommend to screening agencies how AF screening programmes should be run.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Atrial Fibrillation","Humans","Mass Screening","Primary Health Care","Stroke"]}
{"id":"360G-Wellcome-220535_Z_20_Z","title":"Genetic approaches to gain new insights into cellular iron metabolism and oxygen sensing","Region":"East of England","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220535/Z/20/Z","description":"Maintaining appropriate levels of iron in the body is indispensable for human survival. Low iron levels can lead to anaemia and are an important feature of cancer. Too much iron can result in the death of cells and contribute to chronic diseases affecting the lungs, liver and brain. Therefore, most organisms have developed mechanisms to adapt to the abundance of iron in their environment, but our understanding of how iron is regulated within cells remains poorly understood.\n\nHere, I propose to use forward genetic approaches in human cells to uncover new pathways for iron regulation. We have developed a dynamic iron fluorescent reporter, based on the sensitivity of Iron Regulatory Protein 2 (IRP-2) to iron availability, and will use this reporter in genome wide mutagenesis screens to find genes that are required to regulate iron. Ultimately this work will identify new elements of the iron pathway and potentially uncover novel targets for drugs to treat a range of diseases which are worsened by dysregulation of iron levels.\n","plannedDates":[{"endDate":"2023-03-25T00:00:00+00:00","startDate":"2019-08-07T00:00:00+00:00","startDateDateOnly":"2019-08-07","endDateDateOnly":"2023-03-25"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Anthony Martinelli","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Martinelli","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Genetic approaches to gain new insights into cellular iron metabolism and oxygen sensing Maintaining appropriate levels of iron in the body is indispensable for human survival. Low iron levels can lead to anaemia and are an important feature of cancer. Too much iron can result in the death of cells and contribute to chronic diseases affecting the lungs, liver and brain. Therefore, most organisms have developed mechanisms to adapt to the abundance of iron in their environment, but our understanding of how iron is regulated within cells remains poorly understood.\n\nHere, I propose to use forward genetic approaches in human cells to uncover new pathways for iron regulation. We have developed a dynamic iron fluorescent reporter, based on the sensitivity of Iron Regulatory Protein 2 (IRP-2) to iron availability, and will use this reporter in genome wide mutagenesis screens to find genes that are required to regulate iron. Ultimately this work will identify new elements of the iron pathway and potentially uncover novel targets for drugs to treat a range of diseases which are worsened by dysregulation of iron levels.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Genes, Reporter","Humans","Iron","Mutagenesis"]}
{"id":"360G-Wellcome-220534_Z_20_Z","title":"Investigating the ageing phenotype in the bone marrow microenvironment: the role of macrophages in regulating normal and malignant haematopoiesis ","Region":"East of England","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220534/Z/20/Z","description":"Most people diagnosed with Acute Myeloid Leukaemia (AML) die of the disease because the available chemotherapy targeting AML cells cannot kill all the leukaemia cells in the bone marrow. In part, this is because the bone marrow environment promotes leukaemia growth and also provides protection from the drug treatment. It is hoped that future treatment strategies targeting the environment and the tumour (the soil and the seed) will lead to improved outcomes for patients. This project aims to understand the cancer-specific protective functions of the bone marrow with a view to identify new treatments in the future.\n\nWe have recently discovered that AML cells cause senescence, the process of ageing of cells in which cells permanently stop dividing, in the bone marrow and that this supports the survival and growth of leukaemic cells. Senescence normally occurs with ageing and the fact that AML occurs most commonly in older people is consistent with the observation that the leukaemia thrives on converting the bone marrow microenvironment into a senescent environment. During this fellowship I plan to further investigate the impact ageing has on the bone marrow microenvironment and how this in turn impacts on tumour development.\n","plannedDates":[{"endDate":"2023-03-29T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2023-03-29"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Charlotte Hellmich","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Hellmich","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the ageing phenotype in the bone marrow microenvironment: the role of macrophages in regulating normal and malignant haematopoiesis  Most people diagnosed with Acute Myeloid Leukaemia (AML) die of the disease because the available chemotherapy targeting AML cells cannot kill all the leukaemia cells in the bone marrow. In part, this is because the bone marrow environment promotes leukaemia growth and also provides protection from the drug treatment. It is hoped that future treatment strategies targeting the environment and the tumour (the soil and the seed) will lead to improved outcomes for patients. This project aims to understand the cancer-specific protective functions of the bone marrow with a view to identify new treatments in the future.\n\nWe have recently discovered that AML cells cause senescence, the process of ageing of cells in which cells permanently stop dividing, in the bone marrow and that this supports the survival and growth of leukaemic cells. Senescence normally occurs with ageing and the fact that AML occurs most commonly in older people is consistent with the observation that the leukaemia thrives on converting the bone marrow microenvironment into a senescent environment. During this fellowship I plan to further investigate the impact ageing has on the bone marrow microenvironment and how this in turn impacts on tumour development.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aging","Animals","Bone Marrow","Cellular Senescence","Humans","Leukemia, Myeloid, Acute","Macrophages","Tumor Microenvironment"]}
{"id":"360G-Wellcome-220532_Z_20_Z","title":"Creative Health Centre for the UK","Region":"South West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220532/Z/20/Z","description":"Contribution to the establishment of a national Centre for Creative Health as recommended by the APPG report into Creative Health: Arts , Health and Wellbeing (2017).","plannedDates":[{"endDate":"2021-03-02T00:00:00+00:00","startDate":"2020-03-02T00:00:00+00:00","startDateDateOnly":"2020-03-02","endDateDateOnly":"2021-03-02"}],"amountAwarded":50000,"Financial Year":"2019/20","Lead Applicant":"Ms Alexandra Coulter","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Coulter","Partnership Value":50000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Arts-and-Health-South-West","name":"Arts & Health South West","addressCountry":"United Kingdom","id_and_name":"[\"Arts & Health South West\", \"360G-Wellcome-ORG:Arts-and-Health-South-West\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Arts-and-Health-South-West","name":"Arts & Health South West"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Creative Health Centre for the UK Contribution to the establishment of a national Centre for Creative Health as recommended by the APPG report into Creative Health: Arts , Health and Wellbeing (2017).","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Creativity","Humans","United Kingdom"]}
{"id":"360G-Wellcome-220531_Z_20_Z","title":"Defining the pathophysiology of snakebite induced local tissue damage and evaluating tolerance of a repurposed orally administered venom inhibitor","Region":"North West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220531/Z/20/Z","description":"Snakebite is a priority neglected tropical disease and has been under-researched, particularly in sub-Saharan Africa.\n\nThe numbers who suffer snakebite are often under-appreciated, as many victims do not attend hospital. We will survey people in the community to identify the number of bites per year in Kilifi, Kenya. At Kilifi County Hopsital, relatively detailed information about snakebite cases has been collected, and this will be analysed to identify the burden of disease. All new cases of snakebite presenting to Kilifi County Hospital will be invited to enrol in an observational study. This observational study will aim to uncover the important biting species of snake, the rates of skin damage and to explore the underlying causes of skin damage.\n\nMany snake venoms contain \"SVMP\" toxins. These need zinc in order to function. SVMPs can damage blood vessels and interfere with normal blood clotting, and this can lead to bleeding. Unithiol has been used to treat heavy metal poisoning, but recently it has been shown to prevent death in mice following snakebite. We plan to give this drug to healthy volunteers in Kenya, in order to understand its safety, and to decide what dose is best to give in future research studies.\n","plannedDates":[{"endDate":"2023-05-04T00:00:00+00:00","startDate":"2019-09-01T00:00:00+00:00","startDateDateOnly":"2019-09-01","endDateDateOnly":"2023-05-04"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Michael Abouyannis","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Abouyannis","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"Liverpool School of Tropical Medicine\", \"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Defining the pathophysiology of snakebite induced local tissue damage and evaluating tolerance of a repurposed orally administered venom inhibitor Snakebite is a priority neglected tropical disease and has been under-researched, particularly in sub-Saharan Africa.\n\nThe numbers who suffer snakebite are often under-appreciated, as many victims do not attend hospital. We will survey people in the community to identify the number of bites per year in Kilifi, Kenya. At Kilifi County Hopsital, relatively detailed information about snakebite cases has been collected, and this will be analysed to identify the burden of disease. All new cases of snakebite presenting to Kilifi County Hospital will be invited to enrol in an observational study. This observational study will aim to uncover the important biting species of snake, the rates of skin damage and to explore the underlying causes of skin damage.\n\nMany snake venoms contain \"SVMP\" toxins. These need zinc in order to function. SVMPs can damage blood vessels and interfere with normal blood clotting, and this can lead to bleeding. Unithiol has been used to treat heavy metal poisoning, but recently it has been shown to prevent death in mice following snakebite. We plan to give this drug to healthy volunteers in Kenya, in order to understand its safety, and to decide what dose is best to give in future research studies.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adult","Animals","Antivenins","Humans","Kenya","Male","Snake Bites","Snake Venoms","Snakes"]}
{"id":"360G-Wellcome-220530_Z_20_Z","title":"The effect of lipid-lowering agents and the dysregulated metabolism on the risk and progression of head and neck squamous cell carcinoma (HNSCC).","Region":"South West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220530/Z/20/Z","description":"Background\n\nDrugs such as statins reduce blood cholesterol, but they may also lower the risk of getting certain cancers, however the evidence surrounding head and neck cancer is inconclusive. In addition, the mechanisms by which these drugs might prevent head and neck cancer requires further evaluation. \n\nStatins and similar drugs modify circulating blood factors such as cholesterol, hormones and metabolites which result in the exposure of cells to an environment that may alter the chances of a cancer developing. We want to determine whether such changes to the body\u2019s metabolic environment also influences the likelihood of developing and dying from head and neck cancer.\n\nResearch approach\n\n1) Analyse large datasets of people with head and neck cancer, to determine if statins and similar drugs causally protect against cancer development and progression.\n\n2) Explore how changes in cholesterol, hormones and metabolite levels might mechanistically prevent head and neck cancer using laboratory studies.\n\n3) Identify potential drug targets for prevention or therapy in head and neck cancer.\n\nImpact\n\nThis project will investigate the link between changes to the body\u2019s cholesterol, hormones and metabolite levels and head and neck cancer. This could help inform targeted cancer screening, prevention and intervention for these patients.\n","plannedDates":[{"endDate":"2022-12-14T00:00:00+00:00","startDate":"2019-09-14T00:00:00+00:00","startDateDateOnly":"2019-09-14","endDateDateOnly":"2022-12-14"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Mark Gormley","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Gormley","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The effect of lipid-lowering agents and the dysregulated metabolism on the risk and progression of head and neck squamous cell carcinoma (HNSCC). Background\n\nDrugs such as statins reduce blood cholesterol, but they may also lower the risk of getting certain cancers, however the evidence surrounding head and neck cancer is inconclusive. In addition, the mechanisms by which these drugs might prevent head and neck cancer requires further evaluation. \n\nStatins and similar drugs modify circulating blood factors such as cholesterol, hormones and metabolites which result in the exposure of cells to an environment that may alter the chances of a cancer developing. We want to determine whether such changes to the body\u2019s metabolic environment also influences the likelihood of developing and dying from head and neck cancer.\n\nResearch approach\n\n1) Analyse large datasets of people with head and neck cancer, to determine if statins and similar drugs causally protect against cancer development and progression.\n\n2) Explore how changes in cholesterol, hormones and metabolite levels might mechanistically prevent head and neck cancer using laboratory studies.\n\n3) Identify potential drug targets for prevention or therapy in head and neck cancer.\n\nImpact\n\nThis project will investigate the link between changes to the body\u2019s cholesterol, hormones and metabolite levels and head and neck cancer. This could help inform targeted cancer screening, prevention and intervention for these patients.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Carcinoma, Squamous Cell","Cholesterol","Head and Neck Neoplasms","Humans","Hydroxymethylglutaryl-CoA Reductase Inhibitors","Metabolomics"]}
{"id":"360G-Wellcome-220528_Z_20_Z","title":"Our Health Matters","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220528/Z/20/Z","description":"This 12-month pilot project would test how we can use our innovative journalistic approach to find more effective, scalable ways to engage diverse audiences around health issues and research. The opportunity for collaboration with Wellcome will bring together our expertise in local engagement and community-led investigations across the UK with our global health track record of fact-based reporting and expert, external networks. A new Bureau Local health team will explore and test issues that impact nationally and globally with local communities to find connections.\n\nIf successful, an immediate outcome would be that we\u2019d improved relevance and relatability around a critical health topic (and research around it) for affected communities and the wider public across the UK. For the longer term, our project would strengthen understanding of how engaged journalism can support a two-way flow of communication from and to affected communities. We would hope the findings from this project could support a collaborative framework for journalists, communities and researchers to use local investigative journalism to connect and engage people more effectively with health issues.\n","plannedDates":[{"endDate":"2021-11-01T00:00:00+00:00","startDate":"2020-11-02T00:00:00+00:00","startDateDateOnly":"2020-11-02","endDateDateOnly":"2021-11-01"}],"amountAwarded":125000,"Financial Year":"2019/20","Lead Applicant":"Ms Megan Lucero","grantProgramme":[{"title":"Discretionary Award - Public Engagement","title_keyword":"Discretionary Award - Public Engagement"}],"Applicant Surname":"Lucero","Partnership Value":125000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Bureau-of-Investigative-Journalism","name":"Bureau of Investigative Journalism","addressCountry":"United Kingdom","id_and_name":"[\"Bureau of Investigative Journalism\", \"360G-Wellcome-ORG:Bureau-of-Investigative-Journalism\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Bureau-of-Investigative-Journalism","name":"Bureau of Investigative Journalism"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Our Health Matters This 12-month pilot project would test how we can use our innovative journalistic approach to find more effective, scalable ways to engage diverse audiences around health issues and research. The opportunity for collaboration with Wellcome will bring together our expertise in local engagement and community-led investigations across the UK with our global health track record of fact-based reporting and expert, external networks. A new Bureau Local health team will explore and test issues that impact nationally and globally with local communities to find connections.\n\nIf successful, an immediate outcome would be that we\u2019d improved relevance and relatability around a critical health topic (and research around it) for affected communities and the wider public across the UK. For the longer term, our project would strengthen understanding of how engaged journalism can support a two-way flow of communication from and to affected communities. We would hope the findings from this project could support a collaborative framework for journalists, communities and researchers to use local investigative journalism to connect and engage people more effectively with health issues.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Communication","Cooperative Behavior","Global Health","Humans","Pilot Projects","United Kingdom"]}
{"id":"360G-Wellcome-220527_Z_20_Z","title":"Exploiting Radiogenomics for Evaluating Intratumoural Heterogeneity and Therapy Response in Soft Tissue Sarcoma","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220527/Z/20/Z","description":"Soft tissue sarcomas (STS) are a rare group of cancers that can develop throughout the body. There are over 100 subtypes, which often exhibit different tissue compositions across a single tumour. STS tumours therefore behave variably to treatment, and predicting patient response to pre-operative therapy is challenging. Advancements in MRI provide insight into the behaviour of tumours without needing an invasive biopsy. However, we lack research comparing MRI with tumour tissue to allow confidence in MRI interpretation. This project seeks to gain a better understanding of the differences seen in STS, and establish if imaging can reflect the underlying biology of these differences. \n\n \n\nI aim to match image-guided sampling of multiple regions of STS tumours with molecular analysis. The analysis will investigate the DNA, RNA and proteins within the tumour tissues and how this relates to MRI. We will assess whether integrating molecular and imaging data can improve our understanding of whether tumours are responding to treatment. \n\n \n\nMy research will increase our understanding of the complex nature of STS and why distinct tumour regions behave differently. This will impact clinical practice by enhancing our ability to accurately measure and predict responses to pre-operative therapy and facilitate delivery of precision medicine.\n","plannedDates":[{"endDate":"2023-02-17T00:00:00+00:00","startDate":"2019-08-19T00:00:00+00:00","startDateDateOnly":"2019-08-19","endDateDateOnly":"2023-02-17"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Amani Arthur","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Arthur","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Institute-of-Cancer-Research","name":"Institute of Cancer Research","addressCountry":"United Kingdom","id_and_name":"[\"Institute of Cancer Research\", \"360G-Wellcome-ORG:Institute-of-Cancer-Research\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Institute-of-Cancer-Research","name":"Institute of Cancer Research"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Exploiting Radiogenomics for Evaluating Intratumoural Heterogeneity and Therapy Response in Soft Tissue Sarcoma Soft tissue sarcomas (STS) are a rare group of cancers that can develop throughout the body. There are over 100 subtypes, which often exhibit different tissue compositions across a single tumour. STS tumours therefore behave variably to treatment, and predicting patient response to pre-operative therapy is challenging. Advancements in MRI provide insight into the behaviour of tumours without needing an invasive biopsy. However, we lack research comparing MRI with tumour tissue to allow confidence in MRI interpretation. This project seeks to gain a better understanding of the differences seen in STS, and establish if imaging can reflect the underlying biology of these differences. \n\n \n\nI aim to match image-guided sampling of multiple regions of STS tumours with molecular analysis. The analysis will investigate the DNA, RNA and proteins within the tumour tissues and how this relates to MRI. We will assess whether integrating molecular and imaging data can improve our understanding of whether tumours are responding to treatment. \n\n \n\nMy research will increase our understanding of the complex nature of STS and why distinct tumour regions behave differently. This will impact clinical practice by enhancing our ability to accurately measure and predict responses to pre-operative therapy and facilitate delivery of precision medicine.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Magnetic Resonance Imaging","Precision Medicine","Sarcoma","Soft Tissue Neoplasms"]}
{"id":"360G-Wellcome-220526_Z_20_Z","title":"Electrifying Life Science","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220526/Z/20/Z","description":"The ability to image life lies at the heart of biology and medicine. Imaging the molecules of life leads directly to discoveries since they can then be understood in atomic detail. For molecular imaging, electrons give more signal for less damage than X-rays, as demonstrated by the current success of single-particle electron cryomicroscopy. The key recent breakthrough underpinning this technology was the development of direct electron detectors for cryoEM, based on silicon computer chip technology from the 1990s. The promise of using electrons in structural biology more broadly is still held back by several technological hurdles. Here we propose a major cross disciplinary effort to develop new technologies that use electrons to revolutionise biology. There are three components: AMPLUS \u2013 using electrons to visualise proteins inside cells, (electron cryotomography) at unprecedented resolution, cryoEM100 \u2013 a ten-fold cheaper purpose-built cryomicroscope that will democratise single particle imaging, and HEXI \u2013 a project that will create a world-leading combined X-ray and electron beamline, enabling structure determination from crystals ranging from the smallest that exhibit Bragg diffraction up to those useable at a microfocus X-ray beamline.\n","plannedDates":[{"endDate":"2025-11-30T00:00:00+00:00","startDate":"2020-12-01T00:00:00+00:00","startDateDateOnly":"2020-12-01","endDateDateOnly":"2025-11-30"}],"amountAwarded":19231767,"Financial Year":"2019/20","Lead Applicant":"Prof James Naismith","grantProgramme":[{"title":"Strategic Support: Science","title_keyword":"Strategic Support: Science"}],"Applicant Surname":"Naismith","Partnership Value":19231767,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Mark Basham, Prof David Stuart, Dr Christopher Russo, Dr Gwyndaf Evans, Dr Richard Henderson","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Rosalind-Franklin-Institute","name":"Rosalind Franklin Institute","addressCountry":"United Kingdom","id_and_name":"[\"Rosalind Franklin Institute\", \"360G-Wellcome-ORG:Rosalind-Franklin-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Rosalind-Franklin-Institute","name":"Rosalind Franklin Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Electrifying Life Science The ability to image life lies at the heart of biology and medicine. Imaging the molecules of life leads directly to discoveries since they can then be understood in atomic detail. For molecular imaging, electrons give more signal for less damage than X-rays, as demonstrated by the current success of single-particle electron cryomicroscopy. The key recent breakthrough underpinning this technology was the development of direct electron detectors for cryoEM, based on silicon computer chip technology from the 1990s. The promise of using electrons in structural biology more broadly is still held back by several technological hurdles. Here we propose a major cross disciplinary effort to develop new technologies that use electrons to revolutionise biology. There are three components: AMPLUS \u2013 using electrons to visualise proteins inside cells, (electron cryotomography) at unprecedented resolution, cryoEM100 \u2013 a ten-fold cheaper purpose-built cryomicroscope that will democratise single particle imaging, and HEXI \u2013 a project that will create a world-leading combined X-ray and electron beamline, enabling structure determination from crystals ranging from the smallest that exhibit Bragg diffraction up to those useable at a microfocus X-ray beamline.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cryoelectron Microscopy","Electrons","Proteins"]}
{"id":"360G-Wellcome-220526_B_20_Z","title":"Electrifying Life Science","Region":"South West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220526/B/20/Z","description":"The ability to image life lies at the heart of biology and medicine. Imaging the molecules of life leads directly to discoveries since they can then be understood in atomic detail. For molecular imaging, electrons give more signal for less damage than X-rays, as demonstrated by the current success of single-particle electron cryomicroscopy. The key recent breakthrough underpinning this technology was the development of direct electron detectors for cryoEM, based on silicon computer chip technology from the 1990s. The promise of using electrons in structural biology more broadly is still held back by several technological hurdles. Here we propose a major cross disciplinary effort to develop new technologies that use electrons to revolutionise biology. There are three components: AMPLUS \u2013 using electrons to visualise proteins inside cells, (electron cryotomography) at unprecedented resolution, cryoEM100 \u2013 a ten-fold cheaper purpose-built cryomicroscope that will democratise single particle imaging, and HEXI \u2013 a project that will create a world-leading combined X-ray and electron beamline, enabling structure determination from crystals ranging from the smallest that exhibit Bragg diffraction up to those useable at a microfocus X-ray beamline.\n","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":1783532,"Financial Year":"2019/20","Lead Applicant":"Dr Richard Henderson","grantProgramme":[{"title":"Strategic Support: Science","title_keyword":"Strategic Support: Science"}],"Applicant Surname":"Henderson","Partnership Value":1783532,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:UKRI-MRC","name":"UKRI-MRC","addressCountry":"United Kingdom","id_and_name":"[\"UKRI-MRC\", \"360G-Wellcome-ORG:UKRI-MRC\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:UKRI-MRC","name":"UKRI-MRC"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Electrifying Life Science The ability to image life lies at the heart of biology and medicine. Imaging the molecules of life leads directly to discoveries since they can then be understood in atomic detail. For molecular imaging, electrons give more signal for less damage than X-rays, as demonstrated by the current success of single-particle electron cryomicroscopy. The key recent breakthrough underpinning this technology was the development of direct electron detectors for cryoEM, based on silicon computer chip technology from the 1990s. The promise of using electrons in structural biology more broadly is still held back by several technological hurdles. Here we propose a major cross disciplinary effort to develop new technologies that use electrons to revolutionise biology. There are three components: AMPLUS \u2013 using electrons to visualise proteins inside cells, (electron cryotomography) at unprecedented resolution, cryoEM100 \u2013 a ten-fold cheaper purpose-built cryomicroscope that will democratise single particle imaging, and HEXI \u2013 a project that will create a world-leading combined X-ray and electron beamline, enabling structure determination from crystals ranging from the smallest that exhibit Bragg diffraction up to those useable at a microfocus X-ray beamline.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cryoelectron Microscopy","Electrons","Proteins"]}
{"id":"360G-Wellcome-220526_A_20_Z","title":"Electrifying Life Science","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220526/A/20/Z","description":"The ability to image life lies at the heart of biology and medicine. Imaging the molecules of life leads directly to discoveries since they can then be understood in atomic detail. For molecular imaging, electrons give more signal for less damage than X-rays, as demonstrated by the current success of single-particle electron cryomicroscopy. The key recent breakthrough underpinning this technology was the development of direct electron detectors for cryoEM, based on silicon computer chip technology from the 1990s. The promise of using electrons in structural biology more broadly is still held back by several technological hurdles. Here we propose a major cross disciplinary effort to develop new technologies that use electrons to revolutionise biology. There are three components: AMPLUS \u2013 using electrons to visualise proteins inside cells, (electron cryotomography) at unprecedented resolution, cryoEM100 \u2013 a ten-fold cheaper purpose-built cryomicroscope that will democratise single particle imaging, and HEXI \u2013 a project that will create a world-leading combined X-ray and electron beamline, enabling structure determination from crystals ranging from the smallest that exhibit Bragg diffraction up to those useable at a microfocus X-ray beamline.\n","plannedDates":[{"endDate":"2025-11-30T00:00:00+00:00","startDate":"2020-12-01T00:00:00+00:00","startDateDateOnly":"2020-12-01","endDateDateOnly":"2025-11-30"}],"amountAwarded":3916135,"Financial Year":"2019/20","Lead Applicant":"Prof David Stuart","grantProgramme":[{"title":"Strategic Support: Science","title_keyword":"Strategic Support: Science"}],"Applicant Surname":"Stuart","Partnership Value":3916135,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Diamond-Light-Source-Ltd","name":"Diamond Light Source Ltd","addressCountry":"United Kingdom","id_and_name":"[\"Diamond Light Source Ltd\", \"360G-Wellcome-ORG:Diamond-Light-Source-Ltd\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Diamond-Light-Source-Ltd","name":"Diamond Light Source Ltd"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Electrifying Life Science The ability to image life lies at the heart of biology and medicine. Imaging the molecules of life leads directly to discoveries since they can then be understood in atomic detail. For molecular imaging, electrons give more signal for less damage than X-rays, as demonstrated by the current success of single-particle electron cryomicroscopy. The key recent breakthrough underpinning this technology was the development of direct electron detectors for cryoEM, based on silicon computer chip technology from the 1990s. The promise of using electrons in structural biology more broadly is still held back by several technological hurdles. Here we propose a major cross disciplinary effort to develop new technologies that use electrons to revolutionise biology. There are three components: AMPLUS \u2013 using electrons to visualise proteins inside cells, (electron cryotomography) at unprecedented resolution, cryoEM100 \u2013 a ten-fold cheaper purpose-built cryomicroscope that will democratise single particle imaging, and HEXI \u2013 a project that will create a world-leading combined X-ray and electron beamline, enabling structure determination from crystals ranging from the smallest that exhibit Bragg diffraction up to those useable at a microfocus X-ray beamline.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cryoelectron Microscopy","Electrons","Proteins"]}
{"id":"360G-Wellcome-220523_Z_20_Z","title":"Analysis of the interplay between replication stress and immune responses in SMARCA4 and ARID1A mutant cells","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220523/Z/20/Z","description":"Cancer cells are growing and dividing very rapidly. Rapid division is stressful, and can result in signals being sent to the immune system. In this case, therapies that help the immune system (immunotherapy) to attack the cancer cells are very useful. The SWI/SNF complex is a set of proteins in the cell that help to protect the DNA from stress caused by rapid division. This complex is frequently lost in cancer cells. Here, I will investigate whether by helping cells deal with the stress of dividing, the SWI/SNF complex prevents the immune system from turning on. By understanding this, we can have a better idea about which cancers will respond best to immunotherapy, and what other therapies might work well in combination with immunotherapy for these cancers.\n","plannedDates":[{"endDate":"2023-02-09T00:00:00+00:00","startDate":"2019-09-02T00:00:00+00:00","startDateDateOnly":"2019-09-02","endDateDateOnly":"2023-02-09"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Nawa Amin","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Amin","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Institute-of-Cancer-Research","name":"Institute of Cancer Research","addressCountry":"United Kingdom","id_and_name":"[\"Institute of Cancer Research\", \"360G-Wellcome-ORG:Institute-of-Cancer-Research\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Institute-of-Cancer-Research","name":"Institute of Cancer Research"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Analysis of the interplay between replication stress and immune responses in SMARCA4 and ARID1A mutant cells Cancer cells are growing and dividing very rapidly. Rapid division is stressful, and can result in signals being sent to the immune system. In this case, therapies that help the immune system (immunotherapy) to attack the cancer cells are very useful. The SWI/SNF complex is a set of proteins in the cell that help to protect the DNA from stress caused by rapid division. This complex is frequently lost in cancer cells. Here, I will investigate whether by helping cells deal with the stress of dividing, the SWI/SNF complex prevents the immune system from turning on. By understanding this, we can have a better idea about which cancers will respond best to immunotherapy, and what other therapies might work well in combination with immunotherapy for these cancers.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["DNA Replication","DNA-Binding Proteins","Humans","Immunotherapy","Neoplasms","Transcription Factors"]}
{"id":"360G-Wellcome-220522_Z_20_Z","title":"Publishing WHO R&D Roadmaps","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220522/Z/20/Z","description":" \n\nBackground Information:\n\nThe research and development (R & D) Blueprint is a global strategy and preparedness plan to address highly infectious diseases and strengthen the emergency response by bringing medical technologies to patients during epidemics. For each of these priority diseases, WHO is coordinating the elaboration of R & D roadmaps, to serve as collaborative frameworks underpinning strategic goals and research priority areas to accelerate the development of diagnostics, therapeutics and vaccines to prevent and control severe emerging diseases. R & D roadmaps have been developed for 4 priority diseases with epidemic potential: Crimean-Congo hemorrhagic fever and Ebola/Marburg virus diseases, Lassa Fever and Nipah virus disease.\n\nKey Goals:\n\nEffective publication and dissemination of these roadmaps, together with communication and advocacy, will help to achieve the R & D blueprint and roadmaps goals.\n\nHow the funds will be used:\n\nTo support the publishing costs of 4 of the Research and Development (R & D) Blueprint Roadmaps.","plannedDates":[{"endDate":"2020-08-02T00:00:00+00:00","startDate":"2020-02-03T00:00:00+00:00","startDateDateOnly":"2020-02-03","endDateDateOnly":"2020-08-02"}],"amountAwarded":49836,"Financial Year":"2019/20","Lead Applicant":"Dr Marie-Pierre Preziosi","grantProgramme":[{"title":"Discretionary Award - Vaccines","title_keyword":"Discretionary Award - Vaccines"}],"Applicant Surname":"Preziosi","Partnership Value":49836,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:World-Health-Organization-Switzerland","name":"World Health Organization, Switzerland","addressCountry":"Switzerland","id_and_name":"[\"World Health Organization, Switzerland\", \"360G-Wellcome-ORG:World-Health-Organization-Switzerland\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:World-Health-Organization-Switzerland","name":"World Health Organization, Switzerland"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Publishing WHO R&D Roadmaps  \n\nBackground Information:\n\nThe research and development (R & D) Blueprint is a global strategy and preparedness plan to address highly infectious diseases and strengthen the emergency response by bringing medical technologies to patients during epidemics. For each of these priority diseases, WHO is coordinating the elaboration of R & D roadmaps, to serve as collaborative frameworks underpinning strategic goals and research priority areas to accelerate the development of diagnostics, therapeutics and vaccines to prevent and control severe emerging diseases. R & D roadmaps have been developed for 4 priority diseases with epidemic potential: Crimean-Congo hemorrhagic fever and Ebola/Marburg virus diseases, Lassa Fever and Nipah virus disease.\n\nKey Goals:\n\nEffective publication and dissemination of these roadmaps, together with communication and advocacy, will help to achieve the R & D blueprint and roadmaps goals.\n\nHow the funds will be used:\n\nTo support the publishing costs of 4 of the Research and Development (R & D) Blueprint Roadmaps.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biomedical Research","Epidemics","Hemorrhagic Fever, Crimean","Hemorrhagic Fever, Ebola","Humans","Lassa Fever"]}
{"id":"360G-Wellcome-220521_Z_20_Z","title":"International Research Management Staff Development Programme","Region":"Scotland","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220521/Z/20/Z","description":"This project is based on an invitation by the African Academy of Sciences (AAS) to the Association of Research Managers and Administrators (ARMA) in the UK, to contribute to their ongoing ReMPro programme. Drawing on their expertise and strengths as an association of research managers and administrators, ARMA will support ReMPro's strand on developing individual capacity of research management staff through various activities like, needs analysis and mapping workshops and implementation of an International Research Management Staff Development programme. ARMA is seeking funding to reinforce existing support to the project, specifically towards the International Research Management Staff Development Programme and personnel costs for the second phase.  \n\n1. International Research Management Staff Development Programme -  aimed at strengthening capacity of research management staff in Africa, this will be an exchange programme between African and UK institutions. Participants will be drawn from diverse institutions through a competitive application process. \n\n2. Personnel costs - to implement and oversee the activities, ARMA has employed a programme manager with a projected budget covering 12 months. However, their is a clear need to develop and implement outcomes from the mapping workshops. This will be carried out in the second phase of the programme.\n\n \n","plannedDates":[{"endDate":"2021-05-19T00:00:00+00:00","startDate":"2020-05-20T00:00:00+00:00","startDateDateOnly":"2020-05-20","endDateDateOnly":"2021-05-19"}],"amountAwarded":120000,"Financial Year":"2019/20","Lead Applicant":"Ms Eva Kagiri-Kalanzi","grantProgramme":[{"title":"Discretionary Award - REiAA","title_keyword":"Discretionary Award - REiAA"}],"Applicant Surname":"Kagiri-Kalanzi","Partnership Value":120000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Association-of-Research-Managers-and-Administrators","name":"Association of Research Managers and Administrators","addressCountry":"United Kingdom","id_and_name":"[\"Association of Research Managers and Administrators\", \"360G-Wellcome-ORG:Association-of-Research-Managers-and-Administrators\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Association-of-Research-Managers-and-Administrators","name":"Association of Research Managers and Administrators"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"International Research Management Staff Development Programme This project is based on an invitation by the African Academy of Sciences (AAS) to the Association of Research Managers and Administrators (ARMA) in the UK, to contribute to their ongoing ReMPro programme. Drawing on their expertise and strengths as an association of research managers and administrators, ARMA will support ReMPro's strand on developing individual capacity of research management staff through various activities like, needs analysis and mapping workshops and implementation of an International Research Management Staff Development programme. ARMA is seeking funding to reinforce existing support to the project, specifically towards the International Research Management Staff Development Programme and personnel costs for the second phase.  \n\n1. International Research Management Staff Development Programme -  aimed at strengthening capacity of research management staff in Africa, this will be an exchange programme between African and UK institutions. Participants will be drawn from diverse institutions through a competitive application process. \n\n2. Personnel costs - to implement and oversee the activities, ARMA has employed a programme manager with a projected budget covering 12 months. However, their is a clear need to develop and implement outcomes from the mapping workshops. This will be carried out in the second phase of the programme.\n\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa","Africa South of the Sahara","Capacity Building","Humans","International Cooperation","Program Evaluation","United Kingdom"]}
{"id":"360G-Wellcome-220520_Z_20_Z","title":"Wellcome support for Understanding Animal Research","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220520/Z/20/Z","description":"Support for UAR activities as per uploaded document\n","plannedDates":[{"endDate":"2023-02-21T00:00:00+00:00","startDate":"2020-02-21T00:00:00+00:00","startDateDateOnly":"2020-02-21","endDateDateOnly":"2023-02-21"}],"amountAwarded":75000,"Financial Year":"2019/20","Lead Applicant":"Ms Wendy Jarrett","grantProgramme":[{"title":"Discretionary Award - Policy ","title_keyword":"Discretionary Award - Policy "}],"Applicant Surname":"Jarrett","Partnership Value":75000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Understanding-Animal-Research","name":"Understanding Animal Research","addressCountry":"United Kingdom","id_and_name":"[\"Understanding Animal Research\", \"360G-Wellcome-ORG:Understanding-Animal-Research\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Understanding-Animal-Research","name":"Understanding Animal Research"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Wellcome support for Understanding Animal Research Support for UAR activities as per uploaded document\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animal Experimentation","Animal Welfare","Animals","Animals, Laboratory","Humans"]}
{"id":"360G-Wellcome-220518_Z_20_Z","title":"The Cambridge History of Medicine","Region":"East of England","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220518/Z/20/Z","description":"This application is for support to develop a proposal for The Cambridge History of Medicine in six volumes. As General Editor, I will meet with a team of a dozen volume editors at a series of workshops to ask fundamental questions about what the history of medicine is, what it should be, and how best to represent it in these books.\n","plannedDates":[{"endDate":"2023-01-31T00:00:00+00:00","startDate":"2021-02-01T00:00:00+00:00","startDateDateOnly":"2021-02-01","endDateDateOnly":"2023-01-31"}],"amountAwarded":96402,"Financial Year":"2019/20","Lead Applicant":"Prof Lauren Kassell","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Kassell","Partnership Value":96402,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The Cambridge History of Medicine This application is for support to develop a proposal for The Cambridge History of Medicine in six volumes. As General Editor, I will meet with a team of a dozen volume editors at a series of workshops to ask fundamental questions about what the history of medicine is, what it should be, and how best to represent it in these books.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["History, 20th Century"]}
{"id":"360G-Wellcome-220517_Z_20_Z","title":"An integrative approach for improving the immunization of horses for the production of antivenoms","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220517/Z/20/Z","description":"Animal-derived antivenoms are the mainstay in the therapy of snakebite envenoming. There is an urgent need to develop knowledge-based protocols for the immunization of horses, as this key aspect of production has lacked research and innovation. This project is aimed at developing protocols for the management of horses used for immunization with venoms in a pilot farm. The following aspects will be investigated: (1) Evaluation of feeding protocols; (2) veterinary care and management aimed at minimizing the deleterious effects of venoms; (3) selection of the most appropriate adjuvants for immunization and development of new immunization schemes for generating high antibody titers; (4) design of bleeding protocols providing a high yield of plasma while not affecting the overall condition of horses. The project is also aimed at selecting the best combination of venoms from African snakes in order to generate a polyspecific antivenom of wide neutralizing coverage, as well as to device ways to improve the antibody titers against poorly immunogenic low molecular mass neurotoxins from snake venoms. In order to apply the principle of 3Rs (Replacement, Reduction and Refinement) in the assessment of antivenom potency, in vitro tests will be evaluated for their correlation with in vivo toxicity assays.     \n \n","plannedDates":[{"endDate":"2024-11-01T00:00:00+00:00","startDate":"2020-11-02T00:00:00+00:00","startDateDateOnly":"2020-11-02","endDateDateOnly":"2024-11-01"}],"amountAwarded":1987486,"Financial Year":"2019/20","Lead Applicant":"Dr Guillermo Le\u00f3n","grantProgramme":[{"title":"Discretionary Award - Snakebite","title_keyword":"Discretionary Award - Snakebite"}],"Applicant Surname":"Le\u00f3n","Partnership Value":1987486,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Prof Jos\u00e9 Mar\u00eda Guti\u00e9rrez","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Fundaci\u00f3-UCR","name":"Fundaci\u00f3 UCR","addressCountry":"Costa Rica","id_and_name":"[\"Fundaci\\u00f3 UCR\", \"360G-Wellcome-ORG:Fundaci\\u00f3-UCR\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Fundaci\u00f3-UCR","name":"Fundaci\u00f3 UCR"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"An integrative approach for improving the immunization of horses for the production of antivenoms Animal-derived antivenoms are the mainstay in the therapy of snakebite envenoming. There is an urgent need to develop knowledge-based protocols for the immunization of horses, as this key aspect of production has lacked research and innovation. This project is aimed at developing protocols for the management of horses used for immunization with venoms in a pilot farm. The following aspects will be investigated: (1) Evaluation of feeding protocols; (2) veterinary care and management aimed at minimizing the deleterious effects of venoms; (3) selection of the most appropriate adjuvants for immunization and development of new immunization schemes for generating high antibody titers; (4) design of bleeding protocols providing a high yield of plasma while not affecting the overall condition of horses. The project is also aimed at selecting the best combination of venoms from African snakes in order to generate a polyspecific antivenom of wide neutralizing coverage, as well as to device ways to improve the antibody titers against poorly immunogenic low molecular mass neurotoxins from snake venoms. In order to apply the principle of 3Rs (Replacement, Reduction and Refinement) in the assessment of antivenom potency, in vitro tests will be evaluated for their correlation with in vivo toxicity assays.     \n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Antivenins","Horses","Snake Bites"]}
{"id":"360G-Wellcome-220514_Z_20_Z","title":"Proof-of-Concept for a5-GABAAR PAMs in the treatment of psychosis\u2019","Region":"Wales","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220514/Z/20/Z","description":"Recent evidence suggests that a part of the brain called the hippocampus is responsible for\nthe increase in dopamine in a different part of the brain, the striatum, known to cause\npsychosis. Our hypothesis is that by attenuating activity within the hippocampus, we will then\nbe able to reduce the increase in dopamine associated with psychosis. In order to do this,\nwe plan to target the GABA chemical signalling pathway which inhibits nerve cell excitability.\nMore specifically, we aim to increase the inhibitory actions of the so-called alpha5-GABAAR\nprotein, which is highly expressed within the hippocampus and is therefore ideally placed to\ncontrol overall hippocampal activity. In this proposal, we will identify molecules that\nselectively enhance the function of GABA at alpha5-GABAARs and then test representative\ncompounds in an animal model of schizophrenia to see if they do indeed attenuate\nincreased dopamine activity.","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":500971,"Financial Year":"2019/20","Lead Applicant":"Prof John Atack","grantProgramme":[{"title":"Innovator Award","title_keyword":"Innovator Award"}],"Applicant Surname":"Atack","Partnership Value":500971,"Approval Committee":"Innovator Awards Advisory Group","Other Applicant(s)":"Prof Jeremy Lambert, Prof Simon Ward, Dr Olivera Grubisha","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University","addressCountry":"United Kingdom","id_and_name":"[\"Cardiff University\", \"360G-Wellcome-ORG:Cardiff-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Proof-of-Concept for a5-GABAAR PAMs in the treatment of psychosis\u2019 Recent evidence suggests that a part of the brain called the hippocampus is responsible for\nthe increase in dopamine in a different part of the brain, the striatum, known to cause\npsychosis. Our hypothesis is that by attenuating activity within the hippocampus, we will then\nbe able to reduce the increase in dopamine associated with psychosis. In order to do this,\nwe plan to target the GABA chemical signalling pathway which inhibits nerve cell excitability.\nMore specifically, we aim to increase the inhibitory actions of the so-called alpha5-GABAAR\nprotein, which is highly expressed within the hippocampus and is therefore ideally placed to\ncontrol overall hippocampal activity. In this proposal, we will identify molecules that\nselectively enhance the function of GABA at alpha5-GABAARs and then test representative\ncompounds in an animal model of schizophrenia to see if they do indeed attenuate\nincreased dopamine activity.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Disease Models, Animal","Dopamine","GABAergic Neurons","Hippocampus","Schizophrenia","gamma-Aminobutyric Acid"]}
{"id":"360G-Wellcome-220513_Z_20_Z","title":"Evidence Accelerator - Employee Health","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220513/Z/20/Z","description":"Over 30m days are lost to work-related ill health annually in the UK. Of all employers\u2019 health-related investments, only 5.6% are being used by employees and under 15% are evidence-based. \n\nOur aim? \n\nDevelop, test, and scale an \u2018Evidence Accelerator\u2019 that bridges the gap between science, research and the workplace. Using design methods to translate evidence into action, with employers as the bridge, it\u2019ll provide ways marginalised employees can access, use and respond to scientific health research and improve their health.\n\n \n\nWe will\n\n\n \n narrow in on key mission areas where under-utilised EVIDENCE shows most promise to positively impact marginalised workers\u2019 health, (e.g. mental, musculoskeletal)\n \n \n ENGAGE cohorts of employers across industries with marginalised workers most susceptible to those health issues\n \n \n prototype and test a wide range of design-led and evidence-based workplace interventions to ACCELERATE the flow of evidence into the workplace\n \n \n explore which offer demonstrable positive impact on workers and organisations as a result of their involvement, and which show most promise of a model that can SUSTAIN\n \n\n\n \n\nSuccess means: \n\n\n \n Marginalised workers are accessing, using, responding to health research and truly improving their health and wellbeing\n \n \n More researchers and employers engaged in informing evidence-based, design-led workplace interventions \n \n \n Sustainable operating and business model \n \n\n","plannedDates":[{"endDate":"2021-12-27T00:00:00+00:00","startDate":"2020-08-25T00:00:00+00:00","startDateDateOnly":"2020-08-25","endDateDateOnly":"2021-12-27"}],"amountAwarded":497900,"Financial Year":"2019/20","Lead Applicant":"Ms Abi Freeman","grantProgramme":[{"title":"Discretionary Award - Public Engagement","title_keyword":"Discretionary Award - Public Engagement"}],"Applicant Surname":"Freeman","Partnership Value":497900,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Brink","name":"Brink","addressCountry":"United Kingdom","id_and_name":"[\"Brink\", \"360G-Wellcome-ORG:Brink\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Brink","name":"Brink"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Evidence Accelerator - Employee Health Over 30m days are lost to work-related ill health annually in the UK. Of all employers\u2019 health-related investments, only 5.6% are being used by employees and under 15% are evidence-based. \n\nOur aim? \n\nDevelop, test, and scale an \u2018Evidence Accelerator\u2019 that bridges the gap between science, research and the workplace. Using design methods to translate evidence into action, with employers as the bridge, it\u2019ll provide ways marginalised employees can access, use and respond to scientific health research and improve their health.\n\n \n\nWe will\n\n\n \n narrow in on key mission areas where under-utilised EVIDENCE shows most promise to positively impact marginalised workers\u2019 health, (e.g. mental, musculoskeletal)\n \n \n ENGAGE cohorts of employers across industries with marginalised workers most susceptible to those health issues\n \n \n prototype and test a wide range of design-led and evidence-based workplace interventions to ACCELERATE the flow of evidence into the workplace\n \n \n explore which offer demonstrable positive impact on workers and organisations as a result of their involvement, and which show most promise of a model that can SUSTAIN\n \n\n\n \n\nSuccess means: \n\n\n \n Marginalised workers are accessing, using, responding to health research and truly improving their health and wellbeing\n \n \n More researchers and employers engaged in informing evidence-based, design-led workplace interventions \n \n \n Sustainable operating and business model \n \n\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Occupational Health","United Kingdom","Workplace"]}
{"id":"360G-Wellcome-220509_Z_20_Z","title":"Determining the role of Phosphoinositide 3-kinase delta (PI3K\u03b4) in the pathogenesis and progression of COPD ","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220509/Z/20/Z","description":"Smoking and other inhaled toxins can cause chronic obstructive pulmonary disease (COPD). Periodic worsening of symptoms ('exacerbations') can lead to hospital admission or even death. Exacerbations are mostly driven by bacterial infections; a bug called non-typeable Haemophilus influenza (NTHi) is a common culprit. A protein called phosphoinositide 3-kinase delta (PI3K-delta) makes patients more susceptible to respiratory infections in several ways and may increase risk of COPD.\n\nUsing mice with normal or over-active PI3K-delta activity I will assess their susceptibility to developing COPD (using inhaled chemicals that cause COPD) and also NTHi infection (by infecting them with NTHi and seeing how they clear it). I will then give the mice a drug that reduces PI3K-delta activity to see if this has a protective effect on COPD development. I will interrogate samples from COPD patients for evidence of abnormal PI3K-delta activity. I will do this by 1) measuring activation of PI3K-delta in blood immune cells and 2) assessing protein levels of PI3K-delta and its downstream targets in lung tissue. \n\nMy work will offer insights into mechanisms underlying COPD development and potentially identify novel therapeutic targets for this disease. It will also shed light on whether PI3K-delta confers enhanced susceptibility to NTHi infection.\n","plannedDates":[{"endDate":"2022-09-30T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-09-30"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Zena Lam","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Lam","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield","addressCountry":"United Kingdom","id_and_name":"[\"University of Sheffield\", \"360G-Wellcome-ORG:University-of-Sheffield\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Determining the role of Phosphoinositide 3-kinase delta (PI3K\u03b4) in the pathogenesis and progression of COPD  Smoking and other inhaled toxins can cause chronic obstructive pulmonary disease (COPD). Periodic worsening of symptoms ('exacerbations') can lead to hospital admission or even death. Exacerbations are mostly driven by bacterial infections; a bug called non-typeable Haemophilus influenza (NTHi) is a common culprit. A protein called phosphoinositide 3-kinase delta (PI3K-delta) makes patients more susceptible to respiratory infections in several ways and may increase risk of COPD.\n\nUsing mice with normal or over-active PI3K-delta activity I will assess their susceptibility to developing COPD (using inhaled chemicals that cause COPD) and also NTHi infection (by infecting them with NTHi and seeing how they clear it). I will then give the mice a drug that reduces PI3K-delta activity to see if this has a protective effect on COPD development. I will interrogate samples from COPD patients for evidence of abnormal PI3K-delta activity. I will do this by 1) measuring activation of PI3K-delta in blood immune cells and 2) assessing protein levels of PI3K-delta and its downstream targets in lung tissue. \n\nMy work will offer insights into mechanisms underlying COPD development and potentially identify novel therapeutic targets for this disease. It will also shed light on whether PI3K-delta confers enhanced susceptibility to NTHi infection.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Haemophilus Infections","Haemophilus influenzae","Humans","Mice","Phosphatidylinositol 3-Kinases","Pulmonary Disease, Chronic Obstructive"]}
{"id":"360G-Wellcome-220506_Z_20_Z","title":"Evaluation of a heterologous, two-dose preventive Ebola vaccine for effectiveness and safety in the Democratic Republic of the Congo ","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220506/Z/20/Z","description":"A large-scale study in the Democratic Republic of Congo (DRC) to deliver Janssen's candidate Ebola vaccine regimen VAC52150 (Ad26.ZEBOV, MVA-BN-Filo). The vaccine Ad26.ZEBOV (5x1010 viral particles[vp]) will be given as the first dose and the vaccine MVA-BN-Filo (1x108 infectious units [Inf U]) will be given as the second dose 56 (-14 day +28 day) days later, to adults, and children aged 1year or over. Evaluation of this intervention will include the estimation of the effectiveness of the two-dose vaccine regimen to prevent Ebola Virus Disease (EVD) and a qualitative component of the understanding and perceptions of individuals of this study. The primary objective is to estimate the effectiveness of vaccination of the population with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen for the prevention of EVD in adults and children aged 1 year or above. The study sponsor will be the London School of Hygiene and Tropical Medicine (LSHTM). The study PI will be Professor Jean-Jacques Muyembe-Tamfum from the DRC Institut National de Recherche Biom\u00e9dicale (INRB).\n","plannedDates":[{"endDate":"2021-10-31T00:00:00+00:00","startDate":"2019-11-01T00:00:00+00:00","startDateDateOnly":"2019-11-01","endDateDateOnly":"2021-10-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Richard Hatchett IV","grantProgramme":[{"title":"DFID-Wellcome Epidemic Preparedness Grant","title_keyword":"DFID-Wellcome Epidemic Preparedness Grant"}],"Partnership Name":"Wellcome-DFID Epidemic Preparedness","Applicant Surname":"Hatchett IV","Partnership Value":1701696,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Coalition-for-Epidemic-Preparedness-Innovations-CEPI","name":"Coalition for Epidemic Preparedness Innovations (CEPI)","addressCountry":"Norway","id_and_name":"[\"Coalition for Epidemic Preparedness Innovations (CEPI)\", \"360G-Wellcome-ORG:Coalition-for-Epidemic-Preparedness-Innovations-CEPI\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Coalition-for-Epidemic-Preparedness-Innovations-CEPI","name":"Coalition for Epidemic Preparedness Innovations (CEPI)"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Evaluation of a heterologous, two-dose preventive Ebola vaccine for effectiveness and safety in the Democratic Republic of the Congo  A large-scale study in the Democratic Republic of Congo (DRC) to deliver Janssen's candidate Ebola vaccine regimen VAC52150 (Ad26.ZEBOV, MVA-BN-Filo). The vaccine Ad26.ZEBOV (5x1010 viral particles[vp]) will be given as the first dose and the vaccine MVA-BN-Filo (1x108 infectious units [Inf U]) will be given as the second dose 56 (-14 day +28 day) days later, to adults, and children aged 1year or over. Evaluation of this intervention will include the estimation of the effectiveness of the two-dose vaccine regimen to prevent Ebola Virus Disease (EVD) and a qualitative component of the understanding and perceptions of individuals of this study. The primary objective is to estimate the effectiveness of vaccination of the population with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen for the prevention of EVD in adults and children aged 1 year or above. The study sponsor will be the London School of Hygiene and Tropical Medicine (LSHTM). The study PI will be Professor Jean-Jacques Muyembe-Tamfum from the DRC Institut National de Recherche Biom\u00e9dicale (INRB).\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adolescent","Adult","Child","Child, Preschool","Clinical Protocols","Democratic Republic of the Congo","Disease Outbreaks","Ebola Vaccines","Ebolavirus","Hemorrhagic Fever, Ebola","Humans","Infant"]}
{"id":"360G-Wellcome-220506_Z_20_A","title":"Evaluation of a heterologous, two-dose preventive Ebola vaccine for effectiveness and safety in the Democratic Republic of the Congo ","Region":"International","currency":"GBP","awardDate":"2021-01-29T00:00:00+00:00","Internal ID":"220506/Z/20/A","description":"A large-scale study in the Democratic Republic of Congo (DRC) to deliver Janssen's candidate Ebola vaccine regimen VAC52150 (Ad26.ZEBOV, MVA-BN-Filo). The vaccine Ad26.ZEBOV (5x1010 viral particles[vp]) will be given as the first dose and the vaccine MVA-BN-Filo (1x108 infectious units [Inf U]) will be given as the second dose 56 (-14 day +28 day) days later, to adults, and children aged 1year or over. Evaluation of this intervention will include the estimation of the effectiveness of the two-dose vaccine regimen to prevent Ebola Virus Disease (EVD) and a qualitative component of the understanding and perceptions of individuals of this study. The primary objective is to estimate the effectiveness of vaccination of the population with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen for the prevention of EVD in adults and children aged 1 year or above. The study sponsor will be the London School of Hygiene and Tropical Medicine (LSHTM). The study PI will be Professor Jean-Jacques Muyembe-Tamfum from the DRC Institut National de Recherche Biom\u00e9dicale (INRB).\n","plannedDates":[{"endDate":"2021-10-31T00:00:00+00:00","startDate":"2019-11-01T00:00:00+00:00","startDateDateOnly":"2019-11-01","endDateDateOnly":"2021-10-31"}],"amountAwarded":4059969,"Financial Year":"2020/21","Lead Applicant":"Dr Richard Hatchett IV","grantProgramme":[{"title":"DFID-Wellcome Epidemic Preparedness Grant","title_keyword":"DFID-Wellcome Epidemic Preparedness Grant"}],"Partnership Name":"Wellcome-DFID Epidemic Preparedness","Applicant Surname":"Hatchett IV","Partnership Value":5358273,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Coalition-for-Epidemic-Preparedness-Innovations-CEPI","name":"Coalition for Epidemic Preparedness Innovations (CEPI)","addressCountry":"Norway","id_and_name":"[\"Coalition for Epidemic Preparedness Innovations (CEPI)\", \"360G-Wellcome-ORG:Coalition-for-Epidemic-Preparedness-Innovations-CEPI\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Coalition-for-Epidemic-Preparedness-Innovations-CEPI","name":"Coalition for Epidemic Preparedness Innovations (CEPI)"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Evaluation of a heterologous, two-dose preventive Ebola vaccine for effectiveness and safety in the Democratic Republic of the Congo  A large-scale study in the Democratic Republic of Congo (DRC) to deliver Janssen's candidate Ebola vaccine regimen VAC52150 (Ad26.ZEBOV, MVA-BN-Filo). The vaccine Ad26.ZEBOV (5x1010 viral particles[vp]) will be given as the first dose and the vaccine MVA-BN-Filo (1x108 infectious units [Inf U]) will be given as the second dose 56 (-14 day +28 day) days later, to adults, and children aged 1year or over. Evaluation of this intervention will include the estimation of the effectiveness of the two-dose vaccine regimen to prevent Ebola Virus Disease (EVD) and a qualitative component of the understanding and perceptions of individuals of this study. The primary objective is to estimate the effectiveness of vaccination of the population with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen for the prevention of EVD in adults and children aged 1 year or above. The study sponsor will be the London School of Hygiene and Tropical Medicine (LSHTM). The study PI will be Professor Jean-Jacques Muyembe-Tamfum from the DRC Institut National de Recherche Biom\u00e9dicale (INRB).\n","awardDateDateOnly":"2021-01-29","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adolescent","Adult","Child","Child, Preschool","Clinical Protocols","Democratic Republic of the Congo","Disease Outbreaks","Ebola Vaccines","Ebolavirus","Hemorrhagic Fever, Ebola","Humans","Infant"]}
{"id":"360G-Wellcome-220505_Z_20_Z","title":"A multi-centre, prospective, double-blinded, pilot study evaluating artificial intelligence driven automatic detection of proximal deep vein thrombosis (DVT).","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220505/Z/20/Z","description":"Deep vein thrombosis (DVT) is a condition where blood clots form in the veins\nof the body, most frequently the leg. It is a serious condition and if left untreated\nclots can move to the lungs, which can be fatal. Early diagnosis is vital. Normally\nthree steps are needed for a DVT diagnosis: a GP appointment; a hospital DVT\nclinic appointment and a leg ultrasound scan. This process should take only 4\nhours, but it often takes longer and therefore a precautionary anticoagulant\n(blood-thinning) drug is given. Nearly 90% of people investigated for a DVT have\nno clot.","plannedDates":[{"endDate":"2022-07-01T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2022-07-01"}],"amountAwarded":388023,"Financial Year":"2019/20","Lead Applicant":"Mr Fouad Al Noor","grantProgramme":[{"title":"Innovator Award","title_keyword":"Innovator Award"}],"Applicant Surname":"Noor","Partnership Value":388023,"Approval Committee":"Innovator Awards Advisory Group","Other Applicant(s)":"Miss Claire Foley, Ms Alison Deary, Mr Christopher Deane, Dr Nicola Curry, Mrs Helen Thomas","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:ThinkSono-Ltd","name":"ThinkSono Ltd","addressCountry":"United Kingdom","id_and_name":"[\"ThinkSono Ltd\", \"360G-Wellcome-ORG:ThinkSono-Ltd\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:ThinkSono-Ltd","name":"ThinkSono Ltd"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A multi-centre, prospective, double-blinded, pilot study evaluating artificial intelligence driven automatic detection of proximal deep vein thrombosis (DVT). Deep vein thrombosis (DVT) is a condition where blood clots form in the veins\nof the body, most frequently the leg. It is a serious condition and if left untreated\nclots can move to the lungs, which can be fatal. Early diagnosis is vital. Normally\nthree steps are needed for a DVT diagnosis: a GP appointment; a hospital DVT\nclinic appointment and a leg ultrasound scan. This process should take only 4\nhours, but it often takes longer and therefore a precautionary anticoagulant\n(blood-thinning) drug is given. Nearly 90% of people investigated for a DVT have\nno clot.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anticoagulants","Artificial Intelligence","Double-Blind Method","Humans","Pilot Projects","Prospective Studies","Ultrasonography","Venous Thrombosis"]}
{"id":"360G-Wellcome-220501_Z_20_Z","title":"\u2018Modified Outer Membrane Vesicles as safe, effective, low cost, multivalent vaccines against typhoid and paratyphoid fever and invasive non-typhoidal Salmonella infections\u2019","Region":"East of England","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220501/Z/20/Z","description":"Salmonella are bacteria that cause life-threatening infections in adults and children. These diseases co-exist in many geographical areas, especially in Low and Middle Income Countries. Therefore, a vaccine that can protect against all the major Salmonella infections would be highly desirable. The project will exploit the remarkable features of Outer Membrane Vesicles (mOMV) to deliver antigens from many species of Salmonella that cause disease in humans. mOMV are outer membrane blebs naturally shed by Gram-negative bacteria, including Salmonella. These bacteria can be genetically manipulated to increase mOMV production, to decrease adverse reactions and to include additional antigens. mOMV are easy and cheap to produce, strongly immunogenic and protective. The innovator award will therefore allow the development of a multivalent, easy to produce, low-cost, safe, effective Salmonella vaccine to be taken towards the end of preclinical experimentation.","plannedDates":[{"endDate":"2023-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2023-03-31"}],"amountAwarded":285881,"Financial Year":"2019/20","Lead Applicant":"Dr Pietro Mastroeni","grantProgramme":[{"title":"Innovator Award","title_keyword":"Innovator Award"}],"Applicant Surname":"Mastroeni","Partnership Value":285881,"Approval Committee":"Innovator Awards Advisory Group","Other Applicant(s)":"Dr Aldo Tagliabue, Mr Riccardo Baccheschi","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"\u2018Modified Outer Membrane Vesicles as safe, effective, low cost, multivalent vaccines against typhoid and paratyphoid fever and invasive non-typhoidal Salmonella infections\u2019 Salmonella are bacteria that cause life-threatening infections in adults and children. These diseases co-exist in many geographical areas, especially in Low and Middle Income Countries. Therefore, a vaccine that can protect against all the major Salmonella infections would be highly desirable. The project will exploit the remarkable features of Outer Membrane Vesicles (mOMV) to deliver antigens from many species of Salmonella that cause disease in humans. mOMV are outer membrane blebs naturally shed by Gram-negative bacteria, including Salmonella. These bacteria can be genetically manipulated to increase mOMV production, to decrease adverse reactions and to include additional antigens. mOMV are easy and cheap to produce, strongly immunogenic and protective. The innovator award will therefore allow the development of a multivalent, easy to produce, low-cost, safe, effective Salmonella vaccine to be taken towards the end of preclinical experimentation.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Bacterial Outer Membrane Proteins","Bacterial Vaccines","Extracellular Vesicles","Humans","Salmonella Infections"]}
{"id":"360G-Wellcome-220500_Z_20_Z","title":"Defining stem cell states competent to self-organize morphogen signalling centres in human neural tube organoids","Region":"Greater London","currency":"GBP","awardDate":"2020-04-22T00:00:00+00:00","Sponsor(s)":"Dr James Briscoe","Internal ID":"220500/Z/20/Z","description":"Groups of cells called 'organizers' release signals to induce cell fates during development. Remarkably, organizers can undergo \u2018self-organization\u2019 in 3D organoids. Understanding this phenomenon has profound implications for engineering and regenerating patterned tissues with bonafide cell-type complexity and 3D-architecture.\n \n\nMouse pluripotent stem cells (PSCs) can form neural-tube (NT) organoids. Timely retanoic acid (RA) addition induces scattered precursors that self-organize into a floorplate organizer, which drives ventral-dorsal patterning. I will create cognate human (h)NT organoids from single na\u00efve hPSCs. Exploiting advanced bioengineering technologies, I will isolate organoids from confounding inter-organoid communication and promote robust self-organisation. This interdisciplinary approach will enable me to probe previously inaccessible questions regarding complex mechanisms.\n\nUsing this system, I will study how cellular competence to express morphogens is subject to strict temporal regulation. Why is there a restricted window-of-competence for RA response, and how does this trigger self-organization? I will molecularly profile the transient competent state, functionally define the gene-regulatory basis for competence restriction, and investigate how molecular changes at this time serve as the basis for long-range self-organizing behaviour.\n\nThis will provide a 3D model for critical stages of human nervous system formation, and reveal how self-organization processes are adapted for human-specific developmental size and timing.\n","plannedDates":[{"endDate":"2024-07-31T00:00:00+00:00","startDate":"2020-08-01T00:00:00+00:00","startDateDateOnly":"2020-08-01","endDateDateOnly":"2024-07-31"}],"amountAwarded":300000,"Financial Year":"2019/20","Lead Applicant":"Dr Hannah Stuart","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Stuart","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:The-Francis-Crick-Institute","name":"The Francis Crick Institute","addressCountry":"United Kingdom","id_and_name":"[\"The Francis Crick Institute\", \"360G-Wellcome-ORG:The-Francis-Crick-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:The-Francis-Crick-Institute","name":"The Francis Crick Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Defining stem cell states competent to self-organize morphogen signalling centres in human neural tube organoids Groups of cells called 'organizers' release signals to induce cell fates during development. Remarkably, organizers can undergo \u2018self-organization\u2019 in 3D organoids. Understanding this phenomenon has profound implications for engineering and regenerating patterned tissues with bonafide cell-type complexity and 3D-architecture.\n \n\nMouse pluripotent stem cells (PSCs) can form neural-tube (NT) organoids. Timely retanoic acid (RA) addition induces scattered precursors that self-organize into a floorplate organizer, which drives ventral-dorsal patterning. I will create cognate human (h)NT organoids from single na\u00efve hPSCs. Exploiting advanced bioengineering technologies, I will isolate organoids from confounding inter-organoid communication and promote robust self-organisation. This interdisciplinary approach will enable me to probe previously inaccessible questions regarding complex mechanisms.\n\nUsing this system, I will study how cellular competence to express morphogens is subject to strict temporal regulation. Why is there a restricted window-of-competence for RA response, and how does this trigger self-organization? I will molecularly profile the transient competent state, functionally define the gene-regulatory basis for competence restriction, and investigate how molecular changes at this time serve as the basis for long-range self-organizing behaviour.\n\nThis will provide a 3D model for critical stages of human nervous system formation, and reveal how self-organization processes are adapted for human-specific developmental size and timing.\n","awardDateDateOnly":"2020-04-22","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cell Differentiation","Humans","Neurogenesis","Organoids","Pluripotent Stem Cells"]}
{"id":"360G-Wellcome-220497_Z_20_Z","title":"Spineless in the gut - intestinal function of the aryl hydrocarbon receptor from flies to mammals","Region":"Greater London","currency":"GBP","awardDate":"2020-04-22T00:00:00+00:00","Sponsor(s)":"Prof Brigitta Stockinger","Internal ID":"220497/Z/20/Z","description":"The aryl hydrocarbon receptor (AHR) has essential functions in the intestine, protecting mice from infection and cancer. However, the underlying mechanisms are still unclear as research has been hindered by the complex regulation and multiple feedback loops governing mammalian AHR. I will therefore use a simpler model system. Spineless, the homolog of AHR in Drosophila, binds the same DNA motif as AHR, but is regulated only on the gene expression level. My preliminary data suggest that Spineless may have similar functions to AHR, influencing epithelial regeneration and survival during infection. I will take advantage of this simpler pathway and the genetic tools and ease of manipulation in the fly in order to rapidly dissect how AHR/Spineless expression is regulated and to systematically analyse its target genes. I will first generate the necessary tools and then answer three main questions: what are the target genes of Spineless, how is Spineless gene expression regulated, and how does Spineless function in the context of intestinal infection. Results obtained from these experiments will be compared with existing data from the Stockinger group on AHR in mice to advance our understanding of intestinal physiology and the critical functions of AHR/Spineless that are conserved across species.\n \n","plannedDates":[{"endDate":"2024-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2024-08-31"}],"amountAwarded":300000,"Financial Year":"2019/20","Lead Applicant":"Dr Nicola Diny","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Diny","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:The-Francis-Crick-Institute","name":"The Francis Crick Institute","addressCountry":"United Kingdom","id_and_name":"[\"The Francis Crick Institute\", \"360G-Wellcome-ORG:The-Francis-Crick-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:The-Francis-Crick-Institute","name":"The Francis Crick Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Spineless in the gut - intestinal function of the aryl hydrocarbon receptor from flies to mammals The aryl hydrocarbon receptor (AHR) has essential functions in the intestine, protecting mice from infection and cancer. However, the underlying mechanisms are still unclear as research has been hindered by the complex regulation and multiple feedback loops governing mammalian AHR. I will therefore use a simpler model system. Spineless, the homolog of AHR in Drosophila, binds the same DNA motif as AHR, but is regulated only on the gene expression level. My preliminary data suggest that Spineless may have similar functions to AHR, influencing epithelial regeneration and survival during infection. I will take advantage of this simpler pathway and the genetic tools and ease of manipulation in the fly in order to rapidly dissect how AHR/Spineless expression is regulated and to systematically analyse its target genes. I will first generate the necessary tools and then answer three main questions: what are the target genes of Spineless, how is Spineless gene expression regulated, and how does Spineless function in the context of intestinal infection. Results obtained from these experiments will be compared with existing data from the Stockinger group on AHR in mice to advance our understanding of intestinal physiology and the critical functions of AHR/Spineless that are conserved across species.\n \n","awardDateDateOnly":"2020-04-22","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Drosophila","Drosophila Proteins","Drosophila melanogaster","Intestinal Mucosa","Intestines","Mice","Receptors, Aryl Hydrocarbon"]}
{"id":"360G-Wellcome-220488_Z_20_Z","title":"Using genetics, neurophysiology and longitudinal data to disentangle the complex relationship between sleep and mood disorders. ","Region":"Wales","currency":"GBP","awardDate":"2020-04-22T00:00:00+00:00","Sponsor(s)":"Prof Michael O'Donovan","Internal ID":"220488/Z/20/Z","description":"\nEmerging evidence suggests that sleep traits could be useful indicators of risk, relapse and potential treatment targets for mood disorders. However, the longitudinal and genetic relationships between sleep and mood disorders are complex and remain poorly understood. In this fellowship, I will address these gaps and build on my previous work by using cutting edge methods in genetic epidemiology, sleep neurophysiology and longitudinal data analysis.\n\n \n\nKey goals:\n\n \n\n(1) Determine the neurophysiological correlates of genetic liability to sleep traits and mood disorders using polysomnography \u2013 the gold-standard objective measure of sleep. Examining this in healthy populations will circumvent medication effects and bidirectionality, major confounds in existing polysomnography research.\n\n \n\n(2) Examine genetic and longitudinal relationships between adolescent sleep and depression to determine whether genetic variants for sleep traits in adult populations also influence sleep in younger populations, and delineate prospective associations between sleep and depression onset.\n\n \n\n(3) Investigate whether sleep disturbances can be used as an indicator of liability to relapse in bipolar disorder. Using in-depth longitudinal data from digital technologies will elucidate the role of sleep in predicting mood episodes in bipolar disorder.\n\n \n\nThis work will inform sleep interventions and further knowledge on the role of sleep in mood disorders.\n","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":300000,"Financial Year":"2019/20","Lead Applicant":"Dr Katie Swaden Lewis","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Swaden Lewis","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University","addressCountry":"United Kingdom","id_and_name":"[\"Cardiff University\", \"360G-Wellcome-ORG:Cardiff-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Using genetics, neurophysiology and longitudinal data to disentangle the complex relationship between sleep and mood disorders.  \nEmerging evidence suggests that sleep traits could be useful indicators of risk, relapse and potential treatment targets for mood disorders. However, the longitudinal and genetic relationships between sleep and mood disorders are complex and remain poorly understood. In this fellowship, I will address these gaps and build on my previous work by using cutting edge methods in genetic epidemiology, sleep neurophysiology and longitudinal data analysis.\n\n \n\nKey goals:\n\n \n\n(1) Determine the neurophysiological correlates of genetic liability to sleep traits and mood disorders using polysomnography \u2013 the gold-standard objective measure of sleep. Examining this in healthy populations will circumvent medication effects and bidirectionality, major confounds in existing polysomnography research.\n\n \n\n(2) Examine genetic and longitudinal relationships between adolescent sleep and depression to determine whether genetic variants for sleep traits in adult populations also influence sleep in younger populations, and delineate prospective associations between sleep and depression onset.\n\n \n\n(3) Investigate whether sleep disturbances can be used as an indicator of liability to relapse in bipolar disorder. Using in-depth longitudinal data from digital technologies will elucidate the role of sleep in predicting mood episodes in bipolar disorder.\n\n \n\nThis work will inform sleep interventions and further knowledge on the role of sleep in mood disorders.\n","awardDateDateOnly":"2020-04-22","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adolescent","Adult","Bipolar Disorder","Depression","Female","Humans","Longitudinal Studies","Mood Disorders","Polysomnography","Sleep","Sleep Wake Disorders"]}
{"id":"360G-Wellcome-220480_Z_20_Z","title":"Molecular mechanisms actin(g) on endosomal sorting","Region":"South West","currency":"GBP","awardDate":"2020-04-22T00:00:00+00:00","Sponsor(s)":"Dr Emmanuel Derivery","Internal ID":"220480/Z/20/Z","description":"The process of endosomal sorting, where internalised transmembrane proteins (cargoes) are sorted for lysosomal degradation or recycled back to the cell surface, maintains and regulates the cell surface proteome. Thus, endosomal sorting regulates numerous cellular processes including cell signalling.\n\nA fine-tuned amount of endosomal branched actin is required for recycling of cargoes from endosomes to the cell surface. Yet the mechanistic roles of endosomal actin in this process are not understood. Moreover, cargo such as the beta-2 adrenergic receptor (beta2-AR), signal in actin-decorated endosomal recycling domains, suggesting that endosomal actin plays a role in both endosomal recycling and signalling. My project aims to determine the mechanistic and physiological roles of endosomal actin.  \n\nI will focus on the major endosomal actin polymerisation machinery \u2013 the Arp2/3 activating Wiskott\u2013Aldrich syndrome protein and SCAR homolog (WASH) complex. I will investigate the intrinsic regulation of the WASH complex and how external factors it recruits, cumulatively regulate polymerisation of endosomal actin. Furthermore, I will develop new tools including blocking nanobodies and in vitro reconstitution. In combination, these multi-disciplinary approaches will establish a mechanistic and quantitative model of the role of endosomal actin in sorting and signalling. This will further our mechanistic understanding of endosomal recycling.\n","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":300000,"Financial Year":"2019/20","Lead Applicant":"Dr Kerrie McNally","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"McNally","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:UKRI-MRC","name":"UKRI-MRC","addressCountry":"United Kingdom","id_and_name":"[\"UKRI-MRC\", \"360G-Wellcome-ORG:UKRI-MRC\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:UKRI-MRC","name":"UKRI-MRC"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Molecular mechanisms actin(g) on endosomal sorting The process of endosomal sorting, where internalised transmembrane proteins (cargoes) are sorted for lysosomal degradation or recycled back to the cell surface, maintains and regulates the cell surface proteome. Thus, endosomal sorting regulates numerous cellular processes including cell signalling.\n\nA fine-tuned amount of endosomal branched actin is required for recycling of cargoes from endosomes to the cell surface. Yet the mechanistic roles of endosomal actin in this process are not understood. Moreover, cargo such as the beta-2 adrenergic receptor (beta2-AR), signal in actin-decorated endosomal recycling domains, suggesting that endosomal actin plays a role in both endosomal recycling and signalling. My project aims to determine the mechanistic and physiological roles of endosomal actin.  \n\nI will focus on the major endosomal actin polymerisation machinery \u2013 the Arp2/3 activating Wiskott\u2013Aldrich syndrome protein and SCAR homolog (WASH) complex. I will investigate the intrinsic regulation of the WASH complex and how external factors it recruits, cumulatively regulate polymerisation of endosomal actin. Furthermore, I will develop new tools including blocking nanobodies and in vitro reconstitution. In combination, these multi-disciplinary approaches will establish a mechanistic and quantitative model of the role of endosomal actin in sorting and signalling. This will further our mechanistic understanding of endosomal recycling.\n","awardDateDateOnly":"2020-04-22","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Actins","Animals","Endosomes","Humans","Polymerization","Signal Transduction","Wiskott-Aldrich Syndrome Protein"]}
{"id":"360G-Wellcome-220473_Z_20_Z","title":"Revealing microstructural pathology in Parkinson's disease with super-resolution MRI","Region":"Greater London","currency":"GBP","awardDate":"2020-04-22T00:00:00+00:00","Sponsor(s)":"Prof Paul Matthews","Internal ID":"220473/Z/20/Z","description":"Parkinson\u2019s disease (PD) is diagnosed by a clinical examination which typically comes 20 years after the initial symptoms. By this time approximately 70% of vulnerable dopaminergic neurons in the substantia nigra (SN) have already been lost. The nigrosomes (small clusters of dopaminergic cells in the SN) have differential histopathological features which make them ideal targets for detecting and monitoring PD.\n\nMRI is highly sensitive to the pathological iron accumulation in the nigrosomes, which is a hallmark of the earliest stages of PD, but quantitative imaging on this sub-millimetre scale is beyond the limits of traditional techniques. I have developed a non-traditional approach to MRI, based on super-resolution approaches from optical microscopy, which can surpass these limitations and rapidly generate quantitative images of the nigrosomes in vivo. I will develop this as an accurate measure of iron accumulation in PD.\n\nThe aims of this fellowship are:\n\n\n Producing accurate microstructural maps at sub-millimetre resolution\n Modelling and correcting for subject motion\n Testing the hypothesis that microstructural MRI measures in the nigrosomes distinguish PD subjects from healthy controls\n\n\n\nIf successful, this would enable PD diagnosis in its earliest stages, and maximise the likelihood of finding an effective therapy.\n","plannedDates":[{"endDate":"2024-06-30T00:00:00+00:00","startDate":"2020-07-01T00:00:00+00:00","startDateDateOnly":"2020-07-01","endDateDateOnly":"2024-06-30"}],"amountAwarded":300000,"Financial Year":"2019/20","Lead Applicant":"Dr Peter Lally","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Lally","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Revealing microstructural pathology in Parkinson's disease with super-resolution MRI Parkinson\u2019s disease (PD) is diagnosed by a clinical examination which typically comes 20 years after the initial symptoms. By this time approximately 70% of vulnerable dopaminergic neurons in the substantia nigra (SN) have already been lost. The nigrosomes (small clusters of dopaminergic cells in the SN) have differential histopathological features which make them ideal targets for detecting and monitoring PD.\n\nMRI is highly sensitive to the pathological iron accumulation in the nigrosomes, which is a hallmark of the earliest stages of PD, but quantitative imaging on this sub-millimetre scale is beyond the limits of traditional techniques. I have developed a non-traditional approach to MRI, based on super-resolution approaches from optical microscopy, which can surpass these limitations and rapidly generate quantitative images of the nigrosomes in vivo. I will develop this as an accurate measure of iron accumulation in PD.\n\nThe aims of this fellowship are:\n\n\n Producing accurate microstructural maps at sub-millimetre resolution\n Modelling and correcting for subject motion\n Testing the hypothesis that microstructural MRI measures in the nigrosomes distinguish PD subjects from healthy controls\n\n\n\nIf successful, this would enable PD diagnosis in its earliest stages, and maximise the likelihood of finding an effective therapy.\n","awardDateDateOnly":"2020-04-22","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Iron","Magnetic Resonance Imaging","Parkinson Disease","Substantia Nigra"]}
{"id":"360G-Wellcome-220472_Z_20_Z","title":"Understanding host restriction following bacterial phagosome rupture","Region":"East of England","currency":"GBP","awardDate":"2020-04-22T00:00:00+00:00","Sponsor(s)":"Prof Andres Floto","Internal ID":"220472/Z/20/Z","description":"Professional phagocytes engulf bacteria inside phagosomes that mediate cargo degradation via lysosome fusion. Some intracellular pathogens evade this fate by disrupting the phagosomal membrane, which triggers antibacterial autophagy. While autophagy may eliminate bacteria for host defence, more recent studies have demonstrated that autophagy can also promote intracellular bacterial survival or be irrelevant for bacterial restriction. Recently, Endosomal Sorting Complex Required for Transport (ESCRT) proteins have been shown to repair small membrane disruptions, potentially providing an alternative pathway for bacterial restriction. The interplay between autophagy and ESCRT machinery during phagosomal damage, the factors triggering each pathway and their contribution to intracellular bacterial killing are poorly understood.\n \n\nUsing the important human pathogen Staphylococcus aureus, I will:\n(1) investigate the interplay between autophagy and ESCRT machinery;\n(2) identify novel bacterial components that modulate autophagy and ESCRT recruitment; and\n(3) uncover unknown host regulators of autophagy, ESCRT and cell-autonomous immunity. \n\n\nTo complete these objectives, I will use high-resolution microscopy to follow bacteria recruiting autophagy and / or ESCRT machinery at the single bacterial cell level. Additionally, I will use high-content genetic screens to discover novel bacterial (using transposon libraries) and host factors (using CRISPR/Cas9) shaping host-pathogen interactions.\n","plannedDates":[{"endDate":"2024-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2024-08-31"}],"amountAwarded":300000,"Financial Year":"2019/20","Lead Applicant":"Dr Sina Krokowski","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Krokowski","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding host restriction following bacterial phagosome rupture Professional phagocytes engulf bacteria inside phagosomes that mediate cargo degradation via lysosome fusion. Some intracellular pathogens evade this fate by disrupting the phagosomal membrane, which triggers antibacterial autophagy. While autophagy may eliminate bacteria for host defence, more recent studies have demonstrated that autophagy can also promote intracellular bacterial survival or be irrelevant for bacterial restriction. Recently, Endosomal Sorting Complex Required for Transport (ESCRT) proteins have been shown to repair small membrane disruptions, potentially providing an alternative pathway for bacterial restriction. The interplay between autophagy and ESCRT machinery during phagosomal damage, the factors triggering each pathway and their contribution to intracellular bacterial killing are poorly understood.\n \n\nUsing the important human pathogen Staphylococcus aureus, I will:\n(1) investigate the interplay between autophagy and ESCRT machinery;\n(2) identify novel bacterial components that modulate autophagy and ESCRT recruitment; and\n(3) uncover unknown host regulators of autophagy, ESCRT and cell-autonomous immunity. \n\n\nTo complete these objectives, I will use high-resolution microscopy to follow bacteria recruiting autophagy and / or ESCRT machinery at the single bacterial cell level. Additionally, I will use high-content genetic screens to discover novel bacterial (using transposon libraries) and host factors (using CRISPR/Cas9) shaping host-pathogen interactions.\n","awardDateDateOnly":"2020-04-22","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Autophagy","Endosomes","Host-Pathogen Interactions","Humans","Phagosomes","Staphylococcal Infections","Staphylococcus aureus"]}
{"id":"360G-Wellcome-220464_Z_20_Z","title":"The systems biology of oncogenic PI3K\u03b1-driven stemness regulation ","Region":"Greater London","currency":"GBP","awardDate":"2020-04-22T00:00:00+00:00","Sponsor(s)":"Prof Bart Vanhaesebroeck","Internal ID":"220464/Z/20/Z","description":"Cancer stemness is linked to therapy resistance and metastasis. Emerging evidence suggests that PIK3CA-H1047R, a hotspot mutation in breast cancer and the PIK3CA-related overgrowth spectrum (PROS), elicits a stemness phenotype characterised by dedifferentiation and cell plasticity. Nevertheless, PIK3CA-H1047R does not cause malignancy in PROS, perhaps reflecting molecular differences between mammary (cancer) and endothelial (PROS) cell lineages. \n\nBy learning and applying novel systems biology tools, I aim to address the mechanism(s) behind PIK3CA-H1047R-driven stemness in a quantitative manner, taking into account cell type, genetic mosaicism and the strength of genetic PI3K pathway activation. I will generate mosaic cell models with doxycycline-inducible PIK3CA-H1047R expression, focussing on human breast epithelial cells and human endothelial cells due to their relevance for breast cancer and PROS, respectively. The cells will be exposed to short- and long-term PIK3CA-H1047R expression, followed by temporal assessment of: 1.Cell-state-transitions by single-cell RNA sequencing; 2.PI3K signalling dynamics by candidate-based quantitative single-cell imaging. Next, I will use data integration and mathematical modelling to infer the underlying regulatory principles. My ultimate goal is the identification of PIK3CA-mutant- and cell type-specific pharmacological therapies for reversal of aberrant stemness regulation, followed by validation in physiologically-relevant 3D models based on the established mosaic cell systems. \n","plannedDates":[{"endDate":"2024-11-30T00:00:00+00:00","startDate":"2020-12-01T00:00:00+00:00","startDateDateOnly":"2020-12-01","endDateDateOnly":"2024-11-30"}],"amountAwarded":300000,"Financial Year":"2019/20","Lead Applicant":"Dr Ralitsa Madsen","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Madsen","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The systems biology of oncogenic PI3K\u03b1-driven stemness regulation  Cancer stemness is linked to therapy resistance and metastasis. Emerging evidence suggests that PIK3CA-H1047R, a hotspot mutation in breast cancer and the PIK3CA-related overgrowth spectrum (PROS), elicits a stemness phenotype characterised by dedifferentiation and cell plasticity. Nevertheless, PIK3CA-H1047R does not cause malignancy in PROS, perhaps reflecting molecular differences between mammary (cancer) and endothelial (PROS) cell lineages. \n\nBy learning and applying novel systems biology tools, I aim to address the mechanism(s) behind PIK3CA-H1047R-driven stemness in a quantitative manner, taking into account cell type, genetic mosaicism and the strength of genetic PI3K pathway activation. I will generate mosaic cell models with doxycycline-inducible PIK3CA-H1047R expression, focussing on human breast epithelial cells and human endothelial cells due to their relevance for breast cancer and PROS, respectively. The cells will be exposed to short- and long-term PIK3CA-H1047R expression, followed by temporal assessment of: 1.Cell-state-transitions by single-cell RNA sequencing; 2.PI3K signalling dynamics by candidate-based quantitative single-cell imaging. Next, I will use data integration and mathematical modelling to infer the underlying regulatory principles. My ultimate goal is the identification of PIK3CA-mutant- and cell type-specific pharmacological therapies for reversal of aberrant stemness regulation, followed by validation in physiologically-relevant 3D models based on the established mosaic cell systems. \n","awardDateDateOnly":"2020-04-22","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Breast Neoplasms","Class I Phosphatidylinositol 3-Kinases","Endothelial Cells","Female","Humans","Neoplastic Stem Cells","Signal Transduction","Single-Cell Analysis"]}
{"id":"360G-Wellcome-220463_Z_20_Z","title":"Artificial intelligence for rapid epidemic analysis","Region":"East of England","currency":"GBP","awardDate":"2020-04-22T00:00:00+00:00","Sponsor(s)":"Prof James Wood","Internal ID":"220463/Z/20/Z","description":"The aim of this fellowship is to accelerate detection of and response to infectious disease outbreaks, particularly where surveillance, diagnosis, and control are under-resourced.\n\nMy first goal is to develop and validate machine learning methods to rapidly infer outbreak properties. I have demonstrated proof-of-concept for this approach, and I expect to be able to train machine learning models on synthetic outbreak data to infer outbreak properties almost instantaneously from data. By building on this approach, understanding its validity and weaknesses from application to historical data, and creating a database of simulations and trained models, I hope to allow outbreak data to be interpreted more quickly and simply than currently possible.\n\nMy second goal is to complete and test\u2014first against historical data and then prospectively\u2014algorithms for aetiological identification of outbreaks. These algorithms have the potential to allow outbreaks to be detected and controlled faster, as well as to improve guidelines for syndromic surveillance. \n\nFinally, I plan to integrate these analytics for outbreak identification and analysis into lightweight software tools. After testing them in collaboration with field epidemiologists, I hope to enable public health officials to take advantage of epidemiological insights with minimal training, supporting capacity of public health systems.\n","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":300000,"Financial Year":"2019/20","Lead Applicant":"Ms Emma Glennon","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Glennon","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Artificial intelligence for rapid epidemic analysis The aim of this fellowship is to accelerate detection of and response to infectious disease outbreaks, particularly where surveillance, diagnosis, and control are under-resourced.\n\nMy first goal is to develop and validate machine learning methods to rapidly infer outbreak properties. I have demonstrated proof-of-concept for this approach, and I expect to be able to train machine learning models on synthetic outbreak data to infer outbreak properties almost instantaneously from data. By building on this approach, understanding its validity and weaknesses from application to historical data, and creating a database of simulations and trained models, I hope to allow outbreak data to be interpreted more quickly and simply than currently possible.\n\nMy second goal is to complete and test\u2014first against historical data and then prospectively\u2014algorithms for aetiological identification of outbreaks. These algorithms have the potential to allow outbreaks to be detected and controlled faster, as well as to improve guidelines for syndromic surveillance. \n\nFinally, I plan to integrate these analytics for outbreak identification and analysis into lightweight software tools. After testing them in collaboration with field epidemiologists, I hope to enable public health officials to take advantage of epidemiological insights with minimal training, supporting capacity of public health systems.\n","awardDateDateOnly":"2020-04-22","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Algorithms","Artificial Intelligence","Disease Outbreaks","Humans","Machine Learning","Population Surveillance","Software"]}
{"id":"360G-Wellcome-220457_Z_20_Z","title":"Leveraging genealogies for powerful inference of evolutionary processes driving human genetic diversity","Region":"Greater London","currency":"GBP","awardDate":"2020-04-22T00:00:00+00:00","Sponsor(s)":"Dr Garrett Hellenthal","Internal ID":"220457/Z/20/Z","description":"I will develop powerful statistical methods that leverage estimated genealogies to reveal the key processes driving human genetic diversity and how these have evolved over time. Genealogies have the potential to transform how we analyze genomes, by providing a single framework for addressing a broad range of population and statistical genetics questions, and by substantially increasing power compared to conventional approaches.\n\nI have four key research aims that will impact distinct areas. Firstly, I will develop a novel method for uncovering how genetic structure changes through time and along the genome. This method can uncover unknown ancestral groups; for example, I will characterize previously-reported deeply diverged ancestry of unknown origin in the genomes of modern Africans. Secondly, I will develop a framework for incorporating ancient genomes of diverse ages and data quality into genealogies of modern individuals, enabling the direct study of how ancient and modern genomes interrelate. Thirdly, I will study the evolution of complex human traits through time under various modes of selection, to explain genetic architectures observed in genome-wide association studies. Fourthly, I will investigate the evolution of the molecular mechanisms of recombination, a key driver of human genetic diversity and hybrid incompatibility.\n","plannedDates":[{"endDate":"2024-10-11T00:00:00+00:00","startDate":"2020-10-12T00:00:00+00:00","startDateDateOnly":"2020-10-12","endDateDateOnly":"2024-10-11"}],"amountAwarded":300000,"Financial Year":"2019/20","Lead Applicant":"Mr Leo Speidel","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Speidel","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Leveraging genealogies for powerful inference of evolutionary processes driving human genetic diversity I will develop powerful statistical methods that leverage estimated genealogies to reveal the key processes driving human genetic diversity and how these have evolved over time. Genealogies have the potential to transform how we analyze genomes, by providing a single framework for addressing a broad range of population and statistical genetics questions, and by substantially increasing power compared to conventional approaches.\n\nI have four key research aims that will impact distinct areas. Firstly, I will develop a novel method for uncovering how genetic structure changes through time and along the genome. This method can uncover unknown ancestral groups; for example, I will characterize previously-reported deeply diverged ancestry of unknown origin in the genomes of modern Africans. Secondly, I will develop a framework for incorporating ancient genomes of diverse ages and data quality into genealogies of modern individuals, enabling the direct study of how ancient and modern genomes interrelate. Thirdly, I will study the evolution of complex human traits through time under various modes of selection, to explain genetic architectures observed in genome-wide association studies. Fourthly, I will investigate the evolution of the molecular mechanisms of recombination, a key driver of human genetic diversity and hybrid incompatibility.\n","awardDateDateOnly":"2020-04-22","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Evolution, Molecular","Genetic Variation","Genetics, Population","Genome, Human","Genome-Wide Association Study","Humans","Recombination, Genetic","Selection, Genetic"]}
{"id":"360G-Wellcome-220456_Z_20_Z","title":"Determining the role of placental endocrine function in the development of gestational diabetes mellitus and its maternal metabolic long-term health consequences ","Region":"East of England","currency":"GBP","awardDate":"2020-04-22T00:00:00+00:00","Sponsor(s)":"Dr Amanda Sferruzzi-Perri","Internal ID":"220456/Z/20/Z","description":"Gestational diabetes mellitus (GDM) is a serious and common pregnancy complication that can evolve in type-2 diabetes (T2DM) years after delivery. Placental hormones have wide-ranging effects on maternal physiology, including the regulation of glucose metabolism. However, we lack information on whether placental hormones could drive changes in maternal metabolism that leads to GDM and the subsequent progression to T2DM. This fellowship aims assess this by using a newly-developed genetic mouse model of placental endocrine malfunction. This is achieved by selectively disrupting the expression of the imprinted Igf2-H19 locus in the placental endocrine cells. Using this approach, I obtained data showing that mice with placental endocrine malfunction have metabolic disturbances, including high blood glucose concentrations during pregnancy. Also, these females show changes in their metabolism in the months after delivery. This project will further these findings in the model by using state-of-the-art in vivo metabolic tests and use transcriptomics, proteomics and methylome analyses to identify how placental hormones induce changes in maternal tissues that cause metabolic problems during and after pregnancy. My long-term aim is to identify biomarkers that could be explored as diagnostic tools or therapeutic targets to prevent the development of GDM and T2DM.\n \n","plannedDates":[{"endDate":"2024-06-24T00:00:00+00:00","startDate":"2020-06-25T00:00:00+00:00","startDateDateOnly":"2020-06-25","endDateDateOnly":"2024-06-24"}],"amountAwarded":300000,"Financial Year":"2019/20","Lead Applicant":"Dr Jorge Lopez-Tello","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Lopez-Tello","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Determining the role of placental endocrine function in the development of gestational diabetes mellitus and its maternal metabolic long-term health consequences  Gestational diabetes mellitus (GDM) is a serious and common pregnancy complication that can evolve in type-2 diabetes (T2DM) years after delivery. Placental hormones have wide-ranging effects on maternal physiology, including the regulation of glucose metabolism. However, we lack information on whether placental hormones could drive changes in maternal metabolism that leads to GDM and the subsequent progression to T2DM. This fellowship aims assess this by using a newly-developed genetic mouse model of placental endocrine malfunction. This is achieved by selectively disrupting the expression of the imprinted Igf2-H19 locus in the placental endocrine cells. Using this approach, I obtained data showing that mice with placental endocrine malfunction have metabolic disturbances, including high blood glucose concentrations during pregnancy. Also, these females show changes in their metabolism in the months after delivery. This project will further these findings in the model by using state-of-the-art in vivo metabolic tests and use transcriptomics, proteomics and methylome analyses to identify how placental hormones induce changes in maternal tissues that cause metabolic problems during and after pregnancy. My long-term aim is to identify biomarkers that could be explored as diagnostic tools or therapeutic targets to prevent the development of GDM and T2DM.\n \n","awardDateDateOnly":"2020-04-22","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Blood Glucose","Diabetes Mellitus, Type 2","Diabetes, Gestational","Disease Models, Animal","Female","Genomic Imprinting","Insulin-Like Growth Factor II","Mice","Placenta","Pregnancy","Proteomics"]}
{"id":"360G-Wellcome-220452_Z_20_Z","title":"Impact of autophagy on lymphocyte stemness","Region":"South East","currency":"GBP","awardDate":"2020-04-22T00:00:00+00:00","Sponsor(s)":"Prof Anna Katharina (Katja) Simon","Internal ID":"220452/Z/20/Z","description":"Efficient T cell responses rely on heterogeneity, characterized by the rise of effector and memory cells. Autophagy, responsible for homeostatic degradation and recycling of cell cargo, is crucial for T cell differentiation. Upon ageing, autophagy is impaired, which is detrimental for the generation of memory cells retaining stemness. Interestingly, I have observed that na\u00efve CD8+ T cells from aged mice are unable to undergo asymmetric cell division (ACD) (unpublished). ACD is a conserved mechanism to generate diversity, by endowing daughter cells with different fate determinants. As both autophagy and ACD are involved in T cell differentiation and impaired upon ageing, unravelling how they synergistically influence T cell stemness is at the centre of this project. We propose to use state-of-the-art imaging, proteomics, and metabolomics to investigate whether autophagy impacts cell asymmetries upon T cell mitosis. Functional validation will be addressed by using the novel combination of autophagy-deficient and organelle-tagged cells (SnapTag mice), which will enable us to evaluate whether asymmetry inheritance of cell cargoes leads to asymmetric fates in vivo. We anticipate that this research will be relevant to better understand how stemness is coordinated, and potentially lead to the development of therapeutic strategies in the context of regenerative medicine.\n","plannedDates":[{"endDate":"2026-03-31T00:00:00+00:00","startDate":"2022-04-01T00:00:00+00:00","startDateDateOnly":"2022-04-01","endDateDateOnly":"2026-03-31"}],"amountAwarded":300000,"Financial Year":"2019/20","Lead Applicant":"Dr Mariana Borsa","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Borsa","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Impact of autophagy on lymphocyte stemness Efficient T cell responses rely on heterogeneity, characterized by the rise of effector and memory cells. Autophagy, responsible for homeostatic degradation and recycling of cell cargo, is crucial for T cell differentiation. Upon ageing, autophagy is impaired, which is detrimental for the generation of memory cells retaining stemness. Interestingly, I have observed that na\u00efve CD8+ T cells from aged mice are unable to undergo asymmetric cell division (ACD) (unpublished). ACD is a conserved mechanism to generate diversity, by endowing daughter cells with different fate determinants. As both autophagy and ACD are involved in T cell differentiation and impaired upon ageing, unravelling how they synergistically influence T cell stemness is at the centre of this project. We propose to use state-of-the-art imaging, proteomics, and metabolomics to investigate whether autophagy impacts cell asymmetries upon T cell mitosis. Functional validation will be addressed by using the novel combination of autophagy-deficient and organelle-tagged cells (SnapTag mice), which will enable us to evaluate whether asymmetry inheritance of cell cargoes leads to asymmetric fates in vivo. We anticipate that this research will be relevant to better understand how stemness is coordinated, and potentially lead to the development of therapeutic strategies in the context of regenerative medicine.\n","awardDateDateOnly":"2020-04-22","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aging","Animals","Autophagy","CD8-Positive T-Lymphocytes","Cell Differentiation","Immunologic Memory","Metabolomics","Mice","Mitosis","T-Lymphocytes"]}
{"id":"360G-Wellcome-220450_Z_20_Z","title":"Spatial and temporal regulation of immune specific myosins and their role in neuroinflammation","Region":"East of England","currency":"GBP","awardDate":"2020-04-22T00:00:00+00:00","Sponsor(s)":"Prof Folma Buss","Internal ID":"220450/Z/20/Z","description":"Unconventional myosins of class I can directly associate with membranes, thereby providing a dynamic link between the actin cytoskeleton and the plasma membrane or intracellular organelles. Immune cell-specific myosin 1F and myosin 1G (MYO1F and MYO1G respectively) have roles in immune cell migration and regulation of membrane tension. Studies show both motors are upregulated in microglia during neuroinflammation. To uncover the temporal regulation of these motors, a number of biophysical assays will be employed, such as in vitro motility assays, optical trap experiments and stopped-flow spectroscopy. The molecular interactions of MYO1G that determine cellular function will be explored using a combination of proteomics and cell biological assays to identify the motors\u2019 interacting partners and elucidate its spatial regulation in vivo. The effects of two distinct phosphorylation sites on motor domain activity of MYO1G will be explored with mutations to mimic the non- and phosphorylated states. Protein crystallography studies of MYO1F and MYO1G will enable the design of small molecule inhibitors using structure-based in silico screening, with the ultimate goal to treat neuroinflammation in humans. Taken together these approaches will elucidate the cellular and physiological role of these motors and uncover the potential use of MYO1F and MYO1G as therapeutic agents.\n","plannedDates":[{"endDate":"2024-06-30T00:00:00+00:00","startDate":"2020-07-01T00:00:00+00:00","startDateDateOnly":"2020-07-01","endDateDateOnly":"2024-06-30"}],"amountAwarded":300000,"Financial Year":"2019/20","Lead Applicant":"Miss Chloe Johnson","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Johnson","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Spatial and temporal regulation of immune specific myosins and their role in neuroinflammation Unconventional myosins of class I can directly associate with membranes, thereby providing a dynamic link between the actin cytoskeleton and the plasma membrane or intracellular organelles. Immune cell-specific myosin 1F and myosin 1G (MYO1F and MYO1G respectively) have roles in immune cell migration and regulation of membrane tension. Studies show both motors are upregulated in microglia during neuroinflammation. To uncover the temporal regulation of these motors, a number of biophysical assays will be employed, such as in vitro motility assays, optical trap experiments and stopped-flow spectroscopy. The molecular interactions of MYO1G that determine cellular function will be explored using a combination of proteomics and cell biological assays to identify the motors\u2019 interacting partners and elucidate its spatial regulation in vivo. The effects of two distinct phosphorylation sites on motor domain activity of MYO1G will be explored with mutations to mimic the non- and phosphorylated states. Protein crystallography studies of MYO1F and MYO1G will enable the design of small molecule inhibitors using structure-based in silico screening, with the ultimate goal to treat neuroinflammation in humans. Taken together these approaches will elucidate the cellular and physiological role of these motors and uncover the potential use of MYO1F and MYO1G as therapeutic agents.\n","awardDateDateOnly":"2020-04-22","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Humans","Inflammation","Microglia","Models, Molecular","Myosin Heavy Chains","Myosins","Phosphorylation"]}
{"id":"360G-Wellcome-220448_Z_20_Z","title":"Perceiving people from voices","Region":"Greater London","currency":"GBP","awardDate":"2020-04-22T00:00:00+00:00","Sponsor(s)":"Dr Isabelle Mareschal","Internal ID":"220448/Z/20/Z","description":"When hearing voices, we can perceive a wealth of information about the speakers, such as their identity, regional background, and age. This project will investigate how listeners achieve this, thus probing fundamental mechanisms of person perception from voices. To achieve this, I will take a broad perspective to integrate the usually distinct fields of identity perception and the perception of other speaker characteristics. \n\nThrough a programme of behavioural research using acoustic signal processing and methods from the statistical or distributional learning literature, I will first explore how listeners form representations of voice identities through a programme of training studies: What is the acoustic content of mental representations of voices? What kind of information is encoded in such representations?\n\nI will then extend these findings from voice identity perception to the perception of other speaker characteristics: Are such population-level representations formed based on similar mechanisms to identity representations or are there differences? \n\nFinally, I will conduct a magnetoencephalography (MEG) study to describe the timecourse of person perception from voices: Which speaker characteristics are decoded by listeners at which point during perception? Does familiarity with a person change the processing of that voice? Can the low-level acoustic properties (partially) explain the timecourse?\n","plannedDates":[{"endDate":"2024-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2024-08-31"}],"amountAwarded":300000,"Financial Year":"2019/20","Lead Applicant":"Dr Nadine Lavan","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Lavan","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Queen-Mary-University-of-London","name":"Queen Mary University of London","addressCountry":"United Kingdom","id_and_name":"[\"Queen Mary University of London\", \"360G-Wellcome-ORG:Queen-Mary-University-of-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Queen-Mary-University-of-London","name":"Queen Mary University of London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Perceiving people from voices When hearing voices, we can perceive a wealth of information about the speakers, such as their identity, regional background, and age. This project will investigate how listeners achieve this, thus probing fundamental mechanisms of person perception from voices. To achieve this, I will take a broad perspective to integrate the usually distinct fields of identity perception and the perception of other speaker characteristics. \n\nThrough a programme of behavioural research using acoustic signal processing and methods from the statistical or distributional learning literature, I will first explore how listeners form representations of voice identities through a programme of training studies: What is the acoustic content of mental representations of voices? What kind of information is encoded in such representations?\n\nI will then extend these findings from voice identity perception to the perception of other speaker characteristics: Are such population-level representations formed based on similar mechanisms to identity representations or are there differences? \n\nFinally, I will conduct a magnetoencephalography (MEG) study to describe the timecourse of person perception from voices: Which speaker characteristics are decoded by listeners at which point during perception? Does familiarity with a person change the processing of that voice? Can the low-level acoustic properties (partially) explain the timecourse?\n","awardDateDateOnly":"2020-04-22","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Acoustic Stimulation","Adult","Auditory Perception","Female","Humans","Magnetoencephalography","Male","Speech Perception","Voice","Young Adult"]}
{"id":"360G-Wellcome-220442_Z_20_Z","title":"Effective analysis and experimental design for CRISPR screens with scRNA-seq readout","Region":"East of England","currency":"GBP","awardDate":"2020-04-22T00:00:00+00:00","Sponsor(s)":"Dr John Marioni","Internal ID":"220442/Z/20/Z","description":"Understanding how cell fate decisions are regulated is a key question in molecular biology. Building on the CRISPR revolution, exciting technologies (e.g., CROP-seq or direct capture Perturb-seq) induce a genetic perturbation that is characterised, alongside the transcriptome of the cell, by single-cell RNA-sequencing. This enables a range of experimental designs that can, in principle, shed light on the transcriptional response to gene perturbations, its pathogenic and non-pathogenic variation, and the role of gene regulation during differentiation.\n\n \n\n\nHowever, current computational methods do not exploit this potential: in particular, the ability to accurately measure the effect of a given perturbation is lacking, and the potential to efficiently explore the space of all possible perturbations and conditions remain untapped.\n\n \n\n\nTo address this, I will develop a comprehensive suite of computational tools (i) to infer transcriptomic effects of gene knockouts unconfounded by perturbation efficacy, (ii) for optimal experimental setup to increase insights gained from experiments and improve their scalability, (iii) to identify differences in gene regulation across individuals, and (iv) for the study of knockout effects during differentiation. This will lead to an improved understanding of gene regulation, its variation across individuals, and to improved differentiation protocols, with important consequences for cell therapy.\n\n \n\n \n","plannedDates":[{"endDate":"2025-01-14T00:00:00+00:00","startDate":"2021-01-15T00:00:00+00:00","startDateDateOnly":"2021-01-15","endDateDateOnly":"2025-01-14"}],"amountAwarded":300000,"Financial Year":"2019/20","Lead Applicant":"Dr Magdalena Strauss","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Strauss","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:European-Bioinformatics-Institute","name":"European Bioinformatics Institute","addressCountry":"United Kingdom","id_and_name":"[\"European Bioinformatics Institute\", \"360G-Wellcome-ORG:European-Bioinformatics-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:European-Bioinformatics-Institute","name":"European Bioinformatics Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Effective analysis and experimental design for CRISPR screens with scRNA-seq readout Understanding how cell fate decisions are regulated is a key question in molecular biology. Building on the CRISPR revolution, exciting technologies (e.g., CROP-seq or direct capture Perturb-seq) induce a genetic perturbation that is characterised, alongside the transcriptome of the cell, by single-cell RNA-sequencing. This enables a range of experimental designs that can, in principle, shed light on the transcriptional response to gene perturbations, its pathogenic and non-pathogenic variation, and the role of gene regulation during differentiation.\n\n \n\n\nHowever, current computational methods do not exploit this potential: in particular, the ability to accurately measure the effect of a given perturbation is lacking, and the potential to efficiently explore the space of all possible perturbations and conditions remain untapped.\n\n \n\n\nTo address this, I will develop a comprehensive suite of computational tools (i) to infer transcriptomic effects of gene knockouts unconfounded by perturbation efficacy, (ii) for optimal experimental setup to increase insights gained from experiments and improve their scalability, (iii) to identify differences in gene regulation across individuals, and (iv) for the study of knockout effects during differentiation. This will lead to an improved understanding of gene regulation, its variation across individuals, and to improved differentiation protocols, with important consequences for cell therapy.\n\n \n\n \n","awardDateDateOnly":"2020-04-22","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["CRISPR-Cas Systems","Cell Differentiation","Clustered Regularly Interspaced Short Palindromic Repeats","Humans","Sequence Analysis, RNA","Single-Cell Analysis","Transcriptome"]}
{"id":"360G-Wellcome-220439_Z_20_Z","title":"EAT Foundation - Bridge Funding ","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220439/Z/20/Z","description":"With the support from Wellcome Trust during the years 2016-2019, EAT  achieved important results. The EAT SFF is globally recognized as a meeting place for  stakeholders to shape the future of food. The EAT-Lancet Commission  changed the debate around food, environmental sustainability and health, and the scientific targets set by the Commission for healthy diets within safe planetary boundaries are  guiding action by a wide range of actors across policy, business and civil society. EAT is  catalyzing  action through a number of collaborations, such as with C40, influencing food system policy agendas in  50 cities around the world. The GBP200,000 contribution from Wellcome Trust for 2019 will secure EAT\u2019s ability to continue its efforts and avoid delay or disruption of its work, while working with Wellcome Trust ito develop a Phase 2 program. \nEATrecognizes that there is an urgent need to undertake a proactive and strategic organizational review. This review will guide EAT in addressing weaknesses in its financial, operational, fundraising and reporting functions that have exposed risks that must be mitigated prior to the end of 2019 The review will provide a clear pathway to ensure financial and operational sustainability whilst supporting EAT\u2019s agility within focused and strategic structures. \n \n","plannedDates":[{"endDate":"2021-01-21T00:00:00+00:00","startDate":"2020-01-21T00:00:00+00:00","startDateDateOnly":"2020-01-21","endDateDateOnly":"2021-01-21"}],"amountAwarded":200000,"Financial Year":"2019/20","Lead Applicant":"Dr Fabrice DeClerck","grantProgramme":[{"title":"Discretionary Award - OPOH","title_keyword":"Discretionary Award - OPOH"}],"Applicant Surname":"DeClerck","Partnership Value":200000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:EAT-Foundation","name":"EAT Foundation","addressCountry":"Norway","id_and_name":"[\"EAT Foundation\", \"360G-Wellcome-ORG:EAT-Foundation\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:EAT-Foundation","name":"EAT Foundation"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"EAT Foundation - Bridge Funding  With the support from Wellcome Trust during the years 2016-2019, EAT  achieved important results. The EAT SFF is globally recognized as a meeting place for  stakeholders to shape the future of food. The EAT-Lancet Commission  changed the debate around food, environmental sustainability and health, and the scientific targets set by the Commission for healthy diets within safe planetary boundaries are  guiding action by a wide range of actors across policy, business and civil society. EAT is  catalyzing  action through a number of collaborations, such as with C40, influencing food system policy agendas in  50 cities around the world. The GBP200,000 contribution from Wellcome Trust for 2019 will secure EAT\u2019s ability to continue its efforts and avoid delay or disruption of its work, while working with Wellcome Trust ito develop a Phase 2 program. \nEATrecognizes that there is an urgent need to undertake a proactive and strategic organizational review. This review will guide EAT in addressing weaknesses in its financial, operational, fundraising and reporting functions that have exposed risks that must be mitigated prior to the end of 2019 The review will provide a clear pathway to ensure financial and operational sustainability whilst supporting EAT\u2019s agility within focused and strategic structures. \n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Food Supply","Humans"]}
{"id":"360G-Wellcome-220438_Z_20_Z","title":"IMPETUS: Investigating Markers derived from Proteomics for Estimation of Transition from the Ultra high-risk State to psychotic disorder","Region":"Ireland","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220438/Z/20/Z","description":"Mental disorders such as schizophrenia are among the most expensive disorders in\nterms of quality of life and societal cost. Early identification and intervention is\nassociated with improved outcome and is facilitated by targeting those at clinical-highrisk-\nfor-psychosis (CHR) as up to 25-30% develop psychotic disorder (PD) at 6 year\nfollow-up. There is growing evidence for the involvement of the immune system and\ninflammation in this disorder. We have added to this literature by demonstrating that\nthe complement pathway, the blood plasma component of the innate immune system is dysregulated in blood samples of individuals at age 11, many years before these\nindividuals report symptoms in keeping with psychotic disorder at age 17.\nBased on our own plasma proteomic data and machine learning analyses, we now\nhave evidence for a set of biomarker proteins which can predict transition from the\nCHR to PD with a high degree of accuracy. We now seek to refine and replicate these\nfindings.\nOur study: Using state-of-the-art proteomic methods and machine learning approaches\nwe will replicate and refine this biomarker signature of transition from CHR to psychotic\ndisorder in three distinct international samples and one longitudinal cohort with a total\nCHR sample size of over 1000 CHR subjects. We will also undertake functional assays\nthat measure plasma protein levels of the complement and coagulation pathway and\ntheir activation fragments as indicators of complement and coagulation dysregulation.\nOur study includes commercial diagnostic/prognostic biomarker expertise.","plannedDates":[{"endDate":"2024-07-03T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2024-07-03"}],"amountAwarded":1184320,"Financial Year":"2019/20","Lead Applicant":"Prof David Cotter","grantProgramme":[{"title":"Innovations Psychosis Flagship","title_keyword":"Innovations Psychosis Flagship"}],"Applicant Surname":"Cotter","Partnership Value":1184320,"Approval Committee":"Science, Innovation and Translation Programme Advisory Group","Other Applicant(s)":"Mr Colm Healy, Prof Barnaby Nelson, Prof Stan Zammit, Prof Tyrone Cannon, Dr Diana Perkins, Dr Robert Whelan, Dr Clark Jeffries, Dr Melanie Foecking, Prof Bryan Morgan, Prof Mary Cannon, Prof Patrick McGorry, Prof Philip McGuire, Dr David Mongan, Dr Gerard Cagney, Dr Meike Heurich, Prof G. Paul Amminger","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Royal-College-of-Surgeons-in-Ireland","name":"Royal College of Surgeons in Ireland","addressCountry":"Ireland","id_and_name":"[\"Royal College of Surgeons in Ireland\", \"360G-Wellcome-ORG:Royal-College-of-Surgeons-in-Ireland\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Royal-College-of-Surgeons-in-Ireland","name":"Royal College of Surgeons in Ireland"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"IMPETUS: Investigating Markers derived from Proteomics for Estimation of Transition from the Ultra high-risk State to psychotic disorder Mental disorders such as schizophrenia are among the most expensive disorders in\nterms of quality of life and societal cost. Early identification and intervention is\nassociated with improved outcome and is facilitated by targeting those at clinical-highrisk-\nfor-psychosis (CHR) as up to 25-30% develop psychotic disorder (PD) at 6 year\nfollow-up. There is growing evidence for the involvement of the immune system and\ninflammation in this disorder. We have added to this literature by demonstrating that\nthe complement pathway, the blood plasma component of the innate immune system is dysregulated in blood samples of individuals at age 11, many years before these\nindividuals report symptoms in keeping with psychotic disorder at age 17.\nBased on our own plasma proteomic data and machine learning analyses, we now\nhave evidence for a set of biomarker proteins which can predict transition from the\nCHR to PD with a high degree of accuracy. We now seek to refine and replicate these\nfindings.\nOur study: Using state-of-the-art proteomic methods and machine learning approaches\nwe will replicate and refine this biomarker signature of transition from CHR to psychotic\ndisorder in three distinct international samples and one longitudinal cohort with a total\nCHR sample size of over 1000 CHR subjects. We will also undertake functional assays\nthat measure plasma protein levels of the complement and coagulation pathway and\ntheir activation fragments as indicators of complement and coagulation dysregulation.\nOur study includes commercial diagnostic/prognostic biomarker expertise.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adolescent","Biomarkers","Blood Proteins","Child","Female","Humans","Longitudinal Studies","Machine Learning","Male","Prognosis","Proteome","Proteomics","Psychotic Disorders","Schizophrenia"]}
{"id":"360G-Wellcome-220429_Z_20_Z","title":"Making social change happen: What inspires collective action for health and gender equality?","Region":"Greater London","currency":"GBP","awardDate":"2020-04-22T00:00:00+00:00","Sponsor(s)":"Prof Ibrahim Abubakar","Internal ID":"220429/Z/20/Z","description":"Motivation: Interventions mobilising communities in collective action for their own health are some of the most effective known global health interventions. However, they do not always succeed and we cannot presently predict or explain why this happens.\n\nAim: Taking as an example a community mobilisation programme to prevent violence against women in urban slums in Mumbai, India, I will test theory concerning the drivers of collective action from behavioural economics and social psychology.\n\nMethod: (1) To unpack how a community mobilisation programme may stimulate collective action in urban India, I will collect and analyse qualitative interview, media and observational data.\n\n(2) To uncover the determinants of participation in collective action, I will conduct cross-sectional and difference-in-differences analysis of secondary data from a randomised controlled trial of the same community mobilisation programme.\n\n(3) To produce causal evidence for the drivers of collective action, I will conduct a behavioural experiment to test the behavioural effects of changing key messages on programme participants. I will use the answers to (1) and (2) to guide message design.\n\nImpact: The study results will be able to guide policy-makers and practitioners on when, how and why complex participatory interventions work to promote health and gender equality.\n","plannedDates":[{"endDate":"2024-11-30T00:00:00+00:00","startDate":"2020-12-01T00:00:00+00:00","startDateDateOnly":"2020-12-01","endDateDateOnly":"2024-11-30"}],"amountAwarded":300000,"Financial Year":"2019/20","Lead Applicant":"Dr Lu Gram","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Gram","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Making social change happen: What inspires collective action for health and gender equality? Motivation: Interventions mobilising communities in collective action for their own health are some of the most effective known global health interventions. However, they do not always succeed and we cannot presently predict or explain why this happens.\n\nAim: Taking as an example a community mobilisation programme to prevent violence against women in urban slums in Mumbai, India, I will test theory concerning the drivers of collective action from behavioural economics and social psychology.\n\nMethod: (1) To unpack how a community mobilisation programme may stimulate collective action in urban India, I will collect and analyse qualitative interview, media and observational data.\n\n(2) To uncover the determinants of participation in collective action, I will conduct cross-sectional and difference-in-differences analysis of secondary data from a randomised controlled trial of the same community mobilisation programme.\n\n(3) To produce causal evidence for the drivers of collective action, I will conduct a behavioural experiment to test the behavioural effects of changing key messages on programme participants. I will use the answers to (1) and (2) to guide message design.\n\nImpact: The study results will be able to guide policy-makers and practitioners on when, how and why complex participatory interventions work to promote health and gender equality.\n","awardDateDateOnly":"2020-04-22","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adult","Cross-Sectional Studies","Female","Health Behavior","Health Promotion","Humans","India","Motivation","Poverty Areas","Research Design"]}
{"id":"360G-Wellcome-220422_Z_20_Z","title":"The evolution of mobile genetic elements in Gram-negative bacteria","Region":"South East","currency":"GBP","awardDate":"2020-04-22T00:00:00+00:00","Sponsor(s)":"Prof Craig MacLean","Internal ID":"220422/Z/20/Z","description":"I will explore how structural variation can be used to understand the evolution of antimicrobial resistance (AMR) on mobile genetic elements (MGEs). \n\nMost previous research is biased towards nucleotide-level variations in the core genome (high-effect SNPs). Now, the availability of complete genomes means that resolving the larger structural variation of MGEs is both possible and increasingly relevant for the spread of AMR. I will develop a framework to model the non-mutational processes which generate this variation, then apply this to the linked evolution of MGEs and their \u2018host\u2019 genomes.\n\nDuring this fellowship, I will sequentially:\n\n\n Aim 1. Develop a tool to quantify structural variation and resolve common blocks around the flanking region of AMR genes, which I have previously shown can be used for phylogenetic reconstruction.\n Aim 2. Apply this to longitudinal datasets and obtain rate estimates for non-mutational processes.\n Aim 3. Investigate the compensatory evolution of MGEs as they move between genomic backgrounds.\n\n\nTwo major applications will be:\n\n\n Application 1. Small transposons, leading on from my pioneering work on the mcr-1 transposon.\n Application 2. Clinical class 1 integrons, which carry multiple AMR genes.\n\n\n \n\nThis proposal tackles questions of fundamental importance for the evolution of flexible genomes.\n\n \n","plannedDates":[{"endDate":"2025-01-04T00:00:00+00:00","startDate":"2021-01-05T00:00:00+00:00","startDateDateOnly":"2021-01-05","endDateDateOnly":"2025-01-04"}],"amountAwarded":300000,"Financial Year":"2019/20","Lead Applicant":"Dr Liam Shaw","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Shaw","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The evolution of mobile genetic elements in Gram-negative bacteria I will explore how structural variation can be used to understand the evolution of antimicrobial resistance (AMR) on mobile genetic elements (MGEs). \n\nMost previous research is biased towards nucleotide-level variations in the core genome (high-effect SNPs). Now, the availability of complete genomes means that resolving the larger structural variation of MGEs is both possible and increasingly relevant for the spread of AMR. I will develop a framework to model the non-mutational processes which generate this variation, then apply this to the linked evolution of MGEs and their \u2018host\u2019 genomes.\n\nDuring this fellowship, I will sequentially:\n\n\n Aim 1. Develop a tool to quantify structural variation and resolve common blocks around the flanking region of AMR genes, which I have previously shown can be used for phylogenetic reconstruction.\n Aim 2. Apply this to longitudinal datasets and obtain rate estimates for non-mutational processes.\n Aim 3. Investigate the compensatory evolution of MGEs as they move between genomic backgrounds.\n\n\nTwo major applications will be:\n\n\n Application 1. Small transposons, leading on from my pioneering work on the mcr-1 transposon.\n Application 2. Clinical class 1 integrons, which carry multiple AMR genes.\n\n\n \n\nThis proposal tackles questions of fundamental importance for the evolution of flexible genomes.\n\n \n","awardDateDateOnly":"2020-04-22","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anti-Bacterial Agents","DNA Transposable Elements","Drug Resistance, Bacterial","Evolution, Molecular","Genome, Bacterial","Integrons","Phylogeny"]}
{"id":"360G-Wellcome-220421_Z_20_Z","title":"The NCEMA study: Neutrophils in Cerebral Malaria ","Region":"North West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220421/Z/20/Z","description":"Every year half of the world\u2019s population is at risk of getting malaria, caused by the Plasmodium parasite, and almost half a million people die; mostly children in sub-Saharan Africa. Some infected children are at a higher risk of death since malaria can damage their brains as part of a severe complication called cerebral malaria (CM). Neutrophils are one of the first lines of defence against fighting infections by damaging cells, yet their involvement during CM is not entirely understood.\n\nWe hypothesise that neutrophils interact with Plasmodium affecting the blood vessels of the brain and initiate or promote the progression to CM. We aim to perform a detailed analysis of the role of neutrophils in CM, using prospectively collected blood from children with CM, archival post-mortem brain tissue, blood vessel cell cultures and a mouse model. With the exception of the mouse model our project will be based in Malawi, a country endemic for malaria.\n\nOur findings will allow us to understand if neutrophils cause damage to the brain blood vessels leading to CM. This could provide the basis of a search for novel prevention and treatment strategies that can potentially decrease the high rates of death of this disease.\n \n","plannedDates":[{"endDate":"2023-03-27T00:00:00+00:00","startDate":"2019-09-01T00:00:00+00:00","startDateDateOnly":"2019-09-01","endDateDateOnly":"2023-03-27"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Charalampos Attipa","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Attipa","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"Liverpool School of Tropical Medicine\", \"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The NCEMA study: Neutrophils in Cerebral Malaria  Every year half of the world\u2019s population is at risk of getting malaria, caused by the Plasmodium parasite, and almost half a million people die; mostly children in sub-Saharan Africa. Some infected children are at a higher risk of death since malaria can damage their brains as part of a severe complication called cerebral malaria (CM). Neutrophils are one of the first lines of defence against fighting infections by damaging cells, yet their involvement during CM is not entirely understood.\n\nWe hypothesise that neutrophils interact with Plasmodium affecting the blood vessels of the brain and initiate or promote the progression to CM. We aim to perform a detailed analysis of the role of neutrophils in CM, using prospectively collected blood from children with CM, archival post-mortem brain tissue, blood vessel cell cultures and a mouse model. With the exception of the mouse model our project will be based in Malawi, a country endemic for malaria.\n\nOur findings will allow us to understand if neutrophils cause damage to the brain blood vessels leading to CM. This could provide the basis of a search for novel prevention and treatment strategies that can potentially decrease the high rates of death of this disease.\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Brain","Child","Disease Models, Animal","Female","Humans","Malaria","Malaria, Cerebral","Malawi","Male","Mice","Mice, Inbred C57BL","Neutrophils"]}
{"id":"360G-Wellcome-220420_Z_20_Z","title":"Exploring Science Pedagogy with Teacher-Led Randomised Controlled Trials (RCTs) ","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220420/Z/20/Z","description":"\n \n  \n   \n   The collaboration between Education Development Trust (EdDevTrust) and the National STEM Learning Centre (STEM Learning) will enable 60 highly trained and competent science teachers to access a unique approach (\u2018Test and Learn\u2019) and set of tools to guide and support them to carry out their own rigorous classroom-based research. Teachers will test the evidence-based theories, approaches, pedagogies and policies introduced to them through STEM Learning\u2019s CPD programme using randomised controlled trials, applying scientific method to explore science pedagogy.\n   \n  \n \n\n","plannedDates":[{"endDate":"2021-10-31T00:00:00+00:00","startDate":"2020-02-26T00:00:00+00:00","startDateDateOnly":"2020-02-26","endDateDateOnly":"2021-10-31"}],"amountAwarded":97058,"Financial Year":"2019/20","Lead Applicant":"Ms Fran Dainty","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Dainty","Partnership Value":97058,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:STEM-Learning-Limited","name":"STEM Learning Limited","addressCountry":"United Kingdom","id_and_name":"[\"STEM Learning Limited\", \"360G-Wellcome-ORG:STEM-Learning-Limited\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:STEM-Learning-Limited","name":"STEM Learning Limited"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Exploring Science Pedagogy with Teacher-Led Randomised Controlled Trials (RCTs)  \n \n  \n   \n   The collaboration between Education Development Trust (EdDevTrust) and the National STEM Learning Centre (STEM Learning) will enable 60 highly trained and competent science teachers to access a unique approach (\u2018Test and Learn\u2019) and set of tools to guide and support them to carry out their own rigorous classroom-based research. Teachers will test the evidence-based theories, approaches, pedagogies and policies introduced to them through STEM Learning\u2019s CPD programme using randomised controlled trials, applying scientific method to explore science pedagogy.\n   \n  \n \n\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Learning","Randomized Controlled Trials as Topic","Science","Trust"]}
{"id":"360G-Wellcome-220419_Z_20_Z","title":"Research-2-practice: Research-informed science lesson plans for busy teachers","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220419/Z/20/Z","description":"Spoke with Ruba Aljarf today (9 November 2019) and she said to simply upload the attachment.\n","plannedDates":[{"endDate":"2021-10-31T00:00:00+00:00","startDate":"2020-07-20T00:00:00+00:00","startDateDateOnly":"2020-07-20","endDateDateOnly":"2021-10-31"}],"amountAwarded":269680,"Financial Year":"2019/20","Lead Applicant":"Prof Ian Abrahams","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Abrahams","Partnership Value":269680,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Roehampton-University","name":"Roehampton University","addressCountry":"United Kingdom","id_and_name":"[\"Roehampton University\", \"360G-Wellcome-ORG:Roehampton-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Roehampton-University","name":"Roehampton University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Research-2-practice: Research-informed science lesson plans for busy teachers Spoke with Ruba Aljarf today (9 November 2019) and she said to simply upload the attachment.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Research"]}
{"id":"360G-Wellcome-220418_Z_20_Z","title":"Science Teacher Journal Clubs","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220418/Z/20/Z","description":"Our project will support science teachers to engage with research through a \u2018teacher journal club\u2019 (TJC) approach, building on work in both education and in the medical sciences, where journal clubs are a well-established approach to CPD. As well as providing cost- and time-efficient CPD that adheres to the principles of effective learning for teachers, journal clubs are by their nature focused on helping teachers to engage effectively with research evidence. This project proposes to apply the principles of successful journal clubs from medicine to education. The journal clubs will exclusively be online and journal clubs facilitators and participants will receive online training before their first TJC. This online training will cover the background of TJCs and how it relates to effective teacher CPD, research appraisal and journal club facilitation skills. The project will take a 'fading scaffolding' approach where the support for TJC facilitators will fade over time with the goal for them to run TJC independently by the end of the project. \n","plannedDates":[{"endDate":"2021-10-31T00:00:00+00:00","startDate":"2020-02-15T00:00:00+00:00","startDateDateOnly":"2020-02-15","endDateDateOnly":"2021-10-31"}],"amountAwarded":76800,"Financial Year":"2019/20","Lead Applicant":"Dr Lisa-Maria M\u00fcller","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"M\u00fcller","Partnership Value":76800,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:College-of-Teaching-Ltd","name":"College of Teaching Ltd","addressCountry":"United Kingdom","id_and_name":"[\"College of Teaching Ltd\", \"360G-Wellcome-ORG:College-of-Teaching-Ltd\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:College-of-Teaching-Ltd","name":"College of Teaching Ltd"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Science Teacher Journal Clubs Our project will support science teachers to engage with research through a \u2018teacher journal club\u2019 (TJC) approach, building on work in both education and in the medical sciences, where journal clubs are a well-established approach to CPD. As well as providing cost- and time-efficient CPD that adheres to the principles of effective learning for teachers, journal clubs are by their nature focused on helping teachers to engage effectively with research evidence. This project proposes to apply the principles of successful journal clubs from medicine to education. The journal clubs will exclusively be online and journal clubs facilitators and participants will receive online training before their first TJC. This online training will cover the background of TJCs and how it relates to effective teacher CPD, research appraisal and journal club facilitation skills. The project will take a 'fading scaffolding' approach where the support for TJC facilitators will fade over time with the goal for them to run TJC independently by the end of the project. \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Periodicals as Topic"]}
{"id":"360G-Wellcome-220417_Z_20_Z","title":"Learning by Doing (research engagement through evidence-informed lesson plans))","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220417/Z/20/Z","description":"Our project aims to increase teachers\u2019 engagement with and use of research through the provision of teaching resources \u2013 a comprehensive program of work, including adaptable lesson plans \u2013 and training in their use. The lesson plans will be designed based on research evidence and will also contain annotated summaries of relevant research evidence with links to the underlying research. The training will help teachers understand how and why to engage with research evidence by using the lesson plans, and will be participatory in nature. Training will occur three times throughout delivery to remind teachers to engage with evidence.  The intervention will pertain to a particular unit of year 8/9 physics e.g. forces.  We will recruit physics teachers at a diverse mix of UK state-funded schools to test our resources.\n\nIn our approach, engaging with research and learning how to embed it in practice will be made extremely easy for teachers, which is the most effective way to increase the prevalence of desired behaviour (and is especially important in the context of an already overburdened workforce). In particular, this approach will address potential intention-action gaps between teachers engaging with research evidence and actually applying it in their teaching practice. \n\n \n","plannedDates":[{"endDate":"2021-07-01T00:00:00+00:00","startDate":"2020-02-12T00:00:00+00:00","startDateDateOnly":"2020-02-12","endDateDateOnly":"2021-07-01"}],"amountAwarded":109026,"Financial Year":"2019/20","Lead Applicant":"Dr Kathryn Atherton","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Atherton","Partnership Value":109026,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Behavioural-Insights-Team","name":"Behavioural Insights Team","addressCountry":"United Kingdom","id_and_name":"[\"Behavioural Insights Team\", \"360G-Wellcome-ORG:Behavioural-Insights-Team\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Behavioural-Insights-Team","name":"Behavioural Insights Team"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Learning by Doing (research engagement through evidence-informed lesson plans)) Our project aims to increase teachers\u2019 engagement with and use of research through the provision of teaching resources \u2013 a comprehensive program of work, including adaptable lesson plans \u2013 and training in their use. The lesson plans will be designed based on research evidence and will also contain annotated summaries of relevant research evidence with links to the underlying research. The training will help teachers understand how and why to engage with research evidence by using the lesson plans, and will be participatory in nature. Training will occur three times throughout delivery to remind teachers to engage with evidence.  The intervention will pertain to a particular unit of year 8/9 physics e.g. forces.  We will recruit physics teachers at a diverse mix of UK state-funded schools to test our resources.\n\nIn our approach, engaging with research and learning how to embed it in practice will be made extremely easy for teachers, which is the most effective way to increase the prevalence of desired behaviour (and is especially important in the context of an already overburdened workforce). In particular, this approach will address potential intention-action gaps between teachers engaging with research evidence and actually applying it in their teaching practice. \n\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Teaching","United Kingdom"]}
{"id":"360G-Wellcome-220416_Z_20_Z","title":" Participatory Approaches in Mpemba for Developing Clean Air interventions (PAMODZI)","Region":"North West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220416/Z/20/Z","description":"Air pollution is a major health risk worldwide, particularly in countries such as Malawi where smoke is widespread, both indoors and outside, and populations remain reliant on polluting fuels for cooking and heating. Research so far, largely using \u2018improved cookstoves\u2019, has failed to demonstrate the hoped-for health improvements in lung health.\n\nThis study brings together the priorities of the research team with those of the communities which the research aims to benefit, from the start. I will use participant observation to explore the role of smoke in the context of a Malawian village, also measuring individuals\u2019 smoke exposures as they go about their daily lives. Working with community members we will then use this information to develop a set of acceptable, context-appropriate clean air interventions. Finally, I will assess the effectiveness of these interventions in reducing smoke exposure through a small village-based trial.\n\nThe study will build on the knowledge of members of the village, raising awareness of the issues and including participants in developing solutions from the start. This will assist in developing an effective, sustainable clean air intervention, as well as demonstrating a more engaged approach to Global Health research.\n","plannedDates":[{"endDate":"2022-09-03T00:00:00+00:00","startDate":"2018-12-03T00:00:00+00:00","startDateDateOnly":"2018-12-03","endDateDateOnly":"2022-09-03"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Sepeedeh Saleh","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Saleh","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"Liverpool School of Tropical Medicine\", \"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":" Participatory Approaches in Mpemba for Developing Clean Air interventions (PAMODZI) Air pollution is a major health risk worldwide, particularly in countries such as Malawi where smoke is widespread, both indoors and outside, and populations remain reliant on polluting fuels for cooking and heating. Research so far, largely using \u2018improved cookstoves\u2019, has failed to demonstrate the hoped-for health improvements in lung health.\n\nThis study brings together the priorities of the research team with those of the communities which the research aims to benefit, from the start. I will use participant observation to explore the role of smoke in the context of a Malawian village, also measuring individuals\u2019 smoke exposures as they go about their daily lives. Working with community members we will then use this information to develop a set of acceptable, context-appropriate clean air interventions. Finally, I will assess the effectiveness of these interventions in reducing smoke exposure through a small village-based trial.\n\nThe study will build on the knowledge of members of the village, raising awareness of the issues and including participants in developing solutions from the start. This will assist in developing an effective, sustainable clean air intervention, as well as demonstrating a more engaged approach to Global Health research.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adult","Air Pollution, Indoor","Community-Based Participatory Research","Cooking","Environmental Exposure","Female","Humans","Malawi","Research Design","Smoke","Tobacco Smoke Pollution"]}
{"id":"360G-Wellcome-220415_Z_20_Z","title":"Joint Health Systems Research Award \u2013 round 6 \u2013 2019","Region":"South West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220415/Z/20/Z","description":"N/A","plannedDates":[{"endDate":"2023-12-31T00:00:00+00:00","startDate":"2020-01-01T00:00:00+00:00","startDateDateOnly":"2020-01-01","endDateDateOnly":"2023-12-31"}],"amountAwarded":2000000,"Financial Year":"2019/20","Lead Applicant":"Mrs Jill Jones","grantProgramme":[{"title":"Joint Health Systems Research Award","title_keyword":"Joint Health Systems Research Award"}],"Partnership Name":"Joint health systems research initiative","Applicant Surname":"Jones","Partnership Value":2000000,"Approval Committee":"Joint Health Systems Research Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:UKRI-MRC","name":"UKRI-MRC","addressCountry":"United Kingdom","id_and_name":"[\"UKRI-MRC\", \"360G-Wellcome-ORG:UKRI-MRC\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:UKRI-MRC","name":"UKRI-MRC"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Joint Health Systems Research Award \u2013 round 6 \u2013 2019 N/A","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Biomedical Research","Humans","United States"]}
{"id":"360G-Wellcome-220414_Z_20_Z","title":"Epidemiology and outbreak prediction of yellow fever virus","Region":"Greater London","currency":"GBP","awardDate":"2020-04-22T00:00:00+00:00","Sponsor(s)":"Prof Oliver Pybus","Internal ID":"220414/Z/20/Z","description":"Yellow fever virus (YFV) outbreaks are escalating worldwide despite the existence of a vaccine. Global travel raises the chance that YFV will become established in Asia, where populations are not vaccinated and an outbreak would be catastrophic. Our ability to predict and control YFV outbreaks is reduced by our lack of knowledge about (i) transmission of YFV in its sylvatic reservoir (non-human primates) and (ii) how YFV escapes from this reservoir to spread amongst people in urban areas. Severe under-reporting in both humans and non-human primates hampers our ability to directly study YFV transmission behaviour. Recent advances in portable genome sequencing and virus genomic epidemiology (including phylodynamics) offer new opportunities to use virus genomic data to reconstruct unobserved outbreak dynamics, even when sampling is sparse. I will combine these techniques to improve our understanding of YFV epidemiology, by: (i) integrating viral genomic data into newly-refined YFV mathematical models for improved outbreak prediction; (ii) implementing phylodynamic approaches to identify drivers of sylvatic transmission, and; (iii) exploiting new strategies to generate virus sequences from traditionally neglected times and locations. My Fellowship research findings will improve YFV outbreak prediction and contribute to the development of refined vaccination strategies.\n","plannedDates":[{"endDate":"2024-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2024-08-31"}],"amountAwarded":300000,"Financial Year":"2019/20","Lead Applicant":"Dr Sarah Hill","grantProgramme":[{"title":"Sir Henry Wellcome Postdoctoral Fellowship","title_keyword":"Sir Henry Wellcome Postdoctoral Fellowship"}],"Applicant Surname":"Hill","Partnership Value":300000,"Approval Committee":"Basic Science Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Royal-Veterinary-College","name":"Royal Veterinary College","addressCountry":"United Kingdom","id_and_name":"[\"Royal Veterinary College\", \"360G-Wellcome-ORG:Royal-Veterinary-College\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Royal-Veterinary-College","name":"Royal Veterinary College"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Epidemiology and outbreak prediction of yellow fever virus Yellow fever virus (YFV) outbreaks are escalating worldwide despite the existence of a vaccine. Global travel raises the chance that YFV will become established in Asia, where populations are not vaccinated and an outbreak would be catastrophic. Our ability to predict and control YFV outbreaks is reduced by our lack of knowledge about (i) transmission of YFV in its sylvatic reservoir (non-human primates) and (ii) how YFV escapes from this reservoir to spread amongst people in urban areas. Severe under-reporting in both humans and non-human primates hampers our ability to directly study YFV transmission behaviour. Recent advances in portable genome sequencing and virus genomic epidemiology (including phylodynamics) offer new opportunities to use virus genomic data to reconstruct unobserved outbreak dynamics, even when sampling is sparse. I will combine these techniques to improve our understanding of YFV epidemiology, by: (i) integrating viral genomic data into newly-refined YFV mathematical models for improved outbreak prediction; (ii) implementing phylodynamic approaches to identify drivers of sylvatic transmission, and; (iii) exploiting new strategies to generate virus sequences from traditionally neglected times and locations. My Fellowship research findings will improve YFV outbreak prediction and contribute to the development of refined vaccination strategies.\n","awardDateDateOnly":"2020-04-22","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Disease Outbreaks","Humans","Phylogeny","Primates","Yellow Fever","Yellow Fever Vaccine","Yellow fever virus"]}
{"id":"360G-Wellcome-220412_Z_20_Z","title":"VAPRE: Exploring the Relapse Prodrome of ANCA associated Vasculitis","Region":"Ireland","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220412/Z/20/Z","description":"ANCA Vasculitis is a rare autoimmune disease, whereby the immune system is triggered to self-destruct \u2013 the systems normally primed to fight infection and cancer cells are incorrectly activated, resulting in organ destruction, such as kidney failure.\nLike most autoimmune diseases, ANCA vasculitis goes through periods of remission (quiet) and relapse/flare (active). Half of patients will experience a flare over 5 years, resulting in cumulative tissue damage, due to the destructive inflammatory process itself and the powerful medications required. Infection is an unwanted complication.\nThe exact cause of ANCA vasculitis, and indeed autoimmunity, has yet to be discovered. Evidence suggests it is complex interaction between a person\u2019s genetic make-up and unknown triggers in their environment. We aim to identify these triggers, enabling us to predict autoimmune disease risk and hence explore avoidance mechanisms and personalised treatment options.\nThis project will utilise a novel big data approach, bringing together physicians, patients, computer scientists and artificial intelligence expertise to create an iterative model that learns over time about the impact of the environment on disease flare. Our ultimate goal is to create a clinical tool that will indicate flare risk for a particular patient, at a given point in time.\n","plannedDates":[{"endDate":"2022-09-26T00:00:00+00:00","startDate":"2019-07-08T00:00:00+00:00","startDateDateOnly":"2019-07-08","endDateDateOnly":"2022-09-26"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Jennifer Scott","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Partnership Name":"SFI-HRB-Wellcome Trust partnership","Applicant Surname":"Scott","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Trinity-College-Dublin","name":"Trinity College Dublin","addressCountry":"Ireland","id_and_name":"[\"Trinity College Dublin\", \"360G-Wellcome-ORG:Trinity-College-Dublin\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Trinity-College-Dublin","name":"Trinity College Dublin"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"VAPRE: Exploring the Relapse Prodrome of ANCA associated Vasculitis ANCA Vasculitis is a rare autoimmune disease, whereby the immune system is triggered to self-destruct \u2013 the systems normally primed to fight infection and cancer cells are incorrectly activated, resulting in organ destruction, such as kidney failure.\nLike most autoimmune diseases, ANCA vasculitis goes through periods of remission (quiet) and relapse/flare (active). Half of patients will experience a flare over 5 years, resulting in cumulative tissue damage, due to the destructive inflammatory process itself and the powerful medications required. Infection is an unwanted complication.\nThe exact cause of ANCA vasculitis, and indeed autoimmunity, has yet to be discovered. Evidence suggests it is complex interaction between a person\u2019s genetic make-up and unknown triggers in their environment. We aim to identify these triggers, enabling us to predict autoimmune disease risk and hence explore avoidance mechanisms and personalised treatment options.\nThis project will utilise a novel big data approach, bringing together physicians, patients, computer scientists and artificial intelligence expertise to create an iterative model that learns over time about the impact of the environment on disease flare. Our ultimate goal is to create a clinical tool that will indicate flare risk for a particular patient, at a given point in time.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Precision Medicine"]}
{"id":"360G-Wellcome-220411_Z_20_Z","title":"British Academy Small Research Grant, Conference and Policy Workshop Proposal","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220411/Z/20/Z","description":"The British Academy is submitting a funding proposal to the Wellcome Trust which will provide support for researchers in the humanities and social sciences working in areas related to health and wellbeing.  Taking a broad definition of health, the proposal will provide a  portfolio of support for academics, at all stages of their careers, working in the humanities and social sciences by providing funding for Small Research Grants, academic conferences and policy workshops.  The proposal follows discussions with the Trust over a number of months and is valued at \u00a33.97 million including: funding of \u00a32.76 million for Small Research grants; \u00a31.12 million for conferences; and \u00a384,000 for policy workshops (over 3 years).  Funding is proposed to begin in early 2020 and to finish in 2026. The collaboration is designed to demonstrate the relevance of humanities and social science research in relation to health and wellbeing through the scale and breadth of funding options for researchers and the potential for long term impact.  \n","plannedDates":[{"endDate":"2023-05-14T00:00:00+00:00","startDate":"2020-05-14T00:00:00+00:00","startDateDateOnly":"2020-05-14","endDateDateOnly":"2023-05-14"}],"amountAwarded":757562,"Financial Year":"2019/20","Lead Applicant":"Ms Jo Hopkins","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Hopkins","Partnership Value":757562,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:British-Academy","name":"British Academy","addressCountry":"United Kingdom","id_and_name":"[\"British Academy\", \"360G-Wellcome-ORG:British-Academy\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:British-Academy","name":"British Academy"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"British Academy Small Research Grant, Conference and Policy Workshop Proposal The British Academy is submitting a funding proposal to the Wellcome Trust which will provide support for researchers in the humanities and social sciences working in areas related to health and wellbeing.  Taking a broad definition of health, the proposal will provide a  portfolio of support for academics, at all stages of their careers, working in the humanities and social sciences by providing funding for Small Research Grants, academic conferences and policy workshops.  The proposal follows discussions with the Trust over a number of months and is valued at \u00a33.97 million including: funding of \u00a32.76 million for Small Research grants; \u00a31.12 million for conferences; and \u00a384,000 for policy workshops (over 3 years).  Funding is proposed to begin in early 2020 and to finish in 2026. The collaboration is designed to demonstrate the relevance of humanities and social science research in relation to health and wellbeing through the scale and breadth of funding options for researchers and the potential for long term impact.  \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biomedical Research","Humanities","Humans","Research Personnel","Research Support as Topic","Social Sciences","United Kingdom"]}
{"id":"360G-Wellcome-220410_Z_20_Z","title":"Teacher Research Grant - Scoping Phase, Evaluation","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220410/Z/20/Z","description":"This grant will support both Sheffield Hallam University and the National Foundation for Educational Research (NFER) to work with the four grantees of the Teacher Research Scoping Grants and to undertake the writing and costing of the proposal for the research and evaluation study of this programme.","plannedDates":[{"endDate":"2020-01-15T00:00:00+00:00","startDate":"2020-01-01T00:00:00+00:00","startDateDateOnly":"2020-01-01","endDateDateOnly":"2020-01-15"}],"amountAwarded":6525,"Financial Year":"2019/20","Lead Applicant":"Dr Bronwen Maxwell","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Maxwell","Partnership Value":6525,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Sheffield-Hallam-University","name":"Sheffield Hallam University","addressCountry":"United Kingdom","id_and_name":"[\"Sheffield Hallam University\", \"360G-Wellcome-ORG:Sheffield-Hallam-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Sheffield-Hallam-University","name":"Sheffield Hallam University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Teacher Research Grant - Scoping Phase, Evaluation This grant will support both Sheffield Hallam University and the National Foundation for Educational Research (NFER) to work with the four grantees of the Teacher Research Scoping Grants and to undertake the writing and costing of the proposal for the research and evaluation study of this programme.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Research Personnel","Universities"]}
{"id":"360G-Wellcome-220407_Z_20_Z","title":"Maximising T cell cytotoxicity and persistence for long term anti-cancer protection in adoptive cell therapy (ACT).","Region":"Scotland","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220407/Z/20/Z","description":"One of the functions of the immune system is to recognise and kill cancerous cells.  This is done by specialised immune cells called cytotoxic T cells.  However, there are many ways in which this process can go wrong, and this leads to the development of cancer.  Many recently developed treatments for cancer are designed to improve the ability of the T cells to recognise and kill the tumour cells, but this is still imperfect and there is lots of room for improvement.  I aim to make alterations to the signals that occur inside T cells after they \"see\" an abnormal tumour cell, in order to make them more effective at killing cancer cells and to stay around and do this job for longer.  I will test modifications by making relevant alterations to T cells in the lab, and then assessing their ability to kill cancer cells in a petri dish and to destroy tumours in mice with cancer.  Different modifications will enable me to understand how T cells function, and where modifications can be made to improve their tumour killing function.  This could be used in future to modify patients\u2019 own T cells to treat their cancer.\n","plannedDates":[{"endDate":"2023-02-28T00:00:00+00:00","startDate":"2019-08-12T00:00:00+00:00","startDateDateOnly":"2019-08-12","endDateDateOnly":"2023-02-28"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Alexandra Teagle","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Teagle","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Maximising T cell cytotoxicity and persistence for long term anti-cancer protection in adoptive cell therapy (ACT). One of the functions of the immune system is to recognise and kill cancerous cells.  This is done by specialised immune cells called cytotoxic T cells.  However, there are many ways in which this process can go wrong, and this leads to the development of cancer.  Many recently developed treatments for cancer are designed to improve the ability of the T cells to recognise and kill the tumour cells, but this is still imperfect and there is lots of room for improvement.  I aim to make alterations to the signals that occur inside T cells after they \"see\" an abnormal tumour cell, in order to make them more effective at killing cancer cells and to stay around and do this job for longer.  I will test modifications by making relevant alterations to T cells in the lab, and then assessing their ability to kill cancer cells in a petri dish and to destroy tumours in mice with cancer.  Different modifications will enable me to understand how T cells function, and where modifications can be made to improve their tumour killing function.  This could be used in future to modify patients\u2019 own T cells to treat their cancer.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adoptive Transfer","Animals","Humans","Immunotherapy, Adoptive","Mice","Neoplasms","T-Lymphocytes"]}
{"id":"360G-Wellcome-220406_Z_20_Z","title":"Establishing the role of Staphylococcus aureus RNA-binding proteins in regulating host adaptive responses and antibiotic resistance.","Region":"Scotland","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220406/Z/20/Z","description":"Staphylococcus aureus is a major human pathogen associated with thousands of deaths each year. S. aureus can adapt to survive and thrive inside human immune cells (macrophages) and has developed resistance to multiple antibiotic classes making it a dangerous pathogen.  We hypothesise that S. aureus uses the interactions between proteins and RNA to control the adaptation to surviving inside human macrophages and to avoid being killed by antibiotics.\n\n \n\n\nWe will assess how the pathogen changes which proteins are bound to RNA when exposed to environmental challenges including those seen in human infection and antibiotic treatment. We will assess how these changes occur in the whole organism and in specific key proteins. We aim to engineer bacteria which have proteins which can\u2019t properly bind RNA and to see if they are less fit to survive in simulated infection, when infecting human immune cells, in an insect model of infection and when exposed to antibiotic therapy.\n\n \n\n\nThe identification of critical pathways involved in the adaptation of S. aureus to the host environment may reveal new therapeutic targets for the control of infection.\n","plannedDates":[{"endDate":"2023-04-13T00:00:00+00:00","startDate":"2019-08-12T00:00:00+00:00","startDateDateOnly":"2019-08-12","endDateDateOnly":"2023-04-13"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Hugh McCaughan","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"McCaughan","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Establishing the role of Staphylococcus aureus RNA-binding proteins in regulating host adaptive responses and antibiotic resistance. Staphylococcus aureus is a major human pathogen associated with thousands of deaths each year. S. aureus can adapt to survive and thrive inside human immune cells (macrophages) and has developed resistance to multiple antibiotic classes making it a dangerous pathogen.  We hypothesise that S. aureus uses the interactions between proteins and RNA to control the adaptation to surviving inside human macrophages and to avoid being killed by antibiotics.\n\n \n\n\nWe will assess how the pathogen changes which proteins are bound to RNA when exposed to environmental challenges including those seen in human infection and antibiotic treatment. We will assess how these changes occur in the whole organism and in specific key proteins. We aim to engineer bacteria which have proteins which can\u2019t properly bind RNA and to see if they are less fit to survive in simulated infection, when infecting human immune cells, in an insect model of infection and when exposed to antibiotic therapy.\n\n \n\n\nThe identification of critical pathways involved in the adaptation of S. aureus to the host environment may reveal new therapeutic targets for the control of infection.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Host-Pathogen Interactions","Humans","Macrophages","Staphylococcal Infections","Staphylococcus aureus"]}
{"id":"360G-Wellcome-220402_Z_20_Z","title":"Using Neurofind to make individualised inferences in first episode psychosis: feasibility, acceptability and clinical utility in a real-world setting","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220402/Z/20/Z","description":"Brain-based disorders, including psychiatric and neurological illnesses, represent\n10.4% of the global burden of disease. At present, there are no established imagingbased\ntests for detecting these disorders, monitoring their progression over time and\noptimising treatment. In a previous Wellcome Innovator Award, Prof Andrea Mechelli and team at KCL developed Neurofind - a user-friendly web-based tool, which usesdeep learning technology to quantify neuroanatomical abnormalities from structural Magnetic Resonance Imaging scans. This tool compares an individual scan against a\nreference database and generates an individualised report that could support\ndiagnostic, prognostic and treatment decisions in individual patients. In this follow-on\naward, the feasibility, acceptability, safety and clinical utility of Neurofind will now be\nassessed in a real-world setting. Neurofind will be tested in patients with first episode\npsychosis recruited from the South London and Maudsley NHS Foundation Trust.\nThe study aims to test if Neurofind is feasible, acceptable, safe and if the information\nin the individualised patient reports it produces is predictive of clinical outcomes at 6-\nmonths follow-up. If successful, the proposed trial will lead to the adoption of\nNeurofind in real-world clinical services, with tangible benefits for patients, clinicians and service providers\n ","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":466154,"Financial Year":"2019/20","Lead Applicant":"Prof Andrea Mechelli","grantProgramme":[{"title":"Innovations Psychosis Flagship","title_keyword":"Innovations Psychosis Flagship"}],"Applicant Surname":"Mechelli","Partnership Value":466154,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Prof Philip McGuire","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Using Neurofind to make individualised inferences in first episode psychosis: feasibility, acceptability and clinical utility in a real-world setting Brain-based disorders, including psychiatric and neurological illnesses, represent\n10.4% of the global burden of disease. At present, there are no established imagingbased\ntests for detecting these disorders, monitoring their progression over time and\noptimising treatment. In a previous Wellcome Innovator Award, Prof Andrea Mechelli and team at KCL developed Neurofind - a user-friendly web-based tool, which usesdeep learning technology to quantify neuroanatomical abnormalities from structural Magnetic Resonance Imaging scans. This tool compares an individual scan against a\nreference database and generates an individualised report that could support\ndiagnostic, prognostic and treatment decisions in individual patients. In this follow-on\naward, the feasibility, acceptability, safety and clinical utility of Neurofind will now be\nassessed in a real-world setting. Neurofind will be tested in patients with first episode\npsychosis recruited from the South London and Maudsley NHS Foundation Trust.\nThe study aims to test if Neurofind is feasible, acceptable, safe and if the information\nin the individualised patient reports it produces is predictive of clinical outcomes at 6-\nmonths follow-up. If successful, the proposed trial will lead to the adoption of\nNeurofind in real-world clinical services, with tangible benefits for patients, clinicians and service providers\n ","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adult","Brain","Feasibility Studies","Female","Humans","Internet","Magnetic Resonance Imaging","Male","Psychotic Disorders","Young Adult"]}
{"id":"360G-Wellcome-220401_Z_20_Z","title":"Determining Preferred Product Characteristics to Support Uptake of Innovative Antibodies","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220401/Z/20/Z","description":"Through this project, IAVI and WHO Immunizations, Vaccines, and Biologicals (IVB) will harness input from a broad network of stakeholders to produce a Preferred Product Characteristics (PPC) technical document for forthcoming monoclonal antibodies (mAbs) for HIV prevention. Created early in clinical development and with attentiveness to end-user and health systems perspectives, this PPC document will provide strategic guidance as to preferences for new HIV preventative antibodies to inform clinical development and support eventual integration into WHO policy. While the focus of this effort will be on articulating optimal product attributes for antibodies for HIV prophylaxis, it is anticipated that acceptability, suitability and feasibility criteria identified through this process can inform product design, clinical development, and access considerations for a broader array of antibody-based products for infectious and neglected diseases in the pipeline.","plannedDates":[{"endDate":"2022-05-16T00:00:00+00:00","startDate":"2020-05-15T00:00:00+00:00","startDateDateOnly":"2020-05-15","endDateDateOnly":"2022-05-16"}],"amountAwarded":72206,"Financial Year":"2019/20","Lead Applicant":"Ms Shelly Malhotra","grantProgramme":[{"title":"Discretionary Award \u2013 Innovations","title_keyword":"Discretionary Award \u2013 Innovations"}],"Applicant Surname":"Malhotra","Partnership Value":72206,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:International-AIDS-Vaccine-Initiative","name":"International AIDS Vaccine Initiative","addressCountry":"United States","id_and_name":"[\"International AIDS Vaccine Initiative\", \"360G-Wellcome-ORG:International-AIDS-Vaccine-Initiative\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:International-AIDS-Vaccine-Initiative","name":"International AIDS Vaccine Initiative"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Determining Preferred Product Characteristics to Support Uptake of Innovative Antibodies Through this project, IAVI and WHO Immunizations, Vaccines, and Biologicals (IVB) will harness input from a broad network of stakeholders to produce a Preferred Product Characteristics (PPC) technical document for forthcoming monoclonal antibodies (mAbs) for HIV prevention. Created early in clinical development and with attentiveness to end-user and health systems perspectives, this PPC document will provide strategic guidance as to preferences for new HIV preventative antibodies to inform clinical development and support eventual integration into WHO policy. While the focus of this effort will be on articulating optimal product attributes for antibodies for HIV prophylaxis, it is anticipated that acceptability, suitability and feasibility criteria identified through this process can inform product design, clinical development, and access considerations for a broader array of antibody-based products for infectious and neglected diseases in the pipeline.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["AIDS Vaccines","Antibodies, Monoclonal","HIV Antibodies","HIV Infections","Humans"]}
{"id":"360G-Wellcome-220400_Z_20_Z","title":"Investigating the crosstalk between adipocytes and macrophages during wound repair","Region":"Scotland","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220400/Z/20/Z","description":"Our immune system exists to help our bodies fight infection, heal wounds and remove unhealthy cells. In order to gain as much information as possible about this complex system, it is vital to investigate immunological processes in the context of a living animal. Despite evolutionary divergence from humans, the fruit fly Drosophila melanogaster contains a relevant immune cell type, making it an ideal model in which to investigate immune cell functions, such as damage signalling, cell corpse recognition and immune cell memory.\n\nIt has recently emerged that fat cells also play a role in wound healing, and this project seeks to elucidate the mechanism by which fat cells contribute to the immune response. The tractable genetics of Drosophila will allow us to identify potential candidate genes by screening for which genes are \"turned on\" in cells that are responding to laser induced wounds. We will then increase or decrease the level of expression of these candidate genes and use real time imaging in the living Drosophila pupae to identify the effect that these genes have on immune cell and fat cell migration to wounds.\n","plannedDates":[{"endDate":"2022-10-31T00:00:00+00:00","startDate":"2019-08-05T00:00:00+00:00","startDateDateOnly":"2019-08-05","endDateDateOnly":"2022-10-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Henry Todd","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Todd","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the crosstalk between adipocytes and macrophages during wound repair Our immune system exists to help our bodies fight infection, heal wounds and remove unhealthy cells. In order to gain as much information as possible about this complex system, it is vital to investigate immunological processes in the context of a living animal. Despite evolutionary divergence from humans, the fruit fly Drosophila melanogaster contains a relevant immune cell type, making it an ideal model in which to investigate immune cell functions, such as damage signalling, cell corpse recognition and immune cell memory.\n\nIt has recently emerged that fat cells also play a role in wound healing, and this project seeks to elucidate the mechanism by which fat cells contribute to the immune response. The tractable genetics of Drosophila will allow us to identify potential candidate genes by screening for which genes are \"turned on\" in cells that are responding to laser induced wounds. We will then increase or decrease the level of expression of these candidate genes and use real time imaging in the living Drosophila pupae to identify the effect that these genes have on immune cell and fat cell migration to wounds.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cell Movement","Drosophila Proteins","Drosophila melanogaster","Pupa","Wound Healing"]}
{"id":"360G-Wellcome-220399_Z_20_Z","title":"Spatial regulation of core neurodevelopment transcription factors in human glioblastoma stem cells","Region":"Scotland","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220399/Z/20/Z","description":"The most common brain cancer, termed glioblastoma (GBM), is incurable and life expectancy is only ~14 months.  The cells that drive GBM are trapped in a stem cell-like state and exploit pathways used by normal brain stem cells.  GBM stem cell-like cells increase key factors (transcription factors) that are master regulators of brain stem cells, such as SOX2 and FOXG1, which bind to gene control regions called super-enhancers. Many critical genes that drive GBM exist as separate pieces of DNA rather than as part of the organized DNA structure in chromosomes, called extra-chromosomal DNA (ecDNA).  This enables tumour cells to rapidly expand key regulators and may contain super-enhancer areas to switch important genes on.\n\nWe predict that increased amounts of these transcription factors and their clustering at super-enhancers explains the locked-in stem cell state of GBM cells. \n\nThis project aims to confirm that important gene drivers of GBM are found on ecDNA in GBM cells from patients. We will test which transcription factors stick to which enhancers to understand the combinations needed to switch on important genes.  We will evaluate if these factors, enhancers and genes physically converge as condensates to make cancer cells \u2018stuck\u2019 in their stem cell-like state. \n","plannedDates":[{"endDate":"2023-02-28T00:00:00+00:00","startDate":"2019-08-01T00:00:00+00:00","startDateDateOnly":"2019-08-01","endDateDateOnly":"2023-02-28"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Karin Purshouse","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Purshouse","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Spatial regulation of core neurodevelopment transcription factors in human glioblastoma stem cells The most common brain cancer, termed glioblastoma (GBM), is incurable and life expectancy is only ~14 months.  The cells that drive GBM are trapped in a stem cell-like state and exploit pathways used by normal brain stem cells.  GBM stem cell-like cells increase key factors (transcription factors) that are master regulators of brain stem cells, such as SOX2 and FOXG1, which bind to gene control regions called super-enhancers. Many critical genes that drive GBM exist as separate pieces of DNA rather than as part of the organized DNA structure in chromosomes, called extra-chromosomal DNA (ecDNA).  This enables tumour cells to rapidly expand key regulators and may contain super-enhancer areas to switch important genes on.\n\nWe predict that increased amounts of these transcription factors and their clustering at super-enhancers explains the locked-in stem cell state of GBM cells. \n\nThis project aims to confirm that important gene drivers of GBM are found on ecDNA in GBM cells from patients. We will test which transcription factors stick to which enhancers to understand the combinations needed to switch on important genes.  We will evaluate if these factors, enhancers and genes physically converge as condensates to make cancer cells \u2018stuck\u2019 in their stem cell-like state. \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Brain Neoplasms","Cell Line, Tumor","Enhancer Elements, Genetic","Gene Expression Regulation, Neoplastic","Glioblastoma","Humans","Neoplastic Stem Cells","Transcription Factors"]}
{"id":"360G-Wellcome-220398_Z_20_Z","title":"How do dysfunctional endothelial cells in cerebral small vessel disease modulate surrounding oligodendroglia through secretion of heat shock protein 90 alpha?","Region":"Scotland","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220398/Z/20/Z","description":"Dementia is becoming an increasingly important disease, affecting vast numbers of people. Disease of the small blood vessels in the brain is the second most common cause of dementia, and is called cerebral small vessel disease. The endothelial cells which line the blood vessels start the disease process and then affect the surrounding brain cells causing the problems we seen in patients with dementia. I will study how endothelial cells cause disruption to the surrounding brain cells and whether it can be reversed, leading the way to potential treatments for small vessel disease.\n","plannedDates":[{"endDate":"2022-10-31T00:00:00+00:00","startDate":"2019-08-01T00:00:00+00:00","startDateDateOnly":"2019-08-01","endDateDateOnly":"2022-10-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Tessa Procter","grantProgramme":[{"title":"PhD Training Fellowship for Clinicians","title_keyword":"PhD Training Fellowship for Clinicians"}],"Applicant Surname":"Procter","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"How do dysfunctional endothelial cells in cerebral small vessel disease modulate surrounding oligodendroglia through secretion of heat shock protein 90 alpha? Dementia is becoming an increasingly important disease, affecting vast numbers of people. Disease of the small blood vessels in the brain is the second most common cause of dementia, and is called cerebral small vessel disease. The endothelial cells which line the blood vessels start the disease process and then affect the surrounding brain cells causing the problems we seen in patients with dementia. I will study how endothelial cells cause disruption to the surrounding brain cells and whether it can be reversed, leading the way to potential treatments for small vessel disease.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Brain","Cerebral Small Vessel Diseases","Dementia","Endothelial Cells","Endothelium, Vascular","Humans","Oligodendroglia"]}
{"id":"360G-Wellcome-220396_Z_20_Z","title":"Investigating how winners alter losers in Minute cell competition","Region":"South West","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220396/Z/20/Z","description":"I work on cell competition, a process where relatively less fit cells (losers) are eliminated by relatively fitter neighbouring cells (winners). There are many types of cell competition and in my PhD I will focus on Minute cell competition. In Minute cell competition cells that have lost one copy of a ribosome gene (called Minute) are induced to die by wild-type cells. Minute cell competition acts as a quality control to maintain tissues healthy and is likely to contribute to the elimination of cells with tumorigenic potential. We are interested in understanding how proximity with winner cells modifies the cellular state of Minute cells so that they behave as losers and die. Our approach involves introducing groups of wild-type-cells in a Minute background in developing fly epithelia. In my work I will characterise how cell competition changes specific cellular processes such as translation, autophagy and oxidative stress. I will also look at gene expression changes induced during cell competition in loser Minute cells, to identify novel additional factors affected by winners and involved in cell competition. This work is likely to identify new components that, by modulating cell competition, could be important in maintaining tissue health and in cancer prevention.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Alex Mastrogiannopoulos","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Mastrogiannopoulos","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating how winners alter losers in Minute cell competition I work on cell competition, a process where relatively less fit cells (losers) are eliminated by relatively fitter neighbouring cells (winners). There are many types of cell competition and in my PhD I will focus on Minute cell competition. In Minute cell competition cells that have lost one copy of a ribosome gene (called Minute) are induced to die by wild-type cells. Minute cell competition acts as a quality control to maintain tissues healthy and is likely to contribute to the elimination of cells with tumorigenic potential. We are interested in understanding how proximity with winner cells modifies the cellular state of Minute cells so that they behave as losers and die. Our approach involves introducing groups of wild-type-cells in a Minute background in developing fly epithelia. In my work I will characterise how cell competition changes specific cellular processes such as translation, autophagy and oxidative stress. I will also look at gene expression changes induced during cell competition in loser Minute cells, to identify novel additional factors affected by winners and involved in cell competition. This work is likely to identify new components that, by modulating cell competition, could be important in maintaining tissue health and in cancer prevention.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Autophagy","Drosophila melanogaster","Ribosomes"]}
{"id":"360G-Wellcome-220390_Z_20_Z","title":"Using genetics to understand causal mechanisms underlying adverse outcomes of obese pregnancies","Region":"South West","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220390/Z/20/Z","description":"More than 1 in 5 UK pregnant women are clinically obese, a condition associated with heterogeneous health outcomes for mother and baby. Only limited understanding of the associations (e.g. gestational diabetes and high birth weight, hypertension and preterm birth/low birth weight) has been possible in traditional observational studies due to complex interrelated exposures and outcomes. My research will use human genetics to dissect causal pathways and understand how a higher maternal BMI can lead to such diverse outcomes. I hypothesise that maternal effects on fetal growth and gestational duration are moderated by fetal genetics. My first aim is to understand how a fetus regulates its own growth and gestational duration in different maternal environments. We will apply results of new genome-wide association studies of placental weight and umbilical cord insulin to give mechanistic insights. My second aim is to understand how raised maternal BMI impacts gestational duration and growth, and my third aim is to examine whether fetal genetics can influence the maternal environment. By identifying causal mechanisms, this fellowship will be an advance towards better targeting of antenatal healthcare and advice to pregnant women, according to their level of risk to reduce the incidence of adverse pregnancy outcomes.\n","plannedDates":[{"endDate":"2026-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2026-09-30"}],"amountAwarded":1391495,"Financial Year":"2019/20","Lead Applicant":"Dr Rachel Freathy","grantProgramme":[{"title":"Senior Research Fellowship","title_keyword":"Senior Research Fellowship"}],"Applicant Surname":"Freathy","Partnership Value":1391495,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Exeter","name":"University of Exeter","addressCountry":"United Kingdom","id_and_name":"[\"University of Exeter\", \"360G-Wellcome-ORG:University-of-Exeter\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Exeter","name":"University of Exeter"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Using genetics to understand causal mechanisms underlying adverse outcomes of obese pregnancies More than 1 in 5 UK pregnant women are clinically obese, a condition associated with heterogeneous health outcomes for mother and baby. Only limited understanding of the associations (e.g. gestational diabetes and high birth weight, hypertension and preterm birth/low birth weight) has been possible in traditional observational studies due to complex interrelated exposures and outcomes. My research will use human genetics to dissect causal pathways and understand how a higher maternal BMI can lead to such diverse outcomes. I hypothesise that maternal effects on fetal growth and gestational duration are moderated by fetal genetics. My first aim is to understand how a fetus regulates its own growth and gestational duration in different maternal environments. We will apply results of new genome-wide association studies of placental weight and umbilical cord insulin to give mechanistic insights. My second aim is to understand how raised maternal BMI impacts gestational duration and growth, and my third aim is to examine whether fetal genetics can influence the maternal environment. By identifying causal mechanisms, this fellowship will be an advance towards better targeting of antenatal healthcare and advice to pregnant women, according to their level of risk to reduce the incidence of adverse pregnancy outcomes.\n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Birth Weight","Body Mass Index","Female","Fetal Development","Gene-Environment Interaction","Genome-Wide Association Study","Humans","Obesity","Pregnancy","Pregnancy Outcome"]}
{"id":"360G-Wellcome-220387_Z_20_Z","title":"Interlocking nanomechanics of kinesins and tubulins","Region":"West Midlands","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220387/Z/20/Z","description":"Kinesin-microtubule systems transport intracellular cargo in eukaryotes and are essential for life. Recently, we discovered that dynamic microtubules can respond to kinesin by changing their conformation, lattice spacing, curvature and stability, and conversely that kinesin stepping can sense and respond to conformational shifts in the microtubule lattice. These insights fundamentally redraw our picture of the function of kinesin-microtubule transport systems. I now propose to dissect the mechanical mechanisms by which kinesins and microtubules instruct one another, using protein engineering combined with single molecule optical trapping at unprecedented resolution. Working with both wild-type and mutant kinesins and tubulins, principally from S. pombe, we will determine the structural requirements for different microtubule lattices to control kinesin substeps, backsteps and bidirectionality; and the converse requirements for kinesins to manipulate the conformation and fate of microtubules. Our experiments will reveal how tubulins communicate mechanically with one another and with kinesins. Illuminating the molecular mechanisms of active mechanical feedback in kinesin-microtubule systems will transform understanding of the transport machinery and open the way to improved chemical biological manipulation of its in vivo function.\n","plannedDates":[{"endDate":"2025-05-31T00:00:00+00:00","startDate":"2020-06-01T00:00:00+00:00","startDateDateOnly":"2020-06-01","endDateDateOnly":"2025-05-31"}],"amountAwarded":1639257,"Financial Year":"2019/20","Lead Applicant":"Prof Robert Cross","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Cross","Partnership Value":1639257,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Warwick","name":"University of Warwick","addressCountry":"United Kingdom","id_and_name":"[\"University of Warwick\", \"360G-Wellcome-ORG:University-of-Warwick\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Warwick","name":"University of Warwick"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Interlocking nanomechanics of kinesins and tubulins Kinesin-microtubule systems transport intracellular cargo in eukaryotes and are essential for life. Recently, we discovered that dynamic microtubules can respond to kinesin by changing their conformation, lattice spacing, curvature and stability, and conversely that kinesin stepping can sense and respond to conformational shifts in the microtubule lattice. These insights fundamentally redraw our picture of the function of kinesin-microtubule transport systems. I now propose to dissect the mechanical mechanisms by which kinesins and microtubules instruct one another, using protein engineering combined with single molecule optical trapping at unprecedented resolution. Working with both wild-type and mutant kinesins and tubulins, principally from S. pombe, we will determine the structural requirements for different microtubule lattices to control kinesin substeps, backsteps and bidirectionality; and the converse requirements for kinesins to manipulate the conformation and fate of microtubules. Our experiments will reveal how tubulins communicate mechanically with one another and with kinesins. Illuminating the molecular mechanisms of active mechanical feedback in kinesin-microtubule systems will transform understanding of the transport machinery and open the way to improved chemical biological manipulation of its in vivo function.\n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Kinesin","Microtubules","Protein Conformation","Tubulin"]}
{"id":"360G-Wellcome-220382_Z_20_Z","title":"The Intergenerational Transmission of Mental Health Problems: Identifying Causal Pathways and How to Interrupt Them","Region":"Greater London","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220382/Z/20/Z","description":"I propose to use my SRF to investigate the intergenerational transmission of mental health problems. Previously, in my Sir Henry Dale Fellowship, I have developed statistical models for use with genetically informative intergenerational data (composed of many extended families) for use in distinguishing genetic transmission from the potential causal effects of parent on child. In my SRF I will build on this work:\n\n1. I will establish to what extent the treatment of mental health problems in parents reduces the transmission of problems to children (and vice versa). \n\n2. Combine pedigree-based approaches with genomic data to draw on the strengths of each. This will enable the identification of the direction and magnitude of intergenerational causal effects, and identify polygenic scores involverd in gene-environment interplay relevant to the intergenerational transmission of mental health problems. \n\n3. Explore the biases inherent in our use of volunteer based cohorts to understand mental health aetiology. \n\n4. Extend my own children-of-twins study, funded as part of my SHDF, CoTEDS (the Children-of-TEDS). CoTEDS is the second generation of an ongoing twin study, and the first twin study in the world to include information on parents and children from birth. \n","plannedDates":[{"endDate":"2026-01-03T00:00:00+00:00","startDate":"2021-01-04T00:00:00+00:00","startDateDateOnly":"2021-01-04","endDateDateOnly":"2026-01-03"}],"amountAwarded":2035881,"Financial Year":"2019/20","Lead Applicant":"Dr Tom McAdams","grantProgramme":[{"title":"Senior Research Fellowship","title_keyword":"Senior Research Fellowship"}],"Applicant Surname":"McAdams","Partnership Value":2035881,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The Intergenerational Transmission of Mental Health Problems: Identifying Causal Pathways and How to Interrupt Them I propose to use my SRF to investigate the intergenerational transmission of mental health problems. Previously, in my Sir Henry Dale Fellowship, I have developed statistical models for use with genetically informative intergenerational data (composed of many extended families) for use in distinguishing genetic transmission from the potential causal effects of parent on child. In my SRF I will build on this work:\n\n1. I will establish to what extent the treatment of mental health problems in parents reduces the transmission of problems to children (and vice versa). \n\n2. Combine pedigree-based approaches with genomic data to draw on the strengths of each. This will enable the identification of the direction and magnitude of intergenerational causal effects, and identify polygenic scores involverd in gene-environment interplay relevant to the intergenerational transmission of mental health problems. \n\n3. Explore the biases inherent in our use of volunteer based cohorts to understand mental health aetiology. \n\n4. Extend my own children-of-twins study, funded as part of my SHDF, CoTEDS (the Children-of-TEDS). CoTEDS is the second generation of an ongoing twin study, and the first twin study in the world to include information on parents and children from birth. \n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Child","Female","Humans","Intergenerational Relations","Male","Mental Disorders","Mental Health","Parents","Pedigree","Twins","Twins, Monozygotic"]}
{"id":"360G-Wellcome-220379_Z_20_Z","title":"Molecular mechanisms of cell fate decisions in gastrulation and early organogenesis","Region":"East of England","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220379/Z/20/Z","description":"The cell fate decisions that accompany exit from pluripotency and entry into gastrulation and early organogenesis establish the vertebrate body plan. Recent advances in single-cell multiomics have allowed transcriptomes and epigenomes to be mapped at single cell resolution during mouse embryogenesis. These studies suggest that cell fate decisions can be made autonomously, where cell fate derives from an intrinsic regulatory programme, or signalling-based, in which fate is determined by the reception of local extrinsic cues. The potency of precursors is progressively restricted as fate is allocated, but separate developmental routes can lead to convergent cell fates. To understand the fundamental principles of these cell fate determination processes, we will combine in vivo mechanistic studies and quantitative mechanistic modelling. We will integrate cell lineage relationships with spatial information and single cell multi-omics, using (epi)genome editing to perturb cell fate decisions in vivo. By comparing early organogenesis across the three germ layers, we will seek to understand the shared and unique features of the mechanisms that establish the underlying fate map.\n \n","plannedDates":[{"endDate":"2025-11-30T00:00:00+00:00","startDate":"2020-12-01T00:00:00+00:00","startDateDateOnly":"2020-12-01","endDateDateOnly":"2025-11-30"}],"amountAwarded":532692,"Financial Year":"2019/20","Lead Applicant":"Prof Wolf Reik","grantProgramme":[{"title":"Collaborative Award in Science","title_keyword":"Collaborative Award in Science"}],"Applicant Surname":"Reik","Partnership Value":532692,"Approval Committee":"Science Interview Panel","Other Applicant(s)":"Dr John Marioni, Prof Benjamin Simons, Dr Anna-Katerina Hadjantonakis, Prof Berthold Gottgens, Prof Jennifer Nichols, Prof Shankar Srinivas, Dr James Briscoe","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Babraham-Institute","name":"Babraham Institute","addressCountry":"United Kingdom","id_and_name":"[\"Babraham Institute\", \"360G-Wellcome-ORG:Babraham-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Babraham-Institute","name":"Babraham Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Molecular mechanisms of cell fate decisions in gastrulation and early organogenesis The cell fate decisions that accompany exit from pluripotency and entry into gastrulation and early organogenesis establish the vertebrate body plan. Recent advances in single-cell multiomics have allowed transcriptomes and epigenomes to be mapped at single cell resolution during mouse embryogenesis. These studies suggest that cell fate decisions can be made autonomously, where cell fate derives from an intrinsic regulatory programme, or signalling-based, in which fate is determined by the reception of local extrinsic cues. The potency of precursors is progressively restricted as fate is allocated, but separate developmental routes can lead to convergent cell fates. To understand the fundamental principles of these cell fate determination processes, we will combine in vivo mechanistic studies and quantitative mechanistic modelling. We will integrate cell lineage relationships with spatial information and single cell multi-omics, using (epi)genome editing to perturb cell fate decisions in vivo. By comparing early organogenesis across the three germ layers, we will seek to understand the shared and unique features of the mechanisms that establish the underlying fate map.\n \n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cell Differentiation","Cell Lineage","Gastrulation","Gene Expression Regulation, Developmental","Mice","Pluripotent Stem Cells","Single-Cell Analysis"]}
{"id":"360G-Wellcome-220379_E_20_Z","title":"Molecular mechanisms of cell fate decisions in gastrulation and early organogenesis","Region":"International","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220379/E/20/Z","description":"The cell fate decisions that accompany exit from pluripotency and entry into gastrulation and early organogenesis establish the vertebrate body plan. Recent advances in single-cell multiomics have allowed transcriptomes and epigenomes to be mapped at single cell resolution during mouse embryogenesis. These studies suggest that cell fate decisions can be made autonomously, where cell fate derives from an intrinsic regulatory programme, or signalling-based, in which fate is determined by the reception of local extrinsic cues. The potency of precursors is progressively restricted as fate is allocated, but separate developmental routes can lead to convergent cell fates. To understand the fundamental principles of these cell fate determination processes, we will combine in vivo mechanistic studies and quantitative mechanistic modelling. We will integrate cell lineage relationships with spatial information and single cell multi-omics, using (epi)genome editing to perturb cell fate decisions in vivo. By comparing early organogenesis across the three germ layers, we will seek to understand the shared and unique features of the mechanisms that establish the underlying fate map.\n \n","plannedDates":[{"endDate":"2025-11-17T00:00:00+00:00","startDate":"2020-11-18T00:00:00+00:00","startDateDateOnly":"2020-11-18","endDateDateOnly":"2025-11-17"}],"amountAwarded":338511,"Financial Year":"2019/20","Lead Applicant":"Dr Anna-Katerina Hadjantonakis","grantProgramme":[{"title":"Collaborative Award in Science","title_keyword":"Collaborative Award in Science"}],"Applicant Surname":"Hadjantonakis","Partnership Value":338511,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Memorial-Sloan-Kettering-Cancer-Center","name":"Memorial Sloan Kettering Cancer Center","addressCountry":"United States","id_and_name":"[\"Memorial Sloan Kettering Cancer Center\", \"360G-Wellcome-ORG:Memorial-Sloan-Kettering-Cancer-Center\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Memorial-Sloan-Kettering-Cancer-Center","name":"Memorial Sloan Kettering Cancer Center"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Molecular mechanisms of cell fate decisions in gastrulation and early organogenesis The cell fate decisions that accompany exit from pluripotency and entry into gastrulation and early organogenesis establish the vertebrate body plan. Recent advances in single-cell multiomics have allowed transcriptomes and epigenomes to be mapped at single cell resolution during mouse embryogenesis. These studies suggest that cell fate decisions can be made autonomously, where cell fate derives from an intrinsic regulatory programme, or signalling-based, in which fate is determined by the reception of local extrinsic cues. The potency of precursors is progressively restricted as fate is allocated, but separate developmental routes can lead to convergent cell fates. To understand the fundamental principles of these cell fate determination processes, we will combine in vivo mechanistic studies and quantitative mechanistic modelling. We will integrate cell lineage relationships with spatial information and single cell multi-omics, using (epi)genome editing to perturb cell fate decisions in vivo. By comparing early organogenesis across the three germ layers, we will seek to understand the shared and unique features of the mechanisms that establish the underlying fate map.\n \n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cell Differentiation","Cell Lineage","Gastrulation","Gene Expression Regulation, Developmental","Mice","Pluripotent Stem Cells","Single-Cell Analysis"]}
{"id":"360G-Wellcome-220379_D_20_Z","title":"Molecular mechanisms of cell fate decisions in gastrulation and early organogenesis","Region":"Greater London","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220379/D/20/Z","description":"The cell fate decisions that accompany exit from pluripotency and entry into gastrulation and early organogenesis establish the vertebrate body plan. Recent advances in single-cell multiomics have allowed transcriptomes and epigenomes to be mapped at single cell resolution during mouse embryogenesis. These studies suggest that cell fate decisions can be made autonomously, where cell fate derives from an intrinsic regulatory programme, or signalling-based, in which fate is determined by the reception of local extrinsic cues. The potency of precursors is progressively restricted as fate is allocated, but separate developmental routes can lead to convergent cell fates. To understand the fundamental principles of these cell fate determination processes, we will combine in vivo mechanistic studies and quantitative mechanistic modelling. We will integrate cell lineage relationships with spatial information and single cell multi-omics, using (epi)genome editing to perturb cell fate decisions in vivo. By comparing early organogenesis across the three germ layers, we will seek to understand the shared and unique features of the mechanisms that establish the underlying fate map.\n \n","plannedDates":[{"endDate":"2025-11-17T00:00:00+00:00","startDate":"2020-11-18T00:00:00+00:00","startDateDateOnly":"2020-11-18","endDateDateOnly":"2025-11-17"}],"amountAwarded":389120,"Financial Year":"2019/20","Lead Applicant":"Dr James Briscoe","grantProgramme":[{"title":"Collaborative Award in Science","title_keyword":"Collaborative Award in Science"}],"Applicant Surname":"Briscoe","Partnership Value":389120,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:The-Francis-Crick-Institute","name":"The Francis Crick Institute","addressCountry":"United Kingdom","id_and_name":"[\"The Francis Crick Institute\", \"360G-Wellcome-ORG:The-Francis-Crick-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:The-Francis-Crick-Institute","name":"The Francis Crick Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Molecular mechanisms of cell fate decisions in gastrulation and early organogenesis The cell fate decisions that accompany exit from pluripotency and entry into gastrulation and early organogenesis establish the vertebrate body plan. Recent advances in single-cell multiomics have allowed transcriptomes and epigenomes to be mapped at single cell resolution during mouse embryogenesis. These studies suggest that cell fate decisions can be made autonomously, where cell fate derives from an intrinsic regulatory programme, or signalling-based, in which fate is determined by the reception of local extrinsic cues. The potency of precursors is progressively restricted as fate is allocated, but separate developmental routes can lead to convergent cell fates. To understand the fundamental principles of these cell fate determination processes, we will combine in vivo mechanistic studies and quantitative mechanistic modelling. We will integrate cell lineage relationships with spatial information and single cell multi-omics, using (epi)genome editing to perturb cell fate decisions in vivo. By comparing early organogenesis across the three germ layers, we will seek to understand the shared and unique features of the mechanisms that establish the underlying fate map.\n \n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cell Differentiation","Cell Lineage","Gastrulation","Gene Expression Regulation, Developmental","Mice","Pluripotent Stem Cells","Single-Cell Analysis"]}
{"id":"360G-Wellcome-220379_C_20_Z","title":"Molecular mechanisms of cell fate decisions in gastrulation and early organogenesis","Region":"South East","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220379/C/20/Z","description":"The cell fate decisions that accompany exit from pluripotency and entry into gastrulation and early organogenesis establish the vertebrate body plan. Recent advances in single-cell multiomics have allowed transcriptomes and epigenomes to be mapped at single cell resolution during mouse embryogenesis. These studies suggest that cell fate decisions can be made autonomously, where cell fate derives from an intrinsic regulatory programme, or signalling-based, in which fate is determined by the reception of local extrinsic cues. The potency of precursors is progressively restricted as fate is allocated, but separate developmental routes can lead to convergent cell fates. To understand the fundamental principles of these cell fate determination processes, we will combine in vivo mechanistic studies and quantitative mechanistic modelling. We will integrate cell lineage relationships with spatial information and single cell multi-omics, using (epi)genome editing to perturb cell fate decisions in vivo. By comparing early organogenesis across the three germ layers, we will seek to understand the shared and unique features of the mechanisms that establish the underlying fate map.\n \n","plannedDates":[{"endDate":"2025-11-17T00:00:00+00:00","startDate":"2020-11-18T00:00:00+00:00","startDateDateOnly":"2020-11-18","endDateDateOnly":"2025-11-17"}],"amountAwarded":507346,"Financial Year":"2019/20","Lead Applicant":"Prof Shankar Srinivas","grantProgramme":[{"title":"Collaborative Award in Science","title_keyword":"Collaborative Award in Science"}],"Applicant Surname":"Srinivas","Partnership Value":507346,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Molecular mechanisms of cell fate decisions in gastrulation and early organogenesis The cell fate decisions that accompany exit from pluripotency and entry into gastrulation and early organogenesis establish the vertebrate body plan. Recent advances in single-cell multiomics have allowed transcriptomes and epigenomes to be mapped at single cell resolution during mouse embryogenesis. These studies suggest that cell fate decisions can be made autonomously, where cell fate derives from an intrinsic regulatory programme, or signalling-based, in which fate is determined by the reception of local extrinsic cues. The potency of precursors is progressively restricted as fate is allocated, but separate developmental routes can lead to convergent cell fates. To understand the fundamental principles of these cell fate determination processes, we will combine in vivo mechanistic studies and quantitative mechanistic modelling. We will integrate cell lineage relationships with spatial information and single cell multi-omics, using (epi)genome editing to perturb cell fate decisions in vivo. By comparing early organogenesis across the three germ layers, we will seek to understand the shared and unique features of the mechanisms that establish the underlying fate map.\n \n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cell Differentiation","Cell Lineage","Gastrulation","Gene Expression Regulation, Developmental","Mice","Pluripotent Stem Cells","Single-Cell Analysis"]}
{"id":"360G-Wellcome-220379_B_20_Z","title":"Molecular mechanisms of cell fate decisions in gastrulation and early organogenesis","Region":"East of England","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220379/B/20/Z","description":"The cell fate decisions that accompany exit from pluripotency and entry into gastrulation and early organogenesis establish the vertebrate body plan. Recent advances in single-cell multiomics have allowed transcriptomes and epigenomes to be mapped at single cell resolution during mouse embryogenesis. These studies suggest that cell fate decisions can be made autonomously, where cell fate derives from an intrinsic regulatory programme, or signalling-based, in which fate is determined by the reception of local extrinsic cues. The potency of precursors is progressively restricted as fate is allocated, but separate developmental routes can lead to convergent cell fates. To understand the fundamental principles of these cell fate determination processes, we will combine in vivo mechanistic studies and quantitative mechanistic modelling. We will integrate cell lineage relationships with spatial information and single cell multi-omics, using (epi)genome editing to perturb cell fate decisions in vivo. By comparing early organogenesis across the three germ layers, we will seek to understand the shared and unique features of the mechanisms that establish the underlying fate map.\n \n","plannedDates":[{"endDate":"2025-11-17T00:00:00+00:00","startDate":"2020-11-18T00:00:00+00:00","startDateDateOnly":"2020-11-18","endDateDateOnly":"2025-11-17"}],"amountAwarded":2379992,"Financial Year":"2019/20","Lead Applicant":"Prof Berthold Gottgens","grantProgramme":[{"title":"Collaborative Award in Science","title_keyword":"Collaborative Award in Science"}],"Applicant Surname":"Gottgens","Partnership Value":2379992,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Molecular mechanisms of cell fate decisions in gastrulation and early organogenesis The cell fate decisions that accompany exit from pluripotency and entry into gastrulation and early organogenesis establish the vertebrate body plan. Recent advances in single-cell multiomics have allowed transcriptomes and epigenomes to be mapped at single cell resolution during mouse embryogenesis. These studies suggest that cell fate decisions can be made autonomously, where cell fate derives from an intrinsic regulatory programme, or signalling-based, in which fate is determined by the reception of local extrinsic cues. The potency of precursors is progressively restricted as fate is allocated, but separate developmental routes can lead to convergent cell fates. To understand the fundamental principles of these cell fate determination processes, we will combine in vivo mechanistic studies and quantitative mechanistic modelling. We will integrate cell lineage relationships with spatial information and single cell multi-omics, using (epi)genome editing to perturb cell fate decisions in vivo. By comparing early organogenesis across the three germ layers, we will seek to understand the shared and unique features of the mechanisms that establish the underlying fate map.\n \n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cell Differentiation","Cell Lineage","Gastrulation","Gene Expression Regulation, Developmental","Mice","Pluripotent Stem Cells","Single-Cell Analysis"]}
{"id":"360G-Wellcome-220370_Z_20_Z","title":"Improved targeting of stroke prevention by enhanced phenotyping of trends, risk factors, symptomatology, aetiology, and outcome: Oxford Vascular Study","Region":"South East","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220370/Z/20/Z","description":"Having founded the new Centre for Prevention of Stroke and Dementia (CPSD) to allow junior/intermediate colleagues to develop their programmes, my own research will continue to focus on better phenotyping of TIA and stroke and of known risk factors in order to substantially improve the targeting of preventive treatments. My work involves four core themes:\n\n\n Understanding the distinct temporal trends in incidence of different stroke subtypes to monitor the effectiveness of prevention and to develop new strategies;\n Obtaining reliable data on prognosis of different TIA/stroke subtypes to better target preventive treatments;\n Having proved the impact of better prediction and prevention of early recurrent stroke, I aim to substantially improve prevention of later recurrent stroke, focussing particularly on the utility of more detailed phenotyping (e.g. identification of occult atrial fibrillation, intracranial stenosis, and PFO, and remote monitoring of home-BP);\n By more detailed assessment of BP I will inform the treatment of hypertension in primary prevention of stroke (by studying long-term pre-morbid BP) and in secondary prevention (home telemetric BP-monitoring);\n\n\nTaken together the results of this work will impact on the treatment of almost all patients with TIA or stroke (2 million prevalent cases in the UK alone).\n","plannedDates":[{"endDate":"2027-07-31T00:00:00+00:00","startDate":"2020-08-01T00:00:00+00:00","startDateDateOnly":"2020-08-01","endDateDateOnly":"2027-07-31"}],"amountAwarded":3181816,"Financial Year":"2019/20","Lead Applicant":"Prof Peter Rothwell","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Rothwell","Partnership Value":3181816,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Improved targeting of stroke prevention by enhanced phenotyping of trends, risk factors, symptomatology, aetiology, and outcome: Oxford Vascular Study Having founded the new Centre for Prevention of Stroke and Dementia (CPSD) to allow junior/intermediate colleagues to develop their programmes, my own research will continue to focus on better phenotyping of TIA and stroke and of known risk factors in order to substantially improve the targeting of preventive treatments. My work involves four core themes:\n\n\n Understanding the distinct temporal trends in incidence of different stroke subtypes to monitor the effectiveness of prevention and to develop new strategies;\n Obtaining reliable data on prognosis of different TIA/stroke subtypes to better target preventive treatments;\n Having proved the impact of better prediction and prevention of early recurrent stroke, I aim to substantially improve prevention of later recurrent stroke, focussing particularly on the utility of more detailed phenotyping (e.g. identification of occult atrial fibrillation, intracranial stenosis, and PFO, and remote monitoring of home-BP);\n By more detailed assessment of BP I will inform the treatment of hypertension in primary prevention of stroke (by studying long-term pre-morbid BP) and in secondary prevention (home telemetric BP-monitoring);\n\n\nTaken together the results of this work will impact on the treatment of almost all patients with TIA or stroke (2 million prevalent cases in the UK alone).\n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Atrial Fibrillation","Humans","Hypertension","Ischemic Attack, Transient","Primary Prevention","Recurrence","Risk Factors","Secondary Prevention","Stroke","Telemedicine"]}
{"id":"360G-Wellcome-220343_Z_20_Z","title":"A high-quality connectome of the complete adult Drosophila central nervous system","Region":"East of England","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220343/Z/20/Z","description":"Building on advances during our successful connectomics collaboration (2016-20), we now propose a very ambitious new goal: a complete, high-quality connectome for the male Drosophila central nervous system (CNS). With Wellcome support and leveraging Janelia\u2019s unique electron microscopy imaging capability, we could turn image data into a fully analysed connectome. This would be the first CNS connectome of an animal with complex motor and cognitive behaviours. In contrast to existing fly datasets, it will be bilaterally complete, include brain and nerve cord and have intact sensory-motor connectivity.\n\nThis connectome should have an enormous impact on the understanding of CNS-spanning circuitry underlying complex behaviour. We will publicly release initial draft and high-quality versions as soon as they are complete. We will immediately use it to study multisensory integration, memory recall, decision making, modification of brain states, the flexible organisation of motor behaviour, and sexually dimorphic circuits. It will provide a critical resource for  > 200 labs worldwide studying Drosophila neurobiology (with impacts on developmental biology and molecular cell atlases) and provide new opportunities for theoretical neuroscientists to study complete, biologically-defined neural networks in a richly investigated organism. We expect general principles, applicable to all nervous systems, including those of humans, to emerge.\n","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":4119965,"Financial Year":"2019/20","Lead Applicant":"Dr Gregory Jefferis","grantProgramme":[{"title":"Collaborative Award in Science","title_keyword":"Collaborative Award in Science"}],"Applicant Surname":"Jefferis","Partnership Value":4119965,"Approval Committee":"Science Interview Panel","Other Applicant(s)":"Dr Gwyneth Card, Prof Gerald Rubin, Prof Scott Waddell, Dr Matthias Landgraf","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A high-quality connectome of the complete adult Drosophila central nervous system Building on advances during our successful connectomics collaboration (2016-20), we now propose a very ambitious new goal: a complete, high-quality connectome for the male Drosophila central nervous system (CNS). With Wellcome support and leveraging Janelia\u2019s unique electron microscopy imaging capability, we could turn image data into a fully analysed connectome. This would be the first CNS connectome of an animal with complex motor and cognitive behaviours. In contrast to existing fly datasets, it will be bilaterally complete, include brain and nerve cord and have intact sensory-motor connectivity.\n\nThis connectome should have an enormous impact on the understanding of CNS-spanning circuitry underlying complex behaviour. We will publicly release initial draft and high-quality versions as soon as they are complete. We will immediately use it to study multisensory integration, memory recall, decision making, modification of brain states, the flexible organisation of motor behaviour, and sexually dimorphic circuits. It will provide a critical resource for  > 200 labs worldwide studying Drosophila neurobiology (with impacts on developmental biology and molecular cell atlases) and provide new opportunities for theoretical neuroscientists to study complete, biologically-defined neural networks in a richly investigated organism. We expect general principles, applicable to all nervous systems, including those of humans, to emerge.\n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Brain","Central Nervous System","Connectome","Drosophila","Drosophila melanogaster","Male","Microscopy, Electron","Nerve Net"]}
{"id":"360G-Wellcome-220321_Z_20_Z","title":"The fight for success: inter-bacterial competition mediated by the Type VI secretion system and its effectors","Region":"Scotland","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220321/Z/20/Z","description":"The Type VI secretion system (T6SS) is used by many Gram-negative bacteria to deliver toxic \u2018effector\u2019 proteins into rival bacterial cells as a means of inter-bacterial competition. The T6SS likely plays a central role in shaping many polymicrobial communities, but important aspects of effector delivery and action in target cells, and the \u2018real-life\u2019 relevance of T6SSs in a clinical context remain elusive. We will investigate the journey of individual and co-operating groups of effectors, from their recruitment by the T6SS to their fate and action in targeted cells, and dissect the mechanism of individual anti-bacterial effectors. We will also consider the global availability and mobility of anti-bacterial effectors and how the T6SS and its effectors can influence bacterial success in a clinical context. Using multidisciplinary approaches, we aim to:\n\n\n Determine the mechanism of toxicity of novel anti-bacterial effectors \n Elucidate the fate of effectors inside target cells\n Define mechanisms of versatile effector recruitment and delivery in attacker cells\n Use genomics to reveal the diversity, evolution and real-life relevance of T6SS effectors\n\n\nOur findings, combining mechanistic detail with insight into biological relevance, will provide fundamental advances in our understanding of T6SS-mediated anti-bacterial activity and may inform future strategies to counter bacterial pathogens.\n","plannedDates":[{"endDate":"2026-01-27T00:00:00+00:00","startDate":"2021-01-28T00:00:00+00:00","startDateDateOnly":"2021-01-28","endDateDateOnly":"2026-01-27"}],"amountAwarded":1909584,"Financial Year":"2019/20","Lead Applicant":"Prof Sarah Coulthurst","grantProgramme":[{"title":"Senior Research Fellowship Renewal","title_keyword":"Senior Research Fellowship Renewal"}],"Applicant Surname":"Coulthurst","Partnership Value":1909584,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee","addressCountry":"United Kingdom","id_and_name":"[\"University of Dundee\", \"360G-Wellcome-ORG:University-of-Dundee\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The fight for success: inter-bacterial competition mediated by the Type VI secretion system and its effectors The Type VI secretion system (T6SS) is used by many Gram-negative bacteria to deliver toxic \u2018effector\u2019 proteins into rival bacterial cells as a means of inter-bacterial competition. The T6SS likely plays a central role in shaping many polymicrobial communities, but important aspects of effector delivery and action in target cells, and the \u2018real-life\u2019 relevance of T6SSs in a clinical context remain elusive. We will investigate the journey of individual and co-operating groups of effectors, from their recruitment by the T6SS to their fate and action in targeted cells, and dissect the mechanism of individual anti-bacterial effectors. We will also consider the global availability and mobility of anti-bacterial effectors and how the T6SS and its effectors can influence bacterial success in a clinical context. Using multidisciplinary approaches, we aim to:\n\n\n Determine the mechanism of toxicity of novel anti-bacterial effectors \n Elucidate the fate of effectors inside target cells\n Define mechanisms of versatile effector recruitment and delivery in attacker cells\n Use genomics to reveal the diversity, evolution and real-life relevance of T6SS effectors\n\n\nOur findings, combining mechanistic detail with insight into biological relevance, will provide fundamental advances in our understanding of T6SS-mediated anti-bacterial activity and may inform future strategies to counter bacterial pathogens.\n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anti-Bacterial Agents","Humans","Type VI Secretion Systems"]}
{"id":"360G-Wellcome-220318_Z_20_Z","title":"Functional analysis of the downstream mediators of cyclic nucleotide signalling in malaria parasites","Region":"Greater London","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220318/Z/20/Z","description":"Our research programme will deliver mechanistic understanding of how cyclic nucleotide signalling controls the development of two key phases of the malaria parasite lifecycle: the asexual blood stage that causes pathology, and gametogenesis that is required for transmission to the mosquito vector. We have previously shown that there is a temporal switch from cyclic GMP (cGMP) signalling to cAMP signalling as the asexual parasite progresses from egress (escape from its host erythrocyte) to invasion. Cyclic GMP signalling also controls egress of sexual stage parasites to enable fertilisation in the mosquito. In both lifecycle phases, egress requires cGMP-dependent calcium flux. We have recently identified a unique, essential membrane-bound binding partner of the cGMP-dependent protein kinase (PKG). We have also identified a set of high confidence targets of cAMP signalling required for invasion and subsequent parasite development, and have obtained exciting new insights into how cGMP production is governed. We now want to: (1) determine the mechanisms underlying the interrelationship between cGMP and calcium signalling; (2) dissect the role of cAMP-dependent phosphorylation in erythrocyte invasion; and (3) identify the parasite proteins that interact with cyclase and phosphodiesterase enzymes (which balance cellular levels of cyclic nucleotide) to understand how the pathways are regulated.\n","plannedDates":[{"endDate":"2025-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2025-06-30"}],"amountAwarded":689181,"Financial Year":"2019/20","Lead Applicant":"Prof David Baker","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Baker","Partnership Value":689181,"Approval Committee":"Science Interview Panel","Other Applicant(s)":"Prof Michael Blackman","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"London School of Hygiene & Tropical Medicine\", \"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Functional analysis of the downstream mediators of cyclic nucleotide signalling in malaria parasites Our research programme will deliver mechanistic understanding of how cyclic nucleotide signalling controls the development of two key phases of the malaria parasite lifecycle: the asexual blood stage that causes pathology, and gametogenesis that is required for transmission to the mosquito vector. We have previously shown that there is a temporal switch from cyclic GMP (cGMP) signalling to cAMP signalling as the asexual parasite progresses from egress (escape from its host erythrocyte) to invasion. Cyclic GMP signalling also controls egress of sexual stage parasites to enable fertilisation in the mosquito. In both lifecycle phases, egress requires cGMP-dependent calcium flux. We have recently identified a unique, essential membrane-bound binding partner of the cGMP-dependent protein kinase (PKG). We have also identified a set of high confidence targets of cAMP signalling required for invasion and subsequent parasite development, and have obtained exciting new insights into how cGMP production is governed. We now want to: (1) determine the mechanisms underlying the interrelationship between cGMP and calcium signalling; (2) dissect the role of cAMP-dependent phosphorylation in erythrocyte invasion; and (3) identify the parasite proteins that interact with cyclase and phosphodiesterase enzymes (which balance cellular levels of cyclic nucleotide) to understand how the pathways are regulated.\n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Calcium","Cyclic AMP","Cyclic GMP","Cyclic GMP-Dependent Protein Kinases","Erythrocytes","Nucleotides, Cyclic","Phosphoric Diester Hydrolases","Phosphorylation","Protozoan Proteins","Signal Transduction"]}
{"id":"360G-Wellcome-220318_A_20_Z","title":"Functional analysis of the downstream mediators of cyclic nucleotide signalling in malaria parasites","Region":"Greater London","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220318/A/20/Z","description":"Our research programme will deliver mechanistic understanding of how cyclic nucleotide signalling controls the development of two key phases of the malaria parasite lifecycle: the asexual blood stage that causes pathology, and gametogenesis that is required for transmission to the mosquito vector. We have previously shown that there is a temporal switch from cyclic GMP (cGMP) signalling to cAMP signalling as the asexual parasite progresses from egress (escape from its host erythrocyte) to invasion. Cyclic GMP signalling also controls egress of sexual stage parasites to enable fertilisation in the mosquito. In both lifecycle phases, egress requires cGMP-dependent calcium flux. We have recently identified a unique, essential membrane-bound binding partner of the cGMP-dependent protein kinase (PKG). We have also identified a set of high confidence targets of cAMP signalling required for invasion and subsequent parasite development, and have obtained exciting new insights into how cGMP production is governed. We now want to: (1) determine the mechanisms underlying the interrelationship between cGMP and calcium signalling; (2) dissect the role of cAMP-dependent phosphorylation in erythrocyte invasion; and (3) identify the parasite proteins that interact with cyclase and phosphodiesterase enzymes (which balance cellular levels of cyclic nucleotide) to understand how the pathways are regulated.\n","plannedDates":[{"endDate":"2025-06-08T00:00:00+00:00","startDate":"2021-06-09T00:00:00+00:00","startDateDateOnly":"2021-06-09","endDateDateOnly":"2025-06-08"}],"amountAwarded":669703,"Financial Year":"2019/20","Lead Applicant":"Prof Michael Blackman","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Blackman","Partnership Value":669703,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:The-Francis-Crick-Institute","name":"The Francis Crick Institute","addressCountry":"United Kingdom","id_and_name":"[\"The Francis Crick Institute\", \"360G-Wellcome-ORG:The-Francis-Crick-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:The-Francis-Crick-Institute","name":"The Francis Crick Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Functional analysis of the downstream mediators of cyclic nucleotide signalling in malaria parasites Our research programme will deliver mechanistic understanding of how cyclic nucleotide signalling controls the development of two key phases of the malaria parasite lifecycle: the asexual blood stage that causes pathology, and gametogenesis that is required for transmission to the mosquito vector. We have previously shown that there is a temporal switch from cyclic GMP (cGMP) signalling to cAMP signalling as the asexual parasite progresses from egress (escape from its host erythrocyte) to invasion. Cyclic GMP signalling also controls egress of sexual stage parasites to enable fertilisation in the mosquito. In both lifecycle phases, egress requires cGMP-dependent calcium flux. We have recently identified a unique, essential membrane-bound binding partner of the cGMP-dependent protein kinase (PKG). We have also identified a set of high confidence targets of cAMP signalling required for invasion and subsequent parasite development, and have obtained exciting new insights into how cGMP production is governed. We now want to: (1) determine the mechanisms underlying the interrelationship between cGMP and calcium signalling; (2) dissect the role of cAMP-dependent phosphorylation in erythrocyte invasion; and (3) identify the parasite proteins that interact with cyclase and phosphodiesterase enzymes (which balance cellular levels of cyclic nucleotide) to understand how the pathways are regulated.\n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Calcium","Cyclic AMP","Cyclic GMP","Cyclic GMP-Dependent Protein Kinases","Erythrocytes","Nucleotides, Cyclic","Phosphoric Diester Hydrolases","Phosphorylation","Protozoan Proteins","Signal Transduction"]}
{"id":"360G-Wellcome-220300_Z_20_Z","title":"Mechanistic investigation of the cross-talk between spliceosomal complexes and polyadenylation factors","Region":"Greater London","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220300/Z/20/Z","description":"Splicing and polyadenylation are two essential steps of gene expression that account, to a great extent, for the complexity of eukaryotes. The two processes are catalysed by the spliceosome and the polyadenylation apparatus \u2013 two macromolecular machines of megadalton-size which contain more than 70 and 20 proteins, respectively.\n\nThe two machines associate physically to form composite assemblies, where cross-talk events support emerging layers of regulation of splicing and polyadenylation. These assemblies are primarily unexplored from a mechanistic perspective, due to their excessive size, complexity and dynamics.\n\nBy employing state of the art technologies and our long-standing expertise in the structural biology of splicing, the time is now ripe for a thoroughgoing investigation of these assemblies. Thus, we aim to stall and isolate composite assemblies relevant for: (i) the coupling between splicing and polyadenylation, (ii) the definition of exons during constitutive and alternative splicing and (iii) protection of genes from premature polyadenylation. Afterwards, we will characterise their 3D structures and functions by electron cryo-microscopy and complementary biochemical methods. The proposed research is expected to be eye-opening and bring a substantive contribution to our understanding of how fundamental processes of gene expression integrate mechanistically.\n\n \n","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":2141982,"Financial Year":"2019/20","Lead Applicant":"Prof Vlad Pena","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Pena","Partnership Value":2141982,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Institute-of-Cancer-Research","name":"Institute of Cancer Research","addressCountry":"United Kingdom","id_and_name":"[\"Institute of Cancer Research\", \"360G-Wellcome-ORG:Institute-of-Cancer-Research\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Institute-of-Cancer-Research","name":"Institute of Cancer Research"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mechanistic investigation of the cross-talk between spliceosomal complexes and polyadenylation factors Splicing and polyadenylation are two essential steps of gene expression that account, to a great extent, for the complexity of eukaryotes. The two processes are catalysed by the spliceosome and the polyadenylation apparatus \u2013 two macromolecular machines of megadalton-size which contain more than 70 and 20 proteins, respectively.\n\nThe two machines associate physically to form composite assemblies, where cross-talk events support emerging layers of regulation of splicing and polyadenylation. These assemblies are primarily unexplored from a mechanistic perspective, due to their excessive size, complexity and dynamics.\n\nBy employing state of the art technologies and our long-standing expertise in the structural biology of splicing, the time is now ripe for a thoroughgoing investigation of these assemblies. Thus, we aim to stall and isolate composite assemblies relevant for: (i) the coupling between splicing and polyadenylation, (ii) the definition of exons during constitutive and alternative splicing and (iii) protection of genes from premature polyadenylation. Afterwards, we will characterise their 3D structures and functions by electron cryo-microscopy and complementary biochemical methods. The proposed research is expected to be eye-opening and bring a substantive contribution to our understanding of how fundamental processes of gene expression integrate mechanistically.\n\n \n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cryoelectron Microscopy","Poly A","Polyadenylation","RNA Splicing","Spliceosomes"]}
{"id":"360G-Wellcome-220298_Z_20_Z","title":"Mechanistic links between morphogenesis and differentiation","Region":"Scotland","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220298/Z/20/Z","description":"As cells build the body, they use information from localised secreted signals to guide differentiation and morphogenesis. It is often assumed there is unidirectional flow of information from these biochemical signals to the resulting morphological changes, but this 'linear' model cannot explain how development is orchestrated with such remarkable reproducibility.\n\nWe have found that changes in epithelial structure provide a previously underappreciated source of information that feeds back into differentiation decisions by modulating biochemical signalling. Using mouse gastrulation as a paradigm we have identified candidate molecular mechanisms that mediate this feedback: 1) A cadherin-mediated community effect that dampens anti-neural signals to synchronise neural differentiation 2) a cell-clustering process that amplifies juxtacrine pro-mesoderm signalling to coordinate differentiation across collectives of cells.\n\nWe propose that these two interlinked mechanisms coordinate distinct sources of information across different time scales. We will test this in vitro and in vivo using a unique toolkit based on molecular and biophysical manipulation of epithelial structure, mosaic analysis, and custom-developed quantitative image analysis software.\n\nGeneralisable principles emerging from this work will help resolve the currently unpredictable relationship between signalling-input and differentiation-output to give us better control over in-vitro differentiation, organoid formation, tissue repair, and tumorogenesis.\n","plannedDates":[{"endDate":"2026-02-14T00:00:00+00:00","startDate":"2021-02-15T00:00:00+00:00","startDateDateOnly":"2021-02-15","endDateDateOnly":"2026-02-14"}],"amountAwarded":2049477,"Financial Year":"2019/20","Lead Applicant":"Prof Sally Lowell","grantProgramme":[{"title":"Senior Research Fellowship Renewal","title_keyword":"Senior Research Fellowship Renewal"}],"Applicant Surname":"Lowell","Partnership Value":2049477,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mechanistic links between morphogenesis and differentiation As cells build the body, they use information from localised secreted signals to guide differentiation and morphogenesis. It is often assumed there is unidirectional flow of information from these biochemical signals to the resulting morphological changes, but this 'linear' model cannot explain how development is orchestrated with such remarkable reproducibility.\n\nWe have found that changes in epithelial structure provide a previously underappreciated source of information that feeds back into differentiation decisions by modulating biochemical signalling. Using mouse gastrulation as a paradigm we have identified candidate molecular mechanisms that mediate this feedback: 1) A cadherin-mediated community effect that dampens anti-neural signals to synchronise neural differentiation 2) a cell-clustering process that amplifies juxtacrine pro-mesoderm signalling to coordinate differentiation across collectives of cells.\n\nWe propose that these two interlinked mechanisms coordinate distinct sources of information across different time scales. We will test this in vitro and in vivo using a unique toolkit based on molecular and biophysical manipulation of epithelial structure, mosaic analysis, and custom-developed quantitative image analysis software.\n\nGeneralisable principles emerging from this work will help resolve the currently unpredictable relationship between signalling-input and differentiation-output to give us better control over in-vitro differentiation, organoid formation, tissue repair, and tumorogenesis.\n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cadherins","Cell Differentiation","Feedback, Physiological","Gastrulation","Mesoderm","Mice","Signal Transduction"]}
{"id":"360G-Wellcome-220296_Z_20_Z","title":"Neural mechanisms of learning, planning, and decision-making","Region":"Greater London","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220296/Z/20/Z","description":"This proposal examines the neural mechanisms supporting decision-making and prospective planning. We will examine how prefrontal cortex (PFC), hippocampus, and entorhinal cortex (EC) interact to support these processes. We will examine how non-human primates (NHPs) make choices in large decision spaces, particularly when novel choice-values have to be inferred \u2018online\u2019. We will test different models of value-coding, particularly whether PFC uses a \u2018place-like\u2019 and \u2018grid-like\u2019 code to construct cognitive maps of values spaces. We will examine how NHPs make \u2018online\u2019 choices when sequentially navigating between stimuli/states as rewards move or paths blocked. We will test whether \u2018replay\u2019 provides a neural mechanism supporting model-based planning. We will use Transcranial Ultrasound Stimulation to selectively disrupt regions of PFC/hippocampus/EC to examine its effect on neural selectivity and behaviour. These tasks are high-dimensional, yet amenable to mathematical description, and will be combined with high-density recordings to map these computations. Exp.3 will integrate our home-cage training system with wireless data-logging to record neural data continuously, across tasks and sleep, to examine how neural signatures change across days with learning, and acquisition of \u2018learning set\u2019. This provides the technology to continuously map the NHP brain during performance of diverse and naturalistic tasks, radically transforming primate neuroscience.\n \n","plannedDates":[{"endDate":"2026-03-16T00:00:00+00:00","startDate":"2020-12-15T00:00:00+00:00","startDateDateOnly":"2020-12-15","endDateDateOnly":"2026-03-16"}],"amountAwarded":2580251,"Financial Year":"2019/20","Lead Applicant":"Prof Steven Kennerley","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Kennerley","Partnership Value":2580251,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Neural mechanisms of learning, planning, and decision-making This proposal examines the neural mechanisms supporting decision-making and prospective planning. We will examine how prefrontal cortex (PFC), hippocampus, and entorhinal cortex (EC) interact to support these processes. We will examine how non-human primates (NHPs) make choices in large decision spaces, particularly when novel choice-values have to be inferred \u2018online\u2019. We will test different models of value-coding, particularly whether PFC uses a \u2018place-like\u2019 and \u2018grid-like\u2019 code to construct cognitive maps of values spaces. We will examine how NHPs make \u2018online\u2019 choices when sequentially navigating between stimuli/states as rewards move or paths blocked. We will test whether \u2018replay\u2019 provides a neural mechanism supporting model-based planning. We will use Transcranial Ultrasound Stimulation to selectively disrupt regions of PFC/hippocampus/EC to examine its effect on neural selectivity and behaviour. These tasks are high-dimensional, yet amenable to mathematical description, and will be combined with high-density recordings to map these computations. Exp.3 will integrate our home-cage training system with wireless data-logging to record neural data continuously, across tasks and sleep, to examine how neural signatures change across days with learning, and acquisition of \u2018learning set\u2019. This provides the technology to continuously map the NHP brain during performance of diverse and naturalistic tasks, radically transforming primate neuroscience.\n \n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Choice Behavior","Decision Making","Entorhinal Cortex","Hippocampus","Learning","Macaca mulatta","Prefrontal Cortex","Reward","Sleep"]}
{"id":"360G-Wellcome-220295_Z_20_Z","title":"HLA-agnostic T-cell Targeting of Cancer","Region":"Wales","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220295/Z/20/Z","description":"Adoptive transfer of patient T-cells expressing cancer-targeting chimeric antigen receptors (CARs) has achieved remarkable success with some soluble tumours. Unfortunately, CAR-T therapy cannot treat solid tumours. Contrastingly, tumour-infiltrating lymphocyte and checkpoint inhibitor therapies demonstrate that natural T-cells can eradicate end-stage solid cancers in some patients raising interest in engineering T-cells with T-cell receptors (TCRs) for \"TCR-T\" therapy. Conventional anticancer TCRs recognise endogenous proteinaceous antigens as short peptides presented by human leukocyte antigen class I (HLA-I) allowing killer T-cells to scan the internal proteome and eliminate cells bearing anomalies associated with cancerous transformation. Unfortunately, even the best conventional TCR approaches are only applicable in a minority of patients due to substantial variation in HLA across the population. The ultimate TCR-T therapy would bypass HLA-restriction to enable targeting of shared cancer antigens in all individuals. Our recent discoveries that some T-cells can recognise multiple types of cancer without the need for HLA could represent a major advance for immunotherapies. I want to understand the molecular mechanisms by which such \u2018HLA-agnostic\u2019 T-cells recognise cancer and utilise these remarkable cells to identify the cell surface changes that distinguish normal from cancerous cells. These potential cancer-biomarkers and cognate TCRs could underpin novel, broad-spectrum immunotherapies.\n \n\n \n","plannedDates":[{"endDate":"2025-06-30T00:00:00+00:00","startDate":"2020-07-01T00:00:00+00:00","startDateDateOnly":"2020-07-01","endDateDateOnly":"2025-06-30"}],"amountAwarded":1933956,"Financial Year":"2019/20","Lead Applicant":"Prof Andrew Sewell","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Sewell","Partnership Value":1933956,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University","addressCountry":"United Kingdom","id_and_name":"[\"Cardiff University\", \"360G-Wellcome-ORG:Cardiff-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"HLA-agnostic T-cell Targeting of Cancer Adoptive transfer of patient T-cells expressing cancer-targeting chimeric antigen receptors (CARs) has achieved remarkable success with some soluble tumours. Unfortunately, CAR-T therapy cannot treat solid tumours. Contrastingly, tumour-infiltrating lymphocyte and checkpoint inhibitor therapies demonstrate that natural T-cells can eradicate end-stage solid cancers in some patients raising interest in engineering T-cells with T-cell receptors (TCRs) for \"TCR-T\" therapy. Conventional anticancer TCRs recognise endogenous proteinaceous antigens as short peptides presented by human leukocyte antigen class I (HLA-I) allowing killer T-cells to scan the internal proteome and eliminate cells bearing anomalies associated with cancerous transformation. Unfortunately, even the best conventional TCR approaches are only applicable in a minority of patients due to substantial variation in HLA across the population. The ultimate TCR-T therapy would bypass HLA-restriction to enable targeting of shared cancer antigens in all individuals. Our recent discoveries that some T-cells can recognise multiple types of cancer without the need for HLA could represent a major advance for immunotherapies. I want to understand the molecular mechanisms by which such \u2018HLA-agnostic\u2019 T-cells recognise cancer and utilise these remarkable cells to identify the cell surface changes that distinguish normal from cancerous cells. These potential cancer-biomarkers and cognate TCRs could underpin novel, broad-spectrum immunotherapies.\n \n\n \n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Antigens, Neoplasm","Humans","Immunotherapy, Adoptive","Neoplasms","Receptors, Antigen, T-Cell","T-Lymphocytes"]}
{"id":"360G-Wellcome-220291_Z_20_Z","title":"Mechanisms of reading development in deaf children","Region":"Greater London","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220291/Z/20/Z","description":"\nMany severely and profoundly deaf children struggle to learn to read because written text is a visual representation of spoken language, to which they have limited access. I have shown that speechreading (lipreading) relates to deaf children\u2019s reading development.  Fully understanding the mechanisms underlying the speechreading-reading relationship is fundamental to harnessing speechreading as a tool to improve deaf children\u2019s reading. My goal is to investigate this mechanism in 1) a longitudinal study, to determine the relationships between speechreading, phonological skills, language skills and reading over time and 2) in neuroimaging studies with deaf children and adults to investigate neural representations of visual speech and written text and the relationships between them.\n\nAll deaf participants involved in the studies above will use speechreading. A subset will also have learned British Sign Language from an early age. Good quality early sign language exposure is beneficial to reading development in profoundly deaf children. However, the mechanism underlying this relationship is unclear. I will employ parallel methods to those used in the speechreading studies to examine 1) the longitudinal relationships between sign language, fingerspelling and reading and 2) the neural representation of these visual language inputs in deaf children and adults. \n \n","plannedDates":[{"endDate":"2026-12-14T00:00:00+00:00","startDate":"2021-12-15T00:00:00+00:00","startDateDateOnly":"2021-12-15","endDateDateOnly":"2026-12-14"}],"amountAwarded":1580335,"Financial Year":"2019/20","Lead Applicant":"Prof Mairead MacSweeney","grantProgramme":[{"title":"Senior Research Fellowship Renewal","title_keyword":"Senior Research Fellowship Renewal"}],"Applicant Surname":"MacSweeney","Partnership Value":1580335,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mechanisms of reading development in deaf children \nMany severely and profoundly deaf children struggle to learn to read because written text is a visual representation of spoken language, to which they have limited access. I have shown that speechreading (lipreading) relates to deaf children\u2019s reading development.  Fully understanding the mechanisms underlying the speechreading-reading relationship is fundamental to harnessing speechreading as a tool to improve deaf children\u2019s reading. My goal is to investigate this mechanism in 1) a longitudinal study, to determine the relationships between speechreading, phonological skills, language skills and reading over time and 2) in neuroimaging studies with deaf children and adults to investigate neural representations of visual speech and written text and the relationships between them.\n\nAll deaf participants involved in the studies above will use speechreading. A subset will also have learned British Sign Language from an early age. Good quality early sign language exposure is beneficial to reading development in profoundly deaf children. However, the mechanism underlying this relationship is unclear. I will employ parallel methods to those used in the speechreading studies to examine 1) the longitudinal relationships between sign language, fingerspelling and reading and 2) the neural representation of these visual language inputs in deaf children and adults. \n \n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adult","Child","Child, Preschool","Deafness","Female","Humans","Learning","Lipreading","Longitudinal Studies","Magnetic Resonance Imaging","Male","Phonetics","Reading","Sign Language","Speech Perception","Young Adult"]}
{"id":"360G-Wellcome-220283_Z_20_Z","title":"Long-term vascular health effects of cancer and its treatment","Region":"Greater London","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220283/Z/20/Z","description":"There is increasing concern about the long-term vascular health of the large and growing population of cancer survivors. I recently showed that survivors of most types of cancer have increased risks of one or more cardiovascular diseases, beyond those explained by shared risk factors such as smoking.\n\nThe key priorities now are to understand (i) the drivers of these increased risks, and thus how and when we can most effectively intervene; and (ii) whether broader vascular-related outcomes, in particular dementia and kidney disease, are also affected.\n\nIn this fellowship I will address these two priorities by conducting analyses underpinned by cutting-edge statistical and epidemiological methods, and capitalising on rich UK and international e-Health datasets, including game-changing new cancer treatment data.\n\nI will investigate in detail the role of anti-cancer treatments (e.g. chemotherapies/radiotherapy) and changes in traditional vascular risk factors (e.g. blood pressure, BMI) in driving late cardiovascular risk. I will then investigate whether, and through what mechanisms, cancer history affects risk of vascular dementia, chronic kidney disease, and pre-clinical cognitive and renal outcomes (uniquely identifiable in the 500,000-strong UK Biobank cohort).\n\nThroughout, this research will contribute actionable evidence informing clinical/public health policies to improve the long-term outlook of cancer survivors.\n","plannedDates":[{"endDate":"2026-03-30T00:00:00+00:00","startDate":"2021-03-31T00:00:00+00:00","startDateDateOnly":"2021-03-31","endDateDateOnly":"2026-03-30"}],"amountAwarded":1773692,"Financial Year":"2019/20","Lead Applicant":"Prof Krishnan Bhaskaran","grantProgramme":[{"title":"Senior Research Fellowship","title_keyword":"Senior Research Fellowship"}],"Applicant Surname":"Bhaskaran","Partnership Value":1773692,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"London School of Hygiene & Tropical Medicine\", \"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:London-School-of-Hygiene-and-Tropical-Medicine","name":"London School of Hygiene & Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Long-term vascular health effects of cancer and its treatment There is increasing concern about the long-term vascular health of the large and growing population of cancer survivors. I recently showed that survivors of most types of cancer have increased risks of one or more cardiovascular diseases, beyond those explained by shared risk factors such as smoking.\n\nThe key priorities now are to understand (i) the drivers of these increased risks, and thus how and when we can most effectively intervene; and (ii) whether broader vascular-related outcomes, in particular dementia and kidney disease, are also affected.\n\nIn this fellowship I will address these two priorities by conducting analyses underpinned by cutting-edge statistical and epidemiological methods, and capitalising on rich UK and international e-Health datasets, including game-changing new cancer treatment data.\n\nI will investigate in detail the role of anti-cancer treatments (e.g. chemotherapies/radiotherapy) and changes in traditional vascular risk factors (e.g. blood pressure, BMI) in driving late cardiovascular risk. I will then investigate whether, and through what mechanisms, cancer history affects risk of vascular dementia, chronic kidney disease, and pre-clinical cognitive and renal outcomes (uniquely identifiable in the 500,000-strong UK Biobank cohort).\n\nThroughout, this research will contribute actionable evidence informing clinical/public health policies to improve the long-term outlook of cancer survivors.\n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cancer Survivors","Cardiovascular Diseases","Dementia, Vascular","Humans","Kidney Neoplasms","Neoplasms","Risk Factors","United Kingdom"]}
{"id":"360G-Wellcome-220282_Z_20_Z","title":"Biomedical Vacation Scholarship Programme - University of Dundee","Region":"Scotland","currency":"GBP","awardDate":"2019-09-30T00:00:00+00:00","Internal ID":"220282/Z/20/Z","description":"This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","plannedDates":[{"endDate":"2025-07-31T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2025-07-31"}],"amountAwarded":166500,"Financial Year":"2018/19","Lead Applicant":"Dr Louise Stanley","grantProgramme":[{"title":"Biomedical Vacation Scholarship Programme ","title_keyword":"Biomedical Vacation Scholarship Programme "}],"Applicant Surname":"Stanley","Partnership Value":166500,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee","addressCountry":"United Kingdom","id_and_name":"[\"University of Dundee\", \"360G-Wellcome-ORG:University-of-Dundee\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Biomedical Vacation Scholarship Programme - University of Dundee This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","awardDateDateOnly":"2019-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Career Choice","Ethnic Groups","Humans","London","Minority Groups","Students","Universities"]}
{"id":"360G-Wellcome-220281_Z_20_Z","title":"Biomedical Vacation Scholarship Programme - University of Glasgow","Region":"Scotland","currency":"GBP","awardDate":"2019-09-30T00:00:00+00:00","Internal ID":"220281/Z/20/Z","description":"This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2019-12-01T00:00:00+00:00","startDateDateOnly":"2019-12-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":166500,"Financial Year":"2018/19","Lead Applicant":"Dr Donna Lammie","grantProgramme":[{"title":"Biomedical Vacation Scholarship Programme ","title_keyword":"Biomedical Vacation Scholarship Programme "}],"Applicant Surname":"Lammie","Partnership Value":166500,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow","addressCountry":"United Kingdom","id_and_name":"[\"University of Glasgow\", \"360G-Wellcome-ORG:University-of-Glasgow\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Biomedical Vacation Scholarship Programme - University of Glasgow This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","awardDateDateOnly":"2019-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Biomedical Research","Career Choice","Ethnic Groups","Humans","London","Minority Groups","Students","Universities"]}
{"id":"360G-Wellcome-220280_Z_20_Z","title":"Biomedical Vacation Scholarship Programme - King's College London","Region":"Greater London","currency":"GBP","awardDate":"2019-09-30T00:00:00+00:00","Internal ID":"220280/Z/20/Z","description":"This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2019-12-01T00:00:00+00:00","startDateDateOnly":"2019-12-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":197340,"Financial Year":"2018/19","Lead Applicant":"Ms Sam Javed","grantProgramme":[{"title":"Biomedical Vacation Scholarship Programme ","title_keyword":"Biomedical Vacation Scholarship Programme "}],"Applicant Surname":"Javed","Partnership Value":197340,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Biomedical Vacation Scholarship Programme - King's College London This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","awardDateDateOnly":"2019-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Ethnic Groups","Humans","London","Minority Groups","Students","Universities"]}
{"id":"360G-Wellcome-220279_Z_20_Z","title":"Biomedical Vacation Scholarship Programme - Queen Mary, University of London","Region":"Greater London","currency":"GBP","awardDate":"2019-09-30T00:00:00+00:00","Internal ID":"220279/Z/20/Z","description":"This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2020-12-01T00:00:00+00:00","startDateDateOnly":"2020-12-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":197340,"Financial Year":"2018/19","Lead Applicant":"Prof Anthony Michael","grantProgramme":[{"title":"Biomedical Vacation Scholarship Programme ","title_keyword":"Biomedical Vacation Scholarship Programme "}],"Applicant Surname":"Michael","Partnership Value":197340,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Queen-Mary-University-of-London","name":"Queen Mary University of London","addressCountry":"United Kingdom","id_and_name":"[\"Queen Mary University of London\", \"360G-Wellcome-ORG:Queen-Mary-University-of-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Queen-Mary-University-of-London","name":"Queen Mary University of London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Biomedical Vacation Scholarship Programme - Queen Mary, University of London This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","awardDateDateOnly":"2019-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Career Choice","Ethnic Groups","Humans","London","Minority Groups","Students","Universities"]}
{"id":"360G-Wellcome-220277_Z_20_Z","title":"How to connect an eye to a brain","Region":"South East","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220277/Z/20/Z","description":"Retinal ganglion cells (RGCs) are the vertebrate eye\u2019s only projection neurons to the brain. Through RGCs, species transmit ~50 visuo-ecologically relevant image features in parallel. However, what these features are, and how their information is used by central circuits to inform visual decisions remains unclear in any species. A key difficulty has been to link the activity of RGCs in the in vivo eye with behaviour. To address this major knowledge gap, I will capitalise on the visual system of the larval zebrafish where the activity of RGCs in the eye and their presynaptic terminals in the brain can be non-invasively monitored and manipulated in the live animal. I will ask:\n\n\n What information does the fish\u2019s eye send to the fish\u2019s brain?\n Does the brain \"tune\" its own input from the eye?\n How does the brain use information from RGCs to guide behaviour?\n\n\nTaking reference of our and others\u2019 data on RGC processing from mice and primates, we ultimately aim to arrive at a more general theory of how an eye can communicate with its brain, that encompasses coding strategies employed by diverse species with distinct visual abilities and requirements.\n\nKey-words: Vision, projection neuron, zebrafish, 2-photon imaging\n","plannedDates":[{"endDate":"2025-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2025-12-31"}],"amountAwarded":2236593,"Financial Year":"2019/20","Lead Applicant":"Prof Tom Baden","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Baden","Partnership Value":2236593,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Sussex","name":"University of Sussex","addressCountry":"United Kingdom","id_and_name":"[\"University of Sussex\", \"360G-Wellcome-ORG:University-of-Sussex\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Sussex","name":"University of Sussex"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"How to connect an eye to a brain Retinal ganglion cells (RGCs) are the vertebrate eye\u2019s only projection neurons to the brain. Through RGCs, species transmit ~50 visuo-ecologically relevant image features in parallel. However, what these features are, and how their information is used by central circuits to inform visual decisions remains unclear in any species. A key difficulty has been to link the activity of RGCs in the in vivo eye with behaviour. To address this major knowledge gap, I will capitalise on the visual system of the larval zebrafish where the activity of RGCs in the eye and their presynaptic terminals in the brain can be non-invasively monitored and manipulated in the live animal. I will ask:\n\n\n What information does the fish\u2019s eye send to the fish\u2019s brain?\n Does the brain \"tune\" its own input from the eye?\n How does the brain use information from RGCs to guide behaviour?\n\n\nTaking reference of our and others\u2019 data on RGC processing from mice and primates, we ultimately aim to arrive at a more general theory of how an eye can communicate with its brain, that encompasses coding strategies employed by diverse species with distinct visual abilities and requirements.\n\nKey-words: Vision, projection neuron, zebrafish, 2-photon imaging\n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Brain","Retinal Ganglion Cells","Vision, Ocular","Visual Pathways","Zebrafish"]}
{"id":"360G-Wellcome-220273_Z_20_Z","title":"Circuit mechanisms that command and pattern behavioural sequences","Region":"Greater London","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220273/Z/20/Z","description":"Animals accomplish goal-directed behaviours by performing sequences of motor actions. A central goal of neuroscience is to understand how neural circuits regulate behaviour in accordance with external events and internal drives and precisely choreograph diverse actions for a successful outcome. To meet this challenge, I will exploit the unique accessibility of the larval zebrafish and focus on a conserved behaviour \u2013 hunting \u2013 in which a sequence of discrete, specialised actions mediates pursuit and capture of prey. I will use a powerful experimental strategy that combines cellular-resolution calcium imaging, behavioural analyses, optogenetic circuit manipulations, neuroanatomical tracing and computational modelling to discover how brain-wide circuits operate at the cellular level to flexibly control the expression and coordination of behaviour. This paradigm will enable me to discover (1) how sensory and internal state information are integrated to control the sensorimotor decision to hunt, (2) how specific hunting actions are generated and (3) how command signals operate alongside dynamic sensory inputs to assemble a goal-directed sequential behaviour. Overall, the project will produce a mechanistic, cellular-resolution circuit model that explains how the brain controls and patterns multi-component behaviour. I expect this will reveal fundamental principles about the operational logic of the nervous system.\n","plannedDates":[{"endDate":"2025-05-31T00:00:00+00:00","startDate":"2020-06-01T00:00:00+00:00","startDateDateOnly":"2020-06-01","endDateDateOnly":"2025-05-31"}],"amountAwarded":2078748,"Financial Year":"2019/20","Lead Applicant":"Dr Isaac Bianco","grantProgramme":[{"title":"Senior Research Fellowship","title_keyword":"Senior Research Fellowship"}],"Applicant Surname":"Bianco","Partnership Value":2078748,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Circuit mechanisms that command and pattern behavioural sequences Animals accomplish goal-directed behaviours by performing sequences of motor actions. A central goal of neuroscience is to understand how neural circuits regulate behaviour in accordance with external events and internal drives and precisely choreograph diverse actions for a successful outcome. To meet this challenge, I will exploit the unique accessibility of the larval zebrafish and focus on a conserved behaviour \u2013 hunting \u2013 in which a sequence of discrete, specialised actions mediates pursuit and capture of prey. I will use a powerful experimental strategy that combines cellular-resolution calcium imaging, behavioural analyses, optogenetic circuit manipulations, neuroanatomical tracing and computational modelling to discover how brain-wide circuits operate at the cellular level to flexibly control the expression and coordination of behaviour. This paradigm will enable me to discover (1) how sensory and internal state information are integrated to control the sensorimotor decision to hunt, (2) how specific hunting actions are generated and (3) how command signals operate alongside dynamic sensory inputs to assemble a goal-directed sequential behaviour. Overall, the project will produce a mechanistic, cellular-resolution circuit model that explains how the brain controls and patterns multi-component behaviour. I expect this will reveal fundamental principles about the operational logic of the nervous system.\n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Behavior, Animal","Brain","Goals","Larva","Models, Neurological","Optogenetics","Zebrafish"]}
{"id":"360G-Wellcome-220271_Z_20_Z","title":"Targeting the gut in metabolic disease","Region":"East of England","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220271/Z/20/Z","description":"This project aims to identify new strategies to target the gut for the treatment of type 2 diabetes and obesity.  Intestinal hormones regulate intestinal nutrient absorption, insulin secretion and appetite, and therapeutics based on the gut peptide GLP-1 are widely used for type 2 diabetes and obesity. Bariatric surgery causes weight loss and resolves diabetes at least in part via gut endocrine changes.\n\nThis project will characterise human enteroendocrine cells using intestinal organoid cultures, building on our previous work using transgenic mouse models. To identify cells of interest, organoids will be engineered by CRISPR/Cas9 to express fluorescent sensors driven by hormonal promoters, allowing cellular analysis by transcriptomics, electrophysiology and real-time fluorescence imaging of e.g. Ca2+ and cAMP. We will characterize nutrient sensing pathways and identify receptors and signaling pathways potentially modifiable therapeutically. Using mouse and human tissues, we will identify circuitry involved in bidirectional cross-talk between gut endocrine cells and enteric/autonomic nerves.\n\nBuilding on our new methods to analyse peptides and the low molecular weight proteome by mass-spectrometry, we will investigate how plasma peptides respond to nutrient ingestion in health and metabolic diseases including diabetes, obesity, lipodystrophy and anorexia nervosa, and following bariatric surgery or dietary calorie restriction in obesity.\n","plannedDates":[{"endDate":"2026-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2026-03-31"}],"amountAwarded":2381203,"Financial Year":"2019/20","Lead Applicant":"Prof Fiona Gribble","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Gribble","Partnership Value":2381203,"Approval Committee":"Science Interview Panel","Other Applicant(s)":"Prof Frank Reimann","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Targeting the gut in metabolic disease This project aims to identify new strategies to target the gut for the treatment of type 2 diabetes and obesity.  Intestinal hormones regulate intestinal nutrient absorption, insulin secretion and appetite, and therapeutics based on the gut peptide GLP-1 are widely used for type 2 diabetes and obesity. Bariatric surgery causes weight loss and resolves diabetes at least in part via gut endocrine changes.\n\nThis project will characterise human enteroendocrine cells using intestinal organoid cultures, building on our previous work using transgenic mouse models. To identify cells of interest, organoids will be engineered by CRISPR/Cas9 to express fluorescent sensors driven by hormonal promoters, allowing cellular analysis by transcriptomics, electrophysiology and real-time fluorescence imaging of e.g. Ca2+ and cAMP. We will characterize nutrient sensing pathways and identify receptors and signaling pathways potentially modifiable therapeutically. Using mouse and human tissues, we will identify circuitry involved in bidirectional cross-talk between gut endocrine cells and enteric/autonomic nerves.\n\nBuilding on our new methods to analyse peptides and the low molecular weight proteome by mass-spectrometry, we will investigate how plasma peptides respond to nutrient ingestion in health and metabolic diseases including diabetes, obesity, lipodystrophy and anorexia nervosa, and following bariatric surgery or dietary calorie restriction in obesity.\n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Enteroendocrine Cells","Glucagon-Like Peptide 1","Humans","Mice","Mice, Inbred C57BL","Mice, Transgenic","Organoids"]}
{"id":"360G-Wellcome-220268_Z_20_Z","title":"Investigating the phenotype, cellular interactions, and function of kidney-resident natural killer cells in health and chronic kidney disease","Region":"East of England","currency":"GBP","awardDate":"2020-07-14T00:00:00+00:00","Internal ID":"220268/Z/20/Z","description":"Kidneys play a vital role in homeostasis. Chronic kidney disease (CKD) is characterised by kidney dysfunction and organ fibrosis, and affects millions of patients worldwide, but the underlying pathogenic mechanisms are poorly understood.  Using single cell RNA sequencing, we have shown that the human kidney contains a network of tissue-resident immune cells, including macrophages and two subsets of natural killer (NK) cells. These NK subsets have distinct transcriptional signatures suggestive of differing interactions with macrophage subsets, and the potential to variably influence tissue repair/fibrosis by via production of the epidermal growth factor receptor ligand amphiregulin (AREG) and by regulating macrophage polarisation towards a wound-healing M2 phenotype.\n\nMy key goals are:\n1. To determine the functional characteristics, cellular interactions, developmental relationships and lifespan of NK cell subsets in normal human kidney.\n2. To understand how the global kidney immune landscape and NK cell phenotype/function/interactions change in CKD.\n3. To determine if NK-cell depletion or NK cell-specific AREG-deficiency affects macrophage polarisation and kidney fibrosis in mouse models of kidney injury.\nAnswering these questions will provide critical information about tissue immunity in the kidney, delineate previously unappreciated aspects of NK cell biology, and will potentially identify new therapeutic targets for CKD.\n","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":1195323,"Financial Year":"2019/20","Lead Applicant":"Prof Menna Clatworthy","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Clatworthy","Partnership Value":1195323,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the phenotype, cellular interactions, and function of kidney-resident natural killer cells in health and chronic kidney disease Kidneys play a vital role in homeostasis. Chronic kidney disease (CKD) is characterised by kidney dysfunction and organ fibrosis, and affects millions of patients worldwide, but the underlying pathogenic mechanisms are poorly understood.  Using single cell RNA sequencing, we have shown that the human kidney contains a network of tissue-resident immune cells, including macrophages and two subsets of natural killer (NK) cells. These NK subsets have distinct transcriptional signatures suggestive of differing interactions with macrophage subsets, and the potential to variably influence tissue repair/fibrosis by via production of the epidermal growth factor receptor ligand amphiregulin (AREG) and by regulating macrophage polarisation towards a wound-healing M2 phenotype.\n\nMy key goals are:\n1. To determine the functional characteristics, cellular interactions, developmental relationships and lifespan of NK cell subsets in normal human kidney.\n2. To understand how the global kidney immune landscape and NK cell phenotype/function/interactions change in CKD.\n3. To determine if NK-cell depletion or NK cell-specific AREG-deficiency affects macrophage polarisation and kidney fibrosis in mouse models of kidney injury.\nAnswering these questions will provide critical information about tissue immunity in the kidney, delineate previously unappreciated aspects of NK cell biology, and will potentially identify new therapeutic targets for CKD.\n","awardDateDateOnly":"2020-07-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Acute Kidney Injury","Amphiregulin","Animals","Fibrosis","Humans","Kidney","Kidney Diseases","Killer Cells, Natural","Macrophages","Mice","Mice, Inbred C57BL","Renal Insufficiency, Chronic","Single-Cell Analysis"]}
{"id":"360G-Wellcome-220266_Z_20_Z","title":"Cellular dissection of Plasmodium falciparum erythrocyte invasion","Region":"East of England","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220266/Z/20/Z","description":"Plasmodium falciparum parasites still cause nearly half a million deaths each year. The repeated emergence of antimalarial drug resistance and the lack of a highly effective vaccine mean that there is an urgent need to identify new intervention targets. Erythrocyte invasion is an excellent target as it is essential for both parasite survival and for malaria pathology. Invasion involves multiple parasite ligands, but little is known about their function at the cellular level and even less about how they fit into the broader network of invasion proteins. This proposal will revolutionise our understanding of the function of two families of P. falciparum invasion ligands, the EBLs and the RHs, that are together responsible for the key decision point in the invasion process. The key goals are to:\n\n\n Systematically dissect functional equivalence between EBLs and RHs\n Establish the roles that EBLs and RHs play in discriminating between erythrocyte variants within and between humans\n Use innovative combinatorial approaches to move from a gene to a network understanding of EBL and RH function.\n\n\nThe proposal will provide a step change for the field, both biologically and technically, and will identify new candidates for testing in a rationally designed, multi-component invasion-blocking vaccine.\n","plannedDates":[{"endDate":"2025-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2025-12-31"}],"amountAwarded":2214779,"Financial Year":"2019/20","Lead Applicant":"Prof Julian Rayner","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Rayner","Partnership Value":2214779,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Cellular dissection of Plasmodium falciparum erythrocyte invasion Plasmodium falciparum parasites still cause nearly half a million deaths each year. The repeated emergence of antimalarial drug resistance and the lack of a highly effective vaccine mean that there is an urgent need to identify new intervention targets. Erythrocyte invasion is an excellent target as it is essential for both parasite survival and for malaria pathology. Invasion involves multiple parasite ligands, but little is known about their function at the cellular level and even less about how they fit into the broader network of invasion proteins. This proposal will revolutionise our understanding of the function of two families of P. falciparum invasion ligands, the EBLs and the RHs, that are together responsible for the key decision point in the invasion process. The key goals are to:\n\n\n Systematically dissect functional equivalence between EBLs and RHs\n Establish the roles that EBLs and RHs play in discriminating between erythrocyte variants within and between humans\n Use innovative combinatorial approaches to move from a gene to a network understanding of EBL and RH function.\n\n\nThe proposal will provide a step change for the field, both biologically and technically, and will identify new candidates for testing in a rationally designed, multi-component invasion-blocking vaccine.\n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Erythrocytes","Humans","Ligands","Malaria Vaccines","Malaria, Falciparum","Plasmodium falciparum","Protozoan Proteins"]}
{"id":"360G-Wellcome-220260_Z_20_Z","title":"Towards a thorough mechanistic understanding of endosomal cargo sorting.","Region":"South West","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220260/Z/20/Z","description":"An intracellular nexus for regulating the membrane trafficking of many of the 5,000+ integral proteins encoded by the human genome is the endosomal network.  Composed of vesicular and tubular early and late endosomes, the network\u2019s principal role is to sort integral proteins (termed \u2018cargoes\u2019) arriving from the cell surface and the biosynthetic pathway between two fates: either sorting to the lysosome for degradation, or retrieval from this fate for export to the cell surface, the biosynthetic pathway or other specialised organelles.  Whilst the molecular details of degradative cargo sorting have been well documented, those events that conduct cargo retrieval and export remain poorly understood. Our research has sought to fill this fundamental void in metazoan cell biology.\n\nA master conductor of endosomal retrieval and export is the retromer pathway - in human cells this orchestrates the sorting of  > 900 cargoes.  Establishing how this pathway functions is central to understanding the evolution, organisation and activity of endosomal sorting.  With Wellcome support we will address two integrated questions:\n\n\n The fundamental question of how the retromer pathway is organised and integrated with other pathways to orchestrate global endosomal cargo sorting.\n How understanding of retromer pathway function may provide vital insight into neurodegenerative diseases.\n\n","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":1914685,"Financial Year":"2019/20","Lead Applicant":"Prof Peter Cullen","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Cullen","Partnership Value":1914685,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Towards a thorough mechanistic understanding of endosomal cargo sorting. An intracellular nexus for regulating the membrane trafficking of many of the 5,000+ integral proteins encoded by the human genome is the endosomal network.  Composed of vesicular and tubular early and late endosomes, the network\u2019s principal role is to sort integral proteins (termed \u2018cargoes\u2019) arriving from the cell surface and the biosynthetic pathway between two fates: either sorting to the lysosome for degradation, or retrieval from this fate for export to the cell surface, the biosynthetic pathway or other specialised organelles.  Whilst the molecular details of degradative cargo sorting have been well documented, those events that conduct cargo retrieval and export remain poorly understood. Our research has sought to fill this fundamental void in metazoan cell biology.\n\nA master conductor of endosomal retrieval and export is the retromer pathway - in human cells this orchestrates the sorting of  > 900 cargoes.  Establishing how this pathway functions is central to understanding the evolution, organisation and activity of endosomal sorting.  With Wellcome support we will address two integrated questions:\n\n\n The fundamental question of how the retromer pathway is organised and integrated with other pathways to orchestrate global endosomal cargo sorting.\n How understanding of retromer pathway function may provide vital insight into neurodegenerative diseases.\n\n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Endosomes","Humans","Lysosomes","Protein Transport"]}
{"id":"360G-Wellcome-220258_Z_20_Z","title":"Bridging the gap: biophysical models of human frontotemporal lobar degeneration","Region":"East of England","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220258/Z/20/Z","description":"\nTo treat and prevent dementia in patients, it is essential to understand how microscopic changes in the human brain cause complex cognitive and behavioural disorders. My program addresses this critical gap in translational research, to facilitate clinical application of basic science discoveries. I have three goals, set in the context of frontotemproal dementia and progressive supranuclear palsy.\n\nFirst, I will develop quantitative biophysical models of human brain function that capture key cellular and pharmacological pathologies in vivo, with regional, laminar and synaptic specificity. These models of degenerating neuronal circuits are informed by individual measures of synaptic density (PET imaging with a SV2a ligand), GABA and glutamate (ultrahigh-field MR spectroscopy). They are optimised in vivo by inversion to magnetoencephalography, and tested post-mortem against neuropathology.  This synergy of multi-modal imaging, together with Bayesian model comparison of Dynamic Casual Models, means one can drill down to the best mechanistic model of the human cognitive disorder.\n\nSecond, I will show how harmful effects of dementia like apathy can be explained in terms of changes in synaptic density and loss of precision in hierarchical brain networks.\n\nThird, I will I demonstrate the readiness of my approach for experimental medicine, through longitudinal designs and pharmacological interventions. \n","plannedDates":[{"endDate":"2026-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2026-03-31"}],"amountAwarded":2025694,"Financial Year":"2019/20","Lead Applicant":"Prof James Rowe","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Rowe","Partnership Value":2025694,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Bridging the gap: biophysical models of human frontotemporal lobar degeneration \nTo treat and prevent dementia in patients, it is essential to understand how microscopic changes in the human brain cause complex cognitive and behavioural disorders. My program addresses this critical gap in translational research, to facilitate clinical application of basic science discoveries. I have three goals, set in the context of frontotemproal dementia and progressive supranuclear palsy.\n\nFirst, I will develop quantitative biophysical models of human brain function that capture key cellular and pharmacological pathologies in vivo, with regional, laminar and synaptic specificity. These models of degenerating neuronal circuits are informed by individual measures of synaptic density (PET imaging with a SV2a ligand), GABA and glutamate (ultrahigh-field MR spectroscopy). They are optimised in vivo by inversion to magnetoencephalography, and tested post-mortem against neuropathology.  This synergy of multi-modal imaging, together with Bayesian model comparison of Dynamic Casual Models, means one can drill down to the best mechanistic model of the human cognitive disorder.\n\nSecond, I will show how harmful effects of dementia like apathy can be explained in terms of changes in synaptic density and loss of precision in hierarchical brain networks.\n\nThird, I will I demonstrate the readiness of my approach for experimental medicine, through longitudinal designs and pharmacological interventions. \n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Apathy","Bayes Theorem","Brain","Frontotemporal Dementia","Humans","Positron-Emission Tomography","Supranuclear Palsy, Progressive"]}
{"id":"360G-Wellcome-220257_Z_20_Z","title":"Exploring mitochondrial metabolism in health and disease using targeted biological chemistry","Region":"East of England","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220257/Z/20/Z","description":"The molecular mechanisms by which mitochondrial reactive species, metabolites and redox signals contribute to physiology and pathology are unclear. This is in large part because these processes are difficult to assess and modulate in vivo. Our goals are to establish general chemical biology approaches to determine the mechanisms of mitochondrial physiology and dysfunction in vivo and from this develop new therapeutic strategies. The aims are based on the success of our previous Joint Investigator Award, but the specific chemical biology approaches to be used, the insights to be attained and the models have been refined and developed, based on our work over the past four years. These goals will be achieved by addressing three research challenges in cells and in vivo:\n\nA: Can we determine how mitochondria operate during normal physiology, and are disrupted during pathology, by targeting probes to measure reactive species and alterations to signaling pathways?\n\nB: Can targeting bioactive molecules to mitochondria prevent pathological disruption of mitochondrial function and generate potential therapies?\n\nC: Can the above methods to monitor and modulate mitochondrial function be assessed in animal models of human diseases and thus drive the development of rational, translatable therapies?\n\n \n","plannedDates":[{"endDate":"2026-01-31T00:00:00+00:00","startDate":"2021-02-01T00:00:00+00:00","startDateDateOnly":"2021-02-01","endDateDateOnly":"2026-01-31"}],"amountAwarded":875659,"Financial Year":"2019/20","Lead Applicant":"Prof Michael Murphy","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Murphy","Partnership Value":875659,"Approval Committee":"Science Interview Panel","Other Applicant(s)":"Prof Richard Hartley","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Exploring mitochondrial metabolism in health and disease using targeted biological chemistry The molecular mechanisms by which mitochondrial reactive species, metabolites and redox signals contribute to physiology and pathology are unclear. This is in large part because these processes are difficult to assess and modulate in vivo. Our goals are to establish general chemical biology approaches to determine the mechanisms of mitochondrial physiology and dysfunction in vivo and from this develop new therapeutic strategies. The aims are based on the success of our previous Joint Investigator Award, but the specific chemical biology approaches to be used, the insights to be attained and the models have been refined and developed, based on our work over the past four years. These goals will be achieved by addressing three research challenges in cells and in vivo:\n\nA: Can we determine how mitochondria operate during normal physiology, and are disrupted during pathology, by targeting probes to measure reactive species and alterations to signaling pathways?\n\nB: Can targeting bioactive molecules to mitochondria prevent pathological disruption of mitochondrial function and generate potential therapies?\n\nC: Can the above methods to monitor and modulate mitochondrial function be assessed in animal models of human diseases and thus drive the development of rational, translatable therapies?\n\n \n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Humans","Mitochondria","Signal Transduction"]}
{"id":"360G-Wellcome-220257_B_20_Z","title":"Exploring mitochondrial metabolism in health and disease using targeted biological chemistry","Region":"Scotland","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220257/B/20/Z","description":"The molecular mechanisms by which mitochondrial reactive species, metabolites and redox signals contribute to physiology and pathology are unclear. This is in large part because these processes are difficult to assess and modulate in vivo. Our goals are to establish general chemical biology approaches to determine the mechanisms of mitochondrial physiology and dysfunction in vivo and from this develop new therapeutic strategies. The aims are based on the success of our previous Joint Investigator Award, but the specific chemical biology approaches to be used, the insights to be attained and the models have been refined and developed, based on our work over the past four years. These goals will be achieved by addressing three research challenges in cells and in vivo:\n\nA: Can we determine how mitochondria operate during normal physiology, and are disrupted during pathology, by targeting probes to measure reactive species and alterations to signaling pathways?\n\nB: Can targeting bioactive molecules to mitochondria prevent pathological disruption of mitochondrial function and generate potential therapies?\n\nC: Can the above methods to monitor and modulate mitochondrial function be assessed in animal models of human diseases and thus drive the development of rational, translatable therapies?\n\n \n","plannedDates":[{"endDate":"2026-03-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2026-03-31"}],"amountAwarded":803027,"Financial Year":"2019/20","Lead Applicant":"Prof Richard Hartley","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Hartley","Partnership Value":803027,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow","addressCountry":"United Kingdom","id_and_name":"[\"University of Glasgow\", \"360G-Wellcome-ORG:University-of-Glasgow\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Exploring mitochondrial metabolism in health and disease using targeted biological chemistry The molecular mechanisms by which mitochondrial reactive species, metabolites and redox signals contribute to physiology and pathology are unclear. This is in large part because these processes are difficult to assess and modulate in vivo. Our goals are to establish general chemical biology approaches to determine the mechanisms of mitochondrial physiology and dysfunction in vivo and from this develop new therapeutic strategies. The aims are based on the success of our previous Joint Investigator Award, but the specific chemical biology approaches to be used, the insights to be attained and the models have been refined and developed, based on our work over the past four years. These goals will be achieved by addressing three research challenges in cells and in vivo:\n\nA: Can we determine how mitochondria operate during normal physiology, and are disrupted during pathology, by targeting probes to measure reactive species and alterations to signaling pathways?\n\nB: Can targeting bioactive molecules to mitochondria prevent pathological disruption of mitochondrial function and generate potential therapies?\n\nC: Can the above methods to monitor and modulate mitochondrial function be assessed in animal models of human diseases and thus drive the development of rational, translatable therapies?\n\n \n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Humans","Mitochondria","Signal Transduction"]}
{"id":"360G-Wellcome-220254_Z_20_Z","title":"Neuro-immune-stromal pathways sense environmental change to regulate repair versus remodelling during airway disease","Region":"Greater London","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220254/Z/20/Z","description":"This application will test the hypothesis that pulmonary immune homeostasis is maintained by a network of tissue resident cells that continually monitor environmental change. Disruption of local neuro-immune-stromal interactions either by genetic or environmental factors, alters the threshold for immune responses to usually innocuous particles such as dust, pollen or dander leading to chronic airway inflammation and tissue remodelling. I will ascertain the cellular and molecular composition of the airway wall parenchyma in children and adults with severe asthma and use machine learning tools and mouse models to determine the impact on lung function. Viral infection and pollution are common triggers for asthma severity, and I will establish how the immune/stromal niche communicates with the external environment to react to these inhaled stimuli, focussing on interaction with neuronal systems. I will examine how these interactions differ in severe asthma and contribute to the ensuing inflammation, remodelling and lung dysfunction. I will investigate the cellular interactions between fibroblasts, extracellular matrix and type 2 immune cells that facilitate repair versus remodelling during severe asthma. Ultimately this programme will reveal insight into mechanisms underlying tissue remodelling versus repair during severe asthma.\n \n","plannedDates":[{"endDate":"2026-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2026-03-31"}],"amountAwarded":2654295,"Financial Year":"2019/20","Lead Applicant":"Prof Clare Lloyd","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Lloyd","Partnership Value":2654295,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Neuro-immune-stromal pathways sense environmental change to regulate repair versus remodelling during airway disease This application will test the hypothesis that pulmonary immune homeostasis is maintained by a network of tissue resident cells that continually monitor environmental change. Disruption of local neuro-immune-stromal interactions either by genetic or environmental factors, alters the threshold for immune responses to usually innocuous particles such as dust, pollen or dander leading to chronic airway inflammation and tissue remodelling. I will ascertain the cellular and molecular composition of the airway wall parenchyma in children and adults with severe asthma and use machine learning tools and mouse models to determine the impact on lung function. Viral infection and pollution are common triggers for asthma severity, and I will establish how the immune/stromal niche communicates with the external environment to react to these inhaled stimuli, focussing on interaction with neuronal systems. I will examine how these interactions differ in severe asthma and contribute to the ensuing inflammation, remodelling and lung dysfunction. I will investigate the cellular interactions between fibroblasts, extracellular matrix and type 2 immune cells that facilitate repair versus remodelling during severe asthma. Ultimately this programme will reveal insight into mechanisms underlying tissue remodelling versus repair during severe asthma.\n \n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Airway Remodeling","Animals","Asthma","Fibroblasts","Humans","Lung","Mice"]}
{"id":"360G-Wellcome-220253_Z_20_Z","title":"Secretory protein folding, modification and the unfolded protein response","Region":"Scotland","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220253/Z/20/Z","description":"Proteins entering the secretory pathway at the endoplasmic reticulum (ER) undergo a vast array of post-translational modifications some of which are essential for correct folding, assembly and secretion.  Failure to fulfil these functions results in several diseases due to the lack of secretion of proteins such as insulin and antibodies, or due to cell death triggered by an unfolded protein stress response.  The ER provides a unique environment for protein modifications such as disulfide formation and glycosylation.  To ensure efficient protein folding and secretion the cell maintains the environment within the ER that ensures these processes occur efficiently and reacts to situations of cell stress.  This proposal builds on exciting new observations from my group to dissect molecular mechanisms involved in secretory protein biogenesis.  Our particular focus will be on how the cell maintains ER redox balance, how the repertoire of ER folding factors orchestrate correct protein folding and N-linked glycosylation and how the UPR sensor ATF6 is activated following proteotoxic stress.  Our aims will be achieved using a combination of innovative new technological approaches and previously established robust assays to follow protein folding and assembly in both reconstituted and cellular systems.\n\n\n\n","plannedDates":[{"endDate":"2026-05-31T00:00:00+00:00","startDate":"2021-06-01T00:00:00+00:00","startDateDateOnly":"2021-06-01","endDateDateOnly":"2026-05-31"}],"amountAwarded":1639854,"Financial Year":"2019/20","Lead Applicant":"Prof Neil Bulleid","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Bulleid","Partnership Value":1639854,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow","addressCountry":"United Kingdom","id_and_name":"[\"University of Glasgow\", \"360G-Wellcome-ORG:University-of-Glasgow\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Secretory protein folding, modification and the unfolded protein response Proteins entering the secretory pathway at the endoplasmic reticulum (ER) undergo a vast array of post-translational modifications some of which are essential for correct folding, assembly and secretion.  Failure to fulfil these functions results in several diseases due to the lack of secretion of proteins such as insulin and antibodies, or due to cell death triggered by an unfolded protein stress response.  The ER provides a unique environment for protein modifications such as disulfide formation and glycosylation.  To ensure efficient protein folding and secretion the cell maintains the environment within the ER that ensures these processes occur efficiently and reacts to situations of cell stress.  This proposal builds on exciting new observations from my group to dissect molecular mechanisms involved in secretory protein biogenesis.  Our particular focus will be on how the cell maintains ER redox balance, how the repertoire of ER folding factors orchestrate correct protein folding and N-linked glycosylation and how the UPR sensor ATF6 is activated following proteotoxic stress.  Our aims will be achieved using a combination of innovative new technological approaches and previously established robust assays to follow protein folding and assembly in both reconstituted and cellular systems.\n\n\n\n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Endoplasmic Reticulum","Endoplasmic Reticulum Stress","Glycosylation","Humans","Protein Folding","Protein Processing, Post-Translational","Unfolded Protein Response"]}
{"id":"360G-Wellcome-220248_Z_20_Z","title":"Biomedical Vacation Scholarship Programme - HDR-UK","Region":"South West","currency":"GBP","awardDate":"2019-09-30T00:00:00+00:00","Internal ID":"220248/Z/20/Z","description":"This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2019-12-01T00:00:00+00:00","startDateDateOnly":"2019-12-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":197340,"Financial Year":"2018/19","Lead Applicant":"Prof Peter Diggle","grantProgramme":[{"title":"Biomedical Vacation Scholarship Programme ","title_keyword":"Biomedical Vacation Scholarship Programme "}],"Applicant Surname":"Diggle","Partnership Value":197340,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Health-Data-Research-UK","name":"Health Data Research UK","addressCountry":"United Kingdom","id_and_name":"[\"Health Data Research UK\", \"360G-Wellcome-ORG:Health-Data-Research-UK\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Health-Data-Research-UK","name":"Health Data Research UK"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Biomedical Vacation Scholarship Programme - HDR-UK This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","awardDateDateOnly":"2019-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Career Choice","Ethnic Groups","Humans","London","Minority Groups","Students","United Kingdom","Universities"]}
{"id":"360G-Wellcome-220247_Z_20_Z","title":"Biomedical Vacation Scholarship Programme - University of Bristol","Region":"South West","currency":"GBP","awardDate":"2019-09-30T00:00:00+00:00","Internal ID":"220247/Z/20/Z","description":"This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","plannedDates":[{"endDate":"2024-10-01T00:00:00+00:00","startDate":"2019-12-01T00:00:00+00:00","startDateDateOnly":"2019-12-01","endDateDateOnly":"2024-10-01"}],"amountAwarded":166500,"Financial Year":"2018/19","Lead Applicant":"Dr Caroline McKinnon","grantProgramme":[{"title":"Biomedical Vacation Scholarship Programme ","title_keyword":"Biomedical Vacation Scholarship Programme "}],"Applicant Surname":"McKinnon","Partnership Value":166500,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Mr Alex O'Driscoll","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Biomedical Vacation Scholarship Programme - University of Bristol This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","awardDateDateOnly":"2019-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Biomedical Research","Career Choice","Ethnic Groups","Humans","London","Minority Groups","Students","Universities"]}
{"id":"360G-Wellcome-220244_Z_20_Z","title":"The Molecular Basis of Sister Chromatid Cohesion","Region":"Greater London","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220244/Z/20/Z","description":"Cohesion between sister chromatids, mediated by the chromosomal cohesin complex, is a prerequisite for faithful chromosome segregation during cell division. The ring-shaped cohesin complex is a multisubunit ATPase that topologically loads onto DNA in the G1 phase of the cell cycle. The first part of the proposal will elucidate the molecular mechanism of cohesin function. We will employ and develop biophysical, structural and DNA-protein crosslink mass spectrometry tools to map the trajectory by which DNA enters the cohesin ring, fuelled by ATP-dependent conformational changes. The second part of the proposal examines the establishment of sister chromatid cohesion during S phase. We will investigate how, as the replication fork moves along DNA, cohesin transitions from containing one DNA to embracing two newly replicated DNAs. This includes the functional characterisation of replisome components with roles in sister chromatid cohesion, known as \u2018cohesion establishment factors\u2019. Furthermore, we will take advantage of recent success with the biochemical reconstitution of complete DNA replication and work towards recapitulating sister chromatid cohesion establishment in vitro. This will open unique experimental opportunities to understand the process. Together, this programme will provide insight into the molecular mechanism of how cohesin safeguards faithful chromosome segregation.\n","plannedDates":[{"endDate":"2027-04-30T00:00:00+00:00","startDate":"2021-05-01T00:00:00+00:00","startDateDateOnly":"2021-05-01","endDateDateOnly":"2027-04-30"}],"amountAwarded":2088673,"Financial Year":"2019/20","Lead Applicant":"Dr Frank Uhlmann","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Uhlmann","Partnership Value":2088673,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:The-Francis-Crick-Institute","name":"The Francis Crick Institute","addressCountry":"United Kingdom","id_and_name":"[\"The Francis Crick Institute\", \"360G-Wellcome-ORG:The-Francis-Crick-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:The-Francis-Crick-Institute","name":"The Francis Crick Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The Molecular Basis of Sister Chromatid Cohesion Cohesion between sister chromatids, mediated by the chromosomal cohesin complex, is a prerequisite for faithful chromosome segregation during cell division. The ring-shaped cohesin complex is a multisubunit ATPase that topologically loads onto DNA in the G1 phase of the cell cycle. The first part of the proposal will elucidate the molecular mechanism of cohesin function. We will employ and develop biophysical, structural and DNA-protein crosslink mass spectrometry tools to map the trajectory by which DNA enters the cohesin ring, fuelled by ATP-dependent conformational changes. The second part of the proposal examines the establishment of sister chromatid cohesion during S phase. We will investigate how, as the replication fork moves along DNA, cohesin transitions from containing one DNA to embracing two newly replicated DNAs. This includes the functional characterisation of replisome components with roles in sister chromatid cohesion, known as \u2018cohesion establishment factors\u2019. Furthermore, we will take advantage of recent success with the biochemical reconstitution of complete DNA replication and work towards recapitulating sister chromatid cohesion establishment in vitro. This will open unique experimental opportunities to understand the process. Together, this programme will provide insight into the molecular mechanism of how cohesin safeguards faithful chromosome segregation.\n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cell Cycle Proteins","Chromatids","Chromosomal Proteins, Non-Histone","Chromosome Segregation","DNA Replication","Protein Binding","Replication Origin"]}
{"id":"360G-Wellcome-220243_Z_20_Z","title":"Understanding and predicting the evolution of antibiotic resistance in human infection","Region":"North West","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220243/Z/20/Z","description":"The evolution of antibiotic resistance is a threat to modern medicine. Patients with chronic bacterial infections are at particular risk from antibiotic resistant genotypes, which typically arise from within the infection. However, a lack of controlled studies means that we don't understand how antibiotic resistance evolves within the human host environment, and why the emergence of resistance varies among patients. \n\nWe identify randomised clinical trials (RCTs) of new antibiotic treatments as a powerful way to study resistance evolution in action during a controlled, replicated natural experiment. We will exploit a unique opportunity to perform an evolutionary analysis of two parallel Phase-III RCTs for inhaled ciprofloxacin treatment of chronic lung infections caused by Pseudomonas aeruginosa, which is a WHO Priority-1 pathogen in critical need of improved antibiotic therapies. Ciprofloxacin resistance emerged in ~40% of the treated patient infections but this patient-to-patient variation is unexplained.\n\nWe aim to explain why resistance evolved in some patients but not in others. To do this, we will (1) discover the evolutionary mechanisms of resistance emergence in patient infections, (2) identify the bacterial and host properties that drove resistance evolution, and then (3) test how well biomarkers of these drivers predict resistance emergence in other patients. \n","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":1756223,"Financial Year":"2019/20","Lead Applicant":"Prof Michael Brockhurst","grantProgramme":[{"title":"Collaborative Award in Science","title_keyword":"Collaborative Award in Science"}],"Applicant Surname":"Brockhurst","Partnership Value":1756223,"Approval Committee":"Science Interview Panel","Other Applicant(s)":"Dr Dylan Childs, Prof Craig Winstanley, Prof Steve Paterson, Prof James Chalmers","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding and predicting the evolution of antibiotic resistance in human infection The evolution of antibiotic resistance is a threat to modern medicine. Patients with chronic bacterial infections are at particular risk from antibiotic resistant genotypes, which typically arise from within the infection. However, a lack of controlled studies means that we don't understand how antibiotic resistance evolves within the human host environment, and why the emergence of resistance varies among patients. \n\nWe identify randomised clinical trials (RCTs) of new antibiotic treatments as a powerful way to study resistance evolution in action during a controlled, replicated natural experiment. We will exploit a unique opportunity to perform an evolutionary analysis of two parallel Phase-III RCTs for inhaled ciprofloxacin treatment of chronic lung infections caused by Pseudomonas aeruginosa, which is a WHO Priority-1 pathogen in critical need of improved antibiotic therapies. Ciprofloxacin resistance emerged in ~40% of the treated patient infections but this patient-to-patient variation is unexplained.\n\nWe aim to explain why resistance evolved in some patients but not in others. To do this, we will (1) discover the evolutionary mechanisms of resistance emergence in patient infections, (2) identify the bacterial and host properties that drove resistance evolution, and then (3) test how well biomarkers of these drivers predict resistance emergence in other patients. \n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anti-Bacterial Agents","Bacterial Infections","Chronic Disease","Ciprofloxacin","Drug Resistance, Bacterial","Humans","Pseudomonas Infections","Pseudomonas aeruginosa","Randomized Controlled Trials as Topic"]}
{"id":"360G-Wellcome-220241_Z_20_Z","title":"Biomedical Vacation Scholarship Programme - University of Leicester","Region":"East Midlands","currency":"GBP","awardDate":"2019-09-30T00:00:00+00:00","Internal ID":"220241/Z/20/Z","description":"This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2019-12-01T00:00:00+00:00","startDateDateOnly":"2019-12-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":166500,"Financial Year":"2018/19","Lead Applicant":"Dr Alex Goddard","grantProgramme":[{"title":"Biomedical Vacation Scholarship Programme ","title_keyword":"Biomedical Vacation Scholarship Programme "}],"Applicant Surname":"Goddard","Partnership Value":166500,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Leicester","name":"University of Leicester","addressCountry":"United Kingdom","id_and_name":"[\"University of Leicester\", \"360G-Wellcome-ORG:University-of-Leicester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Leicester","name":"University of Leicester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Biomedical Vacation Scholarship Programme - University of Leicester This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","awardDateDateOnly":"2019-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Biomedical Research","Career Choice","Ethnic Groups","Humans","London","Minority Groups","Students","Universities"]}
{"id":"360G-Wellcome-220239_Z_20_Z","title":"Biomedical Vacation Scholarship Programme - University of Nottingham","Region":"East Midlands","currency":"GBP","awardDate":"2019-09-30T00:00:00+00:00","Internal ID":"220239/Z/20/Z","description":"This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":166500,"Financial Year":"2018/19","Lead Applicant":"Miss Emma Szembek","grantProgramme":[{"title":"Biomedical Vacation Scholarship Programme ","title_keyword":"Biomedical Vacation Scholarship Programme "}],"Applicant Surname":"Szembek","Partnership Value":166500,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Nottingham","name":"University of Nottingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Nottingham\", \"360G-Wellcome-ORG:University-of-Nottingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Nottingham","name":"University of Nottingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Biomedical Vacation Scholarship Programme - University of Nottingham This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","awardDateDateOnly":"2019-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Career Choice","Ethnic Groups","Humans","London","Minority Groups","Students","Universities"]}
{"id":"360G-Wellcome-220238_Z_20_Z","title":"Biomedical Vacation Scholarship Programme - University of Cambridge","Region":"East of England","currency":"GBP","awardDate":"2019-09-30T00:00:00+00:00","Internal ID":"220238/Z/20/Z","description":"This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2021-02-01T00:00:00+00:00","startDateDateOnly":"2021-02-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":166500,"Financial Year":"2018/19","Lead Applicant":"Mr Tom Levinson","grantProgramme":[{"title":"Biomedical Vacation Scholarship Programme ","title_keyword":"Biomedical Vacation Scholarship Programme "}],"Applicant Surname":"Levinson","Partnership Value":166500,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Biomedical Vacation Scholarship Programme - University of Cambridge This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","awardDateDateOnly":"2019-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Career Choice","Ethnic Groups","Humans","London","Minority Groups","Students","Universities"]}
{"id":"360G-Wellcome-220237_Z_20_Z","title":"Biomedical Vacation Scholarship Programme - University of Oxford","Region":"South East","currency":"GBP","awardDate":"2019-09-30T00:00:00+00:00","Internal ID":"220237/Z/20/Z","description":"This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","plannedDates":[{"endDate":"2024-10-01T00:00:00+00:00","startDate":"2019-12-01T00:00:00+00:00","startDateDateOnly":"2019-12-01","endDateDateOnly":"2024-10-01"}],"amountAwarded":166500,"Financial Year":"2018/19","Lead Applicant":"Dr Nadia Pollini","grantProgramme":[{"title":"Biomedical Vacation Scholarship Programme ","title_keyword":"Biomedical Vacation Scholarship Programme "}],"Applicant Surname":"Pollini","Partnership Value":166500,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Biomedical Vacation Scholarship Programme - University of Oxford This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","awardDateDateOnly":"2019-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Career Choice","Ethnic Groups","Humans","London","Minority Groups","Students","Universities"]}
{"id":"360G-Wellcome-220236_Z_20_Z","title":"Biomedical Vacation Scholarship Programme - University of Manchester","Region":"North West","currency":"GBP","awardDate":"2019-09-30T00:00:00+00:00","Internal ID":"220236/Z/20/Z","description":"This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2019-12-01T00:00:00+00:00","startDateDateOnly":"2019-12-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":166500,"Financial Year":"2018/19","Lead Applicant":"Miss Stephanie Lee","grantProgramme":[{"title":"Biomedical Vacation Scholarship Programme ","title_keyword":"Biomedical Vacation Scholarship Programme "}],"Applicant Surname":"Lee","Partnership Value":166500,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Biomedical Vacation Scholarship Programme - University of Manchester This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","awardDateDateOnly":"2019-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Biomedical Research","Career Choice","Ethnic Groups","Humans","London","Minority Groups","Students","Universities"]}
{"id":"360G-Wellcome-220234_Z_20_Z","title":"Biomedical Vacation Scholarship Programme - University of Edinburgh","Region":"Scotland","currency":"GBP","awardDate":"2019-09-30T00:00:00+00:00","Internal ID":"220234/Z/20/Z","description":"This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2019-12-01T00:00:00+00:00","startDateDateOnly":"2019-12-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":166500,"Financial Year":"2018/19","Lead Applicant":"Dr Antony Maciocia","grantProgramme":[{"title":"Biomedical Vacation Scholarship Programme ","title_keyword":"Biomedical Vacation Scholarship Programme "}],"Applicant Surname":"Maciocia","Partnership Value":166500,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Biomedical Vacation Scholarship Programme - University of Edinburgh This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","awardDateDateOnly":"2019-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Career Choice","Ethnic Groups","Humans","London","Minority Groups","Students","Universities"]}
{"id":"360G-Wellcome-220233_Z_20_Z","title":"Biomedical Vacation Scholarship Programme - University College London","Region":"Greater London","currency":"GBP","awardDate":"2019-09-30T00:00:00+00:00","Internal ID":"220233/Z/20/Z","description":"This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2019-12-01T00:00:00+00:00","startDateDateOnly":"2019-12-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":197340,"Financial Year":"2018/19","Lead Applicant":"Ms Colby Benari","grantProgramme":[{"title":"Biomedical Vacation Scholarship Programme ","title_keyword":"Biomedical Vacation Scholarship Programme "}],"Applicant Surname":"Benari","Partnership Value":197340,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Biomedical Vacation Scholarship Programme - University College London This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","awardDateDateOnly":"2019-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Career Choice","Ethnic Groups","Humans","London","Minority Groups","Students","Universities"]}
{"id":"360G-Wellcome-220232_Z_20_Z","title":"Biomedical Vacation Scholarship Programme - University of Sheffield","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2019-09-30T00:00:00+00:00","Internal ID":"220232/Z/20/Z","description":"This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2019-12-01T00:00:00+00:00","startDateDateOnly":"2019-12-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":166500,"Financial Year":"2018/19","Lead Applicant":"Mrs Deborah McClean","grantProgramme":[{"title":"Biomedical Vacation Scholarship Programme ","title_keyword":"Biomedical Vacation Scholarship Programme "}],"Applicant Surname":"McClean","Partnership Value":166500,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield","addressCountry":"United Kingdom","id_and_name":"[\"University of Sheffield\", \"360G-Wellcome-ORG:University-of-Sheffield\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Biomedical Vacation Scholarship Programme - University of Sheffield This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research. \nOver 5 years of the Programme we encourage organisations to aim for:  \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.  \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","awardDateDateOnly":"2019-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Biomedical Research","Career Choice","Ethnic Groups","Fellowships and Scholarships","Humans","London","Minority Groups","Students","Universities"]}
{"id":"360G-Wellcome-220231_Z_20_Z","title":"Biomedical Vacation Scholarship Programme - University of East Anglia","Region":"East of England","currency":"GBP","awardDate":"2019-09-30T00:00:00+00:00","Internal ID":"220231/Z/20/Z","description":"This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research.  \nOver 5 years of the Programme we encourage organisations to aim for:   \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.   \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","plannedDates":[{"endDate":"2024-09-30T00:00:00+00:00","startDate":"2019-12-01T00:00:00+00:00","startDateDateOnly":"2019-12-01","endDateDateOnly":"2024-09-30"}],"amountAwarded":166500,"Financial Year":"2018/19","Lead Applicant":"Prof Helena Gillespie","grantProgramme":[{"title":"Biomedical Vacation Scholarship Programme ","title_keyword":"Biomedical Vacation Scholarship Programme "}],"Applicant Surname":"Gillespie","Partnership Value":166500,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-East-Anglia","name":"University of East Anglia","addressCountry":"United Kingdom","id_and_name":"[\"University of East Anglia\", \"360G-Wellcome-ORG:University-of-East-Anglia\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-East-Anglia","name":"University of East Anglia"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Biomedical Vacation Scholarship Programme - University of East Anglia This award is for 6 students per year for 5 years. It includes ?a salary at the national living wage plus holiday pay and national insurance or equivalent,?as well as?funds to cover or significantly subsidise accommodation and travel (\u00a31500 outside of London and up to \u00a32000 in London).??? It includes \u00a3500 to each studentship towards research expenses.??? Unspent funds can be repurposed on further students or recruitment costs.  Wellcome wishes to ensure a greater diversity of students (in relation to socio-economic background and ethnicity) progress to postgraduate research.  \nOver 5 years of the Programme we encourage organisations to aim for:   \n\n-At least 50% of students recruited to the programme to be from underrepresented or disadvantaged groups, depending on priorities set by each organisation.   \n\n-At least 50% of students recruited to the programme to be from non-Russell Group Universities. For the remaining 50%, organisations should consider how to recruit students from other universities as well as their own. Wellcome has included this recommended target as research indicates that most of the high-achieving STEMM graduates from minority ethnic backgrounds are located outside of Russell Group universities.  ","awardDateDateOnly":"2019-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Career Choice","Ethnic Groups","Humans","London","Minority Groups","Students","Universities"]}
{"id":"360G-Wellcome-220225_Z_20_Z","title":"Micronutrient interventions to improve infant neurocognitive development and growth in early infancy","Region":"Greater London","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220225/Z/20/Z","description":"Undernutrition during the early years of life has a harmful and irreversible impact on child growth and cognitive development. Many of the interventions tested to improve outcomes across infancy have had disappointing or inconsistent impact, a common feature being the absence of any attempts to provide nutritional supplements to infants during the first six months. With increasing evidence of micronutrient deficiencies in this age group, alongside strong evidence that growth and developmental deficits begin before six months, a renewed focus on the micronutrient status of infants is required.\n\nHere I propose a randomised efficacy trial of micronutrient supplementation to mothers (during pregnancy or pregnancy and lactation) and infants (birth to six months) in rural Gambia, where rates of micronutrient deficiencies are high. 600 pregnant women ( \n\nThis novel research will identify the most efficacious way of improving micronutrient status in infancy, and assess impact on infant developmental outcomes, providing an evidence base for future effectiveness trials and policy recommendations.\n","plannedDates":[{"endDate":"2025-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2025-08-31"}],"amountAwarded":1140173,"Financial Year":"2019/20","Lead Applicant":"Dr Sophie Moore","grantProgramme":[{"title":"Senior Research Fellowship","title_keyword":"Senior Research Fellowship"}],"Partnership Name":"NIHR/Wellcome Global health Partnership","Applicant Surname":"Moore","Partnership Value":2280346,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Micronutrient interventions to improve infant neurocognitive development and growth in early infancy Undernutrition during the early years of life has a harmful and irreversible impact on child growth and cognitive development. Many of the interventions tested to improve outcomes across infancy have had disappointing or inconsistent impact, a common feature being the absence of any attempts to provide nutritional supplements to infants during the first six months. With increasing evidence of micronutrient deficiencies in this age group, alongside strong evidence that growth and developmental deficits begin before six months, a renewed focus on the micronutrient status of infants is required.\n\nHere I propose a randomised efficacy trial of micronutrient supplementation to mothers (during pregnancy or pregnancy and lactation) and infants (birth to six months) in rural Gambia, where rates of micronutrient deficiencies are high. 600 pregnant women ( \n\nThis novel research will identify the most efficacious way of improving micronutrient status in infancy, and assess impact on infant developmental outcomes, providing an evidence base for future effectiveness trials and policy recommendations.\n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Child Development","Dietary Supplements","Female","Humans","Infant","Infant Nutritional Physiological Phenomena","Maternal Nutritional Physiological Phenomena","Micronutrients","Pregnancy","Randomized Controlled Trials as Topic"]}
{"id":"360G-Wellcome-220223_Z_20_Z","title":"Discovering new pathways of lymphocyte specification and function","Region":"South West","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220223/Z/20/Z","description":"The co-ordinated development and differentiation of lymphocytes is critical to producing the bespoke immune responses required to combat specific pathogens, but also to maintaining tissue homeostasis and repair.  However, dysregulated immune reactions underlie undesirable chronic inflammation and autoimmunity.   Our discovery of type-2 innate lymphoid cells (ILC2) and the description of other ILC subsets has highlighted additional, previously unappreciated, complexity in the processes of lymphocyte specialisation.  Our challenge is to unravel the microenvironmental cues, critical cell-surface receptors, and key transcription factor interactions that lead to lymphocyte specification, tissue-specific roles and cellular interactions. We will employ a unique repertoire of lymphocyte transcription factor reporter \"polychromILC\" mice in combination with CRISPR-mediated screens to identify new regulators of lymphocyte development, differentiation and function.  To facilitate the investigation of these new pathways in specific lymphocyte subsets in vivo we will produce a new generation of mouse strains designed to limit off-target events by employing multiple positive and negative determinants, comparable to Boolean operators (AND, OR, NOT or AND NOT).  Finally, using a combination of genetic screens and in toto adaptive light-sheet microscopy we aim to define molecules and cells that delineate the migration and development of ILC in the context of the stromal environment.\n \n","plannedDates":[{"endDate":"2027-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2027-03-31"}],"amountAwarded":2464967,"Financial Year":"2019/20","Lead Applicant":"Dr Andrew McKenzie","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"McKenzie","Partnership Value":2464967,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:UKRI-MRC","name":"UKRI-MRC","addressCountry":"United Kingdom","id_and_name":"[\"UKRI-MRC\", \"360G-Wellcome-ORG:UKRI-MRC\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:UKRI-MRC","name":"UKRI-MRC"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Discovering new pathways of lymphocyte specification and function The co-ordinated development and differentiation of lymphocytes is critical to producing the bespoke immune responses required to combat specific pathogens, but also to maintaining tissue homeostasis and repair.  However, dysregulated immune reactions underlie undesirable chronic inflammation and autoimmunity.   Our discovery of type-2 innate lymphoid cells (ILC2) and the description of other ILC subsets has highlighted additional, previously unappreciated, complexity in the processes of lymphocyte specialisation.  Our challenge is to unravel the microenvironmental cues, critical cell-surface receptors, and key transcription factor interactions that lead to lymphocyte specification, tissue-specific roles and cellular interactions. We will employ a unique repertoire of lymphocyte transcription factor reporter \"polychromILC\" mice in combination with CRISPR-mediated screens to identify new regulators of lymphocyte development, differentiation and function.  To facilitate the investigation of these new pathways in specific lymphocyte subsets in vivo we will produce a new generation of mouse strains designed to limit off-target events by employing multiple positive and negative determinants, comparable to Boolean operators (AND, OR, NOT or AND NOT).  Finally, using a combination of genetic screens and in toto adaptive light-sheet microscopy we aim to define molecules and cells that delineate the migration and development of ILC in the context of the stromal environment.\n \n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adaptive Immunity","Animals","Cell Differentiation","Immunity, Innate","Lymphocytes","Mice"]}
{"id":"360G-Wellcome-220221_Z_20_Z","title":"Imaging the Redox Microenvironment to Predict Tumour Resistance to Therapy","Region":"Greater London","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220221/Z/20/Z","description":"The majority of lung cancer deaths result from ineffective treatment of late-stage disease. Currently, there is no satisfactory way to identify patients that will not respond to standard-of-care treatments. Positron emission tomography (PET) imaging offers a potential solution to this clinical problem through the non-invasive assessment of molecular processes that underpin therapy-resistance. The identification of cancer patients that are refractory to treatment will allow the selection of second-line therapies that have the potential to improve patient response and survival.\n\n\nFor this SRF, I will develop novel PET radiotracers to predict therapy resistance in mouse models of non-small cell lung cancer. These radiotracers will non-invasively image the aberrant activity of key antioxidant pathways that are causal to therapy resistance. Specifically, I will use structure-activity relationships and in vivo imaging to design highly-specific radiotracers for the cancer stem cell marker, aldehyde dehydrogenase 1A1; nuclear factor erythroid 2-related factor 2, the master regulator of the antioxidant response; and de novo glutathione synthesis. Our library of redox radiotracers will subsequently be used to detect drug resistance in syngeneic, isogenic and patient-derived models of lung cancer. Finally, I will use the radiotracers developed in this programme to assess response to immunotherapy in drug-resistant lung cancer.\n","plannedDates":[{"endDate":"2026-02-28T00:00:00+00:00","startDate":"2021-03-01T00:00:00+00:00","startDateDateOnly":"2021-03-01","endDateDateOnly":"2026-02-28"}],"amountAwarded":2407240,"Financial Year":"2019/20","Lead Applicant":"Dr Timothy Witney","grantProgramme":[{"title":"Senior Research Fellowship","title_keyword":"Senior Research Fellowship"}],"Applicant Surname":"Witney","Partnership Value":2407240,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Imaging the Redox Microenvironment to Predict Tumour Resistance to Therapy The majority of lung cancer deaths result from ineffective treatment of late-stage disease. Currently, there is no satisfactory way to identify patients that will not respond to standard-of-care treatments. Positron emission tomography (PET) imaging offers a potential solution to this clinical problem through the non-invasive assessment of molecular processes that underpin therapy-resistance. The identification of cancer patients that are refractory to treatment will allow the selection of second-line therapies that have the potential to improve patient response and survival.\n\n\nFor this SRF, I will develop novel PET radiotracers to predict therapy resistance in mouse models of non-small cell lung cancer. These radiotracers will non-invasively image the aberrant activity of key antioxidant pathways that are causal to therapy resistance. Specifically, I will use structure-activity relationships and in vivo imaging to design highly-specific radiotracers for the cancer stem cell marker, aldehyde dehydrogenase 1A1; nuclear factor erythroid 2-related factor 2, the master regulator of the antioxidant response; and de novo glutathione synthesis. Our library of redox radiotracers will subsequently be used to detect drug resistance in syngeneic, isogenic and patient-derived models of lung cancer. Finally, I will use the radiotracers developed in this programme to assess response to immunotherapy in drug-resistant lung cancer.\n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Carcinoma, Non-Small-Cell Lung","Drug Resistance, Neoplasm","Humans","Lung Neoplasms","Mice","Neoplastic Stem Cells","Oxidation-Reduction","Positron-Emission Tomography","Radiopharmaceuticals"]}
{"id":"360G-Wellcome-220219_Z_20_Z","title":"Factors Determining Clonal Selection in Germinal Centres","Region":"South East","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220219/Z/20/Z","description":"Antibody affinity maturation occurs in germinal centers (GCs) through iterative rounds of somatic hypermutation (SHM) in dark zones (DZs) and selection in light zones (LZs). Current models state that, following SHM, DZ cells exit cell cycle and move to LZs to test their newly mutated B cell receptors by competing T cell help. High affinity B cells preferentially \"win\" in receiving help, and this causes them to undergo cyclic reentry (defined by S phase initiation and DZ re-entry). We recently demonstrated the possible existence of a second checkpoint, because BCR expression is required for LZ entry. We propose testing the nature of BCR-dependent signals required for this (e.g. cognate vs tonic signaling). Next, we will re-examine the fundamental principle that affinity enhancements are favored by LZ cells competing for cyclic re-entry promoting cues. In unpublished studies, we unexpectedly find that T cell help in not required for initiating cyclic re-entry. We will therefore test whether LZ cells compete for other non-T cell-derived cues, or whether instead cyclic re-entry is controlled independently of selection events. Finally, we will investigate whether GCs utilize innate cell types and signaling pathways for sensing the continued presence of foreign material and for determining GC longevity.\n \n","plannedDates":[{"endDate":"2026-01-01T00:00:00+00:00","startDate":"2021-01-02T00:00:00+00:00","startDateDateOnly":"2021-01-02","endDateDateOnly":"2026-01-01"}],"amountAwarded":2299755,"Financial Year":"2019/20","Lead Applicant":"Dr Oliver Bannard","grantProgramme":[{"title":"Senior Research Fellowship","title_keyword":"Senior Research Fellowship"}],"Applicant Surname":"Bannard","Partnership Value":2299755,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Factors Determining Clonal Selection in Germinal Centres Antibody affinity maturation occurs in germinal centers (GCs) through iterative rounds of somatic hypermutation (SHM) in dark zones (DZs) and selection in light zones (LZs). Current models state that, following SHM, DZ cells exit cell cycle and move to LZs to test their newly mutated B cell receptors by competing T cell help. High affinity B cells preferentially \"win\" in receiving help, and this causes them to undergo cyclic reentry (defined by S phase initiation and DZ re-entry). We recently demonstrated the possible existence of a second checkpoint, because BCR expression is required for LZ entry. We propose testing the nature of BCR-dependent signals required for this (e.g. cognate vs tonic signaling). Next, we will re-examine the fundamental principle that affinity enhancements are favored by LZ cells competing for cyclic re-entry promoting cues. In unpublished studies, we unexpectedly find that T cell help in not required for initiating cyclic re-entry. We will therefore test whether LZ cells compete for other non-T cell-derived cues, or whether instead cyclic re-entry is controlled independently of selection events. Finally, we will investigate whether GCs utilize innate cell types and signaling pathways for sensing the continued presence of foreign material and for determining GC longevity.\n \n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","B-Lymphocytes","Germinal Center","Mice","Signal Transduction","T-Lymphocytes"]}
{"id":"360G-Wellcome-220218_Z_20_Z","title":"lvermectin Safety in Small Children","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220218/Z/20/Z","description":"lvermectin is a very safe and beneficial drug which is used for the treatment of more than a\ndozen different neglected tropical diseases (NTDs), many of which are associated with\nimportant public health problems. Current label indications for ivermectin prevent use in\nsmall children weighing less than 15kg, due to limited safety data in this group. Many of the\nNTD treatment options for small children rely on compounds that are less safe and/or\nefficacious compared to oral ivermectin. Our proposal will establish the safety and\npharmacokinetics of escalating doses of ivermectin to treat scabies infected children weighing less than 15kg. The safety assessment will provide crucial evidence on the use of\nivermectin for numerous diseases in children weighing less than 15kg. The information from\nmeasuring drug concentrations in the patients will inform the optimal dosing of this drug in\nsmall children. Assessment of the efficacy of ivermectin, compared to permethrin cream, for\nthe treatment of scabies in small children can provide an important alternative treatment for\nthis widespread disease.","plannedDates":[{"endDate":"2023-04-01T00:00:00+00:00","startDate":"2020-04-01T00:00:00+00:00","startDateDateOnly":"2020-04-01","endDateDateOnly":"2023-04-01"}],"amountAwarded":510000,"Financial Year":"2019/20","Lead Applicant":"Dr Kevin Kobylinski","grantProgramme":[{"title":"Innovations Priority Project","title_keyword":"Innovations Priority Project"}],"Applicant Surname":"Kobylinski","Partnership Value":510000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"lvermectin Safety in Small Children lvermectin is a very safe and beneficial drug which is used for the treatment of more than a\ndozen different neglected tropical diseases (NTDs), many of which are associated with\nimportant public health problems. Current label indications for ivermectin prevent use in\nsmall children weighing less than 15kg, due to limited safety data in this group. Many of the\nNTD treatment options for small children rely on compounds that are less safe and/or\nefficacious compared to oral ivermectin. Our proposal will establish the safety and\npharmacokinetics of escalating doses of ivermectin to treat scabies infected children weighing less than 15kg. The safety assessment will provide crucial evidence on the use of\nivermectin for numerous diseases in children weighing less than 15kg. The information from\nmeasuring drug concentrations in the patients will inform the optimal dosing of this drug in\nsmall children. Assessment of the efficacy of ivermectin, compared to permethrin cream, for\nthe treatment of scabies in small children can provide an important alternative treatment for\nthis widespread disease.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Administration, Oral","Animals","Antiparasitic Agents","Child","Child, Preschool","Humans","Ivermectin","Neglected Diseases","Scabies"]}
{"id":"360G-Wellcome-220217_Z_20_Z","title":"Unprecedented Movement to drive a Unified Rwandan Initiative for National ZEBOVAC Immunization","Region":"International","currency":"GBP","awardDate":"2019-09-30T00:00:00+00:00","Internal ID":"220217/Z/20/Z","description":"The ongoing outbreak of Ebola Virus Disease (EVD) in the Democratic Republic of Congo (DRC) and the recent identification of Ebola cases in the cities of Goma and Bukavu (which border Rwanda) are of particular concern and have prompted the Rwandan Government to take control measures for preventing cross-border spread of EVD. As demonstrated by the current outbreak, purely reactive measures may be insufficient to fight Ebola. Prophylactic approaches are needed that can prevent emergence of EVD in previously unaffected areas.We propose to conduct a large scale vaccination campaign targeting 196,000 individuals living and working in border-proximate areas; a clinical trial to evaluate the immunogenicity of the AD26.ZEBOV, MVA-BN-Filo vaccine in 2,000 people; and a clinical trial to evaluate the safety of the vaccine among 2,000 pregnant women in the context of this new framework of Ebola prevention. These 3 programs will together generate a large cohort that can be revisited for a long term follow up study to assess long term immunogenicity at different times following vaccination; an evaluation of a potential effect of booster doses and the optimal strategy for booster administration; and an evaluation of long term assessment of effectiveness using a test-negative case control study design.\n","plannedDates":[{"endDate":"2021-08-01T00:00:00+00:00","startDate":"2019-12-01T00:00:00+00:00","startDateDateOnly":"2019-12-01","endDateDateOnly":"2021-08-01"}],"amountAwarded":184755,"Financial Year":"2018/19","Lead Applicant":"Mrs Marie Michele Umulisa","grantProgramme":[{"title":"DFID-Wellcome Epidemic Preparedness Grant","title_keyword":"DFID-Wellcome Epidemic Preparedness Grant"}],"Partnership Name":"Wellcome-DFID Epidemic Preparedness","Applicant Surname":"Umulisa","Partnership Value":369504,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Rinda-Ubuzima","name":"Rinda Ubuzima","addressCountry":"Rwanda","id_and_name":"[\"Rinda Ubuzima\", \"360G-Wellcome-ORG:Rinda-Ubuzima\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Rinda-Ubuzima","name":"Rinda Ubuzima"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Unprecedented Movement to drive a Unified Rwandan Initiative for National ZEBOVAC Immunization The ongoing outbreak of Ebola Virus Disease (EVD) in the Democratic Republic of Congo (DRC) and the recent identification of Ebola cases in the cities of Goma and Bukavu (which border Rwanda) are of particular concern and have prompted the Rwandan Government to take control measures for preventing cross-border spread of EVD. As demonstrated by the current outbreak, purely reactive measures may be insufficient to fight Ebola. Prophylactic approaches are needed that can prevent emergence of EVD in previously unaffected areas.We propose to conduct a large scale vaccination campaign targeting 196,000 individuals living and working in border-proximate areas; a clinical trial to evaluate the immunogenicity of the AD26.ZEBOV, MVA-BN-Filo vaccine in 2,000 people; and a clinical trial to evaluate the safety of the vaccine among 2,000 pregnant women in the context of this new framework of Ebola prevention. These 3 programs will together generate a large cohort that can be revisited for a long term follow up study to assess long term immunogenicity at different times following vaccination; an evaluation of a potential effect of booster doses and the optimal strategy for booster administration; and an evaluation of long term assessment of effectiveness using a test-negative case control study design.\n","awardDateDateOnly":"2019-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Democratic Republic of the Congo","Disease Outbreaks","Ebola Vaccines","Ebolavirus","Female","Hemorrhagic Fever, Ebola","Humans","Pregnancy","Rwanda","Vaccination"]}
{"id":"360G-Wellcome-220214_Z_20_Z","title":"Unprecedented Movement to drive a Unified Rwandan Initiative for National ZEBOVAC Immunization","Region":"International","currency":"GBP","awardDate":"2019-09-30T00:00:00+00:00","Internal ID":"220214/Z/20/Z","description":"The ongoing outbreak of Ebola Virus Disease (EVD) in the Democratic Republic of Congo (DRC) and the recent identification of Ebola cases in the cities of Goma and Bukavu (which border Rwanda) are of particular concern and have prompted the Rwandan Government to take control measures for preventing cross-border spread of EVD. As demonstrated by the current outbreak, purely reactive measures may be insufficient to fight Ebola. Prophylactic approaches are needed that can prevent emergence of EVD in previously unaffected areas. We propose to conduct a large-scale vaccination campaign targeting 196,000 individuals living and working in border-proximate areas; a clinical trial to evaluate the immunogenicity of the AD26.ZEBOV, MVA-BN-Filo vaccine in 2,000 people; and a clinical trial to evaluate the safety of the vaccine among 2,000 pregnant women in the context of this new framework of Ebola prevention. These 3 programs will together generate a large cohort that can be revisited for a long term follow up study to assess long term immunogenicity at different times following vaccination; an evaluation of a potential effect of booster doses and the optimal strategy for booster administration; and an evaluation of long term assessment of effectiveness using a test-negative case control study design.\n\n \n\n \n","plannedDates":[{"endDate":"2021-09-06T00:00:00+00:00","startDate":"2020-01-06T00:00:00+00:00","startDateDateOnly":"2020-01-06","endDateDateOnly":"2021-09-06"}],"amountAwarded":1510287,"Financial Year":"2018/19","Lead Applicant":"Dr Etienne Karita","grantProgramme":[{"title":"DFID-Wellcome Epidemic Preparedness Grant","title_keyword":"DFID-Wellcome Epidemic Preparedness Grant"}],"Partnership Name":"Wellcome-DFID Epidemic Preparedness","Applicant Surname":"Karita","Partnership Value":3325533,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Center-for-Family-Health-Research","name":"Center for Family Health Research","addressCountry":"Rwanda","id_and_name":"[\"Center for Family Health Research\", \"360G-Wellcome-ORG:Center-for-Family-Health-Research\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Center-for-Family-Health-Research","name":"Center for Family Health Research"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Unprecedented Movement to drive a Unified Rwandan Initiative for National ZEBOVAC Immunization The ongoing outbreak of Ebola Virus Disease (EVD) in the Democratic Republic of Congo (DRC) and the recent identification of Ebola cases in the cities of Goma and Bukavu (which border Rwanda) are of particular concern and have prompted the Rwandan Government to take control measures for preventing cross-border spread of EVD. As demonstrated by the current outbreak, purely reactive measures may be insufficient to fight Ebola. Prophylactic approaches are needed that can prevent emergence of EVD in previously unaffected areas. We propose to conduct a large-scale vaccination campaign targeting 196,000 individuals living and working in border-proximate areas; a clinical trial to evaluate the immunogenicity of the AD26.ZEBOV, MVA-BN-Filo vaccine in 2,000 people; and a clinical trial to evaluate the safety of the vaccine among 2,000 pregnant women in the context of this new framework of Ebola prevention. These 3 programs will together generate a large cohort that can be revisited for a long term follow up study to assess long term immunogenicity at different times following vaccination; an evaluation of a potential effect of booster doses and the optimal strategy for booster administration; and an evaluation of long term assessment of effectiveness using a test-negative case control study design.\n\n \n\n \n","awardDateDateOnly":"2019-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Democratic Republic of the Congo","Disease Outbreaks","Ebola Vaccines","Ebolavirus","Female","Hemorrhagic Fever, Ebola","Humans","Pregnancy","Rwanda","Vaccination"]}
{"id":"360G-Wellcome-220212_Z_20_Z","title":"Mechanisms of spliceosome remodeling and splice site selection during the catalytic stage of mammalian pre-mRNA splicing","Region":"South East","currency":"GBP","awardDate":"2020-03-04T00:00:00+00:00","Sponsor(s)":"Prof Francis Barr","Internal ID":"220212/Z/20/Z","description":"The spliceosome produces mRNAs in two sequential transesterifications \u2013 branching and exon ligation. The post-branching C complex is remodeled by the ATPase Prp16 into the C* complex. Prp16 allows binding of the exon ligation factors Cactin and FAM32A, which stabilise docking of the 3\u2019-splice site (3\u2019SS) at the active site. While in yeast Prp18 is constitutively bound to C* spliceosomes, in humans Prp18 and other exon ligation factors of unknown function appear to engage the C* spliceosome in a transcript-specific manner. Here, I will reconstitute the C to C* transition in vitro in mammals and use biochemistry and cryo-electron microscopy to isolate and visualize novel intermediates and dissect the structural mechanisms by which Cactin, FAM32A, Prp18, and additional exon ligation factors cooperate to promote Prp16-mediated remodeling and to ensure correct 3\u2019SS choice. In parallel, iCLIP studies will reveal where these exon ligation factors bind across all human pre-mRNAs and how RNA sequences around the splice sites determine the association of subsets of factors on specific pre-mRNAs. This work will elucidate how Prp16 drives remodeling of the human catalytic spliceosome and will investigate whether exon ligation factors regulate alternative splicing in a sequence-specific manner while proofreading 3'SS recognition during exon ligation.  \n","plannedDates":[{"endDate":"2026-04-30T00:00:00+00:00","startDate":"2021-05-01T00:00:00+00:00","startDateDateOnly":"2021-05-01","endDateDateOnly":"2026-04-30"}],"amountAwarded":1199999,"Financial Year":"2019/20","Lead Applicant":"Dr Sebastian Fica","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Fica","Partnership Value":1199999,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mechanisms of spliceosome remodeling and splice site selection during the catalytic stage of mammalian pre-mRNA splicing The spliceosome produces mRNAs in two sequential transesterifications \u2013 branching and exon ligation. The post-branching C complex is remodeled by the ATPase Prp16 into the C* complex. Prp16 allows binding of the exon ligation factors Cactin and FAM32A, which stabilise docking of the 3\u2019-splice site (3\u2019SS) at the active site. While in yeast Prp18 is constitutively bound to C* spliceosomes, in humans Prp18 and other exon ligation factors of unknown function appear to engage the C* spliceosome in a transcript-specific manner. Here, I will reconstitute the C to C* transition in vitro in mammals and use biochemistry and cryo-electron microscopy to isolate and visualize novel intermediates and dissect the structural mechanisms by which Cactin, FAM32A, Prp18, and additional exon ligation factors cooperate to promote Prp16-mediated remodeling and to ensure correct 3\u2019SS choice. In parallel, iCLIP studies will reveal where these exon ligation factors bind across all human pre-mRNAs and how RNA sequences around the splice sites determine the association of subsets of factors on specific pre-mRNAs. This work will elucidate how Prp16 drives remodeling of the human catalytic spliceosome and will investigate whether exon ligation factors regulate alternative splicing in a sequence-specific manner while proofreading 3'SS recognition during exon ligation.  \n","awardDateDateOnly":"2020-03-04","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adenosine Triphosphatases","Cryoelectron Microscopy","Exons","Humans","Models, Molecular","RNA Precursors","RNA Splicing","Saccharomyces cerevisiae","Saccharomyces cerevisiae Proteins","Spliceosomes"]}
{"id":"360G-Wellcome-220211_Z_20_Z","title":"Thailand Africa and Asia Programme - GBP Core","Region":"South East","currency":"GBP","awardDate":"2020-06-22T00:00:00+00:00","Internal ID":"220211/Z/20/Z","description":"The Wellcome Thailand AAP has conducted high quality impactful research for 40 years on infectious diseases of major public health concern, leading to the widespread adoption of new approaches and treatments for many of them including malaria, melioidosis, and rickettsial infections. In our fifth decade we will focus on ensuring sustainable impact and influence on policymakers by strengthening our research network and developing the capabilities of our partner institutions. Our vision is to:\n\n1. Through research continue to address public health problems with regional and global relevance, using cutting edge approaches to seek affordable and deployable solutions to disease prevention, diagnosis and patient management.\n\n2. Maximise our public health research\u2019s uptake and impact, incorporating health economics analysis and goal-driven engagement with policymakers, national academic institutions, hospitals, industry partners, communities and the general public.\n\n3. Work with our local host institutions to increase their national and global impact by integrating activities including training programmes, joint research projects, and supporting partner-led programmes to translate research into policy and practice.\n\nOur goal is to improve life quality and expectancy by reducing the adverse impact of infectious diseases, which account for much of the disparity in health metrics between low and high income countries.\n","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":17900000,"Financial Year":"2019/20","Lead Applicant":"Prof Nicholas Day","grantProgramme":[{"title":"Africa and Asia Programmes","title_keyword":"Africa and Asia Programmes"}],"Applicant Surname":"Day","Partnership Value":17900000,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Prof Elizabeth Ashley, Prof Frank Smithuis, Dr Direk Limmathurotsakul, Prof Phaik Yeong Cheah, Prof Arjen Dondorp, Prof Francois Nosten, Prof Mallika Imwong, Prof Sir Nicholas White, Prof Guy Thwaites, Prof Kesinee Chotivanich, Prof Paul Turner","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Thailand Africa and Asia Programme - GBP Core The Wellcome Thailand AAP has conducted high quality impactful research for 40 years on infectious diseases of major public health concern, leading to the widespread adoption of new approaches and treatments for many of them including malaria, melioidosis, and rickettsial infections. In our fifth decade we will focus on ensuring sustainable impact and influence on policymakers by strengthening our research network and developing the capabilities of our partner institutions. Our vision is to:\n\n1. Through research continue to address public health problems with regional and global relevance, using cutting edge approaches to seek affordable and deployable solutions to disease prevention, diagnosis and patient management.\n\n2. Maximise our public health research\u2019s uptake and impact, incorporating health economics analysis and goal-driven engagement with policymakers, national academic institutions, hospitals, industry partners, communities and the general public.\n\n3. Work with our local host institutions to increase their national and global impact by integrating activities including training programmes, joint research projects, and supporting partner-led programmes to translate research into policy and practice.\n\nOur goal is to improve life quality and expectancy by reducing the adverse impact of infectious diseases, which account for much of the disparity in health metrics between low and high income countries.\n","awardDateDateOnly":"2020-06-22","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biomedical Research","Global Health","Humans","Public Health","Thailand"]}
{"id":"360G-Wellcome-220211_A_20_Z","title":"Thailand Africa and Asia Programme THB Core Award","Region":"South East","currency":"GBP","awardDate":"2020-06-22T00:00:00+00:00","Internal ID":"220211/A/20/Z","description":"The Wellcome Thailand AAP has conducted high quality impactful research for 40 years on infectious diseases of major public health concern, leading to the widespread adoption of new approaches and treatments for many of them including malaria, melioidosis, and rickettsial infections. In our fifth decade we will focus on ensuring sustainable impact and influence on policymakers by strengthening our research network and developing the capabilities of our partner institutions. Our vision is to:\n\n1. Through research continue to address public health problems with regional and global relevance, using cutting edge approaches to seek affordable and deployable solutions to disease prevention, diagnosis and patient management.\n\n2. Maximise our public health research\u2019s uptake and impact, incorporating health economics analysis and goal-driven engagement with policymakers, national academic institutions, hospitals, industry partners, communities and the general public.\n\n3. Work with our local host institutions to increase their national and global impact by integrating activities including training programmes, joint research projects, and supporting partner-led programmes to translate research into policy and practice.\n\nOur goal is to improve life quality and expectancy by reducing the adverse impact of infectious diseases, which account for much of the disparity in health metrics between low and high income countries.\n","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":24589618,"Financial Year":"2019/20","Lead Applicant":"Prof Nicholas Day","grantProgramme":[{"title":"Africa and Asia Programmes","title_keyword":"Africa and Asia Programmes"}],"Applicant Surname":"Day","Partnership Value":24589618,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Direk Limmathurotsakul, Prof Arjen Dondorp, Prof Francois Nosten, Prof Guy Thwaites, Prof Kesinee Chotivanich, Prof Paul Turner, Prof Frank Smithuis, Prof Sir Nicholas White, Prof Elizabeth Ashley, Prof Mallika Imwong, Prof Phaik Yeong Cheah","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Thailand Africa and Asia Programme THB Core Award The Wellcome Thailand AAP has conducted high quality impactful research for 40 years on infectious diseases of major public health concern, leading to the widespread adoption of new approaches and treatments for many of them including malaria, melioidosis, and rickettsial infections. In our fifth decade we will focus on ensuring sustainable impact and influence on policymakers by strengthening our research network and developing the capabilities of our partner institutions. Our vision is to:\n\n1. Through research continue to address public health problems with regional and global relevance, using cutting edge approaches to seek affordable and deployable solutions to disease prevention, diagnosis and patient management.\n\n2. Maximise our public health research\u2019s uptake and impact, incorporating health economics analysis and goal-driven engagement with policymakers, national academic institutions, hospitals, industry partners, communities and the general public.\n\n3. Work with our local host institutions to increase their national and global impact by integrating activities including training programmes, joint research projects, and supporting partner-led programmes to translate research into policy and practice.\n\nOur goal is to improve life quality and expectancy by reducing the adverse impact of infectious diseases, which account for much of the disparity in health metrics between low and high income countries.\n","awardDateDateOnly":"2020-06-22","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa","Biomedical Research","Global Health","Humans","Public Health","Quality of Life","Thailand"]}
{"id":"360G-Wellcome-220211_A_20_A","title":"Thailand Africa and Asia Programme - PPE Award","Region":"South East","currency":"GBP","awardDate":"2020-06-22T00:00:00+00:00","Internal ID":"220211/A/20/A","description":"The Wellcome Thailand AAP has conducted high quality impactful research for 40 years on infectious diseases of major public health concern, leading to the widespread adoption of new approaches and treatments for many of them including malaria, melioidosis, and rickettsial infections. In our fifth decade we will focus on ensuring sustainable impact and influence on policymakers by strengthening our research network and developing the capabilities of our partner institutions. Our vision is to:\n\n1. Through research continue to address public health problems with regional and global relevance, using cutting edge approaches to seek affordable and deployable solutions to disease prevention, diagnosis and patient management.\n\n2. Maximise our public health research\u2019s uptake and impact, incorporating health economics analysis and goal-driven engagement with policymakers, national academic institutions, hospitals, industry partners, communities and the general public.\n\n3. Work with our local host institutions to increase their national and global impact by integrating activities including training programmes, joint research projects, and supporting partner-led programmes to translate research into policy and practice.\n\nOur goal is to improve life quality and expectancy by reducing the adverse impact of infectious diseases, which account for much of the disparity in health metrics between low and high income countries.\n","plannedDates":[{"endDate":"2025-09-30T00:00:00+00:00","startDate":"2020-10-01T00:00:00+00:00","startDateDateOnly":"2020-10-01","endDateDateOnly":"2025-09-30"}],"amountAwarded":1052228,"Financial Year":"2019/20","Lead Applicant":"Prof Nicholas Day","grantProgramme":[{"title":"Africa and Asia Programmes","title_keyword":"Africa and Asia Programmes"}],"Applicant Surname":"Day","Partnership Value":1052228,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Prof Frank Smithuis, Dr Direk Limmathurotsakul, Prof Francois Nosten, Prof Guy Thwaites, Prof Phaik Yeong Cheah, Prof Arjen Dondorp, Prof Elizabeth Ashley, Prof Mallika Imwong, Prof Sir Nicholas White, Prof Kesinee Chotivanich, Prof Paul Turner","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Thailand Africa and Asia Programme - PPE Award The Wellcome Thailand AAP has conducted high quality impactful research for 40 years on infectious diseases of major public health concern, leading to the widespread adoption of new approaches and treatments for many of them including malaria, melioidosis, and rickettsial infections. In our fifth decade we will focus on ensuring sustainable impact and influence on policymakers by strengthening our research network and developing the capabilities of our partner institutions. Our vision is to:\n\n1. Through research continue to address public health problems with regional and global relevance, using cutting edge approaches to seek affordable and deployable solutions to disease prevention, diagnosis and patient management.\n\n2. Maximise our public health research\u2019s uptake and impact, incorporating health economics analysis and goal-driven engagement with policymakers, national academic institutions, hospitals, industry partners, communities and the general public.\n\n3. Work with our local host institutions to increase their national and global impact by integrating activities including training programmes, joint research projects, and supporting partner-led programmes to translate research into policy and practice.\n\nOur goal is to improve life quality and expectancy by reducing the adverse impact of infectious diseases, which account for much of the disparity in health metrics between low and high income countries.\n","awardDateDateOnly":"2020-06-22","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Africa","Biomedical Research","Global Health","Humans","Public Health","Quality of Life","Thailand"]}
{"id":"360G-Wellcome-220209_Z_20_Z","title":"How cell migration and differentiation are coordinated during morphogenesis","Region":"Greater London","currency":"GBP","awardDate":"2020-03-31T00:00:00+00:00","Internal ID":"220209/Z/20/Z","description":"During development the embryo needs to generate functional organs composed of many different cell types, often originated in different embryonic location.  Thus, it is clear that cell differentiation and migration need to be tightly coordinated, although they are often studied as independent processes. Here I will test the hypothesis that cell migration and differentiations are coordinated by tissue mechanics in vivo. Specifically, I will challenge the current view that cell migration is the result of differentiation, by testing instead whether the reverse occurs, i.e. migration controls differentiation. I will use neural crest cell, a multipotent embryonic cell population in which cell differentiation is always linked to cell migration.\n\nOne of the problems to study biomechanics in vivo is the limited number of tools to measure and modify mechanical properties in vivo. Here I will develop new tools to analyse and change tissue stiffness in vivo. We will analyse how these mechanical changes influence cell migration and differentiation, and we will identify the molecular response elicited in the neural crest cells. We expect that this multidisciplinary project will provide answers to a central yet unresolved question in developmental biology: how cell fate and migration are integrated during embryo development.\n\n \n","plannedDates":[{"endDate":"2026-03-31T00:00:00+00:00","startDate":"2021-04-01T00:00:00+00:00","startDateDateOnly":"2021-04-01","endDateDateOnly":"2026-03-31"}],"amountAwarded":1734742,"Financial Year":"2019/20","Lead Applicant":"Prof Roberto Mayor","grantProgramme":[{"title":"Investigator Award in Science","title_keyword":"Investigator Award in Science"}],"Applicant Surname":"Mayor","Partnership Value":1734742,"Approval Committee":"Science Interview Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"How cell migration and differentiation are coordinated during morphogenesis During development the embryo needs to generate functional organs composed of many different cell types, often originated in different embryonic location.  Thus, it is clear that cell differentiation and migration need to be tightly coordinated, although they are often studied as independent processes. Here I will test the hypothesis that cell migration and differentiations are coordinated by tissue mechanics in vivo. Specifically, I will challenge the current view that cell migration is the result of differentiation, by testing instead whether the reverse occurs, i.e. migration controls differentiation. I will use neural crest cell, a multipotent embryonic cell population in which cell differentiation is always linked to cell migration.\n\nOne of the problems to study biomechanics in vivo is the limited number of tools to measure and modify mechanical properties in vivo. Here I will develop new tools to analyse and change tissue stiffness in vivo. We will analyse how these mechanical changes influence cell migration and differentiation, and we will identify the molecular response elicited in the neural crest cells. We expect that this multidisciplinary project will provide answers to a central yet unresolved question in developmental biology: how cell fate and migration are integrated during embryo development.\n\n \n","awardDateDateOnly":"2020-03-31","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Biomechanical Phenomena","Cell Differentiation","Cell Movement","Embryonic Development","Mice","Neural Crest"]}
{"id":"360G-Wellcome-220206_Z_20_Z","title":"Politics, elections, and inclusive decision-making: Do political institutions affect health?","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220206/Z/20/Z","description":"Do political institutions influence the health of populations? Political institutions once seemed fixed and stable, but now appear to be flexible and open to change. This project seeks to uncover whether changing political institutions could affect health. Political institutions are the rules that govern who participates and how they participate in decision-making processes within societies; for example, they dictate who gets to vote and how votes are counted. Political institutions potentially affect health because they make governments more (less) responsive to what citizens want. However, this straightforward view of how political institutions affect health overlooks how democracies can privilege some voices over others (e.g., party donors may matter more than voters) and so universal suffrage may not necessarily deliver better health. This project will shed light on these questions through a series of empirical case studies. For example, I propose to examine whether political incorporation improves the health of formerly excluded groups, and whether their influence on policy decisions is weaker in majoritarian political systems than proportional representation systems because votes are counted differently. This project speaks to the sustainable development agenda by illuminating whether inclusive and representative decision-making institutions may accelerate progress toward ensuring healthy lives for all.\n","plannedDates":[{"endDate":"2022-09-06T00:00:00+00:00","startDate":"2020-09-07T00:00:00+00:00","startDateDateOnly":"2020-09-07","endDateDateOnly":"2022-09-06"}],"amountAwarded":201914,"Financial Year":"2019/20","Lead Applicant":"Dr Aaron Reeves","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Reeves","Partnership Value":201914,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Politics, elections, and inclusive decision-making: Do political institutions affect health? Do political institutions influence the health of populations? Political institutions once seemed fixed and stable, but now appear to be flexible and open to change. This project seeks to uncover whether changing political institutions could affect health. Political institutions are the rules that govern who participates and how they participate in decision-making processes within societies; for example, they dictate who gets to vote and how votes are counted. Political institutions potentially affect health because they make governments more (less) responsive to what citizens want. However, this straightforward view of how political institutions affect health overlooks how democracies can privilege some voices over others (e.g., party donors may matter more than voters) and so universal suffrage may not necessarily deliver better health. This project will shed light on these questions through a series of empirical case studies. For example, I propose to examine whether political incorporation improves the health of formerly excluded groups, and whether their influence on policy decisions is weaker in majoritarian political systems than proportional representation systems because votes are counted differently. This project speaks to the sustainable development agenda by illuminating whether inclusive and representative decision-making institutions may accelerate progress toward ensuring healthy lives for all.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Decision Making","Health Policy","Humans","Politics"]}
{"id":"360G-Wellcome-220204_Z_20_Z","title":"Highly sensitive brain blood flow measurements using ultra-high field magnetic resonance imaging","Region":"South East","currency":"GBP","awardDate":"2020-03-04T00:00:00+00:00","Sponsor(s)":"Prof Heidi Johansen-Berg","Internal ID":"220204/Z/20/Z","description":"Blood flow is critical for maintaining the steady supply of oxygen and nutrients to the brain, and blood flow changes are present in a range of diseases including stroke and dementia. Conventional methods for in vivo blood flow mapping have limitations and often cannot be used for longitudinal monitoring or research. \n\nIn this proposal I aim to develop highly sensitive imaging methods for measuring brain blood flow based on a non-invasive magnetic resonance imaging technique, arterial spin labelling, applied at ultra-high field. The main goals of this research are: \n\n\n To establish a robust platform for ultra-high field arterial spin labelling by developing novel approaches to overcome a range of technical challenges associated with this technique;\n To develop advanced imaging approaches which allow richer cerebrovascular information to be obtained, including high resolution angiography and vessel-selective imaging;\n To demonstrate the high sensitivity achievable with these novel methods by measuring changes in white matter perfusion in patients with vascular cognitive impairment, and probing the brain\u2019s response to tonic pain at unprecedented spatial resolution.\n\n\n\nThese new methods will be actively shared with local, national and international collaborators, enabling previously unfeasible clinical and basic science research studies to be performed.\n","plannedDates":[{"endDate":"2025-06-14T00:00:00+00:00","startDate":"2020-06-15T00:00:00+00:00","startDateDateOnly":"2020-06-15","endDateDateOnly":"2025-06-14"}],"amountAwarded":1017466,"Financial Year":"2019/20","Lead Applicant":"Dr Thomas Okell","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Okell","Partnership Value":1017466,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Highly sensitive brain blood flow measurements using ultra-high field magnetic resonance imaging Blood flow is critical for maintaining the steady supply of oxygen and nutrients to the brain, and blood flow changes are present in a range of diseases including stroke and dementia. Conventional methods for in vivo blood flow mapping have limitations and often cannot be used for longitudinal monitoring or research. \n\nIn this proposal I aim to develop highly sensitive imaging methods for measuring brain blood flow based on a non-invasive magnetic resonance imaging technique, arterial spin labelling, applied at ultra-high field. The main goals of this research are: \n\n\n To establish a robust platform for ultra-high field arterial spin labelling by developing novel approaches to overcome a range of technical challenges associated with this technique;\n To develop advanced imaging approaches which allow richer cerebrovascular information to be obtained, including high resolution angiography and vessel-selective imaging;\n To demonstrate the high sensitivity achievable with these novel methods by measuring changes in white matter perfusion in patients with vascular cognitive impairment, and probing the brain\u2019s response to tonic pain at unprecedented spatial resolution.\n\n\n\nThese new methods will be actively shared with local, national and international collaborators, enabling previously unfeasible clinical and basic science research studies to be performed.\n","awardDateDateOnly":"2020-03-04","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Brain","Cerebrovascular Circulation","Humans","Magnetic Resonance Angiography","Magnetic Resonance Imaging","Spin Labels"]}
{"id":"360G-Wellcome-220198_Z_20_Z","title":"Stress signalling in intestinal maintenance and regeneration","Region":"South West","currency":"GBP","awardDate":"2020-03-04T00:00:00+00:00","Sponsor(s)":"Prof Anne Ridley","Internal ID":"220198/Z/20/Z","description":"Many adult epithelial tissues lose cells from constant environmental stress. Thus, an epithelium\u2019s ability to sense stress, defend itself and stimulate repair (e.g. by stem cells) is vital to prevent tissue dysfunction, degeneration, inflammation and cancer.\n \n\nDespite its importance, this process is poorly understood. Using the adult Drosophila intestine and its unparalleled genetics, combined with proteomics, transcriptomics and fixed and live imaging, I will determine how stress signalling promotes epithelial resilience, maintenance and regeneration focussing on three main aims.\n\n \n\n1) Reactive oxygen species (ROS) produced by damaged fly intestinal epithelial cells (IECs) promote intestinal stem cell (ISC)-mediated regeneration, partly via p38 signalling in IECs. I will determine how ROS promote intestinal regeneration by identifying ROS-controlled regulators of regeneration and determining molecular responses to ROS/stress signalling.\n\n \n\n2) I have recently found that some stress pathways display rhythmic, circadian activation. I will investigate their role in intestinal maintenance.\n\n \n\n3) I have shown that when new IEC production by ISCs is inhibited, IECs increase their lifespan to prolong epithelial maintenance. I will identify adaptive mechanisms that extend IEC lifespan when new cell production is blocked.\n\n\nUnderstanding these processes could provide novel therapeutic strategies for tissue regeneration, inflammatory diseases, cancer and age-related pathologies.\n","plannedDates":[{"endDate":"2025-08-14T00:00:00+00:00","startDate":"2020-08-15T00:00:00+00:00","startDateDateOnly":"2020-08-15","endDateDateOnly":"2025-08-14"}],"amountAwarded":1392083,"Financial Year":"2019/20","Lead Applicant":"Dr Parthive Patel","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Patel","Partnership Value":1392083,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Stress signalling in intestinal maintenance and regeneration Many adult epithelial tissues lose cells from constant environmental stress. Thus, an epithelium\u2019s ability to sense stress, defend itself and stimulate repair (e.g. by stem cells) is vital to prevent tissue dysfunction, degeneration, inflammation and cancer.\n \n\nDespite its importance, this process is poorly understood. Using the adult Drosophila intestine and its unparalleled genetics, combined with proteomics, transcriptomics and fixed and live imaging, I will determine how stress signalling promotes epithelial resilience, maintenance and regeneration focussing on three main aims.\n\n \n\n1) Reactive oxygen species (ROS) produced by damaged fly intestinal epithelial cells (IECs) promote intestinal stem cell (ISC)-mediated regeneration, partly via p38 signalling in IECs. I will determine how ROS promote intestinal regeneration by identifying ROS-controlled regulators of regeneration and determining molecular responses to ROS/stress signalling.\n\n \n\n2) I have recently found that some stress pathways display rhythmic, circadian activation. I will investigate their role in intestinal maintenance.\n\n \n\n3) I have shown that when new IEC production by ISCs is inhibited, IECs increase their lifespan to prolong epithelial maintenance. I will identify adaptive mechanisms that extend IEC lifespan when new cell production is blocked.\n\n\nUnderstanding these processes could provide novel therapeutic strategies for tissue regeneration, inflammatory diseases, cancer and age-related pathologies.\n","awardDateDateOnly":"2020-03-04","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Drosophila Proteins","Drosophila melanogaster","Intestinal Mucosa","Intestines","Reactive Oxygen Species","Regeneration","Signal Transduction","Stem Cells","Stress, Physiological","p38 Mitogen-Activated Protein Kinases"]}
{"id":"360G-Wellcome-220196_Z_20_Z","title":"RNA helicases as regulators of the response of B-cells to programmed DNA rearrangements","Region":"East of England","currency":"GBP","awardDate":"2020-03-04T00:00:00+00:00","Sponsor(s)":"Prof Michael Wakelam","Internal ID":"220196/Z/20/Z","description":"In mature B-cells, the generation of antibodies of different isotypes relies on class switch recombination (CSR) mechanisms. Although crucial for adaptive immunity, CSR imposes challenges to genome integrity as it involves programmed induction of DNA double-strand breaks (DSBs) in rapidly proliferating B-cells. A key player in the cellular response to CSR DSBs is the protein kinase ataxia telangiectasia mutated (ATM). Evidence suggests RNA-dependent mechanisms control the DNA damage response by ATM, although there is very limited understanding of how these function in B-cells and which RNA-binding proteins (RBPs) are required for CSR. This proposal aims to define the critical roles of RNA helicases as integrators of ATM signals to control class switch recombination mechanisms in B-cells. I propose an integrative approach combining genomic and proteomic methodologies together with ex vivo B-cell differentiation systems and conditional gene-targeting in mice. I will determine RNA helicase-dependent mechanisms controlling the cell-cycle and CSR DSB-repair and investigate their roles in B-cell immune responses. This work will provide new insight into RNA helicase-mediated pathological mechanisms resulting in CSR deregulation and the development of immune disease or B-cell lymphomagenesis.\n","plannedDates":[{"endDate":"2025-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2025-12-31"}],"amountAwarded":1241815,"Financial Year":"2019/20","Lead Applicant":"Dr Claudia de Almeida","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"de Almeida","Partnership Value":1241815,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Babraham-Institute","name":"Babraham Institute","addressCountry":"United Kingdom","id_and_name":"[\"Babraham Institute\", \"360G-Wellcome-ORG:Babraham-Institute\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Babraham-Institute","name":"Babraham Institute"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"RNA helicases as regulators of the response of B-cells to programmed DNA rearrangements In mature B-cells, the generation of antibodies of different isotypes relies on class switch recombination (CSR) mechanisms. Although crucial for adaptive immunity, CSR imposes challenges to genome integrity as it involves programmed induction of DNA double-strand breaks (DSBs) in rapidly proliferating B-cells. A key player in the cellular response to CSR DSBs is the protein kinase ataxia telangiectasia mutated (ATM). Evidence suggests RNA-dependent mechanisms control the DNA damage response by ATM, although there is very limited understanding of how these function in B-cells and which RNA-binding proteins (RBPs) are required for CSR. This proposal aims to define the critical roles of RNA helicases as integrators of ATM signals to control class switch recombination mechanisms in B-cells. I propose an integrative approach combining genomic and proteomic methodologies together with ex vivo B-cell differentiation systems and conditional gene-targeting in mice. I will determine RNA helicase-dependent mechanisms controlling the cell-cycle and CSR DSB-repair and investigate their roles in B-cell immune responses. This work will provide new insight into RNA helicase-mediated pathological mechanisms resulting in CSR deregulation and the development of immune disease or B-cell lymphomagenesis.\n","awardDateDateOnly":"2020-03-04","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Ataxia Telangiectasia Mutated Proteins","B-Lymphocytes","DEAD-box RNA Helicases","DNA Breaks, Double-Stranded","DNA Damage","Immunoglobulin Class Switching","Mice"]}
{"id":"360G-Wellcome-220192_Z_20_Z","title":"Molecular mechanisms of slow axonal transport","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2020-03-04T00:00:00+00:00","Sponsor(s)":"Prof Christopher McDermott","Internal ID":"220192/Z/20/Z","description":"\nNeuronal axons can be a metre long and are maintained for a lifetime, making them acutely vulnerable to defects in microtubule mediated long distance transport. There are two broad categories of axonal transport in neurons, fast and slow. Slow axonal transport carries at least three times the material of fast transport, but ten to a hundred times more slowly. Protein moved by slow transport can be months old in the distal axon, and this process slows further with aging. Despite dysfunctional axonal transport being common in neurodegeneration, where aging is the major risk factor for disease, the mechanisms that regulate slow transport are very poorly characterised. Critically, whether transport time directly affects the accumulated damage and function of its protein cargo is unknown. The aim of this project is to understand how slow transport is regulated, whether transit time can influence the half-life and function of proteins, and further - whether it\u2019s possible to reverse age-related decline in transport. To do this I will employ a multidisciplinary approach through the application of single-molecule light microscopy techniques. This project will define the relationship between the machinery of transport and the life cycle of axonal proteins.\n \n","plannedDates":[{"endDate":"2026-01-17T00:00:00+00:00","startDate":"2021-01-18T00:00:00+00:00","startDateDateOnly":"2021-01-18","endDateDateOnly":"2026-01-17"}],"amountAwarded":1255243,"Financial Year":"2019/20","Lead Applicant":"Dr Alison Twelvetrees","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Twelvetrees","Partnership Value":1255243,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield","addressCountry":"United Kingdom","id_and_name":"[\"University of Sheffield\", \"360G-Wellcome-ORG:University-of-Sheffield\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Molecular mechanisms of slow axonal transport \nNeuronal axons can be a metre long and are maintained for a lifetime, making them acutely vulnerable to defects in microtubule mediated long distance transport. There are two broad categories of axonal transport in neurons, fast and slow. Slow axonal transport carries at least three times the material of fast transport, but ten to a hundred times more slowly. Protein moved by slow transport can be months old in the distal axon, and this process slows further with aging. Despite dysfunctional axonal transport being common in neurodegeneration, where aging is the major risk factor for disease, the mechanisms that regulate slow transport are very poorly characterised. Critically, whether transport time directly affects the accumulated damage and function of its protein cargo is unknown. The aim of this project is to understand how slow transport is regulated, whether transit time can influence the half-life and function of proteins, and further - whether it\u2019s possible to reverse age-related decline in transport. To do this I will employ a multidisciplinary approach through the application of single-molecule light microscopy techniques. This project will define the relationship between the machinery of transport and the life cycle of axonal proteins.\n \n","awardDateDateOnly":"2020-03-04","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Axonal Transport","Axons","Microtubules"]}
{"id":"360G-Wellcome-220188_Z_20_Z","title":"Manipulating wound inflammation and angiogenesis to rescue defective tissue repair","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2020-03-04T00:00:00+00:00","Sponsor(s)":"Prof Stephen Renshaw","Internal ID":"220188/Z/20/Z","description":"Compromised wounds are increasingly prevalent, affecting quality of life for millions of sufferers and incurring a substantial burden on the NHS. I will define how macrophages control angiogenesis to drive wound healing and how this process breaks down to result in compromised wounds, particularly in the context of diabetes, using zebrafish and human co-culture models. Using RNAseq, I will profile zebrafish macrophages and endothelial cells in response to wounding, identifying the critical signals driving angiogenesis and how these fail in diabetic mutants. I will visually verify the roles of these key signalling genes by generating zebrafish transgenic reporters to live-image their wound response. In combination with novel CRISPR gene editing tools, I will establish specific manipulations to clinically relevant candidates, defining their functions and developing models of compromised wounds. The macrophage-HUVEC co-culture model will complement these zebrafish studies, corroborating the functions of macrophages from healthy versus diabetic patients. Expanding on this assay, I will use siRNA knock-down in monocyte-derived macrophages to dissect the role of clinically relevant candidates in perturbing macrophage control of angiogenesis. Together, these fish and human tissue culture models will provide a platform to identify novel therapeutics and propel the translation of these treatments towards the clinic.\n","plannedDates":[{"endDate":"2020-11-30T00:00:00+00:00","startDate":"2020-04-06T00:00:00+00:00","startDateDateOnly":"2020-04-06","endDateDateOnly":"2020-11-30"}],"amountAwarded":1131741,"Financial Year":"2019/20","Lead Applicant":"Dr David Gurevich","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Gurevich","Partnership Value":1131741,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield","addressCountry":"United Kingdom","id_and_name":"[\"University of Sheffield\", \"360G-Wellcome-ORG:University-of-Sheffield\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Manipulating wound inflammation and angiogenesis to rescue defective tissue repair Compromised wounds are increasingly prevalent, affecting quality of life for millions of sufferers and incurring a substantial burden on the NHS. I will define how macrophages control angiogenesis to drive wound healing and how this process breaks down to result in compromised wounds, particularly in the context of diabetes, using zebrafish and human co-culture models. Using RNAseq, I will profile zebrafish macrophages and endothelial cells in response to wounding, identifying the critical signals driving angiogenesis and how these fail in diabetic mutants. I will visually verify the roles of these key signalling genes by generating zebrafish transgenic reporters to live-image their wound response. In combination with novel CRISPR gene editing tools, I will establish specific manipulations to clinically relevant candidates, defining their functions and developing models of compromised wounds. The macrophage-HUVEC co-culture model will complement these zebrafish studies, corroborating the functions of macrophages from healthy versus diabetic patients. Expanding on this assay, I will use siRNA knock-down in monocyte-derived macrophages to dissect the role of clinically relevant candidates in perturbing macrophage control of angiogenesis. Together, these fish and human tissue culture models will provide a platform to identify novel therapeutics and propel the translation of these treatments towards the clinic.\n","awardDateDateOnly":"2020-03-04","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Animals, Genetically Modified","CRISPR-Cas Systems","Coculture Techniques","Disease Models, Animal","Humans","Macrophages","Neovascularization, Physiologic","Wound Healing","Zebrafish"]}
{"id":"360G-Wellcome-220185_Z_20_Z","title":"Identification of genomic components that predict transmission of the malaria parasite in different vector species","Region":"Scotland","currency":"GBP","awardDate":"2020-03-04T00:00:00+00:00","Sponsor(s)":"Prof Daniel Haydon","Internal ID":"220185/Z/20/Z","description":"The malaria parasite (Plasmodium falciparum) has a complex life cycle in which it must transit through multiple environments in a vertebrate host and mosquito vector. Transmission begins with ingestion of an infectious blood meal by one of 40 potential Anopheles mosquito species capable of transmitting the disease. This initiates the most extreme population bottleneck in the life cycle in which the parasite must rapidly undergo fertilisation, develop into an invasive form and transit through the midgut epithelium. The overarching goal of this proposal is to understand how this transmission through the mosquito vector drives selection on the parasite. I hypothesise that parasites have adapted to their local vector community composition, and this shapes their ability to infect sympatric and allopatric vector species. Using large-scale transmissibility assays and single-cell RNA-sequencing, I will identify genomic and transcriptomic vector-dependent signatures of transmission. I will then generate allelic-replacement parasites to unambiguously attribute phenotypic variation in species-specific transmission to specific loci in the parasite. Comprehensively understanding how vector communities shape parasite populations will guide future interventions and vector control programs by providing information that will allow for strategies to be locally tailored based on parasite genomic-surveillance and entomological surveys.\n \n","plannedDates":[{"endDate":"2025-07-31T00:00:00+00:00","startDate":"2020-08-01T00:00:00+00:00","startDateDateOnly":"2020-08-01","endDateDateOnly":"2025-07-31"}],"amountAwarded":1057974,"Financial Year":"2019/20","Lead Applicant":"Dr Virginia Howick","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Howick","Partnership Value":1057974,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow","addressCountry":"United Kingdom","id_and_name":"[\"University of Glasgow\", \"360G-Wellcome-ORG:University-of-Glasgow\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Glasgow","name":"University of Glasgow"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Identification of genomic components that predict transmission of the malaria parasite in different vector species The malaria parasite (Plasmodium falciparum) has a complex life cycle in which it must transit through multiple environments in a vertebrate host and mosquito vector. Transmission begins with ingestion of an infectious blood meal by one of 40 potential Anopheles mosquito species capable of transmitting the disease. This initiates the most extreme population bottleneck in the life cycle in which the parasite must rapidly undergo fertilisation, develop into an invasive form and transit through the midgut epithelium. The overarching goal of this proposal is to understand how this transmission through the mosquito vector drives selection on the parasite. I hypothesise that parasites have adapted to their local vector community composition, and this shapes their ability to infect sympatric and allopatric vector species. Using large-scale transmissibility assays and single-cell RNA-sequencing, I will identify genomic and transcriptomic vector-dependent signatures of transmission. I will then generate allelic-replacement parasites to unambiguously attribute phenotypic variation in species-specific transmission to specific loci in the parasite. Comprehensively understanding how vector communities shape parasite populations will guide future interventions and vector control programs by providing information that will allow for strategies to be locally tailored based on parasite genomic-surveillance and entomological surveys.\n \n","awardDateDateOnly":"2020-03-04","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Anopheles","Malaria","Mosquito Vectors","Plasmodium falciparum","Transcriptome"]}
{"id":"360G-Wellcome-220180_Z_20_Z","title":"Mechanisms and roles of transmissible RNA","Region":"East of England","currency":"GBP","awardDate":"2020-03-04T00:00:00+00:00","Sponsor(s)":"Prof Gerard Evan","Internal ID":"220180/Z/20/Z","description":"Protein coding and non-coding RNA can spread between cells and tissues of an organism. RNA mobility between organisms has been documented within and among different kingdoms of life including fungi, plants and animals. However, the underlying mechanisms and roles of such transmissible RNA are poorly understood. Our recent studies demonstrated that honeybees share biologically active RNA among members of the hive through secretion and ingestion of worker and royal jellies. The jellies harbor naturally occurring exogenous (e.g. viral) and endogenous RNA. These findings suggest that RNA transfer plays a role in social immunity and signaling between honeybees. Therefore, the key goals of this proposal are: to establish a metabolic RNA labeling system in honeybees; and to apply this system to study natural RNA transfer-mediated antiviral immunity and impacts on the physiology of recipient bees. To achieve these goals, I will combine RNA biology techniques and imaging with high-throughput sequencing to establish a functional transmissible RNA pathway in honeybees. This project will provide knowledge and tools that will enable studying the biology of RNA flow in other organisms, including humans, in diverse biological aspects; hence, will ultimately contribute to the development of RNA-based applications to promote health and disease control.\n","plannedDates":[{"endDate":"2026-04-14T00:00:00+00:00","startDate":"2021-04-15T00:00:00+00:00","startDateDateOnly":"2021-04-15","endDateDateOnly":"2026-04-14"}],"amountAwarded":1393480,"Financial Year":"2019/20","Lead Applicant":"Dr Eyal Maori","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Maori","Partnership Value":1393480,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mechanisms and roles of transmissible RNA Protein coding and non-coding RNA can spread between cells and tissues of an organism. RNA mobility between organisms has been documented within and among different kingdoms of life including fungi, plants and animals. However, the underlying mechanisms and roles of such transmissible RNA are poorly understood. Our recent studies demonstrated that honeybees share biologically active RNA among members of the hive through secretion and ingestion of worker and royal jellies. The jellies harbor naturally occurring exogenous (e.g. viral) and endogenous RNA. These findings suggest that RNA transfer plays a role in social immunity and signaling between honeybees. Therefore, the key goals of this proposal are: to establish a metabolic RNA labeling system in honeybees; and to apply this system to study natural RNA transfer-mediated antiviral immunity and impacts on the physiology of recipient bees. To achieve these goals, I will combine RNA biology techniques and imaging with high-throughput sequencing to establish a functional transmissible RNA pathway in honeybees. This project will provide knowledge and tools that will enable studying the biology of RNA flow in other organisms, including humans, in diverse biological aspects; hence, will ultimately contribute to the development of RNA-based applications to promote health and disease control.\n","awardDateDateOnly":"2020-03-04","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Bees","High-Throughput Nucleotide Sequencing","RNA","RNA Viruses"]}
{"id":"360G-Wellcome-220179_Z_20_Z","title":"Understanding the impact of global change on animal-borne diseases","Region":"Greater London","currency":"GBP","awardDate":"2020-03-04T00:00:00+00:00","Sponsor(s)":"Prof Andrew Cunningham","Internal ID":"220179/Z/20/Z","description":"We know little about how future climate change, habitat destruction, human population increases and greater globalisation processes will impact human zoonotic diseases. Here, I investigate the use of dynamic, seasonal host population models to better predict the impact of real-time environmental change on disease-carrying host species, within a general systems-dynamics, disease framework. Specifically, I will combine a mathematical compartmental disease model with a host population ecology model, within a spatial and temporal Bayesian framework.  Using this approach, I will first model Lassa Fever using climate and land-use observations, collaborating with the Nigerian government. I will then augment my model to account for animal movement patterns and vector species abundances, to examine arboviral disease spread in North America. Then, I will integrate these threads into a general, dynamic modelling framework for zoonotic diseases, which will contain both the newly developed components and my previously developed model of human movement and behaviour. Working with the World Health Organisation, I will create short- and long-term disease forecasts for a set of high priority zoonoses. Once validated against human case data, these mechanistic models can be used to test interventions and create future disease management plans that are robust to upcoming global change.\n","plannedDates":[{"endDate":"2025-11-15T00:00:00+00:00","startDate":"2020-11-16T00:00:00+00:00","startDateDateOnly":"2020-11-16","endDateDateOnly":"2025-11-15"}],"amountAwarded":679929,"Financial Year":"2019/20","Lead Applicant":"Dr David Redding","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Redding","Partnership Value":679929,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Zoological-Society-of-London","name":"Zoological Society of London","addressCountry":"United Kingdom","id_and_name":"[\"Zoological Society of London\", \"360G-Wellcome-ORG:Zoological-Society-of-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Zoological-Society-of-London","name":"Zoological Society of London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding the impact of global change on animal-borne diseases We know little about how future climate change, habitat destruction, human population increases and greater globalisation processes will impact human zoonotic diseases. Here, I investigate the use of dynamic, seasonal host population models to better predict the impact of real-time environmental change on disease-carrying host species, within a general systems-dynamics, disease framework. Specifically, I will combine a mathematical compartmental disease model with a host population ecology model, within a spatial and temporal Bayesian framework.  Using this approach, I will first model Lassa Fever using climate and land-use observations, collaborating with the Nigerian government. I will then augment my model to account for animal movement patterns and vector species abundances, to examine arboviral disease spread in North America. Then, I will integrate these threads into a general, dynamic modelling framework for zoonotic diseases, which will contain both the newly developed components and my previously developed model of human movement and behaviour. Working with the World Health Organisation, I will create short- and long-term disease forecasts for a set of high priority zoonoses. Once validated against human case data, these mechanistic models can be used to test interventions and create future disease management plans that are robust to upcoming global change.\n","awardDateDateOnly":"2020-03-04","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Bayes Theorem","Climate Change","Humans","Models, Biological","Models, Theoretical","North America","Seasons","Zoonoses"]}
{"id":"360G-Wellcome-220171_Z_20_Z","title":"Analyses of paired host-virus genomic data to understand disease heterogeneity of chronic viral infections.","Region":"South East","currency":"GBP","awardDate":"2020-03-04T00:00:00+00:00","Sponsor(s)":"Prof Paul Klenerman","Internal ID":"220171/Z/20/Z","description":"Host and pathogen genetic variations are major causes of clinical outcomes of infectious diseases. Traditionally, genetic studies of infectious diseases have sought to explain between-individual variation in disease by assessing genetic factors separately in humans or pathogens, under the assumption that these factors are independent. However, there is strong theoretical evidence that genetic interactions between host and viruses play a major role in viral disease aetiology. The major limiting factor to date has been the lack of cohorts with paired host-virus data. Recent technological developments and reductions in the cost of high-throughput viral sequencing from clinical samples have provided new opportunities to analyse host-virus genomic data generated from the same patients. In this project I propose to analyse paired host-virus genomic data from patient cohorts infected with HBV, HCV and HIV (clinically the most important chronic viruses worldwide) to answer the following questions:\n\n1) What are the host genetic pressures driving virus evolution across different host populations and virus lineages?\n\n2) What host and virus genetic interactions drive disease phenotypes?\n\n3) What are the host genetic variants and pathways linked to disease phenotype across the three chronic viral infections of HBV, HCV and HIV?\n","plannedDates":[{"endDate":"2025-05-01T00:00:00+00:00","startDate":"2020-05-01T00:00:00+00:00","startDateDateOnly":"2020-05-01","endDateDateOnly":"2025-05-01"}],"amountAwarded":1153494,"Financial Year":"2019/20","Lead Applicant":"Dr M. Azim Ansari","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Ansari","Partnership Value":1153494,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Analyses of paired host-virus genomic data to understand disease heterogeneity of chronic viral infections. Host and pathogen genetic variations are major causes of clinical outcomes of infectious diseases. Traditionally, genetic studies of infectious diseases have sought to explain between-individual variation in disease by assessing genetic factors separately in humans or pathogens, under the assumption that these factors are independent. However, there is strong theoretical evidence that genetic interactions between host and viruses play a major role in viral disease aetiology. The major limiting factor to date has been the lack of cohorts with paired host-virus data. Recent technological developments and reductions in the cost of high-throughput viral sequencing from clinical samples have provided new opportunities to analyse host-virus genomic data generated from the same patients. In this project I propose to analyse paired host-virus genomic data from patient cohorts infected with HBV, HCV and HIV (clinically the most important chronic viruses worldwide) to answer the following questions:\n\n1) What are the host genetic pressures driving virus evolution across different host populations and virus lineages?\n\n2) What host and virus genetic interactions drive disease phenotypes?\n\n3) What are the host genetic variants and pathways linked to disease phenotype across the three chronic viral infections of HBV, HCV and HIV?\n","awardDateDateOnly":"2020-03-04","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Coinfection","Genetic Variation","Hepatitis B","Hepatitis B virus","Host-Pathogen Interactions","Humans"]}
{"id":"360G-Wellcome-220169_Z_20_Z","title":"Purpose and Mechanisms of Behavioural Modulation in Retina and Superior Colliculus","Region":"South East","currency":"GBP","awardDate":"2020-03-04T00:00:00+00:00","Sponsor(s)":"Prof Sarah Guthrie","Internal ID":"220169/Z/20/Z","description":"The project aims to uncover why and how behavioural states like arousal affect neural processing in the early visual system by recording from the retina and superior colliculus in awake mice using techniques I have previously developed. Behavioural states affect task performance but their effect on early sensation is unclear; understanding their impact on early visual processing will reveal fundamental computational principles of adaptation.\n\nOur objectives are:\n\n\n determine the effects of behavioural states on different cell types in the early visual system by recording activity of retinal and collicular neurons classified by function, genetics and projection targets in awake mice.\n determine the purpose of behavioural state modulation in terms of information processing in the early visual system by recording activity of retinal and collicular cell types in awake mice viewing visual stimuli that elicit nonlinear responses or are behaviourally relevant.\n determine the mechanisms by which behavioural states influence early visual processing by measuring and manipulating the activity of neuromodulators, serotonin and noradrenaline, controlling behavioural states while recording from retinal and collicular neurons.\n\n\nThe results of this project impact on basic neurosciences and other fields including the development of artificial intelligent systems and the treatment and diagnosis of psychiatric disorders.\n","plannedDates":[{"endDate":"2025-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2025-12-31"}],"amountAwarded":1256713,"Financial Year":"2019/20","Lead Applicant":"Dr Sylvia Schroeder","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Schroeder","Partnership Value":1256713,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Sussex","name":"University of Sussex","addressCountry":"United Kingdom","id_and_name":"[\"University of Sussex\", \"360G-Wellcome-ORG:University-of-Sussex\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Sussex","name":"University of Sussex"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Purpose and Mechanisms of Behavioural Modulation in Retina and Superior Colliculus The project aims to uncover why and how behavioural states like arousal affect neural processing in the early visual system by recording from the retina and superior colliculus in awake mice using techniques I have previously developed. Behavioural states affect task performance but their effect on early sensation is unclear; understanding their impact on early visual processing will reveal fundamental computational principles of adaptation.\n\nOur objectives are:\n\n\n determine the effects of behavioural states on different cell types in the early visual system by recording activity of retinal and collicular neurons classified by function, genetics and projection targets in awake mice.\n determine the purpose of behavioural state modulation in terms of information processing in the early visual system by recording activity of retinal and collicular cell types in awake mice viewing visual stimuli that elicit nonlinear responses or are behaviourally relevant.\n determine the mechanisms by which behavioural states influence early visual processing by measuring and manipulating the activity of neuromodulators, serotonin and noradrenaline, controlling behavioural states while recording from retinal and collicular neurons.\n\n\nThe results of this project impact on basic neurosciences and other fields including the development of artificial intelligent systems and the treatment and diagnosis of psychiatric disorders.\n","awardDateDateOnly":"2020-03-04","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Mice","Mice, Inbred C57BL","Norepinephrine","Photic Stimulation","Retina","Superior Colliculi","Visual Pathways","Visual Perception"]}
{"id":"360G-Wellcome-220163_Z_20_Z","title":"Action in Vision","Region":"North West","currency":"GBP","awardDate":"2020-03-04T00:00:00+00:00","Sponsor(s)":"Prof Judith Hoyland","Internal ID":"220163/Z/20/Z","description":"How do vision and motor actions interact? A textbook will answer that vision guides movements but this view has been challenged over the last decade. The most striking realisation was the extent to which locomotion modulates neural activity in primary visual cortex, thalamus dLGN, superior colliculus and even the retina (collectively Early Visual System or EVS). Therefore movements can guide visual processing but the nature of this effect is unknown.\n\nThe most pressing question regards the specificity of these interactions. In EVS different visual features (size, luminance, colour, direction ...) are processed along parallel channels, at least 30 in the mouse retina. Since different motor actions (e.g. picking a fine thread, kicking a ball) require different visual features, I expect the interactions between vision and movements to be quite specific to the nature of the actions performed.  \n\nDue to technological limitations the only available data are obtained in head-fixed animals where only one type of action \u2013 locomotion \u2013 can be observed. To overcome these limitations I developed a system to quantify movements in unconstrained animals.  I will use this system to understand how different movements affect distinct visual channels in EVS, modify the neural code(s) and ultimately influence behaviour.\n","plannedDates":[{"endDate":"2025-12-31T00:00:00+00:00","startDate":"2021-01-01T00:00:00+00:00","startDateDateOnly":"2021-01-01","endDateDateOnly":"2025-12-31"}],"amountAwarded":844817,"Financial Year":"2019/20","Lead Applicant":"Dr Riccardo Storchi","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Storchi","Partnership Value":844817,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Action in Vision How do vision and motor actions interact? A textbook will answer that vision guides movements but this view has been challenged over the last decade. The most striking realisation was the extent to which locomotion modulates neural activity in primary visual cortex, thalamus dLGN, superior colliculus and even the retina (collectively Early Visual System or EVS). Therefore movements can guide visual processing but the nature of this effect is unknown.\n\nThe most pressing question regards the specificity of these interactions. In EVS different visual features (size, luminance, colour, direction ...) are processed along parallel channels, at least 30 in the mouse retina. Since different motor actions (e.g. picking a fine thread, kicking a ball) require different visual features, I expect the interactions between vision and movements to be quite specific to the nature of the actions performed.  \n\nDue to technological limitations the only available data are obtained in head-fixed animals where only one type of action \u2013 locomotion \u2013 can be observed. To overcome these limitations I developed a system to quantify movements in unconstrained animals.  I will use this system to understand how different movements affect distinct visual channels in EVS, modify the neural code(s) and ultimately influence behaviour.\n","awardDateDateOnly":"2020-03-04","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Locomotion","Mice","Mice, Inbred C57BL","Photic Stimulation","Visual Cortex"]}
{"id":"360G-Wellcome-220160_Z_20_Z","title":"A computer-guided imaging system for prenatal screening and comprehensive diagnosis of fetal abnormalities","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220160/Z/20/Z","description":"In the UK and in many countries around the world, it is routine for women to undergo an\nultrasound (US) screening examination about halfway through pregnancy to check if their\nfetus is developing normally. This is important as undiscovered fetal anomalies can have a\nlifelong impact on the families affected, with huge cost to health services as well as\nsubstantial wider societal impact. Currently, international screening detection rates are\nhighly variable, and are strongly dependent on the skill and experience of the sonographer\nperforming the examination.\nThis project builds on iFIND (www.ifindproject.com), a Wellcome Trust (WT) Innovative\nEngineering in Health award, which has yielded powerful computerized technology that\nuses artificial intelligence to simplify and enhance fetal US screening by automating many\nroutine tasks. This technology has been created by a fully integrated team of computer\nscientists and clinicians working together using a close couple cycle of innovation and\nclinical testing. It has the potential to have a significant impact on fetal screening, but to\nachieve that it is necessary to transition from University developed prototype to healthcare\nproduct. The usual strategy is to license to an existing player or spin-out a company.\nHowever, in both cases the close coupling between technology innovation and clinical\ntesting that has proved so effective can get stressed or broken. We propose an innovative\napproach in which the next stage of development is undertaken by an embedded team of\nengineers working directly within a clinical environment. This will provide opportunities not\navailable by either of the conventional routes, providing an effective pathway to impact.","plannedDates":[{"endDate":"2023-06-30T00:00:00+00:00","startDate":"2021-07-01T00:00:00+00:00","startDateDateOnly":"2021-07-01","endDateDateOnly":"2023-06-30"}],"amountAwarded":501929,"Financial Year":"2019/20","Lead Applicant":"Prof Joseph Hajnal","grantProgramme":[{"title":"Innovations Priority Project","title_keyword":"Innovations Priority Project"}],"Applicant Surname":"Hajnal","Partnership Value":501929,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Prof Julia Schnabel, Dr Bernhard Kainz, Prof Daniel Rueckert, Prof Reza Razavi","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London","addressCountry":"United Kingdom","id_and_name":"[\"King's College London\", \"360G-Wellcome-ORG:Kings-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Kings-College-London","name":"King's College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A computer-guided imaging system for prenatal screening and comprehensive diagnosis of fetal abnormalities In the UK and in many countries around the world, it is routine for women to undergo an\nultrasound (US) screening examination about halfway through pregnancy to check if their\nfetus is developing normally. This is important as undiscovered fetal anomalies can have a\nlifelong impact on the families affected, with huge cost to health services as well as\nsubstantial wider societal impact. Currently, international screening detection rates are\nhighly variable, and are strongly dependent on the skill and experience of the sonographer\nperforming the examination.\nThis project builds on iFIND (www.ifindproject.com), a Wellcome Trust (WT) Innovative\nEngineering in Health award, which has yielded powerful computerized technology that\nuses artificial intelligence to simplify and enhance fetal US screening by automating many\nroutine tasks. This technology has been created by a fully integrated team of computer\nscientists and clinicians working together using a close couple cycle of innovation and\nclinical testing. It has the potential to have a significant impact on fetal screening, but to\nachieve that it is necessary to transition from University developed prototype to healthcare\nproduct. The usual strategy is to license to an existing player or spin-out a company.\nHowever, in both cases the close coupling between technology innovation and clinical\ntesting that has proved so effective can get stressed or broken. We propose an innovative\napproach in which the next stage of development is undertaken by an embedded team of\nengineers working directly within a clinical environment. This will provide opportunities not\navailable by either of the conventional routes, providing an effective pathway to impact.","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Female","Fetus","Humans","Pregnancy","Ultrasonography, Prenatal"]}
{"id":"360G-Wellcome-220151_Z_20_Z","title":"Digital Preservation of Reproductive Health Resources: Archiving the 8th","Region":"Ireland","currency":"GBP","awardDate":"2019-11-14T00:00:00+00:00","Internal ID":"220151/Z/20/Z","description":"On 25th May 2018, Irish citizens voted to remove the controversial \"8th Amendment\" to the Irish Constitution, opening the way for the introduction of legislation governing the termination of pregnancy in the State.\n\nThis project intends to provide long term preservation and access to the many at-risk archives generated by grassroots women\u2019s reproductive health movements during the campaign.\n\nThere is no consensus on the best practice for archiving social media posts, which are supported on third party platforms. It has also been argued that archival curation has been skewed towards the dominant culture. As a result, many of the rich archives of reproductive health generated through the referendum campaign are at-risk.\n\nThis project aims to\n\n\u00b7         Ingest material from the six collaborating organisations for long term preservation in the DRI\n\n\u00b7         develop best practice for archiving social media\n\n\u00b7         create a registry of at-risk reproductive health archives and support further ingest to the DRI\n\n\u00b7         carry out social science research into best practice, ethics and legalities of archiving this material\n\n\u00b7         Provide training and expertise to reproductive health archives in archival best practice\n\n\u00b7         Collect and preserve additional material on the topic from the public\n","plannedDates":[{"endDate":"2023-05-31T00:00:00+00:00","startDate":"2020-06-01T00:00:00+00:00","startDateDateOnly":"2020-06-01","endDateDateOnly":"2023-05-31"}],"amountAwarded":330630,"Financial Year":"2019/20","Lead Applicant":"Dr Kathryn Cassidy","grantProgramme":[{"title":"Research Resources Award","title_keyword":"Research Resources Award"}],"Applicant Surname":"Cassidy","Partnership Value":330630,"Approval Committee":"Research Resources Committee","Other Applicant(s)":"Dr Aileen O'Carroll, Dr Natalie Harrower, Mr Kevin Long","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Trinity-College-Dublin","name":"Trinity College Dublin","addressCountry":"Ireland","id_and_name":"[\"Trinity College Dublin\", \"360G-Wellcome-ORG:Trinity-College-Dublin\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Trinity-College-Dublin","name":"Trinity College Dublin"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Digital Preservation of Reproductive Health Resources: Archiving the 8th On 25th May 2018, Irish citizens voted to remove the controversial \"8th Amendment\" to the Irish Constitution, opening the way for the introduction of legislation governing the termination of pregnancy in the State.\n\nThis project intends to provide long term preservation and access to the many at-risk archives generated by grassroots women\u2019s reproductive health movements during the campaign.\n\nThere is no consensus on the best practice for archiving social media posts, which are supported on third party platforms. It has also been argued that archival curation has been skewed towards the dominant culture. As a result, many of the rich archives of reproductive health generated through the referendum campaign are at-risk.\n\nThis project aims to\n\n\u00b7         Ingest material from the six collaborating organisations for long term preservation in the DRI\n\n\u00b7         develop best practice for archiving social media\n\n\u00b7         create a registry of at-risk reproductive health archives and support further ingest to the DRI\n\n\u00b7         carry out social science research into best practice, ethics and legalities of archiving this material\n\n\u00b7         Provide training and expertise to reproductive health archives in archival best practice\n\n\u00b7         Collect and preserve additional material on the topic from the public\n","awardDateDateOnly":"2019-11-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Female","Humans","Pregnancy","Reproductive Health","Social Media"]}
{"id":"360G-Wellcome-220149_Z_20_Z","title":"Introducing Assyrian Medicine: healthcare fit for a king","Region":"Greater London","currency":"GBP","awardDate":"2019-11-14T00:00:00+00:00","Internal ID":"220149/Z/20/Z","description":"This project makes available for the first time the world\u2019s most standardised, structured and systematised corpus of medical literature prior to Galen: the \"Nineveh Medical Encyclopaedia\" from the library of Ashurbanipal, King of Assyria (669-c.630 BC). Its broken condition and its use of cuneiform script mean that, almost 200 years after their first discovery, still only glimpses of its content are accessible to medical historians. As such the importance of Assyria\u2019s contribution to the history of medicine remains unrecognised.\n\nWhile fragments of Ashurbanipal\u2019s medical library have long been known, the existence of the Encyclopaedia has only recently been recognised thanks to the reconstruction and translation of an ancient medical catalogue. This discovery allows us now to reconstruct the whole Encyclopaedia from its broken fragments and translate it in full. We will then generate a complete index of drug names and technical vocabulary as found in the compendium, and correlate them against the symptoms they were designed to treat. All this material will be made freely available in enriched digital form. The project will therefore enable researchers to gain a clear understanding of ancient Assyrian medicine and its place in the broader history of medicine.\n","plannedDates":[{"endDate":"2023-05-03T00:00:00+00:00","startDate":"2020-05-04T00:00:00+00:00","startDateDateOnly":"2020-05-04","endDateDateOnly":"2023-05-03"}],"amountAwarded":353277,"Financial Year":"2019/20","Lead Applicant":"Dr Jonathan Taylor","grantProgramme":[{"title":"Research Resources Award","title_keyword":"Research Resources Award"}],"Applicant Surname":"Taylor","Partnership Value":353277,"Approval Committee":"Research Resources Committee","Other Applicant(s)":"Dr irving finkel, Prof Markham Geller","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:British-Museum","name":"British Museum","addressCountry":"United Kingdom","id_and_name":"[\"British Museum\", \"360G-Wellcome-ORG:British-Museum\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:British-Museum","name":"British Museum"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Introducing Assyrian Medicine: healthcare fit for a king This project makes available for the first time the world\u2019s most standardised, structured and systematised corpus of medical literature prior to Galen: the \"Nineveh Medical Encyclopaedia\" from the library of Ashurbanipal, King of Assyria (669-c.630 BC). Its broken condition and its use of cuneiform script mean that, almost 200 years after their first discovery, still only glimpses of its content are accessible to medical historians. As such the importance of Assyria\u2019s contribution to the history of medicine remains unrecognised.\n\nWhile fragments of Ashurbanipal\u2019s medical library have long been known, the existence of the Encyclopaedia has only recently been recognised thanks to the reconstruction and translation of an ancient medical catalogue. This discovery allows us now to reconstruct the whole Encyclopaedia from its broken fragments and translate it in full. We will then generate a complete index of drug names and technical vocabulary as found in the compendium, and correlate them against the symptoms they were designed to treat. All this material will be made freely available in enriched digital form. The project will therefore enable researchers to gain a clear understanding of ancient Assyrian medicine and its place in the broader history of medicine.\n","awardDateDateOnly":"2019-11-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["History, 20th Century"]}
{"id":"360G-Wellcome-220148_Z_20_Z","title":"History Bones: opening up the archive of the Brittle Bone Society","Region":"Scotland","currency":"GBP","awardDate":"2019-11-14T00:00:00+00:00","Internal ID":"220148/Z/20/Z","description":"The project will catalogue the archive of the Brittle Bone Society which is primarily held by the University of Dundee Archive Services. Any material remaining at the Society headquarters will be transferred and catalogued and the catalogue will be available online. The material will be re-housed into appropriate archival quality storage containers and a proportion of the material will be digitised. An additional element of the project will be to conduct oral history interviews with Brittle Bone Society members and staff which will become part of the Society's archive. A project board will oversea the progress of the project and will assist in organising a dissemination event. \n\n\n The archive will be fully catalogued allowing researchers to understand its content and identify relevant material\n The material will be properly preserved ensuring its long term survival\n The archive will be supplemented by recordings of people associated with the Society which add to the richness of the research resource\n Awareness of the archive and its research potential will be increased, as will the likelihood of further accruals of material in future\n Two interdisciplinary dissemination events will allow the discussion of archives relating to disability and the Brittle Bone archive in particular\n\n","plannedDates":[{"endDate":"2022-05-03T00:00:00+00:00","startDate":"2021-05-03T00:00:00+00:00","startDateDateOnly":"2021-05-03","endDateDateOnly":"2022-05-03"}],"amountAwarded":50783,"Financial Year":"2019/20","Lead Applicant":"Ms Caroline Brown","grantProgramme":[{"title":"Research Resources Award","title_keyword":"Research Resources Award"}],"Applicant Surname":"Brown","Partnership Value":50783,"Approval Committee":"Research Resources Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee","addressCountry":"United Kingdom","id_and_name":"[\"University of Dundee\", \"360G-Wellcome-ORG:University-of-Dundee\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"History Bones: opening up the archive of the Brittle Bone Society The project will catalogue the archive of the Brittle Bone Society which is primarily held by the University of Dundee Archive Services. Any material remaining at the Society headquarters will be transferred and catalogued and the catalogue will be available online. The material will be re-housed into appropriate archival quality storage containers and a proportion of the material will be digitised. An additional element of the project will be to conduct oral history interviews with Brittle Bone Society members and staff which will become part of the Society's archive. A project board will oversea the progress of the project and will assist in organising a dissemination event. \n\n\n The archive will be fully catalogued allowing researchers to understand its content and identify relevant material\n The material will be properly preserved ensuring its long term survival\n The archive will be supplemented by recordings of people associated with the Society which add to the richness of the research resource\n Awareness of the archive and its research potential will be increased, as will the likelihood of further accruals of material in future\n Two interdisciplinary dissemination events will allow the discussion of archives relating to disability and the Brittle Bone archive in particular\n\n","awardDateDateOnly":"2019-11-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["History, 20th Century","Humans"]}
{"id":"360G-Wellcome-220144_Z_20_Z","title":"Building a Healthier City 2: slum clearance, council housing and renovation in Bath, 1890-1995","Region":"South West","currency":"GBP","awardDate":"2019-11-14T00:00:00+00:00","Internal ID":"220144/Z/20/Z","description":"The project will open up valuable new opportunities for research into the relationship between housing and health, answering a clear need for easily accessible archival resources for studies of housing at a local level. It will enable access to significant records relating to slum clearance, provision of council housing, and renovation of unfit properties in Bath between 1890 and 1995. These records are currently uncatalogued and in a poor state of preservation, inaccessible to the research community.\n \nWe will catalogue approximately 90 linear metres of records to ISAD(G), and publish the resulting catalogue online; the records will be repackaged in accordance with BS4971:2017; remedial conservation will be carried out on those records requiring it. The activities of the project will be strengthened through the input of an Academic Advisory Board which will advise on interaction with the research community and dissemination of the project.\n \nAs a result of the project, access to a significant collection of records will be assured for researchers now and in the future. It will make a valuable contribution to the evidence base for research into the relationship between local housing policy and health, encouraging a long-term perspective on current housing issues, and informing future policies.\n \n","plannedDates":[{"endDate":"2022-12-30T00:00:00+00:00","startDate":"2020-12-31T00:00:00+00:00","startDateDateOnly":"2020-12-31","endDateDateOnly":"2022-12-30"}],"amountAwarded":169117,"Financial Year":"2019/20","Lead Applicant":"Mrs Lucy Powell","grantProgramme":[{"title":"Research Resources Award","title_keyword":"Research Resources Award"}],"Applicant Surname":"Powell","Partnership Value":169117,"Approval Committee":"Research Resources Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Bath-and-North-East-Somerset-Council","name":"Bath and North East Somerset Council","addressCountry":"United Kingdom","id_and_name":"[\"Bath and North East Somerset Council\", \"360G-Wellcome-ORG:Bath-and-North-East-Somerset-Council\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Bath-and-North-East-Somerset-Council","name":"Bath and North East Somerset Council"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Building a Healthier City 2: slum clearance, council housing and renovation in Bath, 1890-1995 The project will open up valuable new opportunities for research into the relationship between housing and health, answering a clear need for easily accessible archival resources for studies of housing at a local level. It will enable access to significant records relating to slum clearance, provision of council housing, and renovation of unfit properties in Bath between 1890 and 1995. These records are currently uncatalogued and in a poor state of preservation, inaccessible to the research community.\n \nWe will catalogue approximately 90 linear metres of records to ISAD(G), and publish the resulting catalogue online; the records will be repackaged in accordance with BS4971:2017; remedial conservation will be carried out on those records requiring it. The activities of the project will be strengthened through the input of an Academic Advisory Board which will advise on interaction with the research community and dissemination of the project.\n \nAs a result of the project, access to a significant collection of records will be assured for researchers now and in the future. It will make a valuable contribution to the evidence base for research into the relationship between local housing policy and health, encouraging a long-term perspective on current housing issues, and informing future policies.\n \n","awardDateDateOnly":"2019-11-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cities","Housing","Humans","Public Housing"]}
{"id":"360G-Wellcome-220140_Z_20_Z","title":"Health-sensitive Implementation of Nationally Determined Contributions","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220140/Z/20/Z","description":"There is strong evidence that climate change presents severe health risks, while addressing the drivers of climate change can bring large health gains. Nationally Determined Contributions (NDCs) reflect countries' self-defined efforts to reduce greenhouse gas emissions, and adapt to climate change impacts, to meet the goals of the 2015 Paris Climate Agreement.  They are renewed every five years, beginning in 2020. The first round of submitted NDCs are neither sufficient to limit warming below the global goal of 2C (aiming at 1.5C) nor to adequately strengthen resilience to climate risks. While 65% cite health, less than 25% include health cobenefits of mitigation, only 3% of proposed NDC actions connect to health, and only 50% of surveyed countries have a health adaptation strategy or plan. \n\nThe project will address barriers that currently hinder governments in systematically considering health in NDC design and implementation.  It will provide national health and development actors with evidence, analytical and capacity building tools to support them in integrating health risks, and the health co-benefits of climate change mitigation, into NDCs.  It will thereby contribute to protecting and promoting health, and to a more coherent and synergistic approach to climate action, health and sustainable development.\n","plannedDates":[{"endDate":"2022-05-13T00:00:00+00:00","startDate":"2020-05-14T00:00:00+00:00","startDateDateOnly":"2020-05-14","endDateDateOnly":"2022-05-13"}],"amountAwarded":1961880,"Financial Year":"2019/20","Lead Applicant":"Dr Diarmid Campbell-Lendrum","grantProgramme":[{"title":"Discretionary Award - OPOH","title_keyword":"Discretionary Award - OPOH"}],"Applicant Surname":"Campbell-Lendrum","Partnership Value":1961880,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:World-Health-Organization-Switzerland","name":"World Health Organization, Switzerland","addressCountry":"Switzerland","id_and_name":"[\"World Health Organization, Switzerland\", \"360G-Wellcome-ORG:World-Health-Organization-Switzerland\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:World-Health-Organization-Switzerland","name":"World Health Organization, Switzerland"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Health-sensitive Implementation of Nationally Determined Contributions There is strong evidence that climate change presents severe health risks, while addressing the drivers of climate change can bring large health gains. Nationally Determined Contributions (NDCs) reflect countries' self-defined efforts to reduce greenhouse gas emissions, and adapt to climate change impacts, to meet the goals of the 2015 Paris Climate Agreement.  They are renewed every five years, beginning in 2020. The first round of submitted NDCs are neither sufficient to limit warming below the global goal of 2C (aiming at 1.5C) nor to adequately strengthen resilience to climate risks. While 65% cite health, less than 25% include health cobenefits of mitigation, only 3% of proposed NDC actions connect to health, and only 50% of surveyed countries have a health adaptation strategy or plan. \n\nThe project will address barriers that currently hinder governments in systematically considering health in NDC design and implementation.  It will provide national health and development actors with evidence, analytical and capacity building tools to support them in integrating health risks, and the health co-benefits of climate change mitigation, into NDCs.  It will thereby contribute to protecting and promoting health, and to a more coherent and synergistic approach to climate action, health and sustainable development.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Climate Change","Humans"]}
{"id":"360G-Wellcome-220138_Z_20_Z","title":"Building Becontree","Region":"Greater London","currency":"GBP","awardDate":"2019-11-14T00:00:00+00:00","Internal ID":"220138/Z/20/Z","description":"This 18-month project aims to improve the accessibility of collections related to the construction, development, and management of the Becontree Estate through a programme of cataloguing, conservation, digitisation, and outreach utilising the following collections:\n\n\n Building and estate plans\n London County Council Property Management Files\n Tuberculosis and Infectious Disease Registers\n The Dagenham Digest\n Community publications - tenants\u2019 handbooks, tenants\u2019 gazettes, gardening guides\n Medical Officer of Health reports\n Rent books\n\n\n\nKey outcomes:\n\n\n Creation of fully searchable catalogues to file- and item-level adhering to relevant international standards hosted on the Valence House Collections website and the Archives Hub\n Conservation, including repair of damaged plans and registers of infectious diseases and the repackaging of other materials using suitable archival-quality packaging\n Digitisation of key records - building and estate plans, tuberculosis and infectious disease registers, and Dagenham Digests - and long-term preservation of digital surrogates\n Creation of a project website for dissemination of digitised materials, publication of blogs, and facilitating of comments/memory-sharing from Becontree residents past and present\n  Ingest of public comments from the website into archive catalogues  \n Outreach activities engaging local residents and aiming to build a stronger lasting relationship with an academic audience\n Writing of research guides to all Becontree-related collections\n\n","plannedDates":[{"endDate":"2022-05-18T00:00:00+00:00","startDate":"2020-11-16T00:00:00+00:00","startDateDateOnly":"2020-11-16","endDateDateOnly":"2022-05-18"}],"amountAwarded":104661,"Financial Year":"2019/20","Lead Applicant":"Ms Karen Rushton","grantProgramme":[{"title":"Research Resources Award","title_keyword":"Research Resources Award"}],"Applicant Surname":"Rushton","Partnership Value":104661,"Approval Committee":"Research Resources Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:London-Borough-of-Barking-and-Dagenham","name":"London Borough of Barking & Dagenham","addressCountry":"United Kingdom","id_and_name":"[\"London Borough of Barking & Dagenham\", \"360G-Wellcome-ORG:London-Borough-of-Barking-and-Dagenham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:London-Borough-of-Barking-and-Dagenham","name":"London Borough of Barking & Dagenham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Building Becontree This 18-month project aims to improve the accessibility of collections related to the construction, development, and management of the Becontree Estate through a programme of cataloguing, conservation, digitisation, and outreach utilising the following collections:\n\n\n Building and estate plans\n London County Council Property Management Files\n Tuberculosis and Infectious Disease Registers\n The Dagenham Digest\n Community publications - tenants\u2019 handbooks, tenants\u2019 gazettes, gardening guides\n Medical Officer of Health reports\n Rent books\n\n\n\nKey outcomes:\n\n\n Creation of fully searchable catalogues to file- and item-level adhering to relevant international standards hosted on the Valence House Collections website and the Archives Hub\n Conservation, including repair of damaged plans and registers of infectious diseases and the repackaging of other materials using suitable archival-quality packaging\n Digitisation of key records - building and estate plans, tuberculosis and infectious disease registers, and Dagenham Digests - and long-term preservation of digital surrogates\n Creation of a project website for dissemination of digitised materials, publication of blogs, and facilitating of comments/memory-sharing from Becontree residents past and present\n  Ingest of public comments from the website into archive catalogues  \n Outreach activities engaging local residents and aiming to build a stronger lasting relationship with an academic audience\n Writing of research guides to all Becontree-related collections\n\n","awardDateDateOnly":"2019-11-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Communicable Diseases","History, 20th Century","Humans","London","Tuberculosis"]}
{"id":"360G-Wellcome-220134_Z_20_Z","title":"Understanding the impact of \u2018near-coding\u2019 variation in human disease","Region":"South East","currency":"GBP","awardDate":"2020-03-04T00:00:00+00:00","Sponsor(s)":"Prof John Todd","Internal ID":"220134/Z/20/Z","description":"Rare diseases (prevalence   250 million people globally. Current approaches for identifying the genetic cause of a disease focus on regions of the genome that code directly for protein, finding a disease-causing variant in only ~50% of cases.\n\nMy aim is to identify novel genetic variants outside of these protein-coding regions that lead to disease, and the mechanisms through which they do so.\n\nI will do this by applying computational and statistical methods to pioneering large-scale genomic datasets, totalling ~700,000 individuals. \n\nMy approach will focus on \u2018near-coding\u2019 regions, defined as those directly adjacent to protein-coding sequence that have important functions regulating protein expression. I will use complementary approaches that (a) look for near-coding variants in rare disease patients without a causative coding variant and (b) assess the strength of negative selection acting on categories of near-coding variants to predict which are deleterious and cause disease.\n\nThe findings from my work will be translated into clinical care to enable more patients to receive a valuable genetic diagnosis. In addition, increasing our understanding of the near-coding variant types that are deleterious will inform on genetic mechanisms underlying disease and suggest novel therapeutic strategies.\n \n","plannedDates":[{"endDate":"2025-08-31T00:00:00+00:00","startDate":"2020-09-01T00:00:00+00:00","startDateDateOnly":"2020-09-01","endDateDateOnly":"2025-08-31"}],"amountAwarded":828055,"Financial Year":"2019/20","Lead Applicant":"Dr Nicola Whiffin","grantProgramme":[{"title":"Sir Henry Dale Fellowship","title_keyword":"Sir Henry Dale Fellowship"}],"Partnership Name":"Royal Society/Wellcome Trust Sir Henry Dale Fellowship","Applicant Surname":"Whiffin","Partnership Value":828055,"Approval Committee":"Sir Henry Dale Fellowship Interview Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding the impact of \u2018near-coding\u2019 variation in human disease Rare diseases (prevalence   250 million people globally. Current approaches for identifying the genetic cause of a disease focus on regions of the genome that code directly for protein, finding a disease-causing variant in only ~50% of cases.\n\nMy aim is to identify novel genetic variants outside of these protein-coding regions that lead to disease, and the mechanisms through which they do so.\n\nI will do this by applying computational and statistical methods to pioneering large-scale genomic datasets, totalling ~700,000 individuals. \n\nMy approach will focus on \u2018near-coding\u2019 regions, defined as those directly adjacent to protein-coding sequence that have important functions regulating protein expression. I will use complementary approaches that (a) look for near-coding variants in rare disease patients without a causative coding variant and (b) assess the strength of negative selection acting on categories of near-coding variants to predict which are deleterious and cause disease.\n\nThe findings from my work will be translated into clinical care to enable more patients to receive a valuable genetic diagnosis. In addition, increasing our understanding of the near-coding variant types that are deleterious will inform on genetic mechanisms underlying disease and suggest novel therapeutic strategies.\n \n","awardDateDateOnly":"2020-03-04","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Computational Biology","Disease","Genetic Predisposition to Disease","Genetic Variation","Genome, Human","Humans","Rare Diseases"]}
{"id":"360G-Wellcome-220130_Z_20_Z","title":"Speaking Out: Cataloguing advocacy, support and empowerment in the Lothian Gay and Lesbian Switchboard archives","Region":"Scotland","currency":"GBP","awardDate":"2019-11-14T00:00:00+00:00","Internal ID":"220130/Z/20/Z","description":"Speaking Out aims to catalogue, rehouse and selectively digitise archives created by the Lothian Gay and Lesbian Switchboard (LGLS), an activist-run mental and physical health service for LGBT people in the Lothians and beyond. The project will disseminate its findings to academics and the wider public, and address key ethical, visibility and sensitivity issues through collaborative engagement with scholarly and stakeholder communities.\n\nOpening on 2 March 1974, LGLS was the UK\u2019s first gay helpline and Scotland's first gay charity. Despite this pioneering history, LGLS archives remain largely invisible to researchers in their current, uncatalogued state. This project aims to open up this collection to researchers through:\n\n\n cataloguing and indexing compliant with archival standards, at levels ensuring maximum general research access;\n identifying sensitivities/ethical issues and applying appropriate closure periods;\n using anonymised transcription to provide a way in to selected otherwise-confidential records (encouraging academic researchers to apply for access through established procedures);\n rehousing records in archival-quality storage;\n digitising selected material (such as locally-specific newsletters unavailable elsewhere in physical or digital form) to aid no-cost, remote research;\n promoting the collection to research audiences through targeted activities;\n recording a small number of oral histories (3 \u2013 5), adding context for researchers.\n\n\n \n","plannedDates":[{"endDate":"2021-04-30T00:00:00+00:00","startDate":"2020-05-01T00:00:00+00:00","startDateDateOnly":"2020-05-01","endDateDateOnly":"2021-04-30"}],"amountAwarded":54548,"Financial Year":"2019/20","Lead Applicant":"Dr Louise Williams","grantProgramme":[{"title":"Research Resources Award","title_keyword":"Research Resources Award"}],"Applicant Surname":"Williams","Partnership Value":54548,"Approval Committee":"Research Resources Committee","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Speaking Out: Cataloguing advocacy, support and empowerment in the Lothian Gay and Lesbian Switchboard archives Speaking Out aims to catalogue, rehouse and selectively digitise archives created by the Lothian Gay and Lesbian Switchboard (LGLS), an activist-run mental and physical health service for LGBT people in the Lothians and beyond. The project will disseminate its findings to academics and the wider public, and address key ethical, visibility and sensitivity issues through collaborative engagement with scholarly and stakeholder communities.\n\nOpening on 2 March 1974, LGLS was the UK\u2019s first gay helpline and Scotland's first gay charity. Despite this pioneering history, LGLS archives remain largely invisible to researchers in their current, uncatalogued state. This project aims to open up this collection to researchers through:\n\n\n cataloguing and indexing compliant with archival standards, at levels ensuring maximum general research access;\n identifying sensitivities/ethical issues and applying appropriate closure periods;\n using anonymised transcription to provide a way in to selected otherwise-confidential records (encouraging academic researchers to apply for access through established procedures);\n rehousing records in archival-quality storage;\n digitising selected material (such as locally-specific newsletters unavailable elsewhere in physical or digital form) to aid no-cost, remote research;\n promoting the collection to research audiences through targeted activities;\n recording a small number of oral histories (3 \u2013 5), adding context for researchers.\n\n\n \n","awardDateDateOnly":"2019-11-14","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Homosexuality, Male","Humans","Sexual and Gender Minorities"]}
{"id":"360G-Wellcome-220129_Z_20_Z","title":"Investigating hormone secretion in response to altered nutrient delivery to the distal gut","Region":"East of England","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220129/Z/20/Z","description":"After a meal, enteroendocrine cells (EECs) along the gut sense nutrients. One type of EEC, the L-cell, responds by releasing hormones like GLP-1 which primes the body to deal with increased blood sugar by instructing the pancreas to release insulin. Gastric-bypass surgery leads to weight loss and in patients suffering from type 2 diabetes can also reverse this disease state, with increased GLP-1 credited in part for this. Blocking SGLT1 (a transporter needed for glucose uptake from intestine to bloodstream), also improves blood sugar control through increased GLP-1 secretion. \n\nHow gastric-bypass or blocking SGLT1 affect GLP-1 secretion is not fully understood but we believe a possible explanation in both cases is that nutrients are present or broken further down the gut than in normal physiology and that these breakdown products are promoting GLP-1 release from resident L-cells in the distal gut. We will study the gut contents of mice after SGLT1 inhibition or gastric-bypass surgery compared to normal mice after a meal. Any candidate break-down products will then be tested on isolated L-cells to measure GLP-1 response. Mimicking GLP-1\u2019s effects forms the basis for many anti-diabetic drugs and we therefore hope that our study may lead to new treatment opportunities. \n","plannedDates":[{"endDate":"2022-11-30T00:00:00+00:00","startDate":"2019-09-02T00:00:00+00:00","startDateDateOnly":"2019-09-02","endDateDateOnly":"2022-11-30"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Elisabeth O'Flaherty Rottenberger","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"O'Flaherty Rottenberger","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating hormone secretion in response to altered nutrient delivery to the distal gut After a meal, enteroendocrine cells (EECs) along the gut sense nutrients. One type of EEC, the L-cell, responds by releasing hormones like GLP-1 which primes the body to deal with increased blood sugar by instructing the pancreas to release insulin. Gastric-bypass surgery leads to weight loss and in patients suffering from type 2 diabetes can also reverse this disease state, with increased GLP-1 credited in part for this. Blocking SGLT1 (a transporter needed for glucose uptake from intestine to bloodstream), also improves blood sugar control through increased GLP-1 secretion. \n\nHow gastric-bypass or blocking SGLT1 affect GLP-1 secretion is not fully understood but we believe a possible explanation in both cases is that nutrients are present or broken further down the gut than in normal physiology and that these breakdown products are promoting GLP-1 release from resident L-cells in the distal gut. We will study the gut contents of mice after SGLT1 inhibition or gastric-bypass surgery compared to normal mice after a meal. Any candidate break-down products will then be tested on isolated L-cells to measure GLP-1 response. Mimicking GLP-1\u2019s effects forms the basis for many anti-diabetic drugs and we therefore hope that our study may lead to new treatment opportunities. \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Diabetes Mellitus, Type 2","Enteroendocrine Cells","Glucagon-Like Peptide 1","Insulin-Secreting Cells","Mice","Sodium-Glucose Transporter 1"]}
{"id":"360G-Wellcome-220128_Z_20_Z","title":"BSA - public engagement with health research","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220128/Z/20/Z","description":"The British Science Association is proposing a new funding scheme to support public engagement with health in the UK.  This new fund will: take a more outcomes-focussed and targeted approach to working with applicants; support and foster innovation; and encourage the sector to diversify its approaches and audiences. \n\nWe are proposing a three in one scheme: an \u2018Incubator Fund\u2019 will provide smaller grants to support innovation and diversity, the \u2018Main Fund\u2019 will establish and expand proven links and approaches, while a \u2018Discretionary Fund\u2019 will allow us to invest in organisations or approaches that show particular promise.\n\nAs a result, the public engagement with health sector will benefit from a grants scheme that\u2019s more flexible and easier to navigate. This will help support and diversify the applicant pool, and hence benefit the public who will be more empowered to engage in research and better equipped to interact with health researchers, or people in allied careers, on topics they\u2019re interested in. Ultimately more people in the UK will be engaged with - and trusting of - health research, and be able to access its benefits.\n","plannedDates":[{"endDate":"2022-10-08T00:00:00+00:00","startDate":"2020-01-08T00:00:00+00:00","startDateDateOnly":"2020-01-08","endDateDateOnly":"2022-10-08"}],"amountAwarded":4502682,"Financial Year":"2019/20","Lead Applicant":"Ms Katherine Mathieson","grantProgramme":[{"title":"Discretionary Award - Public Engagement","title_keyword":"Discretionary Award - Public Engagement"}],"Applicant Surname":"Mathieson","Partnership Value":4502682,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:British-Science-Association","name":"British Science Association","addressCountry":"United Kingdom","id_and_name":"[\"British Science Association\", \"360G-Wellcome-ORG:British-Science-Association\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:British-Science-Association","name":"British Science Association"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"BSA - public engagement with health research The British Science Association is proposing a new funding scheme to support public engagement with health in the UK.  This new fund will: take a more outcomes-focussed and targeted approach to working with applicants; support and foster innovation; and encourage the sector to diversify its approaches and audiences. \n\nWe are proposing a three in one scheme: an \u2018Incubator Fund\u2019 will provide smaller grants to support innovation and diversity, the \u2018Main Fund\u2019 will establish and expand proven links and approaches, while a \u2018Discretionary Fund\u2019 will allow us to invest in organisations or approaches that show particular promise.\n\nAs a result, the public engagement with health sector will benefit from a grants scheme that\u2019s more flexible and easier to navigate. This will help support and diversify the applicant pool, and hence benefit the public who will be more empowered to engage in research and better equipped to interact with health researchers, or people in allied careers, on topics they\u2019re interested in. Ultimately more people in the UK will be engaged with - and trusting of - health research, and be able to access its benefits.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Research Support as Topic","United Kingdom"]}
{"id":"360G-Wellcome-220126_Z_20_Z","title":"Protein Interactomes of Alzheimer\u2019s Disease Risk Genes in Microglia","Region":"Wales","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220126/Z/20/Z","description":"Alzheimer's disease is a fatal condition with currently no cure. In our aging population, it is more important than ever to find ways to treat Alzheimer's, or even prevent it. Understanding the biology of Alzheimer's is a key step to understanding the disease and finding the best possible treatment and preventions. Previous research has found mutations in key genes, mostly expressed in microglia (the brain's immune cells) that increase a person's risk of developing Alzheimer's. Our work will focus on 3 of these genes (ABI3, TREM2, and PLCG2) and will look at how the proteins they code for interact with other proteins within cells. \n\nWe will do this by mapping which proteins interact with our proteins of interest, both the normal and mutant versions, then compare these interactomes. We will then investigate the function of any new proteins found in these results and finally assess if these new proteins also contain mutations that carry a risk for Alzheimer's.\n\nThis impact of this research will be to broaden our understanding of how these mutations increase the risk of Alzheimer's and may highlight potentially druggable targets to treat or reduce the risk of developing Alzheimer's.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Catherine Widnall","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Widnall","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University","addressCountry":"United Kingdom","id_and_name":"[\"Cardiff University\", \"360G-Wellcome-ORG:Cardiff-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Protein Interactomes of Alzheimer\u2019s Disease Risk Genes in Microglia Alzheimer's disease is a fatal condition with currently no cure. In our aging population, it is more important than ever to find ways to treat Alzheimer's, or even prevent it. Understanding the biology of Alzheimer's is a key step to understanding the disease and finding the best possible treatment and preventions. Previous research has found mutations in key genes, mostly expressed in microglia (the brain's immune cells) that increase a person's risk of developing Alzheimer's. Our work will focus on 3 of these genes (ABI3, TREM2, and PLCG2) and will look at how the proteins they code for interact with other proteins within cells. \n\nWe will do this by mapping which proteins interact with our proteins of interest, both the normal and mutant versions, then compare these interactomes. We will then investigate the function of any new proteins found in these results and finally assess if these new proteins also contain mutations that carry a risk for Alzheimer's.\n\nThis impact of this research will be to broaden our understanding of how these mutations increase the risk of Alzheimer's and may highlight potentially druggable targets to treat or reduce the risk of developing Alzheimer's.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Alzheimer Disease","Amyloid beta-Protein Precursor","Humans","Membrane Glycoproteins","Membrane Proteins","Microglia","Mutation","Receptors, Immunologic"]}
{"id":"360G-Wellcome-220125_Z_20_Z","title":"Detecting Ebola at the Last Mile","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220125/Z/20/Z","description":"Ebola virus disease has been declared a Public Health Emergency of International Concern in Democratic Republic of the Congo.\n\nIn the short term, our consortium plans to optimise, manufacture, and validate a novel Ebola rapid diagnostic test  (RDT) for deployment at the point of need \u2014 that is low cost and high performance. A simple, 5 minute, high performance test, that complements complex laboratory tools, is urgently needed to ensure earliest possible detection of Ebola in the heart of communities experiencing an outbreak.\n\nSuccessful deployment will lead to an optimised and evaluated device for manufacture to support the current outbreak in DRC, surveillance in neighbouring regions, and in time post-DRC outbreak surveillance.\n\nIn the long term, we envision substantial impact  generated by establishing a new model for sustainable delivery of high performance outbreak diagnostics, deployed at the point of need. Accordingly, diaTropix - a new manufacturing facility dedicated to epidemics and neglected diseases in Dakar, Senegal - will be set up with the capability, expertise, and reagents to produce rapid diagnostics responsively to evolving outbreaks \u2014 with Ebola demonstrating proof of concept and feasibility, and a portfolio of rapid diagnostics in the pipeline for dengue, yellow fever, measles, and malaria.\n\n \n","plannedDates":[{"endDate":"2021-05-01T00:00:00+00:00","startDate":"2020-03-01T00:00:00+00:00","startDateDateOnly":"2020-03-01","endDateDateOnly":"2021-05-01"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Amadou Sall","grantProgramme":[{"title":"DFID-Wellcome Epidemic Preparedness Grant","title_keyword":"DFID-Wellcome Epidemic Preparedness Grant"}],"Partnership Name":"Wellcome-DFID Epidemic Preparedness","Applicant Surname":"Sall","Partnership Value":542290,"Approval Committee":"Internal Decision Panel","Other Applicant(s)":"Dr Cheikh Tidiane Diagne, Dr Ousmane Faye, Dr Joe Fitchett","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Institut-Pasteur-de-Dakar","name":"Institut Pasteur de Dakar","addressCountry":"Senegal","id_and_name":"[\"Institut Pasteur de Dakar\", \"360G-Wellcome-ORG:Institut-Pasteur-de-Dakar\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Institut-Pasteur-de-Dakar","name":"Institut Pasteur de Dakar"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Detecting Ebola at the Last Mile Ebola virus disease has been declared a Public Health Emergency of International Concern in Democratic Republic of the Congo.\n\nIn the short term, our consortium plans to optimise, manufacture, and validate a novel Ebola rapid diagnostic test  (RDT) for deployment at the point of need \u2014 that is low cost and high performance. A simple, 5 minute, high performance test, that complements complex laboratory tools, is urgently needed to ensure earliest possible detection of Ebola in the heart of communities experiencing an outbreak.\n\nSuccessful deployment will lead to an optimised and evaluated device for manufacture to support the current outbreak in DRC, surveillance in neighbouring regions, and in time post-DRC outbreak surveillance.\n\nIn the long term, we envision substantial impact  generated by establishing a new model for sustainable delivery of high performance outbreak diagnostics, deployed at the point of need. Accordingly, diaTropix - a new manufacturing facility dedicated to epidemics and neglected diseases in Dakar, Senegal - will be set up with the capability, expertise, and reagents to produce rapid diagnostics responsively to evolving outbreaks \u2014 with Ebola demonstrating proof of concept and feasibility, and a portfolio of rapid diagnostics in the pipeline for dengue, yellow fever, measles, and malaria.\n\n \n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Democratic Republic of the Congo","Disease Outbreaks","Ebolavirus","Hemorrhagic Fever, Ebola","Humans","Senegal"]}
{"id":"360G-Wellcome-220123_Z_20_Z","title":"Developing de-novo assembly tools to predict gene transcriptional markers of severe malaria disease and ways to prevent it","Region":"Greater London","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220123/Z/20/Z","description":"219 million cases of malaria occurred globally in 2017. Vaccine development is considered the most cost-effective tool to combat malaria, however identifying suitable vaccine targets is problematic. Malaria disease can have many different symptoms and overall severity. Differences in disease severity have been associated with the parasite gene expression, polymorphisms within a gene and splicesome variation. However, quantifying transcript abundance of highly polymorphic genes is extremely difficult. This research aims to produce a pipeline that assemblies and quantify the abundance of these highly polymorphic genes. I will then investigate the degree of polymorphism for genes expressed in the mosquito stages of Malaria, as this is thought to be the most promising stage for identifying vaccine targets. \n","plannedDates":[{"endDate":"2023-04-15T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2023-04-15"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Ms Clare Andradi-Brown","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Andradi-Brown","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Developing de-novo assembly tools to predict gene transcriptional markers of severe malaria disease and ways to prevent it 219 million cases of malaria occurred globally in 2017. Vaccine development is considered the most cost-effective tool to combat malaria, however identifying suitable vaccine targets is problematic. Malaria disease can have many different symptoms and overall severity. Differences in disease severity have been associated with the parasite gene expression, polymorphisms within a gene and splicesome variation. However, quantifying transcript abundance of highly polymorphic genes is extremely difficult. This research aims to produce a pipeline that assemblies and quantify the abundance of these highly polymorphic genes. I will then investigate the degree of polymorphism for genes expressed in the mosquito stages of Malaria, as this is thought to be the most promising stage for identifying vaccine targets. \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Malaria","Malaria Vaccines","Plasmodium falciparum","Polymorphism, Genetic"]}
{"id":"360G-Wellcome-220122_Z_20_Z","title":"Investigating compounds to increase the efficacy of antimicrobials used for targeting Helicobacter pylori","Region":"East Midlands","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220122/Z/20/Z","description":"The bacteria Helicobacter pylori (H. pylori) is a pathogen that infects the stomach of ~50% of the population, and can led to the development of peptic ulcers and gastric cancer. Although the treatment currently consists of a triple therapy of antibiotics and proton pump inhibitors, many strains have developed a resistance to antibiotics, and the disease can recur within a patient. H. pylori also colonises the stomach within a thick mucus layer, which can prevent drugs from reaching the site of infection. Two compounds have been found to increase the effectiveness of antibiotic therapy against resistant strains within patients; bismuth salts and the long term use of aspirin. I will conduct further research on ways to use these therapies in combination with antibiotics in order to provide a more effective treatment. I will also explore the possibility of encapsulating bismuth salts in a protective protein shell (apoferritin) to aid drug delivery across the stomach mucous. Using additional treatments alongside the antibiotics in treating H. pylori infection may increase their efficacy, and prevent the disease recurring. Elimination of the disease in a patient would also reduce the need for repeated antibiotic treatment, which can lead to incidences of antimicrobial resistance.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-02T00:00:00+00:00","startDateDateOnly":"2019-10-02","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Ms Elizabeth Garvey","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Garvey","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Nottingham","name":"University of Nottingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Nottingham\", \"360G-Wellcome-ORG:University-of-Nottingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Nottingham","name":"University of Nottingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating compounds to increase the efficacy of antimicrobials used for targeting Helicobacter pylori The bacteria Helicobacter pylori (H. pylori) is a pathogen that infects the stomach of ~50% of the population, and can led to the development of peptic ulcers and gastric cancer. Although the treatment currently consists of a triple therapy of antibiotics and proton pump inhibitors, many strains have developed a resistance to antibiotics, and the disease can recur within a patient. H. pylori also colonises the stomach within a thick mucus layer, which can prevent drugs from reaching the site of infection. Two compounds have been found to increase the effectiveness of antibiotic therapy against resistant strains within patients; bismuth salts and the long term use of aspirin. I will conduct further research on ways to use these therapies in combination with antibiotics in order to provide a more effective treatment. I will also explore the possibility of encapsulating bismuth salts in a protective protein shell (apoferritin) to aid drug delivery across the stomach mucous. Using additional treatments alongside the antibiotics in treating H. pylori infection may increase their efficacy, and prevent the disease recurring. Elimination of the disease in a patient would also reduce the need for repeated antibiotic treatment, which can lead to incidences of antimicrobial resistance.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anti-Bacterial Agents","Bismuth","Drug Delivery Systems","Helicobacter Infections","Helicobacter pylori","Humans"]}
{"id":"360G-Wellcome-220121_Z_20_Z","title":"UMURINZI - Unprecedented Movement to drive a Unified Rwandan Initiative for National ZEBOVAC Immunization","Region":"International","currency":"GBP","awardDate":"2019-09-30T00:00:00+00:00","Internal ID":"220121/Z/20/Z","description":"The ongoing outbreak of Ebola Virus Disease (EVD) in the Democratic Republic of Congo (DRC) is of particular concern for the Government of Rwanda, when one considers the high population density of Rwanda and the number of people crossing the border between Rwanda and DRC on a daily basis. Janssen Vaccines and Prevention B. V. (Janssen) and the Rwanda Ministry of Health have recently entered into an agreement for a donation of 200,000 doses of the Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine. Rwanda FDA has granted conditional approval of the vaccine under exceptional emergency circumstances in accordance with SAGE recommendations to put in place approvals for investigational medicines and vaccines as an immediate priority for preparedness.\n\nThis Ebola vaccine initiative consists of: 1) a mass vaccination campaign that will target up to 193,000 individuals crossing or living in sectors/districts sharing the border with DRC; this program is known as UMURINZI (Unprecedented Movement to drive a Unified Rwandan Initiative for National ZEBOVAC Immunization); 2) a clinical trial to evaluate the immunogenicity of the vaccine regimen in 2,000 people; 3) and a clinical trial to evaluate the safety of the vaccine among 5,000 pregnant women.\n\nThis proposal concerns start up of UMURINZI only.\n","plannedDates":[{"endDate":"2020-04-14T00:00:00+00:00","startDate":"2019-10-14T00:00:00+00:00","startDateDateOnly":"2019-10-14","endDateDateOnly":"2020-04-14"}],"amountAwarded":405745,"Financial Year":"2018/19","Lead Applicant":"Dr Etienne Karita","grantProgramme":[{"title":"DFID-Wellcome Epidemic Preparedness Grant","title_keyword":"DFID-Wellcome Epidemic Preparedness Grant"}],"Partnership Name":"Wellcome-DFID Epidemic Preparedness","Applicant Surname":"Karita","Partnership Value":405745,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Center-for-Family-Health-Research","name":"Center for Family Health Research","addressCountry":"Rwanda","id_and_name":"[\"Center for Family Health Research\", \"360G-Wellcome-ORG:Center-for-Family-Health-Research\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Center-for-Family-Health-Research","name":"Center for Family Health Research"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"UMURINZI - Unprecedented Movement to drive a Unified Rwandan Initiative for National ZEBOVAC Immunization The ongoing outbreak of Ebola Virus Disease (EVD) in the Democratic Republic of Congo (DRC) is of particular concern for the Government of Rwanda, when one considers the high population density of Rwanda and the number of people crossing the border between Rwanda and DRC on a daily basis. Janssen Vaccines and Prevention B. V. (Janssen) and the Rwanda Ministry of Health have recently entered into an agreement for a donation of 200,000 doses of the Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine. Rwanda FDA has granted conditional approval of the vaccine under exceptional emergency circumstances in accordance with SAGE recommendations to put in place approvals for investigational medicines and vaccines as an immediate priority for preparedness.\n\nThis Ebola vaccine initiative consists of: 1) a mass vaccination campaign that will target up to 193,000 individuals crossing or living in sectors/districts sharing the border with DRC; this program is known as UMURINZI (Unprecedented Movement to drive a Unified Rwandan Initiative for National ZEBOVAC Immunization); 2) a clinical trial to evaluate the immunogenicity of the vaccine regimen in 2,000 people; 3) and a clinical trial to evaluate the safety of the vaccine among 5,000 pregnant women.\n\nThis proposal concerns start up of UMURINZI only.\n","awardDateDateOnly":"2019-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Democratic Republic of the Congo","Disease Outbreaks","Ebola Vaccines","Ebolavirus","Female","Hemorrhagic Fever, Ebola","Humans","Pregnancy","Rwanda","United States","Vaccination"]}
{"id":"360G-Wellcome-220119_Z_20_Z","title":"Developing Machine Learning Approaches for Survival Analysis and Patient Stratification in Inherited Cardiac Conditions","Region":"Greater London","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220119/Z/20/Z","description":"Inherited Cardiac Conditions (ICCs) include a variety of diseases for which the genetic basis and pathogenesis is still majorly unexplained. The clinical outcomes of patients with ICCs are very diverse, rendering diagnosis, prognosis, and accurate therapeutic decisions very challenging. The purpose of this project is to develop machine learning approaches that will be able to explain some of the survival and clinical differences among patients with the same ICC and describe genetic biomarkers responsible. This will enable better patient stratification which will lead to more accurate diagnosis and assessment of therapeutic actions that need to be taken. The modelling approaches will be based on cardiac imaging and genetic data collected from patients across the ICC spectrum and healthy volunteers. \n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Ms Melpomeni Kasapi","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Kasapi","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Developing Machine Learning Approaches for Survival Analysis and Patient Stratification in Inherited Cardiac Conditions Inherited Cardiac Conditions (ICCs) include a variety of diseases for which the genetic basis and pathogenesis is still majorly unexplained. The clinical outcomes of patients with ICCs are very diverse, rendering diagnosis, prognosis, and accurate therapeutic decisions very challenging. The purpose of this project is to develop machine learning approaches that will be able to explain some of the survival and clinical differences among patients with the same ICC and describe genetic biomarkers responsible. This will enable better patient stratification which will lead to more accurate diagnosis and assessment of therapeutic actions that need to be taken. The modelling approaches will be based on cardiac imaging and genetic data collected from patients across the ICC spectrum and healthy volunteers. \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biomarkers","Genetic Predisposition to Disease","Humans","Machine Learning","Prognosis"]}
{"id":"360G-Wellcome-220118_Z_20_Z","title":"Atomistic Simulations of Cardiac Troponin","Region":"Greater London","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220118/Z/20/Z","description":"Troponin plays an essential role in the skeletal and cardiac muscle contraction process which is mediated by sarcomeric Ca2+ concentration. Phosphorylation on cardiac troponin complex changes troponin's Ca2+ sensitivity hence modulates heart rate. Several point mutations on thin filament disrupt the heart\u2019s normal contractile functionality and eventually lead to inherited cardiomyopathies. It was shown that in the mutated troponin tissues the myofilament Ca2+ sensitivity is not reduced upon phosphorylation by protein kinase A, and this relationship is termed the uncoupling phenomenon. In a recent study of small molecules related to the natural products EGCG and Silybin we found 22 small molecules that were capable of specifically restoring the coupled relationship between Ca2+ sensitivity and phosphorylation state, and these compounds are termed recouplers.\n\nIn previous studies, our group has attempted at elucidating the changes in protein dynamics introduced by phosphorylation and TNNC1 G159D mutation. In this project, we aim to use molecular dynamics simulations to reveal the underlying mechanisms of recouplers. We hope that with a deeper understanding of the molecular mechanisms of both the disease-causing mutations and the recouplers, we can take a rational approach in designing novel therapeutic compounds that are effective in treating cardiomyopathies while having minimal side-effects.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Zeyu Yang","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Yang","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Atomistic Simulations of Cardiac Troponin Troponin plays an essential role in the skeletal and cardiac muscle contraction process which is mediated by sarcomeric Ca2+ concentration. Phosphorylation on cardiac troponin complex changes troponin's Ca2+ sensitivity hence modulates heart rate. Several point mutations on thin filament disrupt the heart\u2019s normal contractile functionality and eventually lead to inherited cardiomyopathies. It was shown that in the mutated troponin tissues the myofilament Ca2+ sensitivity is not reduced upon phosphorylation by protein kinase A, and this relationship is termed the uncoupling phenomenon. In a recent study of small molecules related to the natural products EGCG and Silybin we found 22 small molecules that were capable of specifically restoring the coupled relationship between Ca2+ sensitivity and phosphorylation state, and these compounds are termed recouplers.\n\nIn previous studies, our group has attempted at elucidating the changes in protein dynamics introduced by phosphorylation and TNNC1 G159D mutation. In this project, we aim to use molecular dynamics simulations to reveal the underlying mechanisms of recouplers. We hope that with a deeper understanding of the molecular mechanisms of both the disease-causing mutations and the recouplers, we can take a rational approach in designing novel therapeutic compounds that are effective in treating cardiomyopathies while having minimal side-effects.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Calcium","Humans","Molecular Dynamics Simulation","Phosphorylation"]}
{"id":"360G-Wellcome-220117_Z_20_Z","title":"Early Modern Satire of Experimental Medicine in Spain (1493-1700)","Region":"South West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220117/Z/20/Z","description":"The project will bring to light the forgotten satiric traditions that accompanied the rise of experimental medicine in early modern Spain. Focusing on previously untapped archival and printed sources of Spain, the research will recover literary satires on diverse aspects of medical experimentation, including pharmacological trials, blood transfusions, and surgical experiments. These novel experiments prompted questions regarding the choice of patients, which frequently came from the dispossessed social groups, such as prisoners, soldiers, foreigners, servants, the poor, hospital patients, and asylum in-mates. Satire is inextricable from its public function and can therefore provide a valuable contribution to the understanding of the early modern medical experimental practices. The project aims to answer the following questions: How did satirists react to the choice of experimental bodies? What were their main concerns and how did they express them via the available satiric models? In what ways did physicians themselves use satire to discredit their rivals\u2019 methods? Apart from yielding self-standing results in the form of two research articles and an online database, the research in Spain will prepare the ground for the investigation of satires of experimental medicine in Germany and the Netherlands.\n","plannedDates":[{"endDate":"2021-05-01T00:00:00+00:00","startDate":"2019-11-01T00:00:00+00:00","startDateDateOnly":"2019-11-01","endDateDateOnly":"2021-05-01"}],"amountAwarded":49804,"Financial Year":"2019/20","Lead Applicant":"Dr Ivana Bicak","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Bicak","Partnership Value":49804,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Exeter","name":"University of Exeter","addressCountry":"United Kingdom","id_and_name":"[\"University of Exeter\", \"360G-Wellcome-ORG:University-of-Exeter\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Exeter","name":"University of Exeter"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Early Modern Satire of Experimental Medicine in Spain (1493-1700) The project will bring to light the forgotten satiric traditions that accompanied the rise of experimental medicine in early modern Spain. Focusing on previously untapped archival and printed sources of Spain, the research will recover literary satires on diverse aspects of medical experimentation, including pharmacological trials, blood transfusions, and surgical experiments. These novel experiments prompted questions regarding the choice of patients, which frequently came from the dispossessed social groups, such as prisoners, soldiers, foreigners, servants, the poor, hospital patients, and asylum in-mates. Satire is inextricable from its public function and can therefore provide a valuable contribution to the understanding of the early modern medical experimental practices. The project aims to answer the following questions: How did satirists react to the choice of experimental bodies? What were their main concerns and how did they express them via the available satiric models? In what ways did physicians themselves use satire to discredit their rivals\u2019 methods? Apart from yielding self-standing results in the form of two research articles and an online database, the research in Spain will prepare the ground for the investigation of satires of experimental medicine in Germany and the Netherlands.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biomedical Research","Germany","History, 20th Century","Humans","Netherlands","Spain"]}
{"id":"360G-Wellcome-220116_Z_20_Z","title":"Time Series based dimension reduction methods on scRNA-seq data for Alzheimer's disease","Region":"Greater London","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220116/Z/20/Z","description":"1 in every 14 of the elderly in the UK has Alzheimer\u2019s disease (AD). Identifying early warning signs of AD can provide great clinical benefits. Recent research suggests there are different possible mechanisms leading to the disease and a long-standing hypothesis that the building up of beta-amyloid proteins is the cause of the disease is shown not to be totally true. The mechanism of AD varies between population and different stages of the disease. Rigorous statistical methods are required to study the heterogeneity of the disease. Existing theory on the pathology of AD suggests physiological cycle involving different types of cells in the brain, suggesting it is important to consider the differences of each cell in identifying candidate genes that are differentially expressed. \n\nThe research will improve existing dimension reduction and clustering methods on single-cell RNA sequencing data. Time series analysis techniques will be considered so to identify changes of gene expression across different stages of the disease. \n\nThe research will allow a better understanding of the progression of AD and in another similar neurodegenerative context. Potential therapeutic targets can then be identified with a better understanding of the disease mechanism. \n \n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Thomas Wong","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Wong","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Time Series based dimension reduction methods on scRNA-seq data for Alzheimer's disease 1 in every 14 of the elderly in the UK has Alzheimer\u2019s disease (AD). Identifying early warning signs of AD can provide great clinical benefits. Recent research suggests there are different possible mechanisms leading to the disease and a long-standing hypothesis that the building up of beta-amyloid proteins is the cause of the disease is shown not to be totally true. The mechanism of AD varies between population and different stages of the disease. Rigorous statistical methods are required to study the heterogeneity of the disease. Existing theory on the pathology of AD suggests physiological cycle involving different types of cells in the brain, suggesting it is important to consider the differences of each cell in identifying candidate genes that are differentially expressed. \n\nThe research will improve existing dimension reduction and clustering methods on single-cell RNA sequencing data. Time series analysis techniques will be considered so to identify changes of gene expression across different stages of the disease. \n\nThe research will allow a better understanding of the progression of AD and in another similar neurodegenerative context. Potential therapeutic targets can then be identified with a better understanding of the disease mechanism. \n \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Alzheimer Disease","Amyloid beta-Peptides","Gene Expression Profiling","Humans","Sequence Analysis, RNA","Single-Cell Analysis"]}
{"id":"360G-Wellcome-220114_Z_20_Z","title":"Role of Golgi cells in the cerebellar granule cell layer","Region":"South West","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220114/Z/20/Z","description":"The cerebellum is a brain structure that contains over half of the mammalian brain's neurons. The majority of inputs of the cerebellum enter the granule cell layer, which is therefore called the input layer of the cerebellum. Within this layer, two neuronal populations exist: excitatory granule cells and inhibitory Golgi cells. The latter play a fundamental role in balancing granule cell responsiveness, driven by pre-cerebellar inputs. Understanding the contribution of these inhibitory neurons to granule cell layer activity is indispensable to unveil cerebellar functions. To do so, we will manipulate activity of neurons within this network, by chemical means, in behaving mice. During these manipulations, we will be recording neural activity as well as behavioural parameters. From these data, it will be possible to better understand how inhibition controls excitatory neuron activity, what is the processing of cerebellar inputs operated by the granule cell layer, and cerebellar cortex computations. We will substantiate our work with tools of computational neuroscience that will allow us to formalise our findings.  \n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Ensor Palacios","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Palacios","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Role of Golgi cells in the cerebellar granule cell layer The cerebellum is a brain structure that contains over half of the mammalian brain's neurons. The majority of inputs of the cerebellum enter the granule cell layer, which is therefore called the input layer of the cerebellum. Within this layer, two neuronal populations exist: excitatory granule cells and inhibitory Golgi cells. The latter play a fundamental role in balancing granule cell responsiveness, driven by pre-cerebellar inputs. Understanding the contribution of these inhibitory neurons to granule cell layer activity is indispensable to unveil cerebellar functions. To do so, we will manipulate activity of neurons within this network, by chemical means, in behaving mice. During these manipulations, we will be recording neural activity as well as behavioural parameters. From these data, it will be possible to better understand how inhibition controls excitatory neuron activity, what is the processing of cerebellar inputs operated by the granule cell layer, and cerebellar cortex computations. We will substantiate our work with tools of computational neuroscience that will allow us to formalise our findings.  \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cerebellum","Mice","Nerve Net","Neural Inhibition","Neural Pathways","Neurons"]}
{"id":"360G-Wellcome-220113_Z_20_Z","title":"The role of TIGIT in immune regulation of autoimmune diseases","Region":"West Midlands","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220113/Z/20/Z","description":"The adaptive immune system provides the host with a vast receptor repertoire of immune cells that facilitate protection from a broad range of pathogens1. One consequence of this incredible diversity is the development of immune cells specific for self-tissues, which could lead to the development of autoimmune diseases2. To counteract this auto-reactivity, the immune system uses a number of mechanisms to reinforce the state of tolerance to an individual\u2019s own antigens3. This includes a dominant role for co-inhibitory receptors, such as T cell Ig and ITIM domain (TIGIT), which acts as a brake that determines the balance between activating and inhibitory signals4. While much has been learned recently about which co-inhibitory receptors are expressed in various immunological settings, little is known about how they actually function. We aim to use specific monoclonal antibodies that either block or boost the function of TIGIT and investigate the impact on T cell responses. We will use genetically manipulated mouse models that will provide insight into the role of TIGIT in immune regulation. Data obtained from this study can pave the way for future validation in humans, which will provide novel targets for the treatment of chronic infectious diseases, cancer, allergic and autoimmune diseases.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Ms Konstantina Petkou","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Petkou","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Birmingham\", \"360G-Wellcome-ORG:University-of-Birmingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The role of TIGIT in immune regulation of autoimmune diseases The adaptive immune system provides the host with a vast receptor repertoire of immune cells that facilitate protection from a broad range of pathogens1. One consequence of this incredible diversity is the development of immune cells specific for self-tissues, which could lead to the development of autoimmune diseases2. To counteract this auto-reactivity, the immune system uses a number of mechanisms to reinforce the state of tolerance to an individual\u2019s own antigens3. This includes a dominant role for co-inhibitory receptors, such as T cell Ig and ITIM domain (TIGIT), which acts as a brake that determines the balance between activating and inhibitory signals4. While much has been learned recently about which co-inhibitory receptors are expressed in various immunological settings, little is known about how they actually function. We aim to use specific monoclonal antibodies that either block or boost the function of TIGIT and investigate the impact on T cell responses. We will use genetically manipulated mouse models that will provide insight into the role of TIGIT in immune regulation. Data obtained from this study can pave the way for future validation in humans, which will provide novel targets for the treatment of chronic infectious diseases, cancer, allergic and autoimmune diseases.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adaptive Immunity","Animals","Antibodies, Monoclonal","Autoimmunity","Disease Models, Animal","Humans","Immune Tolerance","Mice","T-Lymphocytes"]}
{"id":"360G-Wellcome-220112_Z_20_Z","title":"Characterising the Role of IN Binding Partners in HTLV Infection and Integration","Region":"Greater London","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220112/Z/20/Z","description":"Human T-cell lymphotropic virus type 1 (HTLV-1) is a virus that can cause a range of debilitating and often fatal diseases including neurological disorders and an aggressive form cancer.  There exists no successful therapy to treat these diseases, therefore research into mechanisms of the viral lifecycle is crucial.  For the virus to replicate efficiently it must integrate a DNA copy of its RNA genome into host DNA using the viral enzyme integrase.  Integration site selection is not random but is influenced by interaction with host proteins. The correlation between the site of integration, production of virus, and disease occurrence indicates the integration site as a point of interest. We have identified a number of host proteins that could (directly or indirectly) be involved in targeting the HTLV-1 pre-integration complex to the site of integration. Using a combination of lentiviral shRNA mediated knock-down and expression of chimeric proteins we will investigate whether proteins that co-purify with HTLV-1 IN affect infectivity and integration.  Understanding these mechanisms is a step towards identifying potential drug targets to prevent HTLV-1 infection. \n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-02T00:00:00+00:00","startDateDateOnly":"2019-10-02","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Bethany Schneiderman","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Schneiderman","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Characterising the Role of IN Binding Partners in HTLV Infection and Integration Human T-cell lymphotropic virus type 1 (HTLV-1) is a virus that can cause a range of debilitating and often fatal diseases including neurological disorders and an aggressive form cancer.  There exists no successful therapy to treat these diseases, therefore research into mechanisms of the viral lifecycle is crucial.  For the virus to replicate efficiently it must integrate a DNA copy of its RNA genome into host DNA using the viral enzyme integrase.  Integration site selection is not random but is influenced by interaction with host proteins. The correlation between the site of integration, production of virus, and disease occurrence indicates the integration site as a point of interest. We have identified a number of host proteins that could (directly or indirectly) be involved in targeting the HTLV-1 pre-integration complex to the site of integration. Using a combination of lentiviral shRNA mediated knock-down and expression of chimeric proteins we will investigate whether proteins that co-purify with HTLV-1 IN affect infectivity and integration.  Understanding these mechanisms is a step towards identifying potential drug targets to prevent HTLV-1 infection. \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Gene Knockdown Techniques","HEK293 Cells","HTLV-I Infections","Host-Pathogen Interactions","Human T-lymphotropic virus 1","Humans","Lentivirus","RNA Interference","RNA, Small Interfering"]}
{"id":"360G-Wellcome-220111_Z_20_Z","title":"The role of innate immunity in respiratory viral infection in the elderly","Region":"Greater London","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220111/Z/20/Z","description":"With age, there is a decline in immune function, which renders the elderly particularly susceptible to lung infections, such as respiratory syncytial virus (RSV). During ageing there are also significant changes to cellular metabolism. Recent discoveries have shown that the function of cells of the immune system is profoundly influenced by their metabolism. We hypothesise that differences in the immune response to lung infection in the elderly are the results of age-related metabolic changes. In this project we will specifically study age-related changes in alveolar macrophages (AM), immune cells that are an important first line of defence against lung infection.\n\n\nWe will compare AM responses to infection in young and elderly mice. Next, we will evaluate differences in metabolic pathways in these cells. If metabolic differences are detected, we will aim to restore macrophage responses to infection in the elderly by manipulating their metabolism. In addition, we will ask whether transfer of AM from young to elderly mice will protect against infection.\n\n\nThe global population is ageing and lung infection is a growing health burden worldwide. In the long term this project may identify new targets for treatment and/or prevention of severe lung infections in the elderly.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Celia Diaz Nicieza","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Diaz Nicieza","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The role of innate immunity in respiratory viral infection in the elderly With age, there is a decline in immune function, which renders the elderly particularly susceptible to lung infections, such as respiratory syncytial virus (RSV). During ageing there are also significant changes to cellular metabolism. Recent discoveries have shown that the function of cells of the immune system is profoundly influenced by their metabolism. We hypothesise that differences in the immune response to lung infection in the elderly are the results of age-related metabolic changes. In this project we will specifically study age-related changes in alveolar macrophages (AM), immune cells that are an important first line of defence against lung infection.\n\n\nWe will compare AM responses to infection in young and elderly mice. Next, we will evaluate differences in metabolic pathways in these cells. If metabolic differences are detected, we will aim to restore macrophage responses to infection in the elderly by manipulating their metabolism. In addition, we will ask whether transfer of AM from young to elderly mice will protect against infection.\n\n\nThe global population is ageing and lung infection is a growing health burden worldwide. In the long term this project may identify new targets for treatment and/or prevention of severe lung infections in the elderly.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Age Factors","Aging","Animals","Immunity, Innate","Lung","Macrophages, Alveolar","Mice","Mice, Inbred C57BL","Respiratory Syncytial Virus Infections"]}
{"id":"360G-Wellcome-220110_Z_20_Z","title":"Investigating the interplay between the Plasmodium oocyst and mosquito vector towards identification of new targets for malaria transmission blocking interventions","Region":"Greater London","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220110/Z/20/Z","description":"Malaria is a significant global health burden, causing over 200 million new infections and 400,000 deaths every year. It is caused by Plasmodium parasites that are transmitted between people by Anopheles mosquitoes. Conventional antimalarial therapies aim to clear parasites in already infected humans, but elimination of the disease can only be achieved by blocking parasite transmission through the mosquito vector. Rising insecticide resistance among mosquitoes and increasing drug resistance among Plasmodium parasites have led to a stall in progress towards malaria control and elimination, respectively. It is therefore of vital importance to identify new therapeutic targets and to develop novel intervention strategies to achieve further progress. This project will focus on the interplay between the mosquito and the Plasmodium oocyst, the longest stage of parasite development that results in an explosion in parasite numbers. A high-throughput screen will aim to identify transporters and other key molecules on the oocyst surface required for normal development. Follow-up experiments will genetically and functionally characterise promising candidate genes and assess their potential as transmission blocking targets. This work will therefore help us to further understand the biology of malaria transmission and inform future interventions towards disease elimination.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Alexander Bailey","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Bailey","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the interplay between the Plasmodium oocyst and mosquito vector towards identification of new targets for malaria transmission blocking interventions Malaria is a significant global health burden, causing over 200 million new infections and 400,000 deaths every year. It is caused by Plasmodium parasites that are transmitted between people by Anopheles mosquitoes. Conventional antimalarial therapies aim to clear parasites in already infected humans, but elimination of the disease can only be achieved by blocking parasite transmission through the mosquito vector. Rising insecticide resistance among mosquitoes and increasing drug resistance among Plasmodium parasites have led to a stall in progress towards malaria control and elimination, respectively. It is therefore of vital importance to identify new therapeutic targets and to develop novel intervention strategies to achieve further progress. This project will focus on the interplay between the mosquito and the Plasmodium oocyst, the longest stage of parasite development that results in an explosion in parasite numbers. A high-throughput screen will aim to identify transporters and other key molecules on the oocyst surface required for normal development. Follow-up experiments will genetically and functionally characterise promising candidate genes and assess their potential as transmission blocking targets. This work will therefore help us to further understand the biology of malaria transmission and inform future interventions towards disease elimination.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Anopheles","Antimalarials","Humans","Malaria","Mosquito Vectors"]}
{"id":"360G-Wellcome-220109_Z_20_Z","title":"Structural and functional analysis of a minor pilin playing a key role in the type IV pilus biology of the opportunistic pathogen Streptococcus sanguinis","Region":"Greater London","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220109/Z/20/Z","description":"Long and flexible hair-like filaments, called type IV pili (Tfp), decorate the surface of many bacteria. Tfp confer an impressive variety of properties upon bacteria, ranging from adhesion and motility to electric conductance. Importantly, Tfp play a key role in the development of diseases, caused by many prominent bacterial pathogens. My research focuses on the opportunistic Gram-positive pathogen Streptococcus sanguinis which causes infective endocarditis. S. sanguinis represents a convenient model for studying poorly defined aspects of Tfp biology due to the simplicity of its Tfp machinery. Tfp are composed of small protein subunits, called major and minor (less abundant) pilins which share sequence and structural features. S. sanguinis has two major pilins (PilE1 and PilE2) and three minor pilins (PilA, PilB and PilC). The minor pilin PilA, essential for S. sanguinis piliation, has an unusual sequence and an uncharacteristic structure. Using a combination of molecular genetics, protein biochemistry and structural biology techniques, I aim to characterise how PilA is assembled into pili and what role it plays in Tfp biology.  A better understanding of Tfp assembly mechanisms and their disease-associated functions can help design anti-bacterial drugs that suppress the ability of bacteria to cause disease.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Meriam Shahin","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Shahin","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Structural and functional analysis of a minor pilin playing a key role in the type IV pilus biology of the opportunistic pathogen Streptococcus sanguinis Long and flexible hair-like filaments, called type IV pili (Tfp), decorate the surface of many bacteria. Tfp confer an impressive variety of properties upon bacteria, ranging from adhesion and motility to electric conductance. Importantly, Tfp play a key role in the development of diseases, caused by many prominent bacterial pathogens. My research focuses on the opportunistic Gram-positive pathogen Streptococcus sanguinis which causes infective endocarditis. S. sanguinis represents a convenient model for studying poorly defined aspects of Tfp biology due to the simplicity of its Tfp machinery. Tfp are composed of small protein subunits, called major and minor (less abundant) pilins which share sequence and structural features. S. sanguinis has two major pilins (PilE1 and PilE2) and three minor pilins (PilA, PilB and PilC). The minor pilin PilA, essential for S. sanguinis piliation, has an unusual sequence and an uncharacteristic structure. Using a combination of molecular genetics, protein biochemistry and structural biology techniques, I aim to characterise how PilA is assembled into pili and what role it plays in Tfp biology.  A better understanding of Tfp assembly mechanisms and their disease-associated functions can help design anti-bacterial drugs that suppress the ability of bacteria to cause disease.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Fimbriae Proteins","Fimbriae, Bacterial","Streptococcal Infections","Streptococcus"]}
{"id":"360G-Wellcome-220108_Z_20_Z","title":"Investigating the acute and chronic effects of E-cigarettes on human lungs, examining functional and mechanistic outcomes.","Region":"West Midlands","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220108/Z/20/Z","description":"E-cigarettes vaporise nicotine-containing fluid for inhalation and have become an increasingly popular alternative to tobacco. The effects of e-cigarettes on the human lung are incompletely characterised. Preliminary evidence indicates that healthy vapers and smokers have similarly protease rich lung environments. This supports evidence from our lab, demonstrating that e-cigarette exposed alveolar macrophages(AM) increase protease output.  \nI aim to understand the effects of e-cigarettes on the cells of the human lung. Lung resection tissue from never smokers/vapers/smokers/ex-smokers will be used to source AM and type-II alveolar cells, as well as precision cut lung slices (PCLS). Effects will be assessed using techniques to assess viability, proinflammatory mediator production/ROS/protease output, wound repair, phagocytosis and efferocytosis. Simple monocultures/co-cultures will provide initial evidence of e-cigarette effects, whilst PCLS and PCLS/AM cultures will allow effects to be examined in the context of the complex cellular architecture of the lung.  \nIn addition, I aim to identify the mechanism(s) of action through which these effects are mediated. Candidate mechanisms will first be tested in co-culture models before validation using our human PCLS model.  \nThese studies will help characterise how and why e-cigarettes affect the lungs. This may help inform regulatory decisions and mitigate risks associated with e-cigarette use.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Ms Lauren Davis","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Davis","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Birmingham\", \"360G-Wellcome-ORG:University-of-Birmingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the acute and chronic effects of E-cigarettes on human lungs, examining functional and mechanistic outcomes. E-cigarettes vaporise nicotine-containing fluid for inhalation and have become an increasingly popular alternative to tobacco. The effects of e-cigarettes on the human lung are incompletely characterised. Preliminary evidence indicates that healthy vapers and smokers have similarly protease rich lung environments. This supports evidence from our lab, demonstrating that e-cigarette exposed alveolar macrophages(AM) increase protease output.  \nI aim to understand the effects of e-cigarettes on the cells of the human lung. Lung resection tissue from never smokers/vapers/smokers/ex-smokers will be used to source AM and type-II alveolar cells, as well as precision cut lung slices (PCLS). Effects will be assessed using techniques to assess viability, proinflammatory mediator production/ROS/protease output, wound repair, phagocytosis and efferocytosis. Simple monocultures/co-cultures will provide initial evidence of e-cigarette effects, whilst PCLS and PCLS/AM cultures will allow effects to be examined in the context of the complex cellular architecture of the lung.  \nIn addition, I aim to identify the mechanism(s) of action through which these effects are mediated. Candidate mechanisms will first be tested in co-culture models before validation using our human PCLS model.  \nThese studies will help characterise how and why e-cigarettes affect the lungs. This may help inform regulatory decisions and mitigate risks associated with e-cigarette use.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cells, Cultured","Coculture Techniques","Electronic Nicotine Delivery Systems","Humans","Lung","Macrophages, Alveolar","Phagocytosis"]}
{"id":"360G-Wellcome-220107_Z_20_Z","title":"Integrated biological and mathematical studies of TTP pathway dynamics","Region":"West Midlands","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220107/Z/20/Z","description":"Inflammation is a protective response of the body against injury and invading pathogens. However, dysregulation of the inflammatory response, especially if sustained, is associated with devastating diseases, including chronic inflammatory ones, such as rheumatoid arthritis but also less obvious conditions such as neuro-degenerative diseases and cancer, causing an enormous socio-economic burden.\n\nTraditionally, therapeutic approaches focused on inhibiting cellular signal pathways producing pro-inflammatory mediators, with mixed success. For example MAPK p38 inhibitors were viewed as strong candidate anti-inflammatory drugs, but failed expensively in clinical trials. We pursue a complementary strategy, utilizing the Tristetraprolin (TTP) pathway, which comprises a natural cellular mechanism for switching off inflammatory gene expression. Compounds targeting this pathway have been developed and show potential as anti-inflammatory drugs.\n\nWe will use a combined mathematical and biological approach to study the dynamic regulation of the TTP pathway in white blood cells during inflammatory responses. We will build a mathematical model of the pathway, based on detailed temporal examination of the biology, and will validate it with cutting edge imaging and analysis techniques. This will allow us to identify new angles in research, drug targets and optimal treatment strategies for chronic inflammatory diseases, improving the lives of many affected patients.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Ms Victoria Hagel","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Hagel","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Birmingham\", \"360G-Wellcome-ORG:University-of-Birmingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Integrated biological and mathematical studies of TTP pathway dynamics Inflammation is a protective response of the body against injury and invading pathogens. However, dysregulation of the inflammatory response, especially if sustained, is associated with devastating diseases, including chronic inflammatory ones, such as rheumatoid arthritis but also less obvious conditions such as neuro-degenerative diseases and cancer, causing an enormous socio-economic burden.\n\nTraditionally, therapeutic approaches focused on inhibiting cellular signal pathways producing pro-inflammatory mediators, with mixed success. For example MAPK p38 inhibitors were viewed as strong candidate anti-inflammatory drugs, but failed expensively in clinical trials. We pursue a complementary strategy, utilizing the Tristetraprolin (TTP) pathway, which comprises a natural cellular mechanism for switching off inflammatory gene expression. Compounds targeting this pathway have been developed and show potential as anti-inflammatory drugs.\n\nWe will use a combined mathematical and biological approach to study the dynamic regulation of the TTP pathway in white blood cells during inflammatory responses. We will build a mathematical model of the pathway, based on detailed temporal examination of the biology, and will validate it with cutting edge imaging and analysis techniques. This will allow us to identify new angles in research, drug targets and optimal treatment strategies for chronic inflammatory diseases, improving the lives of many affected patients.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Inflammation","MAP Kinase Signaling System","Models, Biological","Models, Theoretical","Signal Transduction","p38 Mitogen-Activated Protein Kinases"]}
{"id":"360G-Wellcome-220106_Z_20_Z","title":"Immunomodulatory role of platelets ITAM receptors in systemic inflammation and sepsis associated with cardiovascular diseases","Region":"West Midlands","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220106/Z/20/Z","description":"Sepsis is a dysregulated response to infection that has a high mortality. It is associated with low platelet count, a dysfunctional inflammatory response and multiple organ failure. Patients with cardiovascular disease have a higher risk of developing sepsis with worse outcomes, particularly in the elderly. In this project we will investigate whether cardiovascular diseases and ageing induce a pro-inflammatory and prothrombotic state during sepsis that is mediated by upregulation of platelet activity. We will determine whether this is ameliorated by inhibition of platelet immune receptors GPVI, CLEC-2 and FcgammaRIIa, which modulate inflammation and pathogenic thrombosis but have a minimal role in haemostasis. We will investigate these mechanisms in platelets and immune cells from patients with cardiovascular disease and validate these observations in clinically relevant experimental sepsis models associated with chronic cardiovascular diseases (e.g. atherosclerosis and heart failure). We will inhibit the platelet receptors GPVI, CLEC-2 and FcgammaRIIa using a range of different approaches and determine effects on sepsis progression and outcome. This work will help understanding the influence of cardiovascular disease and age on sepsis and provides a novel approach for targeting platelet-immune cell interactions in sepsis using new drugs that target platelet immune receptors.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Dr Martina Colicchia","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Colicchia","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Birmingham\", \"360G-Wellcome-ORG:University-of-Birmingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Immunomodulatory role of platelets ITAM receptors in systemic inflammation and sepsis associated with cardiovascular diseases Sepsis is a dysregulated response to infection that has a high mortality. It is associated with low platelet count, a dysfunctional inflammatory response and multiple organ failure. Patients with cardiovascular disease have a higher risk of developing sepsis with worse outcomes, particularly in the elderly. In this project we will investigate whether cardiovascular diseases and ageing induce a pro-inflammatory and prothrombotic state during sepsis that is mediated by upregulation of platelet activity. We will determine whether this is ameliorated by inhibition of platelet immune receptors GPVI, CLEC-2 and FcgammaRIIa, which modulate inflammation and pathogenic thrombosis but have a minimal role in haemostasis. We will investigate these mechanisms in platelets and immune cells from patients with cardiovascular disease and validate these observations in clinically relevant experimental sepsis models associated with chronic cardiovascular diseases (e.g. atherosclerosis and heart failure). We will inhibit the platelet receptors GPVI, CLEC-2 and FcgammaRIIa using a range of different approaches and determine effects on sepsis progression and outcome. This work will help understanding the influence of cardiovascular disease and age on sepsis and provides a novel approach for targeting platelet-immune cell interactions in sepsis using new drugs that target platelet immune receptors.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Blood Platelets","Cardiovascular Diseases","Hemostasis","Humans","Inflammation","Receptors, Fc","Receptors, IgG","Sepsis","Thrombosis"]}
{"id":"360G-Wellcome-220105_Z_20_Z","title":"Exploring the function and regulation of surface molecules in the reaction to predation by Gram-negative bacteria during predation by the predatory bacterium Bdellovibrio bacteriovorus in host-appropriate settings. ","Region":"East Midlands","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220105/Z/20/Z","description":"The number of infections caused by bacteria that are resistant to antibiotic treatment is increasing, potentially threating the treatment of infectious disease and other illnesses. New treatment approaches are therefore desperately needed, one of which involves the application of the predatory bacteria Bdellovibrio bacteriovorus. B. bacteriovorus is a bacterium that is able to prey upon a wide range of these antibiotic resistant organisms, potentially providing an alternative treatment for infections.  This work builds on previous work with other clinically relevant bacteria to further characterise the mechanisms behind the prey recognition and invasion of bacteria by B. bacteriovorus predators and how this interaction is affected by components of the host immune system (1, 2) and prey surface factors (3). By looking at the factors that may prevent or decrease predation and experimentally removing them, we can characterise the mechanisms behind this interaction further and aid the potential application of B. bacteriovorus as a novel antimicrobial therapy in the future.\n \n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Callum Clark","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Clark","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Nottingham","name":"University of Nottingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Nottingham\", \"360G-Wellcome-ORG:University-of-Nottingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Nottingham","name":"University of Nottingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Exploring the function and regulation of surface molecules in the reaction to predation by Gram-negative bacteria during predation by the predatory bacterium Bdellovibrio bacteriovorus in host-appropriate settings.  The number of infections caused by bacteria that are resistant to antibiotic treatment is increasing, potentially threating the treatment of infectious disease and other illnesses. New treatment approaches are therefore desperately needed, one of which involves the application of the predatory bacteria Bdellovibrio bacteriovorus. B. bacteriovorus is a bacterium that is able to prey upon a wide range of these antibiotic resistant organisms, potentially providing an alternative treatment for infections.  This work builds on previous work with other clinically relevant bacteria to further characterise the mechanisms behind the prey recognition and invasion of bacteria by B. bacteriovorus predators and how this interaction is affected by components of the host immune system (1, 2) and prey surface factors (3). By looking at the factors that may prevent or decrease predation and experimentally removing them, we can characterise the mechanisms behind this interaction further and aid the potential application of B. bacteriovorus as a novel antimicrobial therapy in the future.\n \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Bdellovibrio","Bdellovibrio bacteriovorus","Predatory Behavior"]}
{"id":"360G-Wellcome-220104_Z_20_Z","title":"Understanding the dynamics of agr expression in vivo and the efficacy of agr pathway inhibitors","Region":"East Midlands","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220104/Z/20/Z","description":"Staphylococcus aureus is a common cause of hospital acquired infections. Infections caused by S. aureus are difficult to treat due to the emergence of drug resistant strains and growth in biofilms which limits the efficacy of antibiotic drugs. Due to emergence of antibiotic resistant bacteria there is a need for drugs which do not succumb to conventional methods of antibiotic resistance. One method is through attenuation of the virulence of the bacteria. This will reduce the infection with less pressure for resistance to emerge. One promising anti-virulence target is cell-cell communication known as quorum sensing. This PhD will involve investigation of the agr quorum sensing system in S. aureuswhich is known to control virulence. This is temporally expressed during infection and a model using bacteria with NanoLuc/GLuc luminescent reporters linked to the agr system will be developed and used to determine when and where this system is activated in vivo. This model can then be used to screen for inhibitors of the agr system and their efficacy determined in in vivo models. \n \n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Ms Isobel Blower","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Blower","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Nottingham","name":"University of Nottingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Nottingham\", \"360G-Wellcome-ORG:University-of-Nottingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Nottingham","name":"University of Nottingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding the dynamics of agr expression in vivo and the efficacy of agr pathway inhibitors Staphylococcus aureus is a common cause of hospital acquired infections. Infections caused by S. aureus are difficult to treat due to the emergence of drug resistant strains and growth in biofilms which limits the efficacy of antibiotic drugs. Due to emergence of antibiotic resistant bacteria there is a need for drugs which do not succumb to conventional methods of antibiotic resistance. One method is through attenuation of the virulence of the bacteria. This will reduce the infection with less pressure for resistance to emerge. One promising anti-virulence target is cell-cell communication known as quorum sensing. This PhD will involve investigation of the agr quorum sensing system in S. aureuswhich is known to control virulence. This is temporally expressed during infection and a model using bacteria with NanoLuc/GLuc luminescent reporters linked to the agr system will be developed and used to determine when and where this system is activated in vivo. This model can then be used to screen for inhibitors of the agr system and their efficacy determined in in vivo models. \n \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Anti-Bacterial Agents","Bacterial Proteins","Biofilms","Quorum Sensing","Staphylococcus aureus","Virulence"]}
{"id":"360G-Wellcome-220103_Z_20_Z","title":"Understanding the mechanistic basis of PARG inhibitor sensitivity in the context of high-grade serous ovarian cancer.","Region":"North West","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220103/Z/20/Z","description":"DNA damage repair (DDR) is frequently activated during normal cellular contexts and is thus instrumental during tumourigenesis when functioning aberrantly. For example, DDR defects are widespread amongst ovarian cancers (1) and thus genomic instability is a defining characteristic of this cancer type (2). Hence, DDR research is extensive, providing insights into mechanisms, therapies and biomarkers. One such research avenue involves the DNA repair enzyme PARG (3), whose inhibitor (PARGi) has shown potential therapeutic usages (4). To widen the opportunities of PARGi as a therapeutic agent, one must first dissect the mechanism of differing PARGi sensitivity. Therefore, a screen identifying genes which, when defective, sensitise cells to PARGi was performed (4), and identified TIMELESS. We aim to decipher the functions of TIMELESS in DDR and PARG dynamics with a focus on TIMELESS\u2019s structure-function relationship. The approach is three-fold: firstly, generation of a series of TIMELESS mutants, with targeted residues spanning the entire gene sequence, followed by characterising the mutants using proliferation and gammaH2AX-production as quantitative outputs. Secondly, hypothesis-driven cell biology-based experiments to focus on the DDR roles of TIMELESS. Finally, an unbiased approach employing mass spectrometry will characterise replication fork modifications upon TIMELESS mutations.\n\n \n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Rosie Brady","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Brady","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding the mechanistic basis of PARG inhibitor sensitivity in the context of high-grade serous ovarian cancer. DNA damage repair (DDR) is frequently activated during normal cellular contexts and is thus instrumental during tumourigenesis when functioning aberrantly. For example, DDR defects are widespread amongst ovarian cancers (1) and thus genomic instability is a defining characteristic of this cancer type (2). Hence, DDR research is extensive, providing insights into mechanisms, therapies and biomarkers. One such research avenue involves the DNA repair enzyme PARG (3), whose inhibitor (PARGi) has shown potential therapeutic usages (4). To widen the opportunities of PARGi as a therapeutic agent, one must first dissect the mechanism of differing PARGi sensitivity. Therefore, a screen identifying genes which, when defective, sensitise cells to PARGi was performed (4), and identified TIMELESS. We aim to decipher the functions of TIMELESS in DDR and PARG dynamics with a focus on TIMELESS\u2019s structure-function relationship. The approach is three-fold: firstly, generation of a series of TIMELESS mutants, with targeted residues spanning the entire gene sequence, followed by characterising the mutants using proliferation and gammaH2AX-production as quantitative outputs. Secondly, hypothesis-driven cell biology-based experiments to focus on the DDR roles of TIMELESS. Finally, an unbiased approach employing mass spectrometry will characterise replication fork modifications upon TIMELESS mutations.\n\n \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cell Line, Tumor","Cell Proliferation","DNA Damage","DNA Repair","Humans","Mutation","Ovarian Neoplasms"]}
{"id":"360G-Wellcome-220102_Z_20_Z","title":"Control of cortex-wide neural activity maturation by local and long-range GABA signalling ","Region":"South West","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220102/Z/20/Z","description":"Animal behavior is generated by the collective activity of many neurons, and thus constitutes an emergent property of the brain, which might not be apparent at the individual level of anatomical regions and single cells. Moreover, these collective interactions and patterns of activity across neuronal populations are not fixed but dynamically shaped by many different processes, such as learning, over multiple timescales. These features suggest that the behavior of such complex dynamical system cannot be fully understood by independently analyzing each of its constituents. For this reason, I aim to examine the role and dynamics of two distinct neuronal populations across early brain development, the most critical learning period, by following a whole-brain imaging approach. This will allow me to investigate how the cross-talk between distant brain regions and cell populations influences the formation of a mature brain. Specifically, by simultaneously assessing the spatial and temporal dynamics of excitatory and inhibitory cell activity patterns across the cortex, I would like to study the interplay between both types of neuronal populations during functional maturation of brain circuits, and after senses come online. This is critical to understand normal brain development and subsequently, potential dysfunctions associated with neurodevelopmental disorders.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Laura Mediavilla Santos","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Mediavilla Santos","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Control of cortex-wide neural activity maturation by local and long-range GABA signalling  Animal behavior is generated by the collective activity of many neurons, and thus constitutes an emergent property of the brain, which might not be apparent at the individual level of anatomical regions and single cells. Moreover, these collective interactions and patterns of activity across neuronal populations are not fixed but dynamically shaped by many different processes, such as learning, over multiple timescales. These features suggest that the behavior of such complex dynamical system cannot be fully understood by independently analyzing each of its constituents. For this reason, I aim to examine the role and dynamics of two distinct neuronal populations across early brain development, the most critical learning period, by following a whole-brain imaging approach. This will allow me to investigate how the cross-talk between distant brain regions and cell populations influences the formation of a mature brain. Specifically, by simultaneously assessing the spatial and temporal dynamics of excitatory and inhibitory cell activity patterns across the cortex, I would like to study the interplay between both types of neuronal populations during functional maturation of brain circuits, and after senses come online. This is critical to understand normal brain development and subsequently, potential dysfunctions associated with neurodevelopmental disorders.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Brain","GABAergic Neurons","Neurons"]}
{"id":"360G-Wellcome-220101_Z_20_Z","title":"Cerebro-cerebellar interactions during learning of cognitive tasks ","Region":"South West","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220101/Z/20/Z","description":"A substantial part of animal, including human, behaviour is goal directed. Learning how to achieve a defined goal requires the interplay between higher brain centres involved in planning and decision making and subcortical structures that coordinate the desired movements. However, there is growing evidence suggesting that subcortical structures such as the cerebellum play a much wider role by also being directly involved in higher cognitive functions. Although much information exists about the cerebellum and neocortex individually, little is known about how the connections between these areas are involved in complex behaviours. In this project I propose to study how the learning mechanisms in these brain structures support each other to give rise to complex behaviours. First, I will develop a computational model of cerebellar-neocortical interactions based on recent developments from deep learning. Next I will test the predictions of this model using electrophysiological recordings during goal-directed behaviours which require higher cognitive functions. This research will provide a better understanding of the neural mechanisms through which the cerebellum controls high-level, non-motor functions. Ultimately this will be of clinical interest for cognitive pathologies like autism and schizophrenia and will have implications for both cognitive sciences and computer science.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Ms Ellen Boven","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Boven","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Cerebro-cerebellar interactions during learning of cognitive tasks  A substantial part of animal, including human, behaviour is goal directed. Learning how to achieve a defined goal requires the interplay between higher brain centres involved in planning and decision making and subcortical structures that coordinate the desired movements. However, there is growing evidence suggesting that subcortical structures such as the cerebellum play a much wider role by also being directly involved in higher cognitive functions. Although much information exists about the cerebellum and neocortex individually, little is known about how the connections between these areas are involved in complex behaviours. In this project I propose to study how the learning mechanisms in these brain structures support each other to give rise to complex behaviours. First, I will develop a computational model of cerebellar-neocortical interactions based on recent developments from deep learning. Next I will test the predictions of this model using electrophysiological recordings during goal-directed behaviours which require higher cognitive functions. This research will provide a better understanding of the neural mechanisms through which the cerebellum controls high-level, non-motor functions. Ultimately this will be of clinical interest for cognitive pathologies like autism and schizophrenia and will have implications for both cognitive sciences and computer science.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cerebellum","Cognition","Computer Simulation","Decision Making","Humans","Learning","Models, Neurological"]}
{"id":"360G-Wellcome-220100_Z_20_Z","title":"Understanding behavioral clustering in epidemics","Region":"Greater London","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220100/Z/20/Z","description":"An increasingly interconnected world provides a greater opportunity for the emergence of epidemics. In the last decade alone, the World Health Organization (WHO) has announced five Public Health Emergencies of International Concern. Additionally, there has recently been a resurgence in vaccine-preventable diseases. The increasing risk of epidemics necessitates a greater ability to understand how they spread.\n\nCurrent outbreak models have struggled to reproduce outbreak data across a number of diseases, from Ebola Virus disease in West Africa, to a measles outbreak in Brazil. One reason for this is that current models do not consider how the behavior of individuals in contact with each other is clustered. For example, people who are hesitant to vaccination are more likely to be in contact with each other, and less likely to be in contact with vaccine adherents. This clustering increases the susceptibility of the unvaccinated population to disease. \n\nThis PhD will use explore how clustering of individuals affects the spread of outbreaks. I will develop a mathematical model which simulates disease outbreaks through a network of individuals with clustering based on behavior. The work could be applied in a number of disease contexts from Ebola in West Africa to Measles in Latam.\n","plannedDates":[{"endDate":"2023-05-23T00:00:00+00:00","startDate":"2019-10-02T00:00:00+00:00","startDateDateOnly":"2019-10-02","endDateDateOnly":"2023-05-23"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr William Green","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Green","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding behavioral clustering in epidemics An increasingly interconnected world provides a greater opportunity for the emergence of epidemics. In the last decade alone, the World Health Organization (WHO) has announced five Public Health Emergencies of International Concern. Additionally, there has recently been a resurgence in vaccine-preventable diseases. The increasing risk of epidemics necessitates a greater ability to understand how they spread.\n\nCurrent outbreak models have struggled to reproduce outbreak data across a number of diseases, from Ebola Virus disease in West Africa, to a measles outbreak in Brazil. One reason for this is that current models do not consider how the behavior of individuals in contact with each other is clustered. For example, people who are hesitant to vaccination are more likely to be in contact with each other, and less likely to be in contact with vaccine adherents. This clustering increases the susceptibility of the unvaccinated population to disease. \n\nThis PhD will use explore how clustering of individuals affects the spread of outbreaks. I will develop a mathematical model which simulates disease outbreaks through a network of individuals with clustering based on behavior. The work could be applied in a number of disease contexts from Ebola in West Africa to Measles in Latam.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Brazil","Disease Outbreaks","Epidemics","Hemorrhagic Fever, Ebola","Humans","Measles","Models, Theoretical"]}
{"id":"360G-Wellcome-220099_Z_20_Z","title":"A global model for the evolutionary dynamics of seasonal influenza ","Region":"Greater London","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220099/Z/20/Z","description":"Influenza epidemics infect between 10% and 20% of the global population each year. Infection typically infers a lifetime immunity on an individual, but due to the gradual accumulation of mutations new strains can emerge that evade the host\u2019s immunity and allow repeat infection. This \u2018antigenic drift\u2019 of influenza has been well characterised, but the origins of the observations are not well understood. A limited number of models have attempted to explain the observed effects. However, none of the models has included a realistic spatial component or realistic population sizes.\n\nThe aim of this project will be to develop a computational model of influenza evolution that incorporates realistic population sizes and spatial spread at a global scale. The model will be based on individuals and allow spatially dependent transmission. The model will include a probability of mutation of a strain upon infection of an individual. By tracking each individual\u2019s immune status based on previous infections evolution will naturally occur in the model to evade population immunity.\n\nThis model will lead to a greater understanding on the complex relationship between human ecology and the evolutionary dynamics of influenza. It is possible it may also inform future surveillance and vaccine protocol.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-02T00:00:00+00:00","startDateDateOnly":"2019-10-02","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Oliver Eales","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Eales","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A global model for the evolutionary dynamics of seasonal influenza  Influenza epidemics infect between 10% and 20% of the global population each year. Infection typically infers a lifetime immunity on an individual, but due to the gradual accumulation of mutations new strains can emerge that evade the host\u2019s immunity and allow repeat infection. This \u2018antigenic drift\u2019 of influenza has been well characterised, but the origins of the observations are not well understood. A limited number of models have attempted to explain the observed effects. However, none of the models has included a realistic spatial component or realistic population sizes.\n\nThe aim of this project will be to develop a computational model of influenza evolution that incorporates realistic population sizes and spatial spread at a global scale. The model will be based on individuals and allow spatially dependent transmission. The model will include a probability of mutation of a strain upon infection of an individual. By tracking each individual\u2019s immune status based on previous infections evolution will naturally occur in the model to evade population immunity.\n\nThis model will lead to a greater understanding on the complex relationship between human ecology and the evolutionary dynamics of influenza. It is possible it may also inform future surveillance and vaccine protocol.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Biological Evolution","Computer Simulation","Evolution, Molecular","Humans","Influenza A virus","Influenza, Human"]}
{"id":"360G-Wellcome-220098_Z_20_Z","title":"Addressing the double burden of HIV and cervical cancer: benefits and costs of integrating care in Kenya","Region":"Greater London","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220098/Z/20/Z","description":"In Kenya, cervical cancer is the leading cause of cancer deaths among women. The Ministry of Health wants to scale-up preventative screening and treatment to reduce this burden but has limited funds. It has been suggested that providing services for two diseases in one clinic is more cost-effective than providing them in separate clinics, because services share the delivery platform (clinic) and costs of inputs such as diagnostic equipment.  However, joint service provision may also be less cost-effective, because the efficiency gains from sharing delivery platforms only materialize if there is spare capacity to deliver both services; otherwise, one intervention with comparably lower benefits may crowd out another with higher benefits. This means that it is unclear whether the ministry should invest in integrated or separate services for cervical cancer.\n\nOur project will test the hypothesis that integrating services for cervical cancer with services for Human Immunodeficiency Virus (HIV) is more cost-effective than providing the screening separately. We will collect data on the cost of providing care and on the number of patients seen, then compare the cost-effectiveness of integrated services to separate services.\n\nOur findings will be translated into recommendations to the Kenyan Ministry of Health.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-02T00:00:00+00:00","startDateDateOnly":"2019-10-02","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Katherine Davis","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Davis","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Addressing the double burden of HIV and cervical cancer: benefits and costs of integrating care in Kenya In Kenya, cervical cancer is the leading cause of cancer deaths among women. The Ministry of Health wants to scale-up preventative screening and treatment to reduce this burden but has limited funds. It has been suggested that providing services for two diseases in one clinic is more cost-effective than providing them in separate clinics, because services share the delivery platform (clinic) and costs of inputs such as diagnostic equipment.  However, joint service provision may also be less cost-effective, because the efficiency gains from sharing delivery platforms only materialize if there is spare capacity to deliver both services; otherwise, one intervention with comparably lower benefits may crowd out another with higher benefits. This means that it is unclear whether the ministry should invest in integrated or separate services for cervical cancer.\n\nOur project will test the hypothesis that integrating services for cervical cancer with services for Human Immunodeficiency Virus (HIV) is more cost-effective than providing the screening separately. We will collect data on the cost of providing care and on the number of patients seen, then compare the cost-effectiveness of integrated services to separate services.\n\nOur findings will be translated into recommendations to the Kenyan Ministry of Health.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cost-Benefit Analysis","Early Detection of Cancer","Female","HIV Infections","Humans","Kenya","Mass Screening","Uterine Cervical Neoplasms"]}
{"id":"360G-Wellcome-220097_Z_20_Z","title":"A multifaceted exploration of the dynamics of acute respiratory infections in Denmark using deep learning approaches","Region":"Greater London","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220097/Z/20/Z","description":"Acute respiratory infections (ARIs) including bronchitis and pneumonia are common illnesses in children in high-income countries [1]. Childhood adversaries such as death, illness or unemployment in the family, alongside environmental factors such as pollution are thought to increase the chances of someone developing an ARI [2]. Previous studies measured the impact of risk factors for ARIs but focused on a single associated risk and did not factor comorbidities including stroke, cancer, diabetes or mental illness. To our knowledge no study has looked at a multifaceted view of the causes and associations of ARIs. I aim to look at a variety of sociodemographic, environmental and individual specific factors and evaluate the landscape of ARI disease risk. I will use a unique dataset collated from Danish Registers for people born after 1980 [3]. This dataset contains unparalleled information on longitudinal health outcomes and childhood adversaries and, unlike single timepoint surveys, allows the study of risk trajectories for the entire susceptible population. I will study the spatial and temporal influence of risk factors on ARI incidence and develop a modelling framework for predicting disease progression and could be used as an early warning system to identify high risk populations and inform intervention strategies.\n","plannedDates":[{"endDate":"2023-06-30T00:00:00+00:00","startDate":"2019-10-02T00:00:00+00:00","startDateDateOnly":"2019-10-02","endDateDateOnly":"2023-06-30"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Ms Helen Coupland","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Coupland","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A multifaceted exploration of the dynamics of acute respiratory infections in Denmark using deep learning approaches Acute respiratory infections (ARIs) including bronchitis and pneumonia are common illnesses in children in high-income countries [1]. Childhood adversaries such as death, illness or unemployment in the family, alongside environmental factors such as pollution are thought to increase the chances of someone developing an ARI [2]. Previous studies measured the impact of risk factors for ARIs but focused on a single associated risk and did not factor comorbidities including stroke, cancer, diabetes or mental illness. To our knowledge no study has looked at a multifaceted view of the causes and associations of ARIs. I aim to look at a variety of sociodemographic, environmental and individual specific factors and evaluate the landscape of ARI disease risk. I will use a unique dataset collated from Danish Registers for people born after 1980 [3]. This dataset contains unparalleled information on longitudinal health outcomes and childhood adversaries and, unlike single timepoint surveys, allows the study of risk trajectories for the entire susceptible population. I will study the spatial and temporal influence of risk factors on ARI incidence and develop a modelling framework for predicting disease progression and could be used as an early warning system to identify high risk populations and inform intervention strategies.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Air Pollution","Deep Learning","Denmark","Disease Progression","Humans","Incidence","Longitudinal Studies","Registries","Respiratory Tract Infections","Risk Factors"]}
{"id":"360G-Wellcome-220096_Z_20_Z","title":"B cell receptor repertoire alterations in immunity and autoimmunity","Region":"Scotland","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220096/Z/20/Z","description":"Rheumatoid arthritis (RA) is a chronic, incurable autoimmune condition that affects more than 400,000 people in the UK and can cause severe disability. The contribution of B cells to pathogenesis in RA has long been recognised but the exact mechanisms by which they influence the inflammatory process are incompletely understood. Large-scale next-generation sequencing (NGS) projects have already begun to elevate our knowledge of the role of B cells in a wide range of diseases, by characterising expressed immunoglobulin (Ig) repertoires. New NGS methods focusing on individual cells, including single-cell RNA sequencing, are incredibly powerful at revealing heterogeneity in immune cell populations. A subset of B cells showing a distinct signature of hypomutated antibody, or IgG, has recently been identified in RA. By combining transcriptomic and antigen receptor repertoire data at a single cell level, I aim to understand the origin and role of this cell population. To do so, I will determine the transcriptional heterogeneity of peripheral B cells in RA, characterise gene expression signatures associated with the production of hypomutated IgG, and develop tools to improve analysis pipelines. This work will help clarify the involvement of B cell subsets in RA and may provide targets for more directed therapy.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Ms Catherine Sutherland","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Sutherland","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"B cell receptor repertoire alterations in immunity and autoimmunity Rheumatoid arthritis (RA) is a chronic, incurable autoimmune condition that affects more than 400,000 people in the UK and can cause severe disability. The contribution of B cells to pathogenesis in RA has long been recognised but the exact mechanisms by which they influence the inflammatory process are incompletely understood. Large-scale next-generation sequencing (NGS) projects have already begun to elevate our knowledge of the role of B cells in a wide range of diseases, by characterising expressed immunoglobulin (Ig) repertoires. New NGS methods focusing on individual cells, including single-cell RNA sequencing, are incredibly powerful at revealing heterogeneity in immune cell populations. A subset of B cells showing a distinct signature of hypomutated antibody, or IgG, has recently been identified in RA. By combining transcriptomic and antigen receptor repertoire data at a single cell level, I aim to understand the origin and role of this cell population. To do so, I will determine the transcriptional heterogeneity of peripheral B cells in RA, characterise gene expression signatures associated with the production of hypomutated IgG, and develop tools to improve analysis pipelines. This work will help clarify the involvement of B cell subsets in RA and may provide targets for more directed therapy.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Arthritis, Rheumatoid","B-Lymphocytes","Gene Expression Profiling","High-Throughput Nucleotide Sequencing","Humans","Sequence Analysis, RNA","Single-Cell Analysis","Transcriptome"]}
{"id":"360G-Wellcome-220095_Z_20_Z","title":"Investigating adaptive immune function in ME/CFS patients","Region":"Scotland","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220095/Z/20/Z","description":"The underlying cause and the mechanisms driving disease in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) are unknown and identifying a marker of disease, even for a subgroup of patients, would open avenues for research into  pathogenesis and better diagnostic tools. B cells in ME/CFS patients have been shown to have unusual features, including an expansion of particular B cell repertoires (BCRs) in the repertoires of a small cohort of ME/CFS patients compared with healthy controls [9]. We will test these initial findings across a large number of patients and examine patterns of diversity or shared responses in the repertoires of patients compared with controls. This will involve sequencing and analysis of B cell samples for approximately 130 severe and moderate ME/CFS patients as well as multiple sclerosis patients and healthy controls. Using machine learning and clustering-based statistical techniques we will stratify individuals based on properties of their B cell repertoires and the available meta-data. Phage display techniques will be used to replicate BCRs in the lab to identify major antigens shaping the repertoires in these patients. This study will generate a comprehensive picture of B cell immune diversity in ME/CFS to improve our understanding of the aetiology and immunopathology of ME/CFS.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Ms Audrey Ryback","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Ryback","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating adaptive immune function in ME/CFS patients The underlying cause and the mechanisms driving disease in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) are unknown and identifying a marker of disease, even for a subgroup of patients, would open avenues for research into  pathogenesis and better diagnostic tools. B cells in ME/CFS patients have been shown to have unusual features, including an expansion of particular B cell repertoires (BCRs) in the repertoires of a small cohort of ME/CFS patients compared with healthy controls [9]. We will test these initial findings across a large number of patients and examine patterns of diversity or shared responses in the repertoires of patients compared with controls. This will involve sequencing and analysis of B cell samples for approximately 130 severe and moderate ME/CFS patients as well as multiple sclerosis patients and healthy controls. Using machine learning and clustering-based statistical techniques we will stratify individuals based on properties of their B cell repertoires and the available meta-data. Phage display techniques will be used to replicate BCRs in the lab to identify major antigens shaping the repertoires in these patients. This study will generate a comprehensive picture of B cell immune diversity in ME/CFS to improve our understanding of the aetiology and immunopathology of ME/CFS.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["B-Lymphocytes","Cohort Studies","Fatigue Syndrome, Chronic","Humans","Machine Learning"]}
{"id":"360G-Wellcome-220094_Z_20_Z","title":"Characterisation of a host receptor for Plasmodium falciparum-infected erythrocyte rosette formation","Region":"Scotland","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220094/Z/20/Z","description":"Rosetting, the binding of two or more uninfected erythrocytes to an infected erythrocyte, is associated with severe P. falciparum malaria. Therefore, anti-rosetting therapies that reduce microvascular obstruction may be beneficial as adjunctive therapy to reduce severe malaria deaths. Rosettes are formed by an interaction between parasite-derived Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) and host erythrocyte membrane receptors. PfEMP1 is highly polymorphic and therefore a challenging target for vaccines. Recent work by the Rowe lab suggests that PfEMP1 mediates rosetting by an interaction with the Wrightb antigen formed by Band 3 and Glycophorin A. An antibody targeting Wrightb has disrupted rosettes in all P. falciparum strains tested to date, suggesting that this small antibody fragment (BRIC14) has therapeutic potential. I propose to test BRIC14 across a panel of rosetting P. falciparum strains to determine the efficacy of BRIC14 in severe disease states. I aim to characterise the interaction between PfEMP 1 and Wrightb to determine if BRIC14 reduces rosetting by direct inhibition of a ligand-receptor interaction or by altering erythrocyte deformability. The present study aims to characterise a key receptor-ligand interaction implicated in rosetting and determine if a rosette-disrupting antibody has potential as a therapy against disease-causing P. falciparum strains.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Ms Molly Carlier","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Carlier","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Characterisation of a host receptor for Plasmodium falciparum-infected erythrocyte rosette formation Rosetting, the binding of two or more uninfected erythrocytes to an infected erythrocyte, is associated with severe P. falciparum malaria. Therefore, anti-rosetting therapies that reduce microvascular obstruction may be beneficial as adjunctive therapy to reduce severe malaria deaths. Rosettes are formed by an interaction between parasite-derived Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) and host erythrocyte membrane receptors. PfEMP1 is highly polymorphic and therefore a challenging target for vaccines. Recent work by the Rowe lab suggests that PfEMP1 mediates rosetting by an interaction with the Wrightb antigen formed by Band 3 and Glycophorin A. An antibody targeting Wrightb has disrupted rosettes in all P. falciparum strains tested to date, suggesting that this small antibody fragment (BRIC14) has therapeutic potential. I propose to test BRIC14 across a panel of rosetting P. falciparum strains to determine the efficacy of BRIC14 in severe disease states. I aim to characterise the interaction between PfEMP 1 and Wrightb to determine if BRIC14 reduces rosetting by direct inhibition of a ligand-receptor interaction or by altering erythrocyte deformability. The present study aims to characterise a key receptor-ligand interaction implicated in rosetting and determine if a rosette-disrupting antibody has potential as a therapy against disease-causing P. falciparum strains.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Antibodies, Protozoan","Antigens, Protozoan","Erythrocytes","Humans","Malaria, Falciparum","Plasmodium falciparum","Protozoan Proteins"]}
{"id":"360G-Wellcome-220093_Z_20_Z","title":"The role of cell cycle exit in EHT and the haematopoietic niche","Region":"Scotland","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220093/Z/20/Z","description":"Haematopoietic stem cells (HSCs) have been used for the treatment of diseases including immune deficiencies and metabolic disorders, as well as bone marrow repair after radiation treatment. In order to harvest their full potential, it is essential that we expand our understanding of HSC development and function. A vital part of HSC generation in the developing embryo is the transition of a subset of endothelial cells into blood cells. This occurs under the control of a multitude of factors within the cell and those present in the surrounding environment, the hematopoietic niche. The cell cycle has been shown to be an important involved in the cellular differentiation process, as some cells need to exit the cell cycle in order to undergo the transcriptional and morphological changes associated with differentiation. In my project I will investigate the impact of various factors as cell cycle regulators in this early differentiation of endothelial cells into haematopoietic cells. These studies will employ genetically modified mice, alongside state-of-the-art in-vitro and transcriptional profiling techniques such as single-cell RNA-sequencing. We expect our research to help elucidate the origin of HSCs and therefore contribute to our understanding of how to generate these cells in-vitro. \n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Ms Leslie Nitsche","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Nitsche","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The role of cell cycle exit in EHT and the haematopoietic niche Haematopoietic stem cells (HSCs) have been used for the treatment of diseases including immune deficiencies and metabolic disorders, as well as bone marrow repair after radiation treatment. In order to harvest their full potential, it is essential that we expand our understanding of HSC development and function. A vital part of HSC generation in the developing embryo is the transition of a subset of endothelial cells into blood cells. This occurs under the control of a multitude of factors within the cell and those present in the surrounding environment, the hematopoietic niche. The cell cycle has been shown to be an important involved in the cellular differentiation process, as some cells need to exit the cell cycle in order to undergo the transcriptional and morphological changes associated with differentiation. In my project I will investigate the impact of various factors as cell cycle regulators in this early differentiation of endothelial cells into haematopoietic cells. These studies will employ genetically modified mice, alongside state-of-the-art in-vitro and transcriptional profiling techniques such as single-cell RNA-sequencing. We expect our research to help elucidate the origin of HSCs and therefore contribute to our understanding of how to generate these cells in-vitro. \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cell Cycle","Cell Differentiation","Endothelial Cells","Hematopoiesis","Hematopoietic Stem Cells","Mice","Single-Cell Analysis"]}
{"id":"360G-Wellcome-220092_Z_20_Z","title":"Investigating the female sexual life-cycle of Cryptosporidium, a diarrhoeal pathogen of global significance","Region":"Scotland","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220092/Z/20/Z","description":"Cryptosporidiosis is a diarrhoeal disease of global significance caused by the intracellular parasite, Cryptosporidium spp. Infections can cause malnutrition, growth stunting and be fatal in children. Unlike other causes of diarrhoea, cryptosporidiosis lacks effective treatment or vaccine.\n\nShortcomings in the clinic persist due to the lack of a continuous in vitro culture system. This year, we established and infected mouse intestinal organoids (miniaturized, self organized organs) in our laboratory. Combining these in vitro culture abilities with gene-editing tools, we can now study the complete life-cycle of Cryptosporidium and stages which precede transmission that were not readily observed previously.\n\nI aim to better define the female life cycle stage of Cryptosporidium. It is important to understand how female parasites regulate building environmentally resilient cyst walls, and sporulate new parasites inside this cyst. I aim to generate a female stage-reporter strain of C. parvum and validate Cryptosporidium-organoid co-culture in the first 6 months. Furthermore, isolated females may be further characterized by single cell RNA-sequencing and proteomics. This research will better define the formation of the transmissible stage of Cryptosporidium and provide a basic understanding on which to develop vaccine and drug discovery. \n","plannedDates":[{"endDate":"2022-12-02T00:00:00+00:00","startDate":"2018-09-03T00:00:00+00:00","startDateDateOnly":"2018-09-03","endDateDateOnly":"2022-12-02"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Emma Sands","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Sands","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee","addressCountry":"United Kingdom","id_and_name":"[\"University of Dundee\", \"360G-Wellcome-ORG:University-of-Dundee\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the female sexual life-cycle of Cryptosporidium, a diarrhoeal pathogen of global significance Cryptosporidiosis is a diarrhoeal disease of global significance caused by the intracellular parasite, Cryptosporidium spp. Infections can cause malnutrition, growth stunting and be fatal in children. Unlike other causes of diarrhoea, cryptosporidiosis lacks effective treatment or vaccine.\n\nShortcomings in the clinic persist due to the lack of a continuous in vitro culture system. This year, we established and infected mouse intestinal organoids (miniaturized, self organized organs) in our laboratory. Combining these in vitro culture abilities with gene-editing tools, we can now study the complete life-cycle of Cryptosporidium and stages which precede transmission that were not readily observed previously.\n\nI aim to better define the female life cycle stage of Cryptosporidium. It is important to understand how female parasites regulate building environmentally resilient cyst walls, and sporulate new parasites inside this cyst. I aim to generate a female stage-reporter strain of C. parvum and validate Cryptosporidium-organoid co-culture in the first 6 months. Furthermore, isolated females may be further characterized by single cell RNA-sequencing and proteomics. This research will better define the formation of the transmissible stage of Cryptosporidium and provide a basic understanding on which to develop vaccine and drug discovery. \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cryptosporidiosis","Cryptosporidium parvum","Female","Life Cycle Stages","Mice","Organoids","Proteomics"]}
{"id":"360G-Wellcome-220091_Z_20_Z","title":"Investigating the impacts of nutrition on gastrointestinal helminth infection and immunity in a wild mouse model ","Region":"Scotland","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220091/Z/20/Z","description":"Gastrointestinal (GI) parasitic helminths, pose a significant threat to the health of humans and animals worldwide. Those affected are continuously exposed and rapidly re-infected post-treatment, however, the level of infection (worm burden) varies among individuals. The underlying drivers of such individual differences are multifaceted; however, host immune and nutritional status influence exposure and susceptibility to helminths. Much of our understanding of GI helminth infections in mammals has derived from lab mouse models that may not reflect real-life scenarios. Instead, using wild hosts and their coevolved wild parasites may provide a more ecologically relevant model of GI helminths for humans and wildlife. Currently, limited research has investigated the relationship between nutrition and immunity in natural host-helminth systems.\n\n\nWe aim to determine the role nutrition plays in immunity and infection within a natural host-helminth system; wood mice (Apodemus sylvaticus) and wild isolates of Heligmosomoides polygyrus. By conducting parallel experiments in the lab and wild, with the same host-parasite system, we can control for variation in parasite exposure and nutritional status to determine the key drivers of susceptibility to infection. We will combine both ecological and immunological data to gain a greater understanding of the interplay between nutrition, immune response and helminth infections.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Rowan Bancroft","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Bancroft","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the impacts of nutrition on gastrointestinal helminth infection and immunity in a wild mouse model  Gastrointestinal (GI) parasitic helminths, pose a significant threat to the health of humans and animals worldwide. Those affected are continuously exposed and rapidly re-infected post-treatment, however, the level of infection (worm burden) varies among individuals. The underlying drivers of such individual differences are multifaceted; however, host immune and nutritional status influence exposure and susceptibility to helminths. Much of our understanding of GI helminth infections in mammals has derived from lab mouse models that may not reflect real-life scenarios. Instead, using wild hosts and their coevolved wild parasites may provide a more ecologically relevant model of GI helminths for humans and wildlife. Currently, limited research has investigated the relationship between nutrition and immunity in natural host-helminth systems.\n\n\nWe aim to determine the role nutrition plays in immunity and infection within a natural host-helminth system; wood mice (Apodemus sylvaticus) and wild isolates of Heligmosomoides polygyrus. By conducting parallel experiments in the lab and wild, with the same host-parasite system, we can control for variation in parasite exposure and nutritional status to determine the key drivers of susceptibility to infection. We will combine both ecological and immunological data to gain a greater understanding of the interplay between nutrition, immune response and helminth infections.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Disease Models, Animal","Gastrointestinal Tract","Helminthiasis, Animal","Helminths","Mice","Nematospiroides dubius","Strongylida Infections"]}
{"id":"360G-Wellcome-220090_Z_20_Z","title":"A system level approach to identify and validate imprinted genes involved in parental care","Region":"Wales","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220090/Z/20/Z","description":"The neural pathways responsible for parenting behaviours have been well characterised, and the Preoptic Area (POA) is considered a parenting 'hub' in many mammals including mice and rats. Imprinted genes (IG) are a set of ~200 genes that have been clearly associated with the quality of parenting behaviour. Our current work plans to unite these two by investigating the role of IG expression in the neural circuitry for parenting.\n\nUsing pre-existing data, we will look for enrichment of IGs in the POA and in specific POA neurons associated with parenting behaviour. We will be guided by this analysis to select an IG to characterise the parenting deficit created from a gene knock-out model. Furthermore, we will utilise RNA-Scope to examine specific gene-expression within the POA of the mouse model looking for the effect that the knock-out model will have on the parenting neurons.\n\nThe quality of parenting behaviour is key to the optimal development of offspring in animals, hence the impact of this work will be to further elucidate one of the genetic underpinnings of parenting behaviour, especially valuable since previous work has associated imprinted gene expression with human pregnancy outcomes including prenatal depression and negative infant mood (Creeth, 2018)\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Matthew Higgs","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Higgs","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University","addressCountry":"United Kingdom","id_and_name":"[\"Cardiff University\", \"360G-Wellcome-ORG:Cardiff-University\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Cardiff-University","name":"Cardiff University"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A system level approach to identify and validate imprinted genes involved in parental care The neural pathways responsible for parenting behaviours have been well characterised, and the Preoptic Area (POA) is considered a parenting 'hub' in many mammals including mice and rats. Imprinted genes (IG) are a set of ~200 genes that have been clearly associated with the quality of parenting behaviour. Our current work plans to unite these two by investigating the role of IG expression in the neural circuitry for parenting.\n\nUsing pre-existing data, we will look for enrichment of IGs in the POA and in specific POA neurons associated with parenting behaviour. We will be guided by this analysis to select an IG to characterise the parenting deficit created from a gene knock-out model. Furthermore, we will utilise RNA-Scope to examine specific gene-expression within the POA of the mouse model looking for the effect that the knock-out model will have on the parenting neurons.\n\nThe quality of parenting behaviour is key to the optimal development of offspring in animals, hence the impact of this work will be to further elucidate one of the genetic underpinnings of parenting behaviour, especially valuable since previous work has associated imprinted gene expression with human pregnancy outcomes including prenatal depression and negative infant mood (Creeth, 2018)\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Disease Models, Animal","Female","Genomic Imprinting","Male","Mice","Neurons","Parenting","Pregnancy","Preoptic Area","RNA, Long Noncoding"]}
{"id":"360G-Wellcome-220089_Z_20_Z","title":"Investigating the effect of colon cancer mutations on human intestinal stem cell dynamics","Region":"East of England","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220089/Z/20/Z","description":"Intestinal stem cells are responsible for the regeneration and maintenance of the intestinal tissue. Due to the high proliferative potential of intestinal stem cells, mutations that disrupt the homeostatic regulatory mechanisms can result in cancer formation. Mouse intestinal stem cell dynamics have been widely studied but our knowledge of human intestinal stem cell dynamics has been lagging behind. Now there is evidence to suggest that mutations in genes driving cancer formation can alter stem cell dynamics to achieve a high mutational burden in the normal human colon but so far only a few cancer-associated genes have been studied. As part of my PhD project I aim to develop an integrative approach by using a three-model system to assess how cancer-driver mutations are affecting human intestinal stem cell dynamics. I will use tissue sections of normal human colon, human intestinal organoids and a conditional knock-out mouse model to address this question. Multiple established methods will be employed including sequencing, immunohistochemistry, genome engineering and lineage tracing. This research will help me explore how stem cells are affected in a diseased context to ultimately understand more about the process of colon cancer initiation.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Maria-Nefeli Skoufou-Papoutsaki","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Skoufou-Papoutsaki","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the effect of colon cancer mutations on human intestinal stem cell dynamics Intestinal stem cells are responsible for the regeneration and maintenance of the intestinal tissue. Due to the high proliferative potential of intestinal stem cells, mutations that disrupt the homeostatic regulatory mechanisms can result in cancer formation. Mouse intestinal stem cell dynamics have been widely studied but our knowledge of human intestinal stem cell dynamics has been lagging behind. Now there is evidence to suggest that mutations in genes driving cancer formation can alter stem cell dynamics to achieve a high mutational burden in the normal human colon but so far only a few cancer-associated genes have been studied. As part of my PhD project I aim to develop an integrative approach by using a three-model system to assess how cancer-driver mutations are affecting human intestinal stem cell dynamics. I will use tissue sections of normal human colon, human intestinal organoids and a conditional knock-out mouse model to address this question. Multiple established methods will be employed including sequencing, immunohistochemistry, genome engineering and lineage tracing. This research will help me explore how stem cells are affected in a diseased context to ultimately understand more about the process of colon cancer initiation.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Colonic Neoplasms","Humans","Mice","Mutation","Organoids","Stem Cells"]}
{"id":"360G-Wellcome-220088_Z_20_Z","title":"Elucidating the functional heterogeneity and fate dynamics of alveolar stem cells in lung regeneration and early oncogenesis","Region":"East of England","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220088/Z/20/Z","description":"Lung cancer, of which adenocarcinoma is the most common subtype, is the leading cause of cancer-related mortality worldwide. Activating mutations in oncogenic KRAS account for approximately 25% of all lung adenocarcinoma cases, and for these tumours in particular, prognosis is poor and effective chemotherapies are severely lacking. Alveolar type II (AT2) cells act as the major stem cell population within the alveoli and are known to be key cells of origin of lung adenocarcinoma, but the molecular mechanisms and early cellular transformation events that drive their tumourigenesis remain elusive. Using a novel, oncogene-associated multi-colour reporter mouse model, I aim to label and track AT2 cells harbouring Kras mutations and compare their behaviour to wildtype AT2 cells. By analysing individual AT2 cell-derived clones over time, I intend to shed physiological insight into the initial steps of tumourigenesis and determine how dynamic cell-to-cell interactions present between mutant AT2 cells and their associated neighbours facilitate tumour propagation. Collectively, this work will help to devise early detection strategies and identify novel therapeutic targets for the treatment of lung adenocarcinoma, whilst simultaneously highlighting the mechanisms by which lung stem cell function can be hijacked during early disease.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Frances England","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"England","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Elucidating the functional heterogeneity and fate dynamics of alveolar stem cells in lung regeneration and early oncogenesis Lung cancer, of which adenocarcinoma is the most common subtype, is the leading cause of cancer-related mortality worldwide. Activating mutations in oncogenic KRAS account for approximately 25% of all lung adenocarcinoma cases, and for these tumours in particular, prognosis is poor and effective chemotherapies are severely lacking. Alveolar type II (AT2) cells act as the major stem cell population within the alveoli and are known to be key cells of origin of lung adenocarcinoma, but the molecular mechanisms and early cellular transformation events that drive their tumourigenesis remain elusive. Using a novel, oncogene-associated multi-colour reporter mouse model, I aim to label and track AT2 cells harbouring Kras mutations and compare their behaviour to wildtype AT2 cells. By analysing individual AT2 cell-derived clones over time, I intend to shed physiological insight into the initial steps of tumourigenesis and determine how dynamic cell-to-cell interactions present between mutant AT2 cells and their associated neighbours facilitate tumour propagation. Collectively, this work will help to devise early detection strategies and identify novel therapeutic targets for the treatment of lung adenocarcinoma, whilst simultaneously highlighting the mechanisms by which lung stem cell function can be hijacked during early disease.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adenocarcinoma","Adenocarcinoma of Lung","Alveolar Epithelial Cells","Animals","Carcinogenesis","Cell Transformation, Neoplastic","Humans","Lung Neoplasms","Mice","Mutation","Neoplastic Stem Cells","Proto-Oncogene Proteins p21(ras)"]}
{"id":"360G-Wellcome-220086_Z_20_Z","title":"Comparative Analysis of NFE2L-family Stress Responses in Cancer","Region":"North West","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220086/Z/20/Z","description":"The human NFE2L gene family encodes three proteins that drive expression of a range of genes that protect cells from different forms of stress. Under normal circumstances, these proteins are beneficial and protect cells from potential damage. Unfortunately, high levels of NFE2L activity can also be detrimental. In some cancers, enhanced activity of NFE2L family members allows cells to survive both chemo and radio therapy, leading to poor rates of survival. Therefore, we are keen to know if it is possible to target NFE2L proteins to make tumours more sensitive to treatment. Before we can do this, we need to know how NFE2L proteins work and how they may be controlled in health and disease. Therefore, we plan to show how human NFE2L proteins interact with other proteins, creating \u2018molecular maps\u2019 which will shed light on why NFE2L activity is increased in cancer, and how this activity may be inhibited. In addition, we will create genetically modified cell lines which we will use to see if blocking NFE2L proteins can make chemotherapy more effective in different cancer cell lines.\n \n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Ms Harriet Lahiff","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Lahiff","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool","addressCountry":"United Kingdom","id_and_name":"[\"University of Liverpool\", \"360G-Wellcome-ORG:University-of-Liverpool\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Comparative Analysis of NFE2L-family Stress Responses in Cancer The human NFE2L gene family encodes three proteins that drive expression of a range of genes that protect cells from different forms of stress. Under normal circumstances, these proteins are beneficial and protect cells from potential damage. Unfortunately, high levels of NFE2L activity can also be detrimental. In some cancers, enhanced activity of NFE2L family members allows cells to survive both chemo and radio therapy, leading to poor rates of survival. Therefore, we are keen to know if it is possible to target NFE2L proteins to make tumours more sensitive to treatment. Before we can do this, we need to know how NFE2L proteins work and how they may be controlled in health and disease. Therefore, we plan to show how human NFE2L proteins interact with other proteins, creating \u2018molecular maps\u2019 which will shed light on why NFE2L activity is increased in cancer, and how this activity may be inhibited. In addition, we will create genetically modified cell lines which we will use to see if blocking NFE2L proteins can make chemotherapy more effective in different cancer cell lines.\n \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cell Line, Tumor","Humans","Neoplasms"]}
{"id":"360G-Wellcome-220085_Z_20_Z","title":"Investigating how Platelets and Inflammation Impact Cancer Cell Metastasis and Extravasation - Live Imaging in Zebrafish Larvae","Region":"South West","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220085/Z/20/Z","description":"Metastasis is the process by which cancer cells migrate from a primary to a secondary tumour site, with 95% of cancer deaths attributed to this metastatic spread.  Cancer cells interact with a variety of host cells at the primary tumour location and as they invade other tissues, these interactions increase their survival and metastatic potential.\n\nPlatelets are the smallest circulating cell type and are often the first cells to escape blood vessels into a growing tumour. As a cancer cell enters the vasculature it becomes further exposed to circulating platelets. Evidence suggests that platelet:cancer cell interactions mediate interactions with innate immune cells, which are beneficial for the survival and metastasis of cancer cells.\n\nMy PhD project will use translucent zebrafish larvae to live image how platelets (thrombocytes in fish) might be pivotal at several stages of cancer metastasis. Specifically:\n\n\n Do platelets mediate cancer cell:macrophage/neutrophil interactions at the site of primary tumours and impact tumour angiogenesis?\n How might microclots enable innate immune cells to interact with circulating cancer cells to enable their extravasation to a secondary cancer site?\n What role do other immune cells, including eosinophils and adaptive immune cells, play in each of these plateletmediated steps?\n\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Juma Ward","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Ward","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating how Platelets and Inflammation Impact Cancer Cell Metastasis and Extravasation - Live Imaging in Zebrafish Larvae Metastasis is the process by which cancer cells migrate from a primary to a secondary tumour site, with 95% of cancer deaths attributed to this metastatic spread.  Cancer cells interact with a variety of host cells at the primary tumour location and as they invade other tissues, these interactions increase their survival and metastatic potential.\n\nPlatelets are the smallest circulating cell type and are often the first cells to escape blood vessels into a growing tumour. As a cancer cell enters the vasculature it becomes further exposed to circulating platelets. Evidence suggests that platelet:cancer cell interactions mediate interactions with innate immune cells, which are beneficial for the survival and metastasis of cancer cells.\n\nMy PhD project will use translucent zebrafish larvae to live image how platelets (thrombocytes in fish) might be pivotal at several stages of cancer metastasis. Specifically:\n\n\n Do platelets mediate cancer cell:macrophage/neutrophil interactions at the site of primary tumours and impact tumour angiogenesis?\n How might microclots enable innate immune cells to interact with circulating cancer cells to enable their extravasation to a secondary cancer site?\n What role do other immune cells, including eosinophils and adaptive immune cells, play in each of these plateletmediated steps?\n\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Animals, Genetically Modified","Blood Platelets","Humans","Immunity, Innate","Macrophages","Neoplasm Metastasis","Neoplasms","Zebrafish"]}
{"id":"360G-Wellcome-220084_Z_20_Z","title":"How are nutrient signalling and membrane trafficking coupled at the lysosome by the Folliculin-FNIP complex?","Region":"South West","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220084/Z/20/Z","description":"BACKGROUND\n\nFolliculin (FLCN) is a tumour-suppressor protein implicated in control of lysosome-associated nutrient signalling pathways. Loss of FLCN function causes Birt-Hogg-Dub\u00e9 (BHD) syndrome, a rare genetic disorder associated with an increased risk of kidney cancer. In complex with its interaction partners FNIP1/2, a role is emerging for FLCN as a co-ordinator of small GTPases at the lysosome. FLCN-FNIP can act as a GTPase activating protein for RagC to control lysosomal mTORC1 activity, and regulates lysosome dynamics by acting through several Rab GTPases and their effector protein RILP. Thus, the FLCN-FNIP complex sits at a pivotal position where it couples nutrient signalling and trafficking/transport events at the lysosome.\n\nAPPROACH\n\nA clear mechanistic understanding of how these complex activities are carried out is currently lacking. I will integrate structural, biochemical and cellular approaches to study the intact human FLCN-FNIP complex, with the aim of describing its activities in molecular detail. I will particularly focus on its potential role as a co-ordinator of GTPases in relation to nutrient signalling and intracellular transport of the lysosome.\n\nIMPACT\n\nBy tying together two branches of lysosome biology we will uncover the normal function of the FLCN-FNIP complex and establish the underlying pathology of BHD syndrome.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Katherine Surridge","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Surridge","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"How are nutrient signalling and membrane trafficking coupled at the lysosome by the Folliculin-FNIP complex? BACKGROUND\n\nFolliculin (FLCN) is a tumour-suppressor protein implicated in control of lysosome-associated nutrient signalling pathways. Loss of FLCN function causes Birt-Hogg-Dub\u00e9 (BHD) syndrome, a rare genetic disorder associated with an increased risk of kidney cancer. In complex with its interaction partners FNIP1/2, a role is emerging for FLCN as a co-ordinator of small GTPases at the lysosome. FLCN-FNIP can act as a GTPase activating protein for RagC to control lysosomal mTORC1 activity, and regulates lysosome dynamics by acting through several Rab GTPases and their effector protein RILP. Thus, the FLCN-FNIP complex sits at a pivotal position where it couples nutrient signalling and trafficking/transport events at the lysosome.\n\nAPPROACH\n\nA clear mechanistic understanding of how these complex activities are carried out is currently lacking. I will integrate structural, biochemical and cellular approaches to study the intact human FLCN-FNIP complex, with the aim of describing its activities in molecular detail. I will particularly focus on its potential role as a co-ordinator of GTPases in relation to nutrient signalling and intracellular transport of the lysosome.\n\nIMPACT\n\nBy tying together two branches of lysosome biology we will uncover the normal function of the FLCN-FNIP complex and establish the underlying pathology of BHD syndrome.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Lysosomes","Mechanistic Target of Rapamycin Complex 1","Monomeric GTP-Binding Proteins","Multiprotein Complexes","Signal Transduction","Tumor Suppressor Proteins","rab GTP-Binding Proteins"]}
{"id":"360G-Wellcome-220083_Z_20_Z","title":"Investigating macrophage behaviour and interactions in normal and pathophysiological erythropoiesis ","Region":"South West","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220083/Z/20/Z","description":"Macrophages are known to be intrinsically involved in nurturing erythroid cells within the bone marrow. They regulate and enhance erythropoiesis, the production of Red Blood Cells (RBCs), through maintenance of the haematopoietic stem cell (HSC) niche and erythroblastic islands (EBIs). Understanding the cellular interactions involved in EBI formation and maintenance is crucial for investigating disease and improving in vitro erythropoiesis. Polycythemia Vera (PV) is a disease involving increased differentiation of progenitor cells towards the RBC lineage, and subsequent overproduction of RBCs. The genetic component, caused by a single acquired mutation in the tyrosine kinase JAK2, is well established. However, current treatments experience issues with resistance and intolerance, and the involvement of other cell types remains largely under-studied. Importantly, recent studies have implicated a role for macrophages in PV. I aim to further elucidate the molecular basis and cellular interactions that underly the role macrophages play in normal erythropoiesis and PV. CD14+ macrophages from PV and normal patients will be isolated to investigate phenotypic changes, including secreted cytokine profile, proteomic profile and mutations in JAK2. Image analysis will be conducted to probe whether there are changes in interactions between macrophages, progenitors, and erythroblasts within the normal and disease contexts. \n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Tiah Oates","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Oates","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating macrophage behaviour and interactions in normal and pathophysiological erythropoiesis  Macrophages are known to be intrinsically involved in nurturing erythroid cells within the bone marrow. They regulate and enhance erythropoiesis, the production of Red Blood Cells (RBCs), through maintenance of the haematopoietic stem cell (HSC) niche and erythroblastic islands (EBIs). Understanding the cellular interactions involved in EBI formation and maintenance is crucial for investigating disease and improving in vitro erythropoiesis. Polycythemia Vera (PV) is a disease involving increased differentiation of progenitor cells towards the RBC lineage, and subsequent overproduction of RBCs. The genetic component, caused by a single acquired mutation in the tyrosine kinase JAK2, is well established. However, current treatments experience issues with resistance and intolerance, and the involvement of other cell types remains largely under-studied. Importantly, recent studies have implicated a role for macrophages in PV. I aim to further elucidate the molecular basis and cellular interactions that underly the role macrophages play in normal erythropoiesis and PV. CD14+ macrophages from PV and normal patients will be isolated to investigate phenotypic changes, including secreted cytokine profile, proteomic profile and mutations in JAK2. Image analysis will be conducted to probe whether there are changes in interactions between macrophages, progenitors, and erythroblasts within the normal and disease contexts. \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cell Differentiation","Erythrocytes","Erythroid Cells","Erythropoiesis","Hematopoietic Stem Cells","Humans","Janus Kinase 2","Macrophages","Mutation","Polycythemia Vera"]}
{"id":"360G-Wellcome-220082_Z_20_Z","title":"Understanding actin-dependent chromosome cohesion in mammalian eggs","Region":"South West","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220082/Z/20/Z","description":"Every human life starts when an egg is fertilised by a sperm. For poorly understood reasons, eggs frequently contain an incorrect number of chromosomes. This chromosomal abnormality is a leading cause of embryo deaths in humans \u2013 it accounts for nearly 35% of miscarriages. Chromosomal abnormality in embryos also leads to genetic disorders such as Down\u2019s syndrome, which affects about 1 in 1,000 live births worldwide. My PhD project is aimed at understanding which cellular processes protect eggs from having an incorrect number of chromosomes before fertilisation. In this regard, I will investigate a recently discovered and unexpected function of the actin cytoskeleton in preventing chromosomal abnormality in eggs. In the future, knowledge obtained from my research project could be exploited to improve the outcomes of fertility treatments as well as prevent pregnancy loss.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Samuel Dunkley","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Dunkley","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Understanding actin-dependent chromosome cohesion in mammalian eggs Every human life starts when an egg is fertilised by a sperm. For poorly understood reasons, eggs frequently contain an incorrect number of chromosomes. This chromosomal abnormality is a leading cause of embryo deaths in humans \u2013 it accounts for nearly 35% of miscarriages. Chromosomal abnormality in embryos also leads to genetic disorders such as Down\u2019s syndrome, which affects about 1 in 1,000 live births worldwide. My PhD project is aimed at understanding which cellular processes protect eggs from having an incorrect number of chromosomes before fertilisation. In this regard, I will investigate a recently discovered and unexpected function of the actin cytoskeleton in preventing chromosomal abnormality in eggs. In the future, knowledge obtained from my research project could be exploited to improve the outcomes of fertility treatments as well as prevent pregnancy loss.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Female","Fertility","Humans","Male"]}
{"id":"360G-Wellcome-220081_Z_20_Z","title":"Mycobacterial drug target deconvolution using Genetic, Phenotypic and Proteomic approaches","Region":"West Midlands","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220081/Z/20/Z","description":"Mycobacterium tuberculosis is the causative agent of tuberculosis (TB) and leads to 1.8 million deaths per year. Resistance to the currently used anti-TB drugs is growing, which will increase death rates in the future if unchecked, hence there is a high demand for new drugs.\nMy project aims to identify how novel anti-TB molecules work, to increase our understanding of their targets and how they can be improved to increase their activity and selectivity. The protein targets will be produced and then purified, allowing the drug-protein interactions to be studied. Specific interactions will be identified, providing evidence for alterations to these drugs to increase their potency. Another section will be the identification of new drug targets, which could be taken forward for targeting by studying the protein-protein interactions occurring in the outer membrane and wall of M. tuberculosis.\nThe main output of my work would be increased knowledge of protein-molecule interactions of novel anti-TB drugs and will allow them to be altered to increase their selectivity and activity. This would hopefully lead to these novel drugs being taken forward as potential drugs for the treatment of TB, expanding treatment options against multi-drug resistant M. tuberculosis strains.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Alexander Kingdon","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Kingdon","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Birmingham\", \"360G-Wellcome-ORG:University-of-Birmingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mycobacterial drug target deconvolution using Genetic, Phenotypic and Proteomic approaches Mycobacterium tuberculosis is the causative agent of tuberculosis (TB) and leads to 1.8 million deaths per year. Resistance to the currently used anti-TB drugs is growing, which will increase death rates in the future if unchecked, hence there is a high demand for new drugs.\nMy project aims to identify how novel anti-TB molecules work, to increase our understanding of their targets and how they can be improved to increase their activity and selectivity. The protein targets will be produced and then purified, allowing the drug-protein interactions to be studied. Specific interactions will be identified, providing evidence for alterations to these drugs to increase their potency. Another section will be the identification of new drug targets, which could be taken forward for targeting by studying the protein-protein interactions occurring in the outer membrane and wall of M. tuberculosis.\nThe main output of my work would be increased knowledge of protein-molecule interactions of novel anti-TB drugs and will allow them to be altered to increase their selectivity and activity. This would hopefully lead to these novel drugs being taken forward as potential drugs for the treatment of TB, expanding treatment options against multi-drug resistant M. tuberculosis strains.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Antitubercular Agents","Bacterial Proteins","Drug Discovery","Humans","Mycobacterium tuberculosis"]}
{"id":"360G-Wellcome-220080_Z_20_Z","title":"Investigating the gut colonisation of Intensive Care Unit Patients","Region":"West Midlands","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220080/Z/20/Z","description":"The spread of antimicrobial resistance (AMR) is a global problem. AMR is a particularly important issue in hospital intensive care settings. Treatment regimes (e.g. broad-spectrum antibiotics) and interventions (e.g. ventilators, feeding tubes) are known to disrupt gut microbiota in adult patients. Opportunistic pathogens (e.g. Escherichia coli) and increased exposure to antimicrobial therapy are more common in critically ill patients. Colonisation with drug-resistant organisms increases risk of developing drug-resistant infections. Understanding the dynamics of colonisation should ultimately help reduce incidence of multi-drug resistant (MDR) infections in high-risk patients. Research is essential to understand how AMR genes move and colonise causing drug resistant infections.\n\nI will use bioinformatics including metagenomics to:\n\n\n investigate E.coli diversity and colonisation dynamics in the the intensive care unit (ITU) environment\n Track prevalent E.coli sequence types (STs) including transmission between different areas of the ITU\n Study AMR genes in ITU patients including effects of antibiotic prescribing on the gut microbiota.\n\n\n\nThis information will show local ITU consultants and microbiologists:\n\n\n which E. coli STs  are prevalent in ITU and which are most commonly transmitted\n effects of specific antimicrobial prescribing \n\n\nso steps can be taken to reduce risks of transmission of colonising organisms and AMR in this high-risk setting.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Ann Snaith","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Snaith","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Birmingham\", \"360G-Wellcome-ORG:University-of-Birmingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the gut colonisation of Intensive Care Unit Patients The spread of antimicrobial resistance (AMR) is a global problem. AMR is a particularly important issue in hospital intensive care settings. Treatment regimes (e.g. broad-spectrum antibiotics) and interventions (e.g. ventilators, feeding tubes) are known to disrupt gut microbiota in adult patients. Opportunistic pathogens (e.g. Escherichia coli) and increased exposure to antimicrobial therapy are more common in critically ill patients. Colonisation with drug-resistant organisms increases risk of developing drug-resistant infections. Understanding the dynamics of colonisation should ultimately help reduce incidence of multi-drug resistant (MDR) infections in high-risk patients. Research is essential to understand how AMR genes move and colonise causing drug resistant infections.\n\nI will use bioinformatics including metagenomics to:\n\n\n investigate E.coli diversity and colonisation dynamics in the the intensive care unit (ITU) environment\n Track prevalent E.coli sequence types (STs) including transmission between different areas of the ITU\n Study AMR genes in ITU patients including effects of antibiotic prescribing on the gut microbiota.\n\n\n\nThis information will show local ITU consultants and microbiologists:\n\n\n which E. coli STs  are prevalent in ITU and which are most commonly transmitted\n effects of specific antimicrobial prescribing \n\n\nso steps can be taken to reduce risks of transmission of colonising organisms and AMR in this high-risk setting.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anti-Bacterial Agents","Drug Resistance, Bacterial","Escherichia coli","Gastrointestinal Microbiome","Humans","Intensive Care Units"]}
{"id":"360G-Wellcome-220079_Z_20_Z","title":"Investigating the impact of the local inflammatory environment on CD4+ T cell metabolism and function","Region":"West Midlands","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220079/Z/20/Z","description":"In inflammatory diseases such as rheumatoid arthritis (RA), T cells (a type of white blood cell) take on multiple different forms. These forms, known as subsets, can contribute to disease or help to resolve it. To develop new drugs for inflammatory diseases, we need to understand how these subsets of T cells are made and maintained. \"Metabolism\" describes the chemical processes cells use to break down nutrients. It is the basis of all changes in cells, even determining what subset they become. Importantly, metabolism can be targeted with drugs. Whether T cell metabolism changes in inflammatory disease is not yet fully understood. We will investigate this, try to understand the processes involved and test if changing the metabolism of inflammatory T cells influences their subset. To do this, we will compare the metabolism of T cells from RA patients with those from healthy people. We will also investigate the role of cytokines \u2013signals released by immune cells to communicate with each other. These are increased in RA and alter metabolism in other cell types, but their effects on T cells is not known. Together, this research will help us to better understand RA and aid the development of new treatments.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Emma Bishop","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Bishop","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham","addressCountry":"United Kingdom","id_and_name":"[\"University of Birmingham\", \"360G-Wellcome-ORG:University-of-Birmingham\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Birmingham","name":"University of Birmingham"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the impact of the local inflammatory environment on CD4+ T cell metabolism and function In inflammatory diseases such as rheumatoid arthritis (RA), T cells (a type of white blood cell) take on multiple different forms. These forms, known as subsets, can contribute to disease or help to resolve it. To develop new drugs for inflammatory diseases, we need to understand how these subsets of T cells are made and maintained. \"Metabolism\" describes the chemical processes cells use to break down nutrients. It is the basis of all changes in cells, even determining what subset they become. Importantly, metabolism can be targeted with drugs. Whether T cell metabolism changes in inflammatory disease is not yet fully understood. We will investigate this, try to understand the processes involved and test if changing the metabolism of inflammatory T cells influences their subset. To do this, we will compare the metabolism of T cells from RA patients with those from healthy people. We will also investigate the role of cytokines \u2013signals released by immune cells to communicate with each other. These are increased in RA and alter metabolism in other cell types, but their effects on T cells is not known. Together, this research will help us to better understand RA and aid the development of new treatments.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Arthritis, Rheumatoid","CD4-Positive T-Lymphocytes","Cytokines","Humans","Inflammation","T-Lymphocyte Subsets"]}
{"id":"360G-Wellcome-220078_Z_20_Z","title":"Probabilistic machine learning for medical applications","Region":"East of England","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220078/Z/20/Z","description":"In recent years, cheaper computing power and higher data availability have prompted a machine learning (ML) explosion. Medicine, however, remains a challenging field of application for ML due to low sample size and overconfidence of traditional models in their predictions. The aim of my project is to tackle these limitations by taking a radically different ML approach, probabilistic ML, that emphasizes uncertainty quantification. I will focus on two systemic diseases that are particularly amenable to the probabilistic ML framework: cancer and type 1 diabetes. Regarding the former, pharma companies are unable to meet the demand of novel anticancer compounds, burdened by the high cost of drug development and the low success rate. I will use probabilistic models such as Gaussian processes (GPs) to predict medically-relevant properties of cancer drug candidates such as the IC50. Then, I will refine the candidates\u2019 structure using Bayesian optimization. On the other hand, type 1 diabetes control is based on a delayed feedback loop between insulin injected and future glucose levels. I will use GPs to better estimate future blood glucose levels and to automatically detect situations that are dangerous to patients such as hypoglycemias, diabetic ketoacedosis and insertion site failure of insulin pumps.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Miguel Garcia Ortegon","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Garcia Ortegon","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Probabilistic machine learning for medical applications In recent years, cheaper computing power and higher data availability have prompted a machine learning (ML) explosion. Medicine, however, remains a challenging field of application for ML due to low sample size and overconfidence of traditional models in their predictions. The aim of my project is to tackle these limitations by taking a radically different ML approach, probabilistic ML, that emphasizes uncertainty quantification. I will focus on two systemic diseases that are particularly amenable to the probabilistic ML framework: cancer and type 1 diabetes. Regarding the former, pharma companies are unable to meet the demand of novel anticancer compounds, burdened by the high cost of drug development and the low success rate. I will use probabilistic models such as Gaussian processes (GPs) to predict medically-relevant properties of cancer drug candidates such as the IC50. Then, I will refine the candidates\u2019 structure using Bayesian optimization. On the other hand, type 1 diabetes control is based on a delayed feedback loop between insulin injected and future glucose levels. I will use GPs to better estimate future blood glucose levels and to automatically detect situations that are dangerous to patients such as hypoglycemias, diabetic ketoacedosis and insertion site failure of insulin pumps.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Bayes Theorem","Diabetes Mellitus, Type 1","Humans","Hypoglycemic Agents","Insulin","Machine Learning","Neoplasms"]}
{"id":"360G-Wellcome-220077_Z_20_Z","title":"Regulation of the Translocase of Outer mitochondrial Membrane (TOM) complex by reversible ubiquitylation.","Region":"North West","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220077/Z/20/Z","description":"Mitochondria are tiny power plants that produce energy for cells in our body. To work properly, mitochondria need to continuously import new parts, mostly proteins, through specialised gates and channels, we call TOM complexes. When mitochondria are damaged and/or proteins get stuck in the gate, TOM complexes are tagged with a protein named ubiquitin. This tag is recognised by the waste disposal machinery in the cell. Diseased mitochondria are wrapped up and safely destroyed through a process we call mitophagy. In people with Parkinson\u2019s disease, mitophagy does not work properly, leading to problems in the brain. We are interested in proteins that remove ubiquitin and can act as a brake on mitophagy. In particular, one of these, USP30, removes ubiquitin from TOM complexes. Interfering with USP30 allows cells to clear away damaged mitochondria more efficiently.\n\n\nOn the mitochondria, a very small amount of USP30 has to survey a large number of TOMs. We want to understand more about the relationship between ubiquitin, USP30 and TOM complexes. In particular, we would like to know what distinguishes those TOM complexes that USP30 works on and how the addition and removal of ubiquitin from these gates affects their function.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Liam Pollock","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Pollock","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool","addressCountry":"United Kingdom","id_and_name":"[\"University of Liverpool\", \"360G-Wellcome-ORG:University-of-Liverpool\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Regulation of the Translocase of Outer mitochondrial Membrane (TOM) complex by reversible ubiquitylation. Mitochondria are tiny power plants that produce energy for cells in our body. To work properly, mitochondria need to continuously import new parts, mostly proteins, through specialised gates and channels, we call TOM complexes. When mitochondria are damaged and/or proteins get stuck in the gate, TOM complexes are tagged with a protein named ubiquitin. This tag is recognised by the waste disposal machinery in the cell. Diseased mitochondria are wrapped up and safely destroyed through a process we call mitophagy. In people with Parkinson\u2019s disease, mitophagy does not work properly, leading to problems in the brain. We are interested in proteins that remove ubiquitin and can act as a brake on mitophagy. In particular, one of these, USP30, removes ubiquitin from TOM complexes. Interfering with USP30 allows cells to clear away damaged mitochondria more efficiently.\n\n\nOn the mitochondria, a very small amount of USP30 has to survey a large number of TOMs. We want to understand more about the relationship between ubiquitin, USP30 and TOM complexes. In particular, we would like to know what distinguishes those TOM complexes that USP30 works on and how the addition and removal of ubiquitin from these gates affects their function.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Mitochondria","Mitochondrial Membranes","Mitochondrial Proteins","Mitophagy","Ubiquitin"]}
{"id":"360G-Wellcome-220076_Z_20_Z","title":"Interpreting the microtubule code","Region":"North West","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220076/Z/20/Z","description":"All our cells contain mesh-like networks that are formed from tube-shaped protein structures called microtubules. These microtubules help to maintain cell shape, allow cell movement and facilitate cell division. Additionally, they also act as railway tracks in which motors can travel down to transport their cargo to specific areas of the cell. Proteins can bind to microtubules to control their function and determine what is transported along them. Many of these proteins have been identified however the list is still not complete. Identifying and exploring further this collection of proteins using a technique called mass spectrometry may help us discover new functions for microtubule networks. To create even more specific functions, individual railway tracks can be decorated with a variety of different removable groups which distinguishes them from each other. This is known as the tubulin code and allows individual tracks to be recognised by different proteins and alter whether they bind or not. As this tubulin code is not well understood, we will modulate these modifications to identify and explore proteins that bind to specifically decorated railway tracks. This research will help us understand the importance of these removable decorations and how they control the functions of microtubules. \n \n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Hannah Glover","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Glover","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool","addressCountry":"United Kingdom","id_and_name":"[\"University of Liverpool\", \"360G-Wellcome-ORG:University-of-Liverpool\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Interpreting the microtubule code All our cells contain mesh-like networks that are formed from tube-shaped protein structures called microtubules. These microtubules help to maintain cell shape, allow cell movement and facilitate cell division. Additionally, they also act as railway tracks in which motors can travel down to transport their cargo to specific areas of the cell. Proteins can bind to microtubules to control their function and determine what is transported along them. Many of these proteins have been identified however the list is still not complete. Identifying and exploring further this collection of proteins using a technique called mass spectrometry may help us discover new functions for microtubule networks. To create even more specific functions, individual railway tracks can be decorated with a variety of different removable groups which distinguishes them from each other. This is known as the tubulin code and allows individual tracks to be recognised by different proteins and alter whether they bind or not. As this tubulin code is not well understood, we will modulate these modifications to identify and explore proteins that bind to specifically decorated railway tracks. This research will help us understand the importance of these removable decorations and how they control the functions of microtubules. \n \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Mass Spectrometry","Microtubules","Tubulin"]}
{"id":"360G-Wellcome-220075_Z_20_Z","title":"Investigating the role of mitophagy regulators in neuronal cell and Drosophila models. ","Region":"North West","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220075/Z/20/Z","description":"Mitochondria are the powerhouses of the cell and are crucial for neuronal function and survival. Disruption of mechanisms governing mitochondrial integrity lead to development and progression of different neurodegenerative disorders (NDs) such as Parkinson\u2019s Disease (PD) and  Alzheimer\u2019s Disease (AD). In fact, the accumulation of defective mitochondria in neurons is a hallmark of NDs. Mutations in genes linked to PD lead to a failure in pathways  designed to rid the cell of low-quality mitochondria. Restoring this pathway offers an attractive therapeutic option.\n\nWhile this pathway is well characterised in cell models, less is known about this process in living organisms (in vivo). Our laboratory has engineered fruit flies (Drosophila) such that the mitochondria undergoing degradation can be directly visualised. I will develop this model system to characterise the influence of various genetic or pharmacological changes upon the mitochondrial degradation process in flies. I aim to shed light on the interplay between various genes linked to this pathway and discover new factors relevant to the process.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Francesco Giovanni Barone","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Barone","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool","addressCountry":"United Kingdom","id_and_name":"[\"University of Liverpool\", \"360G-Wellcome-ORG:University-of-Liverpool\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the role of mitophagy regulators in neuronal cell and Drosophila models.  Mitochondria are the powerhouses of the cell and are crucial for neuronal function and survival. Disruption of mechanisms governing mitochondrial integrity lead to development and progression of different neurodegenerative disorders (NDs) such as Parkinson\u2019s Disease (PD) and  Alzheimer\u2019s Disease (AD). In fact, the accumulation of defective mitochondria in neurons is a hallmark of NDs. Mutations in genes linked to PD lead to a failure in pathways  designed to rid the cell of low-quality mitochondria. Restoring this pathway offers an attractive therapeutic option.\n\nWhile this pathway is well characterised in cell models, less is known about this process in living organisms (in vivo). Our laboratory has engineered fruit flies (Drosophila) such that the mitochondria undergoing degradation can be directly visualised. I will develop this model system to characterise the influence of various genetic or pharmacological changes upon the mitochondrial degradation process in flies. I aim to shed light on the interplay between various genes linked to this pathway and discover new factors relevant to the process.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Animals, Genetically Modified","Disease Models, Animal","Drosophila","Drosophila Proteins","Drosophila melanogaster","Mitochondria","Mitophagy","Neurons","Parkinson Disease"]}
{"id":"360G-Wellcome-220074_Z_20_Z","title":"Investigating how ANCL-causing mutations lead to neurodegeneration ","Region":"North West","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220074/Z/20/Z","description":"Human neurodegenerative diseases impose a great and increasing social, economic and health burden on society, due to our rapidly expanding ageing population. However, these debilitating and fatal disorders lack effective therapies as the underlying mechanisms remain unclear. A rare neurodegenerative disorder, termed adult onset neuronal ceroid lipofuscinosis (ANCL) is a devastating neurodegenerative condition, rendering sufferers with an average life expectancy of 45 years.  This project will use a combined approach, utilising both roundworms and mice to elucidate the mechanisms behind the disease. The worm and mice genetic makeup will be manipulated to mimic the effects of the ANCL-causing mutations, to generate working models of the disease. Additionally, the cells of the brain, neuronal cells, will be extracted from mice to analyse the impact of the mutations on neuronal survival, connectivity and protein localisation. Furthermore, both the worm models and mice neuronal cells will be used to identify new protein interactions, and how these are impacted by ANCL mutations. Ultimately, this project aims to expand our knowledge on the mechanisms behind ANCL disease processes, to aid in the identification of potential therapies for ANCL, and potentially other neurodegenerative diseases.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Eleanor Barker","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Barker","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool","addressCountry":"United Kingdom","id_and_name":"[\"University of Liverpool\", \"360G-Wellcome-ORG:University-of-Liverpool\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Liverpool","name":"University of Liverpool"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating how ANCL-causing mutations lead to neurodegeneration  Human neurodegenerative diseases impose a great and increasing social, economic and health burden on society, due to our rapidly expanding ageing population. However, these debilitating and fatal disorders lack effective therapies as the underlying mechanisms remain unclear. A rare neurodegenerative disorder, termed adult onset neuronal ceroid lipofuscinosis (ANCL) is a devastating neurodegenerative condition, rendering sufferers with an average life expectancy of 45 years.  This project will use a combined approach, utilising both roundworms and mice to elucidate the mechanisms behind the disease. The worm and mice genetic makeup will be manipulated to mimic the effects of the ANCL-causing mutations, to generate working models of the disease. Additionally, the cells of the brain, neuronal cells, will be extracted from mice to analyse the impact of the mutations on neuronal survival, connectivity and protein localisation. Furthermore, both the worm models and mice neuronal cells will be used to identify new protein interactions, and how these are impacted by ANCL mutations. Ultimately, this project aims to expand our knowledge on the mechanisms behind ANCL disease processes, to aid in the identification of potential therapies for ANCL, and potentially other neurodegenerative diseases.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Brain","Disease Models, Animal","Humans","Mice","Mice, Transgenic","Mutation","Neurodegenerative Diseases","Neuronal Ceroid-Lipofuscinoses","Neurons"]}
{"id":"360G-Wellcome-220073_Z_20_Z","title":"Limited Proteolysis Mass Spectrometry: A Pipeline for Investigating Loss of Proteostasis with Age","Region":"North West","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220073/Z/20/Z","description":"Cell populations are intrinsically changed by age, reaching a point of senescence (arrested division) that has been associated with misregulation of metabolism, circadian rhythm, the extracellular matrix and signalling to the immune system. Crucially, studies have demonstrated age-related abrogation of protein homeostasis \u2013 the maintenance of proteins in their functional, folded states.\n\nGiven that the capacity of cells to maintain a correctly folded proteome, and thus functionality, is attenuated in ageing, understanding the biological mechanisms which underlie this loss of protein homeostasis is paramount. In this project, I will use proteomic and bioinformatical techniques to gain a fundamental understanding of the relationship between age and the loss of protein homeostasis.\n\nLimited proteolysis mass spectrometry (LiP-MS) is highly amenable to the study of protein folding, as it facilitates the characterisation of structural changes to the native proteome on both a global and local scale. I will apply LiP-MS to determine the extent of protein unfolding in primary human stem cells. Using replicative senescence as a model of cellular ageing, I will identify a candidate list of proteins whose folding/structure is not maintained at old age and use bioinformatic analyses to predict functional consequences of age-associated protein unfolding.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Ms Ellen Appleton","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Appleton","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Limited Proteolysis Mass Spectrometry: A Pipeline for Investigating Loss of Proteostasis with Age Cell populations are intrinsically changed by age, reaching a point of senescence (arrested division) that has been associated with misregulation of metabolism, circadian rhythm, the extracellular matrix and signalling to the immune system. Crucially, studies have demonstrated age-related abrogation of protein homeostasis \u2013 the maintenance of proteins in their functional, folded states.\n\nGiven that the capacity of cells to maintain a correctly folded proteome, and thus functionality, is attenuated in ageing, understanding the biological mechanisms which underlie this loss of protein homeostasis is paramount. In this project, I will use proteomic and bioinformatical techniques to gain a fundamental understanding of the relationship between age and the loss of protein homeostasis.\n\nLimited proteolysis mass spectrometry (LiP-MS) is highly amenable to the study of protein folding, as it facilitates the characterisation of structural changes to the native proteome on both a global and local scale. I will apply LiP-MS to determine the extent of protein unfolding in primary human stem cells. Using replicative senescence as a model of cellular ageing, I will identify a candidate list of proteins whose folding/structure is not maintained at old age and use bioinformatic analyses to predict functional consequences of age-associated protein unfolding.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aging","Cellular Senescence","Humans","Mass Spectrometry","Protein Folding","Proteome","Proteomics","Proteostasis","Stem Cells"]}
{"id":"360G-Wellcome-220072_Z_20_Z","title":"Algorithms in a functional genomics study of cichlid fish evolution","Region":"East of England","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220072/Z/20/Z","description":"Epigenetics, or \"on top of\" genetics, refers to biochemical modifications to the DNA that do not alter the underlying sequence. Such modifications influence the likelihood that individual genes are expressed, allowing many degrees of freedom for the overall gene expression network in an organism. This is believed to underpin how certain organisms exhibit the ability to diversify into a large number of species in short evolutionary time. A famous example is the cichlid adaptive radiation of the East African Great Lakes, which comprises over 2,000 phenotypically diverse species, in terms of their microhabitat, size, morphology, feeding behaviour and colouration.\n\n \n\nMy PhD project will be a collaboration between myself and Audrey Putman, an experimentalist student from Eric Miska\u2019s lab. Our plan is to explore, characterise and quantify how epigenetic differences can manifest in the cichlid system. I will develop computational and statistical methodologies to analyse epigenomic data, under the guidance of a computational supervisor, Martin Hemberg. The impact of the work include developing efficient algorithms to process large scale datasets, and effectively integrate information from various sequencing technologies, with the ultimate goal of addressing the fundamental biological question of speciation.\n\n \n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Fu Xiang Quah","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Quah","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Algorithms in a functional genomics study of cichlid fish evolution Epigenetics, or \"on top of\" genetics, refers to biochemical modifications to the DNA that do not alter the underlying sequence. Such modifications influence the likelihood that individual genes are expressed, allowing many degrees of freedom for the overall gene expression network in an organism. This is believed to underpin how certain organisms exhibit the ability to diversify into a large number of species in short evolutionary time. A famous example is the cichlid adaptive radiation of the East African Great Lakes, which comprises over 2,000 phenotypically diverse species, in terms of their microhabitat, size, morphology, feeding behaviour and colouration.\n\n \n\nMy PhD project will be a collaboration between myself and Audrey Putman, an experimentalist student from Eric Miska\u2019s lab. Our plan is to explore, characterise and quantify how epigenetic differences can manifest in the cichlid system. I will develop computational and statistical methodologies to analyse epigenomic data, under the guidance of a computational supervisor, Martin Hemberg. The impact of the work include developing efficient algorithms to process large scale datasets, and effectively integrate information from various sequencing technologies, with the ultimate goal of addressing the fundamental biological question of speciation.\n\n \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Algorithms","Animals","Biological Evolution","Cichlids","Epigenesis, Genetic","Epigenomics","Lakes"]}
{"id":"360G-Wellcome-220071_Z_20_Z","title":"The use of machine learning techniques to assess the quality of mammalian pre-implantation embryos","Region":"North West","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220071/Z/20/Z","description":"The popularity of in vitro fertilisation (IVF) is growing with techniques improving over the last few decades. Nevertheless, current success rates remain low, which is partly due to difficulty in selecting the best embryos to be used, as we lack a comprehensive understanding of the visual attributes of a healthy embryo. The aim of this PhD is to develop techniques that will improve the chances of selecting a healthy embryo after IVF procedures, based on a video of the first 5 days of its life. We plan to achieve this using machine learning, an artificial intelligence approach that allows computers to learn from available data. We will follow two approaches; 1) attempt to predict the quality of a human embryo using videos provided by an IVF clinic, and 2) create mouse embryos with abnormalities in genetic material, record their development and develop an algorithm capable of identifying the reasons behind developmental failure from image / video data. If we can correctly predict the viability of an embryo and genetic issues impacting on this, it will pave the way for the development of improved detection and diagnosis systems to support human IVF treatment.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Ms Camilla Mapstone","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Mapstone","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The use of machine learning techniques to assess the quality of mammalian pre-implantation embryos The popularity of in vitro fertilisation (IVF) is growing with techniques improving over the last few decades. Nevertheless, current success rates remain low, which is partly due to difficulty in selecting the best embryos to be used, as we lack a comprehensive understanding of the visual attributes of a healthy embryo. The aim of this PhD is to develop techniques that will improve the chances of selecting a healthy embryo after IVF procedures, based on a video of the first 5 days of its life. We plan to achieve this using machine learning, an artificial intelligence approach that allows computers to learn from available data. We will follow two approaches; 1) attempt to predict the quality of a human embryo using videos provided by an IVF clinic, and 2) create mouse embryos with abnormalities in genetic material, record their development and develop an algorithm capable of identifying the reasons behind developmental failure from image / video data. If we can correctly predict the viability of an embryo and genetic issues impacting on this, it will pave the way for the development of improved detection and diagnosis systems to support human IVF treatment.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Algorithms","Animals","Artificial Intelligence","Embryo, Mammalian","Embryonic Development","Female","Fertilization in Vitro","Humans","Machine Learning","Mice","Video Recording"]}
{"id":"360G-Wellcome-220070_Z_20_Z","title":"Whole-brain structural and functional connectivity in children treated with therapeutic hypothermia for neonatal encephalopathy","Region":"South West","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220070/Z/20/Z","description":"Each year 2 per 1000 newborn babies suffer brain injury due to deprivation of oxygen to the brain around birth leading to severe physical disabilities called cerebral palsy and, in severe cases, death. Cooling therapy reduces the risk of severe brain injury, however when the cooled children reach school-age they still perform less well on cognitive and motor tasks than \u2018healthy\u2019 controls, even in the absence of cerebral palsy.\n\n \n\nUsing advanced brain scans (MRI) from a cohort of cooled children, as well as data from controls with no birth complications, I aim to determine the underlying differences in brain structure and function and assess how these differences contribute to cognitive and motor performance. I will apply techniques to investigate tissue microstructure, as well as techniques from graph theory to characterise whole brain wiring. I will develop the statistical methods used in network neuroscience to facilitate more robust and informative analysis of the structural and functional brain networks.\n\n \n\nDetermining particular brain regions or connections which are affected in cooled children will provide understanding of how the injury affects development and may motivate developing therapeutic interventions. Developing the statistical techniques will allow investigation of the relationship between brain structure and children\u2019s skills.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Arthur Spencer","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Spencer","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Whole-brain structural and functional connectivity in children treated with therapeutic hypothermia for neonatal encephalopathy Each year 2 per 1000 newborn babies suffer brain injury due to deprivation of oxygen to the brain around birth leading to severe physical disabilities called cerebral palsy and, in severe cases, death. Cooling therapy reduces the risk of severe brain injury, however when the cooled children reach school-age they still perform less well on cognitive and motor tasks than \u2018healthy\u2019 controls, even in the absence of cerebral palsy.\n\n \n\nUsing advanced brain scans (MRI) from a cohort of cooled children, as well as data from controls with no birth complications, I aim to determine the underlying differences in brain structure and function and assess how these differences contribute to cognitive and motor performance. I will apply techniques to investigate tissue microstructure, as well as techniques from graph theory to characterise whole brain wiring. I will develop the statistical methods used in network neuroscience to facilitate more robust and informative analysis of the structural and functional brain networks.\n\n \n\nDetermining particular brain regions or connections which are affected in cooled children will provide understanding of how the injury affects development and may motivate developing therapeutic interventions. Developing the statistical techniques will allow investigation of the relationship between brain structure and children\u2019s skills.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Brain","Cerebral Palsy","Child","Humans","Hypothermia, Induced","Hypoxia-Ischemia, Brain","Infant, Newborn","Magnetic Resonance Imaging"]}
{"id":"360G-Wellcome-220069_Z_20_Z","title":"Developing a Methodological Framework to Evaluate the Impact of Health Intervention Sequences","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220069/Z/20/Z","description":"The goal of my research is to uncover how the sequence of health interventions influences their effects. As an example, should a cancer patient be treated first with the newest and costly drug upon diagnosis, or should such drug be reserved as the last resort, after all other drugs have failed? Typically, it is unclear whether there are any other effective treatments when a new drug fails.\n\nQuitting smoking is another example of where the sequence can matter. We know that e-cigarettes are more effective in helping smokers to quit compared to nicotine replacement therapy (NRT). However, this has been shown mostly in people who have tried NRT and failed before trying e-cigarettes. Therefore, it is unknown whether smokers would have been more successful in quitting if they had used e-cigarettes first. Or would e-cigarettes only work after failed quitting attempts with other methods?\n\nIn summary, changing the order of healthcare interventions can result in either positive or negative outcomes. To better understand this phenomenon, I plan to apply novel statistical approaches to existing medical records, surveys and trial data to explore the optimal sequence of interventions and to model the relative cost-effectiveness of different sequences.\n","plannedDates":[{"endDate":"2022-12-09T00:00:00+00:00","startDate":"2019-09-10T00:00:00+00:00","startDateDateOnly":"2019-09-10","endDateDateOnly":"2022-12-09"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Jen-Yu Chang","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Chang","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield","addressCountry":"United Kingdom","id_and_name":"[\"University of Sheffield\", \"360G-Wellcome-ORG:University-of-Sheffield\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Developing a Methodological Framework to Evaluate the Impact of Health Intervention Sequences The goal of my research is to uncover how the sequence of health interventions influences their effects. As an example, should a cancer patient be treated first with the newest and costly drug upon diagnosis, or should such drug be reserved as the last resort, after all other drugs have failed? Typically, it is unclear whether there are any other effective treatments when a new drug fails.\n\nQuitting smoking is another example of where the sequence can matter. We know that e-cigarettes are more effective in helping smokers to quit compared to nicotine replacement therapy (NRT). However, this has been shown mostly in people who have tried NRT and failed before trying e-cigarettes. Therefore, it is unknown whether smokers would have been more successful in quitting if they had used e-cigarettes first. Or would e-cigarettes only work after failed quitting attempts with other methods?\n\nIn summary, changing the order of healthcare interventions can result in either positive or negative outcomes. To better understand this phenomenon, I plan to apply novel statistical approaches to existing medical records, surveys and trial data to explore the optimal sequence of interventions and to model the relative cost-effectiveness of different sequences.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cost-Benefit Analysis","Electronic Nicotine Delivery Systems","Humans","Nicotine","Smoking","Smoking Cessation","Tobacco Use Cessation Devices"]}
{"id":"360G-Wellcome-220068_Z_20_Z","title":"Causal pathways from cognitive function to Alzheimer's disease","Region":"South West","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220068/Z/20/Z","description":"Findings from observational and genetic studies of modifiable risk factors for Alzheimer\u2019s disease (AD) are inconsistent with studies reporting null, positive or negative findings for the same risk factor. Educational attainment and intelligence are the only risk factors to have been consistently related with AD, with studies using different methodologies reporting greater educational attainment and intelligence to be protective for Alzheimer's disease. Recently, in a genetic study more robust to bias than traditional observational studies, we showed little evidence of an effect of educational attainment of AD once intelligence was accounted for. The aim of the project I am proposing is to investigate how structural brain and physiological (proteins, metabolites) changes, play a role in the relationship between cognitive function and AD.  With the use of birth cohorts, with data on childhood measures such as brain structure, and the use of genetics methods for estimating causal effects, we aim to limit biases associated with adult and observational epidemiological studies. This will allow investigation of the relative importance of anatomical and physiological factors for cognitive function on Alzheimer's disease. This project will contribute to an improved understanding of the causes of AD and highlight potential drug targets and intervention strategies.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Roxanna Korologou Linden","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Korologou Linden","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Causal pathways from cognitive function to Alzheimer's disease Findings from observational and genetic studies of modifiable risk factors for Alzheimer\u2019s disease (AD) are inconsistent with studies reporting null, positive or negative findings for the same risk factor. Educational attainment and intelligence are the only risk factors to have been consistently related with AD, with studies using different methodologies reporting greater educational attainment and intelligence to be protective for Alzheimer's disease. Recently, in a genetic study more robust to bias than traditional observational studies, we showed little evidence of an effect of educational attainment of AD once intelligence was accounted for. The aim of the project I am proposing is to investigate how structural brain and physiological (proteins, metabolites) changes, play a role in the relationship between cognitive function and AD.  With the use of birth cohorts, with data on childhood measures such as brain structure, and the use of genetics methods for estimating causal effects, we aim to limit biases associated with adult and observational epidemiological studies. This will allow investigation of the relative importance of anatomical and physiological factors for cognitive function on Alzheimer's disease. This project will contribute to an improved understanding of the causes of AD and highlight potential drug targets and intervention strategies.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Alzheimer Disease","Brain","Cognition","Educational Status","Humans","Intelligence","Risk Factors"]}
{"id":"360G-Wellcome-220067_Z_20_Z","title":"Sensitivity analyses for causal inference","Region":"South West","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220067/Z/20/Z","description":"Many epidemiological studies are interested in estimating the causal effect of an exposure on an outcome. While experiments in which exposure levels are randomly assigned to participants are the ideal setting for this purpose, it is often infeasible for financial, ethical or logistical reasons. Therefore, we are often limited to analysing observational data in which exposure levels across individuals are determined by many complex and often unmeasured factors. Drawing inferences from such data typically requires making untestable assumptions about the distribution of, or relationships among, the variables under study. Causal inferences which depend on these untestable assumptions are rarely convincing. In the last couple of decades, there has been increasing development of sensitivity analyses, which relax the assumptions and measure the extent to which the estimates change as a result. Estimates which have the same qualitative interpretation even when assumptions have been stripped back are much more persuasive. The aim of my PhD is to continue developing sensitivity analyses for causal inference, with particular focus on selection bias and measurement error, and to promote these methods among non-statistician researchers (e.g. epidemiologists, clinicians).\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Matthew Tudball","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Tudball","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Sensitivity analyses for causal inference Many epidemiological studies are interested in estimating the causal effect of an exposure on an outcome. While experiments in which exposure levels are randomly assigned to participants are the ideal setting for this purpose, it is often infeasible for financial, ethical or logistical reasons. Therefore, we are often limited to analysing observational data in which exposure levels across individuals are determined by many complex and often unmeasured factors. Drawing inferences from such data typically requires making untestable assumptions about the distribution of, or relationships among, the variables under study. Causal inferences which depend on these untestable assumptions are rarely convincing. In the last couple of decades, there has been increasing development of sensitivity analyses, which relax the assumptions and measure the extent to which the estimates change as a result. Estimates which have the same qualitative interpretation even when assumptions have been stripped back are much more persuasive. The aim of my PhD is to continue developing sensitivity analyses for causal inference, with particular focus on selection bias and measurement error, and to promote these methods among non-statistician researchers (e.g. epidemiologists, clinicians).\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Bias","Causality","Confounding Factors, Epidemiologic","Data Interpretation, Statistical","Humans","Observational Studies as Topic"]}
{"id":"360G-Wellcome-220066_Z_20_Z","title":"Structural investigation into the Tol-Pal transenvelope machine and how it utilises the proton motive force","Region":"South East","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220066/Z/20/Z","description":"Antibiotic resistance is a global health issue that threatens modern medicine and how we treat bacterial infections. Investigating how bacteria live is important to fight against antibiotic resistance as it can lead to new approaches for dealing with bacterial infections, and new targets for antibiotics. The research project we are proposing aims to further our understanding of a system called Tol-Pal in a class of bacteria called Gram negatives. Tol-Pal has been shown to have a role in cell division and is important for the growth of Gram-negative bacteria. At the moment, we do not fully understand how the components of Tol-Pal work together to carry out this function. In this project we hope to use structural biology techniques to see what a complex of three of the proteins in the Tol-Pal system, TolQRA, look like. We hope that finding out what TolQRA looks like will help us to investigate the mechanism of TolQRA within the Tol-Pal system, and further our understanding of Gram-negative bacteria and how they work.  \n \n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Cara Press","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Press","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Structural investigation into the Tol-Pal transenvelope machine and how it utilises the proton motive force Antibiotic resistance is a global health issue that threatens modern medicine and how we treat bacterial infections. Investigating how bacteria live is important to fight against antibiotic resistance as it can lead to new approaches for dealing with bacterial infections, and new targets for antibiotics. The research project we are proposing aims to further our understanding of a system called Tol-Pal in a class of bacteria called Gram negatives. Tol-Pal has been shown to have a role in cell division and is important for the growth of Gram-negative bacteria. At the moment, we do not fully understand how the components of Tol-Pal work together to carry out this function. In this project we hope to use structural biology techniques to see what a complex of three of the proteins in the Tol-Pal system, TolQRA, look like. We hope that finding out what TolQRA looks like will help us to investigate the mechanism of TolQRA within the Tol-Pal system, and further our understanding of Gram-negative bacteria and how they work.  \n \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Bacterial Proteins","Cell Division","Gram-Negative Bacteria"]}
{"id":"360G-Wellcome-220065_Z_20_Z","title":"Structural Characterization of the Human Endogenous Retrovirus K (HERV-K)","Region":"South East","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220065/Z/20/Z","description":"Approximately 8% of the human genome consists of Human Endogenous Retroviruses (HERVs) which have been found to be active in several diseases such as cancer and HIV infections. This raises several questions as to why these sequences were retained in the genome and why they become active in such a broad range of diseases. We have decided to study HERV-K (HML-2) as a representative of this class as it is the most recently acquired retrovirus, the most transcriptionally active and encodes all structural and enzymatic proteins to form virus-like particles (VLPs).\n\nWe start by studying one polypeptide of the virus which is sufficient to form non-infectious VLPs. We will then include the other proteins step-by-step until we have the structure of the fully formed virus. This gives us the possibility to work up to the more complicated virus on the basis of the earlier results. VLPs can be seen in cryo-electron tomography easily and sub-tomogram averaging of the highly symmetric lattice gives the opportunity to achieve a sub-nanometre structure of HERV-K. These findings lay the basis to find the mechanism of how HERV-K acts and will be tested by in vivo assays to develop compounds for blocking HERV-K.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Ms Anna-Sophia Krebs","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Krebs","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Structural Characterization of the Human Endogenous Retrovirus K (HERV-K) Approximately 8% of the human genome consists of Human Endogenous Retroviruses (HERVs) which have been found to be active in several diseases such as cancer and HIV infections. This raises several questions as to why these sequences were retained in the genome and why they become active in such a broad range of diseases. We have decided to study HERV-K (HML-2) as a representative of this class as it is the most recently acquired retrovirus, the most transcriptionally active and encodes all structural and enzymatic proteins to form virus-like particles (VLPs).\n\nWe start by studying one polypeptide of the virus which is sufficient to form non-infectious VLPs. We will then include the other proteins step-by-step until we have the structure of the fully formed virus. This gives us the possibility to work up to the more complicated virus on the basis of the earlier results. VLPs can be seen in cryo-electron tomography easily and sub-tomogram averaging of the highly symmetric lattice gives the opportunity to achieve a sub-nanometre structure of HERV-K. These findings lay the basis to find the mechanism of how HERV-K acts and will be tested by in vivo assays to develop compounds for blocking HERV-K.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Cryoelectron Microscopy","Endogenous Retroviruses","Humans","Models, Molecular"]}
{"id":"360G-Wellcome-220064_Z_20_Z","title":"Structural and Functional Characterisation of the Very Large G protein-coupled receptor (VLGR1)","Region":"South East","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220064/Z/20/Z","description":"Very Large G protein-coupled receptor 1 (VLGR1) is an adhesion G Protein-Coupled Receptor (aGPCR/ADGR). ADGRs are cell-surface protein receptors which mediate signal transduction through coupling with G-proteins in the cell and with their characteristic large extracellular domains mediate cell-cell and cell-matrix interactions. VLGR1 is the largest cell-surface protein known and none endogenous ligand for its extracellular domain has been identified yet. It is highly expressed in the central nervous system and mutations in Vlgr1 gene lead to the Usher Syndrome Type 2C which is characterised by hearing loss and progressive retinitis pigmentosa. Mutations are also linked to audiogenic seizures in mice and humans. All these suggest VLGR1\u2019s important role in the central nervous system and despite the importance and the recent research progress, the structure and functions of VLGR1 are not known. During my PhD I will use structural analyses, including X-ray Crystallography and cryo-EM, to characterise the structure of the extracellular domain of the VLGR1 receptor and I will aim to identify its biological binding partners using cellular assays. These studies will shed light on the biology of this poorly understood receptor and may suggest new ways of treating the associated diseases.\n \n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Ms Maria Kokolaki","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Kokolaki","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Structural and Functional Characterisation of the Very Large G protein-coupled receptor (VLGR1) Very Large G protein-coupled receptor 1 (VLGR1) is an adhesion G Protein-Coupled Receptor (aGPCR/ADGR). ADGRs are cell-surface protein receptors which mediate signal transduction through coupling with G-proteins in the cell and with their characteristic large extracellular domains mediate cell-cell and cell-matrix interactions. VLGR1 is the largest cell-surface protein known and none endogenous ligand for its extracellular domain has been identified yet. It is highly expressed in the central nervous system and mutations in Vlgr1 gene lead to the Usher Syndrome Type 2C which is characterised by hearing loss and progressive retinitis pigmentosa. Mutations are also linked to audiogenic seizures in mice and humans. All these suggest VLGR1\u2019s important role in the central nervous system and despite the importance and the recent research progress, the structure and functions of VLGR1 are not known. During my PhD I will use structural analyses, including X-ray Crystallography and cryo-EM, to characterise the structure of the extracellular domain of the VLGR1 receptor and I will aim to identify its biological binding partners using cellular assays. These studies will shed light on the biology of this poorly understood receptor and may suggest new ways of treating the associated diseases.\n \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Crystallography, X-Ray","Humans","Models, Molecular","Receptors, G-Protein-Coupled","Usher Syndromes"]}
{"id":"360G-Wellcome-220063_Z_20_Z","title":"Structural and functional characterisation of the fungal proton pump Pma1","Region":"South East","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220063/Z/20/Z","description":"Fungi fuel their nutrient uptake through generating a proton-motive force across their plasma membrane via the membrane protein proton pump Pma1. This proton-motive force is used as an energy source to import nutrients for the cell, and fungi die without the activity of Pma1. To date, knowledge on the molecular structure and function of this protein is limited. I therefore aim to study the structure of Pma1 and understand its molecular function, through the use of structural analyses, including cryoEM and X-ray crystallography and biophysical assays. I will be using protein isolated from the fungus Neurospora crassa and a set of known small molecules that lock the protein in different catalytic conformations to investigate its catalytic cycle. I will also establish a way to produce Pma1 in baker's yeast, allowing me to generate variants of the native protein for functional and structural studies. My findings will broaden our understanding of the structure and function of the protein, opening the possibility of a wide range of secondary research including protein-lipid interaction studies and the possibility of designing novel antifungal agents.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Maxwell Geurts","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Geurts","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Structural and functional characterisation of the fungal proton pump Pma1 Fungi fuel their nutrient uptake through generating a proton-motive force across their plasma membrane via the membrane protein proton pump Pma1. This proton-motive force is used as an energy source to import nutrients for the cell, and fungi die without the activity of Pma1. To date, knowledge on the molecular structure and function of this protein is limited. I therefore aim to study the structure of Pma1 and understand its molecular function, through the use of structural analyses, including cryoEM and X-ray crystallography and biophysical assays. I will be using protein isolated from the fungus Neurospora crassa and a set of known small molecules that lock the protein in different catalytic conformations to investigate its catalytic cycle. I will also establish a way to produce Pma1 in baker's yeast, allowing me to generate variants of the native protein for functional and structural studies. My findings will broaden our understanding of the structure and function of the protein, opening the possibility of a wide range of secondary research including protein-lipid interaction studies and the possibility of designing novel antifungal agents.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Antifungal Agents","Cryoelectron Microscopy","Crystallography, X-Ray","Fungal Proteins","Models, Molecular","Neurospora crassa","Protein Conformation","Protons"]}
{"id":"360G-Wellcome-220062_Z_20_Z","title":"Investigation of the role of small molecule ligands in Hedgehog signalling using molecular dynamics simulations","Region":"South East","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220062/Z/20/Z","description":"The hedgehog (HH) signalling pathway is involved in embryonic development, cell patterning and stem cell homeostasis1. Defects in pathway function lead to cancers such as medulloblastoma or developmental defects such as holoprosencephaly2. Several recent observations3\u20138 have led to the hypothesis that membrane sterols such as cholesterol play a crucial role in the function and regulation of key HH membrane proteins, Patched (PTCH1) and the Class F GPCR Smoothened (SMO).\n\nI will use computer simulations to study the role of sterols in PTCH1 function to inhibit SMO. This will include evaluation of protein dynamics within the cell membrane and calculation of  energy changes along potential sterol transport tunnels within PTCH1 which I have previously identified9. Computer simulations will also be used to investigate how ligands bound within SMO may affect the movement of different regions of the protein. These studies will contribute towards understanding the function and regulation of key HH membrane proteins and how their conformational landscape may be exploited for targeting by drugs. \n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Tillson Ansell","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Ansell","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigation of the role of small molecule ligands in Hedgehog signalling using molecular dynamics simulations The hedgehog (HH) signalling pathway is involved in embryonic development, cell patterning and stem cell homeostasis1. Defects in pathway function lead to cancers such as medulloblastoma or developmental defects such as holoprosencephaly2. Several recent observations3\u20138 have led to the hypothesis that membrane sterols such as cholesterol play a crucial role in the function and regulation of key HH membrane proteins, Patched (PTCH1) and the Class F GPCR Smoothened (SMO).\n\nI will use computer simulations to study the role of sterols in PTCH1 function to inhibit SMO. This will include evaluation of protein dynamics within the cell membrane and calculation of  energy changes along potential sterol transport tunnels within PTCH1 which I have previously identified9. Computer simulations will also be used to investigate how ligands bound within SMO may affect the movement of different regions of the protein. These studies will contribute towards understanding the function and regulation of key HH membrane proteins and how their conformational landscape may be exploited for targeting by drugs. \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cholesterol","Hedgehog Proteins","Humans","Ligands","Molecular Dynamics Simulation","Patched-1 Receptor","Receptors, G-Protein-Coupled","Signal Transduction","Smoothened Receptor"]}
{"id":"360G-Wellcome-220059_Z_19_Z","title":"Longitudinal studies to investigate adult outcomes of autism and autistic traits","Region":"South West","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220059/Z/19/Z","description":"Autism is a lifelong condition characterised by difficulties with social interaction, social communication and repetitive behaviours. In recent decades, the number of children and adults diagnosed with autism has increased. As autism is heritable, genetic risk may explain why some individuals with mild autistic traits may not meet the criteria for an autism diagnosis and subsequent treatment or other support requirements. As more children with autism and mild autistic traits reach adulthood, the need for health and other services will likely increase. However, few large, well-conducted studies involving adults with autism exist, representing a research gap.\n\n\nDuring my PhD project, I will study how autism and autism traits, including genetic risk for them, may be associated with physical health, social and economic circumstances at different stages of adult life. I will take a longitudinal approach to investigate whether there are periods of vulnerability or change in relation to elements of physical health, such as BMI, and social and economic outcomes, such as employment status and level of education. This research will contribute to better understanding of adult outcomes of autism and, potentially, flag the need for more service provisions to meet health and other support requirements.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Ms Amanda Ly","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Ly","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol","addressCountry":"United Kingdom","id_and_name":"[\"University of Bristol\", \"360G-Wellcome-ORG:University-of-Bristol\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Bristol","name":"University of Bristol"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Longitudinal studies to investigate adult outcomes of autism and autistic traits Autism is a lifelong condition characterised by difficulties with social interaction, social communication and repetitive behaviours. In recent decades, the number of children and adults diagnosed with autism has increased. As autism is heritable, genetic risk may explain why some individuals with mild autistic traits may not meet the criteria for an autism diagnosis and subsequent treatment or other support requirements. As more children with autism and mild autistic traits reach adulthood, the need for health and other services will likely increase. However, few large, well-conducted studies involving adults with autism exist, representing a research gap.\n\n\nDuring my PhD project, I will study how autism and autism traits, including genetic risk for them, may be associated with physical health, social and economic circumstances at different stages of adult life. I will take a longitudinal approach to investigate whether there are periods of vulnerability or change in relation to elements of physical health, such as BMI, and social and economic outcomes, such as employment status and level of education. This research will contribute to better understanding of adult outcomes of autism and, potentially, flag the need for more service provisions to meet health and other support requirements.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Adult","Autistic Disorder","Employment","Humans","Longitudinal Studies"]}
{"id":"360G-Wellcome-220058_Z_19_Z","title":"Characterising the regulators of trypanosome development and virulence in selected and natural parasite isolates","Region":"Scotland","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220058/Z/19/Z","description":"Trypanosoma brucei, the causative agent of human and animal trypanosomiasis, has two distinct life stages. The proliferative \u2018slender\u2019 bloodstream-form morphs into a transmissible \u2018stumpy\u2019 form, which is adapted to surviving in its vector\u2019s (Glossina spp.) midgut. The transition occurs in a density-dependent quorum sensing (QS) like process which is initiated by a \u2018stumpy induction factor\u2019 (SIF). I propose to use a wide diversity of pleomorphic (capable of morphing from slender to stumpy) field and laboratory strains of T. brucei to generate, via multiple passages, monomorphic cells (unable to become stumpy). I will create genomic, transcriptomic and epigenetic data from these cells at the beginning and end of the selection in an attempt to determine the cause of monomorphism, and therefore, the integral components of the QS process. By performing the study on diverse T. brucei cell lines, it will be possible to establish if the monomorphic phenotype can arise via convergent evolution. Alongside the genomes produced during this project, publicly available trypanosomatid genomes will be collated to identify conserved genes associated with increased virulence and monomorphism.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Guy Oldrieve","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Oldrieve","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Characterising the regulators of trypanosome development and virulence in selected and natural parasite isolates Trypanosoma brucei, the causative agent of human and animal trypanosomiasis, has two distinct life stages. The proliferative \u2018slender\u2019 bloodstream-form morphs into a transmissible \u2018stumpy\u2019 form, which is adapted to surviving in its vector\u2019s (Glossina spp.) midgut. The transition occurs in a density-dependent quorum sensing (QS) like process which is initiated by a \u2018stumpy induction factor\u2019 (SIF). I propose to use a wide diversity of pleomorphic (capable of morphing from slender to stumpy) field and laboratory strains of T. brucei to generate, via multiple passages, monomorphic cells (unable to become stumpy). I will create genomic, transcriptomic and epigenetic data from these cells at the beginning and end of the selection in an attempt to determine the cause of monomorphism, and therefore, the integral components of the QS process. By performing the study on diverse T. brucei cell lines, it will be possible to establish if the monomorphic phenotype can arise via convergent evolution. Alongside the genomes produced during this project, publicly available trypanosomatid genomes will be collated to identify conserved genes associated with increased virulence and monomorphism.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cell Line","Epigenesis, Genetic","Humans","Quorum Sensing","Trypanosoma brucei brucei","Virulence"]}
{"id":"360G-Wellcome-220057_Z_19_Z","title":"Investigating the emerging pathogen Shigella sonnei","Region":"Greater London","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220057/Z/19/Z","description":"Bacterial dysentery is a major cause of infant morbidity and mortality. Shigella flexneri and sonnei are responsible for 90% of these cases. Interestingly these bacteria are distributed differently and S. sonneiis the dominant serotype in transitional and high-income countries. Recent work has highlighted key differences between these Shigellaspecies including higher lethality of S. sonneiin an infection model, different interaction with immune cells and an increased ability to survive and persist under low nutrient conditions compared to S. flexneri. I aim to identify and understand the underlying molecular mechanisms behind these differences using a multi-disciplinary approach. I will use a combination of targeted and untargeted metabolite profiling (mass spectrometry, NMR spectroscopy and LC-MS) as analytic platforms in addition to the development of novel assays (to dissect polysaccharide biosynthesis pathways and nucleotide biosynthesis) to test specific hypotheses about nutrient flux in S. sonnei. \n\nResults here would better inform our understanding of Shigella persistence and how this could be mitigated in public health and infrastructure settings. In addition, any new techniques developed could be used to study other bacterial pathogens as polysaccharide biosynthesis is an important aspect of pathogen biology. \n","plannedDates":[{"endDate":"2023-04-30T00:00:00+00:00","startDate":"2019-10-07T00:00:00+00:00","startDateDateOnly":"2019-10-07","endDateDateOnly":"2023-04-30"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Pok Yin Brian Leung","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Leung","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London","addressCountry":"United Kingdom","id_and_name":"[\"Imperial College London\", \"360G-Wellcome-ORG:Imperial-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Imperial-College-London","name":"Imperial College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Investigating the emerging pathogen Shigella sonnei Bacterial dysentery is a major cause of infant morbidity and mortality. Shigella flexneri and sonnei are responsible for 90% of these cases. Interestingly these bacteria are distributed differently and S. sonneiis the dominant serotype in transitional and high-income countries. Recent work has highlighted key differences between these Shigellaspecies including higher lethality of S. sonneiin an infection model, different interaction with immune cells and an increased ability to survive and persist under low nutrient conditions compared to S. flexneri. I aim to identify and understand the underlying molecular mechanisms behind these differences using a multi-disciplinary approach. I will use a combination of targeted and untargeted metabolite profiling (mass spectrometry, NMR spectroscopy and LC-MS) as analytic platforms in addition to the development of novel assays (to dissect polysaccharide biosynthesis pathways and nucleotide biosynthesis) to test specific hypotheses about nutrient flux in S. sonnei. \n\nResults here would better inform our understanding of Shigella persistence and how this could be mitigated in public health and infrastructure settings. In addition, any new techniques developed could be used to study other bacterial pathogens as polysaccharide biosynthesis is an important aspect of pathogen biology. \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Mass Spectrometry","Metabolomics","O Antigens","Shigella","Shigella flexneri"]}
{"id":"360G-Wellcome-220056_Z_19_Z","title":"Scaling up effective interventions to reduce maternal hypertensive disorder and gestational diabetes: A return on investment case for Bangladesh","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220056/Z/19/Z","description":"Every year over 130 million children are born around the world. Each year 303,000 mothers die in childbirth while over 2 million children die at birth. Ninety nine percent of these deaths take place in low and middle income countries. In Bangladesh, the mother dies in 196 per 100,000 births per year. There is growing interest in the effect of Non-Communicable Diseases(NCDs) on maternal deaths. Almost 14% of deaths are due to high blood pressure during pregnancy and 28% are due to other causes including diabetes. One in 25 women develop diabetes during pregnancy period. Addressing these two conditions can help prevent serious birth outcomes like the death of the baby or mother. Preventing high blood pressure and diabetes during pregnancy will also reduce the risk of development of other health problems among women and their children. I aim to conduct research focusing on addressing these two conditions in the context of Bangladesh. I will identify a number of interventions to be included within the public health services. In doing so, I will review evidence to understand current practices and analyse data in order to identify the best interventions in terms of saving lives, reducing ill-health and saving costs. \n","plannedDates":[{"endDate":"2022-11-30T00:00:00+00:00","startDate":"2019-09-01T00:00:00+00:00","startDateDateOnly":"2019-09-01","endDateDateOnly":"2022-11-30"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Tazeen Tahsina","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Tahsina","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield","addressCountry":"United Kingdom","id_and_name":"[\"University of Sheffield\", \"360G-Wellcome-ORG:University-of-Sheffield\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Scaling up effective interventions to reduce maternal hypertensive disorder and gestational diabetes: A return on investment case for Bangladesh Every year over 130 million children are born around the world. Each year 303,000 mothers die in childbirth while over 2 million children die at birth. Ninety nine percent of these deaths take place in low and middle income countries. In Bangladesh, the mother dies in 196 per 100,000 births per year. There is growing interest in the effect of Non-Communicable Diseases(NCDs) on maternal deaths. Almost 14% of deaths are due to high blood pressure during pregnancy and 28% are due to other causes including diabetes. One in 25 women develop diabetes during pregnancy period. Addressing these two conditions can help prevent serious birth outcomes like the death of the baby or mother. Preventing high blood pressure and diabetes during pregnancy will also reduce the risk of development of other health problems among women and their children. I aim to conduct research focusing on addressing these two conditions in the context of Bangladesh. I will identify a number of interventions to be included within the public health services. In doing so, I will review evidence to understand current practices and analyse data in order to identify the best interventions in terms of saving lives, reducing ill-health and saving costs. \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Bangladesh","Female","Humans","Hypertension","Infant","Maternal Mortality","Pregnancy"]}
{"id":"360G-Wellcome-220055_Z_19_Z","title":"Social tariffs, preference heterogeneity, and collective choice","Region":"Yorkshire and the Humber","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220055/Z/19/Z","description":"Health economic evaluations are used to compare the costs and (health) benefits of different interventions. Their results often inform policy decisions about the allocation of resources within public health care systems. Since health is, to some extent, a social construct, measuring health requires making value judgments. In the UK, these judgments are supposed to be derived from the general public. To this end, it is established practice to survey a representative sample of individuals and to elicit their preferences over health states. Subsequently, individuals\u2019 preferences are aggregated, using some statistical methods, into a single index of the societal value of health, which is then used to value health outcomes in economic evaluations.\n\nThe proposed research project starts from the premise that no scientific method is value free, and that the aggregation of individual preferences into a societal preference is particularly contingent on underlying assumptions. The objective is to critically appraise what value judgments are inherent to the statistical models for health preferences that are commonly used in economic evaluations. Based on work in other fields, namely democratic and social choice theory, alternative conceptual and technical solutions will be developed, and their feasibility and impact will be empirically assessed.\n","plannedDates":[{"endDate":"2022-11-30T00:00:00+00:00","startDate":"2019-09-01T00:00:00+00:00","startDateDateOnly":"2019-09-01","endDateDateOnly":"2022-11-30"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Paul Schneider","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Schneider","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield","addressCountry":"United Kingdom","id_and_name":"[\"University of Sheffield\", \"360G-Wellcome-ORG:University-of-Sheffield\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Sheffield","name":"University of Sheffield"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Social tariffs, preference heterogeneity, and collective choice Health economic evaluations are used to compare the costs and (health) benefits of different interventions. Their results often inform policy decisions about the allocation of resources within public health care systems. Since health is, to some extent, a social construct, measuring health requires making value judgments. In the UK, these judgments are supposed to be derived from the general public. To this end, it is established practice to survey a representative sample of individuals and to elicit their preferences over health states. Subsequently, individuals\u2019 preferences are aggregated, using some statistical methods, into a single index of the societal value of health, which is then used to value health outcomes in economic evaluations.\n\nThe proposed research project starts from the premise that no scientific method is value free, and that the aggregation of individual preferences into a societal preference is particularly contingent on underlying assumptions. The objective is to critically appraise what value judgments are inherent to the statistical models for health preferences that are commonly used in economic evaluations. Based on work in other fields, namely democratic and social choice theory, alternative conceptual and technical solutions will be developed, and their feasibility and impact will be empirically assessed.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Choice Behavior","Cost-Benefit Analysis","Humans","Judgment","Patient Preference","Quality-Adjusted Life Years","Surveys and Questionnaires","United Kingdom"]}
{"id":"360G-Wellcome-220054_Z_19_Z","title":"Modelling mitotic spindle dynamics in stretched epithelial tissue","Region":"North West","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220054/Z/19/Z","description":"Multicellular organisms are formed by cells dividing multiple times, with the direction of division determining whether tissues expand or new tissues are formed. The mitotic spindle forms during cell division and determines the direction of division. In vertebrates, nuclear and mitotic apparatus protein (NuMA) has been identified as an anchor at the cell periphery which allows motor proteins to apply forces to the spindle and position it appropriately. While current spindle orientation models focus on different characteristics of the shape of the cell as force determinants in single cells and invertebrates, preliminary data from a force-based model shows that spindle orientations best match those seen experimentally when force is amplified at the edges of cells with increased intensity of fluorescently tagged NuMA. We aim to develop this model to include time-dependent NuMA localisation as it accumulates at the periphery and observe the effect on spindle dynamics. We will use in-plane divisions in cells of stretched tissue to investigate whether NuMA localises as a result of the cell shape or applied forces and the subsequent effect on spindle orientation. These studies will go some way to explaining the fundamental process of cell division and its dependence on local and global forces.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Dionn Hargreaves","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Hargreaves","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Modelling mitotic spindle dynamics in stretched epithelial tissue Multicellular organisms are formed by cells dividing multiple times, with the direction of division determining whether tissues expand or new tissues are formed. The mitotic spindle forms during cell division and determines the direction of division. In vertebrates, nuclear and mitotic apparatus protein (NuMA) has been identified as an anchor at the cell periphery which allows motor proteins to apply forces to the spindle and position it appropriately. While current spindle orientation models focus on different characteristics of the shape of the cell as force determinants in single cells and invertebrates, preliminary data from a force-based model shows that spindle orientations best match those seen experimentally when force is amplified at the edges of cells with increased intensity of fluorescently tagged NuMA. We aim to develop this model to include time-dependent NuMA localisation as it accumulates at the periphery and observe the effect on spindle dynamics. We will use in-plane divisions in cells of stretched tissue to investigate whether NuMA localises as a result of the cell shape or applied forces and the subsequent effect on spindle orientation. These studies will go some way to explaining the fundamental process of cell division and its dependence on local and global forces.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cell Division","Mitosis","Models, Biological","Spindle Apparatus"]}
{"id":"360G-Wellcome-220053_Z_19_Z","title":"Molecular characterisation of post-translational regulation in offensive Type VI secretion systems","Region":"Scotland","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220053/Z/19/Z","description":"The Type VI secretion system (T6SS) is a nanoweapon used by many Gram-negative bacteria to deliver toxic \u2018effector\u2019 proteins into neighbouring cells. The targeted cells are most often rival bacteria, but can also include the host or microbial fungi. Understanding what triggers the T6SS weapon to assemble and fire will improve our knowledge of how microbes compete for resources, and how diverse communities of microbes develop. Two T6SS firing \u2018strategies\u2019 have been identified: offensive T6SSs assemble and fire pre-emptively, whereas defensive systems only fire in retaliation upon sensing incoming attacks from neighbours. A signalling system of proteins which mediate both strategies has been identified. However, key molecular details of how this is used to orchestrate \u2018offensive\u2019 T6SS firing are lacking. In this study, we will elucidate the molecular mechanism of these offensive T6SS protein-protein interactions, using the model T6SS of the opportunistic pathogen, Serratia marcescens. Using a combination of genetic, biochemical and cell biology approaches, we will determine the trigger that activates the pathway, how this signal is transduced to activate the T6SS, and the conservation of this regulation in clinical isolates. Long-term, understanding how bacteria interact in diverse communities will contribute to novel strategies to tackle bacterial infections.\n \n","plannedDates":[{"endDate":"2022-12-02T00:00:00+00:00","startDate":"2018-09-03T00:00:00+00:00","startDateDateOnly":"2018-09-03","endDateDateOnly":"2022-12-02"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Ms Hannah Donnelly","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Donnelly","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee","addressCountry":"United Kingdom","id_and_name":"[\"University of Dundee\", \"360G-Wellcome-ORG:University-of-Dundee\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Molecular characterisation of post-translational regulation in offensive Type VI secretion systems The Type VI secretion system (T6SS) is a nanoweapon used by many Gram-negative bacteria to deliver toxic \u2018effector\u2019 proteins into neighbouring cells. The targeted cells are most often rival bacteria, but can also include the host or microbial fungi. Understanding what triggers the T6SS weapon to assemble and fire will improve our knowledge of how microbes compete for resources, and how diverse communities of microbes develop. Two T6SS firing \u2018strategies\u2019 have been identified: offensive T6SSs assemble and fire pre-emptively, whereas defensive systems only fire in retaliation upon sensing incoming attacks from neighbours. A signalling system of proteins which mediate both strategies has been identified. However, key molecular details of how this is used to orchestrate \u2018offensive\u2019 T6SS firing are lacking. In this study, we will elucidate the molecular mechanism of these offensive T6SS protein-protein interactions, using the model T6SS of the opportunistic pathogen, Serratia marcescens. Using a combination of genetic, biochemical and cell biology approaches, we will determine the trigger that activates the pathway, how this signal is transduced to activate the T6SS, and the conservation of this regulation in clinical isolates. Long-term, understanding how bacteria interact in diverse communities will contribute to novel strategies to tackle bacterial infections.\n \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Bacterial Proteins","Protein Processing, Post-Translational","Serratia marcescens","Signal Transduction","Type III Secretion Systems","Type VI Secretion Systems"]}
{"id":"360G-Wellcome-220052_Z_19_Z","title":"New approach to identifying epistasis using harmonic mean p-value","Region":"South East","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220052/Z/19/Z","description":"Epistasis refers to the phenomenon where the effect of one gene in a given trait is dependent on other genes. The effect of such interaction between genes is often ignored in studies that try to identify genetic risk factors in diseases and only the effects of individual genes are considered. Such an approach resulted in missing information and the heritability of genetic risks is only partially explained by these association studies. It is proposed that epistasis might be the missing piece of this puzzle. However, taking epistasis into account would increase the number of candidates dramatically. This presents a statistical challenge as the difficulty to find true signal grows when the number of candidates to be considered increases. In this project, we will leverage a recently published statistical method by Prof Daniel Wilson that can combine numerous signals into one representing signal and thereby reduce the number of candidates to overcome the challenge posts by epistasis. We hope to develop a framework to efficiently and flexibly identify genetic risk factors that includes epistasis in different human diseases.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Shang-Kuan Lin","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Lin","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"New approach to identifying epistasis using harmonic mean p-value Epistasis refers to the phenomenon where the effect of one gene in a given trait is dependent on other genes. The effect of such interaction between genes is often ignored in studies that try to identify genetic risk factors in diseases and only the effects of individual genes are considered. Such an approach resulted in missing information and the heritability of genetic risks is only partially explained by these association studies. It is proposed that epistasis might be the missing piece of this puzzle. However, taking epistasis into account would increase the number of candidates dramatically. This presents a statistical challenge as the difficulty to find true signal grows when the number of candidates to be considered increases. In this project, we will leverage a recently published statistical method by Prof Daniel Wilson that can combine numerous signals into one representing signal and thereby reduce the number of candidates to overcome the challenge posts by epistasis. We hope to develop a framework to efficiently and flexibly identify genetic risk factors that includes epistasis in different human diseases.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Epistasis, Genetic","Humans","Models, Genetic","Risk Factors"]}
{"id":"360G-Wellcome-220051_Z_19_Z","title":"Using phased multi-omic techniques to understand the regulatory landscape of the genome","Region":"South East","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220051/Z/19/Z","description":"Since the completion of the human genome project many genetic studies have discovered variations in our genetic code that are subsequently associated with common diseases. These can be insertions or deletions of genetic code or in-place modifications of the genetic code. Interestingly many of these discovered changes to the genome don't occur within genes but within the so-called non-coding regions of the genome. It is thought that these changes are in fact affecting the regulation of the genes -- switches that control gene activity.\n\nIn this research I intend to build upon existing research that aims to understand how these changes are affecting the gene activity, which genes are affected and how. This is often complicated by factors such as these genetic-changes may well be very distal to the genes they affect in our 2-dimensional representations of the human genome. Overcoming these issues will provide clear insights into human diseases and hopefully will lead to improvements in our understanding of human disease and how to treat such diseases. \n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Edward Sanders","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Sanders","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Using phased multi-omic techniques to understand the regulatory landscape of the genome Since the completion of the human genome project many genetic studies have discovered variations in our genetic code that are subsequently associated with common diseases. These can be insertions or deletions of genetic code or in-place modifications of the genetic code. Interestingly many of these discovered changes to the genome don't occur within genes but within the so-called non-coding regions of the genome. It is thought that these changes are in fact affecting the regulation of the genes -- switches that control gene activity.\n\nIn this research I intend to build upon existing research that aims to understand how these changes are affecting the gene activity, which genes are affected and how. This is often complicated by factors such as these genetic-changes may well be very distal to the genes they affect in our 2-dimensional representations of the human genome. Overcoming these issues will provide clear insights into human diseases and hopefully will lead to improvements in our understanding of human disease and how to treat such diseases. \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Genome, Human","Humans"]}
{"id":"360G-Wellcome-220050_Z_19_Z","title":"Do psychedelic drugs have long-term implications for structural and behavioural plasticity in a mouse model? ","Region":"South East","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220050/Z/19/Z","description":"Plasticity describes changes at various levels of organisation of the nervous system which result from experience. It is hypothesized that psychedelic drugs can induce plasticity at cellular, structural and functional levels, aiding lasting remission from numerous neuropsychiatric disorders. They offer a unique opportunity to study heightened plasticity as a potential neural pre-requisite of behavioural flexibility. Using a mouse model, I aim to determine whether psychedelics induce long-term anatomical and behavioural plasticity changes and to determine if the context of drug administration affects the quality of on- and off-drug experience. Our approach will be a combination of (1) behavioural investigations of the quality of on-drug psychedelic experience under different contexts and of off-drug effects on cognitive flexibility, (2) longitudinal off-drug structural MRI imaging, and (3) in-vivo microelectrode array electrophysiology to understand single network function and information processing. These studies will elucidate whether the psychedelic-induced structural and functional changes persist after the acute intoxication phase and if they can help explain the lasting behavioural changes that have been observed in human studies.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Merima Sabanovic","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Sabanovic","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Do psychedelic drugs have long-term implications for structural and behavioural plasticity in a mouse model?  Plasticity describes changes at various levels of organisation of the nervous system which result from experience. It is hypothesized that psychedelic drugs can induce plasticity at cellular, structural and functional levels, aiding lasting remission from numerous neuropsychiatric disorders. They offer a unique opportunity to study heightened plasticity as a potential neural pre-requisite of behavioural flexibility. Using a mouse model, I aim to determine whether psychedelics induce long-term anatomical and behavioural plasticity changes and to determine if the context of drug administration affects the quality of on- and off-drug experience. Our approach will be a combination of (1) behavioural investigations of the quality of on-drug psychedelic experience under different contexts and of off-drug effects on cognitive flexibility, (2) longitudinal off-drug structural MRI imaging, and (3) in-vivo microelectrode array electrophysiology to understand single network function and information processing. These studies will elucidate whether the psychedelic-induced structural and functional changes persist after the acute intoxication phase and if they can help explain the lasting behavioural changes that have been observed in human studies.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Brain","Disease Models, Animal","Hallucinogens","Magnetic Resonance Imaging","Mice","Neuronal Plasticity"]}
{"id":"360G-Wellcome-220049_Z_19_Z","title":"A large-scale and comprehensive investigation into the B-cell receptor (BCR) and T-cell receptor (TCR) repertoires during the dynamic immune response to sepsis and recovery ","Region":"South East","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220049/Z/19/Z","description":"Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to often-unknown pathogens. Following recovery, individuals exhibit long-term immunosuppression. B and T-cells are vital components of the adaptive immune response, each B/T-cell expresses copies of a single, unique surface B cell/T cell receptor (BCR/TCR) respectively, for antigen binding. Diversity in receptors is generated by V(D)J recombination and for BCRs, through somatic hypermutation and class-switching. The pool of BCRs/TCRs within an individual is termed the BCR/TCR repertoire. In healthy individuals this is highly diverse, yielding a complex immune architecture. However, studies suggest abnormalities in the repertoires of septic shock patients.  \n\nI will generate the first comprehensive analysis of the BCR/TCR repertoire in sepsis using high-throughput BCR/TCR sequencing at multiple timepoints over the course of disease/recovery; one of the largest studies of this kind. Reactivation of Epstein Barr Virus (EBV) is common during sepsis and EBV induces B-cell somatic hypermutation. Therefore, I will use single-cell RNA sequencing to investigate the B-cell transcriptional profile associated with EBV reactivation in sepsis and relate to prognosis. Finally, I will investigate the effect of immunomodulatory therapies (steroids, anti-TNF) on the BCR/TCR repertoire, thus improving our understanding of how therapies can be combined in sepsis. \n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Ms Lauren Overend","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Overend","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"A large-scale and comprehensive investigation into the B-cell receptor (BCR) and T-cell receptor (TCR) repertoires during the dynamic immune response to sepsis and recovery  Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to often-unknown pathogens. Following recovery, individuals exhibit long-term immunosuppression. B and T-cells are vital components of the adaptive immune response, each B/T-cell expresses copies of a single, unique surface B cell/T cell receptor (BCR/TCR) respectively, for antigen binding. Diversity in receptors is generated by V(D)J recombination and for BCRs, through somatic hypermutation and class-switching. The pool of BCRs/TCRs within an individual is termed the BCR/TCR repertoire. In healthy individuals this is highly diverse, yielding a complex immune architecture. However, studies suggest abnormalities in the repertoires of septic shock patients.  \n\nI will generate the first comprehensive analysis of the BCR/TCR repertoire in sepsis using high-throughput BCR/TCR sequencing at multiple timepoints over the course of disease/recovery; one of the largest studies of this kind. Reactivation of Epstein Barr Virus (EBV) is common during sepsis and EBV induces B-cell somatic hypermutation. Therefore, I will use single-cell RNA sequencing to investigate the B-cell transcriptional profile associated with EBV reactivation in sepsis and relate to prognosis. Finally, I will investigate the effect of immunomodulatory therapies (steroids, anti-TNF) on the BCR/TCR repertoire, thus improving our understanding of how therapies can be combined in sepsis. \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["B-Lymphocytes","Herpesvirus 4, Human","Humans","Receptors, Antigen, T-Cell","Single-Cell Analysis","T-Lymphocytes"]}
{"id":"360G-Wellcome-220048_Z_19_Z","title":"Functional and evolutionary characterisation of chromatin organisation in endometrial cancer","Region":"South East","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220048/Z/19/Z","description":"Endometrial, or uterine, cancer affects roughly 9,000 women each year in the UK and has become considerably more common during the past two decades. Although more than 80% of affected women are cured by surgery and post-operative treatments, the prognosis for certain disease subgroups is considerably poorer. Improving this requires a better understanding of the evolution of this disease at a molecular level. We propose to do this by a detailed study of genetic (changes in DNA sequence) and epigenetic (changes other than DNA sequence) perturbations in endometrial cancers of different stages. Using a combination of human tumours, cell lines and experimental models (such as organoids - 3D cell cultures derived from the mouse uterus), we will apply advanced machine learning techniques and state-of-the-art experimental methods to understand the key events in tumour evolution and the underlying biology driving this process. In doing so we ultimately hope to improve prognostication and therapies for patients.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Ms Katarzyna Kedzierska","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Kedzierska","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Functional and evolutionary characterisation of chromatin organisation in endometrial cancer Endometrial, or uterine, cancer affects roughly 9,000 women each year in the UK and has become considerably more common during the past two decades. Although more than 80% of affected women are cured by surgery and post-operative treatments, the prognosis for certain disease subgroups is considerably poorer. Improving this requires a better understanding of the evolution of this disease at a molecular level. We propose to do this by a detailed study of genetic (changes in DNA sequence) and epigenetic (changes other than DNA sequence) perturbations in endometrial cancers of different stages. Using a combination of human tumours, cell lines and experimental models (such as organoids - 3D cell cultures derived from the mouse uterus), we will apply advanced machine learning techniques and state-of-the-art experimental methods to understand the key events in tumour evolution and the underlying biology driving this process. In doing so we ultimately hope to improve prognostication and therapies for patients.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Cell Line, Tumor","Chromatin","Endometrial Neoplasms","Epigenesis, Genetic","Female","Humans","Machine Learning","Mice","Prognosis"]}
{"id":"360G-Wellcome-220047_Z_19_Z","title":"Structure learning with grid-like and axis-aligned codes","Region":"South East","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220047/Z/19/Z","description":"Recent theories of how people comprehend and learn about the world around them have emphasised a distinction between content (i.e. what things are there?) and structure (i.e. how are those things related?). One theory puts forward that \"grid-like\" activity \u2013 a pattern originally discovered in rodent navigation experiments \u2013 is used to organise structural information in the brain. Other work has focused on \"axis-aligned\" codes that organise information along a single axis of \u2018magnitude\u2019 \u2013 such as number (low to high), time (soon to later), and probability (unlikely to likely). We will investigate the relative contributions of these two types of neural activity in structure learning tasks.\nWe will use a combination of human behavioural experiments, functional neuroimaging, and computational modelling. We will record brain activity in humans performing tasks that test specific predictions made by the use of the two neural coding strategies, and design versions of these tasks that can be performed by neural network algorithms, allowing us to make functional predictions about the human neural data.\nDelineating the circumstances under which the brain uses these two types of activity will constrain or unify theories of structure learning and help understand the neural underpinnings of flexible human thought.\n \n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Adam Harris","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Harris","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Structure learning with grid-like and axis-aligned codes Recent theories of how people comprehend and learn about the world around them have emphasised a distinction between content (i.e. what things are there?) and structure (i.e. how are those things related?). One theory puts forward that \"grid-like\" activity \u2013 a pattern originally discovered in rodent navigation experiments \u2013 is used to organise structural information in the brain. Other work has focused on \"axis-aligned\" codes that organise information along a single axis of \u2018magnitude\u2019 \u2013 such as number (low to high), time (soon to later), and probability (unlikely to likely). We will investigate the relative contributions of these two types of neural activity in structure learning tasks.\nWe will use a combination of human behavioural experiments, functional neuroimaging, and computational modelling. We will record brain activity in humans performing tasks that test specific predictions made by the use of the two neural coding strategies, and design versions of these tasks that can be performed by neural network algorithms, allowing us to make functional predictions about the human neural data.\nDelineating the circumstances under which the brain uses these two types of activity will constrain or unify theories of structure learning and help understand the neural underpinnings of flexible human thought.\n \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Algorithms","Brain","Computer Simulation","Humans","Learning","Models, Neurological","Probability"]}
{"id":"360G-Wellcome-220046_Z_19_Z","title":"Dynamics in the regulatory genome.","Region":"South East","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220046/Z/19/Z","description":"The human genome comprises multiple layers of information, from the basic DNA sequence, to the complex folding of DNA into 3D structures in different cell types.  We have an extensive knowledge of the coding genome, and are beginning to build a better picture of how non-coding regions regulate gene expression.  I am interested in the dynamic process of protein localisation and recruitment within the context of gene regulation.  Pre-established techniques  give a steady state, population view of which proteins and regions of DNA interact with one another. However, such processes are highly dynamic, occurring at different rates across the genome.  A method that could demonstrate how interactions form dynamically and which genomic regions employ particular regulatory activities would further advance our understanding of genome regulation. My project will utilise a newly developed technique, called RAPID-release, that enables rapid induction of protein localisation which can be visually traced over time. I will integrate this with time-course Chromatin Immuno Precipitation Sequencing (ChIP-seq). I will use the combination of these techniques to generate genomic data from which a model for protein dynamics can be developed within the context of the regulatory genome.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Emily Georgiades","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Georgiades","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Dynamics in the regulatory genome. The human genome comprises multiple layers of information, from the basic DNA sequence, to the complex folding of DNA into 3D structures in different cell types.  We have an extensive knowledge of the coding genome, and are beginning to build a better picture of how non-coding regions regulate gene expression.  I am interested in the dynamic process of protein localisation and recruitment within the context of gene regulation.  Pre-established techniques  give a steady state, population view of which proteins and regions of DNA interact with one another. However, such processes are highly dynamic, occurring at different rates across the genome.  A method that could demonstrate how interactions form dynamically and which genomic regions employ particular regulatory activities would further advance our understanding of genome regulation. My project will utilise a newly developed technique, called RAPID-release, that enables rapid induction of protein localisation which can be visually traced over time. I will integrate this with time-course Chromatin Immuno Precipitation Sequencing (ChIP-seq). I will use the combination of these techniques to generate genomic data from which a model for protein dynamics can be developed within the context of the regulatory genome.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Chromatin","DNA","Genome, Human","Humans"]}
{"id":"360G-Wellcome-220045_Z_19_Z","title":"Genetic and Molecular Characterisation of Postprandial Insulin Resistance ","Region":"East of England","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220045/Z/19/Z","description":"Diabetes is a health concern currently affecting approximately 451 million individuals worldwide. Ninety per cent of individuals with diabetes are diagnosed with type 2 diabetes (T2D), typically in late adulthood. T2D is characterised by an inability of the body to control blood sugar levels. In part, this is due to cells of the body being unable to optimally respond to insulin, a hormone required to regulate blood sugar levels; a condition known as insulin resistance. There have been many efforts to understand how genetic changes result in an individual\u2019s increased risk of T2D in adulthood, however, the mechanism by which these changes result in increased risk are largely poorly understood.\n\n\nThis research aims to understand the genetic contribution to insulin resistance, using an interdisciplinary approach. Using large population studies we aim to identify novel changes in DNA which are associated with insulin resistance.  In addition, we will identify rare mutations in genes thought to be involved in insulin action, and examine using cellular models the molecular impact of these. This will enable a better understanding of the genetic contribution to insulin resistance and how this contributes to T2D, as well as potentially highlighting novel targets for treatment and prevention.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Alice Williamson","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Williamson","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Genetic and Molecular Characterisation of Postprandial Insulin Resistance  Diabetes is a health concern currently affecting approximately 451 million individuals worldwide. Ninety per cent of individuals with diabetes are diagnosed with type 2 diabetes (T2D), typically in late adulthood. T2D is characterised by an inability of the body to control blood sugar levels. In part, this is due to cells of the body being unable to optimally respond to insulin, a hormone required to regulate blood sugar levels; a condition known as insulin resistance. There have been many efforts to understand how genetic changes result in an individual\u2019s increased risk of T2D in adulthood, however, the mechanism by which these changes result in increased risk are largely poorly understood.\n\n\nThis research aims to understand the genetic contribution to insulin resistance, using an interdisciplinary approach. Using large population studies we aim to identify novel changes in DNA which are associated with insulin resistance.  In addition, we will identify rare mutations in genes thought to be involved in insulin action, and examine using cellular models the molecular impact of these. This will enable a better understanding of the genetic contribution to insulin resistance and how this contributes to T2D, as well as potentially highlighting novel targets for treatment and prevention.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Diabetes Mellitus, Type 2","Humans","Insulin","Insulin Resistance","Mutation"]}
{"id":"360G-Wellcome-220044_Z_19_Z","title":"Prognostic proteomic signatures of type 2 diabetes and related metabolic traits","Region":"East of England","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220044/Z/19/Z","description":"Molecules that can be measured in the blood, such as proteins, show differences in people who will develop T2D, even years before being diagnosed. Recent improvements in technologies, now allow us to measure thousands of proteins (so called proteomics) from a single blood sample. We propose that proteomics can provide information on the causes of T2D and on a person\u2019s risk to develop this disease. In two large studies, we will look for proteins that have different levels between people who will develop T2D and those who won\u2019t. We will use this information to: 1) identify those proteins that can help predict which people will develop T2D and related complications, and can help to classify patients into subgroups with similar characteristics. 2) To evaluate which proteins can cause T2D when altered, and which proteins are altered as a result of developing T2D. This project will improve our understanding of the mechanisms causing T2D and help identify proteins that could be used as treatment targets. Additionally, it could improve how we treat patients by identifying individuals at high risk of T2D and related complications and by identifying subgroups of patients with specific characteristics and risks for complications.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Julia Carrasco Zanini Sanchez","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Carrasco Zanini Sanchez","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Prognostic proteomic signatures of type 2 diabetes and related metabolic traits Molecules that can be measured in the blood, such as proteins, show differences in people who will develop T2D, even years before being diagnosed. Recent improvements in technologies, now allow us to measure thousands of proteins (so called proteomics) from a single blood sample. We propose that proteomics can provide information on the causes of T2D and on a person\u2019s risk to develop this disease. In two large studies, we will look for proteins that have different levels between people who will develop T2D and those who won\u2019t. We will use this information to: 1) identify those proteins that can help predict which people will develop T2D and related complications, and can help to classify patients into subgroups with similar characteristics. 2) To evaluate which proteins can cause T2D when altered, and which proteins are altered as a result of developing T2D. This project will improve our understanding of the mechanisms causing T2D and help identify proteins that could be used as treatment targets. Additionally, it could improve how we treat patients by identifying individuals at high risk of T2D and related complications and by identifying subgroups of patients with specific characteristics and risks for complications.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Diabetes Mellitus, Type 2","Humans","Prognosis","Proteome","Proteomics"]}
{"id":"360G-Wellcome-220043_Z_19_Z","title":"The microbiota-gut-brain axis in preterm infants","Region":"Scotland","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220043/Z/19/Z","description":"Around 11% of infants are born preterm ( \n\nFirst, we will characterise gut microbial composition in infant stool samples and investigate which perinatal factors (e.g. mode of delivery, exposure to breast milk) influence gut microbiota. Second, we will use brain MRI to evaluate how variations in gut microbial composition relate to the integrity of developing brain connections. Third, we will investigate the associations between gut microbial composition and neurobehavioural outcomes (e.g. attention, social cognition, anxiety) in these children at 2 years.\n\nThese studies will determine whether the gut microbiota modifies risk or resilience for healthy brain development in preterm children. If it does, it may inform novel therapeutic strategies to improve neurocognitive outcomes.\n","plannedDates":[{"endDate":"2022-11-30T00:00:00+00:00","startDate":"2019-09-01T00:00:00+00:00","startDateDateOnly":"2019-09-01","endDateDateOnly":"2022-11-30"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Kadi Vaher","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Vaher","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The microbiota-gut-brain axis in preterm infants Around 11% of infants are born preterm ( \n\nFirst, we will characterise gut microbial composition in infant stool samples and investigate which perinatal factors (e.g. mode of delivery, exposure to breast milk) influence gut microbiota. Second, we will use brain MRI to evaluate how variations in gut microbial composition relate to the integrity of developing brain connections. Third, we will investigate the associations between gut microbial composition and neurobehavioural outcomes (e.g. attention, social cognition, anxiety) in these children at 2 years.\n\nThese studies will determine whether the gut microbiota modifies risk or resilience for healthy brain development in preterm children. If it does, it may inform novel therapeutic strategies to improve neurocognitive outcomes.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Anxiety","Brain","Feces","Female","Gastrointestinal Microbiome","Humans","Infant","Infant, Newborn","Infant, Premature","Magnetic Resonance Imaging"]}
{"id":"360G-Wellcome-220042_Z_19_Z","title":"Relationship between anticholinergic drug use, brain health outcomes, and biomarkers of ageing","Region":"Scotland","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220042/Z/19/Z","description":"Many medicines, including some diuretics, vasodilators, antidepressants, anxiolytics, and antihistamines have anticholinergic properties. Such drugs have been linked with impairments in cognition and dementia. Older people are more likely to take multiple drugs and are more susceptible to their side-effects. Thus, there is a need to better understand prescribing and the biology of anticholinergic drugs in this population.\n\nI aim to understand the prevalence of anticholinergic drug use in the Scottish population, their relationship with cognition and with the underlying biology.\n\nI will use data from large and well-characterised cohorts of people and utilise information on their use of prescription drugs to investigate whether individuals with a higher childhood IQ show different patterns of medicine use and how that relates to mortality. Then I will model the ways in which physical function and cognition change in old age as a result of the use of anticholinergic drugs. Finally, I will explore the possible link between these drugs and changes in the brain and the epigenome.\n\nThese studies will help us to better understand the prevalence of anticholinergic drug use, the biological underpinnings of its link to cognitive function, and offer insights into improved management of prescribing in older adults.\n","plannedDates":[{"endDate":"2022-11-30T00:00:00+00:00","startDate":"2019-09-01T00:00:00+00:00","startDateDateOnly":"2019-09-01","endDateDateOnly":"2022-11-30"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Jure Mur","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Mur","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Relationship between anticholinergic drug use, brain health outcomes, and biomarkers of ageing Many medicines, including some diuretics, vasodilators, antidepressants, anxiolytics, and antihistamines have anticholinergic properties. Such drugs have been linked with impairments in cognition and dementia. Older people are more likely to take multiple drugs and are more susceptible to their side-effects. Thus, there is a need to better understand prescribing and the biology of anticholinergic drugs in this population.\n\nI aim to understand the prevalence of anticholinergic drug use in the Scottish population, their relationship with cognition and with the underlying biology.\n\nI will use data from large and well-characterised cohorts of people and utilise information on their use of prescription drugs to investigate whether individuals with a higher childhood IQ show different patterns of medicine use and how that relates to mortality. Then I will model the ways in which physical function and cognition change in old age as a result of the use of anticholinergic drugs. Finally, I will explore the possible link between these drugs and changes in the brain and the epigenome.\n\nThese studies will help us to better understand the prevalence of anticholinergic drug use, the biological underpinnings of its link to cognitive function, and offer insights into improved management of prescribing in older adults.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aged","Child","Cholinergic Antagonists","Cognition","Humans","Scotland"]}
{"id":"360G-Wellcome-220041_Z_19_Z","title":"Circuit mechanisms underlying spatial navigation deficits in early Alzheimer's disease","Region":"Scotland","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220041/Z/19/Z","description":"Alzheimer\u2019s disease (AD) is a progressive neurodegenerative disorder that affects millions worldwide. AD can only be diagnosed late in its progression, when cognitive symptoms such as memory loss are prominent. Many years before this, the pathological AD processes are active and damaging the brain, but the symptoms at this early stage are subtle, making diagnosis challenging. Focusing on early affected areas in AD could hold the key to early diagnosis.\n\nAn early affected area is the entorhinal cortex (EC), which supports spatial navigation. Damage here causes spatial navigation deficits. In early AD, these deficits are subtle and require the development of sensitive tests. Our goal is to help inform the development of these tests by understanding how the EC carries out spatial computations, and how they are altered in AD. To do this, we will reverse engineer the EC circuitry using optogenetics and electrophysiology during navigation tasks performed by healthy and AD mice. In conjunction, we will build computational models (virtual EC circuits) that simulate AD pathology and task performance. These studies will help explain how the EC carries out computations that underlie spatial navigation, and how they go wrong during AD, informing the development of sensitive tests for AD.\n","plannedDates":[{"endDate":"2022-11-30T00:00:00+00:00","startDate":"2019-09-01T00:00:00+00:00","startDateDateOnly":"2019-09-01","endDateDateOnly":"2022-11-30"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Ian Hawes","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Hawes","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Circuit mechanisms underlying spatial navigation deficits in early Alzheimer's disease Alzheimer\u2019s disease (AD) is a progressive neurodegenerative disorder that affects millions worldwide. AD can only be diagnosed late in its progression, when cognitive symptoms such as memory loss are prominent. Many years before this, the pathological AD processes are active and damaging the brain, but the symptoms at this early stage are subtle, making diagnosis challenging. Focusing on early affected areas in AD could hold the key to early diagnosis.\n\nAn early affected area is the entorhinal cortex (EC), which supports spatial navigation. Damage here causes spatial navigation deficits. In early AD, these deficits are subtle and require the development of sensitive tests. Our goal is to help inform the development of these tests by understanding how the EC carries out spatial computations, and how they are altered in AD. To do this, we will reverse engineer the EC circuitry using optogenetics and electrophysiology during navigation tasks performed by healthy and AD mice. In conjunction, we will build computational models (virtual EC circuits) that simulate AD pathology and task performance. These studies will help explain how the EC carries out computations that underlie spatial navigation, and how they go wrong during AD, informing the development of sensitive tests for AD.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Alzheimer Disease","Animals","Disease Models, Animal","Entorhinal Cortex","Humans","Mice","Mice, Transgenic","Optogenetics"]}
{"id":"360G-Wellcome-220040_Z_19_Z","title":"Open Access Award 2019/20 ","Region":"Greater London","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220040/Z/19/Z","description":"Not available","plannedDates":[{"endDate":"2020-09-30T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2020-09-30"}],"amountAwarded":20000,"Financial Year":"2019/20","Lead Applicant":"Prof Willem Hanekom","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Hanekom","Partnership Value":20000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London","addressCountry":"United Kingdom","id_and_name":"[\"University College London\", \"360G-Wellcome-ORG:University-College-London\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-College-London","name":"University College London"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2019/20  Not available","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-220039_Z_19_Z","title":"Open Access Award 2019/20 ","Region":"North West","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220039/Z/19/Z","description":"Not available","plannedDates":[{"endDate":"2020-10-01T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2020-10-01"}],"amountAwarded":50000,"Financial Year":"2019/20","Lead Applicant":"Prof Stephen Gordon","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Gordon","Partnership Value":50000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine","addressCountry":"United Kingdom","id_and_name":"[\"Liverpool School of Tropical Medicine\", \"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:Liverpool-School-of-Tropical-Medicine","name":"Liverpool School of Tropical Medicine"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2019/20  Not available","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-220038_Z_19_Z","title":"Open Access Award 2019/20 ","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220038/Z/19/Z","description":"Not available","plannedDates":[{"endDate":"2020-09-30T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2020-09-30"}],"amountAwarded":120000,"Financial Year":"2019/20","Lead Applicant":"Prof Philip Bejon","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Bejon","Partnership Value":120000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2019/20  Not available","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-220037_Z_19_Z","title":"Open Access Award 2019/20 ","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220037/Z/19/Z","description":"Not available","plannedDates":[{"endDate":"2020-10-01T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2020-10-01"}],"amountAwarded":85000,"Financial Year":"2019/20","Lead Applicant":"Prof Guy Thwaites","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Thwaites","Partnership Value":85000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2019/20  Not available","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-220036_Z_19_Z","title":"Open Access Award 2019/20 ","Region":"South East","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220036/Z/19/Z","description":"Not available","plannedDates":[{"endDate":"2020-10-01T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2020-10-01"}],"amountAwarded":200000,"Financial Year":"2019/20","Lead Applicant":"Prof Nicholas Day","grantProgramme":[{"title":"Open Access Award","title_keyword":"Open Access Award"}],"Applicant Surname":"Day","Partnership Value":200000,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford","addressCountry":"United Kingdom","id_and_name":"[\"University of Oxford\", \"360G-Wellcome-ORG:University-of-Oxford\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Oxford","name":"University of Oxford"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Open Access Award 2019/20  Not available","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Awards and Prizes","Humans","United States"]}
{"id":"360G-Wellcome-220035_Z_19_Z","title":"MicroRNAs in Branchial Arch Development","Region":"North West","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220035/Z/19/Z","description":"Embryonic development of the face and neck is a complex process. In vertebrates it begins with the formation of temporary segments called branchial arches. Within these segments, cells must express the correct genes to properly form various structures and tissues, such as the jawbone. Furthermore, these genes need to be expressed at the correct time and in the correct segment. This requires precise regulation, and one mechanism by which cells can accomplish this tight control is using microRNAs. MicroRNAs are known to be involved in important developmental processes, but no studies have profiled the full collection of microRNAs expressed in developing branchial arches. In this project we aim to identify key microRNAs that function during mouse branchial arch development. We will achieve this using a technology called small RNA-sequencing, which will allow us to determine the abundance of all microRNAs expressed in each stage and time. Following this, we will use computational programs to predict the genes they may regulate and later validate these predictions in the lab. This project will identify new contexts for which microRNAs function in and increase our understanding of the precise regulation in place during facial development.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Sian Goldsworthy","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Goldsworthy","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester","addressCountry":"United Kingdom","id_and_name":"[\"University of Manchester\", \"360G-Wellcome-ORG:University-of-Manchester\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Manchester","name":"University of Manchester"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"MicroRNAs in Branchial Arch Development Embryonic development of the face and neck is a complex process. In vertebrates it begins with the formation of temporary segments called branchial arches. Within these segments, cells must express the correct genes to properly form various structures and tissues, such as the jawbone. Furthermore, these genes need to be expressed at the correct time and in the correct segment. This requires precise regulation, and one mechanism by which cells can accomplish this tight control is using microRNAs. MicroRNAs are known to be involved in important developmental processes, but no studies have profiled the full collection of microRNAs expressed in developing branchial arches. In this project we aim to identify key microRNAs that function during mouse branchial arch development. We will achieve this using a technology called small RNA-sequencing, which will allow us to determine the abundance of all microRNAs expressed in each stage and time. Following this, we will use computational programs to predict the genes they may regulate and later validate these predictions in the lab. This project will identify new contexts for which microRNAs function in and increase our understanding of the precise regulation in place during facial development.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Gene Expression Regulation, Developmental","Mice","MicroRNAs"]}
{"id":"360G-Wellcome-220034_Z_19_Z","title":"Characterising the evolution and development of vertebrate nervous systems using cross-species comparative genomics. ","Region":"East of England","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220034/Z/19/Z","description":"The human brain is enormously complex, consisting of billions of cells, diverse cell types and complicated connectivity. One approach to understand such a complex system is to study instances in more primitive organisms, where homologous cell types and developmental processes can suggest how particular components of the brain may have originated, what purpose they serve and how they function. In this project, I aim to use single-cell RNA sequencing (scRNA-seq) datasets from multiple species to identify homologies across vertebrate and invertebrate nervous systems. To achieve this, I aim to improve existing methods for comparing, integrating and visualising cross-species genomics data, for which current solutions either do not exist or are unsuitable. This will include approaches for identifying gene orthologs, normalising expression levels, matching cell types and, perhaps most challenging, identifying equivalent developmental stages. This research will lead to greater insight into the evolution of neural cell types, gene regulatory networks and neurodevelopmental processes across species and provide general resources for comparative analysis of transcriptomics datasets. These resources may have a wider impact on other areas of biology and medicine, such as in cancer research, for which the same tools may be used, for instance, to compare transcriptomes across cancer samples. \n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Daniel Keitley","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Keitley","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Characterising the evolution and development of vertebrate nervous systems using cross-species comparative genomics.  The human brain is enormously complex, consisting of billions of cells, diverse cell types and complicated connectivity. One approach to understand such a complex system is to study instances in more primitive organisms, where homologous cell types and developmental processes can suggest how particular components of the brain may have originated, what purpose they serve and how they function. In this project, I aim to use single-cell RNA sequencing (scRNA-seq) datasets from multiple species to identify homologies across vertebrate and invertebrate nervous systems. To achieve this, I aim to improve existing methods for comparing, integrating and visualising cross-species genomics data, for which current solutions either do not exist or are unsuitable. This will include approaches for identifying gene orthologs, normalising expression levels, matching cell types and, perhaps most challenging, identifying equivalent developmental stages. This research will lead to greater insight into the evolution of neural cell types, gene regulatory networks and neurodevelopmental processes across species and provide general resources for comparative analysis of transcriptomics datasets. These resources may have a wider impact on other areas of biology and medicine, such as in cancer research, for which the same tools may be used, for instance, to compare transcriptomes across cancer samples. \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Brain","Gene Expression Profiling","Genomics","Humans","Sequence Analysis, RNA","Single-Cell Analysis","Transcriptome"]}
{"id":"360G-Wellcome-220033_Z_19_Z","title":"The role of HIF2\u03b1 in non-alcoholic fatty liver disease","Region":"East of England","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220033/Z/19/Z","description":"Non-alcoholic fatty liver disease (NAFLD), marked by fat accumulation (steatosis), inflammation and scarring of the liver, affects about one third of people. There are no specific treatments available.\nWe believe the activation of a component of the hypoxia response, HIF2alpha, contributes to this disease. HIF2alpha responds to hypoxia (low oxygen levels) in part by limiting the capacity of mitochondria to burn fat, an oxygen demanding process. In the liver, this reduced fat oxidation could contribute to steatosis in NAFLD.\nWe will investigate this using mice that lack HIF2alpha in their livers. These will be fed a diet that induces NAFLD. We will measure metabolic features, such as fuel oxidation, and disease severity to determine whether interfering with HIF2alpha increases fat oxidation in NAFLD, and whether this improves disease severity. We will also investigate what activates HIF2alpha in NAFLD using cell culture approaches.\n\nFinally, we will investigate treatment options for NAFLD that target HIF2alpha. Some of these options are already in clinical trials for other diseases and could be adapted for NAFLD treatment.\nWith this project, we aim to increase our understanding of the harmful processes involved in a very common disease, and use this to explore novel treatment avenues.\n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Lorenz Holzner","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Holzner","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The role of HIF2\u03b1 in non-alcoholic fatty liver disease Non-alcoholic fatty liver disease (NAFLD), marked by fat accumulation (steatosis), inflammation and scarring of the liver, affects about one third of people. There are no specific treatments available.\nWe believe the activation of a component of the hypoxia response, HIF2alpha, contributes to this disease. HIF2alpha responds to hypoxia (low oxygen levels) in part by limiting the capacity of mitochondria to burn fat, an oxygen demanding process. In the liver, this reduced fat oxidation could contribute to steatosis in NAFLD.\nWe will investigate this using mice that lack HIF2alpha in their livers. These will be fed a diet that induces NAFLD. We will measure metabolic features, such as fuel oxidation, and disease severity to determine whether interfering with HIF2alpha increases fat oxidation in NAFLD, and whether this improves disease severity. We will also investigate what activates HIF2alpha in NAFLD using cell culture approaches.\n\nFinally, we will investigate treatment options for NAFLD that target HIF2alpha. Some of these options are already in clinical trials for other diseases and could be adapted for NAFLD treatment.\nWith this project, we aim to increase our understanding of the harmful processes involved in a very common disease, and use this to explore novel treatment avenues.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Diet, High-Fat","Liver","Mice","Mice, Inbred C57BL","Non-alcoholic Fatty Liver Disease","Oxidation-Reduction","Oxygen"]}
{"id":"360G-Wellcome-220032_Z_19_Z","title":"Epigenetic signatures of inflammation in relation to brain structure and connectivity across the lifecourse","Region":"Scotland","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220032/Z/19/Z","description":"How does chronic inflammation affect brain structure and connectivity as we grow older, and what aspects of our lifestyle influence this? We know that inflammation affects the function and integrity of the brain, with adverse outcomes in both development and older-age. Chronic, low grade inflammation is usually assessed by measuring the levels of various proteins in the blood, yet these measures provide only a snapshot of inflammatory exposure. A more reliable indicator may arise from DNA methylation, an epigenetic modification that is influenced by both genes and environment, and is involved in the regulation of gene expression. Using three distinct cohorts (age ranging from newborn ( \n","plannedDates":[{"endDate":"2022-11-30T00:00:00+00:00","startDate":"2019-09-01T00:00:00+00:00","startDateDateOnly":"2019-09-01","endDateDateOnly":"2022-11-30"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Eleanor Conole","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Conole","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Epigenetic signatures of inflammation in relation to brain structure and connectivity across the lifecourse How does chronic inflammation affect brain structure and connectivity as we grow older, and what aspects of our lifestyle influence this? We know that inflammation affects the function and integrity of the brain, with adverse outcomes in both development and older-age. Chronic, low grade inflammation is usually assessed by measuring the levels of various proteins in the blood, yet these measures provide only a snapshot of inflammatory exposure. A more reliable indicator may arise from DNA methylation, an epigenetic modification that is influenced by both genes and environment, and is involved in the regulation of gene expression. Using three distinct cohorts (age ranging from newborn ( \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Aged","Aging","Brain","DNA Methylation","Epigenesis, Genetic","Female","Humans","Infant, Newborn","Inflammation","Male"]}
{"id":"360G-Wellcome-220031_Z_19_Z","title":"Oligodendroglial Dysfunction in Huntington's Disease","Region":"Scotland","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220031/Z/19/Z","description":"Huntington\u2019s disease (HD) is a genetic neurodegenerative disease causing long term disability and life-threatening complications. It is well known that the loss of particular types of nerve cells in the brain causes the main symptoms of HD, but there is evidence that a different type of brain cell, oligodendrocytes, are also involved. Recent evidence has shown that human oligodendrocytes are heterogeneous, suggesting that their functions vary and that these are altered in disease. In this project I will investigate whether oligodendrocyte states are different in HD. I will analyse and validate the heterogeneity of oligodendrocytes in post mortem brain tissue from HD patients, as well as in oligodendrocyte cultures generated from human stem cells. Furthermore, I will investigate whether certain dysfunctional oligodendrocyte states are shared across different diseases by comparing the heterogeneity of oligodendrocytes in HD and Multiple Sclerosis. Finally, I will investigate whether targeting the cause of HD, a mutation in the huntingtin gene, can change oligodendrocyte states to become more like healthy cells. Together these approaches will establish whether and how oligodendrocyte dysfunction is a pathological feature of HD and will provide insight into common oligodendrocyte states across disease.\n","plannedDates":[{"endDate":"2022-11-30T00:00:00+00:00","startDate":"2019-09-01T00:00:00+00:00","startDateDateOnly":"2019-09-01","endDateDateOnly":"2022-11-30"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Ms Sunniva B\u00f8strand","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"B\u00f8strand","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh","addressCountry":"United Kingdom","id_and_name":"[\"University of Edinburgh\", \"360G-Wellcome-ORG:University-of-Edinburgh\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Edinburgh","name":"University of Edinburgh"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Oligodendroglial Dysfunction in Huntington's Disease Huntington\u2019s disease (HD) is a genetic neurodegenerative disease causing long term disability and life-threatening complications. It is well known that the loss of particular types of nerve cells in the brain causes the main symptoms of HD, but there is evidence that a different type of brain cell, oligodendrocytes, are also involved. Recent evidence has shown that human oligodendrocytes are heterogeneous, suggesting that their functions vary and that these are altered in disease. In this project I will investigate whether oligodendrocyte states are different in HD. I will analyse and validate the heterogeneity of oligodendrocytes in post mortem brain tissue from HD patients, as well as in oligodendrocyte cultures generated from human stem cells. Furthermore, I will investigate whether certain dysfunctional oligodendrocyte states are shared across different diseases by comparing the heterogeneity of oligodendrocytes in HD and Multiple Sclerosis. Finally, I will investigate whether targeting the cause of HD, a mutation in the huntingtin gene, can change oligodendrocyte states to become more like healthy cells. Together these approaches will establish whether and how oligodendrocyte dysfunction is a pathological feature of HD and will provide insight into common oligodendrocyte states across disease.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","Brain","Humans","Huntingtin Protein","Huntington Disease","Mutation","Oligodendroglia"]}
{"id":"360G-Wellcome-220030_Z_19_Z","title":"Regulation and function of RNF12 E3 ubiquitin ligase in Tonne-Kalscheuer Syndrome (TOKAS)","Region":"Scotland","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220030/Z/19/Z","description":"Background: Intellectual disability comprises a series of poorly understood neurodevelopmental disorders affecting around 1-2% of the general population. Tonne-Kalscheuer Syndrome (TOKAS) is an intellectual disability syndrome caused by mutations in the RNF12/RLIM gene, which encodes an E3 ubiquitin ligase that tags specific proteins for destruction in a process called ubiquitylation. In order to understand TOKAS disorder, the signals that control RNF12, the proteins it ubiquitylates and the cellular processes RNF12 governs must be identified.\n\nApproach: RNF12 is controlled by a chemical switch known as phosphorylation. My recent work uncovered a new function for a protein kinase called Aurora in phosphorylating RNF12. I will now use biochemistry and cell biology to study how Aurora phosphorylation of RNF12 controls protein ubiquitylation. I will then employ genome-editing technology and stem cell models to explore the impact of Aurora-RNF12 signalling on gene expression and development of the brain and genitals, which is disrupted in TOKAS patients. Finally, I will use proteomic technologies to search for new proteins that are ubiquitylated by RNF12, as these may be relevant to the development of TOKAS.\n\nImpact: These studies will provide new insight into regulation and functions of RNF12 protein ubiquitylation that are disrupted in TOKAS intellectual disability.\n","plannedDates":[{"endDate":"2022-12-02T00:00:00+00:00","startDate":"2018-09-03T00:00:00+00:00","startDateDateOnly":"2018-09-03","endDateDateOnly":"2022-12-02"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Carmen Espejo Serrano","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Espejo Serrano","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee","addressCountry":"United Kingdom","id_and_name":"[\"University of Dundee\", \"360G-Wellcome-ORG:University-of-Dundee\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Regulation and function of RNF12 E3 ubiquitin ligase in Tonne-Kalscheuer Syndrome (TOKAS) Background: Intellectual disability comprises a series of poorly understood neurodevelopmental disorders affecting around 1-2% of the general population. Tonne-Kalscheuer Syndrome (TOKAS) is an intellectual disability syndrome caused by mutations in the RNF12/RLIM gene, which encodes an E3 ubiquitin ligase that tags specific proteins for destruction in a process called ubiquitylation. In order to understand TOKAS disorder, the signals that control RNF12, the proteins it ubiquitylates and the cellular processes RNF12 governs must be identified.\n\nApproach: RNF12 is controlled by a chemical switch known as phosphorylation. My recent work uncovered a new function for a protein kinase called Aurora in phosphorylating RNF12. I will now use biochemistry and cell biology to study how Aurora phosphorylation of RNF12 controls protein ubiquitylation. I will then employ genome-editing technology and stem cell models to explore the impact of Aurora-RNF12 signalling on gene expression and development of the brain and genitals, which is disrupted in TOKAS patients. Finally, I will use proteomic technologies to search for new proteins that are ubiquitylated by RNF12, as these may be relevant to the development of TOKAS.\n\nImpact: These studies will provide new insight into regulation and functions of RNF12 protein ubiquitylation that are disrupted in TOKAS intellectual disability.\n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Intellectual Disability","Mutation","Phosphorylation","Ubiquitin-Protein Ligases","Ubiquitination"]}
{"id":"360G-Wellcome-220029_Z_19_Z","title":"The structure, function and essentiality of Trypanosoma cruzi mitochondrial fucosyltransferase","Region":"Scotland","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220029/Z/19/Z","description":"The protozoan parasites Trypanosoma brucei, Trypanosoma cruzi and Leishmania spp. are the causative agents of neglected tropical diseases. They rely on surface glycans, chains of sugar units attached to proteins and lipids, for their survival and infectivity. These surface glycans are synthesized by enzymes called glycosyltransferases located in the secretory pathway. However, contrary to this canonical model of glycan synthesis and surface expression, our group has recently described the presence of an essential glycosyltransferase, a fucosyltransferase, in the mitochondrion of T. brucei. A similar putative fucosyltransferase gene, called TcFUT1, has been found in the genome of T. cruzi, the causative agent of Chagas\u2019 disease, endemic in the Americas. We aim to obtain recombinant, active TcFUT1 protein in order to analyse its enzymatic activity, define its preferred substrate(s) in vitro, design assays for compound screening and to raise antibodies against it for immuno-localisation. In parallel, we also aim to define its essentiality and characterise its endogenous substrates. This work will provide an opportunity to uncover the function(s) of this novel mitochondrial fucosyltransferase and provide a much-needed drug target for Chagas\u2019 disease.\n \n","plannedDates":[{"endDate":"2022-12-02T00:00:00+00:00","startDate":"2018-09-03T00:00:00+00:00","startDateDateOnly":"2018-09-03","endDateDateOnly":"2022-12-02"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Mr Jose Carlos Paredes-Franco","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Paredes-Franco","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee","addressCountry":"United Kingdom","id_and_name":"[\"University of Dundee\", \"360G-Wellcome-ORG:University-of-Dundee\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Dundee","name":"University of Dundee"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"The structure, function and essentiality of Trypanosoma cruzi mitochondrial fucosyltransferase The protozoan parasites Trypanosoma brucei, Trypanosoma cruzi and Leishmania spp. are the causative agents of neglected tropical diseases. They rely on surface glycans, chains of sugar units attached to proteins and lipids, for their survival and infectivity. These surface glycans are synthesized by enzymes called glycosyltransferases located in the secretory pathway. However, contrary to this canonical model of glycan synthesis and surface expression, our group has recently described the presence of an essential glycosyltransferase, a fucosyltransferase, in the mitochondrion of T. brucei. A similar putative fucosyltransferase gene, called TcFUT1, has been found in the genome of T. cruzi, the causative agent of Chagas\u2019 disease, endemic in the Americas. We aim to obtain recombinant, active TcFUT1 protein in order to analyse its enzymatic activity, define its preferred substrate(s) in vitro, design assays for compound screening and to raise antibodies against it for immuno-localisation. In parallel, we also aim to define its essentiality and characterise its endogenous substrates. This work will provide an opportunity to uncover the function(s) of this novel mitochondrial fucosyltransferase and provide a much-needed drug target for Chagas\u2019 disease.\n \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Humans","Protozoan Proteins","Recombinant Proteins","Substrate Specificity","Trypanosoma cruzi"]}
{"id":"360G-Wellcome-220028_Z_19_Z","title":"Strengthening research ethics systems in Latin America and the Caribbean","Region":"International","currency":"GBP","awardDate":"2020-09-30T00:00:00+00:00","Internal ID":"220028/Z/19/Z","description":"Strengthening research ethics systems in Latin America and the Caribbean\n\nThis proposal of the Regional Program on Bioethics of the Pan American Health Organization (PAHO) aims at significantly improving the regional research ethics landscape and, specifically, at strengthening research ethics systems and enhancing ethics preparedness to conduct research during emergencies. In response to a 2018 explicit request from the countries in the Americas to advance research ethics with a systemic approach, PAHO\u2019s Regional Program on Bioethics developed indicators and a strategy to address the regional challenges. While this action has already triggered progress rapidly in few countries (e.g. Peru), PAHO\u2019s resources to scale up these efforts as requested by the countries are very limited. This grant would allow PAHO to (a) assess the current situation using indicators, (b) advance change in several countries in Latin America and the Caribbean using national research ethics policies as a strategy, (c) support the implementation of such policies through an online tool for ethics review, and (d) share this model so it can be replicated by other regions. PAHO is uniquely positioned to achieve these outcomes due to its ongoing work supporting national health authorities on bioethics.\n","plannedDates":[{"endDate":"2022-03-01T00:00:00+00:00","startDate":"2020-03-01T00:00:00+00:00","startDateDateOnly":"2020-03-01","endDateDateOnly":"2022-03-01"}],"amountAwarded":255939,"Financial Year":"2019/20","Lead Applicant":"Dr Soumya Swaminathan","grantProgramme":[{"title":"Discretionary Award \u2013 C&S","title_keyword":"Discretionary Award \u2013 C&S"}],"Applicant Surname":"Swaminathan","Partnership Value":255939,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:World-Health-Organization-Switzerland","name":"World Health Organization, Switzerland","addressCountry":"Switzerland","id_and_name":"[\"World Health Organization, Switzerland\", \"360G-Wellcome-ORG:World-Health-Organization-Switzerland\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:World-Health-Organization-Switzerland","name":"World Health Organization, Switzerland"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Strengthening research ethics systems in Latin America and the Caribbean Strengthening research ethics systems in Latin America and the Caribbean\n\nThis proposal of the Regional Program on Bioethics of the Pan American Health Organization (PAHO) aims at significantly improving the regional research ethics landscape and, specifically, at strengthening research ethics systems and enhancing ethics preparedness to conduct research during emergencies. In response to a 2018 explicit request from the countries in the Americas to advance research ethics with a systemic approach, PAHO\u2019s Regional Program on Bioethics developed indicators and a strategy to address the regional challenges. While this action has already triggered progress rapidly in few countries (e.g. Peru), PAHO\u2019s resources to scale up these efforts as requested by the countries are very limited. This grant would allow PAHO to (a) assess the current situation using indicators, (b) advance change in several countries in Latin America and the Caribbean using national research ethics policies as a strategy, (c) support the implementation of such policies through an online tool for ethics review, and (d) share this model so it can be replicated by other regions. PAHO is uniquely positioned to achieve these outcomes due to its ongoing work supporting national health authorities on bioethics.\n","awardDateDateOnly":"2020-09-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Bioethics","Biomedical Research","Caribbean Region","Ethics, Research","Humans","International Cooperation","Latin America","Peru","United States"]}
{"id":"360G-Wellcome-220027_Z_19_Z","title":"Mechanisms of cell fate plasticity in adult CNS progenitors","Region":"East of England","currency":"GBP","awardDate":"2020-06-30T00:00:00+00:00","Internal ID":"220027/Z/19/Z","description":"Myelin sheaths provide trophic support to the axons and are essential for rapid nerve impulse conduction, so maintaining their integrity is of utmost importance. In response to demyelinating injuries in the central nervous system (CNS), oligodendrocyte progenitor cells (OPCs) classically differentiate into oligodendrocytes, which make new myelin sheaths. However, lineage tracing studies have demonstrated that OPCs can also generate Schwann cells (SCs), the myelinating cell of the peripheral nervous system. This is surprising because the progenitors that produce SCs and OPCs separate very early during development, so SCs are considered phylogenetically distinct from OPCs. Therefore, I aim to investigate the transcriptomic mechanisms that underlie this unusual cell fate, and to characterise the functional consequences of SC versus oligodendrocyte myelination in the CNS. I will impose a SC identity onto OPCs using CRISPR/Cas9 gene editing to manipulate the activity of core transcription factors, Olig2 and Sox10, then I will use histological, behavioural and sequencing studies to evaluate the functional impact of Schwann cell myelination in vitro and in vivo. These findings will reveal insights into the mechanisms of OPC cell fate decisions and could represent a new therapeutic approach to promote remyelination. \n\n \n\n \n","plannedDates":[{"endDate":"2022-12-31T00:00:00+00:00","startDate":"2019-10-01T00:00:00+00:00","startDateDateOnly":"2019-10-01","endDateDateOnly":"2022-12-31"}],"amountAwarded":0,"Financial Year":"2019/20","Lead Applicant":"Miss Zi-Yu (Civia) Chen","grantProgramme":[{"title":"PhD Studentship (Basic)","title_keyword":"PhD Studentship (Basic)"}],"Applicant Surname":"Chen","Partnership Value":0,"Approval Committee":"Internal Decision Panel","fundingOrganization":[{"id":"GB-CHC-210183","name":"The Wellcome Trust","id_and_name":"[\"The Wellcome Trust\", \"GB-CHC-210183\"]"}],"recipientOrganization":[{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge","addressCountry":"United Kingdom","id_and_name":"[\"University of Cambridge\", \"360G-Wellcome-ORG:University-of-Cambridge\"]"}],"additional_data":{"locationLookup":[],"TSGFundingOrgType":"Grantmaking Organisation","fundingOrganizationCanonical":{"id":"GB-CHC-210183","name":"The Wellcome Trust"},"recipientOrganizationCanonical":{"id":"360G-Wellcome-ORG:University-of-Cambridge","name":"University of Cambridge"}},"filename":"a001p00000xQ047AAC.json","title_and_description":"Mechanisms of cell fate plasticity in adult CNS progenitors Myelin sheaths provide trophic support to the axons and are essential for rapid nerve impulse conduction, so maintaining their integrity is of utmost importance. In response to demyelinating injuries in the central nervous system (CNS), oligodendrocyte progenitor cells (OPCs) classically differentiate into oligodendrocytes, which make new myelin sheaths. However, lineage tracing studies have demonstrated that OPCs can also generate Schwann cells (SCs), the myelinating cell of the peripheral nervous system. This is surprising because the progenitors that produce SCs and OPCs separate very early during development, so SCs are considered phylogenetically distinct from OPCs. Therefore, I aim to investigate the transcriptomic mechanisms that underlie this unusual cell fate, and to characterise the functional consequences of SC versus oligodendrocyte myelination in the CNS. I will impose a SC identity onto OPCs using CRISPR/Cas9 gene editing to manipulate the activity of core transcription factors, Olig2 and Sox10, then I will use histological, behavioural and sequencing studies to evaluate the functional impact of Schwann cell myelination in vitro and in vivo. These findings will reveal insights into the mechanisms of OPC cell fate decisions and could represent a new therapeutic approach to promote remyelination. \n\n \n\n \n","awardDateDateOnly":"2020-06-30","dataset":{"title":"Grants awarded from 1 October 2005 to 30 June 2021","issued":"2018-03-21","license":"https://creativecommons.org/licenses/by/4.0/","modified":"2021-09-09T14:07:48.000+0000","publisher":{"logo":"https://www.threesixtygiving.org/wp-content/uploads/wellcome-logo-black.png","name":"The Wellcome Trust","org_id":"GB-CHC-210183","prefix":"360G-wellcome","website":"https://wellcome.org/","last_published":"2021-11-01"},"identifier":"a001p00000xQ047AAC","description":"","distribution":[{"title":"Grants awarded from 1 October 2005 to 30 June 2021","accessURL":"https://wellcome.org/grant-funding/funded-people-and-projects","downloadURL":"https://cms.wellcome.org/sites/default/files/2021-09/Wellcome-grants-awarded-1-October-2005-to-30-June-2021-as-at-12072021_0.xlsx"}],"license_name":"Creative Commons Attribution 4.0 International (CC BY 4.0)","datagetter_metadata":{"json":"/home/datastore/latest_datagetter//data/json_all/a001p00000xQ047AAC.json","valid":true,"downloads":true,"file_size":11335757,"file_type":"xlsx","acceptable_license":true,"datetime_downloaded":"2022-06-23T00:05:59+01:00"}},"tags":["Animals","CRISPR-Cas Systems","Cell Differentiation","Cell Lineage","Mice","Myelin Sheath","Oligodendroglia","Schwann Cells"]}